Famotidine	B-Chemical	D015738
-	O	O
associated	O	O
delirium	B-Disease	D003693
.	O	O

A	O	O
series	O	O
of	O	O
six	O	O
cases	O	O
.	O	O

Famotidine	B-Chemical	D015738
is	O	O
a	O	O
histamine	O	O
H2	O	O
-	O	O
receptor	O	O
antagonist	O	O
used	O	O
in	O	O
inpatient	O	O
settings	O	O
for	O	O
prevention	O	O
of	O	O
stress	O	O
ulcers	B-Disease	D014456
and	O	O
is	O	O
showing	O	O
increasing	O	O
popularity	O	O
because	O	O
of	O	O
its	O	O
low	O	O
cost	O	O
.	O	O

Although	O	O
all	O	O
of	O	O
the	O	O
currently	O	O
available	O	O
H2	O	O
-	O	O
receptor	O	O
antagonists	O	O
have	O	O
shown	O	O
the	O	O
propensity	O	O
to	O	O
cause	O	O
delirium	B-Disease	D003693
,	O	O
only	O	O
two	O	O
previously	O	O
reported	O	O
cases	O	O
have	O	O
been	O	O
associated	O	O
with	O	O
famotidine	B-Chemical	D015738
.	O	O

The	O	O
authors	O	O
report	O	O
on	O	O
six	O	O
cases	O	O
of	O	O
famotidine	B-Chemical	D015738
-	O	O
associated	O	O
delirium	B-Disease	D003693
in	O	O
hospitalized	O	O
patients	O	O
who	O	O
cleared	O	O
completely	O	O
upon	O	O
removal	O	O
of	O	O
famotidine	B-Chemical	D015738
.	O	O

The	O	O
pharmacokinetics	O	O
of	O	O
famotidine	B-Chemical	D015738
are	O	O
reviewed	O	O
,	O	O
with	O	O
no	O	O
change	O	O
in	O	O
its	O	O
metabolism	O	O
in	O	O
the	O	O
elderly	O	O
population	O	O
seen	O	O
.	O	O

The	O	O
implications	O	O
of	O	O
using	O	O
famotidine	B-Chemical	D015738
in	O	O
elderly	O	O
persons	O	O
are	O	O
discussed	O	O
.	O	O

Indomethacin	B-Chemical	D007213
induced	O	O
hypotension	B-Disease	D007022
in	O	O
sodium	B-Chemical	D012964
and	O	O
volume	O	O
depleted	O	O
rats	O	O
.	O	O

After	O	O
a	O	O
single	O	O
oral	O	O
dose	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
indomethacin	B-Chemical	D007213
(	O	O
IDM	B-Chemical	D007213
)	O	O
to	O	O
sodium	B-Chemical	D012964
and	O	O
volume	O	O
depleted	O	O
rats	O	O
plasma	O	O
renin	O	O
activity	O	O
(	O	O
PRA	O	O
)	O	O
and	O	O
systolic	O	O
blood	O	O
pressure	O	O
fell	O	O
significantly	O	O
within	O	O
four	O	O
hours	O	O
.	O	O

In	O	O
sodium	B-Chemical	D012964
repleted	O	O
animals	O	O
indomethacin	B-Chemical	D007213
did	O	O
not	O	O
change	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
although	O	O
plasma	O	O
renin	O	O
activity	O	O
was	O	O
decreased	O	O
.	O	O

Thus	O	O
,	O	O
indomethacin	B-Chemical	D007213
by	O	O
inhibition	O	O
of	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
may	O	O
diminish	O	O
the	O	O
blood	O	O
pressure	O	O
maintaining	O	O
effect	O	O
of	O	O
the	O	O
stimulated	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000809
system	O	O
in	O	O
sodium	B-Chemical	D012964
and	O	O
volume	O	O
depletion	O	O
.	O	O

Late	O	O
-	O	O
onset	O	O
scleroderma	B-Disease	D007674
renal	I-Disease	D007674
crisis	I-Disease	D007674
induced	O	O
by	O	O
tacrolimus	B-Chemical	D016559
and	O	O
prednisolone	B-Chemical	D011239
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

Scleroderma	B-Disease	D007674
renal	I-Disease	D007674
crisis	I-Disease	D007674
(	O	O
SRC	B-Disease	D007674
)	O	O
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
systemic	B-Disease	D012595
sclerosis	I-Disease	D012595
(	O	O
SSc	B-Disease	D012595
)	O	O
but	O	O
can	O	O
be	O	O
severe	O	O
enough	O	O
to	O	O
require	O	O
temporary	O	O
or	O	O
permanent	O	O
renal	O	O
replacement	O	O
therapy	O	O
.	O	O

Moderate	O	O
to	O	O
high	O	O
dose	O	O
corticosteroid	B-Chemical	D000305
use	O	O
is	O	O
recognized	O	O
as	O	O
a	O	O
major	O	O
risk	O	O
factor	O	O
for	O	O
SRC	B-Disease	D007674
.	O	O

Furthermore	O	O
,	O	O
there	O	O
have	O	O
been	O	O
reports	O	O
of	O	O
thrombotic	B-Disease	D057049
microangiopathy	I-Disease	D057049
precipitated	O	O
by	O	O
cyclosporine	B-Chemical	D016572
in	O	O
patients	O	O
with	O	O
SSc	B-Disease	D012595
.	O	O

In	O	O
this	O	O
article	O	O
,	O	O
we	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
SRC	B-Disease	D007674
induced	O	O
by	O	O
tacrolimus	B-Chemical	D016559
and	O	O
corticosteroids	B-Chemical	D000305
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
work	O	O
is	O	O
to	O	O
call	O	O
attention	O	O
to	O	O
the	O	O
risk	O	O
of	O	O
tacrolimus	B-Chemical	D016559
use	O	O
in	O	O
patients	O	O
with	O	O
SSc	B-Disease	D012595
.	O	O

The	O	O
risk	O	O
and	O	O
associated	O	O
factors	O	O
of	O	O
methamphetamine	B-Chemical	D008694
psychosis	B-Disease	D011605
in	O	O
methamphetamine	B-Chemical	D008694
-	O	O
dependent	O	O
patients	O	O
in	O	O
Malaysia	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
risk	O	O
of	O	O
lifetime	O	O
and	O	O
current	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
in	O	O
patients	O	O
with	O	O
methamphetamine	B-Chemical	D008694
dependence	O	O
.	O	O

The	O	O
association	O	O
between	O	O
psychiatric	O	O
co	O	O
-	O	O
morbidity	O	O
and	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
was	O	O
also	O	O
studied	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
was	O	O
a	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
conducted	O	O
concurrently	O	O
at	O	O
a	O	O
teaching	O	O
hospital	O	O
and	O	O
a	O	O
drug	O	O
rehabilitation	O	O
center	O	O
in	O	O
Malaysia	O	O
.	O	O

Patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
methamphetamine	B-Chemical	D008694
based	O	O
on	O	O
DSM	O	O
-	O	O
IV	O	O
were	O	O
interviewed	O	O
using	O	O
the	O	O
Mini	O	O
International	O	O
Neuropsychiatric	O	O
Interview	O	O
(	O	O
M	O	O
.	O	O

I	O	O
.	O	O

N	O	O
.	O	O

I	O	O
.	O	O

)	O	O
for	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
and	O	O
other	O	O
Axis	O	O
I	O	O
psychiatric	B-Disease	D001523
disorders	I-Disease	D001523
.	O	O

The	O	O
information	O	O
on	O	O
sociodemographic	O	O
background	O	O
and	O	O
drug	O	O
use	O	O
history	O	O
was	O	O
obtained	O	O
from	O	O
interview	O	O
or	O	O
medical	O	O
records	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
292	O	O
subjects	O	O
,	O	O
47	O	O
.	O	O

9%	O	O
of	O	O
the	O	O
subjects	O	O
had	O	O
a	O	O
past	O	O
history	O	O
of	O	O
psychotic	B-Disease	D011605
symptoms	I-Disease	D011605
and	O	O
13	O	O
.	O	O

0%	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
having	O	O
current	O	O
psychotic	B-Disease	D011605
symptoms	I-Disease	D011605
.	O	O

Co	O	O
-	O	O
morbid	O	O
major	O	O
depressive	B-Disease	D003866
disorder	I-Disease	D003866
(	O	O
OR=7	O	O
.	O	O

18	O	O
,	O	O
95	O	O
CI=2	O	O
.	O	O

612	O	O
-	O	O
19	O	O
.	O	O

708	O	O
)	O	O
,	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
(	O	O
OR=13	O	O
.	O	O

807	O	O
,	O	O
95	O	O
CI=5	O	O
.	O	O

194	O	O
-	O	O
36	O	O
.	O	O

706	O	O
)	O	O
,	O	O
antisocial	B-Disease	D000987
personality	I-Disease	D000987
disorder	I-Disease	D000987
(	O	O
OR=12	O	O
.	O	O

619	O	O
,	O	O
95	O	O
CI=6	O	O
.	O	O

702	O	O
-	O	O
23	O	O
.	O	O

759	O	O
)	O	O
and	O	O
heavy	O	O
methamphetamine	B-Chemical	D008694
uses	O	O
were	O	O
significantly	O	O
associated	O	O
with	O	O
lifetime	O	O
methamphetamine	B-Chemical	D008694
-	O	O
induced	O	O
psychosis	B-Disease	D011605
after	O	O
adjusted	O	O
for	O	O
other	O	O
factors	O	O
.	O	O

Major	B-Disease	D003865
depressive	I-Disease	D003865
disorder	I-Disease	D003865
(	O	O
OR=2	O	O
.	O	O

870	O	O
,	O	O
CI=1	O	O
.	O	O

154	O	O
-	O	O
7	O	O
.	O	O

142	O	O
)	O	O
and	O	O
antisocial	B-Disease	D000987
personality	I-Disease	D000987
disorder	I-Disease	D000987
(	O	O
OR=3	O	O
.	O	O

299	O	O
,	O	O
95	O	O
CI=1	O	O
.	O	O

375	O	O
-	O	O
7	O	O
.	O	O

914	O	O
)	O	O
were	O	O
the	O	O
only	O	O
factors	O	O
associated	O	O
with	O	O
current	O	O
psychosis	B-Disease	D011605
.	O	O

CONCLUSION	O	O
:	O	O
There	O	O
was	O	O
a	O	O
high	O	O
risk	O	O
of	O	O
psychosis	B-Disease	D011605
in	O	O
patients	O	O
with	O	O
methamphetamine	B-Chemical	D008694
dependence	O	O
.	O	O

It	O	O
was	O	O
associated	O	O
with	O	O
co	O	O
-	O	O
morbid	O	O
affective	B-Disease	D019964
disorder	I-Disease	D019964
,	O	O
antisocial	B-Disease	D000987
personality	I-Disease	D000987
,	O	O
and	O	O
heavy	O	O
methamphetamine	B-Chemical	D008694
use	O	O
.	O	O

It	O	O
is	O	O
recommended	O	O
that	O	O
all	O	O
cases	O	O
of	O	O
methamphetamine	B-Chemical	D008694
dependence	O	O
should	O	O
be	O	O
screened	O	O
for	O	O
psychotic	B-Disease	D011605
symptoms	I-Disease	D011605
.	O	O

Cerebellar	O	O
sensory	O	O
processing	O	O
alterations	O	O
impact	O	O
motor	O	O
cortical	O	O
plasticity	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
:	O	O
clues	O	O
from	O	O
dyskinetic	B-Disease	D004409
patients	O	O
.	O	O

The	O	O
plasticity	O	O
of	O	O
primary	O	O
motor	O	O
cortex	O	O
(	O	O
M1	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
and	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
(	O	O
LIDs	B-Disease	D004409
)	O	O
is	O	O
severely	O	O
impaired	O	O
.	O	O

We	O	O
recently	O	O
reported	O	O
in	O	O
young	O	O
healthy	O	O
subjects	O	O
that	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
enhanced	O	O
the	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
that	O	O
was	O	O
induced	O	O
by	O	O
paired	O	O
associative	O	O
stimulation	O	O
(	O	O
PAS	O	O
)	O	O
.	O	O

This	O	O
study	O	O
demonstrates	O	O
that	O	O
the	O	O
deficient	O	O
sensorimotor	O	O
M1	O	O
plasticity	O	O
in	O	O
16	O	O
patients	O	O
with	O	O
LIDs	B-Disease	D004409
could	O	O
be	O	O
reinstated	O	O
by	O	O
a	O	O
single	O	O
session	O	O
of	O	O
real	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
but	O	O
not	O	O
sham	O	O
stimulation	O	O
.	O	O

This	O	O
was	O	O
evident	O	O
only	O	O
when	O	O
a	O	O
sensory	O	O
component	O	O
was	O	O
involved	O	O
in	O	O
the	O	O
induction	O	O
of	O	O
plasticity	O	O
,	O	O
indicating	O	O
that	O	O
cerebellar	O	O
sensory	O	O
processing	O	O
function	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
resurgence	O	O
of	O	O
M1	O	O
plasticity	O	O
.	O	O

The	O	O
benefit	O	O
of	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
on	O	O
LIDs	B-Disease	D004409
is	O	O
known	O	O
.	O	O

To	O	O
explore	O	O
whether	O	O
this	O	O
benefit	O	O
is	O	O
linked	O	O
to	O	O
the	O	O
restoration	O	O
of	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
,	O	O
we	O	O
conducted	O	O
an	O	O
additional	O	O
study	O	O
looking	O	O
at	O	O
changes	O	O
in	O	O
LIDs	B-Disease	D004409
and	O	O
PAS	O	O
-	O	O
induced	O	O
plasticity	O	O
after	O	O
10	O	O
sessions	O	O
of	O	O
either	O	O
bilateral	O	O
,	O	O
real	O	O
inhibitory	O	O
cerebellar	O	O
stimulation	O	O
or	O	O
sham	O	O
stimulation	O	O
.	O	O

Only	O	O
real	O	O
and	O	O
not	O	O
sham	O	O
stimulation	O	O
had	O	O
an	O	O
antidyskinetic	O	O
effect	O	O
and	O	O
it	O	O
was	O	O
paralleled	O	O
by	O	O
a	O	O
resurgence	O	O
in	O	O
the	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
alterations	O	O
in	O	O
cerebellar	O	O
sensory	O	O
processing	O	O
function	O	O
,	O	O
occurring	O	O
secondary	O	O
to	O	O
abnormal	O	O
basal	O	O
ganglia	O	O
signals	O	O
reaching	O	O
it	O	O
,	O	O
may	O	O
be	O	O
an	O	O
important	O	O
element	O	O
contributing	O	O
to	O	O
the	O	O
maladaptive	O	O
sensorimotor	O	O
plasticity	O	O
of	O	O
M1	O	O
and	O	O
the	O	O
emergence	O	O
of	O	O
abnormal	B-Disease	D004409
involuntary	I-Disease	D004409
movements	I-Disease	D004409
.	O	O

The	O	O
function	O	O
of	O	O
P2X3	O	O
receptor	O	O
and	O	O
NK1	O	O
receptor	O	O
antagonists	O	O
on	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
in	O	O
rats	O	O
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
purpose	O	O
of	O	O
the	O	O
study	O	O
is	O	O
to	O	O
explore	O	O
the	O	O
function	O	O
of	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
antagonists	O	O
on	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CYP	B-Chemical	D003520
)	O	O
-	O	O
induced	O	O
cystitis	B-Disease	D003556
in	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Sixty	O	O
female	O	O
Sprague	O	O
-	O	O
Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
rats	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
injected	O	O
with	O	O
0	O	O
.	O	O

9%	O	O
saline	O	O
(	O	O
4	O	O
ml	O	O
/	O	O
kg	O	O
)	O	O
;	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
model	O	O
group	O	O
were	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injected	O	O
with	O	O
CYP	B-Chemical	D003520
(	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
;	O	O
and	O	O
the	O	O
rats	O	O
in	O	O
the	O	O
intervention	O	O
group	O	O
were	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injected	O	O
with	O	O
CYP	B-Chemical	D003520
with	O	O
subsequently	O	O
perfusion	O	O
of	O	O
bladder	O	O
with	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors'	O	O
antagonists	O	O
,	O	O
Suramin	B-Chemical	D013498
and	O	O
GR	B-Chemical	C079014
82334	I-Chemical	C079014
.	O	O

Spontaneous	O	O
pain	B-Disease	D010146
behaviors	O	O
following	O	O
the	O	O
administration	O	O
of	O	O
CYP	B-Chemical	D003520
were	O	O
observed	O	O
.	O	O

Urodynamic	O	O
parameters	O	O
,	O	O
bladder	O	O
pressure	O	O
-	O	O
volume	O	O
curve	O	O
,	O	O
maximum	O	O
voiding	O	O
pressure	O	O
(	O	O
MVP	O	O
)	O	O
,	O	O
and	O	O
maximum	O	O
cystometric	O	O
capacity	O	O
(	O	O
MCC	O	O
)	O	O
,	O	O
were	O	O
recorded	O	O
.	O	O

Pathological	O	O
changes	O	O
in	O	O
bladder	O	O
tissue	O	O
were	O	O
observed	O	O
.	O	O

Immunofluorescence	O	O
was	O	O
used	O	O
to	O	O
detect	O	O
the	O	O
expression	O	O
of	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
in	O	O
bladder	O	O
.	O	O

RESULTS	O	O
:	O	O
Cyclophosphamide	B-Chemical	D003520
treatment	O	O
increased	O	O
the	O	O
spontaneous	O	O
pain	B-Disease	D010146
behaviors	O	O
scores	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
bladder	O	O
instability	O	O
during	O	O
urine	O	O
storage	O	O
period	O	O
of	O	O
model	O	O
group	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
intervention	O	O
group	O	O
(	O	O
X	O	O
(	O	O
2	O	O
)	O	O
=	O	O
7	O	O
.	O	O

619	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

007	O	O
)	O	O
and	O	O
control	O	O
group	O	O
(	O	O
X	O	O
(	O	O
2	O	O
)	O	O
=	O	O
13	O	O
.	O	O

755	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

000	O	O
)	O	O
.	O	O

MCC	O	O
in	O	O
the	O	O
model	O	O
group	O	O
was	O	O
lower	O	O
than	O	O
the	O	O
control	O	O
and	O	O
intervention	O	O
groups	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Histological	O	O
changes	O	O
evident	O	O
in	O	O
model	O	O
and	O	O
intervention	O	O
groups	O	O
rats'	O	O
bladder	O	O
included	O	O
edema	B-Disease	D004487
,	O	O
vasodilation	O	O
,	O	O
and	O	O
infiltration	O	O
of	O	O
inflammatory	O	O
cells	O	O
.	O	O

In	O	O
model	O	O
group	O	O
,	O	O
the	O	O
expression	O	O
of	O	O
P2X3	O	O
receptor	O	O
increased	O	O
in	O	O
urothelium	O	O
and	O	O
suburothelium	O	O
,	O	O
and	O	O
NK1	O	O
receptor	O	O
increased	O	O
in	O	O
suburothelium	O	O
,	O	O
while	O	O
the	O	O
expression	O	O
of	O	O
them	O	O
in	O	O
intervention	O	O
group	O	O
was	O	O
lower	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
CYP	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
,	O	O
the	O	O
expression	O	O
of	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
increased	O	O
in	O	O
urothelium	O	O
and	O	O
/	O	O
or	O	O
suburothelium	O	O
.	O	O

Perfusion	O	O
of	O	O
bladder	O	O
with	O	O
P2X3	O	O
and	O	O
NK1	O	O
receptors	O	O
antagonists	O	O
ameliorated	O	O
the	O	O
bladder	O	O
function	O	O
.	O	O

Acute	O	O
hepatitis	B-Disease	D056486
associated	O	O
with	O	O
clopidogrel	B-Chemical	C055162
:	O	O
a	O	O
case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

Drug	O	O
-	O	O
induced	O	O
hepatotoxicity	B-Disease	D056486
is	O	O
a	O	O
common	O	O
cause	O	O
of	O	O
acute	O	O
hepatitis	B-Disease	D056486
,	O	O
and	O	O
the	O	O
recognition	O	O
of	O	O
the	O	O
responsible	O	O
drug	O	O
may	O	O
be	O	O
difficult	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
clopidogrel	B-Chemical	C055162
-	O	O
related	O	O
acute	O	O
hepatitis	B-Disease	D056486
.	O	O

The	O	O
diagnosis	O	O
is	O	O
strongly	O	O
suggested	O	O
by	O	O
an	O	O
accurate	O	O
medical	O	O
history	O	O
and	O	O
liver	O	O
biopsy	O	O
.	O	O

Reports	O	O
about	O	O
cases	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
due	O	O
to	O	O
clopidogrel	B-Chemical	C055162
are	O	O
increasing	O	O
in	O	O
the	O	O
last	O	O
few	O	O
years	O	O
,	O	O
after	O	O
the	O	O
increased	O	O
use	O	O
of	O	O
this	O	O
drug	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
we	O	O
believe	O	O
that	O	O
physicians	O	O
should	O	O
carefully	O	O
consider	O	O
the	O	O
risk	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
when	O	O
clopidogrel	B-Chemical	C055162
is	O	O
prescribed	O	O
.	O	O

Bortezomib	B-Chemical	C400082
and	O	O
dexamethasone	B-Chemical	D003907
as	O	O
salvage	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
:	O	O
analysis	O	O
of	O	O
long	O	O
-	O	O
term	O	O
clinical	O	O
outcomes	O	O
.	O	O

Bortezomib	B-Chemical	C400082
(	O	O
bort	B-Chemical	C400082
)	O	O
-	O	O
dexamethasone	B-Chemical	D003907
(	O	O
dex	B-Chemical	D003907
)	O	O
is	O	O
an	O	O
effective	O	O
therapy	O	O
for	O	O
relapsed	O	O
/	O	O
refractory	O	O
(	O	O
R	O	O
/	O	O
R	O	O
)	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
(	O	O
MM	B-Disease	D009101
)	O	O
.	O	O

This	O	O
retrospective	O	O
study	O	O
investigated	O	O
the	O	O
combination	O	O
of	O	O
bort	B-Chemical	C400082
(	O	O
1	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
4	O	O
,	O	O
8	O	O
,	O	O
and	O	O
11	O	O
every	O	O
3	O	O
weeks	O	O
)	O	O
and	O	O
dex	B-Chemical	D003907
(	O	O
20	O	O
mg	O	O
on	O	O
the	O	O
day	O	O
of	O	O
and	O	O
the	O	O
day	O	O
after	O	O
bort	B-Chemical	C400082
)	O	O
as	O	O
salvage	O	O
treatment	O	O
in	O	O
85	O	O
patients	O	O
with	O	O
R	O	O
/	O	O
R	O	O
MM	B-Disease	D009101
after	O	O
prior	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
or	O	O
conventional	O	O
chemotherapy	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
lines	O	O
of	O	O
therapy	O	O
was	O	O
2	O	O
.	O	O

Eighty	O	O
-	O	O
seven	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
received	O	O
immunomodulatory	O	O
drugs	O	O
included	O	O
in	O	O
some	O	O
line	O	O
of	O	O
therapy	O	O
before	O	O
bort	B-Chemical	C400082
-	O	O
dex	B-Chemical	D003907
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
bort	B-Chemical	C400082
-	O	O
dex	B-Chemical	D003907
cycles	O	O
was	O	O
6	O	O
,	O	O
up	O	O
to	O	O
a	O	O
maximum	O	O
of	O	O
12	O	O
cycles	O	O
.	O	O

On	O	O
an	O	O
intention	O	O
-	O	O
to	O	O
-	O	O
treat	O	O
basis	O	O
,	O	O
55	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
achieved	O	O
at	O	O
least	O	O
partial	O	O
response	O	O
,	O	O
including	O	O
19	O	O
%	O	O
CR	O	O
and	O	O
35	O	O
%	O	O
achieved	O	O
at	O	O
least	O	O
very	O	O
good	O	O
partial	O	O
response	O	O
.	O	O

Median	O	O
durations	O	O
of	O	O
response	O	O
,	O	O
time	O	O
to	O	O
next	O	O
therapy	O	O
and	O	O
treatment	O	O
-	O	O
free	O	O
interval	O	O
were	O	O
8	O	O
,	O	O
11	O	O
.	O	O

2	O	O
,	O	O
and	O	O
5	O	O
.	O	O

1	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
most	O	O
relevant	O	O
adverse	O	O
event	O	O
was	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
,	O	O
which	O	O
occurred	O	O
in	O	O
78	O	O
%	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
grade	O	O
II	O	O
,	O	O
38	O	O
%	O	O
;	O	O
grade	O	O
III	O	O
,	O	O
21	O	O
%	O	O
)	O	O
and	O	O
led	O	O
to	O	O
treatment	O	O
discontinuation	O	O
in	O	O
6	O	O
%	O	O
.	O	O

With	O	O
a	O	O
median	O	O
follow	O	O
up	O	O
of	O	O
22	O	O
months	O	O
,	O	O
median	O	O
time	O	O
to	O	O
progression	O	O
,	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
(	O	O
PFS	O	O
)	O	O
and	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
were	O	O
8	O	O
.	O	O

9	O	O
,	O	O
8	O	O
.	O	O

7	O	O
,	O	O
and	O	O
22	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

Prolonged	O	O
PFS	O	O
and	O	O
OS	O	O
were	O	O
observed	O	O
in	O	O
patients	O	O
achieving	O	O
CR	O	O
and	O	O
receiving	O	O
bort	B-Chemical	C400082
-	O	O
dex	B-Chemical	D003907
a	O	O
single	O	O
line	O	O
of	O	O
prior	O	O
therapy	O	O
.	O	O

Bort	B-Chemical	C400082
-	O	O
dex	B-Chemical	D003907
was	O	O
an	O	O
effective	O	O
salvage	O	O
treatment	O	O
for	O	O
MM	B-Disease	D009101
patients	O	O
,	O	O
particularly	O	O
for	O	O
those	O	O
in	O	O
first	O	O
relapse	O	O
.	O	O

Pubertal	O	O
exposure	O	O
to	O	O
Bisphenol	B-Chemical	C006780
A	I-Chemical	C006780
increases	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behavior	O	O
and	O	O
decreases	O	O
acetylcholinesterase	O	O
activity	O	O
of	O	O
hippocampus	O	O
in	O	O
adult	O	O
male	O	O
mice	O	O
.	O	O

The	O	O
negative	O	O
effects	O	O
of	O	O
Bisphenol	B-Chemical	C006780
A	I-Chemical	C006780
(	O	O
BPA	B-Chemical	C006780
)	O	O
on	O	O
neurodevelopment	O	O
and	O	O
behaviors	O	O
have	O	O
been	O	O
well	O	O
established	O	O
.	O	O

Acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
is	O	O
a	O	O
regulatory	O	O
enzyme	O	O
which	O	O
is	O	O
involved	O	O
in	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behavior	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
behavioral	O	O
phenotypes	O	O
and	O	O
AChE	O	O
activity	O	O
in	O	O
male	O	O
mice	O	O
following	O	O
BPA	B-Chemical	C006780
exposure	O	O
during	O	O
puberty	O	O
.	O	O

On	O	O
postnatal	O	O
day	O	O
(	O	O
PND	O	O
)	O	O
35	O	O
,	O	O
male	O	O
mice	O	O
were	O	O
exposed	O	O
to	O	O
50mg	O	O
BPA	B-Chemical	C006780
/	O	O
kg	O	O
diet	O	O
per	O	O
day	O	O
for	O	O
a	O	O
period	O	O
of	O	O
35	O	O
days	O	O
.	O	O

On	O	O
PND71	O	O
,	O	O
a	O	O
behavioral	O	O
assay	O	O
was	O	O
performed	O	O
using	O	O
the	O	O
elevated	O	O
plus	O	O
maze	O	O
(	O	O
EPM	O	O
)	O	O
and	O	O
the	O	O
light	O	O
/	O	O
dark	O	O
test	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
AChE	O	O
activity	O	O
was	O	O
measured	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
,	O	O
cerebellum	O	O
and	O	O
hippocampus	O	O
.	O	O

Results	O	O
from	O	O
our	O	O
behavioral	O	O
phenotyping	O	O
indicated	O	O
that	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behavior	O	O
was	O	O
increased	O	O
in	O	O
mice	O	O
exposed	O	O
to	O	O
BPA	B-Chemical	C006780
.	O	O

AChE	O	O
activity	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
the	O	O
hippocampus	O	O
of	O	O
mice	O	O
with	O	O
BPA	B-Chemical	C006780
compared	O	O
to	O	O
control	O	O
mice	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
found	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hypothalamus	O	O
and	O	O
cerebellum	O	O
.	O	O

Our	O	O
findings	O	O
showed	O	O
that	O	O
pubertal	O	O
BPA	B-Chemical	C006780
exposure	O	O
increased	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behavior	O	O
,	O	O
which	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
decreased	O	O
AChE	O	O
activity	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
adult	O	O
male	O	O
mice	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
necessary	O	O
to	O	O
investigate	O	O
the	O	O
cholinergic	O	O
signaling	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
PBE	O	O
induced	O	O
anxiety	B-Disease	D001008
-	O	O
like	O	O
behaviors	O	O
.	O	O

Biochemical	O	O
effects	O	O
of	O	O
Solidago	O	O
virgaurea	O	O
extract	O	O
on	O	O
experimental	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Cardiovascular	B-Disease	D002318
diseases	I-Disease	D002318
(	O	O
CVDs	B-Disease	D002318
)	O	O
are	O	O
the	O	O
major	O	O
health	O	O
problem	O	O
of	O	O
advanced	O	O
as	O	O
well	O	O
as	O	O
developing	O	O
countries	O	O
of	O	O
the	O	O
world	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
the	O	O
Solidago	O	O
virgaurea	O	O
extract	O	O
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
rats	O	O
.	O	O

The	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-Chemical	D007545
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
into	O	O
rats	O	O
twice	O	O
at	O	O
an	O	O
interval	O	O
of	O	O
24	O	O
h	O	O
,	O	O
for	O	O
two	O	O
consecutive	O	O
days	O	O
,	O	O
led	O	O
to	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
serum	O	O
lactate	B-Chemical	D019344
dehydrogenase	O	O
,	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
,	O	O
alanine	B-Chemical	D000409
transaminase	O	O
,	O	O
aspartate	B-Chemical	D001224
transaminase	O	O
,	O	O
and	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
activities	O	O
,	O	O
total	O	O
cholesterol	B-Chemical	D002784
,	O	O
triglycerides	B-Chemical	D014280
,	O	O
free	O	O
serum	O	O
fatty	B-Chemical	D005227
acid	I-Chemical	D005227
,	O	O
cardiac	O	O
tissue	O	O
malondialdehyde	B-Chemical	D008315
(	O	O
MDA	B-Chemical	D008315
)	O	O
,	O	O
and	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
levels	O	O
and	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
levels	O	O
of	O	O
glutathione	B-Chemical	D005978
and	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
in	O	O
cardiac	O	O
tissue	O	O
as	O	O
compared	O	O
to	O	O
the	O	O
normal	O	O
control	O	O
group	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Pretreatment	O	O
with	O	O
S	O	O
.	O	O

virgaurea	O	O
extract	O	O
for	O	O
5	O	O
weeks	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
250	O	O
mg	O	O
/	O	O
kg	O	O
followed	O	O
by	O	O
isoproterenol	B-Chemical	D007545
injection	O	O
significantly	O	O
prevented	O	O
the	O	O
observed	O	O
alterations	O	O
.	O	O

Captopril	B-Chemical	D002216
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
,	O	O
given	O	O
orally	O	O
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
used	O	O
as	O	O
a	O	O
standard	O	O
cardioprotective	O	O
drug	O	O
,	O	O
was	O	O
used	O	O
as	O	O
a	O	O
positive	O	O
control	O	O
in	O	O
this	O	O
study	O	O
.	O	O

The	O	O
data	O	O
of	O	O
the	O	O
present	O	O
study	O	O
suggest	O	O
that	O	O
S	O	O
.	O	O

virgaurea	O	O
extract	O	O
exerts	O	O
its	O	O
protective	O	O
effect	O	O
by	O	O
decreasing	O	O
MDA	B-Chemical	D008315
level	O	O
and	O	O
increasing	O	O
the	O	O
antioxidant	O	O
status	O	O
in	O	O
isoproterenol	B-Chemical	D007545
-	O	O
treated	O	O
rats	O	O
.	O	O

The	O	O
study	O	O
emphasizes	O	O
the	O	O
beneficial	O	O
action	O	O
of	O	O
S	O	O
.	O	O

virgaurea	O	O
extract	O	O
as	O	O
a	O	O
cardioprotective	O	O
agent	O	O
.	O	O

"Real	O	O
-	O	O
world"	O	O
data	O	O
on	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
lenalidomide	B-Chemical	C467567
and	O	O
dexamethasone	B-Chemical	D003907
in	O	O
patients	O	O
with	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
who	O	O
were	O	O
treated	O	O
according	O	O
to	O	O
the	O	O
standard	O	O
clinical	O	O
practice	O	O
:	O	O
a	O	O
study	O	O
of	O	O
the	O	O
Greek	O	O
Myeloma	B-Disease	D009101
Study	O	O
Group	O	O
.	O	O

Lenalidomide	B-Chemical	C467567
and	O	O
dexamethasone	B-Chemical	D003907
(	O	O
RD	B-Chemical	C467567
)	O	O
is	O	O
a	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
relapsed	O	O
/	O	O
refractory	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
(	O	O
RRMM	B-Disease	D009101
)	O	O
,	O	O
but	O	O
there	O	O
is	O	O
limited	O	O
published	O	O
data	O	O
on	O	O
its	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
the	O	O
"real	O	O
world"	O	O
(	O	O
RW	O	O
)	O	O
,	O	O
according	O	O
to	O	O
the	O	O
International	O	O
Society	O	O
of	O	O
Pharmacoeconomics	O	O
and	O	O
Outcomes	O	O
Research	O	O
definition	O	O
.	O	O

We	O	O
studied	O	O
212	O	O
RRMM	B-Disease	D009101
patients	O	O
who	O	O
received	O	O
RD	B-Chemical	C467567
in	O	O
RW	O	O
.	O	O

Objective	O	O
response	O	O
(	O	O
>PR	O	O
(	O	O
partial	O	O
response	O	O
)	O	O
)	O	O
rate	O	O
was	O	O
77	O	O
.	O	O

4	O	O
%	O	O
(	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
,	O	O
20	O	O
.	O	O

2	O	O
%	O	O
)	O	O
.	O	O

Median	O	O
time	O	O
to	O	O
first	O	O
and	O	O
best	O	O
response	O	O
was	O	O
2	O	O
and	O	O
5	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

Median	O	O
time	O	O
to	O	O
CR	O	O
when	O	O
RD	B-Chemical	C467567
was	O	O
given	O	O
as	O	O
2nd	O	O
or	O	O
>2	O	O
(	O	O
nd	O	O
)	O	O
-	O	O
line	O	O
treatment	O	O
at	O	O
4	O	O
and	O	O
11	O	O
months	O	O
,	O	O
respectively	O	O
.	O	O

Quality	O	O
of	O	O
response	O	O
was	O	O
independent	O	O
of	O	O
previous	O	O
lines	O	O
of	O	O
therapies	O	O
or	O	O
previous	O	O
exposure	O	O
to	O	O
thalidomide	B-Chemical	D013792
or	O	O
bortezomib	B-Chemical	C400082
.	O	O

Median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
34	O	O
.	O	O

4	O	O
months	O	O
,	O	O
and	O	O
it	O	O
was	O	O
higher	O	O
in	O	O
patients	O	O
who	O	O
received	O	O
RD	B-Chemical	C467567
until	O	O
progression	O	O
(	O	O
not	O	O
reached	O	O
versus	O	O
19	O	O
months	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Improvement	O	O
of	O	O
humoral	O	O
immunity	O	O
occurred	O	O
in	O	O
60	O	O
%	O	O
of	O	O
responders	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
in	O	O
the	O	O
majority	O	O
of	O	O
patients	O	O
who	O	O
achieved	O	O
stable	O	O
disease	O	O
.	O	O

Adverse	O	O
events	O	O
were	O	O
reported	O	O
in	O	O
68	O	O
.	O	O

9	O	O
%	O	O
of	O	O
patients	O	O
(	O	O
myelosuppression	B-Disease	D001855
in	O	O
49	O	O
.	O	O

4	O	O
%	O	O
)	O	O
and	O	O
12	O	O
.	O	O

7	O	O
%	O	O
of	O	O
patients	O	O
needed	O	O
hospitalization	O	O
.	O	O

Peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
observed	O	O
only	O	O
in	O	O
2	O	O
.	O	O

5	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
deep	B-Disease	D020246
vein	I-Disease	D020246
thrombosis	I-Disease	D020246
in	O	O
5	O	O
.	O	O

7	O	O
%	O	O
.	O	O

Dose	O	O
reductions	O	O
were	O	O
needed	O	O
in	O	O
31	O	O
%	O	O
of	O	O
patients	O	O
and	O	O
permanent	O	O
discontinuation	O	O
in	O	O
38	O	O
.	O	O

9	O	O
%	O	O
.	O	O

Median	O	O
time	O	O
to	O	O
treatment	O	O
discontinuation	O	O
was	O	O
16	O	O
.	O	O

8	O	O
months	O	O
.	O	O

Performance	O	O
status	O	O
(	O	O
PS	O	O
)	O	O
and	O	O
initial	O	O
lenalidomide	B-Chemical	C467567
dose	O	O
predicted	O	O
for	O	O
treatment	O	O
discontinuation	O	O
.	O	O

Extra	O	O
-	O	O
medullary	O	O
relapses	O	O
occurred	O	O
in	O	O
3	O	O
.	O	O

8	O	O
%	O	O
of	O	O
patients	O	O
.	O	O

Our	O	O
study	O	O
confirms	O	O
that	O	O
RD	B-Chemical	C467567
is	O	O
effective	O	O
and	O	O
safe	O	O
in	O	O
RRMM	B-Disease	D009101
in	O	O
the	O	O
RW	O	O
;	O	O
it	O	O
produces	O	O
durable	O	O
responses	O	O
especially	O	O
in	O	O
patients	O	O
who	O	O
continue	O	O
on	O	O
treatment	O	O
till	O	O
progression	O	O
and	O	O
improves	O	O
humoral	O	O
immunity	O	O
even	O	O
in	O	O
patients	O	O
with	O	O
stable	O	O
disease	O	O
.	O	O

The	O	O
cytogenetic	O	O
action	O	O
of	O	O
ifosfamide	B-Chemical	D007069
,	O	O
mesna	B-Chemical	D015080
,	O	O
and	O	O
their	O	O
combination	O	O
on	O	O
peripheral	O	O
rabbit	O	O
lymphocytes	O	O
:	O	O
an	O	O
in	O	O
vivo	O	O
/	O	O
in	O	O
vitro	O	O
cytogenetic	O	O
study	O	O
.	O	O

Ifosfamide	B-Chemical	D007069
(	O	O
IFO	B-Chemical	D007069
)	O	O
is	O	O
an	O	O
alkylating	O	O
nitrogen	B-Chemical	D009584
mustard	O	O
,	O	O
administrated	O	O
as	O	O
an	O	O
antineoplasmic	O	O
agent	O	O
.	O	O

It	O	O
is	O	O
characterized	O	O
by	O	O
its	O	O
intense	O	O
urotoxic	O	O
action	O	O
,	O	O
leading	O	O
to	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

This	O	O
side	O	O
effect	O	O
of	O	O
IFO	B-Chemical	D007069
raises	O	O
the	O	O
requirement	O	O
for	O	O
the	O	O
co	O	O
-	O	O
administration	O	O
with	O	O
sodium	B-Chemical	D015080
2	I-Chemical	D015080
-	I-Chemical	D015080
sulfanylethanesulfonate	I-Chemical	D015080
(	O	O
Mesna	B-Chemical	D015080
)	O	O
aiming	O	O
to	O	O
avoid	O	O
or	O	O
minimize	O	O
this	O	O
effect	O	O
.	O	O

IFO	B-Chemical	D007069
and	O	O
Mesna	B-Chemical	D015080
were	O	O
administrated	O	O
separately	O	O
on	O	O
rabbit's	O	O
lymphocytes	O	O
in	O	O
vivo	O	O
,	O	O
which	O	O
were	O	O
later	O	O
developed	O	O
in	O	O
vitro	O	O
.	O	O

Cytogenetic	O	O
markers	O	O
for	O	O
sister	O	O
chromatid	O	O
exchanges	O	O
(	O	O
SCEs	O	O
)	O	O
,	O	O
proliferation	O	O
rate	O	O
index	O	O
(	O	O
PRI	O	O
)	O	O
and	O	O
Mitotic	O	O
Index	O	O
were	O	O
recorded	O	O
.	O	O

Mesna's	O	O
action	O	O
,	O	O
in	O	O
conjunction	O	O
with	O	O
IFO	B-Chemical	D007069
reduces	O	O
the	O	O
frequency	O	O
of	O	O
SCEs	O	O
,	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
SCEs	O	O
recordings	O	O
obtained	O	O
when	O	O
IFO	B-Chemical	D007069
is	O	O
administered	O	O
alone	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
this	O	O
,	O	O
when	O	O
high	O	O
concentrations	O	O
of	O	O
Mesna	B-Chemical	D015080
were	O	O
administered	O	O
alone	O	O
significant	O	O
reductions	O	O
of	O	O
the	O	O
PRI	O	O
were	O	O
noted	O	O
,	O	O
than	O	O
with	O	O
IFO	B-Chemical	D007069
acting	O	O
at	O	O
the	O	O
same	O	O
concentration	O	O
on	O	O
the	O	O
lymphocytes	O	O
.	O	O

Mesna	B-Chemical	D015080
significantly	O	O
reduces	O	O
IFO's	O	O
genotoxicity	B-Disease	D030342
,	O	O
while	O	O
when	O	O
administered	O	O
in	O	O
high	O	O
concentrations	O	O
it	O	O
acts	O	O
in	O	O
an	O	O
inhibitory	O	O
fashion	O	O
on	O	O
the	O	O
cytostatic	O	O
action	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

Risk	O	O
factors	O	O
and	O	O
predictors	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
among	O	O
multiethnic	O	O
Malaysians	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Chronic	O	O
pulsatile	O	O
levodopa	B-Chemical	D007980
therapy	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
leads	O	O
to	O	O
the	O	O
development	O	O
of	O	O
motor	O	O
fluctuations	O	O
and	O	O
dyskinesia	B-Disease	D004409
.	O	O

We	O	O
studied	O	O
the	O	O
prevalence	O	O
and	O	O
predictors	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
among	O	O
multiethnic	O	O
Malaysian	O	O
patients	O	O
with	O	O
PD	B-Disease	D010300
.	O	O

METHODS	O	O
:	O	O
This	O	O
is	O	O
a	O	O
cross	O	O
-	O	O
sectional	O	O
study	O	O
involving	O	O
95	O	O
patients	O	O
with	O	O
PD	B-Disease	D010300
on	O	O
uninterrupted	O	O
levodopa	B-Chemical	D007980
therapy	O	O
for	O	O
at	O	O
least	O	O
6	O	O
months	O	O
.	O	O

The	O	O
instrument	O	O
used	O	O
was	O	O
the	O	O
UPDRS	O	O
questionnaires	O	O
.	O	O

The	O	O
predictors	O	O
of	O	O
dyskinesia	B-Disease	D004409
were	O	O
determined	O	O
using	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
mean	O	O
age	O	O
was	O	O
65	O	O
.	O	O

6	O	O
+	O	O
8	O	O
.	O	O

5	O	O
years	O	O
.	O	O

The	O	O
mean	O	O
onset	O	O
age	O	O
was	O	O
58	O	O
.	O	O

5	O	O
+	O	O
9	O	O
.	O	O

8	O	O
years	O	O
.	O	O

The	O	O
median	O	O
disease	O	O
duration	O	O
was	O	O
6	O	O
(	O	O
7	O	O
)	O	O
years	O	O
.	O	O

Dyskinesia	B-Disease	D004409
was	O	O
present	O	O
in	O	O
44%	O	O
(	O	O
n	O	O
=	O	O
42	O	O
)	O	O
with	O	O
median	O	O
levodopa	B-Chemical	D007980
therapy	O	O
of	O	O
3	O	O
years	O	O
.	O	O

There	O	O
were	O	O
64	O	O
.	O	O

3%	O	O
Chinese	O	O
,	O	O
31%	O	O
Malays	O	O
,	O	O
and	O	O
3	O	O
.	O	O

7%	O	O
Indians	O	O
and	O	O
other	O	O
ethnic	O	O
groups	O	O
.	O	O

Eighty	O	O
-	O	O
one	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
dyskinesia	B-Disease	D004409
had	O	O
clinical	O	O
fluctuations	O	O
.	O	O

Patients	O	O
with	O	O
dyskinesia	B-Disease	D004409
had	O	O
lower	O	O
onset	O	O
age	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
longer	O	O
duration	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
longer	O	O
disease	O	O
duration	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
higher	O	O
total	O	O
daily	O	O
levodopa	B-Chemical	D007980
dose	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
higher	O	O
total	O	O
UPDRS	O	O
scores	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

005	O	O
)	O	O
than	O	O
patients	O	O
without	O	O
dyskinesia	B-Disease	D004409
.	O	O

The	O	O
three	O	O
significant	O	O
predictors	O	O
of	O	O
dyskinesia	B-Disease	D004409
were	O	O
duration	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
,	O	O
onset	O	O
age	O	O
,	O	O
and	O	O
total	O	O
daily	O	O
levodopa	B-Chemical	D007980
dose	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
prevalence	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
in	O	O
our	O	O
patients	O	O
was	O	O
44%	O	O
.	O	O

The	O	O
most	O	O
significant	O	O
predictors	O	O
were	O	O
duration	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
,	O	O
total	O	O
daily	O	O
levodopa	B-Chemical	D007980
dose	O	O
,	O	O
and	O	O
onset	O	O
age	O	O
.	O	O

An	O	O
unexpected	O	O
diagnosis	O	O
in	O	O
a	O	O
renal	O	O
-	O	O
transplant	O	O
patient	O	O
with	O	O
proteinuria	B-Disease	D011507
treated	O	O
with	O	O
everolimus	B-Chemical	C107135
:	O	O
AL	B-Disease	D000686
amyloidosis	B-Disease	D000686
.	O	O

Proteinuria	B-Disease	D011507
is	O	O
an	O	O
expected	O	O
complication	O	O
in	O	O
transplant	O	O
patients	O	O
treated	O	O
with	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-Chemical	D020123
inhibitors	O	O
(	O	O
mTOR	O	O
-	O	O
i	O	O
)	O	O
.	O	O

However	O	O
,	O	O
clinical	O	O
suspicion	O	O
should	O	O
always	O	O
be	O	O
supported	O	O
by	O	O
histological	O	O
evidence	O	O
in	O	O
order	O	O
to	O	O
investigate	O	O
potential	O	O
alternate	O	O
diagnoses	O	O
such	O	O
as	O	O
acute	O	O
or	O	O
chronic	O	O
rejection	O	O
,	O	O
interstitial	O	O
fibrosis	B-Disease	D005355
and	O	O
tubular	O	O
atrophy	B-Disease	D001284
,	O	O
or	O	O
recurrent	O	O
or	O	O
de	O	O
novo	O	O
glomerulopathy	B-Disease	D007674
.	O	O

In	O	O
this	O	O
case	O	O
we	O	O
report	O	O
the	O	O
unexpected	O	O
diagnosis	O	O
of	O	O
amyloidosis	B-Disease	D000686
in	O	O
a	O	O
renal	O	O
-	O	O
transplant	O	O
patient	O	O
with	O	O
pre	O	O
-	O	O
transplant	O	O
monoclonal	O	O
gammapathy	O	O
of	O	O
undetermined	O	O
significance	O	O
who	O	O
developed	O	O
proteinuria	B-Disease	D011507
after	O	O
conversion	O	O
from	O	O
tacrolimus	B-Chemical	D016559
to	O	O
everolimus	B-Chemical	C107135
.	O	O

An	O	O
investigation	O	O
of	O	O
the	O	O
pattern	O	O
of	O	O
kidney	B-Disease	D007674
injury	I-Disease	D007674
in	O	O
HIV	O	O
-	O	O
positive	O	O
persons	O	O
exposed	O	O
to	O	O
tenofovir	B-Chemical	C418563
disoproxil	I-Chemical	C418563
fumarate	I-Chemical	C418563
:	O	O
an	O	O
examination	O	O
of	O	O
a	O	O
large	O	O
population	O	O
database	O	O
(	O	O
MHRA	O	O
database	O	O
)	O	O
.	O	O

The	O	O
potential	O	O
for	O	O
tenofovir	B-Chemical	C096918
to	O	O
cause	O	O
a	O	O
range	O	O
of	O	O
kidney	O	O
syndromes	O	O
has	O	O
been	O	O
established	O	O
from	O	O
mechanistic	O	O
and	O	O
randomised	O	O
clinical	O	O
trials	O	O
.	O	O

However	O	O
,	O	O
the	O	O
exact	O	O
pattern	O	O
of	O	O
kidney	O	O
involvement	O	O
is	O	O
still	O	O
uncertain	O	O
.	O	O

We	O	O
undertook	O	O
a	O	O
descriptive	O	O
analysis	O	O
of	O	O
Yellow	O	O
Card	O	O
records	O	O
of	O	O
407	O	O
HIV	O	O
-	O	O
positive	O	O
persons	O	O
taking	O	O
tenofovir	B-Chemical	C418563
disoproxil	I-Chemical	C418563
fumarate	I-Chemical	C418563
(	O	O
TDF	B-Chemical	C418563
)	O	O
as	O	O
part	O	O
of	O	O
their	O	O
antiretroviral	O	O
therapy	O	O
regimen	O	O
and	O	O
submitted	O	O
to	O	O
the	O	O
Medicines	O	O
and	O	O
Healthcare	O	O
Products	O	O
Regulatory	O	O
Agency	O	O
(	O	O
MHRA	O	O
)	O	O
with	O	O
suspected	O	O
kidney	O	O
adverse	O	O
effects	O	O
.	O	O

Reports	O	O
that	O	O
satisfy	O	O
defined	O	O
criteria	O	O
were	O	O
classified	O	O
as	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
,	O	O
kidney	B-Disease	D007674
tubular	I-Disease	D007674
dysfunction	I-Disease	D007674
and	O	O
Fanconi	B-Disease	D005198
syndrome	I-Disease	D005198
.	O	O

Of	O	O
the	O	O
407	O	O
Yellow	O	O
Card	O	O
records	O	O
analysed	O	O
,	O	O
106	O	O
satisfied	O	O
criteria	O	O
for	O	O
TDF	B-Chemical	C418563
-	O	O
related	O	O
kidney	B-Disease	D007674
disease	I-Disease	D007674
,	O	O
of	O	O
which	O	O
53	O	O
(	O	O
50%	O	O
)	O	O
had	O	O
features	O	O
of	O	O
kidney	B-Disease	D007674
tubular	I-Disease	D007674
dysfunction	I-Disease	D007674
,	O	O
35	O	O
(	O	O
33%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
features	O	O
of	O	O
glomerular	B-Disease	D007674
dysfunction	I-Disease	D007674
and	O	O
18	O	O
(	O	O
17%	O	O
)	O	O
had	O	O
Fanconi	B-Disease	D005198
syndrome	I-Disease	D005198
.	O	O

The	O	O
median	O	O
TDF	B-Chemical	C418563
exposure	O	O
was	O	O
316	O	O
days	O	O
(	O	O
interquartile	O	O
range	O	O
120	O	O
-	O	O
740	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
hospitalisation	O	O
for	O	O
TDF	B-Chemical	C418563
kidney	O	O
adverse	O	O
effects	O	O
was	O	O
high	O	O
,	O	O
particularly	O	O
amongst	O	O
patients	O	O
with	O	O
features	O	O
of	O	O
Fanconi	B-Disease	D005198
syndrome	I-Disease	D005198
.	O	O

The	O	O
pattern	O	O
of	O	O
kidney	O	O
syndromes	O	O
in	O	O
this	O	O
population	O	O
series	O	O
mirrors	O	O
that	O	O
reported	O	O
in	O	O
randomised	O	O
clinical	O	O
trials	O	O
.	O	O

Cessation	O	O
of	O	O
TDF	B-Chemical	C418563
was	O	O
associated	O	O
with	O	O
complete	O	O
restoration	O	O
of	O	O
kidney	O	O
function	O	O
in	O	O
up	O	O
half	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
this	O	O
report	O	O
.	O	O

Incidence	O	O
of	O	O
postoperative	B-Disease	D011183
delirium	I-Disease	D011183
is	O	O
high	O	O
even	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

PURPOSE	O	O
:	O	O
Postoperative	B-Disease	D011183
delirium	I-Disease	D011183
is	O	O
a	O	O
recognized	O	O
complication	O	O
in	O	O
populations	O	O
at	O	O
risk	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
assess	O	O
the	O	O
prevalence	O	O
of	O	O
early	O	O
postoperative	B-Disease	D011183
delirium	I-Disease	D011183
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
admitted	O	O
to	O	O
the	O	O
ICU	O	O
for	O	O
postoperative	O	O
monitoring	O	O
after	O	O
elective	O	O
major	O	O
surgery	O	O
.	O	O

The	O	O
secondary	O	O
outcome	O	O
investigated	O	O
is	O	O
to	O	O
identify	O	O
eventual	O	O
independent	O	O
risk	O	O
factors	O	O
among	O	O
demographic	O	O
data	O	O
and	O	O
anesthetic	O	O
drugs	O	O
used	O	O
.	O	O

METHODS	O	O
:	O	O
An	O	O
observational	O	O
,	O	O
prospective	O	O
study	O	O
was	O	O
conducted	O	O
on	O	O
a	O	O
consecutive	O	O
cohort	O	O
of	O	O
patients	O	O
admitted	O	O
to	O	O
our	O	O
ICU	O	O
within	O	O
and	O	O
for	O	O
at	O	O
least	O	O
24	O	O
h	O	O
after	O	O
major	O	O
surgical	O	O
procedures	O	O
.	O	O

Exclusion	O	O
criteria	O	O
were	O	O
any	O	O
preexisting	O	O
predisposing	O	O
factor	O	O
for	O	O
delirium	B-Disease	D003693
or	O	O
other	O	O
potentially	O	O
confounding	O	O
neurological	B-Disease	D009422
dysfunctions	I-Disease	D009422
.	O	O

Patients	O	O
were	O	O
assessed	O	O
daily	O	O
using	O	O
the	O	O
confusion	B-Disease	D003221
assessment	O	O
method	O	O
for	O	O
the	O	O
ICU	O	O
scale	O	O
for	O	O
3	O	O
days	O	O
after	O	O
the	O	O
surgical	O	O
procedure	O	O
.	O	O

Early	O	O
postoperative	B-Disease	D011183
delirium	I-Disease	D011183
incidence	O	O
risk	O	O
factors	O	O
were	O	O
then	O	O
assessed	O	O
through	O	O
three	O	O
different	O	O
multiple	O	O
regression	O	O
models	O	O
.	O	O

RESULTS	O	O
:	O	O
According	O	O
to	O	O
the	O	O
confusion	B-Disease	D003221
assessment	O	O
method	O	O
for	O	O
the	O	O
ICU	O	O
scale	O	O
,	O	O
28	O	O
%	O	O
of	O	O
patients	O	O
were	O	O
diagnosed	O	O
with	O	O
early	O	O
postoperative	B-Disease	D011183
delirium	I-Disease	D011183
.	O	O

The	O	O
use	O	O
of	O	O
thiopentone	B-Chemical	D013874
was	O	O
significantly	O	O
associated	O	O
with	O	O
an	O	O
eight	O	O
-	O	O
fold	O	O
-	O	O
higher	O	O
risk	O	O
for	O	O
delirium	B-Disease	D003693
compared	O	O
to	O	O
propofol	B-Chemical	D015742
(	O	O
57	O	O
.	O	O

1%	O	O
vs	O	O
.	O	O

7	O	O
.	O	O

1%	O	O
,	O	O
RR	O	O
=	O	O
8	O	O
.	O	O

0	O	O
,	O	O
X2	O	O
=	O	O
4	O	O
.	O	O

256	O	O
;	O	O
df	O	O
=	O	O
1	O	O
;	O	O
0	O	O
.	O	O

05	O	O
<	O	O
p	O	O
<	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
study	O	O
early	O	O
postoperative	B-Disease	D011183
delirium	I-Disease	D011183
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
very	O	O
common	O	O
complication	O	O
after	O	O
major	O	O
surgery	O	O
,	O	O
even	O	O
in	O	O
a	O	O
population	O	O
without	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

Thiopentone	B-Chemical	D013874
was	O	O
independently	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
its	O	O
relative	O	O
risk	O	O
.	O	O

A	O	O
single	O	O
neurotoxic	B-Disease	D020258
dose	O	O
of	O	O
methamphetamine	B-Chemical	D008694
induces	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
depressive	B-Disease	D003866
-	O	O
like	O	O
behaviour	O	O
in	O	O
mice	O	O
.	O	O

Methamphetamine	B-Chemical	D008694
(	O	O
METH	B-Chemical	D008694
)	O	O
triggers	O	O
a	O	O
disruption	O	O
of	O	O
the	O	O
monoaminergic	O	O
system	O	O
and	O	O
METH	B-Chemical	D008694
abuse	O	O
leads	O	O
to	O	O
negative	O	O
emotional	O	O
states	O	O
including	O	O
depressive	B-Disease	D003866
symptoms	O	O
during	O	O
drug	O	O
withdrawal	O	O
.	O	O

However	O	O
,	O	O
it	O	O
is	O	O
currently	O	O
unknown	O	O
if	O	O
the	O	O
acute	O	O
toxic	O	O
dosage	O	O
of	O	O
METH	B-Chemical	D008694
also	O	O
causes	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
depressive	B-Disease	D003866
phenotype	O	O
and	O	O
persistent	O	O
monoaminergic	O	O
deficits	O	O
.	O	O

Thus	O	O
,	O	O
we	O	O
now	O	O
assessed	O	O
the	O	O
depressive	B-Disease	D003866
-	O	O
like	O	O
behaviour	O	O
in	O	O
mice	O	O
at	O	O
early	O	O
and	O	O
long	O	O
-	O	O
term	O	O
periods	O	O
following	O	O
a	O	O
single	O	O
high	O	O
METH	B-Chemical	D008694
dose	O	O
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

METH	B-Chemical	D008694
did	O	O
not	O	O
alter	O	O
the	O	O
motor	O	O
function	O	O
and	O	O
procedural	O	O
memory	O	O
of	O	O
mice	O	O
as	O	O
assessed	O	O
by	O	O
swimming	O	O
speed	O	O
and	O	O
escape	O	O
latency	O	O
to	O	O
find	O	O
the	O	O
platform	O	O
in	O	O
a	O	O
cued	O	O
version	O	O
of	O	O
the	O	O
water	O	O
maze	O	O
task	O	O
.	O	O

However	O	O
,	O	O
METH	B-Chemical	D008694
significantly	O	O
increased	O	O
the	O	O
immobility	O	O
time	O	O
in	O	O
the	O	O
tail	O	O
suspension	O	O
test	O	O
at	O	O
3	O	O
and	O	O
49	O	O
days	O	O
post	O	O
-	O	O
administration	O	O
.	O	O

This	O	O
depressive	B-Disease	D003866
-	O	O
like	O	O
profile	O	O
induced	O	O
by	O	O
METH	B-Chemical	D008694
was	O	O
accompanied	O	O
by	O	O
a	O	O
marked	O	O
depletion	O	O
of	O	O
frontostriatal	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
neurotransmission	O	O
,	O	O
indicated	O	O
by	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
dopamine	B-Chemical	D004298
,	O	O
DOPAC	B-Chemical	D015102
and	O	O
HVA	B-Chemical	D006719
,	O	O
tyrosine	B-Chemical	D014443
hydroxylase	O	O
and	O	O
serotonin	B-Chemical	D012701
,	O	O
observed	O	O
at	O	O
both	O	O
3	O	O
and	O	O
49	O	O
days	O	O
post	O	O
-	O	O
administration	O	O
.	O	O

In	O	O
parallel	O	O
,	O	O
another	O	O
neurochemical	O	O
feature	O	O
of	O	O
depression	B-Disease	D003866
-	O	O
-	O	O
astroglial	O	O
dysfunction	O	O
-	O	O
-	O	O
was	O	O
unaffected	O	O
in	O	O
the	O	O
cortex	O	O
and	O	O
the	O	O
striatal	O	O
levels	O	O
of	O	O
the	O	O
astrocytic	O	O
protein	O	O
marker	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
were	O	O
only	O	O
transiently	O	O
increased	O	O
at	O	O
3	O	O
days	O	O
.	O	O

These	O	O
findings	O	O
demonstrate	O	O
for	O	O
the	O	O
first	O	O
time	O	O
that	O	O
a	O	O
single	O	O
high	O	O
dose	O	O
of	O	O
METH	B-Chemical	D008694
induces	O	O
long	O	O
-	O	O
lasting	O	O
depressive	B-Disease	D003866
-	O	O
like	O	O
behaviour	O	O
in	O	O
mice	O	O
associated	O	O
with	O	O
a	O	O
persistent	O	O
disruption	O	O
of	O	O
frontostriatal	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
homoeostasis	O	O
.	O	O

Linezolid	B-Chemical	C098010
-	O	O
induced	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
.	O	O

Many	O	O
systemic	O	O
antimicrobials	O	O
have	O	O
been	O	O
implicated	O	O
to	O	O
cause	O	O
ocular	O	O
adverse	O	O
effects	O	O
.	O	O

This	O	O
is	O	O
especially	O	O
relevant	O	O
in	O	O
multidrug	O	O
therapy	O	O
where	O	O
more	O	O
than	O	O
one	O	O
drug	O	O
can	O	O
cause	O	O
a	O	O
similar	O	O
ocular	O	O
adverse	O	O
effect	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
progressive	O	O
loss	B-Disease	D014786
of	I-Disease	D014786
vision	I-Disease	D014786
associated	O	O
with	O	O
linezolid	B-Chemical	C098010
therapy	O	O
.	O	O

A	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
who	O	O
was	O	O
on	O	O
treatment	O	O
with	O	O
multiple	O	O
second	O	O
-	O	O
line	O	O
anti	O	O
-	O	O
tuberculous	O	O
drugs	O	O
including	O	O
linezolid	B-Chemical	C098010
and	O	O
ethambutol	B-Chemical	D004977
for	O	O
extensively	B-Disease	D054908
drug	I-Disease	D054908
-	I-Disease	D054908
resistant	I-Disease	D054908
tuberculosis	I-Disease	D054908
(	O	O
XDR	B-Disease	D054908
-	I-Disease	D054908
TB	I-Disease	D054908
)	O	O
presented	O	O
to	O	O
us	O	O
with	O	O
painless	O	O
progressive	O	O
loss	B-Disease	D014786
of	I-Disease	D014786
vision	I-Disease	D014786
in	O	O
both	O	O
eyes	O	O
.	O	O

Color	O	O
vision	O	O
was	O	O
defective	O	O
and	O	O
fundus	O	O
examination	O	O
revealed	O	O
optic	B-Disease	C531767
disc	I-Disease	C531767
edema	I-Disease	C531767
in	O	O
both	O	O
eyes	O	O
.	O	O

Ethambutol	B-Chemical	D004977
-	O	O
induced	O	O
toxic	B-Disease	D009901
optic	I-Disease	D009901
neuropathy	I-Disease	D009901
was	O	O
suspected	O	O
and	O	O
tablet	O	O
ethambutol	B-Chemical	D004977
was	O	O
withdrawn	O	O
.	O	O

Deterioration	B-Disease	D015354
of	I-Disease	D015354
vision	I-Disease	D015354
occurred	O	O
despite	O	O
withdrawal	O	O
of	O	O
ethambutol	B-Chemical	D004977
.	O	O

Discontinuation	O	O
of	O	O
linezolid	B-Chemical	C098010
resulted	O	O
in	O	O
marked	O	O
improvement	O	O
of	O	O
vision	O	O
.	O	O

Our	O	O
report	O	O
emphasizes	O	O
the	O	O
need	O	O
for	O	O
monitoring	O	O
of	O	O
visual	O	O
function	O	O
in	O	O
patients	O	O
on	O	O
long	O	O
-	O	O
term	O	O
linezolid	B-Chemical	C098010
treatment	O	O
.	O	O

Resuscitation	O	O
with	O	O
lipid	O	O
,	O	O
epinephrine	B-Chemical	D004837
,	O	O
or	O	O
both	O	O
in	O	O
levobupivacaine	B-Chemical	C476513
-	O	O
induced	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
in	O	O
newborn	O	O
piglets	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
optimal	O	O
dosing	O	O
regimens	O	O
of	O	O
lipid	O	O
emulsion	O	O
,	O	O
epinephrine	B-Chemical	D004837
,	O	O
or	O	O
both	O	O
are	O	O
not	O	O
yet	O	O
determined	O	O
in	O	O
neonates	O	O
in	O	O
cases	O	O
of	O	O
local	O	O
anaesthetic	O	O
systemic	O	O
toxicity	B-Disease	D064420
(	O	O
LAST	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
Newborn	O	O
piglets	O	O
received	O	O
levobupivacaine	B-Chemical	C476513
until	O	O
cardiovascular	B-Disease	D002318
collapse	I-Disease	D002318
occurred	O	O
.	O	O

Standard	O	O
cardiopulmonary	O	O
resuscitation	O	O
was	O	O
started	O	O
and	O	O
electrocardiogram	O	O
(	O	O
ECG	O	O
)	O	O
was	O	O
monitored	O	O
for	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
,	O	O
fibrillation	B-Disease	D001281
,	O	O
or	O	O
QRS	O	O
prolongation	O	O
.	O	O

Piglets	O	O
were	O	O
then	O	O
randomly	O	O
allocated	O	O
to	O	O
four	O	O
groups	O	O
:	O	O
control	O	O
(	O	O
saline	O	O
)	O	O
,	O	O
Intralipid	O	O
(	O	O
)	O	O
alone	O	O
,	O	O
epinephrine	B-Chemical	D004837
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
Intralipd	O	O
plus	O	O
epinephrine	B-Chemical	D004837
.	O	O

Resuscitation	O	O
continued	O	O
for	O	O
30	O	O
min	O	O
or	O	O
until	O	O
there	O	O
was	O	O
a	O	O
return	O	O
of	O	O
spontaneous	O	O
circulation	O	O
(	O	O
ROSC	O	O
)	O	O
accompanied	O	O
by	O	O
a	O	O
mean	O	O
arterial	O	O
pressure	O	O
at	O	O
or	O	O
superior	O	O
to	O	O
the	O	O
baseline	O	O
pressure	O	O
and	O	O
normal	O	O
sinus	O	O
rhythm	O	O
for	O	O
a	O	O
period	O	O
of	O	O
30	O	O
min	O	O
.	O	O

RESULTS	O	O
:	O	O
ROSC	O	O
was	O	O
achieved	O	O
in	O	O
only	O	O
one	O	O
of	O	O
the	O	O
control	O	O
piglets	O	O
compared	O	O
with	O	O
most	O	O
of	O	O
the	O	O
treated	O	O
piglets	O	O
.	O	O

Mortality	O	O
was	O	O
not	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
three	O	O
treatment	O	O
groups	O	O
,	O	O
but	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
all	O	O
the	O	O
treatment	O	O
groups	O	O
compared	O	O
with	O	O
control	O	O
.	O	O

The	O	O
number	O	O
of	O	O
ECG	O	O
abnormalities	O	O
was	O	O
zero	O	O
in	O	O
the	O	O
Intralipid	O	O
only	O	O
group	O	O
,	O	O
but	O	O
14	O	O
and	O	O
17	O	O
,	O	O
respectively	O	O
,	O	O
in	O	O
the	O	O
epinephrine	B-Chemical	D004837
and	O	O
epinephrine	B-Chemical	D004837
plus	O	O
lipid	O	O
groups	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Lipid	O	O
emulsion	O	O
with	O	O
or	O	O
without	O	O
epinephrine	B-Chemical	D004837
,	O	O
or	O	O
epinephrine	B-Chemical	D004837
alone	O	O
were	O	O
equally	O	O
effective	O	O
in	O	O
achieving	O	O
a	O	O
return	O	O
to	O	O
spontaneous	O	O
circulation	O	O
in	O	O
this	O	O
model	O	O
of	O	O
LAST	O	O
.	O	O

Epinephrine	B-Chemical	D004837
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
lipid	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
number	O	O
of	O	O
ECG	O	O
abnormalities	O	O
compared	O	O
with	O	O
lipid	O	O
emulsion	O	O
alone	O	O
.	O	O

Incidence	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
and	O	O
postoperative	O	O
recovery	O	O
of	O	O
platelet	O	O
count	O	O
in	O	O
liver	O	O
graft	O	O
recipients	O	O
:	O	O
a	O	O
retrospective	O	O
cohort	O	O
analysis	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Thrombocytopenia	B-Disease	D013921
in	O	O
patients	O	O
with	O	O
end	B-Disease	D058625
-	I-Disease	D058625
stage	I-Disease	D058625
liver	I-Disease	D058625
disease	I-Disease	D058625
is	O	O
a	O	O
common	O	O
disorder	O	O
caused	O	O
mainly	O	O
by	O	O
portal	B-Disease	D006975
hypertension	I-Disease	D006975
,	O	O
low	O	O
levels	O	O
of	O	O
thrombopoetin	O	O
,	O	O
and	O	O
endotoxemia	B-Disease	D019446
.	O	O

The	O	O
impact	O	O
of	O	O
immune	O	O
-	O	O
mediated	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
(	O	O
HIT	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
)	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
thrombocytopenia	B-Disease	D013921
after	O	O
liver	O	O
transplantation	O	O
is	O	O
not	O	O
yet	O	O
understood	O	O
,	O	O
with	O	O
few	O	O
literature	O	O
citations	O	O
reporting	O	O
contradictory	O	O
results	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
demonstrate	O	O
the	O	O
perioperative	O	O
course	O	O
of	O	O
thrombocytopenia	B-Disease	D013921
after	O	O
liver	O	O
transplantation	O	O
and	O	O
determine	O	O
the	O	O
occurrence	O	O
of	O	O
clinical	O	O
HIT	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
.	O	O

METHOD	O	O
:	O	O
We	O	O
retrospectively	O	O
evaluated	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
205	O	O
consecutive	O	O
adult	O	O
patients	O	O
who	O	O
underwent	O	O
full	O	O
-	O	O
size	O	O
liver	O	O
transplantation	O	O
between	O	O
January	O	O
2006	O	O
and	O	O
December	O	O
2010	O	O
due	O	O
to	O	O
end	O	O
-	O	O
stage	O	O
or	O	O
malignant	O	O
liver	O	O
disease	O	O
.	O	O

Preoperative	O	O
platelet	O	O
count	O	O
,	O	O
postoperative	O	O
course	O	O
of	O	O
platelets	O	O
,	O	O
and	O	O
clinical	O	O
signs	O	O
of	O	O
HIT	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
were	O	O
analyzed	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
155	O	O
(	O	O
75	O	O
.	O	O

6%	O	O
)	O	O
of	O	O
205	O	O
patients	O	O
had	O	O
thrombocytopenia	B-Disease	D013921
before	O	O
transplantation	O	O
,	O	O
significantly	O	O
influenced	O	O
by	O	O
Model	O	O
of	O	O
End	B-Disease	D058625
-	I-Disease	D058625
Stage	I-Disease	D058625
Liver	I-Disease	D058625
Disease	I-Disease	D058625
score	O	O
and	O	O
liver	B-Disease	D008103
cirrhosis	I-Disease	D008103
.	O	O

The	O	O
platelet	O	O
count	O	O
exceeded	O	O
100	O	O
,	O	O
000	O	O
/	O	O
uL	O	O
in	O	O
most	O	O
of	O	O
the	O	O
patients	O	O
(	O	O
n	O	O
=	O	O
193	O	O
)	O	O
at	O	O
a	O	O
medium	O	O
of	O	O
7	O	O
d	O	O
.	O	O

Regarding	O	O
HIT	B-Disease	D013921
II	I-Disease	D013921
,	O	O
there	O	O
were	O	O
four	O	O
(	O	O
1	O	O
.	O	O

95%	O	O
)	O	O
patients	O	O
with	O	O
a	O	O
background	O	O
of	O	O
HIT	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
HIT	B-Disease	D013921
in	O	O
patients	O	O
with	O	O
end	B-Disease	D058625
-	I-Disease	D058625
stage	I-Disease	D058625
hepatic	I-Disease	D058625
failure	I-Disease	D058625
is	O	O
,	O	O
with	O	O
about	O	O
1	O	O
.	O	O

95%	O	O
,	O	O
rare	O	O
.	O	O

For	O	O
further	O	O
reduction	O	O
of	O	O
HIT	B-Disease	D013921
type	I-Disease	D013921
II	I-Disease	D013921
,	O	O
the	O	O
use	O	O
of	O	O
intravenous	O	O
heparin	B-Chemical	D006493
should	O	O
be	O	O
avoided	O	O
and	O	O
the	O	O
prophylactic	O	O
anticoagulation	O	O
should	O	O
be	O	O
performed	O	O
with	O	O
low	O	O
-	O	O
molecular	O	O
-	O	O
weight	O	O
heparin	B-Chemical	D006493
after	O	O
normalization	O	O
of	O	O
platelet	O	O
count	O	O
.	O	O

Takotsubo	B-Disease	D054549
syndrome	I-Disease	D054549
(	O	O
or	O	O
apical	B-Disease	D054549
ballooning	I-Disease	D054549
syndrome	I-Disease	D054549
)	O	O
secondary	O	O
to	O	O
Zolmitriptan	B-Chemical	C089750
.	O	O

Takotsubo	B-Disease	D054549
syndrome	I-Disease	D054549
(	O	O
TS	B-Disease	D054549
)	O	O
,	O	O
also	O	O
known	O	O
as	O	O
broken	B-Disease	D054549
heart	I-Disease	D054549
syndrome	I-Disease	D054549
,	O	O
is	O	O
characterized	O	O
by	O	O
left	O	O
ventricle	O	O
apical	O	O
ballooning	O	O
with	O	O
elevated	O	O
cardiac	O	O
biomarkers	O	O
and	O	O
electrocardiographic	O	O
changes	O	O
suggestive	O	O
of	O	O
an	O	O
acute	B-Disease	D054058
coronary	I-Disease	D054058
syndrome	I-Disease	D054058
(	O	O
ie	O	O
,	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
,	O	O
T	O	O
wave	O	O
inversions	O	O
,	O	O
and	O	O
pathologic	O	O
Q	O	O
waves	O	O
)	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
medical	O	O
history	O	O
of	O	O
mitral	B-Disease	D008945
valve	I-Disease	D008945
prolapse	I-Disease	D008945
and	O	O
migraines	B-Disease	D008881
,	O	O
who	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
substernal	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
and	O	O
electrocardiogram	O	O
demonstrated	O	O
1	O	O
/	O	O
2	O	O
mm	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
in	O	O
leads	O	O
II	O	O
,	O	O
III	O	O
,	O	O
aVF	O	O
,	O	O
V5	O	O
,	O	O
and	O	O
V6	O	O
and	O	O
positive	O	O
troponin	O	O
I	O	O
.	O	O

Emergent	O	O
coronary	O	O
angiogram	O	O
revealed	O	O
normal	O	O
coronary	O	O
arteries	O	O
with	O	O
moderately	O	O
reduced	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
with	O	O
wall	O	O
motion	O	O
abnormalities	O	O
consistent	O	O
with	O	O
TS	B-Disease	D054549
.	O	O

Detailed	O	O
history	O	O
obtained	O	O
retrospectively	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
took	O	O
zolmitriptan	B-Chemical	C089750
sparingly	O	O
only	O	O
when	O	O
she	O	O
had	O	O
migraines	B-Disease	D008881
.	O	O

But	O	O
before	O	O
this	O	O
event	O	O
,	O	O
she	O	O
was	O	O
taking	O	O
zolmitriptan	B-Chemical	C089750
2	O	O
-	O	O
3	O	O
times	O	O
daily	O	O
for	O	O
several	O	O
days	O	O
because	O	O
of	O	O
a	O	O
persistent	O	O
migraine	B-Disease	D008881
headache	I-Disease	D008881
.	O	O

She	O	O
otherwise	O	O
reported	O	O
that	O	O
she	O	O
is	O	O
quite	O	O
active	O	O
,	O	O
rides	O	O
horses	O	O
,	O	O
and	O	O
does	O	O
show	O	O
jumping	O	O
without	O	O
any	O	O
limitations	O	O
in	O	O
her	O	O
physical	O	O
activity	O	O
.	O	O

There	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
any	O	O
recent	O	O
stress	O	O
or	O	O
status	B-Disease	D008881
migrainosus	I-Disease	D008881
.	O	O

Extensive	O	O
literature	O	O
search	O	O
revealed	O	O
multiple	O	O
cases	O	O
of	O	O
coronary	B-Disease	D003329
artery	I-Disease	D003329
vasospasm	I-Disease	D003329
secondary	O	O
to	O	O
zolmitriptan	B-Chemical	C089750
,	O	O
but	O	O
none	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
associated	O	O
with	O	O
TS	B-Disease	D054549
.	O	O

Depression	B-Disease	D003866
,	O	O
impulsiveness	B-Disease	D010554
,	O	O
sleep	O	O
,	O	O
and	O	O
memory	O	O
in	O	O
past	O	O
and	O	O
present	O	O
polydrug	O	O
users	O	O
of	O	O
3	B-Chemical	D018817
,	I-Chemical	D018817
4	I-Chemical	D018817
-	I-Chemical	D018817
methylenedioxymethamphetamine	I-Chemical	D018817
(	O	O
MDMA	B-Chemical	D018817
,	O	O
ecstasy	B-Chemical	D018817
)	O	O
.	O	O

RATIONALE	O	O
:	O	O
Ecstasy	B-Chemical	D018817
(	O	O
3	B-Chemical	D018817
,	I-Chemical	D018817
4	I-Chemical	D018817
-	I-Chemical	D018817
methylenedioxymethamphetamine	I-Chemical	D018817
,	O	O
MDMA	B-Chemical	D018817
)	O	O
is	O	O
a	O	O
worldwide	O	O
recreational	O	O
drug	O	O
of	O	O
abuse	O	O
.	O	O

Unfortunately	O	O
,	O	O
the	O	O
results	O	O
from	O	O
human	O	O
research	O	O
investigating	O	O
its	O	O
psychological	O	O
effects	O	O
have	O	O
been	O	O
inconsistent	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
be	O	O
the	O	O
largest	O	O
to	O	O
date	O	O
in	O	O
sample	O	O
size	O	O
and	O	O
5HT	O	O
-	O	O
related	O	O
behaviors	O	O
;	O	O
the	O	O
first	O	O
to	O	O
compare	O	O
present	O	O
ecstasy	B-Chemical	D018817
users	O	O
with	O	O
past	O	O
users	O	O
after	O	O
an	O	O
abstinence	O	O
of	O	O
4	O	O
or	O	O
more	O	O
years	O	O
,	O	O
and	O	O
the	O	O
first	O	O
to	O	O
include	O	O
robust	O	O
controls	O	O
for	O	O
other	O	O
recreational	O	O
substances	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
sample	O	O
of	O	O
997	O	O
participants	O	O
(	O	O
52	O	O
%	O	O
male	O	O
)	O	O
was	O	O
recruited	O	O
to	O	O
four	O	O
control	O	O
groups	O	O
(	O	O
non	O	O
-	O	O
drug	O	O
(	O	O
ND	O	O
)	O	O
,	O	O
alcohol	B-Chemical	D000431
/	O	O
nicotine	B-Chemical	D009538
(	O	O
AN	B-Chemical	D000431
)	O	O
,	O	O
cannabis	B-Chemical	D002188
/	O	O
alcohol	B-Chemical	D000431
/	O	O
nicotine	B-Chemical	D009538
(	O	O
CAN	B-Chemical	D002188
)	O	O
,	O	O
non	O	O
-	O	O
ecstasy	B-Chemical	D018817
polydrug	O	O
(	O	O
PD	O	O
)	O	O
)	O	O
,	O	O
and	O	O
two	O	O
ecstasy	B-Chemical	D018817
polydrug	O	O
groups	O	O
(	O	O
present	O	O
(	O	O
MDMA	B-Chemical	D018817
)	O	O
and	O	O
past	O	O
users	O	O
(	O	O
EX	O	O
-	O	O
MDMA	B-Chemical	D018817
)	O	O
.	O	O

Participants	O	O
completed	O	O
a	O	O
drug	O	O
history	O	O
questionnaire	O	O
,	O	O
Beck	O	O
Depression	B-Disease	D003866
Inventory	O	O
,	O	O
Barratt	O	O
Impulsiveness	B-Disease	D010554
Scale	O	O
,	O	O
Pittsburgh	O	O
Sleep	O	O
Quality	O	O
Index	O	O
,	O	O
and	O	O
Wechsler	O	O
Memory	O	O
Scale	O	O
-	O	O
Revised	O	O
which	O	O
,	O	O
in	O	O
total	O	O
,	O	O
provided	O	O
13	O	O
psychometric	O	O
measures	O	O
.	O	O

RESULTS	O	O
:	O	O
While	O	O
the	O	O
CAN	B-Chemical	D002188
and	O	O
PD	O	O
groups	O	O
tended	O	O
to	O	O
record	O	O
greater	O	O
deficits	O	O
than	O	O
the	O	O
non	O	O
-	O	O
drug	O	O
controls	O	O
,	O	O
the	O	O
MDMA	B-Chemical	D018817
and	O	O
EX	O	O
-	O	O
MDMA	B-Chemical	D018817
groups	O	O
recorded	O	O
greater	O	O
deficits	O	O
than	O	O
all	O	O
the	O	O
control	O	O
groups	O	O
on	O	O
ten	O	O
of	O	O
the	O	O
13	O	O
psychometric	O	O
measures	O	O
.	O	O

Strikingly	O	O
,	O	O
despite	O	O
prolonged	O	O
abstinence	O	O
(	O	O
mean	O	O
,	O	O
4	O	O
.	O	O

98	O	O
;	O	O
range	O	O
,	O	O
4	O	O
-	O	O
9	O	O
years	O	O
)	O	O
,	O	O
past	O	O
ecstasy	B-Chemical	D018817
users	O	O
showed	O	O
few	O	O
signs	O	O
of	O	O
recovery	O	O
.	O	O

Compared	O	O
with	O	O
present	O	O
ecstasy	B-Chemical	D018817
users	O	O
,	O	O
the	O	O
past	O	O
users	O	O
showed	O	O
no	O	O
change	O	O
for	O	O
ten	O	O
measures	O	O
,	O	O
increased	O	O
impairment	O	O
for	O	O
two	O	O
measures	O	O
,	O	O
and	O	O
improvement	O	O
on	O	O
just	O	O
one	O	O
measure	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Given	O	O
this	O	O
record	O	O
of	O	O
impaired	B-Disease	D008569
memory	I-Disease	D008569
and	O	O
clinically	O	O
significant	O	O
levels	O	O
of	O	O
depression	B-Disease	D003866
,	O	O
impulsiveness	B-Disease	D010554
,	O	O
and	O	O
sleep	B-Disease	D020920
disturbance	I-Disease	D020920
,	O	O
the	O	O
prognosis	O	O
for	O	O
the	O	O
current	O	O
generation	O	O
of	O	O
ecstasy	B-Chemical	D018817
users	O	O
is	O	O
a	O	O
major	O	O
cause	O	O
for	O	O
concern	O	O
.	O	O

Association	O	O
of	O	O
common	O	O
genetic	O	O
variants	O	O
of	O	O
HOMER1	O	O
gene	O	O
with	O	O
levodopa	B-Chemical	D007980
adverse	O	O
effects	O	O
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
patients	O	O
.	O	O

Levodopa	B-Chemical	D007980
is	O	O
the	O	O
most	O	O
effective	O	O
symptomatic	O	O
therapy	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
,	O	O
but	O	O
its	O	O
chronic	O	O
use	O	O
could	O	O
lead	O	O
to	O	O
chronic	O	O
adverse	O	O
outcomes	O	O
,	O	O
such	O	O
as	O	O
motor	O	O
fluctuations	O	O
,	O	O
dyskinesia	B-Disease	D004409
and	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
.	O	O

HOMER1	O	O
is	O	O
a	O	O
protein	O	O
with	O	O
pivotal	O	O
function	O	O
in	O	O
glutamate	B-Chemical	D018698
transmission	O	O
,	O	O
which	O	O
has	O	O
been	O	O
related	O	O
to	O	O
the	O	O
pathogenesis	O	O
of	O	O
these	O	O
complications	O	O
.	O	O

This	O	O
study	O	O
investigates	O	O
whether	O	O
polymorphisms	O	O
in	O	O
the	O	O
HOMER1	O	O
gene	O	O
promoter	O	O
region	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
chronic	O	O
complications	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
.	O	O

A	O	O
total	O	O
of	O	O
205	O	O
patients	O	O
with	O	O
idiopathic	B-Disease	D010300
Parkinson's	I-Disease	D010300
disease	I-Disease	D010300
were	O	O
investigated	O	O
.	O	O

Patients	O	O
were	O	O
genotyped	O	O
for	O	O
rs4704559	O	O
,	O	O
rs10942891	O	O
and	O	O
rs4704560	O	O
by	O	O
allelic	O	O
discrimination	O	O
with	O	O
Taqman	O	O
assays	O	O
.	O	O

The	O	O
rs4704559	O	O
G	O	O
allele	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
lower	O	O
prevalence	O	O
of	O	O
dyskinesia	B-Disease	D004409
(	O	O
prevalence	O	O
ratio	O	O
(	O	O
PR	O	O
)	O	O
=0	O	O
.	O	O

615	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
0	O	O
.	O	O

426	O	O
-	O	O
0	O	O
.	O	O

887	O	O
,	O	O
P=0	O	O
.	O	O

009	O	O
)	O	O
and	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
(	O	O
PR=0	O	O
.	O	O

515	O	O
,	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

295	O	O
-	O	O
0	O	O
.	O	O

899	O	O
,	O	O
P=0	O	O
.	O	O

020	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
HOMER1	O	O
rs4704559	O	O
G	O	O
allele	O	O
has	O	O
a	O	O
protective	O	O
role	O	O
for	O	O
the	O	O
development	O	O
of	O	O
levodopa	B-Chemical	D007980
adverse	O	O
effects	O	O
.	O	O

Crocin	B-Chemical	C029036
improves	O	O
lipid	O	O
dysregulation	O	O
in	O	O
subacute	O	O
diazinon	B-Chemical	D003976
exposure	O	O
through	O	O
ERK1	O	O
/	O	O
2	O	O
pathway	O	O
in	O	O
rat	O	O
liver	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Diazinon	B-Chemical	D003976
Yis	O	O
one	O	O
of	O	O
the	O	O
most	O	O
broadly	O	O
used	O	O
organophosphorus	B-Chemical	D010755
insecticides	O	O
in	O	O
agriculture	O	O
.	O	O

It	O	O
has	O	O
been	O	O
shown	O	O
that	O	O
exposure	O	O
to	O	O
diazinon	B-Chemical	D003976
may	O	O
interfere	O	O
with	O	O
lipid	O	O
metabolism	O	O
.	O	O

Moreover	O	O
,	O	O
the	O	O
hypolipidemic	O	O
effect	O	O
of	O	O
crocin	B-Chemical	C029036
has	O	O
been	O	O
established	O	O
.	O	O

Earlier	O	O
studies	O	O
revealed	O	O
the	O	O
major	O	O
role	O	O
of	O	O
Extracellular	O	O
signal	O	O
-	O	O
regulated	O	O
kinase	O	O
(	O	O
ERK	O	O
)	O	O
pathways	O	O
in	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
receptor	O	O
(	O	O
LDLr	O	O
)	O	O
expression	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
changes	O	O
in	O	O
the	O	O
regulation	O	O
of	O	O
lipid	O	O
metabolism	O	O
,	O	O
ERK	O	O
and	O	O
LDLr	O	O
expression	O	O
in	O	O
the	O	O
liver	O	O
of	O	O
rats	O	O
exposed	O	O
to	O	O
subacute	O	O
diazinon	B-Chemical	D003976
.	O	O

Furthermore	O	O
ameliorating	O	O
effect	O	O
of	O	O
crocin	B-Chemical	C029036
on	O	O
diazinon	B-Chemical	D003976
induced	O	O
disturbed	O	O
cholesterol	B-Chemical	D002784
homeostasis	O	O
was	O	O
studied	O	O
.	O	O

METHODS	O	O
:	O	O
24	O	O
Rats	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
and	O	O
received	O	O
following	O	O
treatments	O	O
for	O	O
4	O	O
weeks	O	O
;	O	O
Corn	O	O
oil	O	O
(	O	O
control	O	O
)	O	O
,	O	O
diazinon	B-Chemical	D003976
(	O	O
15mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
,	O	O
orally	O	O
)	O	O
and	O	O
crocin	B-Chemical	C029036
(	O	O
12	O	O
.	O	O

5	O	O
and	O	O
25mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
,	O	O
intraperitoneally	O	O
)	O	O
in	O	O
combination	O	O
with	O	O
diazinon	B-Chemical	D003976
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

The	O	O
levels	O	O
of	O	O
cholesterol	B-Chemical	D002784
,	O	O
triglyceride	B-Chemical	D014280
and	O	O
LDL	O	O
in	O	O
blood	O	O
of	O	O
rats	O	O
were	O	O
analyzed	O	O
.	O	O

Moreover	O	O
mRNA	O	O
levels	O	O
of	O	O
LDLr	O	O
and	O	O
ERK1	O	O
/	O	O
2	O	O
as	O	O
well	O	O
as	O	O
protein	O	O
levels	O	O
of	O	O
total	O	O
and	O	O
activated	O	O
forms	O	O
of	O	O
ERK1	O	O
/	O	O
2	O	O
in	O	O
rat	O	O
liver	O	O
were	O	O
evaluated	O	O
by	O	O
Western	O	O
blotting	O	O
and	O	O
quantitative	O	O
real	O	O
time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
analysis	O	O
.	O	O

RESULTS	O	O
:	O	O
Our	O	O
data	O	O
showed	O	O
that	O	O
subacute	O	O
exposure	O	O
to	O	O
diazinon	B-Chemical	D003976
significantly	O	O
increased	O	O
concentrations	O	O
of	O	O
cholesterol	B-Chemical	D002784
,	O	O
triglyceride	B-Chemical	D014280
and	O	O
LDL	O	O
.	O	O

Moreover	O	O
diazinon	B-Chemical	D003976
decreased	O	O
ERK1	O	O
/	O	O
2	O	O
protein	O	O
phosphorylation	O	O
and	O	O
LDLr	O	O
transcript	O	O
.	O	O

Crocin	B-Chemical	C029036
reduced	O	O
inhibition	O	O
of	O	O
ERK	O	O
activation	O	O
and	O	O
diazinon	B-Chemical	D003976
-	O	O
induced	O	O
hyperlipemia	B-Disease	D006949
and	O	O
increased	O	O
levels	O	O
of	O	O
LDLr	O	O
transcript	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Crocin	B-Chemical	C029036
may	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
novel	O	O
protective	O	O
agent	O	O
in	O	O
diazinon	B-Chemical	D003976
-	O	O
induced	O	O
hyperlipemia	B-Disease	D006949
through	O	O
modulating	O	O
of	O	O
ERK	O	O
pathway	O	O
and	O	O
increase	O	O
of	O	O
LDLr	O	O
expression	O	O
.	O	O

GEM	B-Chemical	C056507
-	O	O
P	O	O
chemotherapy	O	O
is	O	O
active	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
relapsed	O	O
Hodgkin	B-Disease	D006689
lymphoma	I-Disease	D006689
.	O	O

Hodgkin	B-Disease	D006689
lymphoma	I-Disease	D006689
(	O	O
HL	B-Disease	D006689
)	O	O
is	O	O
a	O	O
relatively	O	O
chemosensitive	O	O
malignancy	B-Disease	D009369
.	O	O

However	O	O
,	O	O
for	O	O
those	O	O
who	O	O
relapse	O	O
,	O	O
high	O	O
-	O	O
dose	O	O
chemotherapy	O	O
with	O	O
autologous	O	O
stem	O	O
cell	O	O
transplant	O	O
is	O	O
the	O	O
treatment	O	O
of	O	O
choice	O	O
which	O	O
relies	O	O
on	O	O
adequate	O	O
disease	O	O
control	O	O
with	O	O
salvage	O	O
chemotherapy	O	O
.	O	O

Regimens	O	O
commonly	O	O
used	O	O
often	O	O
require	O	O
inpatient	O	O
administration	O	O
and	O	O
can	O	O
be	O	O
difficult	O	O
to	O	O
deliver	O	O
due	O	O
to	O	O
toxicity	B-Disease	D064420
.	O	O

Gemcitabine	B-Chemical	C056507
and	O	O
cisplatin	B-Chemical	D002945
have	O	O
activity	O	O
in	O	O
HL	B-Disease	D006689
,	O	O
non	O	O
-	O	O
overlapping	O	O
toxicity	B-Disease	D064420
with	O	O
first	O	O
-	O	O
line	O	O
chemotherapeutics	O	O
,	O	O
and	O	O
may	O	O
be	O	O
delivered	O	O
in	O	O
an	O	O
outpatient	O	O
setting	O	O
.	O	O

In	O	O
this	O	O
retrospective	O	O
single	O	O
-	O	O
centre	O	O
analysis	O	O
,	O	O
patients	O	O
with	O	O
relapsed	O	O
or	O	O
refractory	O	O
HL	B-Disease	D006689
treated	O	O
with	O	O
gemcitabine	B-Chemical	C056507
1	O	O
,	O	O
000	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
day	O	O
(	O	O
D	O	O
)	O	O
1	O	O
,	O	O
D8	O	O
and	O	O
D15	O	O
;	O	O
methylprednisolone	B-Chemical	D008775
1	O	O
,	O	O
000	O	O
mg	O	O
D1	O	O
-	O	O
5	O	O
;	O	O
and	O	O
cisplatin	B-Chemical	D002945
100	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
D15	O	O
,	O	O
every	O	O
28	O	O
days	O	O
(	O	O
GEM	B-Chemical	C056507
-	O	O
P	O	O
)	O	O
were	O	O
included	O	O
.	O	O

Demographic	O	O
,	O	O
survival	O	O
,	O	O
response	O	O
and	O	O
toxicity	B-Disease	D064420
data	O	O
were	O	O
recorded	O	O
.	O	O

Forty	O	O
-	O	O
one	O	O
eligible	O	O
patients	O	O
were	O	O
identified	O	O
:	O	O
median	O	O
age	O	O
27	O	O
.	O	O

One	O	O
hundred	O	O
and	O	O
twenty	O	O
-	O	O
two	O	O
cycles	O	O
of	O	O
GEM	B-Chemical	C056507
-	O	O
P	O	O
were	O	O
administered	O	O
in	O	O
total	O	O
(	O	O
median	O	O
3	O	O
cycles	O	O
;	O	O
range	O	O
1	O	O
-	O	O
6	O	O
)	O	O
.	O	O

Twenty	O	O
of	O	O
41	O	O
(	O	O
48	O	O
%	O	O
)	O	O
patients	O	O
received	O	O
GEM	B-Chemical	C056507
-	O	O
P	O	O
as	O	O
second	O	O
-	O	O
line	O	O
treatment	O	O
and	O	O
11	O	O
/	O	O
41	O	O
(	O	O
27	O	O
%	O	O
)	O	O
as	O	O
third	O	O
-	O	O
line	O	O
therapy	O	O
.	O	O

Overall	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
to	O	O
GEM	B-Chemical	C056507
-	O	O
P	O	O
in	O	O
the	O	O
entire	O	O
cohort	O	O
was	O	O
80	O	O
%	O	O
(	O	O
complete	O	O
response	O	O
(	O	O
CR	O	O
)	O	O
37	O	O
%	O	O
,	O	O
partial	O	O
response	O	O
44	O	O
%	O	O
)	O	O
with	O	O
14	O	O
/	O	O
15	O	O
CR	O	O
confirmed	O	O
as	O	O
a	O	O
metabolic	O	O
CR	O	O
on	O	O
PET	O	O
and	O	O
ORR	O	O
of	O	O
85	O	O
%	O	O
in	O	O
the	O	O
20	O	O
second	O	O
-	O	O
line	O	O
patients	O	O
.	O	O

The	O	O
most	O	O
common	O	O
grade	O	O
3	O	O
/	O	O
4	O	O
toxicities	B-Disease	D064420
were	O	O
haematological	O	O
:	O	O
neutropenia	B-Disease	D009503
54	O	O
%	O	O
and	O	O
thrombocytopenia	B-Disease	D013921
51	O	O
%	O	O
.	O	O

Median	O	O
follow	O	O
-	O	O
up	O	O
from	O	O
the	O	O
start	O	O
of	O	O
GEM	B-Chemical	C056507
-	O	O
P	O	O
was	O	O
4	O	O
.	O	O

5	O	O
years	O	O
.	O	O

Following	O	O
GEM	B-Chemical	C056507
-	O	O
P	O	O
,	O	O
5	O	O
-	O	O
year	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
was	O	O
46	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
,	O	O
30	O	O
-	O	O
62	O	O
%	O	O
)	O	O
and	O	O
5	O	O
-	O	O
year	O	O
overall	O	O
survival	O	O
was	O	O
59	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
,	O	O
43	O	O
-	O	O
74	O	O
%	O	O
)	O	O
.	O	O

Fourteen	O	O
of	O	O
41	O	O
patients	O	O
proceeded	O	O
directly	O	O
to	O	O
autologous	O	O
transplant	O	O
.	O	O

GEM	B-Chemical	C056507
-	O	O
P	O	O
is	O	O
a	O	O
salvage	O	O
chemotherapy	O	O
with	O	O
relatively	O	O
high	O	O
response	O	O
rates	O	O
,	O	O
leading	O	O
to	O	O
successful	O	O
transplantation	O	O
in	O	O
appropriate	O	O
patients	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
relapsed	O	O
or	O	O
refractory	O	O
HL	B-Disease	D006689
.	O	O

Basal	O	O
functioning	O	O
of	O	O
the	O	O
hypothalamic	O	O
-	O	O
pituitary	O	O
-	O	O
adrenal	O	O
(	O	O
HPA	O	O
)	O	O
axis	O	O
and	O	O
psychological	O	O
distress	O	O
in	O	O
recreational	O	O
ecstasy	B-Chemical	D018817
polydrug	O	O
users	O	O
.	O	O

RATIONALE	O	O
:	O	O
Ecstasy	B-Chemical	D018817
(	O	O
MDMA	B-Chemical	D018817
)	O	O
is	O	O
a	O	O
psychostimulant	O	O
drug	O	O
which	O	O
is	O	O
increasingly	O	O
associated	O	O
with	O	O
psychobiological	B-Disease	D008107
dysfunction	I-Disease	D008107
.	O	O

While	O	O
some	O	O
recent	O	O
studies	O	O
suggest	O	O
acute	O	O
changes	O	O
in	O	O
neuroendocrine	O	O
function	O	O
,	O	O
less	O	O
is	O	O
known	O	O
about	O	O
long	O	O
-	O	O
term	O	O
changes	O	O
in	O	O
HPA	O	O
functionality	O	O
in	O	O
recreational	O	O
users	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
current	O	O
study	O	O
is	O	O
the	O	O
first	O	O
to	O	O
explore	O	O
the	O	O
effects	O	O
of	O	O
ecstasy	B-Chemical	D018817
-	O	O
polydrug	O	O
use	O	O
on	O	O
psychological	O	O
distress	O	O
and	O	O
basal	O	O
functioning	O	O
of	O	O
the	O	O
HPA	O	O
axis	O	O
through	O	O
assessing	O	O
the	O	O
secretion	O	O
of	O	O
cortisol	B-Chemical	D006854
across	O	O
the	O	O
diurnal	O	O
period	O	O
.	O	O

METHOD	O	O
:	O	O
Seventy	O	O
-	O	O
six	O	O
participants	O	O
(	O	O
21	O	O
nonusers	O	O
,	O	O
29	O	O
light	O	O
ecstasy	B-Chemical	D018817
-	O	O
polydrug	O	O
users	O	O
,	O	O
26	O	O
heavy	O	O
ecstasy	B-Chemical	D018817
-	O	O
polydrug	O	O
users	O	O
)	O	O
completed	O	O
a	O	O
substance	O	O
use	O	O
inventory	O	O
and	O	O
measures	O	O
of	O	O
psychological	O	O
distress	O	O
at	O	O
baseline	O	O
,	O	O
then	O	O
two	O	O
consecutive	O	O
days	O	O
of	O	O
cortisol	B-Chemical	D006854
sampling	O	O
(	O	O
on	O	O
awakening	O	O
,	O	O
30	O	O
min	O	O
post	O	O
awakening	O	O
,	O	O
between	O	O
1400	O	O
and	O	O
1600	O	O
hours	O	O
and	O	O
pre	O	O
bedtime	O	O
)	O	O
.	O	O

On	O	O
day	O	O
2	O	O
,	O	O
participants	O	O
also	O	O
attended	O	O
the	O	O
laboratory	O	O
to	O	O
complete	O	O
a	O	O
20	O	O
-	O	O
min	O	O
multitasking	O	O
stressor	O	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
user	O	O
groups	O	O
exhibited	O	O
significantly	O	O
greater	O	O
levels	O	O
of	O	O
anxiety	B-Disease	D001008
and	O	O
depression	B-Disease	D003866
than	O	O
nonusers	O	O
.	O	O

On	O	O
day	O	O
1	O	O
,	O	O
all	O	O
participants	O	O
exhibited	O	O
a	O	O
typical	O	O
cortisol	B-Chemical	D006854
profile	O	O
,	O	O
though	O	O
light	O	O
users	O	O
had	O	O
significantly	O	O
elevated	O	O
levels	O	O
pre	O	O
-	O	O
bed	O	O
.	O	O

On	O	O
day	O	O
2	O	O
,	O	O
heavy	O	O
users	O	O
demonstrated	O	O
elevated	O	O
levels	O	O
upon	O	O
awakening	O	O
and	O	O
all	O	O
ecstasy	B-Chemical	D018817
-	O	O
polydrug	O	O
users	O	O
demonstrated	O	O
elevated	O	O
pre	O	O
-	O	O
bed	O	O
levels	O	O
compared	O	O
to	O	O
non	O	O
-	O	O
users	O	O
.	O	O

Significant	O	O
between	O	O
group	O	O
differences	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
afternoon	O	O
cortisol	B-Chemical	D006854
levels	O	O
and	O	O
in	O	O
overall	O	O
cortisol	B-Chemical	D006854
secretion	O	O
across	O	O
the	O	O
day	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
increases	O	O
in	O	O
anxiety	B-Disease	D001008
and	O	O
depression	B-Disease	D003866
are	O	O
in	O	O
line	O	O
with	O	O
previous	O	O
observations	O	O
in	O	O
recreational	O	O
ecstasy	B-Chemical	D018817
-	O	O
polydrug	O	O
users	O	O
.	O	O

Dysregulated	O	O
diurnal	O	O
cortisol	B-Chemical	D006854
may	O	O
be	O	O
indicative	O	O
of	O	O
inappropriate	O	O
anticipation	O	O
of	O	O
forthcoming	O	O
demands	O	O
and	O	O
hypersecretion	O	O
may	O	O
lead	O	O
to	O	O
the	O	O
increased	O	O
psychological	O	O
and	O	O
physical	O	O
morbidity	O	O
associated	O	O
with	O	O
heavy	O	O
recreational	O	O
use	O	O
of	O	O
ecstasy	B-Chemical	D018817
.	O	O

Ifosfamide	B-Chemical	D007069
related	O	O
encephalopathy	B-Disease	D001927
:	O	O
the	O	O
need	O	O
for	O	O
a	O	O
timely	O	O
EEG	O	O
evaluation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Ifosfamide	B-Chemical	D007069
is	O	O
an	O	O
alkylating	O	O
agent	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
cancers	B-Disease	D009369
including	O	O
sarcomas	B-Disease	D012509
,	O	O
lymphoma	B-Disease	D008223
,	O	O
gynecologic	B-Disease	D009369
and	I-Disease	D009369
testicular	I-Disease	D009369
cancers	I-Disease	D009369
.	O	O

Encephalopathy	B-Disease	D001927
has	O	O
been	O	O
reported	O	O
in	O	O
10	O	O
-	O	O
40%	O	O
of	O	O
patients	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
IV	O	O
ifosfamide	B-Chemical	D007069
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
highlight	O	O
the	O	O
role	O	O
of	O	O
electroencephalogram	O	O
(	O	O
EEG	O	O
)	O	O
in	O	O
the	O	O
early	O	O
detection	O	O
and	O	O
management	O	O
of	O	O
ifosfamide	B-Chemical	D007069
related	O	O
encephalopathy	B-Disease	D001927
.	O	O

METHODS	O	O
:	O	O
Retrospective	O	O
chart	O	O
review	O	O
including	O	O
clinical	O	O
data	O	O
and	O	O
EEG	O	O
recordings	O	O
was	O	O
done	O	O
on	O	O
five	O	O
patients	O	O
,	O	O
admitted	O	O
to	O	O
MD	O	O
Anderson	O	O
Cancer	B-Disease	D009369
Center	O	O
between	O	O
years	O	O
2009	O	O
and	O	O
2012	O	O
,	O	O
who	O	O
developed	O	O
ifosfamide	B-Chemical	D007069
related	O	O
acute	O	O
encephalopathy	B-Disease	D001927
.	O	O

RESULTS	O	O
:	O	O
All	O	O
five	O	O
patients	O	O
experienced	O	O
symptoms	O	O
of	O	O
encephalopathy	B-Disease	D001927
soon	O	O
after	O	O
(	O	O
within	O	O
12	O	O
h	O	O
-	O	O
2	O	O
days	O	O
)	O	O
receiving	O	O
ifosfamide	B-Chemical	D007069
.	O	O

Two	O	O
patients	O	O
developed	O	O
generalized	O	O
convulsions	B-Disease	D012640
while	O	O
one	O	O
patient	O	O
developed	O	O
continuous	O	O
non	B-Disease	D013226
-	I-Disease	D013226
convulsive	I-Disease	D013226
status	I-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
NCSE	B-Disease	D013226
)	O	O
that	O	O
required	O	O
ICU	O	O
admission	O	O
and	O	O
intubation	O	O
.	O	O

Initial	O	O
EEG	O	O
showed	O	O
epileptiform	O	O
discharges	O	O
in	O	O
three	O	O
patients	O	O
;	O	O
run	O	O
of	O	O
triphasic	O	O
waves	O	O
in	O	O
one	O	O
patient	O	O
and	O	O
moderate	O	O
degree	O	O
diffuse	O	O
generalized	O	O
slowing	O	O
.	O	O

Mixed	O	O
pattern	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
both	O	O
sharps	O	O
and	O	O
triphasic	O	O
waves	O	O
were	O	O
also	O	O
noted	O	O
.	O	O

Repeat	O	O
EEGs	O	O
within	O	O
24_h	O	O
of	O	O
symptom	O	O
onset	O	O
showed	O	O
marked	O	O
improvement	O	O
that	O	O
was	O	O
correlated	O	O
with	O	O
clinical	O	O
improvement	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Severity	O	O
of	O	O
ifosfamide	B-Chemical	D007069
related	O	O
encephalopathy	B-Disease	D001927
correlates	O	O
with	O	O
EEG	O	O
changes	O	O
.	O	O

We	O	O
suggest	O	O
a	O	O
timely	O	O
EEG	O	O
evaluation	O	O
for	O	O
patients	O	O
receiving	O	O
ifosfamide	B-Chemical	D007069
who	O	O
develop	O	O
features	O	O
of	O	O
encephalopathy	B-Disease	D001927
.	O	O

Incidence	O	O
of	O	O
contrast	B-Chemical	D003287
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
in	O	O
hospitalised	O	O
patients	O	O
with	O	O
cancer	B-Disease	D009369
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
frequency	O	O
of	O	O
and	O	O
possible	O	O
factors	O	O
related	O	O
to	O	O
contrast	B-Chemical	D003287
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
(	O	O
CIN	O	O
)	O	O
in	O	O
hospitalised	O	O
patients	O	O
with	O	O
cancer	B-Disease	D009369
.	O	O

METHODS	O	O
:	O	O
Ninety	O	O
adult	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Patients	O	O
with	O	O
risk	O	O
factors	O	O
for	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
were	O	O
excluded	O	O
.	O	O

Blood	O	O
samples	O	O
were	O	O
examined	O	O
the	O	O
day	O	O
before	O	O
contrast	B-Chemical	D003287
-	O	O
enhanced	O	O
computed	O	O
tomography	O	O
(	O	O
CT	O	O
)	O	O
and	O	O
serially	O	O
for	O	O
3	O	O
days	O	O
thereafter	O	O
.	O	O

CIN	O	O
was	O	O
defined	O	O
as	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
(	O	O
Cr	B-Chemical	D002857
)	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dl	O	O
or	O	O
more	O	O
,	O	O
or	O	O
elevation	O	O
of	O	O
Cr	B-Chemical	D002857
to	O	O
25	O	O
%	O	O
over	O	O
baseline	O	O
.	O	O

Relationships	O	O
between	O	O
CIN	O	O
and	O	O
possible	O	O
risk	O	O
factors	O	O
were	O	O
investigated	O	O
.	O	O

RESULTS	O	O
:	O	O
CIN	O	O
was	O	O
detected	O	O
in	O	O
18	O	O
/	O	O
90	O	O
(	O	O
20	O	O
%	O	O
)	O	O
patients	O	O
.	O	O

CIN	O	O
developed	O	O
in	O	O
25	O	O
.	O	O

5	O	O
%	O	O
patients	O	O
who	O	O
underwent	O	O
chemotherapy	O	O
and	O	O
in	O	O
11	O	O
%	O	O
patients	O	O
who	O	O
did	O	O
not	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

1	O	O
)	O	O
.	O	O

CIN	O	O
more	O	O
frequently	O	O
developed	O	O
in	O	O
patients	O	O
who	O	O
had	O	O
undergone	O	O
CT	O	O
within	O	O
45	O	O
days	O	O
after	O	O
the	O	O
last	O	O
chemotherapy	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

005	O	O
)	O	O
;	O	O
it	O	O
was	O	O
also	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

017	O	O
)	O	O
.	O	O

CIN	O	O
was	O	O
significantly	O	O
more	O	O
after	O	O
treatment	O	O
with	O	O
bevacizumab	B-Chemical	-1
/	O	O
irinotecan	B-Chemical	C051890
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

021	O	O
)	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
hypertension	B-Disease	D006973
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

044	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
incidence	O	O
of	O	O
CIN	O	O
after	O	O
CT	O	O
in	O	O
hospitalised	O	O
oncological	O	O
patients	O	O
was	O	O
20	O	O
%	O	O
.	O	O

CIN	O	O
developed	O	O
4	O	O
.	O	O

5	O	O
-	O	O
times	O	O
more	O	O
frequently	O	O
in	O	O
patients	O	O
with	O	O
cancer	B-Disease	D009369
who	O	O
had	O	O
undergone	O	O
recent	O	O
chemotherapy	O	O
.	O	O

Hypertension	B-Disease	D006973
and	O	O
the	O	O
combination	O	O
of	O	O
bevacizumab	B-Chemical	-1
/	O	O
irinotecan	B-Chemical	C051890
may	O	O
be	O	O
additional	O	O
risk	O	O
factors	O	O
for	O	O
CIN	O	O
development	O	O
.	O	O

KEY	O	O
POINTS	O	O
:	O	O
.	O	O

Contrast	B-Chemical	D003287
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
(	O	O
CIN	O	O
)	O	O
is	O	O
a	O	O
concern	O	O
for	O	O
oncological	O	O
patients	O	O
undergoing	O	O
CT	O	O
.	O	O

.	O	O

CIN	O	O
occurs	O	O
more	O	O
often	O	O
when	O	O
CT	O	O
is	O	O
performed	O	O
<45	O	O
days	O	O
after	O	O
chemotherapy	O	O
.	O	O

.	O	O

Hypertension	B-Disease	D006973
and	O	O
treatment	O	O
with	O	O
bevacizumab	B-Chemical	-1
appear	O	O
to	O	O
be	O	O
additional	O	O
risk	O	O
factors	O	O
.	O	O

Syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
antidiuretic	I-Disease	D007177
hormone	I-Disease	D007177
secretion	O	O
associated	O	O
with	O	O
desvenlafaxine	B-Chemical	C086816
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
anti	I-Disease	D007177
-	I-Disease	D007177
diuretic	I-Disease	D007177
hormone	I-Disease	D007177
(	O	O
SIADH	B-Disease	D007177
)	O	O
secretion	O	O
associated	O	O
with	O	O
desvenlafaxine	B-Chemical	C086816
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
57	O	O
-	O	O
year	O	O
old	O	O
female	O	O
with	O	O
hyponatraemia	B-Disease	D007010
.	O	O

Her	O	O
medications	O	O
included	O	O
desvenlafaxine	B-Chemical	C086816
,	O	O
and	O	O
symptoms	O	O
included	O	O
nausea	B-Disease	D009325
,	O	O
anxiety	B-Disease	D001008
and	O	O
confusion	B-Disease	D003221
.	O	O

The	O	O
serum	O	O
sodium	B-Chemical	D012964
at	O	O
this	O	O
time	O	O
was	O	O
120	O	O
mmol	O	O
/	O	O
L	O	O
,	O	O
serum	O	O
osmolality	O	O
was	O	O
263	O	O
mosmol	O	O
/	O	O
kg	O	O
,	O	O
urine	O	O
osmolality	O	O
410	O	O
mosmol	O	O
/	O	O
kg	O	O
and	O	O
urine	O	O
sodium	B-Chemical	D012964
63	O	O
mmol	O	O
/	O	O
L	O	O
,	O	O
consistent	O	O
with	O	O
a	O	O
diagnosis	O	O
of	O	O
SIADH	B-Disease	D007177
.	O	O

Desvenlafaxine	B-Chemical	C086816
was	O	O
ceased	O	O
and	O	O
fluid	O	O
restriction	O	O
implemented	O	O
.	O	O

After	O	O
4	O	O
days	O	O
the	O	O
sodium	B-Chemical	D012964
increased	O	O
to	O	O
128	O	O
mmol	O	O
/	O	O
L	O	O
and	O	O
fluid	O	O
restriction	O	O
was	O	O
relaxed	O	O
.	O	O

During	O	O
her	O	O
further	O	O
3	O	O
weeks	O	O
inpatient	O	O
admission	O	O
the	O	O
serum	O	O
sodium	B-Chemical	D012964
ranged	O	O
from	O	O
134	O	O
to	O	O
137	O	O
mmol	O	O
/	O	O
L	O	O
during	O	O
treatment	O	O
with	O	O
mirtazapine	B-Chemical	C035133
.	O	O

DISCUSSION	O	O
:	O	O
SIADH	B-Disease	D007177
has	O	O
been	O	O
widely	O	O
reported	O	O
with	O	O
a	O	O
range	O	O
of	O	O
antidepressants	O	O
.	O	O

This	O	O
case	O	O
report	O	O
suggests	O	O
that	O	O
desvenlafaxine	B-Chemical	C086816
might	O	O
cause	O	O
clinically	O	O
significant	O	O
hyponatremia	B-Disease	D007010
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
potential	O	O
for	O	O
antidepressants	O	O
to	O	O
cause	O	O
hyponatremia	B-Disease	D007010
,	O	O
and	O	O
take	O	O
appropriate	O	O
corrective	O	O
action	O	O
where	O	O
necessary	O	O
.	O	O

Oxidative	O	O
stress	O	O
on	O	O
cardiotoxicity	B-Disease	D066126
after	O	O
treatment	O	O
with	O	O
single	O	O
and	O	O
multiple	O	O
doses	O	O
of	O	O
doxorubicin	B-Chemical	D004317
.	O	O

The	O	O
mechanism	O	O
of	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
remains	O	O
controversial	O	O
.	O	O

Wistar	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
66	O	O
)	O	O
received	O	O
DOX	B-Chemical	D004317
injections	O	O
intraperitoneally	O	O
and	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
2	O	O
experimental	O	O
protocols	O	O
:	O	O
(	O	O
1	O	O
)	O	O
rats	O	O
were	O	O
killed	O	O
before	O	O
(	O	O
-	O	O
24	O	O
h	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
and	O	O
24	O	O
h	O	O
after	O	O
(	O	O
+24	O	O
h	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
DOX	B-Chemical	D004317
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
DOX	B-Chemical	D004317
acute	O	O
effect	O	O
and	O	O
(	O	O
2	O	O
)	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
58	O	O
)	O	O
received	O	O
4	O	O
injections	O	O
of	O	O
DOX	B-Chemical	D004317
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
/	O	O
week	O	O
)	O	O
and	O	O
were	O	O
killed	O	O
before	O	O
the	O	O
first	O	O
injection	O	O
(	O	O
M0	O	O
)	O	O
and	O	O
1	O	O
week	O	O
after	O	O
each	O	O
injection	O	O
(	O	O
M1	O	O
,	O	O
M2	O	O
,	O	O
M3	O	O
,	O	O
and	O	O
M4	O	O
)	O	O
to	O	O
determine	O	O
the	O	O
chronological	O	O
effects	O	O
.	O	O

Animals	O	O
used	O	O
at	O	O
M0	O	O
(	O	O
n	O	O
=	O	O
8	O	O
)	O	O
were	O	O
also	O	O
used	O	O
at	O	O
moment	O	O
-	O	O
24	O	O
h	O	O
of	O	O
acute	O	O
study	O	O
.	O	O

Cardiac	O	O
total	O	O
antioxidant	O	O
performance	O	O
(	O	O
TAP	O	O
)	O	O
,	O	O
DNA	O	O
damage	O	O
,	O	O
and	O	O
morphology	O	O
analyses	O	O
were	O	O
carried	O	O
out	O	O
at	O	O
each	O	O
time	O	O
point	O	O
.	O	O

Single	O	O
dose	O	O
of	O	O
DOX	B-Chemical	D004317
was	O	O
associated	O	O
with	O	O
increased	O	O
cardiac	B-Disease	D006331
disarrangement	I-Disease	D006331
,	O	O
necrosis	B-Disease	D009336
,	O	O
and	O	O
DNA	O	O
damage	O	O
(	O	O
strand	O	O
breaks	O	O
(	O	O
SBs	O	O
)	O	O
and	O	O
oxidized	O	O
pyrimidines	O	O
)	O	O
and	O	O
decreased	O	O
TAP	O	O
.	O	O

The	O	O
chronological	O	O
study	O	O
showed	O	O
an	O	O
effect	O	O
of	O	O
a	O	O
cumulative	O	O
dose	O	O
on	O	O
body	O	O
weight	O	O
(	O	O
R	O	O
=	O	O
-	O	O
0	O	O
.	O	O

99	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

011	O	O
)	O	O
,	O	O
necrosis	B-Disease	D009336
(	O	O
R	O	O
=	O	O
1	O	O
.	O	O

00	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

004	O	O
)	O	O
,	O	O
TAP	O	O
(	O	O
R	O	O
=	O	O
0	O	O
.	O	O

95	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

049	O	O
)	O	O
,	O	O
and	O	O
DNA	O	O
SBs	O	O
(	O	O
R	O	O
=	O	O
-	O	O
0	O	O
.	O	O

95	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

049	O	O
)	O	O
.	O	O

DNA	O	O
SBs	O	O
damage	O	O
was	O	O
negatively	O	O
associated	O	O
with	O	O
TAP	O	O
(	O	O
R	O	O
=	O	O
-	O	O
0	O	O
.	O	O

98	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

018	O	O
)	O	O
,	O	O
and	O	O
necrosis	B-Disease	D009336
(	O	O
R	O	O
=	O	O
-	O	O
0	O	O
.	O	O

97	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

027	O	O
)	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
that	O	O
oxidative	O	O
damage	O	O
is	O	O
associated	O	O
with	O	O
acute	O	O
cardiotoxicity	B-Disease	D066126
induced	O	O
by	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
DOX	B-Chemical	D004317
only	O	O
.	O	O

Increased	O	O
resistance	O	O
to	O	O
the	O	O
oxidative	O	O
stress	O	O
is	O	O
plausible	O	O
for	O	O
the	O	O
multiple	O	O
dose	O	O
of	O	O
DOX	B-Chemical	D004317
.	O	O

Thus	O	O
,	O	O
different	O	O
mechanisms	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
acute	O	O
toxicity	B-Disease	D064420
versus	O	O
chronic	O	O
toxicity	B-Disease	D064420
.	O	O

Tacrolimus	B-Chemical	D016559
-	O	O
related	O	O
seizure	B-Disease	D012640
after	O	O
pediatric	O	O
liver	O	O
transplantation	O	O
-	O	O
-	O	O
a	O	O
single	O	O
-	O	O
center	O	O
experience	O	O
.	O	O

To	O	O
identify	O	O
the	O	O
risk	O	O
factors	O	O
for	O	O
new	O	O
-	O	O
onset	O	O
seizures	B-Disease	D012640
after	O	O
pediatric	O	O
LT	O	O
and	O	O
to	O	O
assess	O	O
their	O	O
clinical	O	O
implications	O	O
and	O	O
long	O	O
-	O	O
term	O	O
prognosis	O	O
.	O	O

The	O	O
clinical	O	O
and	O	O
laboratory	O	O
data	O	O
of	O	O
27	O	O
consecutive	O	O
children	O	O
who	O	O
underwent	O	O
LT	O	O
from	O	O
January	O	O
2007	O	O
to	O	O
December	O	O
2010	O	O
in	O	O
our	O	O
center	O	O
were	O	O
analyzed	O	O
retrospectively	O	O
.	O	O

Patients	O	O
were	O	O
divided	O	O
into	O	O
seizures	B-Disease	D012640
group	O	O
and	O	O
a	O	O
non	O	O
-	O	O
seizures	B-Disease	D012640
group	O	O
.	O	O

Pre	O	O
-	O	O
operative	O	O
,	O	O
intra	O	O
-	O	O
operative	O	O
,	O	O
and	O	O
post	O	O
-	O	O
operative	O	O
data	O	O
were	O	O
collected	O	O
.	O	O

Seizures	B-Disease	D012640
occurred	O	O
in	O	O
four	O	O
children	O	O
,	O	O
an	O	O
incidence	O	O
of	O	O
14	O	O
.	O	O

8%	O	O
.	O	O

All	O	O
exhibited	O	O
generalized	O	O
tonic	B-Disease	D004830
-	I-Disease	D004830
clonic	I-Disease	D004830
seizures	I-Disease	D004830
within	O	O
the	O	O
first	O	O
two	O	O
wk	O	O
after	O	O
LT	O	O
.	O	O

Univariate	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
seizures	B-Disease	D012640
after	O	O
pediatric	O	O
LT	O	O
included	O	O
gender	O	O
,	O	O
pediatric	O	O
end	B-Disease	D058625
-	I-Disease	D058625
stage	I-Disease	D058625
liver	I-Disease	D058625
disease	I-Disease	D058625
score	O	O
before	O	O
surgery	O	O
,	O	O
Child	O	O
-	O	O
Pugh	O	O
score	O	O
before	O	O
surgery	O	O
,	O	O
serum	O	O
total	O	O
bilirubin	B-Chemical	D001663
after	O	O
surgery	O	O
,	O	O
and	O	O
trough	O	O
TAC	B-Chemical	D016559
level	O	O
.	O	O

Multivariate	O	O
analysis	O	O
showed	O	O
that	O	O
trough	O	O
TAC	B-Chemical	D016559
level	O	O
was	O	O
the	O	O
only	O	O
independent	O	O
risk	O	O
factor	O	O
associated	O	O
with	O	O
the	O	O
seizures	B-Disease	D012640
.	O	O

All	O	O
children	O	O
who	O	O
experienced	O	O
seizures	B-Disease	D012640
survived	O	O
with	O	O
good	O	O
graft	O	O
function	O	O
and	O	O
remained	O	O
seizure	B-Disease	D012640
-	O	O
free	O	O
without	O	O
anti	O	O
-	O	O
epileptic	B-Disease	D004827
drugs	O	O
over	O	O
a	O	O
mean	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
of	O	O
33	O	O
.	O	O

7	O	O
+	O	O
14	O	O
.	O	O

6	O	O
months	O	O
.	O	O

High	O	O
trough	O	O
TAC	B-Chemical	D016559
level	O	O
was	O	O
the	O	O
predominant	O	O
factor	O	O
that	O	O
contributed	O	O
to	O	O
seizures	B-Disease	D012640
in	O	O
the	O	O
early	O	O
post	O	O
-	O	O
operative	O	O
period	O	O
after	O	O
pediatric	O	O
LT	O	O
.	O	O

High	O	O
PELD	O	O
and	O	O
Child	O	O
-	O	O
Pugh	O	O
scores	O	O
before	O	O
LT	O	O
and	O	O
high	O	O
post	O	O
-	O	O
operative	O	O
serum	O	O
Tbil	O	O
may	O	O
be	O	O
contributory	O	O
risk	O	O
factors	O	O
for	O	O
TAC	B-Chemical	D016559
-	O	O
related	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
flavonoid	B-Chemical	D005419
apigenin	B-Chemical	D047310
delays	O	O
forgetting	O	O
of	O	O
passive	O	O
avoidance	O	O
conditioning	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
experiments	O	O
were	O	O
performed	O	O
to	O	O
study	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
flavonoid	B-Chemical	D005419
apigenin	B-Chemical	D047310
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
1	O	O
h	O	O
before	O	O
acquisition	O	O
)	O	O
,	O	O
on	O	O
24	O	O
h	O	O
retention	O	O
performance	O	O
and	O	O
forgetting	O	O
of	O	O
a	O	O
step	O	O
-	O	O
through	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
in	O	O
young	O	O
male	O	O
Wistar	O	O
rats	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
saline	O	O
-	O	O
and	O	O
apigenin	B-Chemical	D047310
-	O	O
treated	O	O
groups	O	O
in	O	O
the	O	O
24	O	O
h	O	O
retention	O	O
trial	O	O
.	O	O

Furthermore	O	O
,	O	O
apigenin	B-Chemical	D047310
did	O	O
not	O	O
prevent	O	O
the	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
(	O	O
1mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
30	O	O
min	O	O
before	O	O
the	O	O
acquisition	O	O
)	O	O
.	O	O

The	O	O
saline	O	O
-	O	O
and	O	O
apigenin	B-Chemical	D047310
-	O	O
treated	O	O
rats	O	O
that	O	O
did	O	O
not	O	O
step	O	O
through	O	O
into	O	O
the	O	O
dark	O	O
compartment	O	O
during	O	O
the	O	O
cut	O	O
-	O	O
off	O	O
time	O	O
(	O	O
540	O	O
s	O	O
)	O	O
were	O	O
retested	O	O
weekly	O	O
for	O	O
up	O	O
to	O	O
eight	O	O
weeks	O	O
.	O	O

In	O	O
the	O	O
saline	O	O
treated	O	O
group	O	O
,	O	O
the	O	O
first	O	O
significant	O	O
decline	O	O
in	O	O
passive	O	O
avoidance	O	O
response	O	O
was	O	O
observed	O	O
at	O	O
four	O	O
weeks	O	O
,	O	O
and	O	O
complete	O	O
memory	B-Disease	D008569
loss	I-Disease	D008569
was	O	O
found	O	O
five	O	O
weeks	O	O
after	O	O
the	O	O
acquisition	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
the	O	O
experimental	O	O
period	O	O
,	O	O
60%	O	O
of	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
apigenin	B-Chemical	D047310
still	O	O
did	O	O
not	O	O
step	O	O
through	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
apigenin	B-Chemical	D047310
delays	O	O
the	O	O
long	O	O
-	O	O
term	O	O
forgetting	O	O
but	O	O
did	O	O
not	O	O
modulate	O	O
the	O	O
24	O	O
h	O	O
retention	O	O
of	O	O
fear	O	O
memory	O	O
and	O	O
2	O	O
)	O	O
the	O	O
obtained	O	O
beneficial	O	O
effect	O	O
of	O	O
apigenin	B-Chemical	D047310
on	O	O
the	O	O
passive	O	O
avoidance	O	O
conditioning	O	O
is	O	O
mediated	O	O
by	O	O
mechanisms	O	O
that	O	O
do	O	O
not	O	O
implicate	O	O
its	O	O
action	O	O
on	O	O
the	O	O
muscarinic	O	O
cholinergic	O	O
system	O	O
.	O	O

Cholecystokinin	B-Chemical	D012844
-	I-Chemical	D012844
octapeptide	I-Chemical	D012844
restored	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
hippocampal	O	O
long	O	O
-	O	O
term	O	O
potentiation	O	O
impairment	O	O
in	O	O
rats	O	O
.	O	O

Cholecystokinin	B-Chemical	D012844
-	I-Chemical	D012844
octapeptide	I-Chemical	D012844
(	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
)	O	O
,	O	O
which	O	O
is	O	O
a	O	O
typical	O	O
brain	O	O
-	O	O
gut	O	O
peptide	O	O
,	O	O
exerts	O	O
a	O	O
wide	O	O
range	O	O
of	O	O
biological	O	O
activities	O	O
on	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
reported	O	O
that	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
significantly	O	O
alleviated	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
amnesia	B-Disease	D000647
and	O	O
reversed	O	O
spine	O	O
density	O	O
decreases	O	O
in	O	O
the	O	O
CA1	O	O
region	O	O
of	O	O
the	O	O
hippocampus	O	O
in	O	O
morphine	B-Chemical	D009020
-	O	O
treated	O	O
animals	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
on	O	O
long	O	O
-	O	O
term	O	O
potentiation	O	O
(	O	O
LTP	O	O
)	O	O
in	O	O
the	O	O
lateral	O	O
perforant	O	O
path	O	O
(	O	O
LPP	O	O
)	O	O
-	O	O
granule	O	O
cell	O	O
synapse	O	O
of	O	O
rat	O	O
dentate	O	O
gyrus	O	O
(	O	O
DG	O	O
)	O	O
in	O	O
acute	O	O
saline	O	O
or	O	O
morphine	B-Chemical	D009020
-	O	O
treated	O	O
rats	O	O
.	O	O

Population	O	O
spikes	O	O
(	O	O
PS	O	O
)	O	O
,	O	O
which	O	O
were	O	O
evoked	O	O
by	O	O
stimulation	O	O
of	O	O
the	O	O
LPP	O	O
,	O	O
were	O	O
recorded	O	O
in	O	O
the	O	O
DG	O	O
region	O	O
.	O	O

Acute	O	O
morphine	B-Chemical	D009020
(	O	O
30mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
treatment	O	O
significantly	O	O
attenuated	O	O
hippocampal	O	O
LTP	O	O
and	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
(	O	O
1ug	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
restored	O	O
the	O	O
amplitude	O	O
of	O	O
PS	O	O
that	O	O
was	O	O
attenuated	O	O
by	O	O
morphine	B-Chemical	D009020
injection	O	O
.	O	O

Furthermore	O	O
,	O	O
microinjection	O	O
of	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
(	O	O
0	O	O
.	O	O

1	O	O
and	O	O
1ug	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
also	O	O
significantly	O	O
augmented	O	O
hippocampal	O	O
LTP	O	O
in	O	O
saline	O	O
-	O	O
treated	O	O
(	O	O
1ml	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
rats	O	O
.	O	O

Pre	O	O
-	O	O
treatment	O	O
of	O	O
the	O	O
CCK2	O	O
receptor	O	O
antagonist	O	O
L	O	O
-	O	O
365	O	O
,	O	O
260	O	O
(	O	O
10ug	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
)	O	O
reversed	O	O
the	O	O
effects	O	O
of	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
,	O	O
but	O	O
the	O	O
CCK1	O	O
receptor	O	O
antagonist	O	O
L	O	O
-	O	O
364	O	O
,	O	O
718	O	O
(	O	O
10ug	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
)	O	O
did	O	O
not	O	O
.	O	O

The	O	O
present	O	O
results	O	O
demonstrate	O	O
that	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
attenuates	O	O
the	O	O
effect	O	O
of	O	O
morphine	B-Chemical	D009020
on	O	O
hippocampal	O	O
LTP	O	O
through	O	O
CCK2	O	O
receptors	O	O
and	O	O
suggest	O	O
an	O	O
ameliorative	O	O
function	O	O
of	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
on	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
.	O	O

Glial	O	O
activation	O	O
and	O	O
post	O	O
-	O	O
synaptic	O	O
neurotoxicity	B-Disease	D020258
:	O	O
the	O	O
key	O	O
events	O	O
in	O	O
Streptozotocin	B-Chemical	D013311
(	O	O
ICV	O	O
)	O	O
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
in	O	O
rats	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
the	O	O
role	O	O
of	O	O
glial	O	O
activation	O	O
and	O	O
post	O	O
synaptic	O	O
toxicity	B-Disease	D064420
in	O	O
ICV	O	O
Streptozotocin	B-Chemical	D013311
(	O	O
STZ	B-Chemical	D013311
)	O	O
induced	O	O
memory	B-Disease	D008569
impaired	I-Disease	D008569
rats	O	O
was	O	O
explored	O	O
.	O	O

In	O	O
experiment	O	O
set	O	O
up	O	O
1	O	O
:	O	O
Memory	B-Disease	D008569
deficit	I-Disease	D008569
was	O	O
found	O	O
in	O	O
Morris	O	O
water	O	O
maze	O	O
test	O	O
on	O	O
14	O	O
-	O	O
16	O	O
days	O	O
after	O	O
STZ	B-Chemical	D013311
(	O	O
ICV	O	O
;	O	O
3mg	O	O
/	O	O
Kg	O	O
)	O	O
administration	O	O
.	O	O

STZ	B-Chemical	D013311
causes	O	O
increased	O	O
expression	O	O
of	O	O
GFAP	O	O
,	O	O
CD11b	O	O
and	O	O
TNF	O	O
-	O	O
a	O	O
indicating	O	O
glial	O	O
activation	O	O
and	O	O
neuroinflammation	B-Disease	D007249
.	O	O

STZ	B-Chemical	D013311
also	O	O
significantly	O	O
increased	O	O
the	O	O
level	O	O
of	O	O
ROS	O	O
,	O	O
nitrite	B-Chemical	D009573
,	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
and	O	O
reduced	O	O
the	O	O
mitochondrial	O	O
activity	O	O
in	O	O
synaptosomal	O	O
preparation	O	O
illustrating	O	O
free	O	O
radical	O	O
generation	O	O
and	O	O
excitotoxicity	B-Disease	D064420
.	O	O

Increased	O	O
expression	O	O
and	O	O
activity	O	O
of	O	O
Caspase	O	O
-	O	O
3	O	O
was	O	O
also	O	O
observed	O	O
in	O	O
STZ	B-Chemical	D013311
treated	O	O
rat	O	O
which	O	O
specify	O	O
apoptotic	O	O
cell	O	O
death	O	O
in	O	O
hippocampus	O	O
and	O	O
cortex	O	O
.	O	O

STZ	B-Chemical	D013311
treatment	O	O
showed	O	O
decrease	O	O
expression	O	O
of	O	O
post	O	O
synaptic	O	O
markers	O	O
CaMKIIa	O	O
and	O	O
PSD	O	O
-	O	O
95	O	O
,	O	O
while	O	O
,	O	O
expression	O	O
of	O	O
pre	O	O
synaptic	O	O
markers	O	O
(	O	O
synaptophysin	O	O
and	O	O
SNAP	O	O
-	O	O
25	O	O
)	O	O
remains	O	O
unaltered	O	O
indicating	O	O
selective	O	O
post	O	O
synaptic	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Oral	O	O
treatment	O	O
with	O	O
Memantine	B-Chemical	D008559
(	O	O
10mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
Ibuprofen	B-Chemical	D007052
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
daily	O	O
for	O	O
13	O	O
days	O	O
attenuated	O	O
STZ	B-Chemical	D013311
induced	O	O
glial	O	O
activation	O	O
,	O	O
apoptotic	O	O
cell	O	O
death	O	O
and	O	O
post	O	O
synaptic	O	O
neurotoxicity	B-Disease	D020258
in	O	O
rat	O	O
brain	O	O
.	O	O

Further	O	O
,	O	O
in	O	O
experiment	O	O
set	O	O
up	O	O
2	O	O
:	O	O
where	O	O
memory	O	O
function	O	O
was	O	O
not	O	O
affected	O	O
i	O	O
.	O	O

e	O	O
.	O	O

7	O	O
-	O	O
9	O	O
days	O	O
after	O	O
STZ	B-Chemical	D013311
treatment	O	O
.	O	O

The	O	O
level	O	O
of	O	O
GFAP	O	O
,	O	O
CD11b	O	O
,	O	O
TNF	O	O
-	O	O
a	O	O
,	O	O
ROS	O	O
and	O	O
nitrite	B-Chemical	D009573
levels	O	O
were	O	O
increased	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
apoptotic	O	O
marker	O	O
,	O	O
synaptic	O	O
markers	O	O
,	O	O
mitochondrial	O	O
activity	O	O
and	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
levels	O	O
remained	O	O
unaffected	O	O
.	O	O

Collective	O	O
data	O	O
indicates	O	O
that	O	O
neuroinflammatory	B-Disease	D007249
process	O	O
and	O	O
oxidative	O	O
stress	O	O
occurs	O	O
earlier	O	O
to	O	O
apoptosis	O	O
and	O	O
does	O	O
not	O	O
affect	O	O
memory	O	O
function	O	O
.	O	O

Present	O	O
study	O	O
clearly	O	O
suggests	O	O
that	O	O
glial	O	O
activation	O	O
and	O	O
post	O	O
synaptic	O	O
neurotoxicity	B-Disease	D020258
are	O	O
the	O	O
key	O	O
factors	O	O
in	O	O
STZ	B-Chemical	D013311
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
and	O	O
neuronal	O	O
cell	O	O
death	O	O
.	O	O

Comparison	O	O
of	O	O
effects	O	O
of	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
with	O	O
diltiazem	B-Chemical	D004110
in	O	O
prevention	O	O
of	O	O
contrast	B-Chemical	D003287
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
.	O	O

INTRODUCTION	O	O
AND	O	O
OBJECTIVE	O	O
:	O	O
Contrast	B-Chemical	D003287
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
(	O	O
CIN	O	O
)	O	O
significantly	O	O
increases	O	O
the	O	O
morbidity	O	O
and	O	O
mortality	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
and	O	O
compare	O	O
the	O	O
protective	O	O
effects	O	O
of	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
with	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
infusion	O	O
and	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
infusion	O	O
with	O	O
diltiazem	B-Chemical	D004110
,	O	O
a	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
,	O	O
in	O	O
preventing	O	O
CIN	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Our	O	O
study	O	O
included	O	O
patients	O	O
who	O	O
were	O	O
administered	O	O
30	O	O
-	O	O
60	O	O
mL	O	O
of	O	O
iodinated	O	O
contrast	B-Chemical	D003287
agent	O	O
for	O	O
percutaneous	O	O
coronary	O	O
angiography	O	O
(	O	O
PCAG	O	O
)	O	O
,	O	O
all	O	O
with	O	O
creatinine	B-Chemical	D003404
values	O	O
between	O	O
1	O	O
.	O	O

1	O	O
and	O	O
3	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
dL	O	O
.	O	O

Patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
and	O	O
each	O	O
group	O	O
had	O	O
20	O	O
patients	O	O
.	O	O

The	O	O
first	O	O
group	O	O
of	O	O
patients	O	O
was	O	O
administered	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
;	O	O
the	O	O
second	O	O
group	O	O
was	O	O
administered	O	O
a	O	O
solution	O	O
that	O	O
of	O	O
5%	O	O
dextrose	B-Chemical	D005947
and	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
,	O	O
while	O	O
the	O	O
third	O	O
group	O	O
was	O	O
administered	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
before	O	O
and	O	O
after	O	O
the	O	O
contrast	B-Chemical	D003287
injection	O	O
.	O	O

The	O	O
third	O	O
group	O	O
received	O	O
an	O	O
additional	O	O
injection	O	O
of	O	O
diltiazem	B-Chemical	D004110
the	O	O
day	O	O
before	O	O
and	O	O
first	O	O
2	O	O
days	O	O
after	O	O
the	O	O
contrast	B-Chemical	D003287
injection	O	O
.	O	O

All	O	O
of	O	O
the	O	O
patients'	O	O
plasma	O	O
blood	B-Chemical	D001806
urea	I-Chemical	D001806
nitrogen	I-Chemical	D001806
(	O	O
BUN	B-Chemical	D001806
)	O	O
and	O	O
creatinine	B-Chemical	D003404
levels	O	O
were	O	O
measured	O	O
on	O	O
the	O	O
second	O	O
and	O	O
seventh	O	O
day	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
intravenous	O	O
contrast	B-Chemical	D003287
material	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
basal	O	O
creatinine	B-Chemical	D003404
levels	O	O
were	O	O
similar	O	O
for	O	O
all	O	O
three	O	O
groups	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Among	O	O
a	O	O
total	O	O
of	O	O
60	O	O
patients	O	O
included	O	O
in	O	O
the	O	O
study	O	O
,	O	O
16	O	O
patients	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
(	O	O
ARF	B-Disease	D058186
)	O	O
on	O	O
the	O	O
second	O	O
day	O	O
after	O	O
contrast	B-Chemical	D003287
material	O	O
was	O	O
injected	O	O
(	O	O
26	O	O
.	O	O

6%	O	O
)	O	O
.	O	O

The	O	O
number	O	O
of	O	O
patients	O	O
who	O	O
developed	O	O
ARF	B-Disease	D058186
on	O	O
the	O	O
second	O	O
day	O	O
after	O	O
the	O	O
injection	O	O
in	O	O
the	O	O
first	O	O
group	O	O
was	O	O
five	O	O
(	O	O
25%	O	O
)	O	O
,	O	O
in	O	O
the	O	O
second	O	O
group	O	O
was	O	O
six	O	O
(	O	O
30%	O	O
)	O	O
and	O	O
the	O	O
third	O	O
group	O	O
was	O	O
five	O	O
(	O	O
25%	O	O
)	O	O
(	O	O
p	O	O
>	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
,	O	O
sodium	B-Chemical	D017693
bicarbonate	I-Chemical	D017693
and	O	O
isotonic	O	O
sodium	B-Chemical	D012965
chloride	I-Chemical	D012965
with	O	O
diltiazem	B-Chemical	D004110
application	O	O
in	O	O
prevention	O	O
of	O	O
CIN	O	O
.	O	O

Neurocognitive	O	O
and	O	O
neuroradiologic	O	O
central	O	O
nervous	O	O
system	O	O
late	O	O
effects	O	O
in	O	O
children	O	O
treated	O	O
on	O	O
Pediatric	O	O
Oncology	O	O
Group	O	O
(	O	O
POG	O	O
)	O	O
P9605	O	O
(	O	O
standard	O	O
risk	O	O
)	O	O
and	O	O
P9201	O	O
(	O	O
lesser	O	O
risk	O	O
)	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
protocols	O	O
(	O	O
ACCL0131	O	O
)	O	O
:	O	O
a	O	O
methotrexate	B-Chemical	D008727
consequence?	O	O
A	O	O
report	O	O
from	O	O
the	O	O
Children's	O	O
Oncology	O	O
Group	O	O
.	O	O

Concerns	O	O
about	O	O
long	O	O
-	O	O
term	O	O
methotrexate	B-Chemical	D008727
(	O	O
MTX	B-Chemical	D008727
)	O	O
neurotoxicity	B-Disease	D020258
in	O	O
the	O	O
1990s	O	O
led	O	O
to	O	O
modifications	O	O
in	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
therapy	O	O
,	O	O
leucovorin	O	O
rescue	O	O
,	O	O
and	O	O
frequency	O	O
of	O	O
systemic	O	O
MTX	B-Chemical	D008727
administration	O	O
in	O	O
children	O	O
with	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
neurocognitive	O	O
outcomes	O	O
and	O	O
neuroradiologic	O	O
evidence	O	O
of	O	O
leukoencephalopathy	B-Disease	D056784
were	O	O
compared	O	O
in	O	O
children	O	O
treated	O	O
with	O	O
intense	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
-	O	O
directed	O	O
therapy	O	O
(	O	O
P9605	O	O
)	O	O
versus	O	O
those	O	O
receiving	O	O
fewer	O	O
CNS	O	O
-	O	O
directed	O	O
treatment	O	O
days	O	O
during	O	O
intensive	O	O
consolidation	O	O
(	O	O
P9201	O	O
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
66	O	O
children	O	O
from	O	O
16	O	O
Pediatric	O	O
Oncology	O	O
Group	O	O
institutions	O	O
with	O	O
"standard	O	O
-	O	O
risk"	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
,	O	O
1	O	O
.	O	O

00	O	O
to	O	O
9	O	O
.	O	O

99	O	O
years	O	O
at	O	O
diagnosis	O	O
,	O	O
without	O	O
evidence	O	O
of	O	O
CNS	O	O
leukemia	B-Disease	D007938
at	O	O
diagnosis	O	O
were	O	O
enrolled	O	O
on	O	O
ACCL0131	O	O
:	O	O
28	O	O
from	O	O
P9201	O	O
and	O	O
38	O	O
from	O	O
P9605	O	O
.	O	O

Magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
and	O	O
standard	O	O
neuropsychological	O	O
tests	O	O
were	O	O
performed	O	O
>2	O	O
.	O	O

6	O	O
years	O	O
after	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
.	O	O

Significantly	O	O
more	O	O
P9605	O	O
patients	O	O
developed	O	O
leukoencephalopathy	B-Disease	D056784
compared	O	O
with	O	O
P9201	O	O
patients	O	O
(	O	O
68%	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
49%	O	O
-	O	O
83%	O	O
vs	O	O
.	O	O

22%	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
5%	O	O
-	O	O
44%	O	O
;	O	O
P=0	O	O
.	O	O

001	O	O
)	O	O
identified	O	O
as	O	O
late	O	O
as	O	O
7	O	O
.	O	O

7	O	O
years	O	O
after	O	O
the	O	O
end	O	O
of	O	O
treatment	O	O
.	O	O

Overall	O	O
,	O	O
40%	O	O
of	O	O
patients	O	O
scored	O	O
<85	O	O
on	O	O
either	O	O
Verbal	O	O
or	O	O
Performance	O	O
IQ	O	O
.	O	O

Children	O	O
on	O	O
both	O	O
studies	O	O
had	O	O
significant	O	O
attention	B-Disease	D003072
problems	I-Disease	D003072
,	O	O
but	O	O
P9605	O	O
children	O	O
scored	O	O
below	O	O
average	O	O
on	O	O
more	O	O
neurocognitive	O	O
measures	O	O
than	O	O
those	O	O
treated	O	O
on	O	O
P9201	O	O
(	O	O
82%	O	O
,	O	O
14	O	O
/	O	O
17	O	O
measures	O	O
vs	O	O
.	O	O

24%	O	O
,	O	O
4	O	O
/	O	O
17	O	O
measures	O	O
)	O	O
.	O	O

This	O	O
supports	O	O
ongoing	O	O
concerns	O	O
about	O	O
intensive	O	O
MTX	B-Chemical	D008727
exposure	O	O
as	O	O
a	O	O
major	O	O
contributor	O	O
to	O	O
CNS	O	O
late	O	O
effects	O	O
.	O	O

Tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
overdosage	O	O
-	O	O
induced	O	O
generalized	O	O
seizure	B-Disease	D012640
in	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

We	O	O
report	O	O
a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
lady	O	O
with	O	O
chronic	B-Disease	D051436
kidney	I-Disease	D051436
disease	I-Disease	D051436
stage	O	O
4	O	O
due	O	O
to	O	O
chronic	O	O
tubulointerstial	B-Disease	D004194
disease	I-Disease	D004194
.	O	O

She	O	O
was	O	O
admitted	O	O
to	O	O
our	O	O
center	O	O
for	O	O
severe	O	O
anemia	B-Disease	D000740
due	O	O
to	O	O
menorrhagia	B-Disease	D008595
and	O	O
deterioration	B-Disease	D051437
of	I-Disease	D051437
renal	I-Disease	D051437
function	I-Disease	D051437
.	O	O

She	O	O
was	O	O
infused	O	O
three	O	O
units	O	O
of	O	O
packed	O	O
cells	O	O
during	O	O
a	O	O
session	O	O
of	O	O
hemodialysis	O	O
.	O	O

Tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
(	O	O
TNA	B-Chemical	D014148
)	O	O
1	O	O
g	O	O
8	O	O
-	O	O
hourly	O	O
was	O	O
administered	O	O
to	O	O
her	O	O
to	O	O
control	O	O
bleeding	B-Disease	D006470
per	O	O
vaginum	O	O
.	O	O

Two	O	O
hours	O	O
after	O	O
the	O	O
sixth	O	O
dose	O	O
of	O	O
TNA	B-Chemical	D014148
,	O	O
she	O	O
had	O	O
an	O	O
episode	O	O
of	O	O
generalized	O	O
tonic	B-Disease	D004830
clonic	I-Disease	D004830
convulsions	I-Disease	D004830
.	O	O

TNA	B-Chemical	D014148
was	O	O
discontinued	O	O
.	O	O

Investigations	O	O
of	O	O
the	O	O
patient	O	O
revealed	O	O
no	O	O
biochemical	O	O
or	O	O
structural	O	O
central	O	O
nervous	B-Disease	D009421
system	I-Disease	D009421
abnormalities	I-Disease	D009421
that	O	O
could	O	O
have	O	O
provoked	O	O
the	O	O
convulsions	B-Disease	D012640
.	O	O

She	O	O
did	O	O
not	O	O
require	O	O
any	O	O
further	O	O
dialytic	O	O
support	O	O
.	O	O

She	O	O
had	O	O
no	O	O
further	O	O
episodes	O	O
of	O	O
convulsion	B-Disease	D012640
till	O	O
dis	O	O
-	O	O
charge	O	O
and	O	O
during	O	O
the	O	O
two	O	O
months	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
precipitating	O	O
cause	O	O
of	O	O
convulsions	B-Disease	D012640
was	O	O
believed	O	O
to	O	O
be	O	O
an	O	O
overdose	B-Disease	D062787
of	O	O
TNA	B-Chemical	D014148
.	O	O

Pre	O	O
-	O	O
treatment	O	O
of	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiovascular	B-Disease	D002318
depression	I-Disease	D002318
using	O	O
different	O	O
lipid	O	O
formulations	O	O
of	O	O
propofol	B-Chemical	D015742
.	O	O

BACKGROUND	O	O
:	O	O
Pre	O	O
-	O	O
treatment	O	O
with	O	O
lipid	O	O
emulsions	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
increase	O	O
lethal	O	O
doses	O	O
of	O	O
bupivacaine	B-Chemical	D002045
,	O	O
and	O	O
the	O	O
lipid	O	O
content	O	O
of	O	O
propofol	B-Chemical	D015742
may	O	O
alleviate	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
propofol	B-Chemical	D015742
in	O	O
intralipid	O	O
or	O	O
medialipid	O	O
emulsions	O	O
on	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

METHODS	O	O
:	O	O
Rats	O	O
were	O	O
anaesthetised	O	O
with	O	O
ketamine	B-Chemical	D007649
and	O	O
were	O	O
given	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
propofol	B-Chemical	D015742
in	O	O
intralipid	O	O
(	O	O
Group	O	O
P	O	O
)	O	O
,	O	O
propofol	B-Chemical	D015742
in	O	O
medialipid	O	O
(	O	O
Group	O	O
L	O	O
)	O	O
,	O	O
or	O	O
saline	O	O
(	O	O
Group	O	O
C	O	O
)	O	O
over	O	O
20	O	O
min	O	O
.	O	O

Thereafter	O	O
,	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
bupivacaine	B-Chemical	D002045
0	O	O
.	O	O

5%	O	O
was	O	O
infused	O	O
.	O	O

We	O	O
recorded	O	O
time	O	O
to	O	O
first	O	O
dysrhythmia	B-Disease	D001145
occurrence	O	O
,	O	O
respective	O	O
times	O	O
to	O	O
25%	O	O
and	O	O
50%	O	O
reduction	O	O
of	O	O
the	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
and	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
and	O	O
time	O	O
to	O	O
asystole	B-Disease	D006323
and	O	O
total	O	O
amount	O	O
of	O	O
bupivacaine	B-Chemical	D002045
consumption	O	O
.	O	O

Blood	O	O
and	O	O
tissue	O	O
samples	O	O
were	O	O
collected	O	O
following	O	O
asystole	B-Disease	D006323
.	O	O

RESULTS	O	O
:	O	O
The	O	O
time	O	O
to	O	O
first	O	O
dysrhythmia	B-Disease	D001145
occurrence	O	O
,	O	O
time	O	O
to	O	O
25%	O	O
and	O	O
50%	O	O
reductions	O	O
in	O	O
HR	O	O
,	O	O
and	O	O
time	O	O
to	O	O
asystole	B-Disease	D006323
were	O	O
longer	O	O
in	O	O
Group	O	O
P	O	O
than	O	O
the	O	O
other	O	O
groups	O	O
.	O	O

The	O	O
cumulative	O	O
bupivacaine	B-Chemical	D002045
dose	O	O
given	O	O
at	O	O
those	O	O
time	O	O
points	O	O
was	O	O
higher	O	O
in	O	O
Group	O	O
P	O	O
.	O	O

Plasma	O	O
bupivacaine	B-Chemical	D002045
levels	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
P	O	O
than	O	O
in	O	O
Group	O	O
C	O	O
.	O	O

Bupivacaine	B-Chemical	D002045
levels	O	O
in	O	O
the	O	O
brain	O	O
and	O	O
heart	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
P	O	O
and	O	O
Group	O	O
L	O	O
than	O	O
in	O	O
Group	O	O
C	O	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
propofol	B-Chemical	D015742
in	O	O
intralipid	O	O
,	O	O
compared	O	O
with	O	O
propofol	B-Chemical	D015742
in	O	O
medialipid	O	O
or	O	O
saline	O	O
,	O	O
delayed	O	O
the	O	O
onset	O	O
of	O	O
bupivacaine	B-Chemical	D002045
-	O	O
induced	O	O
cardiotoxic	B-Disease	D066126
effects	O	O
as	O	O
well	O	O
as	O	O
reduced	O	O
plasma	O	O
bupivacaine	B-Chemical	D002045
levels	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
explore	O	O
tissue	O	O
bupivacaine	B-Chemical	D002045
levels	O	O
of	O	O
propofol	B-Chemical	D015742
in	O	O
medialipid	O	O
and	O	O
adapt	O	O
these	O	O
results	O	O
to	O	O
clinical	O	O
practice	O	O
.	O	O

Drug	B-Disease	D056486
-	I-Disease	D056486
Induced	I-Disease	D056486
Acute	I-Disease	D056486
Liver	I-Disease	D056486
Injury	I-Disease	D056486
Within	O	O
12	O	O
Hours	O	O
After	O	O
Fluvastatin	B-Chemical	C065180
Therapy	O	O
.	O	O

Although	O	O
statins	B-Chemical	D019161
are	O	O
generally	O	O
well	O	O
-	O	O
tolerated	O	O
drugs	O	O
,	O	O
recent	O	O
cases	O	O
of	O	O
drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
liver	I-Disease	D056486
injury	I-Disease	D056486
associated	O	O
with	O	O
their	O	O
use	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

A	O	O
52	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Chinese	O	O
man	O	O
reported	O	O
with	O	O
liver	B-Disease	D056486
damage	I-Disease	D056486
,	O	O
which	O	O
appeared	O	O
12	O	O
hours	O	O
after	O	O
beginning	O	O
treatment	O	O
with	O	O
fluvastatin	B-Chemical	C065180
.	O	O

Patient	O	O
presented	O	O
with	O	O
complaints	O	O
of	O	O
increasing	O	O
nausea	B-Disease	D009325
,	O	O
anorexia	B-Disease	D000855
,	O	O
and	O	O
upper	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
.	O	O

His	O	O
laboratory	O	O
values	O	O
showed	O	O
elevated	O	O
creatine	B-Chemical	D003401
kinase	O	O
and	O	O
transaminases	O	O
.	O	O

Testing	O	O
for	O	O
autoantibodies	O	O
was	O	O
also	O	O
negative	O	O
.	O	O

The	O	O
liver	O	O
biochemistries	O	O
eventually	O	O
normalized	O	O
within	O	O
3	O	O
weeks	O	O
of	O	O
stopping	O	O
the	O	O
fluvastatin	B-Chemical	C065180
.	O	O

Therefore	O	O
,	O	O
when	O	O
prescribing	O	O
statins	B-Chemical	D019161
,	O	O
the	O	O
possibility	O	O
of	O	O
hepatic	B-Disease	D056486
damage	I-Disease	D056486
should	O	O
be	O	O
taken	O	O
into	O	O
account	O	O
.	O	O

Fluconazole	B-Chemical	D015725
associated	O	O
agranulocytosis	B-Disease	D000380
and	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

CASE	O	O
:	O	O
We	O	O
describe	O	O
a	O	O
second	O	O
case	O	O
of	O	O
fluconazole	B-Chemical	D015725
associated	O	O
agranulocytosis	B-Disease	D000380
with	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
recovery	O	O
upon	O	O
discontinuation	O	O
of	O	O
therapy	O	O
.	O	O

The	O	O
patient	O	O
began	O	O
to	O	O
have	O	O
changes	O	O
in	O	O
white	O	O
blood	O	O
cells	O	O
and	O	O
platelets	O	O
within	O	O
48	O	O
h	O	O
of	O	O
administration	O	O
of	O	O
fluconazole	B-Chemical	D015725
and	O	O
began	O	O
to	O	O
recover	O	O
with	O	O
48	O	O
h	O	O
of	O	O
discontinuation	O	O
.	O	O

This	O	O
case	O	O
highlights	O	O
that	O	O
drug	O	O
-	O	O
induced	O	O
blood	B-Disease	D006402
dyscrasias	I-Disease	D006402
can	O	O
occur	O	O
unexpectedly	O	O
as	O	O
a	O	O
result	O	O
of	O	O
treatment	O	O
with	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
thought	O	O
to	O	O
be	O	O
"safe"	O	O
.	O	O

CONCLUSION	O	O
:	O	O
According	O	O
to	O	O
Naranjo's	O	O
algorithm	O	O
the	O	O
likelihood	O	O
that	O	O
our	O	O
patient's	O	O
agranulocytosis	B-Disease	D000380
and	O	O
thrombocytopenia	B-Disease	D013921
occurred	O	O
as	O	O
a	O	O
result	O	O
of	O	O
therapy	O	O
with	O	O
fluconazole	B-Chemical	D015725
is	O	O
probable	O	O
,	O	O
with	O	O
a	O	O
total	O	O
of	O	O
six	O	O
points	O	O
.	O	O

We	O	O
feel	O	O
that	O	O
the	O	O
weight	O	O
of	O	O
the	O	O
overall	O	O
evidence	O	O
of	O	O
this	O	O
evidence	O	O
is	O	O
strong	O	O
.	O	O

In	O	O
particular	O	O
the	O	O
temporal	O	O
relationship	O	O
of	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
suppression	I-Disease	D001855
to	O	O
the	O	O
initiation	O	O
of	O	O
fluconazole	B-Chemical	D015725
and	O	O
the	O	O
abatement	O	O
of	O	O
symptoms	O	O
that	O	O
rapidly	O	O
reversed	O	O
immediately	O	O
following	O	O
discontinuation	O	O
.	O	O

Two	O	O
-	O	O
dimensional	O	O
speckle	O	O
tracking	O	O
echocardiography	O	O
combined	O	O
with	O	O
high	O	O
-	O	O
sensitive	O	O
cardiac	O	O
troponin	O	O
T	O	O
in	O	O
early	O	O
detection	O	O
and	O	O
prediction	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
during	O	O
epirubicine	B-Chemical	D015251
-	O	O
based	O	O
chemotherapy	O	O
.	O	O

AIMS	O	O
:	O	O
To	O	O
investigate	O	O
whether	O	O
alterations	O	O
of	O	O
myocardial	B-Disease	D009202
strain	I-Disease	D009202
and	O	O
high	O	O
-	O	O
sensitive	O	O
cardiac	O	O
troponin	O	O
T	O	O
(	O	O
cTnT	O	O
)	O	O
could	O	O
predict	O	O
future	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
in	O	O
patients	O	O
after	O	O
epirubicin	B-Chemical	D015251
exposure	O	O
.	O	O

METHODS	O	O
:	O	O
Seventy	O	O
-	O	O
five	O	O
patients	O	O
with	O	O
non	B-Disease	D008228
-	I-Disease	D008228
Hodgkin	I-Disease	D008228
lymphoma	I-Disease	D008228
treated	O	O
with	O	O
epirubicin	B-Chemical	D015251
were	O	O
studied	O	O
.	O	O

Blood	O	O
collection	O	O
and	O	O
echocardiography	O	O
were	O	O
performed	O	O
at	O	O
baseline	O	O
,	O	O
1	O	O
day	O	O
after	O	O
the	O	O
third	O	O
cycle	O	O
,	O	O
and	O	O
1	O	O
day	O	O
after	O	O
completion	O	O
of	O	O
chemotherapy	O	O
.	O	O

Patients	O	O
were	O	O
studied	O	O
using	O	O
echocardiography	O	O
during	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

Global	O	O
longitudinal	O	O
(	O	O
GLS	O	O
)	O	O
,	O	O
circumferential	O	O
(	O	O
GCS	O	O
)	O	O
,	O	O
and	O	O
radial	O	O
strain	O	O
(	O	O
GRS	O	O
)	O	O
were	O	O
calculated	O	O
using	O	O
speckle	O	O
tracking	O	O
echocardiography	O	O
.	O	O

Left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
was	O	O
analysed	O	O
by	O	O
real	O	O
-	O	O
time	O	O
3D	O	O
echocardiography	O	O
.	O	O

Cardiotoxicity	B-Disease	D066126
was	O	O
defined	O	O
as	O	O
a	O	O
reduction	O	O
of	O	O
the	O	O
LVEF	O	O
of	O	O
>5%	O	O
to	O	O
<55%	O	O
with	O	O
symptoms	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
or	O	O
an	O	O
asymptomatic	O	O
reduction	O	O
of	O	O
the	O	O
LVEF	O	O
of	O	O
>10%	O	O
to	O	O
<55%	O	O
.	O	O

RESULTS	O	O
:	O	O
Fourteen	O	O
patients	O	O
(	O	O
18	O	O
.	O	O

67%	O	O
)	O	O
developed	O	O
cardiotoxicity	B-Disease	D066126
after	O	O
treatment	O	O
.	O	O

GLS	O	O
(	O	O
-	O	O
18	O	O
.	O	O

48	O	O
+	O	O
1	O	O
.	O	O

72%	O	O
vs	O	O
.	O	O

-	O	O
15	O	O
.	O	O

96	O	O
+	O	O
1	O	O
.	O	O

6%	O	O
)	O	O
,	O	O
GCS	O	O
(	O	O
-	O	O
20	O	O
.	O	O

93	O	O
+	O	O
2	O	O
.	O	O

86%	O	O
vs	O	O
.	O	O

-	O	O
19	O	O
.	O	O

20	O	O
+	O	O
3	O	O
.	O	O

21%	O	O
)	O	O
,	O	O
and	O	O
GRS	O	O
(	O	O
39	O	O
.	O	O

23	O	O
+	O	O
6	O	O
.	O	O

44%	O	O
vs	O	O
.	O	O

34	O	O
.	O	O

98	O	O
+	O	O
6	O	O
.	O	O

2%	O	O
)	O	O
were	O	O
markedly	O	O
reduced	O	O
and	O	O
cTnT	O	O
was	O	O
elevated	O	O
from	O	O
0	O	O
.	O	O

0010	O	O
+	O	O
0	O	O
.	O	O

0020	O	O
to	O	O
0	O	O
.	O	O

0073	O	O
+	O	O
0	O	O
.	O	O

0038	O	O
ng	O	O
/	O	O
mL	O	O
(	O	O
P	O	O
all	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
chemotherapy	O	O
compared	O	O
with	O	O
baseline	O	O
values	O	O
.	O	O

A	O	O
>15	O	O
.	O	O

9%	O	O
decrease	O	O
in	O	O
GLS	O	O
[	O	O
sensitivity	O	O
,	O	O
86%	O	O
;	O	O
specificity	O	O
,	O	O
75%	O	O
;	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
(	O	O
AUC	O	O
)	O	O
=	O	O
0	O	O
.	O	O

815	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

001	O	O
]	O	O
and	O	O
a	O	O
>0	O	O
.	O	O

004	O	O
ng	O	O
/	O	O
mL	O	O
elevation	O	O
in	O	O
cTnT	O	O
(	O	O
sensitivity	O	O
,	O	O
79%	O	O
;	O	O
specificity	O	O
,	O	O
64%	O	O
;	O	O
AUC	O	O
=	O	O
0	O	O
.	O	O

757	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

005	O	O
)	O	O
from	O	O
baseline	O	O
to	O	O
the	O	O
third	O	O
cycle	O	O
of	O	O
chemotherapy	O	O
predicted	O	O
later	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

The	O	O
decrease	O	O
in	O	O
GLS	O	O
remained	O	O
the	O	O
only	O	O
independent	O	O
predictor	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

000	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
GLS	O	O
combined	O	O
with	O	O
cTnT	O	O
may	O	O
provide	O	O
a	O	O
reliable	O	O
and	O	O
non	O	O
-	O	O
invasive	O	O
method	O	O
to	O	O
predict	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
in	O	O
patients	O	O
receiving	O	O
anthracycline	B-Chemical	D018943
-	O	O
based	O	O
chemotherapy	O	O
.	O	O

Prevention	O	O
of	O	O
etomidate	B-Chemical	D005045
-	O	O
induced	O	O
myoclonus	B-Disease	D009207
:	O	O
which	O	O
is	O	O
superior	O	O
:	O	O
Fentanyl	B-Chemical	D005283
,	O	O
midazolam	B-Chemical	D008874
,	O	O
or	O	O
a	O	O
combination?	O	O
A	O	O
Retrospective	O	O
comparative	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
this	O	O
retrospective	O	O
comparative	O	O
study	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
compare	O	O
the	O	O
effectiveness	O	O
of	O	O
fentanyl	B-Chemical	D005283
,	O	O
midazolam	B-Chemical	D008874
,	O	O
and	O	O
a	O	O
combination	O	O
of	O	O
fentanyl	B-Chemical	D005283
and	O	O
midazolam	B-Chemical	D008874
to	O	O
prevent	O	O
etomidate	B-Chemical	D005045
-	O	O
induced	O	O
myoclonus	B-Disease	D009207
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
:	O	O
This	O	O
study	O	O
was	O	O
performed	O	O
based	O	O
on	O	O
anesthesia	O	O
records	O	O
.	O	O

Depending	O	O
on	O	O
the	O	O
drugs	O	O
that	O	O
would	O	O
be	O	O
given	O	O
before	O	O
the	O	O
induction	O	O
of	O	O
anesthesia	O	O
with	O	O
etomidate	B-Chemical	D005045
,	O	O
the	O	O
patients	O	O
were	O	O
separated	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
no	O	O
pretreatment	O	O
(	O	O
Group	O	O
NP	O	O
)	O	O
,	O	O
fentanyl	B-Chemical	D005283
1	O	O
ug	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
(	O	O
Group	O	O
F	O	O
)	O	O
,	O	O
midazolam	B-Chemical	D008874
0	O	O
.	O	O

03	O	O
mg	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
(	O	O
Group	O	O
M	O	O
)	O	O
,	O	O
and	O	O
midazolam	B-Chemical	D008874
0	O	O
.	O	O

015	O	O
mg	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
+	O	O
fentanyl	B-Chemical	D005283
0	O	O
.	O	O

5	O	O
ug	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
(	O	O
Group	O	O
FM	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
the	O	O
same	O	O
anesthetic	O	O
procedure	O	O
were	O	O
selected	O	O
:	O	O
2	O	O
minutes	O	O
after	O	O
intravenous	O	O
injections	O	O
of	O	O
the	O	O
pretreatment	O	O
drugs	O	O
,	O	O
anesthesia	O	O
is	O	O
induced	O	O
with	O	O
0	O	O
.	O	O

3	O	O
mg	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
etomidate	B-Chemical	D005045
injected	O	O
intravenously	O	O
over	O	O
a	O	O
period	O	O
of	O	O
20	O	O
-	O	O
30	O	O
seconds	O	O
.	O	O

Myoclonic	B-Disease	D009069
movements	I-Disease	D009069
are	O	O
evaluated	O	O
,	O	O
which	O	O
were	O	O
observed	O	O
and	O	O
graded	O	O
according	O	O
to	O	O
clinical	O	O
severity	O	O
during	O	O
the	O	O
2	O	O
minutes	O	O
after	O	O
etomidate	B-Chemical	D005045
injection	O	O
.	O	O

The	O	O
severity	O	O
of	O	O
pain	B-Disease	D010146
due	O	O
to	O	O
etomidate	B-Chemical	D005045
injection	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
evaluated	O	O
.	O	O

RESULTS	O	O
:	O	O
Study	O	O
results	O	O
showed	O	O
that	O	O
myoclonus	B-Disease	D009207
incidence	O	O
was	O	O
85%	O	O
,	O	O
40%	O	O
,	O	O
70%	O	O
,	O	O
and	O	O
25%	O	O
in	O	O
Group	O	O
NP	O	O
,	O	O
Group	O	O
F	O	O
,	O	O
Group	O	O
M	O	O
,	O	O
and	O	O
Group	O	O
FM	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
were	O	O
significantly	O	O
lower	O	O
in	O	O
Group	O	O
F	O	O
and	O	O
Group	O	O
FM	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
pretreatment	O	O
with	O	O
fentanyl	B-Chemical	D005283
or	O	O
combination	O	O
of	O	O
fentanyl	B-Chemical	D005283
and	O	O
midazolam	B-Chemical	D008874
was	O	O
effective	O	O
in	O	O
preventing	O	O
etomidate	B-Chemical	D005045
-	O	O
induced	O	O
myoclonus	B-Disease	D009207
.	O	O

Cholestatic	B-Disease	D002779
presentation	O	O
of	O	O
yellow	O	O
phosphorus	B-Chemical	D010758
poisoning	B-Disease	D011041
.	O	O

Yellow	O	O
phosphorus	B-Chemical	D010758
,	O	O
a	O	O
component	O	O
of	O	O
certain	O	O
pesticide	O	O
pastes	O	O
and	O	O
fireworks	O	O
,	O	O
is	O	O
well	O	O
known	O	O
to	O	O
cause	O	O
hepatotoxicity	B-Disease	D056486
.	O	O

Poisoning	B-Disease	D011041
with	O	O
yellow	O	O
phosphorus	B-Chemical	D010758
classically	O	O
manifests	O	O
with	O	O
acute	B-Disease	D006505
hepatitis	I-Disease	D006505
leading	O	O
to	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
which	O	O
may	O	O
need	O	O
liver	O	O
transplantation	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
of	O	O
yellow	O	O
phosphorus	B-Chemical	D010758
poisoning	B-Disease	D011041
in	O	O
which	O	O
a	O	O
patient	O	O
presented	O	O
with	O	O
florid	O	O
clinical	O	O
features	O	O
of	O	O
cholestasis	B-Disease	D002779
highlighting	O	O
the	O	O
fact	O	O
that	O	O
cholestasis	B-Disease	D002779
can	O	O
rarely	O	O
be	O	O
a	O	O
presenting	O	O
feature	O	O
of	O	O
yellow	O	O
phosphorus	B-Chemical	D010758
hepatotoxicity	B-Disease	D056486
.	O	O

Vasovagal	B-Disease	D019462
syncope	I-Disease	D019462
and	O	O
severe	O	O
bradycardia	B-Disease	D001919
following	O	O
intranasal	O	O
dexmedetomidine	B-Chemical	D020927
for	O	O
pediatric	O	O
procedural	O	O
sedation	O	O
.	O	O

We	O	O
report	O	O
syncope	B-Disease	D013575
and	O	O
bradycardia	B-Disease	D001919
in	O	O
an	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
following	O	O
administration	O	O
of	O	O
intranasal	O	O
dexmedetomidine	B-Chemical	D020927
for	O	O
sedation	O	O
for	O	O
a	O	O
voiding	O	O
cystourethrogram	O	O
.	O	O

Following	O	O
successful	O	O
completion	O	O
of	O	O
VCUG	O	O
and	O	O
a	O	O
60	O	O
-	O	O
min	O	O
recovery	O	O
period	O	O
,	O	O
the	O	O
patient's	O	O
level	O	O
of	O	O
consciousness	O	O
and	O	O
vital	O	O
signs	O	O
returned	O	O
to	O	O
presedation	O	O
levels	O	O
.	O	O

Upon	O	O
leaving	O	O
the	O	O
sedation	O	O
area	O	O
,	O	O
the	O	O
patient	O	O
collapsed	O	O
,	O	O
with	O	O
no	O	O
apparent	O	O
inciting	O	O
event	O	O
.	O	O

The	O	O
patient	O	O
quickly	O	O
regained	O	O
consciousness	O	O
and	O	O
no	O	O
injury	O	O
occurred	O	O
.	O	O

The	O	O
primary	O	O
abnormality	O	O
found	O	O
was	O	O
persistent	O	O
bradycardia	B-Disease	D001919
,	O	O
and	O	O
she	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
telemetric	O	O
observation	O	O
.	O	O

The	O	O
bradycardia	B-Disease	D001919
lasted	O	O
~2	O	O
h	O	O
,	O	O
and	O	O
further	O	O
cardiac	O	O
workup	O	O
revealed	O	O
no	O	O
underlying	O	O
abnormality	O	O
.	O	O

Unanticipated	O	O
and	O	O
previously	O	O
unreported	O	O
outcomes	O	O
may	O	O
be	O	O
witnessed	O	O
as	O	O
we	O	O
expand	O	O
the	O	O
use	O	O
of	O	O
certain	O	O
sedatives	O	O
to	O	O
alternative	O	O
routes	O	O
of	O	O
administration	O	O
.	O	O

Paradoxical	O	O
severe	O	O
agitation	B-Disease	D011595
induced	O	O
by	O	O
add	O	O
-	O	O
on	O	O
high	O	O
-	O	O
doses	O	O
quetiapine	B-Chemical	C069541
in	O	O
schizo	B-Disease	D011618
-	I-Disease	D011618
affective	I-Disease	D011618
disorder	I-Disease	D011618
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
35	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
suffering	O	O
from	O	O
schizo	B-Disease	D011618
-	I-Disease	D011618
affective	I-Disease	D011618
disorder	I-Disease	D011618
since	O	O
the	O	O
age	O	O
of	O	O
19	O	O
years	O	O
,	O	O
treated	O	O
by	O	O
a	O	O
combination	O	O
of	O	O
first	O	O
-	O	O
generation	O	O
antipsychotics	O	O
,	O	O
zuclopenthixol	B-Chemical	D003006
(	O	O
100	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
and	O	O
lithium	B-Chemical	D008094
(	O	O
1200	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
(	O	O
serum	O	O
lithium=0	O	O
.	O	O

85	O	O
mEq	O	O
/	O	O
l	O	O
)	O	O
.	O	O

This	O	O
patient	O	O
had	O	O
no	O	O
associated	O	O
personality	B-Disease	D010554
disorder	I-Disease	D010554
(	O	O
particularly	O	O
no	O	O
antisocial	B-Disease	D000987
disorder	I-Disease	D000987
)	O	O
and	O	O
no	O	O
substance	B-Disease	D019966
abuse	I-Disease	D019966
disorder	I-Disease	D019966
.	O	O

Within	O	O
the	O	O
48	O	O
h	O	O
following	O	O
the	O	O
gradual	O	O
introduction	O	O
of	O	O
quetiapine	B-Chemical	C069541
(	O	O
up	O	O
to	O	O
600	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
,	O	O
the	O	O
patient	O	O
presented	O	O
severe	O	O
agitation	B-Disease	D011595
without	O	O
an	O	O
environmental	O	O
explanation	O	O
,	O	O
contrasting	O	O
with	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
history	O	O
of	O	O
aggressiveness	B-Disease	D010554
or	O	O
personality	B-Disease	D010554
disorder	I-Disease	D010554
.	O	O

The	O	O
diagnoses	O	O
of	O	O
manic	B-Disease	D001714
shift	O	O
and	O	O
akathisia	B-Disease	D017109
were	O	O
dismissed	O	O
.	O	O

The	O	O
withdrawal	O	O
and	O	O
the	O	O
gradual	O	O
reintroduction	O	O
of	O	O
quetiapine	B-Chemical	C069541
2	O	O
weeks	O	O
later	O	O
,	O	O
which	O	O
led	O	O
to	O	O
another	O	O
severe	O	O
agitation	B-Disease	D011595
,	O	O
enabled	O	O
us	O	O
to	O	O
attribute	O	O
the	O	O
agitation	B-Disease	D011595
specifically	O	O
to	O	O
quetiapine	B-Chemical	C069541
.	O	O

Antioxidant	O	O
effects	O	O
of	O	O
bovine	O	O
lactoferrin	O	O
on	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
rat	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
-	O	O
(	O	O
Dex	B-Chemical	D003907
-	O	O
)	O	O
induced	O	O
hypertension	B-Disease	D006973
is	O	O
associated	O	O
with	O	O
enhanced	O	O
oxidative	O	O
stress	O	O
.	O	O

Lactoferrin	O	O
(	O	O
LF	O	O
)	O	O
is	O	O
an	O	O
iron	B-Chemical	D007501
-	O	O
binding	O	O
glycoprotein	O	O
with	O	O
antihypertensive	O	O
properties	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
administration	O	O
of	O	O
LF	O	O
on	O	O
oxidative	O	O
stress	O	O
and	O	O
hypertension	B-Disease	D006973
upon	O	O
Dex	B-Chemical	D003907
administration	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
treated	O	O
by	O	O
Dex	B-Chemical	D003907
(	O	O
30	O	O
u	O	O
g	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
subcutaneously	O	O
)	O	O
or	O	O
saline	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Oral	O	O
bovine	O	O
LF	O	O
(	O	O
30	O	O
,	O	O
100	O	O
,	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
given	O	O
from	O	O
day	O	O
8	O	O
to	O	O
14	O	O
in	O	O
a	O	O
reversal	O	O
study	O	O
.	O	O

In	O	O
a	O	O
prevention	O	O
study	O	O
,	O	O
rats	O	O
received	O	O
4	O	O
days	O	O
of	O	O
LF	O	O
treatment	O	O
followed	O	O
by	O	O
Dex	B-Chemical	D003907
and	O	O
continued	O	O
during	O	O
the	O	O
test	O	O
period	O	O
.	O	O

Systolic	O	O
blood	O	O
pressure	O	O
(	O	O
SBP	O	O
)	O	O
was	O	O
measured	O	O
using	O	O
tail	O	O
-	O	O
cuff	O	O
method	O	O
.	O	O

Thymus	O	O
weight	O	O
was	O	O
used	O	O
as	O	O
a	O	O
marker	O	O
of	O	O
glucocorticoid	O	O
activity	O	O
.	O	O

Plasma	O	O
hydrogen	B-Chemical	D006861
peroxide	I-Chemical	D006861
(	O	O
H2O2	B-Chemical	D006861
)	O	O
concentration	O	O
and	O	O
ferric	O	O
reducing	O	O
antioxidant	O	O
power	O	O
(	O	O
FRAP	O	O
)	O	O
value	O	O
were	O	O
determined	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
significantly	O	O
increased	O	O
SBP	O	O
and	O	O
plasma	O	O
H2O2	B-Chemical	D006861
level	O	O
and	O	O
decreased	O	O
thymus	O	O
and	O	O
body	O	O
weights	O	O
.	O	O

LF	O	O
lowered	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
and	O	O
dose	O	O
dependently	O	O
prevented	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
Dex	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

LF	O	O
prevented	O	O
body	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
and	O	O
significantly	O	O
reduced	O	O
the	O	O
elevated	O	O
plasma	O	O
H2O2	B-Chemical	D006861
and	O	O
increased	O	O
FRAP	O	O
values	O	O
.	O	O

Chronic	O	O
administration	O	O
of	O	O
LF	O	O
strongly	O	O
reduced	O	O
the	O	O
blood	O	O
pressure	O	O
and	O	O
production	O	O
of	O	O
ROS	O	O
and	O	O
improved	O	O
antioxidant	O	O
capacity	O	O
in	O	O
Dex	B-Chemical	D003907
-	O	O
induced	O	O
hypertension	B-Disease	D006973
,	O	O
suggesting	O	O
the	O	O
role	O	O
of	O	O
inhibition	O	O
of	O	O
oxidative	O	O
stress	O	O
as	O	O
another	O	O
mechanism	O	O
of	O	O
antihypertensive	O	O
action	O	O
of	O	O
LF	O	O
.	O	O

The	O	O
association	O	O
between	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
and	O	O
convulsive	B-Disease	D012640
seizures	B-Disease	D012640
after	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
multivariate	O	O
analysis	O	O
in	O	O
11	O	O
529	O	O
patients	O	O
.	O	O

Because	O	O
of	O	O
a	O	O
lack	O	O
of	O	O
contemporary	O	O
data	O	O
regarding	O	O
seizures	B-Disease	D012640
after	O	O
cardiac	O	O
surgery	O	O
,	O	O
we	O	O
undertook	O	O
a	O	O
retrospective	O	O
analysis	O	O
of	O	O
prospectively	O	O
collected	O	O
data	O	O
from	O	O
11	O	O
529	O	O
patients	O	O
in	O	O
whom	O	O
cardiopulmonary	O	O
bypass	O	O
was	O	O
used	O	O
from	O	O
January	O	O
2004	O	O
to	O	O
December	O	O
2010	O	O
.	O	O

A	O	O
convulsive	B-Disease	D012640
seizure	B-Disease	D012640
was	O	O
defined	O	O
as	O	O
a	O	O
transient	O	O
episode	O	O
of	O	O
disturbed	O	O
brain	O	O
function	O	O
characterised	O	O
by	O	O
abnormal	B-Disease	D004409
involuntary	I-Disease	D004409
motor	I-Disease	D004409
movements	I-Disease	D004409
.	O	O

Multivariate	O	O
regression	O	O
analysis	O	O
was	O	O
performed	O	O
to	O	O
identify	O	O
independent	O	O
predictors	O	O
of	O	O
postoperative	O	O
seizures	B-Disease	D012640
.	O	O

A	O	O
total	O	O
of	O	O
100	O	O
(	O	O
0	O	O
.	O	O

9%	O	O
)	O	O
patients	O	O
developed	O	O
postoperative	O	O
convulsive	B-Disease	D012640
seizures	B-Disease	D012640
.	O	O

Generalised	B-Disease	D012640
and	I-Disease	D012640
focal	I-Disease	D012640
seizures	I-Disease	D012640
were	O	O
identified	O	O
in	O	O
68	O	O
and	O	O
32	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
median	O	O
(	O	O
IQR	O	O
[	O	O
range	O	O
]	O	O
)	O	O
time	O	O
after	O	O
surgery	O	O
when	O	O
the	O	O
seizure	B-Disease	D012640
occurred	O	O
was	O	O
7	O	O
(	O	O
6	O	O
-	O	O
12	O	O
[	O	O
1	O	O
-	O	O
216	O	O
]	O	O
)	O	O
h	O	O
and	O	O
8	O	O
(	O	O
6	O	O
-	O	O
11	O	O
[	O	O
4	O	O
-	O	O
18	O	O
]	O	O
)	O	O
h	O	O
,	O	O
respectively	O	O
.	O	O

Epileptiform	O	O
findings	O	O
on	O	O
electroencephalography	O	O
were	O	O
seen	O	O
in	O	O
19	O	O
patients	O	O
.	O	O

Independent	O	O
predictors	O	O
of	O	O
postoperative	O	O
seizures	B-Disease	D012640
included	O	O
age	O	O
,	O	O
female	O	O
sex	O	O
,	O	O
redo	O	O
cardiac	O	O
surgery	O	O
,	O	O
calcification	O	O
of	O	O
ascending	O	O
aorta	O	O
,	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
,	O	O
deep	O	O
hypothermic	B-Disease	D007035
circulatory	O	O
arrest	O	O
,	O	O
duration	O	O
of	O	O
aortic	O	O
cross	O	O
-	O	O
clamp	O	O
and	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
.	O	O

When	O	O
tested	O	O
in	O	O
a	O	O
multivariate	O	O
regression	O	O
analysis	O	O
,	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
was	O	O
a	O	O
strong	O	O
independent	O	O
predictor	O	O
of	O	O
seizures	B-Disease	D012640
(	O	O
OR	O	O
14	O	O
.	O	O

3	O	O
,	O	O
95%	O	O
CI	O	O
5	O	O
.	O	O

5	O	O
-	O	O
36	O	O
.	O	O

7	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Patients	O	O
with	O	O
convulsive	B-Disease	D012640
seizures	B-Disease	D012640
had	O	O
2	O	O
.	O	O

5	O	O
times	O	O
higher	O	O
in	O	O
-	O	O
hospital	O	O
mortality	O	O
rates	O	O
and	O	O
twice	O	O
the	O	O
length	O	O
of	O	O
hospital	O	O
stay	O	O
compared	O	O
with	O	O
patients	O	O
without	O	O
convulsive	B-Disease	D012640
seizures	B-Disease	D012640
.	O	O

Mean	O	O
(	O	O
IQR	O	O
[	O	O
range	O	O
]	O	O
)	O	O
length	O	O
of	O	O
stay	O	O
in	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
was	O	O
115	O	O
(	O	O
49	O	O
-	O	O
228	O	O
[	O	O
32	O	O
-	O	O
481	O	O
]	O	O
)	O	O
h	O	O
in	O	O
patients	O	O
with	O	O
convulsive	B-Disease	D012640
seizures	B-Disease	D012640
compared	O	O
with	O	O
26	O	O
(	O	O
22	O	O
-	O	O
69	O	O
[	O	O
14	O	O
-	O	O
1080	O	O
]	O	O
)	O	O
h	O	O
in	O	O
patients	O	O
without	O	O
seizures	B-Disease	D012640
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Convulsive	B-Disease	D012640
seizures	B-Disease	D012640
are	O	O
a	O	O
serious	O	O
postoperative	B-Disease	D011183
complication	I-Disease	D011183
after	O	O
cardiac	O	O
surgery	O	O
.	O	O

As	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
is	O	O
the	O	O
only	O	O
modifiable	O	O
factor	O	O
,	O	O
its	O	O
administration	O	O
,	O	O
particularly	O	O
in	O	O
doses	O	O
exceeding	O	O
80	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
should	O	O
be	O	O
weighed	O	O
against	O	O
the	O	O
risk	O	O
of	O	O
postoperative	O	O
seizures	B-Disease	D012640
.	O	O

Dysfunctional	B-Disease	D008569
overnight	I-Disease	D008569
memory	I-Disease	D008569
consolidation	O	O
in	O	O
ecstasy	B-Chemical	D018817
users	O	O
.	O	O

Sleep	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
consolidation	O	O
and	O	O
integration	O	O
of	O	O
memory	O	O
in	O	O
a	O	O
process	O	O
called	O	O
overnight	O	O
memory	O	O
consolidation	O	O
.	O	O

Previous	O	O
studies	O	O
indicate	O	O
that	O	O
ecstasy	B-Chemical	D018817
users	O	O
have	O	O
marked	O	O
and	O	O
persistent	O	O
neurocognitive	O	O
and	O	O
sleep	B-Disease	D012893
-	I-Disease	D012893
related	I-Disease	D012893
impairments	I-Disease	D012893
.	O	O

We	O	O
extend	O	O
past	O	O
research	O	O
by	O	O
examining	O	O
overnight	O	O
memory	O	O
consolidation	O	O
among	O	O
regular	O	O
ecstasy	B-Chemical	D018817
users	O	O
(	O	O
n=12	O	O
)	O	O
and	O	O
drug	O	O
naive	O	O
healthy	O	O
controls	O	O
(	O	O
n=26	O	O
)	O	O
.	O	O

Memory	O	O
recall	O	O
of	O	O
word	O	O
pairs	O	O
was	O	O
evaluated	O	O
before	O	O
and	O	O
after	O	O
a	O	O
period	O	O
of	O	O
sleep	O	O
,	O	O
with	O	O
and	O	O
without	O	O
interference	O	O
prior	O	O
to	O	O
testing	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
assessed	O	O
neurocognitive	O	O
performances	O	O
across	O	O
tasks	O	O
of	O	O
learning	O	O
,	O	O
memory	O	O
and	O	O
executive	O	O
functioning	O	O
.	O	O

Ecstasy	B-Chemical	D018817
users	O	O
demonstrated	O	O
impaired	B-Disease	D008569
overnight	I-Disease	D008569
memory	I-Disease	D008569
consolidation	O	O
,	O	O
a	O	O
finding	O	O
that	O	O
was	O	O
more	O	O
pronounced	O	O
following	O	O
associative	O	O
interference	O	O
.	O	O

Additionally	O	O
,	O	O
ecstasy	B-Chemical	D018817
users	O	O
demonstrated	O	O
impairments	O	O
on	O	O
tasks	O	O
recruiting	O	O
frontostriatal	O	O
and	O	O
hippocampal	O	O
neural	O	O
circuitry	O	O
,	O	O
in	O	O
the	O	O
domains	O	O
of	O	O
proactive	O	O
interference	O	O
memory	O	O
,	O	O
long	O	O
-	O	O
term	O	O
memory	O	O
,	O	O
encoding	O	O
,	O	O
working	O	O
memory	O	O
and	O	O
complex	O	O
planning	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
ecstasy	B-Chemical	D018817
-	O	O
associated	O	O
dysfunction	O	O
in	O	O
fronto	O	O
-	O	O
temporal	O	O
circuitry	O	O
may	O	O
underlie	O	O
overnight	O	O
consolidation	O	O
memory	B-Disease	D008569
impairments	I-Disease	D008569
in	O	O
regular	O	O
ecstasy	B-Chemical	D018817
users	O	O
.	O	O

Normoammonemic	O	O
encephalopathy	B-Disease	D001927
:	O	O
solely	O	O
valproate	B-Chemical	D014635
induced	O	O
or	O	O
multiple	O	O
mechanisms?	O	O
A	O	O
77	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
subacute	O	O
onset	O	O
progressive	O	O
confusion	B-Disease	D003221
,	O	O
aggression	B-Disease	D001523
,	O	O
auditory	B-Disease	D006212
hallucinations	I-Disease	D006212
and	O	O
delusions	B-Disease	D003072
.	O	O

In	O	O
the	O	O
preceding	O	O
months	O	O
,	O	O
the	O	O
patient	O	O
had	O	O
a	O	O
number	O	O
of	O	O
admissions	O	O
with	O	O
transient	O	O
unilateral	O	O
hemiparesis	B-Disease	D010291
with	O	O
facial	O	O
droop	O	O
,	O	O
and	O	O
had	O	O
been	O	O
started	O	O
on	O	O
valproate	B-Chemical	D014635
for	O	O
presumed	O	O
hemiplegic	B-Disease	D020325
migraine	I-Disease	D020325
.	O	O

Valproate	B-Chemical	D014635
was	O	O
withdrawn	O	O
soon	O	O
after	O	O
admission	O	O
and	O	O
her	O	O
cognitive	O	O
abilities	O	O
have	O	O
gradually	O	O
improved	O	O
over	O	O
3	O	O
months	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

Valproate	B-Chemical	D014635
levels	O	O
taken	O	O
prior	O	O
to	O	O
withdrawal	O	O
were	O	O
subtherapeutic	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
normoammonaemic	O	O
.	O	O

EEG	O	O
undertaken	O	O
during	O	O
inpatient	O	O
stay	O	O
showed	O	O
changes	O	O
consistent	O	O
with	O	O
encephalopathy	B-Disease	D001927
,	O	O
and	O	O
low	O	O
titre	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptor	O	O
antibodies	O	O
were	O	O
present	O	O
in	O	O
this	O	O
patient	O	O
.	O	O

The	O	O
possible	O	O
aetiologies	O	O
of	O	O
valproate	B-Chemical	D014635
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
and	O	O
NMDA	B-Chemical	D016202
receptor	O	O
-	O	O
associated	O	O
encephalitis	B-Disease	D004660
present	O	O
a	O	O
diagnostic	O	O
dilemma	O	O
.	O	O

We	O	O
present	O	O
a	O	O
putative	O	O
combinatorial	O	O
hypothesis	O	O
to	O	O
explain	O	O
this	O	O
patient's	O	O
symptoms	O	O
.	O	O

Cerebellar	O	O
and	O	O
oculomotor	O	O
dysfunction	O	O
induced	O	O
by	O	O
rapid	O	O
infusion	O	O
of	O	O
pethidine	B-Chemical	D008614
.	O	O

Pethidine	B-Chemical	D008614
is	O	O
an	O	O
opioid	O	O
that	O	O
gains	O	O
its	O	O
popularity	O	O
for	O	O
the	O	O
effective	O	O
pain	B-Disease	D010146
control	O	O
through	O	O
acting	O	O
on	O	O
the	O	O
opioid	O	O
-	O	O
receptors	O	O
.	O	O

However	O	O
,	O	O
rapid	O	O
pain	B-Disease	D010146
relief	O	O
sometimes	O	O
brings	O	O
about	O	O
unfavourable	O	O
side	O	O
effects	O	O
that	O	O
largely	O	O
limit	O	O
its	O	O
clinical	O	O
utility	O	O
.	O	O

Common	O	O
side	O	O
effects	O	O
include	O	O
nausea	B-Disease	D009325
,	O	O
vomiting	B-Disease	D014839
and	O	O
hypotension	B-Disease	D007022
.	O	O

In	O	O
patients	O	O
with	O	O
impaired	O	O
renal	O	O
and	O	O
liver	O	O
function	O	O
,	O	O
and	O	O
those	O	O
who	O	O
need	O	O
long	O	O
-	O	O
term	O	O
pain	B-Disease	D010146
control	O	O
,	O	O
pethidine	B-Chemical	D008614
may	O	O
cause	O	O
excitatory	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
effects	O	O
through	O	O
its	O	O
neurotoxic	B-Disease	D020258
metabolite	O	O
,	O	O
norpethidine	B-Chemical	C002752
,	O	O
resulting	O	O
in	O	O
irritability	B-Disease	D001523
and	O	O
seizure	B-Disease	D012640
attack	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
though	O	O
not	O	O
clinically	O	O
apparent	O	O
,	O	O
pethidine	B-Chemical	D008614
potentially	O	O
causes	O	O
inhibitory	O	O
impacts	O	O
on	O	O
the	O	O
CNS	O	O
and	O	O
impairs	O	O
normal	O	O
cerebellar	O	O
and	O	O
oculomotor	O	O
function	O	O
in	O	O
the	O	O
short	O	O
term	O	O
.	O	O

In	O	O
this	O	O
case	O	O
report	O	O
,	O	O
we	O	O
highlight	O	O
opioid's	O	O
inhibitory	O	O
side	O	O
effects	O	O
on	O	O
the	O	O
cerebellar	O	O
structure	O	O
that	O	O
causes	O	O
dysmetria	B-Disease	D002524
,	O	O
dysarthria	B-Disease	D004401
,	O	O
reduced	O	O
smooth	O	O
pursuit	O	O
gain	O	O
and	O	O
decreased	O	O
saccadic	O	O
velocity	O	O
.	O	O

Baboon	B-Disease	-1
syndrome	I-Disease	-1
induced	O	O
by	O	O
ketoconazole	B-Chemical	D007654
.	O	O

A	O	O
27	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
presented	O	O
with	O	O
a	O	O
maculopapular	B-Disease	D003875
eruption	I-Disease	D003875
on	O	O
the	O	O
flexural	O	O
areas	O	O
and	O	O
buttocks	O	O
after	O	O
using	O	O
oral	O	O
ketoconazole	B-Chemical	D007654
.	O	O

The	O	O
patient	O	O
was	O	O
diagnosed	O	O
with	O	O
drug	O	O
-	O	O
induced	O	O
baboon	B-Disease	-1
syndrome	I-Disease	-1
based	O	O
on	O	O
his	O	O
history	O	O
,	O	O
which	O	O
included	O	O
prior	O	O
sensitivity	O	O
to	O	O
topical	O	O
ketoconazole	B-Chemical	D007654
,	O	O
a	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
histopathological	O	O
findings	O	O
.	O	O

Baboon	B-Disease	-1
syndrome	I-Disease	-1
is	O	O
a	O	O
drug	O	O
-	O	O
or	O	O
contact	O	O
allergen	O	O
-	O	O
related	O	O
maculopapular	B-Disease	D003875
eruption	I-Disease	D003875
that	O	O
typically	O	O
involves	O	O
the	O	O
flexural	O	O
and	O	O
gluteal	O	O
areas	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
case	O	O
of	O	O
ketoconazole	B-Chemical	D007654
-	O	O
induced	O	O
baboon	B-Disease	-1
syndrome	I-Disease	-1
in	O	O
the	O	O
English	O	O
literature	O	O
.	O	O

A	O	O
Case	O	O
of	O	O
Sudden	B-Disease	D016757
Cardiac	I-Disease	D016757
Death	I-Disease	D016757
due	O	O
to	O	O
Pilsicainide	B-Chemical	C042288
-	O	O
Induced	O	O
Torsades	B-Disease	D016171
de	I-Disease	D016171
Pointes	I-Disease	D016171
.	O	O

An	O	O
84	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
received	O	O
oral	O	O
pilsicainide	B-Chemical	C042288
,	O	O
a	O	O
pure	O	O
sodium	B-Chemical	D012964
channel	O	O
blocker	O	O
with	O	O
slow	O	O
recovery	O	O
kinetics	O	O
,	O	O
to	O	O
convert	O	O
his	O	O
paroxysmal	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
to	O	O
a	O	O
sinus	O	O
rhythm	O	O
;	O	O
the	O	O
patient	O	O
developed	O	O
sudden	B-Disease	D016757
cardiac	I-Disease	D016757
death	I-Disease	D016757
two	O	O
days	O	O
later	O	O
.	O	O

The	O	O
Holter	O	O
electrocardiogram	O	O
,	O	O
which	O	O
was	O	O
worn	O	O
by	O	O
chance	O	O
,	O	O
revealed	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
with	O	O
gradually	O	O
prolonged	O	O
QT	O	O
intervals	O	O
.	O	O

This	O	O
drug	O	O
is	O	O
rapidly	O	O
absorbed	O	O
from	O	O
the	O	O
gastrointestinal	O	O
tract	O	O
,	O	O
and	O	O
most	O	O
of	O	O
it	O	O
is	O	O
excreted	O	O
from	O	O
the	O	O
kidney	O	O
.	O	O

Although	O	O
the	O	O
patient's	O	O
renal	O	O
function	O	O
was	O	O
not	O	O
highly	O	O
impaired	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
pilsicainide	B-Chemical	C042288
was	O	O
low	O	O
,	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
pilsicainide	B-Chemical	C042288
may	O	O
have	O	O
been	O	O
high	O	O
,	O	O
which	O	O
can	O	O
produce	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
in	O	O
the	O	O
octogenarian	O	O
.	O	O

Although	O	O
the	O	O
oral	O	O
administration	O	O
of	O	O
class	O	O
IC	O	O
drugs	O	O
,	O	O
including	O	O
pilsicainide	B-Chemical	C042288
,	O	O
is	O	O
effective	O	O
to	O	O
terminate	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
,	O	O
careful	O	O
consideration	O	O
must	O	O
be	O	O
taken	O	O
before	O	O
giving	O	O
these	O	O
drugs	O	O
to	O	O
octogenarians	O	O
.	O	O

All	B-Chemical	D014212
-	I-Chemical	D014212
trans	I-Chemical	D014212
retinoic	I-Chemical	D014212
acid	I-Chemical	D014212
-	O	O
induced	O	O
inflammatory	O	O
myositis	B-Disease	D009220
in	O	O
a	O	O
patient	O	O
with	O	O
acute	B-Disease	D015473
promyelocytic	I-Disease	D015473
leukemia	I-Disease	D015473
.	O	O

All	B-Chemical	D014212
-	I-Chemical	D014212
trans	I-Chemical	D014212
retinoic	I-Chemical	D014212
acid	I-Chemical	D014212
(	O	O
ATRA	B-Chemical	D014212
)	O	O
,	O	O
a	O	O
component	O	O
of	O	O
standard	O	O
therapy	O	O
for	O	O
acute	B-Disease	D015473
promyelocytic	I-Disease	D015473
leukemia	I-Disease	D015473
(	O	O
APL	B-Disease	D015473
)	O	O
,	O	O
is	O	O
associated	O	O
with	O	O
potentially	O	O
serious	O	O
but	O	O
treatable	O	O
adverse	O	O
effects	O	O
involving	O	O
numerous	O	O
organ	O	O
systems	O	O
,	O	O
including	O	O
rare	O	O
skeletal	O	O
muscle	O	O
involvement	O	O
.	O	O

Only	O	O
a	O	O
handful	O	O
of	O	O
cases	O	O
of	O	O
ATRA	B-Chemical	D014212
-	O	O
induced	O	O
myositis	B-Disease	D009220
in	O	O
children	O	O
have	O	O
been	O	O
reported	O	O
,	O	O
and	O	O
none	O	O
in	O	O
the	O	O
radiology	O	O
literature	O	O
.	O	O

We	O	O
present	O	O
such	O	O
a	O	O
case	O	O
in	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
with	O	O
APL	B-Disease	D015473
,	O	O
where	O	O
recognition	O	O
of	O	O
imaging	O	O
findings	O	O
played	O	O
a	O	O
crucial	O	O
role	O	O
in	O	O
making	O	O
the	O	O
diagnosis	O	O
and	O	O
facilitated	O	O
prompt	O	O
,	O	O
effective	O	O
treatment	O	O
.	O	O

Tolerability	O	O
of	O	O
lomustine	B-Chemical	D008130
in	O	O
combination	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
in	O	O
dogs	O	O
with	O	O
lymphoma	B-Disease	D008223
.	O	O

This	O	O
retrospective	O	O
study	O	O
describes	O	O
toxicity	B-Disease	D064420
associated	O	O
with	O	O
a	O	O
protocol	O	O
of	O	O
lomustine	B-Chemical	D008130
(	O	O
CCNU	B-Chemical	D008130
)	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CTX	B-Chemical	D003520
)	O	O
in	O	O
dogs	O	O
with	O	O
lymphoma	B-Disease	D008223
.	O	O

CCNU	B-Chemical	D008130
was	O	O
administered	O	O
per	O	O
os	O	O
(	O	O
PO	O	O
)	O	O
at	O	O
a	O	O
targeted	O	O
dosage	O	O
of	O	O
60	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
body	O	O
surface	O	O
area	O	O
on	O	O
day	O	O
0	O	O
,	O	O
CTX	B-Chemical	D003520
was	O	O
administered	O	O
PO	O	O
at	O	O
a	O	O
targeted	O	O
dosage	O	O
of	O	O
250	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
divided	O	O
over	O	O
days	O	O
0	O	O
through	O	O
4	O	O
,	O	O
and	O	O
all	O	O
dogs	O	O
received	O	O
prophylactic	O	O
antibiotics	O	O
.	O	O

Ninety	O	O
treatments	O	O
were	O	O
given	O	O
to	O	O
the	O	O
57	O	O
dogs	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Neutropenia	B-Disease	D009503
was	O	O
the	O	O
principal	O	O
toxic	O	O
effect	O	O
,	O	O
and	O	O
the	O	O
overall	O	O
frequency	O	O
of	O	O
grade	O	O
4	O	O
neutropenia	B-Disease	D009503
after	O	O
the	O	O
first	O	O
treatment	O	O
of	O	O
CCNU	B-Chemical	D008130
/	O	O
CTX	B-Chemical	D003520
was	O	O
30%	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
19	O	O
-	O	O
43%	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
body	O	O
weight	O	O
of	O	O
dogs	O	O
with	O	O
grade	O	O
4	O	O
neutropenia	B-Disease	D009503
(	O	O
19	O	O
.	O	O

7	O	O
kg	O	O
+	O	O
13	O	O
.	O	O

4	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
less	O	O
than	O	O
the	O	O
mean	O	O
body	O	O
weight	O	O
of	O	O
dogs	O	O
that	O	O
did	O	O
not	O	O
develop	O	O
grade	O	O
4	O	O
neutropenia	B-Disease	D009503
(	O	O
31	O	O
.	O	O

7	O	O
kg	O	O
+	O	O
12	O	O
.	O	O

4	O	O
kg	O	O
;	O	O
P	O	O
=	O	O
.	O	O

005	O	O
)	O	O
.	O	O

One	O	O
dog	O	O
(	O	O
3%	O	O
)	O	O
developed	O	O
hematologic	O	O
changes	O	O
suggestive	O	O
of	O	O
hepatotoxicity	B-Disease	D056486
.	O	O

No	O	O
dogs	O	O
had	O	O
evidence	O	O
of	O	O
either	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
or	O	O
hemorrhagic	O	O
cystitis	O	O
.	O	O

Adverse	O	O
gastrointestinal	O	O
effects	O	O
were	O	O
uncommon	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
findings	O	O
reported	O	O
herein	O	O
,	O	O
a	O	O
dose	O	O
of	O	O
60	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
of	O	O
CCNU	B-Chemical	D008130
combined	O	O
with	O	O
250	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
of	O	O
CTX	B-Chemical	D003520
(	O	O
divided	O	O
over	O	O
5	O	O
days	O	O
)	O	O
q	O	O
4	O	O
wk	O	O
is	O	O
tolerable	O	O
in	O	O
tumor	B-Disease	D009369
-	O	O
bearing	O	O
dogs	O	O
.	O	O

Nelarabine	B-Chemical	C104457
neurotoxicity	B-Disease	D020258
with	O	O
concurrent	O	O
intrathecal	O	O
chemotherapy	O	O
:	O	O
Case	O	O
report	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O

Severe	O	O
nelarabine	B-Chemical	C104457
neurotoxicity	B-Disease	D020258
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
concurrent	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
chemotherapy	O	O
is	O	O
reported	O	O
.	O	O

A	O	O
37	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Caucasian	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
T	B-Disease	D054218
-	I-Disease	D054218
cell	I-Disease	D054218
lymphoblastic	I-Disease	D054218
lymphoma	I-Disease	D054218
was	O	O
admitted	O	O
for	O	O
relapsed	O	O
disease	O	O
.	O	O

She	O	O
was	O	O
originally	O	O
treated	O	O
with	O	O
induction	O	O
chemotherapy	O	O
followed	O	O
by	O	O
an	O	O
autologous	O	O
transplant	O	O
.	O	O

She	O	O
developed	O	O
relapsed	O	O
disease	O	O
10	O	O
months	O	O
later	O	O
with	O	O
leukemic	B-Disease	D007938
involvement	O	O
.	O	O

She	O	O
was	O	O
re	O	O
-	O	O
induced	O	O
with	O	O
nelarabine	B-Chemical	C104457
1500	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
on	O	O
days	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
5	O	O
with	O	O
1	O	O
dose	O	O
of	O	O
IT	O	O
cytarabine	B-Chemical	D003561
100	O	O
mg	O	O
on	O	O
day	O	O
2	O	O
as	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
prophylaxis	O	O
.	O	O

At	O	O
the	O	O
time	O	O
of	O	O
treatment	O	O
,	O	O
she	O	O
was	O	O
on	O	O
continuous	O	O
renal	O	O
replacement	O	O
therapy	O	O
due	O	O
to	O	O
sequelae	O	O
of	O	O
tumor	B-Disease	D015275
lysis	I-Disease	D015275
syndrome	I-Disease	D015275
(	O	O
TLS	B-Disease	D015275
)	O	O
.	O	O

She	O	O
tolerated	O	O
therapy	O	O
well	O	O
,	O	O
entered	O	O
a	O	O
complete	O	O
remission	O	O
,	O	O
and	O	O
recovered	O	O
her	O	O
renal	O	O
function	O	O
.	O	O

She	O	O
received	O	O
a	O	O
second	O	O
cycle	O	O
of	O	O
nelarabine	B-Chemical	C104457
without	O	O
additional	O	O
IT	O	O
prophylaxis	O	O
one	O	O
month	O	O
later	O	O
.	O	O

A	O	O
week	O	O
after	O	O
this	O	O
second	O	O
cycle	O	O
,	O	O
she	O	O
noted	O	O
numbness	O	O
in	O	O
her	O	O
lower	O	O
extremities	O	O
.	O	O

Predominantly	O	O
sensory	O	O
,	O	O
though	O	O
also	O	O
motor	O	O
and	O	O
autonomic	O	O
,	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
started	O	O
in	O	O
her	O	O
feet	O	O
,	O	O
ascended	O	O
proximally	O	O
to	O	O
the	O	O
mid	O	O
-	O	O
thoracic	O	O
region	O	O
,	O	O
and	O	O
eventually	O	O
included	O	O
her	O	O
distal	O	O
upper	O	O
extremities	O	O
.	O	O

A	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
of	O	O
her	O	O
spine	O	O
demonstrated	O	O
changes	O	O
from	O	O
C2	O	O
to	O	O
C6	O	O
consistent	O	O
with	O	O
subacute	O	O
combined	O	O
degeneration	O	O
.	O	O

Nelarabine	B-Chemical	C104457
was	O	O
felt	O	O
to	O	O
be	O	O
the	O	O
cause	O	O
of	O	O
her	O	O
symptoms	O	O
.	O	O

Her	O	O
neuropathy	B-Disease	D009422
stabilized	O	O
and	O	O
showed	O	O
slight	O	O
improvement	O	O
and	O	O
ultimately	O	O
received	O	O
an	O	O
unrelated	O	O
,	O	O
reduced	O	O
-	O	O
intensity	O	O
allogeneic	O	O
transplant	O	O
while	O	O
in	O	O
complete	O	O
remission	O	O
,	O	O
but	O	O
relapsed	O	O
disease	O	O
10	O	O
weeks	O	O
later	O	O
.	O	O

She	O	O
is	O	O
currently	O	O
being	O	O
treated	O	O
with	O	O
best	O	O
supportive	O	O
care	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
published	O	O
case	O	O
report	O	O
of	O	O
severe	O	O
neurotoxicity	B-Disease	D020258
caused	O	O
by	O	O
nelarabine	B-Chemical	C104457
in	O	O
a	O	O
patient	O	O
who	O	O
received	O	O
concurrent	O	O
IT	O	O
chemotherapy	O	O
.	O	O

Valproate	B-Chemical	D014635
-	O	O
induced	O	O
hyperammonemic	B-Disease	D022124
encephalopathy	B-Disease	D001927
in	O	O
a	O	O
renal	O	O
transplanted	O	O
patient	O	O
.	O	O

Neurological	B-Disease	D009422
complications	I-Disease	D009422
after	O	O
renal	O	O
transplantation	O	O
constitute	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
morbidity	O	O
and	O	O
mortality	O	O
.	O	O

Their	O	O
differential	O	O
diagnosis	O	O
is	O	O
difficult	O	O
and	O	O
essential	O	O
for	O	O
subsequent	O	O
patient's	O	O
management	O	O
.	O	O

Valproate	B-Chemical	D014635
-	O	O
induced	O	O
hyperammonemic	B-Disease	D022124
encephalopathy	B-Disease	D001927
is	O	O
an	O	O
uncommon	O	O
but	O	O
serious	O	O
effect	O	O
of	O	O
valproate	B-Chemical	D014635
treatment	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
was	O	O
on	O	O
a	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
with	O	O
valproate	B-Chemical	D014635
due	O	O
to	O	O
epilepsy	B-Disease	D004827
and	O	O
revealed	O	O
impaired	B-Disease	D003244
consciousness	I-Disease	D003244
with	O	O
hyperammonemia	B-Disease	D022124
12	O	O
days	O	O
after	O	O
renal	O	O
transplantation	O	O
.	O	O

After	O	O
withdraw	O	O
of	O	O
valproate	B-Chemical	D014635
,	O	O
patients'	O	O
symptoms	O	O
resolved	O	O
within	O	O
24	O	O
h	O	O
.	O	O

Clinicians	O	O
should	O	O
increase	O	O
their	O	O
awareness	O	O
for	O	O
potential	O	O
complication	O	O
of	O	O
valproate	B-Chemical	D014635
,	O	O
especially	O	O
in	O	O
transplanted	O	O
patients	O	O
.	O	O

Necrotising	B-Disease	D019115
fasciitis	I-Disease	D019115
after	O	O
bortezomib	B-Chemical	C400082
and	O	O
dexamethasone	B-Chemical	D003907
-	O	O
containing	O	O
regimen	O	O
in	O	O
an	O	O
elderly	O	O
patient	O	O
of	O	O
Waldenstrom	B-Disease	D008258
macroglobulinaemia	I-Disease	D008258
.	O	O

Bortezomib	B-Chemical	C400082
and	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-Chemical	D003907
-	O	O
containing	O	O
regimens	O	O
are	O	O
considered	O	O
to	O	O
be	O	O
generally	O	O
tolerable	O	O
with	O	O
few	O	O
severe	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
in	O	O
patients	O	O
with	O	O
B	O	O
-	O	O
cell	O	O
malignancies	B-Disease	D009369
.	O	O

However	O	O
,	O	O
information	O	O
is	O	O
limited	O	O
concerning	O	O
the	O	O
safety	O	O
of	O	O
the	O	O
regimen	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
76	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
Waldenstrom	B-Disease	D008258
macroglobulinaemia	I-Disease	D008258
who	O	O
suffered	O	O
necrotising	B-Disease	D019115
fasciitis	I-Disease	D019115
without	O	O
neutropenia	B-Disease	D009503
after	O	O
the	O	O
combination	O	O
treatment	O	O
with	O	O
bortezomib	B-Chemical	C400082
,	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-Chemical	D003907
and	O	O
rituximab	O	O
.	O	O

Despite	O	O
immediate	O	O
intravenous	O	O
antimicrobial	O	O
therapy	O	O
,	O	O
he	O	O
succumbed	O	O
23	O	O
h	O	O
after	O	O
the	O	O
onset	O	O
.	O	O

Physicians	O	O
should	O	O
recognise	O	O
the	O	O
possibility	O	O
of	O	O
fatal	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
related	O	O
to	O	O
bortezomib	B-Chemical	C400082
plus	O	O
high	O	O
-	O	O
dose	O	O
dexamethasone	B-Chemical	D003907
in	O	O
elderly	O	O
patients	O	O
,	O	O
and	O	O
we	O	O
believe	O	O
this	O	O
case	O	O
warrants	O	O
further	O	O
investigation	O	O
.	O	O

An	O	O
integrated	O	O
characterization	O	O
of	O	O
serological	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
functional	O	O
events	O	O
in	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Many	O	O
efficacious	O	O
cancer	B-Disease	D009369
treatments	O	O
cause	O	O
significant	O	O
cardiac	O	O
morbidity	O	O
,	O	O
yet	O	O
biomarkers	O	O
or	O	O
functional	O	O
indices	O	O
of	O	O
early	O	O
damage	O	O
,	O	O
which	O	O
would	O	O
allow	O	O
monitoring	O	O
and	O	O
intervention	O	O
,	O	O
are	O	O
lacking	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
have	O	O
utilized	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
progressive	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
,	O	O
applying	O	O
multiple	O	O
approaches	O	O
,	O	O
including	O	O
cardiac	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
,	O	O
to	O	O
provide	O	O
the	O	O
most	O	O
comprehensive	O	O
characterization	O	O
to	O	O
date	O	O
of	O	O
the	O	O
timecourse	O	O
of	O	O
serological	O	O
,	O	O
pathological	O	O
,	O	O
and	O	O
functional	O	O
events	O	O
underlying	O	O
this	O	O
toxicity	B-Disease	D064420
.	O	O

Hannover	O	O
Wistar	O	O
rats	O	O
were	O	O
dosed	O	O
with	O	O
1	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
DOX	B-Chemical	D004317
weekly	O	O
for	O	O
8	O	O
weeks	O	O
followed	O	O
by	O	O
a	O	O
4	O	O
week	O	O
off	O	O
-	O	O
dosing	O	O
"recovery"	O	O
period	O	O
.	O	O

Electron	O	O
microscopy	O	O
of	O	O
the	O	O
myocardium	O	O
revealed	O	O
subcellular	B-Disease	D009410
degeneration	I-Disease	D009410
and	O	O
marked	O	O
mitochondrial	O	O
changes	O	O
after	O	O
a	O	O
single	O	O
dose	O	O
.	O	O

Histopathological	O	O
analysis	O	O
revealed	O	O
progressive	O	O
cardiomyocyte	B-Disease	D009410
degeneration	I-Disease	D009410
,	O	O
hypertrophy	B-Disease	D006984
/	O	O
cytomegaly	O	O
,	O	O
and	O	O
extensive	O	O
vacuolation	O	O
after	O	O
two	O	O
doses	O	O
.	O	O

Extensive	O	O
replacement	O	O
fibrosis	B-Disease	D005355
(	O	O
quantified	O	O
by	O	O
Sirius	O	O
red	O	O
staining	O	O
)	O	O
developed	O	O
during	O	O
the	O	O
off	O	O
-	O	O
dosing	O	O
period	O	O
.	O	O

Functional	O	O
indices	O	O
assessed	O	O
by	O	O
cardiac	O	O
MRI	O	O
(	O	O
including	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
LVEF	O	O
)	O	O
,	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
E	O	O
/	O	O
A	O	O
ratio	O	O
)	O	O
declined	O	O
progressively	O	O
,	O	O
reaching	O	O
statistical	O	O
significance	O	O
after	O	O
two	O	O
doses	O	O
and	O	O
culminating	O	O
in	O	O
"clinical"	O	O
LV	B-Disease	D018487
dysfunction	I-Disease	D018487
by	O	O
12	O	O
weeks	O	O
.	O	O

Significant	O	O
increases	O	O
in	O	O
peak	O	O
myocardial	O	O
contrast	O	O
enhancement	O	O
and	O	O
serological	O	O
cardiac	O	O
troponin	O	O
I	O	O
(	O	O
cTnI	O	O
)	O	O
emerged	O	O
after	O	O
eight	O	O
doses	O	O
,	O	O
importantly	O	O
preceding	O	O
the	O	O
LVEF	O	O
decline	O	O
to	O	O
<50%	O	O
.	O	O

Troponin	O	O
I	O	O
levels	O	O
positively	O	O
correlated	O	O
with	O	O
delayed	O	O
and	O	O
peak	O	O
gadolinium	B-Chemical	D005682
contrast	O	O
enhancement	O	O
,	O	O
histopathological	O	O
grading	O	O
,	O	O
and	O	O
diastolic	B-Disease	D018754
dysfunction	I-Disease	D018754
.	O	O

In	O	O
summary	O	O
,	O	O
subcellular	O	O
cardiomyocyte	B-Disease	D009410
degeneration	I-Disease	D009410
was	O	O
the	O	O
earliest	O	O
marker	O	O
,	O	O
followed	O	O
by	O	O
progressive	O	O
functional	O	O
decline	O	O
and	O	O
histopathological	O	O
manifestations	O	O
.	O	O

Myocardial	O	O
contrast	O	O
enhancement	O	O
and	O	O
elevations	O	O
in	O	O
cTnI	O	O
occurred	O	O
later	O	O
.	O	O

However	O	O
,	O	O
all	O	O
indices	O	O
predated	O	O
"clinical"	O	O
LV	B-Disease	D018487
dysfunction	I-Disease	D018487
and	O	O
thus	O	O
warrant	O	O
further	O	O
evaluation	O	O
as	O	O
predictive	O	O
biomarkers	O	O
.	O	O

Intradermal	O	O
glutamate	B-Chemical	D018698
and	O	O
capsaicin	B-Chemical	D002211
injections	O	O
:	O	O
intra	O	O
-	O	O
and	O	O
interindividual	O	O
variability	O	O
of	O	O
provoked	O	O
hyperalgesia	B-Disease	D006930
and	O	O
allodynia	B-Disease	D006930
.	O	O

Intradermal	O	O
injections	O	O
of	O	O
glutamate	B-Chemical	D018698
and	O	O
capsaicin	B-Chemical	D002211
are	O	O
attractive	O	O
to	O	O
use	O	O
in	O	O
human	O	O
experimental	O	O
pain	B-Disease	D010146
models	O	O
because	O	O
hyperalgesia	B-Disease	D006930
and	O	O
allodynia	B-Disease	D006930
mimic	O	O
isolated	O	O
aspects	O	O
of	O	O
clinical	O	O
pain	B-Disease	D010146
disorders	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
reproducibility	O	O
of	O	O
these	O	O
models	O	O
.	O	O

Twenty	O	O
healthy	O	O
male	O	O
volunteers	O	O
(	O	O
mean	O	O
age	O	O
24	O	O
years	O	O
;	O	O
range	O	O
18	O	O
-	O	O
38	O	O
years	O	O
)	O	O
received	O	O
intradermal	O	O
injections	O	O
of	O	O
glutamate	B-Chemical	D018698
and	O	O
capsaicin	B-Chemical	D002211
in	O	O
the	O	O
volar	O	O
forearm	O	O
.	O	O

Magnitudes	O	O
of	O	O
secondary	O	O
pinprick	O	O
hyperalgesia	B-Disease	D006930
and	O	O
brush	O	O
-	O	O
evoked	O	O
allodynia	B-Disease	D006930
were	O	O
investigated	O	O
using	O	O
von	O	O
Frey	O	O
filaments	O	O
(	O	O
gauges	O	O
10	O	O
,	O	O
15	O	O
,	O	O
60	O	O
and	O	O
100	O	O
g	O	O
)	O	O
and	O	O
brush	O	O
strokes	O	O
.	O	O

Areas	O	O
of	O	O
secondary	B-Disease	D006930
hyperalgesia	I-Disease	D006930
and	O	O
allodynia	B-Disease	D006930
were	O	O
quantified	O	O
immediately	O	O
after	O	O
injection	O	O
and	O	O
after	O	O
15	O	O
,	O	O
30	O	O
and	O	O
60	O	O
min	O	O
.	O	O

Two	O	O
identical	O	O
experiments	O	O
separated	O	O
by	O	O
at	O	O
least	O	O
7	O	O
days	O	O
were	O	O
performed	O	O
.	O	O

Reproducibility	O	O
across	O	O
and	O	O
within	O	O
volunteers	O	O
(	O	O
inter	O	O
-	O	O
and	O	O
intra	O	O
-	O	O
individual	O	O
variation	O	O
,	O	O
respectively	O	O
)	O	O
was	O	O
assessed	O	O
using	O	O
intraclass	O	O
correlation	O	O
coefficient	O	O
(	O	O
ICC	O	O
)	O	O
and	O	O
coefficient	O	O
of	O	O
variation	O	O
(	O	O
CV	O	O
)	O	O
.	O	O

Secondary	O	O
pinprick	O	O
hyperalgesia	B-Disease	D006930
was	O	O
observed	O	O
as	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
the	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
response	O	O
to	O	O
von	O	O
Frey	O	O
gauges	O	O
60	O	O
and	O	O
100	O	O
g	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
after	O	O
glutamate	B-Chemical	D018698
injection	O	O
.	O	O

For	O	O
capsaicin	B-Chemical	D002211
,	O	O
secondary	O	O
pinprick	O	O
hyperalgesia	B-Disease	D006930
was	O	O
detected	O	O
with	O	O
all	O	O
von	O	O
Frey	O	O
gauges	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Glutamate	B-Chemical	D018698
evoked	O	O
reproducible	O	O
VAS	O	O
response	O	O
to	O	O
all	O	O
von	O	O
Frey	O	O
gauges	O	O
(	O	O
ICC	O	O
>	O	O
0	O	O
.	O	O

60	O	O
)	O	O
and	O	O
brush	O	O
strokes	O	O
(	O	O
ICC	O	O
>	O	O
0	O	O
.	O	O

83	O	O
)	O	O
.	O	O

Capsaicin	B-Chemical	D002211
injection	O	O
was	O	O
reproducible	O	O
for	O	O
secondary	B-Disease	D006930
hyperalgesia	I-Disease	D006930
(	O	O
ICC	O	O
>	O	O
0	O	O
.	O	O

70	O	O
)	O	O
and	O	O
allodynia	B-Disease	D006930
(	O	O
ICC	O	O
>	O	O
0	O	O
.	O	O

71	O	O
)	O	O
.	O	O

Intra	O	O
-	O	O
individual	O	O
variability	O	O
was	O	O
generally	O	O
lower	O	O
for	O	O
the	O	O
VAS	O	O
response	O	O
to	O	O
von	O	O
Frey	O	O
and	O	O
brush	O	O
compared	O	O
with	O	O
areas	O	O
of	O	O
secondary	B-Disease	D006930
hyperalgesia	I-Disease	D006930
and	O	O
allodynia	B-Disease	D006930
.	O	O

In	O	O
conclusion	O	O
,	O	O
glutamate	B-Chemical	D018698
and	O	O
capsaicin	B-Chemical	D002211
yield	O	O
reproducible	O	O
hyperalgesic	B-Disease	D006930
and	O	O
allodynic	B-Disease	D006930
responses	O	O
,	O	O
and	O	O
the	O	O
present	O	O
model	O	O
is	O	O
well	O	O
suited	O	O
for	O	O
basic	O	O
research	O	O
,	O	O
as	O	O
well	O	O
as	O	O
for	O	O
assessing	O	O
the	O	O
modulation	O	O
of	O	O
central	O	O
phenomena	O	O
.	O	O

Ocular	O	O
-	O	O
specific	O	O
ER	O	O
stress	O	O
reduction	O	O
rescues	O	O
glaucoma	B-Disease	D005901
in	O	O
murine	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	B-Disease	D005901
.	O	O

Administration	O	O
of	O	O
glucocorticoids	O	O
induces	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
in	O	O
some	O	O
patients	O	O
.	O	O

If	O	O
untreated	O	O
,	O	O
these	O	O
patients	O	O
can	O	O
develop	O	O
a	O	O
secondary	O	O
glaucoma	B-Disease	D005901
that	O	O
resembles	O	O
primary	B-Disease	C562750
open	I-Disease	C562750
-	I-Disease	C562750
angle	I-Disease	C562750
glaucoma	I-Disease	C562750
(	O	O
POAG	B-Disease	C562750
)	O	O
.	O	O

The	O	O
underlying	O	O
pathology	O	O
of	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	B-Disease	D005901
is	O	O
not	O	O
fully	O	O
understood	O	O
,	O	O
due	O	O
in	O	O
part	O	O
to	O	O
lack	O	O
of	O	O
an	O	O
appropriate	O	O
animal	O	O
model	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
developed	O	O
a	O	O
murine	O	O
model	O	O
of	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	B-Disease	D005901
that	O	O
exhibits	O	O
glaucoma	B-Disease	D005901
features	O	O
that	O	O
are	O	O
observed	O	O
in	O	O
patients	O	O
.	O	O

Treatment	O	O
of	O	O
WT	O	O
mice	O	O
with	O	O
topical	O	O
ocular	O	O
0	O	O
.	O	O

1%	O	O
dexamethasone	B-Chemical	D003907
led	O	O
to	O	O
elevation	O	O
of	O	O
intraocular	O	O
pressure	O	O
(	O	O
IOP	O	O
)	O	O
,	O	O
functional	O	O
and	O	O
structural	O	O
loss	O	O
of	O	O
retinal	B-Disease	D012173
ganglion	I-Disease	D012173
cells	O	O
,	O	O
and	O	O
axonal	B-Disease	D009410
degeneration	I-Disease	D009410
,	O	O
resembling	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	B-Disease	D005901
in	O	O
human	O	O
patients	O	O
.	O	O

Furthermore	O	O
,	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
was	O	O
associated	O	O
with	O	O
chronic	O	O
ER	O	O
stress	O	O
of	O	O
the	O	O
trabecular	O	O
meshwork	O	O
(	O	O
TM	O	O
)	O	O
.	O	O

Similar	O	O
to	O	O
patients	O	O
,	O	O
withdrawal	O	O
of	O	O
dexamethasone	B-Chemical	D003907
treatment	O	O
reduced	O	O
elevated	O	O
IOP	O	O
and	O	O
ER	O	O
stress	O	O
in	O	O
this	O	O
animal	O	O
model	O	O
.	O	O

Dexamethasone	B-Chemical	D003907
induced	O	O
the	O	O
transcriptional	O	O
factor	O	O
CHOP	O	O
,	O	O
a	O	O
marker	O	O
for	O	O
chronic	O	O
ER	O	O
stress	O	O
,	O	O
in	O	O
the	O	O
anterior	O	O
segment	O	O
tissues	O	O
,	O	O
and	O	O
Chop	O	O
deletion	O	O
reduced	O	O
ER	O	O
stress	O	O
in	O	O
these	O	O
tissues	O	O
and	O	O
prevented	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
.	O	O

Furthermore	O	O
,	O	O
reduction	O	O
of	O	O
ER	O	O
stress	O	O
in	O	O
the	O	O
TM	O	O
with	O	O
sodium	B-Chemical	C075773
4	I-Chemical	C075773
-	I-Chemical	C075773
phenylbutyrate	I-Chemical	C075773
prevented	O	O
dexamethasone	B-Chemical	D003907
-	O	O
induced	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
in	O	O
WT	O	O
mice	O	O
.	O	O

Our	O	O
data	O	O
indicate	O	O
that	O	O
ER	O	O
stress	O	O
contributes	O	O
to	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
and	O	O
suggest	O	O
that	O	O
reducing	O	O
ER	O	O
stress	O	O
has	O	O
potential	O	O
as	O	O
a	O	O
therapeutic	O	O
strategy	O	O
for	O	O
treating	O	O
glucocorticoid	O	O
-	O	O
induced	O	O
glaucoma	B-Disease	D005901
.	O	O

Effects	O	O
of	O	O
ginsenosides	B-Chemical	D036145
on	O	O
opioid	O	O
-	O	O
induced	O	O
hyperalgesia	B-Disease	D006930
in	O	O
mice	O	O
.	O	O

Opioid	O	O
-	O	O
induced	O	O
hyperalgesia	B-Disease	D006930
(	O	O
OIH	B-Disease	D006930
)	O	O
is	O	O
characterized	O	O
by	O	O
nociceptive	O	O
sensitization	O	O
caused	O	O
by	O	O
the	O	O
cessation	O	O
of	O	O
chronic	O	O
opioid	O	O
use	O	O
.	O	O

OIH	B-Disease	D006930
can	O	O
limit	O	O
the	O	O
clinical	O	O
use	O	O
of	O	O
opioid	O	O
analgesics	O	O
and	O	O
complicate	O	O
withdrawal	O	O
from	O	O
opioid	B-Disease	D009293
addiction	I-Disease	D009293
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
Re	B-Chemical	C049864
,	O	O
Rg1	B-Chemical	C035054
,	O	O
and	O	O
Rb1	B-Chemical	C442759
ginsenosides	B-Chemical	D036145
,	O	O
the	O	O
bioactive	O	O
components	O	O
of	O	O
ginseng	O	O
,	O	O
on	O	O
OIH	B-Disease	D006930
.	O	O

OIH	B-Disease	D006930
was	O	O
achieved	O	O
in	O	O
mice	O	O
after	O	O
subcutaneous	O	O
administration	O	O
of	O	O
morphine	B-Chemical	D009020
for	O	O
7	O	O
consecutive	O	O
days	O	O
three	O	O
times	O	O
per	O	O
day	O	O
.	O	O

During	O	O
withdrawal	O	O
(	O	O
days	O	O
8	O	O
and	O	O
9	O	O
)	O	O
,	O	O
these	O	O
mice	O	O
were	O	O
administered	O	O
Re	B-Chemical	C049864
,	O	O
Rg1	B-Chemical	C035054
,	O	O
or	O	O
Rb1	B-Chemical	C442759
intragastrically	O	O
two	O	O
times	O	O
per	O	O
day	O	O
.	O	O

On	O	O
the	O	O
test	O	O
day	O	O
(	O	O
day	O	O
10	O	O
)	O	O
,	O	O
mice	O	O
were	O	O
subjected	O	O
to	O	O
the	O	O
thermal	O	O
sensitivity	O	O
test	O	O
and	O	O
the	O	O
acetic	B-Chemical	D019342
acid	I-Chemical	D019342
-	O	O
induced	O	O
writhing	O	O
test	O	O
.	O	O

Re	B-Chemical	C049864
(	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
inhibited	O	O
OIH	B-Disease	D006930
in	O	O
both	O	O
the	O	O
thermal	O	O
sensitivity	O	O
test	O	O
and	O	O
the	O	O
acetic	B-Chemical	D019342
acid	I-Chemical	D019342
-	O	O
induced	O	O
writhing	O	O
test	O	O
.	O	O

However	O	O
,	O	O
the	O	O
Rg1	B-Chemical	C035054
and	O	O
Rb1	B-Chemical	C442759
ginsenosides	B-Chemical	D036145
failed	O	O
to	O	O
prevent	O	O
OIH	B-Disease	D006930
in	O	O
either	O	O
test	O	O
.	O	O

Furthermore	O	O
,	O	O
Rg1	B-Chemical	C035054
showed	O	O
a	O	O
tendency	O	O
to	O	O
aggravate	O	O
OIH	B-Disease	D006930
in	O	O
the	O	O
acetic	B-Chemical	D019342
acid	I-Chemical	D019342
-	O	O
induced	O	O
writhing	O	O
test	O	O
.	O	O

Our	O	O
data	O	O
suggested	O	O
that	O	O
the	O	O
ginsenoside	B-Chemical	C049864
Re	I-Chemical	C049864
,	O	O
but	O	O
not	O	O
Rg1	B-Chemical	C035054
or	O	O
Rb1	B-Chemical	C442759
,	O	O
may	O	O
contribute	O	O
toward	O	O
reversal	O	O
of	O	O
OIH	B-Disease	D006930
.	O	O

A	O	O
comparison	O	O
of	O	O
severe	O	O
hemodynamic	O	O
disturbances	O	O
between	O	O
dexmedetomidine	B-Chemical	D020927
and	O	O
propofol	B-Chemical	D015742
for	O	O
sedation	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Dexmedetomidine	B-Chemical	D020927
and	O	O
propofol	B-Chemical	D015742
are	O	O
commonly	O	O
used	O	O
sedatives	O	O
in	O	O
neurocritical	O	O
care	O	O
as	O	O
they	O	O
allow	O	O
for	O	O
frequent	O	O
neurologic	O	O
examinations	O	O
.	O	O

However	O	O
,	O	O
both	O	O
agents	O	O
are	O	O
associated	O	O
with	O	O
significant	O	O
hemodynamic	O	O
side	O	O
effects	O	O
.	O	O

The	O	O
primary	O	O
objective	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
compare	O	O
the	O	O
prevalence	O	O
of	O	O
severe	O	O
hemodynamic	O	O
effects	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
receiving	O	O
dexmedetomidine	B-Chemical	D020927
and	O	O
propofol	B-Chemical	D015742
.	O	O

DESIGN	O	O
:	O	O
Multicenter	O	O
,	O	O
retrospective	O	O
,	O	O
propensity	O	O
-	O	O
matched	O	O
cohort	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Neurocritical	O	O
care	O	O
units	O	O
at	O	O
two	O	O
academic	O	O
medical	O	O
centers	O	O
with	O	O
dedicated	O	O
neurocritical	O	O
care	O	O
teams	O	O
and	O	O
board	O	O
-	O	O
certified	O	O
neurointensivists	O	O
.	O	O

PATIENTS	O	O
:	O	O
Neurocritical	O	O
care	O	O
patients	O	O
admitted	O	O
between	O	O
July	O	O
2009	O	O
and	O	O
September	O	O
2012	O	O
were	O	O
evaluated	O	O
and	O	O
then	O	O
matched	O	O
1	O	O
:	O	O
1	O	O
based	O	O
on	O	O
propensity	O	O
scoring	O	O
of	O	O
baseline	O	O
characteristics	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Continuous	O	O
sedation	O	O
with	O	O
dexmedetomidine	B-Chemical	D020927
or	O	O
propofol	B-Chemical	D015742
.	O	O

MEASUREMENTS	O	O
AND	O	O
MAIN	O	O
RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
342	O	O
patients	O	O
(	O	O
105	O	O
dexmedetomidine	B-Chemical	D020927
and	O	O
237	O	O
propofol	B-Chemical	D015742
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
,	O	O
with	O	O
190	O	O
matched	O	O
(	O	O
95	O	O
in	O	O
each	O	O
group	O	O
)	O	O
by	O	O
propensity	O	O
score	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
of	O	O
this	O	O
study	O	O
was	O	O
a	O	O
composite	O	O
of	O	O
severe	O	O
hypotension	B-Disease	D007022
(	O	O
mean	O	O
arterial	O	O
pressure	O	O
<	O	O
60	O	O
mm	O	O
Hg	O	O
)	O	O
and	O	O
bradycardia	B-Disease	D001919
(	O	O
heart	O	O
rate	O	O
<	O	O
50	O	O
beats	O	O
/	O	O
min	O	O
)	O	O
during	O	O
sedative	O	O
infusion	O	O
.	O	O

No	O	O
difference	O	O
in	O	O
the	O	O
primary	O	O
composite	O	O
outcome	O	O
in	O	O
both	O	O
the	O	O
unmatched	O	O
(	O	O
30%	O	O
vs	O	O
30%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

94	O	O
)	O	O
or	O	O
matched	O	O
cohorts	O	O
(	O	O
28%	O	O
vs	O	O
34%	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

35	O	O
)	O	O
could	O	O
be	O	O
found	O	O
.	O	O

When	O	O
analyzed	O	O
separately	O	O
,	O	O
no	O	O
differences	O	O
could	O	O
be	O	O
found	O	O
in	O	O
the	O	O
prevalence	O	O
of	O	O
severe	O	O
hypotension	B-Disease	D007022
or	O	O
bradycardia	B-Disease	D001919
in	O	O
either	O	O
the	O	O
unmatched	O	O
or	O	O
matched	O	O
cohorts	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Severe	O	O
hypotension	B-Disease	D007022
and	O	O
bradycardia	B-Disease	D001919
occur	O	O
at	O	O
similar	O	O
prevalence	O	O
in	O	O
neurocritical	O	O
care	O	O
patients	O	O
who	O	O
receive	O	O
dexmedetomidine	B-Chemical	D020927
or	O	O
propofol	B-Chemical	D015742
.	O	O

Providers	O	O
should	O	O
similarly	O	O
consider	O	O
the	O	O
likelihood	O	O
of	O	O
hypotension	B-Disease	D007022
or	O	O
bradycardia	B-Disease	D001919
before	O	O
starting	O	O
either	O	O
sedative	O	O
.	O	O

Hydroxytyrosol	B-Chemical	C005975
ameliorates	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
in	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
rats	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Oxidative	O	O
stress	O	O
is	O	O
involved	O	O
in	O	O
several	O	O
processes	O	O
including	O	O
cancer	B-Disease	D009369
,	O	O
aging	O	O
and	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
,	O	O
and	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
potentiate	O	O
the	O	O
therapeutic	O	O
effect	O	O
of	O	O
drugs	O	O
such	O	O
as	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Doxorubicin	B-Chemical	D004317
causes	O	O
significant	O	O
cardiotoxicity	B-Disease	D066126
characterized	O	O
by	O	O
marked	O	O
increases	O	O
in	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
.	O	O

Herein	O	O
,	O	O
we	O	O
investigate	O	O
whether	O	O
doxorubicin	B-Chemical	D004317
-	O	O
associated	O	O
chronic	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
can	O	O
be	O	O
ameliorated	O	O
with	O	O
the	O	O
antioxidant	O	O
hydroxytyrosol	B-Chemical	C005975
in	O	O
rats	O	O
with	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Thirty	O	O
-	O	O
six	O	O
rats	O	O
bearing	O	O
breast	B-Disease	D001943
tumors	I-Disease	D001943
induced	O	O
chemically	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
control	O	O
,	O	O
hydroxytyrosol	B-Chemical	C005975
(	O	O
0	O	O
.	O	O

5mg	O	O
/	O	O
kg	O	O
,	O	O
5days	O	O
/	O	O
week	O	O
)	O	O
,	O	O
doxorubicin	B-Chemical	D004317
(	O	O
1mg	O	O
/	O	O
kg	O	O
/	O	O
week	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B-Chemical	D004317
plus	O	O
hydroxytyrosol	B-Chemical	C005975
.	O	O

Cardiac	B-Disease	D006331
disturbances	I-Disease	D006331
at	O	O
the	O	O
cellular	O	O
and	O	O
mitochondrial	O	O
level	O	O
,	O	O
mitochondrial	O	O
electron	O	O
transport	O	O
chain	O	O
complexes	O	O
I	O	O
-	O	O
IV	O	O
and	O	O
apoptosis	O	O
-	O	O
inducing	O	O
factor	O	O
,	O	O
and	O	O
oxidative	O	O
stress	O	O
markers	O	O
have	O	O
been	O	O
analyzed	O	O
.	O	O

Hydroxytyrosol	B-Chemical	C005975
improved	O	O
the	O	O
cardiac	B-Disease	D006331
disturbances	I-Disease	D006331
enhanced	O	O
by	O	O
doxorubicin	B-Chemical	D004317
by	O	O
significantly	O	O
reducing	O	O
the	O	O
percentage	O	O
of	O	O
altered	O	O
mitochondria	O	O
and	O	O
oxidative	O	O
damage	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
hydroxytyrosol	B-Chemical	C005975
improve	O	O
the	O	O
mitochondrial	O	O
electron	O	O
transport	O	O
chain	O	O
.	O	O

This	O	O
study	O	O
demonstrates	O	O
that	O	O
hydroxytyrosol	B-Chemical	C005975
protect	O	O
rat	O	O
heart	B-Disease	D006331
damage	I-Disease	D006331
provoked	O	O
by	O	O
doxorubicin	B-Chemical	D004317
decreasing	O	O
oxidative	O	O
damage	O	O
and	O	O
mitochondrial	O	O
alterations	O	O
.	O	O

Amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
.	O	O

A	O	O
62	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
was	O	O
found	O	O
to	O	O
have	O	O
bradycardia	B-Disease	D001919
,	O	O
hypothermia	B-Disease	D007035
and	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
3	O	O
weeks	O	O
after	O	O
initiation	O	O
of	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
for	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
.	O	O

Thyroid	O	O
-	O	O
stimulating	O	O
hormone	O	O
was	O	O
found	O	O
to	O	O
be	O	O
168	O	O
uIU	O	O
/	O	O
mL	O	O
(	O	O
nl	O	O
.	O	O

0	O	O
.	O	O

3	O	O
-	O	O
5	O	O
uIU	O	O
/	O	O
mL	O	O
)	O	O
and	O	O
free	O	O
thyroxine	B-Chemical	D013974
(	O	O
FT4	O	O
)	O	O
was	O	O
<0	O	O
.	O	O

2	O	O
ng	O	O
/	O	O
dL	O	O
(	O	O
nl	O	O
.	O	O

0	O	O
.	O	O

8	O	O
-	O	O
1	O	O
.	O	O

8	O	O
ng	O	O
/	O	O
dL	O	O
)	O	O
.	O	O

He	O	O
received	O	O
intravenous	O	O
fluids	O	O
,	O	O
vasopressor	O	O
therapy	O	O
and	O	O
stress	O	O
dose	O	O
steroids	B-Chemical	D013256
;	O	O
he	O	O
was	O	O
intubated	O	O
and	O	O
admitted	O	O
to	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

He	O	O
received	O	O
500	O	O
ug	O	O
of	O	O
intravenous	O	O
levothyroxine	B-Chemical	D013974
in	O	O
the	O	O
first	O	O
18	O	O
h	O	O
of	O	O
therapy	O	O
,	O	O
and	O	O
150	O	O
ug	O	O
intravenous	O	O
daily	O	O
thereafter	O	O
.	O	O

Haemodynamic	O	O
improvement	O	O
,	O	O
along	O	O
with	O	O
complete	O	O
recovery	O	O
of	O	O
mental	O	O
status	O	O
,	O	O
occurred	O	O
after	O	O
48	O	O
h	O	O
.	O	O

Twelve	O	O
hours	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
,	O	O
FT4	O	O
was	O	O
0	O	O
.	O	O

96	O	O
ng	O	O
/	O	O
dL	O	O
.	O	O

The	O	O
patient	O	O
was	O	O
maintained	O	O
on	O	O
levothyroxine	B-Chemical	D013974
175	O	O
(	O	O
g	O	O
POorally	O	O
daily	O	O
.	O	O

A	O	O
thyroid	O	O
ultrasound	O	O
showed	O	O
diffuse	O	O
heterogeneity	O	O
.	O	O

The	O	O
24	O	O
hour	O	O
excretion	O	O
of	O	O
iodine	B-Chemical	D007455
was	O	O
3657	O	O
(	O	O
mcg	O	O
(	O	O
25	O	O
-	O	O
756	O	O
(	O	O
mcg	O	O
)	O	O
.	O	O

The	O	O
only	O	O
two	O	O
cases	O	O
of	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
in	O	O
the	O	O
literature	O	O
report	O	O
patient	O	O
death	O	O
despite	O	O
supportive	O	O
therapy	O	O
and	O	O
thyroid	O	O
hormone	O	O
replacement	O	O
.	O	O

This	O	O
case	O	O
represents	O	O
the	O	O
most	O	O
thoroughly	O	O
investigated	O	O
case	O	O
of	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
myxoedema	O	O
coma	O	O
with	O	O
a	O	O
history	O	O
significant	O	O
for	O	O
subclinical	O	O
thyroid	B-Disease	D013959
disease	I-Disease	D013959
.	O	O

Use	O	O
of	O	O
argatroban	B-Chemical	C031942
and	O	O
catheter	O	O
-	O	O
directed	O	O
thrombolysis	B-Disease	D055499
with	O	O
alteplase	O	O
in	O	O
an	O	O
oncology	O	O
patient	O	O
with	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
with	O	O
thrombosis	B-Disease	D013927
.	O	O

PURPOSE	O	O
:	O	O
The	O	O
case	O	O
of	O	O
an	O	O
oncology	O	O
patient	O	O
who	O	O
developed	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
with	O	O
thrombosis	B-Disease	D013927
(	O	O
HITT	B-Disease	D013921
)	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
argatroban	B-Chemical	C031942
plus	O	O
catheter	O	O
-	O	O
directed	O	O
thrombolysis	B-Disease	D055499
(	O	O
CDT	O	O
)	O	O
with	O	O
alteplase	O	O
is	O	O
presented	O	O
.	O	O

SUMMARY	O	O
:	O	O
A	O	O
63	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Caucasian	O	O
man	O	O
with	O	O
renal	O	O
amyloidosis	B-Disease	D000686
undergoing	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
collection	O	O
for	O	O
an	O	O
autologous	O	O
stem	O	O
cell	O	O
transplant	O	O
developed	O	O
extensive	O	O
bilateral	O	O
upper	B-Disease	D056824
-	I-Disease	D056824
extremity	I-Disease	D056824
deep	I-Disease	D056824
venous	I-Disease	D056824
thrombosis	I-Disease	D056824
(	O	O
DVT	B-Disease	D020246
)	O	O
and	O	O
pulmonary	B-Disease	D011655
embolism	I-Disease	D011655
secondary	O	O
to	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

A	O	O
continuous	O	O
i	O	O
.	O	O

v	O	O
.	O	O

infusion	O	O
of	O	O
argatroban	B-Chemical	C031942
was	O	O
initiated	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
managed	O	O
on	O	O
the	O	O
general	O	O
medical	O	O
floor	O	O
.	O	O

After	O	O
one	O	O
week	O	O
of	O	O
therapy	O	O
,	O	O
he	O	O
was	O	O
transferred	O	O
to	O	O
the	O	O
intensive	O	O
care	O	O
unit	O	O
with	O	O
cardiopulmonary	O	O
compromise	O	O
related	O	O
to	O	O
superior	B-Disease	D013479
vena	I-Disease	D013479
cava	I-Disease	D013479
(	I-Disease	D013479
SVC	I-Disease	D013479
)	I-Disease	D013479
syndrome	I-Disease	D013479
.	O	O

A	O	O
percutaneous	O	O
mechanical	O	O
thrombectomy	O	O
and	O	O
CDT	O	O
with	O	O
alteplase	O	O
were	O	O
attempted	O	O
,	O	O
but	O	O
the	O	O
procedure	O	O
was	O	O
aborted	O	O
due	O	O
to	O	O
epistaxis	B-Disease	D004844
.	O	O

The	O	O
epistaxis	B-Disease	D004844
resolved	O	O
the	O	O
next	O	O
day	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
restarted	O	O
on	O	O
argatroban	B-Chemical	C031942
.	O	O

A	O	O
second	O	O
percutaneous	O	O
mechanical	O	O
thrombectomy	O	O
was	O	O
performed	O	O
six	O	O
days	O	O
later	O	O
and	O	O
resulted	O	O
in	O	O
partial	O	O
revascularization	O	O
of	O	O
the	O	O
SVC	O	O
and	O	O
central	O	O
veins	O	O
.	O	O

Postthrombectomy	O	O
continuous	O	O
CDT	O	O
with	O	O
alteplase	O	O
was	O	O
commenced	O	O
while	O	O
argatroban	B-Chemical	C031942
was	O	O
withheld	O	O
,	O	O
and	O	O
complete	O	O
patency	O	O
of	O	O
the	O	O
SVC	O	O
and	O	O
central	O	O
veins	O	O
was	O	O
achieved	O	O
after	O	O
three	O	O
days	O	O
of	O	O
therapy	O	O
.	O	O

Alteplase	O	O
was	O	O
discontinued	O	O
,	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
reinitiated	O	O
on	O	O
argatroban	B-Chemical	C031942
;	O	O
ultimately	O	O
,	O	O
he	O	O
was	O	O
transitioned	O	O
to	O	O
warfarin	B-Chemical	D014859
for	O	O
long	O	O
-	O	O
term	O	O
anticoagulation	O	O
.	O	O

Although	O	O
the	O	O
patient	O	O
recovered	O	O
,	O	O
he	O	O
experienced	O	O
permanent	O	O
vision	O	O
and	O	O
hearing	O	O
loss	O	O
,	O	O
as	O	O
well	O	O
as	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
.	O	O

CONCLUSION	O	O
:	O	O
A	O	O
63	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
renal	O	O
amyloidosis	B-Disease	D000686
and	O	O
SVC	B-Disease	D013479
syndrome	I-Disease	D013479
secondary	O	O
to	O	O
HITT	B-Disease	D013921
was	O	O
successfully	O	O
treated	O	O
with	O	O
argatroban	B-Chemical	C031942
and	O	O
CDT	O	O
with	O	O
alteplase	O	O
.	O	O

Effects	O	O
of	O	O
dehydroepiandrosterone	B-Chemical	D003687
in	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
schizophrenia	B-Disease	D012559
models	O	O
in	O	O
mice	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
examine	O	O
the	O	O
effects	O	O
of	O	O
dehydroepiandrosterone	B-Chemical	D003687
(	O	O
DHEA	B-Chemical	D003687
)	O	O
on	O	O
animal	O	O
models	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

METHODS	O	O
:	O	O
Seventy	O	O
Swiss	O	O
albino	O	O
female	O	O
mice	O	O
(	O	O
25	O	O
-	O	O
35	O	O
g	O	O
)	O	O
were	O	O
divided	O	O
into	O	O
4	O	O
groups	O	O
:	O	O
amphetamine	B-Chemical	D000661
-	O	O
free	O	O
(	O	O
control	O	O
)	O	O
,	O	O
amphetamine	B-Chemical	D000661
,	O	O
50	O	O
,	O	O
and	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
DHEA	B-Chemical	D003687
.	O	O

The	O	O
DHEA	B-Chemical	D003687
was	O	O
administered	O	O
intraperitoneally	O	O
(	O	O
ip	O	O
)	O	O
for	O	O
5	O	O
days	O	O
.	O	O

Amphetamine	B-Chemical	D000661
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
)	O	O
induced	O	O
hyper	B-Disease	D006948
locomotion	O	O
,	O	O
apomorphine	B-Chemical	D001058
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
subcutaneously	O	O
[	O	O
sc	O	O
]	O	O
)	O	O
induced	O	O
climbing	O	O
,	O	O
and	O	O
haloperidol	B-Chemical	D006220
(	O	O
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
)	O	O
induced	O	O
catalepsy	B-Disease	D002375
tests	O	O
were	O	O
used	O	O
as	O	O
animal	O	O
models	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

The	O	O
study	O	O
was	O	O
conducted	O	O
at	O	O
the	O	O
Animal	O	O
Experiment	O	O
Laboratories	O	O
,	O	O
Department	O	O
of	O	O
Pharmacology	O	O
,	O	O
Medical	O	O
School	O	O
,	O	O
Eskisehir	O	O
Osmangazi	O	O
University	O	O
,	O	O
Eskisehir	O	O
,	O	O
Turkey	O	O
between	O	O
March	O	O
and	O	O
May	O	O
2012	O	O
.	O	O

Statistical	O	O
analysis	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
Kruskal	O	O
-	O	O
Wallis	O	O
test	O	O
for	O	O
hyper	B-Disease	D006948
locomotion	O	O
,	O	O
and	O	O
one	O	O
-	O	O
way	O	O
ANOVA	O	O
for	O	O
climbing	O	O
and	O	O
catalepsy	B-Disease	D002375
tests	O	O
.	O	O

RESULTS	O	O
:	O	O
In	O	O
the	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotion	O	O
test	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
increases	O	O
in	O	O
all	O	O
movements	O	O
compared	O	O
with	O	O
the	O	O
amphetamine	B-Chemical	D000661
-	O	O
free	O	O
group	O	O
.	O	O

Both	O	O
DHEA	B-Chemical	D003687
50	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
and	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
p<0	O	O
.	O	O

01	O	O
)	O	O
significantly	O	O
decreased	O	O
all	O	O
movements	O	O
compared	O	O
with	O	O
the	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotion	O	O
group	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
between	O	O
groups	O	O
in	O	O
the	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
test	O	O
(	O	O
p<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
difference	O	O
between	O	O
groups	O	O
in	O	O
terms	O	O
of	O	O
total	O	O
climbing	O	O
time	O	O
in	O	O
the	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
climbing	O	O
test	O	O
(	O	O
p>0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
observed	O	O
that	O	O
DHEA	B-Chemical	D003687
reduced	O	O
locomotor	O	O
activity	O	O
and	O	O
increased	O	O
catalepsy	B-Disease	D002375
at	O	O
both	O	O
doses	O	O
,	O	O
while	O	O
it	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
climbing	O	O
behavior	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
DHEA	B-Chemical	D003687
displays	O	O
typical	O	O
neuroleptic	O	O
-	O	O
like	O	O
effects	O	O
,	O	O
and	O	O
may	O	O
be	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
schizophrenia	B-Disease	D012559
.	O	O

Availability	O	O
of	O	O
human	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cell	O	O
-	O	O
derived	O	O
cardiomyocytes	O	O
in	O	O
assessment	O	O
of	O	O
drug	O	O
potential	O	O
for	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
.	O	O

Field	O	O
potential	O	O
duration	O	O
(	O	O
FPD	O	O
)	O	O
in	O	O
human	O	O
-	O	O
induced	O	O
pluripotent	O	O
stem	O	O
cell	O	O
-	O	O
derived	O	O
cardiomyocytes	O	O
(	O	O
hiPS	O	O
-	O	O
CMs	O	O
)	O	O
,	O	O
which	O	O
can	O	O
express	O	O
QT	O	O
interval	O	O
in	O	O
an	O	O
electrocardiogram	O	O
,	O	O
is	O	O
reported	O	O
to	O	O
be	O	O
a	O	O
useful	O	O
tool	O	O
to	O	O
predict	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
channel	O	O
and	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
channel	O	O
blocker	O	O
effects	O	O
on	O	O
QT	O	O
interval	O	O
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O	O
report	O	O
showing	O	O
that	O	O
this	O	O
technique	O	O
can	O	O
be	O	O
used	O	O
to	O	O
predict	O	O
multichannel	O	O
blocker	O	O
potential	O	O
for	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
is	O	O
to	O	O
show	O	O
that	O	O
FPD	O	O
from	O	O
MEA	O	O
(	O	O
Multielectrode	O	O
array	O	O
)	O	O
of	O	O
hiPS	O	O
-	O	O
CMs	O	O
can	O	O
detect	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
induced	O	O
by	O	O
multichannel	O	O
blockers	O	O
.	O	O

hiPS	O	O
-	O	O
CMs	O	O
were	O	O
seeded	O	O
onto	O	O
MEA	O	O
and	O	O
FPD	O	O
was	O	O
measured	O	O
for	O	O
2min	O	O
every	O	O
10min	O	O
for	O	O
30min	O	O
after	O	O
drug	O	O
exposure	O	O
for	O	O
the	O	O
vehicle	O	O
and	O	O
each	O	O
drug	O	O
concentration	O	O
.	O	O

IKr	O	O
and	O	O
IKs	O	O
blockers	O	O
concentration	O	O
-	O	O
dependently	O	O
prolonged	O	O
corrected	O	O
FPD	O	O
(	O	O
FPDc	O	O
)	O	O
,	O	O
whereas	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
channel	O	O
blockers	O	O
concentration	O	O
-	O	O
dependently	O	O
shortened	O	O
FPDc	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
multichannel	O	O
blockers	O	O
Amiodarone	B-Chemical	D000638
,	O	O
Paroxetine	B-Chemical	D017374
,	O	O
Terfenadine	B-Chemical	D016593
and	O	O
Citalopram	B-Chemical	D015283
prolonged	O	O
FPDc	O	O
in	O	O
a	O	O
concentration	O	O
dependent	O	O
manner	O	O
.	O	O

Finally	O	O
,	O	O
the	O	O
IKr	O	O
blockers	O	O
,	O	O
Terfenadine	B-Chemical	D016593
and	O	O
Citalopram	B-Chemical	D015283
,	O	O
which	O	O
are	O	O
reported	O	O
to	O	O
cause	O	O
Torsade	B-Disease	D016171
de	I-Disease	D016171
Pointes	I-Disease	D016171
(	O	O
TdP	B-Disease	D016171
)	O	O
in	O	O
clinical	O	O
practice	O	O
,	O	O
produced	O	O
early	O	O
afterdepolarization	O	O
(	O	O
EAD	O	O
)	O	O
.	O	O

hiPS	O	O
-	O	O
CMs	O	O
using	O	O
MEA	O	O
system	O	O
and	O	O
FPDc	O	O
can	O	O
predict	O	O
the	O	O
effects	O	O
of	O	O
drug	O	O
candidates	O	O
on	O	O
QT	O	O
interval	O	O
.	O	O

This	O	O
study	O	O
also	O	O
shows	O	O
that	O	O
this	O	O
assay	O	O
can	O	O
help	O	O
detect	O	O
EAD	O	O
for	O	O
drugs	O	O
with	O	O
TdP	B-Disease	D016171
potential	O	O
.	O	O

Dermal	O	O
developmental	O	O
toxicity	B-Disease	D064420
of	O	O
N	O	O
-	O	O
phenylimide	O	O
herbicides	O	O
in	O	O
rats	O	O
.	O	O

BACKGROUND	O	O
:	O	O
S	B-Chemical	C106487
-	I-Chemical	C106487
53482	I-Chemical	C106487
and	O	O
S	B-Chemical	C083440
-	I-Chemical	C083440
23121	I-Chemical	C083440
are	O	O
N	O	O
-	O	O
phenylimide	O	O
herbicides	O	O
and	O	O
produced	O	O
embryolethality	B-Disease	D020964
,	O	O
teratogenicity	B-Disease	D064793
(	O	O
mainly	O	O
ventricular	B-Disease	D006345
septal	I-Disease	D006345
defects	I-Disease	D006345
and	O	O
wavy	O	O
ribs	O	O
)	O	O
,	O	O
and	O	O
growth	B-Disease	D005317
retardation	I-Disease	D005317
in	O	O
rats	O	O
in	O	O
conventional	O	O
oral	O	O
developmental	O	O
toxicity	B-Disease	D064420
studies	O	O
.	O	O

Our	O	O
objective	O	O
in	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
the	O	O
compounds	O	O
induce	O	O
developmental	O	O
toxicity	B-Disease	D064420
via	O	O
the	O	O
dermal	O	O
route	O	O
,	O	O
which	O	O
is	O	O
more	O	O
relevant	O	O
to	O	O
occupational	O	O
exposure	O	O
,	O	O
hence	O	O
better	O	O
addressing	O	O
human	O	O
health	O	O
risks	O	O
.	O	O

METHODS	O	O
:	O	O
S	B-Chemical	C106487
-	I-Chemical	C106487
53482	I-Chemical	C106487
was	O	O
administered	O	O
dermally	O	O
to	O	O
rats	O	O
at	O	O
30	O	O
,	O	O
100	O	O
,	O	O
and	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
during	O	O
organogenesis	O	O
,	O	O
and	O	O
S	B-Chemical	C083440
-	I-Chemical	C083440
23121	I-Chemical	C083440
was	O	O
administered	O	O
at	O	O
200	O	O
,	O	O
400	O	O
,	O	O
and	O	O
800	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
the	O	O
maximum	O	O
applicable	O	O
dose	O	O
level	O	O
)	O	O
.	O	O

Fetuses	O	O
were	O	O
obtained	O	O
by	O	O
a	O	O
Cesarean	O	O
section	O	O
and	O	O
examined	O	O
for	O	O
external	O	O
,	O	O
visceral	O	O
,	O	O
and	O	O
skeletal	O	O
alterations	O	O
.	O	O

RESULTS	O	O
:	O	O
Dermal	O	O
exposure	O	O
of	O	O
rats	O	O
to	O	O
S	B-Chemical	C106487
-	I-Chemical	C106487
53482	I-Chemical	C106487
at	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
produced	O	O
patterns	O	O
of	O	O
developmental	O	O
toxicity	B-Disease	D064420
similar	O	O
to	O	O
those	O	O
resulting	O	O
from	O	O
oral	O	O
exposure	O	O
.	O	O

Toxicity	B-Disease	D064420
included	O	O
embryolethality	B-Disease	D020964
,	O	O
teratogenicity	B-Disease	D064793
,	O	O
and	O	O
growth	B-Disease	D005317
retardation	I-Disease	D005317
.	O	O

Dermal	O	O
administration	O	O
of	O	O
S	B-Chemical	C083440
-	I-Chemical	C083440
23121	I-Chemical	C083440
at	O	O
800	O	O
mg	O	O
/	O	O
kg	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
embryonic	B-Disease	D020964
death	I-Disease	D020964
and	O	O
ventricular	B-Disease	D006345
septal	I-Disease	D006345
defect	I-Disease	D006345
,	O	O
but	O	O
retarded	O	O
fetal	O	O
growth	O	O
was	O	O
not	O	O
observed	O	O
as	O	O
it	O	O
was	O	O
following	O	O
oral	O	O
exposure	O	O
to	O	O
S	B-Chemical	C083440
-	I-Chemical	C083440
23121	I-Chemical	C083440
.	O	O

CONCLUSIONS	O	O
:	O	O
Based	O	O
on	O	O
the	O	O
results	O	O
,	O	O
S	B-Chemical	C106487
-	I-Chemical	C106487
53482	I-Chemical	C106487
and	O	O
S	B-Chemical	C083440
-	I-Chemical	C083440
23121	I-Chemical	C083440
were	O	O
teratogenic	B-Disease	D064793
when	O	O
administered	O	O
dermally	O	O
to	O	O
pregnant	O	O
rats	O	O
as	O	O
were	O	O
the	O	O
compounds	O	O
administered	O	O
orally	O	O
.	O	O

Thus	O	O
,	O	O
investigation	O	O
of	O	O
the	O	O
mechanism	O	O
and	O	O
its	O	O
human	O	O
relevancy	O	O
become	O	O
more	O	O
important	O	O
.	O	O

Rates	O	O
of	O	O
Renal	B-Disease	D007674
Toxicity	I-Disease	D007674
in	O	O
Cancer	B-Disease	D009369
Patients	O	O
Receiving	O	O
Cisplatin	B-Chemical	D002945
With	O	O
and	O	O
Without	O	O
Mannitol	B-Chemical	D008353
.	O	O

BACKGROUND	O	O
:	O	O
Cisplatin	B-Chemical	D002945
is	O	O
a	O	O
widely	O	O
used	O	O
antineoplastic	O	O
.	O	O

One	O	O
of	O	O
the	O	O
major	O	O
complications	O	O
of	O	O
cisplatin	B-Chemical	D002945
use	O	O
is	O	O
dose	O	O
-	O	O
limiting	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

There	O	O
are	O	O
many	O	O
strategies	O	O
to	O	O
prevent	O	O
this	O	O
toxicity	B-Disease	D064420
,	O	O
including	O	O
the	O	O
use	O	O
of	O	O
mannitol	B-Chemical	D008353
as	O	O
a	O	O
nephroprotectant	O	O
in	O	O
combination	O	O
with	O	O
hydration	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
rates	O	O
of	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
in	O	O
cancer	B-Disease	D009369
patients	O	O
receiving	O	O
single	O	O
-	O	O
agent	O	O
cisplatin	B-Chemical	D002945
with	O	O
and	O	O
without	O	O
mannitol	B-Chemical	D008353
.	O	O

METHODS	O	O
:	O	O
This	O	O
single	O	O
-	O	O
center	O	O
retrospective	O	O
analysis	O	O
was	O	O
a	O	O
quasi	O	O
experiment	O	O
created	O	O
by	O	O
the	O	O
national	O	O
mannitol	B-Chemical	D008353
shortage	O	O
.	O	O

Data	O	O
were	O	O
collected	O	O
on	O	O
adult	O	O
cancer	B-Disease	D009369
patients	O	O
receiving	O	O
single	O	O
-	O	O
agent	O	O
cisplatin	B-Chemical	D002945
as	O	O
an	O	O
outpatient	O	O
from	O	O
January	O	O
2011	O	O
to	O	O
September	O	O
2012	O	O
.	O	O

The	O	O
primary	O	O
outcome	O	O
was	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
(	O	O
AKI	B-Disease	D058186
)	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
evaluated	O	O
143	O	O
patients	O	O
who	O	O
received	O	O
single	O	O
-	O	O
agent	O	O
cisplatin	B-Chemical	D002945
;	O	O
97	O	O
.	O	O

2%	O	O
of	O	O
patients	O	O
had	O	O
head	B-Disease	D006258
and	I-Disease	D006258
neck	I-Disease	D006258
cancer	I-Disease	D006258
as	O	O
their	O	O
primary	O	O
malignancy	B-Disease	D009369
.	O	O

Patients	O	O
who	O	O
did	O	O
not	O	O
receive	O	O
mannitol	B-Chemical	D008353
were	O	O
more	O	O
likely	O	O
to	O	O
develop	O	O
nephrotoxicity	B-Disease	D007674
:	O	O
odds	O	O
ratio	O	O
[	O	O
OR	O	O
]	O	O
=	O	O
2	O	O
.	O	O

646	O	O
(	O	O
95%	O	O
CI	O	O
=	O	O
1	O	O
.	O	O

008	O	O
,	O	O
6	O	O
.	O	O

944	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

048	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
received	O	O
the	O	O
100	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
dosing	O	O
and	O	O
patients	O	O
who	O	O
had	O	O
a	O	O
history	O	O
of	O	O
hypertension	B-Disease	D006973
also	O	O
had	O	O
a	O	O
higher	O	O
likelihood	O	O
of	O	O
developing	O	O
nephrotoxicity	B-Disease	D007674
:	O	O
OR	O	O
=	O	O
11	O	O
.	O	O

494	O	O
(	O	O
95%	O	O
CI	O	O
=	O	O
4	O	O
.	O	O

149	O	O
,	O	O
32	O	O
.	O	O

258	O	O
;	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
and	O	O
OR	O	O
=	O	O
3	O	O
.	O	O

219	O	O
(	O	O
95%	O	O
CI	O	O
=	O	O
1	O	O
.	O	O

228	O	O
,	O	O
8	O	O
.	O	O

439	O	O
;	O	O
P	O	O
=	O	O
0	O	O
.	O	O

017	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
When	O	O
limited	O	O
quantities	O	O
of	O	O
mannitol	B-Chemical	D008353
are	O	O
available	O	O
,	O	O
it	O	O
should	O	O
preferentially	O	O
be	O	O
given	O	O
to	O	O
patients	O	O
at	O	O
particularly	O	O
high	O	O
risk	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Our	O	O
analysis	O	O
suggests	O	O
that	O	O
those	O	O
patients	O	O
receiving	O	O
the	O	O
dosing	O	O
schedule	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
cisplatin	B-Chemical	D002945
every	O	O
3	O	O
weeks	O	O
and	O	O
those	O	O
with	O	O
hypertension	B-Disease	D006973
are	O	O
at	O	O
the	O	O
greatest	O	O
risk	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
and	O	O
would	O	O
benefit	O	O
from	O	O
the	O	O
addition	O	O
of	O	O
mannitol	B-Chemical	D008353
.	O	O

Metformin	B-Chemical	D008687
protects	O	O
against	O	O
seizures	B-Disease	D012640
,	O	O
learning	O	O
and	O	O
memory	O	O
impairments	O	O
and	O	O
oxidative	O	O
damage	O	O
induced	O	O
by	O	O
pentylenetetrazole	B-Chemical	D010433
-	O	O
induced	O	O
kindling	O	O
in	O	O
mice	O	O
.	O	O

Cognitive	B-Disease	D003072
impairment	I-Disease	D003072
,	O	O
the	O	O
most	O	O
common	O	O
and	O	O
severe	O	O
comorbidity	O	O
of	O	O
epilepsy	B-Disease	D004827
,	O	O
greatly	O	O
diminishes	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

However	O	O
,	O	O
current	O	O
therapeutic	O	O
interventions	O	O
for	O	O
epilepsy	B-Disease	D004827
can	O	O
also	O	O
cause	O	O
untoward	O	O
cognitive	O	O
effects	O	O
.	O	O

Thus	O	O
,	O	O
there	O	O
is	O	O
an	O	O
urgent	O	O
need	O	O
for	O	O
new	O	O
kinds	O	O
of	O	O
agents	O	O
targeting	O	O
both	O	O
seizures	B-Disease	D012640
and	O	O
cognition	B-Disease	D003072
deficits	I-Disease	D003072
.	O	O

Oxidative	O	O
stress	O	O
is	O	O
considered	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
epileptogenesis	O	O
and	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
,	O	O
and	O	O
antioxidants	O	O
have	O	O
a	O	O
putative	O	O
antiepileptic	O	O
potential	O	O
.	O	O

Metformin	B-Chemical	D008687
,	O	O
the	O	O
most	O	O
commonly	O	O
prescribed	O	O
antidiabetic	O	O
oral	O	O
drug	O	O
,	O	O
has	O	O
antioxidant	O	O
properties	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
ameliorative	O	O
effects	O	O
of	O	O
metformin	B-Chemical	D008687
on	O	O
seizures	B-Disease	D012640
,	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
and	O	O
brain	O	O
oxidative	O	O
stress	O	O
markers	O	O
observed	O	O
in	O	O
pentylenetetrazole	B-Chemical	D010433
-	O	O
induced	O	O
kindling	O	O
animals	O	O
.	O	O

Male	O	O
C57BL	O	O
/	O	O
6	O	O
mice	O	O
were	O	O
administered	O	O
with	O	O
subconvulsive	O	O
dose	O	O
of	O	O
pentylenetetrazole	B-Chemical	D010433
(	O	O
37	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
every	O	O
other	O	O
day	O	O
for	O	O
14	O	O
injections	O	O
.	O	O

Metformin	B-Chemical	D008687
was	O	O
injected	O	O
intraperitoneally	O	O
in	O	O
dose	O	O
of	O	O
200mg	O	O
/	O	O
kg	O	O
along	O	O
with	O	O
alternate	O	O
-	O	O
day	O	O
PTZ	B-Chemical	D010433
.	O	O

We	O	O
found	O	O
that	O	O
metformin	B-Chemical	D008687
suppressed	O	O
the	O	O
progression	O	O
of	O	O
kindling	O	O
,	O	O
ameliorated	O	O
the	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
and	O	O
decreased	O	O
brain	O	O
oxidative	O	O
stress	O	O
.	O	O

Thus	O	O
the	O	O
present	O	O
study	O	O
concluded	O	O
that	O	O
metformin	B-Chemical	D008687
may	O	O
be	O	O
a	O	O
potential	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
epilepsy	B-Disease	D004827
as	O	O
well	O	O
as	O	O
a	O	O
protective	O	O
medicine	O	O
against	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
induced	O	O
by	O	O
seizures	B-Disease	D012640
.	O	O

P53	O	O
inhibition	O	O
exacerbates	O	O
late	O	O
-	O	O
stage	O	O
anthracycline	B-Chemical	D018943
cardiotoxicity	B-Disease	D066126
.	O	O

AIMS	O	O
:	O	O
Doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
is	O	O
an	O	O
effective	O	O
anti	O	O
-	O	O
cancer	B-Disease	D009369
therapeutic	O	O
,	O	O
but	O	O
is	O	O
associated	O	O
with	O	O
both	O	O
acute	O	O
and	O	O
late	O	O
-	O	O
stage	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Children	O	O
are	O	O
particularly	O	O
sensitive	O	O
to	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Here	O	O
,	O	O
the	O	O
impact	O	O
of	O	O
p53	O	O
inhibition	O	O
on	O	O
acute	O	O
vs	O	O
.	O	O

late	O	O
-	O	O
stage	O	O
DOX	B-Chemical	D004317
cardiotoxicity	B-Disease	D066126
was	O	O
examined	O	O
in	O	O
a	O	O
juvenile	O	O
model	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Two	O	O
-	O	O
week	O	O
-	O	O
old	O	O
MHC	O	O
-	O	O
CB7	O	O
mice	O	O
(	O	O
which	O	O
express	O	O
dominant	O	O
-	O	O
interfering	O	O
p53	O	O
in	O	O
cardiomyocytes	O	O
)	O	O
and	O	O
their	O	O
non	O	O
-	O	O
transgenic	O	O
(	O	O
NON	O	O
-	O	O
TXG	O	O
)	O	O
littermates	O	O
received	O	O
weekly	O	O
DOX	B-Chemical	D004317
injections	O	O
for	O	O
5	O	O
weeks	O	O
(	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
cumulative	O	O
dose	O	O
)	O	O
.	O	O

One	O	O
week	O	O
after	O	O
the	O	O
last	O	O
DOX	B-Chemical	D004317
treatment	O	O
(	O	O
acute	O	O
stage	O	O
)	O	O
,	O	O
MHC	O	O
-	O	O
CB7	O	O
mice	O	O
exhibited	O	O
improved	O	O
cardiac	O	O
function	O	O
and	O	O
lower	O	O
levels	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
NON	O	O
-	O	O
TXG	O	O
mice	O	O
.	O	O

Surprisingly	O	O
,	O	O
by	O	O
13	O	O
weeks	O	O
following	O	O
the	O	O
last	O	O
DOX	B-Chemical	D004317
treatment	O	O
(	O	O
late	O	O
stage	O	O
)	O	O
,	O	O
MHC	O	O
-	O	O
CB7	O	O
exhibited	O	O
a	O	O
progressive	O	O
decrease	O	O
in	O	O
cardiac	O	O
function	O	O
and	O	O
higher	O	O
rates	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
when	O	O
compared	O	O
with	O	O
NON	O	O
-	O	O
TXG	O	O
mice	O	O
.	O	O

p53	O	O
inhibition	O	O
blocked	O	O
transient	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
STAT3	O	O
activation	O	O
in	O	O
MHC	O	O
-	O	O
CB7	O	O
mice	O	O
,	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
enhanced	O	O
induction	O	O
of	O	O
the	O	O
DNA	O	O
repair	O	O
proteins	O	O
Ku70	O	O
and	O	O
Ku80	O	O
.	O	O

Mice	O	O
with	O	O
cardiomyocyte	O	O
-	O	O
restricted	O	O
deletion	O	O
of	O	O
STAT3	O	O
exhibited	O	O
worse	O	O
cardiac	O	O
function	O	O
,	O	O
higher	O	O
levels	O	O
of	O	O
cardiomyocyte	O	O
apoptosis	O	O
,	O	O
and	O	O
a	O	O
greater	O	O
induction	O	O
of	O	O
Ku70	O	O
and	O	O
Ku80	O	O
in	O	O
response	O	O
to	O	O
DOX	B-Chemical	D004317
treatment	O	O
during	O	O
the	O	O
acute	O	O
stage	O	O
when	O	O
compared	O	O
with	O	O
control	O	O
animals	O	O
.	O	O

CONCLUSION	O	O
:	O	O
These	O	O
data	O	O
support	O	O
a	O	O
model	O	O
wherein	O	O
a	O	O
p53	O	O
-	O	O
dependent	O	O
cardioprotective	O	O
pathway	O	O
,	O	O
mediated	O	O
via	O	O
STAT3	O	O
activation	O	O
,	O	O
mitigates	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
myocardial	O	O
stress	O	O
during	O	O
drug	O	O
delivery	O	O
.	O	O

Furthermore	O	O
,	O	O
these	O	O
data	O	O
suggest	O	O
an	O	O
explanation	O	O
as	O	O
to	O	O
how	O	O
p53	O	O
inhibition	O	O
can	O	O
result	O	O
in	O	O
cardioprotection	O	O
during	O	O
drug	O	O
treatment	O	O
and	O	O
,	O	O
paradoxically	O	O
,	O	O
enhanced	O	O
cardiotoxicity	B-Disease	D066126
long	O	O
after	O	O
the	O	O
cessation	O	O
of	O	O
drug	O	O
treatment	O	O
.	O	O

Metronidazole	B-Chemical	D008795
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
:	O	O
an	O	O
uncommon	O	O
scenario	O	O
.	O	O

Metronidazole	B-Chemical	D008795
can	O	O
produce	O	O
neurological	O	O
complications	O	O
although	O	O
it	O	O
is	O	O
not	O	O
a	O	O
common	O	O
scenario	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
where	O	O
a	O	O
patient	O	O
developed	O	O
features	O	O
of	O	O
encephalopathy	B-Disease	D001927
following	O	O
prolonged	O	O
metronidazole	B-Chemical	D008795
intake	O	O
.	O	O

Magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
brain	O	O
showed	O	O
abnormal	O	O
signal	O	O
intensity	O	O
involving	O	O
both	O	O
dentate	O	O
nuclei	O	O
of	O	O
cerebellum	O	O
and	O	O
splenium	O	O
of	O	O
corpus	O	O
callosum	O	O
.	O	O

The	O	O
diagnosis	O	O
of	O	O
metronidazole	B-Chemical	D008795
toxicity	B-Disease	D064420
was	O	O
made	O	O
by	O	O
the	O	O
MRI	O	O
findings	O	O
and	O	O
supported	O	O
clinically	O	O
.	O	O

Aconitine	B-Chemical	D000157
-	O	O
induced	O	O
Ca2+	O	O
overload	O	O
causes	O	O
arrhythmia	B-Disease	D001145
and	O	O
triggers	O	O
apoptosis	O	O
through	O	O
p38	O	O
MAPK	O	O
signaling	O	O
pathway	O	O
in	O	O
rats	O	O
.	O	O

Aconitine	B-Chemical	D000157
is	O	O
a	O	O
major	O	O
bioactive	O	O
diterpenoid	O	O
alkaloid	O	O
with	O	O
high	O	O
content	O	O
derived	O	O
from	O	O
herbal	O	O
aconitum	O	O
plants	O	O
.	O	O

Emerging	O	O
evidence	O	O
indicates	O	O
that	O	O
voltage	O	O
-	O	O
dependent	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
channels	O	O
have	O	O
pivotal	O	O
roles	O	O
in	O	O
the	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
aconitine	B-Chemical	D000157
.	O	O

However	O	O
,	O	O
no	O	O
reports	O	O
are	O	O
available	O	O
on	O	O
the	O	O
role	O	O
of	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
in	O	O
aconitine	B-Chemical	D000157
poisoning	B-Disease	D011041
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
explored	O	O
the	O	O
importance	O	O
of	O	O
pathological	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
signaling	O	O
in	O	O
aconitine	B-Chemical	D000157
poisoning	B-Disease	D011041
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
found	O	O
that	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
overload	O	O
lead	O	O
to	O	O
accelerated	O	O
beating	O	O
rhythm	O	O
in	O	O
adult	O	O
rat	O	O
ventricular	O	O
myocytes	O	O
and	O	O
caused	O	O
arrhythmia	B-Disease	D001145
in	O	O
conscious	O	O
freely	O	O
moving	O	O
rats	O	O
.	O	O

To	O	O
investigate	O	O
effects	O	O
of	O	O
aconitine	B-Chemical	D000157
on	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
,	O	O
we	O	O
performed	O	O
cytotoxicity	B-Disease	D064420
assay	O	O
in	O	O
neonatal	O	O
rat	O	O
ventricular	O	O
myocytes	O	O
(	O	O
NRVMs	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
measured	O	O
lactate	B-Chemical	D019344
dehydrogenase	O	O
level	O	O
in	O	O
the	O	O
culture	O	O
medium	O	O
of	O	O
NRVMs	O	O
and	O	O
activities	O	O
of	O	O
serum	O	O
cardiac	O	O
enzymes	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
aconitine	B-Chemical	D000157
resulted	O	O
in	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
and	O	O
reduced	O	O
NRVMs	O	O
viability	O	O
dose	O	O
-	O	O
dependently	O	O
.	O	O

To	O	O
confirm	O	O
the	O	O
pro	O	O
-	O	O
apoptotic	O	O
effects	O	O
,	O	O
we	O	O
performed	O	O
flow	O	O
cytometric	O	O
detection	O	O
,	O	O
cardiac	O	O
histology	O	O
,	O	O
transmission	O	O
electron	O	O
microscopy	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	O
transferase	O	O
-	O	O
mediated	O	O
dUTP	B-Chemical	-1
-	O	O
biotin	B-Chemical	D001710
nick	O	O
end	O	O
labeling	O	O
assay	O	O
.	O	O

The	O	O
results	O	O
showed	O	O
that	O	O
aconitine	B-Chemical	D000157
stimulated	O	O
apoptosis	O	O
time	O	O
-	O	O
dependently	O	O
.	O	O

The	O	O
expression	O	O
analysis	O	O
of	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
handling	O	O
proteins	O	O
demonstrated	O	O
that	O	O
aconitine	B-Chemical	D000157
promoted	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
overload	O	O
through	O	O
the	O	O
expression	O	O
regulation	O	O
of	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
handling	O	O
proteins	O	O
.	O	O

The	O	O
expression	O	O
analysis	O	O
of	O	O
apoptosis	O	O
-	O	O
related	O	O
proteins	O	O
revealed	O	O
that	O	O
pro	O	O
-	O	O
apoptotic	O	O
protein	O	O
expression	O	O
was	O	O
upregulated	O	O
,	O	O
and	O	O
anti	O	O
-	O	O
apoptotic	O	O
protein	O	O
BCL	O	O
-	O	O
2	O	O
expression	O	O
was	O	O
downregulated	O	O
.	O	O

Furthermore	O	O
,	O	O
increased	O	O
phosphorylation	O	O
of	O	O
MAPK	O	O
family	O	O
members	O	O
,	O	O
especially	O	O
the	O	O
P	O	O
-	O	O
P38	O	O
/	O	O
P38	O	O
ratio	O	O
was	O	O
found	O	O
in	O	O
cardiac	O	O
tissues	O	O
.	O	O

Hence	O	O
,	O	O
our	O	O
results	O	O
suggest	O	O
that	O	O
aconitine	B-Chemical	D000157
significantly	O	O
aggravates	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
overload	O	O
and	O	O
causes	O	O
arrhythmia	B-Disease	D001145
and	O	O
finally	O	O
promotes	O	O
apoptotic	O	O
development	O	O
via	O	O
phosphorylation	O	O
of	O	O
P38	O	O
mitogen	O	O
-	O	O
activated	O	O
protein	O	O
kinase	O	O
.	O	O

Chronic	O	O
treatment	O	O
with	O	O
metformin	B-Chemical	D008687
suppresses	O	O
toll	O	O
-	O	O
like	O	O
receptor	O	O
4	O	O
signaling	O	O
and	O	O
attenuates	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
following	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Acute	O	O
treatment	O	O
with	O	O
metformin	B-Chemical	D008687
has	O	O
a	O	O
protective	O	O
effect	O	O
in	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
by	O	O
suppression	O	O
of	O	O
inflammatory	O	O
responses	O	O
due	O	O
to	O	O
activation	O	O
of	O	O
AMP	B-Chemical	D000667
-	O	O
activated	O	O
protein	O	O
kinase	O	O
(	O	O
AMPK	O	O
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
metformin	B-Chemical	D008687
on	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
and	O	O
toll	O	O
-	O	O
like	O	O
receptor	O	O
4	O	O
(	O	O
TLR4	O	O
)	O	O
activities	O	O
following	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
and	O	O
their	O	O
relation	O	O
with	O	O
AMPK	O	O
were	O	O
assessed	O	O
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
5	O	O
groups	O	O
(	O	O
n=6	O	O
)	O	O
:	O	O
normal	O	O
control	O	O
and	O	O
groups	O	O
were	O	O
injected	O	O
isoproterenol	B-Chemical	D007545
after	O	O
chronic	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
0	O	O
,	O	O
25	O	O
,	O	O
50	O	O
,	O	O
or	O	O
100mg	O	O
/	O	O
kg	O	O
of	O	O
metformin	B-Chemical	D008687
twice	O	O
daily	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Isoproterenol	B-Chemical	D007545
(	O	O
100mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
injected	O	O
subcutaneously	O	O
on	O	O
the	O	O
13th	O	O
and	O	O
14th	O	O
days	O	O
to	O	O
induce	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Isoproterenol	B-Chemical	D007545
alone	O	O
decreased	O	O
left	O	O
ventricular	O	O
systolic	O	O
pressure	O	O
and	O	O
myocardial	O	O
contractility	O	O
indexed	O	O
as	O	O
LVdp	O	O
/	O	O
dtmax	O	O
and	O	O
LVdp	O	O
/	O	O
dtmin	O	O
.	O	O

The	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
groups	O	O
treated	O	O
with	O	O
25	O	O
and	O	O
50mg	O	O
/	O	O
kg	O	O
of	O	O
metformin	B-Chemical	D008687
.	O	O

Metfromin	O	O
markedly	O	O
lowered	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
elevation	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
TLR4	O	O
mRNA	O	O
,	O	O
myeloid	O	O
differentiation	O	O
protein	O	O
88	O	O
(	O	O
MyD88	O	O
)	O	O
,	O	O
tumor	B-Disease	D009369
necrosis	B-Disease	D009336
factor	O	O
-	O	O
alpha	O	O
(	O	O
TNF	O	O
-	O	O
a	O	O
)	O	O
,	O	O
and	O	O
interleukin	O	O
6	O	O
(	O	O
IL	O	O
-	O	O
6	O	O
)	O	O
in	O	O
the	O	O
heart	O	O
tissues	O	O
.	O	O

Similar	O	O
changes	O	O
were	O	O
also	O	O
seen	O	O
in	O	O
the	O	O
serum	O	O
levels	O	O
of	O	O
TNF	O	O
-	O	O
a	O	O
and	O	O
IL	O	O
-	O	O
6	O	O
.	O	O

However	O	O
,	O	O
the	O	O
lower	O	O
doses	O	O
of	O	O
25	O	O
and	O	O
50mg	O	O
/	O	O
kg	O	O
were	O	O
more	O	O
effective	O	O
than	O	O
100mg	O	O
/	O	O
kg	O	O
.	O	O

Phosphorylated	O	O
AMPKa	O	O
(	O	O
p	O	O
-	O	O
AMPK	O	O
)	O	O
in	O	O
the	O	O
myocardium	O	O
was	O	O
significantly	O	O
elevated	O	O
by	O	O
25mg	O	O
/	O	O
kg	O	O
of	O	O
metformin	B-Chemical	D008687
,	O	O
slightly	O	O
by	O	O
50mg	O	O
/	O	O
kg	O	O
,	O	O
but	O	O
not	O	O
by	O	O
100mg	O	O
/	O	O
kg	O	O
.	O	O

Chronic	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
metformin	B-Chemical	D008687
reduces	O	O
post	O	O
-	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
and	O	O
suppresses	O	O
inflammatory	O	O
responses	O	O
,	O	O
possibly	O	O
through	O	O
inhibition	O	O
of	O	O
TLR4	O	O
activities	O	O
.	O	O

This	O	O
mechanism	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
a	O	O
target	O	O
to	O	O
protect	O	O
infarcted	O	O
myocardium	O	O
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
induced	O	O
by	O	O
combination	O	O
therapy	O	O
with	O	O
tetrabenazine	B-Chemical	D013747
and	O	O
tiapride	B-Chemical	D063325
in	O	O
a	O	O
Japanese	O	O
patient	O	O
with	O	O
Huntington's	B-Disease	D006816
disease	I-Disease	D006816
at	O	O
the	O	O
terminal	O	O
stage	O	O
of	O	O
recurrent	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

We	O	O
herein	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
an	O	O
81	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Japanese	O	O
woman	O	O
with	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
that	O	O
occurred	O	O
36	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
combination	O	O
therapy	O	O
with	O	O
tiapride	B-Chemical	D063325
(	O	O
75	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
and	O	O
tetrabenazine	B-Chemical	D013747
(	O	O
12	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
for	O	O
Huntington's	B-Disease	D006816
disease	I-Disease	D006816
.	O	O

The	O	O
patient	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
tiapride	B-Chemical	D063325
or	O	O
tetrabenazine	B-Chemical	D013747
alone	O	O
without	O	O
any	O	O
adverse	O	O
effects	O	O
before	O	O
the	O	O
administration	O	O
of	O	O
the	O	O
combination	O	O
therapy	O	O
.	O	O

She	O	O
also	O	O
had	O	O
advanced	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
when	O	O
the	O	O
combination	O	O
therapy	O	O
was	O	O
initiated	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
,	O	O
the	O	O
occurrence	O	O
of	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
due	O	O
to	O	O
combination	O	O
therapy	O	O
with	O	O
tetrabenazine	B-Chemical	D013747
and	O	O
tiapride	B-Chemical	D063325
has	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

Tetrabenazine	B-Chemical	D013747
should	O	O
be	O	O
administered	O	O
very	O	O
carefully	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
neuroleptic	B-Chemical	D014150
drugs	I-Chemical	D014150
,	O	O
particularly	O	O
in	O	O
patients	O	O
with	O	O
a	O	O
worsening	O	O
general	O	O
condition	O	O
.	O	O

A	O	O
metoprolol	B-Chemical	D008790
-	O	O
terbinafine	B-Chemical	C041359
combination	O	O
induced	O	O
bradycardia	B-Disease	D001919
.	O	O

To	O	O
report	O	O
a	O	O
sinus	B-Disease	D012804
bradycardia	I-Disease	D012804
induced	O	O
by	O	O
metoprolol	B-Chemical	D008790
and	O	O
terbinafine	B-Chemical	C041359
drug	O	O
-	O	O
drug	O	O
interaction	O	O
and	O	O
its	O	O
management	O	O
.	O	O

A	O	O
63	O	O
year	O	O
-	O	O
old	O	O
Caucasian	O	O
man	O	O
on	O	O
metoprolol	B-Chemical	D008790
200	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
stable	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
was	O	O
prescribed	O	O
a	O	O
90	O	O
-	O	O
day	O	O
course	O	O
of	O	O
oral	O	O
terbinafine	B-Chemical	C041359
250	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
onychomycosis	B-Disease	D014009
.	O	O

On	O	O
the	O	O
49th	O	O
day	O	O
of	O	O
terbinafine	B-Chemical	C041359
therapy	O	O
,	O	O
he	O	O
was	O	O
brought	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
for	O	O
a	O	O
decrease	O	O
of	O	O
his	O	O
global	O	O
health	O	O
status	O	O
,	O	O
confusion	B-Disease	D003221
and	O	O
falls	O	O
.	O	O

The	O	O
electrocardiogram	O	O
revealed	O	O
a	O	O
37	O	O
beats	O	O
/	O	O
min	O	O
sinus	B-Disease	D012804
bradycardia	I-Disease	D012804
.	O	O

A	O	O
score	O	O
of	O	O
7	O	O
on	O	O
the	O	O
Naranjo	O	O
adverse	B-Disease	D064420
drug	I-Disease	D064420
reaction	I-Disease	D064420
probability	O	O
scale	O	O
indicates	O	O
a	O	O
probable	O	O
relationship	O	O
between	O	O
the	O	O
patient's	O	O
sinus	B-Disease	D012804
bradycardia	I-Disease	D012804
and	O	O
the	O	O
drug	O	O
interaction	O	O
between	O	O
metoprolol	B-Chemical	D008790
and	O	O
terbinafine	B-Chemical	C041359
.	O	O

The	O	O
heart	O	O
rate	O	O
ameliorated	O	O
first	O	O
with	O	O
a	O	O
decrease	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
metoprolol	B-Chemical	D008790
.	O	O

It	O	O
was	O	O
subsequently	O	O
changed	O	O
to	O	O
bisoprolol	B-Chemical	D017298
and	O	O
the	O	O
heart	O	O
rate	O	O
remained	O	O
normal	O	O
.	O	O

By	O	O
inhibiting	O	O
the	O	O
cytochrome	O	O
P450	O	O
2D6	O	O
,	O	O
terbinafine	B-Chemical	C041359
had	O	O
decreased	O	O
metoprolol's	O	O
clearance	O	O
,	O	O
leading	O	O
in	O	O
metoprolol	B-Chemical	D008790
accumulation	O	O
which	O	O
has	O	O
resulted	O	O
in	O	O
clinically	O	O
significant	O	O
sinus	B-Disease	D012804
bradycardia	I-Disease	D012804
.	O	O

Optochiasmatic	O	O
and	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
due	O	O
to	O	O
ethambutol	B-Chemical	D004977
overtreatment	O	O
.	O	O

Ethambutol	B-Chemical	D004977
is	O	O
known	O	O
to	O	O
cause	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
and	O	O
,	O	O
more	O	O
rarely	O	O
,	O	O
axonal	O	O
polyneuropathy	B-Disease	D011115
.	O	O

We	O	O
characterize	O	O
the	O	O
clinical	O	O
,	O	O
neurophysiological	O	O
,	O	O
and	O	O
neuroimaging	O	O
findings	O	O
in	O	O
a	O	O
72	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
developed	O	O
visual	B-Disease	D014786
loss	I-Disease	D014786
and	O	O
paresthesias	B-Disease	D010292
after	O	O
11	O	O
weeks	O	O
of	O	O
exposure	O	O
to	O	O
a	O	O
supratherapeutic	O	O
dose	O	O
of	O	O
ethambutol	B-Chemical	D004977
.	O	O

This	O	O
case	O	O
demonstrates	O	O
the	O	O
selective	O	O
vulnerability	O	O
of	O	O
the	O	O
anterior	O	O
visual	O	O
pathways	O	O
and	O	O
peripheral	O	O
nerves	O	O
to	O	O
ethambutol	B-Chemical	D004977
toxicity	B-Disease	D064420
.	O	O

Testosterone	B-Chemical	D013739
ameliorates	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
in	O	O
male	O	O
rats	O	O
.	O	O

AIM	O	O
:	O	O
To	O	O
study	O	O
the	O	O
effects	O	O
of	O	O
testosterone	B-Chemical	D013739
on	O	O
streptozotocin	B-Chemical	D013311
(	O	O
STZ	B-Chemical	D013311
)	O	O
-	O	O
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
in	O	O
male	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Adult	O	O
male	O	O
Wistar	O	O
rats	O	O
were	O	O
intracerebroventricularly	O	O
(	O	O
icv	O	O
)	O	O
infused	O	O
with	O	O
STZ	B-Chemical	D013311
(	O	O
750	O	O
ug	O	O
)	O	O
on	O	O
d	O	O
1	O	O
and	O	O
d	O	O
3	O	O
,	O	O
and	O	O
a	O	O
passive	O	O
avoidance	O	O
task	O	O
was	O	O
assessed	O	O
2	O	O
weeks	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
of	O	O
STZ	B-Chemical	D013311
.	O	O

Castration	O	O
surgery	O	O
was	O	O
performed	O	O
in	O	O
another	O	O
group	O	O
of	O	O
rats	O	O
,	O	O
and	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
was	O	O
assessed	O	O
4	O	O
weeks	O	O
after	O	O
the	O	O
operation	O	O
.	O	O

Testosterone	B-Chemical	D013739
(	O	O
1	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
sc	O	O
)	O	O
,	O	O
the	O	O
androgen	B-Chemical	D000728
receptor	O	O
antagonist	O	O
flutamide	B-Chemical	D005485
(	O	O
10	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
,	O	O
the	O	O
estrogen	B-Chemical	D004967
receptor	O	O
antagonist	O	O
tamoxifen	B-Chemical	D013629
(	O	O
1	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
or	O	O
the	O	O
aromatase	O	O
inhibitor	O	O
letrozole	B-Chemical	C067431
(	O	O
4	O	O
mg	O	O
.	O	O

kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
.	O	O

d	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
ip	O	O
)	O	O
were	O	O
administered	O	O
for	O	O
6	O	O
d	O	O
after	O	O
the	O	O
first	O	O
injection	O	O
of	O	O
STZ	B-Chemical	D013311
.	O	O

RESULTS	O	O
:	O	O
STZ	B-Chemical	D013311
administration	O	O
and	O	O
castration	O	O
markedly	O	O
decreased	O	O
both	O	O
STL1	O	O
(	O	O
the	O	O
short	O	O
memory	O	O
)	O	O
and	O	O
STL2	O	O
(	O	O
the	O	O
long	O	O
memory	O	O
)	O	O
in	O	O
passive	O	O
avoidance	O	O
tests	O	O
.	O	O

Testosterone	B-Chemical	D013739
replacement	O	O
almost	O	O
restored	O	O
the	O	O
STL1	O	O
and	O	O
STL2	O	O
in	O	O
castrated	O	O
rats	O	O
,	O	O
and	O	O
significantly	O	O
prolonged	O	O
the	O	O
STL1	O	O
and	O	O
STL2	O	O
in	O	O
STZ	B-Chemical	D013311
-	O	O
treated	O	O
rats	O	O
.	O	O

Administration	O	O
of	O	O
flutamide	B-Chemical	D005485
,	O	O
letrozole	B-Chemical	C067431
or	O	O
tamoxifen	B-Chemical	D013629
significantly	O	O
impaired	B-Disease	D008569
the	I-Disease	D008569
memory	I-Disease	D008569
in	O	O
intact	O	O
rats	O	O
,	O	O
and	O	O
significantly	O	O
attenuated	O	O
the	O	O
testosterone	B-Chemical	D013739
replacement	O	O
in	O	O
improving	O	O
STZ	B-Chemical	D013311
-	O	O
and	O	O
castration	O	O
-	O	O
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
.	O	O

CONCLUSION	O	O
:	O	O
Testosterone	B-Chemical	D013739
administration	O	O
ameliorates	O	O
STZ	B-Chemical	D013311
-	O	O
and	O	O
castration	O	O
-	O	O
induced	O	O
memory	B-Disease	D008569
impairment	I-Disease	D008569
in	O	O
male	O	O
Wistar	O	O
rats	O	O
.	O	O

Behavioral	O	O
and	O	O
neurochemical	O	O
studies	O	O
in	O	O
mice	O	O
pretreated	O	O
with	O	O
garcinielliptone	B-Chemical	C573355
FC	I-Chemical	C573355
in	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Garcinielliptone	B-Chemical	C573355
FC	I-Chemical	C573355
(	O	O
GFC	B-Chemical	C573355
)	O	O
isolated	O	O
from	O	O
hexanic	O	O
fraction	O	O
seed	O	O
extract	O	O
of	O	O
species	O	O
Platonia	O	O
insignis	O	O
Mart	O	O
.	O	O

It	O	O
is	O	O
widely	O	O
used	O	O
in	O	O
folk	O	O
medicine	O	O
to	O	O
treat	O	O
skin	B-Disease	D012871
diseases	I-Disease	D012871
in	O	O
both	O	O
humans	O	O
and	O	O
animals	O	O
as	O	O
well	O	O
as	O	O
the	O	O
seed	O	O
decoction	O	O
has	O	O
been	O	O
used	O	O
to	O	O
treat	O	O
diarrheas	B-Disease	D003967
and	O	O
inflammatory	B-Disease	D007249
diseases	I-Disease	D007249
.	O	O

However	O	O
,	O	O
there	O	O
is	O	O
no	O	O
research	O	O
on	O	O
GFC	B-Chemical	C573355
effects	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
of	O	O
rodents	O	O
.	O	O

The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
evaluate	O	O
the	O	O
GFC	B-Chemical	C573355
effects	O	O
at	O	O
doses	O	O
of	O	O
25	O	O
,	O	O
50	O	O
or	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
on	O	O
seizure	B-Disease	D012640
parameters	O	O
to	O	O
determine	O	O
their	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
its	O	O
effects	O	O
on	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
(	O	O
r	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
GABA	B-Chemical	D005680
)	O	O
,	O	O
glutamine	B-Chemical	D018698
,	O	O
aspartate	B-Chemical	D001224
and	O	O
glutathione	B-Chemical	D005978
)	O	O
levels	O	O
as	O	O
well	O	O
as	O	O
on	O	O
acetylcholinesterase	O	O
(	O	O
AChE	O	O
)	O	O
activity	O	O
in	O	O
mice	O	O
hippocampus	O	O
after	O	O
seizures	B-Disease	D012640
.	O	O

GFC	B-Chemical	C573355
produced	O	O
an	O	O
increased	O	O
latency	O	O
to	O	O
first	O	O
seizure	B-Disease	D012640
,	O	O
at	O	O
doses	O	O
25mg	O	O
/	O	O
kg	O	O
(	O	O
20	O	O
.	O	O

12	O	O
+	O	O
2	O	O
.	O	O

20	O	O
min	O	O
)	O	O
,	O	O
50mg	O	O
/	O	O
kg	O	O
(	O	O
20	O	O
.	O	O

95	O	O
+	O	O
2	O	O
.	O	O

21	O	O
min	O	O
)	O	O
or	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
23	O	O
.	O	O

43	O	O
+	O	O
1	O	O
.	O	O

99	O	O
min	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
GABA	B-Chemical	D005680
content	O	O
of	O	O
mice	O	O
hippocampus	O	O
treated	O	O
with	O	O
GFC75	O	O
plus	O	O
P400	O	O
showed	O	O
an	O	O
increase	O	O
of	O	O
46	O	O
.	O	O

90%	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

In	O	O
aspartate	B-Chemical	D001224
,	O	O
glutamine	B-Chemical	D018698
and	O	O
glutamate	B-Chemical	D018698
levels	O	O
detected	O	O
a	O	O
decrease	O	O
of	O	O
5	O	O
.	O	O

21%	O	O
,	O	O
13	O	O
.	O	O

55%	O	O
and	O	O
21	O	O
.	O	O

80%	O	O
,	O	O
respectively	O	O
in	O	O
mice	O	O
hippocampus	O	O
treated	O	O
with	O	O
GFC75	O	O
plus	O	O
P400	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

Hippocampus	O	O
mice	O	O
treated	O	O
with	O	O
GFC75	O	O
plus	O	O
P400	O	O
showed	O	O
an	O	O
increase	O	O
in	O	O
AChE	O	O
activity	O	O
(	O	O
63	O	O
.	O	O

30%	O	O
)	O	O
when	O	O
compared	O	O
with	O	O
seized	O	O
mice	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
GFC	B-Chemical	C573355
can	O	O
exert	O	O
anticonvulsant	O	O
activity	O	O
and	O	O
reduce	O	O
the	O	O
frequency	O	O
of	O	O
installation	O	O
of	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
,	O	O
as	O	O
demonstrated	O	O
by	O	O
increase	O	O
in	O	O
latency	O	O
to	O	O
first	O	O
seizure	B-Disease	D012640
and	O	O
decrease	O	O
in	O	O
mortality	O	O
rate	O	O
of	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
GFC	B-Chemical	C573355
may	O	O
influence	O	O
in	O	O
epileptogenesis	O	O
and	O	O
promote	O	O
anticonvulsant	O	O
actions	O	O
in	O	O
pilocarpine	B-Chemical	D010862
model	O	O
by	O	O
modulating	O	O
the	O	O
GABA	B-Chemical	D005680
and	O	O
glutamate	B-Chemical	D018698
contents	O	O
and	O	O
of	O	O
AChE	O	O
activity	O	O
in	O	O
seized	O	O
mice	O	O
hippocampus	O	O
.	O	O

This	O	O
compound	O	O
may	O	O
be	O	O
useful	O	O
to	O	O
produce	O	O
neuronal	O	O
protection	O	O
and	O	O
it	O	O
can	O	O
be	O	O
considered	O	O
as	O	O
an	O	O
anticonvulsant	O	O
agent	O	O
.	O	O

Standard	O	O
operating	O	O
procedures	O	O
for	O	O
antibiotic	O	O
therapy	O	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
:	O	O
a	O	O
prospective	O	O
,	O	O
clinical	O	O
,	O	O
non	O	O
-	O	O
interventional	O	O
,	O	O
observational	O	O
study	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
Acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
(	O	O
AKI	B-Disease	D058186
)	O	O
occurs	O	O
in	O	O
7%	O	O
of	O	O
hospitalized	O	O
and	O	O
66%	O	O
of	O	O
Intensive	O	O
Care	O	O
Unit	O	O
(	O	O
ICU	O	O
)	O	O
patients	O	O
.	O	O

It	O	O
increases	O	O
mortality	O	O
,	O	O
hospital	O	O
length	O	O
of	O	O
stay	O	O
,	O	O
and	O	O
costs	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
,	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
adherence	O	O
to	O	O
guidelines	O	O
(	O	O
standard	O	O
operating	O	O
procedures	O	O
(	O	O
SOP	O	O
)	O	O
)	O	O
for	O	O
potentially	O	O
nephrotoxic	B-Disease	D007674
antibiotics	O	O
and	O	O
the	O	O
occurrence	O	O
of	O	O
AKI	B-Disease	D058186
.	O	O

METHODS	O	O
:	O	O
This	O	O
study	O	O
was	O	O
carried	O	O
out	O	O
as	O	O
a	O	O
prospective	O	O
,	O	O
clinical	O	O
,	O	O
non	O	O
-	O	O
interventional	O	O
,	O	O
observational	O	O
study	O	O
.	O	O

Data	O	O
collection	O	O
was	O	O
performed	O	O
over	O	O
a	O	O
total	O	O
of	O	O
170	O	O
days	O	O
in	O	O
three	O	O
ICUs	O	O
at	O	O
Charite	O	O
-	O	O
Universitaetsmedizin	O	O
Berlin	O	O
.	O	O

A	O	O
total	O	O
of	O	O
675	O	O
patients	O	O
were	O	O
included	O	O
;	O	O
163	O	O
of	O	O
these	O	O
had	O	O
therapy	O	O
with	O	O
vancomycin	B-Chemical	D014640
,	O	O
gentamicin	B-Chemical	D005839
,	O	O
or	O	O
tobramycin	B-Chemical	D014031
;	O	O
were	O	O
>18	O	O
years	O	O
;	O	O
and	O	O
treated	O	O
in	O	O
the	O	O
ICU	O	O
for	O	O
>24	O	O
hours	O	O
.	O	O

Patients	O	O
with	O	O
an	O	O
adherence	O	O
to	O	O
SOP	O	O
>70%	O	O
were	O	O
classified	O	O
into	O	O
the	O	O
high	O	O
adherence	O	O
group	O	O
(	O	O
HAG	O	O
)	O	O
and	O	O
patients	O	O
with	O	O
an	O	O
adherence	O	O
of	O	O
<70%	O	O
into	O	O
the	O	O
low	O	O
adherence	O	O
group	O	O
(	O	O
LAG	O	O
)	O	O
.	O	O

AKI	B-Disease	D058186
was	O	O
defined	O	O
according	O	O
to	O	O
RIFLE	O	O
criteria	O	O
.	O	O

Adherence	O	O
to	O	O
SOPs	O	O
was	O	O
evaluated	O	O
by	O	O
retrospective	O	O
expert	O	O
audit	O	O
.	O	O

Development	O	O
of	O	O
AKI	B-Disease	D058186
was	O	O
compared	O	O
between	O	O
groups	O	O
with	O	O
exact	O	O
Chi2	O	O
-	O	O
test	O	O
and	O	O
multivariate	O	O
logistic	O	O
regression	O	O
analysis	O	O
(	O	O
two	O	O
-	O	O
sided	O	O
P	O	O
<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
LAG	O	O
consisted	O	O
of	O	O
75	O	O
patients	O	O
(	O	O
46%	O	O
)	O	O
versus	O	O
88	O	O
HAG	O	O
patients	O	O
(	O	O
54%	O	O
)	O	O
.	O	O

AKI	B-Disease	D058186
occurred	O	O
significantly	O	O
more	O	O
often	O	O
in	O	O
LAG	O	O
with	O	O
36%	O	O
versus	O	O
21%	O	O
in	O	O
HAG	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

035	O	O
)	O	O
.	O	O

Basic	O	O
characteristics	O	O
were	O	O
comparable	O	O
,	O	O
except	O	O
an	O	O
increased	O	O
rate	O	O
of	O	O
soft	O	O
tissue	O	O
infections	B-Disease	D007239
in	O	O
LAG	O	O
.	O	O

Multivariate	O	O
analysis	O	O
revealed	O	O
an	O	O
odds	O	O
ratio	O	O
of	O	O
2	O	O
.	O	O

5	O	O
-	O	O
fold	O	O
for	O	O
LAG	O	O
to	O	O
develop	O	O
AKI	B-Disease	D058186
compared	O	O
with	O	O
HAG	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
1	O	O
.	O	O

195	O	O
to	O	O
5	O	O
.	O	O

124	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

039	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Low	O	O
adherence	O	O
to	O	O
SOPs	O	O
for	O	O
potentially	O	O
nephrotoxic	B-Disease	D007674
antibiotics	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
higher	O	O
occurrence	O	O
of	O	O
AKI	B-Disease	D058186
.	O	O

TRIAL	O	O
REGISTRATION	O	O
:	O	O
Current	O	O
Controlled	O	O
Trials	O	O
ISRCTN54598675	O	O
.	O	O

Registered	O	O
17	O	O
August	O	O
2007	O	O
.	O	O

Rhabdomyolysis	B-Disease	D012206
in	O	O
a	O	O
hepatitis	B-Disease	D006526
C	I-Disease	D006526
virus	I-Disease	D006526
infected	I-Disease	D006526
patient	O	O
treated	O	O
with	O	O
telaprevir	B-Chemical	C486464
and	O	O
simvastatin	B-Chemical	D019821
.	O	O

A	O	O
46	O	O
-	O	O
year	O	O
old	O	O
man	O	O
with	O	O
a	O	O
chronic	O	O
hepatitis	B-Disease	D006526
C	I-Disease	D006526
virus	I-Disease	D006526
infection	I-Disease	D006526
received	O	O
triple	O	O
therapy	O	O
with	O	O
ribavirin	B-Chemical	D012254
,	O	O
pegylated	B-Chemical	C417083
interferon	I-Chemical	C417083
and	O	O
telaprevir	B-Chemical	C486464
.	O	O

The	O	O
patient	O	O
also	O	O
received	O	O
simvastatin	B-Chemical	D019821
.	O	O

One	O	O
month	O	O
after	O	O
starting	O	O
the	O	O
antiviral	O	O
therapy	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
because	O	O
he	O	O
developed	O	O
rhabdomyolysis	B-Disease	D012206
.	O	O

At	O	O
admission	O	O
simvastatin	B-Chemical	D019821
and	O	O
all	O	O
antiviral	O	O
drugs	O	O
were	O	O
discontinued	O	O
because	O	O
toxicity	B-Disease	D064420
due	O	O
to	O	O
a	O	O
drug	O	O
-	O	O
drug	O	O
interaction	O	O
was	O	O
suspected	O	O
.	O	O

The	O	O
creatine	B-Chemical	D003401
kinase	O	O
peaked	O	O
at	O	O
62	O	O
,	O	O
246	O	O
IU	O	O
/	O	O
L	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
intravenous	O	O
normal	O	O
saline	O	O
.	O	O

The	O	O
patient's	O	O
renal	O	O
function	O	O
remained	O	O
unaffected	O	O
.	O	O

Fourteen	O	O
days	O	O
after	O	O
hospitalization	O	O
,	O	O
creatine	B-Chemical	D003401
kinase	O	O
level	O	O
had	O	O
returned	O	O
to	O	O
230	O	O
IU	O	O
/	O	O
L	O	O
and	O	O
the	O	O
patient	O	O
was	O	O
discharged	O	O
.	O	O

Telaprevir	B-Chemical	C486464
was	O	O
considered	O	O
the	O	O
probable	O	O
causative	O	O
agent	O	O
of	O	O
an	O	O
interaction	O	O
with	O	O
simvastatin	B-Chemical	D019821
according	O	O
to	O	O
the	O	O
Drug	O	O
Interaction	O	O
Probability	O	O
Scale	O	O
.	O	O

The	O	O
interaction	O	O
is	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
CYP3A4	O	O
-	O	O
mediated	O	O
simvastatin	B-Chemical	D019821
clearance	O	O
.	O	O

Simvastatin	B-Chemical	D019821
plasma	O	O
concentration	O	O
increased	O	O
30	O	O
times	O	O
in	O	O
this	O	O
patient	O	O
and	O	O
statin	B-Chemical	D019821
induced	O	O
muscle	B-Disease	D009135
toxicity	I-Disease	D009135
is	O	O
related	O	O
to	O	O
the	O	O
concentration	O	O
of	O	O
the	O	O
statin	B-Chemical	D019821
in	O	O
blood	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
with	O	O
this	O	O
case	O	O
we	O	O
illustrate	O	O
that	O	O
telaprevir	B-Chemical	C486464
as	O	O
well	O	O
as	O	O
statins	B-Chemical	D019821
are	O	O
susceptible	O	O
to	O	O
clinical	O	O
relevant	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
.	O	O

Combination	O	O
of	O	O
bortezomib	B-Chemical	C400082
,	O	O
thalidomide	B-Chemical	D013792
,	O	O
and	O	O
dexamethasone	B-Chemical	D003907
(	O	O
VTD	O	O
)	O	O
as	O	O
a	O	O
consolidation	O	O
therapy	O	O
after	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
for	O	O
symptomatic	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
in	O	O
Japanese	O	O
patients	O	O
.	O	O

Consolidation	O	O
therapy	O	O
for	O	O
patients	O	O
with	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
(	O	O
MM	B-Disease	D009101
)	O	O
has	O	O
been	O	O
widely	O	O
adopted	O	O
to	O	O
improve	O	O
treatment	O	O
response	O	O
following	O	O
autologous	O	O
stem	O	O
cell	O	O
transplantation	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
retrospectively	O	O
analyzed	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
combination	O	O
regimen	O	O
of	O	O
bortezomib	B-Chemical	C400082
,	O	O
thalidomide	B-Chemical	D013792
,	O	O
and	O	O
dexamethasone	B-Chemical	D003907
(	O	O
VTD	O	O
)	O	O
as	O	O
consolidation	O	O
therapy	O	O
in	O	O
24	O	O
Japanese	O	O
patients	O	O
with	O	O
newly	O	O
diagnosed	O	O
MM	B-Disease	D009101
.	O	O

VTD	O	O
consisted	O	O
of	O	O
bortezomib	B-Chemical	C400082
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
and	O	O
dexamethasone	B-Chemical	D003907
at	O	O
a	O	O
dose	O	O
of	O	O
40	O	O
mg	O	O
/	O	O
day	O	O
on	O	O
days	O	O
1	O	O
,	O	O
8	O	O
,	O	O
15	O	O
,	O	O
and	O	O
22	O	O
of	O	O
a	O	O
35	O	O
-	O	O
day	O	O
cycle	O	O
,	O	O
with	O	O
daily	O	O
oral	O	O
thalidomide	B-Chemical	D013792
at	O	O
a	O	O
dose	O	O
of	O	O
100	O	O
mg	O	O
/	O	O
day	O	O
.	O	O

Grade	O	O
3	O	O
-	O	O
4	O	O
neutropenia	B-Disease	D009503
and	O	O
thrombocytopenia	B-Disease	D013921
were	O	O
documented	O	O
in	O	O
four	O	O
and	O	O
three	O	O
patients	O	O
(	O	O
17	O	O
and	O	O
13	O	O
%	O	O
)	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
drug	O	O
dose	O	O
reduction	O	O
due	O	O
to	O	O
cytopenia	B-Disease	D006402
was	O	O
not	O	O
required	O	O
in	O	O
any	O	O
case	O	O
.	O	O

Peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
common	O	O
(	O	O
63	O	O
%	O	O
)	O	O
,	O	O
but	O	O
severe	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
not	O	O
observed	O	O
.	O	O

Very	O	O
good	O	O
partial	O	O
response	O	O
or	O	O
better	O	O
response	O	O
(	O	O
>VGPR	O	O
)	O	O
rates	O	O
before	O	O
and	O	O
after	O	O
consolidation	O	O
therapy	O	O
were	O	O
54	O	O
and	O	O
79	O	O
%	O	O
,	O	O
respectively	O	O
.	O	O

Patients	O	O
had	O	O
a	O	O
significant	O	O
probability	O	O
of	O	O
improving	O	O
from	O	O
<VGPR	O	O
before	O	O
consolidation	O	O
therapy	O	O
to	O	O
>VGPR	O	O
after	O	O
consolidation	O	O
therapy	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

041	O	O
)	O	O
.	O	O

The	O	O
VTD	O	O
regimen	O	O
may	O	O
be	O	O
safe	O	O
and	O	O
effective	O	O
as	O	O
a	O	O
consolidation	O	O
therapy	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
MM	B-Disease	D009101
in	O	O
Japanese	O	O
population	O	O
.	O	O

Conversion	O	O
to	O	O
sirolimus	B-Chemical	D020123
ameliorates	O	O
cyclosporine	B-Chemical	D016572
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
in	O	O
the	O	O
rat	O	O
:	O	O
focus	O	O
on	O	O
serum	O	O
,	O	O
urine	O	O
,	O	O
gene	O	O
,	O	O
and	O	O
protein	O	O
renal	O	O
expression	O	O
biomarkers	O	O
.	O	O

Protocols	O	O
of	O	O
conversion	O	O
from	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
(	O	O
CsA	B-Chemical	D016572
)	O	O
to	O	O
sirolimus	B-Chemical	D020123
(	O	O
SRL	B-Chemical	D020123
)	O	O
have	O	O
been	O	O
widely	O	O
used	O	O
in	O	O
immunotherapy	O	O
after	O	O
transplantation	O	O
to	O	O
prevent	O	O
CsA	B-Chemical	D016572
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
,	O	O
but	O	O
the	O	O
molecular	O	O
mechanisms	O	O
underlying	O	O
these	O	O
protocols	O	O
remain	O	O
nuclear	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
to	O	O
identify	O	O
the	O	O
molecular	O	O
pathways	O	O
and	O	O
putative	O	O
biomarkers	O	O
of	O	O
CsA	B-Chemical	D016572
-	O	O
to	O	O
-	O	O
SRL	B-Chemical	D020123
conversion	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
.	O	O

Four	O	O
animal	O	O
groups	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
were	O	O
tested	O	O
during	O	O
9	O	O
weeks	O	O
:	O	O
control	O	O
,	O	O
CsA	B-Chemical	D016572
,	O	O
SRL	B-Chemical	D020123
,	O	O
and	O	O
conversion	O	O
(	O	O
CsA	B-Chemical	D016572
for	O	O
3	O	O
weeks	O	O
followed	O	O
by	O	O
SRL	B-Chemical	D020123
for	O	O
6	O	O
weeks	O	O
)	O	O
.	O	O

Classical	O	O
and	O	O
emergent	O	O
serum	O	O
,	O	O
urinary	O	O
,	O	O
and	O	O
kidney	O	O
tissue	O	O
(	O	O
gene	O	O
and	O	O
protein	O	O
expression	O	O
)	O	O
markers	O	O
were	O	O
assessed	O	O
.	O	O

Renal	B-Disease	D007674
lesions	I-Disease	D007674
were	O	O
analyzed	O	O
in	O	O
hematoxylin	B-Chemical	D006416
and	O	O
eosin	B-Chemical	D004801
,	O	O
periodic	O	O
acid	O	O
-	O	O
Schiff	O	O
,	O	O
and	O	O
Masson's	O	O
trichrome	O	O
stains	O	O
.	O	O

SRL	B-Chemical	D020123
-	O	O
treated	O	O
rats	O	O
presented	O	O
proteinuria	B-Disease	D011507
and	O	O
NGAL	O	O
(	O	O
serum	O	O
and	O	O
urinary	O	O
)	O	O
as	O	O
the	O	O
best	O	O
markers	O	O
of	O	O
renal	B-Disease	D007674
impairment	I-Disease	D007674
.	O	O

Short	O	O
CsA	B-Chemical	D016572
treatment	O	O
presented	O	O
slight	O	O
or	O	O
even	O	O
absent	O	O
kidney	B-Disease	D007674
lesions	I-Disease	D007674
and	O	O
TGF	O	O
-	O	O
b	O	O
,	O	O
NF	O	O
-	O	O
kb	O	O
,	O	O
mTOR	O	O
,	O	O
PCNA	O	O
,	O	O
TP53	O	O
,	O	O
KIM	O	O
-	O	O
1	O	O
,	O	O
and	O	O
CTGF	O	O
as	O	O
relevant	O	O
gene	O	O
and	O	O
protein	O	O
changes	O	O
.	O	O

Prolonged	O	O
CsA	B-Chemical	D016572
exposure	O	O
aggravated	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
,	O	O
without	O	O
clear	O	O
changes	O	O
on	O	O
the	O	O
traditional	O	O
markers	O	O
,	O	O
but	O	O
with	O	O
changes	O	O
in	O	O
serums	O	O
TGF	O	O
-	O	O
b	O	O
and	O	O
IL	O	O
-	O	O
7	O	O
,	O	O
TBARs	O	O
clearance	O	O
,	O	O
and	O	O
kidney	O	O
TGF	O	O
-	O	O
b	O	O
and	O	O
mTOR	O	O
.	O	O

Conversion	O	O
to	O	O
SRL	B-Chemical	D020123
prevented	O	O
CsA	B-Chemical	D016572
-	O	O
induced	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
evolution	O	O
(	O	O
absent	O	O
/	O	O
mild	O	O
grade	O	O
lesions	O	O
)	O	O
,	O	O
while	O	O
NGAL	O	O
(	O	O
serum	O	O
versus	O	O
urine	O	O
)	O	O
seems	O	O
to	O	O
be	O	O
a	O	O
feasible	O	O
biomarker	O	O
of	O	O
CsA	B-Chemical	D016572
replacement	O	O
to	O	O
SRL	B-Chemical	D020123
.	O	O

Kinin	O	O
B2	O	O
receptor	O	O
deletion	O	O
and	O	O
blockage	O	O
ameliorates	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
injury	I-Disease	D058186
.	O	O

Cisplatin	B-Chemical	D002945
treatment	O	O
has	O	O
been	O	O
adopted	O	O
in	O	O
some	O	O
chemotherapies	O	O
;	O	O
however	O	O
,	O	O
this	O	O
drug	O	O
can	O	O
induce	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
due	O	O
its	O	O
ability	O	O
to	O	O
negatively	O	O
affect	O	O
renal	O	O
function	O	O
,	O	O
augment	O	O
serum	O	O
levels	O	O
of	O	O
creatinine	B-Chemical	D003404
and	O	O
urea	B-Chemical	D014508
,	O	O
increase	O	O
the	O	O
acute	B-Disease	D007683
tubular	I-Disease	D007683
necrosis	I-Disease	D007683
score	O	O
and	O	O
up	O	O
-	O	O
regulate	O	O
cytokines	O	O
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

,	O	O
IL	O	O
-	O	O
1b	O	O
and	O	O
TNF	O	O
-	O	O
a	O	O
)	O	O
.	O	O

The	O	O
kinin	O	O
B2	O	O
receptor	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
inflammation	B-Disease	D007249
process	O	O
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
regulation	O	O
of	O	O
cytokine	O	O
expression	O	O
,	O	O
and	O	O
its	O	O
deletion	O	O
resulted	O	O
in	O	O
an	O	O
improvement	O	O
in	O	O
the	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
status	O	O
.	O	O

To	O	O
examine	O	O
the	O	O
role	O	O
of	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
in	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
,	O	O
kinin	O	O
B2	O	O
receptor	O	O
knockout	O	O
mice	O	O
were	O	O
challenged	O	O
with	O	O
cisplatin	B-Chemical	D002945
.	O	O

Additionally	O	O
,	O	O
WT	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
B2	O	O
receptor	O	O
antagonist	O	O
after	O	O
cisplatin	B-Chemical	D002945
administration	O	O
.	O	O

B2	O	O
receptor	O	O
-	O	O
deficient	O	O
mice	O	O
were	O	O
less	O	O
sensitive	O	O
to	O	O
this	O	O
drug	O	O
than	O	O
the	O	O
WT	O	O
mice	O	O
,	O	O
as	O	O
shown	O	O
by	O	O
reduced	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
,	O	O
better	O	O
preservation	O	O
of	O	O
kidney	O	O
function	O	O
,	O	O
down	O	O
regulation	O	O
of	O	O
inflammatory	O	O
cytokines	O	O
and	O	O
less	O	O
acute	B-Disease	D007683
tubular	I-Disease	D007683
necrosis	I-Disease	D007683
.	O	O

Moreover	O	O
,	O	O
treatment	O	O
with	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
antagonist	O	O
effectively	O	O
reduced	O	O
the	O	O
levels	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
and	O	O
blood	O	O
urea	B-Chemical	D014508
after	O	O
cisplatin	B-Chemical	D002945
administration	O	O
.	O	O

Thus	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
is	O	O
involved	O	O
in	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
by	O	O
mediating	O	O
the	O	O
necrotic	B-Disease	D009336
process	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
inflammatory	O	O
cytokines	O	O
,	O	O
thus	O	O
resulting	O	O
in	O	O
declined	O	O
renal	O	O
function	O	O
.	O	O

These	O	O
results	O	O
highlight	O	O
the	O	O
kinin	O	O
B2	O	O
receptor	O	O
antagonist	O	O
treatment	O	O
in	O	O
amelioration	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
induced	O	O
by	O	O
cisplatin	B-Chemical	D002945
therapy	O	O
.	O	O

Safety	O	O
and	O	O
efficacy	O	O
of	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
intravitreal	O	O
implant	O	O
(	O	O
0	O	O
.	O	O

59	O	O
mg	O	O
)	O	O
in	O	O
birdshot	B-Disease	C537630
retinochoroidopathy	I-Disease	C537630
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
report	O	O
the	O	O
treatment	O	O
outcomes	O	O
of	O	O
the	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
intravitreal	O	O
implant	O	O
(	O	O
0	O	O
.	O	O

59	O	O
mg	O	O
)	O	O
in	O	O
patients	O	O
with	O	O
birdshot	B-Disease	C537630
retinochoroidopathy	I-Disease	C537630
whose	O	O
disease	O	O
is	O	O
refractory	O	O
or	O	O
intolerant	O	O
to	O	O
conventional	O	O
immunomodulatory	O	O
therapy	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
retrospective	O	O
case	O	O
series	O	O
involving	O	O
11	O	O
birdshot	B-Disease	C537630
retinochoroidopathy	I-Disease	C537630
patients	O	O
(	O	O
11	O	O
eyes	O	O
)	O	O
.	O	O

Eleven	O	O
patients	O	O
(	O	O
11	O	O
eyes	O	O
)	O	O
underwent	O	O
surgery	O	O
for	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
implant	O	O
(	O	O
0	O	O
.	O	O

59	O	O
mg	O	O
)	O	O
.	O	O

Treatment	O	O
outcomes	O	O
of	O	O
interest	O	O
were	O	O
noted	O	O
at	O	O
baseline	O	O
,	O	O
before	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
implant	O	O
,	O	O
and	O	O
then	O	O
at	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
3	O	O
years	O	O
,	O	O
and	O	O
beyond	O	O
3	O	O
years	O	O
.	O	O

Disease	O	O
activity	O	O
markers	O	O
,	O	O
including	O	O
signs	O	O
of	O	O
ocular	O	O
inflammation	B-Disease	D007249
,	O	O
evidence	O	O
of	O	O
retinal	B-Disease	D031300
vasculitis	I-Disease	D031300
,	O	O
Swedish	O	O
interactive	O	O
threshold	O	O
algorithm	O	O
-	O	O
short	O	O
wavelength	O	O
automated	O	O
perimetry	O	O
Humphrey	O	O
visual	O	O
field	O	O
analysis	O	O
,	O	O
electroretinographic	O	O
parameters	O	O
,	O	O
and	O	O
optical	O	O
coherence	O	O
tomography	O	O
were	O	O
recorded	O	O
.	O	O

Data	O	O
on	O	O
occurrence	O	O
of	O	O
cataract	B-Disease	D002386
and	O	O
raised	B-Disease	D009798
intraocular	I-Disease	D009798
pressure	I-Disease	D009798
were	O	O
collected	O	O
in	O	O
all	O	O
eyes	O	O
.	O	O

RESULTS	O	O
:	O	O
Intraocular	O	O
inflammation	B-Disease	D007249
was	O	O
present	O	O
in	O	O
54	O	O
.	O	O

5	O	O
,	O	O
9	O	O
.	O	O

9	O	O
,	O	O
11	O	O
.	O	O

1	O	O
,	O	O
and	O	O
0%	O	O
of	O	O
patients	O	O
at	O	O
baseline	O	O
,	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
3	O	O
years	O	O
,	O	O
and	O	O
beyond	O	O
3	O	O
years	O	O
after	O	O
receiving	O	O
the	O	O
implant	O	O
,	O	O
respectively	O	O
.	O	O

Active	O	O
vasculitis	B-Disease	D014657
was	O	O
noted	O	O
in	O	O
36	O	O
.	O	O

3%	O	O
patients	O	O
at	O	O
baseline	O	O
and	O	O
0%	O	O
at	O	O
3	O	O
years	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

More	O	O
than	O	O
20%	O	O
(	O	O
47	O	O
.	O	O

61	O	O
-	O	O
67	O	O
.	O	O

2%	O	O
)	O	O
reduction	O	O
in	O	O
central	O	O
retinal	O	O
thickness	O	O
was	O	O
noted	O	O
in	O	O
all	O	O
patients	O	O
with	O	O
cystoid	B-Disease	D008269
macular	I-Disease	D008269
edema	I-Disease	D008269
at	O	O
6	O	O
months	O	O
,	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postimplant	O	O
.	O	O

At	O	O
baseline	O	O
,	O	O
54	O	O
.	O	O

5%	O	O
patients	O	O
were	O	O
on	O	O
immunomodulatory	O	O
agents	O	O
.	O	O

This	O	O
percentage	O	O
decreased	O	O
to	O	O
45	O	O
.	O	O

45	O	O
,	O	O
44	O	O
.	O	O

4	O	O
,	O	O
and	O	O
14	O	O
.	O	O

28%	O	O
at	O	O
1	O	O
year	O	O
,	O	O
2	O	O
years	O	O
,	O	O
and	O	O
3	O	O
years	O	O
postimplant	O	O
,	O	O
respectively	O	O
.	O	O

Adverse	O	O
events	O	O
included	O	O
increased	B-Disease	D009798
intraocular	I-Disease	D009798
pressure	I-Disease	D009798
(	O	O
54	O	O
.	O	O

5%	O	O
)	O	O
and	O	O
cataract	B-Disease	D002386
formation	O	O
(	O	O
100%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
suggest	O	O
that	O	O
fluocinolone	B-Chemical	D005446
acetonide	I-Chemical	D005446
implant	O	O
(	O	O
0	O	O
.	O	O

59	O	O
mg	O	O
)	O	O
helps	O	O
to	O	O
control	O	O
inflammation	B-Disease	D007249
in	O	O
otherwise	O	O
treatment	O	O
-	O	O
refractory	O	O
cases	O	O
of	O	O
birdshot	B-Disease	C537630
retinochoroidopathy	I-Disease	C537630
.	O	O

It	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
side	O	O
effects	O	O
of	O	O
cataract	B-Disease	D002386
and	O	O
ocular	B-Disease	D009798
hypertension	I-Disease	D009798
requiring	O	O
treatment	O	O
.	O	O

Optimal	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-Chemical	C061870
to	O	O
decrease	O	O
fasciculation	B-Disease	D005207
and	O	O
myalgia	B-Disease	D063806
following	O	O
succinylcholine	B-Chemical	D013390
administration	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Succinylcholine	B-Chemical	D013390
commonly	O	O
produces	O	O
frequent	O	O
adverse	O	O
effects	O	O
,	O	O
including	O	O
muscle	B-Disease	D005207
fasciculation	I-Disease	D005207
and	O	O
myalgia	B-Disease	D063806
.	O	O

The	O	O
current	O	O
study	O	O
identified	O	O
the	O	O
optimal	O	O
dose	O	O
of	O	O
rocuronium	B-Chemical	C061870
to	O	O
prevent	O	O
succinylcholine	B-Chemical	D013390
-	O	O
induced	O	O
fasciculation	B-Disease	D005207
and	O	O
myalgia	B-Disease	D063806
and	O	O
evaluated	O	O
the	O	O
influence	O	O
of	O	O
rocuronium	B-Chemical	C061870
on	O	O
the	O	O
speed	O	O
of	O	O
onset	O	O
produced	O	O
by	O	O
succinylcholine	B-Chemical	D013390
.	O	O

METHODS	O	O
:	O	O
This	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blinded	O	O
study	O	O
was	O	O
conducted	O	O
in	O	O
100	O	O
patients	O	O
randomly	O	O
allocated	O	O
into	O	O
five	O	O
groups	O	O
of	O	O
20	O	O
patients	O	O
each	O	O
.	O	O

Patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
0	O	O
.	O	O

02	O	O
,	O	O
0	O	O
.	O	O

03	O	O
,	O	O
0	O	O
.	O	O

04	O	O
,	O	O
0	O	O
.	O	O

05	O	O
and	O	O
0	O	O
.	O	O

06	O	O
mg	O	O
/	O	O
kg	O	O
rocuronium	B-Chemical	C061870
as	O	O
a	O	O
precurarizing	O	O
dose	O	O
.	O	O

Neuromuscular	O	O
monitoring	O	O
after	O	O
each	O	O
precurarizing	O	O
dose	O	O
was	O	O
recorded	O	O
from	O	O
the	O	O
adductor	O	O
pollicis	O	O
muscle	O	O
using	O	O
acceleromyography	O	O
with	O	O
train	O	O
-	O	O
of	O	O
-	O	O
four	O	O
stimulation	O	O
of	O	O
the	O	O
ulnar	O	O
nerve	O	O
.	O	O

All	O	O
patients	O	O
received	O	O
succinylcholine	B-Chemical	D013390
1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
at	O	O
2	O	O
minutes	O	O
after	O	O
the	O	O
precurarization	O	O
,	O	O
and	O	O
were	O	O
assessed	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
fasciculations	B-Disease	D005207
,	O	O
while	O	O
myalgia	B-Disease	D063806
was	O	O
assessed	O	O
at	O	O
24	O	O
hours	O	O
after	O	O
surgery	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
visible	O	O
muscle	B-Disease	D005207
fasciculation	I-Disease	D005207
was	O	O
significantly	O	O
less	O	O
with	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-Chemical	C061870
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Those	O	O
of	O	O
myalgia	B-Disease	D063806
tend	O	O
to	O	O
decrease	O	O
according	O	O
to	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-Chemical	C061870
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
significance	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

072	O	O
)	O	O
.	O	O

The	O	O
onset	O	O
time	O	O
of	O	O
succinylcholine	B-Chemical	D013390
was	O	O
significantly	O	O
longer	O	O
with	O	O
increasing	O	O
the	O	O
amount	O	O
of	O	O
precurarizing	O	O
dose	O	O
of	O	O
rocuronium	B-Chemical	C061870
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Precurarization	O	O
with	O	O
0	O	O
.	O	O

04	O	O
mg	O	O
/	O	O
kg	O	O
rocuronium	B-Chemical	C061870
was	O	O
the	O	O
optimal	O	O
dose	O	O
considering	O	O
the	O	O
reduction	O	O
in	O	O
the	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
fasciculation	B-Disease	D005207
and	O	O
myalgia	B-Disease	D063806
with	O	O
acceptable	O	O
onset	O	O
time	O	O
,	O	O
and	O	O
the	O	O
safe	O	O
and	O	O
effective	O	O
precurarization	O	O
.	O	O

Absence	O	O
of	O	O
PKC	O	O
-	O	O
alpha	O	O
attenuates	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
.	O	O

Lithium	B-Chemical	D008094
,	O	O
an	O	O
effective	O	O
antipsychotic	O	O
,	O	O
induces	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
(	O	O
NDI	B-Disease	D018500
)	O	O
in	O	O
40%	O	O
of	O	O
patients	O	O
.	O	O

The	O	O
decreased	O	O
capacity	O	O
to	O	O
concentrate	O	O
urine	O	O
is	O	O
likely	O	O
due	O	O
to	O	O
lithium	B-Chemical	D008094
acutely	O	O
disrupting	O	O
the	O	O
cAMP	B-Chemical	D000242
pathway	O	O
and	O	O
chronically	O	O
reducing	O	O
urea	B-Chemical	D014508
transporter	O	O
(	O	O
UT	O	O
-	O	O
A1	O	O
)	O	O
and	O	O
water	O	O
channel	O	O
(	O	O
AQP2	O	O
)	O	O
expression	O	O
in	O	O
the	O	O
inner	O	O
medulla	O	O
.	O	O

Targeting	O	O
an	O	O
alternative	O	O
signaling	O	O
pathway	O	O
,	O	O
such	O	O
as	O	O
PKC	O	O
-	O	O
mediated	O	O
signaling	O	O
,	O	O
may	O	O
be	O	O
an	O	O
effective	O	O
method	O	O
of	O	O
treating	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
polyuria	B-Disease	D011141
.	O	O

PKC	O	O
-	O	O
alpha	O	O
null	O	O
mice	O	O
(	O	O
PKCa	O	O
KO	O	O
)	O	O
and	O	O
strain	O	O
-	O	O
matched	O	O
wild	O	O
type	O	O
(	O	O
WT	O	O
)	O	O
controls	O	O
were	O	O
treated	O	O
with	O	O
lithium	B-Chemical	D008094
for	O	O
0	O	O
,	O	O
3	O	O
or	O	O
5	O	O
days	O	O
.	O	O

WT	O	O
mice	O	O
had	O	O
increased	O	O
urine	O	O
output	O	O
and	O	O
lowered	O	O
urine	O	O
osmolality	O	O
after	O	O
3	O	O
and	O	O
5	O	O
days	O	O
of	O	O
treatment	O	O
whereas	O	O
PKCa	O	O
KO	O	O
mice	O	O
had	O	O
no	O	O
change	O	O
in	O	O
urine	O	O
output	O	O
or	O	O
concentration	O	O
.	O	O

Western	O	O
blot	O	O
analysis	O	O
revealed	O	O
that	O	O
AQP2	O	O
expression	O	O
in	O	O
medullary	O	O
tissues	O	O
was	O	O
lowered	O	O
after	O	O
3	O	O
and	O	O
5	O	O
days	O	O
in	O	O
WT	O	O
mice	O	O
;	O	O
however	O	O
,	O	O
AQP2	O	O
was	O	O
unchanged	O	O
in	O	O
PKCa	O	O
KO	O	O
.	O	O

Similar	O	O
results	O	O
were	O	O
observed	O	O
with	O	O
UT	O	O
-	O	O
A1	O	O
expression	O	O
.	O	O

Animals	O	O
were	O	O
also	O	O
treated	O	O
with	O	O
lithium	B-Chemical	D008094
for	O	O
6	O	O
weeks	O	O
.	O	O

Lithium	B-Chemical	D008094
-	O	O
treated	O	O
WT	O	O
mice	O	O
had	O	O
19	O	O
-	O	O
fold	O	O
increased	O	O
urine	O	O
output	O	O
whereas	O	O
treated	O	O
PKCa	O	O
KO	O	O
animals	O	O
had	O	O
a	O	O
4	O	O
-	O	O
fold	O	O
increase	O	O
in	O	O
output	O	O
.	O	O

AQP2	O	O
and	O	O
UT	O	O
-	O	O
A1	O	O
expression	O	O
was	O	O
lowered	O	O
in	O	O
6	O	O
week	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
WT	O	O
animals	O	O
whereas	O	O
in	O	O
treated	O	O
PKCa	O	O
KO	O	O
mice	O	O
,	O	O
AQP2	O	O
was	O	O
only	O	O
reduced	O	O
by	O	O
2	O	O
-	O	O
fold	O	O
and	O	O
UT	O	O
-	O	O
A1	O	O
expression	O	O
was	O	O
unaffected	O	O
.	O	O

Urinary	O	O
sodium	B-Chemical	D012964
,	O	O
potassium	B-Chemical	D011188
and	O	O
calcium	B-Chemical	D002118
were	O	O
elevated	O	O
in	O	O
lithium	B-Chemical	D008094
-	O	O
fed	O	O
WT	O	O
but	O	O
not	O	O
in	O	O
lithium	B-Chemical	D008094
-	O	O
fed	O	O
PKCa	O	O
KO	O	O
mice	O	O
.	O	O

Our	O	O
data	O	O
show	O	O
that	O	O
ablation	O	O
of	O	O
PKCa	O	O
preserves	O	O
AQP2	O	O
and	O	O
UT	O	O
-	O	O
A1	O	O
protein	O	O
expression	O	O
and	O	O
localization	O	O
in	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
NDI	B-Disease	D018500
,	O	O
and	O	O
prevents	O	O
the	O	O
development	O	O
of	O	O
the	O	O
severe	O	O
polyuria	B-Disease	D011141
associated	O	O
with	O	O
lithium	B-Chemical	D008094
therapy	O	O
.	O	O

Is	O	O
Dysguesia	B-Disease	D004408
Going	O	O
to	O	O
be	O	O
a	O	O
Rare	O	O
or	O	O
a	O	O
Common	O	O
Side	O	O
-	O	O
effect	O	O
of	O	O
Amlodipine?	O	O
A	O	O
very	O	O
rare	O	O
side	O	O
-	O	O
effect	O	O
of	O	O
amlodipine	B-Chemical	D017311
is	O	O
dysguesia	B-Disease	D004408
.	O	O

A	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
produced	O	O
only	O	O
one	O	O
case	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
about	O	O
a	O	O
female	O	O
with	O	O
essential	O	O
hypertension	B-Disease	D006973
on	O	O
drug	O	O
treatment	O	O
with	O	O
amlodipine	B-Chemical	D017311
developed	O	O
loss	B-Disease	D012678
of	I-Disease	D012678
taste	I-Disease	D012678
sensation	I-Disease	D012678
.	O	O

Condition	O	O
moderately	O	O
improved	O	O
on	O	O
stoppage	O	O
of	O	O
the	O	O
drug	O	O
for	O	O
25	O	O
days	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
amlodipine	B-Chemical	D017311
can	O	O
cause	O	O
dysguesia	B-Disease	D004408
.	O	O

Here	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
clinical	O	O
presentation	O	O
and	O	O
review	O	O
the	O	O
relevant	O	O
literature	O	O
on	O	O
amlodipine	B-Chemical	D017311
and	O	O
dysguesia	B-Disease	D004408
.	O	O

Rhabdomyolysis	B-Disease	D012206
in	O	O
association	O	O
with	O	O
simvastatin	B-Chemical	D019821
and	O	O
dosage	O	O
increment	O	O
in	O	O
clarithromycin	B-Chemical	D017291
.	O	O

Clarithromycin	B-Chemical	D017291
is	O	O
the	O	O
most	O	O
documented	O	O
cytochrome	O	O
P450	O	O
3A4	O	O
(	O	O
CYP3A4	O	O
)	O	O
inhibitor	O	O
to	O	O
cause	O	O
an	O	O
adverse	O	O
interaction	O	O
with	O	O
simvastatin	B-Chemical	D019821
.	O	O

This	O	O
particular	O	O
case	O	O
is	O	O
of	O	O
interest	O	O
as	O	O
rhabdomyolysis	B-Disease	D012206
only	O	O
occurred	O	O
after	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
dose	O	O
of	O	O
clarithromycin	B-Chemical	D017291
.	O	O

The	O	O
patient	O	O
developed	O	O
raised	O	O
cardiac	O	O
biomarkers	O	O
without	O	O
any	O	O
obvious	O	O
cardiac	O	O
issues	O	O
,	O	O
a	O	O
phenomenon	O	O
that	O	O
has	O	O
been	O	O
linked	O	O
to	O	O
rhabdomyolysis	B-Disease	D012206
previously	O	O
.	O	O

To	O	O
date	O	O
,	O	O
there	O	O
has	O	O
been	O	O
no	O	O
reported	O	O
effect	O	O
of	O	O
rhabdomyolysis	B-Disease	D012206
on	O	O
the	O	O
structure	O	O
and	O	O
function	O	O
of	O	O
cardiac	O	O
muscle	O	O
.	O	O

Clinicians	O	O
need	O	O
to	O	O
be	O	O
aware	O	O
of	O	O
prescribing	O	O
concomitant	O	O
medications	O	O
that	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
myopathy	B-Disease	D009135
or	O	O
inhibit	O	O
the	O	O
CYP3A4	O	O
enzyme	O	O
.	O	O

Our	O	O
case	O	O
suggests	O	O
that	O	O
troponin	O	O
elevation	O	O
could	O	O
be	O	O
associated	O	O
with	O	O
statin	B-Chemical	D019821
induced	O	O
rhabdomyolysis	B-Disease	D012206
,	O	O
which	O	O
may	O	O
warrant	O	O
further	O	O
studies	O	O
.	O	O

Characterization	O	O
of	O	O
a	O	O
novel	O	O
BCHE	O	O
"silent"	O	O
allele	O	O
:	O	O
point	O	O
mutation	O	O
(	O	O
p	O	O
.	O	O

Val204Asp	O	O
)	O	O
causes	O	O
loss	O	O
of	O	O
activity	O	O
and	O	O
prolonged	O	O
apnea	B-Disease	D001049
with	O	O
suxamethonium	B-Chemical	D013390
.	O	O

Butyrylcholinesterase	B-Disease	C537417
deficiency	I-Disease	C537417
is	O	O
characterized	O	O
by	O	O
prolonged	O	O
apnea	B-Disease	D001049
after	O	O
the	O	O
use	O	O
of	O	O
muscle	O	O
relaxants	O	O
(	O	O
suxamethonium	B-Chemical	D013390
or	O	O
mivacurium	B-Chemical	C049430
)	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
mutations	O	O
in	O	O
the	O	O
BCHE	O	O
gene	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
report	O	O
a	O	O
case	O	O
of	O	O
prolonged	O	O
neuromuscular	O	O
block	O	O
after	O	O
administration	O	O
of	O	O
suxamethonium	B-Chemical	D013390
leading	O	O
to	O	O
the	O	O
discovery	O	O
of	O	O
a	O	O
novel	O	O
BCHE	O	O
variant	O	O
(	O	O
c	O	O
.	O	O

695T>A	O	O
,	O	O
p	O	O
.	O	O

Val204Asp	O	O
)	O	O
.	O	O

Inhibition	O	O
studies	O	O
,	O	O
kinetic	O	O
analysis	O	O
and	O	O
molecular	O	O
dynamics	O	O
were	O	O
undertaken	O	O
to	O	O
understand	O	O
how	O	O
this	O	O
mutation	O	O
disrupts	O	O
the	O	O
catalytic	O	O
triad	O	O
and	O	O
determines	O	O
a	O	O
"silent"	O	O
phenotype	O	O
.	O	O

Low	O	O
activity	O	O
of	O	O
patient	O	O
plasma	O	O
butyrylcholinesterase	O	O
with	O	O
butyrylthiocholine	B-Chemical	D002092
(	O	O
BTC	B-Chemical	D002092
)	O	O
and	O	O
benzoylcholine	B-Chemical	D001588
,	O	O
and	O	O
values	O	O
of	O	O
dibucaine	B-Chemical	D003992
and	O	O
fluoride	B-Chemical	D005459
numbers	O	O
fit	O	O
with	O	O
heterozygous	O	O
atypical	O	O
silent	O	O
genotype	O	O
.	O	O

Electrophoretic	O	O
analysis	O	O
of	O	O
plasma	O	O
BChE	O	O
of	O	O
the	O	O
proband	O	O
and	O	O
his	O	O
mother	O	O
showed	O	O
that	O	O
patient	O	O
has	O	O
a	O	O
reduced	O	O
amount	O	O
of	O	O
tetrameric	O	O
enzyme	O	O
in	O	O
plasma	O	O
and	O	O
that	O	O
minor	O	O
fast	O	O
-	O	O
moving	O	O
BChE	O	O
components	O	O
:	O	O
monomer	O	O
,	O	O
dimer	O	O
,	O	O
and	O	O
monomer	O	O
-	O	O
albumin	O	O
conjugate	O	O
are	O	O
missing	O	O
.	O	O

Kinetic	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
p	O	O
.	O	O

Val204Asp	O	O
/	O	O
p	O	O
.	O	O

Asp70Gly	O	O
-	O	O
p	O	O
.	O	O

Ala539Thr	O	O
BChE	O	O
displays	O	O
a	O	O
pure	O	O
Michaelian	O	O
behavior	O	O
with	O	O
BTC	B-Chemical	D002092
as	O	O
the	O	O
substrate	O	O
.	O	O

Both	O	O
catalytic	O	O
parameters	O	O
Km	O	O
=	O	O
265	O	O
uM	O	O
for	O	O
BTC	B-Chemical	D002092
,	O	O
two	O	O
times	O	O
higher	O	O
than	O	O
that	O	O
of	O	O
the	O	O
atypical	O	O
enzyme	O	O
,	O	O
and	O	O
a	O	O
low	O	O
Vmax	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
absence	O	O
of	O	O
activity	O	O
against	O	O
suxamethonium	B-Chemical	D013390
.	O	O

Molecular	O	O
dynamic	O	O
(	O	O
MD	O	O
)	O	O
simulations	O	O
showed	O	O
that	O	O
the	O	O
overall	O	O
effect	O	O
of	O	O
the	O	O
mutation	O	O
p	O	O
.	O	O

Val204Asp	O	O
is	O	O
disruption	O	O
of	O	O
hydrogen	B-Chemical	D006859
bonding	O	O
between	O	O
Gln223	O	O
and	O	O
Glu441	O	O
,	O	O
leading	O	O
Ser198	O	O
and	O	O
His438	O	O
to	O	O
move	O	O
away	O	O
from	O	O
each	O	O
other	O	O
with	O	O
subsequent	O	O
disruption	O	O
of	O	O
the	O	O
catalytic	O	O
triad	O	O
functionality	O	O
regardless	O	O
of	O	O
the	O	O
type	O	O
of	O	O
substrate	O	O
.	O	O

MD	O	O
also	O	O
showed	O	O
that	O	O
the	O	O
enzyme	O	O
volume	O	O
is	O	O
increased	O	O
,	O	O
suggesting	O	O
a	O	O
pre	O	O
-	O	O
denaturation	O	O
state	O	O
.	O	O

This	O	O
fits	O	O
with	O	O
the	O	O
reduced	O	O
concentration	O	O
of	O	O
p	O	O
.	O	O

Ala204Asp	O	O
/	O	O
p	O	O
.	O	O

Asp70Gly	O	O
-	O	O
p	O	O
.	O	O

Ala539Thr	O	O
tetrameric	O	O
enzyme	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
non	O	O
-	O	O
detectable	O	O
fast	O	O
moving	O	O
-	O	O
bands	O	O
on	O	O
electrophoresis	O	O
gels	O	O
.	O	O

Delayed	O	O
anemia	B-Disease	D000740
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B-Chemical	C039726
in	O	O
the	O	O
Democratic	O	O
Republic	O	O
of	O	O
the	O	O
Congo	O	O
:	O	O
a	O	O
manageable	O	O
issue	O	O
.	O	O

Cases	O	O
of	O	O
delayed	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
have	O	O
been	O	O
described	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B-Chemical	C039726
,	O	O
the	O	O
current	O	O
World	O	O
Health	O	O
Organization	O	O
(	O	O
WHO	O	O
)	O	O
-	O	O
recommended	O	O
first	O	O
-	O	O
line	O	O
drug	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
malaria	B-Disease	D008288
.	O	O

A	O	O
total	O	O
of	O	O
350	O	O
patients	O	O
(	O	O
215	O	O
[	O	O
61	O	O
.	O	O

4%	O	O
]	O	O
<	O	O
5	O	O
years	O	O
of	O	O
age	O	O
and	O	O
135	O	O
[	O	O
38	O	O
.	O	O

6%	O	O
]	O	O
>	O	O
5	O	O
years	O	O
of	O	O
age	O	O
)	O	O
were	O	O
followed	O	O
-	O	O
up	O	O
after	O	O
treatment	O	O
with	O	O
injectable	O	O
artesunate	B-Chemical	C039726
for	O	O
severe	O	O
malaria	B-Disease	D008288
in	O	O
hospitals	O	O
and	O	O
health	O	O
centers	O	O
of	O	O
the	O	O
Democratic	O	O
Republic	O	O
of	O	O
the	O	O
Congo	O	O
.	O	O

Complete	O	O
series	O	O
of	O	O
hemoglobin	O	O
(	O	O
Hb	O	O
)	O	O
measurements	O	O
were	O	O
available	O	O
for	O	O
201	O	O
patients	O	O
.	O	O

A	O	O
decrease	O	O
in	O	O
Hb	O	O
levels	O	O
between	O	O
2	O	O
and	O	O
5	O	O
g	O	O
/	O	O
dL	O	O
was	O	O
detected	O	O
in	O	O
23	O	O
(	O	O
11	O	O
.	O	O

4%	O	O
)	O	O
patients	O	O
during	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
.	O	O

For	O	O
five	O	O
patients	O	O
,	O	O
Hb	O	O
levels	O	O
decreased	O	O
below	O	O
5	O	O
g	O	O
/	O	O
dL	O	O
during	O	O
at	O	O
least	O	O
one	O	O
follow	O	O
-	O	O
up	O	O
visit	O	O
.	O	O

All	O	O
cases	O	O
of	O	O
delayed	O	O
anemia	B-Disease	D000740
were	O	O
clinically	O	O
manageable	O	O
and	O	O
resolved	O	O
within	O	O
one	O	O
month	O	O
.	O	O

Regulation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
and	O	O
apoptotic	O	O
pathways	O	O
by	O	O
betaine	B-Chemical	D001622
attenuates	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
acute	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
in	O	O
rats	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
cardioprotective	O	O
effects	O	O
of	O	O
betaine	B-Chemical	D001622
on	O	O
acute	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
induced	O	O
experimentally	O	O
in	O	O
rats	O	O
focusing	O	O
on	O	O
regulation	O	O
of	O	O
signal	O	O
transducer	O	O
and	O	O
activator	O	O
of	O	O
transcription	O	O
3	O	O
(	O	O
STAT3	O	O
)	O	O
and	O	O
apoptotic	O	O
pathways	O	O
as	O	O
the	O	O
potential	O	O
mechanism	O	O
underlying	O	O
the	O	O
drug	O	O
effect	O	O
.	O	O

Male	O	O
Sprague	O	O
Dawley	O	O
rats	O	O
were	O	O
treated	O	O
with	O	O
betaine	B-Chemical	D001622
(	O	O
100	O	O
,	O	O
200	O	O
,	O	O
and	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
orally	O	O
for	O	O
40	O	O
days	O	O
.	O	O

Acute	O	O
myocardial	B-Disease	D017202
ischemic	I-Disease	D017202
injury	I-Disease	D017202
was	O	O
induced	O	O
in	O	O
rats	O	O
by	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-Chemical	D007545
(	O	O
85	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
for	O	O
two	O	O
consecutive	O	O
days	O	O
.	O	O

Serum	O	O
cardiac	O	O
marker	O	O
enzyme	O	O
,	O	O
histopathological	O	O
variables	O	O
and	O	O
expression	O	O
of	O	O
protein	O	O
levels	O	O
were	O	O
analyzed	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
betaine	B-Chemical	D001622
(	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
significantly	O	O
reduced	O	O
the	O	O
level	O	O
of	O	O
cardiac	O	O
marker	O	O
enzyme	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
prevented	O	O
left	O	O
ventricular	B-Disease	D020257
remodeling	I-Disease	D020257
.	O	O

Western	O	O
blot	O	O
analysis	O	O
showed	O	O
that	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
phosphorylation	O	O
of	O	O
STAT3	O	O
was	O	O
maintained	O	O
or	O	O
further	O	O
enhanced	O	O
by	O	O
betaine	B-Chemical	D001622
treatment	O	O
in	O	O
myocardium	O	O
.	O	O

Furthermore	O	O
,	O	O
betaine	B-Chemical	D001622
(	O	O
200	O	O
and	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
treatment	O	O
increased	O	O
the	O	O
ventricular	O	O
expression	O	O
of	O	O
Bcl	O	O
-	O	O
2	O	O
and	O	O
reduced	O	O
the	O	O
level	O	O
of	O	O
Bax	O	O
,	O	O
therefore	O	O
causing	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
ratio	O	O
of	O	O
Bcl	O	O
-	O	O
2	O	O
/	O	O
Bax	O	O
.	O	O

The	O	O
protective	O	O
role	O	O
of	O	O
betaine	B-Chemical	D001622
on	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
was	O	O
further	O	O
confirmed	O	O
by	O	O
histopathological	O	O
examination	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
showed	O	O
that	O	O
betaine	B-Chemical	D001622
pretreatment	O	O
attenuated	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
acute	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
via	O	O
the	O	O
regulation	O	O
of	O	O
STAT3	O	O
and	O	O
apoptotic	O	O
pathways	O	O
.	O	O

Quetiapine	B-Chemical	C069541
-	O	O
induced	O	O
neutropenia	B-Disease	D009503
in	O	O
a	O	O
bipolar	B-Disease	D001714
patient	O	O
with	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
.	O	O

OBJECTIVE	O	O
:	O	O
Quetiapine	B-Chemical	C069541
is	O	O
a	O	O
dibenzothiazepine	O	O
derivative	O	O
,	O	O
similar	O	O
to	O	O
clozapine	B-Chemical	D003024
,	O	O
which	O	O
has	O	O
the	O	O
highest	O	O
risk	O	O
of	O	O
causing	O	O
blood	B-Disease	D006402
dyscrasias	I-Disease	D006402
,	O	O
especially	O	O
neutropenia	B-Disease	D009503
.	O	O

There	O	O
are	O	O
some	O	O
case	O	O
reports	O	O
about	O	O
this	O	O
side	O	O
effect	O	O
of	O	O
quetiapine	B-Chemical	C069541
,	O	O
but	O	O
possible	O	O
risk	O	O
factors	O	O
are	O	O
seldom	O	O
discussed	O	O
and	O	O
identified	O	O
.	O	O

A	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
that	O	O
developed	O	O
neutropenia	B-Disease	D009503
after	O	O
treatment	O	O
with	O	O
quetiapine	B-Chemical	C069541
is	O	O
described	O	O
here	O	O
.	O	O

CASE	O	O
REPORT	O	O
:	O	O
A	O	O
62	O	O
-	O	O
year	O	O
-	O	O
old	O	O
Taiwanese	O	O
widow	O	O
with	O	O
bipolar	B-Disease	D001714
disorder	O	O
was	O	O
diagnosed	O	O
with	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
at	O	O
age	O	O
60	O	O
.	O	O

She	O	O
developed	O	O
leucopenia	B-Disease	D007970
after	O	O
being	O	O
treated	O	O
with	O	O
quetiapine	B-Chemical	C069541
.	O	O

After	O	O
quetiapine	B-Chemical	C069541
was	O	O
discontinued	O	O
,	O	O
her	O	O
white	O	O
blood	O	O
cell	O	O
count	O	O
returned	O	O
to	O	O
normal	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
neutropenia	B-Disease	D009503
is	O	O
not	O	O
a	O	O
common	O	O
side	O	O
effect	O	O
of	O	O
quetiapine	B-Chemical	C069541
,	O	O
physicians	O	O
should	O	O
be	O	O
cautious	O	O
about	O	O
its	O	O
presentation	O	O
and	O	O
associated	O	O
risk	O	O
factors	O	O
.	O	O

Hepatic	B-Disease	D008107
dysfunction	I-Disease	D008107
may	O	O
be	O	O
one	O	O
of	O	O
the	O	O
possible	O	O
risk	O	O
factors	O	O
,	O	O
and	O	O
concomitant	O	O
fever	B-Disease	D005334
may	O	O
be	O	O
a	O	O
diagnostic	O	O
marker	O	O
for	O	O
adverse	O	O
reaction	O	O
to	O	O
quetiapine	B-Chemical	C069541
.	O	O

Lateral	O	O
antebrachial	O	O
cutaneous	O	O
neuropathy	B-Disease	D009422
after	O	O
steroid	B-Chemical	D013256
injection	O	O
at	O	O
lateral	O	O
epicondyle	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
:	O	O
This	O	O
report	O	O
aimed	O	O
to	O	O
present	O	O
a	O	O
case	O	O
of	O	O
lateral	O	O
antebrachial	O	O
cutaneous	O	O
neuropathy	B-Disease	D009422
(	O	O
LACNP	O	O
)	O	O
that	O	O
occurred	O	O
after	O	O
a	O	O
steroid	B-Chemical	D013256
injection	O	O
in	O	O
the	O	O
lateral	O	O
epicondyle	O	O
to	O	O
treat	O	O
lateral	B-Disease	D013716
epicondylitis	I-Disease	D013716
in	O	O
a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHOD	O	O
:	O	O
A	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
with	O	O
decreased	O	O
sensation	O	O
and	O	O
paresthesia	B-Disease	D010292
over	O	O
her	O	O
right	O	O
lateral	O	O
forearm	O	O
;	O	O
the	O	O
paresthesia	B-Disease	D010292
had	O	O
occurred	O	O
after	O	O
a	O	O
steroid	B-Chemical	D013256
injection	O	O
in	O	O
the	O	O
right	O	O
lateral	O	O
epicondyle	O	O
3	O	O
months	O	O
before	O	O
.	O	O

Her	O	O
sensation	O	O
of	O	O
light	O	O
touch	O	O
and	O	O
pain	B-Disease	D010146
was	O	O
diminished	O	O
over	O	O
the	O	O
lateral	O	O
side	O	O
of	O	O
the	O	O
right	O	O
forearm	O	O
and	O	O
wrist	O	O
area	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
sensory	O	O
action	O	O
potential	O	O
amplitude	O	O
of	O	O
the	O	O
right	O	O
lateral	O	O
antebrachial	O	O
cutaneous	O	O
nerve	O	O
(	O	O
LACN	O	O
)	O	O
(	O	O
6	O	O
.	O	O

2	O	O
uV	O	O
)	O	O
was	O	O
lower	O	O
than	O	O
that	O	O
of	O	O
the	O	O
left	O	O
(	O	O
13	O	O
.	O	O

1	O	O
uV	O	O
)	O	O
.	O	O

The	O	O
difference	O	O
of	O	O
amplitude	O	O
between	O	O
both	O	O
sides	O	O
was	O	O
significant	O	O
because	O	O
there	O	O
was	O	O
more	O	O
than	O	O
a	O	O
50%	O	O
reduction	O	O
.	O	O

She	O	O
was	O	O
diagnosed	O	O
with	O	O
right	O	O
LACNP	O	O
(	O	O
mainly	O	O
axonal	O	O
involvement	O	O
)	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
clinical	O	O
manifestation	O	O
and	O	O
the	O	O
electrodiagnostic	O	O
findings	O	O
.	O	O

Her	O	O
symptoms	O	O
improved	O	O
through	O	O
physical	O	O
therapy	O	O
but	O	O
persisted	O	O
to	O	O
some	O	O
degree	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
report	O	O
describes	O	O
the	O	O
case	O	O
of	O	O
a	O	O
woman	O	O
with	O	O
LACNP	O	O
that	O	O
developed	O	O
after	O	O
a	O	O
steroid	B-Chemical	D013256
injection	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
lateral	B-Disease	D013716
epicondylitis	I-Disease	D013716
.	O	O

An	O	O
electrodiagnostic	O	O
study	O	O
,	O	O
including	O	O
a	O	O
nerve	O	O
conduction	O	O
study	O	O
of	O	O
the	O	O
LACN	O	O
,	O	O
was	O	O
helpful	O	O
to	O	O
diagnose	O	O
right	O	O
LACNP	O	O
and	O	O
to	O	O
find	O	O
the	O	O
passage	O	O
of	O	O
the	O	O
LACN	O	O
on	O	O
the	O	O
lateral	O	O
epicondyle	O	O
.	O	O

Curcumin	B-Chemical	D003474
prevents	O	O
maleate	B-Chemical	C030272
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
:	O	O
relation	O	O
to	O	O
hemodynamic	O	O
alterations	O	O
,	O	O
oxidative	O	O
stress	O	O
,	O	O
mitochondrial	O	O
oxygen	B-Chemical	D010100
consumption	O	O
and	O	O
activity	O	O
of	O	O
respiratory	O	O
complex	O	O
I	O	O
.	O	O

The	O	O
potential	O	O
protective	O	O
effect	O	O
of	O	O
the	O	O
dietary	O	O
antioxidant	O	O
curcumin	B-Chemical	D003474
(	O	O
120	O	O
mg	O	O
/	O	O
Kg	O	O
/	O	O
day	O	O
for	O	O
6	O	O
days	O	O
)	O	O
against	O	O
the	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
induced	O	O
by	O	O
maleate	B-Chemical	C030272
was	O	O
evaluated	O	O
.	O	O

Tubular	O	O
proteinuria	B-Disease	D011507
and	O	O
oxidative	O	O
stress	O	O
were	O	O
induced	O	O
by	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
maleate	B-Chemical	C030272
(	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
in	O	O
rats	O	O
.	O	O

Maleate	B-Chemical	C030272
-	O	O
induced	O	O
renal	B-Disease	D007674
injury	I-Disease	D007674
included	O	O
increase	O	O
in	O	O
renal	O	O
vascular	O	O
resistance	O	O
and	O	O
in	O	O
the	O	O
urinary	O	O
excretion	O	O
of	O	O
total	O	O
protein	O	O
,	O	O
glucose	B-Chemical	D005947
,	O	O
sodium	B-Chemical	D012964
,	O	O
neutrophil	O	O
gelatinase	O	O
-	O	O
associated	O	O
lipocalin	O	O
(	O	O
NGAL	O	O
)	O	O
and	O	O
N	O	O
-	O	O
acetyl	O	O
b	O	O
-	O	O
D	O	O
-	O	O
glucosaminidase	O	O
(	O	O
NAG	O	O
)	O	O
,	O	O
upregulation	O	O
of	O	O
kidney	B-Disease	D007674
injury	I-Disease	D007674
molecule	O	O
(	O	O
KIM	O	O
)	O	O
-	O	O
1	O	O
,	O	O
decrease	O	O
in	O	O
renal	O	O
blood	O	O
flow	O	O
and	O	O
claudin	O	O
-	O	O
2	O	O
expression	O	O
besides	O	O
of	O	O
necrosis	B-Disease	D009336
and	O	O
apoptosis	O	O
of	O	O
tubular	O	O
cells	O	O
on	O	O
24	O	O
h	O	O
.	O	O

Oxidative	O	O
stress	O	O
was	O	O
determined	O	O
by	O	O
measuring	O	O
the	O	O
oxidation	O	O
of	O	O
lipids	O	O
and	O	O
proteins	O	O
and	O	O
diminution	O	O
in	O	O
renal	O	O
Nrf2	O	O
levels	O	O
.	O	O

Studies	O	O
were	O	O
also	O	O
conducted	O	O
in	O	O
renal	O	O
epithelial	O	O
LLC	O	O
-	O	O
PK1	O	O
cells	O	O
and	O	O
in	O	O
mitochondria	O	O
isolated	O	O
from	O	O
kidneys	O	O
of	O	O
all	O	O
the	O	O
experimental	O	O
groups	O	O
.	O	O

Maleate	B-Chemical	C030272
induced	O	O
cell	O	O
damage	O	O
and	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
(	O	O
ROS	O	O
)	O	O
production	O	O
in	O	O
LLC	O	O
-	O	O
PK1	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
maleate	B-Chemical	C030272
treatment	O	O
reduced	O	O
oxygen	B-Chemical	D010100
consumption	O	O
in	O	O
ADP	B-Chemical	D000244
-	O	O
stimulated	O	O
mitochondria	O	O
and	O	O
diminished	O	O
respiratory	O	O
control	O	O
index	O	O
when	O	O
using	O	O
malate	B-Chemical	C030298
/	O	O
glutamate	B-Chemical	D018698
as	O	O
substrate	O	O
.	O	O

The	O	O
activities	O	O
of	O	O
both	O	O
complex	O	O
I	O	O
and	O	O
aconitase	O	O
were	O	O
also	O	O
diminished	O	O
.	O	O

All	O	O
the	O	O
above	O	O
-	O	O
described	O	O
alterations	O	O
were	O	O
prevented	O	O
by	O	O
curcumin	B-Chemical	D003474
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
curcumin	B-Chemical	D003474
is	O	O
able	O	O
to	O	O
attenuate	O	O
in	O	O
vivo	O	O
maleate	B-Chemical	C030272
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
and	O	O
in	O	O
vitro	O	O
cell	O	O
damage	O	O
.	O	O

The	O	O
in	O	O
vivo	O	O
protection	O	O
was	O	O
associated	O	O
to	O	O
the	O	O
prevention	O	O
of	O	O
oxidative	O	O
stress	O	O
and	O	O
preservation	O	O
of	O	O
mitochondrial	O	O
oxygen	B-Chemical	D010100
consumption	O	O
and	O	O
activity	O	O
of	O	O
respiratory	O	O
complex	O	O
I	O	O
,	O	O
and	O	O
the	O	O
in	O	O
vitro	O	O
protection	O	O
was	O	O
associated	O	O
to	O	O
the	O	O
prevention	O	O
of	O	O
ROS	O	O
production	O	O
.	O	O

Incidence	O	O
of	O	O
solid	O	O
tumours	B-Disease	D009369
among	O	O
pesticide	O	O
applicators	O	O
exposed	O	O
to	O	O
the	O	O
organophosphate	B-Chemical	D010755
insecticide	O	O
diazinon	B-Chemical	D003976
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
:	O	O
an	O	O
updated	O	O
analysis	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Diazinon	B-Chemical	D003976
,	O	O
a	O	O
common	O	O
organophosphate	B-Chemical	D010755
insecticide	O	O
with	O	O
genotoxic	O	O
properties	O	O
,	O	O
was	O	O
previously	O	O
associated	O	O
with	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
(	O	O
AHS	O	O
)	O	O
cohort	O	O
,	O	O
but	O	O
few	O	O
other	O	O
epidemiological	O	O
studies	O	O
have	O	O
examined	O	O
diazinon	B-Chemical	D003976
-	O	O
associated	O	O
cancer	B-Disease	D009369
risk	O	O
.	O	O

We	O	O
used	O	O
updated	O	O
diazinon	B-Chemical	D003976
exposure	O	O
and	O	O
cancer	B-Disease	D009369
incidence	O	O
information	O	O
to	O	O
evaluate	O	O
solid	O	O
tumour	B-Disease	D009369
risk	O	O
in	O	O
the	O	O
AHS	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
pesticide	O	O
applicators	O	O
in	O	O
Iowa	O	O
and	O	O
North	O	O
Carolina	O	O
reported	O	O
lifetime	O	O
diazinon	B-Chemical	D003976
use	O	O
at	O	O
enrolment	O	O
(	O	O
1993	O	O
-	O	O
1997	O	O
)	O	O
and	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
1998	O	O
-	O	O
2005	O	O
)	O	O
;	O	O
cancer	B-Disease	D009369
incidence	O	O
was	O	O
assessed	O	O
through	O	O
2010	O	O
(	O	O
North	O	O
Carolina	O	O
)	O	O
/	O	O
2011	O	O
(	O	O
Iowa	O	O
)	O	O
.	O	O

Among	O	O
applicators	O	O
with	O	O
usage	O	O
information	O	O
sufficient	O	O
to	O	O
evaluate	O	O
exposure	O	O
-	O	O
response	O	O
patterns	O	O
,	O	O
we	O	O
used	O	O
Poisson	O	O
regression	O	O
to	O	O
estimate	O	O
adjusted	O	O
rate	O	O
ratios	O	O
(	O	O
RRs	O	O
)	O	O
and	O	O
95%	O	O
CI	O	O
for	O	O
cancer	B-Disease	D009369
sites	O	O
with	O	O
>10	O	O
exposed	O	O
cases	O	O
for	O	O
both	O	O
lifetime	O	O
(	O	O
LT	O	O
)	O	O
exposure	O	O
days	O	O
and	O	O
intensity	O	O
-	O	O
weighted	O	O
(	O	O
IW	O	O
)	O	O
lifetime	O	O
exposure	O	O
days	O	O
(	O	O
accounting	O	O
for	O	O
factors	O	O
impacting	O	O
exposure	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
observed	O	O
elevated	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
risks	O	O
(	O	O
N=283	O	O
)	O	O
among	O	O
applicators	O	O
with	O	O
the	O	O
greatest	O	O
number	O	O
of	O	O
LT	O	O
(	O	O
RR=1	O	O
.	O	O

60	O	O
;	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

11	O	O
to	O	O
2	O	O
.	O	O

31	O	O
;	O	O
Ptrend=0	O	O
.	O	O

02	O	O
)	O	O
and	O	O
IW	O	O
days	O	O
of	O	O
diazinon	B-Chemical	D003976
use	O	O
(	O	O
RR=1	O	O
.	O	O

41	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

98	O	O
to	O	O
2	O	O
.	O	O

04	O	O
;	O	O
Ptrend=0	O	O
.	O	O

08	O	O
)	O	O
.	O	O

Kidney	B-Disease	D007680
cancer	I-Disease	D007680
(	O	O
N=94	O	O
)	O	O
risks	O	O
were	O	O
non	O	O
-	O	O
significantly	O	O
elevated	O	O
(	O	O
RRLT	O	O
days=1	O	O
.	O	O

77	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

90	O	O
to	O	O
3	O	O
.	O	O

51	O	O
;	O	O
Ptrend=0	O	O
.	O	O

09	O	O
;	O	O
RRIW	O	O
days	O	O
1	O	O
.	O	O

37	O	O
;	O	O
95%	O	O
CI	O	O
0	O	O
.	O	O

64	O	O
to	O	O
2	O	O
.	O	O

92	O	O
;	O	O
Ptrend=0	O	O
.	O	O

50	O	O
)	O	O
,	O	O
as	O	O
were	O	O
risks	O	O
for	O	O
aggressive	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
(	O	O
N=656	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
updated	O	O
evaluation	O	O
of	O	O
diazinon	B-Chemical	D003976
provides	O	O
additional	O	O
evidence	O	O
of	O	O
an	O	O
association	O	O
with	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
risk	O	O
.	O	O

Newly	O	O
identified	O	O
links	O	O
to	O	O
kidney	B-Disease	D007680
cancer	I-Disease	D007680
and	O	O
associations	O	O
with	O	O
aggressive	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
require	O	O
further	O	O
evaluation	O	O
.	O	O

Associations	O	O
of	O	O
Ozone	B-Chemical	D010126
and	O	O
PM2	O	O
.	O	O

5	O	O
Concentrations	O	O
With	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Among	O	O
Participants	O	O
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
describes	O	O
associations	O	O
of	O	O
ozone	B-Chemical	D010126
and	O	O
fine	O	O
particulate	B-Chemical	D052638
matter	I-Chemical	D052638
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
observed	O	O
among	O	O
farmers	O	O
in	O	O
North	O	O
Carolina	O	O
and	O	O
Iowa	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
logistic	O	O
regression	O	O
to	O	O
determine	O	O
the	O	O
associations	O	O
of	O	O
these	O	O
pollutants	O	O
with	O	O
self	O	O
-	O	O
reported	O	O
,	O	O
doctor	O	O
-	O	O
diagnosed	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Daily	O	O
predicted	O	O
pollutant	O	O
concentrations	O	O
were	O	O
used	O	O
to	O	O
derive	O	O
surrogates	O	O
of	O	O
long	O	O
-	O	O
term	O	O
exposure	O	O
and	O	O
link	O	O
them	O	O
to	O	O
study	O	O
participants'	O	O
geocoded	O	O
addresses	O	O
.	O	O

RESULTS	O	O
:	O	O
We	O	O
observed	O	O
positive	O	O
associations	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
with	O	O
ozone	B-Chemical	D010126
(	O	O
odds	O	O
ratio	O	O
=	O	O
1	O	O
.	O	O

39	O	O
;	O	O
95%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

98	O	O
to	O	O
1	O	O
.	O	O

98	O	O
)	O	O
and	O	O
fine	O	O
particulate	B-Chemical	D052638
matter	I-Chemical	D052638
(	O	O
odds	O	O
ratio	O	O
=	O	O
1	O	O
.	O	O

34	O	O
;	O	O
95%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

93	O	O
to	O	O
1	O	O
.	O	O

93	O	O
)	O	O
in	O	O
North	O	O
Carolina	O	O
but	O	O
not	O	O
in	O	O
Iowa	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
plausibility	O	O
of	O	O
an	O	O
effect	O	O
of	O	O
ambient	O	O
concentrations	O	O
of	O	O
these	O	O
pollutants	O	O
on	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
risk	O	O
is	O	O
supported	O	O
by	O	O
experimental	O	O
data	O	O
demonstrating	O	O
damage	O	O
to	O	O
dopaminergic	O	O
neurons	O	O
at	O	O
relevant	O	O
concentrations	O	O
.	O	O

Additional	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
address	O	O
uncertainties	O	O
related	O	O
to	O	O
confounding	O	O
and	O	O
to	O	O
examine	O	O
temporal	O	O
aspects	O	O
of	O	O
the	O	O
associations	O	O
we	O	O
observed	O	O
.	O	O

Low	O	O
functional	O	O
programming	O	O
of	O	O
renal	O	O
AT2R	O	O
mediates	O	O
the	O	O
developmental	O	O
origin	O	O
of	O	O
glomerulosclerosis	B-Disease	D005921
in	O	O
adult	O	O
offspring	O	O
induced	O	O
by	O	O
prenatal	O	O
caffeine	B-Chemical	D002110
exposure	O	O
.	O	O

UNASSIGNED	O	O
:	O	O
Our	O	O
previous	O	O
study	O	O
has	O	O
indicated	O	O
that	O	O
prenatal	O	O
caffeine	B-Chemical	D002110
exposure	O	O
(	O	O
PCE	O	O
)	O	O
could	O	O
induce	O	O
intrauterine	B-Disease	D005317
growth	I-Disease	D005317
retardation	I-Disease	D005317
(	O	O
IUGR	B-Disease	D005317
)	O	O
of	O	O
offspring	O	O
.	O	O

Recent	O	O
research	O	O
suggested	O	O
that	O	O
IUGR	B-Disease	D005317
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
glomerulosclerosis	B-Disease	D005921
.	O	O

However	O	O
,	O	O
whether	O	O
PCE	O	O
could	O	O
induce	O	O
glomerulosclerosis	B-Disease	D005921
and	O	O
its	O	O
underlying	O	O
mechanisms	O	O
remain	O	O
unknown	O	O
.	O	O

This	O	O
study	O	O
aimed	O	O
to	O	O
demonstrate	O	O
the	O	O
induction	O	O
to	O	O
glomerulosclerosis	B-Disease	D005921
in	O	O
adult	O	O
offspring	O	O
by	O	O
PCE	O	O
and	O	O
its	O	O
intrauterine	O	O
programming	O	O
mechanisms	O	O
.	O	O

A	O	O
rat	O	O
model	O	O
of	O	O
IUGR	B-Disease	D005317
was	O	O
established	O	O
by	O	O
PCE	O	O
,	O	O
male	O	O
fetuses	O	O
and	O	O
adult	O	O
offspring	O	O
at	O	O
the	O	O
age	O	O
of	O	O
postnatal	O	O
week	O	O
24	O	O
were	O	O
euthanized	O	O
.	O	O

The	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
adult	O	O
offspring	O	O
kidneys	O	O
in	O	O
the	O	O
PCE	O	O
group	O	O
exhibited	O	O
glomerulosclerosis	B-Disease	D005921
as	O	O
well	O	O
as	O	O
interstitial	B-Disease	D005355
fibrosis	I-Disease	D005355
,	O	O
accompanied	O	O
by	O	O
elevated	O	O
levels	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
and	O	O
urine	O	O
protein	O	O
.	O	O

Renal	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
receptor	O	O
type	O	O
2	O	O
(	O	O
AT2R	O	O
)	O	O
gene	O	O
expression	O	O
in	O	O
adult	O	O
offspring	O	O
was	O	O
reduced	O	O
by	O	O
PCE	O	O
,	O	O
whereas	O	O
the	O	O
renal	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
receptor	O	O
type	O	O
1a	O	O
(	O	O
AT1aR	O	O
)	O	O
/	O	O
AT2R	O	O
expression	O	O
ratio	O	O
was	O	O
increased	O	O
.	O	O

The	O	O
fetal	O	O
kidneys	O	O
in	O	O
the	O	O
PCE	O	O
group	O	O
displayed	O	O
an	O	O
enlarged	O	O
Bowman's	O	O
space	O	O
and	O	O
a	O	O
shrunken	O	O
glomerular	O	O
tuft	O	O
,	O	O
accompanied	O	O
by	O	O
a	O	O
reduced	O	O
cortex	O	O
width	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
nephrogenic	O	O
zone	O	O
/	O	O
cortical	O	O
zone	O	O
ratio	O	O
.	O	O

Observation	O	O
by	O	O
electronic	O	O
microscope	O	O
revealed	O	O
structural	O	O
damage	O	O
of	O	O
podocytes	O	O
;	O	O
the	O	O
reduced	O	O
expression	O	O
level	O	O
of	O	O
podocyte	O	O
marker	O	O
genes	O	O
,	O	O
nephrin	O	O
and	O	O
podocin	O	O
,	O	O
was	O	O
also	O	O
detected	O	O
by	O	O
q	O	O
-	O	O
PCR	O	O
.	O	O

Moreover	O	O
,	O	O
AT2R	O	O
gene	O	O
and	O	O
protein	O	O
expressions	O	O
in	O	O
fetal	O	O
kidneys	O	O
were	O	O
inhibited	O	O
by	O	O
PCE	O	O
,	O	O
associated	O	O
with	O	O
the	O	O
repression	O	O
of	O	O
the	O	O
gene	O	O
expression	O	O
of	O	O
glial	O	O
-	O	O
cell	O	O
-	O	O
line	O	O
-	O	O
derived	O	O
neurotrophic	O	O
factor	O	O
(	O	O
GDNF	O	O
)	O	O
/	O	O
tyrosine	B-Chemical	D014443
kinase	O	O
receptor	O	O
(	O	O
c	O	O
-	O	O
Ret	O	O
)	O	O
signaling	O	O
pathway	O	O
.	O	O

These	O	O
results	O	O
demonstrated	O	O
that	O	O
PCE	O	O
could	O	O
induce	O	O
dysplasia	B-Disease	D007674
of	I-Disease	D007674
fetal	I-Disease	D007674
kidneys	I-Disease	D007674
as	O	O
well	O	O
as	O	O
glomerulosclerosis	B-Disease	D005921
of	O	O
adult	O	O
offspring	O	O
,	O	O
and	O	O
the	O	O
low	O	O
functional	O	O
programming	O	O
of	O	O
renal	O	O
AT2R	O	O
might	O	O
mediate	O	O
the	O	O
developmental	O	O
origin	O	O
of	O	O
adult	O	O
glomerulosclerosis	B-Disease	D005921
.	O	O

1	B-Chemical	C031763
,	I-Chemical	C031763
3	I-Chemical	C031763
-	I-Chemical	C031763
Butadiene	I-Chemical	C031763
,	O	O
CML	B-Disease	D015464
and	O	O
the	O	O
t	O	O
(	O	O
9	O	O
:	O	O
22	O	O
)	O	O
translocation	O	O
:	O	O
A	O	O
reality	O	O
check	O	O
.	O	O

UNASSIGNED	O	O
:	O	O
Epidemiological	O	O
studies	O	O
of	O	O
1	B-Chemical	C031763
,	I-Chemical	C031763
3	I-Chemical	C031763
-	I-Chemical	C031763
butadiene	I-Chemical	C031763
have	O	O
suggest	O	O
that	O	O
exposures	O	O
to	O	O
humans	O	O
are	O	O
associated	O	O
with	O	O
chronic	B-Disease	D015464
myeloid	I-Disease	D015464
leukemia	I-Disease	D015464
(	O	O
CML	B-Disease	D015464
)	O	O
.	O	O

CML	B-Disease	D015464
has	O	O
a	O	O
well	O	O
-	O	O
documented	O	O
association	O	O
with	O	O
ionizing	O	O
radiation	O	O
,	O	O
but	O	O
reports	O	O
of	O	O
associations	O	O
with	O	O
chemical	O	O
exposures	O	O
have	O	O
been	O	O
questioned	O	O
.	O	O

Ionizing	O	O
radiation	O	O
is	O	O
capable	O	O
of	O	O
inducing	O	O
the	O	O
requisite	O	O
CML	B-Disease	D015464
-	O	O
associated	O	O
t	O	O
(	O	O
9	O	O
:	O	O
22	O	O
)	O	O
translocation	O	O
(	O	O
Philadelphia	B-Disease	D010677
chromosome	I-Disease	D010677
)	O	O
in	O	O
appropriate	O	O
cells	O	O
in	O	O
vitro	O	O
but	O	O
,	O	O
thus	O	O
far	O	O
,	O	O
chemicals	O	O
have	O	O
not	O	O
shown	O	O
this	O	O
capacity	O	O
.	O	O

We	O	O
have	O	O
proposed	O	O
that	O	O
1	B-Chemical	C031763
,	I-Chemical	C031763
3	I-Chemical	C031763
-	I-Chemical	C031763
butadiene	I-Chemical	C031763
metabolites	O	O
be	O	O
so	O	O
tested	O	O
as	O	O
a	O	O
reality	O	O
check	O	O
on	O	O
the	O	O
epidemiological	O	O
reports	O	O
.	O	O

In	O	O
order	O	O
to	O	O
conduct	O	O
reliable	O	O
testing	O	O
in	O	O
this	O	O
regard	O	O
,	O	O
it	O	O
is	O	O
essential	O	O
that	O	O
a	O	O
positive	O	O
control	O	O
for	O	O
induction	O	O
be	O	O
available	O	O
.	O	O

We	O	O
have	O	O
used	O	O
ionizing	O	O
radiation	O	O
to	O	O
develop	O	O
such	O	O
a	O	O
control	O	O
.	O	O

Results	O	O
described	O	O
here	O	O
demonstrate	O	O
that	O	O
this	O	O
agent	O	O
does	O	O
in	O	O
fact	O	O
induce	O	O
pathogenic	O	O
t	O	O
(	O	O
9	O	O
:	O	O
22	O	O
)	O	O
translocations	O	O
in	O	O
a	O	O
human	O	O
myeloid	O	O
cell	O	O
line	O	O
in	O	O
vitro	O	O
,	O	O
but	O	O
does	O	O
so	O	O
at	O	O
low	O	O
frequencies	O	O
.	O	O

Conditions	O	O
that	O	O
will	O	O
be	O	O
required	O	O
for	O	O
studies	O	O
of	O	O
1	B-Chemical	C031763
,	I-Chemical	C031763
3	I-Chemical	C031763
-	I-Chemical	C031763
butadiene	I-Chemical	C031763
are	O	O
discussed	O	O
.	O	O

Cancer	B-Disease	D009369
incidence	O	O
and	O	O
metolachlor	B-Chemical	C051786
use	O	O
in	O	O
the	O	O
Agricultural	O	O
Health	O	O
Study	O	O
:	O	O
An	O	O
update	O	O
.	O	O

UNASSIGNED	O	O
:	O	O
Metolachlor	B-Chemical	C051786
,	O	O
a	O	O
widely	O	O
used	O	O
herbicide	O	O
,	O	O
is	O	O
classified	O	O
as	O	O
a	O	O
Group	O	O
C	O	O
carcinogen	O	O
by	O	O
the	O	O
U	O	O
.	O	O

S	O	O
.	O	O

Environmental	O	O
Protection	O	O
Agency	O	O
based	O	O
on	O	O
increased	O	O
liver	B-Disease	D008113
neoplasms	I-Disease	D008113
in	O	O
female	O	O
rats	O	O
.	O	O

Epidemiologic	O	O
studies	O	O
of	O	O
the	O	O
health	O	O
effects	O	O
of	O	O
metolachlor	B-Chemical	C051786
have	O	O
been	O	O
limited	O	O
.	O	O

The	O	O
Agricultural	O	O
Health	O	O
Study	O	O
(	O	O
AHS	O	O
)	O	O
is	O	O
a	O	O
prospective	O	O
cohort	O	O
study	O	O
including	O	O
licensed	O	O
private	O	O
and	O	O
commercial	O	O
pesticide	O	O
applicators	O	O
in	O	O
Iowa	O	O
and	O	O
North	O	O
Carolina	O	O
enrolled	O	O
1993	O	O
-	O	O
1997	O	O
.	O	O

We	O	O
evaluated	O	O
cancer	B-Disease	D009369
incidence	O	O
through	O	O
2010	O	O
/	O	O
2011	O	O
(	O	O
NC	O	O
/	O	O
IA	O	O
)	O	O
for	O	O
49	O	O
,	O	O
616	O	O
applicators	O	O
,	O	O
53%	O	O
of	O	O
whom	O	O
reported	O	O
ever	O	O
using	O	O
metolachlor	B-Chemical	C051786
.	O	O

We	O	O
used	O	O
Poisson	O	O
regression	O	O
to	O	O
evaluate	O	O
relations	O	O
between	O	O
two	O	O
metrics	O	O
of	O	O
metolachlor	B-Chemical	C051786
use	O	O
(	O	O
lifetime	O	O
days	O	O
,	O	O
intensity	O	O
-	O	O
weighted	O	O
lifetime	O	O
days	O	O
)	O	O
and	O	O
cancer	B-Disease	D009369
incidence	O	O
.	O	O

We	O	O
saw	O	O
no	O	O
association	O	O
between	O	O
metolachlor	B-Chemical	C051786
use	O	O
and	O	O
incidence	O	O
of	O	O
all	O	O
cancers	B-Disease	D009369
combined	O	O
(	O	O
n	O	O
=	O	O
5	O	O
,	O	O
701	O	O
with	O	O
a	O	O
5	O	O
-	O	O
year	O	O
lag	O	O
)	O	O
or	O	O
most	O	O
site	O	O
-	O	O
specific	O	O
cancers	B-Disease	D009369
.	O	O

For	O	O
liver	B-Disease	D008113
cancer	I-Disease	D008113
,	O	O
in	O	O
analyses	O	O
restricted	O	O
to	O	O
exposed	O	O
workers	O	O
,	O	O
elevations	O	O
observed	O	O
at	O	O
higher	O	O
categories	O	O
of	O	O
use	O	O
were	O	O
not	O	O
statistically	O	O
significant	O	O
.	O	O

However	O	O
,	O	O
trends	O	O
for	O	O
both	O	O
lifetime	O	O
and	O	O
intensity	O	O
-	O	O
weighted	O	O
lifetime	O	O
days	O	O
of	O	O
metolachor	B-Chemical	C051786
use	O	O
were	O	O
positive	O	O
and	O	O
statistically	O	O
significant	O	O
with	O	O
an	O	O
unexposed	O	O
reference	O	O
group	O	O
.	O	O

A	O	O
similar	O	O
pattern	O	O
was	O	O
observed	O	O
for	O	O
follicular	B-Disease	D008224
cell	I-Disease	D008224
lymphoma	I-Disease	D008224
,	O	O
but	O	O
no	O	O
other	O	O
lymphoma	B-Disease	D008223
subtypes	O	O
.	O	O

An	O	O
earlier	O	O
suggestion	O	O
of	O	O
increased	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
risk	O	O
at	O	O
high	O	O
levels	O	O
of	O	O
metolachlor	B-Chemical	C051786
use	O	O
in	O	O
this	O	O
cohort	O	O
was	O	O
not	O	O
confirmed	O	O
in	O	O
this	O	O
update	O	O
.	O	O

This	O	O
suggestion	O	O
of	O	O
an	O	O
association	O	O
between	O	O
metolachlor	B-Chemical	C051786
and	O	O
liver	B-Disease	D008113
cancer	I-Disease	D008113
among	O	O
pesticide	O	O
applicators	O	O
is	O	O
a	O	O
novel	O	O
finding	O	O
and	O	O
echoes	O	O
observation	O	O
of	O	O
increased	O	O
liver	B-Disease	D008113
neoplasms	I-Disease	D008113
in	O	O
some	O	O
animal	O	O
studies	O	O
.	O	O

However	O	O
,	O	O
our	O	O
findings	O	O
for	O	O
both	O	O
liver	B-Disease	D008113
cancer	I-Disease	D008113
and	O	O
follicular	B-Disease	D008224
cell	I-Disease	D008224
lymphoma	I-Disease	D008224
warrant	O	O
follow	O	O
-	O	O
up	O	O
to	O	O
better	O	O
differentiate	O	O
effects	O	O
of	O	O
metolachlor	B-Chemical	C051786
use	O	O
from	O	O
other	O	O
factors	O	O
.	O	O

Mechanisms	O	O
Underlying	O	O
Latent	O	O
Disease	O	O
Risk	O	O
Associated	O	O
with	O	O
Early	O	O
-	O	O
Life	O	O
Arsenic	B-Chemical	D001151
Exposure	O	O
:	O	O
Current	O	O
Research	O	O
Trends	O	O
and	O	O
Scientific	O	O
Gaps	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Millions	O	O
of	O	O
individuals	O	O
worldwide	O	O
,	O	O
particularly	O	O
those	O	O
living	O	O
in	O	O
rural	O	O
and	O	O
developing	O	O
areas	O	O
,	O	O
are	O	O
exposed	O	O
to	O	O
harmful	O	O
levels	O	O
of	O	O
inorganic	B-Chemical	D001152
arsenic	I-Chemical	D001152
(	O	O
iAs	B-Chemical	D001152
)	O	O
in	O	O
their	O	O
drinking	O	O
water	O	O
.	O	O

Inorganic	B-Chemical	D001152
As	I-Chemical	D001152
exposure	O	O
during	O	O
key	O	O
developmental	O	O
periods	O	O
is	O	O
associated	O	O
with	O	O
a	O	O
variety	O	O
of	O	O
adverse	O	O
health	O	O
effects	O	O
including	O	O
those	O	O
that	O	O
are	O	O
evident	O	O
in	O	O
adulthood	O	O
.	O	O

There	O	O
is	O	O
considerable	O	O
interest	O	O
in	O	O
identifying	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
relate	O	O
early	O	O
-	O	O
life	O	O
iAs	B-Chemical	D001152
exposure	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
latent	O	O
diseases	O	O
,	O	O
particularly	O	O
in	O	O
relationship	O	O
to	O	O
cancer	B-Disease	D009369
.	O	O

OBJECTIVES	O	O
:	O	O
This	O	O
work	O	O
summarizes	O	O
research	O	O
on	O	O
the	O	O
molecular	O	O
mechanisms	O	O
that	O	O
underlie	O	O
the	O	O
increased	O	O
risk	O	O
of	O	O
cancer	B-Disease	D009369
development	O	O
in	O	O
adulthood	O	O
that	O	O
is	O	O
associated	O	O
with	O	O
early	O	O
-	O	O
life	O	O
iAs	B-Chemical	D001152
exposure	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Epigenetic	O	O
reprogramming	O	O
that	O	O
imparts	O	O
functional	O	O
changes	O	O
in	O	O
gene	O	O
expression	O	O
,	O	O
the	O	O
development	O	O
of	O	O
cancer	B-Disease	D009369
stem	O	O
cells	O	O
,	O	O
and	O	O
immunomodulation	O	O
are	O	O
plausible	O	O
underlying	O	O
mechanisms	O	O
by	O	O
which	O	O
early	O	O
-	O	O
life	O	O
iAs	B-Chemical	D001152
exposure	O	O
elicits	O	O
latent	O	O
carcinogenic	O	O
effects	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Evidence	O	O
is	O	O
mounting	O	O
that	O	O
relates	O	O
early	O	O
-	O	O
life	O	O
iAs	B-Chemical	D001152
exposure	O	O
and	O	O
cancer	B-Disease	D009369
development	O	O
later	O	O
in	O	O
life	O	O
.	O	O

Future	O	O
research	O	O
should	O	O
include	O	O
animal	O	O
studies	O	O
that	O	O
address	O	O
mechanistic	O	O
hypotheses	O	O
and	O	O
studies	O	O
of	O	O
human	O	O
populations	O	O
that	O	O
integrate	O	O
early	O	O
-	O	O
life	O	O
exposure	O	O
,	O	O
molecular	O	O
alterations	O	O
,	O	O
and	O	O
latent	O	O
disease	O	O
outcomes	O	O
.	O	O

On	O	O
the	O	O
antiarrhythmic	O	O
activity	O	O
of	O	O
one	O	O
N	O	O
-	O	O
substituted	O	O
piperazine	B-Chemical	C034930
derivative	O	O
of	O	O
trans	B-Chemical	-1
-	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
amino	I-Chemical	-1
-	I-Chemical	-1
3	I-Chemical	-1
-	I-Chemical	-1
hydroxy	I-Chemical	-1
-	I-Chemical	-1
1	I-Chemical	-1
,	I-Chemical	-1
2	I-Chemical	-1
,	I-Chemical	-1
3	I-Chemical	-1
,	I-Chemical	-1
4	I-Chemical	-1
-	I-Chemical	-1
tetrahydroanaphthalene	I-Chemical	-1
.	O	O

The	O	O
antiarrhythmic	O	O
activity	O	O
of	O	O
the	O	O
compound	O	O
N	B-Chemical	C013741
-	I-Chemical	C013741
(	I-Chemical	C013741
trans	I-Chemical	C013741
-	I-Chemical	C013741
3	I-Chemical	C013741
-	I-Chemical	C013741
hydroxy	I-Chemical	C013741
-	I-Chemical	C013741
1	I-Chemical	C013741
,	I-Chemical	C013741
2	I-Chemical	C013741
,	I-Chemical	C013741
3	I-Chemical	C013741
,	I-Chemical	C013741
4	I-Chemical	C013741
-	I-Chemical	C013741
tetrahydro	I-Chemical	C013741
-	I-Chemical	C013741
2	I-Chemical	C013741
-	I-Chemical	C013741
naphthyl	I-Chemical	C013741
)	I-Chemical	C013741
-	I-Chemical	C013741
N	I-Chemical	C013741
-	I-Chemical	C013741
(	I-Chemical	C013741
3	I-Chemical	C013741
-	I-Chemical	C013741
oxo	I-Chemical	C013741
-	I-Chemical	C013741
3	I-Chemical	C013741
-	I-Chemical	C013741
phenyl	I-Chemical	C013741
-	I-Chemical	C013741
2	I-Chemical	C013741
-	I-Chemical	C013741
methylpropyl	I-Chemical	C013741
)	I-Chemical	C013741
-	I-Chemical	C013741
piperazine	I-Chemical	C013741
hydrochloride	I-Chemical	C013741
,	O	O
referred	O	O
to	O	O
as	O	O
P11	B-Chemical	C013741
,	O	O
is	O	O
studied	O	O
on	O	O
anaesthesized	O	O
cats	O	O
and	O	O
Wistar	O	O
albino	O	O
rats	O	O
,	O	O
as	O	O
well	O	O
as	O	O
on	O	O
non	O	O
-	O	O
anaesthesized	O	O
rabbits	O	O
.	O	O

Four	O	O
types	O	O
of	O	O
experimental	O	O
arrhythmia	B-Disease	D001145
are	O	O
used	O	O
-	O	O
-	O	O
with	O	O
BaCl2	B-Chemical	C024986
,	O	O
with	O	O
chloroform	B-Chemical	D002725
-	O	O
adrenaline	B-Chemical	D004837
,	O	O
with	O	O
strophantine	B-Chemical	D010042
G	I-Chemical	D010042
and	O	O
with	O	O
aconitine	B-Chemical	D000157
.	O	O

The	O	O
compound	O	O
P11	B-Chemical	C013741
is	O	O
introduced	O	O
in	O	O
doses	O	O
of	O	O
0	O	O
.	O	O

25	O	O
and	O	O
0	O	O
.	O	O

50	O	O
mg	O	O
/	O	O
kg	O	O
intravenously	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
orally	O	O
.	O	O

The	O	O
compound	O	O
manifests	O	O
antiarrhythmic	O	O
activity	O	O
in	O	O
all	O	O
models	O	O
of	O	O
experimental	O	O
arrhythmia	B-Disease	D001145
used	O	O
,	O	O
causing	O	O
greatest	O	O
inhibition	O	O
on	O	O
the	O	O
arrhythmia	B-Disease	D001145
induced	O	O
by	O	O
chloroform	B-Chemical	D002725
-	O	O
adrenaline	B-Chemical	D004837
(	O	O
in	O	O
90	O	O
per	O	O
cent	O	O
)	O	O
and	O	O
with	O	O
BaCl2	B-Chemical	C024986
(	O	O
in	O	O
84	O	O
per	O	O
cent	O	O
)	O	O
.	O	O

The	O	O
results	O	O
obtained	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
beta	O	O
-	O	O
adrenoblocking	O	O
and	O	O
with	O	O
the	O	O
membrane	O	O
-	O	O
stabilizing	O	O
action	O	O
of	O	O
the	O	O
compound	O	O
.	O	O

Experimental	O	O
progressive	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
and	O	O
its	O	O
treatment	O	O
with	O	O
high	O	O
doses	O	O
anabolizing	O	O
agents	O	O
.	O	O

We	O	O
are	O	O
still	O	O
a	O	O
long	O	O
way	O	O
from	O	O
discovering	O	O
an	O	O
unequivocal	O	O
pathogenetic	O	O
interpretation	O	O
of	O	O
progressive	O	O
muscular	B-Disease	D009136
dystrophy	I-Disease	D009136
in	O	O
man	O	O
.	O	O

Noteworthy	O	O
efforts	O	O
have	O	O
been	O	O
made	O	O
in	O	O
the	O	O
experimental	O	O
field	O	O
;	O	O
a	O	O
recessive	O	O
autosomic	O	O
form	O	O
found	O	O
in	O	O
the	O	O
mouse	O	O
seems	O	O
to	O	O
bear	O	O
the	O	O
closest	O	O
resemblance	O	O
to	O	O
the	O	O
human	O	O
form	O	O
from	O	O
the	O	O
genetic	O	O
point	O	O
of	O	O
view	O	O
.	O	O

Myopathy	B-Disease	D009135
due	O	O
to	O	O
lack	O	O
of	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
and	O	O
myopathy	B-Disease	D009135
induced	O	O
by	O	O
certain	O	O
viruses	O	O
have	O	O
much	O	O
in	O	O
common	O	O
anatomically	O	O
and	O	O
pathologically	O	O
with	O	O
the	O	O
human	O	O
form	O	O
.	O	O

The	O	O
authors	O	O
induced	O	O
myodystrophy	B-Disease	D009136
in	O	O
the	O	O
rat	O	O
by	O	O
giving	O	O
it	O	O
a	O	O
diet	O	O
lacking	O	O
in	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
.	O	O

The	O	O
pharmacological	O	O
characteristics	O	O
of	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
and	O	O
the	O	O
degenerative	O	O
changes	O	O
brought	O	O
about	O	O
by	O	O
its	O	O
deficiency	O	O
,	O	O
especially	O	O
in	O	O
the	O	O
muscles	O	O
,	O	O
are	O	O
illustrated	O	O
.	O	O

It	O	O
is	O	O
thus	O	O
confirmed	O	O
that	O	O
the	O	O
histological	O	O
characteristics	O	O
of	O	O
myopathic	B-Disease	D009135
rat	O	O
muscle	O	O
induced	O	O
experimentally	O	O
are	O	O
extraordinarily	O	O
similar	O	O
to	O	O
those	O	O
of	O	O
human	O	O
myopathy	B-Disease	D009135
as	O	O
confirmed	O	O
during	O	O
biopsies	O	O
performed	O	O
at	O	O
the	O	O
Orthopaedic	O	O
Traumatological	O	O
Centre	O	O
,	O	O
Florence	O	O
.	O	O

The	O	O
encouraging	O	O
results	O	O
obtained	O	O
in	O	O
various	O	O
authoratative	O	O
departments	O	O
in	O	O
myopathic	B-Disease	D009135
patients	O	O
by	O	O
using	O	O
anabolizing	O	O
steroids	B-Chemical	D013256
have	O	O
encouraged	O	O
the	O	O
authors	O	O
to	O	O
investigate	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
one	O	O
anabolizing	O	O
agent	O	O
(	O	O
Dianabol	B-Chemical	D008696
,	O	O
CIBA	B-Chemical	-1
)	O	O
at	O	O
high	O	O
doses	O	O
in	O	O
rats	O	O
rendered	O	O
myopathic	B-Disease	D009135
by	O	O
a	O	O
diet	O	O
deficient	O	O
in	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
.	O	O

In	O	O
this	O	O
way	O	O
they	O	O
obtained	O	O
appreciable	O	O
changes	O	O
in	O	O
body	O	O
weight	O	O
(	O	O
increased	O	O
from	O	O
50	O	O
to	O	O
70	O	O
g	O	O
after	O	O
forty	O	O
days	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
mg	O	O
per	O	O
day	O	O
of	O	O
anabolizing	O	O
agent	O	O
)	O	O
,	O	O
but	O	O
most	O	O
of	O	O
all	O	O
they	O	O
found	O	O
histological	O	O
changes	O	O
due	O	O
to	O	O
"regenerative"	O	O
changes	O	O
in	O	O
the	O	O
muscle	O	O
tissue	O	O
,	O	O
which	O	O
however	O	O
maintained	O	O
its	O	O
myopathic	B-Disease	D009135
characteristics	O	O
in	O	O
the	O	O
control	O	O
animals	O	O
that	O	O
were	O	O
not	O	O
treated	O	O
with	O	O
the	O	O
anabolizing	O	O
agent	O	O
.	O	O

The	O	O
authors	O	O
conclude	O	O
by	O	O
affirming	O	O
the	O	O
undoubted	O	O
efficacy	O	O
of	O	O
the	O	O
anabolizing	O	O
steroids	B-Chemical	D013256
in	O	O
experimental	O	O
myopathic	B-Disease	D009135
disease	O	O
,	O	O
but	O	O
they	O	O
have	O	O
reservations	O	O
as	O	O
to	O	O
the	O	O
transfer	O	O
of	O	O
the	O	O
results	O	O
into	O	O
the	O	O
human	O	O
field	O	O
,	O	O
where	O	O
high	O	O
dosage	O	O
cannot	O	O
be	O	O
carried	O	O
out	O	O
continuously	O	O
because	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
virility	O	O
;	O	O
because	O	O
the	O	O
tissue	O	O
injury	O	O
too	O	O
often	O	O
occurs	O	O
at	O	O
an	O	O
irreversible	O	O
stage	O	O
vis	O	O
-	O	O
a	O	O
-	O	O
vis	O	O
the	O	O
"regeneration"	O	O
of	O	O
the	O	O
muscle	O	O
tissue	O	O
;	O	O
and	O	O
finally	O	O
because	O	O
the	O	O
dystrophic	O	O
injurious	O	O
agent	O	O
is	O	O
certainly	O	O
not	O	O
the	O	O
lack	O	O
of	O	O
vitamin	B-Chemical	D014810
E	I-Chemical	D014810
but	O	O
something	O	O
as	O	O
yet	O	O
unknown	O	O
.	O	O

Fetal	O	O
risks	O	O
due	O	O
to	O	O
warfarin	B-Chemical	D014859
therapy	O	O
during	O	O
pregnancy	O	O
.	O	O

Two	O	O
mothers	O	O
with	O	O
heart	O	O
valve	O	O
prosthesis	O	O
were	O	O
treated	O	O
with	O	O
warfarin	B-Chemical	D014859
during	O	O
pregnancy	O	O
.	O	O

In	O	O
the	O	O
first	O	O
case	O	O
a	O	O
caesarean	O	O
section	O	O
was	O	O
done	O	O
one	O	O
week	O	O
after	O	O
replacement	O	O
of	O	O
warfarin	B-Chemical	D014859
with	O	O
heparin	B-Chemical	D006493
.	O	O

The	O	O
baby	O	O
died	O	O
of	O	O
cerebral	O	O
and	O	O
pulmonary	O	O
hemorrhage	O	O
.	O	O

The	O	O
second	O	O
mother	O	O
had	O	O
a	O	O
male	O	O
infant	O	O
by	O	O
caesarean	O	O
section	O	O
.	O	O

The	O	O
baby	O	O
showed	O	O
warfarin	B-Chemical	D014859
-	O	O
induced	O	O
embryopathy	B-Disease	D005315
with	O	O
nasal	B-Disease	-1
hypoplasia	I-Disease	-1
and	O	O
stippled	B-Disease	D002806
epiphyses	I-Disease	D002806
(	O	O
chondrodysplasia	B-Disease	D002806
punctata	I-Disease	D002806
)	O	O
.	O	O

Nasal	B-Disease	-1
hypoplasia	I-Disease	-1
with	O	O
or	O	O
without	O	O
stippled	B-Disease	D002806
epiphyses	I-Disease	D002806
has	O	O
now	O	O
been	O	O
reported	O	O
in	O	O
11	O	O
infants	O	O
born	O	O
to	O	O
mothers	O	O
treated	O	O
with	O	O
warfarin	B-Chemical	D014859
during	O	O
the	O	O
first	O	O
trimester	O	O
,	O	O
and	O	O
a	O	O
causal	O	O
association	O	O
is	O	O
probable	O	O
.	O	O

In	O	O
view	O	O
of	O	O
the	O	O
risks	O	O
to	O	O
both	O	O
mother	O	O
and	O	O
fetus	O	O
in	O	O
women	O	O
with	O	O
prosthetic	O	O
cardiac	O	O
valves	O	O
it	O	O
is	O	O
recommended	O	O
that	O	O
therapeutic	O	O
abortion	O	O
be	O	O
advised	O	O
as	O	O
the	O	O
first	O	O
alternative	O	O
.	O	O

Isradipine	B-Chemical	D017275
treatment	O	O
for	O	O
hypertension	B-Disease	D006973
in	O	O
general	O	O
practice	O	O
in	O	O
Hong	O	O
Kong	O	O
.	O	O

A	O	O
6	O	O
-	O	O
week	O	O
open	O	O
study	O	O
of	O	O
the	O	O
introduction	O	O
of	O	O
isradipine	B-Chemical	D017275
treatment	O	O
was	O	O
conducted	O	O
in	O	O
general	O	O
practice	O	O
in	O	O
Hong	O	O
Kong	O	O
.	O	O

303	O	O
Chinese	O	O
patients	O	O
with	O	O
mild	O	O
to	O	O
moderate	O	O
hypertension	B-Disease	D006973
entered	O	O
the	O	O
study	O	O
.	O	O

Side	O	O
effects	O	O
were	O	O
reported	O	O
in	O	O
21%	O	O
of	O	O
patients	O	O
and	O	O
caused	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

The	O	O
main	O	O
side	O	O
-	O	O
effects	O	O
were	O	O
headache	B-Disease	D006261
,	O	O
dizziness	B-Disease	D004244
,	O	O
palpitation	B-Disease	-1
and	O	O
flushing	B-Disease	D005483
and	O	O
these	O	O
were	O	O
not	O	O
more	O	O
frequent	O	O
than	O	O
reported	O	O
in	O	O
other	O	O
studies	O	O
with	O	O
isradipine	B-Chemical	D017275
or	O	O
with	O	O
placebo	O	O
.	O	O

Supine	O	O
blood	O	O
pressure	O	O
was	O	O
reduced	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
from	O	O
170	O	O
+	O	O
/	O	O
-	O	O
20	O	O
/	O	O
102	O	O
+	O	O
/	O	O
-	O	O
6	O	O
mmHg	O	O
to	O	O
153	O	O
+	O	O
/	O	O
-	O	O
19	O	O
/	O	O
92	O	O
+	O	O
/	O	O
-	O	O
8	O	O
,	O	O
147	O	O
+	O	O
/	O	O
-	O	O
18	O	O
/	O	O
88	O	O
+	O	O
/	O	O
-	O	O
7	O	O
and	O	O
144	O	O
+	O	O
/	O	O
-	O	O
14	O	O
/	O	O
87	O	O
+	O	O
/	O	O
-	O	O
6	O	O
mmHg	O	O
at	O	O
2	O	O
,	O	O
4	O	O
and	O	O
6	O	O
weeks	O	O
respectively	O	O
in	O	O
evaluable	O	O
patients	O	O
.	O	O

Similar	O	O
reductions	O	O
occurred	O	O
in	O	O
standing	O	O
blood	O	O
pressure	O	O
and	O	O
there	O	O
was	O	O
no	O	O
evidence	O	O
of	O	O
postural	B-Disease	D007024
hypotension	I-Disease	D007024
.	O	O

Normalization	O	O
and	O	O
responder	O	O
rates	O	O
at	O	O
6	O	O
weeks	O	O
were	O	O
86%	O	O
and	O	O
69%	O	O
respectively	O	O
.	O	O

Dosage	O	O
was	O	O
increased	O	O
from	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
b	O	O
.	O	O

d	O	O
.	O	O

to	O	O
5	O	O
mg	O	O
b	O	O
.	O	O

d	O	O
.	O	O

at	O	O
4	O	O
weeks	O	O
in	O	O
patients	O	O
with	O	O
diastolic	O	O
blood	O	O
pressure	O	O
greater	O	O
than	O	O
90	O	O
mmHg	O	O
and	O	O
their	O	O
further	O	O
response	O	O
was	O	O
greater	O	O
than	O	O
those	O	O
remaining	O	O
on	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
b	O	O
.	O	O

d	O	O
.	O	O

Tachyphylaxis	O	O
to	O	O
systemic	O	O
but	O	O
not	O	O
to	O	O
airway	O	O
responses	O	O
during	O	O
prolonged	O	O
therapy	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B-Chemical	D000420
in	O	O
asthmatics	B-Disease	D001249
.	O	O

High	O	O
doses	O	O
of	O	O
inhaled	O	O
salbutamol	B-Chemical	D000420
produce	O	O
substantial	O	O
improvements	O	O
in	O	O
airway	O	O
response	O	O
in	O	O
patients	O	O
with	O	O
asthma	B-Disease	D001249
,	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
dose	O	O
-	O	O
dependent	O	O
systemic	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
responses	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
whether	O	O
tachyphylaxis	O	O
occurs	O	O
during	O	O
prolonged	O	O
treatment	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B-Chemical	D000420
.	O	O

Twelve	O	O
asthmatic	B-Disease	D001249
patients	O	O
(	O	O
FEV1	O	O
,	O	O
81	O	O
+	O	O
/	O	O
-	O	O
4%	O	O
predicted	O	O
)	O	O
,	O	O
requiring	O	O
only	O	O
occasional	O	O
inhaled	O	O
beta	O	O
-	O	O
agonists	O	O
as	O	O
their	O	O
sole	O	O
therapy	O	O
,	O	O
were	O	O
given	O	O
a	O	O
14	O	O
-	O	O
day	O	O
treatment	O	O
with	O	O
high	O	O
dose	O	O
inhaled	O	O
salbutamol	B-Chemical	D000420
(	O	O
HDS	O	O
)	O	O
,	O	O
4	O	O
,	O	O
000	O	O
micrograms	O	O
daily	O	O
,	O	O
low	O	O
dose	O	O
inhaled	O	O
salbutamol	B-Chemical	D000420
(	O	O
LDS	O	O
)	O	O
,	O	O
800	O	O
micrograms	O	O
daily	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
PI	O	O
)	O	O
by	O	O
metered	O	O
-	O	O
dose	O	O
inhaler	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomized	O	O
crossover	O	O
design	O	O
.	O	O

During	O	O
the	O	O
14	O	O
-	O	O
day	O	O
run	O	O
-	O	O
in	O	O
and	O	O
during	O	O
washout	O	O
periods	O	O
,	O	O
inhaled	O	O
beta	O	O
-	O	O
agonists	O	O
were	O	O
withheld	O	O
and	O	O
ipratropium	B-Chemical	D009241
bromide	I-Chemical	D009241
was	O	O
substituted	O	O
for	O	O
rescue	O	O
purposes	O	O
.	O	O

At	O	O
the	O	O
end	O	O
of	O	O
each	O	O
14	O	O
-	O	O
day	O	O
treatment	O	O
,	O	O
a	O	O
dose	O	O
-	O	O
response	O	O
curve	O	O
(	O	O
DRC	O	O
)	O	O
was	O	O
performed	O	O
,	O	O
and	O	O
airway	O	O
(	O	O
FEV1	O	O
,	O	O
FEF25	O	O
-	O	O
75	O	O
)	O	O
chronotropic	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
tremor	B-Disease	D014202
,	O	O
and	O	O
metabolic	O	O
(	O	O
K	B-Chemical	D011188
,	O	O
Glu	B-Chemical	D005947
)	O	O
responses	O	O
were	O	O
measured	O	O
at	O	O
each	O	O
step	O	O
(	O	O
from	O	O
100	O	O
to	O	O
4	O	O
,	O	O
000	O	O
micrograms	O	O
)	O	O
.	O	O

Treatment	O	O
had	O	O
no	O	O
significant	O	O
effect	O	O
on	O	O
baseline	O	O
values	O	O
.	O	O

There	O	O
were	O	O
dose	O	O
-	O	O
dependent	O	O
increases	O	O
in	O	O
FEV1	O	O
and	O	O
FEF25	O	O
-	O	O
75	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
pretreatment	O	O
with	O	O
HDS	O	O
did	O	O
not	O	O
displace	O	O
the	O	O
DRC	O	O
to	O	O
the	O	O
right	O	O
.	O	O

DRC	O	O
for	O	O
HR	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
K	B-Chemical	D011188
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
Glu	B-Chemical	D005947
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

005	O	O
)	O	O
were	O	O
attenuated	O	O
after	O	O
treatment	O	O
with	O	O
HDS	O	O
compared	O	O
with	O	O
PI	O	O
.	O	O

There	O	O
were	O	O
also	O	O
differences	O	O
between	O	O
HDS	O	O
and	O	O
LDS	O	O
for	O	O
HR	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
Glu	B-Chemical	D005947
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
responses	O	O
.	O	O

Frequency	O	O
and	O	O
severity	O	O
of	O	O
subjective	O	O
adverse	O	O
effects	O	O
were	O	O
also	O	O
reduced	O	O
after	O	O
HDS	O	O
:	O	O
tremor	B-Disease	D014202
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
palpitations	B-Disease	-1
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Increased	O	O
anxiogenic	O	O
effects	O	O
of	O	O
caffeine	B-Chemical	D002110
in	O	O
panic	B-Disease	D016584
disorders	I-Disease	D016584
.	O	O

The	O	O
effects	O	O
of	O	O
oral	O	O
administration	O	O
of	O	O
caffeine	B-Chemical	D002110
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
behavioral	O	O
ratings	O	O
,	O	O
somatic	O	O
symptoms	O	O
,	O	O
blood	O	O
pressure	O	O
and	O	O
plasma	O	O
levels	O	O
of	O	O
3	B-Chemical	D008734
-	I-Chemical	D008734
methoxy	I-Chemical	D008734
-	I-Chemical	D008734
4	I-Chemical	D008734
-	I-Chemical	D008734
hydroxyphenethyleneglycol	I-Chemical	D008734
(	O	O
MHPG	B-Chemical	D008734
)	O	O
and	O	O
cortisol	B-Chemical	D006854
were	O	O
determined	O	O
in	O	O
17	O	O
healthy	O	O
subjects	O	O
and	O	O
21	O	O
patients	O	O
meeting	O	O
DSM	O	O
-	O	O
III	O	O
criteria	O	O
for	O	O
agoraphobia	B-Disease	D000379
with	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
or	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
.	O	O

Caffeine	B-Chemical	D002110
produced	O	O
significantly	O	O
greater	O	O
increases	O	O
in	O	O
subject	O	O
-	O	O
rated	O	O
anxiety	B-Disease	D001008
,	O	O
nervousness	O	O
,	O	O
fear	O	O
,	O	O
nausea	B-Disease	D009325
,	O	O
palpitations	B-Disease	-1
,	O	O
restlessness	B-Disease	D011595
,	O	O
and	O	O
tremors	B-Disease	D014202
in	O	O
the	O	O
patients	O	O
compared	O	O
with	O	O
healthy	O	O
subjects	O	O
.	O	O

In	O	O
the	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
the	O	O
healthy	O	O
subjects	O	O
,	O	O
these	O	O
symptoms	O	O
were	O	O
significantly	O	O
correlated	O	O
with	O	O
plasma	O	O
caffeine	B-Chemical	D002110
levels	O	O
.	O	O

Seventy	O	O
-	O	O
one	O	O
percent	O	O
of	O	O
the	O	O
patients	O	O
reported	O	O
that	O	O
the	O	O
behavioral	O	O
effects	O	O
of	O	O
caffeine	B-Chemical	D002110
were	O	O
similar	O	O
to	O	O
those	O	O
experienced	O	O
during	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
.	O	O

Caffeine	B-Chemical	D002110
did	O	O
not	O	O
alter	O	O
plasma	O	O
MHPG	B-Chemical	D008734
levels	O	O
in	O	O
either	O	O
the	O	O
healthy	O	O
subjects	O	O
or	O	O
patients	O	O
.	O	O

Caffeine	B-Chemical	D002110
increased	O	O
plasma	O	O
cortisol	B-Chemical	D006854
levels	O	O
equally	O	O
in	O	O
the	O	O
patient	O	O
and	O	O
healthy	O	O
groups	O	O
.	O	O

Because	O	O
caffeine	B-Chemical	D002110
is	O	O
an	O	O
adenosine	B-Chemical	D000241
receptor	O	O
antagonist	O	O
,	O	O
these	O	O
results	O	O
suggest	O	O
that	O	O
some	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
patients	O	O
may	O	O
have	O	O
abnormalities	B-Disease	D009421
in	I-Disease	D009421
neuronal	I-Disease	D009421
systems	I-Disease	D009421
involving	O	O
adenosine	B-Chemical	D000241
.	O	O

Patients	O	O
with	O	O
anxiety	B-Disease	D001008
disorders	O	O
may	O	O
benefit	O	O
by	O	O
avoiding	O	O
caffeine	B-Chemical	D002110
-	O	O
containing	O	O
foods	O	O
and	O	O
beverages	O	O
.	O	O

Human	O	O
and	O	O
canine	O	O
ventricular	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
:	O	O
decrease	O	O
with	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
VIP	O	O
)	O	O
is	O	O
a	O	O
systemic	O	O
and	O	O
coronary	O	O
vasodilator	O	O
that	O	O
may	O	O
have	O	O
positive	O	O
inotropic	O	O
properties	O	O
.	O	O

Myocardial	O	O
levels	O	O
of	O	O
VIP	O	O
were	O	O
assayed	O	O
before	O	O
and	O	O
after	O	O
the	O	O
development	O	O
of	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
in	O	O
two	O	O
canine	O	O
models	O	O
.	O	O

In	O	O
the	O	O
first	O	O
,	O	O
cobalt	B-Chemical	D003035
cardiomyopathy	B-Disease	D009202
was	O	O
induced	O	O
in	O	O
eight	O	O
dogs	O	O
;	O	O
VIP	O	O
(	O	O
by	O	O
radioimmunoassay	O	O
)	O	O
decreased	O	O
from	O	O
35	O	O
+	O	O
/	O	O
-	O	O
11	O	O
pg	O	O
/	O	O
mg	O	O
protein	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
to	O	O
5	O	O
+	O	O
/	O	O
-	O	O
4	O	O
pg	O	O
/	O	O
mg	O	O
protein	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

In	O	O
six	O	O
dogs	O	O
with	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
,	O	O
VIP	O	O
decreased	O	O
from	O	O
31	O	O
+	O	O
/	O	O
-	O	O
7	O	O
to	O	O
11	O	O
+	O	O
/	O	O
-	O	O
4	O	O
pg	O	O
/	O	O
mg	O	O
protein	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
VIP	O	O
content	O	O
of	O	O
left	O	O
ventricular	O	O
muscle	O	O
of	O	O
resected	O	O
failing	O	O
hearts	O	O
in	O	O
10	O	O
patients	O	O
receiving	O	O
a	O	O
heart	O	O
transplant	O	O
was	O	O
compared	O	O
with	O	O
the	O	O
papillary	O	O
muscles	O	O
in	O	O
14	O	O
patients	O	O
(	O	O
five	O	O
with	O	O
rheumatic	B-Disease	D012216
disease	I-Disease	D012216
,	O	O
nine	O	O
with	O	O
myxomatous	B-Disease	-1
degeneration	I-Disease	-1
)	O	O
receiving	O	O
mitral	O	O
valve	O	O
prostheses	O	O
.	O	O

The	O	O
lowest	O	O
myocardial	O	O
VIP	O	O
concentration	O	O
was	O	O
found	O	O
in	O	O
the	O	O
hearts	O	O
of	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003327
disease	I-Disease	D003327
(	O	O
one	O	O
patient	O	O
receiving	O	O
a	O	O
transplant	O	O
and	O	O
three	O	O
receiving	O	O
mitral	O	O
prostheses	O	O
)	O	O
(	O	O
6	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

9	O	O
pg	O	O
/	O	O
mg	O	O
protein	O	O
)	O	O
.	O	O

The	O	O
other	O	O
patients	O	O
undergoing	O	O
transplantation	O	O
had	O	O
an	O	O
average	O	O
ejection	O	O
fraction	O	O
of	O	O
17%	O	O
+	O	O
/	O	O
-	O	O
6%	O	O
and	O	O
a	O	O
VIP	O	O
level	O	O
of	O	O
8	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

9	O	O
pg	O	O
/	O	O
mg	O	O
protein	O	O
.	O	O

The	O	O
hearts	O	O
without	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
(	O	O
average	O	O
ejection	O	O
fraction	O	O
of	O	O
this	O	O
group	O	O
62%	O	O
+	O	O
/	O	O
-	O	O
10%	O	O
)	O	O
had	O	O
a	O	O
VIP	O	O
concentration	O	O
of	O	O
14	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
7	O	O
.	O	O

9	O	O
pg	O	O
/	O	O
mg	O	O
protein	O	O
,	O	O
and	O	O
this	O	O
was	O	O
greater	O	O
than	O	O
in	O	O
hearts	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003327
disease	I-Disease	D003327
and	O	O
the	O	O
hearts	O	O
of	O	O
patients	O	O
receiving	O	O
a	O	O
transplant	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Myocardial	O	O
catecholamines	B-Chemical	D002395
were	O	O
also	O	O
determined	O	O
in	O	O
14	O	O
subjects	O	O
;	O	O
a	O	O
weak	O	O
correlation	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

57	O	O
,	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
between	O	O
the	O	O
tissue	O	O
concentrations	O	O
of	O	O
VIP	O	O
and	O	O
norepinephrine	B-Chemical	D009638
was	O	O
noted	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Interstrain	O	O
variation	O	O
in	O	O
acute	O	O
toxic	O	O
response	O	O
to	O	O
caffeine	B-Chemical	D002110
among	O	O
inbred	O	O
mice	O	O
.	O	O

Acute	O	O
toxic	O	O
dosage	O	O
-	O	O
dependent	O	O
behavioral	O	O
effects	O	O
of	O	O
caffeine	B-Chemical	D002110
were	O	O
compared	O	O
in	O	O
adult	O	O
males	O	O
from	O	O
seven	O	O
inbred	O	O
mouse	O	O
strains	O	O
(	O	O
A	O	O
/	O	O
J	O	O
,	O	O
BALB	O	O
/	O	O
cJ	O	O
,	O	O
CBA	O	O
/	O	O
J	O	O
,	O	O
C3H	O	O
/	O	O
HeJ	O	O
,	O	O
C57BL	O	O
/	O	O
6J	O	O
,	O	O
DBA	O	O
/	O	O
2J	O	O
,	O	O
SWR	O	O
/	O	O
J	O	O
)	O	O
.	O	O

C57BL	O	O
/	O	O
6J	O	O
,	O	O
chosen	O	O
as	O	O
a	O	O
"prototypic"	O	O
mouse	O	O
strain	O	O
,	O	O
was	O	O
used	O	O
to	O	O
determine	O	O
behavioral	O	O
responses	O	O
to	O	O
a	O	O
broad	O	O
range	O	O
(	O	O
5	O	O
-	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
of	O	O
caffeine	B-Chemical	D002110
doses	O	O
.	O	O

Five	O	O
phenotypic	O	O
characteristics	O	O
-	O	O
-	O	O
locomotor	O	O
activity	O	O
,	O	O
righting	O	O
ability	O	O
,	O	O
clonic	B-Disease	D012640
seizure	I-Disease	D012640
induction	O	O
,	O	O
stress	O	O
-	O	O
induced	O	O
lethality	O	O
,	O	O
death	O	O
without	O	O
external	O	O
stress	O	O
-	O	O
-	O	O
were	O	O
scored	O	O
at	O	O
various	O	O
caffeine	B-Chemical	D002110
doses	O	O
in	O	O
drug	O	O
-	O	O
naive	O	O
animals	O	O
under	O	O
empirically	O	O
optimized	O	O
,	O	O
rigidly	O	O
constant	O	O
experimental	O	O
conditions	O	O
.	O	O

Mice	O	O
(	O	O
n	O	O
=	O	O
12	O	O
for	O	O
each	O	O
point	O	O
)	O	O
received	O	O
single	O	O
IP	O	O
injections	O	O
of	O	O
a	O	O
fixed	O	O
volume	O	O
/	O	O
g	O	O
body	O	O
weight	O	O
of	O	O
physiological	O	O
saline	O	O
carrier	O	O
with	O	O
or	O	O
without	O	O
caffeine	B-Chemical	D002110
in	O	O
doses	O	O
ranging	O	O
from	O	O
125	O	O
-	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Loss	O	O
of	O	O
righting	O	O
ability	O	O
was	O	O
scored	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
5	O	O
min	O	O
post	O	O
dosing	O	O
and	O	O
at	O	O
5	O	O
min	O	O
intervals	O	O
thereafter	O	O
for	O	O
20	O	O
min	O	O
.	O	O

In	O	O
the	O	O
same	O	O
animals	O	O
the	O	O
occurrence	O	O
of	O	O
clonic	B-Disease	D012640
seizures	I-Disease	D012640
was	O	O
scored	O	O
as	O	O
to	O	O
time	O	O
of	O	O
onset	O	O
and	O	O
severity	O	O
for	O	O
20	O	O
min	O	O
after	O	O
drug	O	O
administration	O	O
.	O	O

When	O	O
these	O	O
proceeded	O	O
to	O	O
tonic	B-Disease	D012640
seizures	I-Disease	D012640
,	O	O
death	O	O
occurred	O	O
in	O	O
less	O	O
than	O	O
20	O	O
min	O	O
.	O	O

Animals	O	O
surviving	O	O
for	O	O
20	O	O
min	O	O
were	O	O
immediately	O	O
stressed	O	O
by	O	O
a	O	O
swim	O	O
test	O	O
in	O	O
25	O	O
degrees	O	O
C	O	O
water	O	O
,	O	O
and	O	O
death	O	O
-	O	O
producing	O	O
tonic	B-Disease	D012640
seizures	I-Disease	D012640
were	O	O
scored	O	O
for	O	O
2	O	O
min	O	O
.	O	O

In	O	O
other	O	O
animals	O	O
locomotor	O	O
activity	O	O
was	O	O
measured	O	O
15	O	O
or	O	O
60	O	O
min	O	O
after	O	O
caffeine	B-Chemical	D002110
administration	O	O
.	O	O

By	O	O
any	O	O
single	O	O
behavioral	O	O
criterion	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
these	O	O
criteria	O	O
,	O	O
marked	O	O
differences	O	O
in	O	O
response	O	O
to	O	O
toxic	O	O
caffeine	B-Chemical	D002110
doses	O	O
were	O	O
observed	O	O
between	O	O
strains	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
behavioral	O	O
toxicity	B-Disease	D064420
testing	O	O
of	O	O
alkylxanthines	B-Chemical	-1
in	O	O
a	O	O
single	O	O
mouse	O	O
strain	O	O
may	O	O
be	O	O
misleading	O	O
and	O	O
suggest	O	O
that	O	O
toxic	O	O
responses	O	O
of	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
to	O	O
this	O	O
class	O	O
of	O	O
compounds	O	O
are	O	O
genetically	O	O
influenced	O	O
in	O	O
mammals	O	O
.	O	O

Invasive	O	O
carcinoma	B-Disease	D010386
of	I-Disease	D010386
the	I-Disease	D010386
renal	I-Disease	D010386
pelvis	I-Disease	D010386
following	O	O
cyclophosphamide	B-Chemical	D003520
therapy	O	O
for	O	O
nonmalignant	O	O
disease	O	O
.	O	O

A	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
right	O	O
hydroureteronephrosis	B-Disease	D006869
due	O	O
to	O	O
ureterovesical	O	O
junction	O	O
obstruction	O	O
had	O	O
gross	O	O
hematuria	B-Disease	D006417
after	O	O
being	O	O
treated	O	O
for	O	O
five	O	O
years	O	O
wtih	O	O
cyclophosphamide	B-Chemical	D003520
for	O	O
cerebral	B-Disease	D020293
vasculitis	I-Disease	D020293
.	O	O

A	O	O
right	O	O
nephroureterectomy	O	O
was	O	O
required	O	O
for	O	O
control	O	O
of	O	O
bleeding	B-Disease	D006470
.	O	O

The	O	O
pathology	O	O
specimen	O	O
contained	O	O
clinically	O	O
occult	O	O
invasive	O	O
carcinoma	B-Disease	D010386
of	I-Disease	D010386
the	I-Disease	D010386
renal	I-Disease	D010386
pelvis	I-Disease	D010386
.	O	O

Although	O	O
the	O	O
ability	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
to	O	O
cause	O	O
hemorrhagic	O	O
cystitis	O	O
and	O	O
urine	O	O
cytologic	O	O
abnormalities	O	O
indistinguishable	O	O
from	O	O
high	O	O
grade	O	O
carcinoma	B-Disease	D002277
is	O	O
well	O	O
known	O	O
,	O	O
it	O	O
is	O	O
less	O	O
widely	O	O
appreciated	O	O
that	O	O
it	O	O
is	O	O
also	O	O
associated	O	O
with	O	O
carcinoma	B-Disease	D002277
of	O	O
the	O	O
urinary	O	O
tract	O	O
.	O	O

Twenty	O	O
carcinomas	B-Disease	D001749
of	I-Disease	D001749
the	I-Disease	D001749
urinary	I-Disease	D001749
bladder	I-Disease	D001749
and	O	O
one	O	O
carcinoma	B-Disease	D002277
of	O	O
the	O	O
prostate	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
its	O	O
use	O	O
.	O	O

The	O	O
present	O	O
case	O	O
is	O	O
the	O	O
first	O	O
carcinoma	B-Disease	D010386
of	I-Disease	D010386
the	I-Disease	D010386
renal	I-Disease	D010386
pelvis	I-Disease	D010386
reported	O	O
in	O	O
association	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
treatment	O	O
.	O	O

It	O	O
is	O	O
the	O	O
third	O	O
urinary	B-Disease	D014571
tract	I-Disease	D014571
cancer	I-Disease	D014571
reported	O	O
in	O	O
association	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
treatment	O	O
for	O	O
nonmalignant	O	O
disease	O	O
.	O	O

The	O	O
association	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
with	O	O
preexisting	O	O
hydroureteronephrosis	B-Disease	D006869
suggests	O	O
that	O	O
stasis	O	O
prolonged	O	O
and	O	O
intensified	O	O
exposure	O	O
of	O	O
upper	O	O
urinary	O	O
tract	O	O
epithelium	O	O
to	O	O
cyclophosphamide	B-Chemical	D003520
.	O	O

Patients	O	O
who	O	O
are	O	O
candidates	O	O
for	O	O
long	O	O
-	O	O
term	O	O
cyclophosphamide	B-Chemical	D003520
treatment	O	O
should	O	O
be	O	O
routinely	O	O
evaluated	O	O
for	O	O
obstructive	B-Disease	-1
uropathy	I-Disease	-1
.	O	O

Ascending	O	O
dose	O	O
tolerance	O	O
study	O	O
of	O	O
intramuscular	O	O
carbetocin	B-Chemical	C020731
administered	O	O
after	O	O
normal	O	O
vaginal	O	O
birth	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
maximum	O	O
tolerated	O	O
dose	O	O
(	O	O
MTD	O	O
)	O	O
of	O	O
carbetocin	B-Chemical	C020731
(	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
synthetic	O	O
analogue	O	O
of	O	O
oxytocin	B-Chemical	D010121
)	O	O
,	O	O
when	O	O
administered	O	O
immediately	O	O
after	O	O
vaginal	O	O
delivery	O	O
at	O	O
term	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Carbetocin	B-Chemical	C020731
was	O	O
given	O	O
as	O	O
an	O	O
intramuscular	O	O
injection	O	O
immediately	O	O
after	O	O
the	O	O
birth	O	O
of	O	O
the	O	O
infant	O	O
in	O	O
45	O	O
healthy	O	O
women	O	O
with	O	O
normal	O	O
singleton	O	O
pregnancies	O	O
who	O	O
delivered	O	O
vaginally	O	O
at	O	O
term	O	O
.	O	O

Dosage	O	O
groups	O	O
of	O	O
15	O	O
,	O	O
30	O	O
,	O	O
50	O	O
,	O	O
75	O	O
,	O	O
100	O	O
,	O	O
125	O	O
,	O	O
150	O	O
,	O	O
175	O	O
or	O	O
200	O	O
microg	O	O
carbetocin	B-Chemical	C020731
were	O	O
assigned	O	O
to	O	O
blocks	O	O
of	O	O
three	O	O
women	O	O
according	O	O
to	O	O
the	O	O
continual	O	O
reassessment	O	O
method	O	O
(	O	O
CRM	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
dosage	O	O
groups	O	O
consisted	O	O
of	O	O
three	O	O
women	O	O
,	O	O
except	O	O
those	O	O
with	O	O
100	O	O
microg	O	O
(	O	O
n=6	O	O
)	O	O
and	O	O
200	O	O
microg	O	O
(	O	O
n=18	O	O
)	O	O
.	O	O

Recorded	O	O
were	O	O
dose	O	O
-	O	O
limiting	O	O
adverse	O	O
events	O	O
:	O	O
hyper	B-Disease	D006973
-	I-Disease	D006973
or	I-Disease	D006973
hypotension	I-Disease	D006973
(	O	O
three	O	O
)	O	O
,	O	O
severe	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
(	O	O
0	O	O
)	O	O
,	O	O
vomiting	B-Disease	D014839
(	O	O
0	O	O
)	O	O
and	O	O
retained	B-Disease	D018457
placenta	I-Disease	D018457
(	O	O
four	O	O
)	O	O
.	O	O

Serious	O	O
adverse	O	O
events	O	O
occurred	O	O
in	O	O
seven	O	O
women	O	O
:	O	O
six	O	O
cases	O	O
with	O	O
blood	B-Disease	D006473
loss	I-Disease	D006473
>	O	O
or	O	O
=	O	O
1000	O	O
ml	O	O
,	O	O
four	O	O
cases	O	O
of	O	O
manual	O	O
placenta	O	O
removal	O	O
,	O	O
five	O	O
cases	O	O
of	O	O
additional	O	O
oxytocics	O	O
administration	O	O
and	O	O
five	O	O
cases	O	O
of	O	O
blood	O	O
transfusion	O	O
.	O	O

Maximum	O	O
blood	B-Disease	D006473
loss	I-Disease	D006473
was	O	O
greatest	O	O
at	O	O
the	O	O
upper	O	O
and	O	O
lower	O	O
dose	O	O
levels	O	O
,	O	O
and	O	O
lowest	O	O
in	O	O
the	O	O
70	O	O
-	O	O
125	O	O
microg	O	O
dose	O	O
range	O	O
.	O	O

Four	O	O
out	O	O
of	O	O
six	O	O
cases	O	O
with	O	O
blood	B-Disease	D006473
loss	I-Disease	D006473
>	O	O
or	O	O
=	O	O
1000	O	O
ml	O	O
occurred	O	O
in	O	O
the	O	O
200	O	O
microg	O	O
group	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
additional	O	O
administration	O	O
of	O	O
oxytocics	O	O
(	O	O
4	O	O
/	O	O
5	O	O
)	O	O
and	O	O
blood	O	O
transfusion	O	O
(	O	O
3	O	O
/	O	O
5	O	O
)	O	O
occurred	O	O
in	O	O
the	O	O
dose	O	O
groups	O	O
of	O	O
200	O	O
microg	O	O
.	O	O

All	O	O
retained	O	O
placentae	O	O
were	O	O
found	O	O
in	O	O
the	O	O
group	O	O
of	O	O
200	O	O
microg	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
MTD	O	O
was	O	O
calculated	O	O
to	O	O
be	O	O
at	O	O
200	O	O
microg	O	O
carbetocin	B-Chemical	C020731
.	O	O

A	O	O
pilot	O	O
study	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
dobutamine	B-Chemical	D004280
stress	O	O
echocardiography	O	O
in	O	O
the	O	O
emergency	O	O
department	O	O
evaluation	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
Chest	B-Disease	D002637
pain	I-Disease	D002637
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-Chemical	D003042
use	O	O
poses	O	O
a	O	O
diagnostic	O	O
dilemma	O	O
.	O	O

Dobutamine	B-Chemical	D004280
stress	O	O
echocardiography	O	O
(	O	O
DSE	O	O
)	O	O
is	O	O
a	O	O
widely	O	O
available	O	O
and	O	O
sensitive	O	O
test	O	O
for	O	O
evaluating	O	O
cardiac	O	O
ischemia	B-Disease	D007511
.	O	O

Because	O	O
of	O	O
the	O	O
theoretical	O	O
concern	O	O
regarding	O	O
administration	O	O
of	O	O
dobutamine	B-Chemical	D004280
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-Chemical	D003042
use	O	O
,	O	O
we	O	O
conducted	O	O
a	O	O
pilot	O	O
study	O	O
to	O	O
assess	O	O
the	O	O
safety	O	O
of	O	O
DSE	O	O
in	O	O
emergency	O	O
department	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

METHODS	O	O
:	O	O
A	O	O
prospective	O	O
case	O	O
series	O	O
was	O	O
conducted	O	O
in	O	O
the	O	O
intensive	O	O
diagnostic	O	O
and	O	O
treatment	O	O
unit	O	O
in	O	O
the	O	O
ED	O	O
of	O	O
an	O	O
urban	O	O
tertiary	O	O
-	O	O
care	O	O
teaching	O	O
hospital	O	O
.	O	O

Patients	O	O
were	O	O
eligible	O	O
for	O	O
DSE	O	O
if	O	O
they	O	O
had	O	O
used	O	O
cocaine	B-Chemical	D003042
within	O	O
24	O	O
hours	O	O
preceding	O	O
the	O	O
onset	O	O
of	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
and	O	O
had	O	O
a	O	O
normal	O	O
ECG	O	O
and	O	O
tropinin	O	O
I	O	O
level	O	O
.	O	O

Patients	O	O
exhibiting	O	O
signs	O	O
of	O	O
continuing	O	O
cocaine	B-Chemical	D003042
toxicity	B-Disease	D064420
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
serial	O	O
testing	O	O
after	O	O
the	O	O
DSE	O	O
testing	O	O
in	O	O
the	O	O
intensive	O	O
diagnostic	O	O
and	O	O
treatment	O	O
unit	O	O
.	O	O

RESULTS	O	O
:	O	O
Twenty	O	O
-	O	O
four	O	O
patients	O	O
were	O	O
enrolled	O	O
.	O	O

Two	O	O
patients	O	O
had	O	O
inadequate	O	O
resting	O	O
images	O	O
,	O	O
one	O	O
DSE	O	O
was	O	O
terminated	O	O
because	O	O
of	O	O
inferior	O	O
hypokinesis	B-Disease	D018476
,	O	O
another	O	O
DSE	O	O
was	O	O
terminated	O	O
because	O	O
of	O	O
a	O	O
rate	O	O
-	O	O
related	O	O
atrial	O	O
conduction	O	O
deficit	O	O
,	O	O
and	O	O
1	O	O
patient	O	O
did	O	O
not	O	O
reach	O	O
the	O	O
target	O	O
heart	O	O
rate	O	O
.	O	O

Thus	O	O
,	O	O
19	O	O
patients	O	O
completed	O	O
a	O	O
DSE	O	O
and	O	O
reached	O	O
their	O	O
target	O	O
heart	O	O
rates	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
experienced	O	O
signs	O	O
of	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
,	O	O
which	O	O
was	O	O
defined	O	O
as	O	O
a	O	O
systolic	O	O
blood	O	O
pressure	O	O
of	O	O
greater	O	O
than	O	O
200	O	O
mm	O	O
Hg	O	O
or	O	O
the	O	O
occurrence	O	O
of	O	O
tachydysrhythmias	B-Disease	-1
(	O	O
excluding	O	O
sinus	B-Disease	D013616
tachycardia	I-Disease	D013616
)	O	O
.	O	O

Further	O	O
suggesting	O	O
lack	O	O
of	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
,	O	O
13	O	O
(	O	O
65%	O	O
)	O	O
of	O	O
20	O	O
patients	O	O
required	O	O
supplemental	O	O
atropine	B-Chemical	D001285
to	O	O
reach	O	O
their	O	O
target	O	O
heart	O	O
rates	O	O
.	O	O

CONCLUSION	O	O
:	O	O
No	O	O
exaggerated	O	O
adrenergic	O	O
response	O	O
was	O	O
detected	O	O
when	O	O
dobutamine	B-Chemical	D004280
was	O	O
administered	O	O
to	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
related	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

Amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
during	O	O
bladder	O	O
irrigation	O	O
:	O	O
an	O	O
unusual	O	O
presentation	O	O
-	O	O
-	O	O
a	O	O
case	O	O
report	O	O
.	O	O

The	O	O
authors	O	O
present	O	O
a	O	O
case	O	O
of	O	O
early	O	O
(	O	O
within	O	O
4	O	O
days	O	O
)	O	O
development	O	O
of	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
TdP	B-Disease	D016171
)	O	O
associated	O	O
with	O	O
oral	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
.	O	O

Consistent	O	O
with	O	O
other	O	O
reports	O	O
this	O	O
case	O	O
of	O	O
TdP	B-Disease	D016171
occurred	O	O
in	O	O
the	O	O
context	O	O
of	O	O
multiple	O	O
exacerbating	O	O
factors	O	O
including	O	O
hypokalemia	B-Disease	D007008
and	O	O
digoxin	B-Chemical	D004077
excess	O	O
.	O	O

Transient	O	O
prolongation	O	O
of	O	O
the	O	O
QT	O	O
during	O	O
bladder	O	O
irrigation	O	O
prompted	O	O
the	O	O
episode	O	O
of	O	O
TdP	B-Disease	D016171
.	O	O

It	O	O
is	O	O
well	O	O
known	O	O
that	O	O
bradycardia	B-Disease	D001919
exacerbates	O	O
acquired	O	O
TdP	B-Disease	D016171
.	O	O

The	O	O
authors	O	O
speculate	O	O
that	O	O
the	O	O
increased	O	O
vagal	O	O
tone	O	O
during	O	O
bladder	O	O
irrigation	O	O
,	O	O
a	O	O
vagal	O	O
maneuver	O	O
,	O	O
in	O	O
the	O	O
context	O	O
of	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
resulted	O	O
in	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
proarrhythmia	B-Disease	-1
.	O	O

In	O	O
the	O	O
absence	O	O
of	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
,	O	O
a	O	O
second	O	O
bladder	O	O
irrigation	O	O
did	O	O
not	O	O
induce	O	O
TdP	B-Disease	D016171
despite	O	O
hypokalemia	B-Disease	D007008
and	O	O
hypomagnesemia	B-Disease	C537153
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
insufficiency	I-Disease	D058186
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-Chemical	D008558
in	O	O
patients	O	O
with	O	O
primary	B-Disease	C531616
systemic	I-Disease	C531616
amyloidosis	I-Disease	C531616
during	O	O
stem	O	O
cell	O	O
transplantation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Patients	O	O
with	O	O
primary	B-Disease	C531616
systemic	I-Disease	C531616
amyloidosis	I-Disease	C531616
(	O	O
AL	B-Disease	D000686
)	O	O
have	O	O
a	O	O
poor	O	O
prognosis	O	O
.	O	O

Median	O	O
survival	O	O
time	O	O
from	O	O
standard	O	O
treatments	O	O
is	O	O
only	O	O
17	O	O
months	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
intravenous	O	O
melphalan	B-Chemical	D008558
followed	O	O
by	O	O
peripheral	O	O
blood	O	O
stem	O	O
cell	O	O
transplant	O	O
(	O	O
PBSCT	O	O
)	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
most	O	O
promising	O	O
therapy	O	O
,	O	O
but	O	O
treatment	O	O
mortality	O	O
can	O	O
be	O	O
high	O	O
.	O	O

The	O	O
authors	O	O
have	O	O
noted	O	O
the	O	O
development	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
insufficiency	I-Disease	D058186
immediately	O	O
after	O	O
melphalan	B-Chemical	D008558
conditioning	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
further	O	O
examine	O	O
its	O	O
risk	O	O
factors	O	O
and	O	O
impact	O	O
on	O	O
posttransplant	O	O
mortality	O	O
.	O	O

METHODS	O	O
:	O	O
Consecutive	O	O
AL	B-Disease	D000686
patients	O	O
who	O	O
underwent	O	O
PBSCT	O	O
were	O	O
studied	O	O
retrospectively	O	O
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
insufficiency	I-Disease	D058186
(	O	O
ARI	B-Disease	D058186
)	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-Chemical	D008558
was	O	O
defined	O	O
by	O	O
a	O	O
minimum	O	O
increase	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
(	O	O
44	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
in	O	O
the	O	O
serum	O	O
creatinine	B-Chemical	D003404
level	O	O
that	O	O
is	O	O
greater	O	O
than	O	O
50%	O	O
of	O	O
baseline	O	O
immediately	O	O
after	O	O
conditioning	O	O
.	O	O

Urine	O	O
sediment	O	O
score	O	O
was	O	O
the	O	O
sum	O	O
of	O	O
the	O	O
individual	O	O
types	O	O
of	O	O
sediment	O	O
identified	O	O
on	O	O
urine	O	O
microscopy	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
80	O	O
patients	O	O
studied	O	O
,	O	O
ARI	B-Disease	D058186
developed	O	O
in	O	O
18	O	O
.	O	O

8%	O	O
of	O	O
the	O	O
patients	O	O
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-Chemical	D008558
.	O	O

Univariate	O	O
analysis	O	O
identified	O	O
age	O	O
,	O	O
hypoalbuminemia	B-Disease	D034141
,	O	O
heavy	O	O
proteinuria	B-Disease	D011507
,	O	O
diuretic	O	O
use	O	O
,	O	O
and	O	O
urine	O	O
sediment	O	O
score	O	O
(	O	O
>3	O	O
)	O	O
as	O	O
risk	O	O
factors	O	O
.	O	O

Age	O	O
and	O	O
urine	O	O
sediment	O	O
score	O	O
remained	O	O
independently	O	O
significant	O	O
risk	O	O
factors	O	O
in	O	O
the	O	O
multivariate	O	O
analysis	O	O
.	O	O

Patients	O	O
who	O	O
had	O	O
ARI	B-Disease	D058186
after	O	O
high	O	O
-	O	O
dose	O	O
melphalan	B-Chemical	D008558
underwent	O	O
dialysis	O	O
more	O	O
often	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

007	O	O
)	O	O
,	O	O
and	O	O
had	O	O
a	O	O
worse	O	O
1	O	O
-	O	O
year	O	O
survival	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
timing	O	O
of	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
strongly	O	O
suggests	O	O
melphalan	B-Chemical	D008558
as	O	O
the	O	O
causative	O	O
agent	O	O
.	O	O

Ongoing	O	O
tubular	B-Disease	-1
injury	I-Disease	-1
may	O	O
be	O	O
a	O	O
prerequisite	O	O
for	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
by	O	O
melphalan	B-Chemical	D008558
as	O	O
evidenced	O	O
by	O	O
the	O	O
active	O	O
urinary	O	O
sediment	O	O
.	O	O

Development	O	O
of	O	O
ARI	B-Disease	D058186
adversely	O	O
affected	O	O
the	O	O
outcome	O	O
after	O	O
PBSCT	O	O
.	O	O

Effective	O	O
preventive	O	O
measures	O	O
may	O	O
help	O	O
decrease	O	O
the	O	O
treatment	O	O
mortality	O	O
of	O	O
PBSCT	O	O
in	O	O
AL	B-Disease	D000686
patients	O	O
.	O	O

Impaired	B-Disease	D001925
fear	I-Disease	D001925
recognition	I-Disease	D001925
in	O	O
regular	O	O
recreational	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

INTRODUCTION	O	O
:	O	O
The	O	O
ability	O	O
to	O	O
read	O	O
facial	O	O
expressions	O	O
is	O	O
essential	O	O
for	O	O
normal	O	O
human	O	O
social	O	O
interaction	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
conduct	O	O
the	O	O
first	O	O
investigation	O	O
of	O	O
facial	O	O
expression	O	O
recognition	O	O
performance	O	O
in	O	O
recreational	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
Three	O	O
groups	O	O
,	O	O
comprised	O	O
of	O	O
21	O	O
cocaine	B-Chemical	D003042
naive	O	O
participants	O	O
(	O	O
CN	O	O
)	O	O
,	O	O
30	O	O
occasional	O	O
cocaine	B-Chemical	D003042
(	O	O
OC	O	O
)	O	O
,	O	O
and	O	O
48	O	O
regular	O	O
recreational	O	O
cocaine	B-Chemical	D003042
(	O	O
RC	O	O
)	O	O
users	O	O
,	O	O
were	O	O
compared	O	O
.	O	O

An	O	O
emotional	O	O
facial	O	O
expression	O	O
(	O	O
EFE	O	O
)	O	O
task	O	O
consisting	O	O
of	O	O
a	O	O
male	O	O
and	O	O
female	O	O
face	O	O
expressing	O	O
six	O	O
basic	O	O
emotions	O	O
(	O	O
happiness	O	O
,	O	O
surprise	O	O
,	O	O
sadness	O	O
,	O	O
anger	O	O
,	O	O
fear	O	O
,	O	O
and	O	O
disgust	O	O
)	O	O
was	O	O
administered	O	O
.	O	O

Mean	O	O
percent	O	O
accuracy	O	O
and	O	O
latencies	O	O
for	O	O
correct	O	O
responses	O	O
across	O	O
eight	O	O
presentations	O	O
of	O	O
each	O	O
basic	O	O
emotion	O	O
were	O	O
derived	O	O
.	O	O

Participants	O	O
were	O	O
also	O	O
assessed	O	O
with	O	O
the	O	O
"Eyes	O	O
task"	O	O
to	O	O
investigate	O	O
their	O	O
ability	O	O
to	O	O
recognize	O	O
more	O	O
complex	O	O
emotional	O	O
states	O	O
and	O	O
the	O	O
Symptom	O	O
CheckList	O	O
-	O	O
90	O	O
-	O	O
Revised	O	O
to	O	O
measure	O	O
psychopathology	O	O
.	O	O

RESULTS	O	O
:	O	O
There	O	O
were	O	O
no	O	O
group	O	O
differences	O	O
in	O	O
psychopathology	O	O
or	O	O
"eyes	O	O
task"	O	O
performance	O	O
,	O	O
but	O	O
the	O	O
RC	O	O
group	O	O
,	O	O
who	O	O
otherwise	O	O
had	O	O
similar	O	O
illicit	O	O
substance	O	O
use	O	O
histories	O	O
to	O	O
the	O	O
OC	O	O
group	O	O
,	O	O
exhibited	O	O
impaired	B-Disease	D001925
fear	I-Disease	D001925
recognition	I-Disease	D001925
accuracy	O	O
compared	O	O
to	O	O
the	O	O
OC	O	O
and	O	O
CN	O	O
groups	O	O
.	O	O

The	O	O
RC	O	O
group	O	O
also	O	O
correctly	O	O
identified	O	O
anger	O	O
,	O	O
fear	O	O
,	O	O
happiness	O	O
,	O	O
and	O	O
surprise	O	O
,	O	O
more	O	O
slowly	O	O
than	O	O
CN	O	O
,	O	O
but	O	O
not	O	O
OC	O	O
participants	O	O
.	O	O

The	O	O
OC	O	O
group	O	O
was	O	O
slower	O	O
than	O	O
CN	O	O
when	O	O
correctly	O	O
identifying	O	O
disgust	O	O
.	O	O

The	O	O
selective	O	O
deficit	B-Disease	D001925
in	I-Disease	D001925
fear	I-Disease	D001925
recognition	I-Disease	D001925
accuracy	O	O
manifested	O	O
by	O	O
the	O	O
RC	O	O
group	O	O
cannot	O	O
be	O	O
explained	O	O
by	O	O
the	O	O
subacute	O	O
effects	O	O
of	O	O
cocaine	B-Chemical	D003042
,	O	O
or	O	O
ecstasy	B-Chemical	D018817
,	O	O
because	O	O
recent	O	O
and	O	O
less	O	O
recent	O	O
users	O	O
of	O	O
these	O	O
drugs	O	O
within	O	O
this	O	O
group	O	O
were	O	O
similarly	O	O
impaired	O	O
.	O	O

Possible	O	O
parallels	O	O
between	O	O
RC	O	O
users	O	O
and	O	O
psychopaths	B-Disease	D001523
with	O	O
respect	O	O
to	O	O
impaired	B-Disease	D001925
fear	I-Disease	D001925
recognition	I-Disease	D001925
,	O	O
amygdala	B-Disease	-1
dysfunction	I-Disease	-1
,	O	O
and	O	O
etiology	O	O
are	O	O
discussed	O	O
.	O	O

Corneal	B-Disease	D003320
ulcers	I-Disease	D003320
associated	O	O
with	O	O
aerosolized	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
use	O	O
.	O	O

PURPOSE	O	O
:	O	O
We	O	O
report	O	O
4	O	O
cases	O	O
of	O	O
corneal	B-Disease	D003320
ulcers	I-Disease	D003320
associated	O	O
with	O	O
drug	B-Disease	D019966
abuse	I-Disease	D019966
.	O	O

The	O	O
pathogenesis	O	O
of	O	O
these	O	O
ulcers	B-Disease	D014456
and	O	O
management	O	O
of	O	O
these	O	O
patients	O	O
are	O	O
also	O	O
reviewed	O	O
.	O	O

METHODS	O	O
:	O	O
Review	O	O
of	O	O
all	O	O
cases	O	O
of	O	O
corneal	B-Disease	D003320
ulcers	I-Disease	D003320
associated	O	O
with	O	O
drug	B-Disease	D019966
abuse	I-Disease	D019966
seen	O	O
at	O	O
our	O	O
institution	O	O
from	O	O
July	O	O
2006	O	O
to	O	O
December	O	O
2006	O	O
.	O	O

RESULTS	O	O
:	O	O
Four	O	O
patients	O	O
with	O	O
corneal	B-Disease	D003320
ulcers	I-Disease	D003320
associated	O	O
with	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
use	O	O
were	O	O
reviewed	O	O
.	O	O

All	O	O
corneal	B-Disease	D003320
ulcers	I-Disease	D003320
were	O	O
cultured	O	O
,	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
intensive	O	O
topical	O	O
antibiotic	O	O
treatment	O	O
.	O	O

Each	O	O
patient	O	O
received	O	O
comprehensive	O	O
health	O	O
care	O	O
,	O	O
including	O	O
medical	O	O
and	O	O
substance	B-Disease	D019966
abuse	I-Disease	D019966
consultations	O	O
.	O	O

Streptococcal	O	O
organisms	O	O
were	O	O
found	O	O
in	O	O
3	O	O
cases	O	O
and	O	O
Capnocytophaga	O	O
and	O	O
Brevibacterium	O	O
casei	O	O
in	O	O
1	O	O
patient	O	O
.	O	O

The	O	O
infections	B-Disease	D007239
responded	O	O
to	O	O
antibiotic	O	O
treatment	O	O
.	O	O

Two	O	O
patients	O	O
needed	O	O
a	O	O
lateral	O	O
tarsorrhaphy	O	O
for	O	O
persistent	O	O
epithelial	B-Disease	-1
defects	I-Disease	-1
.	O	O

CONCLUSIONS	O	O
:	O	O
Aerosolized	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
use	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
corneal	B-Disease	D003320
ulcers	I-Disease	D003320
.	O	O

Drug	B-Disease	D019966
abuse	I-Disease	D019966
provides	O	O
additional	O	O
challenges	O	O
for	O	O
management	O	O
.	O	O

Not	O	O
only	O	O
treatment	O	O
of	O	O
their	O	O
infections	B-Disease	D007239
but	O	O
also	O	O
the	O	O
overall	O	O
poor	O	O
health	O	O
of	O	O
the	O	O
patients	O	O
and	O	O
increased	O	O
risk	O	O
of	O	O
noncompliance	O	O
need	O	O
to	O	O
be	O	O
addressed	O	O
.	O	O

Comprehensive	O	O
care	O	O
may	O	O
provide	O	O
the	O	O
patient	O	O
the	O	O
opportunity	O	O
to	O	O
discontinue	O	O
their	O	O
substance	B-Disease	D019966
abuse	I-Disease	D019966
,	O	O
improve	O	O
their	O	O
overall	O	O
health	O	O
,	O	O
and	O	O
prevent	O	O
future	O	O
corneal	O	O
complications	O	O
.	O	O

Levetiracetam	B-Chemical	C026098
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-Chemical	D010634
treatment	O	O
in	O	O
cats	O	O
with	O	O
suspected	O	O
idiopathic	B-Disease	C562694
epilepsy	I-Disease	C562694
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
pharmacokinetics	O	O
,	O	O
efficacy	O	O
,	O	O
and	O	O
tolerability	O	O
of	O	O
oral	O	O
levetiracetam	B-Chemical	C026098
administered	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-Chemical	D010634
treatment	O	O
in	O	O
cats	O	O
with	O	O
poorly	O	O
controlled	O	O
suspected	O	O
idiopathic	B-Disease	C562694
epilepsy	I-Disease	C562694
.	O	O

DESIGN	O	O
-	O	O
Open	O	O
-	O	O
label	O	O
,	O	O
noncomparative	O	O
clinical	O	O
trial	O	O
.	O	O

ANIMALS	O	O
:	O	O
12	O	O
cats	O	O
suspected	O	O
to	O	O
have	O	O
idiopathic	B-Disease	C562694
epilepsy	I-Disease	C562694
that	O	O
was	O	O
poorly	O	O
controlled	O	O
with	O	O
phenobarbital	B-Chemical	D010634
or	O	O
that	O	O
had	O	O
unacceptable	O	O
adverse	O	O
effects	O	O
when	O	O
treated	O	O
with	O	O
phenobarbital	B-Chemical	D010634
.	O	O

PROCEDURES	O	O
:	O	O
Cats	O	O
were	O	O
treated	O	O
with	O	O
levetiracetam	B-Chemical	C026098
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
[	O	O
9	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
lb	O	O
]	O	O
,	O	O
PO	O	O
,	O	O
q	O	O
8	O	O
h	O	O
)	O	O
.	O	O

After	O	O
a	O	O
minimum	O	O
of	O	O
1	O	O
week	O	O
of	O	O
treatment	O	O
,	O	O
serum	O	O
levetiracetam	B-Chemical	C026098
concentrations	O	O
were	O	O
measured	O	O
before	O	O
and	O	O
2	O	O
,	O	O
4	O	O
,	O	O
and	O	O
6	O	O
hours	O	O
after	O	O
drug	O	O
administration	O	O
,	O	O
and	O	O
maximum	O	O
and	O	O
minimum	O	O
serum	O	O
concentrations	O	O
and	O	O
elimination	O	O
half	O	O
-	O	O
life	O	O
were	O	O
calculated	O	O
.	O	O

Seizure	B-Disease	D012640
frequencies	O	O
before	O	O
and	O	O
after	O	O
initiation	O	O
of	O	O
levetiracetam	B-Chemical	C026098
treatment	O	O
were	O	O
compared	O	O
,	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
recorded	O	O
.	O	O

RESULTS	O	O
:	O	O
Median	O	O
maximum	O	O
serum	O	O
levetiracetam	B-Chemical	C026098
concentration	O	O
was	O	O
25	O	O
.	O	O

5	O	O
microg	O	O
/	O	O
mL	O	O
,	O	O
median	O	O
minimum	O	O
serum	O	O
levetiracetam	B-Chemical	C026098
concentration	O	O
was	O	O
8	O	O
.	O	O

3	O	O
microg	O	O
/	O	O
mL	O	O
,	O	O
and	O	O
median	O	O
elimination	O	O
half	O	O
-	O	O
life	O	O
was	O	O
2	O	O
.	O	O

9	O	O
hours	O	O
.	O	O

Median	O	O
seizure	B-Disease	D012640
frequency	O	O
prior	O	O
to	O	O
treatment	O	O
with	O	O
levetiracetam	B-Chemical	C026098
(	O	O
2	O	O
.	O	O

1	O	O
seizures	B-Disease	D012640
/	O	O
mo	O	O
)	O	O
was	O	O
significantly	O	O
higher	O	O
than	O	O
median	O	O
seizure	B-Disease	D012640
frequency	O	O
after	O	O
initiation	O	O
of	O	O
levetiracetam	B-Chemical	C026098
treatment	O	O
(	O	O
0	O	O
.	O	O

42	O	O
seizures	B-Disease	D012640
/	O	O
mo	O	O
)	O	O
,	O	O
and	O	O
7	O	O
of	O	O
10	O	O
cats	O	O
were	O	O
classified	O	O
as	O	O
having	O	O
responded	O	O
to	O	O
levetiracetam	B-Chemical	C026098
treatment	O	O
(	O	O
ie	O	O
,	O	O
reduction	O	O
in	O	O
seizure	B-Disease	D012640
frequency	O	O
of	O	O
>or=50%	O	O
)	O	O
.	O	O

Two	O	O
cats	O	O
had	O	O
transient	O	O
lethargy	B-Disease	D053609
and	O	O
inappetence	B-Disease	-1
.	O	O

CONCLUSIONS	O	O
AND	O	O
CLINICAL	O	O
RELEVANCE	O	O
:	O	O
Results	O	O
suggested	O	O
that	O	O
levetiracetam	B-Chemical	C026098
is	O	O
well	O	O
tolerated	O	O
in	O	O
cats	O	O
and	O	O
may	O	O
be	O	O
useful	O	O
as	O	O
an	O	O
adjunct	O	O
to	O	O
phenobarbital	B-Chemical	D010634
treatment	O	O
in	O	O
cats	O	O
with	O	O
idiopathic	B-Disease	C562694
epilepsy	I-Disease	C562694
.	O	O

Bilateral	O	O
haemorrhagic	O	O
infarction	O	O
of	O	O
the	O	O
globus	O	O
pallidus	O	O
after	O	O
cocaine	B-Chemical	D003042
and	O	O
alcohol	B-Chemical	D000431
intoxication	O	O
.	O	O

Cocaine	B-Chemical	D003042
is	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
both	O	O
ischemic	O	O
and	O	O
haemorrhagic	O	O
stroke	O	O
.	O	O

We	O	O
present	O	O
the	O	O
case	O	O
of	O	O
a	O	O
31	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
bilateral	O	O
ischemia	B-Disease	D002545
of	I-Disease	D002545
the	I-Disease	D002545
globus	I-Disease	D002545
pallidus	I-Disease	D002545
after	O	O
excessive	O	O
alcohol	B-Chemical	D000431
and	O	O
intranasal	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

Drug	O	O
-	O	O
related	O	O
globus	B-Disease	D020520
pallidus	I-Disease	D020520
infarctions	I-Disease	D020520
are	O	O
most	O	O
often	O	O
associated	O	O
with	O	O
heroin	B-Chemical	D003932
.	O	O

Bilateral	O	O
basal	B-Disease	D020520
ganglia	I-Disease	D020520
infarcts	I-Disease	D020520
after	O	O
the	O	O
use	O	O
of	O	O
cocaine	B-Chemical	D003042
,	O	O
without	O	O
concurrent	O	O
heroin	B-Chemical	D003932
use	O	O
,	O	O
have	O	O
never	O	O
been	O	O
reported	O	O
.	O	O

In	O	O
our	O	O
patient	O	O
,	O	O
transient	O	O
cardiac	B-Disease	D001145
arrhythmia	I-Disease	D001145
or	O	O
respiratory	B-Disease	D012131
dysfunction	I-Disease	D012131
related	O	O
to	O	O
cocaine	B-Chemical	D003042
and	O	O
/	O	O
or	O	O
ethanol	B-Chemical	D000431
use	O	O
were	O	O
the	O	O
most	O	O
likely	O	O
causes	O	O
of	O	O
cerebral	B-Disease	-1
hypoperfusion	I-Disease	-1
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
after	O	O
high	O	O
-	O	O
dose	O	O
methotrexate	B-Chemical	D008727
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ileostomy	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
methotrexate	B-Chemical	D008727
(	O	O
HD	O	O
-	O	O
MTX	B-Chemical	D008727
)	O	O
is	O	O
an	O	O
important	O	O
treatment	O	O
for	O	O
Burkitt	B-Disease	D002051
lymphoma	I-Disease	D002051
,	O	O
but	O	O
can	O	O
cause	O	O
hepatic	O	O
and	O	O
renal	O	O
toxicity	O	O
when	O	O
its	O	O
clearance	O	O
is	O	O
delayed	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
after	O	O
HD	O	O
-	O	O
MTX	B-Chemical	D008727
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
ileostomy	O	O
,	O	O
The	O	O
patient	O	O
was	O	O
a	O	O
3	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
had	O	O
received	O	O
a	O	O
living	O	O
-	O	O
related	O	O
liver	O	O
transplantation	O	O
for	O	O
congenital	O	O
biliary	B-Disease	D001656
atresia	I-Disease	D001656
.	O	O

At	O	O
day	O	O
833	O	O
after	O	O
the	O	O
transplantation	O	O
,	O	O
he	O	O
was	O	O
diagnosed	O	O
with	O	O
PTLD	B-Disease	D008232
(	O	O
post	B-Disease	D008232
-	I-Disease	D008232
transplantation	I-Disease	D008232
lymphoproliferative	I-Disease	D008232
disorder	I-Disease	D008232
,	O	O
Burkitt	B-Disease	D002051
-	I-Disease	D002051
type	I-Disease	D002051
malignant	I-Disease	D002051
lymphoma	I-Disease	D002051
)	O	O
.	O	O

During	O	O
induction	O	O
therapy	O	O
,	O	O
he	O	O
suffered	O	O
ileal	O	O
perforation	O	O
and	O	O
ileostomy	O	O
was	O	O
performed	O	O
.	O	O

Subsequent	O	O
HD	O	O
-	O	O
MTX	B-Chemical	D008727
therapy	O	O
caused	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
that	O	O
required	O	O
continuous	O	O
hemodialysis	O	O
.	O	O

We	O	O
supposed	O	O
that	O	O
intravascular	O	O
hypovolemia	B-Disease	D020896
due	O	O
to	O	O
substantial	O	O
drainage	O	O
from	O	O
the	O	O
ileostoma	O	O
caused	O	O
acute	B-Disease	-1
prerenal	I-Disease	-1
failure	I-Disease	-1
.	O	O

After	O	O
recovery	O	O
of	O	O
his	O	O
renal	O	O
function	O	O
,	O	O
we	O	O
could	O	O
safely	O	O
treat	O	O
the	O	O
patient	O	O
with	O	O
HD	O	O
-	O	O
MTX	B-Chemical	D008727
therapy	O	O
by	O	O
controlling	O	O
drainage	O	O
from	O	O
ileostoma	O	O
with	O	O
total	O	O
parenteral	O	O
nutrition	O	O
.	O	O

Antithrombotic	O	O
drug	O	O
use	O	O
,	O	O
cerebral	B-Disease	-1
microbleeds	I-Disease	-1
,	O	O
and	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
:	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
published	O	O
and	O	O
unpublished	O	O
studies	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
PURPOSE	O	O
:	O	O
Cerebral	B-Disease	-1
microbleeds	I-Disease	-1
(	O	O
MB	B-Disease	-1
)	O	O
are	O	O
potential	O	O
risk	O	O
factors	O	O
for	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
(	O	O
ICH	B-Disease	D002543
)	O	O
,	O	O
but	O	O
it	O	O
is	O	O
unclear	O	O
if	O	O
they	O	O
are	O	O
a	O	O
contraindication	O	O
to	O	O
using	O	O
antithrombotic	O	O
drugs	O	O
.	O	O

Insights	O	O
could	O	O
be	O	O
gained	O	O
by	O	O
pooling	O	O
data	O	O
on	O	O
MB	B-Disease	-1
frequency	O	O
stratified	O	O
by	O	O
antithrombotic	O	O
use	O	O
in	O	O
cohorts	O	O
with	O	O
ICH	B-Disease	D002543
and	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
(	O	O
IS	B-Disease	D002544
)	O	O
/	O	O
transient	B-Disease	D002546
ischemic	I-Disease	D002546
attack	I-Disease	D002546
(	O	O
TIA	B-Disease	D002546
)	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
systematic	O	O
review	O	O
of	O	O
published	O	O
and	O	O
unpublished	O	O
data	O	O
from	O	O
cohorts	O	O
with	O	O
stroke	B-Disease	D020521
or	O	O
TIA	B-Disease	D002546
to	O	O
compare	O	O
the	O	O
presence	O	O
of	O	O
MB	B-Disease	-1
in	O	O
:	O	O
(	O	O
1	O	O
)	O	O
antithrombotic	O	O
users	O	O
vs	O	O
nonantithrombotic	O	O
users	O	O
with	O	O
ICH	B-Disease	D002543
;	O	O
(	O	O
2	O	O
)	O	O
antithrombotic	O	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
IS	B-Disease	D002544
/	O	O
TIA	B-Disease	D002546
;	O	O
and	O	O
(	O	O
3	O	O
)	O	O
ICH	B-Disease	D002543
vs	O	O
ischemic	B-Disease	D007511
events	O	O
stratified	O	O
by	O	O
antithrombotic	O	O
use	O	O
.	O	O

We	O	O
also	O	O
analyzed	O	O
published	O	O
and	O	O
unpublished	O	O
follow	O	O
-	O	O
up	O	O
data	O	O
to	O	O
determine	O	O
the	O	O
risk	O	O
of	O	O
ICH	B-Disease	D002543
in	O	O
antithrombotic	O	O
users	O	O
with	O	O
MB	B-Disease	-1
.	O	O

RESULTS	O	O
:	O	O
In	O	O
a	O	O
pooled	O	O
analysis	O	O
of	O	O
1460	O	O
ICH	B-Disease	D002543
and	O	O
3817	O	O
IS	B-Disease	D002544
/	O	O
TIA	B-Disease	D002546
,	O	O
MB	B-Disease	-1
were	O	O
more	O	O
frequent	O	O
in	O	O
ICH	B-Disease	D002543
vs	O	O
IS	B-Disease	D002544
/	O	O
TIA	B-Disease	D002546
in	O	O
all	O	O
treatment	O	O
groups	O	O
,	O	O
but	O	O
the	O	O
excess	O	O
increased	O	O
from	O	O
2	O	O
.	O	O

8	O	O
(	O	O
odds	O	O
ratio	O	O
;	O	O
range	O	O
,	O	O
2	O	O
.	O	O

3	O	O
-	O	O
3	O	O
.	O	O

5	O	O
)	O	O
in	O	O
nonantithrombotic	O	O
users	O	O
to	O	O
5	O	O
.	O	O

7	O	O
(	O	O
range	O	O
,	O	O
3	O	O
.	O	O

4	O	O
-	O	O
9	O	O
.	O	O

7	O	O
)	O	O
in	O	O
antiplatelet	O	O
users	O	O
and	O	O
8	O	O
.	O	O

0	O	O
(	O	O
range	O	O
,	O	O
3	O	O
.	O	O

5	O	O
-	O	O
17	O	O
.	O	O

8	O	O
)	O	O
in	O	O
warfarin	B-Chemical	D014859
users	O	O
(	O	O
P	O	O
difference=0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
also	O	O
an	O	O
excess	O	O
of	O	O
MB	B-Disease	-1
in	O	O
warfarin	B-Chemical	D014859
users	O	O
vs	O	O
nonusers	O	O
with	O	O
ICH	B-Disease	D002543
(	O	O
OR	O	O
,	O	O
2	O	O
.	O	O

7	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

6	O	O
-	O	O
4	O	O
.	O	O

4	O	O
;	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
but	O	O
none	O	O
in	O	O
warfarin	B-Chemical	D014859
users	O	O
with	O	O
IS	B-Disease	D002544
/	O	O
TIA	B-Disease	D002546
(	O	O
OR	O	O
,	O	O
1	O	O
.	O	O

3	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
0	O	O
.	O	O

9	O	O
-	O	O
1	O	O
.	O	O

7	O	O
;	O	O
P=0	O	O
.	O	O

33	O	O
;	O	O
P	O	O
difference=0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
smaller	O	O
excess	O	O
of	O	O
MB	B-Disease	-1
in	O	O
antiplatelet	O	O
users	O	O
vs	O	O
nonusers	O	O
with	O	O
ICH	B-Disease	D002543
(	O	O
OR	O	O
,	O	O
1	O	O
.	O	O

7	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

3	O	O
-	O	O
2	O	O
.	O	O

3	O	O
;	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
but	O	O
findings	O	O
were	O	O
similar	O	O
for	O	O
antiplatelet	O	O
users	O	O
with	O	O
IS	B-Disease	D002544
/	O	O
TIA	B-Disease	D002546
(	O	O
OR	O	O
,	O	O
1	O	O
.	O	O

4	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
1	O	O
.	O	O

2	O	O
-	O	O
1	O	O
.	O	O

7	O	O
;	O	O
P<0	O	O
.	O	O

001	O	O
;	O	O
P	O	O
difference=0	O	O
.	O	O

25	O	O
)	O	O
.	O	O

In	O	O
pooled	O	O
follow	O	O
-	O	O
up	O	O
data	O	O
for	O	O
768	O	O
antithrombotic	O	O
users	O	O
,	O	O
presence	O	O
of	O	O
MB	B-Disease	-1
at	O	O
baseline	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
substantially	O	O
increased	O	O
risk	O	O
of	O	O
subsequent	O	O
ICH	B-Disease	D002543
(	O	O
OR	O	O
,	O	O
12	O	O
.	O	O

1	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
3	O	O
.	O	O

4	O	O
-	O	O
42	O	O
.	O	O

5	O	O
;	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
excess	O	O
of	O	O
MB	B-Disease	-1
in	O	O
warfarin	B-Chemical	D014859
users	O	O
with	O	O
ICH	B-Disease	D002543
compared	O	O
to	O	O
other	O	O
groups	O	O
suggests	O	O
that	O	O
MB	B-Disease	-1
increase	O	O
the	O	O
risk	O	O
of	O	O
warfarin	B-Chemical	D014859
-	O	O
associated	O	O
ICH	B-Disease	D002543
.	O	O

Limited	O	O
prospective	O	O
data	O	O
corroborate	O	O
these	O	O
findings	O	O
,	O	O
but	O	O
larger	O	O
prospective	O	O
studies	O	O
are	O	O
urgently	O	O
required	O	O
.	O	O

Verapamil	B-Chemical	D014700
stimulation	O	O
test	O	O
in	O	O
hyperprolactinemia	B-Disease	D006966
:	O	O
loss	O	O
of	O	O
prolactin	O	O
response	O	O
in	O	O
anatomic	O	O
or	O	O
functional	O	O
stalk	O	O
effect	O	O
.	O	O

AIM	O	O
:	O	O
Verapamil	B-Chemical	D014700
stimulation	O	O
test	O	O
was	O	O
previously	O	O
investigated	O	O
as	O	O
a	O	O
tool	O	O
for	O	O
differential	O	O
diagnosis	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
,	O	O
but	O	O
with	O	O
conflicting	O	O
results	O	O
.	O	O

Macroprolactinemia	B-Disease	D015175
was	O	O
never	O	O
considered	O	O
in	O	O
those	O	O
previous	O	O
studies	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
aimed	O	O
to	O	O
re	O	O
-	O	O
investigate	O	O
the	O	O
diagnostic	O	O
value	O	O
of	O	O
verapamil	B-Chemical	D014700
in	O	O
a	O	O
population	O	O
who	O	O
were	O	O
all	O	O
screened	O	O
for	O	O
macroprolactinemia	B-Disease	D015175
.	O	O

Prolactin	O	O
responses	O	O
to	O	O
verapamil	B-Chemical	D014700
in	O	O
65	O	O
female	O	O
patients	O	O
(	O	O
age	O	O
:	O	O
29	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

1	O	O
years	O	O
)	O	O
with	O	O
hyperprolactinemia	B-Disease	D006966
were	O	O
tested	O	O
in	O	O
a	O	O
descriptive	O	O
,	O	O
matched	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

METHODS	O	O
:	O	O
Verapamil	B-Chemical	D014700
80	O	O
mg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

was	O	O
administered	O	O
,	O	O
and	O	O
then	O	O
PRL	O	O
levels	O	O
were	O	O
measured	O	O
at	O	O
8th	O	O
and	O	O
16th	O	O
hours	O	O
,	O	O
by	O	O
immunometric	O	O
chemiluminescence	O	O
.	O	O

Verapamil	B-Chemical	D014700
responsiveness	O	O
was	O	O
determined	O	O
by	O	O
peak	O	O
percent	O	O
change	O	O
in	O	O
basal	O	O
prolactin	O	O
levels	O	O
(	O	O
PRL	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Verapamil	B-Chemical	D014700
significantly	O	O
increased	O	O
PRL	O	O
levels	O	O
in	O	O
healthy	O	O
controls	O	O
(	O	O
N	O	O
.	O	O

8	O	O
,	O	O
PRL	O	O
:	O	O
183%	O	O
)	O	O
,	O	O
macroprolactinoma	B-Disease	D015175
(	O	O
N	O	O
.	O	O

8	O	O
,	O	O
PRL	O	O
:	O	O
7%	O	O
)	O	O
,	O	O
microprolactinoma	B-Disease	D015175
(	O	O
N	O	O
.	O	O

19	O	O
,	O	O
PRL	O	O
:	O	O
21%	O	O
)	O	O
,	O	O
macroprolactinemia	B-Disease	D015175
(	O	O
N	O	O
.	O	O

23	O	O
,	O	O
PRL	O	O
:	O	O
126%	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
pseudoprolactinoma	B-Disease	-1
(	O	O
N	O	O
.	O	O

8	O	O
,	O	O
PRL	O	O
:	O	O
0	O	O
.	O	O

8%	O	O
)	O	O
,	O	O
and	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
(	O	O
N	O	O
.	O	O

7	O	O
,	O	O
PRL	O	O
:	O	O
3%	O	O
)	O	O
.	O	O

ROC	O	O
curve	O	O
analysis	O	O
revealed	O	O
that	O	O
unresponsiveness	O	O
to	O	O
verapamil	B-Chemical	D014700
defined	O	O
as	O	O
PRL	O	O
<7%	O	O
,	O	O
discriminated	O	O
anatomical	O	O
or	O	O
functional	O	O
stalk	O	O
effect	O	O
(	O	O
sensitivity	O	O
:	O	O
74%	O	O
,	O	O
specificity	O	O
:	O	O
73%	O	O
,	O	O
AUC	O	O
:	O	O
0	O	O
.	O	O

855+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

04	O	O
,	O	O
P	O	O
<0	O	O
.	O	O

001	O	O
,	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

768	O	O
-	O	O
0	O	O
.	O	O

942	O	O
)	O	O
associated	O	O
with	O	O
pseudoprolactinoma	B-Disease	-1
or	O	O
risperidone	B-Chemical	D018967
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
,	O	O
respectively	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Verapamil	B-Chemical	D014700
responsiveness	O	O
is	O	O
not	O	O
a	O	O
reliable	O	O
finding	O	O
for	O	O
the	O	O
differential	O	O
diagnosis	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

However	O	O
,	O	O
verapamil	B-Chemical	D014700
unresponsiveness	O	O
discriminates	O	O
stalk	O	O
effect	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
anatomically	O	O
or	O	O
functionally	O	O
inhibited	O	O
dopaminergic	O	O
tonus	O	O
)	O	O
from	O	O
other	O	O
causes	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
with	O	O
varying	O	O
degrees	O	O
of	O	O
responsiveness	O	O
.	O	O

Central	O	O
action	O	O
of	O	O
narcotic	O	O
analgesics	O	O
.	O	O

Part	O	O
IV	O	O
.	O	O

Noradrenergic	O	O
influences	O	O
on	O	O
the	O	O
activity	O	O
of	O	O
analgesics	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
clonidine	B-Chemical	D003000
,	O	O
naphazoline	B-Chemical	D009278
and	O	O
xylometazoline	B-Chemical	C009695
on	O	O
analgesia	O	O
induced	O	O
by	O	O
morphine	B-Chemical	D009020
,	O	O
codeine	B-Chemical	D003061
,	O	O
fentanyl	B-Chemical	D005283
and	O	O
pentazocine	B-Chemical	D010423
,	O	O
and	O	O
on	O	O
cataleptic	B-Disease	D002375
effect	O	O
of	O	O
morphine	B-Chemical	D009020
,	O	O
codine	B-Chemical	D003061
and	O	O
fentanyl	B-Chemical	D005283
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
biochemical	O	O
assays	O	O
on	O	O
the	O	O
influence	O	O
of	O	O
four	O	O
analgesics	O	O
on	O	O
the	O	O
brain	O	O
concentration	O	O
and	O	O
turnover	O	O
of	O	O
noradrenaline	B-Chemical	D009638
(	O	O
NA	B-Chemical	D009638
)	O	O
were	O	O
also	O	O
performed	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
three	O	O
drugs	O	O
stimulating	O	O
central	O	O
NA	B-Chemical	D009638
receptors	O	O
failed	O	O
to	O	O
affect	O	O
the	O	O
analgesic	O	O
ED50	O	O
of	O	O
all	O	O
antinociceptive	O	O
agents	O	O
and	O	O
they	O	O
enhanced	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
morphine	B-Chemical	D009020
and	O	O
fentanyl	B-Chemical	D005283
.	O	O

Codeine	B-Chemical	D003061
catalepsy	B-Disease	D002375
was	O	O
increased	O	O
by	O	O
clonidine	B-Chemical	D003000
and	O	O
decreased	O	O
by	O	O
naphazoline	B-Chemical	D009278
and	O	O
xylometazoline	B-Chemical	C009695
.	O	O

The	O	O
brain	O	O
concentration	O	O
of	O	O
NA	B-Chemical	D009638
was	O	O
not	O	O
changed	O	O
by	O	O
morphine	B-Chemical	D009020
and	O	O
fentanyl	B-Chemical	D005283
,	O	O
but	O	O
one	O	O
of	O	O
the	O	O
doses	O	O
of	O	O
codeine	B-Chemical	D003061
(	O	O
45	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
slightly	O	O
enhanced	O	O
it	O	O
.	O	O

Pentazocine	B-Chemical	D010423
dose	O	O
-	O	O
dependently	O	O
decreased	O	O
the	O	O
brain	O	O
level	O	O
of	O	O
NA	B-Chemical	D009638
.	O	O

The	O	O
rate	O	O
of	O	O
NA	B-Chemical	D009638
turnover	O	O
was	O	O
not	O	O
altered	O	O
by	O	O
analgesics	O	O
except	O	O
for	O	O
the	O	O
higher	O	O
dose	O	O
of	O	O
fentanyl	B-Chemical	D005283
(	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
following	O	O
which	O	O
the	O	O
disappearance	O	O
of	O	O
NA	B-Chemical	D009638
from	O	O
the	O	O
brain	O	O
was	O	O
diminished	O	O
.	O	O

The	O	O
results	O	O
are	O	O
discussed	O	O
in	O	O
the	O	O
light	O	O
of	O	O
various	O	O
and	O	O
non	O	O
-	O	O
uniform	O	O
data	O	O
from	O	O
the	O	O
literature	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
in	O	O
rats	O	O
the	O	O
brain	O	O
NA	B-Chemical	D009638
plays	O	O
a	O	O
less	O	O
important	O	O
function	O	O
than	O	O
the	O	O
other	O	O
monoamines	B-Chemical	D015306
in	O	O
the	O	O
behavioural	O	O
activity	O	O
of	O	O
potent	O	O
analgesics	O	O
.	O	O

Modification	O	O
by	O	O
propranolol	B-Chemical	D011433
of	O	O
cardiovascular	O	O
effects	O	O
of	O	O
induced	O	O
hypoglycaemia	B-Disease	D007003
.	O	O

The	O	O
cardiovascular	O	O
effects	O	O
of	O	O
hypoglycaemia	B-Disease	D007003
,	O	O
with	O	O
and	O	O
without	O	O
beta	O	O
-	O	O
blockade	O	O
,	O	O
were	O	O
compared	O	O
in	O	O
fourteen	O	O
healthy	O	O
men	O	O
.	O	O

Eight	O	O
received	O	O
insulin	O	O
alone	O	O
,	O	O
and	O	O
eight	O	O
,	O	O
including	O	O
two	O	O
of	O	O
the	O	O
original	O	O
insulin	O	O
-	O	O
only	O	O
group	O	O
,	O	O
were	O	O
given	O	O
propranolol	B-Chemical	D011433
and	O	O
insulin	O	O
.	O	O

In	O	O
the	O	O
insulin	O	O
-	O	O
group	O	O
the	O	O
period	O	O
of	O	O
hypoglycaemia	B-Disease	D007003
was	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
heart	O	O
-	O	O
rate	O	O
and	O	O
a	O	O
fall	O	O
in	O	O
diastolic	O	O
blood	O	O
-	O	O
pressure	O	O
.	O	O

In	O	O
the	O	O
propranolol	B-Chemical	D011433
-	O	O
insulin	O	O
group	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
fall	O	O
in	O	O
heart	O	O
-	O	O
rate	O	O
in	O	O
most	O	O
subjects	O	O
and	O	O
an	O	O
increase	O	O
in	O	O
diastolic	O	O
pressure	O	O
.	O	O

Typical	O	O
S	O	O
-	O	O
T	O	O
/	O	O
T	O	O
changes	O	O
occurred	O	O
in	O	O
the	O	O
insulin	O	O
-	O	O
group	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
propranolol	B-Chemical	D011433
-	O	O
insulin	O	O
group	O	O
.	O	O

Hypertension	B-Disease	D006973
in	O	O
diabetics	B-Disease	D003920
prone	O	O
to	O	O
hypoglycaemia	B-Disease	D007003
attacks	O	O
should	O	O
not	O	O
be	O	O
treated	O	O
with	O	O
beta	O	O
-	O	O
blockers	O	O
because	O	O
these	O	O
drugs	O	O
may	O	O
cause	O	O
a	O	O
sharp	O	O
rise	O	O
in	O	O
blood	O	O
-	O	O
pressure	O	O
in	O	O
such	O	O
patients	O	O
.	O	O

Prevention	O	O
and	O	O
treatment	O	O
of	O	O
endometrial	B-Disease	D014591
disease	I-Disease	D014591
in	O	O
climacteric	O	O
women	O	O
receiving	O	O
oestrogen	B-Chemical	D004967
therapy	O	O
.	O	O

The	O	O
treatment	O	O
regimens	O	O
are	O	O
described	O	O
in	O	O
74	O	O
patients	O	O
with	O	O
endometrial	B-Disease	D014591
disease	I-Disease	D014591
among	O	O
850	O	O
climacteric	O	O
women	O	O
receiving	O	O
oestrogen	B-Chemical	D004967
therapy	O	O
.	O	O

Cystic	O	O
hyperplasia	B-Disease	D006965
was	O	O
associated	O	O
with	O	O
unopposed	O	O
oestrogen	B-Chemical	D004967
therapy	O	O
without	O	O
progestagen	B-Chemical	D011372
.	O	O

Two	O	O
courses	O	O
of	O	O
21	O	O
days	O	O
of	O	O
5	O	O
mg	O	O
norethisterone	B-Chemical	D009640
daily	O	O
caused	O	O
reversion	O	O
to	O	O
normal	O	O
in	O	O
all	O	O
57	O	O
cases	O	O
of	O	O
cystic	O	O
hyperplasia	B-Disease	D006965
and	O	O
6	O	O
of	O	O
the	O	O
8	O	O
cases	O	O
of	O	O
atypical	O	O
hyperplasia	B-Disease	D006965
.	O	O

4	O	O
cases	O	O
of	O	O
endometrial	B-Disease	D016889
carcinoma	I-Disease	D016889
referred	O	O
from	O	O
elsewhere	O	O
demonstrated	O	O
the	O	O
problems	O	O
of	O	O
inappropriate	O	O
and	O	O
unsupervised	O	O
unopposed	O	O
oestrogen	B-Chemical	D004967
therapy	O	O
and	O	O
the	O	O
difficulty	O	O
in	O	O
distinguishing	O	O
severe	O	O
hyperplasia	B-Disease	D006965
from	O	O
malignancy	B-Disease	D009369
.	O	O

Cyclical	O	O
low	O	O
-	O	O
dose	O	O
oestrogen	B-Chemical	D004967
therapy	O	O
with	O	O
7	O	O
-	O	O
-	O	O
13	O	O
days	O	O
of	O	O
progestagen	B-Chemical	D011372
does	O	O
not	O	O
seem	O	O
to	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
endometrial	B-Disease	D004714
hyperplasia	I-Disease	D004714
or	O	O
carcinoma	B-Disease	D002277
.	O	O

Pure	B-Disease	D012010
red	I-Disease	D012010
cell	I-Disease	D012010
aplasia	I-Disease	D012010
,	O	O
toxic	B-Disease	D003875
dermatitis	I-Disease	D003875
and	O	O
lymphadenopathy	B-Disease	D008206
in	O	O
a	O	O
patient	O	O
taking	O	O
diphenylhydantoin	B-Chemical	D010672
.	O	O

A	O	O
patient	O	O
taking	O	O
diphenylhydantoin	B-Chemical	D010672
for	O	O
3	O	O
weeks	O	O
developed	O	O
a	O	O
generalized	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
,	O	O
lymphadenopathy	B-Disease	D008206
and	O	O
pure	B-Disease	D012010
red	I-Disease	D012010
cell	I-Disease	D012010
aplasia	I-Disease	D012010
.	O	O

After	O	O
withdrawal	O	O
of	O	O
the	O	O
pharmacon	O	O
all	O	O
symptoms	O	O
disappeared	O	O
spontaneously	O	O
.	O	O

Skin	B-Disease	D005076
rash	I-Disease	D005076
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
complication	O	O
of	O	O
diphenylhydantoin	B-Chemical	D010672
treatment	O	O
as	O	O
is	O	O
benign	O	O
and	O	O
malignant	O	O
lymphadenopathy	B-Disease	D008206
.	O	O

Pure	B-Disease	D012010
red	I-Disease	D012010
cell	I-Disease	D012010
aplasia	I-Disease	D012010
associated	O	O
with	O	O
diphenylhydantoin	B-Chemical	D010672
medication	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

The	O	O
exact	O	O
mechanism	O	O
by	O	O
which	O	O
diphenylhydantoin	B-Chemical	D010672
exerts	O	O
its	O	O
toxic	O	O
effects	O	O
is	O	O
not	O	O
known	O	O
.	O	O

In	O	O
this	O	O
patient	O	O
the	O	O
time	O	O
relation	O	O
between	O	O
the	O	O
ingestion	O	O
of	O	O
diphenylhydantoin	B-Chemical	D010672
and	O	O
the	O	O
occurrence	O	O
of	O	O
the	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
,	O	O
lymphadenopathy	B-Disease	D008206
and	O	O
pure	B-Disease	D012010
red	I-Disease	D012010
cell	I-Disease	D012010
aplasia	I-Disease	D012010
is	O	O
very	O	O
suggestive	O	O
of	O	O
a	O	O
direct	O	O
connection	O	O
.	O	O

Continuous	O	O
infusion	O	O
tobramycin	B-Chemical	D014031
combined	O	O
with	O	O
carbenicillin	B-Chemical	D002228
for	O	O
infections	B-Disease	D007239
in	O	O
cancer	B-Disease	D009369
patients	O	O
.	O	O

The	O	O
cure	O	O
rate	O	O
of	O	O
infections	B-Disease	D007239
in	O	O
cancer	B-Disease	D009369
patients	O	O
is	O	O
adversely	O	O
affected	O	O
by	O	O
neutropenia	B-Disease	D009503
(	O	O
less	O	O
than	O	O
1	O	O
,	O	O
000	O	O
/	O	O
mm3	O	O
)	O	O
.	O	O

In	O	O
particular	O	O
,	O	O
patients	O	O
with	O	O
severe	O	O
neutropenia	B-Disease	D009503
(	O	O
less	O	O
than	O	O
100	O	O
/	O	O
mm3	O	O
)	O	O
have	O	O
shown	O	O
a	O	O
poor	O	O
response	O	O
to	O	O
antibiotics	O	O
.	O	O

To	O	O
overcome	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
neutropenia	B-Disease	D009503
,	O	O
tobramycin	B-Chemical	D014031
was	O	O
given	O	O
by	O	O
continuous	O	O
infusion	O	O
and	O	O
combined	O	O
with	O	O
intermittent	O	O
carbenicillin	B-Chemical	D002228
.	O	O

Tobramycin	B-Chemical	D014031
was	O	O
given	O	O
to	O	O
a	O	O
total	O	O
daily	O	O
dose	O	O
of	O	O
300	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
carbenicillin	B-Chemical	D002228
was	O	O
given	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
gm	O	O
every	O	O
four	O	O
hours	O	O
.	O	O

There	O	O
were	O	O
125	O	O
infectious	O	O
episodes	O	O
in	O	O
116	O	O
cancer	B-Disease	D009369
patients	O	O
receiving	O	O
myelosuppressive	O	O
chemotherapy	O	O
.	O	O

The	O	O
overall	O	O
cure	O	O
rate	O	O
was	O	O
70%	O	O
.	O	O

Pneumonia	B-Disease	D011014
was	O	O
the	O	O
most	O	O
common	O	O
infection	B-Disease	D007239
and	O	O
61%	O	O
of	O	O
59	O	O
episodes	O	O
were	O	O
cured	O	O
.	O	O

Gram	O	O
-	O	O
negative	O	O
bacilli	O	O
were	O	O
the	O	O
most	O	O
common	O	O
causative	O	O
organisms	O	O
and	O	O
69%	O	O
of	O	O
these	O	O
infections	B-Disease	D007239
were	O	O
cured	O	O
.	O	O

The	O	O
most	O	O
common	O	O
pathogen	O	O
was	O	O
Klebsiella	O	O
pneumoniae	B-Disease	D011014
and	O	O
this	O	O
,	O	O
together	O	O
with	O	O
Escherichia	O	O
coli	O	O
and	O	O
Pseudomonas	O	O
aeruginosa	O	O
,	O	O
accounted	O	O
for	O	O
74%	O	O
of	O	O
all	O	O
gram	B-Disease	D016905
-	I-Disease	D016905
negative	I-Disease	D016905
bacillary	I-Disease	D016905
infections	I-Disease	D016905
.	O	O

Response	O	O
was	O	O
not	O	O
influenced	O	O
by	O	O
the	O	O
initial	O	O
neutrophil	O	O
count	O	O
,	O	O
with	O	O
a	O	O
62%	O	O
cure	O	O
rate	O	O
for	O	O
39	O	O
episodes	O	O
associated	O	O
with	O	O
severe	O	O
neutropenia	B-Disease	D009503
.	O	O

However	O	O
,	O	O
failure	O	O
of	O	O
the	O	O
neutrophil	O	O
count	O	O
to	O	O
increase	O	O
during	O	O
therapy	O	O
adversely	O	O
affected	O	O
response	O	O
.	O	O

Azotemia	B-Disease	D053099
was	O	O
the	O	O
major	O	O
side	O	O
effect	O	O
recognized	O	O
,	O	O
and	O	O
it	O	O
occurred	O	O
in	O	O
11%	O	O
of	O	O
episodes	O	O
.	O	O

Major	O	O
azotemia	B-Disease	D053099
(	O	O
serum	O	O
creatinine	B-Chemical	D003404
greater	O	O
than	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dl	O	O
or	O	O
BUN	O	O
greater	O	O
than	O	O
50	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
occurred	O	O
in	O	O
only	O	O
2%	O	O
.	O	O

Azotemia	B-Disease	D053099
was	O	O
not	O	O
related	O	O
to	O	O
duration	O	O
of	O	O
therapy	O	O
or	O	O
serum	O	O
tobramycin	B-Chemical	D014031
concentration	O	O
.	O	O

This	O	O
antibiotic	O	O
regimen	O	O
showed	O	O
both	O	O
therapeutic	O	O
efficacy	O	O
and	O	O
acceptable	O	O
renal	B-Disease	D007674
toxicity	I-Disease	D007674
for	O	O
these	O	O
patients	O	O
.	O	O

Recurrent	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
associated	O	O
with	O	O
aminocaproic	B-Chemical	D000614
acid	I-Chemical	D000614
therapy	O	O
and	O	O
acute	B-Disease	D007674
renal	I-Disease	D007674
artery	I-Disease	D007674
thrombosis	I-Disease	D007674
.	O	O

Case	O	O
report	O	O
.	O	O

Epsilon	B-Chemical	D015119
aminocaproic	I-Chemical	D015119
acid	I-Chemical	D015119
(	O	O
EACA	B-Chemical	D015119
)	O	O
has	O	O
been	O	O
used	O	O
to	O	O
prevent	O	O
rebleeding	O	O
in	O	O
patients	O	O
with	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
(	O	O
SAH	B-Disease	D013345
)	O	O
.	O	O

Although	O	O
this	O	O
agent	O	O
does	O	O
decrease	O	O
the	O	O
frequency	O	O
of	O	O
rebleeding	O	O
,	O	O
several	O	O
reports	O	O
have	O	O
described	O	O
thrombotic	B-Disease	D013927
complications	O	O
of	O	O
EACA	B-Chemical	D015119
therapy	O	O
.	O	O

These	O	O
complications	O	O
have	O	O
included	O	O
clinical	O	O
deterioration	O	O
and	O	O
intracranial	B-Disease	D020767
vascular	I-Disease	D020767
thrombosis	I-Disease	D020767
in	O	O
patients	O	O
with	O	O
SAH	B-Disease	D013345
,	O	O
arteriolar	O	O
and	O	O
capillary	O	O
fibrin	O	O
thrombi	B-Disease	D013927
in	O	O
patients	O	O
with	O	O
fibrinolytic	O	O
syndromes	O	O
treated	O	O
with	O	O
EACA	B-Chemical	D015119
,	O	O
or	O	O
other	O	O
thromboembolic	B-Disease	D013923
phenomena	I-Disease	D013923
.	O	O

Since	O	O
intravascular	O	O
fibrin	O	O
thrombi	B-Disease	D013927
are	O	O
often	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
fibrinolytic	O	O
disorders	O	O
,	O	O
EACA	B-Chemical	D015119
should	O	O
not	O	O
be	O	O
implicated	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
fibrin	O	O
thrombi	B-Disease	D013927
in	O	O
patients	O	O
with	O	O
disseminated	B-Disease	D004211
intravascular	I-Disease	D004211
coagulation	I-Disease	D004211
or	O	O
other	O	O
"consumption	O	O
coagulopathies	O	O
.	O	O

"	O	O
This	O	O
report	O	O
describes	O	O
subtotal	O	O
infarction	B-Disease	D007238
of	O	O
the	O	O
kidney	O	O
due	O	O
to	O	O
thrombosis	B-Disease	D007674
of	I-Disease	D007674
a	I-Disease	D007674
normal	I-Disease	D007674
renal	I-Disease	D007674
artery	I-Disease	D007674
.	O	O

This	O	O
occlusion	O	O
occurred	O	O
after	O	O
EACA	B-Chemical	D015119
therapy	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
SAH	B-Disease	D013345
and	O	O
histopathological	O	O
documentation	O	O
of	O	O
recurrent	O	O
SAH	B-Disease	D013345
.	O	O

The	O	O
corresponding	O	O
clinical	O	O
event	O	O
was	O	O
characterized	O	O
by	O	O
marked	O	O
hypertension	B-Disease	D006973
and	O	O
abrupt	O	O
neurological	O	O
deterioration	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
propranolol	B-Chemical	D011433
therapy	O	O
in	O	O
pregnancy	O	O
:	O	O
maternal	O	O
and	O	O
fetal	O	O
outcome	O	O
.	O	O

Propranolol	B-Chemical	D011433
,	O	O
a	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
has	O	O
found	O	O
an	O	O
important	O	O
position	O	O
in	O	O
the	O	O
practice	O	O
of	O	O
medicine	O	O
.	O	O

Its	O	O
use	O	O
in	O	O
pregnancy	O	O
,	O	O
however	O	O
,	O	O
is	O	O
an	O	O
open	O	O
question	O	O
as	O	O
a	O	O
number	O	O
of	O	O
detrimental	O	O
side	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
fetus	O	O
and	O	O
neonate	O	O
.	O	O

Ten	O	O
patients	O	O
and	O	O
12	O	O
pregnancies	O	O
are	O	O
reported	O	O
where	O	O
chronic	O	O
propranolol	B-Chemical	D011433
has	O	O
been	O	O
administered	O	O
.	O	O

Five	O	O
patients	O	O
with	O	O
serial	O	O
pregnancies	O	O
with	O	O
and	O	O
without	O	O
propranolol	B-Chemical	D011433
therapy	O	O
are	O	O
also	O	O
examined	O	O
.	O	O

Maternal	O	O
,	O	O
fetal	O	O
,	O	O
and	O	O
neonatal	O	O
complications	O	O
are	O	O
examined	O	O
.	O	O

An	O	O
attempt	O	O
is	O	O
made	O	O
to	O	O
differentiate	O	O
drug	O	O
-	O	O
related	O	O
complications	O	O
from	O	O
maternal	O	O
disease	O	O
-	O	O
-	O	O
related	O	O
complications	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
previously	O	O
reported	O	O
hypoglycemia	B-Disease	D007003
,	O	O
hyperbilirubinemia	B-Disease	D006932
,	O	O
polycythemia	B-Disease	D011086
,	O	O
neonatal	B-Disease	D001049
apnea	I-Disease	D001049
,	O	O
and	O	O
bradycardia	B-Disease	D001919
are	O	O
not	O	O
invariable	O	O
and	O	O
cannot	O	O
be	O	O
statistically	O	O
correlated	O	O
with	O	O
chronic	O	O
propranolol	B-Chemical	D011433
therapy	O	O
.	O	O

Growth	B-Disease	D005317
retardation	I-Disease	D005317
,	O	O
however	O	O
,	O	O
appears	O	O
to	O	O
be	O	O
significant	O	O
in	O	O
both	O	O
of	O	O
our	O	O
series	O	O
.	O	O

Use	O	O
of	O	O
propranolol	B-Chemical	D011433
in	O	O
the	O	O
treatment	O	O
of	O	O
idiopathic	B-Disease	C544351
orthostatic	I-Disease	C544351
hypotension	I-Disease	C544351
.	O	O

Five	O	O
patients	O	O
with	O	O
idiopathic	B-Disease	C544351
orthostatic	I-Disease	C544351
hypotension	I-Disease	C544351
who	O	O
had	O	O
physiologic	O	O
and	O	O
biochemical	O	O
evidence	O	O
of	O	O
severe	O	O
autonomic	O	O
dysfunction	O	O
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

They	O	O
all	O	O
exhibited	O	O
markedly	O	O
reduced	O	O
plasma	O	O
catecholamines	B-Chemical	D002395
and	O	O
plasma	O	O
renin	O	O
activity	O	O
in	O	O
both	O	O
recumbent	O	O
and	O	O
upright	O	O
positions	O	O
and	O	O
had	O	O
marked	O	O
hypersensitivity	B-Disease	D004342
to	O	O
the	O	O
pressor	O	O
effects	O	O
of	O	O
infused	O	O
norepinephrine	B-Chemical	D009638
.	O	O

Treatment	O	O
with	O	O
propanolol	B-Chemical	D011433
administered	O	O
intravenously	O	O
(	O	O
1	O	O
-	O	O
5	O	O
mg	O	O
)	O	O
produced	O	O
increases	O	O
in	O	O
supine	O	O
and	O	O
upright	O	O
blood	O	O
pressure	O	O
in	O	O
4	O	O
of	O	O
the	O	O
5	O	O
individuals	O	O
with	O	O
rises	O	O
ranging	O	O
from	O	O
11	O	O
/	O	O
6	O	O
to	O	O
22	O	O
/	O	O
11	O	O
mmHg	O	O
.	O	O

Chronic	O	O
oral	O	O
administration	O	O
of	O	O
propranolol	B-Chemical	D011433
(	O	O
40	O	O
-	O	O
160	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
also	O	O
elevated	O	O
the	O	O
blood	O	O
pressures	O	O
of	O	O
these	O	O
individuals	O	O
with	O	O
increases	O	O
in	O	O
the	O	O
order	O	O
of	O	O
20	O	O
-	O	O
35	O	O
/	O	O
15	O	O
-	O	O
25	O	O
mmg	O	O
being	O	O
observed	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
,	O	O
marked	O	O
hypertension	B-Disease	D006973
was	O	O
induced	O	O
by	O	O
propranolol	B-Chemical	D011433
and	O	O
the	O	O
drug	O	O
had	O	O
to	O	O
be	O	O
withdrawn	O	O
.	O	O

It	O	O
otherwise	O	O
was	O	O
well	O	O
tolerated	O	O
and	O	O
no	O	O
important	O	O
side	O	O
effects	O	O
were	O	O
observed	O	O
.	O	O

Treatment	O	O
has	O	O
been	O	O
continued	O	O
in	O	O
3	O	O
individuals	O	O
for	O	O
6	O	O
-	O	O
13	O	O
months	O	O
with	O	O
persistence	O	O
of	O	O
the	O	O
pressor	O	O
effect	O	O
,	O	O
although	O	O
there	O	O
appears	O	O
to	O	O
have	O	O
been	O	O
some	O	O
decrease	O	O
in	O	O
the	O	O
degree	O	O
of	O	O
response	O	O
with	O	O
time	O	O
.	O	O

Hemodynamic	O	O
measurements	O	O
in	O	O
1	O	O
of	O	O
the	O	O
patients	O	O
demonstrated	O	O
an	O	O
increase	O	O
in	O	O
total	O	O
peripheral	O	O
resistance	O	O
and	O	O
essentially	O	O
no	O	O
change	O	O
in	O	O
cardiac	O	O
output	O	O
following	O	O
propranolol	B-Chemical	D011433
therapy	O	O
.	O	O

The	O	O
studies	O	O
suggest	O	O
that	O	O
propranolol	B-Chemical	D011433
is	O	O
a	O	O
useful	O	O
drug	O	O
in	O	O
selected	O	O
patients	O	O
with	O	O
severe	O	O
idiopathic	B-Disease	C544351
orthostatic	I-Disease	C544351
hypotension	I-Disease	C544351
.	O	O

Total	O	O
intravenous	O	O
anesthesia	O	O
with	O	O
etomidate	B-Chemical	D005045
.	O	O

III	O	O
.	O	O

Some	O	O
observations	O	O
in	O	O
adults	O	O
.	O	O

An	O	O
investigation	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
the	O	O
dosage	O	O
of	O	O
etomidate	B-Chemical	D005045
required	O	O
to	O	O
maintain	O	O
sleep	O	O
in	O	O
adults	O	O
undergoing	O	O
surgery	O	O
under	O	O
regional	O	O
local	O	O
anesthesia	O	O
.	O	O

Premedication	O	O
of	O	O
diazepam	B-Chemical	D003975
10	O	O
mg	O	O
and	O	O
atropine	B-Chemical	D001285
0	O	O
.	O	O

5	O	O
mg	O	O
was	O	O
given	O	O
,	O	O
and	O	O
sleep	O	O
was	O	O
induced	O	O
and	O	O
maintained	O	O
by	O	O
intermittent	O	O
intravenous	O	O
injections	O	O
of	O	O
etomidate	B-Chemical	D005045
0	O	O
.	O	O

1	O	O
/	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
given	O	O
whenever	O	O
the	O	O
patient	O	O
would	O	O
open	O	O
his	O	O
eyes	O	O
on	O	O
request	O	O
.	O	O

A	O	O
mean	O	O
overall	O	O
dose	O	O
of	O	O
etomidate	B-Chemical	D005045
17	O	O
.	O	O

4	O	O
microgram	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
.	O	O

was	O	O
required	O	O
to	O	O
maintain	O	O
sleep	O	O
,	O	O
but	O	O
great	O	O
individual	O	O
variation	O	O
occurred	O	O
,	O	O
with	O	O
older	O	O
patients	O	O
requiring	O	O
less	O	O
drug	O	O
.	O	O

The	O	O
investigation	O	O
was	O	O
discontinued	O	O
after	O	O
18	O	O
patients	O	O
because	O	O
of	O	O
the	O	O
frequency	O	O
and	O	O
intensity	O	O
of	O	O
side	O	O
-	O	O
effects	O	O
,	O	O
particularly	O	O
pain	B-Disease	D010146
and	O	O
myoclonia	B-Disease	D009207
,	O	O
which	O	O
caused	O	O
the	O	O
technique	O	O
to	O	O
be	O	O
abandoned	O	O
in	O	O
two	O	O
cases	O	O
.	O	O

It	O	O
is	O	O
considered	O	O
unlikely	O	O
that	O	O
etomidate	B-Chemical	D005045
will	O	O
prove	O	O
to	O	O
be	O	O
the	O	O
hypnotic	O	O
of	O	O
choice	O	O
for	O	O
a	O	O
totally	O	O
intravenous	O	O
anesthetic	O	O
technique	O	O
in	O	O
adults	O	O
because	O	O
of	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
myoclonia	B-Disease	D009207
after	O	O
prolonged	O	O
administration	O	O
.	O	O

In	O	O
several	O	O
patients	O	O
uncontrollable	O	O
muscle	O	O
movements	O	O
persisted	O	O
for	O	O
many	O	O
minutes	O	O
after	O	O
complete	O	O
recovery	O	O
of	O	O
consciousness	O	O
.	O	O

A	O	O
method	O	O
for	O	O
the	O	O
measurement	O	O
of	O	O
tremor	B-Disease	D014202
,	O	O
and	O	O
a	O	O
comparison	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
tocolytic	O	O
beta	O	O
-	O	O
mimetics	O	O
.	O	O

A	O	O
method	O	O
permitting	O	O
measurement	O	O
of	O	O
finger	O	O
tremor	B-Disease	D014202
as	O	O
a	O	O
displacement	O	O
-	O	O
time	O	O
curve	O	O
is	O	O
described	O	O
,	O	O
using	O	O
a	O	O
test	O	O
system	O	O
with	O	O
simple	O	O
amplitude	O	O
calibration	O	O
.	O	O

The	O	O
coordinates	O	O
of	O	O
the	O	O
inversion	O	O
points	O	O
of	O	O
the	O	O
displacement	O	O
-	O	O
time	O	O
curves	O	O
were	O	O
transferred	O	O
through	O	O
graphical	O	O
input	O	O
equipment	O	O
to	O	O
punched	O	O
tape	O	O
.	O	O

By	O	O
means	O	O
of	O	O
a	O	O
computer	O	O
program	O	O
,	O	O
periods	O	O
and	O	O
amplitudes	O	O
of	O	O
tremor	B-Disease	D014202
oscillations	O	O
were	O	O
calculated	O	O
and	O	O
classified	O	O
.	O	O

The	O	O
event	O	O
frequency	O	O
for	O	O
each	O	O
class	O	O
of	O	O
periods	O	O
and	O	O
amplitudes	O	O
was	O	O
determined	O	O
.	O	O

The	O	O
actions	O	O
of	O	O
fenoterol	B-Chemical	D005280
-	I-Chemical	D005280
hydrobromide	I-Chemical	D005280
,	O	O
ritodrin	B-Chemical	D012312
-	I-Chemical	D012312
HCl	I-Chemical	D012312
and	O	O
placebo	O	O
given	O	O
to	O	O
10	O	O
healthy	O	O
subjects	O	O
by	O	O
intravenous	O	O
infusion	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
crossover	O	O
study	O	O
were	O	O
tested	O	O
by	O	O
this	O	O
method	O	O
.	O	O

At	O	O
therapeutic	O	O
doses	O	O
both	O	O
substances	O	O
raised	O	O
the	O	O
mean	O	O
tremor	B-Disease	D014202
amplitude	O	O
to	O	O
about	O	O
three	O	O
times	O	O
the	O	O
control	O	O
level	O	O
.	O	O

At	O	O
the	O	O
same	O	O
time	O	O
,	O	O
the	O	O
mean	O	O
period	O	O
within	O	O
each	O	O
class	O	O
of	O	O
amplitudes	O	O
shortened	O	O
by	O	O
10	O	O
-	O	O
-	O	O
20	O	O
ms	O	O
,	O	O
whereas	O	O
the	O	O
mean	O	O
periods	O	O
calculated	O	O
from	O	O
all	O	O
oscillations	O	O
together	O	O
did	O	O
not	O	O
change	O	O
significantly	O	O
.	O	O

After	O	O
the	O	O
end	O	O
of	O	O
fenoterol	B-Chemical	D005280
-	I-Chemical	D005280
hydrobromide	I-Chemical	D005280
infusion	O	O
,	O	O
tremor	B-Disease	D014202
amplitudes	O	O
decreased	O	O
significantly	O	O
faster	O	O
than	O	O
those	O	O
following	O	O
ritodrin	B-Chemical	D012312
-	I-Chemical	D012312
HCl	I-Chemical	D012312
infusion	O	O
.	O	O

Bilateral	O	O
retinal	B-Disease	D015356
artery	I-Disease	D015356
and	I-Disease	D015356
choriocapillaris	I-Disease	D015356
occlusion	I-Disease	D015356
following	O	O
the	O	O
injection	O	O
of	O	O
long	O	O
-	O	O
acting	O	O
corticosteroid	B-Chemical	D000305
suspensions	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
drugs	O	O
:	O	O
I	O	O
.	O	O

Clinical	O	O
studies	O	O
.	O	O

Two	O	O
well	O	O
-	O	O
documented	O	O
cases	O	O
of	O	O
bilateral	O	O
retinal	B-Disease	D015356
artery	I-Disease	D015356
and	I-Disease	D015356
choriocapillaris	I-Disease	D015356
occlusions	I-Disease	D015356
with	O	O
blindness	B-Disease	D001766
following	O	O
head	O	O
and	O	O
neck	O	O
soft	O	O
-	O	O
tissue	O	O
injection	O	O
with	O	O
methylprednisolone	B-Chemical	C000873
acetate	I-Chemical	C000873
in	O	O
combination	O	O
with	O	O
lidocaine	B-Chemical	D008012
,	O	O
epinephrine	B-Chemical	D004837
,	O	O
or	O	O
penicillin	B-Chemical	D010406
are	O	O
reported	O	O
.	O	O

One	O	O
case	O	O
had	O	O
only	O	O
a	O	O
unilateral	O	O
injection	O	O
.	O	O

The	O	O
acute	O	O
observations	O	O
included	O	O
hazy	O	O
sensorium	O	O
,	O	O
superior	O	O
gaze	O	O
palsy	B-Disease	D010243
,	O	O
pupillary	B-Disease	D011681
abnormalities	I-Disease	D011681
,	O	O
and	O	O
conjunctival	O	O
hemorrhages	B-Disease	D006470
with	O	O
edema	B-Disease	D004487
.	O	O

Follow	O	O
-	O	O
up	O	O
changes	O	O
showed	O	O
marked	O	O
visual	B-Disease	D014786
loss	I-Disease	D014786
,	O	O
constricted	O	O
visual	O	O
fields	O	O
,	O	O
optic	O	O
nerve	O	O
pallor	O	O
,	O	O
vascular	O	O
attenuation	O	O
,	O	O
and	O	O
chorioretinal	B-Disease	C566236
atrophy	I-Disease	C566236
.	O	O

The	O	O
literature	O	O
is	O	O
reviewed	O	O
,	O	O
and	O	O
possible	O	O
causes	O	O
are	O	O
discussed	O	O
.	O	O

Cephalothin	B-Chemical	D002512
-	O	O
induced	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

A	O	O
patient	O	O
with	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
developed	O	O
Coombs	O	O
-	O	O
positive	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
while	O	O
receiving	O	O
cephalothin	B-Chemical	D002512
therapy	O	O
.	O	O

An	O	O
anti	O	O
-	O	O
cephalothin	B-Chemical	D002512
IgG	O	O
antibody	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
patient's	O	O
serum	O	O
and	O	O
in	O	O
the	O	O
eluates	O	O
from	O	O
her	O	O
erythrocytes	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
nonimmunologic	O	O
binding	O	O
of	O	O
normal	O	O
and	O	O
patient's	O	O
serum	O	O
proteins	O	O
to	O	O
her	O	O
own	O	O
and	O	O
cephalothin	B-Chemical	D002512
-	O	O
coated	O	O
normal	O	O
red	O	O
cells	O	O
was	O	O
demonstrated	O	O
.	O	O

Skin	O	O
tests	O	O
and	O	O
in	O	O
vitro	O	O
lymphocyte	O	O
stimulation	O	O
revealed	O	O
that	O	O
the	O	O
patient	O	O
was	O	O
sensitized	O	O
to	O	O
cephalothin	B-Chemical	D002512
and	O	O
also	O	O
to	O	O
ampicillin	B-Chemical	D000667
.	O	O

Careful	O	O
investigation	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemias	I-Disease	D000743
reveals	O	O
the	O	O
complexity	O	O
of	O	O
the	O	O
immune	O	O
mechanisms	O	O
involved	O	O
.	O	O

Kaliuretic	O	O
effect	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
treatment	O	O
in	O	O
parkinsonian	B-Disease	D010300
patients	O	O
.	O	O

Hypokalemia	B-Disease	D007008
,	O	O
sometimes	O	O
severe	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
some	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
-	O	O
treated	O	O
parkinsonian	B-Disease	D010300
patients	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
on	O	O
the	O	O
renal	O	O
excretion	O	O
of	O	O
potassium	B-Chemical	D011188
was	O	O
studied	O	O
in	O	O
3	O	O
patients	O	O
with	O	O
hypokalemia	B-Disease	D007008
and	O	O
in	O	O
5	O	O
normokalemic	O	O
patients	O	O
by	O	O
determination	O	O
of	O	O
renal	O	O
plasma	O	O
flow	O	O
,	O	O
glomerular	O	O
filtration	O	O
rate	O	O
,	O	O
plasma	O	O
concentration	O	O
of	O	O
potassium	B-Chemical	D011188
and	O	O
sodium	B-Chemical	D012964
as	O	O
well	O	O
as	O	O
urinary	O	O
excretion	O	O
of	O	O
potassium	B-Chemical	D011188
,	O	O
sodium	B-Chemical	D012964
and	O	O
aldosterone	B-Chemical	D000450
.	O	O

L	B-Chemical	D007980
-	I-Chemical	D007980
Dopa	I-Chemical	D007980
intake	O	O
was	O	O
found	O	O
to	O	O
cause	O	O
an	O	O
increased	O	O
excretion	O	O
of	O	O
potassium	B-Chemical	D011188
,	O	O
and	O	O
sometimes	O	O
also	O	O
of	O	O
sodium	B-Chemical	D012964
,	O	O
in	O	O
the	O	O
hypokalemic	O	O
but	O	O
not	O	O
in	O	O
the	O	O
normokalemic	O	O
patients	O	O
.	O	O

This	O	O
effect	O	O
on	O	O
the	O	O
renal	O	O
function	O	O
could	O	O
be	O	O
prohibited	O	O
by	O	O
the	O	O
administration	O	O
of	O	O
a	O	O
peripheral	O	O
dopa	O	O
decarbodylase	O	O
inhibitor	O	O
.	O	O

It	O	O
is	O	O
not	O	O
known	O	O
why	O	O
this	O	O
effect	O	O
occurred	O	O
in	O	O
some	O	O
individuals	O	O
but	O	O
not	O	O
in	O	O
others	O	O
,	O	O
but	O	O
our	O	O
results	O	O
indicate	O	O
a	O	O
correlation	O	O
between	O	O
aldosterone	B-Chemical	D000450
production	O	O
and	O	O
this	O	O
renal	O	O
effect	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
dopa	I-Chemical	D007980
.	O	O

Phenytoin	B-Chemical	D010672
encephalopathy	B-Disease	D001927
as	O	O
probable	O	O
idiosyncratic	O	O
reaction	O	O
:	O	O
case	O	O
report	O	O
.	O	O

A	O	O
case	O	O
of	O	O
phenytoin	B-Chemical	D010672
(	O	O
DPH	B-Chemical	D010672
)	O	O
encephalopathy	B-Disease	D001927
with	O	O
increasing	O	O
seizures	B-Disease	D012640
and	O	O
EEG	O	O
and	O	O
mental	O	O
changes	O	O
is	O	O
described	O	O
.	O	O

Despite	O	O
adequate	O	O
oral	O	O
dosage	O	O
of	O	O
DPH	B-Chemical	D010672
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
daily	O	O
)	O	O
the	O	O
plasma	O	O
level	O	O
was	O	O
very	O	O
low	O	O
(	O	O
2	O	O
.	O	O

8	O	O
microgramg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

The	O	O
encephalopathy	B-Disease	D001927
was	O	O
probably	O	O
an	O	O
idiosyncratic	O	O
and	O	O
not	O	O
toxic	O	O
or	O	O
allergic	O	O
reaction	O	O
.	O	O

In	O	O
fact	O	O
the	O	O
concentration	O	O
of	O	O
free	O	O
DPH	B-Chemical	D010672
was	O	O
normal	O	O
,	O	O
the	O	O
patient	O	O
presented	O	O
a	O	O
retarded	O	O
morbilliform	O	O
rash	B-Disease	D005076
during	O	O
DPH	B-Chemical	D010672
treatment	O	O
,	O	O
the	O	O
protidogram	O	O
was	O	O
normal	O	O
,	O	O
and	O	O
an	O	O
intradermic	O	O
DPH	B-Chemical	D010672
injection	O	O
had	O	O
no	O	O
local	O	O
effect	O	O
.	O	O

The	O	O
authors	O	O
conclude	O	O
that	O	O
in	O	O
a	O	O
patient	O	O
starting	O	O
DPH	B-Chemical	D010672
treatment	O	O
an	O	O
unexpected	O	O
increase	O	O
in	O	O
seizures	B-Disease	D012640
,	O	O
with	O	O
EEG	O	O
and	O	O
mental	O	O
changes	O	O
occurring	O	O
simultaneously	O	O
,	O	O
should	O	O
alert	O	O
the	O	O
physician	O	O
to	O	O
the	O	O
possible	O	O
need	O	O
for	O	O
eliminating	O	O
DPH	B-Chemical	D010672
from	O	O
the	O	O
therapeutic	O	O
regimen	O	O
,	O	O
even	O	O
if	O	O
plasma	O	O
concentrations	O	O
are	O	O
low	O	O
.	O	O

Effects	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

The	O	O
effect	O	O
of	O	O
exercise	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
studied	O	O
in	O	O
male	O	O
rats	O	O
.	O	O

Ninety	O	O
-	O	O
three	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
exercise	O	O
-	O	O
isoproterenol	B-Chemical	D007545
(	O	O
E	O	O
-	O	O
1	O	O
)	O	O
and	O	O
exercise	O	O
control	O	O
(	O	O
EC	O	O
)	O	O
groups	O	O
exercised	O	O
daily	O	O
for	O	O
thirty	O	O
days	O	O
on	O	O
a	O	O
treadmill	O	O
at	O	O
1	O	O
mph	O	O
,	O	O
2%	O	O
grade	O	O
while	O	O
animals	O	O
of	O	O
the	O	O
sedentary	O	O
-	O	O
isoproterenol	B-Chemical	D007545
(	O	O
S	O	O
-	O	O
I	O	O
)	O	O
group	O	O
remained	O	O
sedentary	O	O
.	O	O

Eight	O	O
animals	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
sedentary	O	O
control	O	O
(	O	O
SC	O	O
)	O	O
group	O	O
which	O	O
remained	O	O
sedentary	O	O
throughout	O	O
the	O	O
experimental	O	O
period	O	O
.	O	O

Forty	O	O
-	O	O
eight	O	O
hours	O	O
after	O	O
the	O	O
final	O	O
exercise	O	O
period	O	O
,	O	O
S	O	O
-	O	O
I	O	O
and	O	O
E	O	O
-	O	O
I	O	O
animals	O	O
received	O	O
a	O	O
single	O	O
subcutaneous	O	O
injection	O	O
of	O	O
isoproterenol	B-Chemical	D007545
(	O	O
250	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
)	O	O
.	O	O

Animals	O	O
of	O	O
the	O	O
S	O	O
-	O	O
I	O	O
group	O	O
exhibited	O	O
significantly	O	O
(	O	O
Pp	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
greater	O	O
mortality	O	O
from	O	O
the	O	O
effects	O	O
of	O	O
isoproterenol	B-Chemical	D007545
than	O	O
animals	O	O
of	O	O
the	O	O
E	O	O
-	O	O
I	O	O
group	O	O
.	O	O

Serum	O	O
CPK	O	O
activity	O	O
for	O	O
E	O	O
-	O	O
I	O	O
animals	O	O
was	O	O
significantly	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
greater	O	O
than	O	O
for	O	O
animals	O	O
in	O	O
the	O	O
S	O	O
-	O	O
I	O	O
and	O	O
EC	O	O
groups	O	O
twenty	O	O
hours	O	O
following	O	O
isoproterenol	B-Chemical	D007545
injection	O	O
.	O	O

No	O	O
statistically	O	O
significant	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
two	O	O
isoproterenol	B-Chemical	D007545
treated	O	O
groups	O	O
for	O	O
severity	O	O
of	O	O
the	O	O
induced	O	O
lesions	O	O
,	O	O
changes	O	O
in	O	O
heart	O	O
weight	O	O
,	O	O
or	O	O
heart	O	O
weight	O	O
to	O	O
body	O	O
weight	O	O
ratios	O	O
.	O	O

The	O	O
results	O	O
indicated	O	O
that	O	O
exercise	O	O
reduced	O	O
the	O	O
mortality	O	O
associated	O	O
with	O	O
the	O	O
effects	O	O
of	O	O
large	O	O
dosages	O	O
of	O	O
isoproterenol	B-Chemical	D007545
but	O	O
had	O	O
little	O	O
on	O	O
the	O	O
severity	O	O
of	O	O
the	O	O
infarction	B-Disease	D007238
.	O	O

Effect	O	O
of	O	O
D	B-Chemical	D005937
-	I-Chemical	D005937
Glucarates	I-Chemical	D005937
on	O	O
basic	O	O
antibiotic	O	O
-	O	O
induced	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
in	O	O
rats	O	O
.	O	O

Dehydrated	B-Disease	D003681
rats	O	O
regularly	O	O
develop	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
following	O	O
single	O	O
injection	O	O
of	O	O
aminoglycoside	B-Chemical	D000617
antibiotics	O	O
combined	O	O
with	O	O
dextran	O	O
or	O	O
of	O	O
antibiotics	O	O
only	O	O
.	O	O

Oral	O	O
administration	O	O
of	O	O
2	B-Chemical	C038936
,	I-Chemical	C038936
5	I-Chemical	C038936
-	I-Chemical	C038936
di	I-Chemical	C038936
-	I-Chemical	C038936
O	I-Chemical	C038936
-	I-Chemical	C038936
acetyl	I-Chemical	C038936
-	I-Chemical	C038936
D	I-Chemical	C038936
-	I-Chemical	C038936
glucaro	I-Chemical	C038936
-	I-Chemical	C038936
1	I-Chemical	C038936
,	I-Chemical	C038936
4	I-Chemical	C038936
-	I-Chemical	C038936
6	I-Chemical	C038936
,	I-Chemical	C038936
3	I-Chemical	C038936
-	I-Chemical	C038936
dilactone	I-Chemical	C038936
protected	O	O
rats	O	O
against	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
induced	O	O
by	O	O
kanamycin	B-Chemical	D007612
-	O	O
dextran	O	O
.	O	O

The	O	O
protective	O	O
effect	O	O
was	O	O
prevalent	O	O
among	O	O
D	B-Chemical	D005937
-	I-Chemical	D005937
glucarates	I-Chemical	D005937
,	O	O
and	O	O
also	O	O
to	O	O
other	O	O
saccharic	B-Chemical	D005937
acid	I-Chemical	D005937
,	O	O
hexauronic	B-Chemical	D006603
acids	I-Chemical	D006603
and	O	O
hexaaldonic	B-Chemical	-1
acids	I-Chemical	-1
,	O	O
although	O	O
to	O	O
a	O	O
lesser	O	O
degree	O	O
,	O	O
but	O	O
not	O	O
to	O	O
a	O	O
hexaaldose	O	O
,	O	O
sugar	B-Chemical	D013402
alcohols	I-Chemical	D013402
,	O	O
substances	O	O
inthe	O	O
TCA	B-Chemical	D002952
cycle	O	O
and	O	O
other	O	O
acidic	O	O
compounds	O	O
.	O	O

D	B-Chemical	D005937
-	I-Chemical	D005937
Glucarates	I-Chemical	D005937
were	O	O
effective	O	O
against	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
induced	O	O
by	O	O
peptide	O	O
antibiotics	O	O
as	O	O
well	O	O
as	O	O
various	O	O
aminoglycoside	B-Chemical	D000617
antibitocis	O	O
.	O	O

Dose	O	O
-	O	O
responses	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
protective	O	O
effect	O	O
of	O	O
D	B-Chemical	D005937
-	I-Chemical	D005937
Glucarates	I-Chemical	D005937
.	O	O

With	O	O
a	O	O
D	B-Chemical	D005937
-	I-Chemical	D005937
glucarate	I-Chemical	D005937
of	O	O
a	O	O
fixed	O	O
size	O	O
of	O	O
dose	O	O
,	O	O
approximately	O	O
the	O	O
same	O	O
degree	O	O
of	O	O
protection	O	O
was	O	O
obtained	O	O
against	O	O
renal	B-Disease	D007674
damages	I-Disease	D007674
induced	O	O
by	O	O
different	O	O
basic	O	O
antibiotics	O	O
despite	O	O
large	O	O
disparities	O	O
in	O	O
administration	O	O
doses	O	O
of	O	O
different	O	O
antibiotics	O	O
.	O	O

D	B-Chemical	D005937
-	I-Chemical	D005937
Glucarates	I-Chemical	D005937
had	O	O
the	O	O
ability	O	O
to	O	O
prevent	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
but	O	O
not	O	O
to	O	O
cure	O	O
it	O	O
.	O	O

Rats	O	O
excreted	O	O
acidic	O	O
urine	O	O
when	O	O
they	O	O
were	O	O
spared	O	O
from	O	O
renal	B-Disease	D007674
lesions	I-Disease	D007674
by	O	O
monosaccharides	B-Chemical	D009005
.	O	O

The	O	O
reduction	O	O
effect	O	O
of	O	O
D	B-Chemical	D005937
-	I-Chemical	D005937
glucarates	I-Chemical	D005937
against	O	O
nephrotoxicity	B-Disease	D007674
of	O	O
basic	O	O
antibiotics	O	O
was	O	O
discussed	O	O
.	O	O

Paraplegia	B-Disease	D010264
following	O	O
intrathecal	O	O
methotrexate	B-Chemical	D008727
:	O	O
report	O	O
of	O	O
a	O	O
case	O	O
and	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
.	O	O

A	O	O
patient	O	O
who	O	O
developed	O	O
paraplegia	B-Disease	D010264
following	O	O
the	O	O
intrathecal	O	O
instillation	O	O
of	O	O
methotrexate	B-Chemical	D008727
is	O	O
discribed	O	O
.	O	O

The	O	O
ten	O	O
previously	O	O
reported	O	O
cases	O	O
of	O	O
this	O	O
unusual	O	O
complication	O	O
are	O	O
reviewed	O	O
.	O	O

The	O	O
following	O	O
factors	O	O
appear	O	O
to	O	O
predispose	O	O
to	O	O
the	O	O
development	O	O
of	O	O
this	O	O
complication	O	O
:	O	O
abnormal	O	O
cerebrospinal	O	O
dynamics	O	O
related	O	O
to	O	O
the	O	O
presence	O	O
of	O	O
central	B-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
leukemia	I-Disease	D002493
,	O	O
and	O	O
epidural	O	O
cerebrospinal	O	O
leakage	O	O
;	O	O
elevated	O	O
cerebrospinal	O	O
fluid	O	O
methothexate	B-Chemical	D008727
concentration	O	O
related	O	O
to	O	O
abnormal	O	O
cerebrospinal	O	O
fluid	O	O
dynamics	O	O
and	O	O
to	O	O
inappropriately	O	O
high	O	O
methotrexate	B-Chemical	D008727
doses	O	O
based	O	O
on	O	O
body	O	O
surface	O	O
area	O	O
calculations	O	O
in	O	O
older	O	O
children	O	O
and	O	O
adults	O	O
;	O	O
the	O	O
presence	O	O
of	O	O
neurotoxic	B-Disease	D020258
preservatives	O	O
in	O	O
commercially	O	O
available	O	O
methotrexate	B-Chemical	D008727
preparations	O	O
and	O	O
diluents	O	O
;	O	O
and	O	O
the	O	O
use	O	O
of	O	O
methotrexate	B-Chemical	D008727
diluents	O	O
of	O	O
unphysiologic	O	O
pH	O	O
,	O	O
ionic	O	O
content	O	O
and	O	O
osmolarity	O	O
.	O	O

The	O	O
role	O	O
of	O	O
methotrexate	B-Chemical	D008727
contaminants	O	O
,	O	O
local	O	O
folate	B-Disease	C536409
deficiency	I-Disease	C536409
,	O	O
and	O	O
cranial	O	O
irradiation	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
intrathecal	O	O
methotrexate	B-Chemical	D008727
toxicity	B-Disease	D064420
is	O	O
unclear	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
neurotoxicity	B-Disease	D020258
may	O	O
be	O	O
reduced	O	O
by	O	O
employing	O	O
lower	O	O
doses	O	O
of	O	O
methotrexate	B-Chemical	D008727
in	O	O
the	O	O
presence	O	O
of	O	O
central	B-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
leukemia	I-Disease	D002493
,	O	O
in	O	O
older	O	O
children	O	O
and	O	O
adults	O	O
,	O	O
and	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
epidural	O	O
leakage	O	O
.	O	O

Only	O	O
preservative	O	O
-	O	O
free	O	O
methotrexate	B-Chemical	D008727
in	O	O
Elliott's	O	O
B	O	O
Solution	O	O
at	O	O
a	O	O
concentration	O	O
of	O	O
not	O	O
more	O	O
than	O	O
1	O	O
mg	O	O
/	O	O
ml	O	O
should	O	O
be	O	O
used	O	O
for	O	O
intrathecal	O	O
administration	O	O
.	O	O

Periodic	O	O
monitoring	O	O
of	O	O
cerebruspinal	O	O
fluid	O	O
methotrexate	B-Chemical	D008727
levels	O	O
may	O	O
be	O	O
predictive	O	O
of	O	O
the	O	O
development	O	O
of	O	O
serious	O	O
neurotoxicity	B-Disease	D020258
.	O	O

Centrally	O	O
mediated	O	O
cardiovascular	O	O
effects	O	O
of	O	O
intracisternal	O	O
application	O	O
of	O	O
carbachol	B-Chemical	D002217
in	O	O
anesthetized	O	O
rats	O	O
.	O	O

The	O	O
pressor	O	O
response	O	O
to	O	O
the	O	O
intracisternal	O	O
(	O	O
i	O	O
.	O	O

c	O	O
.	O	O

)	O	O
injection	O	O
of	O	O
carbachol	B-Chemical	D002217
(	O	O
1	O	O
mug	O	O
)	O	O
in	O	O
anesthetized	O	O
rats	O	O
was	O	O
analyzed	O	O
.	O	O

This	O	O
response	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
the	O	O
intravenous	O	O
(	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
injection	O	O
of	O	O
guanethidine	B-Chemical	D006145
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
hexamethonium	B-Chemical	D018738
(	O	O
10	O	O
mg	O	O
)	O	O
or	O	O
phentolamine	B-Chemical	D010646
(	O	O
5	O	O
mg	O	O
)	O	O
,	O	O
and	O	O
conversely	O	O
,	O	O
potentiated	O	O
by	O	O
i	O	O
.	O	O

v	O	O
.	O	O

desmethylimipramine	B-Chemical	D003891
(	O	O
0	O	O
.	O	O

3	O	O
mg	O	O
)	O	O
,	O	O
while	O	O
propranolol	B-Chemical	D011433
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
)	O	O
i	O	O
.	O	O

v	O	O
.	O	O

selectively	O	O
inhibited	O	O
the	O	O
enlargement	B-Disease	D006973
of	I-Disease	D006973
pulse	I-Disease	D006973
pressure	I-Disease	D006973
and	O	O
the	O	O
tachycardia	B-Disease	D013610
following	O	O
i	O	O
.	O	O

c	O	O
.	O	O

carbachol	B-Chemical	D002217
(	O	O
1	O	O
mug	O	O
)	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
pressor	O	O
response	O	O
to	O	O
i	O	O
.	O	O

c	O	O
.	O	O

carbachol	B-Chemical	D002217
(	O	O
1	O	O
mug	O	O
)	O	O
was	O	O
almost	O	O
completely	O	O
blocked	O	O
by	O	O
i	O	O
.	O	O

c	O	O
.	O	O

atropine	B-Chemical	D001285
(	O	O
3	O	O
mug	O	O
)	O	O
or	O	O
hexamethonium	B-Chemical	D018738
(	O	O
500	O	O
mug	O	O
)	O	O
,	O	O
and	O	O
significantly	O	O
reduced	O	O
by	O	O
i	O	O
.	O	O

c	O	O
.	O	O

chlorpromazine	B-Chemical	D002746
(	O	O
50	O	O
mug	O	O
)	O	O
but	O	O
significantly	O	O
potentiated	O	O
by	O	O
i	O	O
.	O	O

c	O	O
.	O	O

desmethylimipramine	B-Chemical	D003891
(	O	O
30	O	O
mug	O	O
)	O	O
.	O	O

The	O	O
pressor	O	O
response	O	O
to	O	O
i	O	O
.	O	O

c	O	O
.	O	O

carbachol	B-Chemical	D002217
(	O	O
1	O	O
mug	O	O
)	O	O
remained	O	O
unchanged	O	O
after	O	O
sectioning	O	O
of	O	O
the	O	O
bilateral	O	O
cervical	O	O
vagal	O	O
nerves	O	O
but	O	O
disappeared	O	O
after	O	O
sectioning	O	O
of	O	O
the	O	O
spinal	O	O
cord	O	O
(	O	O
C7	O	O
-	O	O
C8	O	O
)	O	O
.	O	O

From	O	O
the	O	O
above	O	O
result	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
pressor	O	O
response	O	O
to	O	O
i	O	O
.	O	O

c	O	O
.	O	O

carbachol	B-Chemical	D002217
ortral	O	O
and	O	O
peripheral	O	O
adrenergic	O	O
mechanisms	O	O
,	O	O
and	O	O
that	O	O
the	O	O
sympathetic	O	O
trunk	O	O
is	O	O
the	O	O
main	O	O
pathway	O	O
.	O	O

Hyperglycemic	B-Disease	D006943
effect	O	O
of	O	O
amino	B-Chemical	D015119
compounds	O	O
structurally	O	O
related	O	O
to	O	O
caproate	B-Chemical	C037652
in	O	O
rats	O	O
.	O	O

The	O	O
chronic	O	O
feeding	O	O
of	O	O
small	O	O
amounts	O	O
(	O	O
0	O	O
.	O	O

3	O	O
-	O	O
3%	O	O
of	O	O
diet	O	O
weight	O	O
)	O	O
of	O	O
certain	O	O
amino	B-Chemical	D015119
derivatives	O	O
of	O	O
caproate	B-Chemical	C037652
resulted	O	O
in	O	O
hyperglycemia	B-Disease	D006943
,	O	O
an	O	O
elevated	O	O
glucose	B-Chemical	D005947
tolerance	O	O
curve	O	O
and	O	O
,	O	O
occasionally	O	O
,	O	O
glucosuria	B-Disease	D006030
.	O	O

Effective	O	O
compounds	O	O
included	O	O
norleucine	B-Chemical	-1
,	O	O
norvaline	B-Chemical	-1
,	O	O
glutamate	B-Chemical	D018698
,	O	O
epsilon	B-Chemical	-1
-	I-Chemical	-1
aminocaproate	I-Chemical	-1
,	O	O
methionine	B-Chemical	D008715
,	O	O
and	O	O
leucine	B-Chemical	-1
.	O	O

Fatty	B-Disease	D005234
liver	I-Disease	D005234
induced	O	O
by	O	O
tetracycline	B-Chemical	D013752
in	O	O
the	O	O
rat	O	O
.	O	O

Dose	O	O
-	O	O
response	O	O
relationships	O	O
and	O	O
effect	O	O
of	O	O
sex	O	O
.	O	O

Dose	O	O
-	O	O
response	O	O
relationships	O	O
,	O	O
biochemical	O	O
mechanisms	O	O
,	O	O
and	O	O
sex	O	O
differences	O	O
in	O	O
the	O	O
experimental	O	O
fatty	B-Disease	D005234
liver	I-Disease	D005234
induced	O	O
by	O	O
tetracycline	B-Chemical	D013752
were	O	O
studied	O	O
in	O	O
the	O	O
intact	O	O
rat	O	O
and	O	O
with	O	O
the	O	O
isolated	O	O
perfused	O	O
rat	O	O
liver	O	O
in	O	O
vitro	O	O
.	O	O

In	O	O
the	O	O
intact	O	O
male	O	O
and	O	O
female	O	O
rat	O	O
,	O	O
no	O	O
direct	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
dose	O	O
of	O	O
tetracycline	B-Chemical	D013752
and	O	O
hepatic	O	O
accumulation	O	O
of	O	O
triglyceride	B-Chemical	D014280
.	O	O

With	O	O
provision	O	O
of	O	O
adequate	O	O
oleic	B-Chemical	D019301
acid	I-Chemical	D019301
as	O	O
a	O	O
substrate	O	O
for	O	O
the	O	O
isolated	O	O
perfused	O	O
liver	O	O
,	O	O
a	O	O
direct	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
dose	O	O
of	O	O
tetracycline	B-Chemical	D013752
and	O	O
both	O	O
accumulation	O	O
of	O	O
triglyceride	B-Chemical	D014280
in	O	O
the	O	O
liver	O	O
and	O	O
depression	B-Disease	D003866
of	O	O
output	O	O
of	O	O
triglyceride	B-Chemical	D014280
by	O	O
livers	O	O
from	O	O
male	O	O
and	O	O
female	O	O
rats	O	O
.	O	O

Marked	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
female	O	O
and	O	O
male	O	O
rats	O	O
with	O	O
regard	O	O
to	O	O
base	O	O
line	O	O
(	O	O
control	O	O
)	O	O
hepatic	O	O
concentration	O	O
of	O	O
triglyceride	B-Chemical	D014280
and	O	O
output	O	O
of	O	O
triglyceride	B-Chemical	D014280
.	O	O

Accumulation	O	O
of	O	O
hepatic	O	O
triglyceride	B-Chemical	D014280
,	O	O
as	O	O
a	O	O
per	O	O
cent	O	O
of	O	O
control	O	O
values	O	O
,	O	O
in	O	O
response	O	O
to	O	O
graded	O	O
doses	O	O
of	O	O
tetracycline	B-Chemical	D013752
,	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
male	O	O
,	O	O
female	O	O
and	O	O
pregnant	O	O
rat	O	O
livers	O	O
.	O	O

However	O	O
,	O	O
livers	O	O
from	O	O
female	O	O
,	O	O
and	O	O
especially	O	O
pregnant	O	O
female	O	O
rats	O	O
,	O	O
were	O	O
strikingly	O	O
resistant	O	O
to	O	O
the	O	O
effects	O	O
of	O	O
tetracycline	B-Chemical	D013752
on	O	O
depression	B-Disease	D003866
of	O	O
output	O	O
of	O	O
triglyceride	B-Chemical	D014280
under	O	O
these	O	O
experimental	O	O
conditions	O	O
.	O	O

These	O	O
differences	O	O
between	O	O
the	O	O
sexes	O	O
could	O	O
not	O	O
be	O	O
related	O	O
to	O	O
altered	O	O
disposition	O	O
of	O	O
tetracycline	B-Chemical	D013752
or	O	O
altered	O	O
uptake	O	O
of	O	O
oleic	B-Chemical	D019301
acid	I-Chemical	D019301
.	O	O

Depressed	O	O
hepatic	O	O
secretion	O	O
of	O	O
triglyceride	B-Chemical	D014280
accounted	O	O
only	O	O
for	O	O
30	O	O
to	O	O
50%	O	O
of	O	O
accumulated	O	O
hepatic	O	O
triglyceride	B-Chemical	D014280
,	O	O
indicating	O	O
that	O	O
additional	O	O
mechanisms	O	O
must	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
production	O	O
of	O	O
the	O	O
triglyceride	B-Chemical	D014280
-	O	O
rich	O	O
fatty	B-Disease	D005234
liver	I-Disease	D005234
in	O	O
response	O	O
to	O	O
tetracycline	B-Chemical	D013752
.	O	O

Fatal	O	O
myeloencephalopathy	B-Disease	D001927
due	O	O
to	O	O
intrathecal	O	O
vincristine	B-Chemical	D014750
administration	O	O
.	O	O

Vincristine	B-Chemical	D014750
was	O	O
accidentally	O	O
given	O	O
intrathecally	O	O
to	O	O
a	O	O
child	O	O
with	O	O
leukaemia	B-Disease	D007938
,	O	O
producing	O	O
sensory	B-Disease	D007049
and	I-Disease	D007049
motor	I-Disease	D007049
dysfunction	I-Disease	D007049
followed	O	O
by	O	O
encephalopathy	B-Disease	D001927
and	O	O
death	O	O
.	O	O

Separate	O	O
times	O	O
for	O	O
administering	O	O
vincristine	B-Chemical	D014750
and	O	O
intrathecal	O	O
therapy	O	O
is	O	O
recommended	O	O
.	O	O

Progesterone	B-Chemical	D011374
potentiation	O	O
of	O	O
bupivacaine	B-Chemical	D002045
arrhythmogenicity	O	O
in	O	O
pentobarbital	B-Chemical	D010424
-	O	O
anesthetized	O	O
rats	O	O
and	O	O
beating	O	O
rat	O	O
heart	O	O
cell	O	O
cultures	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
progesterone	B-Chemical	D011374
treatment	O	O
on	O	O
bupivacaine	B-Chemical	D002045
arrhythmogenicity	O	O
in	O	O
beating	O	O
rat	O	O
heart	O	O
myocyte	O	O
cultures	O	O
and	O	O
on	O	O
anesthetized	O	O
rats	O	O
were	O	O
determined	O	O
.	O	O

After	O	O
determining	O	O
the	O	O
bupivacaine	B-Chemical	D002045
AD50	O	O
(	O	O
the	O	O
concentration	O	O
of	O	O
bupivacaine	B-Chemical	D002045
that	O	O
caused	O	O
50%	O	O
of	O	O
all	O	O
beating	O	O
rat	O	O
heart	O	O
myocyte	O	O
cultures	O	O
to	O	O
become	O	O
arrhythmic	B-Disease	D001145
)	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
effect	O	O
of	O	O
1	O	O
-	O	O
hour	O	O
progesterone	B-Chemical	D011374
HCl	B-Chemical	D006851
exposure	O	O
on	O	O
myocyte	O	O
contractile	O	O
rhythm	O	O
.	O	O

Each	O	O
concentration	O	O
of	O	O
progesterone	B-Chemical	D011374
(	O	O
6	O	O
.	O	O

25	O	O
,	O	O
12	O	O
.	O	O

5	O	O
,	O	O
25	O	O
,	O	O
and	O	O
50	O	O
micrograms	O	O
/	O	O
ml	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
and	O	O
concentration	O	O
-	O	O
dependent	O	O
reduction	O	O
in	O	O
the	O	O
AD50	O	O
for	O	O
bupivacaine	B-Chemical	D002045
.	O	O

Estradiol	B-Chemical	D004958
treatment	O	O
also	O	O
increased	O	O
the	O	O
arrhythmogenicity	O	O
of	O	O
bupivacaine	B-Chemical	D002045
in	O	O
myocyte	O	O
cultures	O	O
,	O	O
but	O	O
was	O	O
only	O	O
one	O	O
fourth	O	O
as	O	O
potent	O	O
as	O	O
progesterone	B-Chemical	D011374
.	O	O

Neither	O	O
progesterone	B-Chemical	D011374
nor	O	O
estradiol	B-Chemical	D004958
effects	O	O
on	O	O
bupivacaine	B-Chemical	D002045
arrhythmogenicity	O	O
were	O	O
potentiated	O	O
by	O	O
epinephrine	B-Chemical	D004837
.	O	O

Chronic	O	O
progesterone	B-Chemical	D011374
pretreatment	O	O
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
for	O	O
21	O	O
days	O	O
)	O	O
caused	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
bupivacaine	B-Chemical	D002045
arrhythmogenicity	O	O
in	O	O
intact	O	O
pentobarbital	B-Chemical	D010424
-	O	O
anesthetized	O	O
rats	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
the	O	O
time	O	O
to	O	O
onset	O	O
of	O	O
arrhythmia	B-Disease	D001145
as	O	O
compared	O	O
with	O	O
control	O	O
nonprogesterone	O	O
-	O	O
treated	O	O
rats	O	O
(	O	O
6	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
vs	O	O
.	O	O

30	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

5	O	O
min	O	O
,	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
.	O	O

The	O	O
results	O	O
of	O	O
this	O	O
study	O	O
indicate	O	O
that	O	O
progesterone	B-Chemical	D011374
can	O	O
potentiate	O	O
bupivacaine	B-Chemical	D002045
arrhythmogenicity	O	O
both	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
.	O	O

Potentiation	O	O
of	O	O
bupivacaine	B-Chemical	D002045
arrhythmia	B-Disease	D001145
in	O	O
myocyte	O	O
cultures	O	O
suggests	O	O
that	O	O
this	O	O
effect	O	O
is	O	O
at	O	O
least	O	O
partly	O	O
mediated	O	O
at	O	O
the	O	O
myocyte	O	O
level	O	O
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
occurring	O	O
during	O	O
intravenous	O	O
desferrioxamine	B-Chemical	D003676
therapy	O	O
:	O	O
recovery	O	O
after	O	O
haemodialysis	O	O
.	O	O

A	O	O
patient	O	O
with	O	O
transfusion	O	O
-	O	O
dependent	O	O
thalassemia	B-Disease	D013789
was	O	O
undergoing	O	O
home	O	O
intravenous	O	O
desferrioxamine	B-Chemical	D003676
(	O	O
DFX	B-Chemical	D003676
)	O	O
treatment	O	O
by	O	O
means	O	O
of	O	O
a	O	O
totally	O	O
implanted	O	O
system	O	O
because	O	O
of	O	O
his	O	O
poor	O	O
compliance	O	O
with	O	O
the	O	O
nightly	O	O
subcutaneous	O	O
therapy	O	O
.	O	O

Due	O	O
to	O	O
an	O	O
accidental	O	O
malfunctioning	O	O
of	O	O
the	O	O
infusion	O	O
pump	O	O
,	O	O
the	O	O
patient	O	O
was	O	O
inadvertently	O	O
administered	O	O
a	O	O
toxic	O	O
dosage	O	O
of	O	O
the	O	O
drug	O	O
which	O	O
caused	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
.	O	O

Given	O	O
the	O	O
progressive	O	O
deterioration	O	O
of	O	O
the	O	O
symptoms	O	O
and	O	O
of	O	O
the	O	O
laboratory	O	O
values	O	O
,	O	O
despite	O	O
adequate	O	O
medical	O	O
treatment	O	O
,	O	O
a	O	O
decision	O	O
was	O	O
made	O	O
to	O	O
introduce	O	O
haemodialytical	O	O
therapy	O	O
in	O	O
order	O	O
to	O	O
remove	O	O
the	O	O
drug	O	O
and	O	O
therapy	O	O
reduce	O	O
the	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

From	O	O
the	O	O
results	O	O
obtained	O	O
,	O	O
haemodialysis	O	O
can	O	O
therefore	O	O
be	O	O
suggested	O	O
as	O	O
a	O	O
useful	O	O
therapy	O	O
in	O	O
rare	O	O
cases	O	O
of	O	O
progressive	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
caused	O	O
by	O	O
desferrioxamine	B-Chemical	D003676
.	O	O

Neuroleptic	B-Chemical	D014150
-	O	O
associated	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

Can	O	O
it	O	O
be	O	O
treated	O	O
with	O	O
bromocriptine?	O	O
Six	O	O
stable	O	O
psychiatric	O	O
outpatients	O	O
with	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
amenorrhea	B-Disease	D000568
/	O	O
oligomenorrhea	B-Disease	D009839
associated	O	O
with	O	O
their	O	O
neuroleptic	B-Chemical	D014150
medications	I-Chemical	D014150
were	O	O
treated	O	O
with	O	O
bromocriptine	B-Chemical	D001971
.	O	O

Daily	O	O
dosages	O	O
of	O	O
5	O	O
-	O	O
10	O	O
mg	O	O
corrected	O	O
the	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
restored	O	O
menstruation	O	O
in	O	O
four	O	O
of	O	O
the	O	O
six	O	O
patients	O	O
.	O	O

One	O	O
woman	O	O
,	O	O
however	O	O
,	O	O
developed	O	O
worsened	O	O
psychiatric	B-Disease	D011618
symptoms	I-Disease	D011618
while	O	O
taking	O	O
bromocriptine	B-Chemical	D001971
,	O	O
and	O	O
it	O	O
was	O	O
discontinued	O	O
.	O	O

Thus	O	O
,	O	O
three	O	O
of	O	O
six	O	O
patients	O	O
had	O	O
their	O	O
menstrual	O	O
irregularity	O	O
successfully	O	O
corrected	O	O
with	O	O
bromocriptine	B-Chemical	D001971
.	O	O

This	O	O
suggests	O	O
that	O	O
bromocriptine	B-Chemical	D001971
should	O	O
be	O	O
further	O	O
evaluated	O	O
as	O	O
potential	O	O
therapy	O	O
for	O	O
neuroleptic	B-Chemical	D014150
-	O	O
associated	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
amenorrhea	B-Disease	D000568
/	O	O
galactorrhea	B-Disease	D005687
.	O	O

Ethacrynic	B-Chemical	D004976
acid	I-Chemical	D004976
-	O	O
induced	O	O
convulsions	B-Disease	D012640
and	O	O
brain	O	O
neurotransmitters	O	O
in	O	O
mice	O	O
.	O	O

Intracerebroventricular	O	O
injection	O	O
of	O	O
ethacrynic	B-Chemical	D004976
acid	I-Chemical	D004976
(	O	O
50%	O	O
convulsive	B-Disease	D012640
dose	O	O
;	O	O
50	O	O
micrograms	O	O
/	O	O
mouse	O	O
)	O	O
accelerated	O	O
the	O	O
synthesis	O	O
/	O	O
turnover	O	O
of	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamine	I-Chemical	D012701
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
)	O	O
but	O	O
suppressed	O	O
the	O	O
synthesis	O	O
of	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
and	O	O
acetylcholine	B-Chemical	D000109
in	O	O
mouse	O	O
brain	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
completely	O	O
antagonized	O	O
by	O	O
pretreatment	O	O
with	O	O
a	O	O
glutamate	B-Chemical	D018698
/	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
antagonist	O	O
,	O	O
aminophosphonovaleric	B-Chemical	-1
acid	I-Chemical	-1
.	O	O

In	O	O
ethacrynic	B-Chemical	D004976
acid	I-Chemical	D004976
-	O	O
induced	O	O
convulsions	B-Disease	D012640
,	O	O
these	O	O
neurotransmitter	O	O
systems	O	O
may	O	O
be	O	O
differentially	O	O
modulated	O	O
,	O	O
probably	O	O
through	O	O
activation	O	O
of	O	O
glutaminergic	O	O
neurons	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

Pharmacology	O	O
of	O	O
gamma	O	O
-	O	O
aminobutyric	O	O
acidA	O	O
receptor	O	O
complex	O	O
after	O	O
the	O	O
in	O	O
vivo	O	O
administration	O	O
of	O	O
the	O	O
anxioselective	O	O
and	O	O
anticonvulsant	O	O
beta	B-Chemical	D002243
-	I-Chemical	D002243
carboline	I-Chemical	D002243
derivative	O	O
abecarnil	B-Chemical	C062769
.	O	O

In	O	O
rodents	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
beta	B-Chemical	D002243
-	I-Chemical	D002243
carboline	I-Chemical	D002243
derivative	O	O
isopropyl	B-Chemical	C062769
-	I-Chemical	C062769
6	I-Chemical	C062769
-	I-Chemical	C062769
benzyloxy	I-Chemical	C062769
-	I-Chemical	C062769
4	I-Chemical	C062769
-	I-Chemical	C062769
methoxymethyl	I-Chemical	C062769
-	I-Chemical	C062769
beta	I-Chemical	C062769
-	I-Chemical	C062769
carboline	I-Chemical	C062769
-	I-Chemical	C062769
3	I-Chemical	C062769
-	I-Chemical	C062769
carboxylate	I-Chemical	C062769
(	O	O
abecarrnil	B-Chemical	C062769
)	O	O
,	O	O
a	O	O
new	O	O
ligand	O	O
for	O	O
benzodiazepine	B-Chemical	D001569
receptors	O	O
possessing	O	O
anxiolytic	O	O
and	O	O
anticonvulsant	O	O
properties	O	O
,	O	O
was	O	O
evaluated	O	O
on	O	O
the	O	O
function	O	O
of	O	O
central	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
GABA	B-Chemical	D005680
)	O	O
A	O	O
receptor	O	O
complex	O	O
,	O	O
both	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

Added	O	O
in	O	O
vitro	O	O
to	O	O
rat	O	O
cortical	O	O
membrane	O	O
preparation	O	O
,	O	O
abecarnil	B-Chemical	C062769
increased	O	O
[	O	O
3H	O	O
]	O	O
GABA	B-Chemical	D005680
binding	O	O
,	O	O
enhanced	O	O
muscimol	B-Chemical	D009118
-	O	O
stimulated	O	O
36Cl	O	O
-	O	O
uptake	O	O
and	O	O
reduced	O	O
the	O	O
binding	O	O
of	O	O
t	B-Chemical	C037476
-	I-Chemical	C037476
[	I-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
butylbicyclophosphorothionate	I-Chemical	C037476
(	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
)	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
similar	O	O
to	O	O
those	O	O
induced	O	O
by	O	O
diazepam	B-Chemical	D003975
,	O	O
whereas	O	O
the	O	O
partial	O	O
agonist	O	O
Ro	B-Chemical	C054626
16	I-Chemical	C054626
-	I-Chemical	C054626
6028	I-Chemical	C054626
(	O	O
tert	B-Chemical	C054626
-	I-Chemical	C054626
butyl	I-Chemical	C054626
-	I-Chemical	C054626
(	I-Chemical	C054626
S	I-Chemical	C054626
)	I-Chemical	C054626
-	I-Chemical	C054626
8	I-Chemical	C054626
-	I-Chemical	C054626
bromo	I-Chemical	C054626
-	I-Chemical	C054626
11	I-Chemical	C054626
,	I-Chemical	C054626
12	I-Chemical	C054626
,	I-Chemical	C054626
13	I-Chemical	C054626
,	I-Chemical	C054626
13a	I-Chemical	C054626
-	I-Chemical	C054626
tetrahydro	I-Chemical	C054626
-	I-Chemical	C054626
9	I-Chemical	C054626
-	I-Chemical	C054626
oxo	I-Chemical	C054626
-	I-Chemical	C054626
9H	I-Chemical	C054626
-	I-Chemical	C054626
imidazo	I-Chemical	C054626
[	I-Chemical	C054626
1	I-Chemical	C054626
,	I-Chemical	C054626
5	I-Chemical	C054626
-	I-Chemical	C054626
a	I-Chemical	C054626
]	I-Chemical	C054626
-	I-Chemical	C054626
pyrrolo	I-Chemical	C054626
-	I-Chemical	C054626
[	I-Chemical	C054626
2	I-Chemical	C054626
,	I-Chemical	C054626
1	I-Chemical	C054626
-	I-Chemical	C054626
c	I-Chemical	C054626
]	I-Chemical	C054626
[	I-Chemical	C054626
1	I-Chemical	C054626
,	I-Chemical	C054626
4	I-Chemical	C054626
]	I-Chemical	C054626
benzodiazepine	I-Chemical	C054626
-	I-Chemical	C054626
1	I-Chemical	C054626
-	I-Chemical	C054626
carboxylate	I-Chemical	C054626
)	O	O
showed	O	O
very	O	O
weak	O	O
efficacy	O	O
in	O	O
these	O	O
biochemical	O	O
tests	O	O
.	O	O

After	O	O
i	O	O
.	O	O

p	O	O
.	O	O

injection	O	O
to	O	O
rats	O	O
,	O	O
abecarnil	B-Chemical	C062769
and	O	O
diazepam	B-Chemical	D003975
decreased	O	O
in	O	O
a	O	O
time	O	O
-	O	O
dependent	O	O
and	O	O
dose	O	O
-	O	O
related	O	O
(	O	O
0	O	O
.	O	O

25	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
manner	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
binding	O	O
measured	O	O
ex	O	O
vivo	O	O
in	O	O
the	O	O
cerebral	O	O
cortex	O	O
.	O	O

Moreover	O	O
,	O	O
both	O	O
drugs	O	O
at	O	O
the	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
antagonized	O	O
completely	O	O
the	O	O
convulsant	O	O
activity	O	O
and	O	O
the	O	O
increase	O	O
of	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
binding	O	O
induced	O	O
by	O	O
isoniazide	B-Chemical	D007538
(	O	O
350	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
as	O	O
well	O	O
as	O	O
the	O	O
increase	O	O
of	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
binding	O	O
induced	O	O
by	O	O
foot	O	O
-	O	O
shock	O	O
stress	O	O
.	O	O

To	O	O
better	O	O
correlate	O	O
the	O	O
biochemical	O	O
and	O	O
the	O	O
pharmacological	O	O
effects	O	O
,	O	O
we	O	O
studied	O	O
the	O	O
action	O	O
of	O	O
abecarnil	B-Chemical	C062769
on	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
binding	O	O
,	O	O
exploratory	O	O
motility	O	O
and	O	O
on	O	O
isoniazid	B-Chemical	D007538
-	O	O
induced	O	O
biochemical	O	O
and	O	O
pharmacological	O	O
effects	O	O
in	O	O
mice	O	O
.	O	O

In	O	O
these	O	O
animals	O	O
,	O	O
abecarnil	B-Chemical	C062769
produced	O	O
a	O	O
paralleled	O	O
dose	O	O
-	O	O
dependent	O	O
(	O	O
0	O	O
.	O	O

05	O	O
-	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
reduction	O	O
of	O	O
both	O	O
motor	O	O
behavior	O	O
and	O	O
cortical	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
binding	O	O
.	O	O

Moreover	O	O
,	O	O
0	O	O
.	O	O

05	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
this	O	O
beta	B-Chemical	D002243
-	I-Chemical	D002243
carboline	I-Chemical	D002243
reduced	O	O
markedly	O	O
the	O	O
increase	O	O
of	O	O
[	B-Chemical	C037476
35S	I-Chemical	C037476
]	I-Chemical	C037476
TBPS	I-Chemical	C037476
binding	O	O
and	O	O
the	O	O
convulsions	B-Disease	D012640
induced	O	O
by	O	O
isoniazid	B-Chemical	D007538
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Recurrent	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
a	O	O
postpartum	O	O
patient	O	O
receiving	O	O
bromocriptine	B-Chemical	D001971
.	O	O

Myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
puerperium	O	O
is	O	O
infrequently	O	O
reported	O	O
.	O	O

Spasm	B-Disease	D013035
,	O	O
coronary	O	O
dissection	O	O
,	O	O
or	O	O
atheromatous	O	O
etiology	O	O
has	O	O
been	O	O
described	O	O
.	O	O

Bromocriptine	B-Chemical	D001971
has	O	O
been	O	O
implicated	O	O
in	O	O
several	O	O
previous	O	O
case	O	O
reports	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
the	O	O
puerperium	O	O
.	O	O

Our	O	O
case	O	O
(	O	O
including	O	O
an	O	O
inadvertent	O	O
rechallenge	O	O
)	O	O
suggests	O	O
such	O	O
a	O	O
relationship	O	O
.	O	O

Although	O	O
generally	O	O
regarded	O	O
as	O	O
"safe	O	O
,	O	O
"	O	O
possible	O	O
serious	O	O
cardiac	O	O
effects	O	O
of	O	O
bromocriptine	B-Chemical	D001971
should	O	O
be	O	O
acknowledged	O	O
.	O	O

Asterixis	B-Disease	D020820
induced	O	O
by	O	O
carbamazepine	B-Chemical	D002220
therapy	O	O
.	O	O

There	O	O
are	O	O
very	O	O
few	O	O
reports	O	O
about	O	O
asterixis	B-Disease	D020820
as	O	O
a	O	O
side	O	O
effect	O	O
of	O	O
treatment	O	O
with	O	O
psychopharmacologic	O	O
agents	O	O
.	O	O

In	O	O
this	O	O
report	O	O
we	O	O
present	O	O
four	O	O
patients	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
different	O	O
psychotropic	O	O
drugs	O	O
,	O	O
in	O	O
whom	O	O
asterixis	B-Disease	D020820
was	O	O
triggered	O	O
either	O	O
by	O	O
adding	O	O
carbamazepine	B-Chemical	D002220
(	O	O
CBZ	B-Chemical	D002220
)	O	O
to	O	O
a	O	O
treatment	O	O
regimen	O	O
,	O	O
or	O	O
by	O	O
increasing	O	O
its	O	O
dosage	O	O
.	O	O

Neither	O	O
dosage	O	O
nor	O	O
serum	O	O
levels	O	O
of	O	O
CBZ	B-Chemical	D002220
were	O	O
in	O	O
a	O	O
higher	O	O
range	O	O
.	O	O

We	O	O
consider	O	O
asterixis	B-Disease	D020820
to	O	O
be	O	O
an	O	O
easily	O	O
overlooked	O	O
sign	O	O
of	O	O
neurotoxicity	B-Disease	D020258
,	O	O
which	O	O
may	O	O
occur	O	O
even	O	O
at	O	O
low	O	O
or	O	O
moderate	O	O
dosage	O	O
levels	O	O
,	O	O
if	O	O
certain	O	O
drugs	O	O
as	O	O
lithium	B-Chemical	D008094
or	O	O
clozapine	B-Chemical	D003024
are	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
CBZ	B-Chemical	D002220
.	O	O

Pharmacodynamics	O	O
of	O	O
the	O	O
hypotensive	B-Disease	D007022
effect	O	O
of	O	O
levodopa	B-Chemical	D007980
in	O	O
parkinsonian	B-Disease	D010300
patients	O	O
.	O	O

Blood	O	O
pressure	O	O
effects	O	O
of	O	O
i	O	O
.	O	O

v	O	O
.	O	O

levodopa	B-Chemical	D007980
were	O	O
examined	O	O
in	O	O
parkinsonian	B-Disease	D010300
patients	O	O
with	O	O
stable	O	O
and	O	O
fluctuating	O	O
responses	O	O
to	O	O
levodopa	B-Chemical	D007980
.	O	O

The	O	O
magnitude	O	O
of	O	O
the	O	O
hypotensive	B-Disease	D007022
effect	O	O
of	O	O
levodopa	B-Chemical	D007980
was	O	O
concentration	O	O
dependent	O	O
and	O	O
was	O	O
fit	O	O
to	O	O
an	O	O
Emax	O	O
model	O	O
in	O	O
fluctuating	O	O
responders	O	O
.	O	O

Stable	O	O
responders	O	O
demonstrated	O	O
a	O	O
small	O	O
hypotensive	B-Disease	D007022
response	O	O
.	O	O

Baseline	O	O
blood	O	O
pressures	O	O
were	O	O
higher	O	O
in	O	O
fluctuating	O	O
patients	O	O
;	O	O
a	O	O
higher	O	O
baseline	O	O
blood	O	O
pressure	O	O
correlated	O	O
with	O	O
greater	O	O
hypotensive	B-Disease	D007022
effects	O	O
.	O	O

Antiparkinsonian	O	O
effects	O	O
of	O	O
levodopa	B-Chemical	D007980
temporally	O	O
correlated	O	O
with	O	O
blood	O	O
pressure	O	O
changes	O	O
.	O	O

Phenylalanine	B-Chemical	D010649
,	O	O
a	O	O
large	O	O
neutral	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
(	O	O
LNAA	O	O
)	O	O
competing	O	O
with	O	O
levodopa	B-Chemical	D007980
for	O	O
transport	O	O
across	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
,	O	O
reduced	O	O
the	O	O
hypotensive	B-Disease	D007022
and	O	O
antiparkinsonian	O	O
effects	O	O
of	O	O
levodopa	B-Chemical	D007980
.	O	O

We	O	O
conclude	O	O
that	O	O
levodopa	B-Chemical	D007980
has	O	O
a	O	O
central	O	O
hypotensive	B-Disease	D007022
action	O	O
that	O	O
parallels	O	O
the	O	O
motor	O	O
effects	O	O
in	O	O
fluctuating	O	O
patients	O	O
.	O	O

The	O	O
hypotensive	B-Disease	D007022
effect	O	O
appears	O	O
to	O	O
be	O	O
related	O	O
to	O	O
the	O	O
higher	O	O
baseline	O	O
blood	O	O
pressure	O	O
we	O	O
observed	O	O
in	O	O
fluctuating	O	O
patients	O	O
relative	O	O
to	O	O
stable	O	O
patients	O	O
.	O	O

Syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
secretion	I-Disease	D007177
of	I-Disease	D007177
antidiuretic	I-Disease	D007177
hormone	I-Disease	D007177
after	O	O
infusional	O	O
vincristine	B-Chemical	D014750
.	O	O

A	O	O
77	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
refractory	O	O
multiple	B-Disease	D009101
myeloma	I-Disease	D009101
was	O	O
treated	O	O
with	O	O
a	O	O
4	O	O
-	O	O
day	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
vincristine	B-Chemical	D014750
and	O	O
doxorubicin	B-Chemical	D004317
and	O	O
4	O	O
days	O	O
of	O	O
oral	O	O
dexamethasone	B-Chemical	D003907
.	O	O

Nine	O	O
days	O	O
after	O	O
her	O	O
second	O	O
cycle	O	O
she	O	O
presented	O	O
with	O	O
lethargy	B-Disease	D053609
and	O	O
weakness	B-Disease	D018908
associated	O	O
with	O	O
hyponatremia	B-Disease	D007010
.	O	O

Evaluation	O	O
revealed	O	O
the	O	O
syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
secretion	I-Disease	D007177
of	I-Disease	D007177
antidiuretic	I-Disease	D007177
hormone	I-Disease	D007177
,	O	O
which	O	O
was	O	O
attributed	O	O
to	O	O
the	O	O
vincristine	B-Chemical	D014750
infusion	O	O
.	O	O

After	O	O
normal	O	O
serum	O	O
sodium	B-Chemical	D012964
levels	O	O
returned	O	O
,	O	O
further	O	O
doxorubicin	B-Chemical	D004317
and	O	O
dexamethasone	B-Chemical	D003907
chemotherapy	O	O
without	O	O
vincristine	B-Chemical	D014750
did	O	O
not	O	O
produce	O	O
this	O	O
complication	O	O
.	O	O

Heart	B-Disease	D006333
failure	I-Disease	D006333
:	O	O
to	O	O
digitalise	O	O
or	O	O
not?	O	O
The	O	O
view	O	O
against	O	O
.	O	O

Despite	O	O
extensive	O	O
clinical	O	O
experience	O	O
the	O	O
role	O	O
of	O	O
digoxin	B-Chemical	D004077
is	O	O
still	O	O
not	O	O
well	O	O
defined	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
digoxin	B-Chemical	D004077
is	O	O
beneficial	O	O
for	O	O
ventricular	O	O
rate	O	O
control	O	O
.	O	O

For	O	O
patients	O	O
in	O	O
sinus	O	O
rhythm	O	O
and	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
the	O	O
situation	O	O
is	O	O
less	O	O
clear	O	O
.	O	O

Digoxin	B-Chemical	D004077
has	O	O
a	O	O
narrow	O	O
therapeutic	O	O
:	O	O
toxic	O	O
ratio	O	O
and	O	O
concentrations	O	O
are	O	O
affected	O	O
by	O	O
a	O	O
number	O	O
of	O	O
drugs	O	O
.	O	O

Also	O	O
,	O	O
digoxin	B-Chemical	D004077
has	O	O
undesirable	O	O
effects	O	O
such	O	O
as	O	O
increasing	O	O
peripheral	O	O
resistance	O	O
and	O	O
myocardial	O	O
demands	O	O
,	O	O
and	O	O
causing	O	O
arrhythmias	B-Disease	D001145
.	O	O

There	O	O
is	O	O
a	O	O
paucity	O	O
of	O	O
data	O	O
from	O	O
well	O	O
-	O	O
designed	O	O
trials	O	O
.	O	O

The	O	O
trials	O	O
that	O	O
are	O	O
available	O	O
are	O	O
generally	O	O
small	O	O
with	O	O
limitations	O	O
in	O	O
design	O	O
and	O	O
these	O	O
show	O	O
variation	O	O
in	O	O
patient	O	O
benefit	O	O
.	O	O

More	O	O
convincing	O	O
evidence	O	O
is	O	O
required	O	O
showing	O	O
that	O	O
digoxin	B-Chemical	D004077
improves	O	O
symptoms	O	O
or	O	O
exercise	O	O
capacity	O	O
.	O	O

Furthermore	O	O
,	O	O
no	O	O
trial	O	O
has	O	O
had	O	O
sufficient	O	O
power	O	O
to	O	O
evaluate	O	O
mortality	O	O
.	O	O

Pooled	O	O
analysis	O	O
of	O	O
the	O	O
effects	O	O
of	O	O
other	O	O
inotropic	O	O
drugs	O	O
shows	O	O
an	O	O
excess	O	O
mortality	O	O
and	O	O
there	O	O
is	O	O
a	O	O
possibility	O	O
that	O	O
digoxin	B-Chemical	D004077
may	O	O
increase	O	O
mortality	O	O
after	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
MI	B-Disease	D009203
)	O	O
.	O	O

Angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
inhibitors	O	O
should	O	O
be	O	O
used	O	O
first	O	O
as	O	O
they	O	O
are	O	O
safer	O	O
,	O	O
do	O	O
not	O	O
require	O	O
blood	O	O
level	O	O
monitoring	O	O
,	O	O
modify	O	O
progression	O	O
of	O	O
disease	O	O
,	O	O
relieve	O	O
symptoms	O	O
,	O	O
improve	O	O
exercise	O	O
tolerance	O	O
and	O	O
reduce	O	O
mortality	O	O
.	O	O

Caution	O	O
should	O	O
be	O	O
exercised	O	O
in	O	O
using	O	O
digoxin	B-Chemical	D004077
until	O	O
large	O	O
mortality	O	O
trials	O	O
are	O	O
completed	O	O
showing	O	O
either	O	O
benefit	O	O
or	O	O
harm	O	O
.	O	O

Until	O	O
then	O	O
digoxin	B-Chemical	D004077
should	O	O
be	O	O
considered	O	O
a	O	O
third	O	O
-	O	O
line	O	O
therapy	O	O
.	O	O

Intravascular	O	O
hemolysis	B-Disease	D006461
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
following	O	O
intermittent	O	O
rifampin	B-Chemical	D012293
therapy	O	O
.	O	O

Renal	B-Disease	D051437
failure	I-Disease	D051437
is	O	O
a	O	O
rare	O	O
complication	O	O
associated	O	O
with	O	O
the	O	O
use	O	O
of	O	O
rifampin	B-Chemical	D012293
.	O	O

Intravascular	O	O
hemolysis	B-Disease	D006461
leading	O	O
to	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
following	O	O
rifampin	B-Chemical	D012293
therapy	O	O
is	O	O
extremely	O	O
rare	O	O
.	O	O

Two	O	O
patients	O	O
with	O	O
leprosy	B-Disease	D007918
who	O	O
developed	O	O
hemolysis	B-Disease	D006461
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
following	O	O
rifampin	B-Chemical	D012293
are	O	O
reported	O	O
.	O	O

Zidovudine	B-Chemical	D015215
-	O	O
induced	O	O
hepatitis	B-Disease	D056486
.	O	O

A	O	O
case	O	O
of	O	O
acute	O	O
hepatitis	B-Disease	D056486
induced	O	O
by	O	O
zidovudine	B-Chemical	D015215
in	O	O
a	O	O
38	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
with	O	O
AIDS	B-Disease	D000163
is	O	O
presented	O	O
.	O	O

The	O	O
mechanism	O	O
whereby	O	O
the	O	O
hepatitis	B-Disease	D056486
was	O	O
induced	O	O
is	O	O
not	O	O
known	O	O
.	O	O

However	O	O
,	O	O
the	O	O
patient	O	O
tolerated	O	O
well	O	O
an	O	O
alternative	O	O
reverse	O	O
transcriptase	O	O
inhibitor	O	O
,	O	O
2'3'	B-Chemical	D016049
dideoxyinosine	I-Chemical	D016049
.	O	O

Physicians	O	O
caring	O	O
for	O	O
patients	O	O
with	O	O
AIDS	B-Disease	D000163
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
hitherto	O	O
rarely	O	O
reported	O	O
complication	O	O
.	O	O

Thoracic	B-Disease	D020758
hematomyelia	I-Disease	D020758
secondary	O	O
to	O	O
coumadin	B-Chemical	D014859
anticoagulant	O	O
therapy	O	O
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

A	O	O
case	O	O
of	O	O
thoracic	B-Disease	D020758
hematomyelia	I-Disease	D020758
secondary	O	O
to	O	O
anticoagulant	O	O
therapy	O	O
is	O	O
presented	O	O
.	O	O

Clinical	O	O
features	O	O
,	O	O
similar	O	O
to	O	O
2	O	O
other	O	O
previously	O	O
reported	O	O
cases	O	O
,	O	O
are	O	O
discussed	O	O
.	O	O

A	O	O
high	O	O
index	O	O
of	O	O
suspicion	O	O
may	O	O
lead	O	O
to	O	O
a	O	O
quick	O	O
diagnostic	O	O
procedure	O	O
and	O	O
successful	O	O
decompressive	O	O
surgery	O	O
.	O	O

Mania	B-Disease	D001714
associated	O	O
with	O	O
fluoxetine	B-Chemical	D005473
treatment	O	O
in	O	O
adolescents	O	O
.	O	O

Fluoxetine	B-Chemical	D005473
,	O	O
a	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitor	O	O
,	O	O
is	O	O
gaining	O	O
increased	O	O
acceptance	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
adolescent	O	O
depression	B-Disease	D003866
.	O	O

Generally	O	O
safe	O	O
and	O	O
well	O	O
tolerated	O	O
by	O	O
adults	O	O
,	O	O
fluoxetine	B-Chemical	D005473
has	O	O
been	O	O
reported	O	O
to	O	O
induce	O	O
mania	B-Disease	D001714
.	O	O

The	O	O
cases	O	O
of	O	O
five	O	O
depressed	B-Disease	D003866
adolescents	O	O
,	O	O
14	O	O
-	O	O
16	O	O
years	O	O
of	O	O
age	O	O
,	O	O
who	O	O
developed	O	O
mania	B-Disease	D001714
during	O	O
pharmacotherapy	O	O
with	O	O
fluoxetine	B-Chemical	D005473
,	O	O
are	O	O
reported	O	O
here	O	O
.	O	O

Apparent	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
mania	B-Disease	D001714
or	O	O
hypomania	B-Disease	D001714
during	O	O
fluoxetine	B-Chemical	D005473
pharmacotherapy	O	O
in	O	O
this	O	O
population	O	O
were	O	O
the	O	O
combination	O	O
of	O	O
attention	B-Disease	D001289
-	I-Disease	D001289
deficit	I-Disease	D001289
hyperactivity	I-Disease	D001289
disorder	I-Disease	D001289
and	O	O
affective	O	O
instability	O	O
;	O	O
major	O	O
depression	B-Disease	D003866
with	O	O
psychotic	B-Disease	D011618
features	O	O
;	O	O
a	O	O
family	O	O
history	O	O
of	O	O
affective	B-Disease	D019964
disorder	I-Disease	D019964
,	O	O
especially	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
;	O	O
and	O	O
a	O	O
diagnosis	O	O
of	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
.	O	O

Further	O	O
study	O	O
is	O	O
needed	O	O
to	O	O
determine	O	O
the	O	O
optimal	O	O
dosage	O	O
and	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
that	O	O
increase	O	O
individual	O	O
vulnerability	O	O
to	O	O
fluoxetine	B-Chemical	D005473
induced	O	O
mania	B-Disease	D001714
in	O	O
adolescents	O	O
.	O	O

Gemfibrozil	B-Chemical	D015248
-	O	O
lovastatin	B-Chemical	D008148
therapy	O	O
for	O	O
primary	O	O
hyperlipoproteinemias	B-Disease	D006951
.	O	O

The	O	O
specific	O	O
aim	O	O
of	O	O
this	O	O
retrospective	O	O
,	O	O
observational	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
long	O	O
-	O	O
term	O	O
(	O	O
21	O	O
months	O	O
/	O	O
patient	O	O
)	O	O
,	O	O
open	O	O
-	O	O
label	O	O
,	O	O
gemfibrozil	B-Chemical	D015248
-	O	O
lovastatin	B-Chemical	D008148
treatment	O	O
in	O	O
80	O	O
patients	O	O
with	O	O
primary	O	O
mixed	O	O
hyperlipidemia	B-Disease	D006949
(	O	O
68%	O	O
of	O	O
whom	O	O
had	O	O
atherosclerotic	B-Disease	D002340
vascular	I-Disease	D002340
disease	I-Disease	D002340
)	O	O
.	O	O

Because	O	O
ideal	O	O
lipid	O	O
targets	O	O
were	O	O
not	O	O
reached	O	O
(	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
cholesterol	B-Chemical	D002784
less	O	O
than	O	O
130	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
high	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
HDL	O	O
)	O	O
cholesterol	B-Chemical	D002784
greater	O	O
than	O	O
35	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
or	O	O
total	O	O
cholesterol	B-Chemical	D002784
/	O	O
HDL	O	O
cholesterol	B-Chemical	D002784
less	O	O
than	O	O
4	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
with	O	O
diet	O	O
plus	O	O
a	O	O
single	O	O
drug	O	O
,	O	O
gemfibrozil	B-Chemical	D015248
(	O	O
1	O	O
.	O	O

2	O	O
g	O	O
/	O	O
day	O	O
)	O	O
-	O	O
lovastatin	B-Chemical	D008148
(	O	O
primarily	O	O
20	O	O
or	O	O
40	O	O
mg	O	O
)	O	O
treatment	O	O
was	O	O
given	O	O
.	O	O

Follow	O	O
-	O	O
up	O	O
visits	O	O
were	O	O
scheduled	O	O
with	O	O
2	O	O
-	O	O
drug	O	O
therapy	O	O
every	O	O
6	O	O
to	O	O
8	O	O
weeks	O	O
,	O	O
an	O	O
average	O	O
of	O	O
10	O	O
.	O	O

3	O	O
visits	O	O
per	O	O
patient	O	O
,	O	O
with	O	O
741	O	O
batteries	O	O
of	O	O
6	O	O
liver	O	O
function	O	O
tests	O	O
and	O	O
714	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
levels	O	O
measured	O	O
.	O	O

Only	O	O
1	O	O
of	O	O
the	O	O
4	O	O
,	O	O
446	O	O
liver	O	O
function	O	O
tests	O	O
(	O	O
0	O	O
.	O	O

02%	O	O
)	O	O
,	O	O
a	O	O
gamma	O	O
glutamyl	O	O
transferase	O	O
,	O	O
was	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

Of	O	O
the	O	O
714	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
levels	O	O
,	O	O
9%	O	O
were	O	O
high	O	O
;	O	O
only	O	O
1	O	O
(	O	O
0	O	O
.	O	O

1%	O	O
)	O	O
was	O	O
greater	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
3	O	O
times	O	O
the	O	O
upper	O	O
normal	O	O
limit	O	O
.	O	O

With	O	O
2	O	O
-	O	O
drug	O	O
therapy	O	O
,	O	O
mean	O	O
total	O	O
cholesterol	B-Chemical	D002784
decreased	O	O
22%	O	O
from	O	O
255	O	O
to	O	O
200	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
triglyceride	B-Chemical	D014280
levels	O	O
decreased	O	O
35%	O	O
from	O	O
236	O	O
to	O	O
154	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
LDL	O	O
cholesterol	B-Chemical	D002784
decreased	O	O
26%	O	O
from	O	O
176	O	O
to	O	O
131	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
and	O	O
the	O	O
total	O	O
cholesterol	B-Chemical	D002784
/	O	O
HDL	O	O
cholesterol	B-Chemical	D002784
ratio	O	O
decreased	O	O
24%	O	O
from	O	O
7	O	O
.	O	O

1	O	O
to	O	O
5	O	O
.	O	O

4	O	O
,	O	O
all	O	O
p	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
0	O	O
.	O	O

0001	O	O
.	O	O

Myositis	B-Disease	D009220
,	O	O
attributable	O	O
to	O	O
the	O	O
drug	O	O
combination	O	O
and	O	O
symptomatic	O	O
enough	O	O
to	O	O
discontinue	O	O
it	O	O
,	O	O
occurred	O	O
in	O	O
3%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
in	O	O
1%	O	O
with	O	O
concurrent	O	O
high	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
(	O	O
769	O	O
U	O	O
/	O	O
liter	O	O
)	O	O
;	O	O
no	O	O
patients	O	O
had	O	O
rhabdomyolysis	B-Disease	D012206
or	O	O
myoglobinuria	B-Disease	D009212
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
in	O	O
Fanconi's	B-Disease	D005199
anemia	I-Disease	D005199
treated	O	O
with	O	O
androgen	B-Chemical	D000728
and	O	O
corticosteroid	B-Chemical	D000305
.	O	O

The	O	O
case	O	O
of	O	O
an	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
is	O	O
reported	O	O
who	O	O
was	O	O
known	O	O
to	O	O
have	O	O
Fanconi's	B-Disease	D005199
anemia	I-Disease	D005199
for	O	O
3	O	O
years	O	O
and	O	O
was	O	O
treated	O	O
with	O	O
androgens	B-Chemical	D000728
,	O	O
corticosteroids	B-Chemical	D000305
and	O	O
transfusions	O	O
.	O	O

Two	O	O
weeks	O	O
before	O	O
his	O	O
death	O	O
he	O	O
was	O	O
readmitted	O	O
because	O	O
of	O	O
aplastic	O	O
crisis	O	O
with	O	O
septicemia	B-Disease	D018805
and	O	O
marked	O	O
abnormalities	O	O
in	O	O
liver	O	O
function	O	O
and	O	O
died	O	O
of	O	O
hemorrhagic	B-Disease	D001996
bronchopneumonia	I-Disease	D001996
.	O	O

At	O	O
autopsy	O	O
peliosis	B-Disease	D010382
and	O	O
multiple	O	O
hepatic	B-Disease	D008113
tumors	I-Disease	D008113
were	O	O
found	O	O
which	O	O
histologically	O	O
proved	O	O
to	O	O
be	O	O
well	O	O
-	O	O
differentiated	O	O
hepatocellular	B-Disease	D006528
carcinoma	I-Disease	D006528
.	O	O

This	O	O
case	O	O
contributes	O	O
to	O	O
the	O	O
previous	O	O
observations	O	O
that	O	O
non	O	O
-	O	O
metastasizing	O	O
hepatic	B-Disease	D008113
neoplasms	I-Disease	D008113
and	O	O
peliosis	B-Disease	D010382
can	O	O
develop	O	O
in	O	O
patients	O	O
with	O	O
androgen	B-Chemical	D000728
-	O	O
and	O	O
corticosteroid	B-Chemical	D000305
-	O	O
treated	O	O
Fanconi's	B-Disease	D005199
anemia	I-Disease	D005199
.	O	O

Chronic	O	O
lesion	O	O
of	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
in	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
chronic	O	O
selective	O	O
neuronal	O	O
lesion	O	O
of	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
on	O	O
mean	O	O
arterial	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
neurogenic	O	O
tone	O	O
in	O	O
conscious	O	O
,	O	O
unrestrained	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

The	O	O
lesions	O	O
were	O	O
placed	O	O
via	O	O
bilateral	O	O
microinjections	O	O
of	O	O
30	O	O
nmol	O	O
/	O	O
200	O	O
nl	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartic	I-Chemical	D016202
acid	I-Chemical	D016202
.	O	O

The	O	O
restimulation	O	O
of	O	O
this	O	O
area	O	O
with	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartic	I-Chemical	D016202
acid	I-Chemical	D016202
15	O	O
days	O	O
postlesion	O	O
failed	O	O
to	O	O
produce	O	O
a	O	O
pressor	O	O
response	O	O
.	O	O

One	O	O
day	O	O
postlesion	O	O
,	O	O
the	O	O
resting	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
significantly	O	O
decreased	O	O
in	O	O
lesioned	O	O
rats	O	O
when	O	O
compared	O	O
with	O	O
sham	O	O
rats	O	O
(	O	O
100	O	O
+	O	O
/	O	O
-	O	O
7	O	O
versus	O	O
173	O	O
+	O	O
/	O	O
-	O	O
4	O	O
mm	O	O
Hg	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Fifteen	O	O
days	O	O
later	O	O
,	O	O
the	O	O
lesioned	O	O
group	O	O
still	O	O
showed	O	O
values	O	O
significantly	O	O
lower	O	O
than	O	O
the	O	O
sham	O	O
group	O	O
(	O	O
150	O	O
+	O	O
/	O	O
-	O	O
6	O	O
versus	O	O
167	O	O
+	O	O
/	O	O
-	O	O
5	O	O
mm	O	O
Hg	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

No	O	O
significant	O	O
heart	O	O
rate	O	O
differences	O	O
were	O	O
observed	O	O
between	O	O
the	O	O
sham	O	O
and	O	O
lesioned	O	O
groups	O	O
.	O	O

The	O	O
ganglionic	O	O
blocker	O	O
trimethaphan	B-Chemical	D014294
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
caused	O	O
similar	O	O
reductions	O	O
in	O	O
mean	O	O
arterial	O	O
pressure	O	O
in	O	O
both	O	O
lesioned	O	O
and	O	O
sham	O	O
groups	O	O
.	O	O

The	O	O
trimethaphan	B-Chemical	D014294
-	O	O
induced	O	O
hypotension	B-Disease	D007022
was	O	O
accompanied	O	O
by	O	O
a	O	O
significant	O	O
bradycardia	B-Disease	D001919
in	O	O
lesioned	O	O
rats	O	O
(	O	O
-	O	O
32	O	O
+	O	O
/	O	O
-	O	O
13	O	O
beats	O	O
per	O	O
minute	O	O
)	O	O
but	O	O
a	O	O
tachycardia	B-Disease	D013610
in	O	O
sham	O	O
rats	O	O
(	O	O
+33	O	O
+	O	O
/	O	O
-	O	O
12	O	O
beats	O	O
per	O	O
minute	O	O
)	O	O
1	O	O
day	O	O
postlesion	O	O
.	O	O

Therefore	O	O
,	O	O
rostral	O	O
ventrolateral	O	O
medulla	O	O
neurons	O	O
appear	O	O
to	O	O
play	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
maintaining	O	O
hypertension	B-Disease	D006973
in	O	O
conscious	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

Spinal	O	O
or	O	O
suprabulbar	O	O
structures	O	O
could	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
gradual	O	O
recovery	O	O
of	O	O
the	O	O
hypertension	B-Disease	D006973
in	O	O
the	O	O
lesioned	O	O
rats	O	O
.	O	O

Damage	B-Disease	D001930
of	I-Disease	D001930
substantia	I-Disease	D001930
nigra	I-Disease	D001930
pars	I-Disease	D001930
reticulata	I-Disease	D001930
during	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
the	O	O
rat	O	O
:	O	O
immunohistochemical	O	O
study	O	O
of	O	O
neurons	O	O
,	O	O
astrocytes	O	O
and	O	O
serum	O	O
-	O	O
protein	O	O
extravasation	O	O
.	O	O

The	O	O
substantia	O	O
nigra	O	O
has	O	O
a	O	O
gating	O	O
function	O	O
controlling	O	O
the	O	O
spread	O	O
of	O	O
epileptic	B-Disease	D004827
seizure	I-Disease	D004827
activity	O	O
.	O	O

Additionally	O	O
,	O	O
in	O	O
models	O	O
of	O	O
prolonged	B-Disease	D013226
status	I-Disease	D013226
epilepticus	I-Disease	D013226
the	O	O
pars	O	O
reticulata	O	O
of	O	O
substantia	O	O
nigra	O	O
(	O	O
SNR	O	O
)	O	O
suffers	O	O
from	O	O
a	O	O
massive	O	O
lesion	O	O
which	O	O
may	O	O
arise	O	O
from	O	O
a	O	O
massive	O	O
metabolic	B-Disease	D008659
derangement	I-Disease	D008659
and	O	O
hyperexcitation	O	O
developing	O	O
in	O	O
the	O	O
activated	O	O
SNR	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
was	O	O
induced	O	O
by	O	O
systemic	O	O
injection	O	O
of	O	O
pilocarpine	B-Chemical	D010862
in	O	O
rats	O	O
.	O	O

The	O	O
neuropathology	O	O
of	O	O
SNR	O	O
was	O	O
investigated	O	O
using	O	O
immunohistochemical	O	O
techniques	O	O
with	O	O
the	O	O
major	O	O
emphasis	O	O
on	O	O
the	O	O
time	O	O
-	O	O
course	O	O
of	O	O
changes	O	O
in	O	O
neurons	O	O
and	O	O
astrocytes	O	O
.	O	O

Animals	O	O
surviving	O	O
20	O	O
,	O	O
30	O	O
,	O	O
40	O	O
,	O	O
60	O	O
min	O	O
,	O	O
2	O	O
,	O	O
3	O	O
,	O	O
6	O	O
hours	O	O
,	O	O
1	O	O
,	O	O
2	O	O
,	O	O
and	O	O
3	O	O
days	O	O
after	O	O
induction	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
were	O	O
perfusion	O	O
-	O	O
fixed	O	O
,	O	O
and	O	O
brains	O	O
processed	O	O
for	O	O
immunohistochemical	O	O
staining	O	O
of	O	O
SNR	O	O
.	O	O

Nissl	O	O
-	O	O
staining	O	O
and	O	O
antibodies	O	O
against	O	O
the	O	O
neuron	O	O
-	O	O
specific	O	O
calcium	B-Chemical	D002118
-	O	O
binding	O	O
protein	O	O
,	O	O
parvalbumin	O	O
,	O	O
served	O	O
to	O	O
detect	O	O
neuronal	B-Disease	D009422
damage	I-Disease	D009422
in	O	O
SNR	O	O
.	O	O

Antibodies	O	O
against	O	O
the	O	O
astroglia	O	O
-	O	O
specific	O	O
cytoskeletal	O	O
protein	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
(	O	O
GFAP	O	O
)	O	O
,	O	O
and	O	O
against	O	O
the	O	O
glial	O	O
calcium	B-Chemical	D002118
-	O	O
binding	O	O
protein	O	O
,	O	O
S	O	O
-	O	O
100	O	O
protein	O	O
,	O	O
were	O	O
used	O	O
to	O	O
assess	O	O
the	O	O
status	O	O
of	O	O
astrocytes	O	O
.	O	O

Immunohistochemical	O	O
staining	O	O
for	O	O
serum	O	O
-	O	O
albumin	O	O
and	O	O
immunoglobulins	O	O
in	O	O
brain	O	O
tissue	O	O
was	O	O
taken	O	O
as	O	O
indicator	O	O
of	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
disturbances	O	O
and	O	O
vasogenic	B-Disease	D001929
edema	I-Disease	D001929
formation	O	O
.	O	O

Immunohistochemical	O	O
staining	O	O
indicated	O	O
loss	O	O
of	O	O
GFAP	O	O
-	O	O
staining	O	O
already	O	O
at	O	O
30	O	O
min	O	O
after	O	O
induction	O	O
of	O	O
seizures	B-Disease	D012640
in	O	O
an	O	O
oval	O	O
focus	O	O
situated	O	O
in	O	O
the	O	O
center	O	O
of	O	O
SNR	O	O
while	O	O
sparing	O	O
medial	O	O
and	O	O
lateral	O	O
aspects	O	O
.	O	O

At	O	O
1	O	O
h	O	O
there	O	O
was	O	O
additional	O	O
vacuolation	O	O
in	O	O
S	O	O
-	O	O
100	O	O
protein	O	O
staining	O	O
.	O	O

By	O	O
2	O	O
hours	O	O
,	O	O
parvalbumin	O	O
-	O	O
staining	O	O
changed	O	O
in	O	O
the	O	O
central	O	O
SNR	O	O
indicating	O	O
neuronal	B-Disease	D009422
damage	I-Disease	D009422
,	O	O
and	O	O
Nissl	O	O
-	O	O
staining	O	O
visualized	O	O
some	O	O
neuronal	O	O
distortion	O	O
.	O	O

Staining	O	O
for	O	O
serum	O	O
-	O	O
proteins	O	O
occurred	O	O
in	O	O
a	O	O
patchy	O	O
manner	O	O
throughout	O	O
the	O	O
forebrain	O	O
during	O	O
the	O	O
first	O	O
hours	O	O
.	O	O

By	O	O
6	O	O
h	O	O
,	O	O
vasogenic	B-Disease	D001929
edema	I-Disease	D001929
covered	O	O
the	O	O
lesioned	B-Disease	D001930
SNR	I-Disease	D001930
.	O	O

By	O	O
24	O	O
h	O	O
,	O	O
glial	O	O
and	O	O
neuronal	O	O
markers	O	O
indicated	O	O
a	O	O
massive	O	O
lesion	O	O
in	O	O
the	O	O
center	O	O
of	O	O
SNR	O	O
.	O	O

By	O	O
48	O	O
-	O	O
72	O	O
h	O	O
,	O	O
astrocytes	O	O
surrounding	O	O
the	O	O
lesion	O	O
increased	O	O
in	O	O
size	O	O
,	O	O
and	O	O
polymorphic	O	O
phagocytotic	O	O
cells	O	O
invaded	O	O
the	O	O
damaged	O	O
area	O	O
.	O	O

In	O	O
a	O	O
further	O	O
group	O	O
of	O	O
animals	O	O
surviving	O	O
1	O	O
to	O	O
5	O	O
days	O	O
,	O	O
conventional	O	O
paraffin	O	O
-	O	O
sections	O	O
confirmed	O	O
the	O	O
neuronal	O	O
and	O	O
glial	O	O
damage	B-Disease	D001930
of	I-Disease	D001930
SNR	I-Disease	D001930
.	O	O

Additional	O	O
pathology	O	O
of	O	O
similar	O	O
quality	O	O
was	O	O
found	O	O
in	O	O
the	O	O
globus	O	O
pallidus	O	O
.	O	O

Since	O	O
astrocytes	O	O
were	O	O
always	O	O
damaged	O	O
in	O	O
parallel	O	O
with	O	O
neurons	O	O
in	O	O
SNR	O	O
it	O	O
is	O	O
proposed	O	O
that	O	O
the	O	O
anatomical	O	O
and	O	O
functional	O	O
interrelationship	O	O
between	O	O
neurons	O	O
and	O	O
astrocytes	O	O
is	O	O
particularly	O	O
tight	O	O
in	O	O
SNR	O	O
.	O	O

Both	O	O
cell	O	O
elements	O	O
may	O	O
suffer	O	O
in	O	O
common	O	O
from	O	O
metabolic	O	O
disturbance	O	O
and	O	O
neurotransmitter	B-Disease	D001480
dysfunction	I-Disease	D001480
as	O	O
occur	O	O
during	O	O
massive	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

Reduced	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
doxorubicin	B-Chemical	D004317
given	O	O
in	O	O
the	O	O
form	O	O
of	O	O
N	B-Chemical	C032976
-	I-Chemical	C032976
(	I-Chemical	C032976
2	I-Chemical	C032976
-	I-Chemical	C032976
hydroxypropyl	I-Chemical	C032976
)	I-Chemical	C032976
methacrylamide	I-Chemical	C032976
conjugates	O	O
:	O	O
and	O	O
experimental	O	O
study	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

A	O	O
rat	O	O
model	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
general	O	O
acute	O	O
toxicity	B-Disease	D064420
and	O	O
the	O	O
late	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
given	O	O
either	O	O
as	O	O
free	O	O
drug	O	O
or	O	O
in	O	O
the	O	O
form	O	O
of	O	O
three	O	O
N	B-Chemical	C032976
-	I-Chemical	C032976
(	I-Chemical	C032976
2	I-Chemical	C032976
-	I-Chemical	C032976
hydroxypropyl	I-Chemical	C032976
)	I-Chemical	C032976
methacrylamide	I-Chemical	C032976
(	O	O
HPMA	B-Chemical	C032976
)	O	O
copolymer	O	O
conjugates	O	O
.	O	O

In	O	O
these	O	O
HPMA	B-Chemical	C032976
copolymers	O	O
,	O	O
DOX	B-Chemical	D004317
was	O	O
covalently	O	O
bound	O	O
via	O	O
peptide	O	O
linkages	O	O
that	O	O
were	O	O
either	O	O
non	O	O
-	O	O
biodegradable	O	O
(	O	O
Gly	O	O
-	O	O
Gly	O	O
)	O	O
or	O	O
degradable	O	O
by	O	O
lysosomal	O	O
proteinases	O	O
(	O	O
Gly	B-Chemical	C504380
-	I-Chemical	C504380
Phe	I-Chemical	C504380
-	I-Chemical	C504380
Leu	I-Chemical	C504380
-	I-Chemical	C504380
Gly	I-Chemical	C504380
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
one	O	O
biodegradable	O	O
conjugate	O	O
containing	O	O
galactosamine	B-Chemical	D005688
was	O	O
used	O	O
;	O	O
this	O	O
residue	O	O
was	O	O
targeted	O	O
to	O	O
the	O	O
liver	O	O
.	O	O

Over	O	O
the	O	O
first	O	O
3	O	O
weeks	O	O
after	O	O
the	O	O
i	O	O
.	O	O

v	O	O
.	O	O

administration	O	O
of	O	O
free	O	O
and	O	O
polymer	O	O
-	O	O
bound	O	O
DOX	B-Chemical	D004317
,	O	O
all	O	O
animals	O	O
showed	O	O
a	O	O
transient	O	O
reduction	O	O
in	O	O
body	O	O
weight	O	O
.	O	O

However	O	O
,	O	O
the	O	O
maximal	O	O
reduction	O	O
in	O	O
body	O	O
weight	O	O
seen	O	O
in	O	O
animals	O	O
that	O	O
received	O	O
polymer	O	O
-	O	O
bound	O	O
DOX	B-Chemical	D004317
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
lower	O	O
than	O	O
that	O	O
observed	O	O
in	O	O
those	O	O
that	O	O
received	O	O
free	O	O
DOX	B-Chemical	D004317
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
or	O	O
a	O	O
mixture	O	O
of	O	O
the	O	O
unmodified	O	O
parent	O	O
HPMA	B-Chemical	C032976
copolymer	O	O
and	O	O
free	O	O
DOX	B-Chemical	D004317
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Throughout	O	O
the	O	O
study	O	O
(	O	O
20	O	O
weeks	O	O
)	O	O
,	O	O
deaths	O	O
related	O	O
to	O	O
cardiotoxicity	B-Disease	D066126
were	O	O
observed	O	O
only	O	O
in	O	O
animals	O	O
that	O	O
received	O	O
either	O	O
free	O	O
DOX	B-Chemical	D004317
or	O	O
the	O	O
mixture	O	O
of	O	O
HPMA	B-Chemical	C032976
copolymer	O	O
and	O	O
free	O	O
DOX	B-Chemical	D004317
;	O	O
in	O	O
these	O	O
cases	O	O
,	O	O
histological	O	O
investigations	O	O
revealed	O	O
marked	O	O
changes	O	O
in	O	O
the	O	O
heart	O	O
that	O	O
were	O	O
consistent	O	O
with	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

Sequential	O	O
measurements	O	O
of	O	O
cardiac	O	O
output	O	O
in	O	O
surviving	O	O
animals	O	O
that	O	O
received	O	O
either	O	O
free	O	O
DOX	B-Chemical	D004317
or	O	O
the	O	O
mixture	O	O
of	O	O
HPMA	B-Chemical	C032976
copolymer	O	O
and	O	O
free	O	O
DOX	B-Chemical	D004317
showed	O	O
a	O	O
reduction	O	O
of	O	O
approximately	O	O
30%	O	O
in	O	O
function	O	O
beginning	O	O
at	O	O
the	O	O
4th	O	O
week	O	O
after	O	O
drug	O	O
administration	O	O
.	O	O

The	O	O
heart	O	O
rate	O	O
in	O	O
these	O	O
animals	O	O
was	O	O
approximately	O	O
12%	O	O
lower	O	O
than	O	O
that	O	O
measured	O	O
in	O	O
age	O	O
-	O	O
matched	O	O
control	O	O
rats	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Animals	O	O
that	O	O
were	O	O
given	O	O
the	O	O
HPMA	B-Chemical	C032976
copolymer	O	O
conjugates	O	O
containing	O	O
DOX	B-Chemical	D004317
exhibited	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
cardiac	O	O
output	O	O
throughout	O	O
the	O	O
study	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
no	O	O
significant	O	O
histological	O	O
change	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
heart	O	O
of	O	O
animals	O	O
that	O	O
received	O	O
DOX	B-Chemical	D004317
in	O	O
the	O	O
form	O	O
of	O	O
HPMA	B-Chemical	C032976
copolymer	O	O
conjugates	O	O
and	O	O
were	O	O
killed	O	O
at	O	O
the	O	O
end	O	O
of	O	O
the	O	O
study	O	O
.	O	O

However	O	O
,	O	O
these	O	O
animals	O	O
had	O	O
shown	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
beginning	O	O
at	O	O
8	O	O
weeks	O	O
after	O	O
drug	O	O
administration	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
400	O	O
WORDS	O	O
)	O	O
Topical	O	O
0	O	O
.	O	O

025%	O	O
capsaicin	B-Chemical	D002211
in	O	O
chronic	O	O
post	B-Disease	D051474
-	I-Disease	D051474
herpetic	I-Disease	D051474
neuralgia	I-Disease	D051474
:	O	O
efficacy	O	O
,	O	O
predictors	O	O
of	O	O
response	O	O
and	O	O
long	O	O
-	O	O
term	O	O
course	O	O
.	O	O

In	O	O
order	O	O
to	O	O
evaluate	O	O
the	O	O
efficacy	O	O
,	O	O
time	O	O
-	O	O
course	O	O
of	O	O
action	O	O
and	O	O
predictors	O	O
of	O	O
response	O	O
to	O	O
topical	O	O
capsaicin	B-Chemical	D002211
,	O	O
39	O	O
patients	O	O
with	O	O
chronic	O	O
post	B-Disease	D051474
-	I-Disease	D051474
herpetic	I-Disease	D051474
neuralgia	I-Disease	D051474
(	O	O
PHN	B-Disease	D051474
)	O	O
,	O	O
median	O	O
duration	O	O
24	O	O
months	O	O
,	O	O
were	O	O
treated	O	O
with	O	O
0	O	O
.	O	O

025%	O	O
capsaicin	B-Chemical	D002211
cream	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

During	O	O
therapy	O	O
the	O	O
patients	O	O
rated	O	O
their	O	O
pain	B-Disease	D010146
on	O	O
a	O	O
visual	O	O
analogue	O	O
scale	O	O
(	O	O
VAS	O	O
)	O	O
and	O	O
a	O	O
verbal	O	O
outcome	O	O
scale	O	O
.	O	O

A	O	O
follow	O	O
-	O	O
up	O	O
investigation	O	O
was	O	O
performed	O	O
10	O	O
-	O	O
12	O	O
months	O	O
after	O	O
study	O	O
onset	O	O
on	O	O
the	O	O
patients	O	O
who	O	O
had	O	O
improved	O	O
.	O	O

Nineteen	O	O
patients	O	O
(	O	O
48	O	O
.	O	O

7%	O	O
)	O	O
substantially	O	O
improved	O	O
after	O	O
the	O	O
8	O	O
-	O	O
week	O	O
trial	O	O
;	O	O
5	O	O
(	O	O
12	O	O
.	O	O

8%	O	O
)	O	O
discontinued	O	O
therapy	O	O
due	O	O
to	O	O
side	O	O
-	O	O
effects	O	O
such	O	O
as	O	O
intolerable	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
burning	O	O
sensations	O	O
(	O	O
4	O	O
)	O	O
or	O	O
mastitis	B-Disease	D008413
(	O	O
1	O	O
)	O	O
;	O	O
15	O	O
(	O	O
38	O	O
.	O	O

5%	O	O
)	O	O
reported	O	O
no	O	O
benefit	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
VAS	O	O
ratings	O	O
was	O	O
significant	O	O
after	O	O
2	O	O
weeks	O	O
of	O	O
continuous	O	O
application	O	O
.	O	O

Of	O	O
the	O	O
responders	O	O
72	O	O
.	O	O

2%	O	O
were	O	O
still	O	O
improved	O	O
at	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
;	O	O
only	O	O
one	O	O
-	O	O
third	O	O
of	O	O
them	O	O
had	O	O
continued	O	O
application	O	O
irregularly	O	O
.	O	O

Treatment	O	O
effect	O	O
was	O	O
not	O	O
dependent	O	O
on	O	O
patient's	O	O
age	O	O
,	O	O
duration	O	O
or	O	O
localization	O	O
of	O	O
PHN	B-Disease	D051474
(	O	O
trigeminal	O	O
involvement	O	O
was	O	O
excluded	O	O
)	O	O
,	O	O
sensory	B-Disease	-1
disturbance	I-Disease	-1
or	O	O
pain	B-Disease	D010146
character	O	O
.	O	O

Treatment	O	O
response	O	O
was	O	O
not	O	O
correlated	O	O
with	O	O
the	O	O
incidence	O	O
,	O	O
time	O	O
-	O	O
course	O	O
or	O	O
severity	O	O
of	O	O
capsaicin	B-Chemical	D002211
-	O	O
induced	O	O
burning	O	O
.	O	O

If	O	O
confirmed	O	O
in	O	O
controlled	O	O
trials	O	O
,	O	O
the	O	O
long	O	O
-	O	O
term	O	O
results	O	O
of	O	O
this	O	O
open	O	O
,	O	O
non	O	O
-	O	O
randomized	O	O
study	O	O
might	O	O
indicate	O	O
that	O	O
the	O	O
analgesic	O	O
effect	O	O
of	O	O
capsaicin	B-Chemical	D002211
in	O	O
PHN	B-Disease	D051474
is	O	O
mediated	O	O
by	O	O
both	O	O
interference	O	O
with	O	O
neuropeptide	O	O
metabolism	O	O
and	O	O
morphological	O	O
changes	O	O
(	O	O
perhaps	O	O
degeneration	O	O
)	O	O
of	O	O
nociceptive	O	O
afferents	O	O
.	O	O

Serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
,	O	O
paranoia	B-Disease	D010259
,	O	O
and	O	O
the	O	O
ventral	O	O
basal	O	O
ganglia	O	O
.	O	O

Antidepressants	O	O
have	O	O
previously	O	O
been	O	O
associated	O	O
with	O	O
paranoid	B-Disease	D010259
reactions	O	O
in	O	O
psychiatric	O	O
patients	O	O
.	O	O

Five	O	O
cases	O	O
of	O	O
paranoid	B-Disease	D010259
exacerbation	O	O
with	O	O
the	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
fluoxetine	B-Chemical	D005473
and	O	O
amitriptyline	B-Chemical	D000639
are	O	O
reported	O	O
here	O	O
.	O	O

Elements	O	O
common	O	O
to	O	O
these	O	O
cases	O	O
included	O	O
a	O	O
history	O	O
of	O	O
paranoid	B-Disease	D010259
symptomatology	O	O
and	O	O
the	O	O
concomitant	O	O
occurrence	O	O
of	O	O
depressive	O	O
and	O	O
psychotic	O	O
symptoms	O	O
.	O	O

Complicated	O	O
depressive	B-Disease	D003866
disorders	I-Disease	D003866
(	O	O
including	O	O
atypicality	O	O
of	O	O
course	O	O
and	O	O
symptomatology	O	O
,	O	O
chronicity	O	O
,	O	O
psychosis	B-Disease	D011605
,	O	O
bipolarity	O	O
,	O	O
and	O	O
secondary	O	O
onset	O	O
in	O	O
the	O	O
course	O	O
of	O	O
a	O	O
primary	O	O
psychosis	B-Disease	D011605
)	O	O
may	O	O
present	O	O
particular	O	O
vulnerability	O	O
to	O	O
paranoid	B-Disease	D010259
exacerbations	O	O
associated	O	O
with	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
.	O	O

Although	O	O
the	O	O
pharmacology	O	O
and	O	O
neurobiology	O	O
of	O	O
paranoia	B-Disease	D010259
remain	O	O
cryptic	O	O
,	O	O
several	O	O
mechanisms	O	O
,	O	O
including	O	O
5HT3	O	O
receptor	O	O
-	O	O
mediated	O	O
dopamine	B-Chemical	D004298
release	O	O
,	O	O
beta	O	O
-	O	O
noradrenergic	O	O
receptor	O	O
downregulation	O	O
,	O	O
or	O	O
GABAB	O	O
receptor	O	O
upregulation	O	O
acting	O	O
in	O	O
the	O	O
vicinity	O	O
of	O	O
the	O	O
ventral	O	O
basal	O	O
ganglia	O	O
(	O	O
possibly	O	O
in	O	O
lateral	O	O
orbitofrontal	O	O
or	O	O
anterior	O	O
cingulate	O	O
circuits	O	O
)	O	O
,	O	O
might	O	O
apply	O	O
to	O	O
this	O	O
phenomenon	O	O
.	O	O

These	O	O
cases	O	O
call	O	O
attention	O	O
to	O	O
possible	O	O
paranoid	B-Disease	D010259
exacerbations	O	O
with	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
blockers	O	O
in	O	O
select	O	O
patients	O	O
and	O	O
raise	O	O
neurobiological	O	O
considerations	O	O
regarding	O	O
paranoia	B-Disease	D010259
.	O	O

Five	O	O
cases	O	O
of	O	O
encephalitis	B-Disease	D004660
during	O	O
treatment	O	O
of	O	O
loiasis	B-Disease	D008118
with	O	O
diethylcarbamazine	B-Chemical	D004049
.	O	O

Five	O	O
cases	O	O
of	O	O
encephalitis	B-Disease	D004660
following	O	O
treatment	O	O
with	O	O
diethylcarbamazine	B-Chemical	D004049
(	O	O
DEC	B-Chemical	D004049
)	O	O
were	O	O
observed	O	O
in	O	O
Congolese	O	O
patients	O	O
with	O	O
Loa	O	O
loa	O	O
filariasis	B-Disease	D005368
.	O	O

Two	O	O
cases	O	O
had	O	O
a	O	O
fatal	O	O
outcome	O	O
and	O	O
one	O	O
resulted	O	O
in	O	O
severe	O	O
sequelae	O	O
.	O	O

The	O	O
notable	O	O
fact	O	O
was	O	O
that	O	O
this	O	O
complication	O	O
occurred	O	O
in	O	O
three	O	O
patients	O	O
hospitalized	O	O
before	O	O
treatment	O	O
began	O	O
,	O	O
with	O	O
whom	O	O
particularly	O	O
strict	O	O
therapeutic	O	O
precautions	O	O
were	O	O
taken	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
initial	O	O
dose	O	O
less	O	O
than	O	O
10	O	O
mg	O	O
of	O	O
DEC	B-Chemical	D004049
,	O	O
very	O	O
gradual	O	O
dose	O	O
increases	O	O
,	O	O
and	O	O
associated	O	O
anti	O	O
-	O	O
allergic	O	O
treatment	O	O
.	O	O

This	O	O
type	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
complication	O	O
may	O	O
not	O	O
be	O	O
that	O	O
uncommon	O	O
in	O	O
highly	O	O
endemic	O	O
regions	O	O
.	O	O

It	O	O
occurs	O	O
primarily	O	O
,	O	O
but	O	O
not	O	O
exclusively	O	O
,	O	O
in	O	O
subjects	O	O
presenting	O	O
with	O	O
a	O	O
high	O	O
microfilarial	O	O
load	O	O
.	O	O

The	O	O
relationship	O	O
between	O	O
the	O	O
occurrence	O	O
of	O	O
encephalitis	B-Disease	D004660
and	O	O
the	O	O
decrease	O	O
in	O	O
microfilaremia	B-Disease	-1
is	O	O
evident	O	O
.	O	O

The	O	O
pathophysiological	O	O
mechanisms	O	O
are	O	O
discussed	O	O
in	O	O
the	O	O
light	O	O
of	O	O
these	O	O
observations	O	O
and	O	O
the	O	O
few	O	O
other	O	O
comments	O	O
on	O	O
this	O	O
subject	O	O
published	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

Delirium	B-Disease	D003693
in	O	O
an	O	O
elderly	O	O
woman	O	O
possibly	O	O
associated	O	O
with	O	O
administration	O	O
of	O	O
misoprostol	B-Chemical	D016595
.	O	O

Misoprostol	B-Chemical	D016595
has	O	O
been	O	O
associated	O	O
with	O	O
adverse	O	O
reactions	O	O
,	O	O
including	O	O
gastrointestinal	O	O
symptoms	O	O
,	O	O
gynecologic	O	O
problems	O	O
,	O	O
and	O	O
headache	B-Disease	D006261
.	O	O

Changes	O	O
in	O	O
mental	O	O
status	O	O
,	O	O
however	O	O
,	O	O
have	O	O
not	O	O
been	O	O
reported	O	O
.	O	O

We	O	O
present	O	O
a	O	O
case	O	O
in	O	O
which	O	O
an	O	O
89	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
in	O	O
a	O	O
long	O	O
-	O	O
term	O	O
care	O	O
facility	O	O
became	O	O
confused	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
misoprostol	B-Chemical	D016595
therapy	O	O
.	O	O

The	O	O
patient's	O	O
change	O	O
in	O	O
mental	O	O
status	O	O
was	O	O
first	O	O
reported	O	O
nine	O	O
days	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
therapy	O	O
.	O	O

Her	O	O
delirium	B-Disease	D003693
significantly	O	O
improved	O	O
after	O	O
misoprostol	B-Chemical	D016595
was	O	O
discontinued	O	O
and	O	O
her	O	O
mental	O	O
status	O	O
returned	O	O
to	O	O
normal	O	O
within	O	O
a	O	O
week	O	O
.	O	O

Because	O	O
no	O	O
other	O	O
factors	O	O
related	O	O
to	O	O
this	O	O
patient	O	O
changed	O	O
significantly	O	O
,	O	O
the	O	O
delirium	B-Disease	D003693
experienced	O	O
by	O	O
this	O	O
patient	O	O
possibly	O	O
resulted	O	O
from	O	O
misoprostol	B-Chemical	D016595
therapy	O	O
.	O	O

Hepatocellular	O	O
oxidant	O	O
stress	O	O
following	O	O
intestinal	O	O
ischemia	B-Disease	D007511
-	O	O
reperfusion	B-Disease	D015427
injury	I-Disease	D015427
.	O	O

Reperfusion	O	O
of	O	O
ischemic	B-Disease	D007511
intestine	O	O
results	O	O
in	O	O
acute	O	O
liver	B-Disease	D017093
dysfunction	I-Disease	D017093
characterized	O	O
by	O	O
hepatocellular	O	O
enzyme	O	O
release	O	O
into	O	O
plasma	O	O
,	O	O
reduction	O	O
in	O	O
bile	O	O
flow	O	O
rate	O	O
,	O	O
and	O	O
neutrophil	O	O
sequestration	O	O
within	O	O
the	O	O
liver	O	O
.	O	O

The	O	O
pathophysiology	O	O
underlying	O	O
this	O	O
acute	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
is	O	O
unknown	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
determine	O	O
whether	O	O
oxidants	O	O
are	O	O
associated	O	O
with	O	O
the	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
and	O	O
to	O	O
determine	O	O
the	O	O
relative	O	O
value	O	O
of	O	O
several	O	O
indirect	O	O
methods	O	O
of	O	O
assessing	O	O
oxidant	O	O
exposure	O	O
in	O	O
vivo	O	O
.	O	O

Rats	O	O
were	O	O
subjected	O	O
to	O	O
a	O	O
standardized	O	O
intestinal	O	O
ischemia	B-Disease	D007511
-	O	O
reperfusion	B-Disease	D015427
injury	I-Disease	D015427
.	O	O

Hepatic	O	O
tissue	O	O
was	O	O
assayed	O	O
for	O	O
lipid	O	O
peroxidation	O	O
products	O	O
and	O	O
oxidized	O	O
and	O	O
reduced	O	O
glutathione	B-Chemical	D005978
.	O	O

There	O	O
was	O	O
no	O	O
change	O	O
in	O	O
hepatic	O	O
tissue	O	O
total	O	O
glutathione	B-Chemical	D005978
following	O	O
intestinal	O	O
ischemia	B-Disease	D007511
-	O	O
reperfusion	B-Disease	D015427
injury	I-Disease	D015427
.	O	O

Oxidized	B-Chemical	D019803
glutathione	I-Chemical	D019803
(	O	O
GSSG	B-Chemical	D019803
)	O	O
increased	O	O
significantly	O	O
following	O	O
30	O	O
and	O	O
60	O	O
min	O	O
of	O	O
reperfusion	O	O
.	O	O

There	O	O
was	O	O
no	O	O
increase	O	O
in	O	O
any	O	O
of	O	O
the	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
associated	O	O
with	O	O
this	O	O
injury	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
GSSG	B-Chemical	D019803
within	O	O
hepatic	O	O
tissue	O	O
during	O	O
intestinal	O	O
reperfusion	O	O
suggests	O	O
exposure	O	O
of	O	O
hepatocytes	O	O
to	O	O
an	O	O
oxidant	O	O
stress	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
suggests	O	O
that	O	O
the	O	O
oxidant	O	O
stress	O	O
is	O	O
of	O	O
insufficient	O	O
magnitude	O	O
to	O	O
result	O	O
in	O	O
irreversible	O	O
injury	O	O
to	O	O
hepatocyte	O	O
cell	O	O
membranes	O	O
.	O	O

These	O	O
data	O	O
also	O	O
suggest	O	O
that	O	O
the	O	O
measurement	O	O
of	O	O
tissue	O	O
GSSG	B-Chemical	D019803
may	O	O
be	O	O
a	O	O
more	O	O
sensitive	O	O
indicator	O	O
of	O	O
oxidant	O	O
stress	O	O
than	O	O
measurement	O	O
of	O	O
products	O	O
of	O	O
lipid	O	O
peroxidation	O	O
.	O	O

Diphenhydramine	B-Chemical	D004155
prevents	O	O
the	O	O
haemodynamic	O	O
changes	O	O
of	O	O
cimetidine	B-Chemical	D002927
in	O	O
ICU	O	O
patients	O	O
.	O	O

Cimetidine	B-Chemical	D002927
,	O	O
a	O	O
histamine	B-Chemical	D006632
2	O	O
(	O	O
H2	O	O
)	O	O
antagonist	O	O
,	O	O
produces	O	O
a	O	O
decrease	O	O
in	O	O
arterial	O	O
pressure	O	O
due	O	O
to	O	O
vasodilatation	O	O
,	O	O
especially	O	O
in	O	O
critically	O	O
ill	O	O
patients	O	O
.	O	O

This	O	O
may	O	O
be	O	O
because	O	O
cimetidine	B-Chemical	D002927
acts	O	O
as	O	O
a	O	O
histamine	B-Chemical	D006632
agonist	O	O
.	O	O

We	O	O
,	O	O
therefore	O	O
,	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
histamine	B-Chemical	D006632
1	O	O
(	O	O
H1	O	O
)	O	O
receptor	O	O
antagonist	O	O
,	O	O
diphenhydramine	B-Chemical	D004155
,	O	O
on	O	O
the	O	O
haemodynamic	O	O
changes	O	O
observed	O	O
after	O	O
cimetidine	B-Chemical	D002927
in	O	O
ICU	O	O
patients	O	O
.	O	O

Each	O	O
patient	O	O
was	O	O
studied	O	O
on	O	O
two	O	O
separate	O	O
days	O	O
.	O	O

In	O	O
a	O	O
random	O	O
fashion	O	O
,	O	O
they	O	O
received	O	O
cimetidine	B-Chemical	D002927
200	O	O
mg	O	O
iv	O	O
on	O	O
one	O	O
day	O	O
,	O	O
and	O	O
on	O	O
the	O	O
other	O	O
,	O	O
a	O	O
pretreatment	O	O
of	O	O
diphenhydramine	B-Chemical	D004155
40	O	O
mg	O	O
iv	O	O
with	O	O
cimetidine	B-Chemical	D002927
200	O	O
mg	O	O
iv	O	O
.	O	O

In	O	O
the	O	O
non	O	O
-	O	O
pretreatment	O	O
group	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
decreased	O	O
from	O	O
107	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

4	O	O
mmHg	O	O
to	O	O
86	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
11	O	O
.	O	O

4	O	O
mmHg	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
two	O	O
minutes	O	O
after	O	O
cimetidine	B-Chemical	D002927
.	O	O

Also	O	O
,	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
SVR	O	O
)	O	O
decreased	O	O
during	O	O
the	O	O
eight	O	O
-	O	O
minute	O	O
observation	O	O
period	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
in	O	O
the	O	O
pretreatment	O	O
group	O	O
,	O	O
little	O	O
haemodynamic	O	O
change	O	O
was	O	O
seen	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
an	O	O
H1	O	O
antagonist	O	O
may	O	O
be	O	O
useful	O	O
in	O	O
preventing	O	O
hypotension	B-Disease	D007022
caused	O	O
by	O	O
iv	O	O
cimetidine	B-Chemical	D002927
,	O	O
since	O	O
the	O	O
vasodilating	O	O
activity	O	O
of	O	O
cimetidine	B-Chemical	D002927
is	O	O
mediated	O	O
,	O	O
in	O	O
part	O	O
,	O	O
through	O	O
the	O	O
H1	O	O
receptor	O	O
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
due	O	O
to	O	O
rifampicin	B-Chemical	D012293
.	O	O

A	O	O
23	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
with	O	O
bacteriologically	O	O
proven	O	O
pulmonary	B-Disease	D014397
tuberculosis	I-Disease	D014397
was	O	O
treated	O	O
with	O	O
the	O	O
various	O	O
regimens	O	O
of	O	O
antituberculosis	O	O
drugs	O	O
for	O	O
nearly	O	O
15	O	O
months	O	O
.	O	O

Rifampicin	B-Chemical	D012293
was	O	O
administered	O	O
thrice	O	O
as	O	O
one	O	O
of	O	O
the	O	O
3	O	O
-	O	O
4	O	O
drug	O	O
regimen	O	O
and	O	O
each	O	O
time	O	O
he	O	O
developed	O	O
untoward	O	O
side	O	O
effects	O	O
like	O	O
nausea	B-Disease	D009325
,	O	O
vomiting	B-Disease	D014839
and	O	O
fever	B-Disease	D005334
with	O	O
chills	O	O
and	O	O
rigors	O	O
.	O	O

The	O	O
last	O	O
such	O	O
episode	O	O
was	O	O
of	O	O
acute	O	O
renal	O	O
failure	O	O
at	O	O
which	O	O
stage	O	O
the	O	O
patient	O	O
was	O	O
seen	O	O
by	O	O
the	O	O
authors	O	O
of	O	O
this	O	O
report	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
however	O	O
,	O	O
made	O	O
a	O	O
full	O	O
recovery	O	O
.	O	O

Severe	O	O
polyneuropathy	B-Disease	D011115
and	O	O
motor	O	O
loss	O	O
after	O	O
intrathecal	O	O
thiotepa	B-Chemical	D013852
combination	O	O
chemotherapy	O	O
:	O	O
description	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
severe	O	O
delayed	O	O
neurologic	B-Disease	D020258
toxicity	I-Disease	D020258
related	O	O
to	O	O
the	O	O
administration	O	O
of	O	O
intrathecal	O	O
(	O	O
IT	O	O
)	O	O
combination	O	O
chemotherapy	O	O
including	O	O
thiotepa	B-Chemical	D013852
(	O	O
TSPA	B-Chemical	D013852
)	O	O
are	O	O
presented	O	O
.	O	O

Both	O	O
cases	O	O
developed	O	O
axonal	B-Disease	D056768
neuropathy	I-Disease	D056768
with	O	O
motor	O	O
predominance	O	O
in	O	O
the	O	O
lower	O	O
extremities	O	O
1	O	O
and	O	O
6	O	O
months	O	O
after	O	O
IT	O	O
chemotherapy	O	O
was	O	O
administered	O	O
.	O	O

Neurologic	B-Disease	D020258
toxicities	I-Disease	D020258
have	O	O
been	O	O
described	O	O
with	O	O
IT	O	O
-	O	O
methotrexate	B-Chemical	D008727
,	O	O
IT	O	O
-	O	O
cytosine	B-Chemical	D003561
arabinoside	I-Chemical	D003561
and	O	O
IT	O	O
-	O	O
TSPA	B-Chemical	D013852
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
however	O	O
,	O	O
axonal	B-Disease	D056768
neuropathy	I-Disease	D056768
following	O	O
administration	O	O
of	O	O
these	O	O
three	O	O
agents	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
described	O	O
.	O	O

In	O	O
spite	O	O
of	O	O
the	O	O
fact	O	O
that	O	O
TSPA	B-Chemical	D013852
is	O	O
a	O	O
useful	O	O
IT	O	O
agent	O	O
,	O	O
its	O	O
combination	O	O
with	O	O
MTX	B-Chemical	D008727
,	O	O
ara	B-Chemical	D003561
-	I-Chemical	D003561
C	I-Chemical	D003561
and	O	O
radiotherapy	O	O
could	O	O
cause	O	O
severe	O	O
neurotoxicity	B-Disease	D020258
.	O	O

This	O	O
unexpected	O	O
complication	O	O
indicates	O	O
the	O	O
need	O	O
for	O	O
further	O	O
toxicology	O	O
research	O	O
on	O	O
IT	O	O
-	O	O
TSPA	B-Chemical	D013852
.	O	O

Effects	O	O
of	O	O
cromakalim	B-Chemical	D019806
and	O	O
pinacidil	B-Chemical	D020110
on	O	O
large	O	O
epicardial	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
in	O	O
conscious	O	O
dogs	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
i	O	O
.	O	O

v	O	O
.	O	O

bolus	O	O
administration	O	O
of	O	O
cromakalim	B-Chemical	D019806
(	O	O
1	O	O
-	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pinacidil	B-Chemical	D020110
(	O	O
3	O	O
-	O	O
100	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
large	O	O
(	O	O
circumflex	O	O
artery	O	O
)	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
on	O	O
systemic	O	O
hemodynamics	O	O
were	O	O
investigated	O	O
in	O	O
chronically	O	O
instrumented	O	O
conscious	O	O
dogs	O	O
and	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
nitroglycerin	B-Chemical	D005996
(	O	O
0	O	O
.	O	O

03	O	O
-	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

Nitroglycerin	B-Chemical	D005996
,	O	O
up	O	O
to	O	O
0	O	O
.	O	O

3	O	O
micrograms	O	O
/	O	O
kg	O	O
,	O	O
selectively	O	O
increased	O	O
circumflex	O	O
artery	O	O
diameter	O	O
(	O	O
CxAD	O	O
)	O	O
without	O	O
simultaneously	O	O
affecting	O	O
any	O	O
other	O	O
cardiac	O	O
or	O	O
systemic	O	O
hemodynamic	O	O
parameter	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
cromakalim	B-Chemical	D019806
and	O	O
pinacidil	B-Chemical	D020110
at	O	O
all	O	O
doses	O	O
and	O	O
nitroglycerin	B-Chemical	D005996
at	O	O
doses	O	O
higher	O	O
than	O	O
0	O	O
.	O	O

3	O	O
micrograms	O	O
/	O	O
kg	O	O
simultaneously	O	O
and	O	O
dose	O	O
-	O	O
dependently	O	O
increased	O	O
CxAD	O	O
,	O	O
coronary	O	O
blood	O	O
flow	O	O
and	O	O
heart	O	O
rate	O	O
and	O	O
decreased	O	O
coronary	O	O
vascular	O	O
resistance	O	O
and	O	O
aortic	O	O
pressure	O	O
.	O	O

Cromakalim	B-Chemical	D019806
was	O	O
approximately	O	O
8	O	O
-	O	O
to	O	O
9	O	O
.	O	O

5	O	O
-	O	O
fold	O	O
more	O	O
potent	O	O
than	O	O
pinacidil	B-Chemical	D020110
in	O	O
increasing	O	O
CxAD	O	O
.	O	O

Vasodilation	O	O
of	O	O
large	O	O
and	O	O
small	O	O
coronary	O	O
vessels	O	O
and	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
cromakalim	B-Chemical	D019806
and	O	O
pinacidil	B-Chemical	D020110
were	O	O
not	O	O
affected	O	O
by	O	O
prior	O	O
combined	O	O
beta	O	O
adrenergic	O	O
and	O	O
muscarinic	O	O
receptors	O	O
blockade	O	O
but	O	O
drug	O	O
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
was	O	O
abolished	O	O
.	O	O

When	O	O
circumflex	O	O
artery	O	O
blood	O	O
flow	O	O
was	O	O
maintained	O	O
constant	O	O
,	O	O
the	O	O
increases	O	O
in	O	O
CxAD	O	O
induced	O	O
by	O	O
cromakalim	B-Chemical	D019806
(	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
pinacidil	B-Chemical	D020110
(	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
nitroglycerin	B-Chemical	D005996
(	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
reduced	O	O
by	O	O
68	O	O
+	O	O
/	O	O
-	O	O
7	O	O
,	O	O
54	O	O
+	O	O
/	O	O
-	O	O
9	O	O
and	O	O
1	O	O
+	O	O
/	O	O
-	O	O
1%	O	O
,	O	O
respectively	O	O
.	O	O

Thus	O	O
,	O	O
whereas	O	O
nitroglycerin	B-Chemical	D005996
preferentially	O	O
and	O	O
flow	O	O
-	O	O
independently	O	O
dilates	O	O
large	O	O
coronary	O	O
arteries	O	O
,	O	O
cromakalim	B-Chemical	D019806
and	O	O
pinacidil	B-Chemical	D020110
dilate	O	O
both	O	O
large	O	O
and	O	O
small	O	O
coronary	O	O
arteries	O	O
and	O	O
this	O	O
effect	O	O
is	O	O
not	O	O
dependent	O	O
upon	O	O
the	O	O
simultaneous	O	O
beta	O	O
adrenoceptors	O	O
-	O	O
mediated	O	O
rise	O	O
in	O	O
myocardial	O	O
metabolic	O	O
demand	O	O
.	O	O

Finally	O	O
,	O	O
two	O	O
mechanisms	O	O
at	O	O
least	O	O
,	O	O
direct	O	O
vasodilation	O	O
and	O	O
flow	O	O
dependency	O	O
,	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
cromakalim	B-Chemical	D019806
-	O	O
and	O	O
pinacidil	B-Chemical	D020110
-	O	O
induced	O	O
increase	O	O
in	O	O
CxAD	O	O
.	O	O

Mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
-	O	O
induced	O	O
neutropenia	B-Disease	D009503
and	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
in	O	O
elderly	O	O
females	O	O
with	O	O
hypothyroidism	B-Disease	D007037
.	O	O

We	O	O
report	O	O
mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
-	O	O
induced	O	O
non	O	O
-	O	O
oliguric	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
and	O	O
severe	O	O
neutropenia	B-Disease	D009503
occurring	O	O
simultaneously	O	O
in	O	O
two	O	O
elderly	O	O
females	O	O
.	O	O

The	O	O
neutropenia	B-Disease	D009503
was	O	O
due	O	O
to	O	O
maturation	O	O
arrest	O	O
of	O	O
the	O	O
myeloid	O	O
series	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

Both	O	O
patients	O	O
were	O	O
also	O	O
hypothyroid	B-Disease	D007037
,	O	O
but	O	O
it	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
this	O	O
was	O	O
a	O	O
predisposing	O	O
factor	O	O
to	O	O
the	O	O
development	O	O
of	O	O
these	O	O
adverse	O	O
reactions	O	O
.	O	O

However	O	O
,	O	O
it	O	O
would	O	O
seem	O	O
prudent	O	O
not	O	O
to	O	O
use	O	O
mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
in	O	O
hypothyroid	B-Disease	D007037
patients	O	O
until	O	O
the	O	O
hypothyroidism	B-Disease	D007037
has	O	O
been	O	O
corrected	O	O
.	O	O

Etiology	O	O
of	O	O
hypercalcemia	B-Disease	D006934
in	O	O
hemodialysis	O	O
patients	O	O
on	O	O
calcium	B-Chemical	D002119
carbonate	I-Chemical	D002119
therapy	O	O
.	O	O

Fourteen	O	O
of	O	O
39	O	O
dialysis	O	O
patients	O	O
(	O	O
36%	O	O
)	O	O
became	O	O
hypercalcemic	B-Disease	D006934
after	O	O
switching	O	O
to	O	O
calcium	B-Chemical	D002119
carbonate	I-Chemical	D002119
as	O	O
their	O	O
principal	O	O
phosphate	B-Chemical	D010710
binder	O	O
.	O	O

In	O	O
order	O	O
to	O	O
identify	O	O
risk	O	O
factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
hypercalcemia	B-Disease	D006934
,	O	O
indirect	O	O
parameters	O	O
of	O	O
intestinal	O	O
calcium	B-Chemical	D002118
reabsorption	O	O
and	O	O
bone	O	O
turnover	O	O
rate	O	O
in	O	O
these	O	O
14	O	O
patients	O	O
were	O	O
compared	O	O
with	O	O
results	O	O
in	O	O
14	O	O
eucalcemic	O	O
patients	O	O
matched	O	O
for	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
length	O	O
of	O	O
time	O	O
on	O	O
dialysis	O	O
,	O	O
and	O	O
etiology	O	O
of	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
.	O	O

In	O	O
addition	O	O
to	O	O
experiencing	O	O
hypercalcemic	B-Disease	D006934
episodes	O	O
with	O	O
peak	O	O
calcium	B-Chemical	D002118
values	O	O
of	O	O
2	O	O
.	O	O

7	O	O
to	O	O
3	O	O
.	O	O

8	O	O
mmol	O	O
/	O	O
L	O	O
(	O	O
10	O	O
.	O	O

7	O	O
to	O	O
15	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
dL	O	O
)	O	O
,	O	O
patients	O	O
in	O	O
the	O	O
hypercalcemic	B-Disease	D006934
group	O	O
exhibited	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
mean	O	O
calcium	B-Chemical	D002118
concentration	O	O
obtained	O	O
during	O	O
6	O	O
months	O	O
before	O	O
the	O	O
switch	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
mean	O	O
value	O	O
obtained	O	O
during	O	O
the	O	O
7	O	O
months	O	O
of	O	O
observation	O	O
after	O	O
the	O	O
switch	O	O
(	O	O
2	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

03	O	O
to	O	O
2	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

03	O	O
mmol	O	O
/	O	O
L	O	O
[	O	O
9	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
to	O	O
10	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
dL	O	O
]	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

006	O	O
)	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
eucalcemic	O	O
patients	O	O
exhibited	O	O
no	O	O
change	O	O
in	O	O
mean	O	O
calcium	B-Chemical	D002118
values	O	O
over	O	O
the	O	O
same	O	O
time	O	O
period	O	O
(	O	O
2	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

05	O	O
to	O	O
2	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

05	O	O
mmol	O	O
/	O	O
L	O	O
[	O	O
9	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
to	O	O
9	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
dL	O	O
]	O	O
)	O	O
.	O	O

CaCO3	B-Chemical	D002119
dosage	O	O
,	O	O
calculated	O	O
dietary	O	O
calcium	B-Chemical	D002118
intake	O	O
,	O	O
and	O	O
circulating	O	O
levels	O	O
of	O	O
vitamin	B-Chemical	D014807
D	I-Chemical	D014807
metabolites	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

Physical	O	O
activity	O	O
index	O	O
and	O	O
predialysis	O	O
serum	O	O
bicarbonate	B-Chemical	D001639
levels	O	O
also	O	O
were	O	O
similar	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
parameters	O	O
reflecting	O	O
bone	O	O
turnover	O	O
rates	O	O
between	O	O
groups	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Methyldopa	B-Chemical	D008750
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
in	O	O
a	O	O
15	O	O
year	O	O
old	O	O
presenting	O	O
as	O	O
near	O	O
-	O	O
syncope	B-Disease	D013575
.	O	O

Methyldopa	B-Chemical	D008750
is	O	O
an	O	O
antihypertensive	O	O
medication	O	O
which	O	O
is	O	O
available	O	O
generically	O	O
and	O	O
under	O	O
the	O	O
trade	O	O
name	O	O
Aldomet	B-Chemical	D008750
that	O	O
is	O	O
widely	O	O
prescribed	O	O
in	O	O
the	O	O
adult	O	O
population	O	O
and	O	O
infrequently	O	O
used	O	O
in	O	O
children	O	O
.	O	O

Methyldopa	B-Chemical	D008750
causes	O	O
an	O	O
autoimmune	B-Disease	D000744
hemolytic	I-Disease	D000744
anemia	I-Disease	D000744
in	O	O
a	O	O
small	O	O
percentage	O	O
of	O	O
patients	O	O
who	O	O
take	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
methyldopa	B-Chemical	D008750
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
in	O	O
a	O	O
15	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
emergency	B-Disease	D004630
department	I-Disease	D004630
with	O	O
near	O	O
-	O	O
syncope	B-Disease	D013575
.	O	O

The	O	O
boy	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
intravenous	O	O
methyldopa	B-Chemical	D008750
during	O	O
a	O	O
trauma	B-Disease	D014947
admission	O	O
seven	O	O
weeks	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

Evaluation	O	O
revealed	O	O
a	O	O
hemoglobin	O	O
of	O	O
three	O	O
grams	O	O
,	O	O
3+	O	O
Coombs'	O	O
test	O	O
with	O	O
polyspecific	O	O
anti	O	O
-	O	O
human	O	O
globulin	O	O
and	O	O
monospecific	O	O
IgG	O	O
reagents	O	O
,	O	O
and	O	O
a	O	O
warm	O	O
reacting	O	O
autoantibody	O	O
.	O	O

Transfusion	O	O
and	O	O
corticosteroid	B-Chemical	D000305
therapy	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
recovery	O	O
of	O	O
the	O	O
patient	O	O
.	O	O

Emergency	O	O
physicians	O	O
treating	O	O
children	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
syndrome	O	O
in	O	O
order	O	O
to	O	O
diagnose	O	O
and	O	O
treat	O	O
it	O	O
correctly	O	O
.	O	O

A	O	O
brief	O	O
review	O	O
of	O	O
autoimmune	O	O
and	O	O
drug	O	O
-	O	O
induced	O	O
hemolytic	B-Disease	D000743
anemias	I-Disease	D000743
is	O	O
provided	O	O
.	O	O

The	O	O
long	O	O
-	O	O
term	O	O
safety	O	O
of	O	O
danazol	B-Chemical	D003613
in	O	O
women	O	O
with	O	O
hereditary	B-Disease	D054179
angioedema	I-Disease	D054179
.	O	O

Although	O	O
the	O	O
short	O	O
-	O	O
term	O	O
safety	O	O
(	O	O
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
6	O	O
months	O	O
)	O	O
of	O	O
danazol	B-Chemical	D003613
has	O	O
been	O	O
established	O	O
in	O	O
a	O	O
variety	O	O
of	O	O
settings	O	O
,	O	O
no	O	O
information	O	O
exists	O	O
as	O	O
to	O	O
its	O	O
long	O	O
-	O	O
term	O	O
safety	O	O
.	O	O

We	O	O
therefore	O	O
investigated	O	O
the	O	O
long	O	O
-	O	O
term	O	O
safety	O	O
of	O	O
danazol	B-Chemical	D003613
by	O	O
performing	O	O
a	O	O
retrospective	O	O
chart	O	O
review	O	O
of	O	O
60	O	O
female	O	O
patients	O	O
with	O	O
hereditary	B-Disease	D054179
angioedema	I-Disease	D054179
treated	O	O
with	O	O
danazol	B-Chemical	D003613
for	O	O
a	O	O
continuous	O	O
period	O	O
of	O	O
6	O	O
months	O	O
or	O	O
longer	O	O
.	O	O

The	O	O
mean	O	O
age	O	O
of	O	O
the	O	O
patients	O	O
was	O	O
35	O	O
.	O	O

2	O	O
years	O	O
and	O	O
the	O	O
mean	O	O
duration	O	O
of	O	O
therapy	O	O
was	O	O
59	O	O
.	O	O

7	O	O
months	O	O
.	O	O

Virtually	O	O
all	O	O
patients	O	O
experienced	O	O
one	O	O
or	O	O
more	O	O
adverse	O	O
reactions	O	O
.	O	O

Menstrual	B-Disease	D008599
abnormalities	I-Disease	D008599
(	O	O
79%	O	O
)	O	O
,	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
(	O	O
60%	O	O
)	O	O
,	O	O
muscle	B-Disease	D009120
cramps	I-Disease	D009120
/	O	O
myalgias	B-Disease	D063806
(	O	O
40%	O	O
)	O	O
,	O	O
and	O	O
transaminase	O	O
elevations	O	O
(	O	O
40%	O	O
)	O	O
were	O	O
the	O	O
most	O	O
common	O	O
adverse	O	O
reactions	O	O
.	O	O

The	O	O
drug	O	O
was	O	O
discontinued	O	O
due	O	O
to	O	O
adverse	O	O
reactions	O	O
in	O	O
8	O	O
patients	O	O
.	O	O

No	O	O
patient	O	O
has	O	O
died	O	O
or	O	O
suffered	O	O
any	O	O
apparent	O	O
long	O	O
-	O	O
term	O	O
sequelae	O	O
that	O	O
were	O	O
directly	O	O
attributable	O	O
to	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
,	O	O
despite	O	O
a	O	O
relatively	O	O
high	O	O
incidence	O	O
of	O	O
adverse	O	O
reactions	O	O
,	O	O
danazol	B-Chemical	D003613
has	O	O
proven	O	O
to	O	O
be	O	O
remarkably	O	O
safe	O	O
over	O	O
the	O	O
long	O	O
-	O	O
term	O	O
in	O	O
this	O	O
group	O	O
of	O	O
patients	O	O
.	O	O

Patient	O	O
tolerance	O	O
study	O	O
of	O	O
topical	O	O
chlorhexidine	B-Chemical	C048279
diphosphanilate	I-Chemical	C048279
:	O	O
a	O	O
new	O	O
topical	O	O
agent	O	O
for	O	O
burns	B-Disease	D002056
.	O	O

Effective	O	O
topical	O	O
antimicrobial	O	O
agents	O	O
decrease	O	O
infection	B-Disease	D007239
and	O	O
mortality	O	O
in	O	O
burn	B-Disease	D002056
patients	O	O
.	O	O

Chlorhexidine	B-Chemical	C048279
phosphanilate	I-Chemical	C048279
(	O	O
CHP	B-Chemical	C048279
)	O	O
,	O	O
a	O	O
new	O	O
broad	O	O
-	O	O
spectrum	O	O
antimicrobial	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
evaluated	O	O
as	O	O
a	O	O
topical	O	O
burn	B-Disease	D002056
wound	O	O
dressing	O	O
in	O	O
cream	O	O
form	O	O
,	O	O
but	O	O
preliminary	O	O
clinical	O	O
trials	O	O
reported	O	O
that	O	O
it	O	O
was	O	O
painful	O	O
upon	O	O
application	O	O
.	O	O

This	O	O
study	O	O
compared	O	O
various	O	O
concentrations	O	O
of	O	O
CHP	B-Chemical	C048279
to	O	O
determine	O	O
if	O	O
a	O	O
tolerable	O	O
concentration	O	O
could	O	O
be	O	O
identified	O	O
with	O	O
retention	O	O
of	O	O
antimicrobial	O	O
efficacy	O	O
.	O	O

Twenty	O	O
-	O	O
nine	O	O
burn	B-Disease	D002056
patients	O	O
,	O	O
each	O	O
with	O	O
two	O	O
similar	O	O
burns	B-Disease	D002056
which	O	O
could	O	O
be	O	O
separately	O	O
treated	O	O
,	O	O
were	O	O
given	O	O
pairs	O	O
of	O	O
treatments	O	O
at	O	O
successive	O	O
12	O	O
-	O	O
h	O	O
intervals	O	O
over	O	O
a	O	O
3	O	O
-	O	O
day	O	O
period	O	O
.	O	O

One	O	O
burn	B-Disease	D002056
site	O	O
was	O	O
treated	O	O
with	O	O
each	O	O
of	O	O
four	O	O
different	O	O
CHP	B-Chemical	C048279
concentrations	O	O
,	O	O
from	O	O
0	O	O
.	O	O

25	O	O
per	O	O
cent	O	O
to	O	O
2	O	O
per	O	O
cent	O	O
,	O	O
their	O	O
vehicle	O	O
,	O	O
and	O	O
1	O	O
per	O	O
cent	O	O
silver	B-Chemical	D012837
sulphadiazine	I-Chemical	D012837
(	O	O
AgSD	B-Chemical	D012837
)	O	O
cream	O	O
,	O	O
an	O	O
antimicrobial	O	O
agent	O	O
frequently	O	O
used	O	O
for	O	O
topical	O	O
treatment	O	O
of	O	O
burn	B-Disease	D002056
wounds	O	O
.	O	O

The	O	O
other	O	O
site	O	O
was	O	O
always	O	O
treated	O	O
with	O	O
AgSD	B-Chemical	D012837
cream	O	O
.	O	O

There	O	O
was	O	O
a	O	O
direct	O	O
relationship	O	O
between	O	O
CHP	B-Chemical	C048279
concentration	O	O
and	O	O
patients'	O	O
ratings	O	O
of	O	O
pain	B-Disease	D010146
on	O	O
an	O	O
analogue	O	O
scale	O	O
.	O	O

The	O	O
0	O	O
.	O	O

25	O	O
per	O	O
cent	O	O
CHP	B-Chemical	C048279
cream	O	O
was	O	O
closest	O	O
to	O	O
AgSD	B-Chemical	D012837
in	O	O
pain	B-Disease	D010146
tolerance	O	O
;	O	O
however	O	O
,	O	O
none	O	O
of	O	O
the	O	O
treatments	O	O
differed	O	O
statistically	O	O
from	O	O
AgSD	B-Chemical	D012837
or	O	O
from	O	O
each	O	O
other	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
ease	O	O
of	O	O
application	O	O
of	O	O
CHP	B-Chemical	C048279
creams	O	O
was	O	O
less	O	O
satisfactory	O	O
than	O	O
that	O	O
of	O	O
AgSD	B-Chemical	D012837
.	O	O

It	O	O
was	O	O
concluded	O	O
that	O	O
formulations	O	O
at	O	O
or	O	O
below	O	O
0	O	O
.	O	O

5	O	O
per	O	O
cent	O	O
CHP	B-Chemical	C048279
may	O	O
prove	O	O
acceptable	O	O
for	O	O
wound	O	O
care	O	O
,	O	O
but	O	O
the	O	O
vehicle	O	O
system	O	O
needs	O	O
pharmaceutical	O	O
improvement	O	O
to	O	O
render	O	O
it	O	O
more	O	O
tolerable	O	O
and	O	O
easier	O	O
to	O	O
use	O	O
.	O	O

Dose	O	O
-	O	O
dependent	O	O
neurotoxicity	B-Disease	D020258
of	O	O
high	O	O
-	O	O
dose	O	O
busulfan	B-Chemical	D002066
in	O	O
children	O	O
:	O	O
a	O	O
clinical	O	O
and	O	O
pharmacological	O	O
study	O	O
.	O	O

Busulfan	B-Chemical	D002066
is	O	O
known	O	O
to	O	O
be	O	O
neurotoxic	B-Disease	D020258
in	O	O
animals	O	O
and	O	O
humans	O	O
,	O	O
but	O	O
its	O	O
acute	O	O
neurotoxicity	B-Disease	D020258
remains	O	O
poorly	O	O
characterized	O	O
in	O	O
children	O	O
.	O	O

We	O	O
report	O	O
here	O	O
a	O	O
retrospective	O	O
study	O	O
of	O	O
123	O	O
children	O	O
(	O	O
median	O	O
age	O	O
,	O	O
6	O	O
.	O	O

5	O	O
years	O	O
)	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
busulfan	B-Chemical	D002066
in	O	O
combined	O	O
chemotherapy	O	O
before	O	O
bone	O	O
marrow	O	O
transplantation	O	O
for	O	O
malignant	O	O
solid	O	O
tumors	B-Disease	D009369
,	O	O
brain	B-Disease	D001932
tumors	I-Disease	D001932
excluded	O	O
.	O	O

Busulfan	B-Chemical	D002066
was	O	O
given	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
every	O	O
6	O	O
hours	O	O
for	O	O
16	O	O
doses	O	O
over	O	O
4	O	O
days	O	O
.	O	O

Two	O	O
total	O	O
doses	O	O
were	O	O
consecutively	O	O
used	O	O
:	O	O
16	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
then	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

The	O	O
dose	O	O
calculation	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
body	O	O
surface	O	O
area	O	O
results	O	O
in	O	O
higher	O	O
doses	O	O
in	O	O
young	O	O
children	O	O
than	O	O
in	O	O
older	O	O
patients	O	O
(	O	O
16	O	O
to	O	O
28	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

Ninety	O	O
-	O	O
six	O	O
patients	O	O
were	O	O
not	O	O
given	O	O
anticonvulsive	O	O
prophylaxis	O	O
;	O	O
7	O	O
(	O	O
7	O	O
.	O	O

5%	O	O
)	O	O
developed	O	O
seizures	B-Disease	D012640
during	O	O
the	O	O
4	O	O
days	O	O
of	O	O
the	O	O
busulfan	B-Chemical	D002066
course	O	O
or	O	O
within	O	O
24	O	O
h	O	O
after	O	O
the	O	O
last	O	O
dosing	O	O
.	O	O

When	O	O
the	O	O
total	O	O
busulfan	B-Chemical	D002066
dose	O	O
was	O	O
taken	O	O
into	O	O
account	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
terms	O	O
of	O	O
neurotoxicity	B-Disease	D020258
incidence	O	O
among	O	O
patients	O	O
under	O	O
16	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
1	O	O
of	O	O
57	O	O
,	O	O
1	O	O
.	O	O

7%	O	O
)	O	O
and	O	O
patients	O	O
under	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
(	O	O
6	O	O
of	O	O
39	O	O
,	O	O
15	O	O
.	O	O

4%	O	O
)	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

Twenty	O	O
-	O	O
seven	O	O
patients	O	O
were	O	O
given	O	O
a	O	O
600	O	O
-	O	O
mg	O	O
/	O	O
m2	O	O
busulfan	B-Chemical	D002066
total	O	O
dose	O	O
with	O	O
continuous	O	O
i	O	O
.	O	O

v	O	O
.	O	O

infusion	O	O
of	O	O
clonazepam	B-Chemical	D002998
;	O	O
none	O	O
had	O	O
any	O	O
neurological	B-Disease	D009461
symptoms	I-Disease	D009461
.	O	O

Busulfan	B-Chemical	D002066
levels	O	O
were	O	O
measured	O	O
by	O	O
a	O	O
gas	O	O
chromatographic	O	O
-	O	O
mass	O	O
spectrometry	O	O
assay	O	O
in	O	O
the	O	O
plasma	O	O
and	O	O
cerebrospinal	O	O
fluid	O	O
of	O	O
9	O	O
children	O	O
without	O	O
central	B-Disease	D002493
nervous	I-Disease	D002493
system	I-Disease	D002493
disease	I-Disease	D002493
under	O	O
600	O	O
mg	O	O
/	O	O
m2	O	O
busulfan	B-Chemical	D002066
with	O	O
clonazepam	B-Chemical	D002998
:	O	O
busulfan	B-Chemical	D002066
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
was	O	O
1	O	O
.	O	O

39	O	O
.	O	O

This	O	O
was	O	O
significantly	O	O
different	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
from	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
:	O	O
plasma	O	O
ratio	O	O
previously	O	O
defined	O	O
in	O	O
children	O	O
receiving	O	O
a	O	O
16	O	O
-	O	O
mg	O	O
/	O	O
kg	O	O
total	O	O
dose	O	O
of	O	O
busulfan	B-Chemical	D002066
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
busulfan	B-Chemical	D002066
neurotoxicity	B-Disease	D020258
is	O	O
dose	O	O
-	O	O
dependent	O	O
in	O	O
children	O	O
and	O	O
efficiently	O	O
prevented	O	O
by	O	O
clonazepam	B-Chemical	D002998
.	O	O

A	O	O
busulfan	B-Chemical	D002066
dose	O	O
calculated	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
resulting	O	O
in	O	O
higher	O	O
doses	O	O
in	O	O
young	O	O
children	O	O
,	O	O
was	O	O
followed	O	O
by	O	O
increased	O	O
neurotoxicity	B-Disease	D020258
,	O	O
close	O	O
to	O	O
neurotoxicity	B-Disease	D020258
incidence	O	O
observed	O	O
in	O	O
adults	O	O
.	O	O

Since	O	O
plasma	O	O
pharmacokinetic	O	O
studies	O	O
showed	O	O
a	O	O
faster	O	O
busulfan	B-Chemical	D002066
clearance	O	O
in	O	O
children	O	O
than	O	O
in	O	O
adults	O	O
,	O	O
this	O	O
new	O	O
dose	O	O
may	O	O
approximate	O	O
more	O	O
closely	O	O
the	O	O
adult	O	O
systemic	O	O
exposure	O	O
obtained	O	O
after	O	O
the	O	O
usual	O	O
16	O	O
-	O	O
mg	O	O
/	O	O
kg	O	O
total	O	O
dose	O	O
,	O	O
with	O	O
potential	O	O
inferences	O	O
in	O	O
terms	O	O
of	O	O
anticancer	O	O
or	O	O
myeloablative	O	O
effects	O	O
.	O	O

The	O	O
busulfan	B-Chemical	D002066
dose	O	O
in	O	O
children	O	O
and	O	O
infants	O	O
undergoing	O	O
bone	O	O
marrow	O	O
transplantation	O	O
should	O	O
be	O	O
reconsidered	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
pharmacokinetic	O	O
studies	O	O
.	O	O

Histamine	B-Chemical	D006632
antagonists	O	O
and	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
-	O	O
induced	O	O
hypotension	B-Disease	D007022
in	O	O
cardiac	O	O
surgical	O	O
patients	O	O
.	O	O

Hemodynamic	O	O
effects	O	O
and	O	O
histamine	B-Chemical	D006632
release	O	O
by	O	O
bolus	O	O
injection	O	O
of	O	O
0	O	O
.	O	O

35	O	O
mg	O	O
/	O	O
kg	O	O
of	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
were	O	O
studied	O	O
in	O	O
24	O	O
patients	O	O
.	O	O

H1	O	O
-	O	O
and	O	O
H2	O	O
-	O	O
histamine	B-Chemical	D006632
antagonists	O	O
or	O	O
placebo	O	O
were	O	O
given	O	O
before	O	O
dosing	O	O
with	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
in	O	O
a	O	O
randomized	O	O
double	O	O
-	O	O
blind	O	O
fashion	O	O
to	O	O
four	O	O
groups	O	O
:	O	O
group	O	O
1	O	O
-	O	O
-	O	O
placebo	O	O
;	O	O
group	O	O
2	O	O
-	O	O
-	O	O
cimetidine	B-Chemical	D002927
,	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
plus	O	O
placebo	O	O
;	O	O
group	O	O
3	O	O
-	O	O
-	O	O
chlorpheniramine	B-Chemical	D002744
,	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
plus	O	O
placebo	O	O
;	O	O
and	O	O
group	O	O
4	O	O
-	O	O
-	O	O
cimetidine	B-Chemical	D002927
plus	O	O
chlorpheniramine	B-Chemical	D002744
.	O	O

Histamine	B-Chemical	D006632
release	O	O
occurred	O	O
in	O	O
most	O	O
patients	O	O
,	O	O
the	O	O
highest	O	O
level	O	O
2	O	O
minutes	O	O
after	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
dosing	O	O
.	O	O

Group	O	O
1	O	O
had	O	O
a	O	O
moderate	O	O
negative	O	O
correlation	O	O
between	O	O
plasma	O	O
histamine	B-Chemical	D006632
change	O	O
and	O	O
systemic	O	O
vascular	O	O
resistance	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

58	O	O
;	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
not	O	O
present	O	O
in	O	O
group	O	O
4	O	O
.	O	O

Prior	O	O
dosing	O	O
with	O	O
antagonists	O	O
partially	O	O
prevented	O	O
the	O	O
fall	O	O
in	O	O
systemic	O	O
vascular	O	O
resistance	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
the	O	O
hemodynamic	O	O
changes	O	O
associated	O	O
with	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
dosing	O	O
are	O	O
only	O	O
partially	O	O
explained	O	O
by	O	O
histamine	B-Chemical	D006632
release	O	O
.	O	O

Thus	O	O
prior	O	O
dosing	O	O
with	O	O
H1	O	O
-	O	O
and	O	O
H2	O	O
-	O	O
antagonists	O	O
provides	O	O
only	O	O
partial	O	O
protection	O	O
.	O	O

Convulsant	O	O
effect	O	O
of	O	O
lindane	B-Chemical	D001556
and	O	O
regional	O	O
brain	O	O
concentration	O	O
of	O	O
GABA	B-Chemical	D005680
and	O	O
dopamine	B-Chemical	D004298
.	O	O

Lindane	B-Chemical	D001556
(	O	O
gamma	B-Chemical	D001556
-	I-Chemical	D001556
hexachlorocyclohexane	I-Chemical	D001556
)	O	O
is	O	O
an	O	O
organochlorine	O	O
insecticide	O	O
with	O	O
known	O	O
neurotoxic	B-Disease	D020258
effects	O	O
.	O	O

Its	O	O
mechanism	O	O
of	O	O
action	O	O
is	O	O
not	O	O
well	O	O
understood	O	O
although	O	O
it	O	O
has	O	O
been	O	O
proposed	O	O
that	O	O
lindane	B-Chemical	D001556
acts	O	O
as	O	O
a	O	O
non	O	O
-	O	O
competitive	O	O
antagonist	O	O
at	O	O
the	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
GABA	B-Chemical	D005680
)	O	O
-	O	O
A	O	O
receptor	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
lindane	B-Chemical	D001556
(	O	O
150	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
on	O	O
the	O	O
GABAergic	O	O
and	O	O
dopaminergic	O	O
systems	O	O
by	O	O
measuring	O	O
the	O	O
concentration	O	O
of	O	O
GABA	B-Chemical	D005680
,	O	O
dopamine	B-Chemical	D004298
and	O	O
its	O	O
metabolites	O	O
in	O	O
7	O	O
brain	O	O
areas	O	O
at	O	O
the	O	O
onset	O	O
of	O	O
seizures	B-Disease	D012640
.	O	O

All	O	O
animals	O	O
suffered	O	O
tonic	O	O
convulsions	B-Disease	D012640
at	O	O
18	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

4	O	O
min	O	O
after	O	O
lindane	B-Chemical	D001556
administration	O	O
.	O	O

The	O	O
concentration	O	O
of	O	O
GABA	B-Chemical	D005680
was	O	O
only	O	O
slightly	O	O
but	O	O
significantly	O	O
decreased	O	O
in	O	O
the	O	O
colliculi	O	O
without	O	O
modifications	O	O
in	O	O
the	O	O
other	O	O
areas	O	O
.	O	O

The	O	O
concentration	O	O
of	O	O
dopamine	B-Chemical	D004298
was	O	O
increased	O	O
in	O	O
the	O	O
mesencephalon	O	O
and	O	O
that	O	O
of	O	O
its	O	O
metabolite	O	O
DOPAC	B-Chemical	D015102
was	O	O
also	O	O
increased	O	O
in	O	O
the	O	O
mesencephalon	O	O
and	O	O
the	O	O
striatum	O	O
.	O	O

Unusual	O	O
complications	O	O
of	O	O
antithyroid	O	O
drug	O	O
therapy	O	O
:	O	O
four	O	O
case	O	O
reports	O	O
and	O	O
review	O	O
of	O	O
literature	O	O
.	O	O

Two	O	O
cases	O	O
of	O	O
propylthiouracil	B-Chemical	D011441
-	O	O
associated	O	O
acute	O	O
hepatitis	B-Disease	D056486
,	O	O
one	O	O
case	O	O
of	O	O
fatal	O	O
methimazole	B-Chemical	D008713
-	O	O
associated	O	O
hepatocellular	B-Disease	D047508
necrosis	I-Disease	D047508
and	O	O
one	O	O
case	O	O
of	O	O
propylthiouracil	B-Chemical	D011441
-	O	O
associated	O	O
lupus	B-Disease	D008180
-	I-Disease	D008180
like	I-Disease	D008180
syndrome	I-Disease	D008180
are	O	O
described	O	O
.	O	O

The	O	O
literature	O	O
related	O	O
to	O	O
antithyroid	O	O
drug	O	O
side	O	O
effects	O	O
and	O	O
the	O	O
mechanisms	O	O
for	O	O
their	O	O
occurrence	O	O
are	O	O
reviewed	O	O
and	O	O
the	O	O
efficacy	O	O
and	O	O
complications	O	O
of	O	O
thyroidectomy	O	O
and	O	O
radioiodine	O	O
compared	O	O
to	O	O
those	O	O
of	O	O
antithyroid	O	O
drugs	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
in	O	O
most	O	O
circumstances	O	O
131I	O	O
is	O	O
the	O	O
therapy	O	O
of	O	O
choice	O	O
for	O	O
hyperthyroidism	B-Disease	D006980
.	O	O

Anticonvulsant	O	O
actions	O	O
of	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
on	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
pilocarpine	B-Chemical	D010862
model	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
rats	O	O
.	O	O

MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
,	O	O
a	O	O
noncompetitive	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
(	O	O
NMDA	B-Chemical	D016202
)	O	O
receptor	O	O
antagonist	O	O
,	O	O
was	O	O
tested	O	O
for	O	O
anticonvulsant	O	O
effects	O	O
in	O	O
rats	O	O
using	O	O
two	O	O
seizure	B-Disease	D012640
models	O	O
,	O	O
coadministration	O	O
of	O	O
lithium	B-Chemical	D008094
and	O	O
pilocarpine	B-Chemical	D010862
and	O	O
administration	O	O
of	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
pilocarpine	B-Chemical	D010862
alone	O	O
.	O	O

Three	O	O
major	O	O
results	O	O
are	O	O
reported	O	O
.	O	O

First	O	O
,	O	O
pretreatment	O	O
with	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
produced	O	O
an	O	O
effective	O	O
and	O	O
dose	O	O
-	O	O
dependent	O	O
anticonvulsant	O	O
action	O	O
with	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
pilocarpine	B-Chemical	D010862
model	O	O
but	O	O
not	O	O
with	O	O
rats	O	O
treated	O	O
with	O	O
pilocarpine	B-Chemical	D010862
alone	O	O
,	O	O
suggesting	O	O
that	O	O
different	O	O
biochemical	O	O
mechanisms	O	O
control	O	O
seizures	B-Disease	D012640
in	O	O
these	O	O
two	O	O
models	O	O
.	O	O

Second	O	O
,	O	O
the	O	O
anticonvulsant	O	O
effect	O	O
of	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
in	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
pilocarpine	B-Chemical	D010862
model	O	O
only	O	O
occurred	O	O
after	O	O
initial	O	O
periods	O	O
of	O	O
seizure	B-Disease	D012640
activity	O	O
.	O	O

This	O	O
observation	O	O
is	O	O
suggested	O	O
to	O	O
be	O	O
an	O	O
in	O	O
vivo	O	O
demonstration	O	O
of	O	O
the	O	O
conclusion	O	O
derived	O	O
from	O	O
in	O	O
vitro	O	O
experiments	O	O
that	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
binding	O	O
requires	O	O
agonist	O	O
-	O	O
induced	O	O
opening	O	O
of	O	O
the	O	O
channel	O	O
sites	O	O
of	O	O
the	O	O
NMDA	B-Chemical	D016202
receptor	O	O
.	O	O

Third	O	O
,	O	O
although	O	O
it	O	O
is	O	O
relatively	O	O
easy	O	O
to	O	O
block	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
lithium	B-Chemical	D008094
and	O	O
pilocarpine	B-Chemical	D010862
by	O	O
administration	O	O
of	O	O
anticonvulsants	O	O
prior	O	O
to	O	O
pilocarpine	B-Chemical	D010862
,	O	O
it	O	O
is	O	O
more	O	O
difficult	O	O
to	O	O
terminate	O	O
ongoing	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
and	O	O
block	O	O
the	O	O
lethality	O	O
of	O	O
the	O	O
seizures	B-Disease	D012640
.	O	O

Administration	O	O
of	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
30	O	O
or	O	O
60	O	O
min	O	O
after	O	O
pilocarpine	B-Chemical	D010862
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
during	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
,	O	O
gradually	O	O
reduced	O	O
electrical	O	O
and	O	O
behavioral	O	O
seizure	B-Disease	D012640
activity	O	O
and	O	O
greatly	O	O
enhanced	O	O
the	O	O
survival	O	O
rate	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
NMDA	B-Chemical	D016202
receptors	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
and	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
in	O	O
the	O	O
lithium	B-Chemical	D008094
-	O	O
pilocarpine	B-Chemical	D010862
model	O	O
.	O	O

This	O	O
was	O	O
further	O	O
supported	O	O
by	O	O
results	O	O
showing	O	O
that	O	O
nonconvulsive	O	O
doses	O	O
of	O	O
NMDA	B-Chemical	D016202
and	O	O
pilocarpine	B-Chemical	D010862
were	O	O
synergistic	O	O
,	O	O
resulting	O	O
in	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
and	O	O
subsequent	O	O
mortality	O	O
.	O	O

Nifedipine	B-Chemical	D009543
induced	O	O
bradycardia	B-Disease	D001919
in	O	O
a	O	O
patient	O	O
with	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
.	O	O

An	O	O
80	O	O
year	O	O
old	O	O
diabetic	B-Disease	D003920
male	O	O
with	O	O
evidence	O	O
of	O	O
peripheral	O	O
and	O	O
autonomic	B-Disease	D009422
neuropathy	I-Disease	D009422
was	O	O
admitted	O	O
with	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

He	O	O
was	O	O
found	O	O
to	O	O
have	O	O
atrial	B-Disease	D001282
flutter	I-Disease	D001282
at	O	O
a	O	O
ventricular	O	O
rate	O	O
of	O	O
70	O	O
/	O	O
min	O	O
which	O	O
slowed	O	O
down	O	O
to	O	O
30	O	O
-	O	O
40	O	O
/	O	O
min	O	O
when	O	O
nifedipine	B-Chemical	D009543
(	O	O
60	O	O
mg	O	O
)	O	O
in	O	O
3	O	O
divided	O	O
doses	O	O
,	O	O
during	O	O
which	O	O
he	O	O
was	O	O
paced	O	O
at	O	O
a	O	O
rate	O	O
of	O	O
70	O	O
/	O	O
min	O	O
.	O	O

This	O	O
is	O	O
inconsistent	O	O
with	O	O
the	O	O
well	O	O
-	O	O
established	O	O
finding	O	O
that	O	O
nifedipine	B-Chemical	D009543
induces	O	O
tachycardia	B-Disease	D013610
in	O	O
normally	O	O
innervated	O	O
hearts	O	O
.	O	O

However	O	O
,	O	O
in	O	O
hearts	O	O
deprived	O	O
of	O	O
compensatory	O	O
sympathetic	O	O
drive	O	O
,	O	O
it	O	O
may	O	O
lead	O	O
to	O	O
bradycardia	B-Disease	D001919
.	O	O

The	O	O
effect	O	O
of	O	O
haloperidol	B-Chemical	D006220
in	O	O
cocaine	B-Chemical	D003042
and	O	O
amphetamine	B-Chemical	D000661
intoxication	O	O
.	O	O

The	O	O
effectiveness	O	O
of	O	O
haloperidol	B-Chemical	D006220
pretreatment	O	O
in	O	O
preventing	O	O
the	O	O
toxic	O	O
effects	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
amphetamine	B-Chemical	D000661
and	O	O
cocaine	B-Chemical	D003042
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

In	O	O
this	O	O
model	O	O
,	O	O
toxic	O	O
effects	O	O
were	O	O
induced	O	O
by	O	O
intraperitoneal	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
injection	O	O
of	O	O
amphetamine	B-Chemical	D000661
75	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
100%	O	O
death	O	O
rate	O	O
)	O	O
or	O	O
cocaine	B-Chemical	D003042
70	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
82%	O	O
death	O	O
rate	O	O
)	O	O
.	O	O

Haloperidol	B-Chemical	D006220
failed	O	O
to	O	O
prevent	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
seizures	B-Disease	D012640
,	O	O
but	O	O
did	O	O
lower	O	O
the	O	O
mortality	O	O
rate	O	O
at	O	O
most	O	O
doses	O	O
tested	O	O
.	O	O

Haloperidol	B-Chemical	D006220
decreased	O	O
the	O	O
incidence	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
at	O	O
the	O	O
two	O	O
highest	O	O
doses	O	O
,	O	O
but	O	O
the	O	O
lowering	O	O
of	O	O
the	O	O
mortality	O	O
rate	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
at	O	O
any	O	O
dose	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
a	O	O
protective	O	O
role	O	O
for	O	O
the	O	O
central	O	O
dopamine	B-Chemical	D004298
blocker	O	O
haloperidol	B-Chemical	D006220
against	O	O
death	O	O
from	O	O
high	O	O
-	O	O
dose	O	O
amphetamine	B-Chemical	D000661
exposure	O	O
without	O	O
reducing	O	O
the	O	O
incidence	O	O
of	O	O
seizures	B-Disease	D012640
.	O	O

In	O	O
contrast	O	O
,	O	O
haloperidol	B-Chemical	D006220
demonstrated	O	O
an	O	O
ability	O	O
to	O	O
reduce	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
seizures	B-Disease	D012640
without	O	O
significantly	O	O
reducing	O	O
mortality	O	O
.	O	O

Autoradiographic	O	O
evidence	O	O
of	O	O
estrogen	B-Chemical	D004967
binding	O	O
sites	O	O
in	O	O
nuclei	O	O
of	O	O
diethylstilbesterol	B-Chemical	D004054
induced	O	O
hamster	O	O
renal	B-Disease	D002292
carcinomas	I-Disease	D002292
.	O	O

Estrogen	B-Chemical	D004967
binding	O	O
sites	O	O
were	O	O
demonstrated	O	O
by	O	O
autoradiography	O	O
in	O	O
one	O	O
transplantable	O	O
and	O	O
five	O	O
primary	O	O
diethylstilbesterol	B-Chemical	D004054
induced	O	O
renal	B-Disease	D002292
carcinomas	I-Disease	D002292
in	O	O
three	O	O
hamsters	O	O
.	O	O

Radiolabelling	O	O
,	O	O
following	O	O
the	O	O
in	O	O
vivo	O	O
injection	O	O
of	O	O
3H	O	O
-	O	O
17	O	O
beta	O	O
estradiol	B-Chemical	D004958
,	O	O
was	O	O
increased	O	O
only	O	O
over	O	O
the	O	O
nuclei	O	O
of	O	O
tumor	B-Disease	D009369
cells	O	O
;	O	O
stereologic	O	O
analysis	O	O
revealed	O	O
a	O	O
4	O	O
.	O	O

5	O	O
-	O	O
to	O	O
6	O	O
.	O	O

7	O	O
-	O	O
times	O	O
higher	O	O
concentration	O	O
of	O	O
reduced	O	O
silver	B-Chemical	D012834
grains	O	O
over	O	O
nuclei	O	O
than	O	O
cytoplasm	O	O
of	O	O
these	O	O
cells	O	O
.	O	O

Despite	O	O
rapid	O	O
tubular	O	O
excretion	O	O
of	O	O
estradiol	B-Chemical	D004958
which	O	O
peaked	O	O
in	O	O
less	O	O
than	O	O
1	O	O
h	O	O
,	O	O
the	O	O
normal	O	O
cells	O	O
did	O	O
not	O	O
appear	O	O
to	O	O
bind	O	O
the	O	O
ligand	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
published	O	O
report	O	O
documenting	O	O
the	O	O
preferential	O	O
in	O	O
vivo	O	O
binding	O	O
of	O	O
estrogen	B-Chemical	D004967
to	O	O
nuclei	O	O
of	O	O
cells	O	O
in	O	O
estrogen	B-Chemical	D004967
induced	O	O
hamster	O	O
renal	B-Disease	D002292
carcinomas	I-Disease	D002292
.	O	O

Bradycardia	B-Disease	D001919
due	O	O
to	O	O
biperiden	B-Chemical	D001712
.	O	O

In	O	O
a	O	O
38	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
suffering	O	O
from	O	O
a	O	O
severe	O	O
postzosteric	B-Disease	D006562
trigeminal	B-Disease	D014277
neuralgia	I-Disease	D014277
,	O	O
intravenous	O	O
application	O	O
of	O	O
10	O	O
mg	O	O
biperiden	B-Chemical	D001712
lactate	O	O
led	O	O
to	O	O
a	O	O
long	O	O
-	O	O
lasting	O	O
paradoxical	O	O
reaction	O	O
characterized	O	O
by	O	O
considerable	O	O
bradycardia	B-Disease	D001919
,	O	O
dysarthria	B-Disease	D004401
,	O	O
and	O	O
dysphagia	B-Disease	D003680
.	O	O

The	O	O
heart	O	O
rate	O	O
was	O	O
back	O	O
to	O	O
normal	O	O
within	O	O
12	O	O
hours	O	O
upon	O	O
administration	O	O
of	O	O
orciprenaline	B-Chemical	D009921
under	O	O
cardiac	O	O
monitoring	O	O
in	O	O
an	O	O
intensive	O	O
care	O	O
unit	O	O
.	O	O

Bradycardia	B-Disease	D001919
induced	O	O
by	O	O
biperiden	B-Chemical	D001712
is	O	O
attributed	O	O
to	O	O
the	O	O
speed	O	O
of	O	O
injection	O	O
and	O	O
to	O	O
a	O	O
dose	O	O
-	O	O
related	O	O
dual	O	O
effect	O	O
of	O	O
atropine	B-Chemical	D001285
-	O	O
like	O	O
drugs	O	O
on	O	O
muscarine	B-Chemical	D009116
receptors	O	O
.	O	O

Deliberate	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
labetalol	B-Chemical	D007741
with	O	O
halothane	B-Chemical	D006221
,	O	O
enflurane	B-Chemical	D004737
or	O	O
isoflurane	B-Chemical	D007530
for	O	O
middle	O	O
-	O	O
ear	O	O
surgery	O	O
.	O	O

The	O	O
feasibility	O	O
of	O	O
using	O	O
labetalol	B-Chemical	D007741
,	O	O
an	O	O
alpha	O	O
-	O	O
and	O	O
beta	O	O
-	O	O
adrenergic	O	O
blocking	O	O
agent	O	O
,	O	O
as	O	O
a	O	O
hypotensive	B-Disease	D007022
agent	O	O
in	O	O
combination	O	O
with	O	O
inhalation	O	O
anaesthetics	O	O
(	O	O
halothane	B-Chemical	D006221
,	O	O
enflurane	B-Chemical	D004737
or	O	O
isoflurane	B-Chemical	D007530
)	O	O
was	O	O
studied	O	O
in	O	O
23	O	O
adult	O	O
patients	O	O
undergoing	O	O
middle	O	O
-	O	O
ear	O	O
surgery	O	O
.	O	O

The	O	O
mean	O	O
arterial	O	O
pressure	O	O
was	O	O
decreased	O	O
from	O	O
86	O	O
+	O	O
/	O	O
-	O	O
5	O	O
(	O	O
s	O	O
.	O	O

e	O	O
.	O	O

mean	O	O
)	O	O
mmHg	O	O
to	O	O
52	O	O
+	O	O
/	O	O
-	O	O
1	O	O
mmHg	O	O
(	O	O
11	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
to	O	O
6	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
kPa	O	O
)	O	O
for	O	O
98	O	O
+	O	O
/	O	O
-	O	O
10	O	O
min	O	O
in	O	O
the	O	O
halothane	B-Chemical	D006221
(	O	O
H	B-Chemical	D006221
)	O	O
group	O	O
,	O	O
from	O	O
79	O	O
+	O	O
/	O	O
-	O	O
5	O	O
to	O	O
53	O	O
+	O	O
/	O	O
-	O	O
1	O	O
mmHg	O	O
(	O	O
10	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
to	O	O
7	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
kPa	O	O
)	O	O
for	O	O
129	O	O
+	O	O
/	O	O
-	O	O
11	O	O
min	O	O
in	O	O
the	O	O
enflurane	B-Chemical	D004737
(	O	O
E	B-Chemical	D004737
)	O	O
group	O	O
,	O	O
and	O	O
from	O	O
80	O	O
+	O	O
/	O	O
-	O	O
4	O	O
to	O	O
49	O	O
+	O	O
/	O	O
-	O	O
1	O	O
mmHg	O	O
(	O	O
10	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
to	O	O
6	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
kPa	O	O
)	O	O
for	O	O
135	O	O
+	O	O
/	O	O
-	O	O
15	O	O
min	O	O
in	O	O
the	O	O
isoflurane	B-Chemical	D007530
(	O	O
I	B-Chemical	D007530
)	O	O
group	O	O
.	O	O

The	O	O
mean	O	O
H	B-Chemical	D006221
concentration	O	O
during	O	O
hypotension	B-Disease	D007022
in	O	O
the	O	O
inspiratory	O	O
gas	O	O
was	O	O
0	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
vol%	O	O
,	O	O
the	O	O
mean	O	O
E	B-Chemical	D004737
concentration	O	O
1	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

2	O	O
vol%	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
I	B-Chemical	D007530
concentration	O	O
1	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

1	O	O
vol%	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
patients	O	O
received	O	O
fentanyl	B-Chemical	D005283
and	O	O
d	B-Chemical	D014403
-	I-Chemical	D014403
tubocurarine	I-Chemical	D014403
.	O	O

The	O	O
initial	O	O
dose	O	O
of	O	O
labetalol	B-Chemical	D007741
for	O	O
lowering	O	O
blood	O	O
pressure	O	O
was	O	O
similar	O	O
,	O	O
0	O	O
.	O	O

52	O	O
-	O	O
0	O	O
.	O	O

59	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
in	O	O
all	O	O
the	O	O
groups	O	O
.	O	O

During	O	O
hypotension	B-Disease	D007022
,	O	O
the	O	O
heart	O	O
rate	O	O
was	O	O
stable	O	O
without	O	O
tachy	B-Disease	D013610
-	I-Disease	D013610
or	I-Disease	D013610
bradycardia	I-Disease	D013610
.	O	O

The	O	O
operating	O	O
conditions	O	O
regarding	O	O
bleeding	B-Disease	D006470
were	O	O
estimated	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
manner	O	O
,	O	O
and	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
groups	O	O
.	O	O

During	O	O
hypotension	B-Disease	D007022
,	O	O
the	O	O
serum	O	O
creatinine	B-Chemical	D003404
concentration	O	O
rose	O	O
significantly	O	O
in	O	O
all	O	O
groups	O	O
from	O	O
the	O	O
values	O	O
before	O	O
hypotension	B-Disease	D007022
and	O	O
returned	O	O
postoperatively	O	O
to	O	O
the	O	O
initial	O	O
level	O	O
in	O	O
the	O	O
other	O	O
groups	O	O
,	O	O
except	O	O
the	O	O
isoflurane	B-Chemical	D007530
group	O	O
.	O	O

After	O	O
hypotension	B-Disease	D007022
there	O	O
was	O	O
no	O	O
rebound	O	O
phenomenon	O	O
in	O	O
either	O	O
blood	O	O
pressure	O	O
or	O	O
heart	O	O
rate	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
labetalol	B-Chemical	D007741
induces	O	O
easily	O	O
adjustable	O	O
hypotension	B-Disease	D007022
without	O	O
compensatory	O	O
tachycardia	B-Disease	D013610
and	O	O
rebound	O	O
hypertension	B-Disease	D006973
.	O	O

Convulsion	B-Disease	D012640
following	O	O
intravenous	O	O
fluorescein	B-Chemical	D019793
angiography	O	O
.	O	O

Tonic	B-Disease	D004830
-	I-Disease	D004830
clonic	I-Disease	D004830
seizures	I-Disease	D004830
followed	O	O
intravenous	O	O
fluorescein	B-Chemical	D019793
injection	O	O
for	O	O
fundus	O	O
angiography	O	O
in	O	O
a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
.	O	O

Despite	O	O
precautions	O	O
this	O	O
adverse	O	O
reaction	O	O
recurred	O	O
on	O	O
re	O	O
-	O	O
exposure	O	O
to	O	O
intravenous	O	O
fluorescein	B-Chemical	D019793
.	O	O

Pharmacology	O	O
of	O	O
ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
(	O	O
phenytoin	B-Chemical	D010672
prodrug	O	O
)	O	O
.	O	O

ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
,	O	O
the	O	O
disodium	B-Chemical	-1
phosphate	I-Chemical	-1
ester	I-Chemical	-1
of	O	O
3	B-Chemical	C043104
-	I-Chemical	C043104
hydroxymethyl	I-Chemical	C043104
-	I-Chemical	C043104
5	I-Chemical	C043104
,	I-Chemical	C043104
5	I-Chemical	C043104
-	I-Chemical	C043104
diphenylhydantoin	I-Chemical	C043104
,	O	O
is	O	O
a	O	O
prodrug	O	O
of	O	O
phenytoin	B-Chemical	D010672
with	O	O
advantageous	O	O
physicochemical	O	O
properties	O	O
.	O	O

ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
is	O	O
rapidly	O	O
converted	O	O
enzymatically	O	O
to	O	O
phenytoin	B-Chemical	D010672
in	O	O
vivo	O	O
.	O	O

ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
and	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
have	O	O
equivalent	O	O
anticonvulsant	O	O
activity	O	O
against	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
maximal	O	O
electroshock	O	O
(	O	O
MES	O	O
)	O	O
in	O	O
mice	O	O
following	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
oral	O	O
,	O	O
or	O	O
i	O	O
.	O	O

v	O	O
.	O	O

administration	O	O
.	O	O

The	O	O
ED50	O	O
doses	O	O
were	O	O
16	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
i	O	O
.	O	O

v	O	O
.	O	O

ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
and	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
for	O	O
i	O	O
.	O	O

v	O	O
.	O	O

phenytoin	B-Chemical	D010672
sodium	O	O
.	O	O

ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
and	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
have	O	O
similar	O	O
antiarrhythmic	O	O
activity	O	O
against	O	O
ouabain	B-Chemical	D010042
-	O	O
induced	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
in	O	O
anesthetized	O	O
dogs	O	O
.	O	O

The	O	O
total	O	O
doses	O	O
of	O	O
ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
or	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
necessary	O	O
to	O	O
convert	O	O
the	O	O
arrhythmia	B-Disease	D001145
to	O	O
a	O	O
normal	O	O
sinus	O	O
rhythm	O	O
were	O	O
24	O	O
+	O	O
/	O	O
-	O	O
6	O	O
and	O	O
14	O	O
+	O	O
/	O	O
-	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
respectively	O	O
.	O	O

Only	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
displayed	O	O
in	O	O
vitro	O	O
antiarrhythmic	O	O
activity	O	O
against	O	O
strophanthidin	B-Chemical	D013327
-	O	O
induced	O	O
arrhythmias	B-Disease	D001145
in	O	O
guinea	O	O
pig	O	O
right	O	O
atria	O	O
.	O	O

In	O	O
anesthetized	O	O
dogs	O	O
,	O	O
a	O	O
high	O	O
dose	O	O
of	O	O
ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
(	O	O
31	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
infused	O	O
over	O	O
15	O	O
,	O	O
20	O	O
,	O	O
and	O	O
30	O	O
min	O	O
and	O	O
the	O	O
responses	O	O
were	O	O
compared	O	O
to	O	O
an	O	O
equimolar	O	O
dose	O	O
of	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
(	O	O
21	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
.	O	O

The	O	O
ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
and	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
treatments	O	O
produced	O	O
similar	O	O
marked	O	O
reductions	O	O
in	O	O
diastolic	O	O
blood	O	O
pressure	O	O
and	O	O
contractile	O	O
force	O	O
(	O	O
LVdP	O	O
/	O	O
dt	O	O
)	O	O
.	O	O

The	O	O
maximum	O	O
effects	O	O
of	O	O
each	O	O
treatment	O	O
occurred	O	O
at	O	O
the	O	O
time	O	O
of	O	O
maximum	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
levels	O	O
.	O	O

Acute	O	O
toxicity	B-Disease	D064420
studies	O	O
of	O	O
ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
and	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
were	O	O
carried	O	O
out	O	O
in	O	O
mice	O	O
,	O	O
rats	O	O
,	O	O
rabbits	O	O
,	O	O
and	O	O
dogs	O	O
by	O	O
i	O	O
.	O	O

v	O	O
.	O	O

,	O	O
i	O	O
.	O	O

m	O	O
.	O	O

,	O	O
and	O	O
i	O	O
.	O	O

p	O	O
.	O	O

routes	O	O
of	O	O
administration	O	O
.	O	O

The	O	O
systemic	O	O
toxic	O	O
signs	O	O
of	O	O
both	O	O
agents	O	O
were	O	O
similar	O	O
and	O	O
occurred	O	O
at	O	O
approximately	O	O
equivalent	O	O
doses	O	O
.	O	O

Importantly	O	O
,	O	O
the	O	O
local	O	O
irritation	O	O
of	O	O
ACC	B-Chemical	C043114
-	I-Chemical	C043114
9653	I-Chemical	C043114
was	O	O
markedly	O	O
less	O	O
than	O	O
phenytoin	B-Chemical	D010672
sodium	O	O
following	O	O
i	O	O
.	O	O

m	O	O
.	O	O

administration	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Phenytoin	B-Chemical	D010672
induced	O	O
fatal	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
.	O	O

A	O	O
61	O	O
year	O	O
old	O	O
female	O	O
developed	O	O
fatal	O	O
hepatic	B-Disease	D017093
failure	I-Disease	D017093
after	O	O
phenytoin	B-Chemical	D010672
administration	O	O
.	O	O

A	O	O
typical	O	O
multisystem	O	O
clinical	O	O
pattern	O	O
precedes	O	O
the	O	O
manifestations	O	O
of	O	O
hepatic	B-Disease	D056486
injury	I-Disease	D056486
.	O	O

The	O	O
hematologic	O	O
,	O	O
biochemical	O	O
and	O	O
pathologic	O	O
features	O	O
indicate	O	O
a	O	O
mixed	O	O
hepatocellular	B-Disease	D056486
damage	I-Disease	D056486
due	O	O
to	O	O
drug	B-Disease	D004342
hypersensitivity	I-Disease	D004342
.	O	O

In	O	O
a	O	O
patient	O	O
receiving	O	O
phenytoin	B-Chemical	D010672
who	O	O
presents	O	O
a	O	O
viral	O	O
-	O	O
like	O	O
illness	O	O
,	O	O
early	O	O
recognition	O	O
and	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
are	O	O
mandatory	O	O
.	O	O

Treatment	O	O
of	O	O
lethal	O	O
pertussis	B-Chemical	D010567
vaccine	I-Chemical	D010567
reaction	O	O
with	O	O
histamine	B-Chemical	D006632
H1	O	O
antagonists	O	O
.	O	O

We	O	O
studied	O	O
mortality	O	O
after	O	O
pertussis	B-Disease	D014917
immunization	O	O
in	O	O
the	O	O
mouse	O	O
.	O	O

Without	O	O
treatment	O	O
,	O	O
73	O	O
of	O	O
92	O	O
animals	O	O
(	O	O
80%	O	O
)	O	O
died	O	O
after	O	O
injection	O	O
of	O	O
bovine	O	O
serum	O	O
albumin	O	O
(	O	O
BSA	O	O
)	O	O
on	O	O
day	O	O
+7	O	O
of	O	O
pertussis	B-Disease	D014917
immunization	O	O
.	O	O

After	O	O
pretreatment	O	O
with	O	O
3	O	O
mg	O	O
of	O	O
cyproheptadine	B-Chemical	D003533
,	O	O
2	O	O
mg	O	O
mianserin	B-Chemical	D008803
,	O	O
or	O	O
2	O	O
mg	O	O
chlorpheniramine	B-Chemical	D002744
,	O	O
only	O	O
5	O	O
of	O	O
105	O	O
animals	O	O
(	O	O
5%	O	O
)	O	O
died	O	O
after	O	O
receiving	O	O
BSA	O	O
on	O	O
day	O	O
+7	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Blockade	O	O
of	O	O
histamine	B-Chemical	D006632
H1	O	O
receptors	O	O
may	O	O
reduce	O	O
mortality	O	O
in	O	O
pertussis	B-Disease	D014917
immunization	O	O
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
in	O	O
mice	O	O
.	O	O

Support	O	O
for	O	O
adrenaline	B-Chemical	D004837
-	O	O
hypertension	B-Disease	D006973
hypothesis	O	O
:	O	O
18	O	O
hour	O	O
pressor	O	O
effect	O	O
after	O	O
6	O	O
hours	O	O
adrenaline	B-Chemical	D004837
infusion	O	O
.	O	O

In	O	O
a	O	O
double	O	O
blind	O	O
,	O	O
crossover	O	O
study	O	O
6	O	O
h	O	O
infusions	O	O
of	O	O
adrenaline	B-Chemical	D004837
(	O	O
15	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
;	O	O
1	O	O
ng	O	O
=	O	O
5	O	O
.	O	O

458	O	O
pmol	O	O
)	O	O
,	O	O
noradrenaline	B-Chemical	D009638
(	O	O
30	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
;	O	O
1	O	O
ng	O	O
=	O	O
5	O	O
.	O	O

911	O	O
pmol	O	O
)	O	O
,	O	O
and	O	O
a	O	O
5%	O	O
dextrose	B-Chemical	D005947
solution	O	O
(	O	O
5	O	O
.	O	O

4	O	O
ml	O	O
/	O	O
h	O	O
)	O	O
,	O	O
were	O	O
given	O	O
to	O	O
ten	O	O
healthy	O	O
volunteers	O	O
in	O	O
random	O	O
order	O	O
2	O	O
weeks	O	O
apart	O	O
.	O	O

By	O	O
means	O	O
of	O	O
intra	O	O
-	O	O
arterial	O	O
ambulatory	O	O
monitoring	O	O
the	O	O
haemodynamic	O	O
effects	O	O
were	O	O
followed	O	O
for	O	O
18	O	O
h	O	O
after	O	O
the	O	O
infusions	O	O
were	O	O
stopped	O	O
.	O	O

Adrenaline	B-Chemical	D004837
,	O	O
but	O	O
not	O	O
noradrenaline	B-Chemical	D009638
,	O	O
caused	O	O
a	O	O
delayed	O	O
and	O	O
protracted	O	O
pressor	O	O
effect	O	O
.	O	O

Over	O	O
the	O	O
total	O	O
postinfusion	O	O
period	O	O
systolic	O	O
and	O	O
diastolic	O	O
arterial	O	O
pressure	O	O
were	O	O
6	O	O
(	O	O
SEM	O	O
2	O	O
)	O	O
%	O	O
and	O	O
7	O	O
(	O	O
2	O	O
)	O	O
%	O	O
,	O	O
respectively	O	O
,	O	O
higher	O	O
than	O	O
after	O	O
dextrose	B-Chemical	D005947
infusion	O	O
(	O	O
ANOVA	O	O
,	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Thus	O	O
,	O	O
"stress"	O	O
levels	O	O
of	O	O
adrenaline	B-Chemical	D004837
(	O	O
230	O	O
pg	O	O
/	O	O
ml	O	O
)	O	O
for	O	O
6	O	O
h	O	O
cause	O	O
a	O	O
delayed	O	O
and	O	O
protracted	O	O
pressor	O	O
effect	O	O
.	O	O

These	O	O
findings	O	O
are	O	O
strong	O	O
support	O	O
for	O	O
the	O	O
adrenaline	B-Chemical	D004837
-	O	O
hypertension	B-Disease	D006973
hypothesis	O	O
in	O	O
man	O	O
.	O	O

Effect	O	O
of	O	O
alkylxanthines	B-Chemical	-1
on	O	O
gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
in	O	O
the	O	O
rat	O	O
.	O	O

Adenosine	B-Chemical	D000241
antagonists	O	O
have	O	O
been	O	O
previously	O	O
shown	O	O
to	O	O
be	O	O
of	O	O
benefit	O	O
in	O	O
some	O	O
ischaemic	B-Disease	D007511
and	O	O
nephrotoxic	B-Disease	D007674
models	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
(	O	O
ARF	B-Disease	D058186
)	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
three	O	O
alkylxanthines	B-Chemical	-1
with	O	O
different	O	O
potencies	O	O
as	O	O
adenosine	B-Chemical	D000241
antagonists	O	O
8	B-Chemical	C028322
-	I-Chemical	C028322
phenyltheophylline	I-Chemical	C028322
,	O	O
theophylline	B-Chemical	D013806
and	O	O
enprofylline	B-Chemical	C034347
,	O	O
were	O	O
examined	O	O
in	O	O
rats	O	O
developing	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
after	O	O
4	O	O
daily	O	O
injections	O	O
of	O	O
gentamicin	B-Chemical	D005839
(	O	O
200	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Renal	O	O
function	O	O
was	O	O
assessed	O	O
by	O	O
biochemical	O	O
(	O	O
plasma	O	O
urea	B-Chemical	D014508
and	O	O
creatinine	B-Chemical	D003404
)	O	O
,	O	O
functional	O	O
(	O	O
urine	O	O
analysis	O	O
and	O	O
[	O	O
3H	O	O
]	O	O
inulin	O	O
and	O	O
[	O	O
14C	O	O
]	O	O
p	B-Chemical	D010130
-	I-Chemical	D010130
aminohippuric	I-Chemical	D010130
acid	I-Chemical	D010130
clearances	O	O
)	O	O
and	O	O
morphological	O	O
(	O	O
degree	O	O
of	O	O
necrosis	B-Disease	D009336
)	O	O
indices	O	O
.	O	O

The	O	O
various	O	O
drug	O	O
treatments	O	O
produced	O	O
improvements	O	O
in	O	O
some	O	O
,	O	O
but	O	O
not	O	O
all	O	O
,	O	O
measurements	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

However	O	O
,	O	O
any	O	O
improvement	O	O
produced	O	O
by	O	O
drug	O	O
treatment	O	O
was	O	O
largely	O	O
a	O	O
result	O	O
of	O	O
a	O	O
beneficial	O	O
effect	O	O
exerted	O	O
by	O	O
its	O	O
vehicle	O	O
(	O	O
polyethylene	B-Chemical	D011092
glycol	I-Chemical	D011092
and	O	O
NaOH	B-Chemical	D012972
)	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
any	O	O
consistent	O	O
protective	O	O
effect	O	O
noted	O	O
with	O	O
the	O	O
alkylxanthines	B-Chemical	-1
tested	O	O
in	O	O
the	O	O
present	O	O
study	O	O
indicates	O	O
that	O	O
adenosine	B-Chemical	D000241
plays	O	O
little	O	O
,	O	O
if	O	O
any	O	O
,	O	O
pathophysiological	O	O
role	O	O
in	O	O
gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
ARF	B-Disease	D058186
.	O	O

Adverse	O	O
ocular	O	O
reactions	O	O
possibly	O	O
associated	O	O
with	O	O
isotretinoin	B-Chemical	D015474
.	O	O

A	O	O
total	O	O
of	O	O
261	O	O
adverse	O	O
ocular	O	O
reactions	O	O
occurred	O	O
in	O	O
237	O	O
patients	O	O
who	O	O
received	O	O
isotretinoin	B-Chemical	D015474
,	O	O
a	O	O
commonly	O	O
used	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
severe	O	O
cystic	O	O
acne	B-Disease	D000152
.	O	O

Blepharoconjunctivitis	B-Disease	D003231
,	O	O
subjective	O	O
complaints	O	O
of	O	O
dry	B-Disease	D014985
eyes	I-Disease	D014985
,	O	O
blurred	B-Disease	D014786
vision	I-Disease	D014786
,	O	O
contact	O	O
lens	O	O
intolerance	O	O
,	O	O
and	O	O
photodermatitis	B-Disease	D010787
are	O	O
reversible	O	O
side	O	O
effects	O	O
.	O	O

More	O	O
serious	O	O
ocular	O	O
adverse	O	O
reactions	O	O
include	O	O
papilledema	B-Disease	D010211
,	O	O
pseudotumor	B-Disease	D011559
cerebri	I-Disease	D011559
,	O	O
and	O	O
white	O	O
or	O	O
gray	O	O
subepithelial	O	O
corneal	B-Disease	D003318
opacities	I-Disease	D003318
;	O	O
all	O	O
of	O	O
these	O	O
are	O	O
reversible	O	O
if	O	O
the	O	O
drug	O	O
is	O	O
discontinued	O	O
.	O	O

Reported	O	O
cases	O	O
of	O	O
decreased	O	O
dark	O	O
adaptation	O	O
are	O	O
under	O	O
investigation	O	O
.	O	O

Isotretinoin	B-Chemical	D015474
is	O	O
contraindicated	O	O
in	O	O
pregnancy	O	O
because	O	O
of	O	O
the	O	O
many	O	O
reported	O	O
congenital	B-Disease	D000013
abnormalities	I-Disease	D000013
after	O	O
maternal	O	O
use	O	O
(	O	O
including	O	O
microphthalmos	B-Disease	D008850
,	O	O
orbital	O	O
hypertelorism	B-Disease	D006972
,	O	O
and	O	O
optic	B-Disease	C563492
nerve	I-Disease	C563492
hypoplasia	I-Disease	C563492
)	O	O
.	O	O

Procaterol	B-Chemical	D017265
and	O	O
terbutaline	B-Chemical	D013726
in	O	O
bronchial	B-Disease	D001249
asthma	I-Disease	D001249
.	O	O

A	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
study	O	O
.	O	O

Procaterol	B-Chemical	D017265
,	O	O
a	O	O
new	O	O
beta	O	O
-	O	O
2	O	O
adrenoceptor	O	O
stimulant	O	O
,	O	O
was	O	O
studied	O	O
in	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
trial	O	O
in	O	O
patients	O	O
with	O	O
bronchial	B-Disease	D001249
asthma	I-Disease	D001249
.	O	O

Oral	O	O
procaterol	B-Chemical	D017265
50	O	O
micrograms	O	O
b	O	O
.	O	O

d	O	O
.	O	O

,	O	O
procaterol	B-Chemical	D017265
100	O	O
micrograms	O	O
b	O	O
.	O	O

d	O	O
.	O	O

,	O	O
and	O	O
terbutaline	B-Chemical	D013726
5	O	O
mg	O	O
t	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

,	O	O
were	O	O
compared	O	O
when	O	O
given	O	O
randomly	O	O
in	O	O
1	O	O
-	O	O
week	O	O
treatment	O	O
periods	O	O
.	O	O

The	O	O
best	O	O
clinical	O	O
effect	O	O
was	O	O
found	O	O
with	O	O
terbutaline	B-Chemical	D013726
.	O	O

Both	O	O
anti	O	O
-	O	O
asthmatic	B-Disease	D001249
and	O	O
tremorgenic	B-Disease	D014202
effects	O	O
of	O	O
procaterol	B-Chemical	D017265
were	O	O
dose	O	O
-	O	O
related	O	O
.	O	O

Procaterol	B-Chemical	D017265
appeared	O	O
effective	O	O
in	O	O
the	O	O
doses	O	O
tested	O	O
,	O	O
and	O	O
a	O	O
twice	O	O
daily	O	O
regimen	O	O
would	O	O
appear	O	O
to	O	O
be	O	O
suitable	O	O
with	O	O
this	O	O
drug	O	O
.	O	O

Subacute	O	O
effects	O	O
of	O	O
propranolol	B-Chemical	D011433
and	O	O
B	O	O
24	O	O
/	O	O
76	O	O
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
rat	O	O
heart	B-Disease	D006332
hypertrophy	I-Disease	D006332
in	O	O
correlation	O	O
with	O	O
blood	O	O
pressure	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
potential	O	O
beta	O	O
-	O	O
receptor	O	O
blocker	O	O
,	O	O
B	O	O
24	O	O
/	O	O
76	O	O
i	O	O
.	O	O

e	O	O
.	O	O

1	O	O
-	O	O
(	O	O
2	O	O
,	O	O
4	O	O
-	O	O
dichlorophenoxy	O	O
)	O	O
-	O	O
3	O	O
[	O	O
2	O	O
-	O	O
3	O	O
,	O	O
4	O	O
-	O	O
dimethoxyphenyl	O	O
)	O	O
ethanolamino	O	O
]	O	O
-	O	O
prop	O	O
an	O	O
-	O	O
2	O	O
-	O	O
ol	O	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
beta	O	O
1	O	O
-	O	O
adrenoceptor	O	O
blocking	O	O
and	O	O
beta	O	O
2	O	O
-	O	O
adrenoceptor	O	O
stimulating	O	O
properties	O	O
with	O	O
propranolol	B-Chemical	D011433
.	O	O

The	O	O
studies	O	O
were	O	O
performed	O	O
using	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
heart	B-Disease	D006332
hypertrophy	I-Disease	D006332
in	O	O
rats	O	O
.	O	O

A	O	O
correlation	O	O
of	O	O
the	O	O
blood	O	O
pressure	O	O
was	O	O
neither	O	O
found	O	O
in	O	O
the	O	O
development	O	O
nor	O	O
in	O	O
the	O	O
attempt	O	O
to	O	O
suppress	O	O
the	O	O
development	O	O
of	O	O
heart	B-Disease	D006332
hypertrophy	I-Disease	D006332
with	O	O
the	O	O
two	O	O
beta	O	O
-	O	O
receptor	O	O
blockers	O	O
.	O	O

Both	O	O
beta	O	O
-	O	O
blockers	O	O
influenced	O	O
the	O	O
development	O	O
of	O	O
hypertrophy	B-Disease	D006984
to	O	O
a	O	O
different	O	O
,	O	O
but	O	O
not	O	O
reproducible	O	O
extent	O	O
.	O	O

It	O	O
was	O	O
possible	O	O
to	O	O
suppress	O	O
the	O	O
increased	O	O
ornithine	B-Chemical	D009952
decarboxylase	O	O
activity	O	O
with	O	O
both	O	O
beta	O	O
-	O	O
blockers	O	O
in	O	O
hypertrophied	B-Disease	D006332
hearts	I-Disease	D006332
,	O	O
but	O	O
there	O	O
was	O	O
no	O	O
effect	O	O
on	O	O
the	O	O
heart	O	O
mass	O	O
.	O	O

Neither	O	O
propranolol	B-Chemical	D011433
nor	O	O
B	O	O
24	O	O
/	O	O
76	O	O
could	O	O
stop	O	O
the	O	O
changes	O	O
in	O	O
the	O	O
characteristic	O	O
myosin	O	O
isoenzyme	O	O
pattern	O	O
of	O	O
the	O	O
hypertrophied	B-Disease	D006984
rat	O	O
heart	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
investigations	O	O
did	O	O
not	O	O
provide	O	O
any	O	O
evidence	O	O
that	O	O
the	O	O
beta	O	O
-	O	O
receptor	O	O
blockers	O	O
propranolol	B-Chemical	D011433
and	O	O
B	O	O
24	O	O
/	O	O
76	O	O
have	O	O
the	O	O
potency	O	O
to	O	O
prevent	O	O
isoproterenol	B-Chemical	D007545
from	O	O
producing	O	O
heart	B-Disease	D006332
hypertrophy	I-Disease	D006332
.	O	O

Comparison	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
oxitropium	B-Chemical	C017590
bromide	I-Chemical	C017590
and	O	O
of	O	O
slow	O	O
-	O	O
release	O	O
theophylline	B-Chemical	D013806
on	O	O
nocturnal	O	O
asthma	B-Disease	D001249
.	O	O

The	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
inhaled	O	O
antimuscarinic	O	O
drug	O	O
,	O	O
oxitropium	B-Chemical	C017590
bromide	I-Chemical	C017590
,	O	O
and	O	O
of	O	O
a	O	O
slow	O	O
-	O	O
release	O	O
theophylline	B-Chemical	D013806
preparation	O	O
upon	O	O
nocturnal	O	O
asthma	B-Disease	D001249
were	O	O
compared	O	O
in	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
double	O	O
-	O	O
blind	O	O
study	O	O
.	O	O

Two	O	O
samples	O	O
were	O	O
studied	O	O
:	O	O
12	O	O
patients	O	O
received	O	O
oxitropium	B-Chemical	C017590
at	O	O
600	O	O
micrograms	O	O
(	O	O
6	O	O
subjects	O	O
)	O	O
or	O	O
at	O	O
400	O	O
micrograms	O	O
t	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

(	O	O
6	O	O
subjects	O	O
)	O	O
whereas	O	O
11	O	O
received	O	O
theophylline	B-Chemical	D013806
at	O	O
300	O	O
mg	O	O
b	O	O
.	O	O

i	O	O
.	O	O

d	O	O
.	O	O

Morning	O	O
dipping	O	O
,	O	O
assessed	O	O
by	O	O
the	O	O
fall	O	O
in	O	O
peak	O	O
flow	O	O
overnight	O	O
,	O	O
was	O	O
significantly	O	O
reduced	O	O
in	O	O
the	O	O
periods	O	O
when	O	O
either	O	O
active	O	O
drug	O	O
was	O	O
taken	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
noticed	O	O
during	O	O
the	O	O
placebo	O	O
administration	O	O
.	O	O

No	O	O
significant	O	O
difference	O	O
was	O	O
noticed	O	O
between	O	O
results	O	O
obtained	O	O
with	O	O
either	O	O
active	O	O
drug	O	O
,	O	O
as	O	O
well	O	O
as	O	O
with	O	O
either	O	O
dosage	O	O
of	O	O
oxitropium	B-Chemical	C017590
.	O	O

No	O	O
subject	O	O
reported	O	O
side	O	O
effects	O	O
of	O	O
oxitropium	B-Chemical	C017590
,	O	O
as	O	O
compared	O	O
to	O	O
three	O	O
subjects	O	O
reporting	O	O
nausea	B-Disease	D009325
,	O	O
vomiting	B-Disease	D014839
and	O	O
tremors	B-Disease	D014202
after	O	O
theophylline	B-Chemical	D013806
.	O	O

Oxitropium	B-Chemical	C017590
proves	O	O
to	O	O
be	O	O
a	O	O
valuable	O	O
alternative	O	O
to	O	O
theophylline	B-Chemical	D013806
in	O	O
nocturnal	O	O
asthma	B-Disease	D001249
,	O	O
since	O	O
it	O	O
is	O	O
equally	O	O
potent	O	O
,	O	O
safer	O	O
and	O	O
does	O	O
not	O	O
require	O	O
the	O	O
titration	O	O
of	O	O
dosage	O	O
.	O	O

Penicillin	B-Chemical	D010406
anaphylaxis	B-Disease	D000707
.	O	O

A	O	O
case	O	O
of	O	O
oral	O	O
penicillin	B-Chemical	D010406
anaphylaxis	B-Disease	D000707
is	O	O
described	O	O
,	O	O
and	O	O
the	O	O
terminology	O	O
,	O	O
occurrence	O	O
,	O	O
clinical	O	O
manifestations	O	O
,	O	O
pathogenesis	O	O
,	O	O
prevention	O	O
,	O	O
and	O	O
treatment	O	O
of	O	O
anaphylaxis	B-Disease	D000707
are	O	O
reviewed	O	O
.	O	O

Emergency	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
oral	O	O
penicillin	B-Chemical	D010406
anaphylaxis	B-Disease	D000707
in	O	O
order	O	O
to	O	O
prevent	O	O
its	O	O
occurrence	O	O
by	O	O
prescribing	O	O
the	O	O
antibiotic	O	O
judiciously	O	O
and	O	O
knowledgeably	O	O
and	O	O
to	O	O
offer	O	O
optimal	O	O
medical	O	O
therapy	O	O
once	O	O
this	O	O
life	O	O
-	O	O
threatening	O	O
reaction	O	O
has	O	O
begun	O	O
.	O	O

Reversible	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
-	O	O
induced	O	O
dementia	B-Disease	D003704
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

Reversible	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
-	O	O
induced	O	O
dementia	B-Disease	D003704
was	O	O
documented	O	O
in	O	O
a	O	O
21	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
epilepsy	B-Disease	D004827
who	O	O
had	O	O
a	O	O
3	O	O
-	O	O
year	O	O
history	O	O
of	O	O
insidious	O	O
progressive	O	O
decline	O	O
in	O	O
global	O	O
cognitive	O	O
abilities	O	O
documented	O	O
by	O	O
serial	O	O
neuropsychological	O	O
studies	O	O
.	O	O

Repeat	O	O
neuropsychological	O	O
testing	O	O
7	O	O
weeks	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
revealed	O	O
dramatic	O	O
improvement	O	O
in	O	O
IQ	O	O
,	O	O
memory	O	O
,	O	O
naming	O	O
,	O	O
and	O	O
other	O	O
tasks	O	O
commensurate	O	O
with	O	O
clinical	O	O
recovery	O	O
in	O	O
his	O	O
intellectual	O	O
capacity	O	O
.	O	O

Possible	O	O
pathophysiological	O	O
mechanisms	O	O
which	O	O
may	O	O
have	O	O
been	O	O
operative	O	O
in	O	O
this	O	O
case	O	O
include	O	O
:	O	O
a	O	O
direct	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
toxic	O	O
effect	O	O
of	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
;	O	O
a	O	O
paradoxical	O	O
epileptogenic	O	O
effect	O	O
secondary	O	O
to	O	O
the	O	O
drug	O	O
;	O	O
and	O	O
an	O	O
indirect	O	O
CNS	O	O
toxic	O	O
effect	O	O
mediated	O	O
through	O	O
valproic	B-Chemical	D014635
acid	I-Chemical	D014635
-	O	O
induced	O	O
hyperammonemia	B-Disease	D022124
.	O	O

Reversal	O	O
of	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
of	O	O
passive	O	O
avoidance	O	O
by	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
training	O	O
naloxone	B-Chemical	D009270
.	O	O

In	O	O
a	O	O
series	O	O
of	O	O
five	O	O
experiments	O	O
,	O	O
the	O	O
modulating	O	O
role	O	O
of	O	O
naloxone	B-Chemical	D009270
on	O	O
a	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
retention	B-Disease	D008569
deficit	I-Disease	D008569
in	O	O
a	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
was	O	O
investigated	O	O
in	O	O
mice	O	O
.	O	O

Scopolamine	B-Chemical	D012601
,	O	O
but	O	O
not	O	O
methyl	B-Chemical	D019832
scopolamine	I-Chemical	D019832
(	O	O
1	O	O
and	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
induced	O	O
an	O	O
amnesia	B-Disease	D000647
as	O	O
measured	O	O
by	O	O
latency	O	O
and	O	O
duration	O	O
parameters	O	O
.	O	O

Naloxone	B-Chemical	D009270
(	O	O
0	O	O
.	O	O

3	O	O
,	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
injected	O	O
prior	O	O
to	O	O
training	O	O
attenuated	O	O
the	O	O
retention	B-Disease	D008569
deficit	I-Disease	D008569
with	O	O
a	O	O
peak	O	O
of	O	O
activity	O	O
at	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
naloxone	B-Chemical	D009270
could	O	O
be	O	O
antagonized	O	O
with	O	O
morphine	B-Chemical	D009020
(	O	O
1	O	O
,	O	O
3	O	O
,	O	O
and	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
demonstrating	O	O
the	O	O
opioid	O	O
specificity	O	O
of	O	O
the	O	O
naloxone	B-Chemical	D009270
effect	O	O
.	O	O

Post	O	O
-	O	O
training	O	O
administration	O	O
of	O	O
naloxone	B-Chemical	D009270
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
as	O	O
a	O	O
single	O	O
or	O	O
as	O	O
a	O	O
split	O	O
dose	O	O
also	O	O
attenuated	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
amnesia	B-Disease	D000647
.	O	O

Control	O	O
experiments	O	O
indicated	O	O
that	O	O
neither	O	O
an	O	O
increase	O	O
in	O	O
pain	B-Disease	D010146
sensitivity	O	O
(	O	O
pre	O	O
-	O	O
training	O	O
naloxone	B-Chemical	D009270
)	O	O
nor	O	O
an	O	O
induced	O	O
aversive	O	O
state	O	O
(	O	O
post	O	O
-	O	O
training	O	O
naloxone	B-Chemical	D009270
)	O	O
appear	O	O
to	O	O
be	O	O
responsible	O	O
for	O	O
the	O	O
influence	O	O
of	O	O
naloxone	B-Chemical	D009270
on	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
retention	B-Disease	D008569
deficit	I-Disease	D008569
.	O	O

These	O	O
results	O	O
extend	O	O
previous	O	O
findings	O	O
implicating	O	O
a	O	O
cholinergic	O	O
-	O	O
opioid	O	O
interaction	O	O
in	O	O
memory	O	O
processes	O	O
.	O	O

A	O	O
possible	O	O
mechanism	O	O
for	O	O
this	O	O
interaction	O	O
involving	O	O
the	O	O
septo	O	O
-	O	O
hippocampal	O	O
cholinergic	O	O
pathway	O	O
is	O	O
discussed	O	O
.	O	O

Electron	O	O
microscopic	O	O
investigations	O	O
of	O	O
the	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
lesions	B-Disease	D001745
of	I-Disease	D001745
the	I-Disease	D001745
urinary	I-Disease	D001745
bladder	I-Disease	D001745
of	O	O
the	O	O
rat	O	O
and	O	O
their	O	O
prevention	O	O
by	O	O
mesna	B-Chemical	D015080
.	O	O

Fully	O	O
developed	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
is	O	O
characterized	O	O
by	O	O
nearly	O	O
complete	O	O
detachment	O	O
of	O	O
the	O	O
urothelium	O	O
,	O	O
severe	O	O
submucosal	O	O
edema	B-Disease	D004487
owing	O	O
to	O	O
damage	O	O
to	O	O
the	O	O
microvascular	O	O
bed	O	O
and	O	O
focal	O	O
muscle	O	O
necroses	B-Disease	D009336
.	O	O

The	O	O
initial	O	O
response	O	O
to	O	O
the	O	O
primary	O	O
attack	O	O
by	O	O
the	O	O
cyclophosphamide	B-Chemical	D003520
metabolites	O	O
seems	O	O
to	O	O
be	O	O
fragmentation	O	O
of	O	O
the	O	O
luminal	B-Chemical	D010634
membrane	O	O
.	O	O

This	O	O
damages	O	O
the	O	O
cellular	O	O
barrier	O	O
against	O	O
the	O	O
hypertonic	O	O
urine	O	O
.	O	O

Subsequent	O	O
breaks	O	O
in	O	O
the	O	O
lateral	O	O
cell	O	O
membranes	O	O
of	O	O
the	O	O
superficial	O	O
cells	O	O
and	O	O
in	O	O
all	O	O
the	O	O
plasma	O	O
membranes	O	O
of	O	O
the	O	O
intermediate	O	O
and	O	O
basal	O	O
cells	O	O
,	O	O
intercellular	O	O
and	O	O
intracellular	O	O
edema	B-Disease	D004487
and	O	O
disintegration	O	O
of	O	O
the	O	O
desmosomes	O	O
and	O	O
hemidesmosomes	O	O
lead	O	O
to	O	O
progressive	O	O
degeneration	O	O
and	O	O
detachment	O	O
of	O	O
the	O	O
epithelial	O	O
cells	O	O
with	O	O
exposure	O	O
and	O	O
splitting	O	O
of	O	O
the	O	O
basal	O	O
membrane	O	O
.	O	O

The	O	O
morphological	O	O
changes	O	O
of	O	O
the	O	O
endothelial	O	O
cells	O	O
,	O	O
which	O	O
become	O	O
more	O	O
pronounced	O	O
in	O	O
the	O	O
later	O	O
stages	O	O
of	O	O
the	O	O
experiment	O	O
,	O	O
the	O	O
involvement	O	O
of	O	O
blood	O	O
vessels	O	O
regardless	O	O
of	O	O
their	O	O
diameter	O	O
and	O	O
the	O	O
location	O	O
-	O	O
dependent	O	O
extent	O	O
of	O	O
the	O	O
damage	O	O
indicate	O	O
a	O	O
direct	O	O
type	O	O
of	O	O
damage	O	O
which	O	O
is	O	O
preceded	O	O
by	O	O
a	O	O
mediator	O	O
-	O	O
induced	O	O
increase	O	O
in	O	O
permeability	O	O
,	O	O
the	O	O
morphological	O	O
correlate	O	O
of	O	O
which	O	O
is	O	O
the	O	O
formation	O	O
of	O	O
gaps	O	O
in	O	O
the	O	O
interendothelial	O	O
cell	O	O
connections	O	O
on	O	O
the	O	O
venules	O	O
.	O	O

These	O	O
changes	O	O
can	O	O
be	O	O
effectively	O	O
prevented	O	O
by	O	O
mesna	B-Chemical	D015080
.	O	O

The	O	O
only	O	O
sign	O	O
of	O	O
a	O	O
possible	O	O
involvement	O	O
is	O	O
the	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
specific	O	O
granules	O	O
with	O	O
a	O	O
presumed	O	O
lysosomal	O	O
function	O	O
in	O	O
the	O	O
superficial	O	O
cells	O	O
.	O	O

Increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
during	O	O
suxamethonium	B-Chemical	D013390
-	O	O
induced	O	O
muscle	B-Disease	D005207
fasciculations	I-Disease	D005207
in	O	O
children	O	O
:	O	O
inhibition	O	O
by	O	O
alfentanil	B-Chemical	D015760
.	O	O

Changes	O	O
in	O	O
intragastric	O	O
pressure	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
suxamethonium	B-Chemical	D013390
1	O	O
.	O	O

5	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
i	O	O
.	O	O

v	O	O
.	O	O

were	O	O
studied	O	O
in	O	O
32	O	O
children	O	O
(	O	O
mean	O	O
age	O	O
6	O	O
.	O	O

9	O	O
yr	O	O
)	O	O
pretreated	O	O
with	O	O
either	O	O
physiological	O	O
saline	O	O
or	O	O
alfentanil	B-Chemical	D015760
50	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
.	O	O

Anaesthesia	O	O
was	O	O
induced	O	O
with	O	O
thiopentone	B-Chemical	D013874
5	O	O
mg	O	O
kg	O	O
-	O	O
1	O	O
.	O	O

The	O	O
incidence	O	O
and	O	O
intensity	O	O
of	O	O
muscle	B-Disease	D005207
fasciculations	I-Disease	D005207
caused	O	O
by	O	O
suxamethonium	B-Chemical	D013390
were	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
control	O	O
than	O	O
in	O	O
the	O	O
alfentanil	B-Chemical	D015760
group	O	O
.	O	O

The	O	O
intragastric	O	O
pressure	O	O
during	O	O
muscle	B-Disease	D005207
fasciculations	I-Disease	D005207
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
control	O	O
group	O	O
(	O	O
16	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
(	O	O
SEM	O	O
)	O	O
cm	O	O
H2O	B-Chemical	D014867
)	O	O
than	O	O
in	O	O
the	O	O
alfentanil	B-Chemical	D015760
group	O	O
(	O	O
7	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

5	O	O
(	O	O
SEM	O	O
)	O	O
cm	O	O
H2O	B-Chemical	D014867
)	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
intragastric	O	O
pressure	O	O
was	O	O
directly	O	O
related	O	O
to	O	O
the	O	O
intensity	O	O
of	O	O
muscle	B-Disease	D005207
fasciculations	I-Disease	D005207
(	O	O
regression	O	O
line	O	O
:	O	O
y	O	O
=	O	O
0	O	O
.	O	O

5	O	O
+	O	O
4	O	O
.	O	O

78x	O	O
with	O	O
r	O	O
of	O	O
0	O	O
.	O	O

78	O	O
)	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
intragastric	O	O
pressure	O	O
increases	O	O
significantly	O	O
during	O	O
muscle	B-Disease	D005207
fasciculations	I-Disease	D005207
caused	O	O
by	O	O
suxamethonium	B-Chemical	D013390
in	O	O
healthy	O	O
children	O	O
.	O	O

Alfentanil	B-Chemical	D015760
50	O	O
micrograms	O	O
kg	O	O
-	O	O
1	O	O
effectively	O	O
inhibits	O	O
the	O	O
incidence	O	O
and	O	O
intensity	O	O
of	O	O
suxamethonium	B-Chemical	D013390
-	O	O
induced	O	O
muscle	B-Disease	D005207
fasciculations	I-Disease	D005207
;	O	O
moreover	O	O
,	O	O
intragastric	O	O
pressure	O	O
remains	O	O
at	O	O
its	O	O
control	O	O
value	O	O
.	O	O

Acute	O	O
insulin	O	O
treatment	O	O
normalizes	O	O
the	O	O
resistance	O	O
to	O	O
the	O	O
cardiotoxic	B-Disease	D066126
effect	O	O
of	O	O
isoproterenol	B-Chemical	D007545
in	O	O
streptozotocin	B-Chemical	D013311
diabetic	B-Disease	D003920
rats	O	O
.	O	O

A	O	O
morphometric	O	O
study	O	O
of	O	O
isoproterenol	B-Chemical	D007545
induced	O	O
myocardial	O	O
fibrosis	B-Disease	D005355
.	O	O

The	O	O
acute	O	O
effect	O	O
of	O	O
insulin	O	O
treatment	O	O
on	O	O
the	O	O
earlier	O	O
reported	O	O
protective	O	O
effect	O	O
of	O	O
streptozotocin	B-Chemical	D013311
diabetes	B-Disease	D003920
against	O	O
the	O	O
cardiotoxic	B-Disease	D066126
effect	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
isoproterenol	B-Chemical	D007545
(	O	O
ISO	B-Chemical	D007545
)	O	O
was	O	O
investigated	O	O
in	O	O
rats	O	O
.	O	O

Thirty	O	O
to	O	O
135	O	O
min	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
crystalline	O	O
insulin	O	O
,	O	O
ISO	B-Chemical	D007545
was	O	O
given	O	O
subcutaneously	O	O
and	O	O
when	O	O
ISO	B-Chemical	D007545
induced	O	O
fibrosis	B-Disease	D005355
in	O	O
the	O	O
myocardium	O	O
was	O	O
morphometrically	O	O
analyzed	O	O
7	O	O
days	O	O
later	O	O
,	O	O
a	O	O
highly	O	O
significant	O	O
correlation	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

83	O	O
,	O	O
2	O	O
p	O	O
=	O	O
0	O	O
.	O	O

006	O	O
)	O	O
to	O	O
the	O	O
slope	O	O
of	O	O
the	O	O
fall	O	O
in	O	O
blood	O	O
glucose	B-Chemical	D005947
after	O	O
insulin	O	O
treatment	O	O
appeared	O	O
.	O	O

The	O	O
myocardial	O	O
content	O	O
of	O	O
catecholamines	B-Chemical	D002395
was	O	O
estimated	O	O
in	O	O
these	O	O
8	O	O
day	O	O
diabetic	B-Disease	D003920
rats	O	O
.	O	O

The	O	O
norepinephrine	B-Chemical	D009638
content	O	O
was	O	O
significantly	O	O
increased	O	O
while	O	O
epinephrine	B-Chemical	D004837
remained	O	O
unchanged	O	O
.	O	O

An	O	O
enhanced	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
with	O	O
a	O	O
consequent	O	O
down	O	O
regulation	O	O
of	O	O
the	O	O
myocardial	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptors	O	O
could	O	O
,	O	O
therefore	O	O
,	O	O
explain	O	O
this	O	O
catecholamine	B-Chemical	D002395
resistance	O	O
.	O	O

The	O	O
rapid	O	O
reversion	O	O
after	O	O
insulin	O	O
treatment	O	O
excludes	O	O
the	O	O
possibility	O	O
that	O	O
streptozotocin	B-Chemical	D013311
in	O	O
itself	O	O
causes	O	O
the	O	O
ISO	B-Chemical	D007545
resistance	O	O
and	O	O
points	O	O
towards	O	O
a	O	O
direct	O	O
insulin	O	O
effect	O	O
on	O	O
myocardial	O	O
catecholamine	B-Chemical	D002395
sensitivity	O	O
in	O	O
diabetic	B-Disease	D003920
rats	O	O
.	O	O

The	O	O
phenomenon	O	O
described	O	O
might	O	O
elucidate	O	O
pathogenetic	O	O
mechanisms	O	O
behind	O	O
toxic	O	O
myocardial	O	O
cell	O	O
degeneration	O	O
and	O	O
may	O	O
possibly	O	O
have	O	O
relevance	O	O
for	O	O
acute	O	O
cardiovascular	O	O
complications	O	O
in	O	O
diabetic	B-Disease	D003920
patients	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
on	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
in	O	O
rats	O	O
.	O	O

The	O	O
muscarinic	O	O
cholinergic	O	O
agonist	O	O
pilocarpine	B-Chemical	D010862
induces	O	O
in	O	O
rats	O	O
seizures	B-Disease	D012640
and	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
followed	O	O
by	O	O
widespread	O	O
damage	O	O
to	O	O
the	O	O
forebrain	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
the	O	O
effect	O	O
of	O	O
5	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
,	O	O
sodium	B-Chemical	D012980
salicylate	I-Chemical	D012980
,	O	O
phenylbutazone	B-Chemical	D010653
,	O	O
indomethacin	B-Chemical	D007213
,	O	O
ibuprofen	B-Chemical	D007052
and	O	O
mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
,	O	O
on	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
.	O	O

Pretreatment	O	O
of	O	O
rats	O	O
with	O	O
sodium	B-Chemical	D012980
salicylate	I-Chemical	D012980
,	O	O
ED50	O	O
103	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
60	O	O
-	O	O
174	O	O
)	O	O
,	O	O
and	O	O
phenylbutazone	B-Chemical	D010653
,	O	O
59	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
50	O	O
-	O	O
70	O	O
)	O	O
converted	O	O
the	O	O
non	O	O
-	O	O
convulsant	O	O
dose	O	O
of	O	O
pilocarpine	B-Chemical	D010862
,	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
to	O	O
a	O	O
convulsant	O	O
one	O	O
.	O	O

Indomethacin	B-Chemical	D007213
,	O	O
1	O	O
-	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
and	O	O
ibuprofen	B-Chemical	D007052
,	O	O
10	O	O
-	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
failed	O	O
to	O	O
modulate	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
.	O	O

Mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
,	O	O
26	O	O
(	O	O
22	O	O
-	O	O
30	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
prevented	O	O
seizures	B-Disease	D012640
and	O	O
protected	O	O
rats	O	O
from	O	O
seizure	B-Disease	D012640
-	O	O
related	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
,	O	O
380	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
differentially	O	O
modulate	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
.	O	O

Acute	B-Disease	D009422
neurologic	I-Disease	D009422
dysfunction	I-Disease	D009422
after	O	O
high	O	O
-	O	O
dose	O	O
etoposide	B-Chemical	D005047
therapy	O	O
for	O	O
malignant	B-Disease	D005910
glioma	I-Disease	D005910
.	O	O

Etoposide	B-Chemical	D005047
(	O	O
VP	B-Chemical	D005047
-	I-Chemical	D005047
16	I-Chemical	D005047
-	I-Chemical	D005047
213	I-Chemical	D005047
)	O	O
has	O	O
been	O	O
used	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
solid	O	O
tumors	B-Disease	D009369
and	O	O
hematologic	B-Disease	D019337
malignancies	I-Disease	D019337
.	O	O

When	O	O
used	O	O
in	O	O
high	O	O
doses	O	O
and	O	O
in	O	O
conjunction	O	O
with	O	O
autologous	O	O
bone	O	O
marrow	O	O
transplantation	O	O
,	O	O
this	O	O
agent	O	O
has	O	O
activity	O	O
against	O	O
several	O	O
treatment	O	O
-	O	O
resistant	O	O
cancers	B-Disease	D009369
including	O	O
malignant	B-Disease	D005910
glioma	I-Disease	D005910
.	O	O

In	O	O
six	O	O
of	O	O
eight	O	O
patients	O	O
(	O	O
75%	O	O
)	O	O
who	O	O
we	O	O
treated	O	O
for	O	O
recurrent	O	O
or	O	O
resistant	O	O
glioma	B-Disease	D005910
,	O	O
sudden	O	O
severe	O	O
neurologic	B-Disease	D009422
deterioration	I-Disease	D009422
occurred	O	O
.	O	O

This	O	O
developed	O	O
a	O	O
median	O	O
of	O	O
9	O	O
days	O	O
after	O	O
initiation	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
etoposide	B-Chemical	D005047
therapy	O	O
.	O	O

Significant	O	O
clinical	O	O
manifestations	O	O
have	O	O
included	O	O
confusion	B-Disease	D003221
,	O	O
papilledema	B-Disease	D010211
,	O	O
somnolence	B-Disease	D006970
,	O	O
exacerbation	O	O
of	O	O
motor	B-Disease	-1
deficits	I-Disease	-1
,	O	O
and	O	O
sharp	O	O
increase	O	O
in	O	O
seizure	B-Disease	D012640
activity	O	O
.	O	O

These	O	O
abnormalities	O	O
resolved	O	O
rapidly	O	O
after	O	O
initiation	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
dexamethasone	B-Chemical	D003907
therapy	O	O
.	O	O

In	O	O
all	O	O
patients	O	O
,	O	O
computerized	O	O
tomographic	O	O
(	O	O
CT	O	O
)	O	O
brain	O	O
scans	O	O
demonstrated	O	O
stability	O	O
in	O	O
tumor	B-Disease	D009369
size	O	O
and	O	O
peritumor	O	O
edema	B-Disease	D004487
when	O	O
compared	O	O
with	O	O
pretransplant	O	O
scans	O	O
.	O	O

This	O	O
complication	O	O
appears	O	O
to	O	O
represent	O	O
a	O	O
significant	O	O
new	O	O
toxicity	B-Disease	D064420
of	O	O
high	O	O
-	O	O
dose	O	O
etoposide	B-Chemical	D005047
therapy	O	O
for	O	O
malignant	B-Disease	D005910
glioma	I-Disease	D005910
.	O	O

Progressive	O	O
bile	B-Disease	D001649
duct	I-Disease	D001649
injury	I-Disease	D001649
after	O	O
thiabendazole	B-Chemical	D013827
administration	O	O
.	O	O

A	O	O
27	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
man	O	O
developed	O	O
jaundice	B-Disease	D007565
2	O	O
wk	O	O
after	O	O
exposure	O	O
to	O	O
thiabendazole	B-Chemical	D013827
.	O	O

Cholestasis	B-Disease	D002779
persisted	O	O
for	O	O
3	O	O
yr	O	O
,	O	O
at	O	O
which	O	O
time	O	O
a	O	O
liver	O	O
transplant	O	O
was	O	O
performed	O	O
.	O	O

Two	O	O
liver	O	O
biopsy	O	O
specimens	O	O
and	O	O
the	O	O
hepatectomy	O	O
specimen	O	O
were	O	O
remarkable	O	O
for	O	O
almost	O	O
complete	O	O
disappearance	O	O
of	O	O
interlobular	O	O
bile	O	O
ducts	O	O
.	O	O

Prominent	O	O
fibrosis	B-Disease	D005355
and	O	O
hepatocellular	O	O
regeneration	O	O
were	O	O
also	O	O
present	O	O
;	O	O
however	O	O
,	O	O
the	O	O
lobular	O	O
architecture	O	O
was	O	O
preserved	O	O
.	O	O

This	O	O
case	O	O
represents	O	O
an	O	O
example	O	O
of	O	O
"idiosyncratic"	O	O
drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
liver	I-Disease	D056486
damage	I-Disease	D056486
in	O	O
which	O	O
the	O	O
primary	O	O
target	O	O
of	O	O
injury	O	O
is	O	O
the	O	O
bile	O	O
duct	O	O
.	O	O

An	O	O
autoimmune	O	O
pathogenesis	O	O
of	O	O
the	O	O
bile	B-Disease	D001649
duct	I-Disease	D001649
destruction	I-Disease	D001649
is	O	O
suggested	O	O
.	O	O

Differential	O	O
effects	O	O
of	O	O
1	B-Chemical	C038806
,	I-Chemical	C038806
4	I-Chemical	C038806
-	I-Chemical	C038806
dihydropyridine	I-Chemical	C038806
calcium	B-Chemical	D002121
channel	I-Chemical	D002121
blockers	I-Chemical	D002121
:	O	O
therapeutic	O	O
implications	O	O
.	O	O

Increasing	O	O
recognition	O	O
of	O	O
the	O	O
importance	O	O
of	O	O
calcium	B-Chemical	D002118
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
has	O	O
stimulated	O	O
research	O	O
into	O	O
the	O	O
use	O	O
of	O	O
calcium	B-Chemical	D002118
channel	O	O
blocking	O	O
agents	O	O
for	O	O
treatment	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
cardiovascular	B-Disease	D002318
diseases	I-Disease	D002318
.	O	O

The	O	O
favorable	O	O
efficacy	O	O
and	O	O
tolerability	O	O
profiles	O	O
of	O	O
these	O	O
agents	O	O
make	O	O
them	O	O
attractive	O	O
therapeutic	O	O
modalities	O	O
.	O	O

Clinical	O	O
applications	O	O
of	O	O
calcium	B-Chemical	D002121
channel	I-Chemical	D002121
blockers	I-Chemical	D002121
parallel	O	O
their	O	O
tissue	O	O
selectivity	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
verapamil	B-Chemical	D014700
and	O	O
diltiazem	B-Chemical	D004110
,	O	O
which	O	O
are	O	O
roughly	O	O
equipotent	O	O
in	O	O
their	O	O
actions	O	O
on	O	O
the	O	O
heart	O	O
and	O	O
vascular	O	O
smooth	O	O
muscle	O	O
,	O	O
the	O	O
dihydropyridine	B-Chemical	C038806
calcium	B-Chemical	D002121
channel	I-Chemical	D002121
blockers	I-Chemical	D002121
are	O	O
a	O	O
group	O	O
of	O	O
potent	O	O
peripheral	O	O
vasodilator	O	O
agents	O	O
that	O	O
exert	O	O
minimal	O	O
electrophysiologic	O	O
effects	O	O
on	O	O
cardiac	O	O
nodal	O	O
or	O	O
conduction	O	O
tissue	O	O
.	O	O

As	O	O
the	O	O
first	O	O
dihydropyridine	B-Chemical	C038806
available	O	O
for	O	O
use	O	O
in	O	O
the	O	O
United	O	O
States	O	O
,	O	O
nifedipine	B-Chemical	D009543
controls	O	O
angina	B-Disease	D000787
and	O	O
hypertension	B-Disease	D006973
with	O	O
minimal	O	O
depression	O	O
of	O	O
cardiac	O	O
function	O	O
.	O	O

Additional	O	O
members	O	O
of	O	O
this	O	O
group	O	O
of	O	O
calcium	B-Chemical	D002121
channel	I-Chemical	D002121
blockers	I-Chemical	D002121
have	O	O
been	O	O
studied	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
indications	O	O
for	O	O
which	O	O
they	O	O
may	O	O
offer	O	O
advantages	O	O
over	O	O
current	O	O
therapy	O	O
.	O	O

Once	O	O
or	O	O
twice	O	O
daily	O	O
dosage	O	O
possible	O	O
with	O	O
nitrendipine	B-Chemical	D009568
and	O	O
nisoldipine	B-Chemical	D015737
offers	O	O
a	O	O
convenient	O	O
administration	O	O
schedule	O	O
,	O	O
which	O	O
encourages	O	O
patient	O	O
compliance	O	O
in	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
of	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
coronary	O	O
vasodilating	O	O
properties	O	O
of	O	O
nisoldipine	B-Chemical	D015737
have	O	O
led	O	O
to	O	O
the	O	O
investigation	O	O
of	O	O
this	O	O
agent	O	O
for	O	O
use	O	O
in	O	O
angina	B-Disease	D000787
.	O	O

Selectivity	O	O
for	O	O
the	O	O
cerebrovascular	O	O
bed	O	O
makes	O	O
nimodipine	B-Chemical	D009553
potentially	O	O
useful	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
subarachnoid	B-Disease	D013345
hemorrhage	I-Disease	D013345
,	O	O
migraine	B-Disease	D008881
headache	I-Disease	D008881
,	O	O
dementia	B-Disease	D003704
,	O	O
and	O	O
stroke	B-Disease	D020521
.	O	O

In	O	O
general	O	O
,	O	O
the	O	O
dihydropyridine	B-Chemical	C038806
calcium	B-Chemical	D002121
channel	I-Chemical	D002121
blockers	I-Chemical	D002121
are	O	O
usually	O	O
well	O	O
tolerated	O	O
,	O	O
with	O	O
headache	B-Disease	D006261
,	O	O
facial	O	O
flushing	B-Disease	D005483
,	O	O
palpitations	B-Disease	-1
,	O	O
edema	B-Disease	D004487
,	O	O
nausea	B-Disease	D009325
,	O	O
anorexia	B-Disease	D000855
,	O	O
and	O	O
dizziness	B-Disease	D004244
being	O	O
the	O	O
more	O	O
common	O	O
adverse	O	O
effects	O	O
.	O	O

The	O	O
enhancement	O	O
of	O	O
aminonucleoside	B-Chemical	D011692
nephrosis	B-Disease	D009401
by	O	O
the	O	O
co	O	O
-	O	O
administration	O	O
of	O	O
protamine	O	O
.	O	O

An	O	O
experimental	O	O
model	O	O
of	O	O
focal	B-Disease	D005923
segmental	I-Disease	D005923
glomerular	I-Disease	D005923
sclerosis	I-Disease	D005923
(	O	O
FSGS	B-Disease	D005923
)	O	O
was	O	O
developed	O	O
in	O	O
rats	O	O
by	O	O
the	O	O
combined	O	O
administration	O	O
of	O	O
puromycin	B-Chemical	D011692
-	I-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
AMNS	B-Chemical	D011692
)	O	O
and	O	O
protamine	B-Chemical	D011479
sulfate	I-Chemical	D011479
(	O	O
PS	B-Chemical	D011479
)	O	O
.	O	O

Male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
,	O	O
uninephrectomized	O	O
three	O	O
weeks	O	O
before	O	O
,	O	O
received	O	O
daily	O	O
injections	O	O
of	O	O
subcutaneous	O	O
AMNS	B-Chemical	D011692
(	O	O
1	O	O
mg	O	O
/	O	O
100	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
and	O	O
intravenous	O	O
PS	B-Chemical	D011479
(	O	O
2	O	O
separated	O	O
doses	O	O
of	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
100	O	O
g	O	O
body	O	O
wt	O	O
)	O	O
for	O	O
four	O	O
days	O	O
.	O	O

The	O	O
series	O	O
of	O	O
injections	O	O
were	O	O
repeated	O	O
another	O	O
three	O	O
times	O	O
at	O	O
10	O	O
day	O	O
intervals	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
sacrificed	O	O
on	O	O
days	O	O
24	O	O
,	O	O
52	O	O
,	O	O
and	O	O
80	O	O
.	O	O

They	O	O
developed	O	O
nephrotic	B-Disease	D009404
syndrome	I-Disease	D009404
and	O	O
finally	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

The	O	O
time	O	O
-	O	O
course	O	O
curve	O	O
of	O	O
creatinine	B-Chemical	D003404
clearance	O	O
dropped	O	O
and	O	O
showed	O	O
significant	O	O
difference	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
from	O	O
that	O	O
of	O	O
each	O	O
control	O	O
group	O	O
,	O	O
such	O	O
as	O	O
,	O	O
AMNS	B-Chemical	D011692
alone	O	O
,	O	O
PS	B-Chemical	D011479
alone	O	O
or	O	O
saline	O	O
injected	O	O
.	O	O

Their	O	O
glomeruli	O	O
showed	O	O
changes	O	O
of	O	O
progressive	O	O
FSGS	B-Disease	D005923
.	O	O

The	O	O
ultrastructural	O	O
studies	O	O
in	O	O
the	O	O
initial	O	O
stage	O	O
revealed	O	O
significant	O	O
lack	O	O
of	O	O
particles	O	O
of	O	O
perfused	O	O
ruthenium	B-Chemical	D012428
red	O	O
on	O	O
the	O	O
lamina	O	O
rara	O	O
externa	O	O
and	O	O
marked	O	O
changes	O	O
in	O	O
epithelial	O	O
cell	O	O
cytoplasm	O	O
.	O	O

Therefore	O	O
,	O	O
it	O	O
is	O	O
suggested	O	O
that	O	O
the	O	O
administration	O	O
of	O	O
PS	B-Chemical	D011479
enhances	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
AMNS	B-Chemical	D011692
on	O	O
the	O	O
glomerulus	O	O
and	O	O
readily	O	O
produces	O	O
progressive	O	O
FSGS	B-Disease	D005923
in	O	O
rats	O	O
resulting	O	O
in	O	O
the	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
.	O	O

Theophylline	B-Chemical	D013806
neurotoxicity	B-Disease	D020258
in	O	O
pregnant	O	O
rats	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
neurotoxicity	B-Disease	D020258
of	O	O
theophylline	B-Chemical	D013806
is	O	O
altered	O	O
in	O	O
advanced	O	O
pregnancy	O	O
.	O	O

Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
that	O	O
were	O	O
20	O	O
days	O	O
pregnant	O	O
and	O	O
nonpregnant	O	O
rats	O	O
of	O	O
the	O	O
same	O	O
age	O	O
and	O	O
strain	O	O
received	O	O
infusions	O	O
of	O	O
aminophylline	B-Chemical	D000628
until	O	O
onset	O	O
of	O	O
maximal	O	O
seizures	B-Disease	D012640
which	O	O
occurred	O	O
after	O	O
28	O	O
and	O	O
30	O	O
minutes	O	O
respectively	O	O
.	O	O

Theophylline	B-Chemical	D013806
concentrations	O	O
at	O	O
this	O	O
endpoint	O	O
in	O	O
serum	O	O
(	O	O
total	O	O
)	O	O
and	O	O
CSF	O	O
were	O	O
similar	O	O
but	O	O
serum	O	O
(	O	O
free	O	O
)	O	O
and	O	O
brain	O	O
concentrations	O	O
were	O	O
slightly	O	O
different	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

Theophylline	B-Chemical	D013806
serum	O	O
protein	O	O
binding	O	O
determined	O	O
by	O	O
equilibrium	O	O
dialysis	O	O
was	O	O
lower	O	O
in	O	O
pregnant	O	O
rats	O	O
.	O	O

Fetal	O	O
serum	O	O
concentrations	O	O
at	O	O
onset	O	O
of	O	O
seizures	B-Disease	D012640
in	O	O
the	O	O
mother	O	O
were	O	O
similar	O	O
to	O	O
maternal	O	O
brain	O	O
and	O	O
CSF	O	O
concentrations	O	O
and	O	O
correlated	O	O
significantly	O	O
with	O	O
the	O	O
former	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
advanced	O	O
pregnancy	O	O
has	O	O
a	O	O
negligible	O	O
effect	O	O
on	O	O
the	O	O
neurotoxic	B-Disease	D020258
response	O	O
to	O	O
theophylline	B-Chemical	D013806
in	O	O
rats	O	O
.	O	O

Hyperkalemia	B-Disease	D006947
induced	O	O
by	O	O
indomethacin	B-Chemical	D007213
and	O	O
naproxen	B-Chemical	D009288
and	O	O
reversed	O	O
by	O	O
fludrocortisone	B-Chemical	D005438
.	O	O

We	O	O
have	O	O
described	O	O
a	O	O
patient	O	O
with	O	O
severe	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
and	O	O
a	O	O
history	O	O
of	O	O
mefenamic	B-Chemical	D008528
acid	I-Chemical	D008528
nephropathy	B-Disease	D007674
in	O	O
whom	O	O
hyperkalemia	B-Disease	D006947
and	O	O
inappropriate	O	O
hypoaldosteronism	B-Disease	D006994
were	O	O
caused	O	O
by	O	O
both	O	O
indomethacin	B-Chemical	D007213
and	O	O
naproxen	B-Chemical	D009288
,	O	O
without	O	O
major	O	O
decline	O	O
in	O	O
renal	O	O
function	O	O
.	O	O

It	O	O
is	O	O
likely	O	O
that	O	O
preexisting	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
predisposed	O	O
this	O	O
patient	O	O
to	O	O
type	B-Disease	D006994
IV	I-Disease	D006994
renal	I-Disease	D006994
tubular	I-Disease	D006994
acidosis	I-Disease	D006994
with	O	O
prostaglandin	B-Chemical	D011453
synthetase	O	O
inhibitors	O	O
.	O	O

Because	O	O
he	O	O
was	O	O
unable	O	O
to	O	O
discontinue	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
therapy	O	O
,	O	O
fludrocortisone	B-Chemical	D005438
was	O	O
added	O	O
,	O	O
correcting	O	O
the	O	O
hyperkalemia	B-Disease	D006947
and	O	O
allowing	O	O
indomethacin	B-Chemical	D007213
therapy	O	O
to	O	O
be	O	O
continued	O	O
safely	O	O
.	O	O

Hypotension	B-Disease	D007022
as	O	O
a	O	O
manifestation	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
three	O	O
patients	O	O
receiving	O	O
cisplatin	B-Chemical	D002945
and	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
.	O	O

Cardiac	O	O
symptoms	O	O
,	O	O
including	O	O
hypotension	B-Disease	D007022
,	O	O
developed	O	O
in	O	O
three	O	O
patients	O	O
with	O	O
advanced	O	O
colorectal	B-Disease	D015179
carcinoma	I-Disease	D015179
while	O	O
being	O	O
treated	O	O
with	O	O
cisplatin	B-Chemical	D002945
(	O	O
CDDP	B-Chemical	D002945
)	O	O
and	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
.	O	O

In	O	O
two	O	O
patients	O	O
,	O	O
hypotension	B-Disease	D007022
was	O	O
associated	O	O
with	O	O
severe	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
.	O	O

All	O	O
three	O	O
patients	O	O
required	O	O
therapy	O	O
discontinuation	O	O
.	O	O

Cardiac	O	O
enzymes	O	O
remained	O	O
normal	O	O
despite	O	O
transient	O	O
electrocardiographic	O	O
(	O	O
EKG	O	O
)	O	O
changes	O	O
.	O	O

The	O	O
presentation	O	O
and	O	O
cardiac	O	O
evaluation	O	O
(	O	O
hemodynamic	O	O
,	O	O
echocardiographic	O	O
,	O	O
and	O	O
scintigraphic	O	O
)	O	O
of	O	O
these	O	O
patients	O	O
suggest	O	O
new	O	O
manifestations	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
cardiotoxicity	B-Disease	D066126
that	O	O
may	O	O
be	O	O
influenced	O	O
by	O	O
CDDP	B-Chemical	D002945
.	O	O

The	O	O
possible	O	O
pathophysiologic	O	O
mechanisms	O	O
are	O	O
discussed	O	O
.	O	O

Fatal	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
in	O	O
a	O	O
patient	O	O
treated	O	O
with	O	O
carbamazepine	B-Chemical	D002220
.	O	O

A	O	O
case	O	O
of	O	O
fatal	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
due	O	O
to	O	O
carbamazepine	B-Chemical	D002220
treatment	O	O
in	O	O
an	O	O
epileptic	B-Disease	D004827
woman	O	O
is	O	O
reported	O	O
.	O	O

Despite	O	O
concerns	O	O
of	O	O
fatal	O	O
bone	B-Disease	D001855
marrow	I-Disease	D001855
toxicity	I-Disease	D001855
due	O	O
to	O	O
carbamazepine	B-Chemical	D002220
,	O	O
this	O	O
is	O	O
only	O	O
the	O	O
fourth	O	O
documented	O	O
and	O	O
published	O	O
report	O	O
.	O	O

Carbamazepine	B-Chemical	D002220
is	O	O
a	O	O
safe	O	O
drug	O	O
,	O	O
but	O	O
physicians	O	O
and	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
exceedingly	O	O
rare	O	O
but	O	O
potentially	O	O
fatal	O	O
side	O	O
effects	O	O
,	O	O
better	O	O
prevented	O	O
by	O	O
clinical	O	O
than	O	O
by	O	O
laboratory	O	O
monitoring	O	O
.	O	O

Participation	O	O
of	O	O
a	O	O
bulbospinal	O	O
serotonergic	O	O
pathway	O	O
in	O	O
the	O	O
rat	O	O
brain	O	O
in	O	O
clonidine	B-Chemical	D003000
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
bradycardia	B-Disease	D001919
.	O	O

The	O	O
effects	O	O
of	O	O
microinjection	O	O
of	O	O
clonidine	B-Chemical	D003000
(	O	O
1	O	O
-	O	O
10	O	O
micrograms	O	O
in	O	O
1	O	O
microliter	O	O
)	O	O
into	O	O
a	O	O
region	O	O
adjacent	O	O
to	O	O
the	O	O
ventrolateral	O	O
surface	O	O
of	O	O
the	O	O
medulla	O	O
oblongata	O	O
on	O	O
cardiovascular	O	O
function	O	O
were	O	O
assessed	O	O
in	O	O
urethane	B-Chemical	D014520
-	O	O
anesthetized	O	O
rats	O	O
.	O	O

Intramedullary	O	O
administration	O	O
of	O	O
clonidine	B-Chemical	D003000
,	O	O
but	O	O
not	O	O
saline	O	O
vehicle	O	O
,	O	O
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
decrease	O	O
in	O	O
both	O	O
the	O	O
mean	O	O
arterial	O	O
pressure	O	O
and	O	O
the	O	O
heart	O	O
rate	O	O
.	O	O

The	O	O
clonidine	B-Chemical	D003000
-	O	O
induced	O	O
hypotension	B-Disease	D007022
was	O	O
antagonized	O	O
by	O	O
prior	O	O
spinal	O	O
transection	O	O
,	O	O
but	O	O
not	O	O
bilateral	O	O
vagotomy	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
the	O	O
clonidine	B-Chemical	D003000
-	O	O
induced	O	O
bradycardia	B-Disease	D001919
was	O	O
antagonized	O	O
by	O	O
prior	O	O
bilateral	O	O
vagotomy	O	O
,	O	O
but	O	O
not	O	O
spinal	O	O
transection	O	O
.	O	O

Furthermore	O	O
,	O	O
selective	O	O
destruction	O	O
of	O	O
the	O	O
spinal	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
nerves	O	O
,	O	O
produced	O	O
by	O	O
bilateral	O	O
spinal	O	O
injection	O	O
of	O	O
5	B-Chemical	D015116
,	I-Chemical	D015116
7	I-Chemical	D015116
-	I-Chemical	D015116
dihydroxytryptamine	I-Chemical	D015116
,	O	O
reduced	O	O
the	O	O
magnitude	O	O
of	O	O
the	O	O
vasodepressor	O	O
or	O	O
the	O	O
bradycardiac	B-Disease	D001919
responses	O	O
to	O	O
clonidine	B-Chemical	D003000
microinjected	O	O
into	O	O
the	O	O
area	O	O
near	O	O
the	O	O
ventrolateral	O	O
surface	O	O
of	O	O
the	O	O
medulla	O	O
oblongata	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
data	O	O
indicate	O	O
that	O	O
a	O	O
bulbospinal	O	O
serotonergic	O	O
pathway	O	O
is	O	O
involved	O	O
in	O	O
development	O	O
of	O	O
clonidine	B-Chemical	D003000
-	O	O
induced	O	O
hypotension	B-Disease	D007022
and	O	O
bradycardia	B-Disease	D001919
.	O	O

The	O	O
induced	O	O
hypotension	B-Disease	D007022
is	O	O
brought	O	O
about	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
sympathetic	O	O
efferent	O	O
activity	O	O
,	O	O
whereas	O	O
the	O	O
induced	O	O
bradycardia	B-Disease	D001919
was	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
vagal	O	O
efferent	O	O
activity	O	O
.	O	O

Hypertension	B-Disease	D006973
in	O	O
neuroblastoma	B-Disease	D009447
induced	O	O
by	O	O
imipramine	B-Chemical	D007099
.	O	O

Hypertension	B-Disease	D006973
is	O	O
a	O	O
well	O	O
-	O	O
known	O	O
finding	O	O
in	O	O
some	O	O
patients	O	O
with	O	O
neuroblastoma	B-Disease	D009447
.	O	O

However	O	O
,	O	O
it	O	O
has	O	O
not	O	O
previously	O	O
been	O	O
described	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
Imipramine	B-Chemical	D007099
.	O	O

We	O	O
report	O	O
the	O	O
occurrence	O	O
of	O	O
severe	O	O
hypertension	B-Disease	D006973
(	O	O
blood	O	O
pressure	O	O
190	O	O
/	O	O
160	O	O
)	O	O
in	O	O
a	O	O
4	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
neuroblastoma	B-Disease	D009447
who	O	O
was	O	O
given	O	O
Imipramine	B-Chemical	D007099
to	O	O
control	O	O
a	O	O
behavior	B-Disease	D002653
disorder	I-Disease	D002653
.	O	O

It	O	O
was	O	O
determined	O	O
later	O	O
that	O	O
this	O	O
patient's	O	O
tumor	B-Disease	D009369
was	O	O
recurring	O	O
at	O	O
the	O	O
time	O	O
of	O	O
her	O	O
hypertensive	B-Disease	D006973
episode	O	O
.	O	O

Since	O	O
she	O	O
had	O	O
no	O	O
blood	O	O
pressure	O	O
elevation	O	O
at	O	O
initial	O	O
diagnosis	O	O
and	O	O
none	O	O
following	O	O
discontinuation	O	O
of	O	O
the	O	O
Imipramine	B-Chemical	D007099
(	O	O
when	O	O
she	O	O
was	O	O
in	O	O
florid	O	O
relapse	O	O
)	O	O
,	O	O
we	O	O
believe	O	O
that	O	O
this	O	O
drug	O	O
rather	O	O
than	O	O
her	O	O
underlying	O	O
disease	O	O
alone	O	O
caused	O	O
her	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
mechanism	O	O
for	O	O
this	O	O
reaction	O	O
is	O	O
believed	O	O
to	O	O
be	O	O
increased	O	O
levels	O	O
of	O	O
vasoactive	O	O
catecholamines	B-Chemical	D002395
due	O	O
to	O	O
interference	O	O
of	O	O
their	O	O
physiologic	O	O
inactivation	O	O
by	O	O
Imipramine	B-Chemical	D007099
.	O	O

From	O	O
this	O	O
experience	O	O
,	O	O
we	O	O
urge	O	O
extreme	O	O
caution	O	O
in	O	O
the	O	O
use	O	O
of	O	O
tricyclic	O	O
antidepressants	O	O
in	O	O
children	O	O
with	O	O
active	O	O
neuroblastoma	B-Disease	D009447
.	O	O

Rechallenge	O	O
of	O	O
patients	O	O
who	O	O
developed	O	O
oral	B-Disease	D002180
candidiasis	I-Disease	D002180
or	O	O
hoarseness	B-Disease	D006685
with	O	O
beclomethasone	B-Chemical	D001507
dipropionate	I-Chemical	D001507
.	O	O

Of	O	O
158	O	O
asthmatic	B-Disease	D001249
patients	O	O
who	O	O
were	O	O
placed	O	O
on	O	O
inhaled	O	O
beclomethasone	B-Chemical	D001507
,	O	O
15	O	O
(	O	O
9	O	O
.	O	O

5%	O	O
)	O	O
developed	O	O
either	O	O
hoarseness	B-Disease	D006685
(	O	O
8	O	O
)	O	O
,	O	O
oral	O	O
thrush	B-Disease	D002180
(	O	O
6	O	O
)	O	O
,	O	O
or	O	O
both	O	O
(	O	O
1	O	O
)	O	O
.	O	O

When	O	O
their	O	O
adverse	O	O
reactions	O	O
subsided	O	O
,	O	O
seven	O	O
of	O	O
these	O	O
15	O	O
patients	O	O
were	O	O
rechallenged	O	O
with	O	O
inhaled	O	O
beclomethasone	B-Chemical	D001507
.	O	O

These	O	O
included	O	O
five	O	O
cases	O	O
who	O	O
developed	O	O
hoarseness	B-Disease	D006685
and	O	O
three	O	O
who	O	O
developed	O	O
Candidiasis	B-Disease	D002177
.	O	O

One	O	O
patient	O	O
had	O	O
both	O	O
.	O	O

Oral	O	O
thrush	B-Disease	D002180
did	O	O
not	O	O
recur	O	O
,	O	O
but	O	O
60%	O	O
(	O	O
3	O	O
/	O	O
5	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
hoarseness	B-Disease	D006685
had	O	O
recurrence	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
patients	O	O
may	O	O
be	O	O
restarted	O	O
on	O	O
inhaled	O	O
beclomethasone	B-Chemical	D001507
when	O	O
clinically	O	O
indicated	O	O
;	O	O
however	O	O
,	O	O
because	O	O
of	O	O
the	O	O
high	O	O
recurrence	O	O
rate	O	O
,	O	O
patients	O	O
who	O	O
develop	O	O
hoarseness	B-Disease	D006685
should	O	O
not	O	O
be	O	O
re	O	O
-	O	O
challenged	O	O
.	O	O

Concomitant	O	O
use	O	O
of	O	O
oral	O	O
prednisone	B-Chemical	D011241
and	O	O
topical	O	O
beclomethasone	B-Chemical	D001507
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
hoarseness	B-Disease	D006685
or	O	O
candidiasis	B-Disease	D002177
.	O	O

Cyclophosphamide	B-Chemical	D003520
cardiotoxicity	B-Disease	D066126
:	O	O
an	O	O
analysis	O	O
of	O	O
dosing	O	O
as	O	O
a	O	O
risk	O	O
factor	O	O
.	O	O

Patients	O	O
who	O	O
undergo	O	O
bone	O	O
marrow	O	O
transplantation	O	O
are	O	O
generally	O	O
immunosuppressed	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CYA	B-Chemical	D003520
)	O	O
which	O	O
is	O	O
usually	O	O
calculated	O	O
based	O	O
on	O	O
the	O	O
patient's	O	O
weight	O	O
.	O	O

At	O	O
these	O	O
high	O	O
doses	O	O
of	O	O
CYA	B-Chemical	D003520
,	O	O
serious	O	O
cardiotoxicity	B-Disease	D066126
may	O	O
occur	O	O
,	O	O
but	O	O
definitive	O	O
risk	O	O
factors	O	O
for	O	O
the	O	O
development	O	O
of	O	O
such	O	O
cardiotoxicity	B-Disease	D066126
have	O	O
not	O	O
been	O	O
described	O	O
.	O	O

Since	O	O
chemotherapeutic	O	O
agent	O	O
toxicity	B-Disease	D064420
generally	O	O
correlates	O	O
with	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
we	O	O
retrospectively	O	O
calculated	O	O
the	O	O
dose	O	O
of	O	O
CYA	B-Chemical	D003520
in	O	O
patients	O	O
transplanted	O	O
at	O	O
our	O	O
institution	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
incidence	O	O
of	O	O
CYA	B-Chemical	D003520
cardiotoxicity	B-Disease	D066126
correlated	O	O
with	O	O
the	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

Eighty	O	O
patients	O	O
who	O	O
were	O	O
to	O	O
receive	O	O
CYA	B-Chemical	D003520
50	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
d	O	O
for	O	O
four	O	O
days	O	O
as	O	O
preparation	O	O
for	O	O
marrow	O	O
grafting	O	O
underwent	O	O
a	O	O
total	O	O
of	O	O
84	O	O
transplants	O	O
for	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
,	O	O
Wiskott	B-Disease	D014923
-	I-Disease	D014923
Aldrich	I-Disease	D014923
syndrome	I-Disease	D014923
,	O	O
or	O	O
severe	B-Disease	D016511
combined	I-Disease	D016511
immunodeficiency	I-Disease	D016511
syndrome	I-Disease	D016511
.	O	O

Fourteen	O	O
of	O	O
84	O	O
(	O	O
17%	O	O
)	O	O
patients	O	O
had	O	O
symptoms	O	O
and	O	O
signs	O	O
consistent	O	O
with	O	O
CYA	B-Chemical	D003520
cardiotoxicity	B-Disease	D066126
within	O	O
ten	O	O
days	O	O
of	O	O
receiving	O	O
1	O	O
to	O	O
4	O	O
doses	O	O
of	O	O
CYA	B-Chemical	D003520
.	O	O

Six	O	O
of	O	O
the	O	O
14	O	O
patients	O	O
died	O	O
with	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
.	O	O

The	O	O
dose	O	O
of	O	O
CYA	B-Chemical	D003520
per	O	O
body	O	O
surface	O	O
area	O	O
was	O	O
calculated	O	O
for	O	O
all	O	O
patients	O	O
and	O	O
the	O	O
patients	O	O
were	O	O
divided	O	O
into	O	O
two	O	O
groups	O	O
based	O	O
on	O	O
daily	O	O
CYA	B-Chemical	D003520
dose	O	O
:	O	O
Group	O	O
1	O	O
,	O	O
CYA	B-Chemical	D003520
less	O	O
than	O	O
or	O	O
equal	O	O
to	O	O
1	O	O
.	O	O

55	O	O
g	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
;	O	O
Group	O	O
2	O	O
,	O	O
CYA	B-Chemical	D003520
greater	O	O
than	O	O
1	O	O
.	O	O

55	O	O
g	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
.	O	O

Cardiotoxicity	B-Disease	D066126
that	O	O
was	O	O
thought	O	O
to	O	O
be	O	O
related	O	O
to	O	O
CYA	B-Chemical	D003520
occurred	O	O
in	O	O
1	O	O
/	O	O
32	O	O
(	O	O
3%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
Group	O	O
1	O	O
and	O	O
in	O	O
13	O	O
/	O	O
52	O	O
(	O	O
25%	O	O
)	O	O
patients	O	O
in	O	O
Group	O	O
2	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

025	O	O
)	O	O
.	O	O

Congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
caused	O	O
or	O	O
contributed	O	O
to	O	O
death	O	O
in	O	O
0	O	O
/	O	O
32	O	O
patients	O	O
in	O	O
Group	O	O
1	O	O
v	O	O
6	O	O
/	O	O
52	O	O
(	O	O
12%	O	O
)	O	O
of	O	O
patients	O	O
in	O	O
Group	O	O
2	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

25	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
rate	O	O
of	O	O
engraftment	O	O
of	O	O
evaluable	O	O
patients	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
(	O	O
P	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

5	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
CYA	B-Chemical	D003520
cardiotoxicity	B-Disease	D066126
correlates	O	O
with	O	O
CYA	B-Chemical	D003520
dosage	O	O
as	O	O
calculated	O	O
by	O	O
body	O	O
surface	O	O
area	O	O
,	O	O
and	O	O
that	O	O
patients	O	O
with	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
and	O	O
immunodeficiencies	B-Disease	D007153
can	O	O
be	O	O
effectively	O	O
prepared	O	O
for	O	O
bone	O	O
marrow	O	O
grafting	O	O
at	O	O
a	O	O
CYA	B-Chemical	D003520
dose	O	O
of	O	O
1	O	O
.	O	O

55	O	O
g	O	O
/	O	O
m2	O	O
/	O	O
d	O	O
for	O	O
four	O	O
days	O	O
with	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
than	O	O
patients	O	O
whose	O	O
CYA	B-Chemical	D003520
dosage	O	O
is	O	O
calculated	O	O
based	O	O
on	O	O
weight	O	O
.	O	O

This	O	O
study	O	O
reaffirms	O	O
the	O	O
principle	O	O
that	O	O
drug	O	O
toxicity	B-Disease	D064420
correlates	O	O
with	O	O
dose	O	O
per	O	O
body	O	O
surface	O	O
area	O	O
.	O	O

Studies	O	O
of	O	O
risk	O	O
factors	O	O
for	O	O
aminoglycoside	B-Chemical	D000617
nephrotoxicity	B-Disease	D007674
.	O	O

The	O	O
epidemiology	O	O
of	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
is	O	O
not	O	O
fully	O	O
understood	O	O
.	O	O

Experimental	O	O
studies	O	O
in	O	O
healthy	O	O
human	O	O
volunteers	O	O
indicate	O	O
aminoglycosides	B-Chemical	D000617
cause	O	O
proximal	O	O
tubular	O	O
damage	O	O
in	O	O
most	O	O
patients	O	O
,	O	O
but	O	O
rarely	O	O
,	O	O
if	O	O
ever	O	O
,	O	O
cause	O	O
glomerular	B-Disease	D007674
or	I-Disease	D007674
tubular	I-Disease	D007674
dysfunction	I-Disease	D007674
.	O	O

Clinical	O	O
trials	O	O
of	O	O
aminoglycosides	B-Chemical	D000617
in	O	O
seriously	O	O
ill	O	O
patients	O	O
indicate	O	O
that	O	O
the	O	O
relative	O	O
risk	O	O
for	O	O
developing	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
during	O	O
therapy	O	O
ranges	O	O
from	O	O
8	O	O
to	O	O
10	O	O
and	O	O
that	O	O
the	O	O
attributable	O	O
risk	O	O
is	O	O
70%	O	O
to	O	O
80%	O	O
.	O	O

Further	O	O
analysis	O	O
of	O	O
these	O	O
data	O	O
suggests	O	O
that	O	O
the	O	O
duration	O	O
of	O	O
therapy	O	O
,	O	O
plasma	O	O
aminoglycoside	B-Chemical	D000617
levels	O	O
,	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
,	O	O
advanced	O	O
age	O	O
,	O	O
high	O	O
initial	O	O
estimated	O	O
creatinine	B-Chemical	D003404
clearance	O	O
and	O	O
,	O	O
possibly	O	O
,	O	O
female	O	O
gender	O	O
all	O	O
increase	O	O
the	O	O
risk	O	O
for	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Other	O	O
causes	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
,	O	O
such	O	O
as	O	O
shock	B-Disease	D012769
,	O	O
appear	O	O
to	O	O
have	O	O
an	O	O
additive	O	O
effect	O	O
.	O	O

Predictive	O	O
models	O	O
have	O	O
been	O	O
developed	O	O
from	O	O
these	O	O
analyses	O	O
that	O	O
should	O	O
be	O	O
useful	O	O
for	O	O
identifying	O	O
patients	O	O
at	O	O
high	O	O
risk	O	O
.	O	O

These	O	O
models	O	O
may	O	O
also	O	O
be	O	O
useful	O	O
in	O	O
developing	O	O
insights	O	O
into	O	O
the	O	O
pathophysiology	O	O
of	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Flurothyl	B-Chemical	D005481
seizure	B-Disease	D012640
thresholds	O	O
in	O	O
mice	O	O
treated	O	O
neonatally	O	O
with	O	O
a	O	O
single	O	O
injection	O	O
of	O	O
monosodium	B-Chemical	D012970
glutamate	I-Chemical	D012970
(	O	O
MSG	B-Chemical	D012970
)	O	O
:	O	O
evaluation	O	O
of	O	O
experimental	O	O
parameters	O	O
in	O	O
flurothyl	B-Chemical	D005481
seizure	B-Disease	D012640
testing	O	O
.	O	O

Monosodium	B-Chemical	D012970
glutamate	I-Chemical	D012970
(	O	O
MSG	B-Chemical	D012970
)	O	O
administration	O	O
to	O	O
neonatal	O	O
rodents	O	O
produces	O	O
convulsions	B-Disease	D012640
and	O	O
results	O	O
in	O	O
numerous	O	O
biochemical	O	O
and	O	O
behavioral	O	O
deficits	O	O
.	O	O

These	O	O
studies	O	O
were	O	O
undertaken	O	O
to	O	O
determine	O	O
if	O	O
neonatal	O	O
administration	O	O
of	O	O
MSG	B-Chemical	D012970
produced	O	O
permanent	O	O
alterations	O	O
in	O	O
seizure	B-Disease	D012640
susceptibility	O	O
,	O	O
since	O	O
previous	O	O
investigations	O	O
were	O	O
inconclusive	O	O
.	O	O

A	O	O
flurothyl	B-Chemical	D005481
ether	B-Chemical	D004986
seizure	B-Disease	D012640
screening	O	O
technique	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
seizure	B-Disease	D012640
susceptibility	O	O
in	O	O
adult	O	O
mice	O	O
that	O	O
received	O	O
neonatal	O	O
injections	O	O
of	O	O
MSG	B-Chemical	D012970
(	O	O
4	O	O
mg	O	O
/	O	O
g	O	O
and	O	O
1	O	O
mg	O	O
/	O	O
g	O	O
)	O	O
.	O	O

MSG	B-Chemical	D012970
treatment	O	O
resulted	O	O
in	O	O
significant	O	O
reductions	O	O
in	O	O
whole	O	O
brain	O	O
weight	O	O
but	O	O
did	O	O
not	O	O
alter	O	O
seizure	B-Disease	D012640
threshold	O	O
.	O	O

A	O	O
naloxone	B-Chemical	D009270
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
challenge	O	O
was	O	O
also	O	O
ineffective	O	O
in	O	O
altering	O	O
the	O	O
seizure	B-Disease	D012640
thresholds	O	O
of	O	O
either	O	O
control	O	O
of	O	O
MSG	B-Chemical	D012970
-	O	O
treated	O	O
mice	O	O
.	O	O

Flurothyl	B-Chemical	D005481
ether	B-Chemical	D004986
produced	O	O
hypothermia	B-Disease	D007035
which	O	O
was	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
flurothyl	B-Chemical	D005481
exposure	O	O
;	O	O
however	O	O
,	O	O
the	O	O
relationship	O	O
of	O	O
hypothermia	B-Disease	D007035
to	O	O
seizure	B-Disease	D012640
induction	O	O
was	O	O
unclear	O	O
.	O	O

Flurothyl	B-Chemical	D005481
seizure	B-Disease	D012640
testing	O	O
proved	O	O
to	O	O
be	O	O
a	O	O
rapid	O	O
and	O	O
reliable	O	O
technique	O	O
with	O	O
which	O	O
to	O	O
evaluate	O	O
seizure	B-Disease	D012640
susceptibility	O	O
.	O	O

Susceptibility	O	O
to	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
in	O	O
rats	O	O
after	O	O
microinjection	O	O
of	O	O
isoniazid	B-Chemical	D007538
or	O	O
gamma	B-Chemical	D020888
-	I-Chemical	D020888
vinyl	I-Chemical	D020888
-	I-Chemical	D020888
GABA	I-Chemical	D020888
into	O	O
the	O	O
substantia	O	O
nigra	O	O
.	O	O

Pilocarpine	B-Chemical	D010862
,	O	O
given	O	O
intraperitoneally	O	O
to	O	O
rats	O	O
,	O	O
reproduces	O	O
the	O	O
neuropathological	O	O
sequelae	O	O
of	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
and	O	O
provides	O	O
a	O	O
relevant	O	O
animal	O	O
model	O	O
for	O	O
studying	O	O
mechanisms	O	O
of	O	O
buildup	O	O
of	O	O
convulsive	B-Disease	D012640
activity	O	O
and	O	O
pathways	O	O
operative	O	O
in	O	O
the	O	O
generalization	O	O
and	O	O
propagation	O	O
of	O	O
seizures	B-Disease	D012640
within	O	O
the	O	O
forebrain	O	O
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
manipulating	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
(	O	O
GABA	B-Chemical	D005680
)	O	O
-	O	O
mediated	O	O
synaptic	O	O
inhibition	O	O
within	O	O
the	O	O
substantia	O	O
nigra	O	O
on	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
in	O	O
rats	O	O
,	O	O
were	O	O
investigated	O	O
.	O	O

In	O	O
animals	O	O
pretreated	O	O
with	O	O
microinjections	O	O
of	O	O
isoniazid	B-Chemical	D007538
,	O	O
150	O	O
micrograms	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
activity	O	O
of	O	O
the	O	O
GABA	B-Chemical	D005680
-	O	O
synthesizing	O	O
enzyme	O	O
,	O	O
L	B-Chemical	D018698
-	I-Chemical	D018698
glutamic	I-Chemical	D018698
acid	I-Chemical	D018698
decarboxylase	O	O
,	O	O
into	O	O
the	O	O
substantia	O	O
nigra	O	O
pars	O	O
reticulata	O	O
(	O	O
SNR	O	O
)	O	O
,	O	O
bilaterally	O	O
,	O	O
non	O	O
-	O	O
convulsant	O	O
doses	O	O
of	O	O
pilocarpine	B-Chemical	D010862
,	O	O
100	O	O
and	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
resulted	O	O
in	O	O
severe	O	O
motor	O	O
limbic	O	O
seizures	B-Disease	D012640
and	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

Electroencephalographic	O	O
and	O	O
behavioral	O	O
monitoring	O	O
revealed	O	O
a	O	O
profound	O	O
reduction	O	O
of	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
convulsions	B-Disease	D012640
.	O	O

Morphological	O	O
analysis	O	O
of	O	O
frontal	O	O
forebrain	O	O
sections	O	O
with	O	O
light	O	O
microscopy	O	O
revealed	O	O
seizure	B-Disease	D012640
-	O	O
related	O	O
damage	O	O
to	O	O
the	O	O
hippocampal	O	O
formation	O	O
,	O	O
thalamus	O	O
,	O	O
amygdala	O	O
,	O	O
olfactory	O	O
cortex	O	O
,	O	O
substantia	O	O
nigra	O	O
and	O	O
neocortex	O	O
,	O	O
which	O	O
is	O	O
typically	O	O
observed	O	O
with	O	O
pilocarpine	B-Chemical	D010862
in	O	O
doses	O	O
exceeding	O	O
350	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Bilateral	O	O
intrastriatal	O	O
injections	O	O
of	O	O
isoniazid	B-Chemical	D007538
did	O	O
not	O	O
augment	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
,	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Application	O	O
of	O	O
an	O	O
irreversible	O	O
inhibitor	O	O
of	O	O
GABA	B-Chemical	D005680
transaminase	O	O
,	O	O
gamma	B-Chemical	D020888
-	I-Chemical	D020888
vinyl	I-Chemical	D020888
-	I-Chemical	D020888
GABA	I-Chemical	D020888
(	O	O
D	B-Chemical	D020888
,	I-Chemical	D020888
L	I-Chemical	D020888
-	I-Chemical	D020888
4	I-Chemical	D020888
-	I-Chemical	D020888
amino	I-Chemical	D020888
-	I-Chemical	D020888
hex	I-Chemical	D020888
-	I-Chemical	D020888
5	I-Chemical	D020888
-	I-Chemical	D020888
enoic	I-Chemical	D020888
acid	I-Chemical	D020888
)	O	O
,	O	O
5	O	O
micrograms	O	O
,	O	O
into	O	O
the	O	O
SNR	O	O
,	O	O
bilaterally	O	O
,	O	O
suppressed	O	O
the	O	O
appearance	O	O
of	O	O
electrographic	O	O
and	O	O
behavioral	O	O
seizures	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
,	O	O
380	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

This	O	O
treatment	O	O
was	O	O
also	O	O
sufficient	O	O
to	O	O
protect	O	O
animals	O	O
from	O	O
the	O	O
occurrence	O	O
of	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
.	O	O

Microinjections	O	O
of	O	O
gamma	B-Chemical	D020888
-	I-Chemical	D020888
vinyl	I-Chemical	D020888
-	I-Chemical	D020888
GABA	I-Chemical	D020888
,	O	O
5	O	O
micrograms	O	O
,	O	O
into	O	O
the	O	O
dorsal	O	O
striatum	O	O
,	O	O
bilaterally	O	O
,	O	O
failed	O	O
to	O	O
prevent	O	O
the	O	O
development	O	O
of	O	O
convulsions	B-Disease	D012640
produced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
,	O	O
380	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

The	O	O
results	O	O
demonstrate	O	O
that	O	O
the	O	O
threshold	O	O
for	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
rats	O	O
is	O	O
subjected	O	O
to	O	O
the	O	O
regulation	O	O
of	O	O
the	O	O
GABA	B-Chemical	D005680
-	O	O
mediated	O	O
synaptic	O	O
inhibition	O	O
within	O	O
the	O	O
substantia	O	O
nigra	O	O
.	O	O

Non	O	O
-	O	O
invasive	O	O
detection	O	O
of	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
by	O	O
body	O	O
surface	O	O
electrocardiographic	O	O
mapping	O	O
after	O	O
dipyridamole	B-Chemical	D004176
infusion	O	O
.	O	O

Electrocardiographic	O	O
changes	O	O
after	O	O
dipyridamole	B-Chemical	D004176
infusion	O	O
(	O	O
0	O	O
.	O	O

568	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
4	O	O
min	O	O
)	O	O
were	O	O
studied	O	O
in	O	O
41	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
and	O	O
compared	O	O
with	O	O
those	O	O
after	O	O
submaximal	O	O
treadmill	O	O
exercise	O	O
by	O	O
use	O	O
of	O	O
the	O	O
body	O	O
surface	O	O
mapping	O	O
technique	O	O
.	O	O

Patients	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
;	O	O
19	O	O
patients	O	O
without	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
non	O	O
-	O	O
MI	B-Disease	D009203
group	O	O
)	O	O
,	O	O
14	O	O
with	O	O
anterior	B-Disease	D056988
infarction	I-Disease	D056988
(	O	O
ANT	B-Disease	D056988
-	I-Disease	D056988
MI	I-Disease	D056988
)	O	O
and	O	O
eight	O	O
with	O	O
inferior	B-Disease	D056989
infarction	I-Disease	D056989
(	O	O
INF	B-Disease	D056989
-	I-Disease	D056989
MI	I-Disease	D056989
)	O	O
.	O	O

Eighty	O	O
-	O	O
seven	O	O
unipolar	O	O
electrocardiograms	O	O
(	O	O
ECGs	O	O
)	O	O
distributed	O	O
over	O	O
the	O	O
entire	O	O
thoracic	O	O
surface	O	O
were	O	O
simultaneously	O	O
recorded	O	O
.	O	O

After	O	O
dipyridamole	B-Chemical	D004176
,	O	O
ischemic	B-Disease	D007511
ST	O	O
-	O	O
segment	O	O
depression	B-Disease	D003866
(	O	O
0	O	O
.	O	O

05	O	O
mV	O	O
or	O	O
more	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
84%	O	O
of	O	O
the	O	O
non	O	O
-	O	O
MI	B-Disease	D009203
group	O	O
,	O	O
29%	O	O
of	O	O
the	O	O
ANT	B-Disease	D056988
-	I-Disease	D056988
MI	I-Disease	D056988
group	O	O
,	O	O
63%	O	O
of	O	O
the	O	O
INF	B-Disease	D056989
-	I-Disease	D056989
MI	I-Disease	D056989
group	O	O
and	O	O
61%	O	O
of	O	O
the	O	O
total	O	O
population	O	O
.	O	O

Exercise	O	O
-	O	O
induced	O	O
ST	O	O
depression	B-Disease	D003866
was	O	O
observed	O	O
in	O	O
84%	O	O
of	O	O
the	O	O
non	O	O
-	O	O
MI	B-Disease	D009203
group	O	O
,	O	O
43%	O	O
of	O	O
the	O	O
ANT	B-Disease	D056988
-	I-Disease	D056988
MI	I-Disease	D056988
group	O	O
,	O	O
38%	O	O
of	O	O
the	O	O
INF	B-Disease	D056989
-	I-Disease	D056989
MI	I-Disease	D056989
group	O	O
and	O	O
61%	O	O
of	O	O
the	O	O
total	O	O
.	O	O

For	O	O
individual	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
no	O	O
obvious	O	O
differences	O	O
between	O	O
the	O	O
body	O	O
surface	O	O
distribution	O	O
of	O	O
ST	O	O
depression	B-Disease	D003866
in	O	O
both	O	O
tests	O	O
.	O	O

The	O	O
increase	O	O
in	O	O
pressure	O	O
rate	O	O
product	O	O
after	O	O
dipyridamole	B-Chemical	D004176
was	O	O
significantly	O	O
less	O	O
than	O	O
that	O	O
during	O	O
the	O	O
treadmill	O	O
exercise	O	O
.	O	O

The	O	O
data	O	O
suggest	O	O
that	O	O
the	O	O
dipyridamole	B-Chemical	D004176
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
is	O	O
caused	O	O
by	O	O
the	O	O
inhomogenous	O	O
distribution	O	O
of	O	O
myocardial	O	O
blood	O	O
flow	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
dipyridamole	B-Chemical	D004176
ECG	O	O
test	O	O
is	O	O
as	O	O
useful	O	O
as	O	O
the	O	O
exercise	O	O
ECG	O	O
test	O	O
for	O	O
the	O	O
assessment	O	O
of	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

Bradycardia	B-Disease	D001919
after	O	O
high	O	O
-	O	O
dose	O	O
intravenous	O	O
methylprednisolone	B-Chemical	D008775
therapy	O	O
.	O	O

In	O	O
5	O	O
consecutive	O	O
patients	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
who	O	O
received	O	O
intravenous	O	O
high	O	O
-	O	O
dose	O	O
methylprednisolone	B-Chemical	D008775
(	O	O
MP	B-Chemical	D008775
)	O	O
therapy	O	O
(	O	O
1	O	O
g	O	O
daily	O	O
for	O	O
2	O	O
or	O	O
3	O	O
consecutive	O	O
days	O	O
)	O	O
,	O	O
a	O	O
decline	O	O
in	O	O
pulse	O	O
rate	O	O
was	O	O
observed	O	O
,	O	O
most	O	O
pronounced	O	O
on	O	O
day	O	O
4	O	O
.	O	O

In	O	O
one	O	O
of	O	O
the	O	O
5	O	O
patients	O	O
the	O	O
bradycardia	B-Disease	D001919
was	O	O
associated	O	O
with	O	O
complaints	O	O
of	O	O
substernal	O	O
pressure	O	O
.	O	O

Reversal	O	O
to	O	O
normal	O	O
heart	O	O
rate	O	O
was	O	O
found	O	O
on	O	O
day	O	O
7	O	O
.	O	O

Electrocardiographic	O	O
registrations	O	O
showed	O	O
sinus	B-Disease	D012804
bradycardia	I-Disease	D012804
in	O	O
all	O	O
cases	O	O
.	O	O

No	O	O
significant	O	O
changes	O	O
in	O	O
plasma	O	O
concentrations	O	O
of	O	O
electrolytes	O	O
were	O	O
found	O	O
.	O	O

Careful	O	O
observation	O	O
of	O	O
patients	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
MP	B-Chemical	D008775
is	O	O
recommended	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
MP	B-Chemical	D008775
may	O	O
be	O	O
contraindicated	O	O
in	O	O
patients	O	O
with	O	O
known	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
.	O	O

Two	O	O
cases	O	O
of	O	O
downbeat	B-Disease	D009759
nystagmus	I-Disease	D009759
and	O	O
oscillopsia	B-Disease	D015835
associated	O	O
with	O	O
carbamazepine	B-Chemical	D002220
.	O	O

Downbeat	B-Disease	D009759
nystagmus	I-Disease	D009759
is	O	O
often	O	O
associated	O	O
with	O	O
structural	O	O
lesions	O	O
at	O	O
the	O	O
craniocervical	O	O
junction	O	O
,	O	O
but	O	O
has	O	O
occasionally	O	O
been	O	O
reported	O	O
as	O	O
a	O	O
manifestation	O	O
of	O	O
metabolic	O	O
imbalance	O	O
or	O	O
drug	O	O
intoxication	O	O
.	O	O

We	O	O
recorded	O	O
the	O	O
eye	O	O
movements	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
reversible	O	O
downbeat	B-Disease	D009759
nystagmus	I-Disease	D009759
related	O	O
to	O	O
carbamazepine	B-Chemical	D002220
therapy	O	O
.	O	O

The	O	O
nystagmus	B-Disease	D009759
of	O	O
both	O	O
patients	O	O
resolved	O	O
after	O	O
reduction	O	O
of	O	O
the	O	O
serum	O	O
carbamazepine	B-Chemical	D002220
levels	O	O
.	O	O

Neuroradiologic	O	O
investigations	O	O
including	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
scans	O	O
in	O	O
both	O	O
patients	O	O
showed	O	O
no	O	O
evidence	O	O
of	O	O
intracranial	O	O
abnormality	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
downbeat	B-Disease	D009759
nystagmus	I-Disease	D009759
who	O	O
are	O	O
taking	O	O
anticonvulsant	O	O
medications	O	O
,	O	O
consideration	O	O
should	O	O
be	O	O
given	O	O
to	O	O
reduction	O	O
in	O	O
dose	O	O
before	O	O
further	O	O
investigation	O	O
is	O	O
undertaken	O	O
.	O	O

Improvement	O	O
by	O	O
denopamine	B-Chemical	C037293
(	O	O
TA	B-Chemical	C037293
-	I-Chemical	C037293
064	I-Chemical	C037293
)	O	O
of	O	O
pentobarbital	B-Chemical	D010424
-	O	O
induced	O	O
cardiac	B-Disease	D006333
failure	I-Disease	D006333
in	O	O
the	O	O
dog	O	O
heart	O	O
-	O	O
lung	O	O
preparation	O	O
.	O	O

The	O	O
efficacy	O	O
of	O	O
denopamine	B-Chemical	C037293
,	O	O
an	O	O
orally	O	O
active	O	O
beta	O	O
1	O	O
-	O	O
adrenoceptor	O	O
agonist	O	O
,	O	O
in	O	O
improving	O	O
cardiac	B-Disease	D006333
failure	I-Disease	D006333
was	O	O
assessed	O	O
in	O	O
dog	O	O
heart	O	O
-	O	O
lung	O	O
preparations	O	O
.	O	O

Cardiac	O	O
functions	O	O
depressed	O	O
by	O	O
pentobarbital	B-Chemical	D010424
(	O	O
118	O	O
+	O	O
/	O	O
-	O	O
28	O	O
mg	O	O
;	O	O
mean	O	O
value	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
such	O	O
that	O	O
cardiac	O	O
output	O	O
and	O	O
maximum	O	O
rate	O	O
of	O	O
rise	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
(	O	O
LV	O	O
dP	O	O
/	O	O
dt	O	O
max	O	O
)	O	O
had	O	O
been	O	O
reduced	O	O
by	O	O
about	O	O
35%	O	O
and	O	O
26%	O	O
of	O	O
the	O	O
respective	O	O
controls	O	O
were	O	O
improved	O	O
by	O	O
denopamine	B-Chemical	C037293
(	O	O
10	O	O
-	O	O
300	O	O
micrograms	O	O
)	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

With	O	O
100	O	O
micrograms	O	O
denopamine	B-Chemical	C037293
,	O	O
almost	O	O
complete	O	O
restoration	O	O
of	O	O
cardiac	O	O
performance	O	O
was	O	O
attained	O	O
,	O	O
associated	O	O
with	O	O
a	O	O
slight	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
.	O	O

No	O	O
arrhythmias	B-Disease	D001145
were	O	O
induced	O	O
by	O	O
these	O	O
doses	O	O
of	O	O
denopamine	B-Chemical	C037293
.	O	O

The	O	O
results	O	O
warrant	O	O
clinical	O	O
trials	O	O
of	O	O
denopamine	B-Chemical	C037293
in	O	O
the	O	O
treatment	O	O
of	O	O
cardiac	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Clonazepam	B-Chemical	D002998
monotherapy	O	O
for	O	O
epilepsy	B-Disease	D004827
in	O	O
childhood	O	O
.	O	O

Sixty	O	O
patients	O	O
(	O	O
age	O	O
-	O	O
range	O	O
one	O	O
month	O	O
to	O	O
14	O	O
years	O	O
)	O	O
with	O	O
other	O	O
types	O	O
of	O	O
epilepsy	B-Disease	D004827
than	O	O
infantile	B-Disease	D013036
spasms	I-Disease	D013036
were	O	O
treated	O	O
with	O	O
clonazepam	B-Chemical	D002998
.	O	O

Disappearance	O	O
of	O	O
seizures	B-Disease	D012640
and	O	O
normalization	O	O
of	O	O
abnormal	O	O
EEG	O	O
with	O	O
disappearance	O	O
of	O	O
seizures	B-Disease	D012640
were	O	O
recognized	O	O
in	O	O
77%	O	O
and	O	O
50%	O	O
,	O	O
respectively	O	O
.	O	O

Seizures	B-Disease	D012640
disappeared	O	O
in	O	O
71%	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
generalized	O	O
seizures	B-Disease	D012640
and	O	O
89%	O	O
of	O	O
partial	O	O
seizures	B-Disease	D012640
.	O	O

Improvement	O	O
of	O	O
abnormal	O	O
EEG	O	O
was	O	O
noticed	O	O
in	O	O
76%	O	O
of	O	O
diffuse	O	O
paroxysms	O	O
and	O	O
in	O	O
67%	O	O
of	O	O
focal	O	O
paroxysms	O	O
.	O	O

In	O	O
excellent	O	O
cases	O	O
,	O	O
mean	O	O
effective	O	O
dosages	O	O
were	O	O
0	O	O
.	O	O

086	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

021	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
in	O	O
infants	O	O
and	O	O
0	O	O
.	O	O

057	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

022	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
in	O	O
schoolchildren	O	O
,	O	O
this	O	O
difference	O	O
was	O	O
statistically	O	O
significant	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

005	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
such	O	O
as	O	O
drowsiness	B-Disease	D006970
and	O	O
ataxia	B-Disease	D001259
was	O	O
only	O	O
5%	O	O
.	O	O

Postmarketing	O	O
study	O	O
of	O	O
timolol	B-Chemical	D013999
-	O	O
hydrochlorothiazide	B-Chemical	D006852
antihypertensive	O	O
therapy	O	O
.	O	O

A	O	O
postmarketing	O	O
surveillance	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
determine	O	O
the	O	O
safety	O	O
and	O	O
efficacy	O	O
of	O	O
a	O	O
fixed	O	O
-	O	O
ratio	O	O
combination	O	O
containing	O	O
10	O	O
mg	O	O
of	O	O
timolol	B-Chemical	D013999
maleate	O	O
and	O	O
25	O	O
mg	O	O
of	O	O
hydrochlorothiazide	B-Chemical	D006852
,	O	O
administered	O	O
twice	O	O
daily	O	O
for	O	O
one	O	O
month	O	O
to	O	O
hypertensive	B-Disease	D006973
patients	O	O
.	O	O

Data	O	O
on	O	O
9	O	O
,	O	O
037	O	O
patients	O	O
were	O	O
collected	O	O
by	O	O
1	O	O
,	O	O
455	O	O
participating	O	O
physicians	O	O
.	O	O

Mean	O	O
systolic	O	O
blood	O	O
pressure	O	O
decreased	O	O
25	O	O
mmHg	O	O
and	O	O
mean	O	O
diastolic	O	O
blood	O	O
pressure	O	O
declined	O	O
15	O	O
mmHg	O	O
after	O	O
one	O	O
month	O	O
of	O	O
timolol	B-Chemical	D013999
-	O	O
hydrochlorothiazide	B-Chemical	D006852
therapy	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
,	O	O
both	O	O
comparisons	O	O
)	O	O
.	O	O

Age	O	O
,	O	O
race	O	O
,	O	O
and	O	O
sex	O	O
appeared	O	O
to	O	O
have	O	O
no	O	O
influence	O	O
on	O	O
the	O	O
decrease	O	O
in	O	O
blood	O	O
pressure	O	O
.	O	O

The	O	O
antihypertensive	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
was	O	O
greater	O	O
in	O	O
patients	O	O
with	O	O
more	O	O
severe	O	O
hypertension	B-Disease	D006973
.	O	O

Overall	O	O
,	O	O
1	O	O
,	O	O
453	O	O
patients	O	O
experienced	O	O
a	O	O
total	O	O
of	O	O
2	O	O
,	O	O
658	O	O
adverse	O	O
events	O	O
,	O	O
the	O	O
most	O	O
common	O	O
being	O	O
fatigue	B-Disease	D005221
,	O	O
dizziness	B-Disease	D004244
,	O	O
and	O	O
weakness	B-Disease	D018908
.	O	O

Treatment	O	O
in	O	O
590	O	O
patients	O	O
was	O	O
discontinued	O	O
because	O	O
of	O	O
adverse	O	O
events	O	O
.	O	O

Salicylate	B-Chemical	D012459
nephropathy	B-Disease	D007674
in	O	O
the	O	O
Gunn	O	O
rat	O	O
:	O	O
potential	O	O
role	O	O
of	O	O
prostaglandins	B-Chemical	D011453
.	O	O

We	O	O
examined	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
prostaglandins	B-Chemical	D011453
in	O	O
the	O	O
development	O	O
of	O	O
analgesic	O	O
nephropathy	B-Disease	D007674
in	O	O
the	O	O
Gunn	O	O
strain	O	O
of	O	O
rat	O	O
.	O	O

The	O	O
homozygous	O	O
Gunn	O	O
rats	O	O
have	O	O
unconjugated	O	O
hyperbilirubinemia	B-Disease	D006932
due	O	O
to	O	O
the	O	O
absence	O	O
of	O	O
glucuronyl	B-Chemical	-1
transferase	O	O
,	O	O
leading	O	O
to	O	O
marked	O	O
bilirubin	B-Chemical	D001663
deposition	O	O
in	O	O
renal	O	O
medulla	O	O
and	O	O
papilla	O	O
.	O	O

These	O	O
rats	O	O
are	O	O
also	O	O
highly	O	O
susceptible	O	O
to	O	O
develop	O	O
papillary	B-Disease	D007681
necrosis	I-Disease	D007681
with	O	O
analgesic	O	O
administration	O	O
.	O	O

We	O	O
used	O	O
homozygous	O	O
(	O	O
jj	O	O
)	O	O
and	O	O
phenotypically	O	O
normal	O	O
heterozygous	O	O
(	O	O
jJ	O	O
)	O	O
animals	O	O
.	O	O

Four	O	O
groups	O	O
of	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
7	O	O
)	O	O
were	O	O
studied	O	O
:	O	O
jj	O	O
and	O	O
jJ	O	O
rats	O	O
treated	O	O
either	O	O
with	O	O
aspirin	B-Chemical	D001241
300	O	O
mg	O	O
/	O	O
kg	O	O
every	O	O
other	O	O
day	O	O
or	O	O
sham	O	O
-	O	O
treated	O	O
.	O	O

After	O	O
one	O	O
week	O	O
,	O	O
slices	O	O
of	O	O
cortex	O	O
,	O	O
outer	O	O
and	O	O
inner	O	O
medulla	O	O
from	O	O
one	O	O
kidney	O	O
were	O	O
incubated	O	O
in	O	O
buffer	O	O
and	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
was	O	O
determined	O	O
by	O	O
radioimmunoassay	O	O
.	O	O

The	O	O
other	O	O
kidney	O	O
was	O	O
examined	O	O
histologically	O	O
.	O	O

A	O	O
marked	O	O
corticomedullary	O	O
gradient	O	O
of	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
groups	O	O
.	O	O

PGE2	B-Chemical	D015232
synthesis	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
outer	O	O
medulla	O	O
,	O	O
but	O	O
not	O	O
cortex	O	O
or	O	O
inner	O	O
medulla	O	O
,	O	O
of	O	O
jj	O	O
(	O	O
38	O	O
+	O	O
/	O	O
-	O	O
6	O	O
ng	O	O
/	O	O
mg	O	O
prot	O	O
)	O	O
than	O	O
jJ	O	O
rats	O	O
(	O	O
15	O	O
+	O	O
/	O	O
-	O	O
3	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Aspirin	B-Chemical	D001241
treatment	O	O
reduced	O	O
PGE2	B-Chemical	D015232
synthesis	O	O
in	O	O
all	O	O
regions	O	O
,	O	O
but	O	O
outer	O	O
medullary	O	O
PGE2	B-Chemical	D015232
remained	O	O
higher	O	O
in	O	O
jj	O	O
(	O	O
18	O	O
+	O	O
/	O	O
-	O	O
3	O	O
)	O	O
than	O	O
jJ	O	O
rats	O	O
(	O	O
9	O	O
+	O	O
/	O	O
-	O	O
2	O	O
)	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

PGF2	B-Chemical	D015237
alpha	I-Chemical	D015237
was	O	O
also	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
outer	O	O
medulla	O	O
of	O	O
jj	O	O
rats	O	O
with	O	O
and	O	O
without	O	O
aspirin	B-Chemical	D001241
administration	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
changes	O	O
in	O	O
renal	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
were	O	O
accompanied	O	O
by	O	O
evidence	O	O
of	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
in	O	O
aspirin	B-Chemical	D001241
-	O	O
treated	O	O
jj	O	O
but	O	O
not	O	O
jJ	O	O
rats	O	O
as	O	O
evidenced	O	O
by	O	O
:	O	O
increased	O	O
incidence	O	O
and	O	O
severity	O	O
of	O	O
hematuria	B-Disease	D006417
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
;	O	O
increased	O	O
serum	O	O
creatinine	B-Chemical	D003404
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
;	O	O
and	O	O
increase	O	O
in	O	O
outer	O	O
medullary	O	O
histopathologic	O	O
lesions	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

005	O	O
compared	O	O
to	O	O
either	O	O
sham	O	O
-	O	O
treated	O	O
jj	O	O
or	O	O
aspirin	B-Chemical	D001241
-	O	O
treated	O	O
jJ	O	O
)	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
enhanced	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
contributes	O	O
to	O	O
maintenance	O	O
of	O	O
renal	O	O
function	O	O
and	O	O
morphological	O	O
integrity	O	O
,	O	O
and	O	O
that	O	O
inhibition	O	O
of	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
may	O	O
lead	O	O
to	O	O
pathological	B-Disease	D058186
renal	I-Disease	D058186
medullary	I-Disease	D058186
lesions	I-Disease	D058186
and	O	O
deterioration	B-Disease	D007674
of	I-Disease	D007674
renal	I-Disease	D007674
function	I-Disease	D007674
.	O	O

Prophylactic	O	O
lidocaine	B-Chemical	D008012
in	O	O
the	O	O
early	O	O
phase	O	O
of	O	O
suspected	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Four	O	O
hundred	O	O
two	O	O
patients	O	O
with	O	O
suspected	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
seen	O	O
within	O	O
6	O	O
hours	O	O
of	O	O
the	O	O
onset	O	O
of	O	O
symptoms	O	O
entered	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
randomized	O	O
trial	O	O
of	O	O
lidocaine	B-Chemical	D008012
vs	O	O
placebo	O	O
.	O	O

During	O	O
the	O	O
1	O	O
hour	O	O
after	O	O
administration	O	O
of	O	O
the	O	O
drug	O	O
the	O	O
incidence	O	O
of	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
or	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
among	O	O
the	O	O
204	O	O
patients	O	O
with	O	O
acute	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
low	O	O
,	O	O
1	O	O
.	O	O

5%	O	O
.	O	O

Lidocaine	B-Chemical	D008012
,	O	O
given	O	O
in	O	O
a	O	O
300	O	O
mg	O	O
dose	O	O
intramuscularly	O	O
followed	O	O
by	O	O
100	O	O
mg	O	O
intravenously	O	O
,	O	O
did	O	O
not	O	O
prevent	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
,	O	O
although	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
warning	O	O
arrhythmias	B-Disease	D001145
between	O	O
15	O	O
and	O	O
45	O	O
minutes	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
lidocaine	B-Chemical	D008012
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
average	O	O
plasma	O	O
lidocaine	B-Chemical	D008012
level	O	O
10	O	O
minutes	O	O
after	O	O
administration	O	O
for	O	O
patients	O	O
without	O	O
a	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
significantly	O	O
higher	O	O
than	O	O
that	O	O
for	O	O
patients	O	O
with	O	O
an	O	O
acute	O	O
infarction	B-Disease	D007238
.	O	O

The	O	O
mean	O	O
plasma	O	O
lidocaine	B-Chemical	D008012
level	O	O
of	O	O
patients	O	O
on	O	O
beta	O	O
-	O	O
blocking	O	O
agents	O	O
was	O	O
no	O	O
different	O	O
from	O	O
that	O	O
in	O	O
patients	O	O
not	O	O
on	O	O
beta	O	O
blocking	O	O
agents	O	O
.	O	O

During	O	O
the	O	O
1	O	O
-	O	O
hour	O	O
study	O	O
period	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
side	O	O
effects	O	O
was	O	O
significantly	O	O
greater	O	O
in	O	O
the	O	O
lidocaine	B-Chemical	D008012
group	O	O
,	O	O
hypotension	B-Disease	D007022
occurred	O	O
in	O	O
11	O	O
patients	O	O
,	O	O
nine	O	O
of	O	O
whom	O	O
had	O	O
received	O	O
lidocaine	B-Chemical	D008012
,	O	O
and	O	O
four	O	O
patients	O	O
died	O	O
from	O	O
asystole	B-Disease	D006323
,	O	O
three	O	O
of	O	O
whom	O	O
had	O	O
had	O	O
lidocaine	B-Chemical	D008012
.	O	O

We	O	O
cannot	O	O
advocate	O	O
the	O	O
administration	O	O
of	O	O
lidocaine	B-Chemical	D008012
prophylactically	O	O
in	O	O
the	O	O
early	O	O
hours	O	O
of	O	O
suspected	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Evidence	O	O
for	O	O
a	O	O
cholinergic	O	O
role	O	O
in	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

Experiments	O	O
in	O	O
mice	O	O
tested	O	O
previous	O	O
evidence	O	O
that	O	O
activation	O	O
of	O	O
cholinergic	O	O
systems	O	O
promotes	O	O
catalepsy	B-Disease	D002375
and	O	O
that	O	O
cholinergic	O	O
mechanisms	O	O
need	O	O
to	O	O
be	O	O
intact	O	O
for	O	O
full	O	O
expression	O	O
of	O	O
neuroleptic	B-Chemical	D014150
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

Large	O	O
doses	O	O
of	O	O
the	O	O
cholinomimetic	O	O
,	O	O
pilocarpine	B-Chemical	D010862
,	O	O
could	O	O
induce	O	O
catalepsy	B-Disease	D002375
when	O	O
peripheral	O	O
cholinergic	O	O
receptors	O	O
were	O	O
blocked	O	O
.	O	O

Low	O	O
doses	O	O
of	O	O
pilocarpine	B-Chemical	D010862
caused	O	O
a	O	O
pronounced	O	O
enhancement	O	O
of	O	O
the	O	O
catalepsy	B-Disease	D002375
that	O	O
was	O	O
induced	O	O
by	O	O
the	O	O
dopaminergic	O	O
blocker	O	O
,	O	O
haloperidol	B-Chemical	D006220
.	O	O

A	O	O
muscarinic	O	O
receptor	O	O
blocker	O	O
,	O	O
atropine	B-Chemical	D001285
,	O	O
disrupted	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

Intracranial	O	O
injection	O	O
of	O	O
an	O	O
acetylcholine	B-Chemical	D000109
-	O	O
synthesis	O	O
inhibitor	O	O
,	O	O
hemicholinium	B-Chemical	D006426
,	O	O
prevented	O	O
the	O	O
catalepsy	B-Disease	D002375
that	O	O
is	O	O
usually	O	O
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
.	O	O

These	O	O
findings	O	O
suggest	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
catalepsy	B-Disease	D002375
that	O	O
is	O	O
produced	O	O
by	O	O
neuroleptics	B-Chemical	D014150
such	O	O
as	O	O
haloperidol	B-Chemical	D006220
is	O	O
actually	O	O
mediated	O	O
by	O	O
intrinsic	O	O
central	O	O
cholinergic	O	O
systems	O	O
.	O	O

Alternatively	O	O
,	O	O
activation	O	O
of	O	O
central	O	O
cholinergic	O	O
systems	O	O
could	O	O
promote	O	O
catalepsy	B-Disease	D002375
by	O	O
suppression	O	O
of	O	O
dopaminergic	O	O
systems	O	O
.	O	O

Cardiovascular	B-Disease	D002318
dysfunction	I-Disease	D002318
and	O	O
hypersensitivity	B-Disease	D004342
to	O	O
sodium	B-Chemical	D010424
pentobarbital	I-Chemical	D010424
induced	O	O
by	O	O
chronic	O	O
barium	B-Chemical	C024986
chloride	I-Chemical	C024986
ingestion	O	O
.	O	O

Barium	B-Chemical	D001464
-	O	O
supplemented	O	O
Long	O	O
-	O	O
Evans	O	O
hooded	O	O
rats	O	O
were	O	O
characterized	O	O
by	O	O
a	O	O
persistent	O	O
hypertension	B-Disease	D006973
that	O	O
was	O	O
evident	O	O
after	O	O
1	O	O
month	O	O
of	O	O
barium	B-Chemical	D001464
(	O	O
100	O	O
micrograms	O	O
/	O	O
ml	O	O
mineral	O	O
fortified	O	O
water	O	O
)	O	O
treatment	O	O
.	O	O

Analysis	O	O
of	O	O
in	O	O
vivo	O	O
myocardial	O	O
excitability	O	O
,	O	O
contractility	O	O
,	O	O
and	O	O
metabolic	O	O
characteristics	O	O
at	O	O
16	O	O
months	O	O
revealed	O	O
other	O	O
significant	O	O
barium	B-Chemical	D001464
-	O	O
induced	O	O
disturbances	B-Disease	D002318
within	I-Disease	D002318
the	I-Disease	D002318
cardiovascular	I-Disease	D002318
system	I-Disease	D002318
.	O	O

The	O	O
most	O	O
distinctive	O	O
aspect	O	O
of	O	O
the	O	O
barium	B-Chemical	D001464
effect	O	O
was	O	O
a	O	O
demonstrated	O	O
hypersensitivity	B-Disease	D004342
of	O	O
the	O	O
cardiovascular	O	O
system	O	O
to	O	O
sodium	B-Chemical	D010424
pentobarbital	I-Chemical	D010424
.	O	O

Under	O	O
barbiturate	B-Chemical	C032232
anesthesia	O	O
,	O	O
virtually	O	O
all	O	O
of	O	O
the	O	O
myocardial	O	O
contractile	O	O
indices	O	O
were	O	O
depressed	O	O
significantly	O	O
in	O	O
barium	B-Chemical	D001464
-	O	O
exposed	O	O
rats	O	O
relative	O	O
to	O	O
the	O	O
corresponding	O	O
control	O	O
-	O	O
fed	O	O
rats	O	O
.	O	O

The	O	O
lack	O	O
of	O	O
a	O	O
similar	O	O
response	O	O
to	O	O
ketamine	B-Chemical	D007649
and	O	O
xylazine	B-Chemical	D014991
anesthesia	O	O
revealed	O	O
that	O	O
the	O	O
cardiovascular	O	O
actions	O	O
of	O	O
sodium	B-Chemical	D010424
pentobarbital	I-Chemical	D010424
in	O	O
barium	B-Chemical	D001464
-	O	O
treated	O	O
rats	O	O
were	O	O
linked	O	O
specifically	O	O
to	O	O
this	O	O
anesthetic	O	O
,	O	O
and	O	O
were	O	O
not	O	O
representative	O	O
of	O	O
a	O	O
generalized	O	O
anesthetic	O	O
response	O	O
.	O	O

Other	O	O
myocardial	O	O
pathophysiologic	O	O
and	O	O
metabolic	O	O
changes	O	O
induced	O	O
by	O	O
barium	B-Chemical	D001464
were	O	O
manifest	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
anesthetic	O	O
employed	O	O
.	O	O

The	O	O
contractile	O	O
element	O	O
shortening	O	O
velocity	O	O
of	O	O
the	O	O
cardiac	O	O
muscle	O	O
fibers	O	O
was	O	O
significantly	O	O
slower	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
barium	B-Chemical	D001464
-	O	O
treated	O	O
rats	O	O
relative	O	O
to	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
irrespective	O	O
of	O	O
the	O	O
anesthetic	O	O
regimen	O	O
.	O	O

Similarly	O	O
,	O	O
significant	O	O
disturbances	O	O
in	O	O
myocardial	O	O
energy	O	O
metabolism	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
barium	B-Chemical	D001464
-	O	O
exposed	O	O
rats	O	O
which	O	O
were	O	O
consistent	O	O
with	O	O
the	O	O
reduced	O	O
contractile	O	O
element	O	O
shortening	O	O
velocity	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
excitability	O	O
of	O	O
the	O	O
cardiac	O	O
conduction	O	O
system	O	O
was	O	O
depressed	O	O
preferentially	O	O
in	O	O
the	O	O
atrioventricular	O	O
nodal	O	O
region	O	O
of	O	O
hearts	O	O
from	O	O
barium	B-Chemical	D001464
-	O	O
exposed	O	O
rats	O	O
.	O	O

Overall	O	O
,	O	O
the	O	O
altered	O	O
cardiac	O	O
contractility	O	O
and	O	O
excitability	O	O
characteristics	O	O
,	O	O
the	O	O
myocardial	O	O
metabolic	B-Disease	D008659
disturbances	I-Disease	D008659
,	O	O
and	O	O
the	O	O
hypersensitivity	B-Disease	D004342
of	O	O
the	O	O
cardiovascular	O	O
system	O	O
to	O	O
sodium	B-Chemical	D010424
pentobarbital	I-Chemical	D010424
suggest	O	O
the	O	O
existence	O	O
of	O	O
a	O	O
heretofore	O	O
undescribed	O	O
cardiomyopathic	B-Disease	D009202
disorder	I-Disease	D009202
induced	O	O
by	O	O
chronic	O	O
barium	B-Chemical	D001464
exposure	O	O
.	O	O

These	O	O
experimental	O	O
findings	O	O
represent	O	O
the	O	O
first	O	O
indication	O	O
that	O	O
life	O	O
-	O	O
long	O	O
barium	B-Chemical	D001464
ingestion	O	O
may	O	O
have	O	O
significant	O	O
adverse	O	O
effects	O	O
on	O	O
the	O	O
mammalian	O	O
cardiovascular	O	O
system	O	O
.	O	O

Propranolol	B-Chemical	D011433
antagonism	O	O
of	O	O
phenylpropanolamine	B-Chemical	D010665
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

Phenylpropanolamine	B-Chemical	D010665
(	O	O
PPA	B-Chemical	D010665
)	O	O
overdose	B-Disease	D062787
can	O	O
cause	O	O
severe	O	O
hypertension	B-Disease	D006973
,	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
,	O	O
and	O	O
death	O	O
.	O	O

We	O	O
studied	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
propranolol	B-Chemical	D011433
in	O	O
the	O	O
treatment	O	O
of	O	O
PPA	B-Chemical	D010665
-	O	O
induced	O	O
hypertension	B-Disease	D006973
.	O	O

Subjects	O	O
received	O	O
propranolol	B-Chemical	D011433
either	O	O
by	O	O
mouth	O	O
for	O	O
48	O	O
hours	O	O
before	O	O
PPA	B-Chemical	D010665
or	O	O
as	O	O
a	O	O
rapid	O	O
intravenous	O	O
infusion	O	O
after	O	O
PPA	B-Chemical	D010665
.	O	O

PPA	B-Chemical	D010665
,	O	O
75	O	O
mg	O	O
alone	O	O
,	O	O
increased	O	O
blood	O	O
pressure	O	O
(	O	O
31	O	O
+	O	O
/	O	O
-	O	O
14	O	O
mm	O	O
Hg	O	O
systolic	O	O
,	O	O
20	O	O
+	O	O
/	O	O
-	O	O
5	O	O
mm	O	O
Hg	O	O
diastolic	O	O
)	O	O
,	O	O
and	O	O
propranolol	B-Chemical	D011433
pretreatment	O	O
antagonized	O	O
this	O	O
increase	O	O
(	O	O
12	O	O
+	O	O
/	O	O
-	O	O
10	O	O
mm	O	O
Hg	O	O
systolic	O	O
,	O	O
10	O	O
+	O	O
/	O	O
-	O	O
7	O	O
mm	O	O
Hg	O	O
diastolic	O	O
)	O	O
.	O	O

Intravenous	O	O
propranolol	B-Chemical	D011433
after	O	O
PPA	B-Chemical	D010665
also	O	O
decreased	O	O
blood	O	O
pressure	O	O
.	O	O

Left	O	O
ventricular	O	O
function	O	O
(	O	O
assessed	O	O
by	O	O
echocardiography	O	O
)	O	O
showed	O	O
that	O	O
PPA	B-Chemical	D010665
increased	O	O
the	O	O
stroke	B-Disease	D020521
volume	O	O
30%	O	O
(	O	O
from	O	O
62	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
20	O	O
.	O	O

9	O	O
to	O	O
80	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
22	O	O
.	O	O

4	O	O
ml	O	O
)	O	O
,	O	O
the	O	O
ejection	O	O
fraction	O	O
9%	O	O
(	O	O
from	O	O
64%	O	O
+	O	O
/	O	O
-	O	O
10%	O	O
to	O	O
70%	O	O
+	O	O
/	O	O
-	O	O
7%	O	O
)	O	O
,	O	O
and	O	O
cardiac	O	O
output	O	O
14%	O	O
(	O	O
from	O	O
3	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
to	O	O
4	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
L	O	O
/	O	O
min	O	O
)	O	O
.	O	O

Intravenous	O	O
propranolol	B-Chemical	D011433
reversed	O	O
these	O	O
effects	O	O
.	O	O

Systemic	O	O
vascular	O	O
resistance	O	O
was	O	O
increased	O	O
by	O	O
PPA	B-Chemical	D010665
28%	O	O
(	O	O
from	O	O
1710	O	O
+	O	O
/	O	O
-	O	O
200	O	O
to	O	O
2190	O	O
+	O	O
/	O	O
-	O	O
700	O	O
dyne	O	O
X	O	O
sec	O	O
/	O	O
cm5	O	O
)	O	O
and	O	O
was	O	O
further	O	O
increased	O	O
by	O	O
propranolol	B-Chemical	D011433
22%	O	O
(	O	O
to	O	O
2660	O	O
+	O	O
/	O	O
-	O	O
1200	O	O
dyne	O	O
X	O	O
sec	O	O
/	O	O
cm5	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
PPA	B-Chemical	D010665
increases	O	O
blood	O	O
pressure	O	O
by	O	O
increasing	O	O
systemic	O	O
vascular	O	O
resistance	O	O
and	O	O
cardiac	O	O
output	O	O
,	O	O
and	O	O
that	O	O
propranolol	B-Chemical	D011433
antagonizes	O	O
this	O	O
increase	O	O
by	O	O
reversing	O	O
the	O	O
effect	O	O
of	O	O
PPA	B-Chemical	D010665
on	O	O
cardiac	O	O
output	O	O
.	O	O

That	O	O
propranolol	B-Chemical	D011433
antagonizes	O	O
the	O	O
pressor	O	O
effect	O	O
of	O	O
PPA	B-Chemical	D010665
is	O	O
in	O	O
contrast	O	O
to	O	O
the	O	O
interaction	O	O
in	O	O
which	O	O
propranolol	B-Chemical	D011433
enhances	O	O
the	O	O
pressor	O	O
effect	O	O
of	O	O
norepinephrine	B-Chemical	D009638
.	O	O

This	O	O
is	O	O
probably	O	O
because	O	O
PPA	B-Chemical	D010665
has	O	O
less	O	O
beta	O	O
2	O	O
activity	O	O
than	O	O
does	O	O
norepinephrine	B-Chemical	D009638
.	O	O

Mesangial	O	O
function	O	O
and	O	O
glomerular	B-Disease	D007674
sclerosis	I-Disease	D007674
in	O	O
rats	O	O
with	O	O
aminonucleoside	B-Chemical	D011692
nephrosis	B-Disease	D009401
.	O	O

The	O	O
possible	O	O
relationship	O	O
between	O	O
mesangial	B-Disease	D007674
dysfunction	I-Disease	D007674
and	O	O
development	O	O
of	O	O
glomerular	B-Disease	D007674
sclerosis	I-Disease	D007674
was	O	O
studied	O	O
in	O	O
the	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
model	O	O
.	O	O

Five	O	O
male	O	O
Wistar	O	O
rats	O	O
received	O	O
repeated	O	O
subcutaneous	O	O
PAN	B-Chemical	D011692
injections	O	O
;	O	O
five	O	O
controls	O	O
received	O	O
saline	O	O
only	O	O
.	O	O

After	O	O
4	O	O
weeks	O	O
the	O	O
PAN	B-Chemical	D011692
rats	O	O
were	O	O
severely	O	O
proteinuric	B-Disease	D011507
(	O	O
190	O	O
+	O	O
/	O	O
-	O	O
80	O	O
mg	O	O
/	O	O
24	O	O
hr	O	O
)	O	O
,	O	O
and	O	O
all	O	O
rats	O	O
were	O	O
given	O	O
colloidal	O	O
carbon	B-Chemical	D002244
(	O	O
CC	O	O
)	O	O
intravenously	O	O
.	O	O

At	O	O
5	O	O
months	O	O
glomerular	B-Disease	D007674
sclerosis	I-Disease	D007674
was	O	O
found	O	O
in	O	O
7	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

4%	O	O
of	O	O
the	O	O
glomeruli	O	O
of	O	O
PAN	B-Chemical	D011692
rats	O	O
;	O	O
glomeruli	O	O
of	O	O
the	O	O
controls	O	O
were	O	O
normal	O	O
.	O	O

Glomeruli	O	O
of	O	O
PAN	B-Chemical	D011692
rats	O	O
contained	O	O
significantly	O	O
more	O	O
CC	O	O
than	O	O
glomeruli	O	O
of	O	O
controls	O	O
.	O	O

Glomeruli	O	O
with	O	O
sclerosis	B-Disease	D012598
contained	O	O
significantly	O	O
more	O	O
CC	O	O
than	O	O
non	O	O
-	O	O
sclerotic	O	O
glomeruli	O	O
in	O	O
the	O	O
same	O	O
kidneys	O	O
.	O	O

CC	O	O
was	O	O
preferentially	O	O
localized	O	O
within	O	O
the	O	O
sclerotic	O	O
areas	O	O
of	O	O
the	O	O
affected	O	O
glomeruli	O	O
.	O	O

Since	O	O
mesangial	O	O
CC	O	O
clearance	O	O
from	O	O
the	O	O
mesangium	O	O
did	O	O
not	O	O
change	O	O
during	O	O
chronic	O	O
PAN	B-Chemical	D011692
treatment	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
this	O	O
preferential	O	O
CC	O	O
localization	O	O
within	O	O
the	O	O
lesions	O	O
is	O	O
caused	O	O
by	O	O
an	O	O
increased	O	O
CC	O	O
uptake	O	O
shortly	O	O
after	O	O
injection	O	O
in	O	O
apparent	O	O
vulnerable	O	O
areas	O	O
where	O	O
sclerosis	B-Disease	D012598
will	O	O
develop	O	O
subsequently	O	O
.	O	O

Cluster	O	O
analysis	O	O
showed	O	O
a	O	O
random	O	O
distribution	O	O
of	O	O
lesions	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
glomeruli	O	O
in	O	O
concordance	O	O
with	O	O
the	O	O
random	O	O
localization	O	O
of	O	O
mesangial	O	O
areas	O	O
with	O	O
dysfunction	O	O
in	O	O
this	O	O
model	O	O
.	O	O

Similar	O	O
to	O	O
the	O	O
remnant	O	O
kidney	O	O
model	O	O
in	O	O
PAN	B-Chemical	D011692
nephrosis	B-Disease	D009401
the	O	O
development	O	O
of	O	O
glomerular	B-Disease	D007674
sclerosis	I-Disease	D007674
may	O	O
be	O	O
related	O	O
to	O	O
"mesangial	O	O
overloading	O	O
.	O	O

"	O	O
Relationship	O	O
between	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
hippocampal	O	O
nicotinic	O	O
receptors	O	O
.	O	O

A	O	O
controversy	O	O
has	O	O
existed	O	O
for	O	O
several	O	O
years	O	O
concerning	O	O
the	O	O
physiological	O	O
relevance	O	O
of	O	O
the	O	O
nicotinic	O	O
receptor	O	O
measured	O	O
by	O	O
alpha	O	O
-	O	O
bungarotoxin	O	O
binding	O	O
.	O	O

Using	O	O
mice	O	O
derived	O	O
from	O	O
a	O	O
classical	O	O
F2	O	O
and	O	O
backcross	O	O
genetic	O	O
design	O	O
,	O	O
a	O	O
relationship	O	O
between	O	O
nicotine	B-Chemical	D009538
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
alpha	O	O
-	O	O
bungarotoxin	O	O
nicotinic	O	O
receptor	O	O
concentration	O	O
was	O	O
found	O	O
.	O	O

Mice	O	O
sensitive	O	O
to	O	O
the	O	O
convulsant	O	O
effects	O	O
of	O	O
nicotine	B-Chemical	D009538
had	O	O
greater	O	O
alpha	O	O
-	O	O
bungarotoxin	O	O
binding	O	O
in	O	O
the	O	O
hippocampus	O	O
than	O	O
seizure	B-Disease	D012640
insensitive	O	O
mice	O	O
.	O	O

The	O	O
binding	O	O
sites	O	O
from	O	O
seizure	B-Disease	D012640
sensitive	O	O
and	O	O
resistant	O	O
mice	O	O
were	O	O
equally	O	O
affected	O	O
by	O	O
treatment	O	O
with	O	O
dithiothreitol	B-Chemical	D004229
,	O	O
trypsin	O	O
or	O	O
heat	O	O
.	O	O

Thus	O	O
it	O	O
appears	O	O
that	O	O
the	O	O
difference	O	O
between	O	O
seizure	B-Disease	D012640
sensitive	O	O
and	O	O
insensitive	O	O
animals	O	O
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
difference	O	O
in	O	O
hippocampal	O	O
nicotinic	O	O
receptor	O	O
concentration	O	O
as	O	O
measured	O	O
with	O	O
alpha	O	O
-	O	O
bungarotoxin	O	O
binding	O	O
.	O	O

The	O	O
role	O	O
of	O	O
p	B-Chemical	C026729
-	I-Chemical	C026729
aminophenol	I-Chemical	C026729
in	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
:	O	O
effect	O	O
of	O	O
bis	B-Chemical	C002887
(	I-Chemical	C002887
p	I-Chemical	C002887
-	I-Chemical	C002887
nitrophenyl	I-Chemical	C002887
)	I-Chemical	C002887
phosphate	I-Chemical	C002887
on	O	O
acetaminophen	B-Chemical	D000082
and	O	O
p	B-Chemical	C026729
-	I-Chemical	C026729
aminophenol	I-Chemical	C026729
nephrotoxicity	B-Disease	D007674
and	O	O
metabolism	O	O
in	O	O
Fischer	O	O
344	O	O
rats	O	O
.	O	O

Acetaminophen	B-Chemical	D000082
(	O	O
APAP	B-Chemical	D000082
)	O	O
produces	O	O
proximal	O	O
tubular	B-Disease	D007683
necrosis	I-Disease	D007683
in	O	O
Fischer	O	O
344	O	O
(	O	O
F344	O	O
)	O	O
rats	O	O
.	O	O

Recently	O	O
,	O	O
p	B-Chemical	C026729
-	I-Chemical	C026729
aminophenol	I-Chemical	C026729
(	O	O
PAP	B-Chemical	C026729
)	O	O
,	O	O
a	O	O
known	O	O
potent	O	O
nephrotoxicant	O	O
,	O	O
was	O	O
identified	O	O
as	O	O
a	O	O
metabolite	O	O
of	O	O
APAP	B-Chemical	D000082
in	O	O
F344	O	O
rats	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
PAP	B-Chemical	C026729
formation	O	O
is	O	O
a	O	O
requisite	O	O
step	O	O
in	O	O
APAP	B-Chemical	D000082
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Therefore	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
bis	B-Chemical	C002887
(	I-Chemical	C002887
p	I-Chemical	C002887
-	I-Chemical	C002887
nitrophenyl	I-Chemical	C002887
)	I-Chemical	C002887
phosphate	I-Chemical	C002887
(	O	O
BNPP	B-Chemical	C002887
)	O	O
,	O	O
an	O	O
acylamidase	O	O
inhibitor	O	O
,	O	O
on	O	O
APAP	B-Chemical	D000082
and	O	O
PAP	B-Chemical	C026729
nephrotoxicity	B-Disease	D007674
and	O	O
metabolism	O	O
was	O	O
determined	O	O
.	O	O

BNPP	B-Chemical	C002887
(	O	O
1	O	O
to	O	O
8	O	O
mM	O	O
)	O	O
reduced	O	O
APAP	B-Chemical	D000082
deacetylation	O	O
and	O	O
covalent	O	O
binding	O	O
in	O	O
F344	O	O
renal	O	O
cortical	O	O
homogenates	O	O
in	O	O
a	O	O
concentration	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

Pretreatment	O	O
of	O	O
animals	O	O
with	O	O
BNPP	B-Chemical	C002887
prior	O	O
to	O	O
APAP	B-Chemical	D000082
or	O	O
PAP	B-Chemical	C026729
administration	O	O
resulted	O	O
in	O	O
marked	O	O
reduction	O	O
of	O	O
APAP	B-Chemical	D000082
(	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
nephrotoxicity	B-Disease	D007674
but	O	O
not	O	O
PAP	B-Chemical	C026729
nephrotoxicity	B-Disease	D007674
.	O	O

This	O	O
result	O	O
was	O	O
not	O	O
due	O	O
to	O	O
altered	O	O
disposition	O	O
of	O	O
either	O	O
APAP	B-Chemical	D000082
or	O	O
acetylated	O	O
metabolites	O	O
in	O	O
plasma	O	O
or	O	O
renal	O	O
cortical	O	O
and	O	O
hepatic	O	O
tissue	O	O
.	O	O

Rather	O	O
,	O	O
BNPP	B-Chemical	C002887
pretreatment	O	O
reduced	O	O
the	O	O
fraction	O	O
of	O	O
APAP	B-Chemical	D000082
excreted	O	O
as	O	O
PAP	B-Chemical	C026729
by	O	O
64	O	O
and	O	O
75%	O	O
after	O	O
APAP	B-Chemical	D000082
doses	O	O
of	O	O
750	O	O
and	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

BNPP	B-Chemical	C002887
did	O	O
not	O	O
alter	O	O
the	O	O
excretion	O	O
of	O	O
APAP	B-Chemical	D000082
or	O	O
any	O	O
of	O	O
its	O	O
non	O	O
-	O	O
deacetylated	O	O
metabolites	O	O
nor	O	O
did	O	O
BNPP	B-Chemical	C002887
alter	O	O
excretion	O	O
of	O	O
PAP	B-Chemical	C026729
or	O	O
its	O	O
metabolites	O	O
after	O	O
PAP	B-Chemical	C026729
doses	O	O
of	O	O
150	O	O
and	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Therefore	O	O
,	O	O
the	O	O
BNPP	B-Chemical	C002887
-	O	O
induced	O	O
reduction	O	O
in	O	O
APAP	B-Chemical	D000082
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
appears	O	O
to	O	O
be	O	O
due	O	O
to	O	O
inhibition	O	O
of	O	O
APAP	B-Chemical	D000082
deacetylation	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
PAP	B-Chemical	C026729
formation	O	O
,	O	O
in	O	O
vivo	O	O
,	O	O
accounts	O	O
,	O	O
at	O	O
least	O	O
in	O	O
part	O	O
,	O	O
for	O	O
APAP	B-Chemical	D000082
-	O	O
induced	O	O
renal	B-Disease	D007683
tubular	I-Disease	D007683
necrosis	I-Disease	D007683
.	O	O

Morphine	B-Chemical	D009020
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
newborn	O	O
infants	O	O
.	O	O

Two	O	O
neonates	O	O
suffered	O	O
from	O	O
generalized	O	O
seizures	B-Disease	D012640
during	O	O
the	O	O
course	O	O
of	O	O
intravenous	O	O
morphine	B-Chemical	D009020
sulfate	I-Chemical	D009020
for	O	O
post	O	O
-	O	O
operative	O	O
analgesia	O	O
.	O	O

They	O	O
received	O	O
morphine	B-Chemical	D009020
in	O	O
doses	O	O
of	O	O
32	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
hr	O	O
and	O	O
40	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
hr	O	O
larger	O	O
than	O	O
a	O	O
group	O	O
of	O	O
10	O	O
neonates	O	O
who	O	O
received	O	O
6	O	O
-	O	O
24	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
hr	O	O
and	O	O
had	O	O
no	O	O
seizures	B-Disease	D012640
.	O	O

Plasma	O	O
concentrations	O	O
of	O	O
morphine	B-Chemical	D009020
in	O	O
these	O	O
neonates	O	O
was	O	O
excessive	O	O
(	O	O
60	O	O
and	O	O
90	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

Other	O	O
known	O	O
reasons	O	O
for	O	O
seizures	B-Disease	D012640
were	O	O
ruled	O	O
out	O	O
and	O	O
the	O	O
convulsions	B-Disease	D012640
stopped	O	O
a	O	O
few	O	O
hours	O	O
after	O	O
cessation	O	O
of	O	O
morphine	B-Chemical	D009020
and	O	O
did	O	O
not	O	O
reoccur	O	O
in	O	O
the	O	O
subsequent	O	O
8	O	O
months	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
post	O	O
-	O	O
operative	O	O
intravenous	O	O
morphine	B-Chemical	D009020
should	O	O
not	O	O
exceed	O	O
20	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
ml	O	O
in	O	O
neonates	O	O
.	O	O

Effect	O	O
of	O	O
vincristine	B-Chemical	D014750
sulfate	I-Chemical	D014750
on	O	O
Pseudomonas	B-Disease	D011552
infections	I-Disease	D011552
in	O	O
monkeys	O	O
.	O	O

In	O	O
rhesus	O	O
monkeys	O	O
,	O	O
intravenous	O	O
challenge	O	O
with	O	O
0	O	O
.	O	O

6	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
to	O	O
2	O	O
.	O	O

2	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
Pseudomonas	O	O
aeruginosa	O	O
organisms	O	O
caused	O	O
acute	O	O
illness	O	O
of	O	O
4	O	O
to	O	O
5	O	O
days'	O	O
duration	O	O
with	O	O
spontaneous	O	O
recovery	O	O
in	O	O
13	O	O
of	O	O
15	O	O
monkeys	O	O
;	O	O
blood	O	O
cultures	O	O
became	O	O
negative	O	O
3	O	O
to	O	O
17	O	O
days	O	O
after	O	O
challenge	O	O
.	O	O

Leukocytosis	B-Disease	D007964
was	O	O
observed	O	O
in	O	O
all	O	O
monkeys	O	O
.	O	O

Intravenous	O	O
or	O	O
intratracheal	O	O
inoculation	O	O
of	O	O
2	O	O
.	O	O

0	O	O
to	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
of	O	O
vincristine	B-Chemical	D014750
sulfate	I-Chemical	D014750
was	O	O
followed	O	O
by	O	O
leukopenia	B-Disease	D007970
in	O	O
4	O	O
to	O	O
5	O	O
days	O	O
.	O	O

Intravenous	O	O
inoculation	O	O
of	O	O
4	O	O
.	O	O

2	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
to	O	O
7	O	O
.	O	O

8	O	O
x	O	O
10	O	O
(	O	O
10	O	O
)	O	O
pyocin	O	O
type	O	O
6	O	O
Pseudomonas	O	O
organisms	O	O
in	O	O
monkeys	O	O
given	O	O
vincristine	B-Chemical	D014750
sulfate	I-Chemical	D014750
4	O	O
days	O	O
previously	O	O
resulted	O	O
in	O	O
fatal	O	O
infection	B-Disease	D007239
in	O	O
11	O	O
of	O	O
14	O	O
monkeys	O	O
,	O	O
whereas	O	O
none	O	O
of	O	O
four	O	O
receiving	O	O
Pseudomonas	O	O
alone	O	O
died	O	O
.	O	O

These	O	O
studies	O	O
suggest	O	O
that	O	O
an	O	O
antimetabolite	O	O
-	O	O
induced	O	O
leukopenia	B-Disease	D007970
predisposes	O	O
to	O	O
severe	O	O
Pseudomonas	O	O
sepsis	B-Disease	D018805
and	O	O
that	O	O
such	O	O
monkeys	O	O
may	O	O
serve	O	O
as	O	O
a	O	O
biological	O	O
model	O	O
for	O	O
study	O	O
of	O	O
comparative	O	O
efficacy	O	O
of	O	O
antimicrobial	O	O
agents	O	O
.	O	O

Central	O	O
excitatory	O	O
actions	O	O
of	O	O
flurazepam	B-Chemical	D005479
.	O	O

Toxic	O	O
actions	O	O
of	O	O
flurazepam	B-Chemical	D005479
(	O	O
FZP	B-Chemical	D005479
)	O	O
were	O	O
studied	O	O
in	O	O
cats	O	O
,	O	O
mice	O	O
and	O	O
rats	O	O
.	O	O

High	O	O
doses	O	O
caused	O	O
an	O	O
apparent	O	O
central	O	O
excitation	O	O
,	O	O
most	O	O
clearly	O	O
seen	O	O
as	O	O
clonic	O	O
convulsions	B-Disease	D012640
,	O	O
superimposed	O	O
on	O	O
general	O	O
depression	B-Disease	D003866
.	O	O

Following	O	O
a	O	O
lethal	O	O
dose	O	O
,	O	O
death	O	O
was	O	O
always	O	O
associated	O	O
with	O	O
convulsions	B-Disease	D012640
.	O	O

Comparing	O	O
the	O	O
relative	O	O
sensitivity	O	O
to	O	O
central	O	O
depression	B-Disease	D003866
and	O	O
excitation	O	O
revealed	O	O
that	O	O
rats	O	O
were	O	O
least	O	O
likely	O	O
to	O	O
have	O	O
convulsions	B-Disease	D012640
at	O	O
doses	O	O
that	O	O
did	O	O
not	O	O
first	O	O
cause	O	O
loss	B-Disease	D014474
of	I-Disease	D014474
consciousness	I-Disease	D014474
,	O	O
while	O	O
cats	O	O
most	O	O
clearly	O	O
showed	O	O
marked	O	O
central	O	O
excitatory	O	O
actions	O	O
.	O	O

Signs	O	O
of	O	O
FZP	B-Chemical	D005479
toxocity	B-Disease	D064420
in	O	O
cats	O	O
included	O	O
excessive	O	O
salivation	B-Disease	D012798
,	O	O
extreme	O	O
apprehensive	O	O
behavior	O	O
,	O	O
retching	O	O
,	O	O
muscle	B-Disease	D014202
tremors	I-Disease	D014202
and	O	O
convulsions	B-Disease	D012640
.	O	O

An	O	O
interaction	O	O
between	O	O
FZP	B-Chemical	D005479
and	O	O
pentylenetetrazol	B-Chemical	D010433
(	O	O
PTZ	B-Chemical	D010433
)	O	O
was	O	O
shown	O	O
by	O	O
pretreating	O	O
mice	O	O
with	O	O
FZP	B-Chemical	D005479
before	O	O
PTZ	B-Chemical	D010433
challenge	O	O
.	O	O

As	O	O
a	O	O
function	O	O
of	O	O
dose	O	O
,	O	O
FZP	B-Chemical	D005479
first	O	O
protected	O	O
against	O	O
convulsions	B-Disease	D012640
and	O	O
death	O	O
.	O	O

At	O	O
higher	O	O
doses	O	O
,	O	O
however	O	O
,	O	O
convulsions	B-Disease	D012640
again	O	O
emerged	O	O
.	O	O

These	O	O
doses	O	O
of	O	O
FZP	B-Chemical	D005479
were	O	O
lower	O	O
than	O	O
those	O	O
that	O	O
would	O	O
alone	O	O
cause	O	O
convulsions	B-Disease	D012640
.	O	O

These	O	O
results	O	O
may	O	O
be	O	O
relevant	O	O
to	O	O
the	O	O
use	O	O
of	O	O
FZP	B-Chemical	D005479
in	O	O
clinical	O	O
situations	O	O
in	O	O
which	O	O
there	O	O
is	O	O
increased	O	O
neural	O	O
excitability	O	O
,	O	O
such	O	O
as	O	O
epilepsy	B-Disease	D004827
or	O	O
sedative	O	O
-	O	O
hypnotic	O	O
drug	O	O
withdrawal	O	O
.	O	O

Evidence	O	O
for	O	O
cardiac	O	O
beta	O	O
2	O	O
-	O	O
adrenoceptors	O	O
in	O	O
man	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
effects	O	O
of	O	O
single	O	O
doses	O	O
of	O	O
50	O	O
mg	O	O
atenolol	B-Chemical	D001262
(	O	O
cardioselective	O	O
)	O	O
,	O	O
40	O	O
mg	O	O
propranolol	B-Chemical	D011433
(	O	O
nonselective	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
on	O	O
both	O	O
exercise	O	O
-	O	O
and	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
in	O	O
two	O	O
experiments	O	O
involving	O	O
nine	O	O
normal	O	O
subjects	O	O
.	O	O

Maximal	O	O
exercise	O	O
heart	O	O
rate	O	O
was	O	O
reduced	O	O
from	O	O
187	O	O
+	O	O
/	O	O
-	O	O
4	O	O
(	O	O
SEM	O	O
)	O	O
after	O	O
placebo	O	O
to	O	O
146	O	O
+	O	O
/	O	O
-	O	O
7	O	O
bpm	O	O
after	O	O
atenolol	B-Chemical	D001262
and	O	O
138	O	O
+	O	O
/	O	O
-	O	O
6	O	O
bpm	O	O
after	O	O
propranolol	B-Chemical	D011433
,	O	O
but	O	O
there	O	O
were	O	O
no	O	O
differences	O	O
between	O	O
the	O	O
drugs	O	O
.	O	O

The	O	O
effects	O	O
on	O	O
isoproterenol	B-Chemical	D007545
tachycardia	B-Disease	D013610
were	O	O
determined	O	O
before	O	O
and	O	O
after	O	O
atropine	B-Chemical	D001285
(	O	O
0	O	O
.	O	O

04	O	O
mg	O	O
/	O	O
kg	O	O
IV	O	O
)	O	O
.	O	O

Isoproterenol	B-Chemical	D007545
sensitivity	O	O
was	O	O
determined	O	O
as	O	O
the	O	O
intravenous	O	O
dose	O	O
that	O	O
increased	O	O
heart	O	O
rate	O	O
by	O	O
25	O	O
bpm	O	O
(	O	O
CD25	O	O
)	O	O
and	O	O
this	O	O
was	O	O
increased	O	O
from	O	O
1	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
micrograms	O	O
after	O	O
placebo	O	O
to	O	O
38	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

3	O	O
micrograms	O	O
after	O	O
propranolol	B-Chemical	D011433
and	O	O
8	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

7	O	O
micrograms	O	O
after	O	O
atenolol	B-Chemical	D001262
.	O	O

The	O	O
difference	O	O
in	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
two	O	O
was	O	O
significant	O	O
.	O	O

After	O	O
atropine	B-Chemical	D001285
the	O	O
CD25	O	O
was	O	O
unchanged	O	O
after	O	O
placebo	O	O
(	O	O
2	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
micrograms	O	O
)	O	O
and	O	O
atenolol	B-Chemical	D001262
(	O	O
7	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
micrograms	O	O
)	O	O
;	O	O
it	O	O
was	O	O
reduced	O	O
after	O	O
propranolol	B-Chemical	D011433
(	O	O
24	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

0	O	O
micrograms	O	O
)	O	O
,	O	O
but	O	O
remained	O	O
different	O	O
from	O	O
atenolol	B-Chemical	D001262
.	O	O

This	O	O
change	O	O
with	O	O
propranolol	B-Chemical	D011433
sensitivity	O	O
was	O	O
calculated	O	O
as	O	O
the	O	O
apparent	O	O
Ka	O	O
,	O	O
this	O	O
was	O	O
unchanged	O	O
by	O	O
atropine	B-Chemical	D001285
(	O	O
11	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

1	O	O
and	O	O
10	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

5	O	O
ml	O	O
/	O	O
ng	O	O
)	O	O
.	O	O

These	O	O
data	O	O
are	O	O
consistent	O	O
with	O	O
the	O	O
hypothesis	O	O
that	O	O
exercise	O	O
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
results	O	O
largely	O	O
from	O	O
beta	O	O
1	O	O
-	O	O
receptor	O	O
activation	O	O
that	O	O
is	O	O
blocked	O	O
by	O	O
both	O	O
cardioselective	O	O
and	O	O
nonselective	O	O
drugs	O	O
,	O	O
whereas	O	O
isoproterenol	B-Chemical	D007545
activates	O	O
both	O	O
beta	O	O
1	O	O
-	O	O
and	O	O
beta	O	O
2	O	O
-	O	O
receptors	O	O
so	O	O
that	O	O
after	O	O
cardioselective	O	O
blockade	O	O
there	O	O
remains	O	O
a	O	O
beta	O	O
2	O	O
-	O	O
component	O	O
that	O	O
can	O	O
be	O	O
blocked	O	O
with	O	O
a	O	O
nonselective	O	O
drug	O	O
.	O	O

While	O	O
there	O	O
appear	O	O
to	O	O
be	O	O
beta	O	O
2	O	O
-	O	O
receptors	O	O
in	O	O
the	O	O
human	O	O
heart	O	O
,	O	O
their	O	O
physiologic	O	O
or	O	O
pathologic	O	O
roles	O	O
remain	O	O
to	O	O
be	O	O
defined	O	O
.	O	O

Hormones	O	O
and	O	O
risk	O	O
of	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

This	O	O
paper	O	O
reports	O	O
the	O	O
results	O	O
of	O	O
a	O	O
study	O	O
of	O	O
50	O	O
menopausal	O	O
women	O	O
receiving	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
.	O	O

The	O	O
majority	O	O
(	O	O
29	O	O
)	O	O
had	O	O
surgical	O	O
menopause	O	O
;	O	O
their	O	O
mean	O	O
age	O	O
was	O	O
45	O	O
.	O	O

7	O	O
years	O	O
.	O	O

It	O	O
was	O	O
hypothesized	O	O
that	O	O
progestins	B-Chemical	D011372
could	O	O
equilibrate	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
estrogenic	O	O
stimulation	O	O
on	O	O
the	O	O
mammary	O	O
and	O	O
endometrial	O	O
target	O	O
tissues	O	O
of	O	O
women	O	O
on	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
.	O	O

The	O	O
treatment	O	O
schedule	O	O
consisted	O	O
of	O	O
conjugated	B-Chemical	D004966
estrogens	I-Chemical	D004966
(	O	O
Premarin	B-Chemical	D004966
)	O	O
1	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
21	O	O
days	O	O
and	O	O
Medroxyprogesterone	B-Chemical	D017258
acetate	I-Chemical	D017258
10	O	O
mg	O	O
/	O	O
day	O	O
for	O	O
10	O	O
days	O	O
in	O	O
each	O	O
month	O	O
.	O	O

The	O	O
mean	O	O
treatment	O	O
period	O	O
was	O	O
18	O	O
months	O	O
.	O	O

During	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
,	O	O
attention	O	O
was	O	O
paid	O	O
to	O	O
breast	O	O
modifications	O	O
as	O	O
evidenced	O	O
by	O	O
symptomatology	O	O
,	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
plate	O	O
thermography	O	O
.	O	O

Mastodynia	B-Disease	D059373
was	O	O
reported	O	O
by	O	O
21	O	O
patients	O	O
,	O	O
and	O	O
physical	O	O
examination	O	O
revealed	O	O
a	O	O
light	O	O
increase	O	O
in	O	O
breast	O	O
firmness	O	O
in	O	O
12	O	O
women	O	O
and	O	O
a	O	O
moderate	O	O
increase	O	O
in	O	O
breast	O	O
nodularity	O	O
in	O	O
2	O	O
women	O	O
.	O	O

Themography	O	O
confirmed	O	O
the	O	O
existence	O	O
of	O	O
an	O	O
excessive	O	O
breast	O	O
stimulation	O	O
in	O	O
1	O	O
women	O	O
who	O	O
complained	O	O
of	O	O
moderate	O	O
mastodynia	B-Disease	D059373
and	O	O
in	O	O
5	O	O
of	O	O
the	O	O
7	O	O
women	O	O
who	O	O
complained	O	O
of	O	O
severe	O	O
mastodynia	B-Disease	D059373
.	O	O

Normalization	O	O
was	O	O
obtained	O	O
by	O	O
halving	O	O
the	O	O
estrogen	B-Chemical	D004967
dose	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
hormonal	O	O
replacement	O	O
therapy	O	O
can	O	O
be	O	O
safely	O	O
prescribed	O	O
if	O	O
the	O	O
following	O	O
criteria	O	O
are	O	O
satisfied	O	O
:	O	O
1	O	O
)	O	O
preliminary	O	O
evaluation	O	O
of	O	O
patients	O	O
from	O	O
a	O	O
clinical	O	O
,	O	O
metabolic	O	O
,	O	O
cytologic	O	O
,	O	O
and	O	O
mammographic	O	O
perspective	O	O
;	O	O
2	O	O
)	O	O
cyclic	O	O
treatment	O	O
schedule	O	O
,	O	O
with	O	O
a	O	O
progestative	O	O
phase	O	O
of	O	O
10	O	O
days	O	O
;	O	O
and	O	O
3	O	O
)	O	O
periodic	O	O
complete	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
with	O	O
accurate	O	O
thermographic	O	O
evaluation	O	O
of	O	O
the	O	O
breast	O	O
target	O	O
tissues	O	O
.	O	O

Early	O	O
infections	B-Disease	D007239
in	O	O
kidney	O	O
,	O	O
heart	O	O
,	O	O
and	O	O
liver	O	O
transplant	O	O
recipients	O	O
on	O	O
cyclosporine	B-Chemical	D016572
.	O	O

Eighty	O	O
-	O	O
one	O	O
renal	O	O
,	O	O
seventeen	O	O
heart	O	O
,	O	O
and	O	O
twenty	O	O
-	O	O
four	O	O
liver	O	O
transplant	O	O
patients	O	O
were	O	O
followed	O	O
for	O	O
infection	B-Disease	D007239
.	O	O

Seventeen	O	O
renal	O	O
patients	O	O
received	O	O
azathioprine	B-Chemical	D001379
(	O	O
Aza	B-Chemical	D001379
)	O	O
and	O	O
prednisone	B-Chemical	D011241
as	O	O
part	O	O
of	O	O
a	O	O
randomized	O	O
trial	O	O
of	O	O
immunosuppression	O	O
with	O	O
21	O	O
cyclosporine	B-Chemical	D016572
-	O	O
and	O	O
-	O	O
prednisone	B-Chemical	D011241
-	O	O
treated	O	O
renal	O	O
transplant	O	O
patients	O	O
.	O	O

All	O	O
others	O	O
received	O	O
cyclosporine	B-Chemical	D016572
and	O	O
prednisone	B-Chemical	D011241
.	O	O

The	O	O
randomized	O	O
Aza	B-Chemical	D001379
patients	O	O
had	O	O
more	O	O
overall	O	O
infections	B-Disease	D007239
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
more	O	O
nonviral	O	O
infections	B-Disease	D007239
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

02	O	O
)	O	O
than	O	O
the	O	O
randomized	O	O
cyclosporine	B-Chemical	D016572
patients	O	O
.	O	O

Heart	O	O
and	O	O
liver	O	O
patients	O	O
had	O	O
more	O	O
infections	B-Disease	D007239
than	O	O
cyclosporine	B-Chemical	D016572
renal	O	O
patients	O	O
but	O	O
fewer	O	O
infections	B-Disease	D007239
than	O	O
the	O	O
Aza	B-Chemical	D001379
renal	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
infectious	O	O
deaths	O	O
in	O	O
renal	O	O
transplant	O	O
patients	O	O
on	O	O
cyclosporine	B-Chemical	D016572
or	O	O
Aza	B-Chemical	D001379
,	O	O
but	O	O
infection	B-Disease	D007239
played	O	O
a	O	O
major	O	O
role	O	O
in	O	O
3	O	O
out	O	O
of	O	O
6	O	O
cardiac	O	O
transplant	O	O
deaths	O	O
and	O	O
in	O	O
8	O	O
out	O	O
of	O	O
9	O	O
liver	O	O
transplant	O	O
deaths	O	O
.	O	O

Renal	O	O
patients	O	O
on	O	O
cyclosporine	B-Chemical	D016572
had	O	O
the	O	O
fewest	O	O
bacteremias	B-Disease	D016470
.	O	O

Analysis	O	O
of	O	O
site	O	O
of	O	O
infection	B-Disease	D007239
showed	O	O
a	O	O
preponderance	O	O
of	O	O
abdominal	B-Disease	D059413
infections	I-Disease	D059413
in	O	O
liver	O	O
patients	O	O
,	O	O
intrathoracic	O	O
infections	B-Disease	D007239
in	O	O
heart	O	O
patients	O	O
,	O	O
and	O	O
urinary	B-Disease	D014552
tract	I-Disease	D014552
infections	I-Disease	D014552
in	O	O
renal	O	O
patients	O	O
.	O	O

Pulmonary	O	O
infections	B-Disease	D007239
were	O	O
less	O	O
common	O	O
in	O	O
cyclosporine	B-Chemical	D016572
-	O	O
treated	O	O
renal	O	O
patients	O	O
than	O	O
in	O	O
Aza	B-Chemical	D001379
-	O	O
treated	O	O
patients	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Aza	B-Chemical	D001379
patients	O	O
had	O	O
significantly	O	O
more	O	O
staphylococcal	B-Disease	D013203
infections	I-Disease	D013203
than	O	O
all	O	O
other	O	O
transplant	O	O
groups	O	O
(	O	O
P	O	O
less	O	O
than	O	O
0	O	O
.	O	O

005	O	O
)	O	O
,	O	O
and	O	O
systemic	O	O
fungal	B-Disease	D009181
infections	I-Disease	D009181
occurred	O	O
only	O	O
in	O	O
the	O	O
liver	O	O
transplant	O	O
group	O	O
.	O	O

Cytomegalovirus	O	O
(	O	O
CMV	O	O
)	O	O
shedding	O	O
or	O	O
serological	O	O
rises	O	O
in	O	O
antibody	O	O
titer	O	O
,	O	O
or	O	O
both	O	O
occurred	O	O
in	O	O
78%	O	O
of	O	O
cyclosporine	B-Chemical	D016572
patients	O	O
and	O	O
76%	O	O
of	O	O
Aza	B-Chemical	D001379
patients	O	O
.	O	O

Of	O	O
the	O	O
cyclosporine	B-Chemical	D016572
patients	O	O
,	O	O
15%	O	O
had	O	O
symptoms	O	O
related	O	O
to	O	O
CMV	B-Disease	D003586
infection	I-Disease	D003586
.	O	O

Serological	O	O
evidence	O	O
for	O	O
Epstein	B-Disease	D020031
Barr	I-Disease	D020031
Virus	I-Disease	D020031
infection	I-Disease	D020031
was	O	O
found	O	O
in	O	O
20%	O	O
of	O	O
65	O	O
cyclosporine	B-Chemical	D016572
patients	O	O
studied	O	O
.	O	O

Three	O	O
had	O	O
associated	O	O
symptoms	O	O
,	O	O
and	O	O
one	O	O
developed	O	O
a	O	O
lymphoma	B-Disease	D008223
.	O	O

Structure	O	O
-	O	O
activity	O	O
and	O	O
dose	O	O
-	O	O
effect	O	O
relationships	O	O
of	O	O
the	O	O
antagonism	O	O
of	O	O
picrotoxin	B-Chemical	D010852
-	O	O
induced	O	O
seizures	B-Disease	D012640
by	O	O
cholecystokinin	B-Chemical	D002766
,	O	O
fragments	O	O
and	O	O
analogues	O	O
of	O	O
cholecystokinin	B-Chemical	D002766
in	O	O
mice	O	O
.	O	O

Intraperitoneal	O	O
administration	O	O
of	O	O
cholecystokinin	B-Chemical	D002766
octapeptide	O	O
sulphate	O	O
ester	O	O
(	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
SE	O	O
)	O	O
and	O	O
nonsulphated	O	O
cholecystokinin	B-Chemical	D002766
octapeptide	O	O
(	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
NS	O	O
)	O	O
enhanced	O	O
the	O	O
latency	O	O
of	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
picrotoxin	B-Chemical	D010852
in	O	O
mice	O	O
.	O	O

Experiments	O	O
with	O	O
N	O	O
-	O	O
and	O	O
C	O	O
-	O	O
terminal	O	O
fragments	O	O
revealed	O	O
that	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
tetrapeptide	O	O
(	O	O
CCK	O	O
-	O	O
5	O	O
-	O	O
8	O	O
)	O	O
was	O	O
the	O	O
active	O	O
centre	O	O
of	O	O
the	O	O
CCK	O	O
octapeptide	O	O
molecule	O	O
.	O	O

The	O	O
analogues	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
SE	O	O
and	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
NS	O	O
(	O	O
dose	O	O
range	O	O
0	O	O
.	O	O

2	O	O
-	O	O
6	O	O
.	O	O

4	O	O
mumol	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
caerulein	B-Chemical	D002108
dose	O	O
range	O	O
0	O	O
.	O	O

1	O	O
-	O	O
0	O	O
.	O	O

8	O	O
mumol	O	O
/	O	O
kg	O	O
)	O	O
showed	O	O
bell	O	O
-	O	O
shaped	O	O
dose	O	O
-	O	O
effect	O	O
curves	O	O
,	O	O
with	O	O
the	O	O
greatest	O	O
maximum	O	O
inhibition	O	O
for	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
NS	O	O
.	O	O

The	O	O
peptide	O	O
CCK	O	O
-	O	O
5	O	O
-	O	O
8	O	O
had	O	O
weak	O	O
anticonvulsant	O	O
activity	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
octapeptides	O	O
,	O	O
3	O	O
.	O	O

2	O	O
mumol	O	O
/	O	O
kg	O	O
and	O	O
larger	O	O
doses	O	O
of	O	O
the	O	O
reference	O	O
drug	O	O
,	O	O
diazepam	B-Chemical	D003975
,	O	O
totally	O	O
prevented	O	O
picrotoxin	B-Chemical	D010852
-	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
mortality	O	O
.	O	O

The	O	O
maximum	O	O
effect	O	O
of	O	O
the	O	O
peptides	O	O
tested	O	O
was	O	O
less	O	O
than	O	O
that	O	O
of	O	O
diazepam	B-Chemical	D003975
.	O	O

Experiments	O	O
with	O	O
analogues	O	O
and	O	O
derivatives	O	O
of	O	O
CCK	O	O
-	O	O
5	O	O
-	O	O
8	O	O
demonstrated	O	O
that	O	O
the	O	O
effectiveness	O	O
of	O	O
the	O	O
beta	O	O
-	O	O
alanyl	O	O
derivatives	O	O
of	O	O
CCK	O	O
-	O	O
5	O	O
-	O	O
8	O	O
were	O	O
enhanced	O	O
and	O	O
that	O	O
they	O	O
were	O	O
equipotent	O	O
with	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
SE	O	O
.	O	O

Of	O	O
the	O	O
CCK	O	O
-	O	O
2	O	O
-	O	O
8	O	O
analogues	O	O
,	O	O
Ser	O	O
(	O	O
SO3H	O	O
)	O	O
7	O	O
-	O	O
Ac	O	O
-	O	O
CCK	O	O
-	O	O
2	O	O
-	O	O
8	O	O
-	O	O
SE	O	O
and	O	O
Thr	O	O
(	O	O
SO3H	O	O
)	O	O
7	O	O
-	O	O
Ac	O	O
-	O	O
CCK	O	O
-	O	O
2	O	O
-	O	O
8	O	O
-	O	O
SE	O	O
and	O	O
Hyp	O	O
(	O	O
SO3H	O	O
)	O	O
-	O	O
Ac	O	O
-	O	O
CCK	O	O
-	O	O
2	O	O
-	O	O
8	O	O
-	O	O
SE	O	O
were	O	O
slightly	O	O
more	O	O
active	O	O
than	O	O
CCK	B-Chemical	D012844
-	I-Chemical	D012844
8	I-Chemical	D012844
-	O	O
SE	O	O
.	O	O

Vasopressin	B-Chemical	D014667
as	O	O
a	O	O
possible	O	O
contributor	O	O
to	O	O
hypertension	B-Disease	D006973
.	O	O

The	O	O
role	O	O
of	O	O
vasopressin	B-Chemical	D014667
as	O	O
a	O	O
pressor	O	O
agent	O	O
to	O	O
the	O	O
hypertensive	B-Disease	D006973
process	O	O
was	O	O
examined	O	O
.	O	O

Vasopressin	B-Chemical	D014667
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
DOCA	B-Chemical	D003900
-	O	O
salt	O	O
hypertension	B-Disease	D006973
,	O	O
since	O	O
the	O	O
elevation	O	O
of	O	O
blood	O	O
pressure	O	O
was	O	O
not	O	O
substantial	O	O
in	O	O
the	O	O
rats	O	O
with	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
after	O	O
DOCA	B-Chemical	D003900
-	O	O
salt	O	O
treatment	O	O
.	O	O

Administration	O	O
of	O	O
DDAVP	B-Chemical	D003894
which	O	O
has	O	O
antidiuretic	O	O
action	O	O
but	O	O
minimal	O	O
vasopressor	O	O
effect	O	O
failed	O	O
to	O	O
increase	O	O
blood	O	O
pressure	O	O
to	O	O
the	O	O
levels	O	O
observed	O	O
after	O	O
administration	O	O
of	O	O
AVP	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
pressor	O	O
action	O	O
of	O	O
vasopressin	B-Chemical	D014667
appears	O	O
to	O	O
be	O	O
important	O	O
in	O	O
the	O	O
development	O	O
of	O	O
this	O	O
model	O	O
of	O	O
hypertension	B-Disease	D006973
,	O	O
since	O	O
the	O	O
enhanced	O	O
pressor	O	O
responsiveness	O	O
to	O	O
the	O	O
hormone	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
initial	O	O
stage	O	O
of	O	O
hypertension	B-Disease	D006973
.	O	O

Increased	O	O
secretion	O	O
of	O	O
vasopressin	B-Chemical	D014667
from	O	O
neurohypophysis	O	O
also	O	O
promotes	O	O
the	O	O
function	O	O
of	O	O
the	O	O
hormone	O	O
as	O	O
a	O	O
pathogenetic	O	O
factor	O	O
in	O	O
hypertension	B-Disease	D006973
.	O	O

An	O	O
unproportional	O	O
release	O	O
of	O	O
vasopressin	B-Chemical	D014667
compared	O	O
to	O	O
plasma	O	O
osmolality	O	O
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
absence	O	O
of	O	O
an	O	O
adjusting	O	O
control	O	O
of	O	O
angiotensin	B-Chemical	D000809
II	O	O
forming	O	O
and	O	O
receptor	O	O
binding	O	O
capacity	O	O
for	O	O
sodium	B-Chemical	D012964
balance	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

However	O	O
,	O	O
the	O	O
role	O	O
of	O	O
vasopressin	B-Chemical	D014667
remains	O	O
to	O	O
be	O	O
determined	O	O
in	O	O
human	O	O
essential	O	O
hypertension	B-Disease	D006973
.	O	O

Toxic	B-Disease	D056486
hepatitis	I-Disease	D056486
induced	O	O
by	O	O
disulfiram	B-Chemical	D004221
in	O	O
a	O	O
non	O	O
-	O	O
alcoholic	O	O
.	O	O

A	O	O
reversible	O	O
toxic	B-Disease	D056486
liver	I-Disease	D056486
damage	I-Disease	D056486
was	O	O
observed	O	O
in	O	O
a	O	O
non	O	O
-	O	O
alcoholic	O	O
woman	O	O
treated	O	O
with	O	O
disulfiram	B-Chemical	D004221
.	O	O

The	O	O
causative	O	O
relationship	O	O
was	O	O
proven	O	O
by	O	O
challenge	O	O
.	O	O

Atrial	B-Disease	D003328
thrombosis	I-Disease	D003328
involving	O	O
the	O	O
heart	O	O
of	O	O
F	O	O
-	O	O
344	O	O
rats	O	O
ingesting	O	O
quinacrine	B-Chemical	D011796
hydrochloride	I-Chemical	D011796
.	O	O

Quinacrine	B-Chemical	D011796
hydrochloride	I-Chemical	D011796
is	O	O
toxic	O	O
for	O	O
the	O	O
heart	O	O
of	O	O
F	O	O
-	O	O
344	O	O
rats	O	O
.	O	O

Rats	O	O
treated	O	O
with	O	O
500	O	O
ppm	O	O
quinacrine	B-Chemical	D011796
hydrochloride	I-Chemical	D011796
in	O	O
the	O	O
diet	O	O
all	O	O
developed	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
left	O	O
atrial	B-Disease	D003328
thrombosis	I-Disease	D003328
.	O	O

The	O	O
lesion	O	O
was	O	O
associated	O	O
with	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
and	O	O
dilatation	O	O
and	O	O
focal	O	O
myocardial	B-Disease	D009202
degeneration	I-Disease	D009202
.	O	O

Rats	O	O
died	O	O
from	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
with	O	O
severe	O	O
acute	O	O
and	O	O
chronic	O	O
congestion	O	O
of	O	O
the	O	O
lungs	O	O
,	O	O
liver	O	O
,	O	O
and	O	O
other	O	O
organs	O	O
.	O	O

Seventy	O	O
percent	O	O
of	O	O
rats	O	O
given	O	O
250	O	O
ppm	O	O
quinacrine	B-Chemical	D011796
hydrochloride	I-Chemical	D011796
and	O	O
1	O	O
,	O	O
000	O	O
ppm	O	O
sodium	B-Chemical	D012977
nitrite	I-Chemical	D012977
simultaneously	O	O
in	O	O
the	O	O
diet	O	O
had	O	O
thrombosis	B-Disease	D013927
of	O	O
the	O	O
atria	O	O
of	O	O
the	O	O
heart	O	O
,	O	O
while	O	O
untreated	O	O
control	O	O
rats	O	O
in	O	O
this	O	O
laboratory	O	O
did	O	O
not	O	O
have	O	O
atrial	B-Disease	D003328
thrombosis	I-Disease	D003328
.	O	O

Sodium	B-Chemical	D012977
nitrite	I-Chemical	D012977
in	O	O
combination	O	O
with	O	O
quinacrine	B-Chemical	D011796
hydrochloride	I-Chemical	D011796
appeared	O	O
to	O	O
have	O	O
no	O	O
additional	O	O
effect	O	O
.	O	O

Alternating	B-Disease	D001146
sinus	I-Disease	D001146
rhythm	I-Disease	D001146
and	O	O
intermittent	O	O
sinoatrial	B-Disease	D012848
block	I-Disease	D012848
induced	O	O
by	O	O
propranolol	B-Chemical	D011433
.	O	O

Alternating	B-Disease	D001146
sinus	I-Disease	D001146
rhythm	I-Disease	D001146
and	O	O
intermittent	O	O
sinoatrial	B-Disease	D012848
(	I-Disease	D012848
S	I-Disease	D012848
-	I-Disease	D012848
A	I-Disease	D012848
)	I-Disease	D012848
block	I-Disease	D012848
was	O	O
observed	O	O
in	O	O
a	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
,	O	O
under	O	O
treatment	O	O
for	O	O
angina	B-Disease	D000787
with	O	O
80	O	O
mg	O	O
propranolol	B-Chemical	D011433
daily	O	O
.	O	O

The	O	O
electrocardiogram	O	O
showed	O	O
alternation	O	O
of	O	O
long	O	O
and	O	O
short	O	O
P	O	O
-	O	O
P	O	O
intervals	O	O
and	O	O
occasional	O	O
pauses	O	O
.	O	O

These	O	O
pauses	O	O
were	O	O
always	O	O
preceded	O	O
by	O	O
the	O	O
short	O	O
P	O	O
-	O	O
P	O	O
intervals	O	O
and	O	O
were	O	O
usually	O	O
followed	O	O
by	O	O
one	O	O
or	O	O
two	O	O
P	O	O
-	O	O
P	O	O
intervals	O	O
of	O	O
0	O	O
.	O	O

92	O	O
-	O	O
0	O	O
.	O	O

95	O	O
s	O	O
representing	O	O
the	O	O
basic	O	O
sinus	O	O
cycle	O	O
.	O	O

Following	O	O
these	O	O
basic	O	O
sinus	O	O
cycles	O	O
,	O	O
alternating	B-Disease	D001146
rhythm	I-Disease	D001146
started	O	O
with	O	O
the	O	O
longer	O	O
P	O	O
-	O	O
P	O	O
interval	O	O
.	O	O

The	O	O
long	O	O
P	O	O
-	O	O
P	O	O
intervals	O	O
ranged	O	O
between	O	O
1	O	O
.	O	O

04	O	O
-	O	O
1	O	O
.	O	O

12	O	O
s	O	O
and	O	O
the	O	O
short	O	O
P	O	O
-	O	O
P	O	O
intervals	O	O
between	O	O
0	O	O
.	O	O

80	O	O
-	O	O
0	O	O
.	O	O

84	O	O
s	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
duration	O	O
of	O	O
the	O	O
pauses	O	O
were	O	O
equal	O	O
or	O	O
almost	O	O
equal	O	O
to	O	O
one	O	O
short	O	O
plus	O	O
one	O	O
long	O	O
P	O	O
-	O	O
P	O	O
interval	O	O
or	O	O
to	O	O
twice	O	O
the	O	O
basic	O	O
sinus	O	O
cycle	O	O
.	O	O

In	O	O
one	O	O
recording	O	O
a	O	O
short	O	O
period	O	O
of	O	O
regular	O	O
sinus	O	O
rhythm	O	O
with	O	O
intermittent	O	O
2	O	O
/	O	O
1	O	O
S	B-Disease	D012848
-	I-Disease	D012848
A	I-Disease	D012848
block	I-Disease	D012848
was	O	O
observed	O	O
.	O	O

This	O	O
short	O	O
period	O	O
of	O	O
sinus	O	O
rhythm	O	O
was	O	O
interrupted	O	O
by	O	O
sudden	O	O
prolongation	O	O
of	O	O
the	O	O
P	O	O
-	O	O
P	O	O
interval	O	O
starting	O	O
the	O	O
alternative	O	O
rhythm	O	O
.	O	O

There	O	O
were	O	O
small	O	O
changes	O	O
in	O	O
the	O	O
shape	O	O
of	O	O
the	O	O
P	O	O
waves	O	O
and	O	O
P	O	O
-	O	O
R	O	O
intervals	O	O
.	O	O

S	O	O
-	O	O
A	O	O
conduction	O	O
through	O	O
two	O	O
pathways	O	O
,	O	O
the	O	O
first	O	O
with	O	O
2	O	O
/	O	O
1	O	O
block	O	O
the	O	O
second	O	O
having	O	O
0	O	O
.	O	O

12	O	O
-	O	O
0	O	O
.	O	O

14	O	O
s	O	O
longer	O	O
conduction	O	O
time	O	O
and	O	O
with	O	O
occasional	O	O
2	O	O
/	O	O
1	O	O
block	O	O
was	O	O
proposed	O	O
for	O	O
the	O	O
explanation	O	O
of	O	O
the	O	O
alternating	O	O
P	O	O
-	O	O
P	O	O
interval	O	O
and	O	O
other	O	O
electrocardiographic	O	O
features	O	O
seen	O	O
.	O	O

Atropine	B-Chemical	D001285
1	O	O
mg	O	O
given	O	O
intravenously	O	O
resulted	O	O
in	O	O
shortening	O	O
of	O	O
all	O	O
P	O	O
-	O	O
P	O	O
intervals	O	O
without	O	O
changing	O	O
the	O	O
rhythm	O	O
.	O	O

The	O	O
abnormal	O	O
rhythm	O	O
disappeared	O	O
with	O	O
the	O	O
withdrawal	O	O
of	O	O
propranolol	B-Chemical	D011433
and	O	O
when	O	O
the	O	O
drug	O	O
was	O	O
restarted	O	O
a	O	O
2	O	O
/	O	O
1	O	O
S	B-Disease	D012848
-	I-Disease	D012848
A	I-Disease	D012848
block	I-Disease	D012848
was	O	O
seen	O	O
.	O	O

This	O	O
was	O	O
accepted	O	O
as	O	O
evidence	O	O
for	O	O
propranolol	B-Chemical	D011433
being	O	O
the	O	O
cause	O	O
of	O	O
this	O	O
conduction	B-Disease	D019955
disorder	I-Disease	D019955
.	O	O

Antitumor	O	O
effect	O	O
,	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
and	O	O
nephrotoxicity	B-Disease	D007674
of	O	O
doxorubicin	B-Chemical	D004317
in	O	O
the	O	O
IgM	O	O
solid	O	O
immunocytoma	B-Disease	-1
-	O	O
bearing	O	O
LOU	O	O
/	O	O
M	O	O
/	O	O
WSL	O	O
rat	O	O
.	O	O

Antitumor	O	O
activity	O	O
,	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
and	O	O
nephrotoxicity	B-Disease	D007674
induced	O	O
by	O	O
doxorubicin	B-Chemical	D004317
were	O	O
studied	O	O
in	O	O
LOU	O	O
/	O	O
M	O	O
/	O	O
WSL	O	O
inbred	O	O
rats	O	O
each	O	O
bearing	O	O
a	O	O
transplantable	O	O
solid	O	O
IgM	O	O
immunocytoma	B-Disease	-1
.	O	O

Animals	O	O
with	O	O
a	O	O
tumor	B-Disease	D009369
(	O	O
diameter	O	O
,	O	O
15	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

3	O	O
mm	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
iv	O	O
injections	O	O
of	O	O
doxorubicin	B-Chemical	D004317
on	O	O
5	O	O
consecutive	O	O
days	O	O
,	O	O
followed	O	O
by	O	O
1	O	O
weekly	O	O
injection	O	O
for	O	O
7	O	O
weeks	O	O
(	O	O
dose	O	O
range	O	O
,	O	O
0	O	O
.	O	O

015	O	O
-	O	O
4	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
)	O	O
.	O	O

Tumor	B-Disease	D009369
regression	O	O
was	O	O
observed	O	O
with	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
doxorubicin	B-Chemical	D004317
/	O	O
kg	O	O
.	O	O

Complete	O	O
disappearance	O	O
of	O	O
the	O	O
tumor	B-Disease	D009369
was	O	O
induced	O	O
with	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
doxorubicin	B-Chemical	D004317
/	O	O
kg	O	O
.	O	O

Histologic	O	O
evidence	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
scored	O	O
as	O	O
grade	O	O
III	O	O
was	O	O
only	O	O
observed	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
doxorubicin	B-Chemical	D004317
/	O	O
kg	O	O
.	O	O

Light	O	O
microscopic	O	O
evidence	O	O
of	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
was	O	O
seen	O	O
above	O	O
a	O	O
dose	O	O
of	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
doxorubicin	B-Chemical	D004317
/	O	O
kg	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
albuminuria	B-Disease	D000419
and	O	O
very	O	O
low	O	O
serum	O	O
albumin	O	O
levels	O	O
.	O	O

In	O	O
the	O	O
group	O	O
that	O	O
received	O	O
1	O	O
.	O	O

0	O	O
mg	O	O
doxorubicin	B-Chemical	D004317
/	O	O
kg	O	O
,	O	O
the	O	O
serum	O	O
albumin	O	O
level	O	O
decreased	O	O
from	O	O
33	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

1	O	O
to	O	O
1	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
g	O	O
/	O	O
liter	O	O
.	O	O

Ascites	B-Disease	D001201
and	O	O
hydrothorax	B-Disease	D006876
were	O	O
observed	O	O
simultaneously	O	O
.	O	O

The	O	O
same	O	O
experiments	O	O
were	O	O
performed	O	O
with	O	O
non	O	O
-	O	O
tumor	B-Disease	D009369
-	O	O
bearing	O	O
rats	O	O
,	O	O
in	O	O
which	O	O
no	O	O
major	O	O
differences	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
antitumor	O	O
activity	O	O
,	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
and	O	O
nephrotoxicity	B-Disease	D007674
were	O	O
studied	O	O
simultaneously	O	O
in	O	O
the	O	O
same	O	O
LOU	O	O
/	O	O
M	O	O
/	O	O
WSL	O	O
rat	O	O
.	O	O

Albuminuria	B-Disease	D000419
due	O	O
to	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
led	O	O
to	O	O
extremely	O	O
low	O	O
serum	O	O
albumin	O	O
levels	O	O
,	O	O
so	O	O
ascites	B-Disease	D001201
and	O	O
hydrothorax	B-Disease	D006876
were	O	O
not	O	O
necessarily	O	O
a	O	O
consequence	O	O
of	O	O
the	O	O
observed	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

Intraoperative	O	O
bradycardia	B-Disease	D001919
and	O	O
hypotension	B-Disease	D007022
associated	O	O
with	O	O
timolol	B-Chemical	D013999
and	O	O
pilocarpine	B-Chemical	D010862
eye	O	O
drops	O	O
.	O	O

A	O	O
69	O	O
-	O	O
yr	O	O
-	O	O
old	O	O
man	O	O
,	O	O
who	O	O
was	O	O
concurrently	O	O
being	O	O
treated	O	O
with	O	O
pilocarpine	B-Chemical	D010862
nitrate	O	O
and	O	O
timolol	B-Chemical	D013999
maleate	O	O
eye	O	O
drops	O	O
,	O	O
developed	O	O
a	O	O
bradycardia	B-Disease	D001919
and	O	O
became	O	O
hypotensive	B-Disease	D007022
during	O	O
halothane	B-Chemical	D006221
anaesthesia	O	O
.	O	O

Both	O	O
timolol	B-Chemical	D013999
and	O	O
pilocarpine	B-Chemical	D010862
were	O	O
subsequently	O	O
identified	O	O
in	O	O
a	O	O
24	O	O
-	O	O
h	O	O
collection	O	O
of	O	O
urine	O	O
.	O	O

Timolol	B-Chemical	D013999
(	O	O
but	O	O
not	O	O
pilocarpine	B-Chemical	D010862
)	O	O
was	O	O
detected	O	O
in	O	O
a	O	O
sample	O	O
of	O	O
plasma	O	O
removed	O	O
during	O	O
surgery	O	O
;	O	O
the	O	O
plasma	O	O
concentration	O	O
of	O	O
timolol	B-Chemical	D013999
(	O	O
2	O	O
.	O	O

6	O	O
ng	O	O
ml	O	O
-	O	O
1	O	O
)	O	O
was	O	O
consistent	O	O
with	O	O
partial	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
blockade	O	O
.	O	O

It	O	O
is	O	O
postulated	O	O
that	O	O
this	O	O
action	O	O
may	O	O
have	O	O
been	O	O
enhanced	O	O
during	O	O
halothane	B-Chemical	D006221
anaesthesia	O	O
with	O	O
resultant	O	O
bradycardia	B-Disease	D001919
and	O	O
hypotension	B-Disease	D007022
.	O	O

Pilocarpine	B-Chemical	D010862
may	O	O
have	O	O
had	O	O
a	O	O
contributory	O	O
effect	O	O
.	O	O

Succinylcholine	B-Chemical	D013390
apnoea	B-Disease	D001049
:	O	O
attempted	O	O
reversal	O	O
with	O	O
anticholinesterases	O	O
.	O	O

Anticholinesterases	O	O
were	O	O
administered	O	O
in	O	O
an	O	O
attempt	O	O
to	O	O
antagonize	O	O
prolonged	O	O
neuromuscular	B-Disease	D020879
blockade	I-Disease	D020879
following	O	O
the	O	O
administration	O	O
of	O	O
succinylcholine	B-Chemical	D013390
in	O	O
a	O	O
patient	O	O
later	O	O
found	O	O
to	O	O
be	O	O
homozygous	O	O
for	O	O
atypical	O	O
plasma	O	O
cholinesterase	O	O
.	O	O

Edrophonium	B-Chemical	D004491
10	O	O
mg	O	O
,	O	O
given	O	O
74	O	O
min	O	O
after	O	O
succinylcholine	B-Chemical	D013390
,	O	O
when	O	O
train	O	O
-	O	O
of	O	O
-	O	O
four	O	O
stimulation	O	O
was	O	O
characteristic	O	O
of	O	O
phase	O	O
II	O	O
block	O	O
,	O	O
produced	O	O
partial	O	O
antagonism	O	O
which	O	O
was	O	O
not	O	O
sustained	O	O
.	O	O

Repeated	O	O
doses	O	O
of	O	O
edrophonium	B-Chemical	D004491
to	O	O
70	O	O
mg	O	O
and	O	O
neostigmine	B-Chemical	D009388
to	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
did	O	O
not	O	O
antagonize	O	O
or	O	O
augment	O	O
the	O	O
block	O	O
.	O	O

Spontaneous	O	O
respiration	O	O
recommenced	O	O
200	O	O
min	O	O
after	O	O
succinylcholine	B-Chemical	D013390
administration	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
anticholinesterases	O	O
are	O	O
only	O	O
partially	O	O
effective	O	O
in	O	O
restoring	O	O
neuromuscular	O	O
function	O	O
in	O	O
succinylcholine	B-Chemical	D013390
apnoea	B-Disease	D001049
despite	O	O
muscle	O	O
twitch	O	O
activity	O	O
typical	O	O
of	O	O
phase	O	O
II	O	O
block	O	O
.	O	O

Effect	O	O
of	O	O
doxorubicin	B-Chemical	D004317
on	O	O
[	B-Chemical	C013102
omega	I-Chemical	C013102
-	I-Chemical	C013102
I	I-Chemical	C013102
-	I-Chemical	C013102
131	I-Chemical	C013102
]	I-Chemical	C013102
heptadecanoic	I-Chemical	C013102
acid	I-Chemical	C013102
myocardial	O	O
scintigraphy	O	O
and	O	O
echocardiography	O	O
in	O	O
dogs	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
serial	O	O
treatment	O	O
with	O	O
doxorubicin	B-Chemical	D004317
on	O	O
dynamic	O	O
myocardial	O	O
scintigraphy	O	O
with	O	O
[	B-Chemical	C013102
omega	I-Chemical	C013102
-	I-Chemical	C013102
I	I-Chemical	C013102
-	I-Chemical	C013102
131	I-Chemical	C013102
]	I-Chemical	C013102
heptadecanoic	I-Chemical	C013102
acid	I-Chemical	C013102
(	O	O
I	B-Chemical	C013102
-	I-Chemical	C013102
131	I-Chemical	C013102
HA	I-Chemical	C013102
)	O	O
,	O	O
and	O	O
on	O	O
global	O	O
left	O	O
-	O	O
ventricular	O	O
function	O	O
determined	O	O
echocardiographically	O	O
,	O	O
were	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
nine	O	O
mongrel	O	O
dogs	O	O
.	O	O

Total	O	O
extractable	O	O
myocardial	O	O
lipid	O	O
was	O	O
compared	O	O
postmortem	O	O
between	O	O
a	O	O
group	O	O
of	O	O
control	O	O
dogs	O	O
and	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
dogs	O	O
.	O	O

A	O	O
significant	O	O
and	O	O
then	O	O
progressive	O	O
fall	O	O
in	O	O
global	O	O
LV	O	O
function	O	O
was	O	O
observed	O	O
at	O	O
a	O	O
cumulative	O	O
doxorubicin	B-Chemical	D004317
dose	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

A	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
myocardial	O	O
t1	O	O
/	O	O
2	O	O
of	O	O
the	O	O
I	B-Chemical	C013102
-	I-Chemical	C013102
131	I-Chemical	C013102
HA	I-Chemical	C013102
was	O	O
observed	O	O
only	O	O
at	O	O
a	O	O
higher	O	O
cumulative	O	O
dose	O	O
,	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

No	O	O
significant	O	O
alteration	O	O
in	O	O
total	O	O
extractable	O	O
myocardial	O	O
lipids	O	O
was	O	O
observed	O	O
between	O	O
control	O	O
dogs	O	O
and	O	O
those	O	O
treated	O	O
with	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
the	O	O
changes	O	O
leading	O	O
to	O	O
an	O	O
alteration	O	O
of	O	O
myocardial	O	O
dynamic	O	O
imaging	O	O
with	O	O
I	B-Chemical	C013102
-	I-Chemical	C013102
131	I-Chemical	C013102
HA	I-Chemical	C013102
are	O	O
not	O	O
the	O	O
initiating	O	O
factor	O	O
in	O	O
doxorubicin	B-Chemical	D004317
cardiotoxicity	B-Disease	D066126
.	O	O

Hemodynamics	O	O
and	O	O
myocardial	O	O
metabolism	O	O
under	O	O
deliberate	O	O
hypotension	B-Disease	D007022
.	O	O

An	O	O
experimental	O	O
study	O	O
in	O	O
dogs	O	O
.	O	O

Coronary	O	O
blood	O	O
flow	O	O
,	O	O
cardiac	O	O
work	O	O
and	O	O
metabolism	O	O
were	O	O
studied	O	O
in	O	O
dogs	O	O
under	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
(	O	O
SNP	B-Chemical	D009599
)	O	O
and	O	O
trimetaphan	B-Chemical	D014294
(	O	O
TMP	B-Chemical	D014294
)	O	O
deliberate	O	O
hypotension	B-Disease	D007022
(	O	O
20%	O	O
and	O	O
40%	O	O
mean	O	O
pressure	O	O
decrease	O	O
from	O	O
baseline	O	O
)	O	O
.	O	O

Regarding	O	O
the	O	O
effects	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
on	O	O
coronary	O	O
blood	O	O
flow	O	O
,	O	O
aortic	O	O
and	O	O
coronary	O	O
sinus	O	O
metabolic	O	O
data	O	O
(	O	O
pH	O	O
,	O	O
pO2	O	O
,	O	O
pCO2	O	O
)	O	O
we	O	O
could	O	O
confirm	O	O
that	O	O
nitroprusside	B-Chemical	D009599
hypotension	B-Disease	D007022
could	O	O
be	O	O
safely	O	O
used	O	O
to	O	O
30%	O	O
mean	O	O
blood	O	O
pressure	O	O
decrease	O	O
from	O	O
control	O	O
,	O	O
trimetaphan	B-Chemical	D014294
hypotension	B-Disease	D007022
to	O	O
20%	O	O
mean	O	O
blood	O	O
pressure	O	O
decrease	O	O
.	O	O

Cardiac	O	O
work	O	O
was	O	O
significantly	O	O
reduced	O	O
during	O	O
SNP	B-Chemical	D009599
hypotension	B-Disease	D007022
.	O	O

Myocardial	O	O
O2	B-Chemical	D010100
consumption	O	O
and	O	O
O2	B-Chemical	D010100
availability	O	O
were	O	O
directly	O	O
dependent	O	O
on	O	O
the	O	O
coronary	O	O
perfusion	O	O
.	O	O

Careful	O	O
invasive	O	O
monitoring	O	O
of	O	O
the	O	O
blood	O	O
pressure	O	O
,	O	O
blood	O	O
gases	O	O
and	O	O
of	O	O
the	O	O
ECG	O	O
ST	O	O
-	O	O
T	O	O
segment	O	O
is	O	O
mandatory	O	O
.	O	O

Evidence	O	O
for	O	O
a	O	O
selective	O	O
brain	O	O
noradrenergic	O	O
involvement	O	O
in	O	O
the	O	O
locomotor	O	O
stimulant	O	O
effects	O	O
of	O	O
amphetamine	B-Chemical	D000661
in	O	O
the	O	O
rat	O	O
.	O	O

Male	O	O
rats	O	O
received	O	O
the	O	O
noradrenaline	B-Chemical	D009638
neurotoxin	O	O
DSP4	B-Chemical	C012102
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
7	O	O
days	O	O
prior	O	O
to	O	O
injection	O	O
of	O	O
D	B-Chemical	D003913
-	I-Chemical	D003913
amphetamine	I-Chemical	D003913
(	O	O
10	O	O
or	O	O
40	O	O
mumol	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

The	O	O
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
D	B-Chemical	D003913
-	I-Chemical	D003913
amphetamine	I-Chemical	D003913
(	O	O
10	O	O
mumol	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
significantly	O	O
reduced	O	O
by	O	O
DSP4	B-Chemical	C012102
pretreatment	O	O
.	O	O

However	O	O
,	O	O
the	O	O
increased	O	O
rearings	O	O
and	O	O
the	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
stereotypies	B-Disease	D019956
were	O	O
not	O	O
blocked	O	O
by	O	O
pretreatment	O	O
with	O	O
DSP4	B-Chemical	C012102
.	O	O

The	O	O
reduction	O	O
of	O	O
amphetamine	B-Chemical	D000661
hyperactivity	B-Disease	D006948
induced	O	O
by	O	O
DSP4	B-Chemical	C012102
was	O	O
blocked	O	O
by	O	O
pretreatment	O	O
with	O	O
the	O	O
noradrenaline	B-Chemical	D009638
-	O	O
uptake	O	O
blocking	O	O
agent	O	O
,	O	O
desipramine	B-Chemical	D003891
,	O	O
which	O	O
prevents	O	O
the	O	O
neurotoxic	B-Disease	D020258
action	O	O
of	O	O
DSP4	B-Chemical	C012102
.	O	O

The	O	O
present	O	O
results	O	O
suggest	O	O
a	O	O
selective	O	O
involvement	O	O
of	O	O
central	O	O
noradrenergic	O	O
neurones	O	O
in	O	O
the	O	O
locomotor	O	O
stimulant	O	O
effect	O	O
of	O	O
amphetamine	B-Chemical	D000661
in	O	O
the	O	O
rat	O	O
.	O	O

Accelerated	B-Disease	D001145
junctional	I-Disease	D001145
rhythms	I-Disease	D001145
during	O	O
oral	O	O
verapamil	B-Chemical	D014700
therapy	O	O
.	O	O

This	O	O
study	O	O
examined	O	O
the	O	O
frequency	O	O
of	O	O
atrioventricular	O	O
(	O	O
AV	O	O
)	O	O
dissociation	O	O
and	O	O
accelerated	B-Disease	D001145
junctional	I-Disease	D001145
rhythms	I-Disease	D001145
in	O	O
59	O	O
patients	O	O
receiving	O	O
oral	O	O
verapamil	B-Chemical	D014700
.	O	O

Accelerated	B-Disease	D001145
junctional	I-Disease	D001145
rhythms	I-Disease	D001145
and	O	O
AV	O	O
dissociation	O	O
were	O	O
frequent	O	O
in	O	O
patients	O	O
with	O	O
supraventricular	B-Disease	D013617
tachyarrhythmias	I-Disease	D013617
,	O	O
particularly	O	O
AV	O	O
nodal	O	O
reentry	O	O
.	O	O

Verapamil	B-Chemical	D014700
administration	O	O
to	O	O
these	O	O
patients	O	O
led	O	O
to	O	O
an	O	O
asymptomatic	O	O
increase	O	O
in	O	O
activity	O	O
of	O	O
these	O	O
junctional	O	O
pacemakers	O	O
.	O	O

In	O	O
patients	O	O
with	O	O
various	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
syndromes	O	O
,	O	O
verapamil	B-Chemical	D014700
neither	O	O
increased	O	O
the	O	O
frequency	O	O
of	O	O
junctional	O	O
rhythms	O	O
nor	O	O
suppressed	O	O
their	O	O
role	O	O
as	O	O
escape	O	O
rhythms	O	O
under	O	O
physiologically	O	O
appropriate	O	O
circumstances	O	O
.	O	O

Treatment	O	O
of	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
with	O	O
a	O	O
combination	O	O
of	O	O
cis	B-Chemical	D002945
-	I-Chemical	D002945
platinum	I-Chemical	D002945
,	O	O
adriamycin	B-Chemical	D004317
,	O	O
cyclophosphamide	B-Chemical	D003520
and	O	O
hexamethylmelamine	B-Chemical	D006585
.	O	O

During	O	O
the	O	O
last	O	O
2	O	O
1	O	O
/	O	O
2	O	O
years	O	O
,	O	O
38	O	O
patients	O	O
with	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
were	O	O
treated	O	O
with	O	O
a	O	O
combination	O	O
of	O	O
cisplatinum	B-Chemical	D002945
(	O	O
CPDD	B-Chemical	C034868
)	O	O
,	O	O
50	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
adriamycin	B-Chemical	D004317
,	O	O
30	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
cyclophosphamide	B-Chemical	D003520
,	O	O
300	O	O
mg	O	O
/	O	O
m2	O	O
,	O	O
on	O	O
day	O	O
1	O	O
;	O	O
and	O	O
hexamethylmelamine	B-Chemical	D006585
(	O	O
HMM	B-Chemical	D006585
)	O	O
,	O	O
6	O	O
mg	O	O
/	O	O
kg	O	O
daily	O	O
,	O	O
for	O	O
14	O	O
days	O	O
.	O	O

Each	O	O
course	O	O
was	O	O
repeated	O	O
monthly	O	O
.	O	O

2	O	O
patients	O	O
had	O	O
stage	O	O
II	O	O
,	O	O
14	O	O
stage	O	O
III	O	O
and	O	O
22	O	O
stage	O	O
IV	O	O
disease	O	O
.	O	O

14	O	O
of	O	O
the	O	O
38	O	O
patients	O	O
were	O	O
previously	O	O
treated	O	O
with	O	O
chemotherapy	O	O
,	O	O
1	O	O
with	O	O
radiation	O	O
,	O	O
6	O	O
with	O	O
both	O	O
chemotherapy	O	O
and	O	O
radiation	O	O
,	O	O
and	O	O
17	O	O
did	O	O
not	O	O
have	O	O
any	O	O
treatment	O	O
before	O	O
CPDD	B-Chemical	C034868
combination	O	O
.	O	O

31	O	O
of	O	O
the	O	O
38	O	O
cases	O	O
(	O	O
81	O	O
.	O	O

5%	O	O
)	O	O
demonstrated	O	O
objective	O	O
responses	O	O
lasting	O	O
for	O	O
2	O	O
months	O	O
or	O	O
more	O	O
.	O	O

These	O	O
responses	O	O
were	O	O
partial	O	O
in	O	O
19	O	O
and	O	O
complete	O	O
in	O	O
12	O	O
cases	O	O
.	O	O

Hematologic	B-Disease	D006402
toxicity	I-Disease	D006402
was	O	O
moderate	O	O
and	O	O
with	O	O
reversible	O	O
anemia	B-Disease	D000740
developing	O	O
in	O	O
71%	O	O
of	O	O
patients	O	O
.	O	O

Gastrointestinal	O	O
side	O	O
effects	O	O
from	O	O
CPDD	B-Chemical	C034868
were	O	O
universal	O	O
.	O	O

HMM	B-Chemical	D006585
gastrointestinal	B-Disease	D005767
toxicity	I-Disease	D005767
necessitated	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
in	O	O
5	O	O
patients	O	O
.	O	O

Severe	O	O
nephrotoxicity	B-Disease	D007674
was	O	O
observed	O	O
in	O	O
2	O	O
patients	O	O
but	O	O
was	O	O
reversible	O	O
.	O	O

There	O	O
were	O	O
no	O	O
drug	O	O
-	O	O
related	O	O
deaths	O	O
.	O	O

Nontraumatic	O	O
dissecting	B-Disease	D000784
aneurysm	I-Disease	D000784
of	O	O
the	O	O
basilar	O	O
artery	O	O
.	O	O

A	O	O
case	O	O
of	O	O
nontraumatic	O	O
dissecting	B-Disease	D000784
aneurysm	I-Disease	D000784
of	O	O
the	O	O
basilar	O	O
artery	O	O
in	O	O
association	O	O
with	O	O
hypertension	B-Disease	D006973
,	O	O
smoke	O	O
,	O	O
and	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
is	O	O
reported	O	O
in	O	O
a	O	O
young	O	O
female	O	O
patient	O	O
with	O	O
a	O	O
locked	B-Disease	D011782
-	I-Disease	D011782
in	I-Disease	D011782
syndrome	I-Disease	D011782
.	O	O

Propylthiouracil	B-Chemical	D011441
-	O	O
induced	O	O
hepatic	B-Disease	D056486
damage	I-Disease	D056486
.	O	O

Two	O	O
cases	O	O
of	O	O
propylthiouracil	B-Chemical	D011441
-	O	O
induced	O	O
liver	B-Disease	D056486
damage	I-Disease	D056486
have	O	O
been	O	O
observed	O	O
.	O	O

The	O	O
first	O	O
case	O	O
is	O	O
of	O	O
an	O	O
acute	O	O
type	O	O
of	O	O
damage	O	O
,	O	O
proven	O	O
by	O	O
rechallenge	O	O
;	O	O
the	O	O
second	O	O
presents	O	O
a	O	O
clinical	O	O
and	O	O
histologic	O	O
picture	O	O
resembling	O	O
chronic	B-Disease	D006521
active	I-Disease	D006521
hepatitis	I-Disease	D006521
,	O	O
with	O	O
spontaneous	O	O
remission	O	O
.	O	O

Studies	O	O
on	O	O
the	O	O
bradycardia	B-Disease	D001919
induced	O	O
by	O	O
bepridil	B-Chemical	D015764
.	O	O

Bepridil	B-Chemical	D015764
,	O	O
a	O	O
novel	O	O
active	O	O
compound	O	O
for	O	O
prophylactic	O	O
treatment	O	O
of	O	O
anginal	B-Disease	D000787
attacks	I-Disease	D000787
,	O	O
induced	O	O
persistent	O	O
bradycardia	B-Disease	D001919
and	O	O
a	O	O
non	O	O
-	O	O
specific	O	O
anti	O	O
-	O	O
tachycardial	B-Disease	D013610
effect	O	O
,	O	O
the	O	O
mechanisms	O	O
of	O	O
which	O	O
were	O	O
investigated	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

In	O	O
vitro	O	O
perfusion	O	O
of	O	O
bepridil	B-Chemical	D015764
in	O	O
the	O	O
life	O	O
-	O	O
support	O	O
medium	O	O
for	O	O
isolated	O	O
sino	O	O
-	O	O
atrial	O	O
tissue	O	O
from	O	O
rabbit	O	O
heart	O	O
,	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
action	O	O
potential	O	O
(	O	O
AP	O	O
)	O	O
spike	O	O
frequency	O	O
(	O	O
recorded	O	O
by	O	O
KCl	B-Chemical	D011189
microelectrodes	O	O
)	O	O
starting	O	O
at	O	O
doses	O	O
of	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	O
.	O	O

This	O	O
effect	O	O
was	O	O
dose	O	O
-	O	O
dependent	O	O
up	O	O
to	O	O
concentrations	O	O
of	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
M	O	O
,	O	O
whereupon	O	O
blockade	O	O
of	O	O
sinus	O	O
activity	O	O
set	O	O
in	O	O
.	O	O

Bepridil	B-Chemical	D015764
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
X	O	O
10	O	O
(	O	O
-	O	O
6	O	O
)	O	O
M	O	O
,	O	O
induced	O	O
a	O	O
concomitant	O	O
reduction	O	O
in	O	O
AP	O	O
amplitude	O	O
(	O	O
falling	O	O
from	O	O
71	O	O
+	O	O
/	O	O
-	O	O
8	O	O
mV	O	O
to	O	O
47	O	O
+	O	O
/	O	O
-	O	O
6	O	O
mV	O	O
)	O	O
,	O	O
maximum	O	O
systolic	O	O
depolarization	O	O
velocity	O	O
(	O	O
phase	O	O
0	O	O
)	O	O
which	O	O
fell	O	O
from	O	O
1	O	O
.	O	O

85	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

35	O	O
V	O	O
/	O	O
s	O	O
to	O	O
0	O	O
.	O	O

84	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

28	O	O
V	O	O
/	O	O
s	O	O
,	O	O
together	O	O
with	O	O
maximum	O	O
diastolic	O	O
depolarization	O	O
velocity	O	O
(	O	O
phase	O	O
4	O	O
)	O	O
which	O	O
fell	O	O
from	O	O
38	O	O
+	O	O
/	O	O
-	O	O
3	O	O
mV	O	O
/	O	O
s	O	O
to	O	O
24	O	O
+	O	O
/	O	O
-	O	O
5	O	O
mV	O	O
/	O	O
s	O	O
.	O	O

In	O	O
vivo	O	O
injection	O	O
of	O	O
bepridil	B-Chemical	D015764
at	O	O
a	O	O
dose	O	O
of	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
(	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
into	O	O
6	O	O
anaesthetized	O	O
dogs	O	O
which	O	O
had	O	O
undergone	O	O
ablation	O	O
of	O	O
all	O	O
the	O	O
extrinsic	O	O
cardiac	O	O
afferent	O	O
nerve	O	O
supply	O	O
,	O	O
together	O	O
with	O	O
a	O	O
bilateral	O	O
medullo	O	O
-	O	O
adrenalectomy	O	O
,	O	O
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
heart	O	O
rate	O	O
which	O	O
fell	O	O
from	O	O
98	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

2	O	O
beats	O	O
/	O	O
min	O	O
to	O	O
76	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

3	O	O
beats	O	O
/	O	O
min	O	O
sustained	O	O
for	O	O
more	O	O
than	O	O
45	O	O
min	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
bepridil	B-Chemical	D015764
reduces	O	O
heart	O	O
rate	O	O
by	O	O
acting	O	O
directly	O	O
on	O	O
the	O	O
sinus	O	O
node	O	O
.	O	O

This	O	O
effect	O	O
,	O	O
which	O	O
results	O	O
in	O	O
a	O	O
flattening	O	O
of	O	O
the	O	O
phase	O	O
0	O	O
and	O	O
phase	O	O
4	O	O
slope	O	O
,	O	O
together	O	O
with	O	O
a	O	O
longer	O	O
AP	O	O
duration	O	O
,	O	O
may	O	O
be	O	O
due	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
time	O	O
constants	O	O
of	O	O
slow	O	O
inward	O	O
ionic	O	O
currents	O	O
(	O	O
already	O	O
demonstrated	O	O
elsewhere	O	O
)	O	O
,	O	O
but	O	O
also	O	O
to	O	O
an	O	O
increased	O	O
time	O	O
constant	O	O
for	O	O
deactivation	O	O
of	O	O
the	O	O
outward	O	O
potassium	B-Chemical	D011188
current	O	O
(	O	O
Ip	O	O
)	O	O
.	O	O

Hepatitis	B-Disease	D056486
and	O	O
renal	B-Disease	D000141
tubular	I-Disease	D000141
acidosis	I-Disease	D000141
after	O	O
anesthesia	O	O
with	O	O
methoxyflurane	B-Chemical	D008733
.	O	O

A	O	O
69	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
operated	O	O
for	O	O
acute	B-Disease	D041881
cholecystitis	I-Disease	D041881
under	O	O
methoxyflurane	B-Chemical	D008733
anesthesia	O	O
developed	O	O
postoperatively	O	O
a	O	O
hepatic	B-Disease	D048550
insufficiency	I-Disease	D048550
syndrome	I-Disease	D048550
and	O	O
renal	B-Disease	D000141
tubular	I-Disease	D000141
acidosis	I-Disease	D000141
.	O	O

Massive	O	O
bleeding	B-Disease	D006470
appeared	O	O
during	O	O
surgery	O	O
which	O	O
lasted	O	O
for	O	O
six	O	O
hours	O	O
.	O	O

Postoperative	O	O
evolution	O	O
under	O	O
supportive	O	O
therapy	O	O
was	O	O
favourable	O	O
.	O	O

Complete	O	O
recovery	O	O
was	O	O
confirmed	O	O
by	O	O
repeated	O	O
controls	O	O
performed	O	O
over	O	O
a	O	O
period	O	O
of	O	O
one	O	O
year	O	O
after	O	O
surgery	O	O
.	O	O

Pituitary	O	O
response	O	O
to	O	O
luteinizing	O	O
hormone	O	O
-	O	O
releasing	O	O
hormone	O	O
during	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

The	O	O
effects	O	O
of	O	O
a	O	O
6	O	O
-	O	O
hour	O	O
infusion	O	O
with	O	O
haloperidol	B-Chemical	D006220
on	O	O
serum	O	O
prolactin	O	O
and	O	O
luteinizing	O	O
hormone	O	O
(	O	O
LH	O	O
)	O	O
levels	O	O
was	O	O
studied	O	O
in	O	O
a	O	O
group	O	O
of	O	O
male	O	O
subjects	O	O
.	O	O

Five	O	O
hours	O	O
after	O	O
starting	O	O
the	O	O
infusions	O	O
,	O	O
a	O	O
study	O	O
of	O	O
the	O	O
pituitary	O	O
responses	O	O
to	O	O
LH	O	O
-	O	O
releasing	O	O
hormone	O	O
(	O	O
LH	O	O
-	O	O
RH	O	O
)	O	O
was	O	O
carried	O	O
out	O	O
.	O	O

Control	O	O
patients	O	O
received	O	O
infusions	O	O
of	O	O
0	O	O
.	O	O

9%	O	O
NaCl	B-Chemical	D012965
solution	O	O
.	O	O

During	O	O
the	O	O
course	O	O
of	O	O
haloperidol	B-Chemical	D006220
infusions	O	O
,	O	O
significant	O	O
hyperprolactinemia	B-Disease	D006966
was	O	O
found	O	O
,	O	O
together	O	O
with	O	O
an	O	O
abolished	O	O
pituitary	O	O
response	O	O
to	O	O
LH	O	O
-	O	O
RH	O	O
,	O	O
as	O	O
compared	O	O
with	O	O
responses	O	O
of	O	O
control	O	O
subjects	O	O
.	O	O

Antirifampicin	O	O
antibodies	O	O
in	O	O
acute	O	O
rifampicin	B-Chemical	D012293
-	O	O
associated	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

5	O	O
patients	O	O
with	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
(	O	O
3	O	O
with	O	O
thrombopenia	B-Disease	D013921
and	O	O
hemolysis	B-Disease	D006461
)	O	O
induced	O	O
by	O	O
the	O	O
reintroduction	O	O
of	O	O
rifampicin	B-Chemical	D012293
are	O	O
described	O	O
.	O	O

No	O	O
correlation	O	O
was	O	O
found	O	O
between	O	O
the	O	O
severity	O	O
of	O	O
clinical	O	O
manifestations	O	O
and	O	O
the	O	O
total	O	O
dose	O	O
taken	O	O
by	O	O
the	O	O
patients	O	O
.	O	O

In	O	O
all	O	O
but	O	O
1	O	O
patient	O	O
,	O	O
antirifampicin	O	O
antibodies	O	O
were	O	O
detected	O	O
.	O	O

Antibodies	O	O
suggested	O	O
to	O	O
be	O	O
of	O	O
the	O	O
IgM	O	O
class	O	O
were	O	O
detected	O	O
in	O	O
all	O	O
3	O	O
patients	O	O
with	O	O
hematological	B-Disease	D006402
disorders	I-Disease	D006402
.	O	O

The	O	O
pattern	O	O
of	O	O
non	O	O
-	O	O
specific	O	O
acute	B-Disease	D007683
tubular	I-Disease	D007683
necrosis	I-Disease	D007683
found	O	O
in	O	O
the	O	O
2	O	O
biopsied	O	O
patients	O	O
,	O	O
indistinguishable	O	O
from	O	O
that	O	O
of	O	O
ischemic	O	O
origin	O	O
,	O	O
raised	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
vascular	O	O
-	O	O
mediated	O	O
damage	O	O
.	O	O

In	O	O
3	O	O
patients	O	O
,	O	O
the	O	O
possibility	O	O
of	O	O
a	O	O
triggering	O	O
immunoallergic	O	O
mechanism	O	O
is	O	O
discussed	O	O
.	O	O

Cardiovascular	O	O
effects	O	O
of	O	O
hypotension	B-Disease	D007022
induced	O	O
by	O	O
adenosine	B-Chemical	D000255
triphosphate	I-Chemical	D000255
and	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
on	O	O
dogs	O	O
with	O	O
denervated	O	O
hearts	O	O
.	O	O

Adenosine	B-Chemical	D000255
triphosphate	I-Chemical	D000255
(	O	O
ATP	B-Chemical	D000255
)	O	O
and	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
(	O	O
SNP	B-Chemical	D009599
)	O	O
are	O	O
administered	O	O
to	O	O
patients	O	O
to	O	O
induce	O	O
and	O	O
control	O	O
hypotension	B-Disease	D007022
during	O	O
anesthesia	O	O
.	O	O

SNP	B-Chemical	D009599
is	O	O
authorized	O	O
for	O	O
clinical	O	O
use	O	O
in	O	O
USA	O	O
and	O	O
UK	O	O
,	O	O
and	O	O
ATP	B-Chemical	D000255
is	O	O
clinically	O	O
used	O	O
in	O	O
other	O	O
countries	O	O
such	O	O
as	O	O
Japan	O	O
.	O	O

We	O	O
investigated	O	O
how	O	O
these	O	O
two	O	O
drugs	O	O
act	O	O
on	O	O
the	O	O
cardiovascular	O	O
systems	O	O
of	O	O
20	O	O
dogs	O	O
whose	O	O
hearts	O	O
had	O	O
been	O	O
denervated	O	O
by	O	O
a	O	O
procedure	O	O
we	O	O
had	O	O
devised	O	O
.	O	O

ATP	B-Chemical	D000255
(	O	O
10	O	O
dogs	O	O
)	O	O
or	O	O
SNP	B-Chemical	D009599
(	O	O
10	O	O
dogs	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
reduce	O	O
mean	O	O
arterial	O	O
pressure	O	O
by	O	O
30%	O	O
to	O	O
70%	O	O
of	O	O
control	O	O
.	O	O

Before	O	O
,	O	O
during	O	O
and	O	O
after	O	O
induced	O	O
hypotension	B-Disease	D007022
,	O	O
we	O	O
measured	O	O
major	O	O
cardiovascular	O	O
parameters	O	O
.	O	O

Hypotension	B-Disease	D007022
induced	O	O
by	O	O
ATP	B-Chemical	D000255
was	O	O
accompanied	O	O
by	O	O
significant	O	O
decreases	O	O
in	O	O
mean	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
central	O	O
venous	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
total	O	O
body	O	O
oxygen	B-Chemical	D010100
consumption	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
all	O	O
these	O	O
variables	O	O
returned	O	O
normal	O	O
within	O	O
30	O	O
min	O	O
after	O	O
ATP	B-Chemical	D000255
was	O	O
stopped	O	O
.	O	O

Cardiac	O	O
output	O	O
did	O	O
not	O	O
change	O	O
.	O	O

During	O	O
hypotension	B-Disease	D007022
produced	O	O
by	O	O
SNP	B-Chemical	D009599
similar	O	O
decreases	O	O
were	O	O
observed	O	O
in	O	O
mean	O	O
pulmonary	O	O
arterial	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
central	O	O
venous	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
total	O	O
peripheral	O	O
resistance	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
rate	O	O
pressure	O	O
product	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
,	O	O
and	O	O
oxygen	B-Chemical	D010100
content	O	O
difference	O	O
between	O	O
arterial	O	O
and	O	O
mixed	O	O
venous	O	O
blood	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
while	O	O
heart	O	O
rate	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

001	O	O
)	O	O
and	O	O
cardiac	O	O
output	O	O
(	O	O
p	O	O
less	O	O
than	O	O
0	O	O
.	O	O

05	O	O
)	O	O
were	O	O
increased	O	O
.	O	O

Recoveries	O	O
of	O	O
heart	O	O
rate	O	O
and	O	O
left	O	O
ventricular	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
were	O	O
not	O	O
shown	O	O
within	O	O
60	O	O
min	O	O
after	O	O
SNP	B-Chemical	D009599
had	O	O
been	O	O
stopped	O	O
.	O	O

Both	O	O
ATP	B-Chemical	D000255
and	O	O
SNP	B-Chemical	D009599
should	O	O
act	O	O
on	O	O
the	O	O
pacemaker	O	O
tissue	O	O
of	O	O
the	O	O
heart	O	O
.	O	O

Comparative	O	O
study	O	O
:	O	O
Endografine	B-Chemical	C006753
(	O	O
diatrizoate	B-Chemical	D003973
)	O	O
,	O	O
Vasurix	B-Chemical	D000100
polyvidone	I-Chemical	D000100
(	O	O
acetrizoate	B-Chemical	D000100
)	O	O
,	O	O
Dimer	B-Chemical	C025504
-	I-Chemical	C025504
X	I-Chemical	C025504
(	O	O
iocarmate	B-Chemical	C025504
)	O	O
and	O	O
Hexabrix	B-Chemical	D007485
(	O	O
ioxaglate	B-Chemical	D007485
)	O	O
in	O	O
hysterosalpingography	O	O
.	O	O

Side	O	O
effects	O	O
of	O	O
hysterosalpingography	O	O
with	O	O
Dimer	B-Chemical	C025504
-	I-Chemical	C025504
X	I-Chemical	C025504
,	O	O
Hexabrix	B-Chemical	D007485
,	O	O
Vasurix	B-Chemical	D000100
polyvidone	I-Chemical	D000100
and	O	O
Endografine	B-Chemical	C006753
in	O	O
142	O	O
consecutive	O	O
patients	O	O
,	O	O
receiving	O	O
one	O	O
of	O	O
the	O	O
four	O	O
tested	O	O
media	O	O
were	O	O
evaluated	O	O
from	O	O
replies	O	O
to	O	O
postal	O	O
questionnaires	O	O
.	O	O

The	O	O
Dimer	B-Chemical	C025504
-	I-Chemical	C025504
X	I-Chemical	C025504
group	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
nausea	B-Disease	D009325
and	O	O
dizziness	B-Disease	D004244
.	O	O

The	O	O
Endografine	B-Chemical	C006753
group	O	O
had	O	O
a	O	O
higher	O	O
incidence	O	O
of	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
.	O	O

These	O	O
differences	O	O
occur	O	O
especially	O	O
in	O	O
the	O	O
age	O	O
groups	O	O
under	O	O
30	O	O
years	O	O
.	O	O

Hexabrix	B-Chemical	D007485
and	O	O
Vasurix	B-Chemical	D000100
polyvidone	I-Chemical	D000100
are	O	O
considered	O	O
the	O	O
best	O	O
contrast	B-Chemical	D003287
media	I-Chemical	D003287
for	O	O
hysterosalpingography	O	O
and	O	O
perhaps	O	O
because	O	O
of	O	O
its	O	O
low	O	O
toxicity	B-Disease	D064420
Hexabrix	B-Chemical	D007485
should	O	O
be	O	O
preferred	O	O
.	O	O

Post	O	O
-	O	O
suxamethonium	B-Chemical	D013390
pains	B-Disease	D010146
in	O	O
Nigerian	O	O
surgical	O	O
patients	O	O
.	O	O

Contrary	O	O
to	O	O
an	O	O
earlier	O	O
report	O	O
by	O	O
Coxon	O	O
,	O	O
scoline	B-Chemical	D013390
pain	B-Disease	D010146
occurs	O	O
in	O	O
African	O	O
negroes	O	O
.	O	O

Its	O	O
incidence	O	O
was	O	O
determined	O	O
in	O	O
a	O	O
prospective	O	O
study	O	O
involving	O	O
a	O	O
total	O	O
of	O	O
100	O	O
Nigerian	O	O
patients	O	O
(	O	O
50	O	O
out	O	O
-	O	O
patients	O	O
and	O	O
50	O	O
in	O	O
-	O	O
patients	O	O
)	O	O
.	O	O

About	O	O
62%	O	O
of	O	O
the	O	O
out	O	O
-	O	O
patients	O	O
developed	O	O
scoline	B-Chemical	D013390
pain	B-Disease	D010146
as	O	O
compared	O	O
with	O	O
about	O	O
26%	O	O
among	O	O
the	O	O
in	O	O
-	O	O
patients	O	O
.	O	O

The	O	O
abolition	O	O
of	O	O
muscle	O	O
fasciculations	B-Disease	D005207
(	O	O
by	O	O
0	O	O
.	O	O

075mg	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
Fazadinium	B-Chemical	C084773
)	O	O
did	O	O
not	O	O
influence	O	O
the	O	O
occurrence	O	O
of	O	O
scoline	B-Chemical	D013390
pain	B-Disease	D010146
.	O	O

Neither	O	O
the	O	O
type	O	O
of	O	O
induction	O	O
agent	O	O
(	O	O
Althesin	B-Chemical	D000530
or	O	O
Thiopentone	B-Chemical	D013874
)	O	O
nor	O	O
the	O	O
salt	O	O
preparation	O	O
of	O	O
suxamethonium	B-Chemical	D013390
used	O	O
(	O	O
chloride	B-Chemical	D002712
or	O	O
bromide	B-Chemical	D001965
)	O	O
,	O	O
affected	O	O
the	O	O
incidence	O	O
of	O	O
scoline	B-Chemical	D013390
pain	B-Disease	D010146
.	O	O

Medial	O	O
changes	O	O
in	O	O
arterial	O	O
spasm	B-Disease	D013035
induced	O	O
by	O	O
L	B-Chemical	D009638
-	I-Chemical	D009638
norepinephrine	I-Chemical	D009638
.	O	O

In	O	O
normal	O	O
rats	O	O
,	O	O
the	O	O
media	O	O
of	O	O
small	O	O
arteries	O	O
(	O	O
0	O	O
.	O	O

4	O	O
-	O	O
-	O	O
0	O	O
.	O	O

2	O	O
mm	O	O
in	O	O
diameter	O	O
)	O	O
previously	O	O
was	O	O
shown	O	O
to	O	O
contain	O	O
intracellular	O	O
vacuoles	O	O
,	O	O
identified	O	O
ultrastructurally	O	O
as	O	O
herniations	O	O
of	O	O
one	O	O
smooth	O	O
muscle	O	O
cell	O	O
into	O	O
another	O	O
.	O	O

The	O	O
hypothesis	O	O
that	O	O
intense	O	O
vasoconstriction	O	O
would	O	O
increase	O	O
the	O	O
number	O	O
of	O	O
such	O	O
vacuoles	O	O
has	O	O
been	O	O
tested	O	O
.	O	O

In	O	O
the	O	O
media	O	O
of	O	O
the	O	O
saphenous	O	O
artery	O	O
and	O	O
its	O	O
distal	O	O
branch	O	O
,	O	O
vasoconstriction	O	O
induced	O	O
by	O	O
L	B-Chemical	D009638
-	I-Chemical	D009638
norepinephrine	I-Chemical	D009638
produced	O	O
many	O	O
cell	O	O
-	O	O
to	O	O
-	O	O
cell	O	O
hernias	B-Disease	D006547
within	O	O
15	O	O
minutes	O	O
.	O	O

At	O	O
1	O	O
day	O	O
their	O	O
number	O	O
was	O	O
reduced	O	O
to	O	O
about	O	O
1	O	O
/	O	O
10	O	O
of	O	O
the	O	O
original	O	O
number	O	O
.	O	O

By	O	O
7	O	O
days	O	O
the	O	O
vessel	O	O
was	O	O
almost	O	O
restored	O	O
to	O	O
normal	O	O
.	O	O

Triple	O	O
stimulation	O	O
over	O	O
1	O	O
day	O	O
induced	O	O
more	O	O
severe	O	O
changes	O	O
in	O	O
the	O	O
media	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
smooth	O	O
muscle	O	O
cells	O	O
are	O	O
susceptible	O	O
to	O	O
damage	O	O
in	O	O
the	O	O
course	O	O
of	O	O
their	O	O
specific	O	O
function	O	O
.	O	O

The	O	O
experimental	O	O
data	O	O
are	O	O
discussed	O	O
in	O	O
relation	O	O
to	O	O
medial	O	O
changes	O	O
observed	O	O
in	O	O
other	O	O
instances	O	O
of	O	O
arterial	O	O
spasm	B-Disease	D013035
.	O	O

Endothelial	O	O
changes	O	O
that	O	O
developed	O	O
in	O	O
the	O	O
same	O	O
experimental	O	O
model	O	O
were	O	O
described	O	O
in	O	O
a	O	O
previous	O	O
paper	O	O
.	O	O

Abnormalities	O	O
of	O	O
the	O	O
pupil	O	O
and	O	O
visual	O	O
-	O	O
evoked	O	O
potential	O	O
in	O	O
quinine	B-Chemical	D011803
amblyopia	B-Disease	D000550
.	O	O

Total	O	O
blindness	B-Disease	D001766
with	O	O
a	O	O
transient	O	O
tonic	B-Disease	D015845
pupillary	I-Disease	D015845
response	O	O
,	O	O
denervation	O	O
supersensitivity	O	O
,	O	O
and	O	O
abnormal	O	O
visual	O	O
-	O	O
evoked	O	O
potentials	O	O
developed	O	O
in	O	O
a	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
after	O	O
the	O	O
use	O	O
of	O	O
quinine	B-Chemical	D011803
sulfate	O	O
for	O	O
leg	B-Disease	D009120
cramps	I-Disease	D009120
.	O	O

He	O	O
later	O	O
recovered	O	O
normal	O	O
visual	O	O
acuity	O	O
.	O	O

A	O	O
transient	O	O
tonic	B-Disease	D015845
pupillary	I-Disease	D015845
response	O	O
,	O	O
denervation	O	O
supersensitivity	O	O
,	O	O
and	O	O
abnormal	O	O
visual	O	O
-	O	O
evoked	O	O
potentials	O	O
in	O	O
quinine	B-Chemical	D011803
toxicity	B-Disease	D064420
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
reported	O	O
.	O	O

Suxamethonium	B-Chemical	D013390
-	O	O
induced	O	O
jaw	B-Disease	D014313
stiffness	I-Disease	D014313
and	O	O
myalgia	B-Disease	D063806
associated	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
:	O	O
case	O	O
report	O	O
.	O	O

An	O	O
11	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
was	O	O
given	O	O
halothane	B-Chemical	D006221
,	O	O
nitrous	B-Chemical	D009609
oxide	I-Chemical	D009609
and	O	O
oxygen	B-Chemical	D010100
,	O	O
pancuronium	B-Chemical	D010197
0	O	O
.	O	O

4	O	O
mg	O	O
and	O	O
suxamethonium	B-Chemical	D013390
100	O	O
mg	O	O
for	O	O
induction	O	O
of	O	O
anaesthesia	O	O
.	O	O

In	O	O
response	O	O
to	O	O
this	O	O
a	O	O
marked	O	O
jaw	B-Disease	D014313
stiffness	I-Disease	D014313
occurred	O	O
which	O	O
lasted	O	O
for	O	O
two	O	O
minutes	O	O
and	O	O
the	O	O
anaesthesia	O	O
were	O	O
terminated	O	O
.	O	O

Four	O	O
hours	O	O
of	O	O
apnoea	B-Disease	D001049
ensued	O	O
and	O	O
he	O	O
suffered	O	O
generalized	O	O
severe	O	O
myalgia	B-Disease	D063806
lasting	O	O
for	O	O
one	O	O
week	O	O
.	O	O

He	O	O
was	O	O
found	O	O
to	O	O
have	O	O
atypical	O	O
plasma	O	O
cholinesterase	O	O
with	O	O
a	O	O
dibucaine	B-Chemical	D003992
number	O	O
of	O	O
12	O	O
,	O	O
indicating	O	O
homozygocity	O	O
.	O	O

This	O	O
was	O	O
verified	O	O
by	O	O
study	O	O
of	O	O
the	O	O
family	O	O
.	O	O

The	O	O
case	O	O
shows	O	O
that	O	O
prolonged	B-Disease	D014313
jaw	I-Disease	D014313
rigidity	I-Disease	D014313
and	O	O
myalgia	B-Disease	D063806
may	O	O
occur	O	O
after	O	O
suxamethonium	B-Chemical	D013390
in	O	O
patients	O	O
with	O	O
atypical	O	O
cholinesterase	O	O
despite	O	O
pretreatment	O	O
with	O	O
pancuronium	B-Chemical	D010197
.	O	O

Indomethacin	B-Chemical	D007213
-	O	O
induced	O	O
hyperkalemia	B-Disease	D006947
in	O	O
three	O	O
patients	O	O
with	O	O
gouty	B-Disease	D015210
arthritis	I-Disease	D015210
.	O	O

We	O	O
describe	O	O
three	O	O
patients	O	O
in	O	O
whom	O	O
severe	O	O
,	O	O
life	O	O
-	O	O
threatening	O	O
hyperkalemia	B-Disease	D006947
and	O	O
renal	B-Disease	D051437
insufficiency	I-Disease	D051437
developed	O	O
after	O	O
treatment	O	O
of	O	O
acute	O	O
gouty	B-Disease	D015210
arthritis	I-Disease	D015210
with	O	O
indomethacin	B-Chemical	D007213
.	O	O

This	O	O
complication	O	O
may	O	O
result	O	O
from	O	O
an	O	O
inhibition	O	O
of	O	O
prostaglandin	B-Chemical	D011453
synthesis	O	O
and	O	O
consequent	O	O
hyporeninemic	B-Disease	D006994
hypoaidosteronism	I-Disease	D006994
.	O	O

Careful	O	O
attention	O	O
to	O	O
renal	O	O
function	O	O
and	O	O
potassium	B-Chemical	D011188
balance	O	O
in	O	O
patients	O	O
receiving	O	O
indomethacin	B-Chemical	D007213
or	O	O
other	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
agents	O	O
,	O	O
particularly	O	O
in	O	O
those	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
or	O	O
preexisting	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
,	O	O
will	O	O
help	O	O
prevent	O	O
this	O	O
potentially	O	O
serious	O	O
complication	O	O
.	O	O

Etomidate	B-Chemical	D005045
:	O	O
a	O	O
foreshortened	O	O
clinical	O	O
trial	O	O
.	O	O

A	O	O
clinical	O	O
evaluation	O	O
of	O	O
etomidate	B-Chemical	D005045
for	O	O
outpatient	O	O
cystoscopy	O	O
was	O	O
embarked	O	O
upon	O	O
.	O	O

Unpremedicated	O	O
patients	O	O
were	O	O
given	O	O
fentanyl	B-Chemical	D005283
1	O	O
microgram	O	O
/	O	O
kg	O	O
followed	O	O
by	O	O
etomidate	B-Chemical	D005045
0	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

Anaesthesia	O	O
was	O	O
maintained	O	O
with	O	O
intermittent	O	O
etomidate	B-Chemical	D005045
in	O	O
2	O	O
-	O	O
4	O	O
mg	O	O
doses	O	O
.	O	O

Patients	O	O
were	O	O
interviewed	O	O
personally	O	O
later	O	O
the	O	O
same	O	O
day	O	O
,	O	O
and	O	O
by	O	O
questionnaire	O	O
three	O	O
to	O	O
four	O	O
weeks	O	O
later	O	O
.	O	O

The	O	O
trial	O	O
was	O	O
discontinued	O	O
after	O	O
20	O	O
cases	O	O
because	O	O
of	O	O
an	O	O
unacceptable	O	O
incidence	O	O
of	O	O
side	O	O
effects	O	O
.	O	O

Venous	O	O
pain	B-Disease	D010146
occurred	O	O
in	O	O
68%	O	O
of	O	O
patients	O	O
and	O	O
50%	O	O
had	O	O
redness	O	O
,	O	O
pain	B-Disease	D010146
or	O	O
swelling	B-Disease	D004487
related	O	O
to	O	O
the	O	O
injection	O	O
site	O	O
,	O	O
in	O	O
some	O	O
cases	O	O
lasting	O	O
up	O	O
to	O	O
three	O	O
weeks	O	O
after	O	O
anaesthesia	O	O
.	O	O

Skeletal	O	O
movements	O	O
occurred	O	O
in	O	O
50%	O	O
of	O	O
patients	O	O
;	O	O
30%	O	O
experienced	O	O
respiratory	B-Disease	D012140
upset	I-Disease	D012140
,	O	O
one	O	O
sufficiently	O	O
severe	O	O
to	O	O
necessitate	O	O
abandoning	O	O
the	O	O
technique	O	O
.	O	O

Nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
occurred	O	O
in	O	O
40%	O	O
and	O	O
25%	O	O
had	O	O
disturbing	O	O
emergence	O	O
psychoses	B-Disease	D011605
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
are	O	O
improved	O	O
by	O	O
fluoxetine	B-Chemical	D005473
.	O	O

We	O	O
evaluated	O	O
the	O	O
severity	O	O
of	O	O
motor	B-Disease	D009069
disability	I-Disease	D009069
and	O	O
dyskinesias	B-Disease	D004409
in	O	O
seven	O	O
levodopa	B-Chemical	D007980
-	O	O
responsive	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
after	O	O
an	O	O
acute	O	O
challenge	O	O
with	O	O
the	O	O
mixed	O	O
dopamine	B-Chemical	D004298
agonist	O	O
,	O	O
apomorphine	B-Chemical	D001058
,	O	O
before	O	O
and	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
fluoxetine	B-Chemical	D005473
(	O	O
20	O	O
mg	O	O
twice	O	O
per	O	O
day	O	O
)	O	O
for	O	O
11	O	O
+	O	O
/	O	O
-	O	O
1	O	O
days	O	O
.	O	O

After	O	O
fluoxetine	B-Chemical	D005473
treatment	O	O
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
47%	O	O
improvement	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
of	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
without	O	O
modification	O	O
of	O	O
parkinsonian	B-Disease	D010300
motor	B-Disease	D009069
disability	I-Disease	D009069
.	O	O

The	O	O
dyskinesias	B-Disease	D004409
were	O	O
reduced	O	O
predominantly	O	O
in	O	O
the	O	O
lower	O	O
limbs	O	O
during	O	O
the	O	O
onset	O	O
and	O	O
disappearance	O	O
of	O	O
dystonic	O	O
dyskinesias	B-Disease	D004409
(	O	O
onset	O	O
-	O	O
and	O	O
end	O	O
-	O	O
of	O	O
-	O	O
dose	O	O
dyskinesias	B-Disease	D004409
)	O	O
and	O	O
in	O	O
the	O	O
upper	O	O
limbs	O	O
during	O	O
choreic	O	O
mid	O	O
-	O	O
dose	O	O
dyskinesias	B-Disease	D004409
.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
increased	O	O
brain	O	O
serotoninergic	O	O
transmission	O	O
with	O	O
fluoxetine	B-Chemical	D005473
may	O	O
reduce	O	O
levodopa	B-Chemical	D007980
-	O	O
or	O	O
dopamine	B-Chemical	D004298
agonist	O	O
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
without	O	O
aggravating	O	O
parkinsonian	B-Disease	D010300
motor	B-Disease	D009069
disability	I-Disease	D009069
.	O	O

A	O	O
large	O	O
population	O	O
-	O	O
based	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
of	O	O
trimethoprim	B-Chemical	D015662
-	I-Chemical	D015662
sulfamethoxazole	I-Chemical	D015662
,	O	O
trimethoprim	B-Chemical	D014295
,	O	O
and	O	O
cephalexin	B-Chemical	D002506
for	O	O
uncommon	O	O
serious	O	O
drug	B-Disease	D064420
toxicity	I-Disease	D064420
.	O	O

We	O	O
conducted	O	O
a	O	O
population	O	O
-	O	O
based	O	O
45	O	O
-	O	O
day	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
of	O	O
232	O	O
,	O	O
390	O	O
people	O	O
who	O	O
were	O	O
prescribed	O	O
trimethoprim	B-Chemical	D015662
-	I-Chemical	D015662
sulfamethoxazole	I-Chemical	D015662
(	O	O
TMP	B-Chemical	D015662
-	I-Chemical	D015662
SMZ	I-Chemical	D015662
)	O	O
,	O	O
266	O	O
,	O	O
951	O	O
prescribed	O	O
trimethoprim	B-Chemical	D014295
alone	O	O
,	O	O
and	O	O
196	O	O
,	O	O
397	O	O
prescribed	O	O
cephalexin	B-Chemical	D002506
,	O	O
to	O	O
estimate	O	O
the	O	O
risk	O	O
of	O	O
serious	O	O
liver	O	O
,	O	O
blood	O	O
,	O	O
skin	O	O
,	O	O
and	O	O
renal	O	O
disorders	O	O
resulting	O	O
in	O	O
referral	O	O
or	O	O
hospitalization	O	O
associated	O	O
with	O	O
these	O	O
drugs	O	O
.	O	O

The	O	O
results	O	O
were	O	O
based	O	O
on	O	O
information	O	O
recorded	O	O
on	O	O
office	O	O
computers	O	O
by	O	O
selected	O	O
general	O	O
practitioners	O	O
in	O	O
the	O	O
United	O	O
Kingdom	O	O
,	O	O
together	O	O
with	O	O
a	O	O
review	O	O
of	O	O
clinical	O	O
records	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
clinically	O	O
important	O	O
idiopathic	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
was	O	O
similar	O	O
for	O	O
persons	O	O
prescribed	O	O
TMP	B-Chemical	D015662
-	I-Chemical	D015662
SMZ	I-Chemical	D015662
(	O	O
5	O	O
.	O	O

2	O	O
/	O	O
100	O	O
,	O	O
000	O	O
)	O	O
and	O	O
those	O	O
prescribed	O	O
trimethoprim	B-Chemical	D014295
alone	O	O
(	O	O
3	O	O
.	O	O

8	O	O
/	O	O
100	O	O
,	O	O
000	O	O
)	O	O
.	O	O

The	O	O
risk	O	O
for	O	O
those	O	O
prescribed	O	O
cephalexin	B-Chemical	D002506
was	O	O
somewhat	O	O
lower	O	O
(	O	O
2	O	O
.	O	O

0	O	O
/	O	O
100	O	O
,	O	O
000	O	O
)	O	O
.	O	O

Only	O	O
five	O	O
patients	O	O
experienced	O	O
blood	O	O
disorders	O	O
,	O	O
one	O	O
of	O	O
whom	O	O
was	O	O
exposed	O	O
to	O	O
TMP	B-Chemical	D015662
-	I-Chemical	D015662
SMZ	I-Chemical	D015662
;	O	O
of	O	O
seven	O	O
with	O	O
erythema	B-Disease	D004892
multiforme	I-Disease	D004892
and	O	O
Stevens	B-Disease	D013262
-	I-Disease	D013262
Johnson	I-Disease	D013262
syndrome	I-Disease	D013262
,	O	O
four	O	O
were	O	O
exposed	O	O
to	O	O
TMP	B-Chemical	D015662
-	I-Chemical	D015662
SMZ	I-Chemical	D015662
.	O	O

The	O	O
one	O	O
case	O	O
of	O	O
toxic	B-Disease	D013262
epidermal	I-Disease	D013262
necrolysis	I-Disease	D013262
occurred	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
took	O	O
cephalexin	B-Chemical	D002506
.	O	O

Finally	O	O
,	O	O
only	O	O
five	O	O
cases	O	O
of	O	O
acute	O	O
parenchymal	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
occurred	O	O
,	O	O
none	O	O
likely	O	O
to	O	O
be	O	O
caused	O	O
by	O	O
a	O	O
study	O	O
drug	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
the	O	O
serious	O	O
diseases	O	O
studied	O	O
is	O	O
small	O	O
for	O	O
the	O	O
three	O	O
agents	O	O
,	O	O
and	O	O
compares	O	O
reasonably	O	O
with	O	O
the	O	O
risk	O	O
for	O	O
many	O	O
other	O	O
antibiotics	O	O
.	O	O

Clinical	O	O
safety	O	O
of	O	O
lidocaine	B-Chemical	D008012
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

STUDY	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
safety	O	O
of	O	O
lidocaine	B-Chemical	D008012
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
MI	B-Disease	D009203
)	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
retrospective	O	O
,	O	O
multicenter	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
Twenty	O	O
-	O	O
nine	O	O
university	O	O
,	O	O
university	O	O
-	O	O
affiliated	O	O
,	O	O
or	O	O
community	O	O
hospitals	O	O
during	O	O
a	O	O
6	O	O
-	O	O
year	O	O
period	O	O
(	O	O
total	O	O
of	O	O
117	O	O
cumulative	O	O
hospital	O	O
-	O	O
years	O	O
)	O	O
.	O	O

PARTICIPANTS	O	O
:	O	O
Patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
MI	B-Disease	D009203
who	O	O
received	O	O
lidocaine	B-Chemical	D008012
in	O	O
the	O	O
emergency	O	O
department	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
29	O	O
patients	O	O
who	O	O
received	O	O
lidocaine	B-Chemical	D008012
in	O	O
the	O	O
setting	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
MI	B-Disease	D009203
,	O	O
no	O	O
patient	O	O
died	O	O
;	O	O
exhibited	O	O
bradydysrhythmias	B-Disease	D001919
,	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
,	O	O
or	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
;	O	O
or	O	O
experienced	O	O
seizures	B-Disease	D012640
after	O	O
administration	O	O
of	O	O
lidocaine	B-Chemical	D008012
(	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
0%	O	O
to	O	O
11%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Despite	O	O
theoretical	O	O
concerns	O	O
that	O	O
lidocaine	B-Chemical	D008012
may	O	O
enhance	O	O
cocaine	B-Chemical	D003042
toxicity	B-Disease	D064420
,	O	O
the	O	O
use	O	O
of	O	O
lidocaine	B-Chemical	D008012
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
MI	B-Disease	D009203
was	O	O
not	O	O
associated	O	O
with	O	O
significant	O	O
cardiovascular	O	O
or	O	O
central	O	O
nervous	O	O
system	O	O
toxicity	B-Disease	D064420
.	O	O

Paclitaxel	B-Chemical	D017239
3	O	O
-	O	O
hour	O	O
infusion	O	O
given	O	O
alone	O	O
and	O	O
combined	O	O
with	O	O
carboplatin	B-Chemical	D016190
:	O	O
preliminary	O	O
results	O	O
of	O	O
dose	O	O
-	O	O
escalation	O	O
trials	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
(	O	O
Taxol	B-Chemical	D017239
;	O	O
Bristol	O	O
-	O	O
Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
by	O	O
3	O	O
-	O	O
hour	O	O
infusion	O	O
was	O	O
combined	O	O
with	O	O
carboplatin	B-Chemical	D016190
in	O	O
a	O	O
phase	O	O
I	O	O
/	O	O
II	O	O
study	O	O
directed	O	O
to	O	O
patients	O	O
with	O	O
non	B-Disease	D002289
-	I-Disease	D002289
small	I-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
cancer	I-Disease	D002289
.	O	O

Carboplatin	B-Chemical	D016190
was	O	O
given	O	O
at	O	O
a	O	O
fixed	O	O
target	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
-	O	O
time	O	O
curve	O	O
of	O	O
6	O	O
.	O	O

0	O	O
by	O	O
the	O	O
Calvert	O	O
formula	O	O
,	O	O
whereas	O	O
paclitaxel	B-Chemical	D017239
was	O	O
escalated	O	O
in	O	O
patient	O	O
cohorts	O	O
from	O	O
150	O	O
mg	O	O
/	O	O
m2	O	O
(	O	O
dose	O	O
level	O	O
I	O	O
)	O	O
to	O	O
175	O	O
,	O	O
200	O	O
,	O	O
225	O	O
,	O	O
and	O	O
250	O	O
mg	O	O
/	O	O
m2	O	O
.	O	O

The	O	O
225	O	O
mg	O	O
/	O	O
m2	O	O
level	O	O
was	O	O
expanded	O	O
for	O	O
the	O	O
phase	O	O
II	O	O
study	O	O
since	O	O
the	O	O
highest	O	O
level	O	O
achieved	O	O
(	O	O
250	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
required	O	O
modification	O	O
because	O	O
of	O	O
nonhematologic	O	O
toxicities	B-Disease	D064420
(	O	O
arthralgia	B-Disease	D018771
and	O	O
sensory	B-Disease	D012678
neuropathy	I-Disease	D012678
)	O	O
.	O	O

Therapeutic	O	O
effects	O	O
were	O	O
noted	O	O
at	O	O
all	O	O
dose	O	O
levels	O	O
,	O	O
with	O	O
objective	O	O
responses	O	O
in	O	O
17	O	O
(	O	O
two	O	O
complete	O	O
and	O	O
15	O	O
partial	O	O
regressions	O	O
)	O	O
of	O	O
41	O	O
previously	O	O
untreated	O	O
patients	O	O
.	O	O

Toxicities	B-Disease	D064420
were	O	O
compared	O	O
with	O	O
a	O	O
cohort	O	O
of	O	O
patients	O	O
in	O	O
a	O	O
phase	O	O
I	O	O
trial	O	O
of	O	O
paclitaxel	B-Chemical	D017239
alone	O	O
at	O	O
identical	O	O
dose	O	O
levels	O	O
.	O	O

Carboplatin	B-Chemical	D016190
did	O	O
not	O	O
appear	O	O
to	O	O
add	O	O
to	O	O
the	O	O
hematologic	B-Disease	D006402
toxicities	I-Disease	D006402
observed	O	O
,	O	O
and	O	O
the	O	O
paclitaxel	B-Chemical	D017239
/	O	O
carboplatin	B-Chemical	D016190
combination	O	O
could	O	O
be	O	O
dosed	O	O
every	O	O
3	O	O
weeks	O	O
.	O	O

The	O	O
dose	O	O
-	O	O
dependent	O	O
effect	O	O
of	O	O
misoprostol	B-Chemical	D016595
on	O	O
indomethacin	B-Chemical	D007213
-	O	O
induced	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
in	O	O
well	O	O
compensated	O	O
cirrhosis	B-Disease	D005355
.	O	O

Misoprostol	B-Chemical	D016595
(	O	O
200	O	O
micrograms	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
acutely	O	O
counteract	O	O
the	O	O
indomethacin	B-Chemical	D007213
-	O	O
induced	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
in	O	O
well	O	O
compensated	O	O
cirrhotic	B-Disease	D005355
patients	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
the	O	O
prophylactic	O	O
value	O	O
of	O	O
misoprostol	B-Chemical	D016595
was	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

Parameters	O	O
of	O	O
renal	O	O
hemodynamics	O	O
and	O	O
tubular	O	O
sodium	B-Chemical	D012964
and	O	O
water	O	O
handling	O	O
were	O	O
assessed	O	O
by	O	O
clearance	O	O
techniques	O	O
in	O	O
26	O	O
well	O	O
compensated	O	O
cirrhotic	B-Disease	D005355
patients	O	O
before	O	O
and	O	O
after	O	O
an	O	O
oral	O	O
combination	O	O
of	O	O
50	O	O
mg	O	O
of	O	O
indomethacin	B-Chemical	D007213
and	O	O
various	O	O
doses	O	O
of	O	O
misoprostol	B-Chemical	D016595
.	O	O

The	O	O
200	O	O
-	O	O
micrograms	O	O
dose	O	O
was	O	O
able	O	O
to	O	O
totally	O	O
abolish	O	O
the	O	O
deleterious	O	O
renal	O	O
effects	O	O
of	O	O
indomethacin	B-Chemical	D007213
,	O	O
whereas	O	O
the	O	O
800	O	O
-	O	O
micrograms	O	O
dose	O	O
resulted	O	O
in	O	O
significant	O	O
worsening	O	O
of	O	O
renal	O	O
hemodynamics	O	O
and	O	O
sodium	B-Chemical	D012964
retention	O	O
.	O	O

These	O	O
changes	O	O
were	O	O
maximal	O	O
in	O	O
the	O	O
hour	O	O
immediately	O	O
after	O	O
medications	O	O
and	O	O
slowly	O	O
returned	O	O
toward	O	O
base	O	O
-	O	O
line	O	O
levels	O	O
thereafter	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
renal	O	O
protective	O	O
effects	O	O
of	O	O
misoprostol	B-Chemical	D016595
is	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

However	O	O
,	O	O
until	O	O
this	O	O
apparent	O	O
ability	O	O
of	O	O
200	O	O
micrograms	O	O
of	O	O
misoprostol	B-Chemical	D016595
to	O	O
prevent	O	O
the	O	O
adverse	O	O
effects	O	O
of	O	O
indomethacin	B-Chemical	D007213
on	O	O
renal	O	O
function	O	O
is	O	O
confirmed	O	O
with	O	O
chronic	O	O
frequent	O	O
dosing	O	O
,	O	O
it	O	O
would	O	O
be	O	O
prudent	O	O
to	O	O
avoid	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
cirrhosis	B-Disease	D005355
.	O	O

Increased	O	O
frequency	O	O
and	O	O
severity	O	O
of	O	O
angio	B-Disease	D000799
-	I-Disease	D000799
oedema	I-Disease	D000799
related	O	O
to	O	O
long	O	O
-	O	O
term	O	O
therapy	O	O
with	O	O
angiotensin	B-Chemical	D000806
-	I-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
inhibitor	I-Chemical	D000806
in	O	O
two	O	O
patients	O	O
.	O	O

Adverse	O	O
reactions	O	O
to	O	O
drugs	O	O
are	O	O
well	O	O
recognized	O	O
as	O	O
a	O	O
cause	O	O
of	O	O
acute	O	O
or	O	O
chronic	O	O
urticaria	B-Disease	D014581
,	O	O
and	O	O
angio	B-Disease	D000799
-	I-Disease	D000799
oedema	I-Disease	D000799
.	O	O

Angiotensin	B-Chemical	D000806
-	I-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
(	I-Chemical	D000806
ACE	I-Chemical	D000806
)	I-Chemical	D000806
inhibitors	I-Chemical	D000806
,	O	O
used	O	O
to	O	O
treat	O	O
hypertension	B-Disease	D006973
and	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
,	O	O
were	O	O
introduced	O	O
in	O	O
Europe	O	O
in	O	O
the	O	O
middle	O	O
of	O	O
the	O	O
eighties	O	O
,	O	O
and	O	O
the	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
has	O	O
increased	O	O
progressively	O	O
.	O	O

Soon	O	O
after	O	O
the	O	O
introduction	O	O
of	O	O
ACE	B-Chemical	D000806
inhibitors	I-Chemical	D000806
,	O	O
acute	O	O
bouts	O	O
of	O	O
angio	B-Disease	D000799
-	I-Disease	D000799
oedema	I-Disease	D000799
were	O	O
reported	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
these	O	O
drugs	O	O
.	O	O

We	O	O
wish	O	O
to	O	O
draw	O	O
attention	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
adverse	O	O
reactions	O	O
to	O	O
ACE	B-Chemical	D000806
inhibitors	I-Chemical	D000806
after	O	O
long	O	O
-	O	O
term	O	O
use	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
pre	O	O
-	O	O
existing	O	O
angio	B-Disease	D000799
-	I-Disease	D000799
oedema	I-Disease	D000799
.	O	O

Myoclonus	B-Disease	D009207
associated	O	O
with	O	O
lorazepam	B-Chemical	D008140
therapy	O	O
in	O	O
very	O	O
-	O	O
low	O	O
-	O	O
birth	O	O
-	O	O
weight	O	O
infants	O	O
.	O	O

Lorazepam	B-Chemical	D008140
is	O	O
being	O	O
used	O	O
with	O	O
increasing	O	O
frequency	O	O
as	O	O
a	O	O
sedative	O	O
in	O	O
the	O	O
newborn	O	O
and	O	O
the	O	O
young	O	O
infant	O	O
.	O	O

Concern	O	O
has	O	O
been	O	O
raised	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
safety	O	O
of	O	O
lorazepam	B-Chemical	D008140
in	O	O
this	O	O
age	O	O
group	O	O
,	O	O
especially	O	O
in	O	O
very	O	O
-	O	O
low	O	O
-	O	O
birth	O	O
-	O	O
weight	O	O
(	O	O
VLBW	O	O
;	O	O
<	O	O
1	O	O
,	O	O
500	O	O
g	O	O
)	O	O
infants	O	O
.	O	O

Three	O	O
young	O	O
infants	O	O
,	O	O
all	O	O
of	O	O
birth	O	O
weight	O	O
<	O	O
1	O	O
,	O	O
500	O	O
g	O	O
,	O	O
experienced	O	O
myoclonus	B-Disease	D009207
following	O	O
the	O	O
intravenous	O	O
administration	O	O
of	O	O
lorazepam	B-Chemical	D008140
.	O	O

The	O	O
potential	O	O
neurotoxic	B-Disease	D020258
effects	O	O
of	O	O
the	O	O
drug	O	O
(	O	O
and	O	O
its	O	O
vehicle	O	O
)	O	O
in	O	O
this	O	O
population	O	O
are	O	O
discussed	O	O
.	O	O

Injectable	O	O
lorazepam	B-Chemical	D008140
should	O	O
be	O	O
used	O	O
with	O	O
caution	O	O
in	O	O
VLBW	O	O
infants	O	O
.	O	O

Transvenous	O	O
right	O	O
ventricular	O	O
pacing	O	O
during	O	O
cardiopulmonary	O	O
resuscitation	O	O
of	O	O
pediatric	O	O
patients	O	O
with	O	O
acute	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

We	O	O
describe	O	O
the	O	O
cardiopulmonary	O	O
resuscitation	O	O
efforts	O	O
on	O	O
five	O	O
patients	O	O
who	O	O
presented	O	O
in	O	O
acute	O	O
circulatory	B-Disease	D012769
failure	I-Disease	D012769
from	O	O
myocardial	B-Disease	D009202
dysfunction	I-Disease	D009202
.	O	O

Three	O	O
patients	O	O
had	O	O
acute	O	O
viral	O	O
myocarditis	B-Disease	D009205
,	O	O
one	O	O
had	O	O
a	O	O
carbamazepine	B-Chemical	D002220
-	O	O
induced	O	O
acute	O	O
eosinophilic	O	O
myocarditis	B-Disease	D009205
,	O	O
and	O	O
one	O	O
had	O	O
cardiac	O	O
hemosiderosis	O	O
resulting	O	O
in	O	O
acute	O	O
cardiogenic	B-Disease	D012770
shock	I-Disease	D012770
.	O	O

All	O	O
patients	O	O
were	O	O
continuously	O	O
monitored	O	O
with	O	O
central	O	O
venous	O	O
and	O	O
arterial	O	O
catheters	O	O
in	O	O
addition	O	O
to	O	O
routine	O	O
noninvasive	O	O
monitoring	O	O
.	O	O

An	O	O
introducer	O	O
sheath	O	O
,	O	O
a	O	O
pacemaker	O	O
,	O	O
and	O	O
sterile	O	O
pacing	O	O
wires	O	O
were	O	O
made	O	O
readily	O	O
available	O	O
for	O	O
the	O	O
patients	O	O
,	O	O
should	O	O
the	O	O
need	O	O
arise	O	O
to	O	O
terminate	O	O
resistant	O	O
cardiac	O	O
dysrhythmias	B-Disease	D001145
.	O	O

All	O	O
patients	O	O
developed	O	O
cardiocirculatory	O	O
arrest	O	O
associated	O	O
with	O	O
extreme	O	O
hypotension	B-Disease	D007022
and	O	O
dysrhythmias	B-Disease	D001145
within	O	O
the	O	O
first	O	O
48	O	O
hours	O	O
of	O	O
their	O	O
admission	O	O
to	O	O
the	O	O
pediatric	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
PICU	O	O
)	O	O
.	O	O

Right	O	O
ventricular	O	O
pacemaker	O	O
wires	O	O
were	O	O
inserted	O	O
in	O	O
all	O	O
of	O	O
them	O	O
during	O	O
cardiopulmonary	O	O
resuscitation	O	O
(	O	O
CPR	O	O
)	O	O
.	O	O

In	O	O
four	O	O
patients	O	O
,	O	O
cardiac	O	O
pacing	O	O
was	O	O
used	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
temporary	O	O
captured	O	O
rhythm	O	O
and	O	O
restoration	O	O
of	O	O
their	O	O
cardiac	O	O
output	O	O
.	O	O

These	O	O
patients	O	O
had	O	O
a	O	O
second	O	O
event	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
,	O	O
resulting	O	O
in	O	O
death	O	O
,	O	O
within	O	O
10	O	O
to	O	O
60	O	O
minutes	O	O
.	O	O

In	O	O
one	O	O
patient	O	O
,	O	O
cardiac	O	O
pacing	O	O
was	O	O
not	O	O
used	O	O
,	O	O
because	O	O
he	O	O
converted	O	O
to	O	O
normal	O	O
sinus	O	O
rhythm	O	O
by	O	O
electrical	O	O
defibrillation	O	O
within	O	O
three	O	O
minutes	O	O
of	O	O
initiating	O	O
CPR	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
cardiac	O	O
pacing	O	O
during	O	O
resuscitative	O	O
efforts	O	O
in	O	O
pediatric	O	O
patients	O	O
suffering	O	O
from	O	O
acute	O	O
myocardial	B-Disease	D009202
dysfunction	I-Disease	D009202
may	O	O
not	O	O
have	O	O
long	O	O
-	O	O
term	O	O
value	O	O
in	O	O
and	O	O
of	O	O
itself	O	O
;	O	O
however	O	O
,	O	O
if	O	O
temporary	O	O
hemodynamic	O	O
stability	O	O
is	O	O
achieved	O	O
by	O	O
this	O	O
procedure	O	O
,	O	O
it	O	O
may	O	O
provide	O	O
additional	O	O
time	O	O
needed	O	O
to	O	O
institute	O	O
other	O	O
therapeutic	O	O
modalities	O	O
.	O	O

Efficacy	O	O
and	O	O
safety	O	O
of	O	O
granisetron	B-Chemical	D017829
,	O	O
a	O	O
selective	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamine	I-Chemical	D012701
-	O	O
3	O	O
receptor	O	O
antagonist	O	O
,	O	O
in	O	O
the	O	O
prevention	O	O
of	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
induced	O	O
by	O	O
high	O	O
-	O	O
dose	O	O
cisplatin	B-Chemical	D002945
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
antiemetic	O	O
effects	O	O
and	O	O
safety	O	O
profile	O	O
of	O	O
four	O	O
different	O	O
doses	O	O
of	O	O
granisetron	B-Chemical	D017829
(	O	O
Kytril	B-Chemical	D017829
;	O	O
SmithKline	O	O
Beecham	O	O
Pharmaceuticals	O	O
,	O	O
Philadelphia	O	O
,	O	O
PA	O	O
)	O	O
when	O	O
administered	O	O
as	O	O
a	O	O
single	O	O
intravenous	O	O
(	O	O
IV	O	O
)	O	O
dose	O	O
for	O	O
prophylaxis	O	O
of	O	O
cisplatin	B-Chemical	D002945
-	O	O
induced	O	O
nausea	B-Disease	D009325
and	O	O
vomiting	B-Disease	D014839
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
One	O	O
hundred	O	O
eighty	O	O
-	O	O
four	O	O
chemotherapy	O	O
-	O	O
naive	O	O
patients	O	O
receiving	O	O
high	O	O
-	O	O
dose	O	O
cisplatin	B-Chemical	D002945
(	O	O
81	O	O
to	O	O
120	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
one	O	O
of	O	O
four	O	O
granisetron	B-Chemical	D017829
doses	O	O
(	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
or	O	O
40	O	O
micrograms	O	O
/	O	O
kg	O	O
)	O	O
administered	O	O
before	O	O
chemotherapy	O	O
.	O	O

Patients	O	O
were	O	O
observed	O	O
on	O	O
an	O	O
inpatient	O	O
basis	O	O
for	O	O
18	O	O
to	O	O
24	O	O
hours	O	O
,	O	O
and	O	O
vital	O	O
signs	O	O
,	O	O
nausea	B-Disease	D009325
,	O	O
vomiting	B-Disease	D014839
,	O	O
retching	O	O
,	O	O
and	O	O
appetite	O	O
were	O	O
assessed	O	O
.	O	O

Safety	O	O
analyses	O	O
included	O	O
incidence	O	O
of	O	O
adverse	O	O
experiences	O	O
and	O	O
laboratory	O	O
parameter	O	O
changes	O	O
.	O	O

RESULTS	O	O
:	O	O
After	O	O
granisetron	B-Chemical	D017829
doses	O	O
of	O	O
5	O	O
,	O	O
10	O	O
,	O	O
20	O	O
,	O	O
and	O	O
40	O	O
micrograms	O	O
/	O	O
kg	O	O
,	O	O
a	O	O
major	O	O
response	O	O
(	O	O
<	O	O
or	O	O
=	O	O
two	O	O
vomiting	B-Disease	D014839
or	O	O
retching	O	O
episodes	O	O
,	O	O
and	O	O
no	O	O
antiemetic	O	O
rescue	O	O
)	O	O
was	O	O
recorded	O	O
in	O	O
23%	O	O
,	O	O
57%	O	O
,	O	O
58%	O	O
,	O	O
and	O	O
60%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
a	O	O
complete	O	O
response	O	O
(	O	O
no	O	O
vomiting	B-Disease	D014839
or	O	O
retching	O	O
,	O	O
and	O	O
no	O	O
antiemetic	O	O
rescue	O	O
)	O	O
in	O	O
18%	O	O
,	O	O
41%	O	O
,	O	O
40%	O	O
,	O	O
and	O	O
47%	O	O
of	O	O
patients	O	O
,	O	O
respectively	O	O
.	O	O

There	O	O
was	O	O
a	O	O
statistically	O	O
longer	O	O
time	O	O
to	O	O
first	O	O
episode	O	O
of	O	O
nausea	B-Disease	D009325
(	O	O
P	O	O
=	O	O
.	O	O

0015	O	O
)	O	O
and	O	O
vomiting	B-Disease	D014839
(	O	O
P	O	O
=	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
and	O	O
fewer	O	O
patients	O	O
were	O	O
administered	O	O
additional	O	O
antiemetic	O	O
medication	O	O
in	O	O
the	O	O
10	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dosing	O	O
groups	O	O
than	O	O
in	O	O
the	O	O
5	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dosing	O	O
group	O	O
.	O	O

As	O	O
granisetron	B-Chemical	D017829
dose	O	O
increased	O	O
,	O	O
appetite	O	O
return	O	O
increased	O	O
(	O	O
P	O	O
=	O	O
.	O	O

040	O	O
)	O	O
.	O	O

Headache	B-Disease	D006261
was	O	O
the	O	O
most	O	O
frequently	O	O
reported	O	O
adverse	O	O
event	O	O
(	O	O
20%	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
A	O	O
single	O	O
10	O	O
-	O	O
,	O	O
20	O	O
-	O	O
,	O	O
or	O	O
40	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
granisetron	B-Chemical	D017829
was	O	O
effective	O	O
in	O	O
controlling	O	O
vomiting	B-Disease	D014839
in	O	O
57%	O	O
to	O	O
60%	O	O
of	O	O
patients	O	O
who	O	O
received	O	O
cisplatin	B-Chemical	D002945
at	O	O
doses	O	O
greater	O	O
than	O	O
81	O	O
mg	O	O
/	O	O
m2	O	O
and	O	O
totally	O	O
prevented	O	O
vomiting	B-Disease	D014839
in	O	O
40%	O	O
to	O	O
47%	O	O
of	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
efficacy	O	O
between	O	O
the	O	O
10	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
dose	O	O
and	O	O
the	O	O
20	O	O
-	O	O
and	O	O
40	O	O
-	O	O
micrograms	O	O
/	O	O
kg	O	O
doses	O	O
.	O	O

Granisetron	B-Chemical	D017829
was	O	O
well	O	O
tolerated	O	O
at	O	O
all	O	O
doses	O	O
.	O	O

Adverse	O	O
interaction	O	O
between	O	O
clonidine	B-Chemical	D003000
and	O	O
verapamil	B-Chemical	D014700
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
two	O	O
cases	O	O
of	O	O
a	O	O
possible	O	O
adverse	O	O
interaction	O	O
between	O	O
clonidine	B-Chemical	D003000
and	O	O
verapamil	B-Chemical	D014700
resulting	O	O
in	O	O
atrioventricular	B-Disease	D054537
(	I-Disease	D054537
AV	I-Disease	D054537
)	I-Disease	D054537
block	I-Disease	D054537
in	O	O
both	O	O
patients	O	O
and	O	O
severe	O	O
hypotension	B-Disease	D007022
in	O	O
one	O	O
patient	O	O
.	O	O

CASE	O	O
SUMMARIES	O	O
:	O	O
A	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
hyperaldosteronism	B-Disease	D006929
was	O	O
treated	O	O
with	O	O
verapamil	B-Chemical	D014700
480	O	O
mg	O	O
/	O	O
d	O	O
and	O	O
spironolactone	B-Chemical	D013148
100	O	O
mg	O	O
/	O	O
d	O	O
.	O	O

After	O	O
the	O	O
addition	O	O
of	O	O
a	O	O
minimal	O	O
dose	O	O
of	O	O
clonidine	B-Chemical	D003000
(	O	O
0	O	O
.	O	O

15	O	O
mg	O	O
bid	O	O
)	O	O
,	O	O
she	O	O
developed	O	O
complete	O	O
AV	B-Disease	D054537
block	I-Disease	D054537
and	O	O
severe	O	O
hypotension	B-Disease	D007022
,	O	O
which	O	O
resolved	O	O
upon	O	O
cessation	O	O
of	O	O
all	O	O
medications	O	O
.	O	O

A	O	O
65	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
was	O	O
treated	O	O
with	O	O
extended	O	O
-	O	O
release	O	O
verapamil	B-Chemical	D014700
240	O	O
mg	O	O
/	O	O
d	O	O
.	O	O

After	O	O
the	O	O
addition	O	O
of	O	O
clonidine	B-Chemical	D003000
0	O	O
.	O	O

15	O	O
mg	O	O
bid	O	O
she	O	O
developed	O	O
complete	O	O
AV	B-Disease	D054537
block	I-Disease	D054537
,	O	O
which	O	O
resolved	O	O
after	O	O
all	O	O
therapy	O	O
was	O	O
stopped	O	O
.	O	O

DISCUSSION	O	O
:	O	O
An	O	O
adverse	O	O
interaction	O	O
between	O	O
clonidine	B-Chemical	D003000
and	O	O
verapamil	B-Chemical	D014700
has	O	O
not	O	O
been	O	O
reported	O	O
previously	O	O
.	O	O

We	O	O
describe	O	O
two	O	O
such	O	O
cases	O	O
and	O	O
discuss	O	O
the	O	O
various	O	O
mechanisms	O	O
that	O	O
might	O	O
cause	O	O
such	O	O
an	O	O
interaction	O	O
.	O	O

Clinicians	O	O
should	O	O
be	O	O
acquainted	O	O
with	O	O
this	O	O
possibly	O	O
fatal	O	O
interaction	O	O
between	O	O
two	O	O
commonly	O	O
used	O	O
antihypertensive	O	O
drugs	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Caution	O	O
is	O	O
recommended	O	O
in	O	O
combining	O	O
clonidine	B-Chemical	D003000
and	O	O
verapamil	B-Chemical	D014700
therapy	O	O
,	O	O
even	O	O
in	O	O
patients	O	O
who	O	O
do	O	O
not	O	O
have	O	O
sinus	O	O
or	O	O
AV	O	O
node	O	O
dysfunction	O	O
.	O	O

The	O	O
two	O	O
drugs	O	O
may	O	O
act	O	O
synergistically	O	O
on	O	O
both	O	O
the	O	O
AV	O	O
node	O	O
and	O	O
the	O	O
peripheral	O	O
circulation	O	O
.	O	O

Pharmacological	O	O
studies	O	O
on	O	O
a	O	O
new	O	O
dihydrothienopyridine	B-Chemical	-1
calcium	I-Chemical	-1
antagonist	O	O
,	O	O
S	B-Chemical	C059447
-	I-Chemical	C059447
312	I-Chemical	C059447
-	I-Chemical	C059447
d	I-Chemical	C059447
.	O	O

5th	O	O
communication	O	O
:	O	O
anticonvulsant	O	O
effects	O	O
in	O	O
mice	O	O
.	O	O

S	B-Chemical	C059447
-	I-Chemical	C059447
312	I-Chemical	C059447
,	O	O
S	B-Chemical	C059447
-	I-Chemical	C059447
312	I-Chemical	C059447
-	I-Chemical	C059447
d	I-Chemical	C059447
,	O	O
but	O	O
not	O	O
S	B-Chemical	C059447
-	I-Chemical	C059447
312	I-Chemical	C059447
-	O	O
l	O	O
,	O	O
L	O	O
-	O	O
type	O	O
calcium	B-Chemical	D002118
channel	O	O
antagonists	O	O
,	O	O
showed	O	O
anticonvulsant	O	O
effects	O	O
on	O	O
the	O	O
audiogenic	B-Disease	D020195
tonic	I-Disease	D020195
convulsions	I-Disease	D020195
in	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
;	O	O
and	O	O
their	O	O
ED50	O	O
values	O	O
were	O	O
18	O	O
.	O	O

4	O	O
(	O	O
12	O	O
.	O	O

8	O	O
-	O	O
27	O	O
.	O	O

1	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

and	O	O
15	O	O
.	O	O

0	O	O
(	O	O
10	O	O
.	O	O

2	O	O
-	O	O
23	O	O
.	O	O

7	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

,	O	O
respectively	O	O
,	O	O
while	O	O
that	O	O
of	O	O
flunarizine	B-Chemical	D005444
was	O	O
34	O	O
.	O	O

0	O	O
(	O	O
26	O	O
.	O	O

0	O	O
-	O	O
44	O	O
.	O	O

8	O	O
)	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
p	O	O
.	O	O

o	O	O
.	O	O

Although	O	O
moderate	O	O
anticonvulsant	O	O
effects	O	O
of	O	O
S	B-Chemical	C059447
-	I-Chemical	C059447
312	I-Chemical	C059447
-	I-Chemical	C059447
d	I-Chemical	C059447
in	O	O
higher	O	O
doses	O	O
were	O	O
observed	O	O
against	O	O
the	O	O
clonic	O	O
convulsions	B-Disease	D012640
induced	O	O
by	O	O
pentylenetetrazole	B-Chemical	D010433
(	O	O
85	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
or	O	O
bemegride	B-Chemical	D001534
(	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
,	O	O
no	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
convulsions	B-Disease	D012640
induced	O	O
by	O	O
N	B-Chemical	D016202
-	I-Chemical	D016202
methyl	I-Chemical	D016202
-	I-Chemical	D016202
D	I-Chemical	D016202
-	I-Chemical	D016202
aspartate	I-Chemical	D016202
,	O	O
picrotoxin	B-Chemical	D010852
,	O	O
or	O	O
electroshock	O	O
in	O	O
Slc	O	O
:	O	O
ddY	O	O
mice	O	O
.	O	O

S	B-Chemical	C059447
-	I-Chemical	C059447
312	I-Chemical	C059447
-	I-Chemical	C059447
d	I-Chemical	C059447
may	O	O
be	O	O
useful	O	O
in	O	O
the	O	O
therapy	O	O
of	O	O
certain	O	O
types	O	O
of	O	O
human	O	O
epilepsy	B-Disease	D004827
.	O	O

Transmural	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
with	O	O
sumatriptan	B-Chemical	D018170
.	O	O

For	O	O
sumatriptan	B-Chemical	D018170
,	O	O
tightness	O	O
in	O	O
the	O	O
chest	O	O
caused	O	O
by	O	O
an	O	O
unknown	O	O
mechanism	O	O
has	O	O
been	O	O
reported	O	O
in	O	O
3	O	O
-	O	O
5%	O	O
of	O	O
users	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
an	O	O
acute	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
after	O	O
administration	O	O
of	O	O
sumatriptan	B-Chemical	D018170
6	O	O
mg	O	O
subcutaneously	O	O
for	O	O
cluster	B-Disease	D003027
headache	I-Disease	D003027
.	O	O

The	O	O
patient	O	O
had	O	O
no	O	O
history	O	O
of	O	O
underlying	O	O
ischaemic	B-Disease	D017202
heart	I-Disease	D017202
disease	I-Disease	D017202
or	O	O
Prinzmetal's	B-Disease	D000788
angina	I-Disease	D000788
.	O	O

She	O	O
recovered	O	O
without	O	O
complications	O	O
.	O	O

Flumazenil	B-Chemical	D005442
induces	O	O
seizures	B-Disease	D012640
and	O	O
death	O	O
in	O	O
mixed	O	O
cocaine	B-Chemical	D003042
-	O	O
diazepam	B-Chemical	D003975
intoxications	O	O
.	O	O

STUDY	O	O
HYPOTHESIS	O	O
:	O	O
Administration	O	O
of	O	O
the	O	O
benzodiazepine	B-Chemical	D001569
antagonist	O	O
flumazenil	B-Chemical	D005442
may	O	O
unmask	O	O
seizures	B-Disease	D012640
in	O	O
mixed	O	O
cocaine	B-Chemical	D003042
-	O	O
benzodiazepine	B-Chemical	D001569
intoxication	O	O
.	O	O

DESIGN	O	O
:	O	O
Male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
rats	O	O
received	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
cocaine	B-Chemical	D003042
IP	O	O
alone	O	O
,	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
diazepam	B-Chemical	D003975
alone	O	O
,	O	O
or	O	O
a	O	O
combination	O	O
of	O	O
diazepam	B-Chemical	D003975
and	O	O
cocaine	B-Chemical	D003042
.	O	O

Three	O	O
minutes	O	O
later	O	O
,	O	O
groups	O	O
were	O	O
challenged	O	O
with	O	O
vehicle	O	O
or	O	O
flumazenil	B-Chemical	D005442
5	O	O
or	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
IP	O	O
.	O	O

Animal	O	O
behavior	O	O
,	O	O
seizures	B-Disease	D012640
(	O	O
time	O	O
to	O	O
and	O	O
incidence	O	O
)	O	O
,	O	O
death	O	O
(	O	O
time	O	O
to	O	O
and	O	O
incidence	O	O
)	O	O
,	O	O
and	O	O
cortical	O	O
EEG	O	O
tracings	O	O
were	O	O
recorded	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Administration	O	O
of	O	O
flumazenil	B-Chemical	D005442
to	O	O
animals	O	O
after	O	O
they	O	O
had	O	O
received	O	O
a	O	O
combination	O	O
dose	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
diazepam	B-Chemical	D003975
.	O	O

RESULTS	O	O
:	O	O
In	O	O
group	O	O
1	O	O
,	O	O
animals	O	O
received	O	O
cocaine	B-Chemical	D003042
followed	O	O
by	O	O
vehicle	O	O
.	O	O

This	O	O
resulted	O	O
in	O	O
100%	O	O
developing	O	O
seizures	B-Disease	D012640
and	O	O
death	O	O
.	O	O

Group	O	O
2	O	O
received	O	O
diazepam	B-Chemical	D003975
alone	O	O
followed	O	O
by	O	O
vehicle	O	O
.	O	O

Animals	O	O
became	O	O
somnolent	O	O
and	O	O
none	O	O
died	O	O
.	O	O

Group	O	O
3	O	O
received	O	O
diazepam	B-Chemical	D003975
followed	O	O
by	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
flumazenil	B-Chemical	D005442
.	O	O

Animals	O	O
became	O	O
somnolent	O	O
after	O	O
diazepam	B-Chemical	D003975
and	O	O
then	O	O
active	O	O
after	O	O
flumazenil	B-Chemical	D005442
administration	O	O
.	O	O

In	O	O
group	O	O
4	O	O
,	O	O
a	O	O
combination	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
diazepam	B-Chemical	D003975
was	O	O
administered	O	O
simultaneously	O	O
.	O	O

This	O	O
resulted	O	O
in	O	O
no	O	O
overt	O	O
or	O	O
EEG	O	O
-	O	O
detectable	O	O
seizures	B-Disease	D012640
and	O	O
a	O	O
50%	O	O
incidence	O	O
of	O	O
death	O	O
.	O	O

Group	O	O
5	O	O
received	O	O
a	O	O
similar	O	O
combination	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
diazepam	B-Chemical	D003975
,	O	O
followed	O	O
later	O	O
by	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
flumazenil	B-Chemical	D005442
.	O	O

This	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
seizures	B-Disease	D012640
,	O	O
90%	O	O
(	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
,	O	O
and	O	O
death	O	O
,	O	O
100%	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.	O	O

01	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
group	O	O
4	O	O
.	O	O

Group	O	O
6	O	O
received	O	O
cocaine	B-Chemical	D003042
and	O	O
diazepam	B-Chemical	D003975
followed	O	O
by	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
flumazenil	B-Chemical	D005442
.	O	O

This	O	O
also	O	O
resulted	O	O
in	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
seizures	B-Disease	D012640
,	O	O
90%	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.	O	O

01	O	O
)	O	O
,	O	O
and	O	O
death	O	O
,	O	O
90%	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.	O	O

05	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
group	O	O
4	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Flumazenil	B-Chemical	D005442
can	O	O
unmask	O	O
seizures	B-Disease	D012640
and	O	O
increase	O	O
the	O	O
incidence	O	O
of	O	O
death	O	O
in	O	O
a	O	O
model	O	O
of	O	O
combined	O	O
cocaine	B-Chemical	D003042
-	O	O
diazepam	B-Chemical	D003975
intoxications	O	O
.	O	O

Mechanisms	O	O
for	O	O
protective	O	O
effects	O	O
of	O	O
free	O	O
radical	O	O
scavengers	O	O
on	O	O
gentamicin	B-Chemical	D005839
-	O	O
mediated	O	O
nephropathy	B-Disease	D007674
in	O	O
rats	O	O
.	O	O

Studies	O	O
were	O	O
performed	O	O
to	O	O
examine	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
of	O	O
free	O	O
radical	O	O
scavengers	O	O
on	O	O
gentamicin	B-Chemical	D005839
(	O	O
GM	B-Chemical	D005839
)	O	O
-	O	O
mediated	O	O
nephropathy	B-Disease	D007674
.	O	O

Administration	O	O
of	O	O
GM	B-Chemical	D005839
at	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
for	O	O
13	O	O
days	O	O
to	O	O
rats	O	O
induced	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
renal	O	O
blood	O	O
flow	O	O
(	O	O
RBF	O	O
)	O	O
and	O	O
inulin	O	O
clearance	O	O
(	O	O
CIn	O	O
)	O	O
as	O	O
well	O	O
as	O	O
marked	O	O
tubular	B-Disease	D007674
damage	I-Disease	D007674
.	O	O

A	O	O
significant	O	O
reduction	O	O
in	O	O
urinary	O	O
guanosine	B-Chemical	D006152
3'	I-Chemical	D006152
,	I-Chemical	D006152
5'	I-Chemical	D006152
-	I-Chemical	D006152
cyclic	I-Chemical	D006152
monophosphate	I-Chemical	D006152
(	O	O
cGMP	B-Chemical	D006152
)	O	O
excretion	O	O
and	O	O
a	O	O
significant	O	O
increase	O	O
in	O	O
renal	O	O
cortical	O	O
renin	O	O
and	O	O
endothelin	O	O
-	O	O
1	O	O
contents	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
GM	B-Chemical	D005839
-	O	O
mediated	O	O
nephropathy	B-Disease	D007674
.	O	O

Superoxide	B-Chemical	D013481
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
or	O	O
dimethylthiourea	B-Chemical	C038983
(	O	O
DMTU	B-Chemical	C038983
)	O	O
significantly	O	O
lessened	O	O
the	O	O
GM	B-Chemical	D005839
-	O	O
induced	O	O
decrement	O	O
in	O	O
CIn	O	O
.	O	O

The	O	O
SOD	O	O
-	O	O
induced	O	O
increase	O	O
in	O	O
glomerular	O	O
filtration	O	O
rate	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
marked	O	O
improvement	O	O
in	O	O
RBF	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
urinary	O	O
cGMP	B-Chemical	D006152
excretion	O	O
,	O	O
and	O	O
a	O	O
decrease	O	O
in	O	O
renal	O	O
renin	O	O
and	O	O
endothelin	O	O
-	O	O
1	O	O
content	O	O
.	O	O

SOD	O	O
did	O	O
not	O	O
attenuate	O	O
the	O	O
tubular	B-Disease	D007674
damage	I-Disease	D007674
.	O	O

In	O	O
contrast	O	O
,	O	O
DMTU	B-Chemical	C038983
significantly	O	O
reduced	O	O
the	O	O
tubular	B-Disease	D007674
damage	I-Disease	D007674
and	O	O
lipid	O	O
peroxidation	O	O
,	O	O
but	O	O
it	O	O
did	O	O
not	O	O
affect	O	O
renal	O	O
hemodynamics	O	O
and	O	O
vasoactive	O	O
substances	O	O
.	O	O

Neither	O	O
SOD	O	O
nor	O	O
DMTU	B-Chemical	C038983
affected	O	O
the	O	O
renal	O	O
cortical	O	O
GM	B-Chemical	D005839
content	O	O
in	O	O
GM	B-Chemical	D005839
-	O	O
treated	O	O
rats	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
1	O	O
)	O	O
both	O	O
SOD	O	O
and	O	O
DMTU	B-Chemical	C038983
have	O	O
protective	O	O
effects	O	O
on	O	O
GM	B-Chemical	D005839
-	O	O
mediated	O	O
nephropathy	B-Disease	D007674
,	O	O
2	O	O
)	O	O
the	O	O
mechanisms	O	O
for	O	O
the	O	O
protective	O	O
effects	O	O
differ	O	O
for	O	O
SOD	O	O
and	O	O
DMTU	B-Chemical	C038983
,	O	O
and	O	O
3	O	O
)	O	O
superoxide	B-Chemical	D013481
anions	O	O
play	O	O
a	O	O
critical	O	O
role	O	O
in	O	O
GM	B-Chemical	D005839
-	O	O
induced	O	O
renal	O	O
vasoconstriction	O	O
.	O	O

Assessment	O	O
of	O	O
cardiomyocyte	O	O
DNA	O	O
synthesis	O	O
during	O	O
hypertrophy	B-Disease	D006984
in	O	O
adult	O	O
mice	O	O
.	O	O

The	O	O
ability	O	O
of	O	O
cardiomyocytes	O	O
to	O	O
synthesize	O	O
DNA	O	O
in	O	O
response	O	O
to	O	O
experimentally	O	O
induced	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
was	O	O
assessed	O	O
in	O	O
adult	O	O
mice	O	O
.	O	O

Isoproterenol	B-Chemical	D007545
delivered	O	O
by	O	O
osmotic	O	O
minipump	O	O
implantation	O	O
in	O	O
adult	O	O
C3Heb	O	O
/	O	O
FeJ	O	O
mice	O	O
resulted	O	O
in	O	O
a	O	O
46%	O	O
increase	O	O
in	O	O
heart	O	O
weight	O	O
and	O	O
a	O	O
19	O	O
.	O	O

3%	O	O
increase	O	O
in	O	O
cardiomyocyte	O	O
area	O	O
.	O	O

No	O	O
DNA	O	O
synthesis	O	O
,	O	O
as	O	O
assessed	O	O
by	O	O
autoradiographic	O	O
analysis	O	O
of	O	O
isolated	O	O
cardiomyocytes	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
control	O	O
or	O	O
hypertrophic	B-Disease	D006332
hearts	I-Disease	D006332
.	O	O

A	O	O
survey	O	O
of	O	O
15	O	O
independent	O	O
inbred	O	O
strains	O	O
of	O	O
mice	O	O
revealed	O	O
that	O	O
ventricular	O	O
cardiomyocyte	O	O
nuclear	O	O
number	O	O
ranged	O	O
from	O	O
3	O	O
to	O	O
13%	O	O
mononucleate	O	O
,	O	O
suggesting	O	O
that	O	O
cardiomyocyte	O	O
terminal	O	O
differentiation	O	O
is	O	O
influenced	O	O
directly	O	O
or	O	O
indirectly	O	O
by	O	O
genetic	O	O
background	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
the	O	O
capacity	O	O
for	O	O
reactive	O	O
DNA	O	O
synthesis	O	O
was	O	O
also	O	O
subject	O	O
to	O	O
genetic	O	O
regulation	O	O
,	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
was	O	O
induced	O	O
in	O	O
the	O	O
strains	O	O
of	O	O
mice	O	O
comprising	O	O
the	O	O
extremes	O	O
of	O	O
the	O	O
nuclear	O	O
number	O	O
survey	O	O
.	O	O

These	O	O
data	O	O
indicate	O	O
that	O	O
adult	O	O
mouse	O	O
atrial	O	O
and	O	O
ventricular	O	O
cardiomyocytes	O	O
do	O	O
not	O	O
synthesize	O	O
DNA	O	O
in	O	O
response	O	O
to	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
.	O	O

Central	O	O
cardiovascular	O	O
effects	O	O
of	O	O
AVP	B-Chemical	D001127
and	O	O
ANP	O	O
in	O	O
normotensive	O	O
and	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
influence	O	O
of	O	O
central	O	O
arginine	B-Chemical	D001127
vasopressin	I-Chemical	D001127
(	O	O
AVP	B-Chemical	D001127
)	O	O
and	O	O
of	O	O
atrial	O	O
natriuretic	O	O
peptide	O	O
(	O	O
ANP	O	O
)	O	O
on	O	O
control	O	O
of	O	O
arterial	O	O
blood	O	O
pressure	O	O
(	O	O
MAP	O	O
)	O	O
and	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
in	O	O
normotensive	O	O
(	O	O
WKY	O	O
)	O	O
and	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
(	O	O
SHR	O	O
)	O	O
rats	O	O
.	O	O

Three	O	O
series	O	O
of	O	O
experiments	O	O
were	O	O
performed	O	O
on	O	O
30	O	O
WKY	O	O
and	O	O
30	O	O
SHR	O	O
,	O	O
chronically	O	O
instrumented	O	O
with	O	O
guide	O	O
tubes	O	O
in	O	O
the	O	O
lateral	O	O
ventricle	O	O
(	O	O
LV	O	O
)	O	O
and	O	O
arterial	O	O
and	O	O
venous	O	O
catheters	O	O
.	O	O

MAP	O	O
and	O	O
HR	O	O
were	O	O
monitored	O	O
before	O	O
and	O	O
after	O	O
i	O	O
.	O	O

v	O	O
.	O	O

injections	O	O
of	O	O
either	O	O
vehicle	O	O
or	O	O
1	O	O
,	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
of	O	O
AVP	B-Chemical	D001127
and	O	O
25	O	O
,	O	O
125	O	O
and	O	O
500	O	O
ng	O	O
of	O	O
ANP	O	O
.	O	O

Sensitivity	O	O
of	O	O
cardiac	O	O
component	O	O
of	O	O
baroreflex	O	O
(	O	O
CCB	O	O
)	O	O
,	O	O
expressed	O	O
as	O	O
a	O	O
slope	O	O
of	O	O
the	O	O
regression	O	O
line	O	O
was	O	O
determined	O	O
from	O	O
relationships	O	O
between	O	O
systolic	O	O
arterial	O	O
pressure	O	O
(	O	O
SAP	O	O
)	O	O
and	O	O
HR	O	O
period	O	O
(	O	O
HRp	O	O
)	O	O
during	O	O
phenylephrine	B-Chemical	D010656
(	O	O
Phe	B-Chemical	D010656
)	O	O
-	O	O
induced	O	O
hypertension	B-Disease	D006973
and	O	O
sodium	B-Chemical	D009599
nitroprusside	I-Chemical	D009599
(	O	O
SN	B-Chemical	D009599
)	O	O
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

CCB	O	O
was	O	O
measured	O	O
before	O	O
and	O	O
after	O	O
administration	O	O
of	O	O
either	O	O
vehicle	O	O
,	O	O
AVP	B-Chemical	D001127
,	O	O
ANP	O	O
,	O	O
or	O	O
both	O	O
peptides	O	O
together	O	O
.	O	O

Increases	O	O
of	O	O
MAP	O	O
occurred	O	O
after	O	O
LV	O	O
administration	O	O
of	O	O
1	O	O
,	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
of	O	O
AVP	B-Chemical	D001127
in	O	O
WKY	O	O
and	O	O
of	O	O
10	O	O
and	O	O
50	O	O
ng	O	O
in	O	O
SHR	O	O
.	O	O

ANP	O	O
did	O	O
not	O	O
cause	O	O
significant	O	O
changes	O	O
in	O	O
MAP	O	O
in	O	O
both	O	O
strains	O	O
as	O	O
compared	O	O
to	O	O
vehicle	O	O
,	O	O
but	O	O
it	O	O
abolished	O	O
AVP	B-Chemical	D001127
-	O	O
induced	O	O
MAP	O	O
increase	O	O
in	O	O
WKY	O	O
and	O	O
SHR	O	O
.	O	O

CCB	O	O
was	O	O
reduced	O	O
in	O	O
WKY	O	O
and	O	O
SHR	O	O
after	O	O
LV	O	O
administration	O	O
of	O	O
AVP	B-Chemical	D001127
during	O	O
SN	B-Chemical	D009599
-	O	O
induced	O	O
hypotension	B-Disease	D007022
.	O	O

In	O	O
SHR	O	O
but	O	O
not	O	O
in	O	O
WKY	O	O
administration	O	O
of	O	O
ANP	O	O
,	O	O
AVP	B-Chemical	D001127
and	O	O
ANP	O	O
+	O	O
AVP	B-Chemical	D001127
decreased	O	O
CCB	O	O
during	O	O
Phe	B-Chemical	D010656
-	O	O
induced	O	O
MAP	O	O
elevation	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
centrally	O	O
applied	O	O
AVP	B-Chemical	D001127
and	O	O
ANP	O	O
exert	O	O
differential	O	O
effects	O	O
on	O	O
blood	O	O
pressure	O	O
and	O	O
baroreflex	O	O
control	O	O
of	O	O
heart	O	O
rate	O	O
in	O	O
WKY	O	O
and	O	O
SHR	O	O
and	O	O
suggest	O	O
interaction	O	O
of	O	O
these	O	O
two	O	O
peptides	O	O
in	O	O
blood	O	O
pressure	O	O
regulation	O	O
at	O	O
the	O	O
level	O	O
of	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

Cutaneous	O	O
exposure	O	O
to	O	O
warfarin	B-Chemical	D014859
-	O	O
like	O	O
anticoagulant	O	O
causing	O	O
an	O	O
intracerebral	B-Disease	D002543
hemorrhage	I-Disease	D002543
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

A	O	O
case	O	O
of	O	O
intercerebral	O	O
hematoma	B-Disease	D006406
due	O	O
to	O	O
warfarin	B-Chemical	D014859
-	O	O
induced	O	O
coagulopathy	B-Disease	D001778
is	O	O
presented	O	O
.	O	O

The	O	O
39	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
had	O	O
spread	O	O
a	O	O
warfarin	B-Chemical	D014859
-	O	O
type	O	O
rat	O	O
poison	O	O
around	O	O
her	O	O
house	O	O
weekly	O	O
using	O	O
her	O	O
bare	O	O
hands	O	O
,	O	O
with	O	O
no	O	O
washing	O	O
post	O	O
application	O	O
.	O	O

Percutaneous	O	O
absorption	O	O
of	O	O
warfarin	B-Chemical	D014859
causing	O	O
coagulopathy	B-Disease	D001778
,	O	O
reported	O	O
three	O	O
times	O	O
in	O	O
the	O	O
past	O	O
,	O	O
is	O	O
a	O	O
significant	O	O
risk	O	O
if	O	O
protective	O	O
measures	O	O
,	O	O
such	O	O
as	O	O
gloves	O	O
,	O	O
are	O	O
not	O	O
used	O	O
.	O	O

An	O	O
adverse	O	O
drug	O	O
interaction	O	O
with	O	O
piroxicam	B-Chemical	D010894
,	O	O
which	O	O
she	O	O
took	O	O
occasionally	O	O
,	O	O
may	O	O
have	O	O
exacerbated	O	O
the	O	O
coagulopathy	B-Disease	D001778
.	O	O

Pediatric	O	O
heart	O	O
transplantation	O	O
without	O	O
chronic	O	O
maintenance	O	O
steroids	B-Chemical	D013256
.	O	O

From	O	O
1986	O	O
to	O	O
February	O	O
1993	O	O
,	O	O
40	O	O
children	O	O
aged	O	O
2	O	O
months	O	O
to	O	O
18	O	O
years	O	O
(	O	O
average	O	O
age	O	O
10	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
5	O	O
.	O	O

8	O	O
years	O	O
)	O	O
underwent	O	O
heart	O	O
transplantation	O	O
.	O	O

Indications	O	O
for	O	O
transplantation	O	O
were	O	O
idiopathic	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
(	O	O
52%	O	O
)	O	O
,	O	O
congenital	B-Disease	D006331
heart	I-Disease	D006331
disease	I-Disease	D006331
(	O	O
35%	O	O
)	O	O
with	O	O
and	O	O
without	O	O
prior	O	O
repair	O	O
(	O	O
71%	O	O
and	O	O
29%	O	O
,	O	O
respectively	O	O
)	O	O
,	O	O
hypertrophic	B-Disease	D002312
cardiomyopathy	I-Disease	D002312
(	O	O
5%	O	O
)	O	O
,	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
(	O	O
3%	O	O
)	O	O
,	O	O
and	O	O
doxorubicin	B-Chemical	D004317
cardiomyopathy	B-Disease	D009202
(	O	O
5%	O	O
)	O	O
.	O	O

Patients	O	O
were	O	O
managed	O	O
with	O	O
cyclosporine	B-Chemical	D016572
and	O	O
azathioprine	B-Chemical	D001379
.	O	O

No	O	O
prophylaxis	O	O
with	O	O
antilymphocyte	O	O
globulin	O	O
was	O	O
used	O	O
.	O	O

Steroids	B-Chemical	D013256
were	O	O
given	O	O
to	O	O
39%	O	O
of	O	O
patients	O	O
for	O	O
refractory	O	O
rejection	O	O
,	O	O
but	O	O
weaning	O	O
was	O	O
always	O	O
attempted	O	O
and	O	O
generally	O	O
successful	O	O
(	O	O
64%	O	O
)	O	O
.	O	O

Five	O	O
patients	O	O
(	O	O
14%	O	O
)	O	O
received	O	O
maintenance	O	O
steroids	B-Chemical	D013256
.	O	O

Four	O	O
patients	O	O
died	O	O
in	O	O
the	O	O
perioperative	O	O
period	O	O
and	O	O
one	O	O
died	O	O
4	O	O
months	O	O
later	O	O
.	O	O

There	O	O
have	O	O
been	O	O
no	O	O
deaths	O	O
related	O	O
to	O	O
rejection	O	O
or	O	O
infection	B-Disease	D007239
.	O	O

Average	O	O
follow	O	O
-	O	O
up	O	O
was	O	O
36	O	O
+	O	O
/	O	O
-	O	O
19	O	O
months	O	O
(	O	O
range	O	O
1	O	O
to	O	O
65	O	O
months	O	O
)	O	O
.	O	O

Cumulative	O	O
survival	O	O
is	O	O
88%	O	O
at	O	O
5	O	O
years	O	O
.	O	O

In	O	O
patients	O	O
less	O	O
than	O	O
7	O	O
years	O	O
of	O	O
age	O	O
,	O	O
rejection	O	O
was	O	O
monitored	O	O
noninvasively	O	O
.	O	O

In	O	O
the	O	O
first	O	O
postoperative	O	O
month	O	O
,	O	O
89%	O	O
of	O	O
patients	O	O
were	O	O
treated	O	O
for	O	O
rejection	O	O
.	O	O

Freedom	O	O
from	O	O
serious	O	O
infections	B-Disease	D007239
was	O	O
83%	O	O
at	O	O
1	O	O
month	O	O
and	O	O
65%	O	O
at	O	O
1	O	O
year	O	O
.	O	O

Cytomegalovirus	B-Disease	D003586
infections	I-Disease	D003586
were	O	O
treated	O	O
successfully	O	O
with	O	O
ganciclovir	B-Chemical	D015774
in	O	O
11	O	O
patients	O	O
.	O	O

No	O	O
impairment	O	O
of	O	O
growth	O	O
was	O	O
observed	O	O
in	O	O
children	O	O
who	O	O
underwent	O	O
transplantation	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
population	O	O
.	O	O

Twenty	O	O
-	O	O
one	O	O
patients	O	O
(	O	O
60%	O	O
)	O	O
have	O	O
undergone	O	O
annual	O	O
catheterizations	O	O
and	O	O
no	O	O
sign	O	O
of	O	O
graft	O	O
atherosclerosis	B-Disease	D050197
has	O	O
been	O	O
observed	O	O
.	O	O

Seizures	B-Disease	D012640
occurred	O	O
in	O	O
five	O	O
patients	O	O
(	O	O
14%	O	O
)	O	O
and	O	O
hypertension	B-Disease	D006973
was	O	O
treated	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
28%	O	O
)	O	O
.	O	O

No	O	O
patient	O	O
was	O	O
disabled	O	O
and	O	O
no	O	O
lymphoproliferative	B-Disease	D008232
disorder	I-Disease	D008232
was	O	O
observed	O	O
.	O	O

(	O	O
ABSTRACT	O	O
TRUNCATED	O	O
AT	O	O
250	O	O
WORDS	O	O
)	O	O
Delirium	B-Disease	D003693
during	O	O
fluoxetine	B-Chemical	D005473
treatment	O	O
.	O	O

A	O	O
case	O	O
report	O	O
.	O	O

The	O	O
correlation	O	O
between	O	O
high	O	O
serum	O	O
tricyclic	O	O
antidepressant	O	O
concentrations	O	O
and	O	O
central	O	O
nervous	O	O
system	O	O
side	O	O
effects	O	O
has	O	O
been	O	O
well	O	O
established	O	O
.	O	O

Only	O	O
a	O	O
few	O	O
reports	O	O
exist	O	O
,	O	O
however	O	O
,	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
the	O	O
serum	O	O
concentrations	O	O
of	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitors	O	O
(	O	O
SSRIs	O	O
)	O	O
and	O	O
their	O	O
toxic	O	O
effects	O	O
.	O	O

In	O	O
some	O	O
cases	O	O
,	O	O
a	O	O
high	O	O
serum	O	O
concentration	O	O
of	O	O
citalopram	B-Chemical	D015283
(	O	O
>	O	O
600	O	O
nmol	O	O
/	O	O
L	O	O
)	O	O
in	O	O
elderly	O	O
patients	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
increased	O	O
somnolence	B-Disease	D006970
and	O	O
movement	B-Disease	D020820
difficulties	I-Disease	D020820
.	O	O

Widespread	O	O
cognitive	B-Disease	D003072
disorders	I-Disease	D003072
,	O	O
such	O	O
as	O	O
delirium	B-Disease	D003693
,	O	O
have	O	O
not	O	O
been	O	O
previously	O	O
linked	O	O
with	O	O
high	O	O
blood	O	O
levels	O	O
of	O	O
SSRIs	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
describe	O	O
a	O	O
patient	O	O
with	O	O
acute	O	O
hyperkinetic	B-Disease	D006948
delirium	B-Disease	D003693
connected	O	O
with	O	O
a	O	O
high	O	O
serum	O	O
total	O	O
fluoxetine	B-Chemical	D005473
(	O	O
fluoxetine	B-Chemical	D005473
plus	O	O
desmethylfluoxetine	B-Chemical	C036139
)	O	O
concentration	O	O
.	O	O

Pulmonary	B-Disease	D011654
edema	I-Disease	D011654
and	O	O
shock	B-Disease	D012769
after	O	O
high	O	O
-	O	O
dose	O	O
aracytine	B-Chemical	D003561
-	I-Chemical	D003561
C	I-Chemical	D003561
for	O	O
lymphoma	B-Disease	D008223
;	O	O
possible	O	O
role	O	O
of	O	O
TNF	O	O
-	O	O
alpha	O	O
and	O	O
PAF	O	O
.	O	O

Four	O	O
out	O	O
of	O	O
23	O	O
consecutive	O	O
patients	O	O
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
Ara	B-Chemical	D003561
-	I-Chemical	D003561
C	I-Chemical	D003561
for	O	O
lymphomas	B-Disease	D008223
in	O	O
our	O	O
institution	O	O
developed	O	O
a	O	O
strikingly	O	O
similar	O	O
syndrome	O	O
during	O	O
the	O	O
perfusion	O	O
.	O	O

It	O	O
was	O	O
characterized	O	O
by	O	O
the	O	O
onset	O	O
of	O	O
fever	B-Disease	D005334
,	O	O
diarrhea	B-Disease	D003967
,	O	O
shock	B-Disease	D012769
,	O	O
pulmonary	B-Disease	D011654
edema	I-Disease	D011654
,	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
,	O	O
metabolic	B-Disease	D000138
acidosis	I-Disease	D000138
,	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
and	O	O
leukocytosis	B-Disease	D007964
.	O	O

Thorough	O	O
bacteriological	O	O
screening	O	O
failed	O	O
to	O	O
provide	O	O
evidence	O	O
of	O	O
infection	B-Disease	D007239
.	O	O

Sequential	O	O
biological	O	O
assays	O	O
of	O	O
IL	O	O
-	O	O
1	O	O
,	O	O
IL	O	O
-	O	O
2	O	O
,	O	O
TNF	O	O
and	O	O
PAF	O	O
were	O	O
performed	O	O
during	O	O
Ara	B-Chemical	D003561
-	I-Chemical	D003561
C	I-Chemical	D003561
infusion	O	O
to	O	O
ten	O	O
patients	O	O
,	O	O
including	O	O
the	O	O
four	O	O
who	O	O
developed	O	O
the	O	O
syndrome	O	O
.	O	O

TNF	O	O
and	O	O
PAF	O	O
activity	O	O
was	O	O
found	O	O
in	O	O
the	O	O
serum	O	O
of	O	O
respectively	O	O
two	O	O
and	O	O
four	O	O
of	O	O
the	O	O
cases	O	O
,	O	O
but	O	O
not	O	O
in	O	O
the	O	O
six	O	O
controls	O	O
.	O	O

As	O	O
TNF	O	O
and	O	O
PAF	O	O
are	O	O
thought	O	O
to	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
development	O	O
of	O	O
septic	O	O
shock	B-Disease	D012769
and	O	O
adult	B-Disease	D012128
respiratory	I-Disease	D012128
distress	I-Disease	D012128
syndrome	I-Disease	D012128
,	O	O
we	O	O
hypothesize	O	O
that	O	O
high	O	O
-	O	O
dose	O	O
Ara	B-Chemical	D003561
-	I-Chemical	D003561
C	I-Chemical	D003561
may	O	O
be	O	O
associated	O	O
with	O	O
cytokine	O	O
release	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
clentiazem	B-Chemical	C056595
against	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
cardiac	B-Disease	D006331
injury	I-Disease	D006331
in	O	O
rats	O	O
.	O	O

We	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
clentiazem	B-Chemical	C056595
,	O	O
a	O	O
1	B-Chemical	C106746
,	I-Chemical	C106746
5	I-Chemical	C106746
-	I-Chemical	C106746
benzothiazepine	I-Chemical	C106746
calcium	B-Chemical	D002118
antagonist	O	O
,	O	O
on	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
cardiomyopathy	B-Disease	D009202
in	O	O
rats	O	O
.	O	O

With	O	O
2	O	O
-	O	O
week	O	O
chronic	O	O
epinephrine	B-Chemical	D004837
infusion	O	O
,	O	O
16	O	O
of	O	O
30	O	O
rats	O	O
died	O	O
within	O	O
4	O	O
days	O	O
,	O	O
and	O	O
severe	O	O
ischemic	B-Disease	D007511
lesions	I-Disease	D007511
and	O	O
fibrosis	B-Disease	D005355
of	O	O
the	O	O
left	O	O
ventricles	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
epinephrine	B-Chemical	D004837
-	O	O
treated	O	O
rats	O	O
,	O	O
left	O	O
atrial	O	O
and	O	O
left	O	O
ventricular	O	O
papillary	O	O
muscle	O	O
contractile	O	O
responses	O	O
to	O	O
isoproterenol	B-Chemical	D007545
were	O	O
reduced	O	O
,	O	O
but	O	O
responses	O	O
to	O	O
calcium	B-Chemical	D002118
were	O	O
normal	O	O
or	O	O
enhanced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

Left	O	O
ventricular	O	O
alpha	O	O
and	O	O
beta	O	O
adrenoceptor	O	O
densities	O	O
were	O	O
also	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

Treatment	O	O
with	O	O
clentiazem	B-Chemical	C056595
prevented	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
death	O	O
(	O	O
P	O	O
<	O	O
.	O	O

05	O	O
)	O	O
,	O	O
and	O	O
attenuated	O	O
the	O	O
ventricular	O	O
ischemic	B-Disease	D007511
lesions	I-Disease	D007511
and	O	O
fibrosis	B-Disease	D005355
,	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

Left	O	O
atrial	O	O
and	O	O
left	O	O
ventricular	O	O
papillary	O	O
muscle	O	O
contractile	O	O
responses	O	O
to	O	O
isoproterenol	B-Chemical	D007545
were	O	O
reduced	O	O
compared	O	O
to	O	O
controls	O	O
in	O	O
groups	O	O
treated	O	O
with	O	O
clentiazem	B-Chemical	C056595
alone	O	O
,	O	O
but	O	O
combined	O	O
with	O	O
epinephrine	B-Chemical	D004837
,	O	O
clentiazem	B-Chemical	C056595
restored	O	O
left	O	O
atrial	O	O
responses	O	O
and	O	O
enhanced	O	O
left	O	O
ventricular	O	O
papillary	O	O
responses	O	O
to	O	O
isoproterenol	B-Chemical	D007545
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
clentiazem	B-Chemical	C056595
did	O	O
not	O	O
prevent	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
down	O	O
-	O	O
regulation	O	O
of	O	O
alpha	O	O
and	O	O
beta	O	O
adrenoceptors	O	O
.	O	O

Interestingly	O	O
,	O	O
clentiazem	B-Chemical	C056595
,	O	O
infused	O	O
alone	O	O
,	O	O
resulted	O	O
in	O	O
decreased	O	O
adrenergic	O	O
receptor	O	O
densities	O	O
in	O	O
the	O	O
left	O	O
ventricle	O	O
.	O	O

Clentiazem	B-Chemical	C056595
also	O	O
did	O	O
not	O	O
prevent	O	O
the	O	O
enhanced	O	O
responses	O	O
to	O	O
calcium	B-Chemical	D002118
seen	O	O
in	O	O
the	O	O
epinephrine	B-Chemical	D004837
-	O	O
treated	O	O
animals	O	O
,	O	O
although	O	O
the	O	O
high	O	O
dose	O	O
of	O	O
clentiazem	B-Chemical	C056595
partially	O	O
attenuated	O	O
the	O	O
maximal	O	O
response	O	O
to	O	O
calcium	B-Chemical	D002118
compared	O	O
to	O	O
epinephrine	B-Chemical	D004837
-	O	O
treated	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
clentiazem	B-Chemical	C056595
attenuated	O	O
epinephrine	B-Chemical	D004837
-	O	O
induced	O	O
cardiac	B-Disease	D006331
injury	I-Disease	D006331
,	O	O
possibly	O	O
through	O	O
its	O	O
effect	O	O
on	O	O
the	O	O
adrenergic	O	O
pathway	O	O
.	O	O

Cocaine	B-Chemical	D003042
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
induced	O	O
by	O	O
cocaine	B-Chemical	D003042
.	O	O

The	O	O
ischemia	B-Disease	D007511
probably	O	O
induced	O	O
by	O	O
coronary	B-Disease	D003329
artery	I-Disease	D003329
spasm	I-Disease	D003329
was	O	O
reversed	O	O
by	O	O
nitroglycerin	B-Chemical	D005996
and	O	O
calcium	B-Chemical	D002118
blocking	O	O
agents	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
monitored	O	O
by	O	O
ECG	O	O
in	O	O
freely	O	O
moving	O	O
mice	O	O
.	O	O

A	O	O
new	O	O
model	O	O
to	O	O
test	O	O
potential	O	O
protectors	O	O
.	O	O

In	O	O
laboratory	O	O
animals	O	O
,	O	O
histology	O	O
is	O	O
most	O	O
commonly	O	O
used	O	O
to	O	O
study	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

However	O	O
,	O	O
for	O	O
monitoring	O	O
during	O	O
treatment	O	O
,	O	O
large	O	O
numbers	O	O
of	O	O
animals	O	O
are	O	O
needed	O	O
.	O	O

Recently	O	O
we	O	O
developed	O	O
a	O	O
new	O	O
method	O	O
to	O	O
measure	O	O
ECG	O	O
values	O	O
in	O	O
freely	O	O
moving	O	O
mice	O	O
by	O	O
telemetry	O	O
.	O	O

With	O	O
this	O	O
model	O	O
we	O	O
investigated	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
doxorubicin	B-Chemical	D004317
administration	O	O
on	O	O
the	O	O
ECG	O	O
of	O	O
freely	O	O
moving	O	O
BALB	O	O
/	O	O
c	O	O
mice	O	O
and	O	O
the	O	O
efficacy	O	O
of	O	O
ICRF	B-Chemical	D064730
-	I-Chemical	D064730
187	I-Chemical	D064730
as	O	O
a	O	O
protective	O	O
agent	O	O
.	O	O

The	O	O
ST	O	O
interval	O	O
significantly	O	O
widened	O	O
from	O	O
15	O	O
.	O	O

0	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

5	O	O
to	O	O
56	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
11	O	O
.	O	O

8	O	O
ms	O	O
in	O	O
week	O	O
10	O	O
(	O	O
7	O	O
weekly	O	O
doses	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
doxorubicin	B-Chemical	D004317
given	O	O
i	O	O
.	O	O

v	O	O
.	O	O

plus	O	O
3	O	O
weeks	O	O
of	O	O
observation	O	O
)	O	O
.	O	O

The	O	O
ECG	O	O
of	O	O
the	O	O
control	O	O
animals	O	O
did	O	O
not	O	O
change	O	O
during	O	O
the	O	O
entire	O	O
study	O	O
.	O	O

After	O	O
sacrifice	O	O
the	O	O
hearts	O	O
of	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
animals	O	O
were	O	O
enlarged	O	O
and	O	O
the	O	O
atria	O	O
were	O	O
hypertrophic	B-Disease	D006984
.	O	O

As	O	O
this	O	O
schedule	O	O
exerted	O	O
more	O	O
toxicity	B-Disease	D064420
than	O	O
needed	O	O
to	O	O
investigate	O	O
protective	O	O
agents	O	O
,	O	O
the	O	O
protection	O	O
of	O	O
ICRF	B-Chemical	D064730
-	I-Chemical	D064730
187	I-Chemical	D064730
was	O	O
determined	O	O
using	O	O
a	O	O
dose	O	O
schedule	O	O
with	O	O
lower	O	O
general	O	O
toxicity	B-Disease	D064420
(	O	O
6	O	O
weekly	O	O
doses	O	O
of	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
doxorubicin	B-Chemical	D004317
given	O	O
i	O	O
.	O	O

v	O	O
.	O	O

plus	O	O
2	O	O
weeks	O	O
of	O	O
observation	O	O
)	O	O
.	O	O

On	O	O
this	O	O
schedule	O	O
,	O	O
the	O	O
animals'	O	O
hearts	O	O
appeared	O	O
normal	O	O
after	O	O
sacrifice	O	O
and	O	O
ICRF	B-Chemical	D064730
-	I-Chemical	D064730
187	I-Chemical	D064730
(	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
given	O	O
i	O	O
.	O	O

p	O	O
.	O	O

1	O	O
h	O	O
before	O	O
doxorubicin	B-Chemical	D004317
)	O	O
provided	O	O
almost	O	O
full	O	O
protection	O	O
.	O	O

These	O	O
data	O	O
were	O	O
confirmed	O	O
by	O	O
histology	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
this	O	O
new	O	O
model	O	O
is	O	O
very	O	O
sensitive	O	O
and	O	O
enables	O	O
monitoring	O	O
of	O	O
the	O	O
development	O	O
of	O	O
cardiotoxicity	B-Disease	D066126
with	O	O
time	O	O
.	O	O

These	O	O
findings	O	O
result	O	O
in	O	O
a	O	O
model	O	O
that	O	O
allows	O	O
the	O	O
testing	O	O
of	O	O
protectors	O	O
against	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
as	O	O
demonstrated	O	O
by	O	O
the	O	O
protection	O	O
provided	O	O
by	O	O
ICRF	B-Chemical	D064730
-	I-Chemical	D064730
187	I-Chemical	D064730
.	O	O

Epinephrine	B-Chemical	D004837
dysrhythmogenicity	O	O
is	O	O
not	O	O
enhanced	O	O
by	O	O
subtoxic	O	O
bupivacaine	B-Chemical	D002045
in	O	O
dogs	O	O
.	O	O

Since	O	O
bupivacaine	B-Chemical	D002045
and	O	O
epinephrine	B-Chemical	D004837
may	O	O
both	O	O
precipitate	O	O
dysrhythmias	B-Disease	D001145
,	O	O
circulating	O	O
bupivacaine	B-Chemical	D002045
during	O	O
regional	O	O
anesthesia	O	O
could	O	O
potentiate	O	O
dysrhythmogenic	O	O
effects	O	O
of	O	O
epinephrine	B-Chemical	D004837
.	O	O

We	O	O
therefore	O	O
examined	O	O
whether	O	O
bupivacaine	B-Chemical	D002045
alters	O	O
the	O	O
dysrhythmogenicity	O	O
of	O	O
subsequent	O	O
administration	O	O
of	O	O
epinephrine	B-Chemical	D004837
in	O	O
conscious	O	O
,	O	O
healthy	O	O
dogs	O	O
and	O	O
in	O	O
anesthetized	O	O
dogs	O	O
with	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

Forty	O	O
-	O	O
one	O	O
conscious	O	O
dogs	O	O
received	O	O
10	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
epinephrine	B-Chemical	D004837
.	O	O

Seventeen	O	O
animals	O	O
responded	O	O
with	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
(	O	O
VT	B-Disease	D017180
)	O	O
within	O	O
3	O	O
min	O	O
.	O	O

After	O	O
3	O	O
h	O	O
,	O	O
these	O	O
responders	O	O
randomly	O	O
received	O	O
1	O	O
or	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
bupivacaine	B-Chemical	D002045
or	O	O
saline	O	O
over	O	O
5	O	O
min	O	O
,	O	O
followed	O	O
by	O	O
10	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
epinephrine	B-Chemical	D004837
.	O	O

In	O	O
the	O	O
bupivacaine	B-Chemical	D002045
groups	O	O
,	O	O
epinephrine	B-Chemical	D004837
caused	O	O
fewer	O	O
prodysrhythmic	O	O
effects	O	O
than	O	O
without	O	O
bupivacaine	B-Chemical	D002045
.	O	O

VT	B-Disease	D017180
appeared	O	O
in	O	O
fewer	O	O
dogs	O	O
and	O	O
at	O	O
a	O	O
later	O	O
time	O	O
,	O	O
and	O	O
there	O	O
were	O	O
more	O	O
sinoatrial	O	O
beats	O	O
and	O	O
less	O	O
ectopies	O	O
.	O	O

Epinephrine	B-Chemical	D004837
shortened	O	O
QT	O	O
less	O	O
after	O	O
bupivacaine	B-Chemical	D002045
than	O	O
in	O	O
control	O	O
animals	O	O
.	O	O

One	O	O
day	O	O
after	O	O
experimental	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
,	O	O
six	O	O
additional	O	O
halothane	B-Chemical	D006221
-	O	O
anesthetized	O	O
dogs	O	O
received	O	O
4	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
epinephrine	B-Chemical	D004837
until	O	O
VT	B-Disease	D017180
appeared	O	O
.	O	O

After	O	O
45	O	O
min	O	O
,	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
bupivacaine	B-Chemical	D002045
was	O	O
injected	O	O
over	O	O
5	O	O
min	O	O
,	O	O
again	O	O
followed	O	O
by	O	O
4	O	O
micrograms	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
.	O	O

min	O	O
-	O	O
1	O	O
epinephrine	B-Chemical	D004837
.	O	O

In	O	O
these	O	O
dogs	O	O
,	O	O
the	O	O
prodysrhythmic	O	O
response	O	O
to	O	O
epinephrine	B-Chemical	D004837
was	O	O
also	O	O
mitigated	O	O
by	O	O
preceding	O	O
bupivacaine	B-Chemical	D002045
.	O	O

Bupivacaine	B-Chemical	D002045
antagonizes	O	O
epinephrine	B-Chemical	D004837
dysrhythmogenicity	O	O
in	O	O
conscious	O	O
dogs	O	O
susceptible	O	O
to	O	O
VT	B-Disease	D017180
and	O	O
in	O	O
anesthetized	O	O
dogs	O	O
with	O	O
spontaneous	O	O
postinfarct	O	O
dysrhythmias	B-Disease	D001145
.	O	O

There	O	O
is	O	O
no	O	O
evidence	O	O
that	O	O
systemic	O	O
subtoxic	O	O
bupivacaine	B-Chemical	D002045
administration	O	O
enhances	O	O
the	O	O
dysrhythmogenicity	O	O
of	O	O
subsequent	O	O
epinephrine	B-Chemical	D004837
.	O	O

Milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
induced	O	O
by	O	O
1	B-Chemical	D002117
,	I-Chemical	D002117
25	I-Chemical	D002117
(	I-Chemical	D002117
OH	I-Chemical	D002117
)	I-Chemical	D002117
2D	I-Chemical	D002117
in	O	O
a	O	O
patient	O	O
with	O	O
hypoparathyroidism	B-Disease	D007011
.	O	O

Milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
was	O	O
first	O	O
described	O	O
70	O	O
years	O	O
ago	O	O
in	O	O
the	O	O
context	O	O
of	O	O
the	O	O
treatment	O	O
of	O	O
peptic	B-Disease	D010437
ulcer	I-Disease	D010437
disease	I-Disease	D010437
with	O	O
large	O	O
amounts	O	O
of	O	O
calcium	B-Chemical	D002118
and	O	O
alkali	B-Chemical	D000468
.	O	O

Although	O	O
with	O	O
current	O	O
ulcer	B-Disease	D014456
therapy	O	O
(	O	O
H	O	O
-	O	O
2	O	O
blockers	O	O
,	O	O
omeprazole	B-Chemical	D009853
,	O	O
and	O	O
sucralfate	B-Chemical	D013392
)	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
has	O	O
decreased	O	O
significantly	O	O
,	O	O
the	O	O
classic	O	O
triad	O	O
of	O	O
hypercalcemia	B-Disease	D006934
,	O	O
alkalosis	B-Disease	D000471
,	O	O
and	O	O
renal	B-Disease	D051437
impairment	I-Disease	D051437
remains	O	O
the	O	O
hallmark	O	O
of	O	O
the	O	O
syndrome	O	O
.	O	O

Milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
can	O	O
present	O	O
serious	O	O
and	O	O
occasionally	O	O
life	O	O
-	O	O
threatening	O	O
illness	O	O
unless	O	O
diagnosed	O	O
and	O	O
treated	O	O
appropriately	O	O
.	O	O

This	O	O
article	O	O
presents	O	O
a	O	O
patient	O	O
with	O	O
hypoparathyroidism	B-Disease	D007011
who	O	O
was	O	O
treated	O	O
with	O	O
calcium	B-Chemical	D002118
carbonate	O	O
and	O	O
calcitriol	B-Chemical	D002117
resulting	O	O
in	O	O
two	O	O
admissions	O	O
to	O	O
the	O	O
hospital	O	O
for	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
.	O	O

The	O	O
patient	O	O
was	O	O
successfully	O	O
treated	O	O
with	O	O
intravenous	O	O
pamidronate	B-Chemical	C019248
on	O	O
his	O	O
first	O	O
admission	O	O
and	O	O
with	O	O
hydrocortisone	B-Chemical	D006854
on	O	O
the	O	O
second	O	O
.	O	O

This	O	O
illustrates	O	O
intravenous	O	O
pamidronate	B-Chemical	C019248
as	O	O
a	O	O
valuable	O	O
therapeutic	O	O
tool	O	O
when	O	O
milk	B-Disease	D006934
-	I-Disease	D006934
alkali	I-Disease	D006934
syndrome	I-Disease	D006934
presents	O	O
as	O	O
hypercalcemic	B-Disease	D006934
emergency	I-Disease	D006934
.	O	O

Encephalopathy	B-Disease	D001927
during	O	O
amitriptyline	B-Chemical	D000639
therapy	O	O
:	O	O
are	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
and	O	O
serotonin	B-Disease	D020230
syndrome	I-Disease	D020230
spectrum	O	O
disorders?	O	O
This	O	O
report	O	O
describes	O	O
a	O	O
case	O	O
of	O	O
encephalopathy	B-Disease	D001927
developed	O	O
in	O	O
the	O	O
course	O	O
of	O	O
amitriptyline	B-Chemical	D000639
therapy	O	O
,	O	O
during	O	O
a	O	O
remission	O	O
of	O	O
unipolar	B-Disease	D003866
depression	I-Disease	D003866
.	O	O

This	O	O
patient	O	O
could	O	O
have	O	O
been	O	O
diagnosed	O	O
as	O	O
having	O	O
either	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
(	O	O
NMS	B-Disease	D009459
)	O	O
or	O	O
serotonin	B-Disease	D020230
syndrome	I-Disease	D020230
(	O	O
SS	B-Disease	D020230
)	O	O
.	O	O

The	O	O
major	O	O
determinant	O	O
of	O	O
the	O	O
symptoms	O	O
may	O	O
have	O	O
been	O	O
dopamine	B-Chemical	D004298
/	O	O
serotonin	B-Chemical	D012701
imbalance	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
.	O	O

The	O	O
NMS	B-Disease	D009459
-	O	O
like	O	O
encephalopathy	B-Disease	D001927
that	O	O
develops	O	O
in	O	O
association	O	O
with	O	O
the	O	O
use	O	O
of	O	O
antidepressants	O	O
indicates	O	O
that	O	O
NMS	B-Disease	D009459
and	O	O
SS	B-Disease	D020230
are	O	O
spectrum	O	O
disorders	O	O
induced	O	O
by	O	O
drugs	O	O
with	O	O
both	O	O
antidopaminergic	O	O
and	O	O
serotonergic	O	O
effects	O	O
.	O	O

Genetic	O	O
separation	O	O
of	O	O
tumor	B-Disease	D009369
growth	O	O
and	O	O
hemorrhagic	B-Disease	D006470
phenotypes	O	O
in	O	O
an	O	O
estrogen	B-Chemical	D004967
-	O	O
induced	O	O
tumor	B-Disease	D009369
.	O	O

Chronic	O	O
administration	O	O
of	O	O
estrogen	B-Chemical	D004967
to	O	O
the	O	O
Fischer	O	O
344	O	O
(	O	O
F344	O	O
)	O	O
rat	O	O
induces	O	O
growth	O	O
of	O	O
large	O	O
,	O	O
hemorrhagic	B-Disease	D006470
pituitary	B-Disease	D010911
tumors	I-Disease	D010911
.	O	O

Ten	O	O
weeks	O	O
of	O	O
diethylstilbestrol	B-Chemical	D004054
(	O	O
DES	B-Chemical	D004054
)	O	O
treatment	O	O
caused	O	O
female	O	O
F344	O	O
rat	O	O
pituitaries	O	O
to	O	O
grow	O	O
to	O	O
an	O	O
average	O	O
of	O	O
109	O	O
.	O	O

2	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

3	O	O
mg	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SE	O	O
)	O	O
versus	O	O
11	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

4	O	O
mg	O	O
for	O	O
untreated	O	O
rats	O	O
,	O	O
and	O	O
to	O	O
become	O	O
highly	O	O
hemorrhagic	B-Disease	D006470
.	O	O

The	O	O
same	O	O
DES	B-Chemical	D004054
treatment	O	O
produced	O	O
no	O	O
significant	O	O
growth	O	O
(	O	O
8	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
for	O	O
treated	O	O
females	O	O
versus	O	O
8	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

1	O	O
for	O	O
untreated	O	O
females	O	O
)	O	O
or	O	O
morphological	O	O
changes	O	O
in	O	O
Brown	O	O
Norway	O	O
(	O	O
BN	O	O
)	O	O
rat	O	O
pituitaries	O	O
.	O	O

An	O	O
F1	O	O
hybrid	O	O
of	O	O
F344	O	O
and	O	O
BN	O	O
exhibited	O	O
significant	O	O
pituitary	O	O
growth	O	O
after	O	O
10	O	O
weeks	O	O
of	O	O
DES	B-Chemical	D004054
treatment	O	O
with	O	O
an	O	O
average	O	O
mass	O	O
of	O	O
26	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
mg	O	O
compared	O	O
with	O	O
8	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
mg	O	O
for	O	O
untreated	O	O
rats	O	O
.	O	O

Surprisingly	O	O
,	O	O
the	O	O
F1	O	O
hybrid	O	O
tumors	B-Disease	D009369
were	O	O
not	O	O
hemorrhagic	B-Disease	D006470
and	O	O
had	O	O
hemoglobin	O	O
content	O	O
and	O	O
outward	O	O
appearance	O	O
identical	O	O
to	O	O
that	O	O
of	O	O
BN	O	O
.	O	O

Expression	O	O
of	O	O
both	O	O
growth	O	O
and	O	O
morphological	O	O
changes	O	O
is	O	O
due	O	O
to	O	O
multiple	O	O
genes	O	O
.	O	O

However	O	O
,	O	O
while	O	O
DES	B-Chemical	D004054
-	O	O
induced	O	O
pituitary	O	O
growth	O	O
exhibited	O	O
quantitative	O	O
,	O	O
additive	O	O
inheritance	O	O
,	O	O
the	O	O
hemorrhagic	B-Disease	D006470
phenotype	O	O
exhibited	O	O
recessive	O	O
,	O	O
epistatic	O	O
inheritance	O	O
.	O	O

Only	O	O
5	O	O
of	O	O
the	O	O
160	O	O
F2	O	O
pituitaries	O	O
exhibited	O	O
the	O	O
hemorrhagic	B-Disease	D006470
phenotype	O	O
;	O	O
36	O	O
of	O	O
the	O	O
160	O	O
F2	O	O
pituitaries	O	O
were	O	O
in	O	O
the	O	O
F344	O	O
range	O	O
of	O	O
mass	O	O
,	O	O
but	O	O
31	O	O
of	O	O
these	O	O
were	O	O
not	O	O
hemorrhagic	B-Disease	D006470
,	O	O
indicating	O	O
that	O	O
the	O	O
hemorrhagic	B-Disease	D006470
phenotype	O	O
is	O	O
not	O	O
merely	O	O
a	O	O
consequence	O	O
of	O	O
extensive	O	O
growth	O	O
.	O	O

The	O	O
hemorrhagic	B-Disease	D006470
F2	O	O
pituitaries	O	O
were	O	O
all	O	O
among	O	O
the	O	O
most	O	O
massive	O	O
,	O	O
indicating	O	O
that	O	O
some	O	O
of	O	O
the	O	O
genes	O	O
regulate	O	O
both	O	O
phenotypes	O	O
.	O	O

Increased	O	O
expression	O	O
of	O	O
neuronal	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
in	O	O
bladder	O	O
afferent	O	O
pathways	O	O
following	O	O
chronic	O	O
bladder	B-Disease	D001745
irritation	I-Disease	D001745
.	O	O

Immunocytochemical	O	O
techniques	O	O
were	O	O
used	O	O
to	O	O
examine	O	O
alterations	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
neuronal	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
(	O	O
NOS	O	O
)	O	O
in	O	O
bladder	O	O
pathways	O	O
following	O	O
acute	O	O
and	O	O
chronic	O	O
irritation	B-Disease	D014570
of	I-Disease	D014570
the	I-Disease	D014570
urinary	I-Disease	D014570
tract	I-Disease	D014570
of	O	O
the	O	O
rat	O	O
.	O	O

Chemical	O	O
cystitis	B-Disease	D003556
was	O	O
induced	O	O
by	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CYP	B-Chemical	D003520
)	O	O
which	O	O
is	O	O
metabolized	O	O
to	O	O
acrolein	B-Chemical	D000171
,	O	O
an	O	O
irritant	O	O
eliminated	O	O
in	O	O
the	O	O
urine	O	O
.	O	O

Injection	O	O
of	O	O
CYP	B-Chemical	D003520
(	O	O
n	O	O
=	O	O
10	O	O
,	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
2	O	O
hours	O	O
prior	O	O
to	O	O
perfusion	O	O
(	O	O
acute	O	O
treatment	O	O
)	O	O
of	O	O
the	O	O
animals	O	O
increased	O	O
Fos	O	O
-	O	O
immunoreactivity	O	O
(	O	O
IR	O	O
)	O	O
in	O	O
neurons	O	O
in	O	O
the	O	O
dorsal	O	O
commissure	O	O
,	O	O
dorsal	O	O
horn	O	O
,	O	O
and	O	O
autonomic	O	O
regions	O	O
of	O	O
spinal	O	O
segments	O	O
(	O	O
L1	O	O
-	O	O
L2	O	O
and	O	O
L6	O	O
-	O	O
S1	O	O
)	O	O
which	O	O
receive	O	O
afferent	O	O
inputs	O	O
from	O	O
the	O	O
bladder	O	O
,	O	O
urethra	O	O
,	O	O
and	O	O
ureter	O	O
.	O	O

Fos	O	O
-	O	O
IR	O	O
in	O	O
the	O	O
spinal	O	O
cord	O	O
was	O	O
not	O	O
changed	O	O
in	O	O
rats	O	O
receiving	O	O
chronic	O	O
CYP	B-Chemical	D003520
treatment	O	O
(	O	O
n	O	O
=	O	O
15	O	O
,	O	O
75	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

,	O	O
every	O	O
3rd	O	O
day	O	O
for	O	O
2	O	O
weeks	O	O
)	O	O
.	O	O

In	O	O
control	O	O
animals	O	O
and	O	O
in	O	O
animals	O	O
treated	O	O
acutely	O	O
with	O	O
CYP	B-Chemical	D003520
,	O	O
only	O	O
small	O	O
numbers	O	O
of	O	O
NOS	O	O
-	O	O
IR	O	O
cells	O	O
(	O	O
0	O	O
.	O	O

5	O	O
-	O	O
0	O	O
.	O	O

7	O	O
cell	O	O
profiles	O	O
/	O	O
sections	O	O
)	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
L6	O	O
-	O	O
S1	O	O
dorsal	O	O
root	O	O
ganglia	O	O
(	O	O
DRG	O	O
)	O	O
.	O	O

Chronic	O	O
CYP	B-Chemical	D003520
administration	O	O
significantly	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
.	O	O

002	O	O
)	O	O
increased	O	O
bladder	O	O
weight	O	O
by	O	O
60%	O	O
and	O	O
increased	O	O
(	O	O
7	O	O
-	O	O
to	O	O
11	O	O
-	O	O
fold	O	O
)	O	O
the	O	O
numbers	O	O
of	O	O
NOS	O	O
-	O	O
immunoreactive	O	O
(	O	O
IR	O	O
)	O	O
afferent	O	O
neurons	O	O
in	O	O
the	O	O
L6	O	O
-	O	O
S1	O	O
DRG	O	O
.	O	O

A	O	O
small	O	O
increase	O	O
(	O	O
1	O	O
.	O	O

5	O	O
-	O	O
fold	O	O
)	O	O
also	O	O
occurred	O	O
in	O	O
the	O	O
L1	O	O
DRG	O	O
,	O	O
but	O	O
no	O	O
change	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
L2	O	O
and	O	O
L5	O	O
DRG	O	O
.	O	O

Bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
L6	O	O
-	O	O
S1	O	O
DRG	O	O
labeled	O	O
by	O	O
Fluorogold	O	O
(	O	O
40	O	O
microliters	O	O
)	O	O
injected	O	O
into	O	O
the	O	O
bladder	O	O
wall	O	O
did	O	O
not	O	O
exhibit	O	O
NOS	O	O
-	O	O
IR	O	O
in	O	O
control	O	O
animals	O	O
;	O	O
however	O	O
,	O	O
following	O	O
chronic	O	O
CYP	B-Chemical	D003520
administration	O	O
,	O	O
a	O	O
significant	O	O
percentage	O	O
of	O	O
bladder	O	O
afferent	O	O
neurons	O	O
were	O	O
NOS	O	O
-	O	O
IR	O	O
:	O	O
L6	O	O
(	O	O
19	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

6%	O	O
)	O	O
and	O	O
S1	O	O
(	O	O
25	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

9%	O	O
)	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
neuronal	O	O
gene	O	O
expression	O	O
in	O	O
visceral	O	O
sensory	O	O
pathways	O	O
can	O	O
be	O	O
upregulated	O	O
by	O	O
chemical	O	O
irritation	O	O
of	O	O
afferent	O	O
receptors	O	O
in	O	O
the	O	O
urinary	O	O
tract	O	O
and	O	O
/	O	O
or	O	O
that	O	O
pathological	O	O
changes	O	O
in	O	O
the	O	O
urinary	O	O
tract	O	O
can	O	O
initiate	O	O
chemical	O	O
signals	O	O
that	O	O
alter	O	O
the	O	O
chemical	O	O
properties	O	O
of	O	O
visceral	O	O
afferent	O	O
neurons	O	O
.	O	O

Effects	O	O
of	O	O
a	O	O
new	O	O
calcium	B-Chemical	D002118
antagonist	O	O
,	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
,	O	O
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
in	O	O
dogs	O	O
with	O	O
partial	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
.	O	O

Effects	O	O
of	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
on	O	O
isoproterenol	B-Chemical	D007545
(	O	O
ISO	B-Chemical	D007545
)	O	O
-	O	O
induced	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
were	O	O
studied	O	O
in	O	O
dogs	O	O
with	O	O
partial	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
of	O	O
the	O	O
left	O	O
circumflex	O	O
coronary	O	O
artery	O	O
and	O	O
findings	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
for	O	O
nifedipine	B-Chemical	D009543
or	O	O
diltiazem	B-Chemical	D004110
.	O	O

In	O	O
the	O	O
presence	O	O
of	O	O
coronary	B-Disease	D023921
artery	I-Disease	D023921
stenosis	I-Disease	D023921
,	O	O
3	O	O
-	O	O
min	O	O
periods	O	O
of	O	O
intracoronary	O	O
ISO	B-Chemical	D007545
infusion	O	O
(	O	O
10	O	O
ng	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
increased	O	O
heart	O	O
rate	O	O
and	O	O
maximal	O	O
rate	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
rise	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
and	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
of	O	O
the	O	O
epicardial	O	O
electrocardiogram	O	O
.	O	O

After	O	O
the	O	O
control	O	O
ISO	B-Chemical	D007545
infusion	O	O
with	O	O
stenosis	B-Disease	D003251
was	O	O
performed	O	O
,	O	O
equihypotensive	O	O
doses	O	O
of	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
(	O	O
3	O	O
and	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
,	O	O
nifedipine	B-Chemical	D009543
(	O	O
1	O	O
and	O	O
3	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
n	O	O
=	O	O
9	O	O
)	O	O
or	O	O
diltiazem	B-Chemical	D004110
(	O	O
10	O	O
and	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
,	O	O
n	O	O
=	O	O
7	O	O
)	O	O
were	O	O
infused	O	O
5	O	O
min	O	O
before	O	O
and	O	O
during	O	O
the	O	O
second	O	O
and	O	O
third	O	O
ISO	B-Chemical	D007545
infusion	O	O
.	O	O

Both	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
and	O	O
diltiazem	B-Chemical	D004110
,	O	O
but	O	O
not	O	O
nifedipine	B-Chemical	D009543
,	O	O
significantly	O	O
reduced	O	O
the	O	O
increase	O	O
in	O	O
heart	O	O
rate	O	O
induced	O	O
by	O	O
ISO	B-Chemical	D007545
infusion	O	O
.	O	O

In	O	O
contrast	O	O
to	O	O
nifedipine	B-Chemical	D009543
,	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
(	O	O
10	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
from	O	O
32	O	O
+	O	O
/	O	O
-	O	O
12%	O	O
to	O	O
115	O	O
+	O	O
/	O	O
-	O	O
26%	O	O
of	O	O
the	O	O
control	O	O
value	O	O
(	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
and	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
from	O	O
5	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

0	O	O
mV	O	O
to	O	O
1	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
mV	O	O
(	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
at	O	O
3	O	O
min	O	O
after	O	O
ISO	B-Chemical	D007545
infusion	O	O
with	O	O
stenosis	B-Disease	D003251
.	O	O

Diltiazem	B-Chemical	D004110
(	O	O
30	O	O
micrograms	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
)	O	O
also	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
percentage	O	O
segmental	O	O
shortening	O	O
from	O	O
34	O	O
+	O	O
/	O	O
-	O	O
14%	O	O
to	O	O
63	O	O
+	O	O
/	O	O
-	O	O
18%	O	O
of	O	O
the	O	O
control	O	O
value	O	O
(	O	O
P	O	O
<	O	O
.	O	O

05	O	O
)	O	O
and	O	O
ST	O	O
-	O	O
segment	O	O
elevation	O	O
from	O	O
4	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
mV	O	O
to	O	O
2	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
mV	O	O
(	O	O
P	O	O
<	O	O
.	O	O

01	O	O
)	O	O
at	O	O
3	O	O
min	O	O
after	O	O
ISO	B-Chemical	D007545
infusion	O	O
with	O	O
stenosis	B-Disease	D003251
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
improves	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
during	O	O
ISO	B-Chemical	D007545
infusion	O	O
with	O	O
stenosis	B-Disease	D003251
and	O	O
suggest	O	O
that	O	O
the	O	O
negative	O	O
chronotropic	O	O
property	O	O
of	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
beneficial	O	O
effects	O	O
of	O	O
CD	B-Chemical	C082828
-	I-Chemical	C082828
832	I-Chemical	C082828
.	O	O

The	O	O
effect	O	O
of	O	O
recombinant	O	O
human	O	O
insulin	O	O
-	O	O
like	O	O
growth	O	O
factor	O	O
-	O	O
I	O	O
on	O	O
chronic	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
nephropathy	B-Disease	D007674
in	O	O
rats	O	O
.	O	O

We	O	O
recently	O	O
demonstrated	O	O
that	O	O
recombinant	O	O
hGH	O	O
exacerbates	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
injury	O	O
in	O	O
chronic	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
nephropathy	B-Disease	D007674
,	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
glomerular	B-Disease	D007674
disease	I-Disease	D007674
.	O	O

Therefore	O	O
,	O	O
we	O	O
examined	O	O
whether	O	O
recombinant	O	O
human	O	O
(	O	O
rh	O	O
)	O	O
IGF	O	O
-	O	O
I	O	O
is	O	O
a	O	O
safer	O	O
alternative	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
growth	B-Disease	D006130
failure	I-Disease	D006130
in	O	O
rats	O	O
with	O	O
chronic	O	O
PAN	B-Chemical	D011692
nephropathy	B-Disease	D007674
.	O	O

The	O	O
glomerulopathy	B-Disease	D007674
was	O	O
induced	O	O
by	O	O
seven	O	O
serial	O	O
injections	O	O
of	O	O
PAN	B-Chemical	D011692
over	O	O
12	O	O
wk	O	O
.	O	O

Experimental	O	O
animals	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
received	O	O
rhIGF	O	O
-	O	O
I	O	O
,	O	O
400	O	O
micrograms	O	O
/	O	O
d	O	O
,	O	O
whereas	O	O
control	O	O
rats	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
received	O	O
the	O	O
vehicle	O	O
.	O	O

rhIGF	O	O
-	O	O
I	O	O
improved	O	O
weight	O	O
gain	O	O
by	O	O
14%	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
without	O	O
altering	O	O
hematocrit	O	O
or	O	O
blood	O	O
pressure	O	O
in	O	O
rats	O	O
with	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
.	O	O

Urinary	O	O
protein	O	O
excretion	O	O
was	O	O
unaltered	O	O
by	O	O
rhIGF	O	O
-	O	O
I	O	O
treatment	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
PAN	B-Chemical	D011692
nephropathy	B-Disease	D007674
.	O	O

After	O	O
12	O	O
wk	O	O
,	O	O
the	O	O
inulin	O	O
clearance	O	O
was	O	O
higher	O	O
in	O	O
rhIGF	O	O
-	O	O
I	O	O
-	O	O
treated	O	O
rats	O	O
,	O	O
0	O	O
.	O	O

48	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

08	O	O
versus	O	O
0	O	O
.	O	O

24	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

06	O	O
mL	O	O
/	O	O
min	O	O
/	O	O
100	O	O
g	O	O
of	O	O
body	O	O
weight	O	O
in	O	O
untreated	O	O
PAN	B-Chemical	D011692
nephropathy	B-Disease	D007674
animals	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
.	O	O

The	O	O
improvement	O	O
in	O	O
GFR	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
enhanced	O	O
glomerular	B-Disease	D007674
hypertrophy	I-Disease	D007674
or	O	O
increased	O	O
segmental	O	O
glomerulosclerosis	B-Disease	D005921
,	O	O
tubulointerstitial	B-Disease	-1
injury	I-Disease	-1
,	O	O
or	O	O
renal	O	O
cortical	O	O
malondialdehyde	B-Chemical	D008315
content	O	O
.	O	O

In	O	O
rats	O	O
with	O	O
PAN	B-Chemical	D011692
nephropathy	B-Disease	D007674
,	O	O
administration	O	O
of	O	O
rhIGF	O	O
-	O	O
I	O	O
increased	O	O
IGF	O	O
-	O	O
I	O	O
and	O	O
GH	O	O
receptor	O	O
gene	O	O
expression	O	O
,	O	O
without	O	O
altering	O	O
the	O	O
steady	O	O
state	O	O
level	O	O
of	O	O
IGF	O	O
-	O	O
I	O	O
receptor	O	O
mRNA	O	O
.	O	O

In	O	O
normal	O	O
rats	O	O
with	O	O
intact	O	O
kidneys	O	O
,	O	O
rhIGF	O	O
-	O	O
I	O	O
administration	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
did	O	O
not	O	O
alter	O	O
weight	O	O
gain	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
proteinuria	B-Disease	D011507
,	O	O
GFR	O	O
,	O	O
glomerular	O	O
planar	O	O
area	O	O
,	O	O
renal	O	O
cortical	O	O
malondialdehyde	B-Chemical	D008315
content	O	O
,	O	O
or	O	O
glomerular	O	O
or	O	O
tubulointerstitial	B-Disease	D007674
damage	I-Disease	D007674
,	O	O
compared	O	O
with	O	O
untreated	O	O
animals	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

rhIGF	O	O
-	O	O
I	O	O
treatment	O	O
reduced	O	O
the	O	O
steady	O	O
state	O	O
renal	O	O
IGF	O	O
-	O	O
I	O	O
mRNA	O	O
level	O	O
but	O	O
did	O	O
not	O	O
modify	O	O
gene	O	O
expression	O	O
of	O	O
the	O	O
IGF	O	O
-	O	O
I	O	O
or	O	O
GH	O	O
receptors	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
:	O	O
1	O	O
)	O	O
administration	O	O
of	O	O
rhIGF	O	O
-	O	O
I	O	O
improves	O	O
growth	O	O
and	O	O
GFR	O	O
in	O	O
rats	O	O
with	O	O
chronic	O	O
PAN	B-Chemical	D011692
nephropathy	B-Disease	D007674
and	O	O
2	O	O
)	O	O
unlike	O	O
rhGH	O	O
,	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
rhIGF	O	O
-	O	O
I	O	O
does	O	O
not	O	O
worsen	O	O
renal	O	O
functional	O	O
and	O	O
structural	O	O
injury	O	O
in	O	O
this	O	O
disease	O	O
model	O	O
.	O	O

Nefiracetam	B-Chemical	C058876
(	O	O
DM	B-Chemical	C058876
-	I-Chemical	C058876
9384	I-Chemical	C058876
)	O	O
reverses	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
amnesia	B-Disease	D000647
of	O	O
a	O	O
passive	O	O
avoidance	O	O
response	O	O
:	O	O
delayed	O	O
emergence	O	O
of	O	O
the	O	O
memory	O	O
retention	O	O
effects	O	O
.	O	O

Nefiracetam	B-Chemical	C058876
is	O	O
a	O	O
novel	O	O
pyrrolidone	B-Chemical	D011760
derivative	O	O
which	O	O
attenuates	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
learning	B-Disease	D007859
and	I-Disease	D007859
post	I-Disease	D007859
-	I-Disease	D007859
training	I-Disease	D007859
consolidation	I-Disease	D007859
deficits	I-Disease	D007859
.	O	O

Given	O	O
that	O	O
apomorphine	B-Chemical	D001058
inhibits	O	O
passive	O	O
avoidance	O	O
retention	O	O
when	O	O
given	O	O
during	O	O
training	O	O
or	O	O
in	O	O
a	O	O
defined	O	O
10	O	O
-	O	O
12h	O	O
post	O	O
-	O	O
training	O	O
period	O	O
,	O	O
we	O	O
evaluated	O	O
the	O	O
ability	O	O
of	O	O
nefiracetam	B-Chemical	C058876
to	O	O
attenuate	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
dopaminergic	O	O
agonism	O	O
.	O	O

A	O	O
step	O	O
-	O	O
down	O	O
passive	O	O
avoidance	O	O
paradigm	O	O
was	O	O
employed	O	O
and	O	O
nefiracetam	B-Chemical	C058876
(	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
apomorphine	B-Chemical	D001058
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
given	O	O
alone	O	O
or	O	O
in	O	O
combination	O	O
during	O	O
training	O	O
and	O	O
at	O	O
the	O	O
10	O	O
-	O	O
12h	O	O
post	O	O
-	O	O
training	O	O
period	O	O
of	O	O
consolidation	O	O
.	O	O

Co	O	O
-	O	O
administration	O	O
of	O	O
nefiracetam	B-Chemical	C058876
and	O	O
apomorphine	B-Chemical	D001058
during	O	O
training	O	O
or	O	O
10h	O	O
thereafter	O	O
produced	O	O
no	O	O
significant	O	O
anti	O	O
-	O	O
amnesic	O	O
effect	O	O
.	O	O

However	O	O
,	O	O
administration	O	O
of	O	O
nefiracetam	B-Chemical	C058876
during	O	O
training	O	O
completely	O	O
reversed	O	O
the	O	O
amnesia	B-Disease	D000647
induced	O	O
by	O	O
apomorphine	B-Chemical	D001058
at	O	O
the	O	O
10h	O	O
post	O	O
-	O	O
training	O	O
time	O	O
and	O	O
the	O	O
converse	O	O
was	O	O
also	O	O
true	O	O
.	O	O

These	O	O
effects	O	O
were	O	O
not	O	O
mediated	O	O
by	O	O
a	O	O
dopaminergic	O	O
mechanism	O	O
as	O	O
nefiracetam	B-Chemical	C058876
,	O	O
at	O	O
millimolar	O	O
concentrations	O	O
,	O	O
failed	O	O
to	O	O
displace	O	O
either	O	O
[	O	O
3H	O	O
]	O	O
SCH	B-Chemical	C534628
23390	I-Chemical	C534628
or	O	O
[	O	O
3H	O	O
]	O	O
spiperone	B-Chemical	D013134
binding	O	O
from	O	O
D1	O	O
or	O	O
D2	O	O
dopamine	B-Chemical	D004298
receptor	O	O
subtypes	O	O
,	O	O
respectively	O	O
.	O	O

It	O	O
is	O	O
suggested	O	O
that	O	O
nefiracetam	B-Chemical	C058876
augments	O	O
molecular	O	O
processes	O	O
in	O	O
the	O	O
early	O	O
stages	O	O
of	O	O
events	O	O
which	O	O
ultimately	O	O
lead	O	O
to	O	O
consolidation	O	O
of	O	O
memory	O	O
.	O	O

Human	O	O
corticotropin	B-Chemical	D000324
-	O	O
releasing	O	O
hormone	O	O
and	O	O
thyrotropin	B-Chemical	D013972
-	O	O
releasing	O	O
hormone	O	O
modulate	O	O
the	O	O
hypercapnic	B-Disease	D006935
ventilatory	O	O
response	O	O
in	O	O
humans	O	O
.	O	O

Human	O	O
corticotropin	B-Chemical	D000324
-	O	O
releasing	O	O
hormone	O	O
(	O	O
hCRH	O	O
)	O	O
and	O	O
thyrotropin	B-Chemical	D013972
-	O	O
releasing	O	O
hormone	O	O
(	O	O
TRH	O	O
)	O	O
are	O	O
known	O	O
to	O	O
stimulate	O	O
ventilation	O	O
after	O	O
i	O	O
.	O	O

v	O	O
.	O	O

administration	O	O
in	O	O
humans	O	O
.	O	O

In	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
single	O	O
-	O	O
blind	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
clarify	O	O
if	O	O
both	O	O
peptides	O	O
act	O	O
by	O	O
altering	O	O
central	O	O
chemosensitivity	O	O
.	O	O

Two	O	O
subsequent	O	O
CO2	B-Chemical	D002245
-	O	O
rebreathing	O	O
tests	O	O
were	O	O
performed	O	O
in	O	O
healthy	O	O
young	O	O
volunteers	O	O
.	O	O

During	O	O
the	O	O
first	O	O
test	O	O
0	O	O
.	O	O

9%	O	O
NaCl	B-Chemical	D012965
was	O	O
given	O	O
i	O	O
.	O	O

v	O	O
.	O	O

;	O	O
during	O	O
the	O	O
second	O	O
test	O	O
200	O	O
micrograms	O	O
of	O	O
hCRH	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
or	O	O
400	O	O
micrograms	O	O
of	O	O
TRH	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
was	O	O
administered	O	O
i	O	O
.	O	O

v	O	O
.	O	O

Nine	O	O
subjects	O	O
received	O	O
0	O	O
.	O	O

9%	O	O
NaCl	B-Chemical	D012965
i	O	O
.	O	O

v	O	O
.	O	O

during	O	O
both	O	O
rebreathing	O	O
manoeuvres	O	O
.	O	O

The	O	O
CO2	B-Chemical	D002245
-	O	O
response	O	O
curves	O	O
for	O	O
the	O	O
two	O	O
tests	O	O
were	O	O
compared	O	O
within	O	O
the	O	O
same	O	O
subject	O	O
.	O	O

In	O	O
the	O	O
hCRH	O	O
group	O	O
a	O	O
marked	O	O
parallel	O	O
shift	O	O
of	O	O
the	O	O
CO2	B-Chemical	D002245
-	O	O
response	O	O
curve	O	O
to	O	O
the	O	O
left	O	O
was	O	O
observed	O	O
after	O	O
hCRH	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

The	O	O
same	O	O
effect	O	O
occurred	O	O
following	O	O
TRH	O	O
but	O	O
was	O	O
less	O	O
striking	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

hCRH	O	O
and	O	O
TRH	O	O
caused	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
CO2	B-Chemical	D002245
threshold	O	O
.	O	O

The	O	O
CO2	B-Chemical	D002245
-	O	O
response	O	O
curves	O	O
in	O	O
the	O	O
control	O	O
group	O	O
were	O	O
nearly	O	O
identical	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
an	O	O
additive	O	O
effect	O	O
of	O	O
both	O	O
releasing	O	O
hormones	O	O
on	O	O
the	O	O
hypercapnic	B-Disease	D006935
ventilatory	O	O
response	O	O
in	O	O
humans	O	O
,	O	O
presumably	O	O
independent	O	O
of	O	O
central	O	O
chemosensitivity	O	O
.	O	O

Lamivudine	B-Chemical	D019259
is	O	O
effective	O	O
in	O	O
suppressing	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
DNA	O	O
in	O	O
Chinese	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
surface	O	O
antigen	O	O
carriers	O	O
:	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
trial	O	O
.	O	O

Lamivudine	B-Chemical	D019259
is	O	O
a	O	O
novel	O	O
2'	B-Chemical	D019259
,	I-Chemical	D019259
3'	I-Chemical	D019259
-	I-Chemical	D019259
dideoxy	I-Chemical	D019259
cytosine	I-Chemical	D019259
analogue	O	O
that	O	O
has	O	O
potent	O	O
inhibitory	O	O
effects	O	O
on	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
replication	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
single	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
to	O	O
assess	O	O
its	O	O
effectiveness	O	O
and	O	O
safety	O	O
in	O	O
Chinese	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
surface	O	O
antigen	O	O
(	O	O
HBsAg	B-Chemical	D006514
)	O	O
carriers	O	O
.	O	O

Forty	O	O
-	O	O
two	O	O
Chinese	O	O
HBsAg	B-Chemical	D006514
carriers	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
placebo	O	O
(	O	O
6	O	O
patients	O	O
)	O	O
or	O	O
lamivudine	B-Chemical	D019259
orally	O	O
in	O	O
dosages	O	O
of	O	O
25	O	O
mg	O	O
,	O	O
100	O	O
mg	O	O
,	O	O
or	O	O
300	O	O
mg	O	O
daily	O	O
(	O	O
12	O	O
patients	O	O
for	O	O
each	O	O
dosage	O	O
)	O	O
.	O	O

The	O	O
drug	O	O
was	O	O
given	O	O
for	O	O
4	O	O
weeks	O	O
.	O	O

The	O	O
patients	O	O
were	O	O
closely	O	O
monitored	O	O
clinically	O	O
,	O	O
biochemically	O	O
,	O	O
and	O	O
serologically	O	O
up	O	O
to	O	O
4	O	O
weeks	O	O
after	O	O
drug	O	O
treatment	O	O
.	O	O

All	O	O
36	O	O
patients	O	O
receiving	O	O
lamivudine	B-Chemical	D019259
had	O	O
a	O	O
decrease	O	O
in	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
(	O	O
HBV	O	O
)	O	O
DNA	O	O
values	O	O
of	O	O
>90%	O	O
(	O	O
P	O	O
<	O	O
.	O	O

001	O	O
compared	O	O
with	O	O
placebo	O	O
)	O	O
.	O	O

Although	O	O
25	O	O
mg	O	O
of	O	O
lamivudine	B-Chemical	D019259
was	O	O
slightly	O	O
less	O	O
effective	O	O
than	O	O
100	O	O
mg	O	O
(	O	O
P	O	O
=	O	O
.	O	O

011	O	O
)	O	O
and	O	O
300	O	O
mg	O	O
(	O	O
P	O	O
=	O	O
.	O	O

005	O	O
)	O	O
,	O	O
it	O	O
still	O	O
induced	O	O
94%	O	O
suppression	O	O
of	O	O
HBV	O	O
DNA	O	O
after	O	O
the	O	O
fourth	O	O
week	O	O
of	O	O
therapy	O	O
.	O	O

HBV	O	O
DNA	O	O
values	O	O
returned	O	O
to	O	O
pretreatment	O	O
levels	O	O
within	O	O
4	O	O
weeks	O	O
of	O	O
cessation	O	O
of	O	O
therapy	O	O
.	O	O

There	O	O
was	O	O
no	O	O
change	O	O
in	O	O
the	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
e	O	O
antigen	O	O
status	O	O
or	O	O
in	O	O
aminotransferase	O	O
levels	O	O
.	O	O

No	O	O
serious	O	O
adverse	O	O
events	O	O
were	O	O
observed	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
a	O	O
4	O	O
-	O	O
week	O	O
course	O	O
of	O	O
lamivudine	B-Chemical	D019259
was	O	O
safe	O	O
and	O	O
effective	O	O
in	O	O
suppression	O	O
of	O	O
HBV	O	O
DNA	O	O
in	O	O
Chinese	O	O
HBsAg	B-Chemical	D006514
carriers	O	O
.	O	O

The	O	O
suppression	O	O
was	O	O
>90%	O	O
but	O	O
reversible	O	O
.	O	O

Studies	O	O
with	O	O
long	O	O
-	O	O
term	O	O
lamivudine	B-Chemical	D019259
administration	O	O
should	O	O
be	O	O
performed	O	O
to	O	O
determine	O	O
if	O	O
prolonged	O	O
suppression	O	O
of	O	O
HBV	O	O
DNA	O	O
can	O	O
be	O	O
achieved	O	O
.	O	O

Population	O	O
-	O	O
based	O	O
study	O	O
of	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
associated	O	O
with	O	O
various	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
.	O	O

BACKGROUND	O	O
:	O	O
Four	O	O
studies	O	O
published	O	O
since	O	O
December	O	O
,	O	O
1995	O	O
,	O	O
reported	O	O
that	O	O
the	O	O
incidence	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
(	O	O
VTE	B-Disease	D054556
)	O	O
was	O	O
higher	O	O
in	O	O
women	O	O
who	O	O
used	O	O
oral	B-Chemical	D003276
contraceptives	I-Chemical	D003276
(	O	O
OCs	B-Chemical	D003276
)	O	O
containing	O	O
the	O	O
third	O	O
-	O	O
generation	O	O
progestagens	B-Chemical	D011374
gestodene	B-Chemical	C033273
or	O	O
desogestrel	B-Chemical	D017135
than	O	O
in	O	O
users	O	O
of	O	O
OCs	B-Chemical	D003276
containing	O	O
second	O	O
-	O	O
generation	O	O
progestagens	B-Chemical	D011374
.	O	O

However	O	O
,	O	O
confounding	O	O
and	O	O
bias	O	O
in	O	O
the	O	O
design	O	O
of	O	O
these	O	O
studies	O	O
may	O	O
have	O	O
affected	O	O
the	O	O
findings	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
our	O	O
study	O	O
was	O	O
to	O	O
re	O	O
-	O	O
examine	O	O
the	O	O
association	O	O
between	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
and	O	O
OC	B-Chemical	D003276
use	O	O
with	O	O
a	O	O
different	O	O
study	O	O
design	O	O
and	O	O
analysis	O	O
to	O	O
avoid	O	O
some	O	O
of	O	O
the	O	O
bias	O	O
and	O	O
confounding	O	O
of	O	O
the	O	O
earlier	O	O
studies	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
used	O	O
computer	O	O
records	O	O
of	O	O
patients	O	O
from	O	O
143	O	O
general	O	O
practices	O	O
in	O	O
the	O	O
UK	O	O
.	O	O

The	O	O
study	O	O
was	O	O
based	O	O
on	O	O
the	O	O
medical	O	O
records	O	O
of	O	O
about	O	O
540	O	O
,	O	O
000	O	O
women	O	O
born	O	O
between	O	O
1941	O	O
and	O	O
1981	O	O
.	O	O

All	O	O
women	O	O
who	O	O
had	O	O
a	O	O
recorded	O	O
diagnosis	O	O
of	O	O
deep	B-Disease	D020246
-	I-Disease	D020246
vein	I-Disease	D020246
thrombosis	I-Disease	D020246
,	O	O
venous	B-Disease	D020246
thrombosis	I-Disease	D020246
not	O	O
otherwise	O	O
specified	O	O
,	O	O
or	O	O
pulmonary	O	O
embolus	O	O
during	O	O
the	O	O
study	O	O
period	O	O
,	O	O
and	O	O
who	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
an	O	O
anticoagulant	O	O
were	O	O
identified	O	O
as	O	O
potential	O	O
cases	O	O
of	O	O
VTE	B-Disease	D054556
.	O	O

We	O	O
did	O	O
a	O	O
cohort	O	O
analysis	O	O
to	O	O
estimate	O	O
and	O	O
compare	O	O
incidence	O	O
of	O	O
VTE	B-Disease	D054556
in	O	O
users	O	O
of	O	O
the	O	O
main	O	O
OC	B-Chemical	D003276
preparations	O	O
,	O	O
and	O	O
a	O	O
nested	O	O
case	O	O
-	O	O
control	O	O
study	O	O
to	O	O
calculate	O	O
the	O	O
odds	O	O
ratios	O	O
of	O	O
VTE	B-Disease	D054556
associated	O	O
with	O	O
use	O	O
of	O	O
different	O	O
types	O	O
of	O	O
OC	B-Chemical	D003276
,	O	O
after	O	O
adjustment	O	O
for	O	O
potential	O	O
confounding	O	O
factors	O	O
.	O	O

In	O	O
the	O	O
case	O	O
-	O	O
control	O	O
study	O	O
,	O	O
we	O	O
matched	O	O
cases	O	O
to	O	O
controls	O	O
by	O	O
exact	O	O
year	O	O
of	O	O
birth	O	O
,	O	O
practice	O	O
,	O	O
and	O	O
current	O	O
use	O	O
of	O	O
OCs	B-Chemical	D003276
.	O	O

We	O	O
used	O	O
a	O	O
multiple	O	O
logistic	O	O
regression	O	O
model	O	O
that	O	O
included	O	O
body	O	O
-	O	O
mass	O	O
index	O	O
,	O	O
number	O	O
of	O	O
cycles	O	O
,	O	O
change	O	O
in	O	O
type	O	O
of	O	O
OC	B-Chemical	D003276
prescribed	O	O
within	O	O
3	O	O
months	O	O
of	O	O
the	O	O
event	O	O
,	O	O
previous	O	O
pregnancy	O	O
,	O	O
and	O	O
concurrent	O	O
disease	O	O
.	O	O

FINDINGS	O	O
:	O	O
85	O	O
women	O	O
met	O	O
the	O	O
inclusion	O	O
criteria	O	O
for	O	O
VTE	B-Disease	D054556
,	O	O
two	O	O
of	O	O
whom	O	O
were	O	O
users	O	O
of	O	O
progestagen	B-Chemical	D011372
-	O	O
only	O	O
OCs	B-Chemical	D003276
.	O	O

Of	O	O
the	O	O
83	O	O
cases	O	O
of	O	O
VTE	B-Disease	D054556
associated	O	O
with	O	O
use	O	O
of	O	O
combined	O	O
OCs	B-Chemical	D003276
,	O	O
43	O	O
were	O	O
recorded	O	O
as	O	O
deep	B-Disease	D020246
-	I-Disease	D020246
vein	I-Disease	D020246
thrombosis	I-Disease	D020246
,	O	O
35	O	O
as	O	O
pulmonary	O	O
thrombosis	B-Disease	D013927
,	O	O
and	O	O
five	O	O
as	O	O
venous	B-Disease	D020246
thrombosis	I-Disease	D020246
not	O	O
otherwise	O	O
specified	O	O
.	O	O

The	O	O
crude	O	O
rate	O	O
of	O	O
VTE	B-Disease	D054556
per	O	O
10	O	O
,	O	O
000	O	O
woman	O	O
-	O	O
years	O	O
was	O	O
4	O	O
.	O	O

10	O	O
in	O	O
current	O	O
users	O	O
of	O	O
any	O	O
OC	B-Chemical	D003276
,	O	O
3	O	O
.	O	O

10	O	O
in	O	O
users	O	O
of	O	O
second	O	O
-	O	O
generation	O	O
OCs	B-Chemical	D003276
,	O	O
and	O	O
4	O	O
.	O	O

96	O	O
in	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
preparations	O	O
.	O	O

After	O	O
adjustment	O	O
for	O	O
age	O	O
,	O	O
the	O	O
rate	O	O
ratio	O	O
of	O	O
VTE	B-Disease	D054556
in	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
relative	O	O
to	O	O
second	O	O
-	O	O
generation	O	O
OCs	B-Chemical	D003276
was	O	O
1	O	O
.	O	O

68	O	O
(	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

04	O	O
-	O	O
2	O	O
.	O	O

75	O	O
)	O	O
.	O	O

Logistic	O	O
regression	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
between	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
and	O	O
second	O	O
-	O	O
generation	O	O
OCs	B-Chemical	D003276
.	O	O

Among	O	O
users	O	O
of	O	O
third	O	O
-	O	O
generation	O	O
progestagens	B-Chemical	D011374
,	O	O
the	O	O
risk	O	O
of	O	O
VTE	B-Disease	D054556
was	O	O
higher	O	O
in	O	O
users	O	O
of	O	O
desogestrel	B-Chemical	D017135
with	O	O
20	O	O
g	O	O
ethinyloestradiol	B-Chemical	D004997
than	O	O
in	O	O
users	O	O
of	O	O
gestodene	B-Chemical	C033273
or	O	O
desogestrel	B-Chemical	D017135
with	O	O
30	O	O
g	O	O
ethinyloestradiol	B-Chemical	D004997
.	O	O

With	O	O
all	O	O
second	O	O
-	O	O
generation	O	O
OCs	B-Chemical	D003276
as	O	O
the	O	O
reference	O	O
,	O	O
the	O	O
odds	O	O
ratios	O	O
for	O	O
VTE	B-Disease	D054556
were	O	O
3	O	O
.	O	O

49	O	O
(	O	O
1	O	O
.	O	O

21	O	O
-	O	O
10	O	O
.	O	O

12	O	O
)	O	O
for	O	O
desogestrel	B-Chemical	D017135
plus	O	O
20	O	O
g	O	O
ethinyloestradiol	B-Chemical	D004997
and	O	O
1	O	O
.	O	O

18	O	O
(	O	O
0	O	O
.	O	O

66	O	O
-	O	O
2	O	O
.	O	O

17	O	O
)	O	O
for	O	O
the	O	O
other	O	O
third	O	O
-	O	O
generation	O	O
progestagens	B-Chemical	D011374
.	O	O

INTERPRETATION	O	O
:	O	O
The	O	O
previously	O	O
reported	O	O
increase	O	O
in	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
third	O	O
-	O	O
generation	O	O
OCs	B-Chemical	D003276
when	O	O
compared	O	O
with	O	O
second	O	O
-	O	O
generation	O	O
products	O	O
is	O	O
likely	O	O
to	O	O
have	O	O
been	O	O
the	O	O
result	O	O
of	O	O
residual	O	O
confounding	O	O
by	O	O
age	O	O
.	O	O

The	O	O
increased	O	O
odds	O	O
ratio	O	O
associated	O	O
with	O	O
products	O	O
containing	O	O
20	O	O
micrograms	O	O
ethinyloestradiol	B-Chemical	D004997
and	O	O
desogestrel	B-Chemical	D017135
compared	O	O
with	O	O
the	O	O
30	O	O
micrograms	O	O
product	O	O
is	O	O
biologically	O	O
implausible	O	O
,	O	O
and	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
the	O	O
result	O	O
of	O	O
preferential	O	O
prescribing	O	O
and	O	O
,	O	O
thus	O	O
,	O	O
confounding	O	O
.	O	O

MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
augments	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
electrographic	O	O
seizure	B-Disease	D012640
but	O	O
protects	O	O
against	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
in	O	O
rats	O	O
.	O	O

1	O	O
.	O	O

The	O	O
authors	O	O
examined	O	O
the	O	O
anticonvulsant	O	O
effects	O	O
of	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
on	O	O
the	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizure	B-Disease	D012640
model	O	O
.	O	O

Intraperitoneal	O	O
injection	O	O
of	O	O
pilocarpine	B-Chemical	D010862
(	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
induced	O	O
tonic	B-Disease	D012640
and	I-Disease	D012640
clonic	I-Disease	D012640
seizure	I-Disease	D012640
.	O	O

Scopolamine	B-Chemical	D012601
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pentobarbital	B-Chemical	D010424
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
prevented	O	O
development	O	O
of	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
behavioral	O	O
seizure	B-Disease	D012640
but	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
(	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
did	O	O
not	O	O
.	O	O

2	O	O
.	O	O

An	O	O
electrical	O	O
seizure	B-Disease	D012640
measured	O	O
with	O	O
hippocampal	O	O
EEG	O	O
appeared	O	O
in	O	O
the	O	O
pilocarpine	B-Chemical	D010862
-	O	O
treated	O	O
group	O	O
.	O	O

Scopolamine	B-Chemical	D012601
and	O	O
pentobarbital	B-Chemical	D010424
blocked	O	O
the	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
electrographic	O	O
seizure	B-Disease	D012640
,	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
treatment	O	O
augmented	O	O
the	O	O
electrographic	O	O
seizure	B-Disease	D012640
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
.	O	O

3	O	O
.	O	O

Brain	B-Disease	D001930
damage	I-Disease	D001930
was	O	O
assessed	O	O
by	O	O
examining	O	O
the	O	O
hippocampus	O	O
microscopically	O	O
.	O	O

Pilocarpine	B-Chemical	D010862
produced	O	O
neuronal	B-Disease	D009410
death	I-Disease	D009410
in	O	O
the	O	O
hippocampus	O	O
,	O	O
which	O	O
showed	O	O
pyknotic	O	O
changes	O	O
.	O	O

Pentobarbital	B-Chemical	D010424
,	O	O
scopolamine	B-Chemical	D012601
and	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
protected	O	O
the	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
by	O	O
pilocarpine	B-Chemical	D010862
,	O	O
though	O	O
in	O	O
the	O	O
MK	B-Chemical	D016291
-	I-Chemical	D016291
801	I-Chemical	D016291
-	O	O
treated	O	O
group	O	O
,	O	O
the	O	O
pyramidal	O	O
cells	O	O
of	O	O
hippocampus	O	O
appeared	O	O
darker	O	O
than	O	O
normal	O	O
.	O	O

In	O	O
all	O	O
treatments	O	O
,	O	O
granule	O	O
cells	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
were	O	O
not	O	O
affected	O	O
.	O	O

4	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
is	O	O
initiated	O	O
by	O	O
cholinergic	O	O
overstimulation	O	O
and	O	O
propagated	O	O
by	O	O
glutamatergic	O	O
transmission	O	O
,	O	O
the	O	O
elevation	O	O
of	O	O
which	O	O
may	O	O
cause	O	O
brain	B-Disease	D001930
damage	I-Disease	D001930
through	O	O
an	O	O
excitatory	O	O
NMDA	B-Chemical	D016202
receptor	O	O
-	O	O
mediated	O	O
mechanism	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
,	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
,	O	O
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
in	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
:	O	O
BRE	O	O
-	O	O
26	O	O
,	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
.	O	O

5	B-Chemical	D005472
-	I-Chemical	D005472
Fluorouracil	I-Chemical	D005472
plus	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
and	O	O
paclitaxel	B-Chemical	D017239
(	O	O
Taxol	B-Chemical	D017239
;	O	O
Bristol	O	O
-	O	O
Myers	O	O
Squibb	O	O
Company	O	O
,	O	O
Princeton	O	O
,	O	O
NJ	O	O
)	O	O
are	O	O
effective	O	O
salvage	O	O
therapies	O	O
for	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
patients	O	O
.	O	O

Paclitaxel	B-Chemical	D017239
and	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
have	O	O
additive	O	O
cytotoxicity	B-Disease	D064420
in	O	O
MCF	O	O
-	O	O
7	O	O
cell	O	O
lines	O	O
.	O	O

We	O	O
performed	O	O
a	O	O
phase	O	O
II	O	O
trial	O	O
of	O	O
paclitaxel	B-Chemical	D017239
175	O	O
mg	O	O
/	O	O
m2	O	O
over	O	O
3	O	O
hours	O	O
on	O	O
day	O	O
I	O	O
followed	O	O
by	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
300	O	O
mg	O	O
over	O	O
1	O	O
hour	O	O
before	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
350	O	O
mg	O	O
/	O	O
m2	O	O
on	O	O
days	O	O
1	O	O
to	O	O
3	O	O
every	O	O
28	O	O
days	O	O
(	O	O
TFL	O	O
)	O	O
in	O	O
women	O	O
with	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Analysis	O	O
is	O	O
reported	O	O
on	O	O
37	O	O
patients	O	O
with	O	O
a	O	O
minimum	O	O
of	O	O
6	O	O
months	O	O
follow	O	O
-	O	O
up	O	O
who	O	O
received	O	O
a	O	O
total	O	O
of	O	O
192	O	O
cycles	O	O
of	O	O
TFL	O	O
:	O	O
nine	O	O
cycles	O	O
(	O	O
5%	O	O
)	O	O
were	O	O
associated	O	O
with	O	O
grade	O	O
3	O	O
/	O	O
4	O	O
neutropenia	B-Disease	D009503
requiring	O	O
hospitalization	O	O
;	O	O
seven	O	O
(	O	O
4%	O	O
)	O	O
cycles	O	O
in	O	O
two	O	O
patients	O	O
required	O	O
granulocyte	B-Chemical	D016179
colony	I-Chemical	D016179
-	I-Chemical	D016179
stimulating	I-Chemical	D016179
factor	I-Chemical	D016179
due	O	O
to	O	O
neutropenia	B-Disease	D009503
;	O	O
no	O	O
patient	O	O
required	O	O
platelet	O	O
transfusions	O	O
.	O	O

Grade	O	O
3	O	O
/	O	O
4	O	O
nonhematologic	O	O
toxicities	B-Disease	D064420
were	O	O
uncommon	O	O
.	O	O

Among	O	O
the	O	O
34	O	O
patients	O	O
evaluable	O	O
for	O	O
response	O	O
,	O	O
there	O	O
were	O	O
three	O	O
complete	O	O
responses	O	O
(	O	O
9%	O	O
)	O	O
and	O	O
18	O	O
partial	O	O
responses	O	O
(	O	O
53%	O	O
)	O	O
for	O	O
an	O	O
overall	O	O
response	O	O
rate	O	O
of	O	O
62%	O	O
.	O	O

Of	O	O
the	O	O
19	O	O
evaluable	O	O
patients	O	O
with	O	O
prior	O	O
doxorubicin	B-Chemical	D004317
exposure	O	O
,	O	O
11	O	O
(	O	O
58%	O	O
)	O	O
responded	O	O
compared	O	O
with	O	O
nine	O	O
of	O	O
15	O	O
(	O	O
60%	O	O
)	O	O
without	O	O
prior	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Plasma	O	O
paclitaxel	B-Chemical	D017239
concentrations	O	O
were	O	O
measured	O	O
at	O	O
the	O	O
completion	O	O
of	O	O
paclitaxel	B-Chemical	D017239
infusion	O	O
and	O	O
at	O	O
24	O	O
hours	O	O
in	O	O
19	O	O
patients	O	O
.	O	O

TFL	O	O
is	O	O
an	O	O
active	O	O
,	O	O
well	O	O
-	O	O
tolerated	O	O
regimen	O	O
in	O	O
metastatic	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
.	O	O

Efficacy	O	O
and	O	O
proarrhythmia	B-Disease	-1
with	O	O
the	O	O
use	O	O
of	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
for	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachyarrhythmias	I-Disease	D017180
.	O	O

This	O	O
study	O	O
prospectively	O	O
evaluated	O	O
the	O	O
clinical	O	O
efficacy	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
,	O	O
and	O	O
the	O	O
presumable	O	O
risk	O	O
factors	O	O
for	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
in	O	O
patients	O	O
treated	O	O
with	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
for	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachyarrhythmias	I-Disease	D017180
.	O	O

Eighty	O	O
-	O	O
one	O	O
consecutive	O	O
patients	O	O
(	O	O
54	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
and	O	O
20	O	O
with	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
)	O	O
with	O	O
inducible	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
or	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
received	O	O
oral	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
to	O	O
prevent	O	O
induction	O	O
of	O	O
the	O	O
ventricular	B-Disease	D017180
tachyarrhythmia	I-Disease	D017180
.	O	O

During	O	O
oral	O	O
loading	O	O
with	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
,	O	O
continuous	O	O
electrocardiographic	O	O
(	O	O
ECG	O	O
)	O	O
monitoring	O	O
was	O	O
performed	O	O
.	O	O

Those	O	O
patients	O	O
in	O	O
whom	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
prevented	O	O
induction	O	O
of	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
or	O	O
ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
were	O	O
discharged	O	O
with	O	O
the	O	O
drug	O	O
and	O	O
followed	O	O
up	O	O
on	O	O
an	O	O
outpatient	O	O
basis	O	O
for	O	O
21	O	O
+	O	O
/	O	O
-	O	O
18	O	O
months	O	O
.	O	O

Induction	O	O
of	O	O
the	O	O
ventricular	B-Disease	D017180
tachyarrhythmia	I-Disease	D017180
was	O	O
prevented	O	O
by	O	O
oral	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
in	O	O
35	O	O
(	O	O
43%	O	O
)	O	O
patients	O	O
;	O	O
the	O	O
ventricular	B-Disease	D017180
tachyarrhythmia	I-Disease	D017180
remained	O	O
inducible	O	O
in	O	O
40	O	O
(	O	O
49%	O	O
)	O	O
patients	O	O
;	O	O
and	O	O
two	O	O
(	O	O
2	O	O
.	O	O

5%	O	O
)	O	O
patients	O	O
did	O	O
not	O	O
tolerate	O	O
even	O	O
40	O	O
mg	O	O
of	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
once	O	O
daily	O	O
.	O	O

Four	O	O
(	O	O
5%	O	O
)	O	O
patients	O	O
had	O	O
from	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
during	O	O
the	O	O
initial	O	O
oral	O	O
treatment	O	O
with	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
.	O	O

Neither	O	O
ECG	O	O
[	O	O
sinus	O	O
-	O	O
cycle	O	O
length	O	O
(	O	O
SCL	O	O
)	O	O
,	O	O
QT	O	O
or	O	O
QTc	O	O
interval	O	O
,	O	O
or	O	O
U	O	O
wave	O	O
]	O	O
nor	O	O
clinical	O	O
parameters	O	O
identified	O	O
patients	O	O
at	O	O
risk	O	O
for	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

However	O	O
,	O	O
the	O	O
oral	O	O
dose	O	O
of	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
was	O	O
significantly	O	O
lower	O	O
in	O	O
patients	O	O
with	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
200	O	O
+	O	O
/	O	O
-	O	O
46	O	O
vs	O	O
.	O	O

328	O	O
+	O	O
/	O	O
-	O	O
53	O	O
mg	O	O
/	O	O
day	O	O
;	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0017	O	O
)	O	O
.	O	O

Risk	O	O
factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
were	O	O
the	O	O
appearance	O	O
of	O	O
an	O	O
U	O	O
wave	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

049	O	O
)	O	O
,	O	O
female	O	O
gender	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

015	O	O
)	O	O
,	O	O
and	O	O
significant	O	O
dose	O	O
-	O	O
corrected	O	O
changes	O	O
of	O	O
SCL	O	O
,	O	O
QT	O	O
interval	O	O
,	O	O
and	O	O
QTc	O	O
interval	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

During	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
seven	O	O
(	O	O
20%	O	O
)	O	O
patients	O	O
had	O	O
a	O	O
nonfatal	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
recurrence	O	O
,	O	O
and	O	O
two	O	O
(	O	O
6%	O	O
)	O	O
patients	O	O
died	O	O
suddenly	O	O
.	O	O

One	O	O
female	O	O
patient	O	O
with	O	O
stable	O	O
cardiac	B-Disease	D006331
disease	I-Disease	D006331
had	O	O
recurrent	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
after	O	O
2	O	O
years	O	O
of	O	O
successful	O	O
treatment	O	O
with	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
.	O	O

Torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
occurred	O	O
early	O	O
during	O	O
treatment	O	O
even	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
oral	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
.	O	O

Pronounced	O	O
changes	O	O
in	O	O
the	O	O
surface	O	O
ECG	O	O
(	O	O
cycle	O	O
length	O	O
,	O	O
QT	O	O
,	O	O
and	O	O
QTc	O	O
)	O	O
in	O	O
relation	O	O
to	O	O
the	O	O
dose	O	O
of	O	O
oral	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
might	O	O
identify	O	O
a	O	O
subgroup	O	O
of	O	O
patients	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

Other	O	O
ECG	O	O
parameters	O	O
before	O	O
the	O	O
application	O	O
of	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
did	O	O
not	O	O
identify	O	O
patients	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

Recurrence	O	O
rates	O	O
of	O	O
ventricular	B-Disease	D017180
tachyarrhythmias	I-Disease	D017180
are	O	O
high	O	O
despite	O	O
complete	O	O
suppression	O	O
of	O	O
the	O	O
arrhythmia	B-Disease	D001145
during	O	O
programmed	O	O
stimulation	O	O
.	O	O

Therefore	O	O
programmed	O	O
electrical	O	O
stimulation	O	O
in	O	O
the	O	O
case	O	O
of	O	O
d	B-Chemical	D013015
,	I-Chemical	D013015
l	I-Chemical	D013015
-	I-Chemical	D013015
sotalol	I-Chemical	D013015
seems	O	O
to	O	O
be	O	O
of	O	O
limited	O	O
prognostic	O	O
value	O	O
.	O	O

Chronic	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
changes	O	O
in	O	O
dopamine	B-Chemical	D004298
neurons	O	O
.	O	O

The	O	O
tuberoinfundibular	O	O
dopaminergic	O	O
(	O	O
TIDA	O	O
)	O	O
system	O	O
is	O	O
known	O	O
to	O	O
inhibit	O	O
prolactin	O	O
(	O	O
PRL	O	O
)	O	O
secretion	O	O
.	O	O

In	O	O
young	O	O
animals	O	O
this	O	O
system	O	O
responds	O	O
to	O	O
acute	O	O
elevations	O	O
in	O	O
serum	O	O
PRL	O	O
by	O	O
increasing	O	O
its	O	O
activity	O	O
.	O	O

However	O	O
,	O	O
this	O	O
responsiveness	O	O
is	O	O
lost	O	O
in	O	O
aging	O	O
rats	O	O
with	O	O
chronically	O	O
high	O	O
serum	O	O
PRL	O	O
levels	O	O
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
induce	O	O
hyperprolactinemia	B-Disease	D006966
in	O	O
rats	O	O
for	O	O
extended	O	O
periods	O	O
of	O	O
time	O	O
and	O	O
examine	O	O
its	O	O
effects	O	O
on	O	O
dopaminergic	O	O
systems	O	O
in	O	O
the	O	O
brain	O	O
.	O	O

Hyperprolactinemia	B-Disease	D006966
was	O	O
induced	O	O
by	O	O
treatment	O	O
with	O	O
haloperidol	B-Chemical	D006220
,	O	O
a	O	O
dopamine	B-Chemical	D004298
receptor	O	O
antagonist	O	O
,	O	O
and	O	O
Palkovits'	O	O
microdissection	O	O
technique	O	O
in	O	O
combination	O	O
with	O	O
high	O	O
-	O	O
performance	O	O
liquid	O	O
chromatography	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
neurotransmitter	O	O
concentrations	O	O
in	O	O
several	O	O
areas	O	O
of	O	O
the	O	O
brain	O	O
.	O	O

After	O	O
6	O	O
months	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
,	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
concentrations	O	O
in	O	O
the	O	O
median	O	O
eminence	O	O
(	O	O
ME	O	O
)	O	O
increased	O	O
by	O	O
84%	O	O
over	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Nine	O	O
months	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
produced	O	O
a	O	O
50%	O	O
increase	O	O
in	O	O
DA	B-Chemical	D004298
concentrations	O	O
in	O	O
the	O	O
ME	O	O
over	O	O
the	O	O
control	O	O
group	O	O
.	O	O

However	O	O
,	O	O
DA	B-Chemical	D004298
response	O	O
was	O	O
lost	O	O
if	O	O
a	O	O
9	O	O
-	O	O
month	O	O
long	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
hyperprolactinemia	B-Disease	D006966
was	O	O
followed	O	O
by	O	O
a	O	O
1	O	O
1	O	O
/	O	O
2	O	O
month	O	O
-	O	O
long	O	O
extremely	O	O
high	O	O
increase	O	O
in	O	O
serum	O	O
PRL	O	O
levels	O	O
produced	O	O
by	O	O
implantation	O	O
of	O	O
MMQ	O	O
cells	O	O
under	O	O
the	O	O
kidney	O	O
capsule	O	O
.	O	O

There	O	O
was	O	O
no	O	O
change	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
DA	B-Chemical	D004298
,	O	O
norepinephrine	B-Chemical	D009638
(	O	O
NE	B-Chemical	D009638
)	O	O
,	O	O
serotonin	B-Chemical	D012701
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
)	O	O
,	O	O
or	O	O
their	O	O
metabolites	O	O
in	O	O
the	O	O
arcuate	O	O
nucleus	O	O
(	O	O
AN	O	O
)	O	O
,	O	O
medial	O	O
preoptic	O	O
area	O	O
(	O	O
MPA	O	O
)	O	O
,	O	O
caudate	O	O
putamen	O	O
(	O	O
CP	O	O
)	O	O
,	O	O
substantia	O	O
nigra	O	O
(	O	O
SN	O	O
)	O	O
,	O	O
and	O	O
zona	O	O
incerta	O	O
(	O	O
ZI	O	O
)	O	O
,	O	O
except	O	O
for	O	O
a	O	O
decrease	O	O
in	O	O
5	B-Chemical	D006897
-	I-Chemical	D006897
hydroxyindoleacetic	I-Chemical	D006897
acid	I-Chemical	D006897
(	O	O
5	B-Chemical	D006897
-	I-Chemical	D006897
HIAA	I-Chemical	D006897
)	O	O
in	O	O
the	O	O
AN	O	O
after	O	O
6	O	O
-	O	O
months	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
and	O	O
an	O	O
increase	O	O
in	O	O
DA	B-Chemical	D004298
concentrations	O	O
in	O	O
the	O	O
AN	O	O
after	O	O
9	O	O
-	O	O
months	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

These	O	O
results	O	O
demonstrate	O	O
that	O	O
hyperprolactinemia	B-Disease	D006966
specifically	O	O
affects	O	O
TIDA	O	O
neurons	O	O
and	O	O
these	O	O
effects	O	O
vary	O	O
,	O	O
depending	O	O
on	O	O
the	O	O
duration	O	O
and	O	O
intensity	O	O
of	O	O
hyperprolactinemia	B-Disease	D006966
.	O	O

The	O	O
age	O	O
-	O	O
related	O	O
decrease	O	O
in	O	O
hypothalamic	O	O
dopamine	B-Chemical	D004298
function	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
increases	O	O
in	O	O
PRL	O	O
secretion	O	O
.	O	O

Treatment	O	O
-	O	O
related	O	O
disseminated	O	O
necrotizing	O	O
leukoencephalopathy	B-Disease	D056784
with	O	O
characteristic	O	O
contrast	O	O
enhancement	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
.	O	O

This	O	O
report	O	O
describes	O	O
unique	O	O
contrast	O	O
enhancement	O	O
of	O	O
the	O	O
white	O	O
matter	O	O
on	O	O
T1	O	O
-	O	O
weighted	O	O
magnetic	O	O
resonance	O	O
images	O	O
of	O	O
two	O	O
patients	O	O
with	O	O
disseminated	O	O
necrotizing	O	O
leukoencephalopathy	B-Disease	D056784
,	O	O
which	O	O
developed	O	O
from	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
methotrexate	B-Chemical	D008727
.	O	O

In	O	O
both	O	O
patients	O	O
,	O	O
the	O	O
enhancement	O	O
was	O	O
more	O	O
pronounced	O	O
near	O	O
the	O	O
base	O	O
of	O	O
the	O	O
brain	O	O
than	O	O
at	O	O
the	O	O
vertex	O	O
.	O	O

Necropsy	O	O
of	O	O
the	O	O
first	O	O
case	O	O
revealed	O	O
loss	B-Disease	D003711
of	I-Disease	D003711
myelination	I-Disease	D003711
and	O	O
necrosis	B-Disease	D009336
of	O	O
the	O	O
white	O	O
matter	O	O
.	O	O

Possible	O	O
mechanisms	O	O
causing	O	O
such	O	O
a	O	O
leukoencephalopathy	B-Disease	D056784
are	O	O
discussed	O	O
.	O	O

Thrombotic	B-Disease	D013927
complications	O	O
in	O	O
acute	B-Disease	D015473
promyelocytic	I-Disease	D015473
leukemia	I-Disease	D015473
during	O	O
all	B-Chemical	D014212
-	I-Chemical	D014212
trans	I-Chemical	D014212
-	I-Chemical	D014212
retinoic	I-Chemical	D014212
acid	I-Chemical	D014212
therapy	O	O
.	O	O

A	O	O
case	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
,	O	O
due	O	O
to	O	O
occlusion	B-Disease	-1
of	I-Disease	-1
renal	I-Disease	-1
vessels	I-Disease	-1
in	O	O
a	O	O
patient	O	O
with	O	O
acute	B-Disease	D015473
promyelocytic	I-Disease	D015473
leukemia	I-Disease	D015473
(	O	O
APL	B-Disease	D015473
)	O	O
treated	O	O
with	O	O
all	B-Chemical	D014212
-	I-Chemical	D014212
trans	I-Chemical	D014212
-	I-Chemical	D014212
retinoic	I-Chemical	D014212
acid	I-Chemical	D014212
(	O	O
ATRA	B-Chemical	D014212
)	O	O
and	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
has	O	O
been	O	O
described	O	O
recently	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
in	O	O
an	O	O
APL	B-Disease	D015473
patient	O	O
treated	O	O
with	O	O
ATRA	B-Chemical	D014212
alone	O	O
.	O	O

This	O	O
case	O	O
further	O	O
supports	O	O
the	O	O
concern	O	O
about	O	O
thromboembolic	B-Disease	D013923
complications	O	O
associated	O	O
with	O	O
ATRA	B-Chemical	D014212
therapy	O	O
in	O	O
APL	B-Disease	D015473
patients	O	O
.	O	O

The	O	O
patients	O	O
,	O	O
a	O	O
43	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
presented	O	O
all	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
APL	B-Disease	D015473
and	O	O
was	O	O
included	O	O
in	O	O
a	O	O
treatment	O	O
protocol	O	O
with	O	O
ATRA	B-Chemical	D014212
.	O	O

After	O	O
10	O	O
days	O	O
of	O	O
treatment	O	O
,	O	O
he	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
that	O	O
was	O	O
completely	O	O
reversible	O	O
after	O	O
complete	O	O
remission	O	O
of	O	O
APL	B-Disease	D015473
was	O	O
achieved	O	O
and	O	O
therapy	O	O
discontinued	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
ATRA	B-Chemical	D014212
is	O	O
a	O	O
valid	O	O
therapeutic	O	O
choice	O	O
for	O	O
patients	O	O
with	O	O
APL	B-Disease	D015473
,	O	O
although	O	O
the	O	O
procoagulant	O	O
tendency	O	O
is	O	O
not	O	O
completely	O	O
corrected	O	O
.	O	O

Thrombotic	B-Disease	D013927
events	O	O
,	O	O
however	O	O
,	O	O
could	O	O
be	O	O
avoided	O	O
by	O	O
using	O	O
low	O	O
-	O	O
dose	O	O
heparin	B-Chemical	D006493
.	O	O

Pupillary	O	O
changes	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
stimulant	O	O
-	O	O
induced	O	O
mania	B-Disease	D001714
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

A	O	O
30	O	O
-	O	O
year	O	O
-	O	O
old	O	O
cocaine	B-Chemical	D003042
-	O	O
dependent	O	O
man	O	O
who	O	O
was	O	O
a	O	O
subject	O	O
in	O	O
a	O	O
study	O	O
evaluating	O	O
the	O	O
anticraving	O	O
efficacy	O	O
of	O	O
the	O	O
stimulant	O	O
medication	O	O
diethylpropion	B-Chemical	D004053
(	O	O
DEP	B-Chemical	D004053
)	O	O
became	O	O
manic	B-Disease	D001714
during	O	O
his	O	O
second	O	O
week	O	O
on	O	O
the	O	O
study	O	O
drug	O	O
.	O	O

Pupillometric	O	O
changes	O	O
while	O	O
on	O	O
DEP	B-Chemical	D004053
,	O	O
especially	O	O
changes	O	O
in	O	O
the	O	O
total	O	O
power	O	O
of	O	O
pupillary	B-Disease	D011681
oscillation	I-Disease	D011681
,	O	O
were	O	O
dramatically	O	O
different	O	O
than	O	O
those	O	O
observed	O	O
in	O	O
the	O	O
eight	O	O
other	O	O
study	O	O
subjects	O	O
who	O	O
did	O	O
not	O	O
become	O	O
manic	B-Disease	D001714
.	O	O

The	O	O
large	O	O
changes	O	O
in	O	O
total	O	O
power	O	O
of	O	O
pupillary	B-Disease	D011681
oscillation	I-Disease	D011681
occurred	O	O
a	O	O
few	O	O
days	O	O
before	O	O
the	O	O
patient	O	O
became	O	O
fully	O	O
manic	B-Disease	D001714
.	O	O

Such	O	O
medication	O	O
-	O	O
associated	O	O
changes	O	O
in	O	O
the	O	O
total	O	O
power	O	O
of	O	O
pupillary	B-Disease	D011681
oscillation	I-Disease	D011681
might	O	O
be	O	O
of	O	O
utility	O	O
in	O	O
identifying	O	O
persons	O	O
at	O	O
risk	O	O
for	O	O
manic	B-Disease	D001714
-	O	O
like	O	O
adverse	O	O
effects	O	O
during	O	O
the	O	O
medical	O	O
use	O	O
of	O	O
psychomotor	O	O
stimulants	O	O
or	O	O
sympathomimetic	O	O
agents	O	O
.	O	O

The	O	O
negative	O	O
mucosal	O	O
potential	O	O
:	O	O
separating	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
NSAIDs	O	O
in	O	O
man	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
wanted	O	O
to	O	O
test	O	O
whether	O	O
assessment	O	O
of	O	O
both	O	O
a	O	O
central	O	O
pain	B-Disease	D010146
-	O	O
related	O	O
signal	O	O
(	O	O
chemo	O	O
-	O	O
somatosensory	O	O
evoked	O	O
potential	O	O
,	O	O
CSSEP	O	O
)	O	O
and	O	O
a	O	O
concomitantly	O	O
recorded	O	O
peripheral	O	O
signal	O	O
(	O	O
negative	O	O
mucosal	O	O
potential	O	O
,	O	O
NMP	O	O
)	O	O
allows	O	O
for	O	O
separation	O	O
of	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
NSAIDs	O	O
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
experimental	O	O
conditions	O	O
were	O	O
created	O	O
in	O	O
which	O	O
NSAIDs	O	O
had	O	O
previously	O	O
been	O	O
observed	O	O
to	O	O
produce	O	O
effects	O	O
on	O	O
phasic	O	O
and	O	O
tonic	O	O
pain	B-Disease	D010146
by	O	O
either	O	O
central	O	O
or	O	O
peripheral	O	O
mechanisms	O	O
.	O	O

METHODS	O	O
:	O	O
According	O	O
to	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
randomised	O	O
,	O	O
controlled	O	O
,	O	O
threefold	O	O
cross	O	O
-	O	O
over	O	O
design	O	O
,	O	O
18	O	O
healthy	O	O
subjects	O	O
(	O	O
11	O	O
males	O	O
,	O	O
7	O	O
females	O	O
;	O	O
mean	O	O
age	O	O
26	O	O
years	O	O
)	O	O
received	O	O
either	O	O
placebo	O	O
,	O	O
400	O	O
mg	O	O
ibuprofen	B-Chemical	D007052
,	O	O
or	O	O
800	O	O
mg	O	O
ibuprofen	B-Chemical	D007052
.	O	O

Phasic	O	O
pain	B-Disease	D010146
was	O	O
applied	O	O
by	O	O
means	O	O
of	O	O
short	O	O
pulses	O	O
of	O	O
CO2	B-Chemical	D002245
to	O	O
the	O	O
nasal	O	O
mucosa	O	O
(	O	O
stimulus	O	O
duration	O	O
500	O	O
ms	O	O
,	O	O
interval	O	O
approximately	O	O
60	O	O
s	O	O
)	O	O
,	O	O
and	O	O
tonic	O	O
pain	B-Disease	D010146
was	O	O
induced	O	O
in	O	O
the	O	O
nasal	O	O
cavity	O	O
by	O	O
means	O	O
of	O	O
dry	O	O
air	O	O
of	O	O
controlled	O	O
temperature	O	O
,	O	O
humidity	O	O
and	O	O
flow	O	O
rate	O	O
(	O	O
22	O	O
degrees	O	O
C	O	O
,	O	O
0%	O	O
relative	O	O
humidity	O	O
,	O	O
145	O	O
ml	O	O
.	O	O

s	O	O
-	O	O
1	O	O
)	O	O
.	O	O

Both	O	O
CSSEPs	O	O
as	O	O
central	O	O
and	O	O
NMPs	O	O
as	O	O
peripheral	O	O
correlates	O	O
of	O	O
pain	B-Disease	D010146
were	O	O
obtained	O	O
in	O	O
response	O	O
to	O	O
the	O	O
CO2	B-Chemical	D002245
stimuli	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
subjects	O	O
rated	O	O
the	O	O
intensity	O	O
of	O	O
both	O	O
phasic	O	O
and	O	O
tonic	O	O
pain	B-Disease	D010146
by	O	O
means	O	O
of	O	O
visual	O	O
analogue	O	O
scales	O	O
.	O	O

RESULTS	O	O
:	O	O
As	O	O
described	O	O
earlier	O	O
,	O	O
administration	O	O
of	O	O
ibuprofen	B-Chemical	D007052
was	O	O
followed	O	O
by	O	O
a	O	O
decrease	O	O
in	O	O
tonic	O	O
pain	B-Disease	D010146
but	O	O
-	O	O
relative	O	O
to	O	O
placebo	O	O
-	O	O
an	O	O
increase	O	O
in	O	O
correlates	O	O
of	O	O
phasic	O	O
pain	B-Disease	D010146
,	O	O
indicating	O	O
a	O	O
specific	O	O
effect	O	O
of	O	O
ibuprofen	B-Chemical	D007052
on	O	O
the	O	O
interaction	O	O
between	O	O
the	O	O
pain	B-Disease	D010146
stimuli	O	O
under	O	O
these	O	O
special	O	O
experimental	O	O
conditions	O	O
.	O	O

Based	O	O
on	O	O
the	O	O
similar	O	O
behaviour	O	O
of	O	O
CSSEP	O	O
and	O	O
NMP	O	O
,	O	O
it	O	O
was	O	O
concluded	O	O
that	O	O
the	O	O
pharmacological	O	O
process	O	O
underlying	O	O
this	O	O
phenomenon	O	O
was	O	O
localised	O	O
in	O	O
the	O	O
periphery	O	O
.	O	O

By	O	O
means	O	O
of	O	O
the	O	O
simultaneous	O	O
recording	O	O
of	O	O
interrelated	O	O
peripheral	O	O
and	O	O
central	O	O
electrophysiologic	O	O
correlates	O	O
of	O	O
nociception	O	O
,	O	O
it	O	O
was	O	O
possible	O	O
to	O	O
separate	O	O
central	O	O
and	O	O
peripheral	O	O
effects	O	O
of	O	O
an	O	O
NSAID	O	O
.	O	O

The	O	O
major	O	O
advantage	O	O
of	O	O
this	O	O
pain	B-Disease	D010146
model	O	O
is	O	O
the	O	O
possibility	O	O
of	O	O
obtaining	O	O
peripheral	O	O
pain	B-Disease	D010146
-	O	O
related	O	O
activity	O	O
directly	O	O
using	O	O
a	O	O
non	O	O
-	O	O
invasive	O	O
technique	O	O
in	O	O
humans	O	O
.	O	O

Acute	O	O
severe	O	O
depression	B-Disease	D003866
following	O	O
peri	O	O
-	O	O
operative	O	O
ondansetron	B-Chemical	D017294
.	O	O

A	O	O
41	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
strong	O	O
history	O	O
of	O	O
postoperative	B-Disease	D020250
nausea	I-Disease	D020250
and	I-Disease	D020250
vomiting	I-Disease	D020250
presented	O	O
for	O	O
abdominal	O	O
hysterectomy	O	O
3	O	O
months	O	O
after	O	O
a	O	O
previous	O	O
anaesthetic	O	O
where	O	O
ondansetron	B-Chemical	D017294
prophylaxis	O	O
had	O	O
been	O	O
used	O	O
.	O	O

She	O	O
had	O	O
developed	O	O
a	O	O
severe	O	O
acute	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
disorder	I-Disease	D003865
almost	O	O
immediately	O	O
thereafter	O	O
,	O	O
possibly	O	O
related	O	O
to	O	O
the	O	O
use	O	O
of	O	O
a	O	O
serotonin	B-Chemical	D012701
antagonist	O	O
.	O	O

Nine	O	O
years	O	O
before	O	O
she	O	O
had	O	O
experienced	O	O
a	O	O
self	O	O
-	O	O
limited	O	O
puerperal	O	O
depressive	B-Disease	D003866
episode	I-Disease	D003866
.	O	O

Anaesthesia	O	O
with	O	O
a	O	O
propofol	B-Chemical	D015742
infusion	O	O
and	O	O
avoidance	O	O
of	O	O
serotonin	B-Chemical	D012701
antagonists	O	O
provided	O	O
a	O	O
nausea	B-Disease	D009325
-	O	O
free	O	O
postoperative	O	O
course	O	O
without	O	O
exacerbation	O	O
of	O	O
the	O	O
depression	B-Disease	D003866
disorder	O	O
.	O	O

Hypertensive	B-Disease	D006973
response	O	O
during	O	O
dobutamine	B-Chemical	D004280
stress	O	O
echocardiography	O	O
.	O	O

Among	O	O
3	O	O
,	O	O
129	O	O
dobutamine	B-Chemical	D004280
stress	O	O
echocardiographic	O	O
studies	O	O
,	O	O
a	O	O
hypertensive	B-Disease	D006973
response	O	O
,	O	O
defined	O	O
as	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
>	O	O
or	O	O
=	O	O
220	O	O
mm	O	O
Hg	O	O
and	O	O
/	O	O
or	O	O
diastolic	O	O
BP	O	O
>	O	O
or	O	O
=	O	O
110	O	O
mm	O	O
Hg	O	O
,	O	O
occurred	O	O
in	O	O
30	O	O
patients	O	O
(	O	O
1%	O	O
)	O	O
.	O	O

Patients	O	O
with	O	O
this	O	O
response	O	O
more	O	O
often	O	O
had	O	O
a	O	O
history	O	O
of	O	O
hypertension	B-Disease	D006973
and	O	O
had	O	O
higher	O	O
resting	O	O
systolic	O	O
and	O	O
diastolic	O	O
BP	O	O
before	O	O
dobutamine	B-Chemical	D004280
infusion	O	O
.	O	O

Continuously	O	O
nebulized	O	O
albuterol	B-Chemical	D000420
in	O	O
severe	O	O
exacerbations	O	O
of	O	O
asthma	B-Disease	D001249
in	O	O
adults	O	O
:	O	O
a	O	O
case	O	O
-	O	O
controlled	O	O
study	O	O
.	O	O

A	O	O
retrospective	O	O
,	O	O
case	O	O
-	O	O
controlled	O	O
analysis	O	O
comparing	O	O
patients	O	O
admitted	O	O
to	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
with	O	O
severe	O	O
exacerbations	O	O
of	O	O
asthma	B-Disease	D001249
who	O	O
received	O	O
continuously	O	O
nebulized	O	O
albuterol	B-Chemical	D000420
(	O	O
CNA	O	O
)	O	O
versus	O	O
intermittent	O	O
albuterol	B-Chemical	D000420
(	O	O
INA	O	O
)	O	O
treatments	O	O
is	O	O
reported	O	O
.	O	O

Forty	O	O
matched	O	O
pairs	O	O
of	O	O
patients	O	O
with	O	O
asthma	B-Disease	D001249
are	O	O
compared	O	O
.	O	O

CNA	O	O
was	O	O
administered	O	O
for	O	O
a	O	O
mean	O	O
of	O	O
11	O	O
+	O	O
/	O	O
-	O	O
10	O	O
hr	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiac	B-Disease	D001145
dysrhythmias	I-Disease	D001145
was	O	O
similar	O	O
between	O	O
groups	O	O
.	O	O

Symptomatic	O	O
hypokalemia	B-Disease	D007008
did	O	O
not	O	O
occur	O	O
.	O	O

CNA	O	O
patients	O	O
had	O	O
higher	O	O
heart	O	O
rates	O	O
during	O	O
treatment	O	O
,	O	O
which	O	O
may	O	O
reflect	O	O
severity	O	O
of	O	O
illness	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
intubation	O	O
was	O	O
similar	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
CNA	O	O
and	O	O
INA	O	O
demonstrated	O	O
similar	O	O
profiles	O	O
with	O	O
regard	O	O
to	O	O
safety	O	O
,	O	O
morbidity	O	O
,	O	O
and	O	O
mortality	O	O
.	O	O

Hyperosmolar	B-Disease	D006944
nonketotic	I-Disease	D006944
coma	I-Disease	D006944
precipitated	O	O
by	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
.	O	O

A	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
,	O	O
with	O	O
a	O	O
10	O	O
-	O	O
year	O	O
history	O	O
of	O	O
manic	B-Disease	D001714
depression	I-Disease	D001714
treated	O	O
with	O	O
lithium	B-Chemical	D008094
,	O	O
was	O	O
admitted	O	O
with	O	O
hyperosmolar	B-Disease	D006944
,	I-Disease	D006944
nonketotic	I-Disease	D006944
coma	I-Disease	D006944
.	O	O

He	O	O
gave	O	O
a	O	O
five	O	O
-	O	O
year	O	O
history	O	O
of	O	O
polyuria	B-Disease	D011141
and	O	O
polydipsia	B-Disease	D059606
,	O	O
during	O	O
which	O	O
time	O	O
urinalysis	O	O
had	O	O
been	O	O
negative	O	O
for	O	O
glucose	B-Chemical	D005947
.	O	O

After	O	O
recovery	O	O
from	O	O
hyperglycaemia	B-Disease	-1
,	O	O
he	O	O
remained	O	O
polyuric	B-Disease	D011141
despite	O	O
normal	O	O
blood	O	O
glucose	B-Chemical	D005947
concentrations	O	O
;	O	O
water	O	O
deprivation	O	O
testing	O	O
indicated	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
,	O	O
likely	O	O
to	O	O
be	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
.	O	O

We	O	O
hypothesize	O	O
that	O	O
when	O	O
this	O	O
man	O	O
developed	O	O
type	B-Disease	D003924
2	I-Disease	D003924
diabetes	I-Disease	D003924
,	O	O
chronic	O	O
polyuria	B-Disease	D011141
due	O	O
to	O	O
nephrogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
was	O	O
sufficient	O	O
to	O	O
precipitate	O	O
hyperosmolar	O	O
dehydration	B-Disease	D003681
.	O	O

Effects	O	O
of	O	O
the	O	O
intracoronary	O	O
infusion	O	O
of	O	O
cocaine	B-Chemical	D003042
on	O	O
left	O	O
ventricular	O	O
systolic	O	O
and	O	O
diastolic	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
dogs	O	O
,	O	O
a	O	O
large	O	O
amount	O	O
of	O	O
intravenous	O	O
cocaine	B-Chemical	D003042
causes	O	O
a	O	O
profound	O	O
deterioration	B-Disease	D018487
of	I-Disease	D018487
left	I-Disease	D018487
ventricular	I-Disease	D018487
(	I-Disease	D018487
LV	I-Disease	D018487
)	I-Disease	D018487
systolic	I-Disease	D018487
function	I-Disease	D018487
and	O	O
an	O	O
increase	O	O
in	O	O
LV	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
.	O	O

This	O	O
study	O	O
was	O	O
done	O	O
to	O	O
assess	O	O
the	O	O
influence	O	O
of	O	O
a	O	O
high	O	O
intracoronary	O	O
cocaine	B-Chemical	D003042
concentration	O	O
on	O	O
LV	O	O
systolic	O	O
and	O	O
diastolic	O	O
function	O	O
in	O	O
humans	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
In	O	O
20	O	O
patients	O	O
(	O	O
14	O	O
men	O	O
and	O	O
6	O	O
women	O	O
aged	O	O
39	O	O
to	O	O
72	O	O
years	O	O
)	O	O
referred	O	O
for	O	O
cardiac	O	O
catheterization	O	O
for	O	O
the	O	O
evaluation	O	O
of	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
we	O	O
measured	O	O
heart	O	O
rate	O	O
,	O	O
systemic	O	O
arterial	O	O
pressure	O	O
,	O	O
LV	O	O
pressure	O	O
and	O	O
its	O	O
first	O	O
derivative	O	O
(	O	O
dP	O	O
/	O	O
dt	O	O
)	O	O
,	O	O
and	O	O
LV	O	O
volumes	O	O
and	O	O
ejection	O	O
fraction	O	O
before	O	O
and	O	O
during	O	O
the	O	O
final	O	O
2	O	O
to	O	O
3	O	O
minutes	O	O
of	O	O
a	O	O
15	O	O
-	O	O
minute	O	O
intracoronary	O	O
infusion	O	O
of	O	O
saline	O	O
(	O	O
n=10	O	O
,	O	O
control	O	O
subjects	O	O
)	O	O
or	O	O
cocaine	B-Chemical	D003042
hydrochloride	O	O
1	O	O
mg	O	O
/	O	O
min	O	O
(	O	O
n=10	O	O
)	O	O
.	O	O

No	O	O
variable	O	O
changed	O	O
with	O	O
saline	O	O
.	O	O

With	O	O
cocaine	B-Chemical	D003042
,	O	O
the	O	O
drug	O	O
concentration	O	O
in	O	O
blood	O	O
obtained	O	O
from	O	O
the	O	O
coronary	O	O
sinus	O	O
was	O	O
3	O	O
.	O	O

0+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
(	O	O
mean+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
mg	O	O
/	O	O
L	O	O
,	O	O
similar	O	O
in	O	O
magnitude	O	O
to	O	O
the	O	O
blood	O	O
cocaine	B-Chemical	D003042
concentration	O	O
reported	O	O
in	O	O
abusers	O	O
dying	O	O
of	O	O
cocaine	B-Chemical	D003042
intoxication	O	O
.	O	O

Cocaine	B-Chemical	D003042
induced	O	O
no	O	O
significant	O	O
change	O	O
in	O	O
heart	O	O
rate	O	O
,	O	O
LV	O	O
dP	O	O
/	O	O
dt	O	O
(	O	O
positive	O	O
or	O	O
negative	O	O
)	O	O
,	O	O
or	O	O
LV	O	O
end	O	O
-	O	O
diastolic	O	O
volume	O	O
,	O	O
but	O	O
it	O	O
caused	O	O
an	O	O
increase	O	O
in	O	O
systolic	O	O
and	O	O
mean	O	O
arterial	O	O
pressures	O	O
,	O	O
LV	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
,	O	O
and	O	O
LV	O	O
end	O	O
-	O	O
systolic	O	O
volume	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
decrease	O	O
in	O	O
LV	O	O
ejection	O	O
fraction	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
humans	O	O
,	O	O
the	O	O
intracoronary	O	O
infusion	O	O
of	O	O
cocaine	B-Chemical	D003042
sufficient	O	O
in	O	O
amount	O	O
to	O	O
achieve	O	O
a	O	O
high	O	O
drug	O	O
concentration	O	O
in	O	O
coronary	O	O
sinus	O	O
blood	O	O
causes	O	O
a	O	O
deterioration	B-Disease	D018487
of	I-Disease	D018487
LV	I-Disease	D018487
systolic	I-Disease	D018487
and	I-Disease	D018487
diastolic	I-Disease	D018487
performance	I-Disease	D018487
.	O	O

Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
paradoxical	O	O
thromboembolism	B-Disease	D013923
,	O	O
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B-Chemical	D006493
therapy	O	O
.	O	O

Although	O	O
several	O	O
new	O	O
anticoagulant	O	O
drugs	O	O
are	O	O
in	O	O
development	O	O
,	O	O
heparin	B-Chemical	D006493
remains	O	O
the	O	O
drug	O	O
of	O	O
choice	O	O
for	O	O
most	O	O
anticoagulation	O	O
needs	O	O
.	O	O

The	O	O
clinical	O	O
effects	O	O
of	O	O
heparin	B-Chemical	D006493
are	O	O
meritorious	O	O
,	O	O
but	O	O
side	O	O
effects	O	O
do	O	O
exist	O	O
.	O	O

Important	O	O
untoward	O	O
effects	O	O
of	O	O
heparin	B-Chemical	D006493
therapy	O	O
including	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
heparin	B-Chemical	D006493
-	O	O
associated	O	O
osteoporosis	B-Disease	D010024
,	O	O
eosinophilia	B-Disease	D004802
,	O	O
skin	B-Disease	D012871
reactions	I-Disease	D012871
,	O	O
allergic	B-Disease	D004342
reactions	I-Disease	D004342
other	O	O
than	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
alopecia	B-Disease	D000505
will	O	O
be	O	O
discussed	O	O
in	O	O
this	O	O
article	O	O
.	O	O

Nonopaque	O	O
crystal	O	O
deposition	O	O
causing	O	O
ureteric	B-Disease	D014517
obstruction	I-Disease	D014517
in	O	O
patients	O	O
with	O	O
HIV	O	O
undergoing	O	O
indinavir	B-Chemical	D019469
therapy	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
describe	O	O
the	O	O
unique	O	O
CT	O	O
features	O	O
of	O	O
ureteric	B-Disease	D014514
calculi	I-Disease	D014514
in	O	O
six	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
patients	O	O
receiving	O	O
indinavir	B-Chemical	D019469
,	O	O
the	O	O
most	O	O
commonly	O	O
used	O	O
HIV	O	O
protease	O	O
inhibitor	O	O
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
urolithiasis	B-Disease	D052878
.	O	O

CONCLUSION	O	O
:	O	O
Ureteric	B-Disease	D014517
obstruction	I-Disease	D014517
caused	O	O
by	O	O
precipitated	O	O
indinavir	B-Chemical	D019469
crystals	O	O
may	O	O
be	O	O
difficult	O	O
to	O	O
diagnose	O	O
with	O	O
unenhanced	O	O
CT	O	O
.	O	O

The	O	O
calculi	O	O
are	O	O
not	O	O
opaque	O	O
,	O	O
and	O	O
secondary	O	O
signs	O	O
of	O	O
obstruction	O	O
may	O	O
be	O	O
absent	O	O
or	O	O
minimal	O	O
and	O	O
should	O	O
be	O	O
sought	O	O
carefully	O	O
.	O	O

Images	O	O
may	O	O
need	O	O
to	O	O
be	O	O
obtained	O	O
using	O	O
i	O	O
.	O	O

v	O	O
.	O	O

contrast	O	O
material	O	O
to	O	O
enable	O	O
diagnosis	O	O
of	O	O
ureteric	O	O
stones	O	O
or	O	O
obstruction	O	O
in	O	O
patients	O	O
with	O	O
HIV	B-Disease	D015658
infection	I-Disease	D015658
who	O	O
receive	O	O
indinavir	B-Chemical	D019469
therapy	O	O
.	O	O

Ischemic	B-Disease	D017091
colitis	I-Disease	D017091
and	O	O
sumatriptan	B-Chemical	D018170
use	O	O
.	O	O

Sumatriptan	B-Chemical	D018170
succinate	I-Chemical	D018170
,	O	O
a	O	O
serotonin	B-Chemical	D012701
-	O	O
1	O	O
(	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
hydroxytryptamine	I-Chemical	D012701
-	O	O
1	O	O
)	O	O
receptor	O	O
agonist	O	O
,	O	O
is	O	O
an	O	O
antimigraine	O	O
drug	O	O
that	O	O
is	O	O
reported	O	O
to	O	O
act	O	O
by	O	O
selectively	O	O
constricting	O	O
intracranial	O	O
arteries	O	O
.	O	O

Recently	O	O
,	O	O
vasopressor	O	O
responses	O	O
that	O	O
are	O	O
distinct	O	O
from	O	O
the	O	O
cranial	O	O
circulation	O	O
have	O	O
been	O	O
demonstrated	O	O
to	O	O
occur	O	O
in	O	O
the	O	O
systemic	O	O
,	O	O
pulmonary	O	O
,	O	O
and	O	O
coronary	O	O
circulations	O	O
.	O	O

Cases	O	O
have	O	O
been	O	O
published	O	O
of	O	O
coronary	B-Disease	D003329
vasospasm	I-Disease	D003329
,	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
,	O	O
and	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
occurring	O	O
after	O	O
sumatriptan	B-Chemical	D018170
use	O	O
.	O	O

We	O	O
report	O	O
on	O	O
the	O	O
development	O	O
of	O	O
8	O	O
serious	O	O
cases	O	O
of	O	O
ischemic	B-Disease	D017091
colitis	I-Disease	D017091
in	O	O
patients	O	O
with	O	O
migraine	B-Disease	D008881
treated	O	O
with	O	O
sumatriptan	B-Chemical	D018170
.	O	O

Pallidotomy	O	O
with	O	O
the	O	O
gamma	O	O
knife	O	O
:	O	O
a	O	O
positive	O	O
experience	O	O
.	O	O

51	O	O
patients	O	O
with	O	O
medically	O	O
refractory	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
underwent	O	O
stereotactic	O	O
posteromedial	O	O
pallidotomy	O	O
between	O	O
August	O	O
1993	O	O
and	O	O
February	O	O
1997	O	O
for	O	O
treatment	O	O
of	O	O
bradykinesia	B-Disease	D018476
,	O	O
rigidity	B-Disease	D009127
,	O	O
and	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
.	O	O

In	O	O
29	O	O
patients	O	O
,	O	O
the	O	O
pallidotomies	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
Leksell	O	O
Gamma	O	O
Knife	O	O
and	O	O
in	O	O
22	O	O
they	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
standard	O	O
radiofrequency	O	O
(	O	O
RF	O	O
)	O	O
method	O	O
.	O	O

Clinical	O	O
assessment	O	O
as	O	O
well	O	O
as	O	O
blinded	O	O
ratings	O	O
of	O	O
Unified	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Rating	O	O
Scale	O	O
(	O	O
UPDRS	O	O
)	O	O
scores	O	O
were	O	O
carried	O	O
out	O	O
pre	O	O
-	O	O
and	O	O
postoperatively	O	O
.	O	O

Mean	O	O
follow	O	O
-	O	O
up	O	O
time	O	O
is	O	O
20	O	O
.	O	O

6	O	O
months	O	O
(	O	O
range	O	O
6	O	O
-	O	O
48	O	O
)	O	O
and	O	O
all	O	O
except	O	O
4	O	O
patients	O	O
have	O	O
been	O	O
followed	O	O
more	O	O
than	O	O
one	O	O
year	O	O
.	O	O

85	O	O
percent	O	O
of	O	O
patients	O	O
with	O	O
dyskinesias	B-Disease	D004409
were	O	O
relieved	O	O
of	O	O
symptoms	O	O
,	O	O
regardless	O	O
of	O	O
whether	O	O
the	O	O
pallidotomies	O	O
were	O	O
performed	O	O
with	O	O
the	O	O
Gamma	O	O
Knife	O	O
or	O	O
radiofrequency	O	O
methods	O	O
.	O	O

About	O	O
2	O	O
/	O	O
3	O	O
of	O	O
the	O	O
patients	O	O
in	O	O
both	O	O
Gamma	O	O
Knife	O	O
and	O	O
radiofrequency	O	O
groups	O	O
showed	O	O
improvements	O	O
in	O	O
bradykinesia	B-Disease	D018476
and	O	O
rigidity	B-Disease	D009127
,	O	O
although	O	O
when	O	O
considered	O	O
as	O	O
a	O	O
group	O	O
neither	O	O
the	O	O
Gamma	O	O
Knife	O	O
nor	O	O
the	O	O
radiofrequency	O	O
group	O	O
showed	O	O
statistically	O	O
significant	O	O
improvements	O	O
in	O	O
UPDRS	O	O
scores	O	O
.	O	O

One	O	O
patient	O	O
in	O	O
the	O	O
Gamma	O	O
Knife	O	O
group	O	O
(	O	O
3	O	O
.	O	O

4%	O	O
)	O	O
developed	O	O
a	O	O
homonymous	B-Disease	D006423
hemianopsia	I-Disease	D006423
9	O	O
months	O	O
following	O	O
treatment	O	O
and	O	O
5	O	O
patients	O	O
(	O	O
27	O	O
.	O	O

7%	O	O
)	O	O
in	O	O
the	O	O
radiofrequency	O	O
group	O	O
became	O	O
transiently	O	O
confused	O	O
postoperatively	O	O
.	O	O

No	O	O
other	O	O
complications	O	O
were	O	O
seen	O	O
.	O	O

Gamma	O	O
Knife	O	O
pallidotomy	O	O
is	O	O
as	O	O
effective	O	O
as	O	O
radiofrequency	O	O
pallidotomy	O	O
in	O	O
controlling	O	O
certain	O	O
of	O	O
the	O	O
symptoms	O	O
of	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

It	O	O
may	O	O
be	O	O
the	O	O
only	O	O
practical	O	O
technique	O	O
available	O	O
in	O	O
certain	O	O
patients	O	O
,	O	O
such	O	O
as	O	O
those	O	O
who	O	O
take	O	O
anticoagulants	O	O
,	O	O
have	O	O
bleeding	B-Disease	D006470
diatheses	O	O
or	O	O
serious	O	O
systemic	O	O
medical	O	O
illnesses	O	O
.	O	O

It	O	O
is	O	O
a	O	O
viable	O	O
option	O	O
for	O	O
other	O	O
patients	O	O
as	O	O
well	O	O
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
and	O	O
methylphenidate	B-Chemical	D008774
.	O	O

A	O	O
1	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
presented	O	O
with	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
probably	O	O
caused	O	O
by	O	O
methylphenidate	B-Chemical	D008774
.	O	O

She	O	O
had	O	O
defects	O	O
in	O	O
the	O	O
supratentorial	O	O
brain	O	O
including	O	O
the	O	O
basal	O	O
ganglia	O	O
and	O	O
the	O	O
striatum	O	O
(	O	O
multicystic	B-Disease	D004678
encephalomalacia	I-Disease	D004678
)	O	O
due	O	O
to	O	O
severe	O	O
perinatal	O	O
hypoxic	B-Disease	D020925
-	I-Disease	D020925
ischemic	I-Disease	D020925
encephalopathy	I-Disease	D020925
,	O	O
which	O	O
was	O	O
considered	O	O
to	O	O
be	O	O
a	O	O
possible	O	O
predisposing	O	O
factor	O	O
causing	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
.	O	O

A	O	O
dopaminergic	O	O
blockade	O	O
mechanism	O	O
generally	O	O
is	O	O
accepted	O	O
as	O	O
the	O	O
pathogenesis	O	O
of	O	O
this	O	O
syndrome	O	O
.	O	O

However	O	O
,	O	O
methylphenidate	B-Chemical	D008774
is	O	O
a	O	O
dopamine	B-Chemical	D004298
agonist	O	O
via	O	O
the	O	O
inhibition	O	O
of	O	O
uptake	O	O
of	O	O
dopamine	B-Chemical	D004298
,	O	O
and	O	O
therefore	O	O
dopaminergic	O	O
systems	O	O
in	O	O
the	O	O
brainstem	O	O
(	O	O
mainly	O	O
the	O	O
midbrain	O	O
)	O	O
and	O	O
the	O	O
spinal	O	O
cord	O	O
were	O	O
unlikely	O	O
to	O	O
participate	O	O
in	O	O
the	O	O
onset	O	O
of	O	O
this	O	O
syndrome	O	O
.	O	O

A	O	O
relative	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
-	O	O
ergic	O	O
deficiency	O	O
might	O	O
occur	O	O
because	O	O
diazepam	B-Chemical	D003975
,	O	O
a	O	O
gamma	B-Chemical	D005680
-	I-Chemical	D005680
aminobutyric	I-Chemical	D005680
acid	I-Chemical	D005680
-	O	O
mimetic	O	O
agent	O	O
,	O	O
was	O	O
strikingly	O	O
effective	O	O
.	O	O

This	O	O
is	O	O
the	O	O
first	O	O
reported	O	O
patient	O	O
with	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
probably	O	O
caused	O	O
by	O	O
methylphenidate	B-Chemical	D008774
.	O	O

Differential	O	O
effects	O	O
of	O	O
17alpha	B-Chemical	D004997
-	I-Chemical	D004997
ethinylestradiol	I-Chemical	D004997
on	O	O
the	O	O
neutral	O	O
and	O	O
acidic	O	O
pathways	O	O
of	O	O
bile	B-Chemical	D001647
salt	I-Chemical	D001647
synthesis	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

Effects	O	O
of	O	O
17alpha	B-Chemical	D004997
-	I-Chemical	D004997
ethinylestradiol	I-Chemical	D004997
(	O	O
EE	B-Chemical	D004997
)	O	O
on	O	O
the	O	O
neutral	O	O
and	O	O
acidic	O	O
biosynthetic	O	O
pathways	O	O
of	O	O
bile	B-Chemical	D001647
salt	I-Chemical	D001647
(	O	O
BS	B-Chemical	D001647
)	O	O
synthesis	O	O
were	O	O
evaluated	O	O
in	O	O
rats	O	O
with	O	O
an	O	O
intact	O	O
enterohepatic	O	O
circulation	O	O
and	O	O
in	O	O
rats	O	O
with	O	O
long	O	O
-	O	O
term	O	O
bile	O	O
diversion	O	O
to	O	O
induce	O	O
BS	B-Chemical	D001647
synthesis	O	O
.	O	O

For	O	O
this	O	O
purpose	O	O
,	O	O
bile	B-Chemical	D001647
salt	I-Chemical	D001647
pool	O	O
composition	O	O
,	O	O
synthesis	O	O
of	O	O
individual	O	O
BS	B-Chemical	D001647
in	O	O
vivo	O	O
,	O	O
hepatic	O	O
activities	O	O
,	O	O
and	O	O
expression	O	O
levels	O	O
of	O	O
cholesterol	B-Chemical	D002784
7alpha	O	O
-	O	O
hydroxylase	O	O
(	O	O
CYP7A	O	O
)	O	O
,	O	O
and	O	O
sterol	B-Chemical	D013261
27	O	O
-	O	O
hydroxylase	O	O
(	O	O
CYP27	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
of	O	O
other	O	O
enzymes	O	O
involved	O	O
in	O	O
BS	B-Chemical	D001647
synthesis	O	O
,	O	O
were	O	O
analyzed	O	O
in	O	O
rats	O	O
treated	O	O
with	O	O
EE	B-Chemical	D004997
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
3	O	O
days	O	O
)	O	O
or	O	O
its	O	O
vehicle	O	O
.	O	O

BS	B-Chemical	D001647
pool	O	O
size	O	O
was	O	O
decreased	O	O
by	O	O
27%	O	O
but	O	O
total	O	O
BS	B-Chemical	D001647
synthesis	O	O
was	O	O
not	O	O
affected	O	O
by	O	O
EE	B-Chemical	D004997
in	O	O
intact	O	O
rats	O	O
.	O	O

Synthesis	O	O
of	O	O
cholate	B-Chemical	D020355
was	O	O
reduced	O	O
by	O	O
68%	O	O
in	O	O
EE	B-Chemical	D004997
-	O	O
treated	O	O
rats	O	O
,	O	O
while	O	O
that	O	O
of	O	O
chenodeoxycholate	B-Chemical	D002635
was	O	O
increased	O	O
by	O	O
60%	O	O
.	O	O

The	O	O
recently	O	O
identified	O	O
Delta22	O	O
-	O	O
isomer	O	O
of	O	O
beta	O	O
-	O	O
muricholate	O	O
contributed	O	O
for	O	O
5	O	O
.	O	O

4%	O	O
and	O	O
18	O	O
.	O	O

3	O	O
%	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
to	O	O
the	O	O
pool	O	O
in	O	O
control	O	O
and	O	O
EE	B-Chemical	D004997
-	O	O
treated	O	O
rats	O	O
,	O	O
respectively	O	O
,	O	O
but	O	O
could	O	O
not	O	O
be	O	O
detected	O	O
in	O	O
bile	O	O
after	O	O
exhaustion	O	O
of	O	O
the	O	O
pool	O	O
.	O	O

A	O	O
clear	O	O
reduction	O	O
of	O	O
BS	B-Chemical	D001647
synthesis	O	O
was	O	O
found	O	O
in	O	O
bile	O	O
-	O	O
diverted	O	O
rats	O	O
treated	O	O
with	O	O
EE	B-Chemical	D004997
,	O	O
yet	O	O
biliary	O	O
BS	B-Chemical	D001647
composition	O	O
was	O	O
only	O	O
minimally	O	O
affected	O	O
.	O	O

Activity	O	O
of	O	O
CYP7A	O	O
was	O	O
decreased	O	O
by	O	O
EE	B-Chemical	D004997
in	O	O
both	O	O
intact	O	O
and	O	O
bile	O	O
-	O	O
diverted	O	O
rats	O	O
,	O	O
whereas	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
CYP27	O	O
was	O	O
not	O	O
affected	O	O
.	O	O

Hepatic	O	O
mRNA	O	O
levels	O	O
of	O	O
CYP7A	O	O
were	O	O
significantly	O	O
reduced	O	O
by	O	O
EE	B-Chemical	D004997
in	O	O
bile	O	O
-	O	O
diverted	O	O
rats	O	O
only	O	O
;	O	O
CYP27	O	O
mRNA	O	O
levels	O	O
were	O	O
not	O	O
affected	O	O
by	O	O
EE	B-Chemical	D004997
.	O	O

In	O	O
addition	O	O
,	O	O
mRNA	O	O
levels	O	O
of	O	O
sterol	B-Chemical	D013261
12alpha	O	O
-	O	O
hydroxylase	O	O
and	O	O
lithocholate	O	O
6beta	O	O
-	O	O
hydroxylase	O	O
were	O	O
increased	O	O
by	O	O
bile	O	O
diversion	O	O
and	O	O
suppressed	O	O
by	O	O
EE	B-Chemical	D004997
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
17alpha	B-Chemical	D004997
-	I-Chemical	D004997
ethinylestradiol	I-Chemical	D004997
(	O	O
EE	B-Chemical	D004997
)	O	O
-	O	O
induced	O	O
intrahepatic	B-Disease	D002780
cholestasis	I-Disease	D002780
in	O	O
rats	O	O
is	O	O
associated	O	O
with	O	O
selective	O	O
inhibition	O	O
of	O	O
the	O	O
neutral	O	O
pathway	O	O
of	O	O
bile	B-Chemical	D001647
salt	I-Chemical	D001647
(	O	O
BS	B-Chemical	D001647
)	O	O
synthesis	O	O
.	O	O

Simultaneous	O	O
impairment	O	O
of	O	O
other	O	O
enzymes	O	O
in	O	O
the	O	O
BS	B-Chemical	D001647
biosynthetic	O	O
pathways	O	O
may	O	O
contribute	O	O
to	O	O
overall	O	O
effects	O	O
of	O	O
EE	B-Chemical	D004997
on	O	O
BS	B-Chemical	D001647
synthesis	O	O
.	O	O

Glibenclamide	B-Chemical	D005905
-	O	O
sensitive	O	O
hypotension	B-Disease	D007022
produced	O	O
by	O	O
helodermin	B-Chemical	C040442
assessed	O	O
in	O	O
the	O	O
rat	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
helodermin	B-Chemical	C040442
,	O	O
a	O	O
basic	O	O
35	O	O
-	O	O
amino	B-Chemical	D000596
acid	I-Chemical	D000596
peptide	O	O
isolated	O	O
from	O	O
the	O	O
venom	O	O
of	O	O
a	O	O
lizard	O	O
salivary	O	O
gland	O	O
,	O	O
on	O	O
arterial	O	O
blood	O	O
pressure	O	O
and	O	O
heart	O	O
rate	O	O
were	O	O
examined	O	O
in	O	O
the	O	O
rat	O	O
,	O	O
focusing	O	O
on	O	O
the	O	O
possibility	O	O
that	O	O
activation	O	O
of	O	O
ATP	B-Chemical	D000255
sensitive	O	O
K+	O	O
(	O	O
K	B-Chemical	D011188
(	O	O
ATP	B-Chemical	D000255
)	O	O
)	O	O
channels	O	O
is	O	O
involved	O	O
in	O	O
the	O	O
responses	O	O
.	O	O

The	O	O
results	O	O
were	O	O
also	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
vasoactive	O	O
intestinal	O	O
polypeptide	O	O
(	O	O
VIP	O	O
)	O	O
.	O	O

Helodermin	B-Chemical	C040442
produced	O	O
hypotension	B-Disease	D007022
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
with	O	O
approximately	O	O
similar	O	O
potency	O	O
and	O	O
duration	O	O
to	O	O
VIP	O	O
.	O	O

Hypotension	B-Disease	D007022
induced	O	O
by	O	O
both	O	O
peptides	O	O
was	O	O
significantly	O	O
attenuated	O	O
by	O	O
glibenclamide	B-Chemical	D005905
,	O	O
which	O	O
abolished	O	O
a	O	O
levcromakalim	B-Chemical	D019806
-	O	O
produced	O	O
decrease	O	O
in	O	O
arterial	O	O
blood	O	O
pressure	O	O
.	O	O

Oxyhemoglobin	O	O
did	O	O
not	O	O
affect	O	O
helodermin	B-Chemical	C040442
-	O	O
induced	O	O
hypotension	B-Disease	D007022
,	O	O
whereas	O	O
it	O	O
shortened	O	O
the	O	O
duration	O	O
of	O	O
acetylcholine	B-Chemical	D000109
(	O	O
ACh	B-Chemical	D000109
)	O	O
-	O	O
produced	O	O
hypotension	B-Disease	D007022
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
helodermin	B-Chemical	C040442
-	O	O
produced	O	O
hypotension	B-Disease	D007022
is	O	O
partly	O	O
attributable	O	O
to	O	O
the	O	O
activation	O	O
of	O	O
glibenclamide	B-Chemical	D005905
-	O	O
sensitive	O	O
K+	O	O
channels	O	O
(	O	O
K	B-Chemical	D011188
(	O	O
ATP	B-Chemical	D000255
)	O	O
channels	O	O
)	O	O
,	O	O
which	O	O
presumably	O	O
exist	O	O
on	O	O
arterial	O	O
smooth	O	O
muscle	O	O
cells	O	O
.	O	O

EDRF	O	O
(	O	O
endothelium	O	O
-	O	O
derived	O	O
relaxing	O	O
factor	O	O
)	O	O
/	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
does	O	O
not	O	O
seem	O	O
to	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
peptide	O	O
-	O	O
produced	O	O
hypotension	B-Disease	D007022
.	O	O

Long	O	O
-	O	O
term	O	O
efficacy	O	O
and	O	O
adverse	O	O
event	O	O
of	O	O
nifedipine	B-Chemical	D009543
sustained	O	O
-	O	O
release	O	O
tablets	O	O
for	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
-	O	O
induced	O	O
hypertension	B-Disease	D006973
in	O	O
patients	O	O
with	O	O
psoriasis	B-Disease	D011565
.	O	O

Thirteen	O	O
psoriatic	B-Disease	D011565
patients	O	O
with	O	O
hypertension	B-Disease	D006973
during	O	O
the	O	O
course	O	O
of	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
therapy	O	O
were	O	O
treated	O	O
for	O	O
25	O	O
months	O	O
with	O	O
a	O	O
calcium	B-Chemical	D002118
channel	O	O
blocker	O	O
,	O	O
sustained	O	O
-	O	O
release	O	O
nifedipine	B-Chemical	D009543
,	O	O
to	O	O
study	O	O
the	O	O
clinical	O	O
antihypertensive	O	O
effects	O	O
and	O	O
adverse	O	O
events	O	O
during	O	O
treatment	O	O
with	O	O
both	O	O
drugs	O	O
.	O	O

Seven	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
had	O	O
exhibited	O	O
a	O	O
subclinical	O	O
hypertensive	B-Disease	D006973
state	O	O
before	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
therapy	O	O
.	O	O

Both	O	O
systolic	O	O
and	O	O
diastolic	O	O
blood	O	O
pressures	O	O
of	O	O
these	O	O
13	O	O
patients	O	O
were	O	O
decreased	O	O
significantly	O	O
after	O	O
4	O	O
weeks	O	O
of	O	O
nifedipine	B-Chemical	D009543
therapy	O	O
,	O	O
and	O	O
blood	O	O
pressure	O	O
was	O	O
maintained	O	O
within	O	O
the	O	O
normal	O	O
range	O	O
thereafter	O	O
for	O	O
25	O	O
months	O	O
.	O	O

The	O	O
adverse	O	O
events	O	O
during	O	O
combined	O	O
therapy	O	O
with	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
and	O	O
nifedipine	B-Chemical	D009543
included	O	O
an	O	O
increase	O	O
in	O	O
blood	B-Chemical	D001806
urea	I-Chemical	D001806
nitrogen	I-Chemical	D001806
levels	O	O
in	O	O
9	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
and	O	O
development	O	O
of	O	O
gingival	B-Disease	D005885
hyperplasia	I-Disease	D005885
in	O	O
2	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
.	O	O

Our	O	O
findings	O	O
indicate	O	O
that	O	O
sustained	O	O
-	O	O
release	O	O
nifedipine	B-Chemical	D009543
is	O	O
useful	O	O
for	O	O
hypertensive	B-Disease	D006973
psoriatic	B-Disease	D011565
patients	O	O
under	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
cyclosporin	B-Chemical	D016572
A	I-Chemical	D016572
,	O	O
but	O	O
that	O	O
these	O	O
patients	O	O
should	O	O
be	O	O
monitored	O	O
for	O	O
gingival	B-Disease	D005885
hyperplasia	I-Disease	D005885
.	O	O

Torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
during	O	O
low	O	O
dose	O	O
intermittent	O	O
dobutamine	B-Chemical	D004280
treatment	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
and	O	O
congestive	B-Disease	D006333
heart	I-Disease	D006333
failure	I-Disease	D006333
.	O	O

The	O	O
authors	O	O
describe	O	O
the	O	O
case	O	O
of	O	O
a	O	O
56	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
chronic	O	O
,	O	O
severe	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
secondary	O	O
to	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
and	O	O
absence	O	O
of	O	O
significant	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
who	O	O
developed	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
and	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
during	O	O
one	O	O
cycle	O	O
of	O	O
intermittent	O	O
low	O	O
dose	O	O
(	O	O
2	O	O
.	O	O

5	O	O
mcg	O	O
/	O	O
kg	O	O
per	O	O
min	O	O
)	O	O
dobutamine	B-Chemical	D004280
.	O	O

This	O	O
report	O	O
of	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
during	O	O
intermittent	O	O
dobutamine	B-Chemical	D004280
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
unpredictable	O	O
fatal	O	O
arrhythmias	B-Disease	D001145
may	O	O
occur	O	O
even	O	O
with	O	O
low	O	O
doses	O	O
and	O	O
in	O	O
patients	O	O
with	O	O
no	O	O
history	O	O
of	O	O
significant	O	O
rhythm	O	O
disturbances	O	O
.	O	O

The	O	O
mechanisms	O	O
of	O	O
proarrhythmic	O	O
effects	O	O
of	O	O
Dubutamine	B-Chemical	D004280
are	O	O
discussed	O	O
.	O	O

Positive	O	O
skin	O	O
tests	O	O
in	O	O
late	O	O
reactions	O	O
to	O	O
radiographic	O	O
contrast	B-Chemical	D003287
media	I-Chemical	D003287
.	O	O

In	O	O
the	O	O
last	O	O
few	O	O
years	O	O
delayed	O	O
reactions	O	O
several	O	O
hours	O	O
after	O	O
the	O	O
injection	O	O
of	O	O
radiographic	O	O
and	O	O
contrast	B-Chemical	D003287
materials	I-Chemical	D003287
(	O	O
PRC	B-Chemical	D003287
)	O	O
have	O	O
been	O	O
described	O	O
with	O	O
increasing	O	O
frequency	O	O
.	O	O

The	O	O
authors	O	O
report	O	O
two	O	O
observations	O	O
on	O	O
patients	O	O
with	O	O
delayed	O	O
reactions	O	O
in	O	O
whom	O	O
intradermoreactions	O	O
(	O	O
IDR	O	O
)	O	O
and	O	O
patch	O	O
tests	O	O
to	O	O
a	O	O
series	O	O
of	O	O
ionic	O	O
and	O	O
non	O	O
ionic	O	O
PRC	B-Chemical	D003287
were	O	O
studied	O	O
.	O	O

After	O	O
angiography	O	O
by	O	O
the	O	O
venous	O	O
route	O	O
in	O	O
patient	O	O
n	O	O
degree	O	O
1	O	O
a	O	O
biphasic	O	O
reaction	O	O
with	O	O
an	O	O
immediate	O	O
reaction	O	O
(	O	O
dyspnea	B-Disease	D004417
,	O	O
loss	B-Disease	D014474
of	I-Disease	D014474
consciousness	I-Disease	D014474
)	O	O
and	O	O
delayed	O	O
macro	B-Disease	D003875
-	I-Disease	D003875
papular	I-Disease	D003875
rash	I-Disease	D003875
appeared	O	O
,	O	O
whilst	O	O
patient	O	O
n	O	O
degree	O	O
2	O	O
developed	O	O
a	O	O
generalised	O	O
sensation	O	O
of	O	O
heat	O	O
,	O	O
persistent	O	O
pain	B-Disease	D010146
at	O	O
the	O	O
site	O	O
of	O	O
injection	O	O
immediately	O	O
and	O	O
a	O	O
generalised	O	O
macro	O	O
-	O	O
papular	O	O
reaction	O	O
after	O	O
24	O	O
hours	O	O
.	O	O

The	O	O
skin	O	O
tests	O	O
revealed	O	O
positive	O	O
delayed	O	O
reactions	O	O
of	O	O
24	O	O
hours	O	O
and	O	O
48	O	O
hours	O	O
by	O	O
IDR	O	O
and	O	O
patch	O	O
tests	O	O
to	O	O
only	O	O
some	O	O
PRC	B-Chemical	D003287
with	O	O
common	O	O
chains	O	O
in	O	O
their	O	O
structures	O	O
.	O	O

The	O	O
positive	O	O
skin	O	O
tests	O	O
are	O	O
in	O	O
favour	O	O
of	O	O
immunological	O	O
reactions	O	O
and	O	O
may	O	O
help	O	O
in	O	O
diagnosis	O	O
of	O	O
allergy	B-Disease	D004342
in	O	O
the	O	O
patients	O	O
.	O	O

Risk	O	O
of	O	O
transient	O	O
hyperammonemic	O	O
encephalopathy	O	O
in	O	O
cancer	B-Disease	D009369
patients	O	O
who	O	O
received	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
with	O	O
the	O	O
complication	O	O
of	O	O
dehydration	B-Disease	D003681
and	O	O
infection	B-Disease	D007239
.	O	O

From	O	O
1986	O	O
to	O	O
1998	O	O
,	O	O
29	O	O
cancer	B-Disease	D009369
patients	O	O
who	O	O
had	O	O
32	O	O
episodes	O	O
of	O	O
transient	O	O
hyperammonemic	O	O
encephalopathy	O	O
related	O	O
to	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
were	O	O
identified	O	O
.	O	O

None	O	O
of	O	O
the	O	O
patients	O	O
had	O	O
decompensated	O	O
liver	B-Disease	D008107
disease	I-Disease	D008107
.	O	O

Onset	O	O
of	O	O
hyperammonemic	O	O
encephalopathy	O	O
varied	O	O
from	O	O
0	O	O
.	O	O

5	O	O
to	O	O
5	O	O
days	O	O
(	O	O
mean	O	O
:	O	O
2	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

3	O	O
days	O	O
)	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
chemotherapy	O	O
.	O	O

Plasma	O	O
ammonium	B-Chemical	D000644
level	O	O
ranged	O	O
from	O	O
248	O	O
to	O	O
2387	O	O
microg%	O	O
(	O	O
mean	O	O
:	O	O
626	O	O
+	O	O
/	O	O
-	O	O
431	O	O
microg%	O	O
)	O	O
.	O	O

Among	O	O
the	O	O
32	O	O
episodes	O	O
,	O	O
26	O	O
(	O	O
81%	O	O
)	O	O
had	O	O
various	O	O
degrees	O	O
of	O	O
azotemia	B-Disease	D053099
,	O	O
18	O	O
(	O	O
56%	O	O
)	O	O
occurred	O	O
during	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
and	O	O
14	O	O
(	O	O
44%	O	O
)	O	O
without	O	O
infection	B-Disease	D007239
occurred	O	O
during	O	O
periods	O	O
of	O	O
dehydration	B-Disease	D003681
.	O	O

Higher	O	O
plasma	O	O
ammonium	B-Chemical	D000644
levels	O	O
and	O	O
more	O	O
rapid	O	O
onset	O	O
of	O	O
hyperammonemia	B-Disease	D022124
were	O	O
seen	O	O
in	O	O
18	O	O
patients	O	O
with	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
(	O	O
p=0	O	O
.	O	O

003	O	O
and	O	O
0	O	O
.	O	O

0006	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
in	O	O
nine	O	O
patients	O	O
receiving	O	O
high	O	O
daily	O	O
doses	O	O
(	O	O
2600	O	O
or	O	O
1800	O	O
mg	O	O
/	O	O
m2	O	O
)	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
(	O	O
p=0	O	O
.	O	O

0001	O	O
and	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

In	O	O
25	O	O
out	O	O
of	O	O
32	O	O
episodes	O	O
(	O	O
78%	O	O
)	O	O
,	O	O
plasma	O	O
ammonium	B-Chemical	D000644
levels	O	O
and	O	O
mental	O	O
status	O	O
returned	O	O
to	O	O
normal	O	O
within	O	O
2	O	O
days	O	O
after	O	O
adequate	O	O
management	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
hyperammonemic	O	O
encephalopathy	O	O
can	O	O
occur	O	O
in	O	O
patients	O	O
receiving	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
.	O	O

Azotemia	B-Disease	D053099
,	O	O
body	O	O
fluid	O	O
insufficiency	O	O
and	O	O
bacterial	B-Disease	D001424
infections	I-Disease	D001424
were	O	O
frequently	O	O
found	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

It	O	O
is	O	O
therefore	O	O
important	O	O
to	O	O
recognize	O	O
this	O	O
condition	O	O
in	O	O
patients	O	O
receiving	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
.	O	O

The	O	O
effects	O	O
of	O	O
quinine	B-Chemical	D011803
and	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
on	O	O
conditioned	O	O
place	O	O
preference	O	O
and	O	O
changes	O	O
in	O	O
motor	O	O
activity	O	O
induced	O	O
by	O	O
morphine	B-Chemical	D009020
in	O	O
rats	O	O
.	O	O

1	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
two	O	O
unselective	O	O
potassium	B-Chemical	D011188
(	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
)	O	O
channel	O	O
blockers	O	O
,	O	O
quinine	B-Chemical	D011803
(	O	O
12	O	O
.	O	O

5	O	O
,	O	O
25	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
(	O	O
1	O	O
and	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
on	O	O
conditioned	O	O
place	O	O
preference	O	O
and	O	O
biphasic	O	O
changes	O	O
in	O	O
motor	O	O
activity	O	O
induced	O	O
by	O	O
morphine	B-Chemical	D009020
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
tested	O	O
in	O	O
Wistar	O	O
rats	O	O
.	O	O

Quinine	B-Chemical	D011803
is	O	O
known	O	O
to	O	O
block	O	O
voltage	O	O
-	O	O
,	O	O
calcium	B-Chemical	D002118
-	O	O
and	O	O
ATP	B-Chemical	D000255
-	O	O
sensitive	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
while	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
is	O	O
known	O	O
to	O	O
block	O	O
voltage	O	O
-	O	O
sensitive	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
.	O	O

2	O	O
.	O	O

In	O	O
the	O	O
counterbalanced	O	O
method	O	O
,	O	O
quinine	B-Chemical	D011803
attenuated	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
place	O	O
preference	O	O
,	O	O
whereas	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
was	O	O
ineffective	O	O
.	O	O

In	O	O
the	O	O
motor	O	O
activity	O	O
test	O	O
measured	O	O
with	O	O
an	O	O
Animex	O	O
-	O	O
activity	O	O
meter	O	O
neither	O	O
of	O	O
the	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channel	O	O
blockers	O	O
affected	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
hypoactivity	B-Disease	D009069
,	O	O
but	O	O
both	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channel	O	O
blockers	O	O
prevented	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
secondary	O	O
hyperactivity	B-Disease	D006948
.	O	O

3	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
the	O	O
involvement	O	O
of	O	O
quinine	B-Chemical	D011803
-	O	O
sensitive	O	O
but	O	O
not	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
-	O	O
sensitive	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
in	O	O
morphine	B-Chemical	D009020
reward	O	O
.	O	O

It	O	O
is	O	O
also	O	O
suggested	O	O
that	O	O
the	O	O
blockade	O	O
of	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
sensitive	O	O
to	O	O
these	O	O
blockers	O	O
is	O	O
not	O	O
sufficient	O	O
to	O	O
prevent	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
hypoactivity	B-Disease	D009069
whereas	O	O
morphine	B-Chemical	D009020
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
seems	O	O
to	O	O
be	O	O
connected	O	O
to	O	O
both	O	O
quinine	B-Chemical	D011803
-	O	O
and	O	O
4	B-Chemical	D015761
-	I-Chemical	D015761
aminopyridine	I-Chemical	D015761
-	O	O
sensitive	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
channels	O	O
.	O	O

Nociceptin	B-Chemical	C096012
/	O	O
orphanin	B-Chemical	C096012
FQ	I-Chemical	C096012
and	O	O
nocistatin	B-Chemical	C111148
on	O	O
learning	O	O
and	O	O
memory	O	O
impairment	O	O
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
in	O	O
mice	O	O
.	O	O

1	O	O
.	O	O

Nociceptin	B-Chemical	C096012
,	O	O
also	O	O
known	O	O
as	O	O
orphanin	B-Chemical	C096012
FQ	I-Chemical	C096012
,	O	O
is	O	O
an	O	O
endogenous	O	O
ligand	O	O
for	O	O
the	O	O
orphan	O	O
opioid	O	O
receptor	O	O
-	O	O
like	O	O
receptor	O	O
1	O	O
(	O	O
ORL1	O	O
)	O	O
and	O	O
involves	O	O
in	O	O
various	O	O
functions	O	O
in	O	O
the	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
nocistatin	B-Chemical	C111148
is	O	O
recently	O	O
isolated	O	O
from	O	O
the	O	O
same	O	O
precursor	O	O
as	O	O
nociceptin	B-Chemical	C096012
and	O	O
blocks	O	O
nociceptin	B-Chemical	C096012
-	O	O
induced	O	O
allodynia	B-Disease	D006930
and	O	O
hyperalgesia	B-Disease	D006930
.	O	O

2	O	O
.	O	O

Although	O	O
ORL1	O	O
receptors	O	O
which	O	O
display	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
sequence	O	O
homology	O	O
with	O	O
classical	O	O
opioid	O	O
receptors	O	O
are	O	O
abundant	O	O
in	O	O
the	O	O
hippocampus	O	O
,	O	O
little	O	O
is	O	O
known	O	O
regarding	O	O
their	O	O
role	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

3	O	O
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
investigate	O	O
whether	O	O
nociceptin	B-Chemical	C096012
/	O	O
orphanin	B-Chemical	C096012
FQ	I-Chemical	C096012
and	O	O
nocistatin	B-Chemical	C111148
could	O	O
modulate	O	O
impairment	O	O
of	O	O
learning	O	O
and	O	O
memory	O	O
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
,	O	O
a	O	O
muscarinic	O	O
cholinergic	O	O
receptor	O	O
antagonist	O	O
,	O	O
using	O	O
spontaneous	O	O
alternation	O	O
of	O	O
Y	O	O
-	O	O
maze	O	O
and	O	O
step	O	O
-	O	O
down	O	O
type	O	O
passive	O	O
avoidance	O	O
tasks	O	O
in	O	O
mice	O	O
.	O	O

4	O	O
.	O	O

While	O	O
nocistatin	B-Chemical	C111148
(	O	O
0	O	O
.	O	O

5	O	O
-	O	O
5	O	O
.	O	O

0	O	O
nmol	O	O
mouse	O	O
-	O	O
1	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
administered	O	O
30	O	O
min	O	O
before	O	O
spontaneous	O	O
alternation	O	O
performance	O	O
or	O	O
the	O	O
training	O	O
session	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
spontaneous	O	O
alternation	O	O
or	O	O
passive	O	O
avoidance	O	O
behaviours	O	O
,	O	O
a	O	O
lower	O	O
per	O	O
cent	O	O
alternation	O	O
and	O	O
shorter	O	O
median	O	O
step	O	O
-	O	O
down	O	O
latency	O	O
in	O	O
the	O	O
retention	O	O
test	O	O
were	O	O
obtained	O	O
in	O	O
nociceptin	B-Chemical	C096012
(	O	O
1	O	O
.	O	O

5	O	O
and	O	O
/	O	O
or	O	O
5	O	O
.	O	O

0	O	O
nmol	O	O
mouse	O	O
-	O	O
1	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
-	O	O
treated	O	O
normal	O	O
mice	O	O
.	O	O

5	O	O
.	O	O

Administration	O	O
of	O	O
nocistatin	B-Chemical	C111148
(	O	O
1	O	O
.	O	O

5	O	O
and	O	O
/	O	O
or	O	O
5	O	O
.	O	O

0	O	O
nmol	O	O
mouse	O	O
-	O	O
1	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
.	O	O

)	O	O
30	O	O
min	O	O
before	O	O
spontaneous	O	O
alternation	O	O
performance	O	O
or	O	O
the	O	O
training	O	O
session	O	O
of	O	O
the	O	O
passive	O	O
avoidance	O	O
task	O	O
,	O	O
attenuated	O	O
the	O	O
scopolamine	B-Chemical	D012601
-	O	O
induced	O	O
impairment	O	O
of	O	O
spontaneous	O	O
alternation	O	O
and	O	O
passive	O	O
avoidance	O	O
behaviours	O	O
.	O	O

6	O	O
.	O	O

These	O	O
results	O	O
indicated	O	O
that	O	O
nocistatin	B-Chemical	C111148
,	O	O
a	O	O
new	O	O
biologically	O	O
active	O	O
peptide	O	O
,	O	O
ameliorates	O	O
impairments	O	O
of	O	O
spontaneous	O	O
alternation	O	O
and	O	O
passive	O	O
avoidance	O	O
induced	O	O
by	O	O
scopolamine	B-Chemical	D012601
,	O	O
and	O	O
suggested	O	O
that	O	O
these	O	O
peptides	O	O
play	O	O
opposite	O	O
roles	O	O
in	O	O
learning	O	O
and	O	O
memory	O	O
.	O	O

Meloxicam	B-Chemical	C065757
-	O	O
induced	O	O
liver	B-Disease	D056486
toxicity	I-Disease	D056486
.	O	O

We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
rheumatoid	B-Disease	D001172
arthritis	I-Disease	D001172
who	O	O
developed	O	O
acute	O	O
cytolytic	O	O
hepatitis	B-Disease	D056486
due	O	O
to	O	O
meloxicam	B-Chemical	C065757
.	O	O

Recently	O	O
introduced	O	O
in	O	O
Belgium	O	O
,	O	O
meloxicam	B-Chemical	C065757
is	O	O
the	O	O
first	O	O
nonsteroidal	O	O
antiinflammatory	O	O
drug	O	O
with	O	O
selective	O	O
action	O	O
on	O	O
the	O	O
inducible	O	O
form	O	O
of	O	O
cyclooxygenase	O	O
2	O	O
.	O	O

The	O	O
acute	O	O
cytolytic	O	O
hepatitis	B-Disease	D056486
occurred	O	O
rapidly	O	O
after	O	O
meloxicam	B-Chemical	C065757
administration	O	O
and	O	O
was	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
antinuclear	O	O
antibodies	O	O
suggesting	O	O
a	O	O
hypersensitivity	B-Disease	D004342
mechanism	O	O
.	O	O

This	O	O
first	O	O
case	O	O
of	O	O
meloxicam	B-Chemical	C065757
related	O	O
liver	B-Disease	D056486
toxicity	I-Disease	D056486
demonstrates	O	O
the	O	O
potential	O	O
of	O	O
this	O	O
drug	O	O
to	O	O
induce	O	O
hepatic	B-Disease	D056486
damage	I-Disease	D056486
.	O	O

Induction	O	O
of	O	O
apoptosis	O	O
by	O	O
remoxipride	B-Chemical	D017330
metabolites	O	O
in	O	O
HL60	O	O
and	O	O
CD34+	O	O
/	O	O
CD19	O	O
-	O	O
human	O	O
bone	O	O
marrow	O	O
progenitor	O	O
cells	O	O
:	O	O
potential	O	O
relevance	O	O
to	O	O
remoxipride	B-Chemical	D017330
-	O	O
induced	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
.	O	O

The	O	O
antipsychotic	O	O
agent	O	O
,	O	O
remoxipride	B-Chemical	D017330
[	O	O
(	B-Chemical	D017330
S	I-Chemical	D017330
)	I-Chemical	D017330
-	I-Chemical	D017330
(	I-Chemical	D017330
-	I-Chemical	D017330
)	I-Chemical	D017330
-	I-Chemical	D017330
3	I-Chemical	D017330
-	I-Chemical	D017330
bromo	I-Chemical	D017330
-	I-Chemical	D017330
N	I-Chemical	D017330
-	I-Chemical	D017330
[	I-Chemical	D017330
(	I-Chemical	D017330
1	I-Chemical	D017330
-	I-Chemical	D017330
ethyl	I-Chemical	D017330
-	I-Chemical	D017330
2	I-Chemical	D017330
-	I-Chemical	D017330
pyrrolidinyl	I-Chemical	D017330
)	I-Chemical	D017330
methyl	I-Chemical	D017330
]	I-Chemical	D017330
-	I-Chemical	D017330
2	I-Chemical	D017330
,	I-Chemical	D017330
6	I-Chemical	D017330
-	I-Chemical	D017330
dimethoxybenz	I-Chemical	D017330
amide	I-Chemical	D017330
]	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
acquired	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
ability	O	O
of	O	O
remoxipride	B-Chemical	D017330
,	O	O
three	O	O
pyrrolidine	B-Chemical	C032519
ring	O	O
metabolites	O	O
and	O	O
five	O	O
aromatic	O	O
ring	O	O
metabolites	O	O
of	O	O
the	O	O
parent	O	O
compound	O	O
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
HL60	O	O
cells	O	O
and	O	O
human	O	O
bone	O	O
marrow	O	O
progenitor	O	O
(	O	O
HBMP	O	O
)	O	O
cells	O	O
.	O	O

Cells	O	O
were	O	O
treated	O	O
for	O	O
0	O	O
-	O	O
24	O	O
h	O	O
with	O	O
each	O	O
compound	O	O
(	O	O
0	O	O
-	O	O
200	O	O
microM	O	O
)	O	O
.	O	O

Apoptosis	O	O
was	O	O
assessed	O	O
by	O	O
fluorescence	O	O
microscopy	O	O
in	O	O
Hoechst	B-Chemical	C017807
33342	I-Chemical	C017807
-	O	O
and	O	O
propidium	B-Chemical	D011419
iodide	I-Chemical	D011419
stained	O	O
cell	O	O
samples	O	O
.	O	O

Results	O	O
were	O	O
confirmed	O	O
by	O	O
determination	O	O
of	O	O
internucleosomal	O	O
DNA	O	O
fragmentation	O	O
using	O	O
gel	O	O
electrophoresis	O	O
for	O	O
HL60	O	O
cell	O	O
samples	O	O
and	O	O
terminal	O	O
deoxynucleotidyl	O	O
transferase	O	O
assay	O	O
in	O	O
HBMP	O	O
cells	O	O
.	O	O

The	O	O
catechol	B-Chemical	C034221
and	O	O
hydroquinone	B-Chemical	C031927
metabolites	O	O
,	O	O
NCQ436	B-Chemical	C084325
and	O	O
NCQ344	B-Chemical	C112341
,	O	O
induced	O	O
apoptosis	O	O
in	O	O
HL60	O	O
and	O	O
HBMP	O	O
cells	O	O
in	O	O
a	O	O
time	O	O
-	O	O
and	O	O
concentration	O	O
dependent	O	O
manner	O	O
,	O	O
while	O	O
the	O	O
phenols	B-Chemical	D010636
,	O	O
NCR181	O	O
,	O	O
FLA873	O	O
,	O	O
and	O	O
FLA797	B-Chemical	C050313
,	O	O
and	O	O
the	O	O
derivatives	O	O
formed	O	O
by	O	O
oxidation	O	O
of	O	O
the	O	O
pyrrolidine	B-Chemical	C032519
ring	O	O
,	O	O
FLA838	O	O
,	O	O
NCM001	O	O
,	O	O
and	O	O
NCL118	O	O
,	O	O
had	O	O
no	O	O
effect	O	O
.	O	O

No	O	O
necrosis	B-Disease	D009336
was	O	O
observed	O	O
in	O	O
cells	O	O
treated	O	O
with	O	O
NCQ436	B-Chemical	C084325
but	O	O
NCQ344	B-Chemical	C112341
had	O	O
a	O	O
biphasic	O	O
effect	O	O
in	O	O
both	O	O
cell	O	O
types	O	O
,	O	O
inducing	O	O
apoptosis	O	O
at	O	O
lower	O	O
concentrations	O	O
and	O	O
necrosis	B-Disease	D009336
at	O	O
higher	O	O
concentrations	O	O
.	O	O

These	O	O
data	O	O
show	O	O
that	O	O
the	O	O
catechol	B-Chemical	C034221
and	O	O
hydroquinone	B-Chemical	C031927
metabolites	O	O
of	O	O
remoxipride	B-Chemical	D017330
have	O	O
direct	O	O
toxic	O	O
effects	O	O
in	O	O
HL60	O	O
and	O	O
HBMP	O	O
cells	O	O
,	O	O
leading	O	O
to	O	O
apoptosis	O	O
,	O	O
while	O	O
the	O	O
phenol	B-Chemical	D019800
metabolites	O	O
were	O	O
inactive	O	O
.	O	O

Similarly	O	O
,	O	O
benzene	B-Chemical	D001554
-	O	O
derived	O	O
catechol	B-Chemical	C034221
and	O	O
hydroquinone	B-Chemical	C031927
,	O	O
but	O	O
not	O	O
phenol	B-Chemical	D019800
,	O	O
induce	O	O
apoptosis	O	O
in	O	O
HBMP	O	O
cells	O	O
[	O	O
Moran	O	O
et	O	O
al	O	O
.	O	O

,	O	O
Mol	O	O
.	O	O

Pharmacol	O	O
.	O	O

,	O	O
50	O	O
(	O	O
1996	O	O
)	O	O
610	O	O
-	O	O
615	O	O
]	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
remoxipride	B-Chemical	D017330
and	O	O
benzene	B-Chemical	D001554
may	O	O
induce	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
via	O	O
production	O	O
of	O	O
similar	O	O
reactive	O	O
metabolites	O	O
and	O	O
that	O	O
the	O	O
ability	O	O
of	O	O
NCQ436	B-Chemical	C084325
and	O	O
NCQ344	B-Chemical	C112341
to	O	O
induce	O	O
apoptosis	O	O
in	O	O
HBMP	O	O
cells	O	O
may	O	O
contribute	O	O
to	O	O
the	O	O
mechanism	O	O
underlying	O	O
acquired	O	O
aplastic	B-Disease	D000741
anemia	I-Disease	D000741
that	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
remoxipride	B-Chemical	D017330
.	O	O

Synthesis	O	O
and	O	O
preliminary	O	O
pharmacological	O	O
investigations	O	O
of	O	O
1	B-Chemical	-1
-	I-Chemical	-1
(	I-Chemical	-1
1	I-Chemical	-1
,	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
dihydro	I-Chemical	-1
-	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
acenaphthylenyl	I-Chemical	-1
)	I-Chemical	-1
piperazine	I-Chemical	-1
derivatives	O	O
as	O	O
potential	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
in	O	O
mice	O	O
.	O	O

In	O	O
research	O	O
towards	O	O
the	O	O
development	O	O
of	O	O
new	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
,	O	O
one	O	O
strategy	O	O
is	O	O
that	O	O
the	O	O
dopaminergic	O	O
system	O	O
can	O	O
be	O	O
modulated	O	O
through	O	O
manipulation	O	O
of	O	O
the	O	O
serotonergic	O	O
system	O	O
.	O	O

The	O	O
synthesis	O	O
and	O	O
preliminary	O	O
pharmacological	O	O
evaluation	O	O
of	O	O
a	O	O
series	O	O
of	O	O
potential	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
based	O	O
on	O	O
the	O	O
structure	O	O
of	O	O
1	B-Chemical	-1
-	I-Chemical	-1
(	I-Chemical	-1
1	I-Chemical	-1
,	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
dihydro	I-Chemical	-1
-	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
acenaphthylenyl	I-Chemical	-1
)	I-Chemical	-1
piperazine	I-Chemical	-1
(	O	O
7	O	O
)	O	O
is	O	O
described	O	O
.	O	O

Compound	O	O
7e	O	O
,	O	O
5	B-Chemical	-1
-	I-Chemical	-1
{2	I-Chemical	-1
-	I-Chemical	-1
[	I-Chemical	-1
4	I-Chemical	-1
-	I-Chemical	-1
(	I-Chemical	-1
1	I-Chemical	-1
,	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
dihydro	I-Chemical	-1
-	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
acenaphthylenyl	I-Chemical	-1
)	I-Chemical	-1
piperazinyl	I-Chemical	-1
]	I-Chemical	-1
ethyl}	I-Chemical	-1
-	I-Chemical	-1
2	I-Chemical	-1
,	I-Chemical	-1
3	I-Chemical	-1
-	I-Chemical	-1
dihy	I-Chemical	-1
dro	I-Chemical	-1
-	I-Chemical	-1
1H	I-Chemical	-1
-	I-Chemical	-1
indol	I-Chemical	-1
-	I-Chemical	-1
2	I-Chemical	-1
-	I-Chemical	-1
one	I-Chemical	-1
,	O	O
from	O	O
this	O	O
series	O	O
showed	O	O
significant	O	O
affinities	O	O
at	O	O
the	O	O
5	O	O
-	O	O
HT1A	O	O
and	O	O
5	O	O
-	O	O
HT2A	O	O
receptors	O	O
and	O	O
moderate	O	O
affinity	O	O
at	O	O
the	O	O
D2	O	O
receptor	O	O
.	O	O

7e	O	O
exhibits	O	O
a	O	O
high	O	O
reversal	O	O
of	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
indicating	O	O
its	O	O
atypical	O	O
antipsychotic	O	O
nature	O	O
.	O	O

Sub	O	O
-	O	O
chronic	O	O
inhibition	O	O
of	O	O
nitric	B-Chemical	D009569
-	I-Chemical	D009569
oxide	I-Chemical	D009569
synthesis	O	O
modifies	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
and	O	O
the	O	O
number	O	O
of	O	O
NADPH	B-Chemical	D009249
-	O	O
diaphorase	O	O
neurons	O	O
in	O	O
mice	O	O
.	O	O

RATIONALE	O	O
:	O	O
NG	B-Chemical	D019335
-	I-Chemical	D019335
nitro	I-Chemical	D019335
-	I-Chemical	D019335
L	I-Chemical	D019335
-	I-Chemical	D019335
arginine	I-Chemical	D019335
(	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
)	O	O
,	O	O
an	O	O
inhibitor	O	O
of	O	O
nitric	B-Chemical	D009569
-	I-Chemical	D009569
oxide	I-Chemical	D009569
synthase	O	O
(	O	O
NOS	O	O
)	O	O
,	O	O
induces	O	O
catalepsy	B-Disease	D002375
in	O	O
mice	O	O
.	O	O

This	O	O
effect	O	O
undergoes	O	O
rapid	O	O
tolerance	O	O
,	O	O
showing	O	O
a	O	O
significant	O	O
decrease	O	O
after	O	O
2	O	O
days	O	O
of	O	O
sub	O	O
-	O	O
chronic	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
treatment	O	O
.	O	O

Nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
influence	O	O
dopaminergic	O	O
neurotransmission	O	O
in	O	O
the	O	O
striatum	O	O
.	O	O

Neuroleptic	O	O
drugs	O	O
such	O	O
as	O	O
haloperidol	B-Chemical	D006220
,	O	O
which	O	O
block	O	O
dopamine	B-Chemical	D004298
receptors	O	O
,	O	O
also	O	O
cause	O	O
catalepsy	B-Disease	D002375
in	O	O
rodents	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
subchronic	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
treatment	O	O
in	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
and	O	O
the	O	O
number	O	O
of	O	O
NOS	O	O
neurons	O	O
in	O	O
areas	O	O
related	O	O
to	O	O
motor	O	O
control	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
albino	O	O
Swiss	O	O
mice	O	O
were	O	O
treated	O	O
sub	O	O
-	O	O
chronically	O	O
(	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
4	O	O
days	O	O
)	O	O
with	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
(	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
or	O	O
haloperidol	B-Chemical	D006220
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

Catalepsy	B-Disease	D002375
was	O	O
evaluated	O	O
at	O	O
the	O	O
beginning	O	O
and	O	O
the	O	O
end	O	O
of	O	O
the	O	O
treatments	O	O
.	O	O

Reduced	O	O
nicotinamide	B-Chemical	D009249
adenine	I-Chemical	D009249
dinucleotide	I-Chemical	D009249
phosphate	I-Chemical	D009249
-	O	O
diaphorase	O	O
(	O	O
NADPH	B-Chemical	D009249
-	O	O
d	O	O
)	O	O
histochemistry	O	O
was	O	O
also	O	O
employed	O	O
to	O	O
visualize	O	O
NOS	O	O
as	O	O
an	O	O
index	O	O
of	O	O
enzyme	O	O
expression	O	O
in	O	O
mice	O	O
brain	O	O
regions	O	O
related	O	O
to	O	O
motor	O	O
control	O	O
.	O	O

RESULTS	O	O
:	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
sub	O	O
-	O	O
chronic	O	O
administration	O	O
produced	O	O
tolerance	O	O
of	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
and	O	O
of	O	O
haloperidol	B-Chemical	D006220
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

It	O	O
also	O	O
induced	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
NADPH	B-Chemical	D009249
-	O	O
d	O	O
-	O	O
positive	O	O
cells	O	O
in	O	O
the	O	O
dorsal	O	O
part	O	O
of	O	O
the	O	O
caudate	O	O
and	O	O
accumbens	O	O
nuclei	O	O
compared	O	O
with	O	O
haloperidol	B-Chemical	D006220
and	O	O
in	O	O
the	O	O
pedunculopontine	O	O
tegmental	O	O
nucleus	O	O
compared	O	O
with	O	O
saline	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
there	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
NADPH	B-Chemical	D009249
-	O	O
d	O	O
neuron	O	O
number	O	O
in	O	O
the	O	O
substantia	O	O
nigra	O	O
,	O	O
pars	O	O
compacta	O	O
in	O	O
both	O	O
haloperidol	B-Chemical	D006220
-	O	O
treated	O	O
and	O	O
L	B-Chemical	D019335
-	I-Chemical	D019335
NOARG	I-Chemical	D019335
-	O	O
treated	O	O
animals	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
results	O	O
give	O	O
further	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
NO	B-Chemical	D009569
plays	O	O
a	O	O
role	O	O
in	O	O
motor	O	O
behavior	O	O
control	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
may	O	O
take	O	O
part	O	O
in	O	O
the	O	O
synaptic	O	O
changes	O	O
produced	O	O
by	O	O
antipsychotic	O	O
treatment	O	O
.	O	O

Prolonged	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
occurs	O	O
in	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
after	O	O
both	O	O
dobutamine	B-Chemical	D004280
and	O	O
exercise	O	O
induced	O	O
myocardial	B-Disease	D017202
ischaemia	I-Disease	D017202
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
determine	O	O
whether	O	O
pharmacological	O	O
stress	O	O
leads	O	O
to	O	O
prolonged	O	O
but	O	O
reversible	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
in	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
after	O	O
exercise	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
randomised	O	O
crossover	O	O
study	O	O
of	O	O
recovery	O	O
time	O	O
of	O	O
systolic	O	O
and	O	O
diastolic	O	O
left	O	O
ventricular	O	O
function	O	O
after	O	O
exercise	O	O
and	O	O
dobutamine	B-Chemical	D004280
induced	O	O
ischaemia	B-Disease	D007511
.	O	O

SUBJECTS	O	O
:	O	O
10	O	O
patients	O	O
with	O	O
stable	B-Disease	D060050
angina	I-Disease	D060050
,	O	O
angiographically	O	O
proven	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
and	O	O
normal	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

INTERVENTIONS	O	O
:	O	O
Treadmill	O	O
exercise	O	O
and	O	O
dobutamine	B-Chemical	D004280
stress	O	O
were	O	O
performed	O	O
on	O	O
different	O	O
days	O	O
.	O	O

Quantitative	O	O
assessment	O	O
of	O	O
systolic	O	O
and	O	O
diastolic	O	O
left	O	O
ventricular	O	O
function	O	O
was	O	O
performed	O	O
using	O	O
transthoracic	O	O
echocardiography	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
regular	O	O
intervals	O	O
after	O	O
each	O	O
test	O	O
.	O	O

RESULTS	O	O
:	O	O
Both	O	O
forms	O	O
of	O	O
stress	O	O
led	O	O
to	O	O
prolonged	O	O
but	O	O
reversible	O	O
systolic	O	O
and	O	O
diastolic	O	O
dysfunction	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
maximum	O	O
double	O	O
product	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

53	O	O
)	O	O
or	O	O
ST	O	O
depression	B-Disease	D003866
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

63	O	O
)	O	O
with	O	O
either	O	O
form	O	O
of	O	O
stress	O	O
.	O	O

After	O	O
exercise	O	O
,	O	O
ejection	O	O
fraction	O	O
was	O	O
reduced	O	O
at	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
compared	O	O
with	O	O
baseline	O	O
(	O	O
mean	O	O
(	O	O
SEM	O	O
)	O	O
,	O	O
-	O	O
5	O	O
.	O	O

6	O	O
(	O	O
1	O	O
.	O	O

5	O	O
)	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
;	O	O
and	O	O
-	O	O
6	O	O
.	O	O

1	O	O
(	O	O
2	O	O
.	O	O

2	O	O
)	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
and	O	O
at	O	O
30	O	O
and	O	O
45	O	O
minutes	O	O
after	O	O
dobutamine	B-Chemical	D004280
(	O	O
-	O	O
10	O	O
.	O	O

8	O	O
(	O	O
1	O	O
.	O	O

8	O	O
)	O	O
%	O	O
and	O	O
-	O	O
5	O	O
.	O	O

5	O	O
(	O	O
1	O	O
.	O	O

8	O	O
)	O	O
%	O	O
,	O	O
both	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Regional	O	O
analysis	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
the	O	O
worst	O	O
affected	O	O
segment	O	O
15	O	O
and	O	O
30	O	O
minutes	O	O
after	O	O
exercise	O	O
(	O	O
-	O	O
27	O	O
.	O	O

9	O	O
(	O	O
7	O	O
.	O	O

2	O	O
)	O	O
%	O	O
and	O	O
-	O	O
28	O	O
.	O	O

6	O	O
(	O	O
5	O	O
.	O	O

7	O	O
)	O	O
%	O	O
,	O	O
both	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
and	O	O
at	O	O
30	O	O
minutes	O	O
after	O	O
dobutamine	B-Chemical	D004280
(	O	O
-	O	O
32	O	O
(	O	O
5	O	O
.	O	O

3	O	O
)	O	O
%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

The	O	O
isovolumic	O	O
relaxation	O	O
period	O	O
was	O	O
prolonged	O	O
45	O	O
minutes	O	O
after	O	O
each	O	O
form	O	O
of	O	O
stress	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
,	O	O
dobutamine	B-Chemical	D004280
induced	O	O
ischaemia	B-Disease	D007511
results	O	O
in	O	O
prolonged	O	O
reversible	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
,	O	O
presumed	O	O
to	O	O
be	O	O
myocardial	B-Disease	D017682
stunning	I-Disease	D017682
,	O	O
similar	O	O
to	O	O
that	O	O
seen	O	O
after	O	O
exercise	O	O
.	O	O

Dobutamine	B-Chemical	D004280
induced	O	O
ischaemia	B-Disease	D007511
could	O	O
therefore	O	O
be	O	O
used	O	O
to	O	O
study	O	O
the	O	O
pathophysiology	O	O
of	O	O
this	O	O
phenomenon	O	O
further	O	O
in	O	O
patients	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

Anorexigens	O	O
and	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
in	O	O
the	O	O
United	O	O
States	O	O
:	O	O
results	O	O
from	O	O
the	O	O
surveillance	O	O
of	O	O
North	O	O
American	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
use	O	O
of	O	O
appetite	O	O
suppressants	O	O
in	O	O
Europe	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
primary	B-Disease	D006976
pulmonary	I-Disease	D006976
hypertension	I-Disease	D006976
(	O	O
PPH	B-Disease	D006976
)	O	O
.	O	O

Recently	O	O
,	O	O
fenfluramine	B-Chemical	D005277
appetite	O	O
suppressants	O	O
became	O	O
widely	O	O
used	O	O
in	O	O
the	O	O
United	O	O
States	O	O
but	O	O
were	O	O
withdrawn	O	O
in	O	O
September	O	O
1997	O	O
because	O	O
of	O	O
concerns	O	O
over	O	O
adverse	O	O
effects	O	O
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
prospective	O	O
surveillance	O	O
study	O	O
on	O	O
patients	O	O
diagnosed	O	O
with	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
at	O	O
12	O	O
large	O	O
referral	O	O
centers	O	O
in	O	O
North	O	O
America	O	O
.	O	O

Data	O	O
collected	O	O
on	O	O
patients	O	O
seen	O	O
from	O	O
September	O	O
1	O	O
,	O	O
1996	O	O
,	O	O
to	O	O
December	O	O
31	O	O
,	O	O
1997	O	O
,	O	O
included	O	O
the	O	O
cause	O	O
of	O	O
the	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
and	O	O
its	O	O
severity	O	O
.	O	O

Patients	O	O
with	O	O
no	O	O
identifiable	O	O
cause	O	O
of	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
were	O	O
classed	O	O
as	O	O
PPH	B-Disease	D006976
.	O	O

A	O	O
history	O	O
of	O	O
drug	O	O
exposure	O	O
also	O	O
was	O	O
taken	O	O
with	O	O
special	O	O
attention	O	O
on	O	O
the	O	O
use	O	O
of	O	O
antidepressants	O	O
,	O	O
anorexigens	O	O
,	O	O
and	O	O
amphetamines	B-Chemical	D000662
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
hundred	O	O
seventy	O	O
-	O	O
nine	O	O
patients	O	O
were	O	O
studied	O	O
,	O	O
205	O	O
with	O	O
PPH	B-Disease	D006976
and	O	O
374	O	O
with	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
from	O	O
other	O	O
causes	O	O
(	O	O
secondary	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
[	O	O
SPH	O	O
]	O	O
)	O	O
.	O	O

The	O	O
use	O	O
of	O	O
anorexigens	O	O
was	O	O
common	O	O
in	O	O
both	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
of	O	O
the	O	O
medications	O	O
surveyed	O	O
,	O	O
only	O	O
the	O	O
fenfluramines	B-Chemical	D005277
had	O	O
a	O	O
significant	O	O
preferential	O	O
association	O	O
with	O	O
PPH	B-Disease	D006976
as	O	O
compared	O	O
with	O	O
SPH	O	O
(	O	O
adjusted	O	O
odds	O	O
ratio	O	O
for	O	O
use	O	O
>	O	O
6	O	O
months	O	O
,	O	O
7	O	O
.	O	O

5	O	O
;	O	O
95%	O	O
confidence	O	O
interval	O	O
,	O	O
1	O	O
.	O	O

7	O	O
to	O	O
32	O	O
.	O	O

4	O	O
)	O	O
.	O	O

The	O	O
association	O	O
was	O	O
stronger	O	O
with	O	O
longer	O	O
duration	O	O
of	O	O
use	O	O
when	O	O
compared	O	O
to	O	O
shorter	O	O
duration	O	O
of	O	O
use	O	O
and	O	O
was	O	O
more	O	O
pronounced	O	O
in	O	O
recent	O	O
users	O	O
than	O	O
in	O	O
remote	O	O
users	O	O
.	O	O

An	O	O
unexpectedly	O	O
high	O	O
(	O	O
11	O	O
.	O	O

4%	O	O
)	O	O
number	O	O
of	O	O
patients	O	O
with	O	O
SPH	O	O
had	O	O
used	O	O
anorexigens	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
magnitude	O	O
of	O	O
the	O	O
association	O	O
with	O	O
PPH	B-Disease	D006976
,	O	O
the	O	O
increase	O	O
of	O	O
association	O	O
with	O	O
increasing	O	O
duration	O	O
of	O	O
use	O	O
,	O	O
and	O	O
the	O	O
specificity	O	O
for	O	O
fenfluramines	B-Chemical	D005277
are	O	O
consistent	O	O
with	O	O
previous	O	O
studies	O	O
indicating	O	O
that	O	O
fenfluramines	B-Chemical	D005277
are	O	O
causally	O	O
related	O	O
to	O	O
PPH	B-Disease	D006976
.	O	O

The	O	O
high	O	O
prevalence	O	O
of	O	O
anorexigen	O	O
use	O	O
in	O	O
patients	O	O
with	O	O
SPH	O	O
also	O	O
raises	O	O
the	O	O
possibility	O	O
that	O	O
these	O	O
drugs	O	O
precipitate	O	O
pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
in	O	O
patients	O	O
with	O	O
underlying	O	O
conditions	O	O
associated	O	O
with	O	O
SPH	O	O
.	O	O

Clinical	O	O
aspects	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
and	O	O
thrombosis	B-Disease	D013927
and	O	O
other	O	O
side	O	O
effects	O	O
of	O	O
heparin	B-Chemical	D006493
therapy	O	O
.	O	O

Heparin	B-Chemical	D006493
,	O	O
first	O	O
used	O	O
to	O	O
prevent	O	O
the	O	O
clotting	O	O
of	O	O
blood	O	O
in	O	O
vitro	O	O
,	O	O
has	O	O
been	O	O
clinically	O	O
used	O	O
to	O	O
treat	O	O
thrombosis	B-Disease	D013927
for	O	O
more	O	O
than	O	O
50	O	O
years	O	O
.	O	O

Although	O	O
several	O	O
new	O	O
anticoagulant	O	O
drugs	O	O
are	O	O
in	O	O
development	O	O
,	O	O
heparin	B-Chemical	D006493
remains	O	O
the	O	O
anticoagulant	O	O
of	O	O
choice	O	O
to	O	O
treat	O	O
acute	O	O
thrombotic	B-Disease	D013927
episodes	O	O
.	O	O

The	O	O
clinical	O	O
effects	O	O
of	O	O
heparin	B-Chemical	D006493
are	O	O
meritorious	O	O
,	O	O
but	O	O
side	O	O
effects	O	O
do	O	O
exist	O	O
.	O	O

Bleeding	B-Disease	D006470
is	O	O
the	O	O
primary	O	O
untoward	O	O
effect	O	O
of	O	O
heparin	B-Chemical	D006493
.	O	O

Major	O	O
bleeding	B-Disease	D006470
is	O	O
of	O	O
primary	O	O
concern	O	O
in	O	O
patients	O	O
receiving	O	O
heparin	B-Chemical	D006493
therapy	O	O
.	O	O

However	O	O
,	O	O
additional	O	O
important	O	O
untoward	O	O
effects	O	O
of	O	O
heparin	B-Chemical	D006493
therapy	O	O
include	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
heparin	B-Chemical	D006493
-	O	O
associated	O	O
osteoporosis	B-Disease	D010024
,	O	O
eosinophilia	B-Disease	D004802
,	O	O
skin	B-Disease	D012871
reactions	I-Disease	D012871
,	O	O
allergic	B-Disease	D004342
reactions	I-Disease	D004342
other	O	O
than	O	O
thrombocytopenia	B-Disease	D013921
,	O	O
alopecia	B-Disease	D000505
,	O	O
transaminasemia	O	O
,	O	O
hyperkalemia	B-Disease	D006947
,	O	O
hypoaldosteronism	B-Disease	D006994
,	O	O
and	O	O
priapism	B-Disease	D011317
.	O	O

These	O	O
side	O	O
effects	O	O
are	O	O
relatively	O	O
rare	O	O
in	O	O
a	O	O
given	O	O
individual	O	O
,	O	O
but	O	O
given	O	O
the	O	O
extremely	O	O
widespread	O	O
use	O	O
of	O	O
heparin	B-Chemical	D006493
,	O	O
some	O	O
are	O	O
quite	O	O
common	O	O
,	O	O
particularly	O	O
HITT	B-Disease	D013921
and	O	O
osteoporosis	B-Disease	D010024
.	O	O

Although	O	O
reasonable	O	O
incidences	O	O
of	O	O
many	O	O
of	O	O
these	O	O
side	O	O
effects	O	O
can	O	O
be	O	O
"softly"	O	O
deduced	O	O
from	O	O
current	O	O
reports	O	O
dealing	O	O
with	O	O
unfractionated	O	O
heparin	B-Chemical	D006493
,	O	O
at	O	O
present	O	O
the	O	O
incidences	O	O
of	O	O
these	O	O
side	O	O
effects	O	O
with	O	O
newer	O	O
low	O	O
molecular	O	O
weight	O	O
heparins	B-Chemical	D006493
appear	O	O
to	O	O
be	O	O
much	O	O
less	O	O
common	O	O
.	O	O

However	O	O
,	O	O
only	O	O
longer	O	O
experience	O	O
will	O	O
more	O	O
clearly	O	O
define	O	O
the	O	O
incidence	O	O
of	O	O
each	O	O
side	O	O
effect	O	O
with	O	O
low	O	O
molecular	O	O
weight	O	O
preparations	O	O
.	O	O

A	O	O
case	O	O
of	O	O
bilateral	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
in	O	O
a	O	O
patient	O	O
on	O	O
tacrolimus	B-Chemical	D016559
(	O	O
FK506	B-Chemical	D016559
)	O	O
therapy	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
bilateral	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
in	O	O
a	O	O
patient	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
(	O	O
FK	B-Chemical	D016559
506	I-Chemical	D016559
,	O	O
Prograf	O	O
;	O	O
Fujisawa	O	O
USA	O	O
,	O	O
Inc	O	O
,	O	O
Deerfield	O	O
,	O	O
Illinois	O	O
)	O	O
for	O	O
immunosuppression	O	O
after	O	O
orthotropic	O	O
liver	O	O
transplantation	O	O
.	O	O

METHOD	O	O
:	O	O
Case	O	O
report	O	O
.	O	O

In	O	O
a	O	O
58	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
receiving	O	O
tacrolimus	B-Chemical	D016559
after	O	O
orthotropic	O	O
liver	O	O
transplantation	O	O
,	O	O
serial	O	O
neuro	O	O
-	O	O
ophthalmologic	O	O
examinations	O	O
and	O	O
laboratory	O	O
studies	O	O
were	O	O
performed	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
patient	O	O
had	O	O
episodic	O	O
deterioration	O	O
of	O	O
vision	O	O
in	O	O
both	O	O
eyes	O	O
,	O	O
with	O	O
clinical	O	O
features	O	O
resembling	O	O
ischemic	B-Disease	D018917
optic	I-Disease	D018917
neuropathies	I-Disease	D018917
.	O	O

Deterioration	B-Disease	D015354
of	I-Disease	D015354
vision	I-Disease	D015354
occurred	O	O
despite	O	O
discontinuation	O	O
of	O	O
the	O	O
tacrolimus	B-Chemical	D016559
.	O	O

CONCLUSION	O	O
:	O	O
Tacrolimus	B-Chemical	D016559
and	O	O
other	O	O
immunosuppressive	O	O
agents	O	O
may	O	O
be	O	O
associated	O	O
with	O	O
optic	B-Disease	D009901
nerve	I-Disease	D009901
toxicity	I-Disease	D009901
.	O	O

Hypercalcemia	B-Disease	D006934
,	O	O
arrhythmia	B-Disease	D001145
,	O	O
and	O	O
mood	O	O
stabilizers	O	O
.	O	O

Recent	O	O
findings	O	O
in	O	O
a	O	O
bipolar	B-Disease	D001714
patient	O	O
receiving	O	O
maintenance	O	O
lithium	B-Chemical	D008094
therapy	O	O
who	O	O
developed	O	O
hypercalcemia	B-Disease	D006934
and	O	O
severe	O	O
bradyarrhythmia	B-Disease	D001919
prompted	O	O
the	O	O
authors	O	O
to	O	O
conduct	O	O
a	O	O
retrospective	O	O
study	O	O
of	O	O
bipolar	B-Disease	D001714
patients	O	O
with	O	O
lithium	B-Chemical	D008094
-	O	O
associated	O	O
hypercalcemia	B-Disease	D006934
.	O	O

A	O	O
printout	O	O
of	O	O
all	O	O
cases	O	O
of	O	O
hypercalcemia	B-Disease	D006934
that	O	O
presented	O	O
during	O	O
a	O	O
1	O	O
-	O	O
year	O	O
period	O	O
was	O	O
generated	O	O
.	O	O

After	O	O
eliminating	O	O
spurious	O	O
hypercalcemias	B-Disease	D006934
or	O	O
those	O	O
associated	O	O
with	O	O
intravenous	O	O
fluids	O	O
,	O	O
the	O	O
authors	O	O
identified	O	O
18	O	O
non	O	O
-	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
patients	O	O
with	O	O
hypercalcemias	B-Disease	D006934
related	O	O
to	O	O
malignancies	B-Disease	D009369
and	O	O
other	O	O
medical	O	O
conditions	O	O
(	O	O
group	O	O
A	O	O
)	O	O
and	O	O
12	O	O
patients	O	O
with	O	O
lithium	B-Chemical	D008094
-	O	O
associated	O	O
hypercalcemia	B-Disease	D006934
(	O	O
group	O	O
B	O	O
)	O	O
.	O	O

Patients	O	O
in	O	O
group	O	O
B	O	O
were	O	O
not	O	O
comparable	O	O
to	O	O
those	O	O
in	O	O
group	O	O
A	O	O
,	O	O
as	O	O
the	O	O
latter	O	O
were	O	O
medically	O	O
compromised	O	O
and	O	O
were	O	O
receiving	O	O
multiple	O	O
pharmacotherapies	O	O
.	O	O

Thus	O	O
,	O	O
two	O	O
control	O	O
groups	O	O
were	O	O
generated	O	O
:	O	O
group	O	O
C1	O	O
,	O	O
which	O	O
included	O	O
age	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
comparable	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
bipolar	B-Disease	D001714
normocalcemic	O	O
patients	O	O
,	O	O
and	O	O
group	O	O
C2	O	O
,	O	O
which	O	O
included	O	O
bipolar	B-Disease	D001714
normocalcemic	O	O
patients	O	O
treated	O	O
with	O	O
anticonvulsant	O	O
mood	O	O
stabilizers	O	O
.	O	O

The	O	O
electrocardiographic	O	O
(	O	O
ECG	O	O
)	O	O
findings	O	O
for	O	O
patients	O	O
in	O	O
group	O	O
B	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
patients	O	O
in	O	O
groups	O	O
C1	O	O
and	O	O
C2	O	O
.	O	O

It	O	O
was	O	O
found	O	O
that	O	O
these	O	O
groups	O	O
did	O	O
not	O	O
differ	O	O
in	O	O
their	O	O
overall	O	O
frequency	O	O
of	O	O
ECG	O	O
abnormalities	O	O
;	O	O
however	O	O
,	O	O
there	O	O
were	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
frequency	O	O
of	O	O
conduction	O	O
defects	O	O
.	O	O

Patients	O	O
with	O	O
hypercalcemia	B-Disease	D006934
resulting	O	O
from	O	O
medical	O	O
diseases	O	O
and	O	O
bipolar	B-Disease	D001714
patients	O	O
with	O	O
lithium	B-Chemical	D008094
-	O	O
associated	O	O
hypercalcemia	B-Disease	D006934
had	O	O
significantly	O	O
higher	O	O
frequencies	O	O
of	O	O
conduction	O	O
defects	O	O
.	O	O

Patients	O	O
in	O	O
group	O	O
A	O	O
had	O	O
significant	O	O
mortality	O	O
at	O	O
2	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
28%	O	O
)	O	O
,	O	O
in	O	O
contrast	O	O
to	O	O
zero	O	O
mortality	O	O
in	O	O
the	O	O
other	O	O
three	O	O
groups	O	O
.	O	O

The	O	O
clinical	O	O
implications	O	O
of	O	O
these	O	O
findings	O	O
are	O	O
discussed	O	O
.	O	O

Attenuation	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
by	O	O
a	O	O
novel	O	O
lipid	O	O
nanosphere	O	O
(	O	O
NS	O	O
-	O	O
718	O	O
)	O	O
incorporating	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
.	O	O

NS	O	O
-	O	O
718	O	O
,	O	O
a	O	O
lipid	O	O
nanosphere	O	O
incorporating	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
,	O	O
is	O	O
effective	O	O
against	O	O
pathogenic	O	O
fungi	O	O
and	O	O
has	O	O
low	O	O
toxicity	B-Disease	D064420
.	O	O

We	O	O
compared	O	O
the	O	O
toxicity	B-Disease	D064420
of	O	O
NS	O	O
-	O	O
718	O	O
with	O	O
that	O	O
of	O	O
Fungizone	B-Chemical	D000666
(	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
-	O	O
sodium	O	O
deoxycholate	O	O
;	O	O
D	B-Chemical	C059765
-	I-Chemical	C059765
AmB	I-Chemical	C059765
)	O	O
in	O	O
vitro	O	O
using	O	O
renal	O	O
cell	O	O
cultures	O	O
and	O	O
in	O	O
vivo	O	O
by	O	O
biochemical	O	O
analysis	O	O
,	O	O
histopathological	O	O
study	O	O
of	O	O
the	O	O
kidney	O	O
and	O	O
pharmacokinetic	O	O
study	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
following	O	O
intravenous	O	O
infusion	O	O
of	O	O
the	O	O
formulation	O	O
in	O	O
rats	O	O
.	O	O

Incubation	O	O
with	O	O
NS	O	O
-	O	O
718	O	O
resulted	O	O
in	O	O
significantly	O	O
less	O	O
damage	O	O
of	O	O
cultured	O	O
human	O	O
renal	O	O
proximal	O	O
tubular	O	O
epithelial	O	O
cells	O	O
compared	O	O
with	O	O
D	B-Chemical	C059765
-	I-Chemical	C059765
AmB	I-Chemical	C059765
.	O	O

Serum	O	O
blood	O	O
urea	B-Chemical	D014508
and	O	O
creatinine	B-Chemical	D003404
concentrations	O	O
increased	O	O
significantly	O	O
in	O	O
rats	O	O
given	O	O
an	O	O
iv	O	O
infusion	O	O
of	O	O
D	B-Chemical	C059765
-	I-Chemical	C059765
AmB	I-Chemical	C059765
3	O	O
mg	O	O
/	O	O
kg	O	O
but	O	O
not	O	O
in	O	O
those	O	O
given	O	O
the	O	O
same	O	O
dose	O	O
of	O	O
NS	O	O
-	O	O
718	O	O
.	O	O

Histopathological	O	O
examination	O	O
of	O	O
the	O	O
kidney	O	O
showed	O	O
tubular	B-Disease	D007683
necrosis	I-Disease	D007683
in	O	O
D	B-Chemical	C059765
-	I-Chemical	C059765
AmB	I-Chemical	C059765
-	O	O
treated	O	O
rats	O	O
but	O	O
no	O	O
change	O	O
in	O	O
NS	O	O
-	O	O
718	O	O
-	O	O
treated	O	O
rats	O	O
.	O	O

Amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
concentrations	O	O
in	O	O
the	O	O
kidney	O	O
in	O	O
NS	O	O
-	O	O
718	O	O
-	O	O
treated	O	O
rats	O	O
were	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
D	B-Chemical	C059765
-	I-Chemical	C059765
AmB	I-Chemical	C059765
-	O	O
treated	O	O
rats	O	O
.	O	O

Our	O	O
in	O	O
vitro	O	O
and	O	O
in	O	O
vivo	O	O
results	O	O
suggest	O	O
that	O	O
incorporation	O	O
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
into	O	O
lipid	O	O
nanospheres	O	O
of	O	O
NS	O	O
-	O	O
718	O	O
attenuates	O	O
the	O	O
nephrotoxicity	B-Disease	D007674
of	O	O
amphotericin	B-Chemical	D000666
B	I-Chemical	D000666
.	O	O

Patterns	O	O
of	O	O
sulfadiazine	B-Chemical	D013411
acute	B-Disease	D058186
nephrotoxicity	I-Disease	D058186
.	O	O

Sulfadiazine	B-Chemical	D013411
acute	B-Disease	D058186
nephrotoxicity	I-Disease	D058186
is	O	O
reviving	O	O
specially	O	O
because	O	O
of	O	O
its	O	O
use	O	O
in	O	O
toxoplasmosis	B-Disease	D014123
in	O	O
HIV	O	O
-	O	O
positive	O	O
patients	O	O
.	O	O

We	O	O
report	O	O
4	O	O
cases	O	O
,	O	O
one	O	O
of	O	O
them	O	O
in	O	O
a	O	O
previously	O	O
healthy	O	O
person	O	O
.	O	O

Under	O	O
treatment	O	O
with	O	O
sulfadiazine	B-Chemical	D013411
they	O	O
developed	O	O
oliguria	B-Disease	D009846
,	O	O
abdominal	B-Disease	D015746
pain	I-Disease	D015746
,	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
and	O	O
showed	O	O
multiple	O	O
radiolucent	O	O
renal	B-Disease	D007669
calculi	I-Disease	D007669
in	O	O
echography	O	O
.	O	O

All	O	O
patients	O	O
recovered	O	O
their	O	O
previous	O	O
normal	O	O
renal	O	O
function	O	O
after	O	O
adequate	O	O
hydration	O	O
and	O	O
alcalinization	O	O
.	O	O

A	O	O
nephrostomy	O	O
tube	O	O
had	O	O
to	O	O
be	O	O
placed	O	O
in	O	O
one	O	O
of	O	O
the	O	O
patients	O	O
for	O	O
ureteral	B-Disease	D052878
lithiasis	I-Disease	D052878
in	O	O
a	O	O
single	O	O
functional	O	O
kidney	O	O
.	O	O

None	O	O
of	O	O
them	O	O
needed	O	O
dialysis	O	O
or	O	O
a	O	O
renal	O	O
biopsy	O	O
because	O	O
of	O	O
a	O	O
typical	O	O
benign	O	O
course	O	O
.	O	O

Treatment	O	O
with	O	O
sulfadiazine	B-Chemical	D013411
requires	O	O
exquisite	O	O
control	O	O
of	O	O
renal	O	O
function	O	O
,	O	O
an	O	O
increase	O	O
in	O	O
water	O	O
ingestion	O	O
and	O	O
possibly	O	O
the	O	O
alcalinization	O	O
of	O	O
the	O	O
urine	O	O
.	O	O

We	O	O
communicate	O	O
a	O	O
case	O	O
in	O	O
a	O	O
previously	O	O
healthy	O	O
person	O	O
,	O	O
a	O	O
fact	O	O
not	O	O
found	O	O
in	O	O
the	O	O
recent	O	O
literature	O	O
.	O	O

Probably	O	O
many	O	O
more	O	O
cases	O	O
are	O	O
not	O	O
detected	O	O
.	O	O

We	O	O
think	O	O
that	O	O
a	O	O
prospective	O	O
study	O	O
would	O	O
be	O	O
useful	O	O
.	O	O

Downbeat	B-Disease	D009759
nystagmus	I-Disease	D009759
associated	O	O
with	O	O
intravenous	O	O
patient	O	O
-	O	O
controlled	O	O
administration	O	O
of	O	O
morphine	B-Chemical	D009020
.	O	O

IMPLICATIONS	O	O
:	O	O
This	O	O
case	O	O
documents	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
dizziness	B-Disease	D004244
with	O	O
downbeating	B-Disease	D009759
nystagmus	I-Disease	D009759
while	O	O
receiving	O	O
a	O	O
relatively	O	O
large	O	O
dose	O	O
of	O	O
IV	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
morphine	B-Chemical	D009020
.	O	O

Although	O	O
there	O	O
have	O	O
been	O	O
case	O	O
reports	O	O
of	O	O
epidural	O	O
morphine	B-Chemical	D009020
with	O	O
these	O	O
symptoms	O	O
and	O	O
signs	O	O
,	O	O
this	O	O
has	O	O
not	O	O
been	O	O
previously	O	O
documented	O	O
with	O	O
IV	O	O
or	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
morphine	B-Chemical	D009020
.	O	O

Hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B-Chemical	C118667
and	O	O
amiodarone	B-Chemical	D000638
in	O	O
animals	O	O
with	O	O
a	O	O
healed	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

The	O	O
hemodynamic	O	O
and	O	O
antiadrenergic	O	O
effects	O	O
of	O	O
dronedarone	B-Chemical	C118667
,	O	O
a	O	O
noniodinated	O	O
compound	O	O
structurally	O	O
related	O	O
to	O	O
amiodarone	B-Chemical	D000638
,	O	O
were	O	O
compared	O	O
with	O	O
those	O	O
of	O	O
amiodarone	B-Chemical	D000638
after	O	O
prolonged	O	O
oral	O	O
administration	O	O
,	O	O
both	O	O
at	O	O
rest	O	O
and	O	O
during	O	O
sympathetic	O	O
stimulation	O	O
in	O	O
conscious	O	O
dogs	O	O
with	O	O
a	O	O
healed	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

All	O	O
dogs	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
randomly	O	O
received	O	O
orally	O	O
dronedarone	B-Chemical	C118667
(	O	O
10	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
amiodarone	B-Chemical	D000638
(	O	O
10	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
and	O	O
placebo	O	O
twice	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
,	O	O
with	O	O
a	O	O
3	O	O
-	O	O
week	O	O
washout	O	O
between	O	O
consecutive	O	O
treatments	O	O
.	O	O

Heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
,	O	O
mean	O	O
arterial	O	O
pressure	O	O
(	O	O
MBP	O	O
)	O	O
,	O	O
positive	O	O
rate	O	O
of	O	O
increase	O	O
of	O	O
left	O	O
ventricular	O	O
pressure	O	O
(	O	O
+LVdP	O	O
/	O	O
dt	O	O
)	O	O
,	O	O
echocardiographically	O	O
assessed	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
(	O	O
LVEF	O	O
)	O	O
,	O	O
and	O	O
fractional	O	O
shortening	O	O
(	O	O
FS	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
chronotropic	O	O
response	O	O
to	O	O
isoproterenol	B-Chemical	D007545
and	O	O
exercise	O	O
-	O	O
induced	O	O
sympathetic	O	O
stimulation	O	O
were	O	O
evaluated	O	O
under	O	O
baseline	O	O
and	O	O
posttreatment	O	O
conditions	O	O
.	O	O

Resting	O	O
values	O	O
of	O	O
LVEF	O	O
,	O	O
FS	O	O
,	O	O
+LVdP	O	O
/	O	O
dt	O	O
,	O	O
and	O	O
MBP	O	O
remained	O	O
unchanged	O	O
whatever	O	O
the	O	O
drug	O	O
and	O	O
the	O	O
dosing	O	O
regimen	O	O
,	O	O
whereas	O	O
resting	O	O
HR	O	O
was	O	O
significantly	O	O
and	O	O
dose	O	O
-	O	O
dependently	O	O
lowered	O	O
after	O	O
dronedarone	B-Chemical	C118667
and	O	O
to	O	O
a	O	O
lesser	O	O
extent	O	O
after	O	O
amiodarone	B-Chemical	D000638
.	O	O

Both	O	O
dronedarone	B-Chemical	C118667
and	O	O
amiodarone	B-Chemical	D000638
significantly	O	O
reduced	O	O
the	O	O
exercise	O	O
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
and	O	O
,	O	O
at	O	O
the	O	O
highest	O	O
dose	O	O
,	O	O
decreased	O	O
the	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
tachycardia	B-Disease	D013610
.	O	O

Thus	O	O
,	O	O
dronedarone	B-Chemical	C118667
and	O	O
amiodarone	B-Chemical	D000638
displayed	O	O
a	O	O
similar	O	O
level	O	O
of	O	O
antiadrenergic	O	O
effect	O	O
and	O	O
did	O	O
not	O	O
impair	O	O
the	O	O
resting	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

Consequently	O	O
,	O	O
dronedarone	B-Chemical	C118667
might	O	O
be	O	O
particularly	O	O
suitable	O	O
for	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
various	O	O
clinical	O	O
arrhythmias	B-Disease	D001145
,	O	O
without	O	O
compromising	O	O
the	O	O
left	O	O
ventricular	O	O
function	O	O
.	O	O

Phase	O	O
2	O	O
trial	O	O
of	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
(	O	O
40	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
in	O	O
platinum	B-Chemical	D010984
/	O	O
paclitaxel	B-Chemical	D017239
-	O	O
refractory	O	O
ovarian	O	O
and	O	O
fallopian	O	O
tube	O	O
cancers	O	O
and	O	O
primary	O	O
carcinoma	B-Disease	D010534
of	I-Disease	D010534
the	I-Disease	D010534
peritoneum	I-Disease	D010534
.	O	O

BACKGROUND	O	O
:	O	O
Several	O	O
studies	O	O
have	O	O
demonstrated	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
(	O	O
Doxil	B-Chemical	D004317
)	O	O
to	O	O
be	O	O
an	O	O
active	O	O
antineoplastic	O	O
agent	O	O
in	O	O
platinum	B-Chemical	D010984
-	O	O
resistant	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
with	O	O
dose	O	O
limiting	O	O
toxicity	B-Disease	D064420
of	O	O
the	O	O
standard	O	O
dosing	O	O
regimen	O	O
(	O	O
50	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
q	O	O
4	O	O
weeks	O	O
)	O	O
being	O	O
severe	O	O
erythrodysesthesia	B-Disease	D060831
(	O	O
"hand	O	O
-	O	O
foot	O	O
syndrome"	O	O
)	O	O
and	O	O
stomatitis	B-Disease	D013280
.	O	O

We	O	O
wished	O	O
to	O	O
develop	O	O
a	O	O
more	O	O
tolerable	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
treatment	O	O
regimen	O	O
and	O	O
document	O	O
its	O	O
level	O	O
of	O	O
activity	O	O
in	O	O
a	O	O
well	O	O
-	O	O
defined	O	O
patient	O	O
population	O	O
with	O	O
platinum	B-Chemical	D010984
/	O	O
paclitaxel	B-Chemical	D017239
-	O	O
refractory	O	O
disease	O	O
.	O	O

METHODS	O	O
AND	O	O
MATERIALS	O	O
:	O	O
Patients	O	O
with	O	O
ovarian	O	O
or	O	O
fallopian	O	O
tube	O	O
cancers	O	O
or	O	O
primary	O	O
peritoneal	B-Disease	D010534
carcinoma	I-Disease	D010534
with	O	O
platinum	B-Chemical	D010984
/	O	O
paclitaxel	B-Chemical	D017239
-	O	O
refractory	O	O
disease	O	O
(	O	O
stable	O	O
or	O	O
progressive	O	O
disease	O	O
following	O	O
treatment	O	O
with	O	O
these	O	O
agents	O	O
or	O	O
previous	O	O
objective	O	O
response	O	O
<3	O	O
months	O	O
in	O	O
duration	O	O
)	O	O
were	O	O
treated	O	O
with	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
at	O	O
a	O	O
dose	O	O
of	O	O
40	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
q	O	O
4	O	O
weeks	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
49	O	O
patients	O	O
(	O	O
median	O	O
age	O	O
:	O	O
60	O	O
;	O	O
range	O	O
41	O	O
-	O	O
81	O	O
)	O	O
entered	O	O
this	O	O
phase	O	O
2	O	O
trial	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
prior	O	O
regimens	O	O
was	O	O
2	O	O
(	O	O
range	O	O
:	O	O
1	O	O
-	O	O
6	O	O
)	O	O
.	O	O

Six	O	O
(	O	O
12%	O	O
)	O	O
and	O	O
4	O	O
(	O	O
8%	O	O
)	O	O
patients	O	O
experienced	O	O
grade	O	O
2	O	O
hand	B-Disease	D060831
-	I-Disease	D060831
foot	I-Disease	D060831
syndrome	I-Disease	D060831
and	O	O
stomatitis	B-Disease	D013280
,	O	O
respectively	O	O
(	O	O
no	O	O
episodes	O	O
of	O	O
grade	O	O
3	O	O
)	O	O
.	O	O

One	O	O
patient	O	O
developed	O	O
grade	O	O
3	O	O
diarrhea	B-Disease	D003967
requiring	O	O
hospitalization	O	O
for	O	O
hydration	O	O
.	O	O

Six	O	O
(	O	O
12%	O	O
)	O	O
individuals	O	O
required	O	O
dose	O	O
reductions	O	O
.	O	O

The	O	O
median	O	O
number	O	O
of	O	O
courses	O	O
of	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
administered	O	O
on	O	O
this	O	O
protocol	O	O
was	O	O
2	O	O
(	O	O
range	O	O
:	O	O
1	O	O
-	O	O
12	O	O
)	O	O
.	O	O

Four	O	O
of	O	O
44	O	O
patients	O	O
(	O	O
9%	O	O
)	O	O
evaluable	O	O
for	O	O
response	O	O
exhibited	O	O
objective	O	O
and	O	O
subjective	O	O
evidence	O	O
of	O	O
an	O	O
antineoplastic	O	O
effect	O	O
of	O	O
therapy	O	O
.	O	O

CONCLUSION	O	O
:	O	O
This	O	O
modified	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
regimen	O	O
results	O	O
in	O	O
less	O	O
toxicity	B-Disease	D064420
(	O	O
stomatitis	B-Disease	D013280
,	O	O
hand	B-Disease	D060831
-	I-Disease	D060831
foot	I-Disease	D060831
syndrome	I-Disease	D060831
)	O	O
than	O	O
the	O	O
standard	O	O
FDA	O	O
-	O	O
approved	O	O
dose	O	O
schedule	O	O
.	O	O

Definite	O	O
,	O	O
although	O	O
limited	O	O
,	O	O
antineoplastic	O	O
activity	O	O
is	O	O
observed	O	O
in	O	O
patients	O	O
with	O	O
well	O	O
-	O	O
defined	O	O
platinum	B-Chemical	D010984
-	O	O
and	O	O
paclitaxel	B-Chemical	D017239
-	O	O
refractory	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
.	O	O

Efficacy	O	O
of	O	O
olanzapine	B-Chemical	C076029
in	O	O
acute	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
:	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
.	O	O

The	O	O
Olanzipine	B-Chemical	C076029
HGGW	O	O
Study	O	O
Group	O	O
.	O	O

BACKGROUND	O	O
:	O	O
We	O	O
compared	O	O
the	O	O
efficacy	O	O
and	O	O
safety	O	O
of	O	O
olanzapine	B-Chemical	C076029
vs	O	O
placebo	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
.	O	O

METHODS	O	O
:	O	O
Four	O	O
-	O	O
week	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
parallel	O	O
study	O	O
.	O	O

A	O	O
total	O	O
of	O	O
115	O	O
patients	O	O
with	O	O
a	O	O
DSM	O	O
-	O	O
IV	O	O
diagnosis	O	O
of	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
,	O	O
manic	B-Disease	D001714
or	O	O
mixed	O	O
,	O	O
were	O	O
randomized	O	O
to	O	O
olanzapine	B-Chemical	C076029
,	O	O
5	O	O
to	O	O
20	O	O
mg	O	O
/	O	O
d	O	O
(	O	O
n	O	O
=	O	O
55	O	O
)	O	O
,	O	O
or	O	O
placebo	O	O
(	O	O
n	O	O
=	O	O
60	O	O
)	O	O
.	O	O

The	O	O
primary	O	O
efficacy	O	O
measure	O	O
was	O	O
the	O	O
Young	O	O
-	O	O
Mania	B-Disease	D001714
Rating	O	O
Scale	O	O
(	O	O
Y	O	O
-	O	O
MRS	O	O
)	O	O
total	O	O
score	O	O
.	O	O

Response	O	O
and	O	O
euthymia	O	O
were	O	O
defined	O	O
,	O	O
a	O	O
priori	O	O
,	O	O
as	O	O
at	O	O
least	O	O
a	O	O
50%	O	O
improvement	O	O
from	O	O
baseline	O	O
to	O	O
end	O	O
point	O	O
and	O	O
as	O	O
a	O	O
score	O	O
of	O	O
no	O	O
less	O	O
than	O	O
12	O	O
at	O	O
end	O	O
point	O	O
in	O	O
the	O	O
Y	O	O
-	O	O
MRS	O	O
total	O	O
score	O	O
,	O	O
respectively	O	O
.	O	O

Safety	O	O
was	O	O
assessed	O	O
using	O	O
adverse	O	O
events	O	O
,	O	O
Extrapyramidal	B-Disease	D001480
Symptom	I-Disease	D001480
(	O	O
EPS	B-Disease	D001480
)	O	O
rating	O	O
scales	O	O
,	O	O
laboratory	O	O
values	O	O
,	O	O
electrocardiograms	O	O
,	O	O
vital	O	O
signs	O	O
,	O	O
and	O	O
weight	O	O
change	O	O
.	O	O

RESULTS	O	O
:	O	O
Olanzapine	B-Chemical	C076029
-	O	O
treated	O	O
patients	O	O
demonstrated	O	O
a	O	O
statistically	O	O
significant	O	O
greater	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
improvement	O	O
in	O	O
Y	O	O
-	O	O
MRS	O	O
total	O	O
score	O	O
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
(	O	O
-	O	O
14	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
12	O	O
.	O	O

5	O	O
and	O	O
-	O	O
8	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
12	O	O
.	O	O

7	O	O
,	O	O
respectively	O	O
;	O	O
P<	O	O
.	O	O

001	O	O
)	O	O
,	O	O
which	O	O
was	O	O
evident	O	O
at	O	O
the	O	O
first	O	O
postbaseline	O	O
observation	O	O
1	O	O
week	O	O
after	O	O
randomization	O	O
and	O	O
was	O	O
maintained	O	O
throughout	O	O
the	O	O
study	O	O
(	O	O
last	O	O
observation	O	O
carried	O	O
forward	O	O
)	O	O
.	O	O

Olanzapine	B-Chemical	C076029
-	O	O
treated	O	O
patients	O	O
demonstrated	O	O
a	O	O
higher	O	O
rate	O	O
of	O	O
response	O	O
(	O	O
65%	O	O
vs	O	O
43%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
=	O	O
.	O	O

02	O	O
)	O	O
and	O	O
euthymia	O	O
(	O	O
61%	O	O
vs	O	O
36%	O	O
,	O	O
respectively	O	O
;	O	O
P	O	O
=	O	O
.	O	O

01	O	O
)	O	O
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
.	O	O

There	O	O
were	O	O
no	O	O
statistically	O	O
significant	O	O
differences	O	O
in	O	O
EPSs	B-Disease	D001480
between	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
olanzapine	B-Chemical	C076029
-	O	O
treated	O	O
patients	O	O
had	O	O
a	O	O
statistically	O	O
significant	O	O
greater	O	O
mean	O	O
(	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
than	O	O
placebo	O	O
-	O	O
treated	O	O
patients	O	O
(	O	O
2	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

8	O	O
vs	O	O
0	O	O
.	O	O

45	O	O
+	O	O
/	O	O
-	O	O
2	O	O
.	O	O

3	O	O
kg	O	O
,	O	O
respectively	O	O
)	O	O
and	O	O
also	O	O
experienced	O	O
more	O	O
treatment	O	O
-	O	O
emergent	O	O
somnolence	B-Disease	D006970
(	O	O
21	O	O
patients	O	O
[	O	O
38	O	O
.	O	O

2%	O	O
]	O	O
vs	O	O
5	O	O
[	O	O
8	O	O
.	O	O

3%	O	O
]	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Olanzapine	B-Chemical	C076029
demonstrated	O	O
greater	O	O
efficacy	O	O
than	O	O
placebo	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
acute	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
and	O	O
was	O	O
generally	O	O
well	O	O
tolerated	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
pupil	B-Disease	D015878
dilation	I-Disease	D015878
with	O	O
tropicamide	B-Chemical	D014331
on	O	O
vision	O	O
and	O	O
driving	O	O
simulator	O	O
performance	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
pupil	B-Disease	D015878
dilation	I-Disease	D015878
on	O	O
vision	O	O
and	O	O
driving	O	O
ability	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
series	O	O
of	O	O
tests	O	O
on	O	O
various	O	O
parameters	O	O
of	O	O
visual	O	O
function	O	O
and	O	O
driving	O	O
simulator	O	O
performance	O	O
were	O	O
performed	O	O
on	O	O
12	O	O
healthy	O	O
drivers	O	O
,	O	O
before	O	O
and	O	O
after	O	O
pupil	B-Disease	D015878
dilation	I-Disease	D015878
using	O	O
guttae	O	O
tropicamide	B-Chemical	D014331
1%	O	O
.	O	O

A	O	O
driving	O	O
simulator	O	O
(	O	O
Transport	O	O
Research	O	O
Laboratory	O	O
)	O	O
was	O	O
used	O	O
to	O	O
measure	O	O
reaction	O	O
time	O	O
(	O	O
RT	O	O
)	O	O
,	O	O
speed	O	O
maintenance	O	O
and	O	O
steering	O	O
accuracy	O	O
.	O	O

Tests	O	O
of	O	O
basic	O	O
visual	O	O
function	O	O
included	O	O
high	O	O
-	O	O
and	O	O
low	O	O
-	O	O
contrast	O	O
visual	O	O
acuity	O	O
(	O	O
HCVA	O	O
and	O	O
LCVA	O	O
)	O	O
,	O	O
Pelli	O	O
-	O	O
Robson	O	O
contrast	O	O
threshold	O	O
(	O	O
CT	O	O
)	O	O
and	O	O
Goldmann	O	O
perimetry	O	O
(	O	O
FIELDS	O	O
)	O	O
.	O	O

Useful	O	O
Field	O	O
of	O	O
View	O	O
(	O	O
UFOV	O	O
-	O	O
-	O	O
a	O	O
test	O	O
of	O	O
visual	O	O
attention	O	O
)	O	O
was	O	O
also	O	O
undertaken	O	O
.	O	O

The	O	O
mean	O	O
differences	O	O
in	O	O
the	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
dilatation	O	O
measurements	O	O
were	O	O
tested	O	O
for	O	O
statistical	O	O
significance	O	O
at	O	O
the	O	O
95%	O	O
level	O	O
using	O	O
one	O	O
-	O	O
tail	O	O
paired	O	O
t	O	O
-	O	O
tests	O	O
.	O	O

RESULTS	O	O
:	O	O
Pupillary	B-Disease	D015878
dilation	I-Disease	D015878
resulted	O	O
in	O	O
a	O	O
statistically	O	O
significant	O	O
deterioration	O	O
in	O	O
CT	O	O
and	O	O
HCVA	O	O
only	O	O
.	O	O

Five	O	O
of	O	O
12	O	O
drivers	O	O
also	O	O
exhibited	O	O
deterioration	O	O
in	O	O
LCVA	O	O
,	O	O
CT	O	O
and	O	O
RT	O	O
.	O	O

Little	O	O
evidence	O	O
emerged	O	O
for	O	O
deterioration	O	O
in	O	O
FIELDS	O	O
and	O	O
UFOV	O	O
.	O	O

Also	O	O
,	O	O
7	O	O
of	O	O
12	O	O
drivers	O	O
appeared	O	O
to	O	O
adjust	O	O
their	O	O
driving	O	O
behaviour	O	O
by	O	O
reducing	O	O
their	O	O
speed	O	O
on	O	O
the	O	O
driving	O	O
simulator	O	O
,	O	O
leading	O	O
to	O	O
improved	O	O
steering	O	O
accuracy	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Pupillary	B-Disease	D015878
dilation	I-Disease	D015878
may	O	O
lead	O	O
to	O	O
a	O	O
decrease	O	O
in	O	O
vision	O	O
and	O	O
daylight	O	O
driving	O	O
performance	O	O
in	O	O
young	O	O
people	O	O
.	O	O

A	O	O
larger	O	O
study	O	O
,	O	O
including	O	O
a	O	O
broader	O	O
spectrum	O	O
of	O	O
subjects	O	O
,	O	O
is	O	O
warranted	O	O
before	O	O
guidelines	O	O
can	O	O
be	O	O
recommended	O	O
.	O	O

A	O	O
case	O	O
of	O	O
isotretinoin	B-Disease	C535670
embryopathy	I-Disease	C535670
with	O	O
bilateral	O	O
anotia	B-Disease	D065817
and	O	O
Taussig	B-Disease	D004310
-	I-Disease	D004310
Bing	I-Disease	D004310
malformation	I-Disease	D004310
.	O	O

We	O	O
report	O	O
a	O	O
newborn	O	O
infant	O	O
with	O	O
multiple	O	O
congenital	O	O
anomalies	O	O
(	O	O
anotia	B-Disease	D065817
and	O	O
Taussig	B-Disease	D004310
-	I-Disease	D004310
Bing	I-Disease	D004310
malformation	I-Disease	D004310
)	O	O
due	O	O
to	O	O
exposure	O	O
to	O	O
isotretinoin	B-Chemical	D015474
within	O	O
the	O	O
first	O	O
trimester	O	O
.	O	O

In	O	O
this	O	O
paper	O	O
we	O	O
aim	O	O
to	O	O
draw	O	O
to	O	O
the	O	O
fact	O	O
that	O	O
caution	O	O
is	O	O
needed	O	O
when	O	O
prescribing	O	O
vitamin	B-Chemical	D014801
A	I-Chemical	D014801
-	O	O
containing	O	O
drugs	O	O
to	O	O
women	O	O
of	O	O
childbearing	O	O
years	O	O
.	O	O

Effect	O	O
of	O	O
methoxamine	B-Chemical	D008729
on	O	O
maximum	O	O
urethral	O	O
pressure	O	O
in	O	O
women	O	O
with	O	O
genuine	O	O
stress	B-Disease	D014550
incontinence	I-Disease	D014550
:	O	O
a	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
crossover	O	O
study	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
evaluate	O	O
the	O	O
potential	O	O
role	O	O
for	O	O
a	O	O
selective	O	O
alpha1	O	O
-	O	O
adrenoceptor	O	O
agonist	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
urinary	B-Disease	D014550
stress	I-Disease	D014550
incontinence	I-Disease	D014550
.	O	O

A	O	O
randomised	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
,	O	O
crossover	O	O
study	O	O
design	O	O
was	O	O
employed	O	O
.	O	O

Half	O	O
log	O	O
incremental	O	O
doses	O	O
of	O	O
intravenous	O	O
methoxamine	B-Chemical	D008729
or	O	O
placebo	O	O
(	O	O
saline	O	O
)	O	O
were	O	O
administered	O	O
to	O	O
a	O	O
group	O	O
of	O	O
women	O	O
with	O	O
genuine	O	O
stress	B-Disease	D014550
incontinence	I-Disease	D014550
while	O	O
measuring	O	O
maximum	O	O
urethral	O	O
pressure	O	O
(	O	O
MUP	O	O
)	O	O
,	O	O
blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
and	O	O
symptomatic	O	O
side	O	O
effects	O	O
.	O	O

Methoxamine	B-Chemical	D008729
evoked	O	O
non	O	O
-	O	O
significant	O	O
increases	O	O
in	O	O
MUP	O	O
and	O	O
diastolic	O	O
blood	O	O
pressure	O	O
but	O	O
caused	O	O
a	B-Disease	D006973
significant	I-Disease	D006973
rise	I-Disease	D006973
in	I-Disease	D006973
systolic	I-Disease	D006973
blood	I-Disease	D006973
pressure	I-Disease	D006973
and	O	O
significant	O	O
fall	O	O
in	O	O
heart	O	O
rate	O	O
at	O	O
maximum	O	O
dosage	O	O
.	O	O

Systemic	O	O
side	O	O
effects	O	O
including	O	O
piloerection	O	O
,	O	O
headache	B-Disease	D006261
,	O	O
and	O	O
cold	O	O
extremities	O	O
were	O	O
experienced	O	O
in	O	O
all	O	O
subjects	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
clinical	O	O
usefulness	O	O
of	O	O
direct	O	O
,	O	O
peripherally	O	O
acting	O	O
sub	O	O
-	O	O
type	O	O
-	O	O
selective	O	O
alpha1	O	O
-	O	O
adrenoceptor	O	O
agonists	O	O
in	O	O
the	O	O
medical	O	O
treatment	O	O
of	O	O
stress	B-Disease	D014550
incontinence	I-Disease	D014550
may	O	O
be	O	O
limited	O	O
by	O	O
associated	O	O
piloerection	O	O
and	O	O
cardiovascular	O	O
side	O	O
effects	O	O
.	O	O

Toleration	O	O
of	O	O
high	O	O
doses	O	O
of	O	O
angiotensin	B-Chemical	D000806
-	I-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
inhibitors	I-Chemical	D000806
in	O	O
patients	O	O
with	O	O
chronic	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
:	O	O
results	O	O
from	O	O
the	O	O
ATLAS	O	O
trial	O	O
.	O	O

The	O	O
Assessment	O	O
of	O	O
Treatment	O	O
with	O	O
Lisinopril	B-Chemical	D017706
and	O	O
Survival	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Treatment	O	O
with	O	O
angiotensin	B-Chemical	D000806
-	I-Chemical	D000806
converting	I-Chemical	D000806
enzyme	I-Chemical	D000806
(	I-Chemical	D000806
ACE	I-Chemical	D000806
)	I-Chemical	D000806
inhibitors	I-Chemical	D000806
reduces	O	O
mortality	O	O
and	O	O
morbidity	O	O
in	O	O
patients	O	O
with	O	O
chronic	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
(	O	O
CHF	B-Disease	D006333
)	O	O
,	O	O
but	O	O
most	O	O
affected	O	O
patients	O	O
are	O	O
not	O	O
receiving	O	O
these	O	O
agents	O	O
or	O	O
are	O	O
being	O	O
treated	O	O
with	O	O
doses	O	O
lower	O	O
than	O	O
those	O	O
found	O	O
to	O	O
be	O	O
efficacious	O	O
in	O	O
trials	O	O
,	O	O
primarily	O	O
because	O	O
of	O	O
concerns	O	O
about	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
these	O	O
agents	O	O
,	O	O
especially	O	O
at	O	O
the	O	O
recommended	O	O
doses	O	O
.	O	O

The	O	O
present	O	O
study	O	O
examines	O	O
the	O	O
safety	O	O
and	O	O
tolerability	O	O
of	O	O
high	O	O
-	O	O
compared	O	O
with	O	O
low	O	O
-	O	O
dose	O	O
lisinopril	B-Chemical	D017706
in	O	O
CHF	B-Disease	D006333
.	O	O

METHODS	O	O
:	O	O
The	O	O
Assessment	O	O
of	O	O
Lisinopril	B-Chemical	D017706
and	O	O
Survival	O	O
study	O	O
was	O	O
a	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
trial	O	O
in	O	O
which	O	O
patients	O	O
with	O	O
or	O	O
without	O	O
previous	O	O
ACE	B-Chemical	D000806
inhibitor	I-Chemical	D000806
treatment	O	O
were	O	O
stabilized	O	O
receiving	O	O
medium	O	O
-	O	O
dose	O	O
lisinopril	B-Chemical	D017706
(	O	O
12	O	O
.	O	O

5	O	O
or	O	O
15	O	O
.	O	O

0	O	O
mg	O	O
once	O	O
daily	O	O
[	O	O
OD	O	O
]	O	O
)	O	O
for	O	O
2	O	O
to	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
randomized	O	O
to	O	O
high	O	O
-	O	O
(	O	O
35	O	O
.	O	O

0	O	O
or	O	O
32	O	O
.	O	O

5	O	O
mg	O	O
OD	O	O
)	O	O
or	O	O
low	O	O
-	O	O
dose	O	O
(	O	O
5	O	O
.	O	O

0	O	O
or	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
OD	O	O
)	O	O
groups	O	O
.	O	O

Patients	O	O
with	O	O
New	O	O
York	O	O
Heart	O	O
Association	O	O
classes	O	O
II	O	O
to	O	O
IV	O	O
CHF	B-Disease	D006333
and	O	O
left	O	O
ventricular	O	O
ejection	O	O
fractions	O	O
of	O	O
no	O	O
greater	O	O
than	O	O
0	O	O
.	O	O

30	O	O
(	O	O
n	O	O
=	O	O
3164	O	O
)	O	O
were	O	O
randomized	O	O
and	O	O
followed	O	O
up	O	O
for	O	O
a	O	O
median	O	O
of	O	O
46	O	O
months	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
occurrence	O	O
of	O	O
adverse	O	O
events	O	O
and	O	O
the	O	O
need	O	O
for	O	O
discontinuation	O	O
and	O	O
dose	O	O
reduction	O	O
during	O	O
treatment	O	O
,	O	O
with	O	O
a	O	O
focus	O	O
on	O	O
hypotension	B-Disease	D007022
and	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
405	O	O
patients	O	O
not	O	O
previously	O	O
receiving	O	O
an	O	O
ACE	B-Chemical	D000806
inhibitor	I-Chemical	D000806
,	O	O
doses	O	O
in	O	O
only	O	O
4	O	O
.	O	O

2%	O	O
could	O	O
not	O	O
be	O	O
titrated	O	O
to	O	O
the	O	O
medium	O	O
doses	O	O
required	O	O
for	O	O
randomization	O	O
because	O	O
of	O	O
symptoms	O	O
possibly	O	O
related	O	O
to	O	O
hypotension	B-Disease	D007022
(	O	O
2	O	O
.	O	O

0%	O	O
)	O	O
or	O	O
because	O	O
of	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
or	O	O
hyperkalemia	B-Disease	D006947
(	O	O
2	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

Doses	O	O
in	O	O
more	O	O
than	O	O
90%	O	O
of	O	O
randomized	O	O
patients	O	O
in	O	O
the	O	O
high	O	O
-	O	O
and	O	O
low	O	O
-	O	O
dose	O	O
groups	O	O
were	O	O
titrated	O	O
to	O	O
their	O	O
assigned	O	O
target	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
doses	O	O
of	O	O
blinded	O	O
medication	O	O
in	O	O
both	O	O
groups	O	O
remained	O	O
similar	O	O
throughout	O	O
the	O	O
study	O	O
.	O	O

Withdrawals	O	O
occurred	O	O
in	O	O
27	O	O
.	O	O

1%	O	O
of	O	O
the	O	O
high	O	O
-	O	O
and	O	O
30	O	O
.	O	O

7%	O	O
of	O	O
the	O	O
low	O	O
-	O	O
dose	O	O
groups	O	O
.	O	O

Subgroups	O	O
presumed	O	O
to	O	O
be	O	O
at	O	O
higher	O	O
risk	O	O
for	O	O
ACE	B-Chemical	D000806
inhibitor	I-Chemical	D000806
intolerance	O	O
(	O	O
blood	O	O
pressure	O	O
,	O	O
<120	O	O
mm	O	O
Hg	O	O
;	O	O
creatinine	B-Chemical	D003404
,	O	O
>	O	O
or	O	O
=132	O	O
.	O	O

6	O	O
micromol	O	O
/	O	O
L	O	O
[	O	O
>	O	O
or	O	O
=1	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dL	O	O
]	O	O
;	O	O
age	O	O
,	O	O
>	O	O
or	O	O
=70	O	O
years	O	O
;	O	O
and	O	O
patients	O	O
with	O	O
diabetes	B-Disease	D003920
)	O	O
generally	O	O
tolerated	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
strategy	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
findings	O	O
demonstrate	O	O
that	O	O
ACE	B-Chemical	D000806
inhibitor	I-Chemical	D000806
therapy	O	O
in	O	O
most	O	O
patients	O	O
with	O	O
CHF	B-Disease	D006333
can	O	O
be	O	O
successfully	O	O
titrated	O	O
to	O	O
and	O	O
maintained	O	O
at	O	O
high	O	O
doses	O	O
,	O	O
and	O	O
that	O	O
more	O	O
aggressive	O	O
use	O	O
of	O	O
these	O	O
agents	O	O
is	O	O
warranted	O	O
.	O	O

Cocaine	B-Chemical	D003042
,	O	O
ethanol	B-Chemical	D000431
,	O	O
and	O	O
cocaethylene	B-Chemical	C066444
cardiotoxity	B-Disease	D066126
in	O	O
an	O	O
animal	O	O
model	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
ethanol	B-Chemical	D000431
abuse	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
Simultaneous	O	O
abuse	O	O
of	O	O
cocaine	B-Chemical	D003042
and	O	O
ethanol	B-Chemical	D000431
affects	O	O
12	O	O
million	O	O
Americans	O	O
annually	O	O
.	O	O

In	O	O
combination	O	O
,	O	O
these	O	O
substances	O	O
are	O	O
substantially	O	O
more	O	O
toxic	O	O
than	O	O
either	O	O
drug	O	O
alone	O	O
.	O	O

Their	O	O
combined	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
may	O	O
be	O	O
due	O	O
to	O	O
independent	O	O
effects	O	O
of	O	O
each	O	O
drug	O	O
;	O	O
however	O	O
,	O	O
they	O	O
may	O	O
also	O	O
be	O	O
due	O	O
to	O	O
cocaethylene	B-Chemical	C066444
(	O	O
CE	B-Chemical	C066444
)	O	O
,	O	O
a	O	O
cocaine	B-Chemical	D003042
metabolite	O	O
formed	O	O
only	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
ethanol	B-Chemical	D000431
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
delineate	O	O
the	O	O
role	O	O
of	O	O
CE	B-Chemical	C066444
in	O	O
the	O	O
combined	O	O
cardiotoxicity	B-Disease	D066126
of	O	O
cocaine	B-Chemical	D003042
and	O	O
ethanol	B-Chemical	D000431
in	O	O
a	O	O
model	O	O
simulating	O	O
their	O	O
abuse	O	O
.	O	O

METHODS	O	O
:	O	O
Twenty	O	O
-	O	O
three	O	O
dogs	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
1	O	O
)	O	O
three	O	O
intravenous	O	O
(	O	O
IV	O	O
)	O	O
boluses	O	O
of	O	O
cocaine	B-Chemical	D003042
7	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
with	O	O
ethanol	B-Chemical	D000431
(	O	O
1	O	O
g	O	O
/	O	O
kg	O	O
)	O	O
as	O	O
an	O	O
IV	O	O
infusion	O	O
(	O	O
C+E	O	O
,	O	O
n	O	O
=	O	O
8	O	O
)	O	O
,	O	O
2	O	O
)	O	O
three	O	O
cocaine	B-Chemical	D003042
boluses	O	O
only	O	O
(	O	O
C	O	O
,	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
3	O	O
)	O	O
ethanol	B-Chemical	D000431
infusion	O	O
only	O	O
(	O	O
E	O	O
,	O	O
n	O	O
=	O	O
5	O	O
)	O	O
,	O	O
or	O	O
4	O	O
)	O	O
placebo	O	O
boluses	O	O
and	O	O
infusion	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
.	O	O

Hemodynamic	O	O
measurements	O	O
,	O	O
electrocardiograms	O	O
,	O	O
and	O	O
serum	O	O
drug	O	O
concentrations	O	O
were	O	O
obtained	O	O
at	O	O
baseline	O	O
,	O	O
and	O	O
then	O	O
at	O	O
fixed	O	O
time	O	O
intervals	O	O
after	O	O
each	O	O
drug	O	O
was	O	O
administered	O	O
.	O	O

RESULTS	O	O
:	O	O
Two	O	O
of	O	O
eight	O	O
dogs	O	O
in	O	O
the	O	O
C+E	O	O
group	O	O
experienced	O	O
cardiovascular	B-Disease	-1
collapse	I-Disease	-1
.	O	O

The	O	O
most	O	O
dramatic	O	O
hemodynamic	O	O
changes	O	O
occurred	O	O
after	O	O
each	O	O
cocaine	B-Chemical	D003042
bolus	O	O
in	O	O
the	O	O
C+E	O	O
and	O	O
C	O	O
only	O	O
groups	O	O
;	O	O
however	O	O
,	O	O
persistent	O	O
hemodynamic	O	O
changes	O	O
occurred	O	O
in	O	O
the	O	O
C+E	O	O
group	O	O
.	O	O

Peak	O	O
CE	B-Chemical	C066444
levels	O	O
were	O	O
associated	O	O
with	O	O
a	O	O
45%	O	O
(	O	O
SD	O	O
+	O	O
/	O	O
-	O	O
22%	O	O
,	O	O
95%	O	O
CI	O	O
=	O	O
22%	O	O
to	O	O
69%	O	O
)	O	O
decrease	B-Disease	D002303
in	I-Disease	D002303
cardiac	I-Disease	D002303
output	I-Disease	D002303
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
,	O	O
a	O	O
56%	O	O
(	O	O
SD	O	O
+	O	O
/	O	O
-	O	O
23%	O	O
,	O	O
95%	O	O
CI	O	O
=	O	O
32%	O	O
to	O	O
80%	O	O
)	O	O
decrease	O	O
in	O	O
dP	O	O
/	O	O
dt	O	O
(	O	O
max	O	O
)	O	O
(	O	O
p	O	O
<	O	O
.	O	O

006	O	O
)	O	O
,	O	O
and	O	O
a	O	O
23%	O	O
(	O	O
SD	O	O
+	O	O
/	O	O
-	O	O
15%	O	O
,	O	O
95%	O	O
CI	O	O
=	O	O
7%	O	O
to	O	O
49%	O	O
)	O	O
decrease	O	O
in	O	O
SVO	O	O
(	O	O
2	O	O
)	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

025	O	O
)	O	O
.	O	O

Ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
were	O	O
primarily	O	O
observed	O	O
in	O	O
the	O	O
C+E	O	O
group	O	O
,	O	O
in	O	O
which	O	O
four	O	O
of	O	O
eight	O	O
dogs	O	O
experienced	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

CONCLUSIONS	O	O
:	O	O
Cocaine	B-Chemical	D003042
and	O	O
ethanol	B-Chemical	D000431
in	O	O
combination	O	O
were	O	O
more	O	O
toxic	O	O
than	O	O
either	O	O
substance	O	O
alone	O	O
.	O	O

Co	O	O
-	O	O
administration	O	O
resulted	O	O
in	O	O
prolonged	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
and	O	O
was	O	O
dysrhythmogenic	O	O
.	O	O

Peak	O	O
serum	O	O
cocaethylene	B-Chemical	C066444
concentrations	O	O
were	O	O
associated	O	O
with	O	O
prolonged	O	O
myocardial	B-Disease	D009202
depression	I-Disease	D009202
.	O	O

Worsening	O	O
of	O	O
Parkinsonism	B-Disease	D010302
after	O	O
the	O	O
use	O	O
of	O	O
veralipride	B-Chemical	C027429
for	O	O
treatment	O	O
of	O	O
menopause	O	O
:	O	O
case	O	O
report	O	O
.	O	O

We	O	O
describe	O	O
a	O	O
female	O	O
patient	O	O
with	O	O
stable	O	O
Parkinson's	B-Disease	D010302
disease	I-Disease	D010302
who	O	O
has	O	O
shown	O	O
a	O	O
marked	O	O
worsening	O	O
of	O	O
her	O	O
motor	O	O
functions	O	O
following	O	O
therapy	O	O
of	O	O
menopause	O	O
related	O	O
symptoms	O	O
with	O	O
veralipride	B-Chemical	C027429
,	O	O
as	O	O
well	O	O
as	O	O
the	O	O
improvement	O	O
of	O	O
her	O	O
symptoms	O	O
back	O	O
to	O	O
baseline	O	O
after	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
.	O	O

We	O	O
emphasize	O	O
the	O	O
anti	O	O
-	O	O
dopaminergic	O	O
effect	O	O
of	O	O
veralipride	B-Chemical	C027429
.	O	O

Viracept	B-Chemical	D019888
and	O	O
irregular	B-Disease	D001145
heartbeat	I-Disease	D001145
warning	O	O
.	O	O

A	O	O
group	O	O
of	O	O
doctors	O	O
in	O	O
Boston	O	O
warn	O	O
that	O	O
the	O	O
protease	O	O
inhibitor	O	O
Viracept	B-Chemical	D019888
may	O	O
cause	O	O
an	O	O
irregular	B-Disease	D001145
heart	I-Disease	D001145
beat	I-Disease	D001145
,	O	O
known	O	O
as	O	O
bradycardia	B-Disease	D001919
,	O	O
in	O	O
people	O	O
with	O	O
HIV	O	O
.	O	O

Bradycardia	B-Disease	D001919
occurred	O	O
in	O	O
a	O	O
45	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
patient	O	O
who	O	O
was	O	O
Viracept	B-Chemical	D019888
in	O	O
combination	O	O
with	O	O
other	O	O
anti	O	O
-	O	O
HIV	O	O
drugs	O	O
.	O	O

The	O	O
symptoms	O	O
ceased	O	O
after	O	O
switching	O	O
to	O	O
another	O	O
drug	O	O
combination	O	O
.	O	O

Frequency	O	O
of	O	O
appearance	O	O
of	O	O
myeloperoxidase	O	O
-	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
MPO	O	O
-	O	O
ANCA	O	O
)	O	O
in	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
patients	O	O
treated	O	O
with	O	O
propylthiouracil	B-Chemical	D011441
and	O	O
the	O	O
relationship	O	O
between	O	O
MPO	O	O
-	O	O
ANCA	O	O
and	O	O
clinical	O	O
manifestations	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
Myeloperoxidase	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
(	O	O
MPO	O	O
-	O	O
ANCA	O	O
)	O	O
-	O	O
positive	O	O
vasculitis	B-Disease	D014657
has	O	O
been	O	O
reported	O	O
in	O	O
patients	O	O
with	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
who	O	O
were	O	O
treated	O	O
with	O	O
propylthiouracil	B-Chemical	D011441
(	O	O
PTU	B-Chemical	D011441
)	O	O
.	O	O

The	O	O
appearance	O	O
of	O	O
MPO	O	O
-	O	O
ANCA	O	O
in	O	O
these	O	O
cases	O	O
was	O	O
suspected	O	O
of	O	O
being	O	O
related	O	O
to	O	O
PTU	B-Chemical	D011441
because	O	O
the	O	O
titres	O	O
of	O	O
MPO	O	O
-	O	O
ANCA	O	O
decreased	O	O
when	O	O
PTU	B-Chemical	D011441
was	O	O
stopped	O	O
.	O	O

Nevertheless	O	O
,	O	O
there	O	O
have	O	O
been	O	O
no	O	O
studies	O	O
on	O	O
the	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
appearance	O	O
of	O	O
MPO	O	O
-	O	O
ANCA	O	O
and	O	O
vasculitis	B-Disease	D014657
during	O	O
PTU	B-Chemical	D011441
therapy	O	O
,	O	O
or	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
MPO	O	O
-	O	O
ANCA	O	O
in	O	O
untreated	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
patients	O	O
.	O	O

Therefore	O	O
,	O	O
we	O	O
sought	O	O
to	O	O
address	O	O
these	O	O
parameters	O	O
in	O	O
patients	O	O
with	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
.	O	O

PATIENTS	O	O
:	O	O
We	O	O
investigated	O	O
102	O	O
untreated	O	O
patients	O	O
with	O	O
hyperthyroidism	B-Disease	D006980
due	O	O
to	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
for	O	O
the	O	O
presence	O	O
of	O	O
MPO	O	O
-	O	O
ANCA	O	O
,	O	O
and	O	O
for	O	O
the	O	O
development	O	O
vasculitis	B-Disease	D014657
after	O	O
starting	O	O
PTU	B-Chemical	D011441
therapy	O	O
.	O	O

Twenty	O	O
-	O	O
nine	O	O
of	O	O
them	O	O
were	O	O
later	O	O
excluded	O	O
because	O	O
of	O	O
adverse	O	O
effects	O	O
of	O	O
PTU	B-Chemical	D011441
or	O	O
because	O	O
the	O	O
observation	O	O
period	O	O
was	O	O
less	O	O
than	O	O
3	O	O
months	O	O
.	O	O

The	O	O
remaining	O	O
73	O	O
patients	O	O
(	O	O
55	O	O
women	O	O
and	O	O
18	O	O
men	O	O
)	O	O
,	O	O
all	O	O
of	O	O
whom	O	O
were	O	O
examined	O	O
for	O	O
more	O	O
than	O	O
3	O	O
months	O	O
,	O	O
were	O	O
adopted	O	O
as	O	O
the	O	O
subjects	O	O
of	O	O
the	O	O
investigation	O	O
.	O	O

The	O	O
median	O	O
observation	O	O
period	O	O
was	O	O
23	O	O
.	O	O

6	O	O
months	O	O
(	O	O
range	O	O
:	O	O
3	O	O
-	O	O
37	O	O
months	O	O
)	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
MPO	O	O
-	O	O
ANCA	O	O
was	O	O
measured	O	O
at	O	O
intervals	O	O
of	O	O
2	O	O
-	O	O
6	O	O
months	O	O
.	O	O

RESULTS	O	O
:	O	O
Before	O	O
treatment	O	O
,	O	O
the	O	O
MPO	O	O
-	O	O
ANCA	O	O
titres	O	O
of	O	O
all	O	O
102	O	O
untreated	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
patients	O	O
were	O	O
within	O	O
the	O	O
reference	O	O
range	O	O
(	O	O
below	O	O
10	O	O
U	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

Three	O	O
(	O	O
4	O	O
.	O	O

1%	O	O
)	O	O
of	O	O
the	O	O
73	O	O
patients	O	O
were	O	O
positive	O	O
for	O	O
MPO	O	O
-	O	O
ANCA	O	O
at	O	O
13	O	O
,	O	O
16	O	O
and	O	O
17	O	O
months	O	O
,	O	O
respectively	O	O
,	O	O
after	O	O
the	O	O
start	O	O
of	O	O
PTU	B-Chemical	D011441
therapy	O	O
.	O	O

In	O	O
two	O	O
of	O	O
them	O	O
,	O	O
the	O	O
MPO	O	O
-	O	O
ANCA	O	O
titres	O	O
transiently	O	O
increased	O	O
to	O	O
12	O	O
.	O	O

8	O	O
and	O	O
15	O	O
.	O	O

0	O	O
U	O	O
/	O	O
ml	O	O
,	O	O
respectively	O	O
,	O	O
despite	O	O
continued	O	O
PTU	B-Chemical	D011441
therapy	O	O
,	O	O
but	O	O
no	O	O
vasculitic	B-Disease	D014652
disorders	I-Disease	D014652
developed	O	O
.	O	O

In	O	O
the	O	O
third	O	O
patient	O	O
,	O	O
the	O	O
MPO	O	O
-	O	O
ANCA	O	O
titre	O	O
increased	O	O
to	O	O
204	O	O
U	O	O
/	O	O
ml	O	O
and	O	O
she	O	O
developed	O	O
a	O	O
higher	O	O
fever	B-Disease	D005334
,	O	O
oral	B-Disease	D019226
ulcers	I-Disease	D019226
and	O	O
polyarthralgia	B-Disease	D018771
,	O	O
but	O	O
the	O	O
symptoms	O	O
resolved	O	O
2	O	O
weeks	O	O
after	O	O
stopping	O	O
PTU	B-Chemical	D011441
therapy	O	O
,	O	O
and	O	O
the	O	O
MPO	O	O
-	O	O
ANCA	O	O
titre	O	O
decreased	O	O
to	O	O
20	O	O
.	O	O

7	O	O
U	O	O
/	O	O
ml	O	O
by	O	O
4	O	O
months	O	O
after	O	O
discontinuing	O	O
PTU	B-Chemical	D011441
.	O	O

CONCLUSIONS	O	O
:	O	O
PTU	B-Chemical	D011441
therapy	O	O
may	O	O
be	O	O
related	O	O
to	O	O
the	O	O
appearance	O	O
of	O	O
MPO	O	O
-	O	O
ANCA	O	O
,	O	O
but	O	O
MPO	O	O
-	O	O
ANCA	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
be	O	O
closely	O	O
related	O	O
to	O	O
vasculitis	B-Disease	D014657
.	O	O

Prevalence	O	O
of	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
in	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
prevalence	O	O
of	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
in	O	O
outpatient	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-Chemical	D003042
users	O	O
,	O	O
35	O	O
cocaine	B-Chemical	D003042
users	O	O
and	O	O
32	O	O
age	O	O
-	O	O
matched	O	O
controls	O	O
underwent	O	O
resting	O	O
and	O	O
exercise	O	O
electrocardiography	O	O
(	O	O
ECG	O	O
)	O	O
and	O	O
Doppler	O	O
echocardiography	O	O
.	O	O

Findings	O	O
consistent	O	O
with	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
were	O	O
detected	O	O
in	O	O
12	O	O
(	O	O
34%	O	O
)	O	O
patients	O	O
and	O	O
3	O	O
(	O	O
9%	O	O
)	O	O
controls	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Decreased	O	O
left	O	O
ventricular	O	O
systolic	O	O
function	O	O
was	O	O
demonstrated	O	O
in	O	O
5	O	O
(	O	O
14%	O	O
)	O	O
patients	O	O
,	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
controls	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

055	O	O
)	O	O
.	O	O

Finally	O	O
,	O	O
resting	O	O
and	O	O
peak	O	O
exercise	O	O
abnormal	B-Disease	D018487
left	I-Disease	D018487
ventricular	I-Disease	D018487
filling	I-Disease	D018487
was	O	O
detected	O	O
in	O	O
38	O	O
and	O	O
35%	O	O
of	O	O
patients	O	O
as	O	O
compared	O	O
to	O	O
19	O	O
and	O	O
9%	O	O
of	O	O
controls	O	O
,	O	O
respectively	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

11	O	O
and	O	O
0	O	O
.	O	O

02	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
coronary	O	O
artery	O	O
or	O	O
myocardial	O	O
disease	O	O
is	O	O
common	O	O
(	O	O
38%	O	O
)	O	O
in	O	O
young	O	O
asymptomatic	O	O
chronic	O	O
cocaine	B-Chemical	D003042
users	O	O
.	O	O

Therefore	O	O
,	O	O
screening	O	O
ECG	O	O
and	O	O
echocardiography	O	O
may	O	O
be	O	O
warranted	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

Cardioprotective	O	O
effects	O	O
of	O	O
Picrorrhiza	O	O
kurroa	O	O
against	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	O	O
stress	O	O
in	O	O
rats	O	O
.	O	O

The	O	O
cardioprotective	O	O
effect	O	O
of	O	O
the	O	O
ethanol	B-Chemical	D000431
extract	O	O
of	O	O
Picrorrhiza	O	O
kurroa	O	O
rhizomes	O	O
and	O	O
roots	O	O
(	O	O
PK	O	O
)	O	O
on	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
rats	O	O
with	O	O
respect	O	O
to	O	O
lipid	O	O
metabolism	O	O
in	O	O
serum	O	O
and	O	O
heart	O	O
tissue	O	O
has	O	O
been	O	O
investigated	O	O
.	O	O

Oral	O	O
pre	O	O
-	O	O
treatment	O	O
with	O	O
PK	O	O
(	O	O
80	O	O
mg	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
day	O	O
(	O	O
-	O	O
1	O	O
)	O	O
for	O	O
15	O	O
days	O	O
)	O	O
significantly	O	O
prevented	O	O
the	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
and	O	O
maintained	O	O
the	O	O
rats	O	O
at	O	O
near	O	O
normal	O	O
status	O	O
.	O	O

Phase	O	O
2	O	O
early	O	O
afterdepolarization	O	O
as	O	O
a	O	O
trigger	O	O
of	O	O
polymorphic	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
in	O	O
acquired	O	O
long	B-Disease	D008133
-	I-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
:	O	O
direct	O	O
evidence	O	O
from	O	O
intracellular	O	O
recordings	O	O
in	O	O
the	O	O
intact	O	O
left	O	O
ventricular	O	O
wall	O	O
.	O	O

BACKGROUND	O	O
:	O	O
This	O	O
study	O	O
examined	O	O
the	O	O
role	O	O
of	O	O
phase	O	O
2	O	O
early	O	O
afterdepolarization	O	O
(	O	O
EAD	O	O
)	O	O
in	O	O
producing	O	O
a	O	O
trigger	O	O
to	O	O
initiate	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
TdP	B-Disease	D016171
)	O	O
with	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
induced	O	O
by	O	O
dl	O	O
-	O	O
sotalol	B-Chemical	D013015
and	O	O
azimilide	B-Chemical	C086123
.	O	O

The	O	O
contribution	O	O
of	O	O
transmural	O	O
dispersion	O	O
of	O	O
repolarization	O	O
(	O	O
TDR	O	O
)	O	O
to	O	O
transmural	O	O
propagation	O	O
of	O	O
EAD	O	O
and	O	O
the	O	O
maintenance	O	O
of	O	O
TdP	B-Disease	D016171
was	O	O
also	O	O
evaluated	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Transmembrane	O	O
action	O	O
potentials	O	O
from	O	O
epicardium	O	O
,	O	O
midmyocardium	O	O
,	O	O
and	O	O
endocardium	O	O
were	O	O
recorded	O	O
simultaneously	O	O
,	O	O
together	O	O
with	O	O
a	O	O
transmural	O	O
ECG	O	O
,	O	O
in	O	O
arterially	O	O
perfused	O	O
canine	O	O
and	O	O
rabbit	O	O
left	O	O
ventricular	O	O
preparations	O	O
.	O	O

dl	O	O
-	O	O
Sotalol	B-Chemical	D013015
preferentially	O	O
prolonged	O	O
action	O	O
potential	O	O
duration	O	O
(	O	O
APD	O	O
)	O	O
in	O	O
M	O	O
cells	O	O
dose	O	O
-	O	O
dependently	O	O
(	O	O
1	O	O
to	O	O
100	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
,	O	O
leading	O	O
to	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
and	O	O
an	O	O
increase	O	O
in	O	O
TDR	O	O
.	O	O

Azimilide	B-Chemical	C086123
,	O	O
however	O	O
,	O	O
significantly	O	O
prolonged	O	O
APD	O	O
and	O	O
QT	O	O
interval	O	O
at	O	O
concentrations	O	O
from	O	O
0	O	O
.	O	O

1	O	O
to	O	O
10	O	O
micromol	O	O
/	O	O
L	O	O
but	O	O
shortened	O	O
them	O	O
at	O	O
30	O	O
micromol	O	O
/	O	O
L	O	O
.	O	O

Unlike	O	O
dl	O	O
-	O	O
sotalol	B-Chemical	D013015
,	O	O
azimilide	B-Chemical	C086123
(	O	O
>3	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
increased	O	O
epicardial	O	O
APD	O	O
markedly	O	O
,	O	O
causing	O	O
a	O	O
diminished	O	O
TDR	O	O
.	O	O

Although	O	O
both	O	O
dl	O	O
-	O	O
sotalol	B-Chemical	D013015
and	O	O
azimilide	B-Chemical	C086123
rarely	O	O
induced	O	O
EADs	O	O
in	O	O
canine	O	O
left	O	O
ventricles	O	O
,	O	O
they	O	O
produced	O	O
frequent	O	O
EADs	O	O
in	O	O
rabbits	O	O
,	O	O
in	O	O
which	O	O
more	O	O
pronounced	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
was	O	O
seen	O	O
.	O	O

An	O	O
increase	O	O
in	O	O
TDR	O	O
by	O	O
dl	O	O
-	O	O
sotalol	B-Chemical	D013015
facilitated	O	O
transmural	O	O
propagation	O	O
of	O	O
EADs	O	O
that	O	O
initiated	O	O
multiple	O	O
episodes	O	O
of	O	O
spontaneous	O	O
TdP	B-Disease	D016171
in	O	O
3	O	O
of	O	O
6	O	O
rabbit	O	O
left	O	O
ventricles	O	O
.	O	O

Of	O	O
note	O	O
,	O	O
although	O	O
azimilide	B-Chemical	C086123
(	O	O
3	O	O
to	O	O
10	O	O
micromol	O	O
/	O	O
L	O	O
)	O	O
increased	O	O
APD	O	O
more	O	O
than	O	O
dl	O	O
-	O	O
sotalol	B-Chemical	D013015
,	O	O
its	O	O
EADs	O	O
often	O	O
failed	O	O
to	O	O
propagate	O	O
transmurally	O	O
,	O	O
probably	O	O
because	O	O
of	O	O
a	O	O
diminished	O	O
TDR	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
provides	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
from	O	O
intracellular	O	O
action	O	O
potential	O	O
recordings	O	O
that	O	O
phase	O	O
2	O	O
EAD	O	O
can	O	O
be	O	O
generated	O	O
from	O	O
intact	O	O
ventricular	O	O
wall	O	O
and	O	O
produce	O	O
a	O	O
trigger	O	O
to	O	O
initiate	O	O
the	O	O
onset	O	O
of	O	O
TdP	B-Disease	D016171
under	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
.	O	O

Prenatal	O	O
cocaine	B-Chemical	D003042
exposure	O	O
and	O	O
cranial	O	O
sonographic	O	O
findings	O	O
in	O	O
preterm	B-Disease	D007235
infants	I-Disease	D007235
.	O	O

PURPOSE	O	O
:	O	O
Prenatal	O	O
cocaine	B-Chemical	D003042
exposure	O	O
has	O	O
been	O	O
linked	O	O
with	O	O
subependymal	O	O
hemorrhage	B-Disease	D006470
and	O	O
the	O	O
formation	O	O
of	O	O
cysts	B-Disease	D003560
that	O	O
are	O	O
detectable	O	O
on	O	O
cranial	O	O
sonography	O	O
in	O	O
neonates	O	O
born	O	O
at	O	O
term	O	O
.	O	O

We	O	O
sought	O	O
to	O	O
determine	O	O
if	O	O
prenatal	O	O
cocaine	B-Chemical	D003042
exposure	O	O
increases	O	O
the	O	O
incidence	O	O
of	O	O
subependymal	O	O
cysts	B-Disease	D003560
in	O	O
preterm	B-Disease	D007235
infants	I-Disease	D007235
.	O	O

METHODS	O	O
:	O	O
We	O	O
retrospectively	O	O
reviewed	O	O
the	O	O
medical	O	O
records	O	O
and	O	O
cranial	O	O
sonograms	O	O
obtained	O	O
during	O	O
a	O	O
1	O	O
-	O	O
year	O	O
period	O	O
on	O	O
122	O	O
premature	B-Disease	D007235
(	I-Disease	D007235
<	I-Disease	D007235
36	I-Disease	D007235
weeks	I-Disease	D007235
of	I-Disease	D007235
gestation	I-Disease	D007235
)	I-Disease	D007235
infants	I-Disease	D007235
.	O	O

Infants	O	O
were	O	O
categorized	O	O
into	O	O
1	O	O
of	O	O
2	O	O
groups	O	O
:	O	O
those	O	O
exposed	O	O
to	O	O
cocaine	B-Chemical	D003042
and	O	O
those	O	O
not	O	O
exposed	O	O
to	O	O
cocaine	B-Chemical	D003042
.	O	O

Infants	O	O
were	O	O
assigned	O	O
to	O	O
the	O	O
cocaine	B-Chemical	D003042
-	O	O
exposed	O	O
group	O	O
if	O	O
there	O	O
was	O	O
a	O	O
maternal	O	O
history	O	O
of	O	O
cocaine	B-Chemical	D003042
abuse	O	O
during	O	O
pregnancy	O	O
or	O	O
if	O	O
maternal	O	O
or	O	O
neonatal	O	O
urine	O	O
toxicology	O	O
results	O	O
were	O	O
positive	O	O
at	O	O
the	O	O
time	O	O
of	O	O
delivery	O	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
of	O	O
the	O	O
122	O	O
infants	O	O
were	O	O
excluded	O	O
from	O	O
the	O	O
study	O	O
because	O	O
of	O	O
insufficient	O	O
medical	O	O
and	O	O
drug	O	O
histories	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
subependymal	O	O
cysts	B-Disease	D003560
in	O	O
the	O	O
117	O	O
remaining	O	O
infants	O	O
was	O	O
14%	O	O
(	O	O
16	O	O
of	O	O
117	O	O
)	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
subependymal	O	O
cysts	B-Disease	D003560
in	O	O
infants	O	O
exposed	O	O
to	O	O
cocaine	B-Chemical	D003042
prenatally	O	O
was	O	O
44%	O	O
(	O	O
8	O	O
of	O	O
18	O	O
)	O	O
compared	O	O
with	O	O
8%	O	O
(	O	O
8	O	O
of	O	O
99	O	O
)	O	O
in	O	O
the	O	O
unexposed	O	O
group	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
We	O	O
found	O	O
an	O	O
increased	O	O
incidence	O	O
of	O	O
subependymal	O	O
cyst	O	O
formation	O	O
in	O	O
preterm	B-Disease	D007235
infants	I-Disease	D007235
who	O	O
were	O	O
exposed	O	O
to	O	O
cocaine	B-Chemical	D003042
prenatally	O	O
.	O	O

This	O	O
result	O	O
is	O	O
consistent	O	O
with	O	O
results	O	O
of	O	O
similar	O	O
studies	O	O
in	O	O
term	O	O
infants	O	O
.	O	O

Thalidomide	B-Chemical	D013792
neuropathy	B-Disease	D009422
in	O	O
patients	O	O
treated	O	O
for	O	O
metastatic	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

We	O	O
prospectively	O	O
evaluated	O	O
thalidomide	B-Chemical	D013792
-	O	O
induced	O	O
neuropathy	B-Disease	D009422
using	O	O
electrodiagnostic	O	O
studies	O	O
.	O	O

Sixty	O	O
-	O	O
seven	O	O
men	O	O
with	O	O
metastatic	O	O
androgen	B-Chemical	D000728
-	O	O
independent	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
in	O	O
an	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
of	O	O
oral	O	O
thalidomide	B-Chemical	D013792
underwent	O	O
neurologic	O	O
examinations	O	O
and	O	O
nerve	O	O
conduction	O	O
studies	O	O
(	O	O
NCS	O	O
)	O	O
prior	O	O
to	O	O
and	O	O
at	O	O
3	O	O
-	O	O
month	O	O
intervals	O	O
during	O	O
treatment	O	O
.	O	O

NCS	O	O
included	O	O
recording	O	O
of	O	O
sensory	O	O
nerve	O	O
action	O	O
potentials	O	O
(	O	O
SNAPs	O	O
)	O	O
from	O	O
median	O	O
,	O	O
radial	O	O
,	O	O
ulnar	O	O
,	O	O
and	O	O
sural	O	O
nerves	O	O
.	O	O

SNAP	O	O
amplitudes	O	O
for	O	O
each	O	O
nerve	O	O
were	O	O
expressed	O	O
as	O	O
the	O	O
percentage	O	O
of	O	O
its	O	O
baseline	O	O
,	O	O
and	O	O
the	O	O
mean	O	O
of	O	O
the	O	O
four	O	O
was	O	O
termed	O	O
the	O	O
SNAP	O	O
index	O	O
.	O	O

A	O	O
40%	O	O
decline	O	O
in	O	O
the	O	O
SNAP	O	O
index	O	O
was	O	O
considered	O	O
clinically	O	O
significant	O	O
.	O	O

Thalidomide	B-Chemical	D013792
was	O	O
discontinued	O	O
in	O	O
55	O	O
patients	O	O
for	O	O
lack	O	O
of	O	O
therapeutic	O	O
response	O	O
.	O	O

Of	O	O
67	O	O
patients	O	O
initially	O	O
enrolled	O	O
,	O	O
24	O	O
remained	O	O
on	O	O
thalidomide	B-Chemical	D013792
for	O	O
3	O	O
months	O	O
,	O	O
8	O	O
remained	O	O
at	O	O
6	O	O
months	O	O
,	O	O
and	O	O
3	O	O
remained	O	O
at	O	O
9	O	O
months	O	O
.	O	O

Six	O	O
patients	O	O
developed	O	O
neuropathy	B-Disease	D009422
.	O	O

Clinical	O	O
symptoms	O	O
and	O	O
a	O	O
decline	O	O
in	O	O
the	O	O
SNAP	O	O
index	O	O
occurred	O	O
concurrently	O	O
.	O	O

Older	O	O
age	O	O
and	O	O
cumulative	O	O
dose	O	O
were	O	O
possible	O	O
contributing	O	O
factors	O	O
.	O	O

Neuropathy	B-Disease	D009422
may	O	O
thus	O	O
be	O	O
a	O	O
common	O	O
complication	O	O
of	O	O
thalidomide	B-Chemical	D013792
in	O	O
older	O	O
patients	O	O
.	O	O

The	O	O
SNAP	O	O
index	O	O
can	O	O
be	O	O
used	O	O
to	O	O
monitor	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
,	O	O
but	O	O
not	O	O
for	O	O
early	O	O
detection	O	O
.	O	O

Overexpression	O	O
of	O	O
copper	B-Chemical	D003300
/	O	O
zinc	B-Chemical	D015032
-	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
protects	O	O
from	O	O
kanamycin	B-Chemical	D007612
-	O	O
induced	O	O
hearing	B-Disease	D034381
loss	I-Disease	D034381
.	O	O

The	O	O
participation	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
in	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
induced	O	O
ototoxicity	B-Disease	D006311
has	O	O
been	O	O
deduced	O	O
from	O	O
observations	O	O
that	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
iron	B-Chemical	D007501
complexes	O	O
catalyze	O	O
the	O	O
formation	O	O
of	O	O
superoxide	B-Chemical	D013481
radicals	O	O
in	O	O
vitro	O	O
and	O	O
that	O	O
antioxidants	O	O
attenuate	O	O
ototoxicity	B-Disease	D006311
in	O	O
vivo	O	O
.	O	O

We	O	O
therefore	O	O
hypothesized	O	O
that	O	O
overexpression	O	O
of	O	O
Cu	B-Chemical	D003300
/	O	O
Zn	B-Chemical	D015032
-	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
(	O	O
h	O	O
-	O	O
SOD1	O	O
)	O	O
should	O	O
protect	O	O
transgenic	O	O
mice	O	O
from	O	O
ototoxicity	B-Disease	D006311
.	O	O

Immunocytochemistry	O	O
confirmed	O	O
expression	O	O
of	O	O
h	O	O
-	O	O
SOD1	O	O
in	O	O
inner	O	O
ear	O	O
tissues	O	O
of	O	O
transgenic	O	O
C57BL	O	O
/	O	O
6	O	O
-	O	O
TgN	O	O
[	O	O
SOD1	O	O
]	O	O
3Cje	O	O
mice	O	O
.	O	O

Transgenic	O	O
and	O	O
nontransgenic	O	O
littermates	O	O
received	O	O
kanamycin	B-Chemical	D007612
(	O	O
400	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
/	O	O
day	O	O
)	O	O
for	O	O
10	O	O
days	O	O
beginning	O	O
on	O	O
day	O	O
10	O	O
after	O	O
birth	O	O
.	O	O

Auditory	O	O
thresholds	O	O
were	O	O
tested	O	O
by	O	O
evoked	O	O
auditory	O	O
brain	O	O
stem	O	O
responses	O	O
at	O	O
1	O	O
month	O	O
after	O	O
birth	O	O
.	O	O

In	O	O
nontransgenic	O	O
animals	O	O
,	O	O
the	O	O
threshold	O	O
in	O	O
the	O	O
kanamycin	B-Chemical	D007612
-	O	O
treated	O	O
group	O	O
was	O	O
45	O	O
-	O	O
50	O	O
dB	O	O
higher	O	O
than	O	O
in	O	O
saline	O	O
-	O	O
injected	O	O
controls	O	O
.	O	O

In	O	O
the	O	O
transgenic	O	O
group	O	O
,	O	O
kanamycin	B-Chemical	D007612
increased	O	O
the	O	O
threshold	O	O
by	O	O
only	O	O
15	O	O
dB	O	O
over	O	O
the	O	O
respective	O	O
controls	O	O
.	O	O

The	O	O
effects	O	O
were	O	O
similar	O	O
at	O	O
12	O	O
and	O	O
24	O	O
kHz	O	O
.	O	O

The	O	O
protection	O	O
by	O	O
overexpression	O	O
of	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
supports	O	O
the	O	O
hypothesis	O	O
that	O	O
oxidant	O	O
stress	O	O
plays	O	O
a	O	O
significant	O	O
role	O	O
in	O	O
aminoglycoside	B-Chemical	D000617
-	O	O
induced	O	O
ototoxicity	B-Disease	D006311
.	O	O

The	O	O
results	O	O
also	O	O
suggest	O	O
transgenic	O	O
animals	O	O
as	O	O
suitable	O	O
models	O	O
to	O	O
investigate	O	O
the	O	O
underlying	O	O
mechanisms	O	O
and	O	O
possible	O	O
strategies	O	O
for	O	O
prevention	O	O
.	O	O

Prednisone	B-Chemical	D011241
induces	O	O
anxiety	B-Disease	D001008
and	O	O
glial	O	O
cerebral	O	O
changes	O	O
in	O	O
rats	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
whether	O	O
prednisone	B-Chemical	D011241
(	O	O
PDN	B-Chemical	D011241
)	O	O
produces	O	O
anxiety	B-Disease	D001008
and	O	O
/	O	O
or	O	O
cerebral	O	O
glial	O	O
changes	O	O
in	O	O
rats	O	O
.	O	O

METHODS	O	O
:	O	O
Male	O	O
Wistar	O	O
rats	O	O
were	O	O
studied	O	O
and	O	O
3	O	O
groups	O	O
were	O	O
formed	O	O
(	O	O
8	O	O
rats	O	O
per	O	O
group	O	O
)	O	O
.	O	O

The	O	O
moderate	O	O
-	O	O
dose	O	O
group	O	O
received	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
PDN	B-Chemical	D011241
released	O	O
from	O	O
a	O	O
subcutaneous	O	O
implant	O	O
.	O	O

In	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
,	O	O
implants	O	O
containing	O	O
PDN	B-Chemical	D011241
equivalent	O	O
to	O	O
60	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
were	O	O
applied	O	O
.	O	O

In	O	O
the	O	O
control	O	O
group	O	O
implants	O	O
contained	O	O
no	O	O
PDN	B-Chemical	D011241
.	O	O

Anxiety	B-Disease	D001008
was	O	O
assessed	O	O
using	O	O
an	O	O
open	O	O
field	O	O
and	O	O
elevated	O	O
plus	O	O
-	O	O
maze	O	O
devices	O	O
.	O	O

The	O	O
number	O	O
of	O	O
cells	O	O
and	O	O
cytoplasmic	O	O
transformation	O	O
of	O	O
astrocytes	O	O
and	O	O
microglia	O	O
cells	O	O
were	O	O
assessed	O	O
by	O	O
immunohistochemical	O	O
analyses	O	O
.	O	O

RESULTS	O	O
:	O	O
Anxiety	B-Disease	D001008
was	O	O
documented	O	O
in	O	O
both	O	O
groups	O	O
of	O	O
PDN	B-Chemical	D011241
treated	O	O
rats	O	O
compared	O	O
with	O	O
controls	O	O
.	O	O

The	O	O
magnitude	O	O
of	O	O
transformation	O	O
of	O	O
the	O	O
microglia	O	O
assessed	O	O
by	O	O
the	O	O
number	O	O
of	O	O
intersections	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
PDN	B-Chemical	D011241
groups	O	O
than	O	O
in	O	O
controls	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
(	O	O
moderate	O	O
-	O	O
dose	O	O
,	O	O
24	O	O
.	O	O

1	O	O
;	O	O
high	O	O
-	O	O
dose	O	O
,	O	O
23	O	O
.	O	O

6	O	O
;	O	O
controls	O	O
18	O	O
.	O	O

7	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
and	O	O
striatum	O	O
(	O	O
moderate	O	O
-	O	O
dose	O	O
25	O	O
.	O	O

6	O	O
;	O	O
high	O	O
-	O	O
dose	O	O
26	O	O
.	O	O

3	O	O
;	O	O
controls	O	O
18	O	O
.	O	O

9	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
but	O	O
not	O	O
in	O	O
hippocampus	O	O
.	O	O

The	O	O
number	O	O
of	O	O
stained	O	O
microglia	O	O
cells	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
PDN	B-Chemical	D011241
treated	O	O
groups	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
than	O	O
in	O	O
controls	O	O
(	O	O
moderate	O	O
-	O	O
dose	O	O
,	O	O
29	O	O
.	O	O

1	O	O
;	O	O
high	O	O
-	O	O
dose	O	O
,	O	O
28	O	O
.	O	O

4	O	O
;	O	O
control	O	O
,	O	O
17	O	O
.	O	O

7	O	O
cells	O	O
per	O	O
field	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Stained	O	O
microglia	O	O
cells	O	O
were	O	O
significantly	O	O
more	O	O
numerous	O	O
striatum	O	O
and	O	O
hippocampus	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Subacute	O	O
exposure	O	O
to	O	O
PDN	B-Chemical	D011241
induced	O	O
anxiety	B-Disease	D001008
and	O	O
reactivity	O	O
of	O	O
microglia	O	O
.	O	O

The	O	O
relevance	O	O
of	O	O
these	O	O
features	O	O
for	O	O
patients	O	O
using	O	O
PDN	B-Chemical	D011241
remains	O	O
to	O	O
be	O	O
elucidated	O	O
.	O	O

Phase	O	O
II	O	O
study	O	O
of	O	O
carboplatin	B-Chemical	D016190
and	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
in	O	O
patients	O	O
with	O	O
recurrent	O	O
squamous	O	O
cell	O	O
carcinoma	O	O
of	O	O
the	O	O
cervix	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
activity	O	O
of	O	O
the	O	O
combination	O	O
of	O	O
carboplatin	B-Chemical	D016190
and	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
was	O	O
tested	O	O
in	O	O
a	O	O
Phase	O	O
II	O	O
study	O	O
of	O	O
patients	O	O
with	O	O
recurrent	O	O
cervical	B-Disease	D002583
carcinoma	I-Disease	D002583
.	O	O

METHODS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
carboplatin	B-Chemical	D016190
(	O	O
area	O	O
under	O	O
the	O	O
concentration	O	O
curve	O	O
[	O	O
AUC	O	O
]	O	O
,	O	O
5	O	O
)	O	O
and	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
(	O	O
Doxil	B-Chemical	D004317
;	O	O
starting	O	O
dose	O	O
,	O	O
40	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
)	O	O
was	O	O
administered	O	O
intravenously	O	O
every	O	O
28	O	O
days	O	O
to	O	O
37	O	O
patients	O	O
with	O	O
recurrent	O	O
squamous	O	O
cell	O	O
cervical	B-Disease	D002583
carcinoma	I-Disease	D002583
to	O	O
determine	O	O
antitumor	O	O
activity	O	O
and	O	O
toxicity	B-Disease	D064420
profile	O	O
.	O	O

RESULTS	O	O
:	O	O
Twenty	O	O
-	O	O
nine	O	O
patients	O	O
were	O	O
assessable	O	O
for	O	O
response	O	O
,	O	O
and	O	O
35	O	O
patients	O	O
were	O	O
assessable	O	O
for	O	O
toxicity	B-Disease	D064420
.	O	O

The	O	O
overall	O	O
response	O	O
rate	O	O
was	O	O
38%	O	O
,	O	O
the	O	O
median	O	O
time	O	O
to	O	O
response	O	O
was	O	O
10	O	O
weeks	O	O
,	O	O
the	O	O
median	O	O
duration	O	O
of	O	O
response	O	O
was	O	O
26	O	O
weeks	O	O
,	O	O
and	O	O
the	O	O
median	O	O
survival	O	O
was	O	O
37	O	O
weeks	O	O
.	O	O

The	O	O
main	O	O
toxic	O	O
effect	O	O
was	O	O
myelosuppression	B-Disease	D001855
,	O	O
with	O	O
Grade	O	O
3	O	O
and	O	O
4	O	O
neutropenia	B-Disease	D009503
in	O	O
16	O	O
patients	O	O
,	O	O
anemia	B-Disease	D000740
in	O	O
12	O	O
patients	O	O
,	O	O
thrombocytopenia	B-Disease	D013921
in	O	O
11	O	O
patients	O	O
,	O	O
and	O	O
neutropenic	O	O
fever	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

Four	O	O
patients	O	O
had	O	O
five	O	O
infusion	O	O
-	O	O
related	O	O
reactions	O	O
during	O	O
the	O	O
infusion	O	O
of	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
,	O	O
leading	O	O
to	O	O
treatment	O	O
discontinuation	O	O
in	O	O
three	O	O
patients	O	O
.	O	O

Grade	O	O
>	O	O
or	O	O
=	O	O
2	O	O
nonhematologic	O	O
toxicity	B-Disease	D064420
included	O	O
nausea	B-Disease	D009325
in	O	O
17	O	O
patients	O	O
,	O	O
emesis	B-Disease	D014839
in	O	O
14	O	O
patients	O	O
,	O	O
fatigue	B-Disease	D005221
in	O	O
9	O	O
patients	O	O
,	O	O
mucositis	B-Disease	D052016
and	O	O
/	O	O
or	O	O
stomatitis	B-Disease	D013280
in	O	O
8	O	O
patients	O	O
,	O	O
constipation	B-Disease	D003248
in	O	O
6	O	O
patients	O	O
,	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
in	O	O
5	O	O
patients	O	O
,	O	O
hand	B-Disease	D060831
-	I-Disease	D060831
foot	I-Disease	D060831
syndrome	I-Disease	D060831
in	O	O
2	O	O
patients	O	O
,	O	O
and	O	O
skin	B-Disease	D012871
reactions	I-Disease	D012871
in	O	O
3	O	O
patients	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
combination	O	O
of	O	O
carboplatin	B-Chemical	D016190
and	O	O
liposomal	O	O
doxorubicin	B-Chemical	D004317
has	O	O
modest	O	O
activity	O	O
in	O	O
patients	O	O
with	O	O
recurrent	O	O
cervical	B-Disease	D002583
carcinoma	I-Disease	D002583
.	O	O

Antimicrobial	O	O
-	O	O
induced	O	O
mania	B-Disease	D001714
(	O	O
antibiomania	B-Disease	D001714
)	O	O
:	O	O
a	O	O
review	O	O
of	O	O
spontaneous	O	O
reports	O	O
.	O	O

The	O	O
authors	O	O
reviewed	O	O
reported	O	O
cases	O	O
of	O	O
antibiotic	O	O
-	O	O
induced	O	O
manic	B-Disease	D001714
episodes	O	O
by	O	O
means	O	O
of	O	O
a	O	O
MEDLINE	O	O
and	O	O
PsychLit	O	O
search	O	O
for	O	O
reports	O	O
of	O	O
antibiotic	O	O
-	O	O
induced	O	O
mania	B-Disease	D001714
.	O	O

Unpublished	O	O
reports	O	O
were	O	O
requested	O	O
from	O	O
the	O	O
World	O	O
Health	O	O
Organization	O	O
(	O	O
WHO	O	O
)	O	O
and	O	O
the	O	O
Food	O	O
and	O	O
Drug	O	O
Administration	O	O
(	O	O
FDA	O	O
)	O	O
.	O	O

Twenty	O	O
-	O	O
one	O	O
reports	O	O
of	O	O
antimicrobial	O	O
-	O	O
induced	O	O
mania	B-Disease	D001714
were	O	O
found	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

There	O	O
were	O	O
6	O	O
cases	O	O
implicating	O	O
clarithromycin	B-Chemical	D017291
,	O	O
13	O	O
implicating	O	O
isoniazid	B-Chemical	D007538
,	O	O
and	O	O
1	O	O
case	O	O
each	O	O
implicating	O	O
erythromycin	B-Chemical	D004917
and	O	O
amoxicillin	B-Chemical	D000658
.	O	O

The	O	O
WHO	O	O
reported	O	O
82	O	O
cases	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
clarithromycin	B-Chemical	D017291
was	O	O
implicated	O	O
in	O	O
23	O	O
(	O	O
27	O	O
.	O	O

6%	O	O
)	O	O
cases	O	O
,	O	O
ciprofloxacin	B-Chemical	D002939
in	O	O
12	O	O
(	O	O
14	O	O
.	O	O

4%	O	O
)	O	O
cases	O	O
,	O	O
and	O	O
ofloxacin	B-Chemical	D015242
in	O	O
10	O	O
(	O	O
12%	O	O
)	O	O
cases	O	O
.	O	O

Cotrimoxazole	B-Chemical	D015662
,	O	O
metronidazole	B-Chemical	D008795
,	O	O
and	O	O
erythromycin	B-Chemical	D004917
were	O	O
involved	O	O
in	O	O
15	O	O
reported	O	O
manic	B-Disease	D001714
episodes	O	O
.	O	O

Cases	O	O
reported	O	O
by	O	O
the	O	O
FDA	O	O
showed	O	O
clarithromycin	B-Chemical	D017291
and	O	O
ciprofloxacin	B-Chemical	D002939
to	O	O
be	O	O
the	O	O
most	O	O
frequently	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
mania	B-Disease	D001714
.	O	O

Statistical	O	O
analysis	O	O
of	O	O
the	O	O
data	O	O
would	O	O
not	O	O
have	O	O
demonstrated	O	O
a	O	O
significant	O	O
statistical	O	O
correlative	O	O
risk	O	O
and	O	O
was	O	O
therefore	O	O
not	O	O
undertaken	O	O
.	O	O

Patients	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
developing	O	O
mania	B-Disease	D001714
while	O	O
being	O	O
treated	O	O
with	O	O
antimicrobials	O	O
.	O	O

Although	O	O
this	O	O
is	O	O
not	O	O
a	O	O
statistically	O	O
significant	O	O
risk	O	O
,	O	O
physicians	O	O
must	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
effect	O	O
and	O	O
reversibility	O	O
.	O	O

Further	O	O
research	O	O
clearly	O	O
is	O	O
required	O	O
to	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
antimicrobial	O	O
-	O	O
induced	O	O
mania	B-Disease	D001714
,	O	O
the	O	O
relative	O	O
risk	O	O
factors	O	O
of	O	O
developing	O	O
an	O	O
antimicrobial	O	O
-	O	O
induced	O	O
manic	B-Disease	D001714
episode	O	O
among	O	O
various	O	O
demographic	O	O
populations	O	O
,	O	O
and	O	O
the	O	O
incidence	O	O
of	O	O
patients	O	O
who	O	O
continue	O	O
to	O	O
have	O	O
persistent	O	O
affective	O	O
disorders	O	O
once	O	O
the	O	O
initial	O	O
episode	O	O
,	O	O
which	O	O
occurs	O	O
while	O	O
the	O	O
patient	O	O
is	O	O
taking	O	O
antibiotics	O	O
,	O	O
subsides	O	O
.	O	O

The	O	O
authors	O	O
elected	O	O
to	O	O
name	O	O
this	O	O
syndrome	O	O
"antibiomania	O	O
.	O	O

"	O	O
Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
ocular	B-Disease	D015835
dyskinesias	I-Disease	D015835
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Levodopa	B-Chemical	D007980
-	O	O
induced	O	O
ocular	B-Disease	D015835
dyskinesias	I-Disease	D015835
are	O	O
very	O	O
uncommon	O	O
.	O	O

Usually	O	O
they	O	O
occur	O	O
simultaneously	O	O
with	O	O
limb	O	O
peak	O	O
-	O	O
dose	O	O
choreatic	B-Disease	D002819
dyskinesias	I-Disease	D002819
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
patient	O	O
with	O	O
leftward	O	O
and	O	O
upward	O	O
deviations	O	O
of	O	O
gaze	O	O
during	O	O
the	O	O
peak	O	O
effect	O	O
of	O	O
levodopa	B-Chemical	D007980
,	O	O
and	O	O
hypothesize	O	O
that	O	O
a	O	O
severe	O	O
dopaminergic	O	O
denervation	O	O
in	O	O
the	O	O
caudate	O	O
nucleus	O	O
is	O	O
needed	O	O
for	O	O
the	O	O
appearance	O	O
of	O	O
these	O	O
levodopa	B-Chemical	D007980
-	O	O
induce	O	O
ocular	B-Disease	D015835
dyskinesias	I-Disease	D015835
.	O	O

A	O	O
comparison	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
with	O	O
diclofenac	B-Chemical	D004008
for	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
dysmenorrhea	B-Disease	D004412
:	O	O
an	O	O
open	O	O
,	O	O
randomized	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
trial	O	O
.	O	O

Primary	O	O
dysmenorrhea	B-Disease	D004412
is	O	O
a	O	O
syndrome	O	O
characterized	O	O
by	O	O
painful	O	O
uterine	O	O
contractility	O	O
caused	O	O
by	O	O
a	O	O
hypersecretion	O	O
of	O	O
endometrial	O	O
prostaglandins	B-Chemical	D011453
;	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
are	O	O
the	O	O
first	O	O
choice	O	O
for	O	O
its	O	O
treatment	O	O
.	O	O

However	O	O
,	O	O
in	O	O
vivo	O	O
and	O	O
in	O	O
vitro	O	O
studies	O	O
have	O	O
demonstrated	O	O
that	O	O
myometrial	O	O
cells	O	O
are	O	O
also	O	O
targets	O	O
of	O	O
the	O	O
relaxant	O	O
effects	O	O
of	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
efficacy	O	O
of	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
(	O	O
GTN	B-Chemical	D005996
)	O	O
,	O	O
an	O	O
NO	B-Chemical	D009569
donor	O	O
,	O	O
in	O	O
the	O	O
resolution	O	O
of	O	O
primary	O	O
dysmenorrhea	B-Disease	D004412
in	O	O
comparison	O	O
with	O	O
diclofenac	B-Chemical	D004008
(	O	O
DCF	B-Chemical	D004008
)	O	O
.	O	O

A	O	O
total	O	O
of	O	O
24	O	O
patients	O	O
with	O	O
the	O	O
diagnosis	O	O
of	O	O
severe	O	O
primary	O	O
dysmenorrhea	B-Disease	D004412
were	O	O
studied	O	O
during	O	O
two	O	O
consecutive	O	O
menstrual	O	O
cycles	O	O
.	O	O

In	O	O
an	O	O
open	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
,	O	O
controlled	O	O
design	O	O
,	O	O
patients	O	O
were	O	O
randomized	O	O
to	O	O
receive	O	O
either	O	O
DCF	B-Chemical	D004008
per	O	O
os	O	O
or	O	O
GTN	B-Chemical	D005996
patches	O	O
the	O	O
first	O	O
days	O	O
of	O	O
menses	O	O
,	O	O
when	O	O
menstrual	O	O
cramps	O	O
became	O	O
unendurable	O	O
.	O	O

In	O	O
the	O	O
subsequent	O	O
cycle	O	O
the	O	O
other	O	O
treatment	O	O
was	O	O
used	O	O
.	O	O

Patients	O	O
received	O	O
up	O	O
to	O	O
3	O	O
doses	O	O
/	O	O
day	O	O
of	O	O
50	O	O
mg	O	O
DCF	B-Chemical	D004008
or	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
24	O	O
h	O	O
transdermal	O	O
GTN	B-Chemical	D005996
for	O	O
the	O	O
first	O	O
3	O	O
days	O	O
of	O	O
the	O	O
cycle	O	O
,	O	O
according	O	O
to	O	O
their	O	O
needs	O	O
.	O	O

The	O	O
participants	O	O
recorded	O	O
menstrual	O	O
symptoms	O	O
and	O	O
possible	O	O
side	O	O
-	O	O
effects	O	O
at	O	O
different	O	O
times	O	O
(	O	O
0	O	O
,	O	O
30	O	O
,	O	O
60	O	O
,	O	O
120	O	O
minutes	O	O
)	O	O
after	O	O
the	O	O
first	O	O
dose	O	O
of	O	O
medication	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
the	O	O
cycle	O	O
,	O	O
with	O	O
both	O	O
drugs	O	O
.	O	O

The	O	O
difference	O	O
in	O	O
pain	B-Disease	D010146
intensity	O	O
score	O	O
(	O	O
DPI	O	O
)	O	O
was	O	O
the	O	O
main	O	O
outcome	O	O
variable	O	O
.	O	O

Both	O	O
treatments	O	O
significantly	O	O
reduced	O	O
DPI	O	O
by	O	O
the	O	O
30th	O	O
minute	O	O
(	O	O
GTN	B-Chemical	D005996
,	O	O
-	O	O
12	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
17	O	O
.	O	O

9	O	O
;	O	O
DCF	B-Chemical	D004008
,	O	O
-	O	O
18	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
16	O	O
.	O	O

6	O	O
)	O	O
.	O	O

However	O	O
,	O	O
DCF	B-Chemical	D004008
continued	O	O
to	O	O
be	O	O
effective	O	O
in	O	O
reducing	O	O
pelvic	B-Disease	D017699
pain	I-Disease	D017699
for	O	O
two	O	O
hours	O	O
,	O	O
whereas	O	O
GTN	B-Chemical	D005996
scores	O	O
remained	O	O
more	O	O
or	O	O
less	O	O
stable	O	O
after	O	O
30	O	O
min	O	O
and	O	O
significantly	O	O
higher	O	O
than	O	O
those	O	O
for	O	O
DFC	O	O
(	O	O
after	O	O
one	O	O
hour	O	O
:	O	O
GTN	B-Chemical	D005996
,	O	O
-	O	O
12	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
17	O	O
.	O	O

9	O	O
;	O	O
DFC	O	O
,	O	O
-	O	O
18	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
16	O	O
.	O	O

6	O	O
and	O	O
after	O	O
two	O	O
hours	O	O
:	O	O
GTN	B-Chemical	D005996
,	O	O
-	O	O
23	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
20	O	O
.	O	O

5	O	O
;	O	O
DFC	O	O
,	O	O
-	O	O
59	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
17	O	O
.	O	O

9	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

Low	B-Disease	D017116
back	I-Disease	D017116
pain	I-Disease	D017116
was	O	O
also	O	O
relieved	O	O
by	O	O
both	O	O
drugs	O	O
.	O	O

Headache	B-Disease	D006261
was	O	O
significantly	O	O
increased	O	O
by	O	O
GTN	B-Chemical	D005996
but	O	O
not	O	O
by	O	O
DCF	B-Chemical	D004008
.	O	O

Eight	O	O
patients	O	O
stopped	O	O
using	O	O
GTN	B-Chemical	D005996
because	O	O
headache	B-Disease	D006261
-	O	O
-	O	O
attributed	O	O
to	O	O
its	O	O
use	O	O
-	O	O
-	O	O
became	O	O
intolerable	O	O
.	O	O

These	O	O
findings	O	O
indicate	O	O
that	O	O
GTN	B-Chemical	D005996
has	O	O
a	O	O
reduced	O	O
efficacy	O	O
and	O	O
tolerability	O	O
by	O	O
comparison	O	O
with	O	O
DCF	B-Chemical	D004008
in	O	O
the	O	O
treatment	O	O
of	O	O
primary	O	O
dysmenorrhea	B-Disease	D004412
.	O	O

Temocapril	B-Chemical	C055603
,	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
non	O	O
-	O	O
SH	O	O
group	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
inhibitor	O	O
,	O	O
modulates	O	O
glomerular	B-Disease	D007674
injury	I-Disease	D007674
in	O	O
chronic	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
nephrosis	B-Disease	D009401
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
chronic	O	O
administration	O	O
of	O	O
temocapril	B-Chemical	C055603
,	O	O
a	O	O
long	O	O
-	O	O
acting	O	O
non	O	O
-	O	O
SH	O	O
group	O	O
angiotensin	B-Chemical	D000809
converting	O	O
enzyme	O	O
(	O	O
ACE	O	O
)	O	O
inhibitor	O	O
,	O	O
reduced	O	O
proteinuria	B-Disease	D011507
,	O	O
inhibited	O	O
glomerular	O	O
hypertrophy	B-Disease	D006984
and	O	O
prevented	O	O
glomerulosclerosis	B-Disease	D005921
in	O	O
chronic	O	O
puromycin	B-Chemical	D011692
aminonucleoside	I-Chemical	D011692
(	O	O
PAN	B-Chemical	D011692
)	O	O
-	O	O
induced	O	O
nephrotic	B-Disease	D009404
rats	O	O
.	O	O

Nephrosis	B-Disease	D009401
was	O	O
induced	O	O
by	O	O
injection	O	O
of	O	O
PAN	B-Chemical	D011692
(	O	O
15mg	O	O
/	O	O
100g	O	O
body	O	O
weight	O	O
)	O	O
in	O	O
male	O	O
Sprague	O	O
-	O	O
Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
.	O	O

Four	O	O
groups	O	O
were	O	O
used	O	O
,	O	O
i	O	O
)	O	O
the	O	O
PAN	B-Chemical	D011692
group	O	O
(	O	O
14	O	O
)	O	O
,	O	O
ii	O	O
)	O	O
PAN	B-Chemical	D011692
/	O	O
temocapril	B-Chemical	C055603
(	O	O
13	O	O
)	O	O
,	O	O
iii	O	O
)	O	O
temocapril	B-Chemical	C055603
(	O	O
14	O	O
)	O	O
and	O	O
iv	O	O
)	O	O
untreated	O	O
controls	O	O
(	O	O
15	O	O
)	O	O
.	O	O

Temocapril	B-Chemical	C055603
(	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
was	O	O
administered	O	O
to	O	O
the	O	O
rats	O	O
which	O	O
were	O	O
killed	O	O
at	O	O
weeks	O	O
4	O	O
,	O	O
14	O	O
or	O	O
20	O	O
.	O	O

At	O	O
each	O	O
time	O	O
point	O	O
,	O	O
systolic	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
,	O	O
urinary	O	O
protein	O	O
excretion	O	O
and	O	O
renal	O	O
histopathological	O	O
findings	O	O
were	O	O
evaluated	O	O
,	O	O
and	O	O
morphometric	O	O
image	O	O
analysis	O	O
was	O	O
done	O	O
.	O	O

Systolic	O	O
BP	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
group	O	O
was	O	O
significantly	O	O
high	O	O
at	O	O
4	O	O
,	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
,	O	O
but	O	O
was	O	O
normal	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
/	O	O
temocapril	B-Chemical	C055603
group	O	O
.	O	O

Urinary	O	O
protein	O	O
excretion	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
group	O	O
increased	O	O
significantly	O	O
,	O	O
peaking	O	O
at	O	O
8	O	O
days	O	O
,	O	O
then	O	O
decreased	O	O
at	O	O
4	O	O
weeks	O	O
,	O	O
but	O	O
rose	O	O
again	O	O
significantly	O	O
at	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
.	O	O

Temocapril	B-Chemical	C055603
did	O	O
not	O	O
attenuate	O	O
proteinuria	B-Disease	D011507
at	O	O
8	O	O
days	O	O
,	O	O
but	O	O
it	O	O
did	O	O
markedly	O	O
lower	O	O
it	O	O
from	O	O
weeks	O	O
4	O	O
to	O	O
20	O	O
.	O	O

The	O	O
glomerulosclerosis	B-Disease	D005921
index	O	O
(	O	O
GSI	O	O
)	O	O
was	O	O
6	O	O
.	O	O

21	O	O
%	O	O
at	O	O
4	O	O
weeks	O	O
and	O	O
respectively	O	O
25	O	O
.	O	O

35	O	O
%	O	O
and	O	O
30	O	O
.	O	O

49	O	O
%	O	O
at	O	O
14	O	O
and	O	O
20	O	O
weeks	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
group	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
correlation	O	O
between	O	O
urinary	O	O
protein	O	O
excretion	O	O
and	O	O
GSI	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

808	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

The	O	O
ratio	O	O
of	O	O
glomerular	O	O
tuft	O	O
area	O	O
to	O	O
the	O	O
area	O	O
of	O	O
Bowman's	O	O
capsules	O	O
(	O	O
GT	O	O
/	O	O
BC	O	O
)	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
group	O	O
was	O	O
significantly	O	O
increased	O	O
,	O	O
but	O	O
it	O	O
was	O	O
significantly	O	O
lower	O	O
in	O	O
the	O	O
PAN	B-Chemical	D011692
/	O	O
temocapril	B-Chemical	C055603
group	O	O
.	O	O

It	O	O
appears	O	O
that	O	O
temocapril	B-Chemical	C055603
was	O	O
effective	O	O
in	O	O
retarding	O	O
renal	O	O
progression	O	O
and	O	O
protected	O	O
renal	O	O
function	O	O
in	O	O
PAN	B-Chemical	D011692
neprotic	B-Disease	D009401
rats	O	O
.	O	O

Pulmonary	B-Disease	D006976
hypertension	I-Disease	D006976
after	O	O
ibuprofen	B-Chemical	D007052
prophylaxis	O	O
in	O	O
very	O	O
preterm	O	O
infants	O	O
.	O	O

We	O	O
report	O	O
three	O	O
cases	O	O
of	O	O
severe	O	O
hypoxaemia	B-Disease	D000860
after	O	O
ibuprofen	B-Chemical	D007052
administration	O	O
during	O	O
a	O	O
randomised	O	O
controlled	O	O
trial	O	O
of	O	O
prophylactic	O	O
treatment	O	O
of	O	O
patent	B-Disease	D004374
ductus	I-Disease	D004374
arteriosus	I-Disease	D004374
with	O	O
ibuprofen	B-Chemical	D007052
in	O	O
premature	O	O
infants	O	O
born	O	O
at	O	O
less	O	O
than	O	O
28	O	O
weeks	O	O
of	O	O
gestation	O	O
.	O	O

Echocardiography	O	O
showed	O	O
severely	O	O
decreased	O	O
pulmonary	O	O
blood	O	O
flow	O	O
.	O	O

Hypoxaemia	B-Disease	D000860
resolved	O	O
quickly	O	O
on	O	O
inhaled	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
therapy	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
investigators	O	O
involved	O	O
in	O	O
similar	O	O
trials	O	O
pay	O	O
close	O	O
attention	O	O
to	O	O
pulmonary	O	O
pressure	O	O
if	O	O
hypoxaemia	B-Disease	D000860
occurs	O	O
after	O	O
prophylactic	O	O
administration	O	O
of	O	O
ibuprofen	B-Chemical	D007052
.	O	O

Hyponatremia	B-Disease	D007010
and	O	O
syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
anti	I-Disease	D007177
-	I-Disease	D007177
diuretic	I-Disease	D007177
hormone	I-Disease	D007177
reported	O	O
with	O	O
the	O	O
use	O	O
of	O	O
Vincristine	B-Chemical	D014750
:	O	O
an	O	O
over	O	O
-	O	O
representation	O	O
of	O	O
Asians?	O	O
PURPOSE	O	O
:	O	O
This	O	O
retrospective	O	O
study	O	O
used	O	O
a	O	O
pharmaceutical	O	O
company's	O	O
global	O	O
safety	O	O
database	O	O
to	O	O
determine	O	O
the	O	O
reporting	O	O
rate	O	O
of	O	O
hyponatremia	B-Disease	D007010
and	O	O
/	O	O
or	O	O
syndrome	B-Disease	D007177
of	I-Disease	D007177
inappropriate	I-Disease	D007177
secretion	I-Disease	D007177
of	I-Disease	D007177
anti	I-Disease	D007177
-	I-Disease	D007177
diuretic	I-Disease	D007177
hormone	I-Disease	D007177
(	O	O
SIADH	B-Disease	D007177
)	O	O
among	O	O
vincristine	B-Chemical	D014750
-	O	O
treated	O	O
patients	O	O
and	O	O
to	O	O
explore	O	O
the	O	O
possibility	O	O
of	O	O
at	O	O
-	O	O
risk	O	O
population	O	O
subgroups	O	O
.	O	O

METHOD	O	O
:	O	O
We	O	O
searched	O	O
the	O	O
Eli	O	O
Lilly	O	O
and	O	O
Company's	O	O
computerized	O	O
adverse	O	O
event	O	O
database	O	O
for	O	O
all	O	O
reported	O	O
cases	O	O
of	O	O
hyponatremia	B-Disease	D007010
and	O	O
/	O	O
or	O	O
SIADH	B-Disease	D007177
as	O	O
of	O	O
1	O	O
November	O	O
1999	O	O
that	O	O
had	O	O
been	O	O
reported	O	O
during	O	O
the	O	O
use	O	O
of	O	O
vincristine	B-Chemical	D014750
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
76	O	O
cases	O	O
of	O	O
hyponatremia	B-Disease	D007010
and	O	O
/	O	O
or	O	O
SIADH	B-Disease	D007177
associated	O	O
with	O	O
vincristine	B-Chemical	D014750
use	O	O
were	O	O
identified	O	O
.	O	O

The	O	O
overall	O	O
reporting	O	O
rate	O	O
was	O	O
estimated	O	O
to	O	O
be	O	O
1	O	O
.	O	O

3	O	O
/	O	O
100	O	O
,	O	O
000	O	O
treated	O	O
patients	O	O
.	O	O

The	O	O
average	O	O
age	O	O
of	O	O
patients	O	O
was	O	O
35	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
28	O	O
.	O	O

3	O	O
years	O	O
,	O	O
and	O	O
62%	O	O
were	O	O
males	O	O
.	O	O

Approximately	O	O
75%	O	O
of	O	O
the	O	O
patients	O	O
were	O	O
receiving	O	O
treatment	O	O
for	O	O
leukemia	B-Disease	D007938
or	O	O
lymphoma	B-Disease	D008223
.	O	O

Among	O	O
the	O	O
39	O	O
reports	O	O
that	O	O
included	O	O
information	O	O
on	O	O
race	O	O
,	O	O
the	O	O
racial	O	O
distribution	O	O
was	O	O
:	O	O
1	O	O
Black	O	O
,	O	O
3	O	O
Caucasian	O	O
,	O	O
and	O	O
35	O	O
Asian	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
data	O	O
suggest	O	O
that	O	O
Asian	O	O
patients	O	O
may	O	O
be	O	O
at	O	O
increased	O	O
risk	O	O
of	O	O
hyponatremia	B-Disease	D007010
and	O	O
/	O	O
or	O	O
SIADH	B-Disease	D007177
associated	O	O
with	O	O
vincristine	B-Chemical	D014750
use	O	O
.	O	O

Although	O	O
the	O	O
overall	O	O
reported	O	O
rate	O	O
of	O	O
SIADH	B-Disease	D007177
associated	O	O
with	O	O
vincristine	B-Chemical	D014750
is	O	O
very	O	O
low	O	O
,	O	O
physicians	O	O
caring	O	O
for	O	O
Asian	O	O
oncology	O	O
patients	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
this	O	O
potential	O	O
serious	O	O
but	O	O
reversible	O	O
adverse	O	O
event	O	O
.	O	O

Delayed	O	O
toxicity	B-Disease	D064420
of	O	O
cyclophosphamide	B-Chemical	D003520
on	O	O
the	O	O
bladder	O	O
of	O	O
DBA	O	O
/	O	O
2	O	O
and	O	O
C57BL	O	O
/	O	O
6	O	O
female	O	O
mouse	O	O
.	O	O

The	O	O
present	O	O
study	O	O
describes	O	O
the	O	O
delayed	O	O
development	O	O
of	O	O
a	O	O
severe	O	O
bladder	O	O
pathology	O	O
in	O	O
a	O	O
susceptible	O	O
strain	O	O
of	O	O
mice	O	O
(	O	O
DBA	O	O
/	O	O
2	O	O
)	O	O
but	O	O
not	O	O
in	O	O
a	O	O
resistant	O	O
strain	O	O
(	O	O
C57BL	O	O
/	O	O
6	O	O
)	O	O
when	O	O
both	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
dose	O	O
of	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CY	B-Chemical	D003520
)	O	O
.	O	O

Inbred	O	O
DBA	O	O
/	O	O
2	O	O
and	O	O
C57BL	O	O
/	O	O
6	O	O
female	O	O
mice	O	O
were	O	O
injected	O	O
with	O	O
CY	B-Chemical	D003520
,	O	O
and	O	O
the	O	O
effect	O	O
of	O	O
the	O	O
drug	O	O
on	O	O
the	O	O
bladder	O	O
was	O	O
assessed	O	O
during	O	O
100	O	O
days	O	O
by	O	O
light	O	O
microscopy	O	O
using	O	O
different	O	O
staining	O	O
procedures	O	O
,	O	O
and	O	O
after	O	O
30	O	O
days	O	O
by	O	O
conventional	O	O
electron	O	O
microscopy	O	O
.	O	O

Early	O	O
CY	B-Chemical	D003520
toxicity	B-Disease	D064420
caused	O	O
a	O	O
typical	O	O
haemorrhagic	B-Disease	D006470
cystitis	B-Disease	D003556
in	O	O
both	O	O
strains	O	O
that	O	O
was	O	O
completely	O	O
repaired	O	O
in	O	O
about	O	O
7	O	O
-	O	O
10	O	O
days	O	O
.	O	O

After	O	O
30	O	O
days	O	O
of	O	O
CY	B-Chemical	D003520
injection	O	O
ulcerous	O	O
and	O	O
non	O	O
-	O	O
ulcerous	O	O
forms	O	O
of	O	O
chronic	O	O
cystitis	B-Disease	D003556
appeared	O	O
in	O	O
86%	O	O
of	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
but	O	O
only	O	O
in	O	O
4%	O	O
of	O	O
C57BL	O	O
/	O	O
6	O	O
mice	O	O
.	O	O

Delayed	O	O
cystitis	B-Disease	D003556
was	O	O
characterized	O	O
by	O	O
infiltration	O	O
and	O	O
transepithelial	O	O
passage	O	O
into	O	O
the	O	O
lumen	O	O
of	O	O
inflammatory	O	O
cells	O	O
and	O	O
by	O	O
frequent	O	O
exfoliation	O	O
of	O	O
the	O	O
urothelium	O	O
.	O	O

Mast	O	O
cells	O	O
appeared	O	O
in	O	O
the	O	O
connective	O	O
and	O	O
muscular	O	O
layers	O	O
of	O	O
the	O	O
bladder	O	O
at	O	O
a	O	O
much	O	O
higher	O	O
number	O	O
in	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
than	O	O
in	O	O
C57BL	O	O
/	O	O
6	O	O
mice	O	O
or	O	O
untreated	O	O
controls	O	O
.	O	O

Electron	O	O
microscopy	O	O
disclosed	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
typical	O	O
discoidal	O	O
vesicles	O	O
normally	O	O
present	O	O
in	O	O
the	O	O
cytoplasm	O	O
of	O	O
surface	O	O
cells	O	O
.	O	O

Instead	O	O
,	O	O
numerous	O	O
abnormal	O	O
vesicles	O	O
containing	O	O
one	O	O
or	O	O
several	O	O
dark	O	O
granules	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
cytoplasm	O	O
of	O	O
cells	O	O
from	O	O
all	O	O
the	O	O
epithelial	O	O
layers	O	O
.	O	O

Delayed	O	O
cystitis	B-Disease	D003556
still	O	O
persisted	O	O
in	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
100	O	O
days	O	O
after	O	O
treatment	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
delayed	O	O
toxicity	B-Disease	D064420
of	O	O
CY	B-Chemical	D003520
in	O	O
female	O	O
DBA	O	O
/	O	O
2	O	O
mice	O	O
causes	O	O
a	O	O
bladder	O	O
pathology	O	O
that	O	O
is	O	O
not	O	O
observed	O	O
in	O	O
C57BL	O	O
/	O	O
6	O	O
mice	O	O
.	O	O

This	O	O
pathology	O	O
resembles	O	O
interstitial	B-Disease	D018856
cystitis	I-Disease	D018856
in	O	O
humans	O	O
and	O	O
could	O	O
perhaps	O	O
be	O	O
used	O	O
as	O	O
an	O	O
animal	O	O
model	O	O
for	O	O
studies	O	O
on	O	O
the	O	O
disease	O	O
.	O	O

High	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
/	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
in	O	O
combination	O	O
with	O	O
three	O	O
-	O	O
weekly	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
in	O	O
the	O	O
treatment	O	O
of	O	O
advanced	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
.	O	O

A	O	O
phase	O	O
II	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
24	O	O
-	O	O
hour	O	O
continuous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
and	O	O
folinic	B-Chemical	D002955
acid	I-Chemical	D002955
(	O	O
FA	B-Chemical	D002955
)	O	O
as	O	O
part	O	O
of	O	O
several	O	O
new	O	O
multidrug	O	O
chemotherapy	O	O
regimens	O	O
in	O	O
advanced	O	O
gastric	B-Disease	D013274
cancer	I-Disease	D013274
(	O	O
AGC	B-Disease	D013274
)	O	O
has	O	O
shown	O	O
to	O	O
be	O	O
effective	O	O
,	O	O
with	O	O
low	O	O
toxicity	B-Disease	D064420
.	O	O

In	O	O
a	O	O
previous	O	O
phase	O	O
II	O	O
study	O	O
with	O	O
3	O	O
-	O	O
weekly	O	O
bolus	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
,	O	O
FA	B-Chemical	D002955
and	O	O
mitomycin	B-Chemical	D016685
C	I-Chemical	D016685
(	O	O
MMC	B-Chemical	D016685
)	O	O
we	O	O
found	O	O
a	O	O
low	O	O
toxicity	B-Disease	D064420
rate	O	O
and	O	O
response	O	O
rates	O	O
comparable	O	O
to	O	O
those	O	O
of	O	O
regimens	O	O
such	O	O
as	O	O
ELF	O	O
,	O	O
FAM	O	O
or	O	O
FAMTX	O	O
,	O	O
and	O	O
a	O	O
promising	O	O
median	O	O
overall	O	O
survival	O	O
.	O	O

In	O	O
order	O	O
to	O	O
improve	O	O
this	O	O
MMC	B-Chemical	D016685
-	O	O
dependent	O	O
schedule	O	O
we	O	O
initiated	O	O
a	O	O
phase	O	O
II	O	O
study	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
/	O	O
FA	B-Chemical	D002955
and	O	O
3	O	O
-	O	O
weekly	O	O
bolus	O	O
MMC	B-Chemical	D016685
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
From	O	O
February	O	O
,	O	O
1998	O	O
to	O	O
September	O	O
,	O	O
2000	O	O
we	O	O
recruited	O	O
33	O	O
patients	O	O
with	O	O
AGC	B-Disease	D013274
to	O	O
receive	O	O
weekly	O	O
24	O	O
-	O	O
hour	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
2	O	O
,	O	O
600	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
preceded	O	O
by	O	O
2	O	O
-	O	O
hour	O	O
FA	B-Chemical	D002955
500	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
for	O	O
6	O	O
weeks	O	O
,	O	O
followed	O	O
by	O	O
a	O	O
2	O	O
-	O	O
week	O	O
rest	O	O
period	O	O
.	O	O

Bolus	O	O
MMC	B-Chemical	D016685
10	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
was	O	O
added	O	O
in	O	O
3	O	O
-	O	O
weekly	O	O
intervals	O	O
.	O	O

Treatment	O	O
given	O	O
on	O	O
an	O	O
outpatient	O	O
basis	O	O
,	O	O
using	O	O
portable	O	O
pump	O	O
systems	O	O
,	O	O
was	O	O
repeated	O	O
on	O	O
day	O	O
57	O	O
.	O	O

Patients'	O	O
characteristics	O	O
were	O	O
:	O	O
male	O	O
/	O	O
female	O	O
ratio	O	O
20	O	O
/	O	O
13	O	O
;	O	O
median	O	O
age	O	O
57	O	O
(	O	O
27	O	O
-	O	O
75	O	O
)	O	O
years	O	O
;	O	O
median	O	O
WHO	O	O
status	O	O
1	O	O
(	O	O
0	O	O
-	O	O
2	O	O
)	O	O
.	O	O

18	O	O
patients	O	O
had	O	O
a	O	O
primary	O	O
AGC	B-Disease	D013274
,	O	O
and	O	O
15	O	O
showed	O	O
a	O	O
relapsed	O	O
AGC	B-Disease	D013274
.	O	O

Median	O	O
follow	O	O
-	O	O
up	O	O
was	O	O
11	O	O
.	O	O

8	O	O
months	O	O
(	O	O
range	O	O
of	O	O
those	O	O
surviving	O	O
:	O	O
2	O	O
.	O	O

7	O	O
-	O	O
11	O	O
.	O	O

8	O	O
months	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
32	O	O
patients	O	O
were	O	O
evaluable	O	O
for	O	O
response	O	O
-	O	O
complete	O	O
remission	O	O
9	O	O
.	O	O

1%	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
,	O	O
partial	O	O
remission	O	O
45	O	O
.	O	O

5%	O	O
(	O	O
n	O	O
=	O	O
15	O	O
)	O	O
,	O	O
no	O	O
change	O	O
27	O	O
.	O	O

3%	O	O
(	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
progressive	O	O
disease	O	O
15	O	O
.	O	O

1%	O	O
(	O	O
n	O	O
=	O	O
5	O	O
)	O	O
.	O	O

Median	O	O
overall	O	O
survival	O	O
time	O	O
was	O	O
10	O	O
.	O	O

2	O	O
months	O	O
[	O	O
95%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
:	O	O
8	O	O
.	O	O

7	O	O
-	O	O
11	O	O
.	O	O

6	O	O
]	O	O
,	O	O
and	O	O
median	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
time	O	O
was	O	O
7	O	O
.	O	O

6	O	O
months	O	O
(	O	O
95%	O	O
CI	O	O
:	O	O
4	O	O
.	O	O

4	O	O
-	O	O
10	O	O
.	O	O

9	O	O
)	O	O
.	O	O

The	O	O
worst	O	O
toxicities	B-Disease	D064420
(	O	O
%	O	O
)	O	O
observed	O	O
were	O	O
(	O	O
CTC	O	O
-	O	O
NCI	O	O
1	O	O
/	O	O
2	O	O
/	O	O
3	O	O
)	O	O
:	O	O
leukopenia	B-Disease	D007970
45	O	O
.	O	O

5	O	O
/	O	O
18	O	O
.	O	O

2	O	O
/	O	O
6	O	O
.	O	O

1	O	O
,	O	O
thrombocytopenia	B-Disease	D013921
33	O	O
.	O	O

3	O	O
/	O	O
9	O	O
.	O	O

1	O	O
/	O	O
6	O	O
.	O	O

1	O	O
,	O	O
vomitus	B-Disease	D014839
24	O	O
.	O	O

2	O	O
/	O	O
9	O	O
.	O	O

1	O	O
/	O	O
0	O	O
,	O	O
diarrhea	B-Disease	D003967
36	O	O
.	O	O

4	O	O
/	O	O
6	O	O
.	O	O

1	O	O
/	O	O
3	O	O
.	O	O

0	O	O
,	O	O
stomatitis	B-Disease	D013280
18	O	O
.	O	O

2	O	O
/	O	O
9	O	O
.	O	O

1	O	O
/	O	O
0	O	O
,	O	O
hand	B-Disease	D060831
-	I-Disease	D060831
foot	I-Disease	D060831
syndrome	I-Disease	D060831
12	O	O
.	O	O

1	O	O
/	O	O
0	O	O
/	O	O
0	O	O
.	O	O

Two	O	O
patients	O	O
developed	O	O
hemolytic	B-Disease	D006463
-	I-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
(	O	O
HUS	B-Disease	D006463
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
High	O	O
-	O	O
dose	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
/	O	O
FA	B-Chemical	D002955
/	O	O
MMC	B-Chemical	D016685
is	O	O
an	O	O
effective	O	O
and	O	O
well	O	O
-	O	O
tolerated	O	O
outpatient	O	O
regimen	O	O
for	O	O
AGC	B-Disease	D013274
(	O	O
objective	O	O
response	O	O
rate	O	O
54	O	O
.	O	O

6%	O	O
)	O	O
.	O	O

It	O	O
may	O	O
serve	O	O
as	O	O
an	O	O
alternative	O	O
to	O	O
cisplatin	B-Chemical	D002945
-	O	O
containing	O	O
regimens	O	O
;	O	O
however	O	O
,	O	O
it	O	O
has	O	O
to	O	O
be	O	O
considered	O	O
that	O	O
possibly	O	O
HUS	B-Disease	D006463
may	O	O
occur	O	O
.	O	O

Persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
is	O	O
associated	O	O
with	O	O
impaired	B-Disease	D007674
renal	I-Disease	D007674
function	I-Disease	D007674
in	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
type	I-Disease	D015658
1	I-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
children	O	O
treated	O	O
with	O	O
indinavir	B-Chemical	D019469
.	O	O

BACKGROUND	O	O
:	O	O
Prolonged	O	O
administration	O	O
of	O	O
indinavir	B-Chemical	D019469
is	O	O
associated	O	O
with	O	O
the	O	O
occurrence	O	O
of	O	O
a	O	O
variety	O	O
of	O	O
renal	O	O
complications	O	O
in	O	O
adults	O	O
.	O	O

These	O	O
well	O	O
-	O	O
documented	O	O
side	O	O
effects	O	O
have	O	O
restricted	O	O
the	O	O
use	O	O
of	O	O
this	O	O
potent	O	O
protease	O	O
inhibitor	O	O
in	O	O
children	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
prospective	O	O
study	O	O
to	O	O
monitor	O	O
indinavir	B-Chemical	D019469
-	O	O
related	O	O
nephrotoxicity	B-Disease	D007674
in	O	O
a	O	O
cohort	O	O
of	O	O
30	O	O
human	B-Disease	D015658
immunodeficiency	I-Disease	D015658
virus	I-Disease	D015658
type	I-Disease	D015658
1	I-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
children	O	O
treated	O	O
with	O	O
indinavir	B-Chemical	D019469
.	O	O

METHODS	O	O
:	O	O
Urinary	O	O
pH	O	O
,	O	O
albumin	O	O
,	O	O
creatinine	B-Chemical	D003404
,	O	O
the	O	O
presence	O	O
of	O	O
erythrocytes	O	O
,	O	O
leukocytes	O	O
,	O	O
bacteria	O	O
and	O	O
crystals	O	O
,	O	O
and	O	O
culture	O	O
were	O	O
analyzed	O	O
every	O	O
3	O	O
months	O	O
for	O	O
96	O	O
weeks	O	O
.	O	O

Serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
were	O	O
routinely	O	O
determined	O	O
at	O	O
the	O	O
same	O	O
time	O	O
points	O	O
.	O	O

Steady	O	O
-	O	O
state	O	O
pharmacokinetics	O	O
of	O	O
indinavir	B-Chemical	D019469
were	O	O
done	O	O
at	O	O
week	O	O
4	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
indinavir	B-Chemical	D019469
.	O	O

RESULTS	O	O
:	O	O
The	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
(	O	O
>	O	O
or	O	O
=75	O	O
cells	O	O
/	O	O
micro	O	O
L	O	O
in	O	O
at	O	O
least	O	O
2	O	O
consecutive	O	O
visits	O	O
)	O	O
after	O	O
96	O	O
weeks	O	O
was	O	O
53%	O	O
.	O	O

Persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
was	O	O
frequently	O	O
associated	O	O
with	O	O
a	O	O
mild	O	O
increase	O	O
in	O	O
the	O	O
urine	O	O
albumin	O	O
/	O	O
creatinine	B-Chemical	D003404
ratio	O	O
and	O	O
by	O	O
microscopic	O	O
hematuria	B-Disease	D006417
.	O	O

The	O	O
cumulative	O	O
incidence	O	O
of	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
>50%	O	O
above	O	O
normal	O	O
was	O	O
33%	O	O
after	O	O
96	O	O
weeks	O	O
.	O	O

Children	O	O
with	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
more	O	O
frequently	O	O
had	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
of	O	O
50%	O	O
above	O	O
normal	O	O
than	O	O
those	O	O
children	O	O
without	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
.	O	O

In	O	O
children	O	O
younger	O	O
than	O	O
5	O	O
.	O	O

6	O	O
years	O	O
,	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
was	O	O
significantly	O	O
more	O	O
frequent	O	O
than	O	O
in	O	O
older	O	O
children	O	O
.	O	O

A	O	O
higher	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
leukocyturia	B-Disease	-1
was	O	O
found	O	O
in	O	O
children	O	O
with	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
>19	O	O
mg	O	O
/	O	O
L	O	O
x	O	O
h	O	O
or	O	O
a	O	O
peak	O	O
serum	O	O
level	O	O
of	O	O
indinavir	B-Chemical	D019469
>12	O	O
mg	O	O
/	O	O
L	O	O
.	O	O

In	O	O
4	O	O
children	O	O
,	O	O
indinavir	B-Chemical	D019469
was	O	O
discontinued	O	O
because	O	O
of	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

Subsequently	O	O
,	O	O
the	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
decreased	O	O
,	O	O
the	O	O
urine	O	O
albumin	O	O
/	O	O
creatinine	B-Chemical	D003404
ratios	O	O
returned	O	O
to	O	O
zero	O	O
,	O	O
and	O	O
the	O	O
leukocyturia	B-Disease	-1
disappeared	O	O
within	O	O
3	O	O
months	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Children	O	O
treated	O	O
with	O	O
indinavir	B-Chemical	D019469
have	O	O
a	O	O
high	O	O
cumulative	O	O
incidence	O	O
of	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
.	O	O

Children	O	O
with	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
more	O	O
frequently	O	O
had	O	O
an	O	O
increase	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
levels	O	O
of	O	O
>50%	O	O
above	O	O
normal	O	O
.	O	O

Younger	O	O
children	O	O
have	O	O
an	O	O
additional	O	O
risk	O	O
for	O	O
renal	O	O
complications	O	O
.	O	O

The	O	O
impairment	B-Disease	D007674
of	I-Disease	D007674
the	I-Disease	D007674
renal	I-Disease	D007674
function	I-Disease	D007674
in	O	O
these	O	O
children	O	O
occurred	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
clinical	O	O
symptoms	O	O
of	O	O
nephrolithiasis	B-Disease	D053040
.	O	O

Indinavir	B-Chemical	D019469
-	O	O
associated	O	O
nephrotoxicity	B-Disease	D007674
must	O	O
be	O	O
monitored	O	O
closely	O	O
,	O	O
especially	O	O
in	O	O
children	O	O
with	O	O
risk	O	O
factors	O	O
such	O	O
as	O	O
persistent	O	O
sterile	O	O
leukocyturia	B-Disease	-1
,	O	O
age	O	O
<5	O	O
.	O	O

6	O	O
years	O	O
,	O	O
an	O	O
area	O	O
under	O	O
the	O	O
curve	O	O
of	O	O
indinavir	B-Chemical	D019469
>19	O	O
mg	O	O
/	O	O
L	O	O
x	O	O
h	O	O
,	O	O
and	O	O
a	O	O
C	O	O
(	O	O
max	O	O
)	O	O
>12	O	O
mg	O	O
/	O	O
L	O	O
.	O	O

Utility	O	O
of	O	O
troponin	O	O
I	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

Baseline	O	O
electrocardiogram	O	O
abnormalities	O	O
and	O	O
market	O	O
elevations	O	O
not	O	O
associated	O	O
with	O	O
myocardial	B-Disease	D009202
necrosis	I-Disease	D009202
make	O	O
accurate	O	O
diagnosis	O	O
of	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
MI	B-Disease	D009203
)	O	O
difficult	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

Troponin	O	O
sampling	O	O
may	O	O
offer	O	O
greater	O	O
diagnostic	O	O
utility	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
assess	O	O
outcomes	O	O
based	O	O
on	O	O
troponin	O	O
positivity	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
chest	B-Disease	D002637
pain	I-Disease	D002637
admitted	O	O
for	O	O
exclusion	O	O
of	O	O
MI	B-Disease	D009203
.	O	O

METHODS	O	O
:	O	O
Outcomes	O	O
were	O	O
examined	O	O
in	O	O
patients	O	O
admitted	O	O
for	O	O
possible	O	O
MI	B-Disease	D009203
after	O	O
cocaine	B-Chemical	D003042
use	O	O
.	O	O

All	O	O
patients	O	O
underwent	O	O
a	O	O
rapid	O	O
rule	O	O
-	O	O
in	O	O
protocol	O	O
that	O	O
included	O	O
serial	O	O
sampling	O	O
of	O	O
creatine	B-Chemical	D003401
kinase	O	O
(	O	O
CK	O	O
)	O	O
,	O	O
CK	O	O
-	O	O
MB	O	O
,	O	O
and	O	O
cardiac	O	O
troponin	O	O
I	O	O
(	O	O
cTnI	O	O
)	O	O
over	O	O
eight	O	O
hours	O	O
.	O	O

Outcomes	O	O
included	O	O
CK	O	O
-	O	O
MB	O	O
MI	B-Disease	D009203
(	O	O
CK	O	O
-	O	O
MB	O	O
>or=	O	O
8	O	O
ng	O	O
/	O	O
mL	O	O
with	O	O
a	O	O
relative	O	O
index	O	O
[	O	O
(	O	O
CK	O	O
-	O	O
MB	O	O
x	O	O
100	O	O
)	O	O
/	O	O
total	O	O
CK	O	O
]	O	O
>or=	O	O
4	O	O
,	O	O
cardiac	B-Disease	D003643
death	I-Disease	D003643
,	O	O
and	O	O
significant	O	O
coronary	B-Disease	D003327
disease	I-Disease	D003327
(	O	O
>or=50%	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
246	O	O
admitted	O	O
patients	O	O
,	O	O
34	O	O
(	O	O
14%	O	O
)	O	O
met	O	O
CK	O	O
-	O	O
MB	O	O
criteria	O	O
for	O	O
MI	B-Disease	D009203
and	O	O
38	O	O
(	O	O
16%	O	O
)	O	O
had	O	O
cTnI	O	O
elevations	O	O
.	O	O

Angiography	O	O
was	O	O
performed	O	O
in	O	O
29	O	O
of	O	O
38	O	O
patients	O	O
who	O	O
were	O	O
cTnI	O	O
-	O	O
positive	O	O
,	O	O
with	O	O
significant	O	O
disease	O	O
present	O	O
in	O	O
25	O	O
(	O	O
86%	O	O
)	O	O
.	O	O

Three	O	O
of	O	O
the	O	O
four	O	O
patients	O	O
without	O	O
significant	O	O
disease	O	O
who	O	O
had	O	O
cTnI	O	O
elevations	O	O
met	O	O
CK	O	O
-	O	O
MB	O	O
criteria	O	O
for	O	O
MI	B-Disease	D009203
,	O	O
and	O	O
the	O	O
other	O	O
had	O	O
a	O	O
peak	O	O
CK	O	O
-	O	O
MB	O	O
level	O	O
of	O	O
13	O	O
ng	O	O
/	O	O
mL	O	O
.	O	O

Sensitivities	O	O
,	O	O
specificities	O	O
,	O	O
and	O	O
positive	O	O
and	O	O
negative	O	O
likelihood	O	O
ratios	O	O
for	O	O
predicting	O	O
cardiac	B-Disease	D003643
death	I-Disease	D003643
or	O	O
significant	O	O
disease	O	O
were	O	O
high	O	O
for	O	O
both	O	O
CK	O	O
-	O	O
MB	O	O
MI	B-Disease	D009203
and	O	O
cTnI	O	O
and	O	O
were	O	O
not	O	O
significantly	O	O
different	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Most	O	O
patients	O	O
with	O	O
cTnI	O	O
elevations	O	O
meet	O	O
CK	O	O
-	O	O
MB	O	O
criteria	O	O
for	O	O
MI	B-Disease	D009203
,	O	O
as	O	O
well	O	O
as	O	O
have	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
underlying	O	O
significant	O	O
disease	O	O
.	O	O

Troponin	O	O
appears	O	O
to	O	O
have	O	O
an	O	O
equivalent	O	O
diagnostic	O	O
accuracy	O	O
compared	O	O
with	O	O
CK	O	O
-	O	O
MB	O	O
for	O	O
diagnosing	O	O
necrosis	B-Disease	D009336
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
and	O	O
suspected	O	O
MI	B-Disease	D009203
.	O	O

Acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
due	O	O
to	O	O
nicergoline	B-Chemical	D009530
(	O	O
Sermion	B-Chemical	D009530
)	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
(	O	O
AIN	B-Disease	D009395
)	O	O
due	O	O
to	O	O
nicergoline	B-Chemical	D009530
(	O	O
Sermion	B-Chemical	D009530
)	O	O
.	O	O

A	O	O
50	O	O
-	O	O
year	O	O
-	O	O
old	O	O
patient	O	O
admitted	O	O
to	O	O
our	O	O
hospital	O	O
for	O	O
fever	B-Disease	D005334
and	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
.	O	O

Before	O	O
admission	O	O
,	O	O
he	O	O
had	O	O
been	O	O
taking	O	O
nicergoline	B-Chemical	D009530
and	O	O
bendazac	B-Chemical	C036067
lysine	I-Chemical	C036067
due	O	O
to	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
at	O	O
ophthalmologic	O	O
department	O	O
.	O	O

Thereafter	O	O
,	O	O
he	O	O
experienced	O	O
intermittent	O	O
fever	B-Disease	D005334
and	O	O
skin	B-Disease	D005076
rash	I-Disease	D005076
.	O	O

On	O	O
admission	O	O
,	O	O
clinical	O	O
symptoms	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

arthralgia	B-Disease	D018771
and	O	O
fever	B-Disease	D005334
)	O	O
and	O	O
laboratory	O	O
findings	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

eosinophilia	B-Disease	D004802
and	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
)	O	O
suggested	O	O
AIN	B-Disease	D009395
,	O	O
and	O	O
which	O	O
was	O	O
confirmed	O	O
by	O	O
pathologic	O	O
findings	O	O
on	O	O
renal	O	O
biopsy	O	O
.	O	O

A	O	O
lymphocyte	O	O
transformation	O	O
test	O	O
demonstrated	O	O
a	O	O
positive	O	O
result	O	O
against	O	O
nicergoline	B-Chemical	D009530
.	O	O

Treatment	O	O
was	O	O
consisted	O	O
of	O	O
withdrawal	O	O
of	O	O
nicergoline	B-Chemical	D009530
and	O	O
intravenous	O	O
methylprednisolone	B-Chemical	D008775
,	O	O
and	O	O
his	O	O
renal	O	O
function	O	O
was	O	O
completely	O	O
recovered	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
of	O	O
nicergoline	B-Chemical	D009530
-	O	O
associated	O	O
AIN	B-Disease	D009395
.	O	O

Neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
complicated	O	O
by	O	O
massive	O	O
intestinal	O	O
bleeding	B-Disease	D006470
in	O	O
a	O	O
patient	O	O
with	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
.	O	O

A	O	O
patient	O	O
with	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
(	O	O
CRF	B-Disease	D007676
)	O	O
developed	O	O
neuroleptic	B-Disease	D009459
malignant	I-Disease	D009459
syndrome	I-Disease	D009459
(	O	O
NMS	B-Disease	D009459
)	O	O
after	O	O
administration	O	O
of	O	O
risperidone	B-Chemical	D018967
and	O	O
levomepromazine	B-Chemical	D008728
.	O	O

In	O	O
addition	O	O
to	O	O
the	O	O
typical	O	O
symptoms	O	O
of	O	O
NMS	B-Disease	D009459
,	O	O
massive	O	O
intestinal	O	O
bleeding	B-Disease	D006470
was	O	O
observed	O	O
during	O	O
the	O	O
episode	O	O
.	O	O

This	O	O
report	O	O
suggests	O	O
that	O	O
NMS	B-Disease	D009459
in	O	O
a	O	O
patient	O	O
with	O	O
CRF	B-Disease	D007676
may	O	O
be	O	O
complicated	O	O
by	O	O
intestinal	O	O
bleeding	B-Disease	D006470
and	O	O
needs	O	O
special	O	O
caution	O	O
for	O	O
this	O	O
complication	O	O
.	O	O

Blood	O	O
brain	O	O
barrier	O	O
in	O	O
right	O	O
-	O	O
and	O	O
left	O	O
-	O	O
pawed	O	O
female	O	O
rats	O	O
assessed	O	O
by	O	O
a	O	O
new	O	O
staining	O	O
method	O	O
.	O	O

The	O	O
asymmetrical	O	O
breakdown	O	O
of	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
(	O	O
BBB	O	O
)	O	O
was	O	O
studied	O	O
in	O	O
female	O	O
rats	O	O
.	O	O

Paw	O	O
preference	O	O
was	O	O
assessed	O	O
by	O	O
a	O	O
food	O	O
reaching	O	O
test	O	O
.	O	O

Adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
hypertension	B-Disease	D006973
was	O	O
used	O	O
to	O	O
destroy	O	O
the	O	O
BBB	O	O
,	O	O
which	O	O
was	O	O
evaluated	O	O
using	O	O
triphenyltetrazolium	B-Chemical	C009591
(	O	O
TTC	B-Chemical	C009591
)	O	O
staining	O	O
of	O	O
the	O	O
brain	O	O
slices	O	O
just	O	O
after	O	O
giving	O	O
adrenaline	B-Chemical	D004837
for	O	O
30	O	O
s	O	O
.	O	O

In	O	O
normal	O	O
rats	O	O
,	O	O
the	O	O
whole	O	O
brain	O	O
sections	O	O
exhibited	O	O
complete	O	O
staining	O	O
with	O	O
TTC	B-Chemical	C009591
.	O	O

After	O	O
adrenaline	B-Chemical	D004837
infusion	O	O
for	O	O
30	O	O
s	O	O
,	O	O
there	O	O
were	O	O
large	O	O
unstained	O	O
areas	O	O
in	O	O
the	O	O
left	O	O
brain	O	O
in	O	O
right	O	O
-	O	O
pawed	O	O
animals	O	O
,	O	O
and	O	O
vice	O	O
versa	O	O
in	O	O
left	O	O
-	O	O
pawed	O	O
animals	O	O
.	O	O

Similar	O	O
results	O	O
were	O	O
obtained	O	O
in	O	O
seizure	B-Disease	D012640
-	O	O
induced	O	O
breakdown	O	O
of	O	O
BBB	O	O
.	O	O

These	O	O
results	O	O
were	O	O
explained	O	O
by	O	O
an	O	O
asymmetric	O	O
cerebral	O	O
blood	O	O
flow	O	O
depending	O	O
upon	O	O
the	O	O
paw	O	O
preference	O	O
in	O	O
rats	O	O
.	O	O

It	O	O
was	O	O
suggested	O	O
that	O	O
this	O	O
new	O	O
method	O	O
and	O	O
the	O	O
results	O	O
are	O	O
consistent	O	O
with	O	O
contralateral	O	O
motor	O	O
control	O	O
that	O	O
may	O	O
be	O	O
important	O	O
in	O	O
determining	O	O
the	O	O
dominant	O	O
cerebral	O	O
hemisphere	O	O
in	O	O
animals	O	O
.	O	O

Carvedilol	B-Chemical	C043211
protects	O	O
against	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
mitochondrial	O	O
cardiomyopathy	B-Disease	D009202
.	O	O

Several	O	O
cytopathic	O	O
mechanisms	O	O
have	O	O
been	O	O
suggested	O	O
to	O	O
mediate	O	O
the	O	O
dose	O	O
-	O	O
limiting	O	O
cumulative	O	O
and	O	O
irreversible	O	O
cardiomyopathy	B-Disease	D009202
caused	O	O
by	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Recent	O	O
evidence	O	O
indicates	O	O
that	O	O
oxidative	O	O
stress	O	O
and	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
are	O	O
key	O	O
factors	O	O
in	O	O
the	O	O
pathogenic	O	O
process	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
investigation	O	O
was	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
that	O	O
carvedilol	B-Chemical	C043211
,	O	O
a	O	O
nonselective	O	O
beta	O	O
-	O	O
adrenergic	O	O
receptor	O	O
antagonist	O	O
with	O	O
potent	O	O
antioxidant	O	O
properties	O	O
,	O	O
protects	O	O
against	O	O
the	O	O
cardiac	O	O
and	O	O
hepatic	O	O
mitochondrial	O	O
bioenergetic	O	O
dysfunction	O	O
associated	O	O
with	O	O
subchronic	O	O
doxorubicin	B-Chemical	D004317
toxicity	B-Disease	D064420
.	O	O

Heart	O	O
and	O	O
liver	O	O
mitochondria	O	O
were	O	O
isolated	O	O
from	O	O
rats	O	O
treated	O	O
for	O	O
7	O	O
weeks	O	O
with	O	O
doxorubicin	B-Chemical	D004317
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
sc	O	O
/	O	O
week	O	O
)	O	O
,	O	O
carvedilol	B-Chemical	C043211
(	O	O
1	O	O
mg	O	O
/	O	O
kg	O	O
ip	O	O
/	O	O
week	O	O
)	O	O
,	O	O
or	O	O
the	O	O
combination	O	O
of	O	O
the	O	O
two	O	O
drugs	O	O
.	O	O

Heart	O	O
mitochondria	O	O
isolated	O	O
from	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
rats	O	O
exhibited	O	O
depressed	O	O
rates	O	O
for	O	O
state	O	O
3	O	O
respiration	O	O
(	O	O
336	O	O
+	O	O
/	O	O
-	O	O
26	O	O
versus	O	O
425	O	O
+	O	O
/	O	O
-	O	O
53	O	O
natom	O	O
O	O	O
/	O	O
min	O	O
/	O	O
mg	O	O
protein	O	O
)	O	O
and	O	O
a	O	O
lower	O	O
respiratory	O	O
control	O	O
ratio	O	O
(	O	O
RCR	O	O
)	O	O
(	O	O
4	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
versus	O	O
5	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

4	O	O
)	O	O
compared	O	O
with	O	O
cardiac	O	O
mitochondria	O	O
isolated	O	O
from	O	O
saline	O	O
-	O	O
treated	O	O
rats	O	O
.	O	O

Mitochondrial	O	O
calcium	B-Chemical	D002118
-	O	O
loading	O	O
capacity	O	O
and	O	O
the	O	O
activity	O	O
of	O	O
NADH	O	O
-	O	O
dehydrogenase	O	O
were	O	O
also	O	O
suppressed	O	O
in	O	O
cardiac	O	O
mitochondria	O	O
from	O	O
doxorubicin	B-Chemical	D004317
-	O	O
treated	O	O
rats	O	O
.	O	O

Doxorubicin	B-Chemical	D004317
treatment	O	O
also	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
RCR	O	O
for	O	O
liver	O	O
mitochondria	O	O
(	O	O
3	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
versus	O	O
5	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
for	O	O
control	O	O
rats	O	O
)	O	O
and	O	O
inhibition	O	O
of	O	O
hepatic	O	O
cytochrome	O	O
oxidase	O	O
activity	O	O
.	O	O

Coadministration	O	O
of	O	O
carvedilol	B-Chemical	C043211
decreased	O	O
the	O	O
extent	O	O
of	O	O
cellular	O	O
vacuolization	O	O
in	O	O
cardiac	O	O
myocytes	O	O
and	O	O
prevented	O	O
the	O	O
inhibitory	O	O
effect	O	O
of	O	O
doxorubicin	B-Chemical	D004317
on	O	O
mitochondrial	O	O
respiration	O	O
in	O	O
both	O	O
heart	O	O
and	O	O
liver	O	O
.	O	O

Carvedilol	B-Chemical	C043211
also	O	O
prevented	O	O
the	O	O
decrease	O	O
in	O	O
mitochondrial	O	O
Ca	B-Chemical	D002118
(	O	O
2+	O	O
)	O	O
loading	O	O
capacity	O	O
and	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
respiratory	O	O
complexes	O	O
of	O	O
heart	O	O
mitochondria	O	O
caused	O	O
by	O	O
doxorubicin	B-Chemical	D004317
.	O	O

Carvedilol	B-Chemical	C043211
by	O	O
itself	O	O
did	O	O
not	O	O
affect	O	O
any	O	O
of	O	O
the	O	O
parameters	O	O
measured	O	O
for	O	O
heart	O	O
or	O	O
liver	O	O
mitochondria	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
this	O	O
protection	O	O
by	O	O
carvedilol	B-Chemical	C043211
against	O	O
both	O	O
the	O	O
structural	O	O
and	O	O
functional	O	O
cardiac	O	O
tissue	O	O
damage	O	O
may	O	O
afford	O	O
significant	O	O
clinical	O	O
advantage	O	O
in	O	O
minimizing	O	O
the	O	O
dose	O	O
-	O	O
limiting	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
and	O	O
cardiomyopathy	B-Disease	D009202
that	O	O
accompanies	O	O
long	O	O
-	O	O
term	O	O
doxorubicin	B-Chemical	D004317
therapy	O	O
in	O	O
cancer	B-Disease	D009369
patients	O	O
.	O	O

Cocaine	B-Chemical	D003042
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
is	O	O
more	O	O
influenced	O	O
by	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
than	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
.	O	O

The	O	O
influence	O	O
of	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
and	O	O
antagonists	O	O
on	O	O
cocaine	B-Chemical	D003042
-	O	O
and	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
was	O	O
examined	O	O
in	O	O
mice	O	O
.	O	O

All	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
significantly	O	O
decreased	B-Disease	D004409
the	I-Disease	D004409
locomotor	I-Disease	D004409
activity	I-Disease	D004409
in	O	O
mice	O	O
,	O	O
and	O	O
the	O	O
effects	O	O
were	O	O
dose	O	O
-	O	O
dependent	O	O
.	O	O

It	O	O
seems	O	O
that	O	O
adenosine	B-Chemical	D000241
A1	O	O
and	O	O
A2	O	O
receptors	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
this	O	O
reaction	O	O
.	O	O

Moreover	O	O
,	O	O
all	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
:	O	O
2	B-Chemical	C061282
-	I-Chemical	C061282
p	I-Chemical	C061282
-	I-Chemical	C061282
(	I-Chemical	C061282
2	I-Chemical	C061282
-	I-Chemical	C061282
carboxyethyl	I-Chemical	C061282
)	I-Chemical	C061282
phenethylamino	I-Chemical	C061282
-	I-Chemical	C061282
5'	I-Chemical	C061282
-	I-Chemical	C061282
N	I-Chemical	C061282
-	I-Chemical	C061282
ethylcarboxamidoadenosine	I-Chemical	C061282
(	O	O
CGS	B-Chemical	C061282
21680	I-Chemical	C061282
)	O	O
,	O	O
A2A	O	O
receptor	O	O
agonist	O	O
,	O	O
N6	B-Chemical	C048599
-	I-Chemical	C048599
cyclopentyladenosine	I-Chemical	C048599
(	O	O
CPA	B-Chemical	C048599
)	O	O
,	O	O
A1	O	O
receptor	O	O
agonist	O	O
,	O	O
and	O	O
5'	B-Chemical	D019830
-	I-Chemical	D019830
N	I-Chemical	D019830
-	I-Chemical	D019830
ethylcarboxamidoadenosine	I-Chemical	D019830
(	O	O
NECA	B-Chemical	D019830
)	O	O
,	O	O
A2	O	O
/	O	O
A1	O	O
receptor	O	O
agonist	O	O
significantly	O	O
and	O	O
dose	O	O
-	O	O
dependently	O	O
decreased	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
.	O	O

CPA	B-Chemical	C048599
reduced	O	O
cocaine	B-Chemical	D003042
action	O	O
at	O	O
the	O	O
doses	O	O
which	O	O
,	O	O
given	O	O
alone	O	O
,	O	O
did	O	O
not	O	O
influence	O	O
motility	O	O
,	O	O
while	O	O
CGS	B-Chemical	C061282
21680	I-Chemical	C061282
and	O	O
NECA	B-Chemical	D019830
decreased	O	O
the	O	O
action	O	O
of	O	O
cocaine	B-Chemical	D003042
at	O	O
the	O	O
doses	O	O
which	O	O
,	O	O
given	O	O
alone	O	O
,	O	O
decreased	O	O
locomotor	O	O
activity	O	O
in	O	O
animals	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
the	O	O
involvement	O	O
of	O	O
both	O	O
adenosine	B-Chemical	D000241
receptors	O	O
in	O	O
the	O	O
action	O	O
of	O	O
cocaine	B-Chemical	D003042
although	O	O
agonists	O	O
of	O	O
A1	O	O
receptors	O	O
seem	O	O
to	O	O
have	O	O
stronger	O	O
influence	O	O
on	O	O
it	O	O
.	O	O

The	O	O
selective	O	O
blockade	O	O
of	O	O
A2	O	O
adenosine	B-Chemical	D000241
receptor	O	O
by	O	O
DMPX	B-Chemical	C057837
(	O	O
3	B-Chemical	C057837
,	I-Chemical	C057837
7	I-Chemical	C057837
-	I-Chemical	C057837
dimethyl	I-Chemical	C057837
-	I-Chemical	C057837
1	I-Chemical	C057837
-	I-Chemical	C057837
propargylxanthine	I-Chemical	C057837
)	O	O
significantly	O	O
enhanced	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
of	O	O
animals	O	O
.	O	O

Caffeine	B-Chemical	D002110
had	O	O
similar	O	O
action	O	O
but	O	O
the	O	O
effect	O	O
was	O	O
not	O	O
significant	O	O
.	O	O

CPT	B-Chemical	C053907
(	O	O
8	B-Chemical	C053907
-	I-Chemical	C053907
cyclopentyltheophylline	I-Chemical	C053907
)	O	O
-	O	O
-	O	O
A1	O	O
receptor	O	O
antagonist	O	O
,	O	O
did	O	O
not	O	O
show	O	O
any	O	O
influence	O	O
in	O	O
this	O	O
test	O	O
.	O	O

Similarly	O	O
,	O	O
all	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
decreased	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
,	O	O
but	O	O
at	O	O
the	O	O
higher	O	O
doses	O	O
than	O	O
those	O	O
which	O	O
were	O	O
active	O	O
in	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
.	O	O

The	O	O
selective	O	O
blockade	O	O
of	O	O
A2	O	O
adenosine	B-Chemical	D000241
receptors	O	O
(	O	O
DMPX	B-Chemical	C057837
)	O	O
and	O	O
non	O	O
-	O	O
selective	O	O
blockade	O	O
of	O	O
adenosine	B-Chemical	D000241
receptors	O	O
(	O	O
caffeine	B-Chemical	D002110
)	O	O
significantly	O	O
increased	O	O
the	O	O
action	O	O
of	O	O
amphetamine	B-Chemical	D000661
in	O	O
the	O	O
locomotor	O	O
activity	O	O
test	O	O
.	O	O

Our	O	O
results	O	O
have	O	O
shown	O	O
that	O	O
all	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
(	O	O
A1	O	O
and	O	O
A2	O	O
)	O	O
reduce	O	O
cocaine	B-Chemical	D003042
-	O	O
and	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
locomotor	O	O
activity	O	O
and	O	O
indicate	O	O
that	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
is	O	O
more	O	O
influenced	O	O
by	O	O
adenosine	B-Chemical	D000241
receptor	O	O
agonists	O	O
(	O	O
particularly	O	O
A1	O	O
receptors	O	O
)	O	O
than	O	O
amphetamine	B-Chemical	D000661
-	O	O
induced	O	O
hyperactivity	B-Disease	D006948
.	O	O

Amiodarone	B-Chemical	D000638
and	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	B-Disease	D001919
requiring	O	O
permanent	O	O
pacemaker	O	O
in	O	O
elderly	O	O
patients	O	O
with	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
and	O	O
prior	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
whether	O	O
the	O	O
use	O	O
of	O	O
amiodarone	B-Chemical	D000638
in	O	O
patients	O	O
with	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
(	O	O
AF	B-Disease	D001281
)	O	O
increases	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	B-Disease	D001919
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Reports	O	O
of	O	O
severe	O	O
bradyarrhythmia	B-Disease	D001919
during	O	O
amiodarone	B-Chemical	D000638
therapy	O	O
are	O	O
infrequent	O	O
and	O	O
limited	O	O
to	O	O
studies	O	O
assessing	O	O
the	O	O
therapy's	O	O
use	O	O
in	O	O
the	O	O
management	O	O
of	O	O
patients	O	O
with	O	O
ventricular	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

METHODS	O	O
:	O	O
A	O	O
study	O	O
cohort	O	O
of	O	O
8	O	O
,	O	O
770	O	O
patients	O	O
age	O	O
>	O	O
or	O	O
=65	O	O
years	O	O
with	O	O
a	O	O
new	O	O
diagnosis	O	O
of	O	O
AF	B-Disease	D001281
was	O	O
identified	O	O
from	O	O
a	O	O
provincewide	O	O
database	O	O
of	O	O
Quebec	O	O
residents	O	O
with	O	O
a	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
MI	B-Disease	D009203
)	O	O
between	O	O
1991	O	O
and	O	O
1999	O	O
.	O	O

Using	O	O
a	O	O
nested	O	O
case	O	O
-	O	O
control	O	O
design	O	O
,	O	O
477	O	O
cases	O	O
of	O	O
bradyarrhythmia	B-Disease	D001919
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
were	O	O
matched	O	O
(	O	O
1	O	O
:	O	O
4	O	O
)	O	O
to	O	O
1	O	O
,	O	O
908	O	O
controls	O	O
.	O	O

Multivariable	O	O
logistic	O	O
regression	O	O
was	O	O
used	O	O
to	O	O
estimate	O	O
the	O	O
odds	O	O
ratio	O	O
(	O	O
OR	O	O
)	O	O
of	O	O
pacemaker	O	O
insertion	O	O
associated	O	O
with	O	O
amiodarone	B-Chemical	D000638
use	O	O
,	O	O
controlling	O	O
for	O	O
baseline	O	O
risk	O	O
factors	O	O
and	O	O
exposure	O	O
to	O	O
sotalol	B-Chemical	D013015
,	O	O
Class	O	O
I	O	O
antiarrhythmic	O	O
agents	O	O
,	O	O
beta	O	O
-	O	O
blockers	O	O
,	O	O
calcium	B-Chemical	D002118
channel	O	O
blockers	O	O
,	O	O
and	O	O
digoxin	B-Chemical	D004077
.	O	O

RESULTS	O	O
:	O	O
amiodarone	B-Chemical	D000638
use	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
(	O	O
OR	O	O
:	O	O
2	O	O
.	O	O

14	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
:	O	O
1	O	O
.	O	O

30	O	O
to	O	O
3	O	O
.	O	O

54	O	O
)	O	O
.	O	O

This	O	O
effect	O	O
was	O	O
modified	O	O
by	O	O
gender	O	O
,	O	O
with	O	O
a	O	O
greater	O	O
risk	O	O
in	O	O
women	O	O
versus	O	O
men	O	O
(	O	O
OR	O	O
:	O	O
3	O	O
.	O	O

86	O	O
,	O	O
95%	O	O
CI	O	O
:	O	O
1	O	O
.	O	O

70	O	O
to	O	O
8	O	O
.	O	O

75	O	O
vs	O	O
.	O	O

OR	O	O
:	O	O
1	O	O
.	O	O

52	O	O
,	O	O
95%	O	O
CI	O	O
:	O	O
0	O	O
.	O	O

80	O	O
to	O	O
2	O	O
.	O	O

89	O	O
)	O	O
.	O	O

Digoxin	B-Chemical	D004077
was	O	O
the	O	O
only	O	O
other	O	O
medication	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
(	O	O
OR	O	O
:	O	O
1	O	O
.	O	O

78	O	O
,	O	O
95%	O	O
CI	O	O
:	O	O
1	O	O
.	O	O

37	O	O
to	O	O
2	O	O
.	O	O

31	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
This	O	O
study	O	O
suggests	O	O
that	O	O
the	O	O
use	O	O
of	O	O
amiodarone	B-Chemical	D000638
in	O	O
elderly	O	O
patients	O	O
with	O	O
AF	B-Disease	D001281
and	O	O
a	O	O
previous	O	O
MI	B-Disease	D009203
increases	O	O
the	O	O
risk	O	O
of	O	O
bradyarrhythmia	B-Disease	D001919
requiring	O	O
a	O	O
permanent	O	O
pacemaker	O	O
.	O	O

The	O	O
finding	O	O
of	O	O
an	O	O
augmented	O	O
risk	O	O
of	O	O
pacemaker	O	O
insertion	O	O
in	O	O
elderly	O	O
women	O	O
receiving	O	O
amiodarone	B-Chemical	D000638
requires	O	O
further	O	O
investigation	O	O
.	O	O

Indomethacin	B-Chemical	D007213
-	O	O
induced	O	O
morphologic	O	O
changes	O	O
in	O	O
the	O	O
rat	O	O
urinary	O	O
bladder	O	O
epithelium	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
morphologic	O	O
changes	O	O
in	O	O
rat	O	O
urothelium	O	O
induced	O	O
by	O	O
indomethacin	B-Chemical	D007213
.	O	O

Nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
-	O	O
induced	O	O
cystitis	B-Disease	D003556
is	O	O
a	O	O
poorly	O	O
recognized	O	O
and	O	O
under	O	O
-	O	O
reported	O	O
condition	O	O
.	O	O

In	O	O
addition	O	O
to	O	O
tiaprofenic	B-Chemical	C021270
acid	I-Chemical	C021270
,	O	O
indomethacin	B-Chemical	D007213
has	O	O
been	O	O
reported	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
this	O	O
condition	O	O
.	O	O

METHODS	O	O
:	O	O
Three	O	O
groups	O	O
were	O	O
established	O	O
:	O	O
a	O	O
control	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
a	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
,	O	O
treated	O	O
with	O	O
one	O	O
intraperitoneal	O	O
injection	O	O
of	O	O
indomethacin	B-Chemical	D007213
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
and	O	O
a	O	O
therapeutic	O	O
dose	O	O
group	O	O
(	O	O
n	O	O
=	O	O
10	O	O
)	O	O
in	O	O
which	O	O
oral	O	O
indomethacin	B-Chemical	D007213
was	O	O
administered	O	O
3	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
weight	O	O
daily	O	O
for	O	O
3	O	O
weeks	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
then	O	O
killed	O	O
and	O	O
the	O	O
bladders	O	O
removed	O	O
for	O	O
light	O	O
and	O	O
electron	O	O
microscopic	O	O
studies	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
light	O	O
microscopic	O	O
findings	O	O
showed	O	O
some	O	O
focal	O	O
epithelial	O	O
degeneration	O	O
that	O	O
was	O	O
more	O	O
prominent	O	O
in	O	O
the	O	O
high	O	O
-	O	O
dose	O	O
group	O	O
.	O	O

When	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
,	O	O
both	O	O
indomethacin	B-Chemical	D007213
groups	O	O
revealed	O	O
statistically	O	O
increased	O	O
numbers	O	O
of	O	O
mast	O	O
cells	O	O
in	O	O
the	O	O
mucosa	O	O
(	O	O
P	O	O
<0	O	O
.	O	O

0001	O	O
)	O	O
and	O	O
penetration	O	O
of	O	O
lanthanum	B-Chemical	C016534
nitrate	I-Chemical	C016534
through	O	O
intercellular	O	O
areas	O	O
of	O	O
the	O	O
epithelium	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
difference	O	O
in	O	O
mast	O	O
cell	O	O
counts	O	O
between	O	O
the	O	O
high	O	O
and	O	O
therapeutic	O	O
dose	O	O
groups	O	O
was	O	O
also	O	O
statistically	O	O
significant	O	O
(	O	O
P	O	O
<0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Indomethacin	B-Chemical	D007213
resulted	O	O
in	O	O
histopathologic	O	O
findings	O	O
typical	O	O
of	O	O
interstitial	B-Disease	D018856
cystitis	I-Disease	D018856
,	O	O
such	O	O
as	O	O
leaky	O	O
bladder	O	O
epithelium	O	O
and	O	O
mucosal	O	O
mastocytosis	B-Disease	D008415
.	O	O

The	O	O
true	O	O
incidence	O	O
of	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
-	O	O
induced	O	O
cystitis	B-Disease	D003556
in	O	O
humans	O	O
must	O	O
be	O	O
clarified	O	O
by	O	O
prospective	O	O
clinical	O	O
trials	O	O
.	O	O

An	O	O
open	O	O
-	O	O
label	O	O
phase	O	O
II	O	O
study	O	O
of	O	O
low	O	O
-	O	O
dose	O	O
thalidomide	B-Chemical	D013792
in	O	O
androgen	B-Chemical	D000728
-	O	O
independent	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

The	O	O
antiangiogenic	O	O
effects	O	O
of	O	O
thalidomide	B-Chemical	D013792
have	O	O
been	O	O
assessed	O	O
in	O	O
clinical	O	O
trials	O	O
in	O	O
patients	O	O
with	O	O
various	O	O
solid	O	O
and	O	O
haematological	B-Disease	D019337
malignancies	I-Disease	D019337
.	O	O

Thalidomide	B-Chemical	D013792
blocks	O	O
the	O	O
activity	O	O
of	O	O
angiogenic	O	O
agents	O	O
including	O	O
bFGF	O	O
,	O	O
VEGF	O	O
and	O	O
IL	O	O
-	O	O
6	O	O
.	O	O

We	O	O
undertook	O	O
an	O	O
open	O	O
-	O	O
label	O	O
study	O	O
using	O	O
thalidomide	B-Chemical	D013792
100	O	O
mg	O	O
once	O	O
daily	O	O
for	O	O
up	O	O
to	O	O
6	O	O
months	O	O
in	O	O
20	O	O
men	O	O
with	O	O
androgen	B-Chemical	D000728
-	O	O
independent	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

The	O	O
mean	O	O
time	O	O
of	O	O
study	O	O
was	O	O
109	O	O
days	O	O
(	O	O
median	O	O
107	O	O
,	O	O
range	O	O
4	O	O
-	O	O
184	O	O
days	O	O
)	O	O
.	O	O

Patients	O	O
underwent	O	O
regular	O	O
measurement	O	O
of	O	O
prostate	O	O
-	O	O
specific	O	O
antigen	O	O
(	O	O
PSA	O	O
)	O	O
,	O	O
urea	B-Chemical	D014508
and	O	O
electrolytes	O	O
,	O	O
serum	O	O
bFGF	O	O
and	O	O
VEGF	O	O
.	O	O

Three	O	O
men	O	O
(	O	O
15%	O	O
)	O	O
showed	O	O
a	O	O
decline	O	O
in	O	O
serum	O	O
PSA	O	O
of	O	O
at	O	O
least	O	O
50%	O	O
,	O	O
sustained	O	O
throughout	O	O
treatment	O	O
.	O	O

Of	O	O
16	O	O
men	O	O
treated	O	O
for	O	O
at	O	O
least	O	O
2	O	O
months	O	O
,	O	O
six	O	O
(	O	O
37	O	O
.	O	O

5%	O	O
)	O	O
showed	O	O
a	O	O
fall	O	O
in	O	O
absolute	O	O
PSA	O	O
by	O	O
a	O	O
median	O	O
of	O	O
48%	O	O
.	O	O

Increasing	O	O
levels	O	O
of	O	O
serum	O	O
bFGF	O	O
and	O	O
VEGF	O	O
were	O	O
associated	O	O
with	O	O
progressive	O	O
disease	O	O
;	O	O
five	O	O
of	O	O
six	O	O
men	O	O
who	O	O
demonstrated	O	O
a	O	O
fall	O	O
in	O	O
PSA	O	O
also	O	O
showed	O	O
a	O	O
decline	O	O
in	O	O
bFGF	O	O
and	O	O
VEGF	O	O
levels	O	O
,	O	O
and	O	O
three	O	O
of	O	O
four	O	O
men	O	O
with	O	O
a	O	O
rising	O	O
PSA	O	O
showed	O	O
an	O	O
increase	O	O
in	O	O
both	O	O
growth	O	O
factors	O	O
.	O	O

Adverse	O	O
effects	O	O
included	O	O
constipation	B-Disease	D003248
,	O	O
morning	O	O
drowsiness	B-Disease	D006970
,	O	O
dizziness	B-Disease	D004244
and	O	O
rash	B-Disease	D005076
,	O	O
and	O	O
resulted	O	O
in	O	O
withdrawal	O	O
from	O	O
the	O	O
study	O	O
by	O	O
three	O	O
men	O	O
.	O	O

Evidence	O	O
of	O	O
peripheral	B-Disease	D010523
sensory	I-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
found	O	O
in	O	O
nine	O	O
of	O	O
13	O	O
men	O	O
before	O	O
treatment	O	O
.	O	O

In	O	O
the	O	O
seven	O	O
men	O	O
who	O	O
completed	O	O
six	O	O
months	O	O
on	O	O
thalidomide	B-Chemical	D013792
,	O	O
subclinical	O	O
evidence	O	O
of	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
was	O	O
found	O	O
in	O	O
four	O	O
before	O	O
treatment	O	O
,	O	O
but	O	O
in	O	O
all	O	O
seven	O	O
at	O	O
repeat	O	O
testing	O	O
.	O	O

The	O	O
findings	O	O
indicate	O	O
that	O	O
thalidomide	B-Chemical	D013792
may	O	O
be	O	O
an	O	O
option	O	O
for	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
other	O	O
forms	O	O
of	O	O
therapy	O	O
,	O	O
provided	O	O
close	O	O
follow	O	O
-	O	O
up	O	O
is	O	O
maintained	O	O
for	O	O
development	O	O
of	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
.	O	O

Central	B-Disease	D020258
nervous	I-Disease	D020258
system	I-Disease	D020258
toxicity	I-Disease	D020258
following	O	O
the	O	O
administration	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
for	O	O
lumbar	O	O
plexus	O	O
block	O	O
:	O	O
A	O	O
report	O	O
of	O	O
two	O	O
cases	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
OBJECTIVES	O	O
:	O	O
Central	O	O
nervous	O	O
system	O	O
and	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
following	O	O
the	O	O
administration	O	O
of	O	O
local	O	O
anesthetics	O	O
is	O	O
a	O	O
recognized	O	O
complication	O	O
of	O	O
regional	O	O
anesthesia	O	O
.	O	O

Levobupivacaine	B-Chemical	C476513
,	O	O
the	O	O
pure	O	O
S	O	O
(	O	O
-	O	O
)	O	O
enantiomer	O	O
of	O	O
bupivacaine	B-Chemical	D002045
,	O	O
was	O	O
developed	O	O
to	O	O
improve	O	O
the	O	O
cardiac	O	O
safety	O	O
profile	O	O
of	O	O
bupivacaine	B-Chemical	D002045
.	O	O

We	O	O
describe	O	O
2	O	O
cases	O	O
of	O	O
grand	B-Disease	D004830
mal	I-Disease	D004830
seizures	I-Disease	D004830
following	O	O
accidental	O	O
intravascular	O	O
injection	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
.	O	O

CASE	O	O
REPORT	O	O
:	O	O
Two	O	O
patients	O	O
presenting	O	O
for	O	O
elective	O	O
orthopedic	O	O
surgery	O	O
of	O	O
the	O	O
lower	O	O
limb	O	O
underwent	O	O
blockade	O	O
of	O	O
the	O	O
lumbar	O	O
plexus	O	O
via	O	O
the	O	O
posterior	O	O
approach	O	O
.	O	O

Immediately	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
0	O	O
.	O	O

5%	O	O
with	O	O
epinephrine	B-Chemical	D004837
2	O	O
.	O	O

5	O	O
microgram	O	O
/	O	O
mL	O	O
,	O	O
the	O	O
patients	O	O
developed	O	O
grand	B-Disease	D004830
mal	I-Disease	D004830
seizures	I-Disease	D004830
,	O	O
despite	O	O
negative	O	O
aspiration	O	O
for	O	O
blood	O	O
and	O	O
no	O	O
clinical	O	O
signs	O	O
of	O	O
intravenous	O	O
epinephrine	B-Chemical	D004837
administration	O	O
.	O	O

The	O	O
seizures	B-Disease	D012640
were	O	O
successfully	O	O
treated	O	O
with	O	O
sodium	B-Chemical	D013874
thiopental	I-Chemical	D013874
in	O	O
addition	O	O
to	O	O
succinylcholine	B-Chemical	D013390
in	O	O
1	O	O
patient	O	O
.	O	O

Neither	O	O
patient	O	O
developed	O	O
signs	O	O
of	O	O
cardiovascular	B-Disease	D002318
toxicity	I-Disease	D002318
.	O	O

Both	O	O
patients	O	O
were	O	O
treated	O	O
preoperatively	O	O
with	O	O
beta	O	O
-	O	O
adrenergic	O	O
antagonist	O	O
medications	O	O
,	O	O
which	O	O
may	O	O
have	O	O
masked	O	O
the	O	O
cardiovascular	O	O
signs	O	O
of	O	O
the	O	O
unintentional	O	O
intravascular	O	O
administration	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
with	O	O
epinephrine	B-Chemical	D004837
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
levobupivacaine	B-Chemical	C476513
may	O	O
have	O	O
a	O	O
safer	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
profile	O	O
than	O	O
racemic	O	O
bupivacaine	B-Chemical	D002045
,	O	O
if	O	O
adequate	O	O
amounts	O	O
of	O	O
levobupivacaine	B-Chemical	C476513
reach	O	O
the	O	O
circulation	O	O
,	O	O
it	O	O
will	O	O
result	O	O
in	O	O
convulsions	B-Disease	D012640
.	O	O

Plasma	O	O
concentrations	O	O
sufficient	O	O
to	O	O
result	O	O
in	O	O
central	B-Disease	D020258
nervous	I-Disease	D020258
system	I-Disease	D020258
toxicity	I-Disease	D020258
did	O	O
not	O	O
produce	O	O
manifestations	O	O
of	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
in	O	O
these	O	O
2	O	O
patients	O	O
.	O	O

Anaesthetic	O	O
complications	O	O
associated	O	O
with	O	O
myotonia	B-Disease	D009224
congenita	I-Disease	D009224
:	O	O
case	O	O
study	O	O
and	O	O
comparison	O	O
with	O	O
other	O	O
myotonic	B-Disease	D020967
disorders	I-Disease	D020967
.	O	O

Myotonia	B-Disease	D009224
congenita	I-Disease	D009224
(	O	O
MC	B-Disease	D009224
)	O	O
is	O	O
caused	O	O
by	O	O
a	O	O
defect	O	O
in	O	O
the	O	O
skeletal	O	O
muscle	O	O
chloride	B-Chemical	D002712
channel	O	O
function	O	O
,	O	O
which	O	O
may	O	O
cause	O	O
sustained	B-Disease	-1
membrane	I-Disease	-1
depolarisation	I-Disease	-1
.	O	O

We	O	O
describe	O	O
a	O	O
previously	O	O
healthy	O	O
32	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
developed	O	O
a	O	O
life	O	O
-	O	O
threatening	O	O
muscle	B-Disease	D013035
spasm	I-Disease	D013035
and	O	O
secondary	O	O
ventilation	O	O
difficulties	O	O
following	O	O
a	O	O
preoperative	O	O
injection	O	O
of	O	O
suxamethonium	B-Chemical	D013390
.	O	O

The	O	O
muscle	B-Disease	D013035
spasms	I-Disease	D013035
disappeared	O	O
spontaneously	O	O
and	O	O
the	O	O
surgery	O	O
proceeded	O	O
without	O	O
further	O	O
problems	O	O
.	O	O

When	O	O
subsequently	O	O
questioned	O	O
,	O	O
she	O	O
reported	O	O
minor	O	O
symptoms	O	O
suggesting	O	O
a	O	O
myotonic	B-Disease	D020967
condition	I-Disease	D020967
.	O	O

Myotonia	B-Disease	D009222
was	O	O
found	O	O
on	O	O
clinical	O	O
examination	O	O
and	O	O
EMG	O	O
.	O	O

The	O	O
diagnosis	O	O
MC	B-Disease	D009224
was	O	O
confirmed	O	O
genetically	O	O
.	O	O

Neither	O	O
the	O	O
patient	O	O
nor	O	O
the	O	O
anaesthetist	O	O
were	O	O
aware	O	O
of	O	O
the	O	O
diagnosis	O	O
before	O	O
this	O	O
potentially	O	O
lethal	O	O
complication	O	O
occurred	O	O
.	O	O

We	O	O
give	O	O
a	O	O
brief	O	O
overview	O	O
of	O	O
ion	B-Disease	-1
channel	I-Disease	-1
disorders	I-Disease	-1
including	O	O
malignant	B-Disease	D008305
hyperthermia	I-Disease	D008305
and	O	O
their	O	O
anaesthetic	O	O
considerations	O	O
.	O	O

Respiratory	O	O
pattern	O	O
in	O	O
a	O	O
rat	O	O
model	O	O
of	O	O
epilepsy	B-Disease	D004827
.	O	O

PURPOSE	O	O
:	O	O
Apnea	B-Disease	D001049
is	O	O
known	O	O
to	O	O
occur	O	O
during	O	O
seizures	B-Disease	D012640
,	O	O
but	O	O
systematic	O	O
studies	O	O
of	O	O
ictal	O	O
respiratory	O	O
changes	O	O
in	O	O
adults	O	O
are	O	O
few	O	O
.	O	O

Data	O	O
regarding	O	O
respiratory	O	O
pattern	O	O
defects	O	O
during	O	O
interictal	O	O
periods	O	O
also	O	O
are	O	O
scarce	O	O
.	O	O

Here	O	O
we	O	O
sought	O	O
to	O	O
generate	O	O
information	O	O
with	O	O
regard	O	O
to	O	O
the	O	O
interictal	O	O
period	O	O
in	O	O
animals	O	O
with	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
epilepsy	B-Disease	D004827
.	O	O

METHODS	O	O
:	O	O
Twelve	O	O
rats	O	O
(	O	O
six	O	O
chronically	O	O
epileptic	B-Disease	D004827
animals	O	O
and	O	O
six	O	O
controls	O	O
)	O	O
were	O	O
anesthetized	O	O
,	O	O
given	O	O
tracheotomies	O	O
,	O	O
and	O	O
subjected	O	O
to	O	O
hyperventilation	B-Disease	D006985
or	O	O
hypoventilation	O	O
conditions	O	O
.	O	O

Breathing	O	O
movements	O	O
caused	O	O
changes	O	O
in	O	O
thoracic	O	O
volume	O	O
and	O	O
forced	O	O
air	O	O
to	O	O
flow	O	O
tidally	O	O
through	O	O
a	O	O
pneumotachograph	O	O
.	O	O

This	O	O
flow	O	O
was	O	O
measured	O	O
by	O	O
using	O	O
a	O	O
differential	O	O
pressure	O	O
transducer	O	O
,	O	O
passed	O	O
through	O	O
a	O	O
polygraph	O	O
,	O	O
and	O	O
from	O	O
this	O	O
to	O	O
a	O	O
computer	O	O
with	O	O
custom	O	O
software	O	O
that	O	O
derived	O	O
ventilation	O	O
(	O	O
VE	O	O
)	O	O
,	O	O
tidal	O	O
volume	O	O
(	O	O
VT	O	O
)	O	O
,	O	O
inspiratory	O	O
time	O	O
(	O	O
TI	O	O
)	O	O
,	O	O
expiratory	O	O
time	O	O
(	O	O
TE	O	O
)	O	O
,	O	O
breathing	O	O
frequency	O	O
(	O	O
f	O	O
)	O	O
,	O	O
and	O	O
mean	O	O
inspiratory	O	O
flow	O	O
(	O	O
VT	O	O
/	O	O
TI	O	O
)	O	O
on	O	O
a	O	O
breath	O	O
-	O	O
by	O	O
-	O	O
breath	O	O
basis	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
hyperventilation	B-Disease	D006985
maneuver	O	O
caused	O	O
a	O	O
decrease	O	O
in	O	O
spontaneous	O	O
ventilation	O	O
in	O	O
pilocarpine	B-Chemical	D010862
-	O	O
treated	O	O
and	O	O
control	O	O
rats	O	O
.	O	O

Although	O	O
VE	O	O
had	O	O
a	O	O
similar	O	O
decrease	O	O
in	O	O
both	O	O
groups	O	O
,	O	O
in	O	O
the	O	O
epileptic	B-Disease	D004827
group	O	O
,	O	O
the	O	O
decrease	O	O
in	O	O
VE	O	O
was	O	O
due	O	O
to	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
increase	O	O
in	O	O
TE	O	O
peak	O	O
in	O	O
relation	O	O
to	O	O
that	O	O
of	O	O
the	O	O
control	O	O
animals	O	O
.	O	O

The	O	O
hypoventilation	O	O
maneuver	O	O
led	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
arterial	O	O
Paco2	O	O
,	O	O
followed	O	O
by	O	O
an	O	O
increase	O	O
in	O	O
VE	O	O
.	O	O

In	O	O
the	O	O
epileptic	B-Disease	D004827
group	O	O
,	O	O
the	O	O
increase	O	O
in	O	O
VE	O	O
was	O	O
mediated	O	O
by	O	O
a	O	O
significant	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
decrease	O	O
in	O	O
TE	O	O
peak	O	O
compared	O	O
with	O	O
the	O	O
control	O	O
group	O	O
.	O	O

Systemic	O	O
application	O	O
of	O	O
KCN	O	O
,	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
peripheral	O	O
chemoreception	O	O
activation	O	O
on	O	O
ventilation	O	O
,	O	O
led	O	O
to	O	O
a	O	O
similar	O	O
increase	O	O
in	O	O
VE	O	O
for	O	O
both	O	O
groups	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
data	O	O
indicate	O	O
that	O	O
pilocarpine	B-Chemical	D010862
-	O	O
treated	O	O
animals	O	O
have	O	O
an	O	O
altered	O	O
ability	O	O
to	O	O
react	O	O
to	O	O
(	O	O
or	O	O
compensate	O	O
for	O	O
)	O	O
blood	O	O
gas	O	O
changes	O	O
with	O	O
changes	O	O
in	O	O
ventilation	O	O
and	O	O
suggest	O	O
that	O	O
it	O	O
is	O	O
centrally	O	O
determined	O	O
.	O	O

We	O	O
speculate	O	O
on	O	O
the	O	O
possible	O	O
relation	O	O
of	O	O
the	O	O
current	O	O
findings	O	O
on	O	O
treating	O	O
different	O	O
epilepsy	B-Disease	D004827
-	O	O
associated	O	O
conditions	O	O
.	O	O

Increased	O	O
serum	O	O
soluble	O	O
Fas	O	O
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
due	O	O
to	O	O
paracetamol	B-Chemical	D000082
overdose	B-Disease	D062787
.	O	O

BACKGROUND	O	O
/	O	O
AIMS	O	O
:	O	O
Experimental	O	O
studies	O	O
have	O	O
suggested	O	O
that	O	O
apoptosis	O	O
via	O	O
the	O	O
Fas	O	O
/	O	O
Fas	O	O
Ligand	O	O
signaling	O	O
system	O	O
may	O	O
play	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
development	O	O
of	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
soluble	O	O
form	O	O
of	O	O
Fas	O	O
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

METHODOLOGY	O	O
:	O	O
Serum	O	O
levels	O	O
of	O	O
sFas	O	O
(	O	O
soluble	O	O
Fas	O	O
)	O	O
were	O	O
measured	O	O
by	O	O
ELISA	O	O
in	O	O
24	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
and	O	O
10	O	O
normal	O	O
control	O	O
subjects	O	O
.	O	O

Serum	O	O
levels	O	O
of	O	O
tumor	B-Disease	D009369
necrosis	B-Disease	D009336
factor	O	O
-	O	O
alpha	O	O
and	O	O
interferon	O	O
-	O	O
gamma	O	O
were	O	O
also	O	O
determined	O	O
by	O	O
ELISA	O	O
.	O	O

RESULTS	O	O
:	O	O
Serum	O	O
sFas	O	O
was	O	O
significantly	O	O
increased	O	O
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
(	O	O
median	O	O
,	O	O
26	O	O
.	O	O

8	O	O
U	O	O
/	O	O
mL	O	O
;	O	O
range	O	O
,	O	O
6	O	O
.	O	O

9	O	O
-	O	O
52	O	O
.	O	O

7	O	O
U	O	O
/	O	O
mL	O	O
)	O	O
compared	O	O
to	O	O
the	O	O
normal	O	O
controls	O	O
(	O	O
median	O	O
,	O	O
8	O	O
.	O	O

6	O	O
U	O	O
/	O	O
mL	O	O
;	O	O
range	O	O
,	O	O
6	O	O
.	O	O

5	O	O
-	O	O
12	O	O
.	O	O

0	O	O
U	O	O
/	O	O
mL	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

Levels	O	O
were	O	O
significantly	O	O
greater	O	O
in	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
due	O	O
to	O	O
paracetamol	B-Chemical	D000082
overdose	B-Disease	D062787
(	O	O
median	O	O
,	O	O
28	O	O
.	O	O

7	O	O
U	O	O
/	O	O
mL	O	O
;	O	O
range	O	O
,	O	O
12	O	O
.	O	O

8	O	O
-	O	O
52	O	O
.	O	O

7	O	O
U	O	O
/	O	O
mL	O	O
,	O	O
n	O	O
=	O	O
17	O	O
)	O	O
than	O	O
those	O	O
due	O	O
to	O	O
non	O	O
-	O	O
A	O	O
to	O	O
E	O	O
hepatitis	B-Disease	D056486
(	O	O
median	O	O
,	O	O
12	O	O
.	O	O

5	O	O
U	O	O
/	O	O
mL	O	O
;	O	O
range	O	O
,	O	O
6	O	O
.	O	O

9	O	O
-	O	O
46	O	O
.	O	O

0	O	O
U	O	O
/	O	O
mL	O	O
,	O	O
n	O	O
=	O	O
7	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

There	O	O
was	O	O
no	O	O
relationship	O	O
of	O	O
sFas	O	O
to	O	O
eventual	O	O
outcome	O	O
in	O	O
the	O	O
patients	O	O
.	O	O

A	O	O
significant	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
serum	O	O
sFas	O	O
levels	O	O
and	O	O
aspartate	B-Chemical	D001224
aminotransferase	O	O
(	O	O
r	O	O
=	O	O
0	O	O
.	O	O

613	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
increased	O	O
concentration	O	O
of	O	O
sFas	O	O
in	O	O
serum	O	O
of	O	O
patients	O	O
with	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
may	O	O
reflect	O	O
activation	O	O
of	O	O
Fas	O	O
-	O	O
mediated	O	O
apoptosis	O	O
in	O	O
the	O	O
liver	O	O
and	O	O
this	O	O
together	O	O
with	O	O
increased	O	O
tumor	B-Disease	D009369
necrosis	B-Disease	D009336
factor	O	O
-	O	O
alpha	O	O
may	O	O
be	O	O
an	O	O
important	O	O
factor	O	O
in	O	O
liver	O	O
cell	O	O
loss	O	O
.	O	O

Bilateral	O	O
subthalamic	O	O
nucleus	O	O
stimulation	O	O
for	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

High	O	O
frequency	O	O
stimulation	O	O
of	O	O
the	O	O
subthalamic	O	O
nucleus	O	O
(	O	O
STN	O	O
)	O	O
is	O	O
known	O	O
to	O	O
ameliorate	O	O
the	O	O
signs	O	O
and	O	O
symptoms	O	O
of	O	O
advanced	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

AIM	O	O
:	O	O
We	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
high	O	O
frequency	O	O
STN	O	O
stimulation	O	O
in	O	O
23	O	O
patients	O	O
.	O	O

METHOD	O	O
:	O	O
Twenty	O	O
-	O	O
three	O	O
patients	O	O
suffering	O	O
from	O	O
severe	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
Stages	O	O
III	O	O
-	O	O
V	O	O
on	O	O
Hoehn	O	O
and	O	O
Yahr	O	O
scale	O	O
)	O	O
and	O	O
,	O	O
particularly	O	O
bradykinesia	B-Disease	D018476
,	O	O
rigidity	B-Disease	D009127
,	O	O
and	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
underwent	O	O
bilateral	O	O
implantation	O	O
of	O	O
electrodes	O	O
in	O	O
the	O	O
STN	O	O
.	O	O

Preoperative	O	O
and	O	O
postoperative	O	O
assessments	O	O
of	O	O
these	O	O
patients	O	O
at	O	O
1	O	O
,	O	O
3	O	O
,	O	O
6	O	O
and	O	O
12	O	O
months	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
in	O	O
"on"	O	O
and	O	O
"off"	O	O
drug	O	O
conditions	O	O
,	O	O
was	O	O
carried	O	O
out	O	O
using	O	O
Unified	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Rating	O	O
Scale	O	O
,	O	O
Hoehn	O	O
and	O	O
Yahr	O	O
staging	O	O
,	O	O
England	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
score	O	O
and	O	O
video	O	O
recordings	O	O
.	O	O

RESULTS	O	O
:	O	O
After	O	O
one	O	O
year	O	O
of	O	O
electrical	O	O
stimulation	O	O
of	O	O
the	O	O
STN	O	O
,	O	O
the	O	O
patients'	O	O
scores	O	O
for	O	O
activities	O	O
of	O	O
daily	O	O
living	O	O
and	O	O
motor	O	O
examination	O	O
scores	O	O
(	O	O
Unified	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Rating	O	O
Scale	O	O
parts	O	O
II	O	O
and	O	O
III	O	O
)	O	O
off	O	O
medication	O	O
improved	O	O
by	O	O
62%	O	O
and	O	O
61%	O	O
respectively	O	O
(	O	O
p<0	O	O
.	O	O

0005	O	O
)	O	O
.	O	O

The	O	O
subscores	O	O
for	O	O
the	O	O
akinesia	B-Disease	D004409
,	O	O
rigidity	B-Disease	D009127
,	O	O
tremor	B-Disease	D014202
and	O	O
gait	O	O
also	O	O
improved	O	O
.	O	O

(	O	O
p<0	O	O
.	O	O

0005	O	O
)	O	O
.	O	O

The	O	O
average	O	O
levodopa	B-Chemical	D007980
dose	O	O
decreased	O	O
from	O	O
813	O	O
mg	O	O
to	O	O
359	O	O
mg	O	O
.	O	O

The	O	O
cognitive	O	O
functions	O	O
remained	O	O
unchanged	O	O
.	O	O

Two	O	O
patients	O	O
developed	O	O
device	O	O
-	O	O
related	O	O
complications	O	O
and	O	O
two	O	O
patients	O	O
experienced	O	O
abnormal	O	O
weight	O	O
gain	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Bilateral	O	O
subthalamic	O	O
nucleus	O	O
stimulation	O	O
is	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
advanced	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

It	O	O
reduces	O	O
the	O	O
severity	O	O
of	O	O
"off"	O	O
phase	O	O
symptoms	O	O
,	O	O
improves	O	O
the	O	O
axial	O	O
symptoms	O	O
and	O	O
reduces	O	O
levodopa	B-Chemical	D007980
requirements	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
the	O	O
levodopa	B-Chemical	D007980
dose	O	O
is	O	O
useful	O	O
in	O	O
controlling	O	O
drug	B-Disease	D004409
-	I-Disease	D004409
induced	I-Disease	D004409
dyskinesias	I-Disease	D004409
.	O	O

Ocular	O	O
motility	O	O
changes	O	O
after	O	O
subtenon	O	O
carboplatin	B-Chemical	D016190
chemotherapy	O	O
for	O	O
retinoblastoma	B-Disease	D012175
.	O	O

BACKGROUND	O	O
:	O	O
Focal	O	O
subtenon	O	O
carboplatin	B-Chemical	D016190
injections	O	O
have	O	O
recently	O	O
been	O	O
used	O	O
as	O	O
a	O	O
presumably	O	O
toxicity	B-Disease	D064420
-	O	O
free	O	O
adjunct	O	O
to	O	O
systemic	O	O
chemotherapy	O	O
for	O	O
intraocular	O	O
retinoblastoma	B-Disease	D012175
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
our	O	O
clinical	O	O
experience	O	O
with	O	O
abnormal	B-Disease	D015835
ocular	I-Disease	D015835
motility	I-Disease	D015835
in	O	O
patients	O	O
treated	O	O
with	O	O
subtenon	O	O
carboplatin	B-Chemical	D016190
chemotherapy	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
noted	O	O
abnormal	B-Disease	D015835
ocular	I-Disease	D015835
motility	I-Disease	D015835
in	O	O
10	O	O
consecutive	O	O
patients	O	O
with	O	O
retinoblastoma	B-Disease	D012175
who	O	O
had	O	O
received	O	O
subtenon	O	O
carboplatin	B-Chemical	D016190
.	O	O

During	O	O
ocular	O	O
manipulation	O	O
under	O	O
general	O	O
anesthesia	O	O
,	O	O
we	O	O
assessed	O	O
their	O	O
eyes	O	O
by	O	O
forced	O	O
duction	O	O
testing	O	O
,	O	O
comparing	O	O
ocular	O	O
motility	O	O
after	O	O
tumor	B-Disease	D009369
control	O	O
with	O	O
ocular	O	O
motility	O	O
at	O	O
diagnosis	O	O
.	O	O

Eyes	O	O
subsequently	O	O
enucleated	O	O
because	O	O
of	O	O
treatment	O	O
failure	O	O
(	O	O
n	O	O
=	O	O
4	O	O
)	O	O
were	O	O
examined	O	O
histologically	O	O
.	O	O

RESULTS	O	O
:	O	O
Limitation	O	O
of	O	O
ocular	O	O
motility	O	O
was	O	O
detected	O	O
in	O	O
all	O	O
12	O	O
eyes	O	O
of	O	O
10	O	O
patients	O	O
treated	O	O
for	O	O
intraocular	O	O
retinoblastoma	B-Disease	D012175
with	O	O
1	O	O
to	O	O
6	O	O
injections	O	O
of	O	O
subtenon	O	O
carboplatin	B-Chemical	D016190
as	O	O
part	O	O
of	O	O
multimodality	O	O
therapy	O	O
.	O	O

Histopathological	O	O
examination	O	O
revealed	O	O
many	O	O
lipophages	O	O
in	O	O
the	O	O
periorbital	O	O
fat	O	O
surrounding	O	O
the	O	O
optic	O	O
nerve	O	O
in	O	O
1	O	O
eye	O	O
,	O	O
indicative	O	O
of	O	O
phagocytosis	O	O
of	O	O
previously	O	O
existing	O	O
fat	O	O
cells	O	O
and	O	O
suggesting	O	O
prior	O	O
fat	O	O
necrosis	B-Disease	D009336
.	O	O

The	O	O
enucleations	O	O
were	O	O
technically	O	O
difficult	O	O
and	O	O
hazardous	O	O
for	O	O
globe	O	O
rupture	B-Disease	D012421
because	O	O
of	O	O
extensive	O	O
orbital	O	O
soft	O	O
tissue	O	O
adhesions	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Subtenon	O	O
carboplatin	B-Chemical	D016190
chemotherapy	O	O
is	O	O
associated	O	O
with	O	O
significant	O	O
fibrosis	B-Disease	D005355
of	O	O
orbital	O	O
soft	O	O
tissues	O	O
,	O	O
leading	O	O
to	O	O
mechanical	O	O
restriction	O	O
of	O	O
eye	O	O
movements	O	O
and	O	O
making	O	O
subsequent	O	O
enucleation	O	O
difficult	O	O
.	O	O

Subtenon	O	O
carboplatin	B-Chemical	D016190
is	O	O
not	O	O
free	O	O
of	O	O
toxicity	B-Disease	D064420
,	O	O
and	O	O
its	O	O
use	O	O
is	O	O
best	O	O
restricted	O	O
to	O	O
specific	O	O
indications	O	O
.	O	O

Ethambutol	B-Chemical	D004977
and	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
demonstrate	O	O
the	O	O
association	O	O
between	O	O
ethambutol	B-Chemical	D004977
and	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
.	O	O

METHOD	O	O
:	O	O
Thirteen	O	O
patients	O	O
who	O	O
developed	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
after	O	O
being	O	O
treated	O	O
with	O	O
ethambutol	B-Chemical	D004977
for	O	O
tuberculosis	O	O
of	O	O
the	O	O
lung	O	O
or	O	O
lymph	O	O
node	O	O
at	O	O
Siriraj	O	O
Hospital	O	O
between	O	O
1997	O	O
and	O	O
2001	O	O
were	O	O
retrospectively	O	O
reviewed	O	O
.	O	O

The	O	O
clinical	O	O
characteristics	O	O
and	O	O
initial	O	O
and	O	O
final	O	O
visual	O	O
acuity	O	O
were	O	O
analyzed	O	O
to	O	O
determine	O	O
visual	O	O
outcome	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
patients	O	O
had	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
between	O	O
1	O	O
to	O	O
6	O	O
months	O	O
(	O	O
mean	O	O
=	O	O
2	O	O
.	O	O

9	O	O
months	O	O
)	O	O
after	O	O
starting	O	O
ethambutol	B-Chemical	D004977
therapy	O	O
at	O	O
a	O	O
dosage	O	O
ranging	O	O
from	O	O
13	O	O
to	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
(	O	O
mean	O	O
=	O	O
17	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
.	O	O

Seven	O	O
(	O	O
54%	O	O
)	O	O
of	O	O
the	O	O
13	O	O
patients	O	O
experienced	O	O
visual	O	O
recovery	O	O
after	O	O
stopping	O	O
the	O	O
drug	O	O
.	O	O

Of	O	O
6	O	O
patients	O	O
with	O	O
irreversible	O	O
visual	B-Disease	D014786
impairment	I-Disease	D014786
,	O	O
4	O	O
patients	O	O
had	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
,	O	O
glaucoma	B-Disease	D005901
and	O	O
a	O	O
history	O	O
of	O	O
heavy	O	O
smoking	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Early	O	O
recognition	O	O
of	O	O
optic	B-Disease	D009901
neuropathy	I-Disease	D009901
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
ethambutol	B-Chemical	D004977
therapy	O	O
.	O	O

A	O	O
low	O	O
dose	O	O
and	O	O
prompt	O	O
discontinuation	O	O
of	O	O
the	O	O
drug	O	O
is	O	O
recommended	O	O
particularly	O	O
in	O	O
individuals	O	O
with	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
,	O	O
glaucoma	B-Disease	D005901
or	O	O
who	O	O
are	O	O
heavy	O	O
smokers	O	O
.	O	O

Treatment	O	O
of	O	O
compensatory	O	O
gustatory	B-Disease	D013547
hyperhidrosis	I-Disease	D013547
with	O	O
topical	O	O
glycopyrrolate	B-Chemical	D006024
.	O	O

Gustatory	B-Disease	D013547
hyperhidrosis	I-Disease	D013547
is	O	O
facial	O	O
sweating	B-Disease	D013547
usually	O	O
associated	O	O
with	O	O
the	O	O
eating	O	O
of	O	O
hot	O	O
spicy	O	O
food	O	O
or	O	O
even	O	O
smelling	O	O
this	O	O
food	O	O
.	O	O

Current	O	O
options	O	O
of	O	O
treatment	O	O
include	O	O
oral	O	O
anticholinergic	O	O
drugs	O	O
,	O	O
the	O	O
topical	O	O
application	O	O
of	O	O
anticholinergics	O	O
or	O	O
aluminum	B-Chemical	C010845
chloride	I-Chemical	C010845
,	O	O
and	O	O
the	O	O
injection	O	O
of	O	O
botulinum	O	O
toxin	O	O
.	O	O

Thirteen	O	O
patients	O	O
have	O	O
been	O	O
treated	O	O
to	O	O
date	O	O
with	O	O
1	O	O
.	O	O

5%	O	O
or	O	O
2%	O	O
topical	O	O
glycopyrrolate	B-Chemical	D006024
.	O	O

All	O	O
patients	O	O
had	O	O
gustatory	B-Disease	D013547
hyperhidrosis	I-Disease	D013547
,	O	O
which	O	O
interfered	O	O
with	O	O
their	O	O
social	O	O
activities	O	O
,	O	O
after	O	O
transthroacic	O	O
endoscopic	O	O
sympathectomy	O	O
,	O	O
and	O	O
which	O	O
was	O	O
associated	O	O
with	O	O
compensatory	O	O
focal	O	O
hyperhidrosis	B-Disease	D006945
.	O	O

After	O	O
applying	O	O
topical	O	O
glycopyrrolate	B-Chemical	D006024
,	O	O
the	O	O
subjective	O	O
effect	O	O
was	O	O
excellent	O	O
(	O	O
no	O	O
sweating	B-Disease	D013547
after	O	O
eating	O	O
hot	O	O
spicy	O	O
food	O	O
)	O	O
in	O	O
10	O	O
patients	O	O
(	O	O
77%	O	O
)	O	O
,	O	O
and	O	O
fair	O	O
(	O	O
clearly	O	O
reduced	O	O
sweating	B-Disease	D013547
)	O	O
in	O	O
3	O	O
patients	O	O
(	O	O
23%	O	O
)	O	O
.	O	O

All	O	O
had	O	O
reported	O	O
incidents	O	O
of	O	O
being	O	O
very	O	O
embarrassed	O	O
whilst	O	O
eating	O	O
hot	O	O
spicy	O	O
foods	O	O
.	O	O

Adverse	O	O
effects	O	O
included	O	O
a	O	O
mildly	O	O
dry	B-Disease	D014987
mouth	I-Disease	D014987
and	O	O
a	O	O
sore	B-Disease	D010612
throat	I-Disease	D010612
in	O	O
2	O	O
patients	O	O
(	O	O
2%	O	O
glycopyrrolate	B-Chemical	D006024
)	O	O
,	O	O
a	O	O
light	O	O
headache	B-Disease	D006261
in	O	O
1	O	O
patient	O	O
(	O	O
1	O	O
.	O	O

5%	O	O
glycopyrrolate	B-Chemical	D006024
)	O	O
.	O	O

The	O	O
topical	O	O
application	O	O
of	O	O
a	O	O
glycopyrrolate	B-Chemical	D006024
pad	O	O
appeared	O	O
to	O	O
be	O	O
safe	O	O
,	O	O
efficacious	O	O
,	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
a	O	O
convenient	O	O
method	O	O
of	O	O
treatment	O	O
for	O	O
moderate	O	O
to	O	O
severe	O	O
symptoms	O	O
of	O	O
gustatory	B-Disease	D013547
hyperhidrosis	I-Disease	D013547
in	O	O
post	O	O
transthoracic	O	O
endoscopic	O	O
sympathectomy	O	O
or	O	O
sympathicotomy	O	O
patients	O	O
,	O	O
with	O	O
few	O	O
side	O	O
effects	O	O
.	O	O

Pharmacological	O	O
characteristics	O	O
and	O	O
side	O	O
effects	O	O
of	O	O
a	O	O
new	O	O
galenic	O	O
formulation	O	O
of	O	O
propofol	B-Chemical	D015742
without	O	O
soyabean	O	O
oil	O	O
.	O	O

We	O	O
compared	O	O
the	O	O
pharmacokinetics	O	O
,	O	O
pharmacodynamics	O	O
and	O	O
safety	O	O
profile	O	O
of	O	O
a	O	O
new	O	O
galenic	O	O
formulation	O	O
of	O	O
propofol	B-Chemical	D015742
(	O	O
AM149	O	O
1%	O	O
)	O	O
,	O	O
which	O	O
does	O	O
not	O	O
contain	O	O
soyabean	O	O
oil	O	O
,	O	O
with	O	O
a	O	O
standard	O	O
formulation	O	O
of	O	O
propofol	B-Chemical	D015742
(	O	O
Disoprivan	B-Chemical	D015742
1%	O	O
)	O	O
.	O	O

In	O	O
a	O	O
randomised	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
cross	O	O
-	O	O
over	O	O
study	O	O
,	O	O
30	O	O
healthy	O	O
volunteers	O	O
received	O	O
a	O	O
single	O	O
intravenous	O	O
bolus	O	O
injection	O	O
of	O	O
2	O	O
.	O	O

5	O	O
mg	O	O
.	O	O

kg	O	O
-	O	O
1	O	O
propofol	B-Chemical	D015742
.	O	O

Plasma	O	O
propofol	B-Chemical	D015742
levels	O	O
were	O	O
measured	O	O
for	O	O
48	O	O
h	O	O
following	O	O
drug	O	O
administration	O	O
and	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
three	O	O
-	O	O
compartment	O	O
model	O	O
.	O	O

The	O	O
pharmacodynamic	O	O
parameters	O	O
assessed	O	O
included	O	O
induction	O	O
and	O	O
emergence	O	O
times	O	O
,	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
effects	O	O
,	O	O
and	O	O
pain	B-Disease	D010146
on	O	O
injection	O	O
.	O	O

Patients	O	O
were	O	O
monitored	O	O
for	O	O
side	O	O
effects	O	O
over	O	O
48	O	O
h	O	O
.	O	O

Owing	O	O
to	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
thrombophlebitis	B-Disease	D013924
,	O	O
the	O	O
study	O	O
was	O	O
terminated	O	O
prematurely	O	O
and	O	O
only	O	O
the	O	O
data	O	O
of	O	O
the	O	O
two	O	O
parallel	O	O
treatment	O	O
groups	O	O
(	O	O
15	O	O
patients	O	O
in	O	O
each	O	O
group	O	O
)	O	O
were	O	O
analysed	O	O
.	O	O

Plasma	O	O
concentrations	O	O
did	O	O
not	O	O
differ	O	O
significantly	O	O
between	O	O
the	O	O
two	O	O
formulations	O	O
.	O	O

Anaesthesia	O	O
induction	O	O
and	O	O
emergence	O	O
times	O	O
,	O	O
respiratory	O	O
and	O	O
cardiovascular	O	O
variables	O	O
showed	O	O
no	O	O
significant	O	O
differences	O	O
between	O	O
the	O	O
two	O	O
treatment	O	O
groups	O	O
.	O	O

Pain	B-Disease	D010146
on	O	O
injection	O	O
(	O	O
80	O	O
vs	O	O
.	O	O

20%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
and	O	O
thrombophlebitis	B-Disease	D013924
(	O	O
93	O	O
.	O	O

3	O	O
vs	O	O
.	O	O

6	O	O
.	O	O

6%	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
occurred	O	O
more	O	O
frequently	O	O
with	O	O
AM149	O	O
than	O	O
with	O	O
Disoprivan	B-Chemical	D015742
.	O	O

Although	O	O
both	O	O
formulations	O	O
had	O	O
similar	O	O
pharmacokinetic	O	O
and	O	O
pharmacodynamic	O	O
profiles	O	O
the	O	O
new	O	O
formulation	O	O
is	O	O
not	O	O
suitable	O	O
for	O	O
clinical	O	O
use	O	O
due	O	O
to	O	O
the	O	O
high	O	O
incidence	O	O
of	O	O
thrombophlebitis	B-Disease	D013924
produced	O	O
.	O	O

Vinorelbine	B-Chemical	C030852
-	O	O
related	O	O
cardiac	O	O
events	O	O
:	O	O
a	O	O
meta	O	O
-	O	O
analysis	O	O
of	O	O
randomized	O	O
clinical	O	O
trials	O	O
.	O	O

Several	O	O
cases	O	O
of	O	O
cardiac	O	O
adverse	O	O
reactions	O	O
related	O	O
to	O	O
vinorelbine	B-Chemical	C030852
(	O	O
VNR	B-Chemical	C030852
)	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

In	O	O
order	O	O
to	O	O
quantify	O	O
the	O	O
incidence	O	O
of	O	O
these	O	O
cardiac	O	O
events	O	O
,	O	O
we	O	O
performed	O	O
a	O	O
meta	O	O
-	O	O
analysis	O	O
of	O	O
clinical	O	O
trials	O	O
comparing	O	O
VNR	B-Chemical	C030852
with	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
various	O	O
malignancies	B-Disease	D009369
.	O	O

Randomized	O	O
clinical	O	O
trials	O	O
comparing	O	O
VNR	B-Chemical	C030852
with	O	O
other	O	O
drugs	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
cancer	B-Disease	D009369
were	O	O
searched	O	O
in	O	O
Medline	O	O
,	O	O
Embase	O	O
,	O	O
Evidence	O	O
-	O	O
based	O	O
Medicine	O	O
Reviews	O	O
databases	O	O
and	O	O
the	O	O
Cochrane	O	O
library	O	O
from	O	O
1987	O	O
to	O	O
2002	O	O
.	O	O

Outcomes	O	O
of	O	O
interest	O	O
were	O	O
severe	O	O
cardiac	O	O
events	O	O
,	O	O
toxic	O	O
deaths	O	O
and	O	O
cardiac	O	O
event	O	O
-	O	O
related	O	O
deaths	O	O
reported	O	O
in	O	O
each	O	O
publication	O	O
.	O	O

We	O	O
found	O	O
19	O	O
trials	O	O
,	O	O
involving	O	O
2441	O	O
patients	O	O
treated	O	O
by	O	O
VNR	B-Chemical	C030852
and	O	O
2050	O	O
control	O	O
patients	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
cardiac	O	O
events	O	O
with	O	O
VNR	B-Chemical	C030852
was	O	O
1	O	O
.	O	O

19%	O	O
[	O	O
95%	O	O
confidence	O	O
interval	O	O
(	O	O
CI	O	O
)	O	O
(	O	O
0	O	O
.	O	O

75	O	O
;	O	O
1	O	O
.	O	O

67	O	O
)	O	O
]	O	O
.	O	O

There	O	O
was	O	O
no	O	O
difference	O	O
in	O	O
the	O	O
risk	O	O
of	O	O
cardiac	O	O
events	O	O
between	O	O
VNR	B-Chemical	C030852
and	O	O
other	O	O
drugs	O	O
[	O	O
odds	O	O
ratio	O	O
:	O	O
0	O	O
.	O	O

92	O	O
,	O	O
95%	O	O
CI	O	O
(	O	O
0	O	O
.	O	O

54	O	O
;	O	O
1	O	O
.	O	O

55	O	O
)	O	O
]	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
VNR	B-Chemical	C030852
cardiac	O	O
events	O	O
was	O	O
similar	O	O
to	O	O
vindesine	B-Chemical	D014751
(	O	O
VDS	B-Chemical	D014751
)	O	O
and	O	O
other	O	O
cardiotoxic	B-Disease	D066126
drugs	O	O
[	O	O
fluorouracil	B-Chemical	D005472
,	O	O
anthracyclines	B-Chemical	D018943
,	O	O
gemcitabine	B-Chemical	C056507
(	O	O
GEM	B-Chemical	C056507
)	O	O
em	O	O
leader	O	O
]	O	O
.	O	O

Even	O	O
if	O	O
it	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
because	O	O
of	O	O
a	O	O
few	O	O
number	O	O
of	O	O
cases	O	O
,	O	O
the	O	O
risk	O	O
was	O	O
lower	O	O
in	O	O
trials	O	O
excluding	O	O
patients	O	O
with	O	O
cardiac	O	O
history	O	O
,	O	O
and	O	O
seemed	O	O
to	O	O
be	O	O
higher	O	O
in	O	O
trials	O	O
including	O	O
patients	O	O
with	O	O
pre	O	O
-	O	O
existing	O	O
cardiac	B-Disease	D006331
diseases	I-Disease	D006331
.	O	O

Vinorelbine	B-Chemical	C030852
-	O	O
related	O	O
cardiac	O	O
events	O	O
concern	O	O
about	O	O
1%	O	O
of	O	O
treated	O	O
patients	O	O
in	O	O
clinical	O	O
trials	O	O
.	O	O

However	O	O
,	O	O
the	O	O
risk	O	O
associated	O	O
with	O	O
VNR	B-Chemical	C030852
seems	O	O
to	O	O
be	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
other	O	O
chemotherapeutic	O	O
agents	O	O
in	O	O
the	O	O
same	O	O
indications	O	O
.	O	O

MRI	O	O
findings	O	O
of	O	O
hypoxic	O	O
cortical	O	O
laminar	O	O
necrosis	B-Disease	D009336
in	O	O
a	O	O
child	O	O
with	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
crisis	O	O
.	O	O

We	O	O
present	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
findings	O	O
of	O	O
a	O	O
5	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
who	O	O
had	O	O
a	O	O
rapidly	O	O
installing	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
crisis	O	O
induced	O	O
by	O	O
trimethoprim	B-Chemical	D015662
-	I-Chemical	D015662
sulfomethoxazole	I-Chemical	D015662
,	O	O
resulting	O	O
in	O	O
cerebral	B-Disease	D002534
anoxia	I-Disease	D002534
leading	O	O
to	O	O
permanent	O	O
damage	O	O
.	O	O

Magnetic	O	O
Resonance	O	O
imaging	O	O
revealed	O	O
cortical	O	O
laminar	O	O
necrosis	B-Disease	D009336
in	O	O
arterial	O	O
border	O	O
zones	O	O
in	O	O
both	O	O
cerebral	O	O
hemispheres	O	O
,	O	O
ischemic	O	O
changes	O	O
in	O	O
subcortical	O	O
white	O	O
matter	O	O
of	O	O
left	O	O
cerebral	O	O
hemisphere	O	O
,	O	O
and	O	O
in	O	O
the	O	O
left	O	O
putamen	O	O
.	O	O

Although	O	O
cortical	O	O
laminar	O	O
necrosis	B-Disease	D009336
is	O	O
a	O	O
classic	O	O
entity	O	O
in	O	O
adulthood	O	O
related	O	O
to	O	O
conditions	O	O
of	O	O
energy	O	O
depletions	O	O
,	O	O
there	O	O
are	O	O
few	O	O
reports	O	O
available	O	O
in	O	O
children	O	O
.	O	O

A	O	O
wide	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
is	O	O
also	O	O
presented	O	O
.	O	O

The	O	O
natural	O	O
history	O	O
of	O	O
Vigabatrin	B-Chemical	D020888
associated	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
defects	I-Disease	D014786
in	O	O
patients	O	O
electing	O	O
to	O	O
continue	O	O
their	O	O
medication	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
natural	O	O
history	O	O
of	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
defects	I-Disease	D014786
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
known	O	O
to	O	O
have	O	O
Vigabatrin	B-Chemical	D020888
-	O	O
associated	O	O
changes	O	O
who	O	O
elected	O	O
to	O	O
continue	O	O
the	O	O
medication	O	O
because	O	O
of	O	O
good	O	O
seizure	B-Disease	D012640
control	O	O
.	O	O

METHODS	O	O
:	O	O
All	O	O
patients	O	O
taking	O	O
Vigabatrin	B-Chemical	D020888
alone	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
other	O	O
antiepileptic	O	O
drugs	O	O
for	O	O
at	O	O
least	O	O
5	O	O
years	O	O
(	O	O
range	O	O
5	O	O
-	O	O
12	O	O
years	O	O
)	O	O
were	O	O
entered	O	O
into	O	O
a	O	O
visual	O	O
surveillance	O	O
programme	O	O
.	O	O

Patients	O	O
were	O	O
followed	O	O
up	O	O
at	O	O
6	O	O
-	O	O
monthly	O	O
intervals	O	O
for	O	O
not	O	O
less	O	O
than	O	O
18	O	O
months	O	O
(	O	O
range	O	O
18	O	O
-	O	O
43	O	O
months	O	O
)	O	O
.	O	O

In	O	O
all	O	O
,	O	O
16	O	O
patients	O	O
with	O	O
unequivocal	O	O
defects	O	O
continued	O	O
the	O	O
medication	O	O
.	O	O

Following	O	O
already	O	O
published	O	O
methodology	O	O
(	O	O
Eye	O	O
2002	O	O
;	O	O
16	O	O
;	O	O
567	O	O
-	O	O
571	O	O
)	O	O
monocular	O	O
mean	O	O
radial	O	O
degrees	O	O
(	O	O
MRDs	O	O
)	O	O
to	O	O
the	O	O
I	O	O
/	O	O
4e	O	O
isopter	O	O
on	O	O
Goldmann	O	O
perimetry	O	O
was	O	O
calculated	O	O
for	O	O
the	O	O
right	O	O
eye	O	O
at	O	O
the	O	O
time	O	O
of	O	O
discovery	O	O
of	O	O
a	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
defect	I-Disease	D014786
and	O	O
again	O	O
after	O	O
not	O	O
less	O	O
than	O	O
18	O	O
months	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

RESULTS	O	O
:	O	O
Mean	O	O
right	O	O
eye	O	O
MRD	O	O
at	O	O
presentation	O	O
was	O	O
36	O	O
.	O	O

98	O	O
degrees	O	O
(	O	O
range	O	O
22	O	O
.	O	O

25	O	O
-	O	O
51	O	O
.	O	O

0	O	O
)	O	O
,	O	O
compared	O	O
to	O	O
38	O	O
.	O	O

40	O	O
degrees	O	O
(	O	O
range	O	O
22	O	O
.	O	O

5	O	O
-	O	O
49	O	O
.	O	O

75	O	O
)	O	O
after	O	O
follow	O	O
-	O	O
up	O	O
;	O	O
P=0	O	O
.	O	O

338	O	O
unpaired	O	O
t	O	O
-	O	O
test	O	O
.	O	O

Only	O	O
one	O	O
patient	O	O
demonstrated	O	O
a	O	O
deterioration	B-Disease	D014786
in	I-Disease	D014786
visual	I-Disease	D014786
field	I-Disease	D014786
during	O	O
the	O	O
study	O	O
period	O	O
and	O	O
discontinued	O	O
treatment	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Established	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
defects	I-Disease	D014786
presumed	O	O
to	O	O
be	O	O
due	O	O
to	O	O
Vigabatrin	B-Chemical	D020888
therapy	O	O
did	O	O
not	O	O
usually	O	O
progress	O	O
in	O	O
spite	O	O
of	O	O
continuing	O	O
use	O	O
of	O	O
the	O	O
medication	O	O
.	O	O

These	O	O
data	O	O
give	O	O
support	O	O
to	O	O
the	O	O
hypothesis	O	O
that	O	O
the	O	O
pathogenesis	O	O
of	O	O
Vigabatrin	B-Chemical	D020888
-	O	O
associated	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
defects	I-Disease	D014786
may	O	O
be	O	O
an	O	O
idiosyncratic	O	O
adverse	O	O
drug	O	O
reaction	O	O
rather	O	O
than	O	O
dose	O	O
-	O	O
dependent	O	O
toxicity	B-Disease	D064420
.	O	O

Induction	O	O
of	O	O
rosaceiform	O	O
dermatitis	B-Disease	D003872
during	O	O
treatment	O	O
of	O	O
facial	B-Disease	D005148
inflammatory	I-Disease	D005148
dermatoses	I-Disease	D005148
with	O	O
tacrolimus	B-Chemical	D016559
ointment	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Tacrolimus	B-Chemical	D016559
ointment	O	O
is	O	O
increasingly	O	O
used	O	O
for	O	O
anti	O	O
-	O	O
inflammatory	O	O
treatment	O	O
of	O	O
sensitive	O	O
areas	O	O
such	O	O
as	O	O
the	O	O
face	O	O
,	O	O
and	O	O
recent	O	O
observations	O	O
indicate	O	O
that	O	O
the	O	O
treatment	O	O
is	O	O
effective	O	O
in	O	O
steroid	B-Chemical	D013256
-	O	O
aggravated	O	O
rosacea	B-Disease	D012393
and	O	O
perioral	B-Disease	D019557
dermatitis	I-Disease	D019557
.	O	O

We	O	O
report	O	O
on	O	O
rosaceiform	O	O
dermatitis	B-Disease	D003872
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B-Chemical	D016559
ointment	O	O
.	O	O

OBSERVATIONS	O	O
:	O	O
Six	O	O
adult	O	O
patients	O	O
with	O	O
inflammatory	B-Disease	D005148
facial	I-Disease	D005148
dermatoses	I-Disease	D005148
were	O	O
treated	O	O
with	O	O
tacrolimus	B-Chemical	D016559
ointment	O	O
because	O	O
of	O	O
the	O	O
ineffectiveness	O	O
of	O	O
standard	O	O
treatments	O	O
.	O	O

Within	O	O
2	O	O
to	O	O
3	O	O
weeks	O	O
of	O	O
initially	O	O
effective	O	O
and	O	O
well	O	O
-	O	O
tolerated	O	O
treatment	O	O
,	O	O
3	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
rosacea	B-Disease	D012393
and	O	O
1	O	O
with	O	O
a	O	O
history	O	O
of	O	O
acne	B-Disease	D000152
experienced	O	O
sudden	O	O
worsening	O	O
with	O	O
pustular	O	O
rosaceiform	O	O
lesions	O	O
.	O	O

Biopsy	O	O
revealed	O	O
an	O	O
abundance	O	O
of	O	O
Demodex	O	O
mites	O	O
in	O	O
2	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
with	O	O
eyelid	O	O
eczema	B-Disease	D004485
,	O	O
rosaceiform	O	O
periocular	B-Disease	D019557
dermatitis	I-Disease	D019557
gradually	O	O
appeared	O	O
after	O	O
3	O	O
weeks	O	O
of	O	O
treatment	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
with	O	O
atopic	B-Disease	D003876
dermatitis	I-Disease	D003876
,	O	O
telangiectatic	O	O
and	O	O
papular	B-Disease	D012393
rosacea	I-Disease	D012393
insidiously	O	O
appeared	O	O
after	O	O
5	O	O
months	O	O
of	O	O
treatment	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
observations	O	O
suggest	O	O
that	O	O
the	O	O
spectrum	O	O
of	O	O
rosaceiform	O	O
dermatitis	B-Disease	D003872
as	O	O
a	O	O
complication	O	O
of	O	O
treatment	O	O
with	O	O
tacrolimus	B-Chemical	D016559
ointment	O	O
is	O	O
heterogeneous	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
factors	O	O
,	O	O
such	O	O
as	O	O
vasoactive	O	O
properties	O	O
of	O	O
tacrolimus	B-Chemical	D016559
,	O	O
proliferation	O	O
of	O	O
Demodex	O	O
due	O	O
to	O	O
local	O	O
immunosuppression	O	O
,	O	O
and	O	O
the	O	O
occlusive	O	O
properties	O	O
of	O	O
the	O	O
ointment	O	O
,	O	O
may	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
observed	O	O
phenomena	O	O
.	O	O

Future	O	O
studies	O	O
are	O	O
needed	O	O
to	O	O
identify	O	O
individual	O	O
risk	O	O
factors	O	O
.	O	O

Structural	O	O
abnormalities	O	O
in	O	O
the	O	O
brains	O	O
of	O	O
human	O	O
subjects	O	O
who	O	O
use	O	O
methamphetamine	B-Chemical	D008694
.	O	O

We	O	O
visualize	O	O
,	O	O
for	O	O
the	O	O
first	O	O
time	O	O
,	O	O
the	O	O
profile	O	O
of	O	O
structural	B-Disease	D001930
deficits	I-Disease	D001930
in	I-Disease	D001930
the	I-Disease	D001930
human	I-Disease	D001930
brain	I-Disease	D001930
associated	O	O
with	O	O
chronic	O	O
methamphetamine	B-Chemical	D008694
(	O	O
MA	B-Chemical	D008694
)	O	O
abuse	O	O
.	O	O

Studies	O	O
of	O	O
human	O	O
subjects	O	O
who	O	O
have	O	O
used	O	O
MA	B-Chemical	D008694
chronically	O	O
have	O	O
revealed	O	O
deficits	O	O
in	O	O
dopaminergic	O	O
and	O	O
serotonergic	O	O
systems	O	O
and	O	O
cerebral	O	O
metabolic	B-Disease	D008659
abnormalities	I-Disease	D008659
.	O	O

Using	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
(	O	O
MRI	O	O
)	O	O
and	O	O
new	O	O
computational	O	O
brain	O	O
-	O	O
mapping	O	O
techniques	O	O
,	O	O
we	O	O
determined	O	O
the	O	O
pattern	O	O
of	O	O
structural	O	O
brain	O	O
alterations	O	O
associated	O	O
with	O	O
chronic	O	O
MA	B-Chemical	D008694
abuse	O	O
in	O	O
human	O	O
subjects	O	O
and	O	O
related	O	O
these	O	O
deficits	O	O
to	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
.	O	O

We	O	O
used	O	O
high	O	O
-	O	O
resolution	O	O
MRI	O	O
and	O	O
surface	O	O
-	O	O
based	O	O
computational	O	O
image	O	O
analyses	O	O
to	O	O
map	O	O
regional	O	O
abnormalities	B-Disease	D001930
in	I-Disease	D001930
the	I-Disease	D001930
cortex	I-Disease	D001930
,	I-Disease	D001930
hippocampus	I-Disease	D001930
,	I-Disease	D001930
white	I-Disease	D001930
matter	I-Disease	D001930
,	I-Disease	D001930
and	I-Disease	D001930
ventricles	I-Disease	D001930
in	O	O
22	O	O
human	O	O
subjects	O	O
who	O	O
used	O	O
MA	B-Chemical	D008694
and	O	O
21	O	O
age	O	O
-	O	O
matched	O	O
,	O	O
healthy	O	O
controls	O	O
.	O	O

Cortical	O	O
maps	O	O
revealed	O	O
severe	O	O
gray	O	O
-	O	O
matter	O	O
deficits	O	O
in	O	O
the	O	O
cingulate	O	O
,	O	O
limbic	O	O
,	O	O
and	O	O
paralimbic	O	O
cortices	O	O
of	O	O
MA	B-Chemical	D008694
abusers	O	O
(	O	O
averaging	O	O
11	O	O
.	O	O

3%	O	O
below	O	O
control	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

On	O	O
average	O	O
,	O	O
MA	B-Chemical	D008694
abusers	O	O
had	O	O
7	O	O
.	O	O

8%	O	O
smaller	O	O
hippocampal	O	O
volumes	O	O
than	O	O
control	O	O
subjects	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
;	O	O
left	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

01	O	O
;	O	O
right	O	O
,	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
and	O	O
significant	O	O
white	O	O
-	O	O
matter	O	O
hypertrophy	B-Disease	D006984
(	O	O
7	O	O
.	O	O

0%	O	O
;	O	O
p	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Hippocampal	O	O
deficits	O	O
were	O	O
mapped	O	O
and	O	O
correlated	O	O
with	O	O
memory	O	O
performance	O	O
on	O	O
a	O	O
word	O	O
-	O	O
recall	O	O
test	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

MRI	O	O
-	O	O
based	O	O
maps	O	O
suggest	O	O
that	O	O
chronic	O	O
methamphetamine	B-Chemical	D008694
abuse	O	O
causes	O	O
a	O	O
selective	O	O
pattern	O	O
of	O	O
cerebral	O	O
deterioration	O	O
that	O	O
contributes	O	O
to	O	O
impaired	B-Disease	D008569
memory	I-Disease	D008569
performance	I-Disease	D008569
.	O	O

MA	B-Chemical	D008694
may	O	O
selectively	O	O
damage	O	O
the	O	O
medial	O	O
temporal	O	O
lobe	O	O
and	O	O
,	O	O
consistent	O	O
with	O	O
metabolic	O	O
studies	O	O
,	O	O
the	O	O
cingulate	O	O
-	O	O
limbic	O	O
cortex	O	O
,	O	O
inducing	O	O
neuroadaptation	O	O
,	O	O
neuropil	O	O
reduction	O	O
,	O	O
or	O	O
cell	O	O
death	O	O
.	O	O

Prominent	O	O
white	O	O
-	O	O
matter	O	O
hypertrophy	B-Disease	D006984
may	O	O
result	O	O
from	O	O
altered	O	O
myelination	O	O
and	O	O
adaptive	O	O
glial	O	O
changes	O	O
,	O	O
including	O	O
gliosis	B-Disease	D005911
secondary	O	O
to	O	O
neuronal	B-Disease	D009422
damage	I-Disease	D009422
.	O	O

These	O	O
brain	O	O
substrates	O	O
may	O	O
help	O	O
account	O	O
for	O	O
the	O	O
symptoms	O	O
of	O	O
MA	B-Chemical	D008694
abuse	O	O
,	O	O
providing	O	O
therapeutic	O	O
targets	O	O
for	O	O
drug	O	O
-	O	O
induced	O	O
brain	B-Disease	D001930
injury	I-Disease	D001930
.	O	O

Disruption	O	O
of	O	O
hepatic	O	O
lipid	O	O
homeostasis	O	O
in	O	O
mice	O	O
after	O	O
amiodarone	B-Chemical	D000638
treatment	O	O
is	O	O
associated	O	O
with	O	O
peroxisome	O	O
proliferator	O	O
-	O	O
activated	O	O
receptor	O	O
-	O	O
alpha	O	O
target	O	O
gene	O	O
activation	O	O
.	O	O

Amiodarone	B-Chemical	D000638
,	O	O
an	O	O
efficacious	O	O
and	O	O
widely	O	O
used	O	O
antiarrhythmic	O	O
agent	O	O
,	O	O
has	O	O
been	O	O
reported	O	O
to	O	O
cause	O	O
hepatotoxicity	B-Disease	D056486
in	O	O
some	O	O
patients	O	O
.	O	O

To	O	O
gain	O	O
insight	O	O
into	O	O
the	O	O
mechanism	O	O
of	O	O
this	O	O
unwanted	O	O
effect	O	O
,	O	O
mice	O	O
were	O	O
administered	O	O
various	O	O
doses	O	O
of	O	O
amiodarone	B-Chemical	D000638
and	O	O
examined	O	O
for	O	O
changes	O	O
in	O	O
hepatic	O	O
histology	O	O
and	O	O
gene	O	O
regulation	O	O
.	O	O

Amiodarone	B-Chemical	D000638
induced	O	O
hepatomegaly	B-Disease	D006529
,	O	O
hepatocyte	O	O
microvesicular	O	O
lipid	O	O
accumulation	O	O
,	O	O
and	O	O
a	O	O
significant	O	O
decrease	O	O
in	O	O
serum	O	O
triglycerides	B-Chemical	D014280
and	O	O
glucose	B-Chemical	D005947
.	O	O

Northern	O	O
blot	O	O
analysis	O	O
of	O	O
hepatic	O	O
RNA	O	O
revealed	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
increase	O	O
in	O	O
the	O	O
expression	O	O
of	O	O
a	O	O
number	O	O
of	O	O
genes	O	O
critical	O	O
for	O	O
fatty	B-Chemical	D005227
acid	I-Chemical	D005227
oxidation	O	O
,	O	O
lipoprotein	O	O
assembly	O	O
,	O	O
and	O	O
lipid	O	O
transport	O	O
.	O	O

Many	O	O
of	O	O
these	O	O
genes	O	O
are	O	O
regulated	O	O
by	O	O
the	O	O
peroxisome	O	O
proliferator	O	O
-	O	O
activated	O	O
receptor	O	O
-	O	O
alpha	O	O
(	O	O
PPARalpha	O	O
)	O	O
,	O	O
a	O	O
ligand	O	O
-	O	O
activated	O	O
nuclear	O	O
hormone	O	O
receptor	O	O
transcription	O	O
factor	O	O
.	O	O

The	O	O
absence	O	O
of	O	O
induction	O	O
of	O	O
these	O	O
genes	O	O
as	O	O
well	O	O
as	O	O
hepatomegaly	B-Disease	D006529
in	O	O
PPARalpha	O	O
knockout	O	O
[	O	O
PPARalpha	O	O
-	O	O
/	O	O
-	O	O
]	O	O
mice	O	O
indicated	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
amiodarone	B-Chemical	D000638
were	O	O
dependent	O	O
upon	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
functional	O	O
PPARalpha	O	O
gene	O	O
.	O	O

Compared	O	O
to	O	O
wild	O	O
-	O	O
type	O	O
mice	O	O
,	O	O
treatment	O	O
of	O	O
PPARalpha	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
with	O	O
amiodarone	B-Chemical	D000638
resulted	O	O
in	O	O
an	O	O
increased	O	O
rate	O	O
and	O	O
extent	O	O
of	O	O
total	O	O
body	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
.	O	O

The	O	O
inability	O	O
of	O	O
amiodarone	B-Chemical	D000638
to	O	O
directly	O	O
activate	O	O
either	O	O
human	O	O
or	O	O
mouse	O	O
PPARalpha	O	O
transiently	O	O
expressed	O	O
in	O	O
human	O	O
HepG2	O	O
hepatoma	B-Disease	D006528
cells	O	O
indicates	O	O
that	O	O
the	O	O
effects	O	O
of	O	O
amiodarone	B-Chemical	D000638
on	O	O
the	O	O
function	O	O
of	O	O
this	O	O
receptor	O	O
were	O	O
indirect	O	O
.	O	O

Based	O	O
upon	O	O
these	O	O
results	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
amiodarone	B-Chemical	D000638
disrupts	O	O
hepatic	O	O
lipid	O	O
homeostasis	O	O
and	O	O
that	O	O
the	O	O
increased	O	O
expression	O	O
of	O	O
PPARalpha	O	O
target	O	O
genes	O	O
is	O	O
secondary	O	O
to	O	O
this	O	O
toxic	O	O
effect	O	O
.	O	O

These	O	O
results	O	O
provide	O	O
important	O	O
new	O	O
mechanistic	O	O
information	O	O
regarding	O	O
the	O	O
hepatotoxic	B-Disease	D056486
effects	O	O
of	O	O
amiodarone	B-Chemical	D000638
and	O	O
indicate	O	O
that	O	O
PPARalpha	O	O
protects	O	O
against	O	O
amiodarone	B-Chemical	D000638
-	O	O
induced	O	O
hepatotoxicity	B-Disease	D056486
.	O	O

Safety	O	O
and	O	O
compliance	O	O
with	O	O
once	O	O
-	O	O
daily	O	O
niacin	B-Chemical	C451780
extended	I-Chemical	C451780
-	I-Chemical	C451780
release	I-Chemical	C451780
/	I-Chemical	C451780
lovastatin	I-Chemical	C451780
as	O	O
initial	O	O
therapy	O	O
in	O	O
the	O	O
Impact	O	O
of	O	O
Medical	O	O
Subspecialty	O	O
on	O	O
Patient	O	O
Compliance	O	O
to	O	O
Treatment	O	O
(	O	O
IMPACT	O	O
)	O	O
study	O	O
.	O	O

Niacin	B-Chemical	C451780
extended	I-Chemical	C451780
-	I-Chemical	C451780
release	I-Chemical	C451780
/	I-Chemical	C451780
lovastatin	I-Chemical	C451780
is	O	O
a	O	O
new	O	O
combination	O	O
product	O	O
approved	O	O
for	O	O
treatment	O	O
of	O	O
primary	O	O
hypercholesterolemia	B-Disease	D006937
and	O	O
mixed	O	O
dyslipidemia	B-Disease	D050171
.	O	O

This	O	O
open	O	O
-	O	O
labeled	O	O
,	O	O
multicenter	O	O
study	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
bedtime	O	O
niacin	B-Chemical	C451780
extended	I-Chemical	C451780
-	I-Chemical	C451780
release	I-Chemical	C451780
/	I-Chemical	C451780
lovastatin	I-Chemical	C451780
when	O	O
dosed	O	O
as	O	O
initial	O	O
therapy	O	O
and	O	O
patient	O	O
compliance	O	O
to	O	O
treatment	O	O
in	O	O
various	O	O
clinical	O	O
practice	O	O
settings	O	O
.	O	O

A	O	O
total	O	O
of	O	O
4	O	O
,	O	O
499	O	O
patients	O	O
with	O	O
dyslipidemia	B-Disease	D050171
requiring	O	O
drug	O	O
intervention	O	O
was	O	O
enrolled	O	O
at	O	O
1	O	O
,	O	O
081	O	O
sites	O	O
.	O	O

Patients	O	O
were	O	O
treated	O	O
with	O	O
1	O	O
tablet	O	O
(	O	O
500	O	O
mg	O	O
of	O	O
niacin	B-Chemical	D009525
extended	O	O
-	O	O
release	O	O
/	O	O
20	O	O
mg	O	O
of	O	O
lovastatin	B-Chemical	D008148
)	O	O
once	O	O
nightly	O	O
for	O	O
4	O	O
weeks	O	O
and	O	O
then	O	O
2	O	O
tablets	O	O
for	O	O
8	O	O
weeks	O	O
.	O	O

Patients	O	O
also	O	O
received	O	O
dietary	O	O
counseling	O	O
,	O	O
educational	O	O
materials	O	O
,	O	O
and	O	O
reminders	O	O
to	O	O
call	O	O
a	O	O
toll	O	O
-	O	O
free	O	O
number	O	O
that	O	O
provided	O	O
further	O	O
education	O	O
about	O	O
dyslipidemia	B-Disease	D050171
and	O	O
niacin	B-Chemical	C451780
extended	I-Chemical	C451780
-	I-Chemical	C451780
release	I-Chemical	C451780
/	I-Chemical	C451780
lovastatin	I-Chemical	C451780
.	O	O

Primary	O	O
end	O	O
points	O	O
were	O	O
study	O	O
compliance	O	O
,	O	O
increases	O	O
in	O	O
liver	O	O
transaminases	O	O
to	O	O
>3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
,	O	O
and	O	O
clinical	O	O
myopathy	B-Disease	D009135
.	O	O

Final	O	O
study	O	O
status	O	O
was	O	O
available	O	O
for	O	O
4	O	O
,	O	O
217	O	O
patients	O	O
(	O	O
94%	O	O
)	O	O
.	O	O

Compliance	O	O
to	O	O
niacin	B-Chemical	C451780
extended	I-Chemical	C451780
-	I-Chemical	C451780
release	I-Chemical	C451780
/	I-Chemical	C451780
lovastatin	I-Chemical	C451780
was	O	O
77%	O	O
,	O	O
with	O	O
3	O	O
,	O	O
245	O	O
patients	O	O
completing	O	O
the	O	O
study	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
southeast	O	O
and	O	O
those	O	O
enrolled	O	O
by	O	O
endocrinologists	O	O
had	O	O
the	O	O
lowest	O	O
compliance	O	O
and	O	O
highest	O	O
adverse	O	O
event	O	O
rates	O	O
.	O	O

Flushing	B-Disease	D005483
was	O	O
the	O	O
most	O	O
common	O	O
adverse	O	O
event	O	O
,	O	O
reported	O	O
by	O	O
18%	O	O
of	O	O
patients	O	O
and	O	O
leading	O	O
to	O	O
discontinuation	O	O
by	O	O
6%	O	O
.	O	O

Incidence	O	O
of	O	O
increased	O	O
aspartate	B-Chemical	D001224
aminotransferase	O	O
and	O	O
/	O	O
or	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
>3	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
was	O	O
<0	O	O
.	O	O

3%	O	O
.	O	O

An	O	O
increase	O	O
of	O	O
creatine	B-Chemical	D003401
phosphokinase	O	O
to	O	O
>5	O	O
times	O	O
the	O	O
upper	O	O
limit	O	O
of	O	O
normal	O	O
occurred	O	O
in	O	O
0	O	O
.	O	O

24%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
no	O	O
cases	O	O
of	O	O
drug	O	O
-	O	O
induced	O	O
myopathy	B-Disease	D009135
were	O	O
observed	O	O
.	O	O

Niacin	B-Chemical	C451780
extended	I-Chemical	C451780
-	I-Chemical	C451780
release	I-Chemical	C451780
/	I-Chemical	C451780
lovastatin	I-Chemical	C451780
1	O	O
,	O	O
000	O	O
/	O	O
40	O	O
mg	O	O
,	O	O
dosed	O	O
as	O	O
initial	O	O
therapy	O	O
,	O	O
was	O	O
associated	O	O
with	O	O
good	O	O
compliance	O	O
and	O	O
safety	O	O
and	O	O
had	O	O
very	O	O
low	O	O
incidences	O	O
of	O	O
increased	O	O
liver	O	O
and	O	O
muscle	O	O
enzymes	O	O
.	O	O

Protective	O	O
effect	O	O
of	O	O
Terminalia	B-Chemical	D010936
chebula	I-Chemical	D010936
against	O	O
experimental	O	O
myocardial	B-Disease	D009202
injury	I-Disease	D009202
induced	O	O
by	O	O
isoproterenol	B-Chemical	D007545
.	O	O

Cardioprotective	O	O
effect	O	O
of	O	O
ethanolic	B-Chemical	D010936
extract	I-Chemical	D010936
of	I-Chemical	D010936
Terminalia	I-Chemical	D010936
chebula	I-Chemical	D010936
fruits	I-Chemical	D010936
(	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
)	O	O
was	O	O
examined	O	O
in	O	O
isoproterenol	B-Chemical	D007545
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
body	O	O
wt	O	O
)	O	O
induced	O	O
myocardial	B-Disease	D009202
damage	I-Disease	D009202
in	O	O
rats	O	O
.	O	O

In	O	O
isoproterenol	B-Chemical	D007545
administered	O	O
rats	O	O
,	O	O
the	O	O
level	O	O
of	O	O
lipid	O	O
peroxides	B-Chemical	D010545
increased	O	O
significantly	O	O
in	O	O
the	O	O
serum	O	O
and	O	O
heart	O	O
.	O	O

A	O	O
significant	O	O
decrease	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
activity	O	O
of	O	O
the	O	O
myocardial	O	O
marker	O	O
enzymes	O	O
with	O	O
a	O	O
concomitant	O	O
increase	O	O
in	O	O
their	O	O
activity	O	O
in	O	O
serum	O	O
.	O	O

Histopathological	O	O
examination	O	O
was	O	O
carried	O	O
out	O	O
to	O	O
confirm	O	O
the	O	O
myocardial	O	O
necrosis	B-Disease	D009336
.	O	O

T	B-Chemical	D010936
.	I-Chemical	D010936

chebula	I-Chemical	D010936
extract	I-Chemical	D010936
pretreatment	O	O
was	O	O
found	O	O
to	O	O
ameliorate	O	O
the	O	O
effect	O	O
of	O	O
isoproterenol	B-Chemical	D007545
on	O	O
lipid	O	O
peroxide	B-Chemical	D010545
formation	O	O
and	O	O
retained	O	O
the	O	O
activities	O	O
of	O	O
the	O	O
diagnostic	O	O
marker	O	O
enzymes	O	O
.	O	O

A	O	O
case	O	O
of	O	O
postoperative	O	O
anxiety	B-Disease	D001008
due	O	O
to	O	O
low	O	O
dose	O	O
droperidol	B-Chemical	D004329
used	O	O
with	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
.	O	O

A	O	O
multiparous	O	O
woman	O	O
in	O	O
good	O	O
psychological	O	O
health	O	O
underwent	O	O
urgent	O	O
caesarean	O	O
section	O	O
in	O	O
labour	O	O
.	O	O

Postoperatively	O	O
,	O	O
she	O	O
was	O	O
given	O	O
a	O	O
patient	O	O
-	O	O
controlled	O	O
analgesia	O	O
device	O	O
delivering	O	O
boluses	O	O
of	O	O
diamorphine	B-Chemical	D003932
0	O	O
.	O	O

5	O	O
mg	O	O
and	O	O
droperidol	B-Chemical	D004329
0	O	O
.	O	O

025	O	O
mg	O	O
.	O	O

Whilst	O	O
using	O	O
the	O	O
device	O	O
she	O	O
gradually	O	O
became	O	O
anxious	O	O
,	O	O
the	O	O
feeling	O	O
worsening	O	O
after	O	O
each	O	O
bolus	O	O
.	O	O

The	O	O
diagnosis	O	O
of	O	O
droperidol	B-Chemical	D004329
-	O	O
induced	O	O
psychological	B-Disease	D001008
disturbance	I-Disease	D001008
was	O	O
not	O	O
made	O	O
straight	O	O
away	O	O
although	O	O
on	O	O
subsequent	O	O
close	O	O
questioning	O	O
the	O	O
patient	O	O
gave	O	O
a	O	O
very	O	O
clear	O	O
history	O	O
.	O	O

After	O	O
she	O	O
had	O	O
received	O	O
a	O	O
total	O	O
of	O	O
only	O	O
0	O	O
.	O	O

9	O	O
mg	O	O
droperidol	B-Chemical	D004329
,	O	O
a	O	O
syringe	O	O
containing	O	O
diamorphine	B-Chemical	D003932
only	O	O
was	O	O
substituted	O	O
and	O	O
her	O	O
unease	O	O
resolved	O	O
completely	O	O
.	O	O

We	O	O
feel	O	O
that	O	O
,	O	O
although	O	O
the	O	O
dramatic	O	O
extrapyramidal	O	O
side	O	O
effects	O	O
of	O	O
dopaminergic	O	O
antiemetics	O	O
are	O	O
well	O	O
known	O	O
,	O	O
more	O	O
subtle	O	O
manifestations	O	O
may	O	O
easily	O	O
be	O	O
overlooked	O	O
.	O	O

Accurate	O	O
patient	O	O
history	O	O
contributes	O	O
to	O	O
differentiating	O	O
diabetes	B-Disease	D003919
insipidus	I-Disease	D003919
:	O	O
a	O	O
case	O	O
study	O	O
.	O	O

This	O	O
case	O	O
study	O	O
highlights	O	O
the	O	O
important	O	O
contribution	O	O
of	O	O
nursing	O	O
in	O	O
obtaining	O	O
an	O	O
accurate	O	O
health	O	O
history	O	O
.	O	O

The	O	O
case	O	O
discussed	O	O
herein	O	O
initially	O	O
appeared	O	O
to	O	O
be	O	O
neurogenic	B-Disease	D018500
diabetes	I-Disease	D018500
insipidus	I-Disease	D018500
(	O	O
DI	B-Disease	D003919
)	O	O
secondary	O	O
to	O	O
a	O	O
traumatic	B-Disease	D001930
brain	I-Disease	D001930
injury	I-Disease	D001930
.	O	O

The	O	O
nursing	O	O
staff	O	O
,	O	O
by	O	O
reviewing	O	O
the	O	O
patient's	O	O
health	O	O
history	O	O
with	O	O
his	O	O
family	O	O
,	O	O
discovered	O	O
a	O	O
history	O	O
of	O	O
polydipsia	B-Disease	D059606
and	O	O
long	O	O
-	O	O
standing	O	O
lithium	B-Chemical	D008094
use	O	O
.	O	O

Lithium	B-Chemical	D008094
is	O	O
implicated	O	O
in	O	O
drug	O	O
-	O	O
induced	O	O
nephrogenic	B-Disease	D018500
DI	I-Disease	D018500
,	O	O
and	O	O
because	O	O
the	O	O
patient	O	O
had	O	O
not	O	O
received	O	O
lithium	B-Chemical	D008094
since	O	O
being	O	O
admitted	O	O
to	O	O
the	O	O
hospital	O	O
,	O	O
his	O	O
treatment	O	O
changed	O	O
to	O	O
focus	O	O
on	O	O
nephrogenic	B-Disease	D018500
DI	I-Disease	D018500
.	O	O

By	O	O
combining	O	O
information	O	O
from	O	O
the	O	O
patient	O	O
history	O	O
,	O	O
the	O	O
physical	O	O
examination	O	O
,	O	O
and	O	O
radiologic	O	O
and	O	O
laboratory	O	O
studies	O	O
,	O	O
the	O	O
critical	O	O
care	O	O
team	O	O
demonstrated	O	O
that	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
self	O	O
-	O	O
treating	O	O
his	O	O
lithium	B-Chemical	D008094
-	O	O
induced	O	O
nephrogenic	B-Disease	D018500
DI	I-Disease	D018500
and	O	O
developed	O	O
neurogenic	B-Disease	D018500
DI	I-Disease	D018500
secondary	O	O
to	O	O
brain	B-Disease	D001930
trauma	I-Disease	D001930
.	O	O

Thus	O	O
successful	O	O
treatment	O	O
required	O	O
that	O	O
nephrogenic	O	O
and	O	O
neurogenic	B-Disease	D018500
DI	I-Disease	D018500
be	O	O
treated	O	O
concomitantly	O	O
.	O	O

Factors	O	O
contributing	O	O
to	O	O
ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
anemia	B-Disease	D000740
.	O	O

BACKGROUND	O	O
AND	O	O
AIM	O	O
:	O	O
Interferon	B-Chemical	D016898
and	O	O
ribavirin	B-Chemical	D012254
combination	O	O
therapy	O	O
for	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
produces	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
.	O	O

This	O	O
study	O	O
was	O	O
conducted	O	O
to	O	O
identify	O	O
the	O	O
factors	O	O
contributing	O	O
to	O	O
ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
anemia	B-Disease	D000740
.	O	O

METHODS	O	O
:	O	O
Eighty	O	O
-	O	O
eight	O	O
patients	O	O
with	O	O
chronic	B-Disease	D019698
hepatitis	I-Disease	D019698
C	I-Disease	D019698
who	O	O
received	O	O
interferon	B-Chemical	D016898
-	I-Chemical	D016898
alpha	I-Chemical	D016898
-	I-Chemical	D016898
2b	I-Chemical	D016898
at	O	O
a	O	O
dose	O	O
of	O	O
6	O	O
MU	O	O
administered	O	O
intramuscularly	O	O
for	O	O
24	O	O
weeks	O	O
in	O	O
combination	O	O
with	O	O
ribavirin	B-Chemical	D012254
administered	O	O
orally	O	O
at	O	O
a	O	O
dose	O	O
of	O	O
600	O	O
mg	O	O
or	O	O
800	O	O
mg	O	O
participated	O	O
in	O	O
the	O	O
study	O	O
.	O	O

A	O	O
hemoglobin	O	O
concentration	O	O
of	O	O
<10	O	O
g	O	O
/	O	O
dL	O	O
was	O	O
defined	O	O
as	O	O
ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
anemia	B-Disease	D000740
.	O	O

RESULTS	O	O
:	O	O
Ribavirin	B-Chemical	D012254
-	O	O
induced	O	O
anemia	B-Disease	D000740
occurred	O	O
in	O	O
18	O	O
(	O	O
20	O	O
.	O	O

5%	O	O
)	O	O
patients	O	O
during	O	O
treatment	O	O
.	O	O

A	O	O
2	O	O
g	O	O
/	O	O
dL	O	O
decrease	O	O
in	O	O
hemoglobin	O	O
concentrations	O	O
in	O	O
patients	O	O
with	O	O
anemia	B-Disease	D000740
was	O	O
observed	O	O
at	O	O
week	O	O
2	O	O
after	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
.	O	O

The	O	O
hemoglobin	O	O
concentration	O	O
in	O	O
patients	O	O
with	O	O
>	O	O
or	O	O
=2	O	O
g	O	O
/	O	O
dL	O	O
decrease	O	O
at	O	O
week	O	O
2	O	O
was	O	O
observed	O	O
to	O	O
be	O	O
significantly	O	O
lower	O	O
even	O	O
after	O	O
week	O	O
2	O	O
than	O	O
in	O	O
patients	O	O
with	O	O
<2	O	O
g	O	O
/	O	O
dL	O	O
decrease	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

A	O	O
significant	O	O
relationship	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
rate	O	O
of	O	O
reduction	O	O
of	O	O
hemoglobin	O	O
concentrations	O	O
at	O	O
week	O	O
2	O	O
and	O	O
the	O	O
severity	O	O
of	O	O
anemia	B-Disease	D000740
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Such	O	O
factors	O	O
as	O	O
sex	O	O
(	O	O
female	O	O
)	O	O
,	O	O
age	O	O
(	O	O
>	O	O
or	O	O
=60	O	O
years	O	O
old	O	O
)	O	O
,	O	O
and	O	O
the	O	O
ribavirin	B-Chemical	D012254
dose	O	O
by	O	O
body	O	O
weight	O	O
(	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
or	O	O
more	O	O
)	O	O
were	O	O
significant	O	O
by	O	O
univariate	O	O
analysis	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Careful	O	O
administration	O	O
is	O	O
necessary	O	O
in	O	O
patients	O	O
>	O	O
or	O	O
=60	O	O
years	O	O
old	O	O
,	O	O
in	O	O
female	O	O
patients	O	O
,	O	O
and	O	O
in	O	O
patients	O	O
receiving	O	O
a	O	O
ribavirin	B-Chemical	D012254
dose	O	O
of	O	O
12	O	O
mg	O	O
/	O	O
kg	O	O
or	O	O
more	O	O
.	O	O

Patients	O	O
who	O	O
experience	O	O
a	O	O
fall	O	O
in	O	O
hemoglobin	O	O
concentrations	O	O
of	O	O
2	O	O
g	O	O
/	O	O
dL	O	O
or	O	O
more	O	O
at	O	O
week	O	O
2	O	O
after	O	O
the	O	O
start	O	O
of	O	O
treatment	O	O
should	O	O
be	O	O
monitored	O	O
with	O	O
particular	O	O
care	O	O
.	O	O

Oxidative	O	O
damage	O	O
precedes	O	O
nitrative	O	O
damage	O	O
in	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
cardiac	O	O
mitochondrial	B-Disease	D028361
injury	I-Disease	D028361
.	O	O

The	O	O
purpose	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
if	O	O
elevated	O	O
reactive	O	O
oxygen	B-Chemical	D010100
(	O	O
ROS	O	O
)	O	O
/	O	O
nitrogen	B-Chemical	D009584
species	O	O
(	O	O
RNS	O	O
)	O	O
reported	O	O
to	O	O
be	O	O
present	O	O
in	O	O
adriamycin	B-Chemical	D004317
(	O	O
ADR	B-Chemical	D004317
)	O	O
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
actually	O	O
resulted	O	O
in	O	O
cardiomyocyte	O	O
oxidative	O	O
/	O	O
nitrative	O	O
damage	O	O
,	O	O
and	O	O
to	O	O
quantitatively	O	O
determine	O	O
the	O	O
time	O	O
course	O	O
and	O	O
subcellular	O	O
localization	O	O
of	O	O
these	O	O
postulated	O	O
damage	O	O
products	O	O
using	O	O
an	O	O
in	O	O
vivo	O	O
approach	O	O
.	O	O

B6C3	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
ADR	B-Chemical	D004317
.	O	O

Ultrastructural	O	O
damage	O	O
and	O	O
levels	O	O
of	O	O
4	B-Chemical	C027576
-	I-Chemical	C027576
hydroxy	I-Chemical	C027576
-	I-Chemical	C027576
2	I-Chemical	C027576
-	I-Chemical	C027576
nonenal	I-Chemical	C027576
(	O	O
4HNE	B-Chemical	C027576
)	O	O
-	O	O
protein	O	O
adducts	O	O
and	O	O
3	B-Chemical	C002744
-	I-Chemical	C002744
nitrotyrosine	I-Chemical	C002744
(	O	O
3NT	B-Chemical	C002744
)	O	O
were	O	O
analyzed	O	O
.	O	O

Quantitative	O	O
ultrastructural	O	O
damage	O	O
using	O	O
computerized	O	O
image	O	O
techniques	O	O
showed	O	O
cardiomyocyte	O	O
injury	O	O
as	O	O
early	O	O
as	O	O
3	O	O
hours	O	O
,	O	O
with	O	O
mitochondria	O	O
being	O	O
the	O	O
most	O	O
extensively	O	O
and	O	O
progressively	O	O
injured	O	O
subcellular	O	O
organelle	O	O
.	O	O

Analysis	O	O
of	O	O
4HNE	B-Chemical	C027576
protein	O	O
adducts	O	O
by	O	O
immunogold	O	O
electron	O	O
microscopy	O	O
showed	O	O
appearance	O	O
of	O	O
4HNE	B-Chemical	C027576
protein	O	O
adducts	O	O
in	O	O
mitochondria	O	O
as	O	O
early	O	O
as	O	O
3	O	O
hours	O	O
,	O	O
with	O	O
a	O	O
peak	O	O
at	O	O
6	O	O
hours	O	O
and	O	O
subsequent	O	O
decline	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

3NT	B-Chemical	C002744
levels	O	O
were	O	O
significantly	O	O
increased	O	O
in	O	O
all	O	O
subcellular	O	O
compartments	O	O
at	O	O
6	O	O
hours	O	O
and	O	O
subsequently	O	O
declined	O	O
at	O	O
24	O	O
hours	O	O
.	O	O

Our	O	O
data	O	O
showed	O	O
ADR	B-Chemical	D004317
induced	O	O
4HNE	B-Chemical	C027576
-	O	O
protein	O	O
adducts	O	O
in	O	O
mitochondria	O	O
at	O	O
the	O	O
same	O	O
time	O	O
point	O	O
as	O	O
when	O	O
mitochondrial	B-Disease	D028361
injury	I-Disease	D028361
initially	O	O
appeared	O	O
.	O	O

These	O	O
results	O	O
document	O	O
for	O	O
the	O	O
first	O	O
time	O	O
in	O	O
vivo	O	O
that	O	O
mitochondrial	B-Disease	D028361
oxidative	I-Disease	D028361
damage	I-Disease	D028361
precedes	O	O
nitrative	O	O
damage	O	O
.	O	O

The	O	O
progressive	O	O
nature	O	O
of	O	O
mitochondrial	B-Disease	D028361
injury	I-Disease	D028361
suggests	O	O
that	O	O
mitochondria	O	O
,	O	O
not	O	O
other	O	O
subcellular	O	O
organelles	O	O
,	O	O
are	O	O
the	O	O
major	O	O
site	O	O
of	O	O
intracellular	O	O
injury	O	O
.	O	O

Sotalol	B-Chemical	D013015
-	O	O
induced	O	O
coronary	B-Disease	D003329
spasm	I-Disease	D003329
in	O	O
a	O	O
patient	O	O
with	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
associated	O	O
with	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
.	O	O

A	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
severe	O	O
left	O	O
ventricular	B-Disease	D018754
dysfunction	I-Disease	D018754
due	O	O
to	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
was	O	O
referred	O	O
to	O	O
our	O	O
hospital	O	O
for	O	O
symptomatic	O	O
incessant	O	O
sustained	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
(	O	O
VT	B-Disease	D017180
)	O	O
.	O	O

After	O	O
the	O	O
administration	O	O
of	O	O
nifekalant	B-Chemical	C076259
hydrochloride	I-Chemical	C076259
,	O	O
sustained	O	O
VT	B-Disease	D017180
was	O	O
terminated	O	O
.	O	O

An	O	O
alternate	O	O
class	O	O
III	O	O
agent	O	O
,	O	O
sotalol	B-Chemical	D013015
,	O	O
was	O	O
also	O	O
effective	O	O
for	O	O
the	O	O
prevention	O	O
of	O	O
VT	B-Disease	D017180
.	O	O

However	O	O
,	O	O
one	O	O
month	O	O
after	O	O
switching	O	O
over	O	O
nifekalant	B-Chemical	C076259
to	O	O
sotalol	B-Chemical	D013015
,	O	O
a	O	O
short	O	O
duration	O	O
of	O	O
ST	O	O
elevation	O	O
was	O	O
documented	O	O
in	O	O
ECG	O	O
monitoring	O	O
at	O	O
almost	O	O
the	O	O
same	O	O
time	O	O
for	O	O
three	O	O
consecutive	O	O
days	O	O
.	O	O

ST	O	O
elevation	O	O
with	O	O
chest	O	O
discomfort	O	O
disappeared	O	O
since	O	O
he	O	O
began	O	O
taking	O	O
long	O	O
-	O	O
acting	O	O
diltiazem	B-Chemical	D004110
.	O	O

Coronary	B-Disease	D003329
vasospasm	I-Disease	D003329
may	O	O
be	O	O
induced	O	O
by	O	O
the	O	O
non	O	O
-	O	O
selective	O	O
beta	O	O
-	O	O
blocking	O	O
properties	O	O
of	O	O
sotalol	B-Chemical	D013015
.	O	O

Effects	O	O
of	O	O
the	O	O
antidepressant	O	O
trazodone	B-Chemical	D014196
,	O	O
a	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2A	O	O
/	O	O
2C	O	O
receptor	O	O
antagonist	O	O
,	O	O
on	O	O
dopamine	B-Chemical	D004298
-	O	O
dependent	O	O
behaviors	O	O
in	O	O
rats	O	O
.	O	O

RATIONALE	O	O
:	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
Hydroxytryptamine	I-Chemical	D012701
,	O	O
via	O	O
stimulation	O	O
of	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2C	O	O
receptors	O	O
,	O	O
exerts	O	O
a	O	O
tonic	O	O
inhibitory	O	O
influence	O	O
on	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
whereas	O	O
activation	O	O
of	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2A	O	O
receptors	O	O
enhances	O	O
stimulated	O	O
DAergic	O	O
neurotransmission	O	O
.	O	O

The	O	O
antidepressant	O	O
trazodone	B-Chemical	D014196
is	O	O
a	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2A	O	O
/	O	O
2C	O	O
receptor	O	O
antagonist	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
effect	O	O
of	O	O
trazodone	B-Chemical	D014196
treatment	O	O
on	O	O
behaviors	O	O
dependent	O	O
on	O	O
the	O	O
functional	O	O
status	O	O
of	O	O
the	O	O
nigrostriatal	O	O
DAergic	O	O
system	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
effect	O	O
of	O	O
pretreatment	O	O
with	O	O
trazodone	B-Chemical	D014196
on	O	O
dexamphetamine	B-Chemical	D003913
-	O	O
and	O	O
apomorphine	B-Chemical	D001058
-	O	O
induced	O	O
oral	B-Disease	D009062
stereotypies	I-Disease	D009062
,	O	O
on	O	O
catalepsy	B-Disease	D002375
induced	O	O
by	O	O
haloperidol	B-Chemical	D006220
and	O	O
apomorphine	B-Chemical	D001058
(	O	O
0	O	O
.	O	O

05	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
,	O	O
on	O	O
ergometrine	B-Chemical	D004874
-	O	O
induced	O	O
wet	O	O
dog	O	O
shake	O	O
(	O	O
WDS	O	O
)	O	O
behavior	O	O
and	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
penile	O	O
erections	O	O
was	O	O
studied	O	O
in	O	O
rats	O	O
.	O	O

We	O	O
also	O	O
investigated	O	O
whether	O	O
trazodone	B-Chemical	D014196
induces	O	O
catalepsy	B-Disease	D002375
in	O	O
rats	O	O
.	O	O

RESULTS	O	O
:	O	O
Trazodone	B-Chemical	D014196
at	O	O
2	O	O
.	O	O

5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

did	O	O
not	O	O
induce	O	O
catalepsy	B-Disease	D002375
,	O	O
and	O	O
did	O	O
not	O	O
antagonize	O	O
apomorphine	B-Chemical	D001058
(	O	O
1	O	O
.	O	O

5	O	O
and	O	O
3	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
stereotypy	O	O
and	O	O
apomorphine	B-Chemical	D001058
(	O	O
0	O	O
.	O	O

05	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
-	O	O
induced	O	O
catalepsy	B-Disease	D002375
.	O	O

However	O	O
,	O	O
pretreatment	O	O
with	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

trazodone	B-Chemical	D014196
enhanced	O	O
dexamphetamine	B-Chemical	D003913
stereotypy	O	O
,	O	O
and	O	O
antagonized	O	O
haloperidol	B-Chemical	D006220
catalepsy	B-Disease	D002375
,	O	O
ergometrine	B-Chemical	D004874
-	O	O
induced	O	O
WDS	O	O
behavior	O	O
and	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
penile	O	O
erections	O	O
.	O	O

Trazodone	B-Chemical	D014196
at	O	O
30	O	O
,	O	O
40	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

induced	O	O
catalepsy	B-Disease	D002375
and	O	O
antagonized	O	O
apomorphine	B-Chemical	D001058
and	O	O
dexamphetamine	B-Chemical	D003913
stereotypies	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
results	O	O
indicate	O	O
that	O	O
trazodone	B-Chemical	D014196
at	O	O
2	O	O
.	O	O

5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
does	O	O
not	O	O
block	O	O
pre	O	O
-	O	O
and	O	O
postsynaptic	O	O
striatal	O	O
D2	O	O
DA	O	O
receptors	O	O
,	O	O
while	O	O
at	O	O
30	O	O
,	O	O
40	O	O
and	O	O
50	O	O
mg	O	O
/	O	O
kg	O	O
it	O	O
blocks	O	O
postsynaptic	O	O
striatal	O	O
D2	O	O
DA	O	O
receptors	O	O
.	O	O

Furthermore	O	O
,	O	O
at	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
trazodone	B-Chemical	D014196
blocks	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2A	O	O
and	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2C	O	O
receptors	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
trazodone	B-Chemical	D014196
(	O	O
5	O	O
,	O	O
10	O	O
and	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
,	O	O
by	O	O
blocking	O	O
the	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
2C	O	O
receptors	O	O
,	O	O
releases	O	O
the	O	O
nigrostriatal	O	O
DAergic	O	O
neurons	O	O
from	O	O
tonic	O	O
inhibition	O	O
caused	O	O
by	O	O
5	B-Chemical	D012701
-	I-Chemical	D012701
HT	I-Chemical	D012701
,	O	O
and	O	O
thereby	O	O
potentiates	O	O
dexamphetamine	B-Chemical	D003913
stereotypy	O	O
and	O	O
antagonizes	O	O
haloperidol	B-Chemical	D006220
catalepsy	B-Disease	D002375
.	O	O

Swallowing	B-Disease	D020447
abnormalities	I-Disease	D020447
and	O	O
dyskinesia	B-Disease	D004409
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
.	O	O

Gastrointestinal	B-Disease	D005767
abnormalities	I-Disease	D005767
in	O	O
Parkinson's	B-Disease	D010300
disease	I-Disease	D010300
(	O	O
PD	B-Disease	D010300
)	O	O
have	O	O
been	O	O
known	O	O
for	O	O
almost	O	O
two	O	O
centuries	O	O
,	O	O
but	O	O
many	O	O
aspects	O	O
concerning	O	O
their	O	O
pathophysiology	O	O
have	O	O
not	O	O
been	O	O
completely	O	O
clarified	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
characterize	O	O
the	O	O
oropharyngeal	O	O
dynamics	O	O
in	O	O
PD	B-Disease	D010300
patients	O	O
with	O	O
and	O	O
without	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
dyskinesia	B-Disease	D004409
.	O	O

Fifteen	O	O
dyskinetic	B-Disease	D004409
,	O	O
12	O	O
nondyskinetic	O	O
patients	O	O
,	O	O
and	O	O
a	O	O
control	O	O
group	O	O
were	O	O
included	O	O
.	O	O

Patients	O	O
were	O	O
asked	O	O
about	O	O
dysphagia	B-Disease	D003680
and	O	O
evaluated	O	O
with	O	O
the	O	O
Unified	O	O
Parkinson's	B-Disease	D010300
Disease	I-Disease	D010300
Rating	O	O
Scale	O	O
Parts	O	O
II	O	O
and	O	O
III	O	O
and	O	O
the	O	O
Hoehn	O	O
and	O	O
Yahr	O	O
scale	O	O
.	O	O

Deglutition	O	O
was	O	O
assessed	O	O
using	O	O
modified	O	O
barium	B-Chemical	D001464
swallow	O	O
with	O	O
videofluoroscopy	O	O
.	O	O

Nondyskinetic	O	O
patients	O	O
,	O	O
but	O	O
not	O	O
the	O	O
dyskinetic	B-Disease	D004409
ones	O	O
,	O	O
showed	O	O
less	O	O
oropharyngeal	O	O
swallowing	O	O
efficiency	O	O
(	O	O
OPSE	O	O
)	O	O
for	O	O
liquid	O	O
food	O	O
than	O	O
controls	O	O
(	O	O
Dunnett	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

Dyskinetic	B-Disease	D004409
patients	O	O
tended	O	O
to	O	O
have	O	O
a	O	O
greater	O	O
OPSE	O	O
than	O	O
nondyskinetic	O	O
(	O	O
Dunnett	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

06	O	O
)	O	O
.	O	O

Patients	O	O
who	O	O
were	O	O
using	O	O
a	O	O
higher	O	O
dose	O	O
of	O	O
levodopa	B-Chemical	D007980
had	O	O
a	O	O
greater	O	O
OPSE	O	O
and	O	O
a	O	O
trend	O	O
toward	O	O
a	O	O
smaller	O	O
oral	O	O
transit	O	O
time	O	O
(	O	O
Pearson's	O	O
correlation	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

01	O	O
and	O	O
0	O	O
.	O	O

08	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Neither	O	O
the	O	O
report	O	O
of	O	O
dysphagia	B-Disease	D003680
nor	O	O
any	O	O
of	O	O
the	O	O
PD	B-Disease	D010300
severity	O	O
parameters	O	O
correlated	O	O
to	O	O
the	O	O
videofluoroscopic	O	O
variables	O	O
.	O	O

In	O	O
the	O	O
current	O	O
study	O	O
,	O	O
dyskinetic	B-Disease	D004409
patients	O	O
performed	O	O
better	O	O
in	O	O
swallowing	O	O
function	O	O
,	O	O
which	O	O
could	O	O
be	O	O
explained	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
a	O	O
greater	O	O
levodopa	B-Chemical	D007980
dose	O	O
.	O	O

Our	O	O
results	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
levodopa	B-Chemical	D007980
in	O	O
the	O	O
oral	O	O
phase	O	O
of	O	O
deglutition	O	O
and	O	O
confirm	O	O
that	O	O
dysphagia	B-Disease	D003680
is	O	O
not	O	O
a	O	O
good	O	O
predictor	O	O
of	O	O
deglutition	O	O
alterations	O	O
in	O	O
PD	B-Disease	D010300
.	O	O

Inhibition	O	O
of	O	O
nuclear	O	O
factor	O	O
-	O	O
kappaB	O	O
activation	O	O
attenuates	O	O
tubulointerstitial	B-Disease	D009395
nephritis	I-Disease	D009395
induced	O	O
by	O	O
gentamicin	B-Chemical	D005839
.	O	O

BACKGROUND	O	O
:	O	O
Animals	O	O
treated	O	O
with	O	O
gentamicin	B-Chemical	D005839
can	O	O
show	O	O
residual	O	O
areas	O	O
of	O	O
interstitial	O	O
fibrosis	B-Disease	D005355
in	O	O
the	O	O
renal	O	O
cortex	O	O
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
expression	O	O
of	O	O
nuclear	O	O
factor	O	O
-	O	O
kappaB	O	O
(	O	O
NF	O	O
-	O	O
kappaB	O	O
)	O	O
,	O	O
mitogen	O	O
-	O	O
activated	O	O
protein	O	O
(	O	O
MAP	O	O
)	O	O
kinases	O	O
and	O	O
macrophages	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
and	O	O
structural	O	O
and	O	O
functional	O	O
renal	O	O
changes	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
gentamicin	B-Chemical	D005839
or	O	O
gentamicin	B-Chemical	D005839
+	O	O
pyrrolidine	B-Chemical	C020972
dithiocarbamate	I-Chemical	C020972
(	O	O
PDTC	B-Chemical	C020972
)	O	O
,	O	O
an	O	O
NF	O	O
-	O	O
kappaB	O	O
inhibitor	O	O
.	O	O

METHODS	O	O
:	O	O
38	O	O
female	O	O
Wistar	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
gentamicin	B-Chemical	D005839
,	O	O
40	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
twice	O	O
a	O	O
day	O	O
for	O	O
9	O	O
days	O	O
,	O	O
38	O	O
with	O	O
gentamicin	B-Chemical	D005839
+	O	O
PDTC	B-Chemical	C020972
,	O	O
and	O	O
28	O	O
with	O	O
0	O	O
.	O	O

15	O	O
M	O	O
NaCl	B-Chemical	D012965
solution	O	O
.	O	O

The	O	O
animals	O	O
were	O	O
killed	O	O
5	O	O
and	O	O
30	O	O
days	O	O
after	O	O
these	O	O
injections	O	O
and	O	O
the	O	O
kidneys	O	O
were	O	O
removed	O	O
for	O	O
histological	O	O
and	O	O
immunohistochemical	O	O
studies	O	O
.	O	O

The	O	O
results	O	O
of	O	O
the	O	O
immunohistochemical	O	O
studies	O	O
were	O	O
scored	O	O
according	O	O
to	O	O
the	O	O
extent	O	O
of	O	O
staining	O	O
.	O	O

The	O	O
fractional	O	O
interstitial	O	O
area	O	O
was	O	O
determined	O	O
by	O	O
morphometry	O	O
.	O	O

RESULTS	O	O
:	O	O
Gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
rats	O	O
presented	O	O
a	O	O
transitory	O	O
increase	O	O
in	O	O
plasma	O	O
creatinine	B-Chemical	D003404
levels	O	O
.	O	O

Increased	O	O
ED	O	O
-	O	O
1	O	O
,	O	O
MAP	O	O
kinases	O	O
and	O	O
NF	O	O
-	O	O
kappaB	O	O
staining	O	O
were	O	O
also	O	O
observed	O	O
in	O	O
the	O	O
renal	O	O
cortex	O	O
from	O	O
all	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
rats	O	O
compared	O	O
to	O	O
control	O	O
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

The	O	O
animals	O	O
killed	O	O
on	O	O
day	O	O
30	O	O
also	O	O
presented	O	O
fibrosis	B-Disease	D005355
in	O	O
the	O	O
renal	O	O
cortex	O	O
despite	O	O
the	O	O
recovery	O	O
of	O	O
renal	O	O
function	O	O
.	O	O

Treatment	O	O
with	O	O
PDTC	B-Chemical	C020972
reduced	O	O
the	O	O
functional	O	O
and	O	O
structural	O	O
changes	O	O
induced	O	O
by	O	O
gentamicin	B-Chemical	D005839
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
data	O	O
show	O	O
that	O	O
inhibition	O	O
of	O	O
NF	O	O
-	O	O
kappaB	O	O
activation	O	O
attenuates	O	O
tubulointerstitial	B-Disease	D009395
nephritis	I-Disease	D009395
induced	O	O
by	O	O
gentamicin	B-Chemical	D005839
.	O	O

Glucose	B-Chemical	D005947
metabolism	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	B-Disease	D012559
treated	O	O
with	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
:	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-Chemical	D005947
tolerance	O	O
test	O	O
and	O	O
minimal	O	O
model	O	O
analysis	O	O
.	O	O

BACKGROUND	O	O
:	O	O
While	O	O
the	O	O
incidence	O	O
of	O	O
new	O	O
-	O	O
onset	O	O
diabetes	B-Disease	D003920
mellitus	I-Disease	D003920
may	O	O
be	O	O
increasing	O	O
in	O	O
patients	O	O
with	O	O
schizophrenia	B-Disease	D012559
treated	O	O
with	O	O
certain	O	O
atypical	O	O
antipsychotic	O	O
agents	O	O
,	O	O
it	O	O
remains	O	O
unclear	O	O
whether	O	O
atypical	O	O
agents	O	O
are	O	O
directly	O	O
affecting	O	O
glucose	B-Chemical	D005947
metabolism	O	O
or	O	O
simply	O	O
increasing	O	O
known	O	O
risk	O	O
factors	O	O
for	O	O
diabetes	B-Disease	D003920
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
study	O	O
the	O	O
2	O	O
drugs	O	O
most	O	O
clearly	O	O
implicated	O	O
(	O	O
clozapine	B-Chemical	D003024
and	O	O
olanzapine	B-Chemical	C076029
)	O	O
and	O	O
risperidone	B-Chemical	D018967
using	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-Chemical	D005947
tolerance	O	O
test	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
cross	O	O
-	O	O
sectional	O	O
design	O	O
in	O	O
stable	O	O
,	O	O
treated	O	O
patients	O	O
with	O	O
schizophrenia	B-Disease	D012559
evaluated	O	O
using	O	O
a	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-Chemical	D005947
tolerance	O	O
test	O	O
and	O	O
the	O	O
Bergman	O	O
minimal	O	O
model	O	O
analysis	O	O
.	O	O

SETTING	O	O
:	O	O
Subjects	O	O
were	O	O
recruited	O	O
from	O	O
an	O	O
urban	O	O
community	O	O
mental	O	O
health	O	O
clinic	O	O
and	O	O
were	O	O
studied	O	O
at	O	O
a	O	O
general	O	O
clinical	O	O
research	O	O
center	O	O
.	O	O

Patients	O	O
Fifty	O	O
subjects	O	O
signed	O	O
informed	O	O
consent	O	O
and	O	O
41	O	O
underwent	O	O
the	O	O
frequently	O	O
sampled	O	O
intravenous	O	O
glucose	B-Chemical	D005947
tolerance	O	O
test	O	O
.	O	O

Thirty	O	O
-	O	O
six	O	O
nonobese	O	O
subjects	O	O
with	O	O
schizophrenia	B-Disease	D012559
or	O	O
schizoaffective	B-Disease	D011618
disorder	I-Disease	D011618
,	O	O
matched	O	O
by	O	O
body	O	O
mass	O	O
index	O	O
and	O	O
treated	O	O
with	O	O
either	O	O
clozapine	B-Chemical	D003024
,	O	O
olanzapine	B-Chemical	C076029
,	O	O
or	O	O
risperidone	B-Chemical	D018967
,	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

MAIN	O	O
OUTCOME	O	O
MEASURES	O	O
:	O	O
Fasting	O	O
plasma	O	O
glucose	B-Chemical	D005947
and	O	O
fasting	O	O
serum	O	O
insulin	O	O
levels	O	O
,	O	O
insulin	B-Disease	D007333
sensitivity	I-Disease	D007333
index	O	O
,	O	O
homeostasis	O	O
model	O	O
assessment	O	O
of	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
,	O	O
and	O	O
glucose	B-Chemical	D005947
effectiveness	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
duration	O	O
of	O	O
treatment	O	O
with	O	O
the	O	O
identified	O	O
atypical	O	O
antipsychotic	O	O
agent	O	O
was	O	O
68	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
28	O	O
.	O	O

9	O	O
months	O	O
(	O	O
clozapine	B-Chemical	D003024
)	O	O
,	O	O
29	O	O
.	O	O

5	O	O
+	O	O
/	O	O
-	O	O
17	O	O
.	O	O

5	O	O
months	O	O
(	O	O
olanzapine	B-Chemical	C076029
)	O	O
,	O	O
and	O	O
40	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
33	O	O
.	O	O

7	O	O
(	O	O
risperidone	B-Chemical	D018967
)	O	O
.	O	O

Fasting	O	O
serum	O	O
insulin	O	O
concentrations	O	O
differed	O	O
among	O	O
groups	O	O
(	O	O
F	O	O
(	O	O
33	O	O
)	O	O
=	O	O
3	O	O
.	O	O

35	O	O
;	O	O
P	O	O
=	O	O
.	O	O

047	O	O
)	O	O
(	O	O
clozapine>olanzapine>risperidone	O	O
)	O	O
with	O	O
significant	O	O
differences	O	O
between	O	O
clozapine	B-Chemical	D003024
and	O	O
risperidone	B-Chemical	D018967
(	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
2	O	O
.	O	O

32	O	O
;	O	O
P	O	O
=	O	O
.	O	O

03	O	O
)	O	O
and	O	O
olanzapine	B-Chemical	C076029
and	O	O
risperidone	B-Chemical	D018967
(	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
2	O	O
.	O	O

15	O	O
;	O	O
P	O	O
=	O	O
.	O	O

04	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
in	O	O
insulin	B-Disease	D007333
sensitivity	I-Disease	D007333
index	O	O
among	O	O
groups	O	O
(	O	O
F	O	O
(	O	O
33	O	O
)	O	O
=	O	O
10	O	O
.	O	O

66	O	O
;	O	O
P<	O	O
.	O	O

001	O	O
)	O	O
(	O	O
clozapine<olanzapine<risperidone	O	O
)	O	O
,	O	O
with	O	O
subjects	O	O
who	O	O
received	O	O
clozapine	B-Chemical	D003024
and	O	O
olanzapine	B-Chemical	C076029
exhibiting	O	O
significant	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
compared	O	O
with	O	O
subjects	O	O
who	O	O
were	O	O
treated	O	O
with	O	O
risperidone	B-Chemical	D018967
(	O	O
clozapine	B-Chemical	D003024
vs	O	O
risperidone	B-Chemical	D018967
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
-	O	O
4	O	O
.	O	O

29	O	O
;	O	O
P<	O	O
.	O	O

001	O	O
;	O	O
olanzapine	B-Chemical	C076029
vs	O	O
risperidone	B-Chemical	D018967
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
-	O	O
3	O	O
.	O	O

62	O	O
;	O	O
P	O	O
=	O	O
.	O	O

001	O	O
[	O	O
P<	O	O
.	O	O

001	O	O
]	O	O
)	O	O
.	O	O

The	O	O
homeostasis	O	O
model	O	O
assessment	O	O
of	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
also	O	O
differed	O	O
significantly	O	O
among	O	O
groups	O	O
(	O	O
F	O	O
(	O	O
33	O	O
)	O	O
=	O	O
4	O	O
.	O	O

92	O	O
;	O	O
P	O	O
=	O	O
.	O	O

01	O	O
)	O	O
(	O	O
clozapine>olanzapine>risperidone	O	O
)	O	O
(	O	O
clozapine	B-Chemical	D003024
vs	O	O
risperidone	B-Chemical	D018967
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
2	O	O
.	O	O

94	O	O
;	O	O
P	O	O
=	O	O
.	O	O

006	O	O
;	O	O
olanzapine	B-Chemical	C076029
vs	O	O
risperidone	B-Chemical	D018967
,	O	O
t	O	O
(	O	O
33	O	O
)	O	O
=	O	O
2	O	O
.	O	O

42	O	O
;	O	O
P	O	O
=	O	O
.	O	O

02	O	O
)	O	O
.	O	O

There	O	O
was	O	O
a	O	O
significant	O	O
difference	O	O
among	O	O
groups	O	O
in	O	O
glucose	B-Chemical	D005947
effectiveness	O	O
(	O	O
F	O	O
(	O	O
30	O	O
)	O	O
=	O	O
4	O	O
.	O	O

18	O	O
;	O	O
P	O	O
=	O	O
.	O	O

02	O	O
)	O	O
(	O	O
clozapine<olanzapine<risperidone	O	O
)	O	O
with	O	O
significant	O	O
differences	O	O
between	O	O
clozapine	B-Chemical	D003024
and	O	O
risperidone	B-Chemical	D018967
(	O	O
t	O	O
(	O	O
30	O	O
)	O	O
=	O	O
-	O	O
2	O	O
.	O	O

59	O	O
;	O	O
P	O	O
=	O	O
.	O	O

02	O	O
)	O	O
and	O	O
olanzapine	B-Chemical	C076029
and	O	O
risperidone	B-Chemical	D018967
(	O	O
t	O	O
(	O	O
30	O	O
)	O	O
=	O	O
-	O	O
2	O	O
.	O	O

34	O	O
,	O	O
P	O	O
=	O	O
.	O	O

03	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Both	O	O
nonobese	O	O
clozapine	B-Chemical	D003024
-	O	O
and	O	O
olanzapine	B-Chemical	C076029
-	O	O
treated	O	O
groups	O	O
displayed	O	O
significant	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
and	O	O
impairment	O	O
of	O	O
glucose	B-Chemical	D005947
effectiveness	O	O
compared	O	O
with	O	O
risperidone	B-Chemical	D018967
-	O	O
treated	O	O
subjects	O	O
.	O	O

Patients	O	O
taking	O	O
clozapine	B-Chemical	D003024
and	O	O
olanzapine	B-Chemical	C076029
must	O	O
be	O	O
examined	O	O
for	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
and	O	O
its	O	O
consequences	O	O
.	O	O

Focal	O	O
cerebral	B-Disease	D002545
ischemia	I-Disease	D002545
in	O	O
rats	O	O
:	O	O
effect	O	O
of	O	O
phenylephrine	B-Chemical	D010656
-	O	O
induced	O	O
hypertension	B-Disease	D006973
during	O	O
reperfusion	O	O
.	O	O

After	O	O
180	O	O
min	O	O
of	O	O
temporary	O	O
middle	B-Disease	D020244
cerebral	I-Disease	D020244
artery	I-Disease	D020244
occlusion	I-Disease	D020244
in	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
,	O	O
the	O	O
effect	O	O
of	O	O
phenylephrine	B-Chemical	D010656
-	O	O
induced	O	O
hypertension	B-Disease	D006973
on	O	O
ischemic	B-Disease	D001930
brain	I-Disease	D001930
injury	I-Disease	D001930
and	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
permeability	O	O
was	O	O
determined	O	O
.	O	O

Blood	O	O
pressure	O	O
was	O	O
manipulated	O	O
by	O	O
one	O	O
of	O	O
the	O	O
following	O	O
schedules	O	O
during	O	O
120	O	O
min	O	O
of	O	O
reperfusion	O	O
:	O	O
Control	O	O
,	O	O
normotensive	O	O
reperfusion	O	O
;	O	O
90	O	O
/	O	O
hypertension	B-Disease	D006973
(	O	O
90	O	O
/	O	O
HTN	B-Disease	D006973
)	O	O
,	O	O
blood	O	O
pressure	O	O
was	O	O
increased	O	O
by	O	O
35	O	O
mm	O	O
Hg	O	O
during	O	O
the	O	O
initial	O	O
90	O	O
min	O	O
of	O	O
reperfusion	O	O
only	O	O
;	O	O
15	O	O
/	O	O
hypertension	B-Disease	D006973
(	O	O
15	O	O
/	O	O
HTN	B-Disease	D006973
)	O	O
,	O	O
normotensive	O	O
reperfusion	O	O
for	O	O
30	O	O
min	O	O
followed	O	O
by	O	O
15	O	O
min	O	O
of	O	O
hypertension	B-Disease	D006973
and	O	O
75	O	O
min	O	O
of	O	O
normotension	O	O
.	O	O

Part	O	O
A	O	O
,	O	O
for	O	O
eight	O	O
rats	O	O
in	O	O
each	O	O
group	O	O
brain	B-Disease	D001930
injury	I-Disease	D001930
was	O	O
evaluated	O	O
by	O	O
staining	O	O
tissue	O	O
using	O	O
2	B-Chemical	C009591
,	I-Chemical	C009591
3	I-Chemical	C009591
,	I-Chemical	C009591
5	I-Chemical	C009591
-	I-Chemical	C009591
triphenyltetrazolium	I-Chemical	C009591
chloride	I-Chemical	C009591
and	O	O
edema	B-Disease	D004487
was	O	O
evaluated	O	O
by	O	O
microgravimetry	O	O
.	O	O

Part	O	O
B	O	O
,	O	O
for	O	O
eight	O	O
different	O	O
rats	O	O
in	O	O
each	O	O
group	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
permeability	O	O
was	O	O
evaluated	O	O
by	O	O
measuring	O	O
the	O	O
amount	O	O
and	O	O
extent	O	O
of	O	O
extravasation	O	O
of	O	O
Evans	B-Chemical	D005070
Blue	I-Chemical	D005070
dye	O	O
.	O	O

Brain	B-Disease	D001930
injury	I-Disease	D001930
(	O	O
percentage	O	O
of	O	O
the	O	O
ischemic	B-Disease	D002545
hemisphere	I-Disease	D002545
)	O	O
was	O	O
less	O	O
in	O	O
the	O	O
15	O	O
/	O	O
HTN	B-Disease	D006973
group	O	O
(	O	O
16	O	O
+	O	O
/	O	O
-	O	O
6	O	O
,	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
)	O	O
versus	O	O
the	O	O
90	O	O
/	O	O
HTN	B-Disease	D006973
group	O	O
(	O	O
30	O	O
+	O	O
/	O	O
-	O	O
6	O	O
)	O	O
,	O	O
which	O	O
was	O	O
in	O	O
turn	O	O
less	O	O
than	O	O
the	O	O
control	O	O
group	O	O
(	O	O
42	O	O
+	O	O
/	O	O
-	O	O
5	O	O
)	O	O
.	O	O

Specific	O	O
gravity	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
15	O	O
/	O	O
HTN	B-Disease	D006973
group	O	O
(	O	O
1	O	O
.	O	O

043	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

002	O	O
)	O	O
versus	O	O
the	O	O
90	O	O
/	O	O
HTN	B-Disease	D006973
(	O	O
1	O	O
.	O	O

036	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

003	O	O
)	O	O
and	O	O
control	O	O
(	O	O
1	O	O
.	O	O

037	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

003	O	O
)	O	O
groups	O	O
.	O	O

Evans	B-Chemical	D005070
Blue	I-Chemical	D005070
(	O	O
mug	O	O
g	O	O
-	O	O
1	O	O
of	O	O
brain	O	O
tissue	O	O
)	O	O
was	O	O
greater	O	O
in	O	O
the	O	O
90	O	O
/	O	O
HTN	B-Disease	D006973
group	O	O
(	O	O
24	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

0	O	O
)	O	O
versus	O	O
the	O	O
control	O	O
group	O	O
(	O	O
12	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

1	O	O
)	O	O
,	O	O
which	O	O
was	O	O
in	O	O
turn	O	O
greater	O	O
than	O	O
the	O	O
15	O	O
/	O	O
HTN	B-Disease	D006973
group	O	O
(	O	O
7	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

2	O	O
)	O	O
.	O	O

This	O	O
study	O	O
supports	O	O
a	O	O
hypothesis	O	O
that	O	O
during	O	O
reperfusion	O	O
,	O	O
a	O	O
short	O	O
interval	O	O
of	O	O
hypertension	B-Disease	D006973
decreases	O	O
brain	B-Disease	D001930
injury	I-Disease	D001930
and	O	O
edema	B-Disease	D004487
;	O	O
and	O	O
that	O	O
sustained	O	O
hypertension	B-Disease	D006973
increases	O	O
the	O	O
risk	O	O
of	O	O
vasogenic	B-Disease	D001929
edema	I-Disease	D001929
.	O	O

People	O	O
aged	O	O
over	O	O
75	O	O
in	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
on	O	O
warfarin	B-Chemical	D014859
:	O	O
the	O	O
rate	O	O
of	O	O
major	O	O
hemorrhage	B-Disease	D006470
and	O	O
stroke	B-Disease	D020521
in	O	O
more	O	O
than	O	O
500	O	O
patient	O	O
-	O	O
years	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
major	O	O
hemorrhage	B-Disease	D006470
and	O	O
stroke	B-Disease	D020521
in	O	O
people	O	O
aged	O	O
76	O	O
and	O	O
older	O	O
with	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
on	O	O
adjusted	O	O
-	O	O
dose	O	O
warfarin	B-Chemical	D014859
who	O	O
had	O	O
been	O	O
recently	O	O
been	O	O
admitted	O	O
to	O	O
hospital	O	O
.	O	O

DESIGN	O	O
:	O	O
A	O	O
retrospective	O	O
observational	O	O
cohort	O	O
study	O	O
.	O	O

SETTING	O	O
:	O	O
A	O	O
major	O	O
healthcare	O	O
network	O	O
involving	O	O
four	O	O
tertiary	O	O
hospitals	O	O
.	O	O

PARTICIPANTS	O	O
:	O	O
Two	O	O
hundred	O	O
thirty	O	O
-	O	O
five	O	O
patients	O	O
aged	O	O
76	O	O
and	O	O
older	O	O
admitted	O	O
to	O	O
a	O	O
major	O	O
healthcare	O	O
network	O	O
between	O	O
July	O	O
1	O	O
,	O	O
2001	O	O
,	O	O
and	O	O
June	O	O
30	O	O
,	O	O
2002	O	O
,	O	O
with	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
on	O	O
warfarin	B-Chemical	D014859
were	O	O
enrolled	O	O
.	O	O

MEASUREMENTS	O	O
:	O	O
Information	O	O
regarding	O	O
major	O	O
bleeding	B-Disease	D006470
episodes	O	O
,	O	O
strokes	B-Disease	D020521
,	O	O
and	O	O
warfarin	B-Chemical	D014859
use	O	O
was	O	O
obtained	O	O
from	O	O
patients	O	O
,	O	O
relatives	O	O
,	O	O
primary	O	O
physicians	O	O
,	O	O
and	O	O
medical	O	O
records	O	O
.	O	O

RESULTS	O	O
:	O	O
Two	O	O
hundred	O	O
twenty	O	O
-	O	O
eight	O	O
patients	O	O
(	O	O
42%	O	O
men	O	O
)	O	O
with	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
81	O	O
.	O	O

1	O	O
(	O	O
range	O	O
76	O	O
-	O	O
94	O	O
)	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

Total	O	O
follow	O	O
-	O	O
up	O	O
on	O	O
warfarin	B-Chemical	D014859
was	O	O
530	O	O
years	O	O
(	O	O
mean	O	O
28	O	O
months	O	O
)	O	O
.	O	O

There	O	O
were	O	O
53	O	O
major	O	O
hemorrhages	B-Disease	D006470
,	O	O
for	O	O
an	O	O
annual	O	O
rate	O	O
of	O	O
10	O	O
.	O	O

0%	O	O
,	O	O
including	O	O
24	O	O
(	O	O
45	O	O
.	O	O

3%	O	O
)	O	O
life	O	O
-	O	O
threatening	O	O
and	O	O
five	O	O
(	O	O
9	O	O
.	O	O

4%	O	O
)	O	O
fatal	O	O
bleeds	O	O
.	O	O

The	O	O
annual	O	O
stroke	B-Disease	D020521
rate	O	O
after	O	O
initiation	O	O
of	O	O
warfarin	B-Chemical	D014859
was	O	O
2	O	O
.	O	O

6%	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
rate	O	O
of	O	O
major	O	O
hemorrhage	B-Disease	D006470
was	O	O
high	O	O
in	O	O
this	O	O
old	O	O
,	O	O
frail	O	O
group	O	O
,	O	O
but	O	O
excluding	O	O
fatalities	O	O
,	O	O
resulted	O	O
in	O	O
no	O	O
long	O	O
-	O	O
term	O	O
sequelae	O	O
,	O	O
and	O	O
the	O	O
stroke	B-Disease	D020521
rate	O	O
on	O	O
warfarin	B-Chemical	D014859
was	O	O
low	O	O
,	O	O
demonstrating	O	O
how	O	O
effective	O	O
warfarin	B-Chemical	D014859
treatment	O	O
is	O	O
.	O	O

Safety	O	O
of	O	O
celecoxib	B-Chemical	C105934
in	O	O
patients	O	O
with	O	O
adverse	O	O
skin	B-Disease	D003875
reactions	I-Disease	D003875
to	O	O
acetaminophen	B-Chemical	D000082
(	O	O
paracetamol	B-Chemical	D000082
)	O	O
and	O	O
nimesulide	B-Chemical	C012655
associated	O	O
or	O	O
not	O	O
with	O	O
common	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Acetaminophen	B-Chemical	D000082
(	O	O
paracetamol	B-Chemical	D000082
-	O	O
-	O	O
P	B-Chemical	D000082
)	O	O
and	O	O
Nimesulide	B-Chemical	C012655
(	O	O
N	B-Chemical	C012655
)	O	O
are	O	O
widely	O	O
used	O	O
analgesic	O	O
-	O	O
antipyretic	O	O
/	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
.	O	O

The	O	O
rate	O	O
of	O	O
adverse	O	O
hypersensitivity	B-Disease	D004342
reactions	O	O
to	O	O
these	O	O
agents	O	O
is	O	O
generally	O	O
low	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
are	O	O
commonly	O	O
involved	O	O
in	O	O
such	O	O
reactions	O	O
.	O	O

Celecoxib	B-Chemical	C105934
(	O	O
CE	B-Chemical	C105934
)	O	O
is	O	O
a	O	O
novel	O	O
drug	O	O
,	O	O
with	O	O
high	O	O
selectivity	O	O
and	O	O
affinity	O	O
for	O	O
COX	O	O
-	O	O
2	O	O
enzyme	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
We	O	O
evaluated	O	O
the	O	O
tolerability	O	O
of	O	O
CE	B-Chemical	C105934
in	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
with	O	O
documented	O	O
history	O	O
of	O	O
adverse	O	O
cutaneous	B-Disease	D003875
reactions	I-Disease	D003875
to	O	O
P	B-Chemical	D000082
and	O	O
N	B-Chemical	C012655
associated	O	O
or	O	O
not	O	O
to	O	O
classic	O	O
NSAIDs	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
studied	O	O
9	O	O
patients	O	O
with	O	O
hypersensitivity	B-Disease	D004342
to	O	O
P	B-Chemical	D000082
and	O	O
N	B-Chemical	C012655
with	O	O
or	O	O
without	O	O
associated	O	O
reactions	O	O
to	O	O
classic	O	O
NSAIDs	O	O
.	O	O

The	O	O
diagnosis	O	O
of	O	O
P	B-Chemical	D000082
and	O	O
N	B-Chemical	C012655
-	O	O
induced	O	O
skin	B-Disease	D003875
reactions	I-Disease	D003875
was	O	O
based	O	O
in	O	O
vivo	O	O
challenge	O	O
.	O	O

The	O	O
placebo	O	O
was	O	O
blindly	O	O
administered	O	O
at	O	O
the	O	O
beginning	O	O
of	O	O
each	O	O
challenge	O	O
.	O	O

After	O	O
three	O	O
days	O	O
,	O	O
a	O	O
cumulative	O	O
dosage	O	O
of	O	O
200	O	O
mg	O	O
of	O	O
CE	B-Chemical	C105934
in	O	O
refracted	O	O
doses	O	O
were	O	O
given	O	O
.	O	O

After	O	O
2	O	O
-	O	O
3	O	O
days	O	O
,	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
200	O	O
mg	O	O
was	O	O
administered	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
observed	O	O
for	O	O
6	O	O
hours	O	O
after	O	O
each	O	O
challenge	O	O
,	O	O
and	O	O
controlled	O	O
again	O	O
after	O	O
24	O	O
hours	O	O
to	O	O
exclude	O	O
delayed	O	O
reactions	O	O
.	O	O

The	O	O
challenge	O	O
was	O	O
considered	O	O
positive	O	O
if	O	O
one	O	O
or	O	O
more	O	O
of	O	O
the	O	O
following	O	O
appeared	O	O
:	O	O
erythema	B-Disease	D004890
,	O	O
rush	O	O
or	O	O
urticaria	B-Disease	D014581
-	O	O
angioedema	B-Disease	D000799
.	O	O

RESULTS	O	O
:	O	O
No	O	O
reaction	O	O
was	O	O
observed	O	O
with	O	O
placebo	O	O
and	O	O
eight	O	O
patients	O	O
(	O	O
88	O	O
.	O	O

8%	O	O
)	O	O
tolerated	O	O
CE	B-Chemical	C105934
.	O	O

Only	O	O
one	O	O
patient	O	O
developed	O	O
a	O	O
moderate	O	O
angioedema	B-Disease	D000799
of	O	O
the	O	O
lips	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Only	O	O
one	O	O
hypersensitivity	B-Disease	D004342
reaction	O	O
to	O	O
CE	B-Chemical	C105934
was	O	O
documented	O	O
among	O	O
9	O	O
P	B-Chemical	D000082
and	O	O
N	B-Chemical	C012655
-	O	O
highly	O	O
NSAIDs	O	O
intolerant	O	O
patients	O	O
.	O	O

Thus	O	O
,	O	O
we	O	O
conclude	O	O
that	O	O
CE	B-Chemical	C105934
is	O	O
a	O	O
reasonably	O	O
safe	O	O
alternative	O	O
to	O	O
be	O	O
used	O	O
in	O	O
subjects	O	O
who	O	O
do	O	O
not	O	O
tolerate	O	O
P	B-Chemical	D000082
and	O	O
N	B-Chemical	C012655
.	O	O

Case	O	O
-	O	O
control	O	O
study	O	O
of	O	O
regular	O	O
analgesic	O	O
and	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
use	O	O
and	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
.	O	O

BACKGROUND	O	O
:	O	O
Studies	O	O
on	O	O
the	O	O
association	O	O
between	O	O
the	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
aspirin	B-Chemical	D001241
and	O	O
other	O	O
analgesic	O	O
and	O	O
nonsteroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
and	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
(	O	O
ESRD	B-Disease	D007676
)	O	O
have	O	O
given	O	O
conflicting	O	O
results	O	O
.	O	O

In	O	O
order	O	O
to	O	O
examine	O	O
this	O	O
association	O	O
,	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
with	O	O
incident	O	O
cases	O	O
of	O	O
ESRD	B-Disease	D007676
was	O	O
carried	O	O
out	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
cases	O	O
were	O	O
all	O	O
patients	O	O
entering	O	O
the	O	O
local	O	O
dialysis	O	O
program	O	O
because	O	O
of	O	O
ESRD	B-Disease	D007676
in	O	O
the	O	O
study	O	O
area	O	O
between	O	O
June	O	O
1	O	O
,	O	O
1995	O	O
and	O	O
November	O	O
30	O	O
,	O	O
1997	O	O
.	O	O

They	O	O
were	O	O
classified	O	O
according	O	O
to	O	O
the	O	O
underlying	O	O
disease	O	O
,	O	O
which	O	O
had	O	O
presumably	O	O
led	O	O
them	O	O
to	O	O
ESRD	B-Disease	D007676
.	O	O

Controls	O	O
were	O	O
patients	O	O
admitted	O	O
to	O	O
the	O	O
same	O	O
hospitals	O	O
from	O	O
where	O	O
the	O	O
cases	O	O
arose	O	O
,	O	O
also	O	O
matched	O	O
by	O	O
age	O	O
and	O	O
sex	O	O
.	O	O

Odds	O	O
ratios	O	O
were	O	O
calculated	O	O
using	O	O
a	O	O
conditional	O	O
logistic	O	O
model	O	O
,	O	O
including	O	O
potential	O	O
confounding	O	O
factors	O	O
,	O	O
both	O	O
for	O	O
the	O	O
whole	O	O
study	O	O
population	O	O
and	O	O
for	O	O
the	O	O
various	O	O
underlying	O	O
diseases	O	O
.	O	O

RESULTS	O	O
:	O	O
Five	O	O
hundred	O	O
and	O	O
eighty	O	O
-	O	O
three	O	O
cases	O	O
and	O	O
1190	O	O
controls	O	O
were	O	O
included	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

Long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
any	O	O
analgesic	O	O
was	O	O
associated	O	O
with	O	O
an	O	O
overall	O	O
odds	O	O
ratio	O	O
of	O	O
1	O	O
.	O	O

22	O	O
(	O	O
95%	O	O
CI	O	O
,	O	O
0	O	O
.	O	O

89	O	O
-	O	O
1	O	O
.	O	O

66	O	O
)	O	O
.	O	O

For	O	O
specific	O	O
groups	O	O
of	O	O
drugs	O	O
,	O	O
the	O	O
risks	O	O
were	O	O
1	O	O
.	O	O

56	O	O
(	O	O
1	O	O
.	O	O

05	O	O
-	O	O
2	O	O
.	O	O

30	O	O
)	O	O
for	O	O
aspirin	B-Chemical	D001241
,	O	O
1	O	O
.	O	O

03	O	O
(	O	O
0	O	O
.	O	O

60	O	O
-	O	O
1	O	O
.	O	O

76	O	O
)	O	O
for	O	O
pyrazolones	B-Chemical	D047069
,	O	O
0	O	O
.	O	O

80	O	O
(	O	O
0	O	O
.	O	O

39	O	O
-	O	O
1	O	O
.	O	O

63	O	O
)	O	O
for	O	O
paracetamol	B-Chemical	D000082
,	O	O
and	O	O
0	O	O
.	O	O

94	O	O
(	O	O
0	O	O
.	O	O

57	O	O
-	O	O
1	O	O
.	O	O

56	O	O
)	O	O
for	O	O
nonaspirin	O	O
NSAIDs	O	O
.	O	O

The	O	O
risk	O	O
of	O	O
ESRD	B-Disease	D007676
associated	O	O
with	O	O
aspirin	B-Chemical	D001241
was	O	O
related	O	O
to	O	O
the	O	O
cumulated	O	O
dose	O	O
and	O	O
duration	O	O
of	O	O
use	O	O
,	O	O
and	O	O
it	O	O
was	O	O
particularly	O	O
high	O	O
among	O	O
the	O	O
subset	O	O
of	O	O
patients	O	O
with	O	O
vascular	O	O
nephropathy	B-Disease	D007674
as	O	O
underlying	O	O
disease	O	O
[	O	O
2	O	O
.	O	O

35	O	O
(	O	O
1	O	O
.	O	O

17	O	O
-	O	O
4	O	O
.	O	O

72	O	O
)	O	O
]	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
data	O	O
indicate	O	O
that	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
nonaspirin	O	O
analgesic	O	O
drugs	O	O
and	O	O
NSAIDs	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
increased	O	O
risk	O	O
of	O	O
ESRD	B-Disease	D007676
.	O	O

However	O	O
,	O	O
the	O	O
chronic	O	O
use	O	O
of	O	O
aspirin	B-Chemical	D001241
may	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
ESRD	B-Disease	D007676
.	O	O

Two	O	O
cases	O	O
of	O	O
amisulpride	B-Chemical	C012052
overdose	B-Disease	D062787
:	O	O
a	O	O
cause	O	O
for	O	O
prolonged	B-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
.	O	O

Two	O	O
cases	O	O
of	O	O
deliberate	O	O
self	O	O
-	O	O
poisoning	B-Disease	D011041
with	O	O
5	O	O
g	O	O
and	O	O
3	O	O
.	O	O

6	O	O
g	O	O
of	O	O
amisulpride	B-Chemical	C012052
,	O	O
respectively	O	O
,	O	O
are	O	O
reported	O	O
.	O	O

In	O	O
both	O	O
cases	O	O
,	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
and	O	O
hypocalcaemia	B-Disease	D006996
were	O	O
noted	O	O
.	O	O

The	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
appeared	O	O
to	O	O
respond	O	O
to	O	O
administration	O	O
of	O	O
i	O	O
.	O	O

v	O	O
.	O	O

calcium	B-Chemical	D002125
gluconate	I-Chemical	D002125
.	O	O

Growth	O	O
-	O	O
associated	O	O
protein	O	O
43	O	O
expression	O	O
in	O	O
hippocampal	O	O
molecular	O	O
layer	O	O
of	O	O
chronic	O	O
epileptic	B-Disease	D004827
rats	O	O
treated	O	O
with	O	O
cycloheximide	B-Chemical	D003513
.	O	O

PURPOSE	O	O
:	O	O
GAP43	O	O
has	O	O
been	O	O
thought	O	O
to	O	O
be	O	O
linked	O	O
with	O	O
mossy	O	O
fiber	O	O
sprouting	O	O
(	O	O
MFS	O	O
)	O	O
in	O	O
various	O	O
experimental	O	O
models	O	O
of	O	O
epilepsy	B-Disease	D004827
.	O	O

To	O	O
investigate	O	O
how	O	O
GAP43	O	O
expression	O	O
(	O	O
GAP43	O	O
-	O	O
ir	O	O
)	O	O
correlates	O	O
with	O	O
MFS	O	O
,	O	O
we	O	O
assessed	O	O
the	O	O
intensity	O	O
(	O	O
densitometry	O	O
)	O	O
and	O	O
extension	O	O
(	O	O
width	O	O
)	O	O
of	O	O
GAP43	O	O
-	O	O
ir	O	O
in	O	O
the	O	O
inner	O	O
molecular	O	O
layer	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
(	O	O
IML	O	O
)	O	O
of	O	O
rats	O	O
subject	O	O
to	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
(	O	O
Pilo	B-Chemical	D010862
)	O	O
,	O	O
previously	O	O
injected	O	O
or	O	O
not	O	O
with	O	O
cycloheximide	B-Chemical	D003513
(	O	O
CHX	B-Chemical	D003513
)	O	O
,	O	O
which	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
inhibit	O	O
MFS	O	O
.	O	O

METHODS	O	O
:	O	O
CHX	B-Chemical	D003513
was	O	O
injected	O	O
before	O	O
the	O	O
Pilo	B-Chemical	D010862
injection	O	O
in	O	O
adult	O	O
Wistar	O	O
rats	O	O
.	O	O

The	O	O
Pilo	B-Chemical	D010862
group	O	O
was	O	O
injected	O	O
with	O	O
the	O	O
same	O	O
drugs	O	O
,	O	O
except	O	O
for	O	O
CHX	B-Chemical	D003513
.	O	O

Animals	O	O
were	O	O
killed	O	O
between	O	O
30	O	O
and	O	O
60	O	O
days	O	O
later	O	O
,	O	O
and	O	O
brain	O	O
sections	O	O
were	O	O
processed	O	O
for	O	O
GAP43	O	O
immunohistochemistry	O	O
.	O	O

RESULTS	O	O
:	O	O
Densitometry	O	O
showed	O	O
no	O	O
significant	O	O
difference	O	O
regarding	O	O
GAP43	O	O
-	O	O
ir	O	O
in	O	O
the	O	O
IML	O	O
between	O	O
Pilo	B-Chemical	D010862
,	O	O
CHX+Pilo	O	O
,	O	O
and	O	O
control	O	O
groups	O	O
.	O	O

However	O	O
,	O	O
the	O	O
results	O	O
of	O	O
the	O	O
width	O	O
of	O	O
the	O	O
GAP43	O	O
-	O	O
ir	O	O
band	O	O
in	O	O
the	O	O
IML	O	O
showed	O	O
that	O	O
CHX+Pilo	O	O
and	O	O
control	O	O
animals	O	O
had	O	O
a	O	O
significantly	O	O
larger	O	O
band	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

03	O	O
)	O	O
as	O	O
compared	O	O
with	O	O
that	O	O
in	O	O
the	O	O
Pilo	B-Chemical	D010862
group	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
current	O	O
finding	O	O
that	O	O
animals	O	O
in	O	O
the	O	O
CHX+Pilo	O	O
group	O	O
have	O	O
a	O	O
GAP43	O	O
-	O	O
ir	O	O
band	O	O
in	O	O
the	O	O
IML	O	O
,	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
controls	O	O
,	O	O
reinforces	O	O
prior	O	O
data	O	O
on	O	O
the	O	O
blockade	O	O
of	O	O
MFS	O	O
in	O	O
these	O	O
animals	O	O
.	O	O

The	O	O
change	O	O
in	O	O
GAP43	O	O
-	O	O
ir	O	O
present	O	O
in	O	O
Pilo	B-Chemical	D010862
-	O	O
treated	O	O
animals	O	O
was	O	O
a	O	O
thinning	O	O
of	O	O
the	O	O
band	O	O
to	O	O
a	O	O
very	O	O
narrow	O	O
layer	O	O
just	O	O
above	O	O
the	O	O
granule	O	O
cell	O	O
layer	O	O
that	O	O
is	O	O
likely	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
loss	O	O
of	O	O
hilar	O	O
cell	O	O
projections	O	O
that	O	O
express	O	O
GAP	O	O
-	O	O
43	O	O
.	O	O

Nicotine	B-Chemical	D009538
antagonizes	O	O
caffeine	B-Chemical	D002110
-	O	O
but	O	O
not	O	O
pentylenetetrazole	B-Chemical	D010433
-	O	O
induced	O	O
anxiogenic	O	O
effect	O	O
in	O	O
mice	O	O
.	O	O

RATIONALE	O	O
:	O	O
Nicotine	B-Chemical	D009538
and	O	O
caffeine	B-Chemical	D002110
are	O	O
widely	O	O
consumed	O	O
licit	O	O
psychoactive	O	O
drugs	O	O
worldwide	O	O
.	O	O

Epidemiological	O	O
studies	O	O
showed	O	O
that	O	O
they	O	O
were	O	O
generally	O	O
used	O	O
concurrently	O	O
.	O	O

Although	O	O
some	O	O
studies	O	O
in	O	O
experimental	O	O
animals	O	O
indicate	O	O
clear	O	O
pharmacological	O	O
interactions	O	O
between	O	O
them	O	O
,	O	O
no	O	O
studies	O	O
have	O	O
shown	O	O
a	O	O
specific	O	O
interaction	O	O
on	O	O
anxiety	B-Disease	D001008
responses	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
present	O	O
study	O	O
investigates	O	O
the	O	O
effects	O	O
of	O	O
nicotine	B-Chemical	D009538
on	O	O
anxiety	B-Disease	D001008
induced	O	O
by	O	O
caffeine	B-Chemical	D002110
and	O	O
another	O	O
anxiogenic	O	O
drug	O	O
,	O	O
pentylenetetrazole	B-Chemical	D010433
,	O	O
in	O	O
mice	O	O
.	O	O

The	O	O
elevated	O	O
plus	O	O
-	O	O
maze	O	O
(	O	O
EPM	O	O
)	O	O
test	O	O
was	O	O
used	O	O
to	O	O
evaluate	O	O
the	O	O
effects	O	O
of	O	O
drugs	O	O
on	O	O
anxiety	B-Disease	D001008
.	O	O

METHODS	O	O
:	O	O
Adult	O	O
male	O	O
Swiss	O	O
Webster	O	O
mice	O	O
(	O	O
25	O	O
-	O	O
32	O	O
g	O	O
)	O	O
were	O	O
given	O	O
nicotine	B-Chemical	D009538
(	O	O
0	O	O
.	O	O

05	O	O
-	O	O
0	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
or	O	O
saline	O	O
10	O	O
min	O	O
before	O	O
caffeine	B-Chemical	D002110
(	O	O
70	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
or	O	O
pentylenetetrazole	B-Chemical	D010433
(	O	O
15	O	O
and	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
injections	O	O
.	O	O

After	O	O
15	O	O
min	O	O
,	O	O
mice	O	O
were	O	O
evaluated	O	O
for	O	O
their	O	O
open	O	O
-	O	O
and	O	O
closed	O	O
-	O	O
arm	O	O
time	O	O
and	O	O
entries	O	O
on	O	O
the	O	O
EPM	O	O
for	O	O
a	O	O
10	O	O
-	O	O
min	O	O
session	O	O
.	O	O

Locomotor	O	O
activity	O	O
was	O	O
recorded	O	O
for	O	O
individual	O	O
groups	O	O
by	O	O
using	O	O
the	O	O
same	O	O
treatment	O	O
protocol	O	O
with	O	O
the	O	O
EPM	O	O
test	O	O
.	O	O

RESULTS	O	O
:	O	O
Nicotine	B-Chemical	D009538
(	O	O
0	O	O
.	O	O

05	O	O
-	O	O
0	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
itself	O	O
did	O	O
not	O	O
produce	O	O
any	O	O
significant	O	O
effect	O	O
in	O	O
the	O	O
EPM	O	O
test	O	O
,	O	O
whereas	O	O
caffeine	B-Chemical	D002110
(	O	O
70	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
and	O	O
pentylenetetrazole	B-Chemical	D010433
(	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
produced	O	O
an	O	O
anxiogenic	O	O
effect	O	O
,	O	O
apparent	O	O
with	O	O
decreases	O	O
in	O	O
open	O	O
-	O	O
arm	O	O
time	O	O
and	O	O
entry	O	O
.	O	O

Nicotine	B-Chemical	D009538
(	O	O
0	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
pretreatment	O	O
blocked	O	O
the	O	O
caffeine	B-Chemical	D002110
-	O	O
but	O	O
not	O	O
pentylenetetrazole	B-Chemical	D010433
-	O	O
induced	O	O
anxiety	B-Disease	D001008
.	O	O

Administration	O	O
of	O	O
each	O	O
drug	O	O
and	O	O
their	O	O
combinations	O	O
did	O	O
not	O	O
produce	O	O
any	O	O
effect	O	O
on	O	O
locomotor	O	O
activity	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Our	O	O
results	O	O
suggest	O	O
that	O	O
the	O	O
antagonistic	O	O
effect	O	O
of	O	O
nicotine	B-Chemical	D009538
on	O	O
caffeine	B-Chemical	D002110
-	O	O
induced	O	O
anxiety	B-Disease	D001008
is	O	O
specific	O	O
to	O	O
caffeine	B-Chemical	D002110
,	O	O
instead	O	O
of	O	O
a	O	O
non	O	O
-	O	O
specific	O	O
anxiolytic	O	O
effect	O	O
.	O	O

Thus	O	O
,	O	O
it	O	O
may	O	O
extend	O	O
the	O	O
current	O	O
findings	O	O
on	O	O
the	O	O
interaction	O	O
between	O	O
nicotine	B-Chemical	D009538
and	O	O
caffeine	B-Chemical	D002110
.	O	O

Long	O	O
term	O	O
hormone	O	O
therapy	O	O
for	O	O
perimenopausal	O	O
and	O	O
postmenopausal	O	O
women	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Hormone	O	O
therapy	O	O
(	O	O
HT	O	O
)	O	O
is	O	O
widely	O	O
used	O	O
for	O	O
controlling	O	O
menopausal	B-Disease	D008594
symptoms	I-Disease	D008594
.	O	O

It	O	O
has	O	O
also	O	O
been	O	O
used	O	O
for	O	O
the	O	O
management	O	O
and	O	O
prevention	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
,	O	O
osteoporosis	B-Disease	D010024
and	O	O
dementia	B-Disease	D003704
in	O	O
older	O	O
women	O	O
but	O	O
the	O	O
evidence	O	O
supporting	O	O
its	O	O
use	O	O
for	O	O
these	O	O
indications	O	O
is	O	O
largely	O	O
observational	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
To	O	O
assess	O	O
the	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
HT	O	O
on	O	O
mortality	O	O
,	O	O
heart	B-Disease	D006331
disease	I-Disease	D006331
,	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
,	O	O
stroke	B-Disease	D020521
,	O	O
transient	B-Disease	D002546
ischaemic	I-Disease	D002546
attacks	I-Disease	D002546
,	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
,	O	O
colorectal	B-Disease	D015179
cancer	I-Disease	D015179
,	O	O
ovarian	B-Disease	D010051
cancer	I-Disease	D010051
,	O	O
endometrial	B-Disease	D016889
cancer	I-Disease	D016889
,	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
,	O	O
cognitive	O	O
function	O	O
,	O	O
dementia	B-Disease	D003704
,	O	O
fractures	B-Disease	D050723
and	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

SEARCH	O	O
STRATEGY	O	O
:	O	O
We	O	O
searched	O	O
the	O	O
following	O	O
databases	O	O
up	O	O
to	O	O
November	O	O
2004	O	O
:	O	O
the	O	O
Cochrane	O	O
Menstrual	O	O
Disorders	O	O
and	O	O
Subfertility	O	O
Group	O	O
Trials	O	O
Register	O	O
,	O	O
Cochrane	O	O
Central	O	O
Register	O	O
of	O	O
Controlled	O	O
Trials	O	O
(	O	O
CENTRAL	O	O
)	O	O
,	O	O
MEDLINE	O	O
,	O	O
EMBASE	O	O
,	O	O
Biological	O	O
Abstracts	O	O
.	O	O

Relevant	O	O
non	O	O
-	O	O
indexed	O	O
journals	O	O
and	O	O
conference	O	O
abstracts	O	O
were	O	O
also	O	O
searched	O	O
.	O	O

SELECTION	O	O
CRITERIA	O	O
:	O	O
Randomised	O	O
double	O	O
-	O	O
blind	O	O
trials	O	O
of	O	O
HT	O	O
(	O	O
oestrogens	B-Chemical	D004967
with	O	O
or	O	O
without	O	O
progestogens	B-Chemical	D011374
)	O	O
versus	O	O
placebo	O	O
,	O	O
taken	O	O
for	O	O
at	O	O
least	O	O
one	O	O
year	O	O
by	O	O
perimenopausal	O	O
or	O	O
postmenopausal	O	O
women	O	O
.	O	O

DATA	O	O
COLLECTION	O	O
AND	O	O
ANALYSIS	O	O
:	O	O
Fifteen	O	O
RCTs	O	O
were	O	O
included	O	O
.	O	O

Trials	O	O
were	O	O
assessed	O	O
for	O	O
quality	O	O
and	O	O
two	O	O
review	O	O
authors	O	O
extracted	O	O
data	O	O
independently	O	O
.	O	O

They	O	O
calculated	O	O
risk	O	O
ratios	O	O
for	O	O
dichotomous	O	O
outcomes	O	O
and	O	O
weighted	O	O
mean	O	O
differences	O	O
for	O	O
continuous	O	O
outcomes	O	O
.	O	O

Clinical	O	O
heterogeneity	O	O
precluded	O	O
meta	O	O
-	O	O
analysis	O	O
for	O	O
most	O	O
outcomes	O	O
.	O	O

MAIN	O	O
RESULTS	O	O
:	O	O
All	O	O
the	O	O
statistically	O	O
significant	O	O
results	O	O
were	O	O
derived	O	O
from	O	O
the	O	O
two	O	O
biggest	O	O
trials	O	O
.	O	O

In	O	O
relatively	O	O
healthy	O	O
women	O	O
,	O	O
combined	O	O
continuous	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
or	O	O
coronary	O	O
event	O	O
(	O	O
after	O	O
one	O	O
year's	O	O
use	O	O
)	O	O
,	O	O
stroke	B-Disease	D020521
(	O	O
after	O	O
3	O	O
years	O	O
)	O	O
,	O	O
breast	B-Disease	D001943
cancer	I-Disease	D001943
(	O	O
after	O	O
5	O	O
years	O	O
)	O	O
and	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
.	O	O

Long	O	O
-	O	O
term	O	O
oestrogen	B-Chemical	D004967
-	O	O
only	O	O
HT	O	O
also	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
stroke	B-Disease	D020521
and	O	O
gallbladder	B-Disease	D005705
disease	I-Disease	D005705
.	O	O

Overall	O	O
,	O	O
the	O	O
only	O	O
statistically	O	O
significant	O	O
benefits	O	O
of	O	O
HT	O	O
were	O	O
a	O	O
decreased	O	O
incidence	O	O
of	O	O
fractures	B-Disease	D050723
and	O	O
colon	B-Disease	D003110
cancer	I-Disease	D003110
with	O	O
long	O	O
-	O	O
term	O	O
use	O	O
.	O	O

Among	O	O
relatively	O	O
healthy	O	O
women	O	O
over	O	O
65	O	O
years	O	O
taking	O	O
continuous	O	O
combined	O	O
HT	O	O
,	O	O
there	O	O
was	O	O
a	O	O
statistically	O	O
significant	O	O
increase	O	O
in	O	O
the	O	O
incidence	O	O
of	O	O
dementia	B-Disease	D003704
.	O	O

Among	O	O
women	O	O
with	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
,	O	O
long	O	O
-	O	O
term	O	O
use	O	O
of	O	O
combined	O	O
continuous	O	O
HT	O	O
significantly	O	O
increased	O	O
the	O	O
risk	O	O
of	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
.	O	O

No	O	O
trials	O	O
focussed	O	O
specifically	O	O
on	O	O
younger	O	O
women	O	O
.	O	O

However	O	O
,	O	O
one	O	O
trial	O	O
analysed	O	O
subgroups	O	O
of	O	O
2839	O	O
relatively	O	O
healthy	O	O
50	O	O
to	O	O
59	O	O
year	O	O
-	O	O
old	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
HT	O	O
and	O	O
1637	O	O
taking	O	O
oestrogen	B-Chemical	D004967
-	O	O
only	O	O
HT	O	O
,	O	O
versus	O	O
similar	O	O
-	O	O
sized	O	O
placebo	O	O
groups	O	O
.	O	O

The	O	O
only	O	O
significantly	O	O
increased	O	O
risk	O	O
reported	O	O
was	O	O
for	O	O
venous	B-Disease	D054556
thromboembolism	I-Disease	D054556
in	O	O
women	O	O
taking	O	O
combined	O	O
continuous	O	O
HT	O	O
;	O	O
their	O	O
absolute	O	O
risk	O	O
remained	O	O
very	O	O
low	O	O
.	O	O

AUTHORS'	O	O
CONCLUSIONS	O	O
:	O	O
HT	O	O
is	O	O
not	O	O
indicated	O	O
for	O	O
the	O	O
routine	O	O
management	O	O
of	O	O
chronic	B-Disease	D002908
disease	I-Disease	D002908
.	O	O

We	O	O
need	O	O
more	O	O
evidence	O	O
on	O	O
the	O	O
safety	O	O
of	O	O
HT	O	O
for	O	O
menopausal	O	O
symptom	O	O
control	O	O
,	O	O
though	O	O
short	O	O
-	O	O
term	O	O
use	O	O
appears	O	O
to	O	O
be	O	O
relatively	O	O
safe	O	O
for	O	O
healthy	O	O
younger	O	O
women	O	O
.	O	O

Drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
liver	I-Disease	D056486
injury	I-Disease	D056486
:	O	O
an	O	O
analysis	O	O
of	O	O
461	O	O
incidences	O	O
submitted	O	O
to	O	O
the	O	O
Spanish	O	O
registry	O	O
over	O	O
a	O	O
10	O	O
-	O	O
year	O	O
period	O	O
.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
:	O	O
Progress	O	O
in	O	O
the	O	O
understanding	O	O
of	O	O
susceptibility	O	O
factors	O	O
to	O	O
drug	B-Disease	D056486
-	I-Disease	D056486
induced	I-Disease	D056486
liver	I-Disease	D056486
injury	I-Disease	D056486
(	O	O
DILI	B-Disease	D056486
)	O	O
and	O	O
outcome	O	O
predictability	O	O
are	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
systematic	O	O
programs	O	O
to	O	O
detect	O	O
bona	O	O
fide	O	O
cases	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
cooperative	O	O
network	O	O
was	O	O
created	O	O
in	O	O
1994	O	O
in	O	O
Spain	O	O
to	O	O
identify	O	O
all	O	O
suspicions	O	O
of	O	O
DILI	B-Disease	D056486
following	O	O
a	O	O
prospective	O	O
structured	O	O
report	O	O
form	O	O
.	O	O

The	O	O
liver	B-Disease	D056486
damage	I-Disease	D056486
was	O	O
characterized	O	O
according	O	O
to	O	O
hepatocellular	O	O
,	O	O
cholestatic	B-Disease	D002779
,	O	O
and	O	O
mixed	O	O
laboratory	O	O
criteria	O	O
and	O	O
to	O	O
histologic	O	O
criteria	O	O
when	O	O
available	O	O
.	O	O

Further	O	O
evaluation	O	O
of	O	O
causality	O	O
assessment	O	O
was	O	O
centrally	O	O
performed	O	O
.	O	O

RESULTS	O	O
:	O	O
Since	O	O
April	O	O
1994	O	O
to	O	O
August	O	O
2004	O	O
,	O	O
461	O	O
out	O	O
of	O	O
570	O	O
submitted	O	O
cases	O	O
,	O	O
involving	O	O
505	O	O
drugs	O	O
,	O	O
were	O	O
deemed	O	O
to	O	O
be	O	O
related	O	O
to	O	O
DILI	B-Disease	D056486
.	O	O

The	O	O
antiinfective	O	O
group	O	O
of	O	O
drugs	O	O
was	O	O
the	O	O
more	O	O
frequently	O	O
incriminated	O	O
,	O	O
amoxicillin	B-Chemical	D019980
-	I-Chemical	D019980
clavulanate	I-Chemical	D019980
accounting	O	O
for	O	O
the	O	O
12	O	O
.	O	O

8%	O	O
of	O	O
the	O	O
whole	O	O
series	O	O
.	O	O

The	O	O
hepatocellular	O	O
pattern	O	O
of	O	O
damage	O	O
was	O	O
the	O	O
most	O	O
common	O	O
(	O	O
58%	O	O
)	O	O
,	O	O
was	O	O
inversely	O	O
correlated	O	O
with	O	O
age	O	O
(	O	O
P	O	O
<	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
and	O	O
had	O	O
the	O	O
worst	O	O
outcome	O	O
(	O	O
Cox	O	O
regression	O	O
,	O	O
P	O	O
<	O	O
.	O	O

034	O	O
)	O	O
.	O	O

Indeed	O	O
,	O	O
the	O	O
incidence	O	O
of	O	O
liver	O	O
transplantation	O	O
and	O	O
death	O	O
in	O	O
this	O	O
group	O	O
was	O	O
11	O	O
.	O	O

7%	O	O
if	O	O
patients	O	O
had	O	O
jaundice	B-Disease	D007565
at	O	O
presentation	O	O
,	O	O
whereas	O	O
the	O	O
corresponding	O	O
figure	O	O
was	O	O
3	O	O
.	O	O

8%	O	O
in	O	O
nonjaundiced	O	O
patients	O	O
(	O	O
P	O	O
<	O	O
.	O	O

04	O	O
)	O	O
.	O	O

Factors	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
were	O	O
female	O	O
sex	O	O
(	O	O
OR	O	O
=	O	O
25	O	O
;	O	O
95%	O	O
CI	O	O
:	O	O
4	O	O
.	O	O

1	O	O
-	O	O
151	O	O
;	O	O
P	O	O
<	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
hepatocellular	O	O
damage	O	O
(	O	O
OR	O	O
=	O	O
7	O	O
.	O	O

9	O	O
;	O	O
95%	O	O
CI	O	O
:	O	O
1	O	O
.	O	O

6	O	O
-	O	O
37	O	O
;	O	O
P	O	O
<	O	O
.	O	O

009	O	O
)	O	O
,	O	O
and	O	O
higher	O	O
baseline	O	O
plasma	O	O
bilirubin	B-Chemical	D001663
value	O	O
(	O	O
OR	O	O
=	O	O
1	O	O
.	O	O

15	O	O
;	O	O
95%	O	O
CI	O	O
:	O	O
1	O	O
.	O	O

09	O	O
-	O	O
1	O	O
.	O	O

22	O	O
;	O	O
P	O	O
<	O	O
.	O	O

0001	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Patients	O	O
with	O	O
drug	O	O
-	O	O
induced	O	O
hepatocellular	O	O
jaundice	B-Disease	D007565
have	O	O
11	O	O
.	O	O

7%	O	O
chance	O	O
of	O	O
progressing	O	O
to	O	O
death	O	O
or	O	O
transplantation	O	O
.	O	O

Amoxicillin	B-Chemical	D019980
-	I-Chemical	D019980
clavulanate	I-Chemical	D019980
stands	O	O
out	O	O
as	O	O
the	O	O
most	O	O
common	O	O
drug	O	O
related	O	O
to	O	O
DILI	B-Disease	D056486
.	O	O

Morphological	O	O
evaluation	O	O
of	O	O
the	O	O
effect	O	O
of	O	O
d	B-Chemical	D012266
-	I-Chemical	D012266
ribose	I-Chemical	D012266
on	O	O
adriamycin	B-Chemical	D004317
-	O	O
evoked	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
rats	O	O
.	O	O

The	O	O
influence	O	O
of	O	O
d	B-Chemical	D012266
-	I-Chemical	D012266
ribose	I-Chemical	D012266
on	O	O
adriamycin	B-Chemical	D004317
-	O	O
induced	O	O
myocardiopathy	B-Disease	D009202
in	O	O
rats	O	O
was	O	O
studied	O	O
.	O	O

Adriamycin	B-Chemical	D004317
in	O	O
the	O	O
cumulative	O	O
dose	O	O
of	O	O
25	O	O
mg	O	O
/	O	O
kg	O	O
evoked	O	O
fully	O	O
developed	O	O
cardiac	B-Disease	D066126
toxicity	I-Disease	D066126
.	O	O

D	B-Chemical	D012266
-	I-Chemical	D012266
ribose	I-Chemical	D012266
in	O	O
the	O	O
multiple	O	O
doses	O	O
of	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
did	O	O
not	O	O
influence	O	O
ADR	B-Chemical	D004317
cardiotoxicity	B-Disease	D066126
.	O	O

In	O	O
vivo	O	O
evidences	O	O
suggesting	O	O
the	O	O
role	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
pathogenesis	O	O
of	O	O
vancomycin	B-Chemical	D014640
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
:	O	O
protection	O	O
by	O	O
erdosteine	B-Chemical	C048498
.	O	O

The	O	O
aims	O	O
of	O	O
this	O	O
study	O	O
were	O	O
to	O	O
examine	O	O
vancomycin	B-Chemical	D014640
(	O	O
VCM	B-Chemical	D014640
)	O	O
-	O	O
induced	O	O
oxidative	O	O
stress	O	O
that	O	O
promotes	O	O
production	O	O
of	O	O
reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
(	O	O
ROS	O	O
)	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
role	O	O
of	O	O
erdosteine	B-Chemical	C048498
,	O	O
an	O	O
expectorant	O	O
agent	O	O
,	O	O
which	O	O
has	O	O
also	O	O
antioxidant	O	O
properties	O	O
,	O	O
on	O	O
kidney	O	O
tissue	O	O
against	O	O
the	O	O
possible	O	O
VCM	B-Chemical	D014640
-	O	O
induced	O	O
renal	B-Disease	D007674
impairment	I-Disease	D007674
in	O	O
rats	O	O
.	O	O

Rats	O	O
were	O	O
divided	O	O
into	O	O
three	O	O
groups	O	O
:	O	O
sham	O	O
,	O	O
VCM	B-Chemical	D014640
and	O	O
VCM	B-Chemical	D014640
plus	O	O
erdosteine	B-Chemical	C048498
.	O	O

VCM	B-Chemical	D014640
was	O	O
administrated	O	O
intraperitoneally	O	O
(	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
with	O	O
200mgkg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
twice	O	O
daily	O	O
for	O	O
7	O	O
days	O	O
.	O	O

Erdosteine	B-Chemical	C048498
was	O	O
administered	O	O
orally	O	O
.	O	O

VCM	B-Chemical	D014640
administration	O	O
to	O	O
control	O	O
rats	O	O
significantly	O	O
increased	O	O
renal	O	O
malondialdehyde	B-Chemical	D008315
(	O	O
MDA	B-Chemical	D008315
)	O	O
and	O	O
urinary	O	O
N	O	O
-	O	O
acetyl	O	O
-	O	O
beta	O	O
-	O	O
d	O	O
-	O	O
glucosaminidase	O	O
(	O	O
NAG	O	O
,	O	O
a	O	O
marker	O	O
of	O	O
renal	B-Disease	D007674
tubular	I-Disease	D007674
injury	I-Disease	D007674
)	O	O
excretion	O	O
but	O	O
decreased	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
(	O	O
SOD	O	O
)	O	O
and	O	O
catalase	O	O
(	O	O
CAT	O	O
)	O	O
activities	O	O
.	O	O

Erdosteine	B-Chemical	C048498
administration	O	O
with	O	O
VCM	B-Chemical	D014640
injections	O	O
caused	O	O
significantly	O	O
decreased	O	O
renal	O	O
MDA	B-Chemical	D008315
and	O	O
urinary	O	O
NAG	O	O
excretion	O	O
,	O	O
and	O	O
increased	O	O
SOD	O	O
activity	O	O
,	O	O
but	O	O
not	O	O
CAT	O	O
activity	O	O
in	O	O
renal	O	O
tissue	O	O
when	O	O
compared	O	O
with	O	O
VCM	B-Chemical	D014640
alone	O	O
.	O	O

Erdosteine	B-Chemical	C048498
showed	O	O
histopathological	O	O
protection	O	O
against	O	O
VCM	B-Chemical	D014640
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
.	O	O

There	O	O
were	O	O
a	O	O
significant	O	O
dilatation	O	O
of	O	O
tubular	O	O
lumens	O	O
,	O	O
extensive	O	O
epithelial	O	O
cell	O	O
vacuolization	O	O
,	O	O
atrophy	B-Disease	D001284
,	O	O
desquamation	B-Disease	-1
,	O	O
and	O	O
necrosis	B-Disease	D009336
in	O	O
VCM	B-Chemical	D014640
-	O	O
treated	O	O
rats	O	O
more	O	O
than	O	O
those	O	O
of	O	O
the	O	O
control	O	O
and	O	O
the	O	O
erdosteine	B-Chemical	C048498
groups	O	O
.	O	O

Erdosteine	B-Chemical	C048498
caused	O	O
a	O	O
marked	O	O
reduction	O	O
in	O	O
the	O	O
extent	O	O
of	O	O
tubular	O	O
damage	O	O
.	O	O

It	O	O
is	O	O
concluded	O	O
that	O	O
oxidative	O	O
tubular	O	O
damage	O	O
plays	O	O
an	O	O
important	O	O
role	O	O
in	O	O
the	O	O
VCM	B-Chemical	D014640
-	O	O
induced	O	O
nephrotoxicity	B-Disease	D007674
and	O	O
the	O	O
modulation	O	O
of	O	O
oxidative	O	O
stress	O	O
with	O	O
erdosteine	B-Chemical	C048498
reduces	O	O
the	O	O
VCM	B-Chemical	D014640
-	O	O
induced	O	O
kidney	B-Disease	D007674
damage	I-Disease	D007674
both	O	O
at	O	O
the	O	O
biochemical	O	O
and	O	O
histological	O	O
levels	O	O
.	O	O

Does	O	O
domperidone	B-Chemical	D004294
potentiate	O	O
mirtazapine	B-Chemical	C035133
-	O	O
associated	O	O
restless	O	O
legs	O	O
syndrome?	O	O
There	O	O
is	O	O
now	O	O
evidence	O	O
to	O	O
suggest	O	O
a	O	O
central	O	O
role	O	O
for	O	O
the	O	O
dopaminergic	O	O
system	O	O
in	O	O
restless	B-Disease	D012148
legs	I-Disease	D012148
syndrome	I-Disease	D012148
(	O	O
RLS	B-Disease	D012148
)	O	O
.	O	O

For	O	O
example	O	O
,	O	O
the	O	O
symptoms	O	O
of	O	O
RLS	B-Disease	D012148
can	O	O
be	O	O
dramatically	O	O
improved	O	O
by	O	O
levodopa	B-Chemical	D007980
and	O	O
dopamine	B-Chemical	D004298
agonists	O	O
,	O	O
whereas	O	O
central	O	O
dopamine	B-Chemical	D004298
D2	O	O
receptor	O	O
antagonists	O	O
can	O	O
induce	O	O
or	O	O
aggravate	O	O
RLS	B-Disease	D012148
symptoms	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
there	O	O
is	O	O
no	O	O
previous	O	O
report	O	O
regarding	O	O
whether	O	O
domperidone	B-Chemical	D004294
,	O	O
a	O	O
peripheral	O	O
dopamine	B-Chemical	D004298
D2	O	O
receptor	O	O
antagonist	O	O
,	O	O
can	O	O
also	O	O
induce	O	O
or	O	O
aggravate	O	O
symptoms	O	O
of	O	O
RLS	B-Disease	D012148
.	O	O

Mirtazapine	B-Chemical	C035133
,	O	O
the	O	O
first	O	O
noradrenergic	O	O
and	O	O
specific	O	O
serotonergic	O	O
antidepressant	O	O
(	O	O
NaSSA	O	O
)	O	O
,	O	O
has	O	O
been	O	O
associated	O	O
with	O	O
RLS	B-Disease	D012148
in	O	O
several	O	O
recent	O	O
publications	O	O
.	O	O

The	O	O
authors	O	O
report	O	O
here	O	O
a	O	O
depressed	O	O
patient	O	O
comorbid	O	O
with	O	O
postprandial	B-Disease	D004415
dyspepsia	I-Disease	D004415
who	O	O
developed	O	O
RLS	B-Disease	D012148
after	O	O
mirtazapine	B-Chemical	C035133
had	O	O
been	O	O
added	O	O
to	O	O
his	O	O
domperidone	B-Chemical	D004294
therapy	O	O
.	O	O

Our	O	O
patient	O	O
started	O	O
to	O	O
have	O	O
symptoms	O	O
of	O	O
RLS	B-Disease	D012148
only	O	O
after	O	O
he	O	O
had	O	O
been	O	O
treated	O	O
with	O	O
mirtazapine	B-Chemical	C035133
,	O	O
and	O	O
his	O	O
RLS	B-Disease	D012148
symptoms	O	O
resolved	O	O
completely	O	O
upon	O	O
discontinuation	O	O
of	O	O
his	O	O
mirtazapine	B-Chemical	C035133
.	O	O

Such	O	O
a	O	O
temporal	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
mirtazapine	B-Chemical	C035133
and	O	O
the	O	O
symptoms	O	O
of	O	O
RLS	B-Disease	D012148
in	O	O
our	O	O
patient	O	O
did	O	O
not	O	O
support	O	O
a	O	O
potentiating	O	O
effect	O	O
of	O	O
domperione	B-Chemical	D004294
on	O	O
mirtazapine	B-Chemical	C035133
-	O	O
associated	O	O
RLS	B-Disease	D012148
.	O	O

However	O	O
,	O	O
physicians	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
possibility	O	O
that	O	O
mirtazapine	B-Chemical	C035133
can	O	O
be	O	O
associated	O	O
with	O	O
RLS	B-Disease	D012148
in	O	O
some	O	O
individuals	O	O
,	O	O
especially	O	O
those	O	O
receiving	O	O
concomitant	O	O
dopamine	B-Chemical	D004298
D2	O	O
receptor	O	O
antagonists	O	O
.	O	O

Antiandrogenic	O	O
therapy	O	O
can	O	O
cause	O	O
coronary	B-Disease	D003324
arterial	I-Disease	D003324
disease	I-Disease	D003324
.	O	O

AIM	O	O
:	O	O
To	O	O
study	O	O
the	O	O
change	O	O
of	O	O
lipid	O	O
metabolism	O	O
by	O	O
antiandrogen	O	O
therapy	O	O
in	O	O
patients	O	O
with	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
.	O	O

MATERIALS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
studied	O	O
with	O	O
a	O	O
2	O	O
.	O	O

5	O	O
years	O	O
follow	O	O
-	O	O
up	O	O
the	O	O
changes	O	O
in	O	O
plasma	O	O
cholesterols	B-Chemical	D002784
(	O	O
C	B-Chemical	D002784
)	O	O
,	O	O
triglycerides	B-Chemical	D014280
(	O	O
TG	B-Chemical	D014280
)	O	O
,	O	O
lipoproteins	O	O
(	O	O
LP	O	O
)	O	O
,	O	O
and	O	O
apolipoproteins	O	O
(	O	O
Apo	O	O
)	O	O
B	O	O
-	O	O
100	O	O
,	O	O
A	O	O
-	O	O
I	O	O
,	O	O
and	O	O
A	O	O
-	O	O
II	O	O
pro	O	O
fi	O	O
les	O	O
in	O	O
24	O	O
patients	O	O
of	O	O
mean	O	O
age	O	O
60	O	O
years	O	O
with	O	O
low	O	O
risk	O	O
prostate	B-Disease	D011471
cancer	I-Disease	D011471
(	O	O
stage	O	O
:	O	O
T1cN0M0	O	O
,	O	O
Gleason	O	O
score	O	O
:	O	O
2	O	O
-	O	O
5	O	O
)	O	O
during	O	O
treatment	O	O
with	O	O
cyproterone	B-Chemical	D017373
acetate	I-Chemical	D017373
(	O	O
CPA	B-Chemical	D017373
)	O	O
without	O	O
surgical	O	O
management	O	O
or	O	O
radiation	O	O
therapy	O	O
.	O	O

RESULTS	O	O
:	O	O
Significant	O	O
decreases	O	O
of	O	O
HDL	O	O
-	O	O
C	B-Chemical	D002784
,	O	O
Apo	O	O
A	O	O
-	O	O
I	O	O
and	O	O
Apo	O	O
A	O	O
-	O	O
II	O	O
and	O	O
an	O	O
increase	O	O
of	O	O
triglyceride	B-Chemical	D014280
levels	O	O
in	O	O
VLDL	O	O
were	O	O
induced	O	O
by	O	O
CPA	B-Chemical	D017373
.	O	O

After	O	O
a	O	O
period	O	O
of	O	O
2	O	O
.	O	O

5	O	O
years	O	O
on	O	O
CPA	B-Chemical	D017373
treatment	O	O
,	O	O
four	O	O
patients	O	O
out	O	O
of	O	O
twenty	O	O
-	O	O
four	O	O
were	O	O
found	O	O
to	O	O
be	O	O
affected	O	O
by	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
.	O	O

CONCLUSIONS	O	O
:	O	O
Ischaemic	O	O
coronary	B-Disease	D003324
arteriosclerosis	I-Disease	D003324
with	O	O
an	O	O
incidence	O	O
rate	O	O
of	O	O
16	O	O
.	O	O

6%	O	O
as	O	O
caused	O	O
by	O	O
prolonged	O	O
CPA	B-Chemical	D017373
therapy	O	O
is	O	O
mediated	O	O
through	O	O
changes	O	O
in	O	O
HDL	O	O
cholesterol	B-Chemical	D002784
,	O	O
Apo	O	O
A	O	O
-	O	O
I	O	O
and	O	O
Apo	O	O
A	O	O
-	O	O
II	O	O
pro	O	O
fi	O	O
les	O	O
,	O	O
other	O	O
than	O	O
the	O	O
well	O	O
-	O	O
known	O	O
hyperglyceridemic	B-Disease	D050171
effect	I-Disease	D050171
caused	O	O
by	O	O
estrogen	B-Chemical	D004967
.	O	O

5	B-Chemical	D005472
-	I-Chemical	D005472
Fluorouracil	I-Chemical	D005472
cardiotoxicity	B-Disease	D066126
induced	O	O
by	O	O
alpha	B-Chemical	C032348
-	I-Chemical	C032348
fluoro	I-Chemical	C032348
-	I-Chemical	C032348
beta	I-Chemical	C032348
-	I-Chemical	C032348
alanine	I-Chemical	C032348
.	O	O

Cardiotoxicity	B-Disease	D066126
is	O	O
a	O	O
rare	O	O
complication	O	O
occurring	O	O
during	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
treatment	O	O
for	O	O
malignancies	B-Disease	D009369
.	O	O

We	O	O
herein	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
70	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
in	O	O
whom	O	O
a	O	O
high	O	O
serum	O	O
level	O	O
of	O	O
alpha	B-Chemical	C032348
-	I-Chemical	C032348
fluoro	I-Chemical	C032348
-	I-Chemical	C032348
beta	I-Chemical	C032348
-	I-Chemical	C032348
alanine	I-Chemical	C032348
(	O	O
FBAL	B-Chemical	C032348
)	O	O
was	O	O
observed	O	O
.	O	O

The	O	O
patient	O	O
,	O	O
who	O	O
had	O	O
unresectable	O	O
colon	B-Disease	D003110
cancer	I-Disease	D003110
metastases	O	O
to	O	O
the	O	O
liver	O	O
and	O	O
lung	O	O
,	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
chemotherapy	O	O
from	O	O
an	O	O
affiliated	O	O
hospital	O	O
;	O	O
he	O	O
had	O	O
no	O	O
cardiac	O	O
history	O	O
.	O	O

After	O	O
admission	O	O
,	O	O
the	O	O
patient	O	O
received	O	O
a	O	O
continuous	O	O
intravenous	O	O
infusion	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
(	O	O
1000	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
,	O	O
during	O	O
which	O	O
precordial	B-Disease	D002637
pain	I-Disease	D002637
with	O	O
right	B-Disease	D002037
bundle	I-Disease	D002037
branch	I-Disease	D002037
block	I-Disease	D002037
occurred	O	O
concomitantly	O	O
with	O	O
a	O	O
high	O	O
serum	O	O
FBAL	B-Chemical	C032348
concentration	O	O
of	O	O
1955	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

Both	O	O
the	O	O
precordial	B-Disease	D002637
pain	I-Disease	D002637
and	O	O
the	O	O
electrocardiographic	O	O
changes	O	O
disappeared	O	O
spontaneously	O	O
after	O	O
the	O	O
discontinuation	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
.	O	O

As	O	O
the	O	O
precordial	B-Disease	D002637
pain	I-Disease	D002637
in	O	O
this	O	O
patient	O	O
was	O	O
considered	O	O
to	O	O
have	O	O
been	O	O
due	O	O
to	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
the	O	O
administration	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
was	O	O
abandoned	O	O
.	O	O

Instead	O	O
,	O	O
oral	O	O
administration	O	O
of	O	O
S	O	O
-	O	O
1	O	O
(	O	O
a	O	O
derivative	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
,	O	O
at	O	O
200	O	O
mg	O	O
/	O	O
day	O	O
twice	O	O
a	O	O
week	O	O
,	O	O
was	O	O
instituted	O	O
,	O	O
because	O	O
S	O	O
-	O	O
1	O	O
has	O	O
a	O	O
strong	O	O
inhibitory	O	O
effect	O	O
on	O	O
dihydropyrimidine	B-Chemical	C020047
dehydrogenase	O	O
,	O	O
which	O	O
catalyzes	O	O
the	O	O
degradative	O	O
of	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
into	O	O
FBAL	B-Chemical	C032348
.	O	O

The	O	O
serum	O	O
FBAL	B-Chemical	C032348
concentration	O	O
subsequently	O	O
decreased	O	O
to	O	O
352	O	O
ng	O	O
/	O	O
ml	O	O
,	O	O
the	O	O
same	O	O
as	O	O
the	O	O
value	O	O
measured	O	O
on	O	O
the	O	O
first	O	O
day	O	O
of	O	O
S	O	O
-	O	O
1	O	O
administration	O	O
.	O	O

Thereafter	O	O
,	O	O
no	O	O
cardiac	B-Disease	D009461
symptoms	I-Disease	D009461
were	O	O
observed	O	O
.	O	O

The	O	O
patient	O	O
achieved	O	O
a	O	O
partial	O	O
response	O	O
6	O	O
months	O	O
after	O	O
the	O	O
initiation	O	O
of	O	O
the	O	O
S	O	O
-	O	O
1	O	O
treatment	O	O
.	O	O

The	O	O
experience	O	O
of	O	O
this	O	O
case	O	O
,	O	O
together	O	O
with	O	O
a	O	O
review	O	O
of	O	O
the	O	O
literature	O	O
,	O	O
suggests	O	O
that	O	O
FBAL	B-Chemical	C032348
is	O	O
related	O	O
to	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

S	O	O
-	O	O
1	O	O
may	O	O
be	O	O
administered	O	O
safely	O	O
to	O	O
patients	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
.	O	O

The	O	O
influence	O	O
of	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B-Chemical	C522803
and	O	O
doxorubicin	B-Chemical	D004317
administration	O	O
on	O	O
the	O	O
protection	O	O
against	O	O
doxorubicin	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
in	O	O
mice	O	O
.	O	O

PURPOSE	O	O
:	O	O
Despite	O	O
its	O	O
well	O	O
-	O	O
known	O	O
cardiotoxicity	B-Disease	D066126
,	O	O
the	O	O
anthracyclin	O	O
doxorubicin	B-Chemical	D004317
(	O	O
DOX	B-Chemical	D004317
)	O	O
continues	O	O
to	O	O
be	O	O
an	O	O
effective	O	O
and	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
.	O	O

DOX	B-Chemical	D004317
-	O	O
induced	O	O
cardiac	B-Disease	D006331
damage	I-Disease	D006331
presumably	O	O
results	O	O
from	O	O
the	O	O
formation	O	O
of	O	O
free	O	O
radicals	O	O
by	O	O
DOX	B-Chemical	D004317
.	O	O

Reactive	O	O
oxygen	B-Chemical	D010100
species	O	O
particularly	O	O
affect	O	O
the	O	O
cardiac	O	O
myocytes	O	O
because	O	O
these	O	O
cells	O	O
seem	O	O
to	O	O
have	O	O
a	O	O
relatively	O	O
poor	O	O
antioxidant	O	O
defense	O	O
system	O	O
.	O	O

The	O	O
semisynthetic	O	O
flavonoid	B-Chemical	D005419
monohydroxyethylrutoside	B-Chemical	C522803
(	O	O
monoHER	B-Chemical	C522803
)	O	O
showed	O	O
cardioprotection	O	O
against	O	O
DOX	B-Chemical	D004317
-	O	O
induced	O	O
cardiotoxicity	B-Disease	D066126
through	O	O
its	O	O
radical	O	O
scavenging	O	O
and	O	O
iron	B-Chemical	D007501
chelating	O	O
properties	O	O
.	O	O

Because	O	O
of	O	O
the	O	O
relatively	O	O
short	O	O
final	O	O
half	O	O
-	O	O
life	O	O
of	O	O
monoHER	B-Chemical	C522803
(	O	O
about	O	O
30	O	O
min	O	O
)	O	O
,	O	O
it	O	O
is	O	O
expected	O	O
that	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B-Chemical	C522803
and	O	O
DOX	B-Chemical	D004317
might	O	O
be	O	O
of	O	O
influence	O	O
on	O	O
the	O	O
cardioprotective	O	O
effect	O	O
of	O	O
monoHER	B-Chemical	C522803
.	O	O

Therefore	O	O
,	O	O
the	O	O
aim	O	O
of	O	O
the	O	O
present	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
this	O	O
possible	O	O
effect	O	O
.	O	O

METHODS	O	O
:	O	O
Six	O	O
groups	O	O
of	O	O
6	O	O
BALB	O	O
/	O	O
c	O	O
mice	O	O
were	O	O
treated	O	O
with	O	O
saline	O	O
,	O	O
DOX	B-Chemical	D004317
alone	O	O
or	O	O
DOX	B-Chemical	D004317
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
preceded	O	O
by	O	O
monoHER	B-Chemical	C522803
(	O	O
500	O	O
mg	O	O
/	O	O
kg	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
with	O	O
an	O	O
interval	O	O
of	O	O
10	O	O
,	O	O
30	O	O
,	O	O
60	O	O
or	O	O
120	O	O
min	O	O
.	O	O

After	O	O
a	O	O
6	O	O
-	O	O
week	O	O
treatment	O	O
period	O	O
and	O	O
additional	O	O
observation	O	O
for	O	O
2	O	O
weeks	O	O
,	O	O
the	O	O
mice	O	O
were	O	O
sacrificed	O	O
.	O	O

Their	O	O
cardiac	O	O
tissues	O	O
were	O	O
processed	O	O
for	O	O
light	O	O
microscopy	O	O
,	O	O
after	O	O
which	O	O
cardiomyocyte	B-Disease	D009202
damage	I-Disease	D009202
was	O	O
evaluated	O	O
according	O	O
to	O	O
Billingham	O	O
(	O	O
in	O	O
Cancer	B-Disease	D009369
Treat	O	O
Rep	O	O
62	O	O
(	O	O
6	O	O
)	O	O
:	O	O
865	O	O
-	O	O
872	O	O
,	O	O
1978	O	O
)	O	O
.	O	O

Microscopic	O	O
evaluation	O	O
revealed	O	O
that	O	O
treatment	O	O
with	O	O
DOX	B-Chemical	D004317
alone	O	O
induced	O	O
significant	O	O
cardiac	B-Disease	D006331
damage	I-Disease	D006331
in	O	O
comparison	O	O
to	O	O
the	O	O
saline	O	O
control	O	O
group	O	O
(	O	O
P<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
number	O	O
of	O	O
damaged	O	O
cardiomyocytes	O	O
was	O	O
9	O	O
.	O	O

6	O	O
-	O	O
fold	O	O
(	O	O
95%	O	O
CI	O	O
4	O	O
.	O	O

4	O	O
-	O	O
21	O	O
.	O	O

0	O	O
)	O	O
higher	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
DOX	B-Chemical	D004317
alone	O	O
than	O	O
that	O	O
in	O	O
animals	O	O
of	O	O
the	O	O
control	O	O
group	O	O
.	O	O

The	O	O
ratio	O	O
of	O	O
aberrant	O	O
cardiomyocytes	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
DOX	B-Chemical	D004317
preceded	O	O
by	O	O
monoHER	B-Chemical	C522803
and	O	O
those	O	O
in	O	O
mice	O	O
treated	O	O
with	O	O
saline	O	O
ranged	O	O
from	O	O
1	O	O
.	O	O

6	O	O
to	O	O
2	O	O
.	O	O

8	O	O
(	O	O
mean	O	O
2	O	O
.	O	O

2	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

2	O	O
-	O	O
4	O	O
.	O	O

1	O	O
,	O	O
P=0	O	O
.	O	O

019	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
protective	O	O
effect	O	O
by	O	O
adding	O	O
monoHER	B-Chemical	C522803
before	O	O
DOX	B-Chemical	D004317
led	O	O
to	O	O
a	O	O
significant	O	O
4	O	O
.	O	O

4	O	O
-	O	O
fold	O	O
reduction	O	O
(	O	O
P<0	O	O
.	O	O

001	O	O
,	O	O
95%	O	O
CI	O	O
2	O	O
.	O	O

3	O	O
-	O	O
8	O	O
.	O	O

2	O	O
)	O	O
of	O	O
abnormal	O	O
cardiomyocytes	O	O
.	O	O

This	O	O
protective	O	O
effect	O	O
did	O	O
not	O	O
depend	O	O
on	O	O
the	O	O
time	O	O
interval	O	O
between	O	O
monoHER	B-Chemical	C522803
and	O	O
DOX	B-Chemical	D004317
administration	O	O
(	O	O
P=0	O	O
.	O	O

345	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
results	O	O
indicate	O	O
that	O	O
in	O	O
an	O	O
outpatient	O	O
clinical	O	O
setting	O	O
monoHER	B-Chemical	C522803
may	O	O
be	O	O
administered	O	O
shortly	O	O
before	O	O
DOX	B-Chemical	D004317
.	O	O

Clinical	O	O
evaluation	O	O
of	O	O
adverse	O	O
effects	O	O
during	O	O
bepridil	B-Chemical	D015764
administration	O	O
for	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
and	O	O
flutter	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Bepridil	B-Chemical	D015764
hydrochloride	I-Chemical	D015764
(	O	O
Bpd	B-Chemical	D015764
)	O	O
has	O	O
attracted	O	O
attention	O	O
as	O	O
an	O	O
effective	O	O
drug	O	O
for	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
(	O	O
AF	B-Disease	D001281
)	O	O
and	O	O
atrial	B-Disease	D001282
flutter	I-Disease	D001282
(	O	O
AFL	B-Disease	D001282
)	O	O
.	O	O

However	O	O
,	O	O
serious	O	O
adverse	O	O
effects	O	O
,	O	O
including	O	O
torsade	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
(	O	O
Tdp	B-Disease	D016171
)	O	O
,	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

METHODS	O	O
AND	O	O
RESULTS	O	O
:	O	O
Adverse	O	O
effects	O	O
of	O	O
Bpd	B-Chemical	D015764
requiring	O	O
discontinuation	O	O
of	O	O
treatment	O	O
were	O	O
evaluated	O	O
.	O	O

Bpd	B-Chemical	D015764
was	O	O
administered	O	O
to	O	O
459	O	O
patients	O	O
(	O	O
361	O	O
males	O	O
,	O	O
63+	O	O
/	O	O
-	O	O
12	O	O
years	O	O
old	O	O
)	O	O
comprising	O	O
378	O	O
AF	B-Disease	D001281
and	O	O
81	O	O
AFL	B-Disease	D001282
cases	O	O
.	O	O

Mean	O	O
left	O	O
ventricular	O	O
ejection	O	O
fraction	O	O
and	O	O
atrial	O	O
dimension	O	O
(	O	O
LAD	O	O
)	O	O
were	O	O
66+	O	O
/	O	O
-	O	O
11%	O	O
and	O	O
40+	O	O
/	O	O
-	O	O
6	O	O
mm	O	O
,	O	O
respectively	O	O
.	O	O

Adverse	O	O
effects	O	O
were	O	O
observed	O	O
in	O	O
19	O	O
patients	O	O
(	O	O
4%	O	O
)	O	O
during	O	O
an	O	O
average	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
20	O	O
months	O	O
.	O	O

There	O	O
was	O	O
marked	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
greater	O	O
than	O	O
0	O	O
.	O	O

55	O	O
s	O	O
in	O	O
13	O	O
patients	O	O
,	O	O
bradycardia	B-Disease	D001919
less	O	O
than	O	O
40	O	O
beats	O	O
/	O	O
min	O	O
in	O	O
6	O	O
patients	O	O
,	O	O
dizziness	B-Disease	D004244
and	O	O
general	O	O
fatigue	B-Disease	D005221
in	O	O
1	O	O
patient	O	O
each	O	O
.	O	O

In	O	O
4	O	O
of	O	O
13	O	O
patients	O	O
with	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
,	O	O
Tdp	B-Disease	D016171
occurred	O	O
.	O	O

The	O	O
major	O	O
triggering	O	O
factors	O	O
of	O	O
Tdp	B-Disease	D016171
were	O	O
hypokalemia	B-Disease	D007008
and	O	O
sudden	O	O
decrease	O	O
in	O	O
heart	O	O
rate	O	O
.	O	O

There	O	O
were	O	O
no	O	O
differences	O	O
in	O	O
the	O	O
clinical	O	O
backgrounds	O	O
of	O	O
the	O	O
patients	O	O
with	O	O
and	O	O
without	O	O
Tdp	B-Disease	D016171
other	O	O
than	O	O
LAD	O	O
and	O	O
age	O	O
,	O	O
which	O	O
were	O	O
larger	O	O
and	O	O
older	O	O
in	O	O
the	O	O
patients	O	O
with	O	O
Tdp	B-Disease	D016171
.	O	O

CONCLUSION	O	O
:	O	O
Careful	O	O
observation	O	O
of	O	O
serum	O	O
potassium	B-Chemical	D011188
concentration	O	O
and	O	O
the	O	O
ECG	O	O
should	O	O
always	O	O
be	O	O
done	O	O
during	O	O
Bpd	B-Chemical	D015764
administration	O	O
,	O	O
particularly	O	O
in	O	O
elderly	O	O
patients	O	O
.	O	O

Enhanced	O	O
isoproterenol	B-Chemical	D007545
-	O	O
induced	O	O
cardiac	B-Disease	D006332
hypertrophy	I-Disease	D006332
in	O	O
transgenic	O	O
rats	O	O
with	O	O
low	O	O
brain	O	O
angiotensinogen	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
shown	O	O
that	O	O
a	O	O
permanent	O	O
deficiency	O	O
in	O	O
the	O	O
brain	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000804
system	O	O
(	O	O
RAS	O	O
)	O	O
may	O	O
increase	O	O
the	O	O
sensitivity	O	O
of	O	O
the	O	O
baroreflex	O	O
control	O	O
of	O	O
heart	O	O
rate	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
at	O	O
studying	O	O
the	O	O
involvement	O	O
of	O	O
the	O	O
brain	O	O
RAS	O	O
in	O	O
the	O	O
cardiac	O	O
reactivity	O	O
to	O	O
the	O	O
beta	O	O
-	O	O
adrenoceptor	O	O
(	O	O
beta	O	O
-	O	O
AR	O	O
)	O	O
agonist	O	O
isoproterenol	B-Chemical	D007545
(	O	O
Iso	B-Chemical	D007545
)	O	O
.	O	O

Transgenic	O	O
rats	O	O
with	O	O
low	O	O
brain	O	O
angiotensinogen	O	O
(	O	O
TGR	O	O
)	O	O
were	O	O
used	O	O
.	O	O

In	O	O
isolated	O	O
hearts	O	O
,	O	O
Iso	B-Chemical	D007545
induced	O	O
a	O	O
significantly	O	O
greater	O	O
increase	O	O
in	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
pressure	O	O
and	O	O
maximal	O	O
contraction	O	O
(	O	O
+dP	O	O
/	O	O
dt	O	O
(	O	O
max	O	O
)	O	O
)	O	O
in	O	O
the	O	O
TGR	O	O
than	O	O
in	O	O
the	O	O
Sprague	O	O
-	O	O
Dawley	O	O
(	O	O
SD	O	O
)	O	O
rats	O	O
.	O	O

LV	B-Disease	D006332
hypertrophy	I-Disease	D006332
induced	O	O
by	O	O
Iso	B-Chemical	D007545
treatment	O	O
was	O	O
significantly	O	O
higher	O	O
in	O	O
TGR	O	O
than	O	O
in	O	O
SD	O	O
rats	O	O
(	O	O
in	O	O
g	O	O
LV	O	O
wt	O	O
/	O	O
100	O	O
g	O	O
body	O	O
wt	O	O
,	O	O
0	O	O
.	O	O

28	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

004	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

24	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

004	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
greater	O	O
LV	B-Disease	D006332
hypertrophy	I-Disease	D006332
in	O	O
TGR	O	O
rats	O	O
was	O	O
associated	O	O
with	O	O
more	O	O
pronounced	O	O
downregulation	O	O
of	O	O
beta	O	O
-	O	O
AR	O	O
and	O	O
upregulation	O	O
of	O	O
LV	O	O
beta	O	O
-	O	O
AR	O	O
kinase	O	O
-	O	O
1	O	O
mRNA	O	O
levels	O	O
compared	O	O
with	O	O
those	O	O
in	O	O
SD	O	O
rats	O	O
.	O	O

The	O	O
decrease	O	O
in	O	O
the	O	O
heart	O	O
rate	O	O
(	O	O
HR	O	O
)	O	O
induced	O	O
by	O	O
the	O	O
beta	O	O
-	O	O
AR	O	O
antagonist	O	O
metoprolol	B-Chemical	D008790
in	O	O
conscious	O	O
rats	O	O
was	O	O
significantly	O	O
attenuated	O	O
in	O	O
TGR	O	O
compared	O	O
with	O	O
SD	O	O
rats	O	O
(	O	O
-	O	O
9	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

7%	O	O
vs	O	O
.	O	O

-	O	O
18	O	O
.	O	O

1	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

5%	O	O
)	O	O
,	O	O
whereas	O	O
the	O	O
effect	O	O
of	O	O
parasympathetic	O	O
blockade	O	O
by	O	O
atropine	B-Chemical	D001285
on	O	O
HR	O	O
was	O	O
similar	O	O
in	O	O
both	O	O
strains	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
TGR	O	O
are	O	O
more	O	O
sensitive	O	O
to	O	O
beta	O	O
-	O	O
AR	O	O
agonist	O	O
-	O	O
induced	O	O
cardiac	B-Disease	D006331
inotropic	I-Disease	D006331
response	O	O
and	O	O
hypertrophy	B-Disease	D006984
,	O	O
possibly	O	O
due	O	O
to	O	O
chronically	O	O
low	O	O
sympathetic	O	O
outflow	O	O
directed	O	O
to	O	O
the	O	O
heart	O	O
.	O	O

Drug	O	O
-	O	O
induced	O	O
long	B-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
in	O	O
injection	O	O
drug	O	O
users	O	O
receiving	O	O
methadone	B-Chemical	D008691
:	O	O
high	O	O
frequency	O	O
in	O	O
hospitalized	O	O
patients	O	O
and	O	O
risk	O	O
factors	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Drug	O	O
-	O	O
induced	O	O
long	B-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
is	O	O
a	O	O
serious	O	O
adverse	O	O
drug	O	O
reaction	O	O
.	O	O

Methadone	B-Chemical	D008691
prolongs	O	O
the	O	O
QT	O	O
interval	O	O
in	O	O
vitro	O	O
in	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

In	O	O
the	O	O
inpatient	O	O
setting	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
QT	B-Disease	D008133
interval	I-Disease	D008133
prolongation	I-Disease	D008133
with	O	O
methadone	B-Chemical	D008691
treatment	O	O
,	O	O
its	O	O
dose	O	O
dependence	O	O
,	O	O
and	O	O
the	O	O
importance	O	O
of	O	O
cofactors	O	O
such	O	O
as	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
remain	O	O
unknown	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
performed	O	O
a	O	O
systematic	O	O
,	O	O
retrospective	O	O
study	O	O
comparing	O	O
active	O	O
or	O	O
former	O	O
intravenous	O	O
drug	O	O
users	O	O
receiving	O	O
methadone	B-Chemical	D008691
and	O	O
those	O	O
not	O	O
receiving	O	O
methadone	B-Chemical	D008691
among	O	O
all	O	O
patients	O	O
hospitalized	O	O
over	O	O
a	O	O
5	O	O
-	O	O
year	O	O
period	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
hospital	O	O
.	O	O

A	O	O
total	O	O
of	O	O
167	O	O
patients	O	O
receiving	O	O
methadone	B-Chemical	D008691
fulfilled	O	O
the	O	O
inclusion	O	O
criteria	O	O
and	O	O
were	O	O
compared	O	O
with	O	O
a	O	O
control	O	O
group	O	O
of	O	O
80	O	O
injection	O	O
drug	O	O
users	O	O
not	O	O
receiving	O	O
methadone	B-Chemical	D008691
.	O	O

In	O	O
addition	O	O
to	O	O
methadone	B-Chemical	D008691
dose	O	O
,	O	O
15	O	O
demographic	O	O
,	O	O
biological	O	O
,	O	O
and	O	O
pharmacological	O	O
variables	O	O
were	O	O
considered	O	O
as	O	O
potential	O	O
risk	O	O
factors	O	O
for	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
.	O	O

RESULTS	O	O
:	O	O
Among	O	O
167	O	O
methadone	B-Chemical	D008691
maintenance	O	O
patients	O	O
,	O	O
the	O	O
prevalence	O	O
of	O	O
QTc	O	O
prolongation	O	O
to	O	O
0	O	O
.	O	O

50	O	O
second	O	O
(	O	O
(	O	O
1	O	O
/	O	O
2	O	O
)	O	O
)	O	O
or	O	O
longer	O	O
was	O	O
16	O	O
.	O	O

2%	O	O
compared	O	O
with	O	O
0%	O	O
in	O	O
80	O	O
control	O	O
subjects	O	O
.	O	O

Six	O	O
patients	O	O
(	O	O
3	O	O
.	O	O

6%	O	O
)	O	O
in	O	O
the	O	O
methadone	B-Chemical	D008691
group	O	O
presented	O	O
torsades	B-Disease	D016171
de	I-Disease	D016171
pointes	I-Disease	D016171
.	O	O

QTc	O	O
length	O	O
was	O	O
weakly	O	O
but	O	O
significantly	O	O
associated	O	O
with	O	O
methadone	B-Chemical	D008691
daily	O	O
dose	O	O
(	O	O
Spearman	O	O
rank	O	O
correlation	O	O
coefficient	O	O
,	O	O
0	O	O
.	O	O

20	O	O
;	O	O
P<	O	O
.	O	O

01	O	O
)	O	O
.	O	O

Multivariate	O	O
regression	O	O
analysis	O	O
allowed	O	O
attribution	O	O
of	O	O
31	O	O
.	O	O

8%	O	O
of	O	O
QTc	O	O
variability	O	O
to	O	O
methadone	B-Chemical	D008691
dose	O	O
,	O	O
cytochrome	O	O
P	O	O
-	O	O
450	O	O
3A4	O	O
drug	O	O
-	O	O
drug	O	O
interactions	O	O
,	O	O
hypokalemia	B-Disease	D007008
,	O	O
and	O	O
altered	O	O
liver	O	O
function	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
QT	B-Disease	D008133
interval	I-Disease	D008133
prolongation	I-Disease	D008133
in	O	O
methadone	B-Chemical	D008691
maintenance	O	O
patients	O	O
hospitalized	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
center	O	O
is	O	O
a	O	O
frequent	O	O
finding	O	O
.	O	O

Methadone	B-Chemical	D008691
dose	O	O
,	O	O
presence	O	O
of	O	O
cytochrome	O	O
P	O	O
-	O	O
450	O	O
3A4	O	O
inhibitors	O	O
,	O	O
potassium	B-Chemical	D011188
level	O	O
,	O	O
and	O	O
liver	O	O
function	O	O
contribute	O	O
to	O	O
QT	B-Disease	D008133
prolongation	I-Disease	D008133
.	O	O

Long	B-Disease	D008133
QT	I-Disease	D008133
syndrome	I-Disease	D008133
can	O	O
occur	O	O
with	O	O
low	O	O
doses	O	O
of	O	O
methadone	B-Chemical	D008691
.	O	O

Mechanisms	O	O
of	O	O
hypertension	B-Disease	D006973
induced	O	O
by	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
deficiency	O	O
:	O	O
focus	O	O
on	O	O
venous	O	O
function	O	O
.	O	O

Loss	O	O
of	O	O
endothelial	O	O
cell	O	O
-	O	O
derived	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
in	O	O
hypertension	B-Disease	D006973
is	O	O
a	O	O
hallmark	O	O
of	O	O
arterial	B-Disease	D018754
dysfunction	I-Disease	D018754
.	O	O

Experimental	O	O
hypertension	B-Disease	D006973
created	O	O
by	O	O
the	O	O
removal	O	O
of	O	O
NO	B-Chemical	D009569
,	O	O
however	O	O
,	O	O
involves	O	O
mechanisms	O	O
in	O	O
addition	O	O
to	O	O
decreased	O	O
arterial	O	O
vasodilator	O	O
activity	O	O
.	O	O

These	O	O
include	O	O
augmented	O	O
endothelin	O	O
-	O	O
1	O	O
(	O	O
ET	O	O
-	O	O
1	O	O
)	O	O
release	O	O
,	O	O
increased	O	O
sympathetic	O	O
nervous	O	O
system	O	O
activity	O	O
,	O	O
and	O	O
elevated	O	O
tissue	O	O
oxidative	O	O
stress	O	O
.	O	O

We	O	O
hypothesized	O	O
that	O	O
increased	O	O
venous	O	O
smooth	O	O
muscle	O	O
(	O	O
venomotor	O	O
)	O	O
tone	O	O
plays	O	O
a	O	O
role	O	O
in	O	O
Nomega	B-Chemical	D019335
-	I-Chemical	D019335
nitro	I-Chemical	D019335
-	I-Chemical	D019335
L	I-Chemical	D019335
-	I-Chemical	D019335
arginine	I-Chemical	D019335
(	O	O
LNNA	B-Chemical	D019335
)	O	O
hypertension	B-Disease	D006973
through	O	O
these	O	O
mechanisms	O	O
.	O	O

Rats	O	O
were	O	O
treated	O	O
with	O	O
the	O	O
NO	B-Chemical	D009569
synthase	O	O
inhibitor	O	O
LNNA	B-Chemical	D019335
(	O	O
0	O	O
.	O	O

5	O	O
g	O	O
/	O	O
L	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
for	O	O
2	O	O
weeks	O	O
.	O	O

Mean	O	O
arterial	O	O
pressure	O	O
of	O	O
conscious	O	O
rats	O	O
was	O	O
119	O	O
+	O	O
/	O	O
-	O	O
2	O	O
mm	O	O
Hg	O	O
in	O	O
control	O	O
and	O	O
194	O	O
+	O	O
/	O	O
-	O	O
5	O	O
mm	O	O
Hg	O	O
in	O	O
LNNA	B-Chemical	D019335
rats	O	O
(	O	O
P<0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Carotid	O	O
arteries	O	O
and	O	O
vena	O	O
cava	O	O
were	O	O
removed	O	O
for	O	O
measurement	O	O
of	O	O
isometric	O	O
contraction	O	O
.	O	O

Maximal	O	O
contraction	O	O
to	O	O
norepinephrine	B-Chemical	D009638
was	O	O
modestly	O	O
reduced	O	O
in	O	O
arteries	O	O
from	O	O
LNNA	B-Chemical	D019335
compared	O	O
with	O	O
control	O	O
rats	O	O
whereas	O	O
the	O	O
maximum	O	O
contraction	O	O
to	O	O
ET	O	O
-	O	O
1	O	O
was	O	O
significantly	O	O
reduced	O	O
(	O	O
54%	O	O
control	O	O
)	O	O
.	O	O

Maximum	O	O
contraction	O	O
of	O	O
vena	O	O
cava	O	O
to	O	O
norepinephrine	B-Chemical	D009638
(	O	O
37%	O	O
control	O	O
)	O	O
also	O	O
was	O	O
reduced	O	O
but	O	O
no	O	O
change	O	O
in	O	O
response	O	O
to	O	O
ET	O	O
-	O	O
1	O	O
was	O	O
observed	O	O
.	O	O

Mean	O	O
circulatory	O	O
filling	O	O
pressure	O	O
,	O	O
an	O	O
in	O	O
vivo	O	O
measure	O	O
of	O	O
venomotor	O	O
tone	O	O
,	O	O
was	O	O
not	O	O
elevated	O	O
in	O	O
LNNA	B-Chemical	D019335
hypertension	B-Disease	D006973
at	O	O
1	O	O
or	O	O
2	O	O
weeks	O	O
after	O	O
LNNA	B-Chemical	D019335
.	O	O

The	O	O
superoxide	B-Chemical	D013481
scavenger	O	O
tempol	B-Chemical	C001803
(	O	O
30	O	O
,	O	O
100	O	O
,	O	O
and	O	O
300	O	O
micromol	O	O
kg	O	O
(	O	O
-	O	O
1	O	O
)	O	O
,	O	O
IV	O	O
)	O	O
did	O	O
not	O	O
change	O	O
arterial	O	O
pressure	O	O
in	O	O
control	O	O
rats	O	O
but	O	O
caused	O	O
a	O	O
dose	O	O
-	O	O
dependent	O	O
decrease	O	O
in	O	O
LNNA	B-Chemical	D019335
rats	O	O
(	O	O
-	O	O
18	O	O
+	O	O
/	O	O
-	O	O
8	O	O
,	O	O
-	O	O
26	O	O
+	O	O
/	O	O
-	O	O
15	O	O
,	O	O
and	O	O
-	O	O
54	O	O
+	O	O
/	O	O
-	O	O
11	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

Similarly	O	O
,	O	O
ganglionic	O	O
blockade	O	O
with	O	O
hexamethonium	B-Chemical	D018738
caused	O	O
a	O	O
significantly	O	O
greater	O	O
fall	O	O
in	O	O
LNNA	B-Chemical	D019335
hypertensive	B-Disease	D006973
rats	O	O
(	O	O
76	O	O
+	O	O
/	O	O
-	O	O
9	O	O
mm	O	O
Hg	O	O
)	O	O
compared	O	O
with	O	O
control	O	O
rats	O	O
(	O	O
35	O	O
+	O	O
/	O	O
-	O	O
10	O	O
mm	O	O
Hg	O	O
)	O	O
.	O	O

Carotid	O	O
arteries	O	O
,	O	O
vena	O	O
cava	O	O
,	O	O
and	O	O
sympathetic	O	O
ganglia	O	O
from	O	O
LNNA	B-Chemical	D019335
rats	O	O
had	O	O
higher	O	O
basal	O	O
levels	O	O
of	O	O
superoxide	B-Chemical	D013481
compared	O	O
with	O	O
those	O	O
from	O	O
control	O	O
rats	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
while	O	O
NO	B-Chemical	D009569
deficiency	O	O
increases	O	O
oxidative	O	O
stress	O	O
and	O	O
sympathetic	O	O
activity	O	O
in	O	O
both	O	O
arterial	O	O
and	O	O
venous	O	O
vessels	O	O
,	O	O
the	O	O
impact	O	O
on	O	O
veins	O	O
does	O	O
not	O	O
make	O	O
a	O	O
major	O	O
contribution	O	O
to	O	O
this	O	O
form	O	O
of	O	O
hypertension	B-Disease	D006973
.	O	O

Association	O	O
of	O	O
DRD2	O	O
polymorphisms	O	O
and	O	O
chlorpromazine	B-Chemical	D002746
-	O	O
induced	O	O
extrapyramidal	B-Disease	D001480
syndrome	I-Disease	D001480
in	O	O
Chinese	O	O
schizophrenic	B-Disease	D012559
patients	O	O
.	O	O

AIM	O	O
:	O	O
Extrapyramidal	B-Disease	D001480
syndrome	I-Disease	D001480
(	O	O
EPS	B-Disease	D001480
)	O	O
is	O	O
most	O	O
commonly	O	O
affected	O	O
by	O	O
typical	O	O
antipsychotic	O	O
drugs	O	O
that	O	O
have	O	O
a	O	O
high	O	O
affinity	O	O
with	O	O
the	O	O
D2	O	O
receptor	O	O
.	O	O

Recently	O	O
,	O	O
many	O	O
research	O	O
groups	O	O
have	O	O
reported	O	O
on	O	O
the	O	O
positive	O	O
relationship	O	O
between	O	O
the	O	O
genetic	O	O
variations	O	O
in	O	O
the	O	O
DRD2	O	O
gene	O	O
and	O	O
the	O	O
therapeutic	O	O
response	O	O
in	O	O
schizophrenia	B-Disease	D012559
patients	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
role	O	O
of	O	O
variations	O	O
in	O	O
the	O	O
receptor	O	O
in	O	O
modulating	O	O
receptor	O	O
expression	O	O
.	O	O

In	O	O
this	O	O
study	O	O
,	O	O
we	O	O
evaluate	O	O
the	O	O
role	O	O
DRD2	O	O
plays	O	O
in	O	O
chlorpromazine	B-Chemical	D002746
-	O	O
induced	O	O
EPS	B-Disease	D001480
in	O	O
schizophrenic	B-Disease	D012559
patients	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
identified	O	O
seven	O	O
SNP	O	O
(	O	O
single	O	O
nucleotide	O	O
polymorphism	O	O
)	O	O
(	O	O
-	O	O
141Cins>del	O	O
,	O	O
TaqIB	O	O
,	O	O
TaqID	O	O
,	O	O
Ser311Cys	O	O
,	O	O
rs6275	O	O
,	O	O
rs6277	O	O
and	O	O
TaqIA	O	O
)	O	O
in	O	O
the	O	O
DRD2	O	O
gene	O	O
in	O	O
146	O	O
schizophrenic	B-Disease	D012559
inpatients	O	O
(	O	O
59	O	O
with	O	O
EPS	B-Disease	D001480
and	O	O
87	O	O
without	O	O
EPS	B-Disease	D001480
according	O	O
to	O	O
the	O	O
Simpson	O	O
-	O	O
Angus	O	O
Scale	O	O
)	O	O
treated	O	O
with	O	O
chlorpromazine	B-Chemical	D002746
after	O	O
8	O	O
weeks	O	O
.	O	O

The	O	O
alleles	O	O
of	O	O
all	O	O
loci	O	O
were	O	O
determined	O	O
by	O	O
PCR	O	O
(	O	O
polymerase	O	O
chain	O	O
reaction	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Polymorphisms	O	O
TaqID	O	O
,	O	O
Ser311Cys	O	O
and	O	O
rs6277	O	O
were	O	O
not	O	O
polymorphic	O	O
in	O	O
the	O	O
population	O	O
recruited	O	O
in	O	O
the	O	O
present	O	O
study	O	O
.	O	O

No	O	O
statistical	O	O
significance	O	O
was	O	O
found	O	O
in	O	O
the	O	O
allele	O	O
distribution	O	O
of	O	O
-	O	O
141Cins>del	O	O
,	O	O
TaqIB	O	O
,	O	O
rs6275	O	O
and	O	O
TaqIA	O	O
or	O	O
in	O	O
the	O	O
estimated	O	O
haplotypes	O	O
(	O	O
constituted	O	O
by	O	O
TaqIB	O	O
,	O	O
rs6275	O	O
and	O	O
TaqIA	O	O
)	O	O
in	O	O
linkage	O	O
disequilibrium	O	O
between	O	O
the	O	O
two	O	O
groups	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Our	O	O
results	O	O
did	O	O
not	O	O
lend	O	O
strong	O	O
support	O	O
to	O	O
the	O	O
view	O	O
that	O	O
the	O	O
genetic	O	O
variation	O	O
of	O	O
the	O	O
DRD2	O	O
gene	O	O
plays	O	O
a	O	O
major	O	O
role	O	O
in	O	O
the	O	O
individually	O	O
variable	O	O
adverse	O	O
effect	O	O
induced	O	O
by	O	O
chlorpromazine	B-Chemical	D002746
,	O	O
at	O	O
least	O	O
in	O	O
Chinese	O	O
patients	O	O
with	O	O
schizophrenia	B-Disease	D012559
.	O	O

Our	O	O
results	O	O
confirmed	O	O
a	O	O
previous	O	O
study	O	O
on	O	O
the	O	O
relationship	O	O
between	O	O
DRD2	O	O
and	O	O
EPS	B-Disease	D001480
in	O	O
Caucasians	O	O
.	O	O

Physical	O	O
training	O	O
decreases	O	O
susceptibility	O	O
to	O	O
subsequent	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
in	O	O
the	O	O
rat	O	O
.	O	O

Regular	O	O
motor	O	O
activity	O	O
has	O	O
many	O	O
benefits	O	O
for	O	O
mental	O	O
and	O	O
physical	O	O
condition	O	O
but	O	O
its	O	O
implications	O	O
for	O	O
epilepsy	B-Disease	D004827
are	O	O
still	O	O
controversial	O	O
.	O	O

In	O	O
order	O	O
to	O	O
elucidate	O	O
this	O	O
problem	O	O
,	O	O
we	O	O
have	O	O
studied	O	O
the	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
physical	O	O
activity	O	O
on	O	O
susceptibility	O	O
to	O	O
subsequent	O	O
seizures	B-Disease	D012640
.	O	O

Male	O	O
Wistar	O	O
rats	O	O
were	O	O
subjected	O	O
to	O	O
repeated	O	O
training	O	O
sessions	O	O
in	O	O
a	O	O
treadmill	O	O
and	O	O
swimming	O	O
pool	O	O
.	O	O

Thereafter	O	O
,	O	O
seizures	B-Disease	D012640
were	O	O
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
injections	O	O
in	O	O
trained	O	O
and	O	O
non	O	O
-	O	O
trained	O	O
control	O	O
groups	O	O
.	O	O

During	O	O
the	O	O
acute	O	O
period	O	O
of	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
,	O	O
we	O	O
measured	O	O
:	O	O
(	O	O
1	O	O
)	O	O
the	O	O
latency	O	O
of	O	O
the	O	O
first	O	O
motor	O	O
sign	O	O
,	O	O
(	O	O
2	O	O
)	O	O
the	O	O
intensity	O	O
of	O	O
seizures	B-Disease	D012640
,	O	O
(	O	O
3	O	O
)	O	O
the	O	O
time	O	O
when	O	O
it	O	O
occurred	O	O
within	O	O
the	O	O
6	O	O
-	O	O
h	O	O
observation	O	O
period	O	O
,	O	O
and	O	O
(	O	O
4	O	O
)	O	O
the	O	O
time	O	O
when	O	O
the	O	O
acute	O	O
period	O	O
ended	O	O
.	O	O

All	O	O
these	O	O
behavioral	O	O
parameters	O	O
showed	O	O
statistically	O	O
significant	O	O
changes	O	O
suggesting	O	O
that	O	O
regular	O	O
physical	O	O
exercises	O	O
decrease	O	O
susceptibility	O	O
to	O	O
subsequently	O	O
induced	O	O
seizures	B-Disease	D012640
and	O	O
ameliorate	O	O
the	O	O
course	O	O
of	O	O
experimentally	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

Tonic	O	O
dopaminergic	O	O
stimulation	O	O
impairs	B-Disease	D007859
associative	I-Disease	D007859
learning	I-Disease	D007859
in	O	O
healthy	O	O
subjects	O	O
.	O	O

Endogenous	O	O
dopamine	B-Chemical	D004298
plays	O	O
a	O	O
central	O	O
role	O	O
in	O	O
salience	O	O
coding	O	O
during	O	O
associative	O	O
learning	O	O
.	O	O

Administration	O	O
of	O	O
the	O	O
dopamine	B-Chemical	D004298
precursor	O	O
levodopa	B-Chemical	D007980
enhances	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
and	O	O
stroke	B-Disease	D020521
patients	O	O
.	O	O

Because	O	O
levodopa	B-Chemical	D007980
increases	O	O
both	O	O
phasic	O	O
and	O	O
tonic	O	O
dopaminergic	O	O
neurotransmission	O	O
,	O	O
the	O	O
critical	O	O
mechanism	O	O
mediating	O	O
the	O	O
enhancement	O	O
of	O	O
learning	O	O
is	O	O
unresolved	O	O
.	O	O

We	O	O
here	O	O
probed	O	O
how	O	O
selective	O	O
tonic	O	O
dopaminergic	O	O
stimulation	O	O
affects	O	O
associative	O	O
learning	O	O
.	O	O

Forty	O	O
healthy	O	O
subjects	O	O
were	O	O
trained	O	O
in	O	O
a	O	O
novel	O	O
vocabulary	O	O
of	O	O
45	O	O
concrete	O	O
nouns	O	O
over	O	O
the	O	O
course	O	O
of	O	O
5	O	O
consecutive	O	O
training	O	O
days	O	O
in	O	O
a	O	O
prospective	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
design	O	O
.	O	O

Subjects	O	O
received	O	O
the	O	O
tonically	O	O
stimulating	O	O
dopamine	B-Chemical	D004298
-	O	O
receptor	O	O
agonist	O	O
pergolide	B-Chemical	D010479
(	O	O
0	O	O
.	O	O

1	O	O
mg	O	O
)	O	O
vs	O	O
placebo	O	O
120	O	O
min	O	O
before	O	O
training	O	O
on	O	O
each	O	O
training	O	O
day	O	O
.	O	O

The	O	O
dopamine	B-Chemical	D004298
agonist	O	O
significantly	O	O
impaired	B-Disease	D007859
novel	I-Disease	D007859
word	I-Disease	D007859
learning	I-Disease	D007859
compared	O	O
to	O	O
placebo	O	O
.	O	O

This	O	O
learning	O	O
decrement	O	O
persisted	O	O
up	O	O
to	O	O
the	O	O
last	O	O
follow	O	O
-	O	O
up	O	O
4	O	O
weeks	O	O
post	O	O
-	O	O
training	O	O
.	O	O

Subjects	O	O
treated	O	O
with	O	O
pergolide	B-Chemical	D010479
also	O	O
showed	O	O
restricted	O	O
emotional	O	O
responses	O	O
compared	O	O
to	O	O
the	O	O
PLACEBO	O	O
group	O	O
.	O	O

The	O	O
extent	O	O
of	O	O
'flattened'	O	O
affect	O	O
with	O	O
pergolide	B-Chemical	D010479
was	O	O
related	O	O
to	O	O
the	O	O
degree	O	O
of	O	O
learning	O	O
inhibition	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
tonic	O	O
occupation	O	O
of	O	O
dopamine	B-Chemical	D004298
receptors	O	O
impairs	O	O
learning	O	O
by	O	O
competition	O	O
with	O	O
phasic	O	O
dopamine	B-Chemical	D004298
signals	O	O
.	O	O

Thus	O	O
,	O	O
phasic	O	O
signaling	O	O
seems	O	O
to	O	O
be	O	O
the	O	O
critical	O	O
mechanism	O	O
by	O	O
which	O	O
dopamine	B-Chemical	D004298
enhances	O	O
associative	O	O
learning	O	O
in	O	O
healthy	O	O
subjects	O	O
and	O	O
stroke	B-Disease	D020521
patients	O	O
.	O	O

Minocycline	B-Chemical	D008911
-	O	O
induced	O	O
vasculitis	B-Disease	D014657
fulfilling	O	O
the	O	O
criteria	O	O
of	O	O
polyarteritis	B-Disease	D010488
nodosa	I-Disease	D010488
.	O	O

A	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
who	O	O
had	O	O
been	O	O
taking	O	O
minocycline	B-Chemical	D008911
for	O	O
palmoplantar	B-Disease	D011565
pustulosis	I-Disease	D011565
developed	O	O
fever	B-Disease	D005334
,	O	O
myalgias	B-Disease	D063806
,	O	O
polyneuropathy	B-Disease	D011115
,	O	O
and	O	O
testicular	B-Disease	D013733
pain	I-Disease	D013733
,	O	O
with	O	O
elevated	O	O
C	O	O
-	O	O
reactive	O	O
protein	O	O
(	O	O
CRP	O	O
)	O	O
.	O	O

Neither	O	O
myeloperoxidase	O	O
-	O	O
nor	O	O
proteinase	O	O
-	O	O
3	O	O
-	O	O
antineutrophil	O	O
cytoplasmic	O	O
antibody	O	O
was	O	O
positive	O	O
.	O	O

These	O	O
manifestations	O	O
met	O	O
the	O	O
American	O	O
College	O	O
of	O	O
Rheumatology	O	O
1990	O	O
criteria	O	O
for	O	O
the	O	O
classification	O	O
of	O	O
polyarteritis	B-Disease	D010488
nodosa	I-Disease	D010488
.	O	O

Stopping	O	O
minocycline	B-Chemical	D008911
led	O	O
to	O	O
amelioration	O	O
of	O	O
symptoms	O	O
and	O	O
normalization	O	O
of	O	O
CRP	O	O
level	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
minocycline	B-Chemical	D008911
-	O	O
induced	O	O
vasculitis	B-Disease	D014657
satisfying	O	O
the	O	O
criteria	O	O
.	O	O

Differential	O	O
diagnosis	O	O
for	O	O
drug	O	O
-	O	O
induced	O	O
disease	O	O
is	O	O
invaluable	O	O
even	O	O
for	O	O
patients	O	O
with	O	O
classical	O	O
polyarteritis	B-Disease	D010488
nodosa	I-Disease	D010488
.	O	O

Intramuscular	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
combined	O	O
with	O	O
lamivudine	B-Chemical	D019259
in	O	O
prevention	O	O
of	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
recurrence	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Combined	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
immune	O	O
globulin	O	O
(	O	O
HBIg	O	O
)	O	O
and	O	O
lamivudine	B-Chemical	D019259
in	O	O
prophylaxis	O	O
of	O	O
the	O	O
recurrence	O	O
of	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
after	O	O
liver	O	O
transplantation	O	O
has	O	O
significantly	O	O
improved	O	O
the	O	O
survival	O	O
of	O	O
HBsAg	B-Chemical	D006514
positive	O	O
patients	O	O
.	O	O

This	O	O
study	O	O
was	O	O
undertaken	O	O
to	O	O
evaluate	O	O
the	O	O
outcomes	O	O
of	O	O
liver	O	O
transplantation	O	O
for	O	O
patients	O	O
with	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
(	O	O
HBV	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
A	O	O
retrospective	O	O
chart	O	O
analysis	O	O
and	O	O
a	O	O
review	O	O
of	O	O
the	O	O
organ	O	O
transplant	O	O
database	O	O
identified	O	O
51	O	O
patients	O	O
(	O	O
43	O	O
men	O	O
and	O	O
8	O	O
women	O	O
)	O	O
transplanted	O	O
for	O	O
benign	O	O
HBV	O	O
-	O	O
related	O	O
cirrhotic	B-Disease	D008103
diseases	I-Disease	D008103
between	O	O
June	O	O
2002	O	O
and	O	O
December	O	O
2004	O	O
who	O	O
had	O	O
survived	O	O
more	O	O
than	O	O
3	O	O
months	O	O
.	O	O

HBIg	O	O
was	O	O
administered	O	O
intravenously	O	O
during	O	O
the	O	O
first	O	O
week	O	O
and	O	O
intramuscularly	O	O
thereafter	O	O
.	O	O

RESULTS	O	O
:	O	O
At	O	O
a	O	O
median	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
14	O	O
.	O	O

1	O	O
months	O	O
,	O	O
the	O	O
overall	O	O
recurrence	O	O
rate	O	O
in	O	O
the	O	O
51	O	O
patients	O	O
was	O	O
3	O	O
.	O	O

9%	O	O
(	O	O
2	O	O
/	O	O
51	O	O
)	O	O
.	O	O

The	O	O
overall	O	O
patient	O	O
survival	O	O
was	O	O
88	O	O
.	O	O

3%	O	O
,	O	O
and	O	O
82	O	O
.	O	O

4%	O	O
after	O	O
1	O	O
and	O	O
2	O	O
years	O	O
,	O	O
respectively	O	O
.	O	O

A	O	O
daily	O	O
oral	O	O
dose	O	O
of	O	O
100	O	O
mg	O	O
lamivudine	B-Chemical	D019259
for	O	O
2	O	O
weeks	O	O
before	O	O
transplantation	O	O
for	O	O
10	O	O
patients	O	O
enabled	O	O
57	O	O
.	O	O

1%	O	O
(	O	O
4	O	O
/	O	O
7	O	O
)	O	O
and	O	O
62	O	O
.	O	O

5%	O	O
(	O	O
5	O	O
/	O	O
8	O	O
)	O	O
of	O	O
HBV	O	O
-	O	O
DNA	O	O
and	O	O
HBeAg	B-Chemical	D006513
positive	O	O
patients	O	O
respectively	O	O
to	O	O
convert	O	O
to	O	O
be	O	O
negative	O	O
.	O	O

Intramuscular	O	O
HBIg	O	O
was	O	O
well	O	O
tolerated	O	O
in	O	O
all	O	O
patients	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Lamivudine	B-Chemical	D019259
combined	O	O
with	O	O
intramuscular	O	O
HBIg	O	O
can	O	O
effectively	O	O
prevent	O	O
allograft	O	O
from	O	O
the	O	O
recurrence	O	O
of	O	O
HBV	O	O
after	O	O
liver	O	O
transplantation	O	O
.	O	O

Anticonvulsant	O	O
effect	O	O
of	O	O
eslicarbazepine	B-Chemical	C416835
acetate	I-Chemical	C416835
(	O	O
BIA	B-Chemical	C416835
2	I-Chemical	C416835
-	I-Chemical	C416835
093	I-Chemical	C416835
)	O	O
on	O	O
seizures	B-Disease	D012640
induced	O	O
by	O	O
microperfusion	O	O
of	O	O
picrotoxin	B-Chemical	D010852
in	O	O
the	O	O
hippocampus	O	O
of	O	O
freely	O	O
moving	O	O
rats	O	O
.	O	O

Eslicarbazepine	B-Chemical	C416835
acetate	I-Chemical	C416835
(	O	O
BIA	B-Chemical	C416835
2	I-Chemical	C416835
-	I-Chemical	C416835
093	I-Chemical	C416835
,	O	O
S	B-Chemical	C416835
-	I-Chemical	C416835
(	I-Chemical	C416835
-	I-Chemical	C416835
)	I-Chemical	C416835
-	I-Chemical	C416835
10	I-Chemical	C416835
-	I-Chemical	C416835
acetoxy	I-Chemical	C416835
-	I-Chemical	C416835
10	I-Chemical	C416835
,	I-Chemical	C416835
11	I-Chemical	C416835
-	I-Chemical	C416835
dihydro	I-Chemical	C416835
-	I-Chemical	C416835
5H	I-Chemical	C416835
-	I-Chemical	C416835
dibenzo	I-Chemical	C416835
/	I-Chemical	C416835
b	I-Chemical	C416835
,	I-Chemical	C416835
f	I-Chemical	C416835
/	I-Chemical	C416835
azepine	I-Chemical	C416835
-	I-Chemical	C416835
5	I-Chemical	C416835
-	I-Chemical	C416835
carboxamide	I-Chemical	C416835
)	O	O
is	O	O
a	O	O
novel	O	O
antiepileptic	O	O
drug	O	O
,	O	O
now	O	O
in	O	O
Phase	O	O
III	O	O
clinical	O	O
trials	O	O
,	O	O
designed	O	O
with	O	O
the	O	O
aim	O	O
of	O	O
improving	O	O
efficacy	O	O
and	O	O
safety	O	O
in	O	O
comparison	O	O
with	O	O
the	O	O
structurally	O	O
related	O	O
drugs	O	O
carbamazepine	B-Chemical	D002220
(	O	O
CBZ	B-Chemical	D002220
)	O	O
and	O	O
oxcarbazepine	B-Chemical	C036006
(	O	O
OXC	B-Chemical	C036006
)	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
effects	O	O
of	O	O
oral	O	O
treatment	O	O
with	O	O
eslicarbazepine	B-Chemical	C416835
acetate	I-Chemical	C416835
on	O	O
a	O	O
whole	O	O
-	O	O
animal	O	O
model	O	O
in	O	O
which	O	O
partial	O	O
seizures	B-Disease	D012640
can	O	O
be	O	O
elicited	O	O
repeatedly	O	O
on	O	O
different	O	O
days	O	O
without	O	O
changes	O	O
in	O	O
threshold	O	O
or	O	O
seizure	B-Disease	D012640
patterns	O	O
.	O	O

In	O	O
the	O	O
animals	O	O
treated	O	O
with	O	O
threshold	O	O
doses	O	O
of	O	O
picrotoxin	B-Chemical	D010852
,	O	O
the	O	O
average	O	O
number	O	O
of	O	O
seizures	B-Disease	D012640
was	O	O
2	O	O
.	O	O

3+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

2	O	O
,	O	O
and	O	O
average	O	O
seizure	B-Disease	D012640
duration	O	O
was	O	O
39	O	O
.	O	O

5+	O	O
/	O	O
-	O	O
8	O	O
.	O	O

4s	O	O
.	O	O

Pre	O	O
-	O	O
treatment	O	O
with	O	O
a	O	O
dose	O	O
of	O	O
30	O	O
mg	O	O
/	O	O
kg	O	O
2h	O	O
before	O	O
picrotoxin	B-Chemical	D010852
microperfusion	O	O
prevented	O	O
seizures	B-Disease	D012640
in	O	O
the	O	O
75%	O	O
of	O	O
the	O	O
rats	O	O
.	O	O

Lower	O	O
doses	O	O
(	O	O
3	O	O
and	O	O
10mg	O	O
/	O	O
kg	O	O
)	O	O
did	O	O
not	O	O
suppress	O	O
seizures	B-Disease	D012640
,	O	O
however	O	O
,	O	O
after	O	O
administration	O	O
of	O	O
10mg	O	O
/	O	O
kg	O	O
,	O	O
significant	O	O
reductions	O	O
in	O	O
seizures	B-Disease	D012640
duration	O	O
(	O	O
24	O	O
.	O	O

3+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

8s	O	O
)	O	O
and	O	O
seizure	B-Disease	D012640
number	O	O
(	O	O
1	O	O
.	O	O

6+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

34	O	O
)	O	O
were	O	O
found	O	O
.	O	O

No	O	O
adverse	O	O
effects	O	O
of	O	O
eslicarbazepine	B-Chemical	C416835
acetate	I-Chemical	C416835
were	O	O
observed	O	O
in	O	O
the	O	O
behavioral	O	O
/	O	O
EEG	O	O
patterns	O	O
studied	O	O
,	O	O
including	O	O
sleep	O	O
/	O	O
wakefulness	O	O
cycle	O	O
,	O	O
at	O	O
the	O	O
doses	O	O
studied	O	O
.	O	O

Acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
associated	O	O
with	O	O
prolonged	O	O
intake	O	O
of	O	O
slimming	O	O
pills	O	O
containing	O	O
anthraquinones	B-Chemical	D000880
.	O	O

Chinese	B-Chemical	D004365
herbal	I-Chemical	D004365
medicine	O	O
preparations	O	O
are	O	O
widely	O	O
available	O	O
and	O	O
often	O	O
regarded	O	O
by	O	O
the	O	O
public	O	O
as	O	O
natural	O	O
and	O	O
safe	O	O
remedies	O	O
for	O	O
a	O	O
variety	O	O
of	O	O
medical	O	O
conditions	O	O
.	O	O

Nephropathy	B-Disease	D007674
caused	O	O
by	O	O
Chinese	B-Chemical	D004365
herbs	I-Chemical	D004365
has	O	O
previously	O	O
been	O	O
reported	O	O
,	O	O
usually	O	O
involving	O	O
the	O	O
use	O	O
of	O	O
aristolochic	B-Chemical	D034341
acids	I-Chemical	D034341
.	O	O

We	O	O
report	O	O
a	O	O
23	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
following	O	O
prolonged	O	O
use	O	O
of	O	O
a	O	O
proprietary	O	O
Chinese	B-Chemical	D004365
herbal	I-Chemical	D004365
slimming	O	O
pill	O	O
that	O	O
contained	O	O
anthraquinone	B-Chemical	D000880
derivatives	O	O
,	O	O
extracted	O	O
from	O	O
Rhizoma	O	O
Rhei	O	O
(	O	O
rhubarb	O	O
)	O	O
.	O	O

The	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
was	O	O
probably	O	O
aggravated	O	O
by	O	O
the	O	O
concomitant	O	O
intake	O	O
of	O	O
a	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drug	O	O
,	O	O
diclofenac	B-Chemical	D004008
.	O	O

Renal	O	O
pathology	O	O
was	O	O
that	O	O
of	O	O
hypocellular	O	O
interstitial	O	O
fibrosis	B-Disease	D005355
.	O	O

Spontaneous	O	O
renal	O	O
recovery	O	O
occurred	O	O
upon	O	O
cessation	O	O
of	O	O
the	O	O
slimming	O	O
pills	O	O
,	O	O
but	O	O
mild	O	O
interstitial	O	O
fibrosis	B-Disease	D005355
and	O	O
tubular	O	O
atrophy	B-Disease	D001284
was	O	O
still	O	O
evident	O	O
histologically	O	O
4	O	O
months	O	O
later	O	O
.	O	O

Although	O	O
a	O	O
causal	O	O
relationship	O	O
between	O	O
the	O	O
use	O	O
of	O	O
an	O	O
anthraquinone	B-Chemical	D000880
-	O	O
containing	O	O
herbal	O	O
agent	O	O
and	O	O
renal	B-Disease	D058186
injury	I-Disease	D058186
remains	O	O
to	O	O
be	O	O
proven	O	O
,	O	O
phytotherapy	O	O
-	O	O
associated	O	O
interstitial	O	O
nephropathy	B-Disease	D007674
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
who	O	O
present	O	O
with	O	O
unexplained	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
.	O	O

Chloroacetaldehyde	B-Chemical	C004656
as	O	O
a	O	O
sulfhydryl	B-Chemical	-1
reagent	O	O
:	O	O
the	O	O
role	O	O
of	O	O
critical	O	O
thiol	B-Chemical	D013438
groups	O	O
in	O	O
ifosfamide	B-Chemical	D007069
nephropathy	B-Disease	D007674
.	O	O

Chloroacetaldehyde	B-Chemical	C004656
(	O	O
CAA	B-Chemical	C004656
)	O	O
is	O	O
a	O	O
metabolite	O	O
of	O	O
the	O	O
alkylating	O	O
agent	O	O
ifosfamide	B-Chemical	D007069
(	O	O
IFO	B-Chemical	D007069
)	O	O
and	O	O
putatively	O	O
responsible	O	O
for	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
following	O	O
anti	O	O
-	O	O
tumor	B-Disease	D009369
therapy	O	O
with	O	O
IFO	B-Chemical	D007069
.	O	O

Depletion	O	O
of	O	O
sulfhydryl	B-Chemical	-1
(	O	O
SH	B-Chemical	-1
)	O	O
groups	O	O
has	O	O
been	O	O
reported	O	O
from	O	O
cell	O	O
culture	O	O
,	O	O
animal	O	O
and	O	O
clinical	O	O
studies	O	O
.	O	O

In	O	O
this	O	O
work	O	O
the	O	O
effect	O	O
of	O	O
CAA	B-Chemical	C004656
on	O	O
human	O	O
proximal	O	O
tubule	O	O
cells	O	O
in	O	O
primary	O	O
culture	O	O
(	O	O
hRPTEC	O	O
)	O	O
was	O	O
investigated	O	O
.	O	O

Toxicity	B-Disease	D064420
of	O	O
CAA	B-Chemical	C004656
was	O	O
determined	O	O
by	O	O
protein	O	O
content	O	O
,	O	O
cell	O	O
number	O	O
,	O	O
LDH	O	O
release	O	O
,	O	O
trypan	B-Chemical	D014343
blue	I-Chemical	D014343
exclusion	O	O
assay	O	O
and	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
.	O	O

Free	O	O
thiols	B-Chemical	D013438
were	O	O
measured	O	O
by	O	O
the	O	O
method	O	O
of	O	O
Ellman	O	O
.	O	O

CAA	B-Chemical	C004656
reduced	O	O
hRPTEC	O	O
cell	O	O
number	O	O
and	O	O
protein	O	O
,	O	O
induced	O	O
a	O	O
loss	O	O
in	O	O
free	O	O
intracellular	O	O
thiols	B-Chemical	D013438
and	O	O
an	O	O
increase	O	O
in	O	O
necrosis	B-Disease	D009336
markers	O	O
.	O	O

CAA	B-Chemical	C004656
but	O	O
not	O	O
acrolein	B-Chemical	D000171
inhibited	O	O
the	O	O
cysteine	B-Chemical	D003545
proteases	O	O
caspase	O	O
-	O	O
3	O	O
,	O	O
caspase	O	O
-	O	O
8	O	O
and	O	O
cathepsin	O	O
B	O	O
.	O	O

Caspase	O	O
activation	O	O
by	O	O
cisplatin	B-Chemical	D002945
was	O	O
inhibited	O	O
by	O	O
CAA	B-Chemical	C004656
.	O	O

In	O	O
cells	O	O
stained	O	O
with	O	O
fluorescent	O	O
dyes	O	O
targeting	O	O
lysosomes	O	O
,	O	O
CAA	B-Chemical	C004656
induced	O	O
an	O	O
increase	O	O
in	O	O
lysosomal	O	O
size	O	O
and	O	O
lysosomal	O	O
leakage	O	O
.	O	O

The	O	O
effects	O	O
of	O	O
CAA	B-Chemical	C004656
on	O	O
cysteine	B-Chemical	D003545
protease	O	O
activities	O	O
and	O	O
thiols	B-Chemical	D013438
could	O	O
be	O	O
reproduced	O	O
in	O	O
cell	O	O
lysate	O	O
.	O	O

Acidification	O	O
,	O	O
which	O	O
slowed	O	O
the	O	O
reaction	O	O
of	O	O
CAA	B-Chemical	C004656
with	O	O
thiol	B-Chemical	D013438
donors	O	O
,	O	O
could	O	O
also	O	O
attenuate	O	O
effects	O	O
of	O	O
CAA	B-Chemical	C004656
on	O	O
necrosis	B-Disease	D009336
markers	O	O
,	O	O
thiol	B-Chemical	D013438
depletion	O	O
and	O	O
cysteine	B-Chemical	D003545
protease	O	O
inhibition	O	O
in	O	O
living	O	O
cells	O	O
.	O	O

Thus	O	O
,	O	O
CAA	B-Chemical	C004656
directly	O	O
reacts	O	O
with	O	O
cellular	O	O
protein	O	O
and	O	O
non	O	O
-	O	O
protein	O	O
thiols	B-Chemical	D013438
,	O	O
mediating	O	O
its	O	O
toxicity	B-Disease	D064420
on	O	O
hRPTEC	O	O
.	O	O

This	O	O
effect	O	O
can	O	O
be	O	O
reduced	O	O
by	O	O
acidification	O	O
.	O	O

Therefore	O	O
,	O	O
urinary	O	O
acidification	O	O
could	O	O
be	O	O
an	O	O
option	O	O
to	O	O
prevent	O	O
IFO	B-Chemical	D007069
nephropathy	B-Disease	D007674
in	O	O
patients	O	O
.	O	O

Stereological	O	O
methods	O	O
reveal	O	O
the	O	O
robust	O	O
size	O	O
and	O	O
stability	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
after	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
the	O	O
adult	O	O
rat	O	O
.	O	O

Following	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
in	O	O
the	O	O
rat	O	O
,	O	O
dentate	O	O
granule	O	O
cell	O	O
neurogenesis	O	O
increases	O	O
greatly	O	O
,	O	O
and	O	O
many	O	O
of	O	O
the	O	O
new	O	O
neurons	O	O
appear	O	O
to	O	O
develop	O	O
ectopically	O	O
,	O	O
in	O	O
the	O	O
hilar	O	O
region	O	O
of	O	O
the	O	O
hippocampal	O	O
formation	O	O
.	O	O

It	O	O
has	O	O
been	O	O
suggested	O	O
that	O	O
the	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
could	O	O
contribute	O	O
to	O	O
the	O	O
spontaneous	O	O
seizures	B-Disease	D012640
that	O	O
ultimately	O	O
develop	O	O
after	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

However	O	O
,	O	O
the	O	O
population	O	O
has	O	O
never	O	O
been	O	O
quantified	O	O
,	O	O
so	O	O
it	O	O
is	O	O
unclear	O	O
whether	O	O
it	O	O
is	O	O
substantial	O	O
enough	O	O
to	O	O
have	O	O
a	O	O
strong	O	O
influence	O	O
on	O	O
epileptogenesis	O	O
.	O	O

To	O	O
quantify	O	O
this	O	O
population	O	O
,	O	O
the	O	O
total	O	O
number	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
was	O	O
estimated	O	O
using	O	O
unbiased	O	O
stereology	O	O
at	O	O
different	O	O
times	O	O
after	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

The	O	O
number	O	O
of	O	O
hilar	O	O
neurons	O	O
immunoreactive	O	O
for	O	O
Prox	O	O
-	O	O
1	O	O
,	O	O
a	O	O
granule	O	O
-	O	O
cell	O	O
-	O	O
specific	O	O
marker	O	O
,	O	O
was	O	O
estimated	O	O
using	O	O
the	O	O
optical	O	O
fractionator	O	O
method	O	O
.	O	O

The	O	O
results	O	O
indicate	O	O
that	O	O
the	O	O
size	O	O
of	O	O
the	O	O
hilar	O	O
ectopic	O	O
granule	O	O
cell	O	O
population	O	O
after	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
is	O	O
substantial	O	O
,	O	O
and	O	O
stable	O	O
over	O	O
time	O	O
.	O	O

Interestingly	O	O
,	O	O
the	O	O
size	O	O
of	O	O
the	O	O
population	O	O
appears	O	O
to	O	O
be	O	O
correlated	O	O
with	O	O
the	O	O
frequency	O	O
of	O	O
behavioral	O	O
seizures	B-Disease	D012640
,	O	O
because	O	O
animals	O	O
with	O	O
more	O	O
ectopic	O	O
granule	O	O
cells	O	O
in	O	O
the	O	O
hilus	O	O
have	O	O
more	O	O
frequent	O	O
behavioral	O	O
seizures	B-Disease	D012640
.	O	O

The	O	O
hilar	O	O
ectopic	O	O
granule	O	O
cell	O	O
population	O	O
does	O	O
not	O	O
appear	O	O
to	O	O
vary	O	O
systematically	O	O
across	O	O
the	O	O
septotemporal	O	O
axis	O	O
,	O	O
although	O	O
it	O	O
is	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
volume	O	O
of	O	O
the	O	O
hilus	O	O
.	O	O

The	O	O
results	O	O
provide	O	O
new	O	O
insight	O	O
into	O	O
the	O	O
potential	O	O
role	O	O
of	O	O
ectopic	O	O
hilar	O	O
granule	O	O
cells	O	O
in	O	O
the	O	O
pilocarpine	B-Chemical	D010862
model	O	O
of	O	O
temporal	B-Disease	D004833
lobe	I-Disease	D004833
epilepsy	I-Disease	D004833
.	O	O

A	O	O
prospective	O	O
,	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
of	O	O
galantamine	B-Chemical	D005702
in	O	O
autistic	B-Disease	D001321
disorder	I-Disease	D001321
.	O	O

OBJECTIVE	O	O
:	O	O
Post	O	O
-	O	O
mortem	O	O
studies	O	O
have	O	O
reported	O	O
abnormalities	O	O
of	O	O
the	O	O
cholinergic	O	O
system	O	O
in	O	O
autism	B-Disease	D001321
.	O	O

The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
the	O	O
use	O	O
of	O	O
galantamine	B-Chemical	D005702
,	O	O
an	O	O
acetylcholinesterase	O	O
inhibitor	O	O
and	O	O
nicotinic	O	O
receptor	O	O
modulator	O	O
,	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
interfering	O	O
behaviors	O	O
in	O	O
children	O	O
with	O	O
autism	B-Disease	D001321
.	O	O

METHODS	O	O
:	O	O
Thirteen	O	O
medication	O	O
-	O	O
free	O	O
children	O	O
with	O	O
autism	B-Disease	D001321
(	O	O
mean	O	O
age	O	O
,	O	O
8	O	O
.	O	O

8	O	O
+	O	O
/	O	O
-	O	O
3	O	O
.	O	O

5	O	O
years	O	O
)	O	O
participated	O	O
in	O	O
a	O	O
12	O	O
-	O	O
week	O	O
,	O	O
open	O	O
-	O	O
label	O	O
trial	O	O
of	O	O
galantamine	B-Chemical	D005702
.	O	O

Patients	O	O
were	O	O
rated	O	O
monthly	O	O
by	O	O
parents	O	O
on	O	O
the	O	O
Aberrant	O	O
Behavior	O	O
Checklist	O	O
(	O	O
ABC	O	O
)	O	O
and	O	O
the	O	O
Conners'	O	O
Parent	O	O
Rating	O	O
Scale	O	O
-	O	O
Revised	O	O
,	O	O
and	O	O
by	O	O
a	O	O
physician	O	O
using	O	O
the	O	O
Children's	O	O
Psychiatric	O	O
Rating	O	O
Scale	O	O
and	O	O
the	O	O
Clinical	O	O
Global	O	O
Impressions	O	O
scale	O	O
.	O	O

RESULTS	O	O
:	O	O
Patients	O	O
showed	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
parent	O	O
-	O	O
rated	O	O
irritability	B-Disease	D001523
and	O	O
social	O	O
withdrawal	O	O
on	O	O
the	O	O
ABC	O	O
as	O	O
well	O	O
as	O	O
significant	O	O
improvements	O	O
in	O	O
emotional	O	O
lability	O	O
and	O	O
inattention	B-Disease	D019958
on	O	O
the	O	O
Conners'	O	O
Parent	O	O
Rating	O	O
Scale	O	O
-	O	O
-	O	O
Revised	O	O
.	O	O

Similarly	O	O
,	O	O
clinician	O	O
ratings	O	O
showed	O	O
reductions	O	O
in	O	O
the	O	O
anger	O	O
subscale	O	O
of	O	O
the	O	O
Children's	O	O
Psychiatric	O	O
Rating	O	O
Scale	O	O
.	O	O

Eight	O	O
of	O	O
13	O	O
participants	O	O
were	O	O
rated	O	O
as	O	O
responders	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
their	O	O
improvement	O	O
scores	O	O
on	O	O
the	O	O
Clinical	O	O
Global	O	O
Impressions	O	O
scale	O	O
.	O	O

Overall	O	O
,	O	O
galantamine	B-Chemical	D005702
was	O	O
well	O	O
-	O	O
tolerated	O	O
,	O	O
with	O	O
no	O	O
significant	O	O
adverse	O	O
effects	O	O
apart	O	O
from	O	O
headaches	B-Disease	D006261
in	O	O
one	O	O
patient	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
open	O	O
trial	O	O
,	O	O
galantamine	B-Chemical	D005702
was	O	O
well	O	O
-	O	O
tolerated	O	O
and	O	O
appeared	O	O
to	O	O
be	O	O
beneficial	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
interfering	O	O
behaviors	O	O
in	O	O
children	O	O
with	O	O
autism	B-Disease	D001321
,	O	O
particularly	O	O
aggression	B-Disease	D001523
,	O	O
behavioral	B-Disease	D002653
dyscontrol	I-Disease	D002653
,	O	O
and	O	O
inattention	B-Disease	D019958
.	O	O

Further	O	O
controlled	O	O
trials	O	O
are	O	O
warranted	O	O
.	O	O

Randomized	O	O
comparison	O	O
of	O	O
olanzapine	B-Chemical	C076029
versus	O	O
risperidone	B-Chemical	D018967
for	O	O
the	O	O
treatment	O	O
of	O	O
first	O	O
-	O	O
episode	O	O
schizophrenia	B-Disease	D012559
:	O	O
4	O	O
-	O	O
month	O	O
outcomes	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
The	O	O
authors	O	O
compared	O	O
4	O	O
-	O	O
month	O	O
treatment	O	O
outcomes	O	O
for	O	O
olanzapine	B-Chemical	C076029
versus	O	O
risperidone	B-Chemical	D018967
in	O	O
patients	O	O
with	O	O
first	O	O
-	O	O
episode	O	O
schizophrenia	B-Disease	D012559
spectrum	O	O
disorders	O	O
.	O	O

METHOD	O	O
:	O	O
One	O	O
hundred	O	O
twelve	O	O
subjects	O	O
(	O	O
70%	O	O
male	O	O
;	O	O
mean	O	O
age=23	O	O
.	O	O

3	O	O
years	O	O
[	O	O
SD	O	O
=	O	O
5	O	O
.	O	O

1	O	O
]	O	O
)	O	O
with	O	O
first	O	O
-	O	O
episode	O	O
schizophrenia	B-Disease	D012559
(	O	O
75%	O	O
)	O	O
,	O	O
schizophreniform	B-Disease	D011618
disorder	I-Disease	D011618
(	O	O
17%	O	O
)	O	O
,	O	O
or	O	O
schizoaffective	B-Disease	D011618
disorder	I-Disease	D011618
(	O	O
8%	O	O
)	O	O
were	O	O
randomly	O	O
assigned	O	O
to	O	O
treatment	O	O
with	O	O
olanzapine	B-Chemical	C076029
(	O	O
2	O	O
.	O	O

5	O	O
-	O	O
20	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
or	O	O
risperidone	B-Chemical	D018967
(	O	O
1	O	O
-	O	O
6	O	O
mg	O	O
/	O	O
day	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Response	O	O
rates	O	O
did	O	O
not	O	O
significantly	O	O
differ	O	O
between	O	O
olanzapine	B-Chemical	C076029
(	O	O
43	O	O
.	O	O

7%	O	O
,	O	O
95%	O	O
CI=28	O	O
.	O	O

8%	O	O
-	O	O
58	O	O
.	O	O

6%	O	O
)	O	O
and	O	O
risperidone	B-Chemical	D018967
(	O	O
54	O	O
.	O	O

3%	O	O
,	O	O
95%	O	O
CI=39	O	O
.	O	O

9%	O	O
-	O	O
68	O	O
.	O	O

7%	O	O
)	O	O
.	O	O

Among	O	O
those	O	O
responding	O	O
to	O	O
treatment	O	O
,	O	O
more	O	O
subjects	O	O
in	O	O
the	O	O
olanzapine	B-Chemical	C076029
group	O	O
(	O	O
40	O	O
.	O	O

9%	O	O
,	O	O
95%	O	O
CI=16	O	O
.	O	O

8%	O	O
-	O	O
65	O	O
.	O	O

0%	O	O
)	O	O
than	O	O
in	O	O
the	O	O
risperidone	B-Chemical	D018967
group	O	O
(	O	O
18	O	O
.	O	O

9%	O	O
,	O	O
95%	O	O
CI=0%	O	O
-	O	O
39	O	O
.	O	O

2%	O	O
)	O	O
had	O	O
subsequent	O	O
ratings	O	O
not	O	O
meeting	O	O
response	O	O
criteria	O	O
.	O	O

Negative	O	O
symptom	O	O
outcomes	O	O
and	O	O
measures	O	O
of	O	O
parkinsonism	B-Disease	D010302
and	O	O
akathisia	B-Disease	D017109
did	O	O
not	O	O
differ	O	O
between	O	O
medications	O	O
.	O	O

Extrapyramidal	B-Disease	D001480
symptom	I-Disease	D001480
severity	O	O
scores	O	O
were	O	O
1	O	O
.	O	O

4	O	O
(	O	O
95%	O	O
CI=1	O	O
.	O	O

2	O	O
-	O	O
1	O	O
.	O	O

6	O	O
)	O	O
with	O	O
risperidone	B-Chemical	D018967
and	O	O
1	O	O
.	O	O

2	O	O
(	O	O
95%	O	O
CI=1	O	O
.	O	O

0	O	O
-	O	O
1	O	O
.	O	O

4	O	O
)	O	O
with	O	O
olanzapine	B-Chemical	C076029
.	O	O

Significantly	O	O
more	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
occurred	O	O
with	O	O
olanzapine	B-Chemical	C076029
than	O	O
with	O	O
risperidone	B-Chemical	D018967
:	O	O
the	O	O
increase	O	O
in	O	O
weight	O	O
at	O	O
4	O	O
months	O	O
relative	O	O
to	O	O
baseline	O	O
weight	O	O
was	O	O
17	O	O
.	O	O

3%	O	O
(	O	O
95%	O	O
CI=14	O	O
.	O	O

2%	O	O
-	O	O
20	O	O
.	O	O

5%	O	O
)	O	O
with	O	O
olanzapine	B-Chemical	C076029
and	O	O
11	O	O
.	O	O

3%	O	O
(	O	O
95%	O	O
CI=8	O	O
.	O	O

4%	O	O
-	O	O
14	O	O
.	O	O

3%	O	O
)	O	O
with	O	O
risperidone	B-Chemical	D018967
.	O	O

Body	O	O
mass	O	O
index	O	O
at	O	O
baseline	O	O
and	O	O
at	O	O
4	O	O
months	O	O
was	O	O
24	O	O
.	O	O

3	O	O
(	O	O
95%	O	O
CI=22	O	O
.	O	O

8	O	O
-	O	O
25	O	O
.	O	O

7	O	O
)	O	O
versus	O	O
28	O	O
.	O	O

2	O	O
(	O	O
95%	O	O
CI=26	O	O
.	O	O

7	O	O
-	O	O
29	O	O
.	O	O

7	O	O
)	O	O
with	O	O
olanzapine	B-Chemical	C076029
and	O	O
23	O	O
.	O	O

9	O	O
(	O	O
95%	O	O
CI=22	O	O
.	O	O

5	O	O
-	O	O
25	O	O
.	O	O

3	O	O
)	O	O
versus	O	O
26	O	O
.	O	O

7	O	O
(	O	O
95%	O	O
CI=25	O	O
.	O	O

2	O	O
-	O	O
28	O	O
.	O	O

2	O	O
)	O	O
with	O	O
risperidone	B-Chemical	D018967
.	O	O

CONCLUSIONS	O	O
:	O	O
Clinical	O	O
outcomes	O	O
with	O	O
risperidone	B-Chemical	D018967
were	O	O
equal	O	O
to	O	O
those	O	O
with	O	O
olanzapine	B-Chemical	C076029
,	O	O
and	O	O
response	O	O
may	O	O
be	O	O
more	O	O
stable	O	O
.	O	O

Olanzapine	B-Chemical	C076029
may	O	O
have	O	O
an	O	O
advantage	O	O
for	O	O
motor	O	O
side	O	O
effects	O	O
.	O	O

Both	O	O
medications	O	O
caused	O	O
substantial	O	O
rapid	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
,	O	O
but	O	O
weight	B-Disease	D015430
gain	I-Disease	D015430
was	O	O
greater	O	O
with	O	O
olanzapine	B-Chemical	C076029
.	O	O

Early	O	O
paracentral	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
loss	I-Disease	D014786
in	O	O
patients	O	O
taking	O	O
hydroxychloroquine	B-Chemical	D006886
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
review	O	O
the	O	O
natural	O	O
history	O	O
and	O	O
ocular	O	O
and	O	O
systemic	O	O
adverse	O	O
effects	O	O
of	O	O
patients	O	O
taking	O	O
hydroxychloroquine	B-Chemical	D006886
sulfate	O	O
who	O	O
attended	O	O
an	O	O
ophthalmic	O	O
screening	O	O
program	O	O
.	O	O

DESIGN	O	O
:	O	O
Retrospective	O	O
study	O	O
.	O	O

RESULTS	O	O
:	O	O
Records	O	O
of	O	O
262	O	O
patients	O	O
who	O	O
were	O	O
taking	O	O
hydroxychloroquine	B-Chemical	D006886
and	O	O
screened	O	O
in	O	O
the	O	O
Department	O	O
of	O	O
Ophthalmology	O	O
were	O	O
reviewed	O	O
.	O	O

Of	O	O
the	O	O
262	O	O
patients	O	O
,	O	O
14	O	O
(	O	O
18%	O	O
)	O	O
of	O	O
76	O	O
who	O	O
had	O	O
stopped	O	O
treatment	O	O
at	O	O
the	O	O
time	O	O
of	O	O
the	O	O
study	O	O
experienced	O	O
documented	O	O
adverse	O	O
effects	O	O
.	O	O

Systemic	O	O
adverse	O	O
effects	O	O
occurred	O	O
in	O	O
8	O	O
patients	O	O
(	O	O
10	O	O
.	O	O

5%	O	O
)	O	O
and	O	O
ocular	O	O
adverse	O	O
effects	O	O
,	O	O
in	O	O
5	O	O
(	O	O
6	O	O
.	O	O

5%	O	O
)	O	O
.	O	O

Thirty	O	O
-	O	O
five	O	O
patients	O	O
(	O	O
13	O	O
.	O	O

4%	O	O
)	O	O
had	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
abnormalities	I-Disease	D014786
,	O	O
which	O	O
were	O	O
attributed	O	O
to	O	O
hydroxychloroquine	B-Chemical	D006886
treatment	O	O
in	O	O
4	O	O
patients	O	O
(	O	O
1	O	O
.	O	O

5%	O	O
)	O	O
.	O	O

Three	O	O
of	O	O
the	O	O
4	O	O
patients	O	O
were	O	O
taking	O	O
less	O	O
than	O	O
6	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
and	O	O
all	O	O
patients	O	O
had	O	O
normal	O	O
renal	O	O
and	O	O
liver	O	O
function	O	O
test	O	O
results	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
current	O	O
study	O	O
used	O	O
a	O	O
protocol	O	O
of	O	O
visual	O	O
acuity	O	O
and	O	O
color	O	O
vision	O	O
assessment	O	O
,	O	O
funduscopy	O	O
,	O	O
and	O	O
Humphrey	O	O
10	O	O
-	O	O
2	O	O
visual	O	O
field	O	O
testing	O	O
and	O	O
shows	O	O
that	O	O
visual	B-Disease	D014786
field	I-Disease	D014786
defects	I-Disease	D014786
appeared	O	O
before	O	O
any	O	O
corresponding	O	O
changes	O	O
in	O	O
any	O	O
other	O	O
tested	O	O
clinical	O	O
parameters	O	O
;	O	O
the	O	O
defects	O	O
were	O	O
reproducible	O	O
and	O	O
the	O	O
test	O	O
parameters	O	O
were	O	O
reliable	O	O
.	O	O

Patients	O	O
taking	O	O
hydroxychloroquine	B-Chemical	D006886
can	O	O
demonstrate	O	O
a	O	O
toxic	O	O
reaction	O	O
in	O	O
the	O	O
retina	O	O
despite	O	O
the	O	O
absence	O	O
of	O	O
known	O	O
risk	O	O
factors	O	O
.	O	O

Screening	O	O
,	O	O
including	O	O
Humphrey	O	O
10	O	O
-	O	O
2	O	O
visual	O	O
field	O	O
assessment	O	O
,	O	O
is	O	O
recommended	O	O
2	O	O
years	O	O
after	O	O
the	O	O
initial	O	O
baseline	O	O
and	O	O
yearly	O	O
thereafter	O	O
.	O	O

Peri	O	O
-	O	O
operative	O	O
atrioventricular	B-Disease	D054537
block	I-Disease	D054537
as	O	O
a	O	O
result	O	O
of	O	O
chemotherapy	O	O
with	O	O
epirubicin	B-Chemical	D015251
and	O	O
paclitaxel	B-Chemical	D017239
.	O	O

A	O	O
47	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
presented	O	O
for	O	O
mastectomy	O	O
and	O	O
immediate	O	O
latissimus	O	O
dorsi	O	O
flap	O	O
reconstruction	O	O
having	O	O
been	O	O
diagnosed	O	O
with	O	O
carcinoma	B-Disease	D001943
of	I-Disease	D001943
the	I-Disease	D001943
breast	I-Disease	D001943
6	O	O
months	O	O
previously	O	O
.	O	O

In	O	O
the	O	O
preceding	O	O
months	O	O
she	O	O
had	O	O
received	O	O
neo	O	O
-	O	O
adjuvant	O	O
chemotherapy	O	O
with	O	O
epirubicin	B-Chemical	D015251
,	O	O
paclitaxel	B-Chemical	D017239
(	O	O
Taxol	B-Chemical	D017239
)	O	O
and	O	O
cyclophosphamide	B-Chemical	D003520
.	O	O

This	O	O
had	O	O
been	O	O
apparently	O	O
uncomplicated	O	O
and	O	O
she	O	O
had	O	O
maintained	O	O
a	O	O
remarkably	O	O
high	O	O
level	O	O
of	O	O
physical	O	O
activity	O	O
.	O	O

She	O	O
was	O	O
found	O	O
to	O	O
be	O	O
bradycardic	B-Disease	D001919
at	O	O
pre	O	O
-	O	O
operative	O	O
assessment	O	O
but	O	O
had	O	O
no	O	O
cardiac	O	O
symptoms	O	O
.	O	O

Second	O	O
degree	O	O
Mobitz	O	O
type	O	O
II	O	O
atrioventricular	B-Disease	D054537
block	I-Disease	D054537
was	O	O
diagnosed	O	O
on	O	O
electrocardiogram	O	O
,	O	O
and	O	O
temporary	O	O
transvenous	O	O
ventricular	O	O
pacing	O	O
instituted	O	O
in	O	O
the	O	O
peri	O	O
-	O	O
operative	O	O
period	O	O
.	O	O

We	O	O
discuss	O	O
how	O	O
evidence	O	O
-	O	O
based	O	O
guidelines	O	O
would	O	O
not	O	O
have	O	O
been	O	O
helpful	O	O
in	O	O
this	O	O
case	O	O
,	O	O
and	O	O
how	O	O
chemotherapy	O	O
can	O	O
exhibit	O	O
substantial	O	O
cardiotoxicity	B-Disease	D066126
that	O	O
may	O	O
develop	O	O
over	O	O
many	O	O
years	O	O
.	O	O

We	O	O
suggest	O	O
that	O	O
patients	O	O
who	O	O
have	O	O
received	O	O
chemotherapy	O	O
at	O	O
any	O	O
time	O	O
should	O	O
have	O	O
a	O	O
pre	O	O
-	O	O
operative	O	O
electrocardiogram	O	O
even	O	O
if	O	O
they	O	O
are	O	O
asymptomatic	O	O
.	O	O

Risks	O	O
and	O	O
benefits	O	O
of	O	O
COX	B-Chemical	D052246
-	I-Chemical	D052246
2	I-Chemical	D052246
inhibitors	I-Chemical	D052246
vs	O	O
non	O	O
-	O	O
selective	O	O
NSAIDs	O	O
:	O	O
does	O	O
their	O	O
cardiovascular	O	O
risk	O	O
exceed	O	O
their	O	O
gastrointestinal	O	O
benefit?	O	O
A	O	O
retrospective	O	O
cohort	O	O
study	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
risk	O	O
of	O	O
acute	B-Disease	D009203
myocardial	I-Disease	D009203
infarction	I-Disease	D009203
(	O	O
AMI	B-Disease	D009203
)	O	O
with	O	O
COX	B-Chemical	D052246
-	I-Chemical	D052246
2	I-Chemical	D052246
inhibitors	I-Chemical	D052246
may	O	O
offset	O	O
their	O	O
gastrointestinal	O	O
(	O	O
GI	O	O
)	O	O
benefit	O	O
compared	O	O
with	O	O
non	O	O
-	O	O
selective	O	O
(	O	O
NS	O	O
)	O	O
non	B-Chemical	D000894
-	I-Chemical	D000894
steroidal	I-Chemical	D000894
anti	I-Chemical	D000894
-	I-Chemical	D000894
inflammatory	I-Chemical	D000894
drugs	I-Chemical	D000894
(	O	O
NSAIDs	O	O
)	O	O
.	O	O

We	O	O
aimed	O	O
to	O	O
compare	O	O
the	O	O
risks	O	O
of	O	O
hospitalization	O	O
for	O	O
AMI	B-Disease	D009203
and	O	O
GI	B-Disease	D006471
bleeding	I-Disease	D006471
among	O	O
elderly	O	O
patients	O	O
using	O	O
COX	B-Chemical	D052246
-	I-Chemical	D052246
2	I-Chemical	D052246
inhibitors	I-Chemical	D052246
,	O	O
NS	O	O
-	O	O
NSAIDs	O	O
and	O	O
acetaminophen	B-Chemical	D000082
.	O	O

METHODS	O	O
:	O	O
We	O	O
conducted	O	O
a	O	O
retrospective	O	O
cohort	O	O
study	O	O
using	O	O
administrative	O	O
data	O	O
of	O	O
patients	O	O
>	O	O
or	O	O
=65	O	O
years	O	O
of	O	O
age	O	O
who	O	O
filled	O	O
a	O	O
prescription	O	O
for	O	O
NSAID	O	O
or	O	O
acetaminophen	B-Chemical	D000082
during	O	O
1999	O	O
-	O	O
2002	O	O
.	O	O

Outcomes	O	O
were	O	O
compared	O	O
using	O	O
Cox	O	O
regression	O	O
models	O	O
with	O	O
time	O	O
-	O	O
dependent	O	O
exposures	O	O
.	O	O

RESULTS	O	O
:	O	O
Person	O	O
-	O	O
years	O	O
of	O	O
exposure	O	O
among	O	O
non	O	O
-	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
were	O	O
:	O	O
75	O	O
,	O	O
761	O	O
to	O	O
acetaminophen	B-Chemical	D000082
,	O	O
42	O	O
,	O	O
671	O	O
to	O	O
rofecoxib	B-Chemical	C116926
65	O	O
,	O	O
860	O	O
to	O	O
celecoxib	B-Chemical	C105934
,	O	O
and	O	O
37	O	O
,	O	O
495	O	O
to	O	O
NS	O	O
-	O	O
NSAIDs	O	O
.	O	O

Among	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
,	O	O
they	O	O
were	O	O
:	O	O
14	O	O
,	O	O
671	O	O
to	O	O
rofecoxib	B-Chemical	C116926
,	O	O
22	O	O
,	O	O
875	O	O
to	O	O
celecoxib	B-Chemical	C105934
,	O	O
9	O	O
,	O	O
832	O	O
to	O	O
NS	O	O
-	O	O
NSAIDs	O	O
and	O	O
38	O	O
,	O	O
048	O	O
to	O	O
acetaminophen	B-Chemical	D000082
.	O	O

Among	O	O
non	O	O
-	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
,	O	O
the	O	O
adjusted	O	O
hazard	O	O
ratios	O	O
(	O	O
95%	O	O
confidence	O	O
interval	O	O
)	O	O
of	O	O
hospitalization	O	O
for	O	O
AMI	B-Disease	D009203
/	O	O
GI	O	O
vs	O	O
the	O	O
acetaminophen	B-Chemical	D000082
(	O	O
with	O	O
no	O	O
aspirin	B-Chemical	D001241
)	O	O
group	O	O
were	O	O
:	O	O
rofecoxib	B-Chemical	C116926
1	O	O
.	O	O

27	O	O
(	O	O
1	O	O
.	O	O

13	O	O
,	O	O
1	O	O
.	O	O

42	O	O
)	O	O
,	O	O
celecoxib	B-Chemical	C105934
0	O	O
.	O	O

93	O	O
(	O	O
0	O	O
.	O	O

83	O	O
,	O	O
1	O	O
.	O	O

03	O	O
)	O	O
,	O	O
naproxen	B-Chemical	D009288
1	O	O
.	O	O

59	O	O
(	O	O
1	O	O
.	O	O

31	O	O
,	O	O
1	O	O
.	O	O

93	O	O
)	O	O
,	O	O
diclofenac	B-Chemical	D004008
1	O	O
.	O	O

17	O	O
(	O	O
0	O	O
.	O	O

99	O	O
,	O	O
1	O	O
.	O	O

38	O	O
)	O	O
and	O	O
ibuprofen	B-Chemical	D007052
1	O	O
.	O	O

05	O	O
(	O	O
0	O	O
.	O	O

74	O	O
,	O	O
1	O	O
.	O	O

51	O	O
)	O	O
.	O	O

Among	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
,	O	O
they	O	O
were	O	O
:	O	O
rofecoxib	B-Chemical	C116926
1	O	O
.	O	O

73	O	O
(	O	O
1	O	O
.	O	O

52	O	O
,	O	O
1	O	O
.	O	O

98	O	O
)	O	O
,	O	O
celecoxib	B-Chemical	C105934
1	O	O
.	O	O

34	O	O
(	O	O
1	O	O
.	O	O

19	O	O
,	O	O
1	O	O
.	O	O

52	O	O
)	O	O
,	O	O
ibuprofen	B-Chemical	D007052
1	O	O
.	O	O

51	O	O
(	O	O
0	O	O
.	O	O

95	O	O
,	O	O
2	O	O
.	O	O

41	O	O
)	O	O
,	O	O
diclofenac	B-Chemical	D004008
1	O	O
.	O	O

69	O	O
(	O	O
1	O	O
.	O	O

35	O	O
,	O	O
2	O	O
.	O	O

10	O	O
)	O	O
,	O	O
naproxen	B-Chemical	D009288
1	O	O
.	O	O

35	O	O
(	O	O
0	O	O
.	O	O

97	O	O
,	O	O
1	O	O
.	O	O

88	O	O
)	O	O
and	O	O
acetaminophen	B-Chemical	D000082
1	O	O
.	O	O

29	O	O
(	O	O
1	O	O
.	O	O

17	O	O
,	O	O
1	O	O
.	O	O

42	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Among	O	O
non	O	O
-	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
,	O	O
naproxen	B-Chemical	D009288
seemed	O	O
to	O	O
carry	O	O
the	O	O
highest	O	O
risk	O	O
for	O	O
AMI	B-Disease	D009203
/	O	O
GI	B-Disease	D006471
bleeding	I-Disease	D006471
.	O	O

The	O	O
AMI	B-Disease	D009203
/	O	O
GI	O	O
toxicity	B-Disease	D064420
of	O	O
celecoxib	B-Chemical	C105934
was	O	O
similar	O	O
to	O	O
that	O	O
of	O	O
acetaminophen	B-Chemical	D000082
and	O	O
seemed	O	O
to	O	O
be	O	O
better	O	O
than	O	O
those	O	O
of	O	O
rofecoxib	B-Chemical	C116926
and	O	O
NS	O	O
-	O	O
NSAIDs	O	O
.	O	O

Among	O	O
users	O	O
of	O	O
aspirin	B-Chemical	D001241
,	O	O
both	O	O
celecoxib	B-Chemical	C105934
and	O	O
naproxen	B-Chemical	D009288
seemed	O	O
to	O	O
be	O	O
the	O	O
least	O	O
toxic	O	O
.	O	O

Quinine	B-Chemical	D011803
-	O	O
induced	O	O
arrhythmia	B-Disease	D001145
in	O	O
a	O	O
patient	O	O
with	O	O
severe	B-Disease	D016778
malaria	I-Disease	D016778
.	O	O

It	O	O
was	O	O
reported	O	O
that	O	O
there	O	O
was	O	O
a	O	O
case	O	O
of	O	O
severe	B-Disease	D016778
malaria	I-Disease	D016778
patient	O	O
with	O	O
jaundice	B-Disease	D007565
who	O	O
presented	O	O
with	O	O
arrhythmia	B-Disease	D001145
(	O	O
premature	B-Disease	D018879
ventricular	I-Disease	D018879
contraction	I-Disease	D018879
)	O	O
while	O	O
getting	O	O
quinine	B-Chemical	D011803
infusion	O	O
was	O	O
reported	O	O
.	O	O

A	O	O
man	O	O
,	O	O
25	O	O
years	O	O
old	O	O
,	O	O
was	O	O
admitted	O	O
to	O	O
hospital	O	O
with	O	O
high	O	O
fever	B-Disease	D005334
,	O	O
chill	B-Disease	D023341
,	O	O
vomiting	B-Disease	D014839
,	O	O
jaundice	B-Disease	D007565
.	O	O

The	O	O
patient	O	O
was	O	O
fully	O	O
conscious	O	O
,	O	O
blood	O	O
pressure	O	O
120	O	O
/	O	O
80	O	O
mmHg	O	O
,	O	O
pulse	O	O
rate	O	O
100	O	O
x	O	O
/	O	O
minute	O	O
,	O	O
regular	O	O
.	O	O

On	O	O
admission	O	O
,	O	O
laboratory	O	O
examination	O	O
showed	O	O
Plasmodium	O	O
falciparum	O	O
(	O	O
++++	O	O
)	O	O
,	O	O
total	O	O
bilirubin	B-Chemical	D001663
8	O	O
.	O	O

25	O	O
mg	O	O
/	O	O
dL	O	O
,	O	O
conjugated	O	O
bilirubin	B-Chemical	D001663
4	O	O
.	O	O

36	O	O
mg	O	O
/	O	O
dL	O	O
,	O	O
unconjugated	O	O
bilirubin	B-Chemical	D001663
3	O	O
.	O	O

89	O	O
mg	O	O
/	O	O
dL	O	O
,	O	O
potassium	B-Chemical	D011188
3	O	O
.	O	O

52	O	O
meq	O	O
/	O	O
L	O	O
Patient	O	O
was	O	O
diagnosed	O	O
as	O	O
severe	B-Disease	D016778
malaria	I-Disease	D016778
with	O	O
jaundice	B-Disease	D007565
and	O	O
got	O	O
quinine	B-Chemical	D011803
infusion	O	O
in	O	O
dextrose	B-Chemical	D005947
5%	O	O
500	O	O
mg	O	O
/	O	O
8	O	O
hour	O	O
.	O	O

On	O	O
the	O	O
second	O	O
day	O	O
the	O	O
patient	O	O
had	O	O
vomitus	B-Disease	D014839
,	O	O
diarrhea	B-Disease	D003967
,	O	O
tinnitus	B-Disease	D014012
,	O	O
loss	B-Disease	D034381
of	I-Disease	D034381
hearing	I-Disease	D034381
.	O	O

After	O	O
30	O	O
hours	O	O
of	O	O
quinine	B-Chemical	D011803
infusion	O	O
the	O	O
patient	O	O
felt	O	O
palpitation	B-Disease	-1
and	O	O
electrocardiography	O	O
(	O	O
ECG	O	O
)	O	O
recording	O	O
showed	O	O
premature	B-Disease	D018879
ventricular	I-Disease	D018879
contraction	I-Disease	D018879
(	O	O
PVC	B-Disease	D018879
)	O	O
>	O	O
5	O	O
x	O	O
/	O	O
minute	O	O
,	O	O
trigemini	O	O
,	O	O
constant	O	O
type	O	O
-	O	O
-	O	O
sinoatrial	B-Disease	D012848
block	I-Disease	D012848
,	O	O
positive	O	O
U	O	O
wave	O	O
.	O	O

He	O	O
was	O	O
treated	O	O
with	O	O
lidocaine	B-Chemical	D008012
50	O	O
mg	O	O
intravenously	O	O
followed	O	O
by	O	O
infusion	O	O
1500	O	O
mg	O	O
in	O	O
dextrose	B-Chemical	D005947
5%	O	O
/	O	O
24	O	O
hour	O	O
and	O	O
potassium	B-Chemical	D011188
aspartate	O	O
tablet	O	O
.	O	O

Quinine	B-Chemical	D011803
infusion	O	O
was	O	O
discontinued	O	O
and	O	O
changed	O	O
with	O	O
sulfate	O	O
quinine	B-Chemical	D011803
tablets	O	O
.	O	O

Three	O	O
hours	O	O
later	O	O
the	O	O
patient	O	O
felt	O	O
better	O	O
,	O	O
the	O	O
frequency	O	O
of	O	O
PVC	B-Disease	D018879
reduced	O	O
to	O	O
4	O	O
-	O	O
5	O	O
x	O	O
/	O	O
minute	O	O
and	O	O
on	O	O
the	O	O
third	O	O
day	O	O
ECG	O	O
was	O	O
normal	O	O
,	O	O
potassium	B-Chemical	D011188
level	O	O
was	O	O
3	O	O
.	O	O

34	O	O
meq	O	O
/	O	O
L	O	O
.	O	O

He	O	O
was	O	O
discharged	O	O
on	O	O
7th	O	O
day	O	O
in	O	O
good	O	O
condition	O	O
.	O	O

Quinine	B-Chemical	D011803
,	O	O
like	O	O
quinidine	B-Chemical	D011802
,	O	O
is	O	O
a	O	O
chincona	O	O
alkaloid	O	O
that	O	O
has	O	O
anti	O	O
-	O	O
arrhythmic	B-Disease	D001145
property	O	O
,	O	O
although	O	O
it	O	O
also	O	O
pro	O	O
-	O	O
arrhythmic	B-Disease	D001145
that	O	O
can	O	O
cause	O	O
various	O	O
arrhythmias	B-Disease	D001145
,	O	O
including	O	O
severe	O	O
arrhythmia	B-Disease	D001145
such	O	O
as	O	O
multiple	O	O
PVC	B-Disease	D018879
.	O	O

Administration	O	O
of	O	O
parenteral	O	O
quinine	B-Chemical	D011803
must	O	O
be	O	O
done	O	O
carefully	O	O
and	O	O
with	O	O
good	O	O
observation	O	O
because	O	O
of	O	O
its	O	O
pro	O	O
-	O	O
arrhythmic	B-Disease	D001145
effect	O	O
,	O	O
especially	O	O
in	O	O
older	O	O
patients	O	O
who	O	O
have	O	O
heart	B-Disease	D006331
diseases	I-Disease	D006331
or	O	O
patients	O	O
with	O	O
electrolyte	B-Disease	D014883
disorder	I-Disease	D014883
(	O	O
hypokalemia	B-Disease	D007008
)	O	O
which	O	O
frequently	O	O
occurs	O	O
due	O	O
to	O	O
vomiting	B-Disease	D014839
and	O	O
or	O	O
diarrhea	B-Disease	D003967
in	O	O
malaria	B-Disease	D008288
cases	O	O
.	O	O

Penicillamine	B-Chemical	D010396
-	O	O
related	O	O
lichenoid	B-Disease	D017512
dermatitis	I-Disease	D017512
and	O	O
utility	O	O
of	O	O
zinc	B-Chemical	D019345
acetate	I-Chemical	D019345
in	O	O
a	O	O
Wilson	B-Disease	D006527
disease	I-Disease	D006527
patient	O	O
with	O	O
hepatic	O	O
presentation	O	O
,	O	O
anxiety	B-Disease	D001008
and	O	O
SPECT	O	O
abnormalities	O	O
.	O	O

Wilson's	B-Disease	D006527
disease	I-Disease	D006527
is	O	O
an	O	O
autosomal	O	O
recessive	O	O
disorder	O	O
of	O	O
hepatic	O	O
copper	B-Chemical	D003300
metabolism	O	O
with	O	O
consequent	O	O
copper	B-Chemical	D003300
accumulation	O	O
and	O	O
toxicity	B-Disease	D064420
in	O	O
many	O	O
tissues	O	O
and	O	O
consequent	O	O
hepatic	O	O
,	O	O
neurologic	O	O
and	O	O
psychiatric	O	O
disorders	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
with	O	O
chronic	B-Disease	D008107
liver	I-Disease	D008107
disease	I-Disease	D008107
;	O	O
moreover	O	O
,	O	O
in	O	O
our	O	O
patient	O	O
,	O	O
presenting	O	O
also	O	O
with	O	O
high	O	O
levels	O	O
of	O	O
state	O	O
anxiety	B-Disease	D001008
without	O	O
depression	B-Disease	D003866
,	O	O
99mTc	O	O
-	O	O
ECD	O	O
-	O	O
SPECT	O	O
showed	O	O
cortical	O	O
hypoperfusion	O	O
in	O	O
frontal	O	O
lobes	O	O
,	O	O
more	O	O
marked	O	O
on	O	O
the	O	O
left	O	O
frontal	O	O
lobe	O	O
.	O	O

During	O	O
the	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
our	O	O
patient	O	O
,	O	O
penicillamine	B-Chemical	D010396
was	O	O
interrupted	O	O
after	O	O
the	O	O
appearance	O	O
of	O	O
a	O	O
lichenoid	B-Disease	D017512
dermatitis	I-Disease	D017512
,	O	O
and	O	O
zinc	B-Chemical	D019345
acetate	I-Chemical	D019345
permitted	O	O
to	O	O
continue	O	O
the	O	O
successful	O	O
treatment	O	O
of	O	O
the	O	O
patient	O	O
without	O	O
side	O	O
-	O	O
effects	O	O
.	O	O

In	O	O
our	O	O
case	O	O
the	O	O
therapy	O	O
with	O	O
zinc	B-Chemical	D019345
acetate	I-Chemical	D019345
represented	O	O
an	O	O
effective	O	O
treatment	O	O
for	O	O
a	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
patient	O	O
in	O	O
which	O	O
penicillamine	B-Chemical	D010396
-	O	O
related	O	O
side	O	O
effects	O	O
appeared	O	O
.	O	O

The	O	O
safety	O	O
of	O	O
the	O	O
zinc	B-Chemical	D019345
acetate	I-Chemical	D019345
allowed	O	O
us	O	O
to	O	O
avoid	O	O
other	O	O
potentially	O	O
toxic	O	O
chelating	O	O
drugs	O	O
;	O	O
this	O	O
observation	O	O
is	O	O
in	O	O
line	O	O
with	O	O
the	O	O
growing	O	O
evidence	O	O
on	O	O
the	O	O
efficacy	O	O
of	O	O
the	O	O
drug	O	O
in	O	O
the	O	O
treatment	O	O
of	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
.	O	O

Since	O	O
most	O	O
of	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
penicillamine	B-Chemical	D010396
-	O	O
treated	O	O
patients	O	O
do	O	O
not	O	O
seem	O	O
to	O	O
develop	O	O
this	O	O
skin	B-Disease	D012871
lesion	I-Disease	D012871
,	O	O
it	O	O
could	O	O
be	O	O
conceivable	O	O
that	O	O
a	O	O
specific	O	O
genetic	O	O
factor	O	O
is	O	O
involved	O	O
in	O	O
drug	O	O
response	O	O
.	O	O

Further	O	O
studies	O	O
are	O	O
needed	O	O
for	O	O
a	O	O
better	O	O
clarification	O	O
of	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
therapy	O	O
,	O	O
and	O	O
in	O	O
particular	O	O
to	O	O
differentiate	O	O
specific	O	O
therapies	O	O
for	O	O
different	O	O
Wilson's	B-Disease	D006527
disease	I-Disease	D006527
phenotypes	O	O
.	O	O

A	O	O
dramatic	O	O
drop	B-Disease	D007022
in	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
following	O	O
prehospital	O	O
GTN	B-Chemical	D005996
administration	O	O
.	O	O

A	O	O
male	O	O
in	O	O
his	O	O
sixties	O	O
with	O	O
no	O	O
history	O	O
of	O	O
cardiac	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
awoke	O	O
with	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
following	O	O
an	O	O
afternoon	O	O
sleep	O	O
.	O	O

The	O	O
patient	O	O
did	O	O
not	O	O
self	O	O
medicate	O	O
.	O	O

The	O	O
patient's	O	O
observations	O	O
were	O	O
within	O	O
normal	O	O
limits	O	O
,	O	O
he	O	O
was	O	O
administered	O	O
oxygen	B-Chemical	D010100
via	O	O
a	O	O
face	O	O
mask	O	O
and	O	O
glyceryl	B-Chemical	D005996
trinitrate	I-Chemical	D005996
(	O	O
GTN	B-Chemical	D005996
)	O	O
.	O	O

Several	O	O
minutes	O	O
after	O	O
the	O	O
GTN	B-Chemical	D005996
the	O	O
patient	O	O
experienced	O	O
a	O	O
sudden	O	O
drop	B-Disease	D007022
in	I-Disease	D007022
blood	I-Disease	D007022
pressure	I-Disease	D007022
and	O	O
heart	O	O
rate	O	O
,	O	O
this	O	O
was	O	O
rectified	O	O
by	O	O
atropine	B-Chemical	D001285
sulphate	I-Chemical	D001285
and	O	O
a	O	O
fluid	O	O
challenge	O	O
.	O	O

There	O	O
was	O	O
no	O	O
further	O	O
deterioration	O	O
in	O	O
the	O	O
patient's	O	O
condition	O	O
during	O	O
transport	O	O
to	O	O
hospital	O	O
.	O	O

There	O	O
are	O	O
very	O	O
few	O	O
documented	O	O
case	O	O
like	O	O
this	O	O
in	O	O
the	O	O
prehospital	O	O
scientific	O	O
literature	O	O
.	O	O

The	O	O
cause	O	O
appears	O	O
to	O	O
be	O	O
the	O	O
Bezold	O	O
-	O	O
Jarish	O	O
reflex	O	O
,	O	O
stimulation	O	O
of	O	O
the	O	O
ventricular	O	O
walls	O	O
which	O	O
in	O	O
turn	O	O
decreases	O	O
sympathetic	O	O
outflow	O	O
from	O	O
the	O	O
vasomotor	O	O
centre	O	O
.	O	O

Prehospital	O	O
care	O	O
providers	O	O
who	O	O
are	O	O
managing	O	O
any	O	O
patient	O	O
with	O	O
a	O	O
syncopal	B-Disease	D013575
episode	I-Disease	D013575
that	O	O
fails	O	O
to	O	O
recover	O	O
within	O	O
a	O	O
reasonable	O	O
time	O	O
frame	O	O
should	O	O
consider	O	O
the	O	O
Bezold	O	O
-	O	O
Jarisch	O	O
reflex	O	O
as	O	O
the	O	O
cause	O	O
and	O	O
manage	O	O
the	O	O
patient	O	O
accordingly	O	O
.	O	O

Acute	B-Disease	D020803
encephalopathy	I-Disease	D020803
and	O	O
cerebral	B-Disease	D020301
vasospasm	I-Disease	D020301
after	O	O
multiagent	O	O
chemotherapy	O	O
including	O	O
PEG	B-Chemical	C042705
-	I-Chemical	C042705
asparaginase	I-Chemical	C042705
and	O	O
intrathecal	O	O
cytarabine	B-Chemical	D003561
for	O	O
the	O	O
treatment	O	O
of	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
.	O	O

A	O	O
7	O	O
-	O	O
year	O	O
-	O	O
old	O	O
girl	O	O
with	O	O
an	O	O
unusual	O	O
reaction	O	O
to	O	O
induction	O	O
chemotherapy	O	O
for	O	O
precursor	O	O
B	O	O
-	O	O
cell	O	O
acute	B-Disease	D054198
lymphoblastic	I-Disease	D054198
leukemia	I-Disease	D054198
(	O	O
ALL	B-Disease	D054198
)	O	O
is	O	O
described	O	O
.	O	O

The	O	O
patient	O	O
developed	O	O
acute	B-Disease	D020803
encephalopathy	I-Disease	D020803
evidenced	O	O
by	O	O
behavioral	O	O
changes	O	O
,	O	O
aphasia	B-Disease	D001037
,	O	O
incontinence	B-Disease	D014549
,	O	O
visual	B-Disease	D006212
hallucinations	I-Disease	D006212
,	O	O
and	O	O
right	O	O
-	O	O
sided	O	O
weakness	B-Disease	D018908
with	O	O
diffuse	O	O
cerebral	B-Disease	D020301
vasospasm	I-Disease	D020301
on	O	O
magnetic	O	O
resonance	O	O
angiography	O	O
after	O	O
the	O	O
administration	O	O
of	O	O
intrathecal	O	O
cytarabine	B-Chemical	D003561
.	O	O

Vincristine	B-Chemical	D014750
,	O	O
dexamethasone	B-Chemical	D003907
,	O	O
and	O	O
polyethylene	B-Chemical	C042705
glycol	I-Chemical	C042705
-	I-Chemical	C042705
asparaginase	I-Chemical	C042705
were	O	O
also	O	O
administered	O	O
before	O	O
the	O	O
episode	O	O
as	O	O
part	O	O
of	O	O
induction	O	O
therapy	O	O
.	O	O

Neurologic	O	O
status	O	O
returned	O	O
to	O	O
baseline	O	O
within	O	O
10	O	O
days	O	O
of	O	O
the	O	O
acute	O	O
event	O	O
,	O	O
and	O	O
magnetic	O	O
resonance	O	O
angiography	O	O
findings	O	O
returned	O	O
to	O	O
normal	O	O
4	O	O
months	O	O
later	O	O
.	O	O

Comparison	O	O
of	O	O
valsartan	B-Chemical	C081489
/	O	O
hydrochlorothiazide	B-Chemical	D006852
combination	O	O
therapy	O	O
at	O	O
doses	O	O
up	O	O
to	O	O
320	O	O
/	O	O
25	O	O
mg	O	O
versus	O	O
monotherapy	O	O
:	O	O
a	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
-	O	O
controlled	O	O
study	O	O
followed	O	O
by	O	O
long	O	O
-	O	O
term	O	O
combination	O	O
therapy	O	O
in	O	O
hypertensive	B-Disease	D006973
adults	O	O
.	O	O

BACKGROUND	O	O
:	O	O
One	O	O
third	O	O
of	O	O
patients	O	O
treated	O	O
for	O	O
hypertension	B-Disease	D006973
attain	O	O
adequate	O	O
blood	O	O
pressure	O	O
(	O	O
BP	O	O
)	O	O
control	O	O
,	O	O
and	O	O
multidrug	O	O
regimens	O	O
are	O	O
often	O	O
required	O	O
.	O	O

Given	O	O
the	O	O
lifelong	O	O
nature	O	O
of	O	O
hypertension	B-Disease	D006973
,	O	O
there	O	O
is	O	O
a	O	O
need	O	O
to	O	O
evaluate	O	O
the	O	O
long	O	O
-	O	O
term	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
higher	O	O
doses	O	O
of	O	O
combination	O	O
anti	O	O
-	O	O
hypertensive	B-Disease	D006973
therapies	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
investigated	O	O
the	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
valsartan	B-Chemical	C081489
(	O	O
VAL	B-Chemical	C081489
)	O	O
or	O	O
hydrochlorothiazide	B-Chemical	D006852
(	O	O
HCTZ	B-Chemical	D006852
)	O	O
-	O	O
monotherapy	O	O
and	O	O
higher	O	O
-	O	O
dose	O	O
combinations	O	O
in	O	O
patients	O	O
with	O	O
essential	B-Disease	C562386
hypertension	I-Disease	C562386
.	O	O

METHODS	O	O
:	O	O
The	O	O
first	O	O
part	O	O
of	O	O
this	O	O
study	O	O
was	O	O
an	O	O
8	O	O
-	O	O
week	O	O
,	O	O
multicenter	O	O
,	O	O
randomized	O	O
,	O	O
double	O	O
-	O	O
blind	O	O
,	O	O
placebo	O	O
controlled	O	O
,	O	O
parallel	O	O
-	O	O
group	O	O
trial	O	O
.	O	O

Patients	O	O
with	O	O
essential	B-Disease	C562386
hypertension	I-Disease	C562386
(	O	O
mean	O	O
sitting	O	O
diastolic	O	O
BP	O	O
[	O	O
MSDBP	O	O
]	O	O
,	O	O
>	O	O
or	O	O
=95	O	O
mm	O	O
Hg	O	O
and	O	O
<110	O	O
mm	O	O
Hg	O	O
)	O	O
were	O	O
randomized	O	O
to	O	O
1	O	O
of	O	O
8	O	O
treatment	O	O
groups	O	O
:	O	O
VAL	B-Chemical	C081489
160	O	O
or	O	O
320	O	O
mg	O	O
;	O	O
HCTZ	B-Chemical	D006852
12	O	O
.	O	O

5	O	O
or	O	O
25	O	O
mg	O	O
;	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
160	O	O
/	O	O
12	O	O
.	O	O

5	O	O
,	O	O
320	O	O
/	O	O
12	O	O
.	O	O

5	O	O
,	O	O
or	O	O
320	O	O
/	O	O
25	O	O
mg	O	O
;	O	O
or	O	O
placebo	O	O
.	O	O

Mean	O	O
changes	O	O
in	O	O
MSDBP	O	O
and	O	O
mean	O	O
sitting	O	O
systolic	O	O
BP	O	O
(	O	O
MSSBP	O	O
)	O	O
were	O	O
analyzed	O	O
at	O	O
the	O	O
8	O	O
-	O	O
week	O	O
core	O	O
study	O	O
end	O	O
point	O	O
.	O	O

VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
320	O	O
/	O	O
12	O	O
.	O	O

5	O	O
and	O	O
320	O	O
/	O	O
25	O	O
mg	O	O
were	O	O
further	O	O
investigated	O	O
in	O	O
a	O	O
54	O	O
-	O	O
week	O	O
,	O	O
open	O	O
-	O	O
label	O	O
extension	O	O
.	O	O

Response	O	O
was	O	O
defined	O	O
as	O	O
MSDBP	O	O
<90	O	O
mm	O	O
Hg	O	O
or	O	O
a	O	O
>	O	O
or	O	O
=10	O	O
mm	O	O
Hg	O	O
decrease	O	O
compared	O	O
to	O	O
baseline	O	O
.	O	O

Control	O	O
was	O	O
defined	O	O
as	O	O
MSDBP	O	O
<90	O	O
mm	O	O
Hg	O	O
compared	O	O
with	O	O
baseline	O	O
.	O	O

Tolerability	O	O
was	O	O
assessed	O	O
by	O	O
monitoring	O	O
adverse	O	O
events	O	O
at	O	O
randomization	O	O
and	O	O
all	O	O
subsequent	O	O
study	O	O
visits	O	O
and	O	O
regular	O	O
evaluation	O	O
of	O	O
hematology	O	O
and	O	O
blood	O	O
chemistry	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
1346	O	O
patients	O	O
were	O	O
randomized	O	O
into	O	O
the	O	O
8	O	O
-	O	O
week	O	O
core	O	O
study	O	O
(	O	O
734	O	O
men	O	O
,	O	O
612	O	O
women	O	O
;	O	O
924	O	O
white	O	O
,	O	O
291	O	O
black	O	O
,	O	O
23	O	O
Asian	O	O
,	O	O
108	O	O
other	O	O
;	O	O
mean	O	O
age	O	O
,	O	O
52	O	O
.	O	O

7	O	O
years	O	O
;	O	O
mean	O	O
weight	O	O
,	O	O
92	O	O
.	O	O

6	O	O
kg	O	O
)	O	O
.	O	O

All	O	O
active	O	O
treatments	O	O
were	O	O
associated	O	O
with	O	O
significantly	O	O
reduced	O	O
MSSBP	O	O
and	O	O
MSDBP	O	O
during	O	O
the	O	O
core	O	O
8	O	O
-	O	O
week	O	O
study	O	O
,	O	O
with	O	O
each	O	O
monotherapy	O	O
significantly	O	O
contributing	O	O
to	O	O
the	O	O
overall	O	O
effect	O	O
of	O	O
combination	O	O
therapy	O	O
(	O	O
VAL	B-Chemical	C081489
and	O	O
HCTZ	B-Chemical	D006852
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Each	O	O
combination	O	O
was	O	O
associated	O	O
with	O	O
significantly	O	O
greater	O	O
reductions	O	O
in	O	O
MSSBP	O	O
and	O	O
MSDBP	O	O
compared	O	O
with	O	O
the	O	O
monotherapies	O	O
and	O	O
placebo	O	O
(	O	O
all	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
reduction	O	O
in	O	O
MSSBP	O	O
/	O	O
MSDBP	O	O
with	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
320	O	O
/	O	O
25	O	O
mg	O	O
was	O	O
24	O	O
.	O	O

7	O	O
/	O	O
16	O	O
.	O	O

6	O	O
mm	O	O
Hg	O	O
,	O	O
compared	O	O
with	O	O
5	O	O
.	O	O

9	O	O
/	O	O
7	O	O
.	O	O

0	O	O
mm	O	O
Hg	O	O
with	O	O
placebo	O	O
.	O	O

The	O	O
reduction	O	O
in	O	O
MSSBP	O	O
was	O	O
significantly	O	O
greater	O	O
with	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
320	O	O
/	O	O
25	O	O
mg	O	O
compared	O	O
with	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
160	O	O
/	O	O
12	O	O
.	O	O

5	O	O
mg	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

002	O	O
)	O	O
.	O	O

Rates	O	O
of	O	O
response	O	O
and	O	O
BP	O	O
control	O	O
were	O	O
significantly	O	O
higher	O	O
in	O	O
the	O	O
groups	O	O
that	O	O
received	O	O
combination	O	O
treatment	O	O
compared	O	O
with	O	O
those	O	O
that	O	O
received	O	O
monotherapy	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
hypokalemia	B-Disease	D007008
was	O	O
lower	O	O
with	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
combinations	O	O
(	O	O
1	O	O
.	O	O

8%	O	O
-	O	O
6	O	O
.	O	O

1%	O	O
)	O	O
than	O	O
with	O	O
HCTZ	B-Chemical	D006852
monotherapies	O	O
(	O	O
7	O	O
.	O	O

1%	O	O
-	O	O
13	O	O
.	O	O

3%	O	O
)	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
adverse	O	O
events	O	O
in	O	O
the	O	O
core	O	O
study	O	O
were	O	O
of	O	O
mild	O	O
to	O	O
moderate	O	O
severity	O	O
.	O	O

The	O	O
efficacy	O	O
and	O	O
tolerability	O	O
of	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
combinations	O	O
were	O	O
maintained	O	O
during	O	O
the	O	O
extension	O	O
(	O	O
797	O	O
patients	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
In	O	O
this	O	O
study	O	O
population	O	O
,	O	O
combination	O	O
therapies	O	O
with	O	O
VAL	B-Chemical	C081489
/	O	O
HCTZ	B-Chemical	D006852
were	O	O
associated	O	O
with	O	O
significantly	O	O
greater	O	O
BP	O	O
reductions	O	O
compared	O	O
with	O	O
either	O	O
monotherapy	O	O
,	O	O
were	O	O
well	O	O
tolerated	O	O
,	O	O
and	O	O
were	O	O
associated	O	O
with	O	O
less	O	O
hypokalemia	B-Disease	D007008
than	O	O
HCTZ	B-Chemical	D006852
alone	O	O
.	O	O

Succimer	B-Chemical	D004113
chelation	O	O
improves	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
in	O	O
lead	B-Chemical	D007854
-	O	O
exposed	O	O
rats	O	O
but	O	O
produces	O	O
lasting	O	O
cognitive	B-Disease	D003072
impairment	I-Disease	D003072
in	O	O
the	O	O
absence	O	O
of	O	O
lead	B-Chemical	D007854
exposure	O	O
.	O	O

BACKGROUND	O	O
:	O	O
There	O	O
is	O	O
growing	O	O
pressure	O	O
for	O	O
clinicians	O	O
to	O	O
prescribe	O	O
chelation	O	O
therapy	O	O
at	O	O
only	O	O
slightly	O	O
elevated	O	O
blood	O	O
lead	B-Chemical	D007854
levels	O	O
.	O	O

However	O	O
,	O	O
very	O	O
few	O	O
studies	O	O
have	O	O
evaluated	O	O
whether	O	O
chelation	O	O
improves	O	O
cognitive	O	O
outcomes	O	O
in	O	O
Pb	B-Chemical	D007854
-	O	O
exposed	O	O
children	O	O
,	O	O
or	O	O
whether	O	O
these	O	O
agents	O	O
have	O	O
adverse	O	O
effects	O	O
that	O	O
may	O	O
affect	O	O
brain	O	O
development	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
Pb	B-Chemical	D007854
exposure	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
The	O	O
present	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
answer	O	O
these	O	O
questions	O	O
,	O	O
using	O	O
a	O	O
rodent	O	O
model	O	O
of	O	O
early	O	O
childhood	O	O
Pb	B-Chemical	D007854
exposure	O	O
and	O	O
treatment	O	O
with	O	O
succimer	B-Chemical	D004113
,	O	O
a	O	O
widely	O	O
used	O	O
chelating	O	O
agent	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
Pb	B-Chemical	D007854
poisoning	O	O
.	O	O

RESULTS	O	O
:	O	O
Pb	B-Chemical	D007854
exposure	O	O
produced	O	O
lasting	O	O
impairments	O	O
in	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
inhibitory	O	O
control	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
,	O	O
paralleling	O	O
the	O	O
areas	O	O
of	O	O
dysfunction	O	O
seen	O	O
in	O	O
Pb	B-Chemical	D007854
-	O	O
exposed	O	O
children	O	O
.	O	O

Succimer	B-Chemical	D004113
treatment	O	O
of	O	O
the	O	O
Pb	B-Chemical	D007854
-	O	O
exposed	O	O
rats	O	O
significantly	O	O
improved	O	O
learning	O	O
,	O	O
attention	O	O
,	O	O
and	O	O
arousal	O	O
regulation	O	O
,	O	O
although	O	O
the	O	O
efficacy	O	O
of	O	O
the	O	O
treatment	O	O
varied	O	O
as	O	O
a	O	O
function	O	O
of	O	O
the	O	O
Pb	B-Chemical	D007854
exposure	O	O
level	O	O
and	O	O
the	O	O
specific	O	O
functional	O	O
deficit	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
succimer	B-Chemical	D004113
treatment	O	O
of	O	O
rats	O	O
not	O	O
previously	O	O
exposed	O	O
to	O	O
Pb	B-Chemical	D007854
produced	O	O
lasting	O	O
and	O	O
pervasive	O	O
cognitive	O	O
and	O	O
affective	O	O
dysfunction	O	O
comparable	O	O
in	O	O
magnitude	O	O
to	O	O
that	O	O
produced	O	O
by	O	O
the	O	O
higher	O	O
Pb	B-Chemical	D007854
exposure	O	O
regimen	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
are	O	O
the	O	O
first	O	O
data	O	O
,	O	O
to	O	O
our	O	O
knowledge	O	O
,	O	O
to	O	O
show	O	O
that	O	O
treatment	O	O
with	O	O
any	O	O
chelating	O	O
agent	O	O
can	O	O
alleviate	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
due	O	O
to	O	O
Pb	B-Chemical	D007854
exposure	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
it	O	O
may	O	O
be	O	O
possible	O	O
to	O	O
identify	O	O
a	O	O
succimer	B-Chemical	D004113
treatment	O	O
protocol	O	O
that	O	O
improves	O	O
cognitive	O	O
outcomes	O	O
in	O	O
Pb	B-Chemical	D007854
-	O	O
exposed	O	O
children	O	O
.	O	O

However	O	O
,	O	O
they	O	O
also	O	O
suggest	O	O
that	O	O
succimer	B-Chemical	D004113
treatment	O	O
should	O	O
be	O	O
strongly	O	O
discouraged	O	O
for	O	O
children	O	O
who	O	O
do	O	O
not	O	O
have	O	O
elevated	O	O
tissue	O	O
levels	O	O
of	O	O
Pb	B-Chemical	D007854
or	O	O
other	O	O
heavy	O	O
metals	O	O
.	O	O

Caffeine	B-Chemical	D002110
challenge	O	O
test	O	O
in	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
and	O	O
depression	B-Disease	D003866
with	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
.	O	O

Our	O	O
aim	O	O
was	O	O
to	O	O
observe	O	O
if	O	O
patients	O	O
with	O	O
panic	B-Disease	D016584
disorder	I-Disease	D016584
(	O	O
PD	B-Disease	D016584
)	O	O
and	O	O
patients	O	O
with	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
with	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
(	O	O
MDP	B-Disease	D003865
)	O	O
(	O	O
Diagnostic	O	O
and	O	O
Statistical	O	O
Manual	O	O
of	O	O
Mental	B-Disease	D001523
Disorders	I-Disease	D001523
,	O	O
Fourth	O	O
Edition	O	O
criteria	O	O
)	O	O
respond	O	O
in	O	O
a	O	O
similar	O	O
way	O	O
to	O	O
the	O	O
induction	O	O
of	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
by	O	O
an	O	O
oral	O	O
caffeine	B-Chemical	D002110
challenge	O	O
test	O	O
.	O	O

We	O	O
randomly	O	O
selected	O	O
29	O	O
patients	O	O
with	O	O
PD	B-Disease	D016584
,	O	O
27	O	O
with	O	O
MDP	B-Disease	D003865
,	O	O
25	O	O
with	O	O
major	B-Disease	D003865
depression	I-Disease	D003865
without	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
(	O	O
MD	B-Disease	D003865
)	O	O
,	O	O
and	O	O
28	O	O
healthy	O	O
volunteers	O	O
.	O	O

The	O	O
patients	O	O
had	O	O
no	O	O
psychotropic	O	O
drug	O	O
for	O	O
at	O	O
least	O	O
a	O	O
4	O	O
-	O	O
week	O	O
period	O	O
.	O	O

In	O	O
a	O	O
randomized	O	O
double	O	O
-	O	O
blind	O	O
experiment	O	O
performed	O	O
in	O	O
2	O	O
occasions	O	O
7	O	O
days	O	O
apart	O	O
,	O	O
480	O	O
mg	O	O
caffeine	B-Chemical	D002110
and	O	O
a	O	O
caffeine	B-Chemical	D002110
-	O	O
free	O	O
(	O	O
placebo	O	O
)	O	O
solution	O	O
were	O	O
administered	O	O
in	O	O
a	O	O
coffee	O	O
form	O	O
and	O	O
anxiety	B-Disease	D001008
scales	O	O
were	O	O
applied	O	O
before	O	O
and	O	O
after	O	O
each	O	O
test	O	O
.	O	O

A	O	O
total	O	O
of	O	O
58	O	O
.	O	O

6%	O	O
(	O	O
n	O	O
=	O	O
17	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
PD	B-Disease	D016584
,	O	O
44	O	O
.	O	O

4%	O	O
(	O	O
n	O	O
=	O	O
12	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
MDP	B-Disease	D003865
,	O	O
12	O	O
.	O	O

0%	O	O
(	O	O
n	O	O
=	O	O
3	O	O
)	O	O
of	O	O
patients	O	O
with	O	O
MD	B-Disease	D003865
,	O	O
and	O	O
7	O	O
.	O	O

1%	O	O
(	O	O
n=	O	O
2	O	O
)	O	O
of	O	O
control	O	O
subjects	O	O
had	O	O
a	O	O
panic	B-Disease	D016584
attack	I-Disease	D016584
after	O	O
the	O	O
480	O	O
-	O	O
mg	O	O
caffeine	B-Chemical	D002110
challenge	O	O
test	O	O
(	O	O
chi	O	O
(	O	O
2	O	O
)	O	O
(	O	O
3	O	O
)	O	O
=	O	O
16	O	O
.	O	O

22	O	O
,	O	O
P	O	O
=	O	O
.	O	O

001	O	O
)	O	O
.	O	O

The	O	O
patients	O	O
with	O	O
PD	B-Disease	D016584
and	O	O
MDP	B-Disease	D003865
were	O	O
more	O	O
sensitive	O	O
to	O	O
caffeine	B-Chemical	D002110
than	O	O
were	O	O
patients	O	O
with	O	O
MD	B-Disease	D003865
and	O	O
healthy	O	O
volunteers	O	O
.	O	O

No	O	O
panic	B-Disease	D016584
attack	I-Disease	D016584
was	O	O
observed	O	O
after	O	O
the	O	O
caffeine	B-Chemical	D002110
-	O	O
free	O	O
solution	O	O
intake	O	O
.	O	O

The	O	O
patients	O	O
with	O	O
MD	B-Disease	D003865
had	O	O
a	O	O
lower	O	O
heart	O	O
rate	O	O
response	O	O
to	O	O
the	O	O
test	O	O
than	O	O
all	O	O
the	O	O
other	O	O
groups	O	O
(	O	O
2	O	O
-	O	O
way	O	O
analysis	O	O
of	O	O
variance	O	O
,	O	O
group	O	O
by	O	O
time	O	O
interaction	O	O
with	O	O
Greenhouse	O	O
-	O	O
Geisser	O	O
correction	O	O
:	O	O
F	O	O
(	O	O
3	O	O
,	O	O
762	O	O
)	O	O
=	O	O
2	O	O
.	O	O

85	O	O
,	O	O
P	O	O
=	O	O
.	O	O

026	O	O
)	O	O
.	O	O

Our	O	O
data	O	O
suggest	O	O
that	O	O
there	O	O
is	O	O
an	O	O
association	O	O
between	O	O
panic	B-Disease	D016584
attacks	I-Disease	D016584
,	O	O
no	O	O
matter	O	O
if	O	O
associated	O	O
with	O	O
PD	B-Disease	D016584
or	O	O
MDP	B-Disease	D003865
,	O	O
and	O	O
hyperreactivity	O	O
to	O	O
an	O	O
oral	O	O
caffeine	B-Chemical	D002110
challenge	O	O
test	O	O
.	O	O

Mitral	O	O
annuloplasty	O	O
as	O	O
a	O	O
ventricular	O	O
restoration	O	O
method	O	O
for	O	O
the	O	O
failing	B-Disease	D006333
left	I-Disease	D006333
ventricle	I-Disease	D006333
:	O	O
a	O	O
pilot	O	O
study	O	O
.	O	O

BACKGROUND	O	O
AND	O	O
AIM	O	O
OF	O	O
THE	O	O
STUDY	O	O
:	O	O
Undersized	O	O
mitral	O	O
annuloplasty	O	O
(	O	O
MAP	O	O
)	O	O
is	O	O
effective	O	O
in	O	O
patients	O	O
with	O	O
dilated	B-Disease	D002311
cardiomyopathy	I-Disease	D002311
and	O	O
functional	O	O
mitral	B-Disease	D008944
regurgitation	I-Disease	D008944
(	O	O
MR	B-Disease	D008944
)	O	O
since	O	O
,	O	O
as	O	O
well	O	O
as	O	O
addressing	O	O
the	O	O
MR	B-Disease	D008944
,	O	O
the	O	O
MAP	O	O
may	O	O
also	O	O
reshape	O	O
the	O	O
dilated	O	O
left	O	O
ventricular	O	O
(	O	O
LV	O	O
)	O	O
base	O	O
.	O	O

However	O	O
,	O	O
the	O	O
direct	O	O
benefits	O	O
of	O	O
this	O	O
possible	O	O
reshaping	O	O
on	O	O
LV	O	O
function	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
underlying	O	O
MR	B-Disease	D008944
remain	O	O
incompletely	O	O
understood	O	O
.	O	O

The	O	O
study	O	O
aim	O	O
was	O	O
to	O	O
identify	O	O
these	O	O
benefits	O	O
in	O	O
a	O	O
canine	O	O
model	O	O
of	O	O
acute	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

METHODS	O	O
:	O	O
Six	O	O
dogs	O	O
underwent	O	O
MAP	O	O
with	O	O
a	O	O
prosthetic	O	O
band	O	O
on	O	O
the	O	O
posterior	O	O
mitral	O	O
annulus	O	O
,	O	O
using	O	O
four	O	O
mattress	O	O
sutures	O	O
.	O	O

The	O	O
sutures	O	O
were	O	O
passed	O	O
individually	O	O
through	O	O
four	O	O
tourniquets	O	O
and	O	O
exteriorized	O	O
untied	O	O
via	O	O
the	O	O
left	O	O
atriotomy	O	O
.	O	O

Sonomicrometry	O	O
crystals	O	O
were	O	O
implanted	O	O
around	O	O
the	O	O
mitral	O	O
annulus	O	O
and	O	O
left	O	O
ventricle	O	O
to	O	O
measure	O	O
geometry	O	O
and	O	O
regional	O	O
function	O	O
.	O	O

Acute	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
was	O	O
induced	O	O
by	O	O
propranolol	B-Chemical	D011433
and	O	O
volume	O	O
loading	O	O
after	O	O
weaning	O	O
from	O	O
cardiopulmonary	O	O
bypass	O	O
;	O	O
an	O	O
absence	O	O
of	O	O
MR	B-Disease	D008944
was	O	O
confirmed	O	O
by	O	O
echocardiography	O	O
.	O	O

MAP	O	O
was	O	O
accomplished	O	O
by	O	O
cinching	O	O
the	O	O
tourniquets	O	O
.	O	O

Data	O	O
were	O	O
acquired	O	O
at	O	O
baseline	O	O
,	O	O
after	O	O
induction	O	O
of	O	O
acute	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
,	O	O
and	O	O
after	O	O
MAP	O	O
.	O	O

RESULTS	O	O
:	O	O
MAP	O	O
decreased	O	O
mitral	O	O
annular	O	O
dimensions	O	O
in	O	O
both	O	O
commissure	O	O
-	O	O
commissure	O	O
and	O	O
septal	O	O
-	O	O
lateral	O	O
directions	O	O
.	O	O

Concomitantly	O	O
,	O	O
the	O	O
diastolic	O	O
diameter	O	O
of	O	O
the	O	O
LV	O	O
base	O	O
and	O	O
LV	O	O
sphericity	O	O
decreased	O	O
(	O	O
i	O	O
.	O	O

e	O	O
.	O	O

,	O	O
improved	O	O
)	O	O
from	O	O
37	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
9	O	O
.	O	O

3	O	O
to	O	O
35	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
10	O	O
mm	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

063	O	O
)	O	O
,	O	O
and	O	O
from	O	O
67	O	O
.	O	O

9	O	O
+	O	O
/	O	O
-	O	O
18	O	O
.	O	O

6%	O	O
to	O	O
65	O	O
.	O	O

3	O	O
+	O	O
/	O	O
-	O	O
18	O	O
.	O	O

9%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

016	O	O
)	O	O
,	O	O
respectively	O	O
.	O	O

Decreases	O	O
were	O	O
evident	O	O
in	O	O
both	O	O
LV	O	O
end	O	O
-	O	O
diastolic	O	O
pressure	O	O
(	O	O
from	O	O
17	O	O
+	O	O
/	O	O
-	O	O
7	O	O
to	O	O
15	O	O
+	O	O
/	O	O
-	O	O
6	O	O
mmHg	O	O
,	O	O
p	O	O
=	O	O
0	O	O
.	O	O

0480	O	O
and	O	O
Tau	O	O
(	O	O
from	O	O
48	O	O
+	O	O
/	O	O
-	O	O
8	O	O
to	O	O
45	O	O
+	O	O
/	O	O
-	O	O
8	O	O
ms	O	O
,	O	O
p	O	O
<0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
while	O	O
fractional	O	O
shortening	O	O
at	O	O
the	O	O
LV	O	O
base	O	O
increased	O	O
from	O	O
7	O	O
.	O	O

7	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

5%	O	O
to	O	O
9	O	O
.	O	O

4	O	O
+	O	O
/	O	O
-	O	O
4	O	O
.	O	O

5%	O	O
(	O	O
p	O	O
=	O	O
0	O	O
.	O	O

045	O	O
)	O	O
.	O	O

After	O	O
MAP	O	O
,	O	O
increases	O	O
were	O	O
identified	O	O
in	O	O
both	O	O
cardiac	O	O
output	O	O
(	O	O
from	O	O
1	O	O
.	O	O

54	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

57	O	O
to	O	O
1	O	O
.	O	O

65	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

57	O	O
1	O	O
/	O	O
min	O	O
)	O	O
and	O	O
Emax	O	O
(	O	O
from	O	O
1	O	O
.	O	O

86	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

9	O	O
to	O	O
2	O	O
.	O	O

41	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

31	O	O
mmHg	O	O
/	O	O
ml	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
acquired	O	O
suggest	O	O
that	O	O
isolated	O	O
MAP	O	O
may	O	O
have	O	O
certain	O	O
benefits	O	O
on	O	O
LV	O	O
dimension	O	O
/	O	O
function	O	O
in	O	O
acute	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
,	O	O
even	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
MR	B-Disease	D008944
.	O	O

However	O	O
,	O	O
further	O	O
investigations	O	O
are	O	O
warranted	O	O
in	O	O
a	O	O
model	O	O
of	O	O
chronic	O	O
heart	B-Disease	D006333
failure	I-Disease	D006333
.	O	O

Piperacillin	B-Chemical	C085143
/	I-Chemical	C085143
tazobactam	I-Chemical	C085143
-	O	O
induced	O	O
seizure	B-Disease	D012640
rapidly	O	O
reversed	O	O
by	O	O
high	O	O
flux	O	O
hemodialysis	O	O
in	O	O
a	O	O
patient	O	O
on	O	O
peritoneal	O	O
dialysis	O	O
.	O	O

Despite	O	O
popular	O	O
use	O	O
of	O	O
piperacillin	B-Chemical	D010878
,	O	O
the	O	O
dire	O	O
neurotoxicity	B-Disease	D020258
associated	O	O
with	O	O
piperacillin	B-Chemical	D010878
still	O	O
goes	O	O
unrecognized	O	O
,	O	O
leading	O	O
to	O	O
a	O	O
delay	O	O
in	O	O
appropriate	O	O
management	O	O
.	O	O

We	O	O
report	O	O
a	O	O
57	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
receiving	O	O
continuous	O	O
ambulatory	O	O
peritoneal	O	O
dialysis	O	O
(	O	O
CAPD	O	O
)	O	O
,	O	O
who	O	O
developed	O	O
slurred	O	O
speech	O	O
,	O	O
tremor	B-Disease	D014202
,	O	O
bizarre	O	O
behavior	O	O
,	O	O
progressive	O	O
mental	O	O
confusion	B-Disease	D003221
,	O	O
and	O	O
2	O	O
episodes	O	O
of	O	O
generalized	O	O
tonic	B-Disease	D004830
-	I-Disease	D004830
clonic	I-Disease	D004830
seizure	I-Disease	D004830
(	O	O
GTCS	B-Disease	D004830
)	O	O
after	O	O
5	O	O
doses	O	O
of	O	O
piperacillin	B-Chemical	D010878
/	O	O
tazobactam	O	O
(	O	O
2	O	O
g	O	O
/	O	O
250	O	O
mg	O	O
)	O	O
were	O	O
given	O	O
for	O	O
bronchiectasis	B-Disease	D001987
with	O	O
secondary	B-Disease	D060085
infection	I-Disease	D060085
.	O	O

The	O	O
laboratory	O	O
data	O	O
revealed	O	O
normal	O	O
plasma	O	O
electrolyte	O	O
and	O	O
ammonia	B-Chemical	D000641
levels	O	O
but	O	O
leukocytosis	B-Disease	D007964
.	O	O

Neurologic	O	O
examinations	O	O
showed	O	O
dysarthria	B-Disease	D004401
and	O	O
bilateral	O	O
Babinski	O	O
sign	O	O
.	O	O

Computed	O	O
tomography	O	O
of	O	O
brain	O	O
and	O	O
electroencephalogram	O	O
were	O	O
unremarkable	O	O
.	O	O

Despite	O	O
the	O	O
use	O	O
of	O	O
antiepileptic	O	O
agents	O	O
,	O	O
another	O	O
GTCS	B-Disease	D004830
episode	O	O
recurred	O	O
after	O	O
the	O	O
sixth	O	O
dose	O	O
of	O	O
piperacillin	B-Chemical	D010878
/	O	O
tazobactam	O	O
.	O	O

Brain	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
did	O	O
not	O	O
demonstrate	O	O
acute	O	O
infarction	B-Disease	D007238
and	O	O
organic	B-Disease	-1
brain	I-Disease	-1
lesions	I-Disease	-1
.	O	O

Initiation	O	O
of	O	O
high	O	O
-	O	O
flux	O	O
hemodialysis	O	O
rapidly	O	O
reversed	O	O
the	O	O
neurologic	O	O
symptoms	O	O
within	O	O
4	O	O
hours	O	O
.	O	O

Piperacillin	B-Chemical	D010878
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
should	O	O
be	O	O
considered	O	O
in	O	O
any	O	O
uremic	B-Disease	D006463
patients	O	O
with	O	O
unexplained	O	O
neurological	O	O
manifestations	O	O
.	O	O

CAPD	O	O
is	O	O
inefficient	O	O
in	O	O
removing	O	O
piperacillin	B-Chemical	D010878
,	O	O
whereas	O	O
hemodialysis	O	O
can	O	O
rapidly	O	O
terminate	O	O
the	O	O
piperacillin	B-Chemical	D010878
-	O	O
induced	O	O
encephalopathy	B-Disease	D001927
.	O	O

Frequency	O	O
of	O	O
transient	O	O
ipsilateral	O	O
vocal	B-Disease	D014826
cord	I-Disease	D014826
paralysis	I-Disease	D014826
in	O	O
patients	O	O
undergoing	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Especially	O	O
because	O	O
of	O	O
improvements	O	O
in	O	O
clinical	O	O
neurologic	O	O
monitoring	O	O
,	O	O
carotid	O	O
endarterectomy	O	O
done	O	O
under	O	O
local	O	O
anesthesia	O	O
has	O	O
become	O	O
the	O	O
technique	O	O
of	O	O
choice	O	O
in	O	O
several	O	O
centers	O	O
.	O	O

Temporary	O	O
ipsilateral	O	O
vocal	B-Disease	D014826
nerve	I-Disease	D014826
palsies	I-Disease	D014826
due	O	O
to	O	O
local	O	O
anesthetics	O	O
have	O	O
been	O	O
described	O	O
,	O	O
however	O	O
.	O	O

Such	O	O
complications	O	O
are	O	O
most	O	O
important	O	O
in	O	O
situations	O	O
where	O	O
there	O	O
is	O	O
a	O	O
pre	O	O
-	O	O
existing	O	O
contralateral	O	O
paralysis	B-Disease	D010243
.	O	O

We	O	O
therefore	O	O
examined	O	O
the	O	O
effect	O	O
of	O	O
local	O	O
anesthesia	O	O
on	O	O
vocal	O	O
cord	O	O
function	O	O
to	O	O
better	O	O
understand	O	O
its	O	O
possible	O	O
consequences	O	O
.	O	O

METHODS	O	O
:	O	O
This	O	O
prospective	O	O
study	O	O
included	O	O
28	O	O
patients	O	O
undergoing	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
.	O	O

Vocal	O	O
cord	O	O
function	O	O
was	O	O
evaluated	O	O
before	O	O
,	O	O
during	O	O
,	O	O
and	O	O
after	O	O
surgery	O	O
(	O	O
postoperative	O	O
day	O	O
1	O	O
)	O	O
using	O	O
flexible	O	O
laryngoscopy	O	O
.	O	O

Anesthesia	O	O
was	O	O
performed	O	O
by	O	O
injecting	O	O
20	O	O
to	O	O
40	O	O
mL	O	O
of	O	O
a	O	O
mixture	O	O
of	O	O
long	O	O
-	O	O
acting	O	O
(	O	O
ropivacaine	B-Chemical	C037663
)	O	O
and	O	O
short	O	O
-	O	O
acting	O	O
(	O	O
prilocaine	B-Chemical	D011318
)	O	O
anesthetic	O	O
.	O	O

RESULTS	O	O
:	O	O
All	O	O
patients	O	O
had	O	O
normal	O	O
vocal	O	O
cord	O	O
function	O	O
preoperatively	O	O
.	O	O

Twelve	O	O
patients	O	O
(	O	O
43%	O	O
)	O	O
were	O	O
found	O	O
to	O	O
have	O	O
intraoperative	O	O
ipsilateral	O	O
vocal	B-Disease	D014826
cord	I-Disease	D014826
paralysis	I-Disease	D014826
.	O	O

It	O	O
resolved	O	O
in	O	O
all	O	O
cases	O	O
<	O	O
or	O	O
=24	O	O
hours	O	O
.	O	O

There	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
operating	O	O
time	O	O
or	O	O
volume	O	O
or	O	O
frequency	O	O
of	O	O
anesthetic	O	O
administration	O	O
in	O	O
patients	O	O
with	O	O
temporary	O	O
vocal	B-Disease	D014826
cord	I-Disease	D014826
paralysis	I-Disease	D014826
compared	O	O
with	O	O
those	O	O
without	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Local	O	O
anesthesia	O	O
led	O	O
to	O	O
temporary	O	O
ipsilateral	O	O
vocal	B-Disease	D014826
cord	I-Disease	D014826
paralysis	I-Disease	D014826
in	O	O
almost	O	O
half	O	O
of	O	O
these	O	O
patients	O	O
.	O	O

Because	O	O
pre	O	O
-	O	O
existing	O	O
paralysis	B-Disease	D010243
is	O	O
of	O	O
a	O	O
relevant	O	O
frequency	O	O
(	O	O
up	O	O
to	O	O
3%	O	O
)	O	O
,	O	O
a	O	O
preoperative	O	O
evaluation	O	O
of	O	O
vocal	O	O
cord	O	O
function	O	O
before	O	O
carotid	O	O
endarterectomy	O	O
under	O	O
local	O	O
anesthesia	O	O
is	O	O
recommended	O	O
to	O	O
avoid	O	O
intraoperative	O	O
bilateral	O	O
paralysis	B-Disease	D010243
.	O	O

In	O	O
patients	O	O
with	O	O
preoperative	O	O
contralateral	O	O
vocal	B-Disease	D014826
cord	I-Disease	D014826
paralysis	I-Disease	D014826
,	O	O
surgery	O	O
under	O	O
general	O	O
anesthesia	O	O
should	O	O
be	O	O
considered	O	O
.	O	O

Neuroprotective	O	O
effects	O	O
of	O	O
melatonin	B-Chemical	D008550
upon	O	O
the	O	O
offspring	O	O
cerebellar	O	O
cortex	O	O
in	O	O
the	O	O
rat	O	O
model	O	O
of	O	O
BCNU	B-Chemical	D002330
-	O	O
induced	O	O
cortical	B-Disease	D054220
dysplasia	I-Disease	D054220
.	O	O

Cortical	B-Disease	D054220
dysplasia	I-Disease	D054220
is	O	O
a	O	O
malformation	O	O
characterized	O	O
by	O	O
defects	O	O
in	O	O
proliferation	O	O
,	O	O
migration	O	O
and	O	O
maturation	O	O
.	O	O

This	O	O
study	O	O
was	O	O
designed	O	O
to	O	O
evaluate	O	O
the	O	O
alterations	O	O
in	O	O
offspring	O	O
rat	O	O
cerebellum	O	O
induced	O	O
by	O	O
maternal	O	O
exposure	O	O
to	O	O
carmustine	B-Chemical	D002330
-	O	O
[	O	O
1	B-Chemical	D002330
,	I-Chemical	D002330
3	I-Chemical	D002330
-	I-Chemical	D002330
bis	I-Chemical	D002330
(	I-Chemical	D002330
2	I-Chemical	D002330
-	I-Chemical	D002330
chloroethyl	I-Chemical	D002330
)	I-Chemical	D002330
-	I-Chemical	D002330
1	I-Chemical	D002330
-	I-Chemical	D002330
nitrosoure	I-Chemical	D002330
]	O	O
(	O	O
BCNU	B-Chemical	D002330
)	O	O
and	O	O
to	O	O
investigate	O	O
the	O	O
effects	O	O
of	O	O
exogenous	O	O
melatonin	B-Chemical	D008550
upon	O	O
cerebellar	O	O
BCNU	B-Chemical	D002330
-	O	O
induced	O	O
cortical	B-Disease	D054220
dysplasia	I-Disease	D054220
,	O	O
using	O	O
histological	O	O
and	O	O
biochemical	O	O
analyses	O	O
.	O	O

Pregnant	O	O
Wistar	O	O
rats	O	O
were	O	O
assigned	O	O
to	O	O
five	O	O
groups	O	O
:	O	O
intact	O	O
-	O	O
control	O	O
,	O	O
saline	O	O
-	O	O
control	O	O
,	O	O
melatonin	B-Chemical	D008550
-	O	O
treated	O	O
,	O	O
BCNU	B-Chemical	D002330
-	O	O
exposed	O	O
and	O	O
BCNU	B-Chemical	D002330
-	O	O
exposed	O	O
plus	O	O
melatonin	B-Chemical	D008550
.	O	O

Rats	O	O
were	O	O
exposed	O	O
to	O	O
BCNU	B-Chemical	D002330
on	O	O
embryonic	O	O
day	O	O
15	O	O
and	O	O
melatonin	B-Chemical	D008550
was	O	O
given	O	O
until	O	O
delivery	O	O
.	O	O

Immuno	O	O
/	O	O
histochemistry	O	O
and	O	O
electron	O	O
microscopy	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
the	O	O
offspring	O	O
cerebellum	O	O
,	O	O
and	O	O
levels	O	O
of	O	O
malondialdehyde	B-Chemical	D008315
and	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
were	O	O
determined	O	O
.	O	O

Histopathologically	O	O
,	O	O
typical	O	O
findings	O	O
were	O	O
observed	O	O
in	O	O
the	O	O
cerebella	O	O
from	O	O
the	O	O
control	O	O
groups	O	O
,	O	O
but	O	O
the	O	O
findings	O	O
consistent	O	O
with	O	O
early	O	O
embryonic	O	O
development	O	O
were	O	O
noted	O	O
in	O	O
BCNU	B-Chemical	D002330
-	O	O
exposed	O	O
cortical	B-Disease	D054220
dysplasia	I-Disease	D054220
group	O	O
.	O	O

There	O	O
was	O	O
a	O	O
marked	O	O
increase	O	O
in	O	O
the	O	O
number	O	O
of	O	O
TUNEL	O	O
positive	O	O
cells	O	O
and	O	O
nestin	O	O
positive	O	O
cells	O	O
in	O	O
BCNU	B-Chemical	D002330
-	O	O
exposed	O	O
group	O	O
,	O	O
but	O	O
a	O	O
decreased	O	O
immunoreactivity	O	O
to	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
,	O	O
synaptophysin	O	O
and	O	O
transforming	O	O
growth	O	O
factor	O	O
beta1	O	O
was	O	O
observed	O	O
,	O	O
indicating	O	O
a	O	O
delayed	O	O
maturation	O	O
,	O	O
and	O	O
melatonin	B-Chemical	D008550
significantly	O	O
reversed	O	O
these	O	O
changes	O	O
.	O	O

Malondialdehyde	B-Chemical	D008315
level	O	O
in	O	O
BCNU	B-Chemical	D002330
-	O	O
exposed	O	O
group	O	O
was	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
control	O	O
groups	O	O
and	O	O
melatonin	B-Chemical	D008550
decreased	O	O
malondialdehyde	B-Chemical	D008315
levels	O	O
in	O	O
BCNU	B-Chemical	D002330
group	O	O
(	O	O
P<0	O	O
.	O	O

01	O	O
)	O	O
,	O	O
while	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
the	O	O
superoxide	B-Chemical	D013481
dismutase	O	O
levels	O	O
between	O	O
these	O	O
groups	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
exposure	O	O
of	O	O
animals	O	O
to	O	O
BCNU	B-Chemical	D002330
during	O	O
pregnancy	O	O
leads	O	O
to	O	O
delayed	O	O
maturation	O	O
of	O	O
offspring	O	O
cerebellum	O	O
and	O	O
melatonin	B-Chemical	D008550
protects	O	O
the	O	O
cerebellum	O	O
against	O	O
the	O	O
effects	O	O
of	O	O
BCNU	B-Chemical	D002330
.	O	O

Myo	B-Chemical	C002647
-	I-Chemical	C002647
inositol	I-Chemical	C002647
-	I-Chemical	C002647
1	I-Chemical	C002647
-	I-Chemical	C002647
phosphate	I-Chemical	C002647
(	O	O
MIP	B-Chemical	C002647
)	O	O
synthase	O	O
inhibition	O	O
:	O	O
in	O	O
-	O	O
vivo	O	O
study	O	O
in	O	O
rats	O	O
.	O	O

Lithium	B-Chemical	D008094
and	O	O
valproate	B-Chemical	D014635
are	O	O
the	O	O
prototypic	O	O
mood	O	O
stabilizers	O	O
and	O	O
have	O	O
diverse	O	O
structures	O	O
and	O	O
targets	O	O
.	O	O

Both	O	O
drugs	O	O
influence	O	O
inositol	B-Chemical	D007294
metabolism	O	O
.	O	O

Lithium	B-Chemical	D008094
inhibits	O	O
IMPase	O	O
and	O	O
valproate	B-Chemical	D014635
inhibits	O	O
MIP	B-Chemical	C002647
synthase	O	O
.	O	O

This	O	O
study	O	O
shows	O	O
that	O	O
MIP	B-Chemical	C002647
synthase	O	O
inhibition	O	O
does	O	O
not	O	O
replicate	O	O
or	O	O
augment	O	O
the	O	O
effects	O	O
of	O	O
lithium	B-Chemical	D008094
in	O	O
the	O	O
inositol	B-Chemical	D007294
sensitive	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
seizures	B-Disease	D012640
model	O	O
.	O	O

This	O	O
lack	O	O
of	O	O
effects	O	O
may	O	O
stem	O	O
from	O	O
the	O	O
low	O	O
contribution	O	O
of	O	O
de	O	O
-	O	O
novo	O	O
synthesis	O	O
to	O	O
cellular	O	O
inositol	B-Chemical	D007294
supply	O	O
or	O	O
to	O	O
the	O	O
inhibition	O	O
of	O	O
the	O	O
de	O	O
-	O	O
novo	O	O
synthesis	O	O
by	O	O
lithium	B-Chemical	D008094
itself	O	O
.	O	O

Non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
-	O	O
associated	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
with	O	O
granular	O	O
tubular	O	O
basement	O	O
membrane	O	O
deposits	O	O
.	O	O

Acute	B-Disease	C564356
tubulo	I-Disease	C564356
-	I-Disease	C564356
interstitial	I-Disease	C564356
nephritis	I-Disease	C564356
(	O	O
ATIN	B-Disease	C564356
)	O	O
is	O	O
an	O	O
important	O	O
cause	O	O
of	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
resulting	O	O
from	O	O
a	O	O
variety	O	O
of	O	O
insults	O	O
,	O	O
including	O	O
immune	O	O
complex	O	O
-	O	O
mediated	O	O
tubulo	B-Disease	D009395
-	I-Disease	D009395
interstitial	I-Disease	D009395
injury	I-Disease	D009395
,	O	O
but	O	O
drugs	O	O
such	O	O
as	O	O
non	O	O
-	O	O
steroidal	O	O
anti	O	O
-	O	O
inflammatory	O	O
drugs	O	O
(	O	O
NSAIDs	O	O
)	O	O
are	O	O
a	O	O
far	O	O
more	O	O
frequent	O	O
cause	O	O
.	O	O

Overall	O	O
,	O	O
as	O	O
an	O	O
entity	O	O
,	O	O
ATIN	B-Disease	C564356
remains	O	O
under	O	O
-	O	O
diagnosed	O	O
,	O	O
as	O	O
symptoms	O	O
resolve	O	O
spontaneously	O	O
if	O	O
the	O	O
medication	O	O
is	O	O
stopped	O	O
.	O	O

We	O	O
report	O	O
on	O	O
a	O	O
14	O	O
-	O	O
year	O	O
-	O	O
old	O	O
boy	O	O
who	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
2	O	O
weeks	O	O
after	O	O
aortic	O	O
valve	O	O
surgery	O	O
.	O	O

He	O	O
was	O	O
put	O	O
on	O	O
aspirin	B-Chemical	D001241
following	O	O
surgery	O	O
and	O	O
took	O	O
ibuprofen	B-Chemical	D007052
for	O	O
fever	B-Disease	D005334
for	O	O
nearly	O	O
a	O	O
week	O	O
prior	O	O
to	O	O
presentation	O	O
.	O	O

He	O	O
then	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
feeling	O	O
quite	O	O
ill	O	O
and	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
blood	B-Chemical	D001806
urea	I-Chemical	D001806
nitrogen	I-Chemical	D001806
(	O	O
BUN	B-Chemical	D001806
)	O	O
concentration	O	O
of	O	O
of	O	O
147	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
creatinine	B-Chemical	D003404
of	O	O
15	O	O
.	O	O

3	O	O
mg	O	O
/	O	O
dl	O	O
and	O	O
serum	O	O
potassium	B-Chemical	D011188
of	O	O
8	O	O
.	O	O

7	O	O
mEq	O	O
/	O	O
l	O	O
.	O	O

Dialysis	O	O
was	O	O
immediately	O	O
initiated	O	O
.	O	O

A	O	O
kidney	O	O
biopsy	O	O
showed	O	O
inflammatory	O	O
infiltrate	O	O
consistent	O	O
with	O	O
ATIN	B-Disease	C564356
.	O	O

However	O	O
,	O	O
in	O	O
the	O	O
tubular	O	O
basement	O	O
membrane	O	O
(	O	O
TBM	O	O
)	O	O
,	O	O
very	O	O
intense	O	O
granular	O	O
deposits	O	O
of	O	O
polyclonal	O	O
IgG	O	O
and	O	O
C3	O	O
were	O	O
noted	O	O
.	O	O

He	O	O
needed	O	O
dialysis	O	O
for	O	O
2	O	O
weeks	O	O
and	O	O
was	O	O
treated	O	O
successfully	O	O
with	O	O
steroids	B-Chemical	D013256
for	O	O
6	O	O
months	O	O
.	O	O

His	O	O
renal	O	O
recovery	O	O
and	O	O
disappearance	O	O
of	O	O
proteinuria	B-Disease	D011507
took	O	O
a	O	O
year	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
this	O	O
is	O	O
a	O	O
first	O	O
report	O	O
of	O	O
NSAIDs	O	O
-	O	O
associated	O	O
ATIN	B-Disease	C564356
,	O	O
showing	O	O
deposits	O	O
of	O	O
granular	O	O
immune	O	O
complex	O	O
present	O	O
only	O	O
in	O	O
the	O	O
TBM	O	O
and	O	O
not	O	O
in	O	O
the	O	O
glomeruli	O	O
.	O	O

Rifampicin	B-Chemical	D012293
-	O	O
associated	O	O
segmental	O	O
necrotizing	O	O
glomerulonephritis	B-Disease	D005921
in	O	O
staphylococcal	O	O
endocarditis	O	O
.	O	O

Segmental	O	O
necrotising	O	O
glomerulonephritis	B-Disease	D005921
has	O	O
been	O	O
reported	O	O
as	O	O
complication	O	O
of	O	O
rifampicin	B-Chemical	D012293
therapy	O	O
in	O	O
patients	O	O
receiving	O	O
treatment	O	O
for	O	O
tuberculosis	B-Disease	D014376
.	O	O

Changing	O	O
epidemiology	O	O
of	O	O
infections	B-Disease	D007239
such	O	O
as	O	O
infective	B-Disease	D004696
endocarditis	I-Disease	D004696
(	O	O
IE	B-Disease	D004696
)	O	O
has	O	O
led	O	O
to	O	O
an	O	O
increase	O	O
in	O	O
the	O	O
use	O	O
of	O	O
rifampicin	B-Chemical	D012293
for	O	O
Staphylococcal	B-Disease	D013203
infections	I-Disease	D013203
.	O	O

We	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
a	O	O
patient	O	O
with	O	O
Staphylococcal	O	O
IE	B-Disease	D004696
who	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
secondary	O	O
to	O	O
a	O	O
segmental	O	O
necrotising	O	O
glomerulonephritis	B-Disease	D005921
while	O	O
being	O	O
treated	O	O
with	O	O
rifampicin	B-Chemical	D012293
,	O	O
and	O	O
review	O	O
the	O	O
literature	O	O
regarding	O	O
this	O	O
complication	O	O
of	O	O
rifampicin	B-Chemical	D012293
therapy	O	O
.	O	O

Rate	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine	B-Chemical	D019259
-	O	O
untreated	O	O
Iranian	O	O
patients	O	O
with	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
virus	I-Disease	D019694
infection	I-Disease	D019694
.	O	O

BACKGROUND	O	O
:	O	O
Lamivudine	B-Chemical	D019259
is	O	O
used	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
patients	O	O
.	O	O

Recent	O	O
studies	O	O
show	O	O
that	O	O
the	O	O
YMDD	O	O
motif	O	O
mutants	O	O
(	O	O
resistant	O	O
hepatitis	B-Disease	D006509
B	I-Disease	D006509
virus	O	O
)	O	O
occur	O	O
as	O	O
natural	O	O
genome	O	O
variability	O	O
in	O	O
lamivudine	B-Chemical	D019259
-	O	O
untreated	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
patients	O	O
.	O	O

In	O	O
this	O	O
study	O	O
we	O	O
aimed	O	O
to	O	O
determine	O	O
the	O	O
rate	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine	B-Chemical	D019259
-	O	O
untreated	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
patients	O	O
in	O	O
Iran	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
77	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
patients	O	O
who	O	O
had	O	O
not	O	O
been	O	O
treated	O	O
with	O	O
lamivudine	B-Chemical	D019259
were	O	O
included	O	O
in	O	O
the	O	O
study	O	O
.	O	O

Serum	O	O
samples	O	O
from	O	O
patients	O	O
were	O	O
tested	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphism	O	O
(	O	O
PCR	O	O
-	O	O
RFLP	O	O
)	O	O
for	O	O
detection	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
.	O	O

All	O	O
patients	O	O
were	O	O
also	O	O
tested	O	O
for	O	O
liver	O	O
enzymes	O	O
,	O	O
anti	O	O
-	O	O
HCV	O	O
,	O	O
HBeAg	B-Chemical	D006513
,	O	O
and	O	O
anti	O	O
-	O	O
HBe	O	O
.	O	O

RESULTS	O	O
:	O	O
Of	O	O
the	O	O
77	O	O
patients	O	O
enrolled	O	O
in	O	O
the	O	O
study	O	O
,	O	O
73%	O	O
were	O	O
male	O	O
and	O	O
27%	O	O
were	O	O
female	O	O
.	O	O

Mean	O	O
ALT	O	O
and	O	O
AST	O	O
levels	O	O
were	O	O
124	O	O
.	O	O

4+	O	O
/	O	O
-	O	O
73	O	O
.	O	O

4	O	O
and	O	O
103	O	O
.	O	O

1+	O	O
/	O	O
-	O	O
81	O	O
IU	O	O
/	O	O
l	O	O
,	O	O
respectively	O	O
.	O	O

HBeAg	B-Chemical	D006513
was	O	O
positive	O	O
in	O	O
40%	O	O
and	O	O
anti	O	O
-	O	O
HBe	O	O
in	O	O
60%	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

Anti	O	O
-	O	O
HCV	O	O
was	O	O
negative	O	O
in	O	O
all	O	O
of	O	O
them	O	O
.	O	O

YMDD	O	O
motif	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
any	O	O
of	O	O
the	O	O
patients	O	O
despite	O	O
the	O	O
liver	O	O
enzyme	O	O
levels	O	O
and	O	O
the	O	O
presence	O	O
of	O	O
HBeAg	B-Chemical	D006513
or	O	O
anti	O	O
-	O	O
HBe	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Although	O	O
the	O	O
natural	O	O
occurrence	O	O
of	O	O
YMDD	O	O
motif	O	O
mutants	O	O
in	O	O
lamivudine	B-Chemical	D019259
-	O	O
untreated	O	O
patients	O	O
with	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
has	O	O
been	O	O
reported	O	O
,	O	O
these	O	O
mutants	O	O
were	O	O
not	O	O
detected	O	O
in	O	O
Iranian	O	O
lamivudine	B-Chemical	D019259
-	O	O
untreated	O	O
chronic	B-Disease	D019694
hepatitis	I-Disease	D019694
B	I-Disease	D019694
patients	O	O
.	O	O

Branch	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
and	O	O
fluoxetine	B-Chemical	D005473
.	O	O

A	O	O
case	O	O
of	O	O
branch	O	O
retinal	B-Disease	D012170
vein	I-Disease	D012170
occlusion	I-Disease	D012170
associated	O	O
with	O	O
fluoxetine	B-Chemical	D005473
-	O	O
induced	O	O
secondary	O	O
hypertension	B-Disease	D006973
is	O	O
described	O	O
.	O	O

Although	O	O
an	O	O
infrequent	O	O
complication	O	O
of	O	O
selective	O	O
serotonin	B-Chemical	D012701
reuptake	O	O
inhibitor	O	O
therapy	O	O
,	O	O
it	O	O
is	O	O
important	O	O
that	O	O
ophthalmologists	O	O
are	O	O
aware	O	O
that	O	O
these	O	O
agents	O	O
can	O	O
cause	O	O
hypertension	B-Disease	D006973
because	O	O
this	O	O
class	O	O
of	O	O
drugs	O	O
is	O	O
widely	O	O
prescribed	O	O
.	O	O

The	O	O
differential	O	O
effects	O	O
of	O	O
bupivacaine	B-Chemical	D002045
and	O	O
lidocaine	B-Chemical	D008012
on	O	O
prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
release	O	O
,	O	O
cyclooxygenase	O	O
gene	O	O
expression	O	O
and	O	O
pain	B-Disease	D010146
in	O	O
a	O	O
clinical	O	O
pain	B-Disease	D010146
model	O	O
.	O	O

BACKGROUND	O	O
:	O	O
In	O	O
addition	O	O
to	O	O
blocking	O	O
nociceptive	O	O
input	O	O
from	O	O
surgical	O	O
sites	O	O
,	O	O
long	O	O
-	O	O
acting	O	O
local	O	O
anesthetics	O	O
might	O	O
directly	O	O
modulate	O	O
inflammation	B-Disease	D007249
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
describe	O	O
the	O	O
proinflammatory	O	O
effects	O	O
of	O	O
bupivacaine	B-Chemical	D002045
on	O	O
local	O	O
prostaglandin	B-Chemical	D015232
E2	I-Chemical	D015232
(	O	O
PGE2	B-Chemical	D015232
)	O	O
production	O	O
and	O	O
cyclooxygenase	O	O
(	O	O
COX	O	O
)	O	O
gene	O	O
expression	O	O
that	O	O
increases	O	O
postoperative	B-Disease	D010149
pain	I-Disease	D010149
in	O	O
human	O	O
subjects	O	O
.	O	O

METHODS	O	O
:	O	O
Subjects	O	O
(	O	O
n	O	O
=	O	O
114	O	O
)	O	O
undergoing	O	O
extraction	O	O
of	O	O
impacted	O	O
third	O	O
molars	O	O
received	O	O
either	O	O
2%	O	O
lidocaine	B-Chemical	D008012
or	O	O
0	O	O
.	O	O

5%	O	O
bupivacaine	B-Chemical	D002045
before	O	O
surgery	O	O
and	O	O
either	O	O
rofecoxib	B-Chemical	C116926
50	O	O
mg	O	O
or	O	O
placebo	O	O
orally	O	O
90	O	O
min	O	O
before	O	O
surgery	O	O
and	O	O
for	O	O
the	O	O
following	O	O
48	O	O
h	O	O
.	O	O

Oral	O	O
mucosal	O	O
biopsies	O	O
were	O	O
taken	O	O
before	O	O
surgery	O	O
and	O	O
48	O	O
h	O	O
after	O	O
surgery	O	O
.	O	O

After	O	O
extraction	O	O
,	O	O
a	O	O
microdialysis	O	O
probe	O	O
was	O	O
placed	O	O
at	O	O
the	O	O
surgical	O	O
site	O	O
for	O	O
PGE2	B-Chemical	D015232
and	O	O
thromboxane	B-Chemical	D013929
B2	I-Chemical	D013929
(	O	O
TXB2	B-Chemical	D013929
)	O	O
measurements	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
bupivacaine	B-Chemical	D002045
/	O	O
rofecoxib	B-Chemical	C116926
group	O	O
reported	O	O
significantly	O	O
less	O	O
pain	B-Disease	D010146
,	O	O
as	O	O
assessed	O	O
by	O	O
a	O	O
visual	O	O
analog	O	O
scale	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
over	O	O
the	O	O
first	O	O
4	O	O
h	O	O
.	O	O

However	O	O
,	O	O
the	O	O
bupivacaine	B-Chemical	D002045
/	O	O
placebo	O	O
group	O	O
reported	O	O
significantly	O	O
more	O	O
pain	B-Disease	D010146
at	O	O
24	O	O
h	O	O
and	O	O
PGE2	B-Chemical	D015232
levels	O	O
during	O	O
the	O	O
first	O	O
4	O	O
h	O	O
were	O	O
significantly	O	O
higher	O	O
than	O	O
the	O	O
other	O	O
three	O	O
treatment	O	O
groups	O	O
.	O	O

Moreover	O	O
,	O	O
bupivacaine	B-Chemical	D002045
significantly	O	O
increased	O	O
COX	O	O
-	O	O
2	O	O
gene	O	O
expression	O	O
at	O	O
48	O	O
h	O	O
as	O	O
compared	O	O
with	O	O
the	O	O
lidocaine	B-Chemical	D008012
/	O	O
placebo	O	O
group	O	O
.	O	O

Thromboxane	B-Chemical	D013931
levels	O	O
were	O	O
not	O	O
significantly	O	O
affected	O	O
by	O	O
any	O	O
of	O	O
the	O	O
treatments	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
effects	O	O
seen	O	O
were	O	O
attributable	O	O
to	O	O
inhibition	O	O
of	O	O
COX	O	O
-	O	O
2	O	O
,	O	O
but	O	O
not	O	O
COX	O	O
-	O	O
1	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
These	O	O
results	O	O
suggest	O	O
that	O	O
bupivacaine	B-Chemical	D002045
stimulates	O	O
COX	O	O
-	O	O
2	O	O
gene	O	O
expression	O	O
after	O	O
tissue	B-Disease	D017695
injury	I-Disease	D017695
,	O	O
which	O	O
is	O	O
associated	O	O
with	O	O
higher	O	O
PGE2	B-Chemical	D015232
production	O	O
and	O	O
pain	B-Disease	D010146
after	O	O
the	O	O
local	O	O
anesthetic	O	O
effect	O	O
dissipates	O	O
.	O	O

p75NTR	O	O
expression	O	O
in	O	O
rat	O	O
urinary	O	O
bladder	O	O
sensory	O	O
neurons	O	O
and	O	O
spinal	O	O
cord	O	O
with	O	O
cyclophosphamide	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
.	O	O

A	O	O
role	O	O
for	O	O
nerve	O	O
growth	O	O
factor	O	O
(	O	O
NGF	O	O
)	O	O
in	O	O
contributing	O	O
to	O	O
increased	O	O
voiding	O	O
frequency	O	O
and	O	O
altered	O	O
sensation	O	O
from	O	O
the	O	O
urinary	O	O
bladder	O	O
has	O	O
been	O	O
suggested	O	O
.	O	O

Previous	O	O
studies	O	O
have	O	O
examined	O	O
the	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
tyrosine	B-Chemical	D014443
kinase	O	O
receptors	O	O
(	O	O
Trks	O	O
)	O	O
in	O	O
micturition	O	O
reflexes	O	O
with	O	O
urinary	B-Disease	D003556
bladder	I-Disease	D003556
inflammation	I-Disease	D003556
.	O	O

The	O	O
present	O	O
studies	O	O
examine	O	O
the	O	O
expression	O	O
and	O	O
regulation	O	O
of	O	O
another	O	O
receptor	O	O
known	O	O
to	O	O
bind	O	O
NGF	O	O
,	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
,	O	O
after	O	O
various	O	O
durations	O	O
of	O	O
bladder	B-Disease	D003556
inflammation	I-Disease	D003556
induced	O	O
by	O	O
cyclophosphamide	B-Chemical	D003520
(	O	O
CYP	B-Chemical	D003520
)	O	O
.	O	O

CYP	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
increased	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
expression	O	O
in	O	O
the	O	O
superficial	O	O
lateral	O	O
and	O	O
medial	O	O
dorsal	O	O
horn	O	O
in	O	O
L1	O	O
-	O	O
L2	O	O
and	O	O
L6	O	O
-	O	O
S1	O	O
spinal	O	O
segments	O	O
.	O	O

The	O	O
number	O	O
of	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
-	O	O
immunoreactive	O	O
(	O	O
-	O	O
IR	O	O
)	O	O
cells	O	O
in	O	O
the	O	O
lumbosacral	O	O
dorsal	O	O
root	O	O
ganglia	O	O
(	O	O
DRG	O	O
)	O	O
also	O	O
increased	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

05	O	O
)	O	O
with	O	O
CYP	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
(	O	O
acute	O	O
,	O	O
intermediate	O	O
,	O	O
and	O	O
chronic	O	O
)	O	O
.	O	O

Quantitative	O	O
,	O	O
real	O	O
-	O	O
time	O	O
polymerase	O	O
chain	O	O
reaction	O	O
also	O	O
demonstrated	O	O
significant	O	O
increases	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
in	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
mRNA	O	O
in	O	O
DRG	O	O
with	O	O
intermediate	O	O
and	O	O
chronic	O	O
CYP	B-Chemical	D003520
-	O	O
induced	O	O
cystitis	B-Disease	D003556
.	O	O

Retrograde	O	O
dye	O	O
-	O	O
tracing	O	O
techniques	O	O
with	O	O
Fastblue	O	O
were	O	O
used	O	O
to	O	O
identify	O	O
presumptive	O	O
bladder	O	O
afferent	O	O
cells	O	O
in	O	O
the	O	O
lumbosacral	O	O
DRG	O	O
.	O	O

In	O	O
bladder	O	O
afferent	O	O
cells	O	O
in	O	O
DRG	O	O
,	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
-	O	O
IR	O	O
was	O	O
also	O	O
increased	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

01	O	O
)	O	O
with	O	O
cystitis	B-Disease	D003556
.	O	O

In	O	O
addition	O	O
to	O	O
increases	O	O
in	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
-	O	O
IR	O	O
in	O	O
DRG	O	O
cell	O	O
bodies	O	O
,	O	O
increases	O	O
(	O	O
P	O	O
<	O	O
or	O	O
=	O	O
0	O	O
.	O	O

001	O	O
)	O	O
in	O	O
pericellular	O	O
(	O	O
encircling	O	O
DRG	O	O
cells	O	O
)	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
-	O	O
IR	O	O
in	O	O
DRG	O	O
also	O	O
increased	O	O
.	O	O

Confocal	O	O
analyses	O	O
demonstrated	O	O
that	O	O
pericellular	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
-	O	O
IR	O	O
was	O	O
not	O	O
colocalized	O	O
with	O	O
the	O	O
glial	O	O
marker	O	O
,	O	O
glial	O	O
fibrillary	O	O
acidic	O	O
protein	O	O
(	O	O
GFAP	O	O
)	O	O
.	O	O

These	O	O
studies	O	O
demonstrate	O	O
that	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
expression	O	O
in	O	O
micturition	O	O
reflexes	O	O
is	O	O
present	O	O
constitutively	O	O
and	O	O
modified	O	O
by	O	O
bladder	B-Disease	D003556
inflammation	I-Disease	D003556
.	O	O

The	O	O
functional	O	O
significance	O	O
of	O	O
p75	O	O
(	O	O
NTR	O	O
)	O	O
expression	O	O
in	O	O
micturition	O	O
reflexes	O	O
remains	O	O
to	O	O
be	O	O
determined	O	O
.	O	O

Azathioprine	B-Chemical	D001379
-	O	O
induced	O	O
suicidal	O	O
erythrocyte	O	O
death	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Azathioprine	B-Chemical	D001379
is	O	O
widely	O	O
used	O	O
as	O	O
an	O	O
immunosuppressive	O	O
drug	O	O
.	O	O

The	O	O
side	O	O
effects	O	O
of	O	O
azathioprine	B-Chemical	D001379
include	O	O
anemia	B-Disease	D000740
,	O	O
which	O	O
has	O	O
been	O	O
attributed	O	O
to	O	O
bone	O	O
marrow	O	O
suppression	O	O
.	O	O

Alternatively	O	O
,	O	O
anemia	B-Disease	D000740
could	O	O
result	O	O
from	O	O
accelerated	O	O
suicidal	O	O
erythrocyte	O	O
death	O	O
or	O	O
eryptosis	O	O
,	O	O
which	O	O
is	O	O
characterized	O	O
by	O	O
exposure	O	O
of	O	O
phosphatidylserine	B-Chemical	D010718
(	O	O
PS	B-Chemical	D010718
)	O	O
at	O	O
the	O	O
erythrocyte	O	O
surface	O	O
and	O	O
by	O	O
cell	O	O
shrinkage	O	O
.	O	O

METHODS	O	O
:	O	O
The	O	O
present	O	O
experiments	O	O
explored	O	O
whether	O	O
azathioprine	B-Chemical	D001379
influences	O	O
eryptosis	O	O
.	O	O

According	O	O
to	O	O
annexin	O	O
V	O	O
binding	O	O
,	O	O
erythrocytes	O	O
from	O	O
patients	O	O
indeed	O	O
showed	O	O
a	O	O
significant	O	O
increase	O	O
of	O	O
PS	B-Chemical	D010718
exposure	O	O
within	O	O
1	O	O
week	O	O
of	O	O
treatment	O	O
with	O	O
azathioprine	B-Chemical	D001379
.	O	O

In	O	O
a	O	O
second	O	O
series	O	O
,	O	O
cytosolic	O	O
Ca2+	O	O
activity	O	O
(	O	O
Fluo3	B-Chemical	C059715
fluorescence	O	O
)	O	O
,	O	O
cell	O	O
volume	O	O
(	O	O
forward	O	O
scatter	O	O
)	O	O
,	O	O
and	O	O
PS	B-Chemical	D010718
-	O	O
exposure	O	O
(	O	O
annexin	O	O
V	O	O
binding	O	O
)	O	O
were	O	O
determined	O	O
by	O	O
FACS	O	O
analysis	O	O
in	O	O
erythrocytes	O	O
from	O	O
healthy	O	O
volunteers	O	O
.	O	O

RESULTS	O	O
:	O	O
Exposure	O	O
to	O	O
azathioprine	B-Chemical	D001379
(	O	O
>	O	O
or	O	O
=2	O	O
microg	O	O
/	O	O
mL	O	O
)	O	O
for	O	O
48	O	O
hours	O	O
increased	O	O
cytosolic	O	O
Ca2+	O	O
activity	O	O
and	O	O
annexin	O	O
V	O	O
binding	O	O
and	O	O
decreased	O	O
forward	O	O
scatter	O	O
.	O	O

The	O	O
effect	O	O
of	O	O
azathioprine	B-Chemical	D001379
on	O	O
both	O	O
annexin	O	O
V	O	O
binding	O	O
and	O	O
forward	O	O
scatter	O	O
was	O	O
significantly	O	O
blunted	O	O
in	O	O
the	O	O
nominal	O	O
absence	O	O
of	O	O
extracellular	O	O
Ca2+	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Azathioprine	B-Chemical	D001379
triggers	O	O
suicidal	O	O
erythrocyte	O	O
death	O	O
,	O	O
an	O	O
effect	O	O
presumably	O	O
contributing	O	O
to	O	O
azathioprine	B-Chemical	D001379
-	O	O
induced	O	O
anemia	B-Disease	D000740
.	O	O

Clinical	O	O
comparison	O	O
of	O	O
cardiorespiratory	O	O
effects	O	O
during	O	O
unilateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Spinal	O	O
anaesthesia	O	O
is	O	O
widely	O	O
employed	O	O
in	O	O
clinical	O	O
practice	O	O
but	O	O
has	O	O
the	O	O
main	O	O
drawback	O	O
of	O	O
post	O	O
-	O	O
spinal	O	O
block	O	O
hypotension	B-Disease	D007022
.	O	O

Efforts	O	O
must	O	O
therefore	O	O
continue	O	O
to	O	O
be	O	O
made	O	O
to	O	O
obviate	O	O
this	O	O
setback	O	O
OBJECTIVE	O	O
:	O	O
To	O	O
evaluate	O	O
the	O	O
cardiovascular	O	O
and	O	O
respiratory	O	O
changes	O	O
during	O	O
unilateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
.	O	O

METHODS	O	O
:	O	O
With	O	O
ethical	O	O
approval	O	O
,	O	O
we	O	O
studied	O	O
74	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
(	O	O
ASA	O	O
)	O	O
,	O	O
physical	O	O
status	O	O
class	O	O
1	O	O
and	O	O
2	O	O
patients	O	O
scheduled	O	O
for	O	O
elective	O	O
unilateral	O	O
lower	O	O
limb	O	O
surgery	O	O
.	O	O

Patients	O	O
were	O	O
randomly	O	O
allocated	O	O
into	O	O
one	O	O
of	O	O
two	O	O
groups	O	O
:	O	O
lateral	O	O
and	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
groups	O	O
.	O	O

In	O	O
the	O	O
lateral	O	O
position	O	O
with	O	O
operative	O	O
side	O	O
down	O	O
,	O	O
patients	O	O
recived	O	O
10	O	O
mg	O	O
(	O	O
2mls	O	O
)	O	O
of	O	O
0	O	O
.	O	O

5%	O	O
hyperbaric	O	O
bupivacaine	B-Chemical	D002045
through	O	O
a	O	O
25	O	O
-	O	O
gauge	O	O
spinal	O	O
needle	O	O
.	O	O

Patients	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
were	O	O
maintained	O	O
in	O	O
the	O	O
lateral	O	O
position	O	O
for	O	O
15	O	O
minutes	O	O
following	O	O
spinal	O	O
injection	O	O
while	O	O
those	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
were	O	O
turned	O	O
supine	O	O
immediately	O	O
after	O	O
injection	O	O
.	O	O

Blood	O	O
pressure	O	O
,	O	O
heart	O	O
rate	O	O
,	O	O
respiratory	O	O
rate	O	O
and	O	O
oxygen	B-Chemical	D010100
saturation	O	O
were	O	O
monitored	O	O
over	O	O
1	O	O
hour	O	O
.	O	O

RESULTS	O	O
:	O	O
Three	O	O
patients	O	O
(	O	O
8	O	O
.	O	O

1%	O	O
)	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
and	O	O
5	O	O
(	O	O
13	O	O
.	O	O

5%	O	O
)	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
developed	O	O
hypotension	B-Disease	D007022
,	O	O
P=	O	O
0	O	O
.	O	O

71	O	O
.	O	O

Four	O	O
(	O	O
10	O	O
.	O	O

8%	O	O
)	O	O
patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
and	O	O
1	O	O
(	O	O
2	O	O
.	O	O

7%	O	O
)	O	O
in	O	O
the	O	O
unilateral	O	O
group	O	O
,	O	O
P=	O	O
0	O	O
.	O	O

17	O	O
required	O	O
epinephrine	B-Chemical	D004837
infusion	O	O
to	O	O
treat	O	O
hypotension	B-Disease	D007022
.	O	O

Patients	O	O
in	O	O
the	O	O
conventional	O	O
group	O	O
had	O	O
statistically	O	O
significant	O	O
greater	O	O
fall	O	O
in	O	O
the	O	O
systolic	O	O
blood	O	O
pressures	O	O
at	O	O
15	O	O
,	O	O
30	O	O
and	O	O
45	O	O
minutes	O	O
when	O	O
compared	O	O
to	O	O
the	O	O
baseline	O	O
(	O	O
P=	O	O
0	O	O
.	O	O

003	O	O
,	O	O
0	O	O
.	O	O

001	O	O
and	O	O
0	O	O
.	O	O

004	O	O
)	O	O
.	O	O

The	O	O
mean	O	O
respiratory	O	O
rate	O	O
and	O	O
oxygen	B-Chemical	D010100
saturations	O	O
in	O	O
the	O	O
two	O	O
groups	O	O
were	O	O
similar	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Compared	O	O
to	O	O
conventional	O	O
spinal	O	O
anaesthesia	O	O
,	O	O
unilateral	O	O
spinal	O	O
anaesthesia	O	O
was	O	O
associated	O	O
with	O	O
fewer	O	O
cardiovascular	O	O
perturbations	O	O
.	O	O

Also	O	O
,	O	O
the	O	O
type	O	O
of	O	O
spinal	O	O
block	O	O
instituted	O	O
affected	O	O
neither	O	O
the	O	O
respiratory	O	O
rate	O	O
nor	O	O
the	O	O
arterial	O	O
oxygen	B-Chemical	D010100
saturation	O	O
.	O	O

Spectrum	O	O
of	O	O
adverse	O	O
events	O	O
after	O	O
generic	O	O
HAART	O	O
in	O	O
southern	O	O
Indian	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
patients	O	O
.	O	O

To	O	O
determine	O	O
the	O	O
incidence	O	O
of	O	O
clinically	O	O
significant	O	O
adverse	O	O
events	O	O
after	O	O
long	O	O
-	O	O
term	O	O
,	O	O
fixed	O	O
-	O	O
dose	O	O
,	O	O
generic	O	O
highly	O	O
active	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
HAART	O	O
)	O	O
use	O	O
among	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
individuals	O	O
in	O	O
South	O	O
India	O	O
,	O	O
we	O	O
examined	O	O
the	O	O
experiences	O	O
of	O	O
3154	O	O
HIV	B-Disease	D015658
-	I-Disease	D015658
infected	I-Disease	D015658
individuals	O	O
who	O	O
received	O	O
a	O	O
minimum	O	O
of	O	O
3	O	O
months	O	O
of	O	O
generic	O	O
HAART	O	O
between	O	O
February	O	O
1996	O	O
and	O	O
December	O	O
2006	O	O
at	O	O
a	O	O
tertiary	O	O
HIV	O	O
care	O	O
referral	O	O
center	O	O
in	O	O
South	O	O
India	O	O
.	O	O

The	O	O
most	O	O
common	O	O
regimens	O	O
were	O	O
3TC	B-Chemical	D019259
+	O	O
d4T	B-Chemical	D018119
+	O	O
nevirapine	B-Chemical	D019829
(	O	O
NVP	B-Chemical	D019829
)	O	O
(	O	O
54	O	O
.	O	O

8%	O	O
)	O	O
,	O	O
zidovudine	B-Chemical	D015215
(	O	O
AZT	B-Chemical	D015215
)	O	O
+	O	O
3TC	B-Chemical	D019259
+	O	O
NVP	B-Chemical	D019829
(	O	O
14	O	O
.	O	O

5%	O	O
)	O	O
,	O	O
3TC	B-Chemical	D019259
+	O	O
d4T	B-Chemical	D018119
+	O	O
efavirenz	B-Chemical	C098320
(	O	O
EFV	B-Chemical	C098320
)	O	O
(	O	O
20	O	O
.	O	O

1%	O	O
)	O	O
,	O	O
and	O	O
AZT	B-Chemical	D015215
+	O	O
3TC	B-Chemical	D019259
+	O	O
EFV	B-Chemical	C098320
(	O	O
5	O	O
.	O	O

4%	O	O
)	O	O
.	O	O

The	O	O
most	O	O
common	O	O
adverse	O	O
events	O	O
and	O	O
median	O	O
CD4	O	O
at	O	O
time	O	O
of	O	O
event	O	O
were	O	O
rash	B-Disease	D005076
(	O	O
15	O	O
.	O	O

2%	O	O
;	O	O
CD4	O	O
,	O	O
285	O	O
cells	O	O
/	O	O
microL	O	O
)	O	O
and	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
(	O	O
9	O	O
.	O	O

0%	O	O
and	O	O
348	O	O
cells	O	O
/	O	O
microL	O	O
)	O	O
.	O	O

Clinically	O	O
significant	O	O
anemia	B-Disease	D000740
(	O	O
hemoglobin	O	O
<7	O	O
g	O	O
/	O	O
dL	O	O
)	O	O
was	O	O
observed	O	O
in	O	O
5	O	O
.	O	O

4%	O	O
of	O	O
patients	O	O
(	O	O
CD4	O	O
,	O	O
165	O	O
cells	O	O
/	O	O
microL	O	O
)	O	O
and	O	O
hepatitis	B-Disease	D056486
(	O	O
clinical	O	O
jaundice	B-Disease	D007565
with	O	O
alanine	B-Chemical	D000409
aminotransferase	O	O
>	O	O
5	O	O
times	O	O
upper	O	O
limits	O	O
of	O	O
normal	O	O
)	O	O
in	O	O
3	O	O
.	O	O

5%	O	O
of	O	O
patients	O	O
(	O	O
CD4	O	O
,	O	O
260	O	O
cells	O	O
/	O	O
microL	O	O
)	O	O
.	O	O

Women	O	O
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
lactic	B-Disease	D000140
acidosis	I-Disease	D000140
,	O	O
while	O	O
men	O	O
were	O	O
significantly	O	O
more	O	O
likely	O	O
to	O	O
experience	O	O
immune	B-Disease	D054019
reconstitution	I-Disease	D054019
syndrome	I-Disease	D054019
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Among	O	O
the	O	O
patients	O	O
with	O	O
1	O	O
year	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
,	O	O
NVP	B-Chemical	D019829
therapy	O	O
was	O	O
significantly	O	O
associated	O	O
with	O	O
developing	O	O
rash	B-Disease	D005076
and	O	O
d4T	B-Chemical	D018119
therapy	O	O
with	O	O
developing	O	O
peripheral	B-Disease	D010523
neuropathy	I-Disease	D010523
(	O	O
p	O	O
<	O	O
0	O	O
.	O	O

05	O	O
)	O	O
.	O	O

Anemia	B-Disease	D000740
and	O	O
hepatitis	B-Disease	D056486
often	O	O
occur	O	O
within	O	O
12	O	O
weeks	O	O
of	O	O
initiating	O	O
generic	O	O
HAART	O	O
.	O	O

Frequent	O	O
and	O	O
early	O	O
monitoring	O	O
for	O	O
these	O	O
toxicities	B-Disease	D064420
is	O	O
warranted	O	O
in	O	O
developing	O	O
countries	O	O
where	O	O
generic	O	O
HAART	O	O
is	O	O
increasingly	O	O
available	O	O
.	O	O

Thalidomide	B-Chemical	D013792
and	O	O
sensory	B-Disease	D010523
neurotoxicity	I-Disease	D010523
:	O	O
a	O	O
neurophysiological	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Recent	O	O
studies	O	O
confirmed	O	O
a	O	O
high	O	O
incidence	O	O
of	O	O
sensory	B-Disease	D010523
axonal	I-Disease	D010523
neuropathy	I-Disease	D010523
in	O	O
patients	O	O
treated	O	O
with	O	O
different	O	O
doses	O	O
of	O	O
thalidomide	B-Chemical	D013792
.	O	O

The	O	O
study's	O	O
aims	O	O
were	O	O
to	O	O
measure	O	O
variations	O	O
in	O	O
sural	O	O
nerve	O	O
sensory	O	O
action	O	O
potential	O	O
(	O	O
SAP	O	O
)	O	O
amplitude	O	O
in	O	O
patients	O	O
with	O	O
refractory	O	O
cutaneous	B-Disease	D008178
lupus	I-Disease	D008178
erythematosus	I-Disease	D008178
(	O	O
CLE	B-Disease	D008178
)	O	O
treated	O	O
with	O	O
thalidomide	B-Chemical	D013792
and	O	O
use	O	O
these	O	O
findings	O	O
to	O	O
identify	O	O
the	O	O
neurotoxic	B-Disease	D020258
potential	O	O
of	O	O
thalidomide	B-Chemical	D013792
and	O	O
the	O	O
recovery	O	O
capacity	O	O
of	O	O
sensory	O	O
fibres	O	O
after	O	O
discontinuation	O	O
of	O	O
treatment	O	O
.	O	O

PATIENTS	O	O
AND	O	O
METHODS	O	O
:	O	O
Clinical	O	O
and	O	O
electrophysiological	O	O
data	O	O
in	O	O
12	O	O
female	O	O
patients	O	O
with	O	O
CLE	B-Disease	D008178
during	O	O
treatment	O	O
with	O	O
thalidomide	B-Chemical	D013792
and	O	O
up	O	O
to	O	O
47	O	O
months	O	O
after	O	O
discontinuation	O	O
of	O	O
treatment	O	O
were	O	O
analysed	O	O
.	O	O

Sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
reduction	O	O
>	O	O
or	O	O
=40%	O	O
was	O	O
the	O	O
criteria	O	O
for	O	O
discontinuing	O	O
therapy	O	O
.	O	O

RESULTS	O	O
:	O	O
During	O	O
treatment	O	O
,	O	O
11	O	O
patients	O	O
showed	O	O
a	O	O
reduction	O	O
in	O	O
sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
compared	O	O
to	O	O
baseline	O	O
values	O	O
(	O	O
9	O	O
with	O	O
a	O	O
reduction	O	O
>	O	O
or	O	O
=50%	O	O
and	O	O
2	O	O
<50%	O	O
)	O	O
.	O	O

One	O	O
patient	O	O
showed	O	O
no	O	O
changes	O	O
in	O	O
SAP	O	O
amplitude	O	O
.	O	O

Five	O	O
patients	O	O
complained	O	O
of	O	O
paresthesias	B-Disease	D010292
and	O	O
leg	O	O
cramps	B-Disease	D009120
.	O	O

After	O	O
thalidomide	B-Chemical	D013792
treatment	O	O
,	O	O
sural	O	O
SAP	O	O
amplitude	O	O
recovered	O	O
in	O	O
3	O	O
patients	O	O
.	O	O

At	O	O
detection	O	O
of	O	O
reduction	O	O
in	O	O
sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
,	O	O
the	O	O
median	O	O
thalidomide	B-Chemical	D013792
cumulative	O	O
dose	O	O
was	O	O
21	O	O
.	O	O

4	O	O
g	O	O
.	O	O

The	O	O
threshold	O	O
neurotoxic	B-Disease	D020258
dosage	O	O
is	O	O
lower	O	O
than	O	O
previously	O	O
reported	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Sural	O	O
nerve	O	O
SAP	O	O
amplitude	O	O
reduction	O	O
is	O	O
a	O	O
reliable	O	O
and	O	O
sensitive	O	O
marker	O	O
of	O	O
degeneration	O	O
and	O	O
recovery	O	O
of	O	O
sensory	O	O
fibres	O	O
.	O	O

This	O	O
electrophysiological	O	O
parameter	O	O
provides	O	O
information	O	O
about	O	O
subclinical	O	O
neurotoxic	B-Disease	D020258
potential	O	O
of	O	O
thalidomide	B-Chemical	D013792
but	O	O
is	O	O
not	O	O
helpful	O	O
in	O	O
predicting	O	O
the	O	O
appearance	O	O
of	O	O
sensory	O	O
symptoms	O	O
.	O	O

Amiodarone	B-Chemical	D000638
-	O	O
related	O	O
pulmonary	B-Disease	D055370
mass	I-Disease	D055370
and	O	O
unique	O	O
membranous	B-Disease	D015433
glomerulonephritis	I-Disease	D015433
in	O	O
a	O	O
patient	O	O
with	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
:	O	O
Diagnostic	O	O
pitfall	O	O
and	O	O
new	O	O
findings	O	O
.	O	O

Amiodarone	B-Chemical	D000638
is	O	O
an	O	O
anti	O	O
-	O	O
arrhythmic	B-Disease	D001145
drug	O	O
for	O	O
life	O	O
-	O	O
threatening	O	O
tachycardia	B-Disease	D013610
,	O	O
but	O	O
various	O	O
adverse	O	O
effects	O	O
have	O	O
been	O	O
reported	O	O
.	O	O

Reported	O	O
herein	O	O
is	O	O
an	O	O
autopsy	O	O
case	O	O
of	O	O
valvular	B-Disease	D006349
heart	I-Disease	D006349
disease	I-Disease	D006349
,	O	O
in	O	O
a	O	O
patient	O	O
who	O	O
developed	O	O
a	O	O
lung	B-Disease	D055370
mass	I-Disease	D055370
(	O	O
1	O	O
.	O	O

5	O	O
cm	O	O
in	O	O
diameter	O	O
)	O	O
and	O	O
proteinuria	B-Disease	D011507
(	O	O
2	O	O
.	O	O

76	O	O
g	O	O
/	O	O
day	O	O
)	O	O
after	O	O
treatment	O	O
with	O	O
amiodarone	B-Chemical	D000638
for	O	O
a	O	O
long	O	O
time	O	O
.	O	O

The	O	O
lung	B-Disease	D055370
mass	I-Disease	D055370
was	O	O
highly	O	O
suspected	O	O
to	O	O
be	O	O
lung	B-Disease	D008175
cancer	I-Disease	D008175
on	O	O
CT	O	O
and	O	O
positron	O	O
emission	O	O
tomography	O	O
,	O	O
but	O	O
histologically	O	O
the	O	O
lesion	O	O
was	O	O
composed	O	O
of	O	O
lymphoplasmacytic	O	O
infiltrates	O	O
in	O	O
alveolar	O	O
walls	O	O
and	O	O
intra	O	O
-	O	O
alveolar	O	O
accumulation	O	O
of	O	O
foamy	O	O
macrophages	O	O
containing	O	O
characteristic	O	O
myelinoid	O	O
bodies	O	O
,	O	O
indicating	O	O
that	O	O
it	O	O
was	O	O
an	O	O
amiodarone	B-Chemical	D000638
-	O	O
related	O	O
lesion	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
the	O	O
lung	O	O
tissue	O	O
had	O	O
unevenly	O	O
distributed	O	O
hemosiderin	B-Disease	D006486
deposition	O	O
,	O	O
and	O	O
abnormally	O	O
tortuous	O	O
capillaries	O	O
were	O	O
seen	O	O
in	O	O
the	O	O
mass	O	O
and	O	O
in	O	O
heavily	O	O
hemosiderotic	B-Disease	D006486
lung	O	O
portions	O	O
outside	O	O
the	O	O
mass	O	O
.	O	O

In	O	O
the	O	O
kidneys	O	O
,	O	O
glomeruli	O	O
had	O	O
membrane	O	O
spikes	O	O
,	O	O
prominent	O	O
swelling	O	O
of	O	O
podocytes	O	O
and	O	O
subepithelial	O	O
deposits	O	O
,	O	O
which	O	O
were	O	O
sometimes	O	O
large	O	O
and	O	O
hump	O	O
-	O	O
like	O	O
.	O	O

Autoimmune	B-Disease	D001327
diseases	I-Disease	D001327
,	O	O
viral	B-Disease	D006525
hepatitis	I-Disease	D006525
,	O	O
malignant	O	O
neoplasms	B-Disease	D009369
or	O	O
other	O	O
diseases	O	O
with	O	O
a	O	O
known	O	O
relationship	O	O
to	O	O
membranous	B-Disease	D015433
glomerulonephritis	I-Disease	D015433
were	O	O
not	O	O
found	O	O
.	O	O

The	O	O
present	O	O
case	O	O
highlights	O	O
the	O	O
possibility	O	O
that	O	O
differential	O	O
diagnosis	O	O
between	O	O
an	O	O
amiodarone	B-Chemical	D000638
-	O	O
related	O	O
pulmonary	B-Disease	D055370
lesion	I-Disease	D055370
and	O	O
a	O	O
neoplasm	B-Disease	D009369
can	O	O
be	O	O
very	O	O
difficult	O	O
radiologically	O	O
,	O	O
and	O	O
suggests	O	O
that	O	O
membranous	B-Disease	D015433
glomerulonephritis	I-Disease	D015433
might	O	O
be	O	O
another	O	O
possible	O	O
complication	O	O
of	O	O
amiodarone	B-Chemical	D000638
treatment	O	O
.	O	O

Risk	O	O
of	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
associated	O	O
with	O	O
initial	O	O
sulphonylurea	B-Chemical	-1
treatment	O	O
of	O	O
patients	O	O
with	O	O
type	B-Disease	D003924
2	I-Disease	D003924
diabetes	I-Disease	D003924
:	O	O
a	O	O
matched	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

AIMS	O	O
:	O	O
This	O	O
study	O	O
sought	O	O
to	O	O
assess	O	O
the	O	O
risk	O	O
of	O	O
developing	O	O
coronary	B-Disease	D003324
artery	I-Disease	D003324
disease	I-Disease	D003324
(	O	O
CAD	B-Disease	D003324
)	O	O
associated	O	O
with	O	O
initial	O	O
treatment	O	O
of	O	O
type	B-Disease	D003924
2	I-Disease	D003924
diabetes	I-Disease	D003924
with	O	O
different	O	O
sulphonylureas	B-Chemical	-1
.	O	O

METHODS	O	O
:	O	O
In	O	O
type	B-Disease	D003924
2	I-Disease	D003924
diabetic	I-Disease	D003924
patients	O	O
,	O	O
cases	O	O
who	O	O
developed	O	O
CAD	B-Disease	D003324
were	O	O
compared	O	O
retrospectively	O	O
with	O	O
controls	O	O
that	O	O
did	O	O
not	O	O
.	O	O

The	O	O
20	O	O
-	O	O
year	O	O
risk	O	O
of	O	O
CAD	B-Disease	D003324
at	O	O
diagnosis	O	O
of	O	O
diabetes	B-Disease	D003920
,	O	O
using	O	O
the	O	O
UKPDS	O	O
risk	O	O
engine	O	O
,	O	O
was	O	O
used	O	O
to	O	O
match	O	O
cases	O	O
with	O	O
controls	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
76	O	O
cases	O	O
of	O	O
CAD	B-Disease	D003324
were	O	O
compared	O	O
with	O	O
152	O	O
controls	O	O
.	O	O

The	O	O
hazard	O	O
of	O	O
developing	O	O
CAD	B-Disease	D003324
(	O	O
95%	O	O
CI	O	O
)	O	O
associated	O	O
with	O	O
initial	O	O
treatment	O	O
increased	O	O
by	O	O
2	O	O
.	O	O

4	O	O
-	O	O
fold	O	O
(	O	O
1	O	O
.	O	O

3	O	O
-	O	O
4	O	O
.	O	O

3	O	O
,	O	O
P=0	O	O
.	O	O

004	O	O
)	O	O
with	O	O
glibenclamide	B-Chemical	D005905
;	O	O
2	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O

9	O	O
-	O	O
4	O	O
.	O	O

6	O	O
,	O	O
P=0	O	O
.	O	O

099	O	O
)	O	O
with	O	O
glipizide	B-Chemical	D005913
;	O	O
2	O	O
.	O	O

9	O	O
-	O	O
fold	O	O
(	O	O
1	O	O
.	O	O

6	O	O
-	O	O
5	O	O
.	O	O

1	O	O
,	O	O
P=0	O	O
.	O	O

000	O	O
)	O	O
with	O	O
either	O	O
,	O	O
and	O	O
was	O	O
unchanged	O	O
with	O	O
metformin	B-Chemical	D008687
.	O	O

The	O	O
hazard	O	O
decreased	O	O
0	O	O
.	O	O

3	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O

7	O	O
-	O	O
1	O	O
.	O	O

7	O	O
,	O	O
P=0	O	O
.	O	O

385	O	O
)	O	O
with	O	O
glimepiride	B-Chemical	C057619
,	O	O
0	O	O
.	O	O

4	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O

7	O	O
-	O	O
1	O	O
.	O	O

3	O	O
,	O	O
P=0	O	O
.	O	O

192	O	O
)	O	O
with	O	O
gliclazide	B-Chemical	D005907
,	O	O
and	O	O
0	O	O
.	O	O

4	O	O
-	O	O
fold	O	O
(	O	O
0	O	O
.	O	O

7	O	O
-	O	O
1	O	O
.	O	O

1	O	O
,	O	O
P=0	O	O
.	O	O

09	O	O
)	O	O
with	O	O
either	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Initiating	O	O
treatment	O	O
of	O	O
type	B-Disease	D003924
2	I-Disease	D003924
diabetes	I-Disease	D003924
with	O	O
glibenclamide	B-Chemical	D005905
or	O	O
glipizide	B-Chemical	D005913
is	O	O
associated	O	O
with	O	O
increased	O	O
risk	O	O
of	O	O
CAD	B-Disease	D003324
in	O	O
comparison	O	O
to	O	O
gliclazide	B-Chemical	D005907
or	O	O
glimepiride	B-Chemical	C057619
.	O	O

If	O	O
confirmed	O	O
,	O	O
this	O	O
may	O	O
be	O	O
important	O	O
because	O	O
most	O	O
Indian	O	O
patients	O	O
receive	O	O
the	O	O
cheaper	O	O
older	O	O
sulphonylureas	B-Chemical	-1
,	O	O
and	O	O
present	O	O
guidelines	O	O
do	O	O
not	O	O
distinguish	O	O
between	O	O
individual	O	O
agents	O	O
.	O	O

Reduced	O	O
progression	O	O
of	O	O
adriamycin	B-Chemical	D004317
nephropathy	B-Disease	D007674
in	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
treated	O	O
by	O	O
losartan	B-Chemical	D019808
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
aim	O	O
of	O	O
the	O	O
study	O	O
was	O	O
to	O	O
investigate	O	O
the	O	O
antihypertensive	O	O
effects	O	O
of	O	O
angiotensin	B-Chemical	D000804
II	I-Chemical	D000804
type	O	O
-	O	O
1	O	O
receptor	O	O
blocker	O	O
,	O	O
losartan	B-Chemical	D019808
,	O	O
and	O	O
its	O	O
potential	O	O
in	O	O
slowing	O	O
down	O	O
renal	B-Disease	D007674
disease	I-Disease	D007674
progression	O	O
in	O	O
spontaneously	O	O
hypertensive	B-Disease	D006973
rats	O	O
(	O	O
SHR	O	O
)	O	O
with	O	O
adriamycin	B-Chemical	D004317
(	O	O
ADR	B-Chemical	D004317
)	O	O
nephropathy	B-Disease	D007674
.	O	O

METHODS	O	O
:	O	O
Six	O	O
-	O	O
month	O	O
-	O	O
old	O	O
female	O	O
SHR	O	O
were	O	O
randomly	O	O
selected	O	O
in	O	O
six	O	O
groups	O	O
.	O	O

Two	O	O
control	O	O
groups	O	O
(	O	O
SH	O	O
(	O	O
6	O	O
)	O	O
,	O	O
SH	O	O
(	O	O
12	O	O
)	O	O
)	O	O
received	O	O
vehicle	O	O
.	O	O

Groups	O	O
ADR	B-Chemical	D004317
(	O	O
6	O	O
)	O	O
,	O	O
ADR+LOS	O	O
(	O	O
6	O	O
)	O	O
and	O	O
ADR	B-Chemical	D004317
(	O	O
12	O	O
)	O	O
,	O	O
and	O	O
ADR+LOS	O	O
(	O	O
12	O	O
)	O	O
received	O	O
ADR	B-Chemical	D004317
(	O	O
2	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
b	O	O
.	O	O

w	O	O
.	O	O

i	O	O
.	O	O

v	O	O
.	O	O

)	O	O
twice	O	O
in	O	O
a	O	O
3	O	O
-	O	O
week	O	O
interval	O	O
.	O	O

Group	O	O
ADR+LOS	O	O
(	O	O
6	O	O
)	O	O
received	O	O
losartan	B-Chemical	D019808
(	O	O
10	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
b	O	O
.	O	O

w	O	O
.	O	O

/	O	O
day	O	O
by	O	O
gavages	O	O
)	O	O
for	O	O
6	O	O
weeks	O	O
and	O	O
group	O	O
ADR+LOS	O	O
(	O	O
12	O	O
)	O	O
for	O	O
12	O	O
weeks	O	O
after	O	O
second	O	O
injection	O	O
of	O	O
ADR	B-Chemical	D004317
.	O	O

Animals	O	O
were	O	O
killed	O	O
after	O	O
6	O	O
or	O	O
12	O	O
weeks	O	O
,	O	O
respectively	O	O
.	O	O

Haemodynamic	O	O
measurements	O	O
were	O	O
performed	O	O
on	O	O
anaesthetized	O	O
animals	O	O
,	O	O
blood	O	O
and	O	O
urine	O	O
samples	O	O
were	O	O
taken	O	O
for	O	O
biochemical	O	O
analysis	O	O
and	O	O
the	O	O
left	O	O
kidney	O	O
was	O	O
processed	O	O
for	O	O
morphological	O	O
studies	O	O
.	O	O

RESULTS	O	O
:	O	O
Short	O	O
-	O	O
term	O	O
losartan	B-Chemical	D019808
treatment	O	O
,	O	O
besides	O	O
antihypertensive	O	O
effect	O	O
,	O	O
improved	O	O
glomerular	O	O
filtration	O	O
rate	O	O
and	O	O
ameliorated	O	O
glomerulosclerosis	B-Disease	D005921
resulting	O	O
in	O	O
decreased	O	O
proteinuria	B-Disease	D011507
.	O	O

Prolonged	O	O
treatment	O	O
with	O	O
losartan	B-Chemical	D019808
showed	O	O
further	O	O
reduction	O	O
of	O	O
glomerulosclerosis	B-Disease	D005921
associated	O	O
with	O	O
reduced	O	O
progression	O	O
of	O	O
tubular	O	O
atrophy	B-Disease	D001284
and	O	O
interstitial	B-Disease	D005355
fibrosis	I-Disease	D005355
,	O	O
thus	O	O
preventing	O	O
heavy	O	O
proteinuria	B-Disease	D011507
and	O	O
chronic	B-Disease	D007676
renal	I-Disease	D007676
failure	I-Disease	D007676
.	O	O

Losartan	B-Chemical	D019808
reduced	O	O
uraemia	B-Disease	D014511
and	O	O
increased	O	O
urea	B-Chemical	D014508
clearance	O	O
in	O	O
advanced	O	O
ADR	B-Chemical	D004317
nephropathy	B-Disease	D007674
in	O	O
SHR	O	O
.	O	O

Histological	O	O
examination	O	O
showed	O	O
that	O	O
losartan	B-Chemical	D019808
could	O	O
prevent	O	O
tubular	O	O
atrophy	B-Disease	D001284
,	O	O
interstitial	O	O
infiltration	O	O
and	O	O
fibrosis	B-Disease	D005355
in	O	O
ADR	B-Chemical	D004317
nephropathy	B-Disease	D007674
.	O	O

CONCLUSION	O	O
:	O	O
Losartan	B-Chemical	D019808
reduces	O	O
the	O	O
rate	O	O
of	O	O
progression	O	O
of	O	O
ADR	B-Chemical	D004317
-	O	O
induced	O	O
focal	B-Disease	D005923
segmental	I-Disease	D005923
glomerulosclerosis	I-Disease	D005923
to	O	O
end	B-Disease	D007676
-	I-Disease	D007676
stage	I-Disease	D007676
renal	I-Disease	D007676
disease	I-Disease	D007676
in	O	O
SHR	O	O
.	O	O

The	O	O
risks	O	O
of	O	O
aprotinin	O	O
and	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
in	O	O
cardiac	O	O
surgery	O	O
:	O	O
a	O	O
one	O	O
-	O	O
year	O	O
follow	O	O
-	O	O
up	O	O
of	O	O
1188	O	O
consecutive	O	O
patients	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Our	O	O
aim	O	O
was	O	O
to	O	O
investigate	O	O
postoperative	O	O
complications	O	O
and	O	O
mortality	O	O
after	O	O
administration	O	O
of	O	O
aprotinin	O	O
compared	O	O
to	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
in	O	O
an	O	O
unselected	O	O
,	O	O
consecutive	O	O
cohort	O	O
.	O	O

METHODS	O	O
:	O	O
Perioperative	O	O
data	O	O
from	O	O
consecutive	O	O
cardiac	O	O
surgery	O	O
patients	O	O
were	O	O
prospectively	O	O
collected	O	O
between	O	O
September	O	O
2005	O	O
and	O	O
June	O	O
2006	O	O
in	O	O
a	O	O
university	O	O
-	O	O
affiliated	O	O
clinic	O	O
(	O	O
n	O	O
=	O	O
1188	O	O
)	O	O
.	O	O

During	O	O
the	O	O
first	O	O
5	O	O
mo	O	O
,	O	O
596	O	O
patients	O	O
received	O	O
aprotinin	O	O
(	O	O
Group	O	O
A	O	O
)	O	O
;	O	O
in	O	O
the	O	O
next	O	O
5	O	O
mo	O	O
,	O	O
592	O	O
patients	O	O
were	O	O
treated	O	O
with	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
(	O	O
Group	O	O
T	O	O
)	O	O
.	O	O

Except	O	O
for	O	O
antifibrinolytic	O	O
therapy	O	O
,	O	O
the	O	O
anesthetic	O	O
and	O	O
surgical	O	O
protocols	O	O
remained	O	O
unchanged	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
pre	O	O
-	O	O
and	O	O
intraoperative	O	O
variables	O	O
were	O	O
comparable	O	O
between	O	O
the	O	O
treatment	O	O
groups	O	O
.	O	O

Postoperatively	O	O
,	O	O
a	O	O
significantly	O	O
higher	O	O
incidence	O	O
of	O	O
seizures	B-Disease	D012640
was	O	O
found	O	O
in	O	O
Group	O	O
T	O	O
(	O	O
4	O	O
.	O	O

6%	O	O
vs	O	O
1	O	O
.	O	O

2%	O	O
,	O	O
P	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
also	O	O
significant	O	O
in	O	O
the	O	O
primary	O	O
valve	O	O
surgery	O	O
and	O	O
the	O	O
high	O	O
risk	O	O
surgery	O	O
subgroups	O	O
(	O	O
7	O	O
.	O	O

9%	O	O
vs	O	O
1	O	O
.	O	O

2%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

003	O	O
;	O	O
7	O	O
.	O	O

3%	O	O
vs	O	O
2	O	O
.	O	O

4%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

035	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

Persistent	O	O
atrial	O	O
fibrillation	O	O
(	O	O
7	O	O
.	O	O

9%	O	O
vs	O	O
2	O	O
.	O	O

3%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

020	O	O
)	O	O
and	O	O
renal	B-Disease	D051437
failure	I-Disease	D051437
(	O	O
9	O	O
.	O	O

7%	O	O
vs	O	O
1	O	O
.	O	O

7%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

002	O	O
)	O	O
were	O	O
also	O	O
more	O	O
common	O	O
in	O	O
Group	O	O
T	O	O
,	O	O
in	O	O
the	O	O
primary	O	O
valve	O	O
surgery	O	O
subgroup	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
among	O	O
primary	O	O
coronary	O	O
artery	O	O
bypass	O	O
surgery	O	O
patients	O	O
,	O	O
there	O	O
were	O	O
more	O	O
acute	O	O
myocardial	B-Disease	D009203
infarctions	I-Disease	D009203
and	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
in	O	O
Group	O	O
A	O	O
(	O	O
5	O	O
.	O	O

8%	O	O
vs	O	O
2	O	O
.	O	O

0%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

027	O	O
;	O	O
22	O	O
.	O	O

5%	O	O
vs	O	O
15	O	O
.	O	O

2%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

036	O	O
,	O	O
respectively	O	O
)	O	O
.	O	O

The	O	O
1	O	O
-	O	O
yr	O	O
mortality	O	O
was	O	O
significantly	O	O
higher	O	O
after	O	O
aprotinin	O	O
treatment	O	O
in	O	O
the	O	O
high	O	O
risk	O	O
surgery	O	O
group	O	O
(	O	O
17	O	O
.	O	O

7%	O	O
vs	O	O
9	O	O
.	O	O

8%	O	O
,	O	O
P	O	O
=	O	O
0	O	O
.	O	O

034	O	O
)	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Both	O	O
antifibrinolytic	O	O
drugs	O	O
bear	O	O
the	O	O
risk	O	O
of	O	O
adverse	O	O
outcome	O	O
depending	O	O
on	O	O
the	O	O
type	O	O
of	O	O
cardiac	O	O
surgery	O	O
.	O	O

Administration	O	O
of	O	O
aprotinin	O	O
should	O	O
be	O	O
avoided	O	O
in	O	O
coronary	O	O
artery	O	O
bypass	O	O
graft	O	O
and	O	O
high	O	O
risk	O	O
patients	O	O
,	O	O
whereas	O	O
administration	O	O
of	O	O
tranexamic	B-Chemical	D014148
acid	I-Chemical	D014148
is	O	O
not	O	O
recommended	O	O
in	O	O
valve	O	O
surgery	O	O
.	O	O

The	O	O
biological	O	O
properties	O	O
of	O	O
the	O	O
optical	O	O
isomers	O	O
of	O	O
propranolol	B-Chemical	D011433
and	O	O
their	O	O
effects	O	O
on	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
.	O	O

1	O	O
.	O	O

The	O	O
optical	O	O
isomers	O	O
of	O	O
propranolol	B-Chemical	D011433
have	O	O
been	O	O
compared	O	O
for	O	O
their	O	O
beta	O	O
-	O	O
blocking	O	O
and	O	O
antiarrhythmic	O	O
activities	O	O
.	O	O

2	O	O
.	O	O

In	O	O
blocking	O	O
the	O	O
positive	O	O
inotropic	O	O
and	O	O
chronotropic	O	O
responses	O	O
to	O	O
isoprenaline	B-Chemical	D007545
,	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
had	O	O
less	O	O
than	O	O
one	O	O
hundredth	O	O
the	O	O
potency	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
.	O	O

At	O	O
dose	O	O
levels	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
which	O	O
attenuated	O	O
the	O	O
responses	O	O
to	O	O
isoprenaline	B-Chemical	D007545
,	O	O
there	O	O
was	O	O
a	O	O
significant	O	O
prolongation	O	O
of	O	O
the	O	O
PR	O	O
interval	O	O
of	O	O
the	O	O
electrocardiogram	O	O
.	O	O

3	O	O
.	O	O

The	O	O
metabolic	O	O
responses	O	O
to	O	O
isoprenaline	B-Chemical	D007545
in	O	O
dogs	O	O
(	O	O
an	O	O
increase	O	O
in	O	O
circulating	O	O
glucose	B-Chemical	D005947
,	O	O
lactate	B-Chemical	D019344
and	O	O
free	O	O
fatty	B-Chemical	D005227
acids	I-Chemical	D005227
)	O	O
were	O	O
all	O	O
blocked	O	O
by	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
.	O	O

(	O	O
+	O	O
)	O	O
-	O	O
Propranolol	B-Chemical	D011433
had	O	O
no	O	O
effect	O	O
on	O	O
fatty	B-Chemical	D005227
acid	I-Chemical	D005227
mobilization	O	O
but	O	O
significantly	O	O
reduced	O	O
the	O	O
increments	O	O
in	O	O
both	O	O
lactate	B-Chemical	D019344
and	O	O
glucose	B-Chemical	D005947
.	O	O

4	O	O
.	O	O

Both	O	O
isomers	O	O
of	O	O
propranolol	B-Chemical	D011433
possessed	O	O
similar	O	O
depressant	O	O
potency	O	O
on	O	O
isolated	O	O
atrial	O	O
muscle	O	O
taken	O	O
from	O	O
guinea	O	O
-	O	O
pigs	O	O
.	O	O

5	O	O
.	O	O

The	O	O
isomers	O	O
of	O	O
propranolol	B-Chemical	D011433
exhibited	O	O
similar	O	O
local	O	O
anaesthetic	O	O
potencies	O	O
on	O	O
an	O	O
isolated	O	O
frog	O	O
nerve	O	O
preparation	O	O
at	O	O
a	O	O
level	O	O
approximately	O	O
three	O	O
times	O	O
that	O	O
of	O	O
procaine	B-Chemical	D011343
.	O	O

The	O	O
racemic	O	O
compound	O	O
was	O	O
significantly	O	O
less	O	O
potent	O	O
than	O	O
either	O	O
isomer	O	O
.	O	O

6	O	O
.	O	O

Both	O	O
isomers	O	O
of	O	O
propranolol	B-Chemical	D011433
were	O	O
capable	O	O
of	O	O
preventing	O	O
adrenaline	B-Chemical	D004837
-	O	O
induced	O	O
cardiac	B-Disease	D001145
arrhythmias	I-Disease	D001145
in	O	O
cats	O	O
anaesthetized	O	O
with	O	O
halothane	B-Chemical	D006221
,	O	O
but	O	O
the	O	O
mean	O	O
dose	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
was	O	O
0	O	O
.	O	O

09+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

02	O	O
mg	O	O
/	O	O
kg	O	O
whereas	O	O
that	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
was	O	O
4	O	O
.	O	O

2+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
.	O	O

At	O	O
the	O	O
effective	O	O
dose	O	O
level	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
there	O	O
was	O	O
a	O	O
significant	O	O
prolongation	O	O
of	O	O
the	O	O
PR	O	O
interval	O	O
of	O	O
the	O	O
electrocardiogram	O	O
.	O	O

Blockade	O	O
of	O	O
arrhythmias	B-Disease	D001145
with	O	O
both	O	O
isomers	O	O
was	O	O
surmountable	O	O
by	O	O
increasing	O	O
the	O	O
dose	O	O
of	O	O
adrenaline	B-Chemical	D004837
.	O	O

7	O	O
.	O	O

Both	O	O
isomers	O	O
of	O	O
propranolol	B-Chemical	D011433
were	O	O
also	O	O
capable	O	O
of	O	O
reversing	O	O
ventricular	B-Disease	D017180
tachycardia	I-Disease	D017180
caused	O	O
by	O	O
ouabain	B-Chemical	D010042
in	O	O
anaesthetized	O	O
cats	O	O
and	O	O
dogs	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
(	O	O
-	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
was	O	O
significantly	O	O
smaller	O	O
than	O	O
that	O	O
of	O	O
(	O	O
+	O	O
)	O	O
-	O	O
propranolol	B-Chemical	D011433
in	O	O
both	O	O
species	O	O
but	O	O
much	O	O
higher	O	O
than	O	O
that	O	O
required	O	O
to	O	O
produce	O	O
evidence	O	O
of	O	O
beta	O	O
-	O	O
blockade	O	O
.	O	O

8	O	O
.	O	O

The	O	O
implications	O	O
of	O	O
these	O	O
results	O	O
are	O	O
discussed	O	O
.	O	O

Topotecan	B-Chemical	D019772
in	O	O
combination	O	O
with	O	O
radiotherapy	O	O
in	O	O
unresectable	O	O
glioblastoma	B-Disease	D005909
:	O	O
a	O	O
phase	O	O
2	O	O
study	O	O
.	O	O

Improving	O	O
glioblastoma	B-Disease	D005909
multiforme	O	O
(	O	O
GBM	B-Disease	D005909
)	O	O
treatment	O	O
with	O	O
radio	O	O
-	O	O
chemotherapy	O	O
remains	O	O
a	O	O
challenge	O	O
.	O	O

Topotecan	B-Chemical	D019772
is	O	O
an	O	O
attractive	O	O
option	O	O
as	O	O
it	O	O
exhibits	O	O
growth	O	O
inhibition	O	O
of	O	O
human	O	O
glioma	B-Disease	D005910
as	O	O
well	O	O
as	O	O
brain	O	O
penetration	O	O
.	O	O

The	O	O
present	O	O
study	O	O
assessed	O	O
the	O	O
combination	O	O
of	O	O
radiotherapy	O	O
(	O	O
60	O	O
Gy	O	O
/	O	O
30	O	O
fractions	O	O
/	O	O
40	O	O
days	O	O
)	O	O
and	O	O
topotecan	B-Chemical	D019772
(	O	O
0	O	O
.	O	O

9	O	O
mg	O	O
/	O	O
m	O	O
(	O	O
2	O	O
)	O	O
/	O	O
day	O	O
on	O	O
days	O	O
1	O	O
-	O	O
5	O	O
on	O	O
weeks	O	O
1	O	O
,	O	O
3	O	O
and	O	O
5	O	O
)	O	O
in	O	O
50	O	O
adults	O	O
with	O	O
histologically	O	O
proven	O	O
and	O	O
untreated	O	O
GBM	B-Disease	D005909
.	O	O

The	O	O
incidence	O	O
of	O	O
non	O	O
-	O	O
hematological	O	O
toxicities	B-Disease	D064420
was	O	O
low	O	O
and	O	O
grade	O	O
3	O	O
-	O	O
4	O	O
hematological	O	O
toxicities	B-Disease	D064420
were	O	O
reported	O	O
in	O	O
20	O	O
patients	O	O
(	O	O
mainly	O	O
lymphopenia	B-Disease	D008231
and	O	O
neutropenia	B-Disease	D009503
)	O	O
.	O	O

Partial	O	O
response	O	O
and	O	O
stabilization	O	O
rates	O	O
were	O	O
2%	O	O
and	O	O
32%	O	O
,	O	O
respectively	O	O
,	O	O
with	O	O
an	O	O
overall	O	O
time	O	O
to	O	O
progression	O	O
of	O	O
12	O	O
weeks	O	O
.	O	O

One	O	O
-	O	O
year	O	O
overall	O	O
survival	O	O
(	O	O
OS	O	O
)	O	O
rate	O	O
was	O	O
42%	O	O
,	O	O
with	O	O
a	O	O
median	O	O
OS	O	O
of	O	O
40	O	O
weeks	O	O
.	O	O

Topotecan	B-Chemical	D019772
in	O	O
combination	O	O
with	O	O
radiotherapy	O	O
was	O	O
well	O	O
tolerated	O	O
.	O	O

However	O	O
,	O	O
while	O	O
response	O	O
and	O	O
stabilization	O	O
concerned	O	O
one	O	O
-	O	O
third	O	O
of	O	O
the	O	O
patients	O	O
,	O	O
the	O	O
study	O	O
did	O	O
not	O	O
show	O	O
increased	O	O
benefits	O	O
in	O	O
terms	O	O
of	O	O
survival	O	O
in	O	O
patients	O	O
with	O	O
unresectable	O	O
GBM	B-Disease	D005909
.	O	O

Long	O	O
-	O	O
term	O	O
lithium	B-Chemical	D008094
therapy	O	O
leading	O	O
to	O	O
hyperparathyroidism	B-Disease	D006961
:	O	O
a	O	O
case	O	O
report	O	O
.	O	O

PURPOSE	O	O
:	O	O
This	O	O
paper	O	O
reviews	O	O
the	O	O
effect	O	O
of	O	O
chronic	O	O
lithium	B-Chemical	D008094
therapy	O	O
on	O	O
serum	O	O
calcium	B-Chemical	D002118
level	O	O
and	O	O
parathyroid	O	O
glands	O	O
,	O	O
its	O	O
pathogenesis	O	O
,	O	O
and	O	O
treatment	O	O
options	O	O
.	O	O

We	O	O
examined	O	O
the	O	O
case	O	O
of	O	O
a	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
patient	O	O
who	O	O
had	O	O
recurrent	O	O
hypercalcemia	B-Disease	D006934
to	O	O
better	O	O
understand	O	O
the	O	O
disease	O	O
process	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Primary	B-Disease	D049950
hyperparathyroidism	I-Disease	D049950
is	O	O
a	O	O
rare	O	O
but	O	O
potentially	O	O
life	O	O
-	O	O
threatening	O	O
side	O	O
effect	O	O
of	O	O
long	O	O
-	O	O
term	O	O
lithium	B-Chemical	D008094
therapy	O	O
.	O	O

Careful	O	O
patient	O	O
selection	O	O
and	O	O
long	O	O
-	O	O
term	O	O
follow	O	O
-	O	O
up	O	O
can	O	O
reduce	O	O
morbidity	O	O
.	O	O

PRACTICAL	O	O
IMPLICATIONS	O	O
:	O	O
As	O	O
much	O	O
as	O	O
15%	O	O
of	O	O
lithium	B-Chemical	D008094
-	O	O
treated	O	O
patients	O	O
become	O	O
hypercalcemic	B-Disease	D006934
.	O	O

By	O	O
routinely	O	O
monitoring	O	O
serum	O	O
calcium	B-Chemical	D002118
levels	O	O
,	O	O
healthcare	O	O
providers	O	O
can	O	O
improve	O	O
the	O	O
quality	O	O
of	O	O
life	O	O
of	O	O
this	O	O
patient	O	O
group	O	O
.	O	O

Comparison	O	O
of	O	O
laryngeal	O	O
mask	O	O
with	O	O
endotracheal	O	O
tube	O	O
for	O	O
anesthesia	O	O
in	O	O
endoscopic	O	O
sinus	O	O
surgery	O	O
.	O	O

BACKGROUND	O	O
:	O	O
The	O	O
purpose	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
compare	O	O
surgical	O	O
conditions	O	O
,	O	O
including	O	O
the	O	O
amount	O	O
of	O	O
intraoperative	O	O
bleeding	B-Disease	D006470
as	O	O
well	O	O
as	O	O
intraoperative	O	O
blood	O	O
pressure	O	O
,	O	O
during	O	O
functional	O	O
endoscopic	O	O
sinus	O	O
surgery	O	O
(	O	O
FESS	O	O
)	O	O
using	O	O
flexible	O	O
reinforced	O	O
laryngeal	O	O
mask	O	O
airway	O	O
(	O	O
FRLMA	O	O
)	O	O
versus	O	O
endotracheal	O	O
tube	O	O
(	O	O
ETT	O	O
)	O	O
in	O	O
maintaining	O	O
controlled	O	O
hypotension	B-Disease	D007022
anesthesia	O	O
induced	O	O
by	O	O
propofol	B-Chemical	D015742
-	O	O
remifentanil	B-Chemical	C071741
total	O	O
i	O	O
.	O	O

v	O	O
.	O	O

anesthesia	O	O
(	O	O
TIVA	O	O
)	O	O
.	O	O

METHODS	O	O
:	O	O
Sixty	O	O
normotensive	O	O
American	O	O
Society	O	O
of	O	O
Anesthesiologists	O	O
I	O	O
-	O	O
II	O	O
adult	O	O
patients	O	O
undergoing	O	O
FESS	O	O
under	O	O
controlled	O	O
hypotension	B-Disease	D007022
anesthesia	O	O
caused	O	O
by	O	O
propofol	B-Chemical	D015742
-	O	O
remifentanil	B-Chemical	C071741
-	O	O
TIVA	O	O
were	O	O
randomly	O	O
assigned	O	O
into	O	O
two	O	O
groups	O	O
:	O	O
group	O	O
I	O	O
,	O	O
FRLMA	O	O
;	O	O
group	O	O
II	O	O
,	O	O
ETT	O	O
.	O	O

Hemorrhage	B-Disease	D006470
was	O	O
measured	O	O
and	O	O
the	O	O
visibility	O	O
of	O	O
the	O	O
operative	O	O
field	O	O
was	O	O
evaluated	O	O
according	O	O
to	O	O
a	O	O
six	O	O
-	O	O
point	O	O
scale	O	O
.	O	O

RESULTS	O	O
:	O	O
Controlled	O	O
hypotension	B-Disease	D007022
was	O	O
achieved	O	O
within	O	O
a	O	O
shorter	O	O
period	O	O
using	O	O
laryngeal	O	O
mask	O	O
using	O	O
lower	O	O
rates	O	O
of	O	O
remifentanil	B-Chemical	C071741
infusion	O	O
and	O	O
lower	O	O
total	O	O
dose	O	O
of	O	O
remifentanil	B-Chemical	C071741
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
summary	O	O
,	O	O
our	O	O
results	O	O
indicate	O	O
that	O	O
airway	O	O
management	O	O
using	O	O
FRLMA	O	O
during	O	O
controlled	O	O
hypotension	B-Disease	D007022
anesthesia	O	O
provided	O	O
better	O	O
surgical	O	O
conditions	O	O
in	O	O
terms	O	O
of	O	O
quality	O	O
of	O	O
operative	O	O
field	O	O
and	O	O
blood	O	O
loss	O	O
and	O	O
allowed	O	O
for	O	O
convenient	O	O
induced	O	O
hypotension	B-Disease	D007022
with	O	O
low	O	O
doses	O	O
of	O	O
remifentanil	B-Chemical	C071741
during	O	O
TIVA	O	O
in	O	O
patients	O	O
undergoing	O	O
FESS	O	O
.	O	O

Nonalcoholic	B-Disease	D065626
fatty	I-Disease	D065626
liver	I-Disease	D065626
disease	I-Disease	D065626
during	O	O
valproate	B-Chemical	D014635
therapy	O	O
.	O	O

Valproic	B-Chemical	D014635
acid	I-Chemical	D014635
(	O	O
VPA	B-Chemical	D014635
)	O	O
is	O	O
effective	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
many	O	O
types	O	O
of	O	O
epilepsy	B-Disease	D004827
,	O	O
but	O	O
its	O	O
use	O	O
can	O	O
be	O	O
associated	O	O
with	O	O
an	O	O
increase	O	O
in	O	O
body	O	O
weight	O	O
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
nonalcoholic	B-Disease	D065626
fatty	I-Disease	D065626
liver	I-Disease	D065626
disease	I-Disease	D065626
(	O	O
NAFLD	B-Disease	D065626
)	O	O
arising	O	O
in	O	O
a	O	O
child	O	O
who	O	O
developed	O	O
obesity	B-Disease	D009765
during	O	O
VPA	B-Chemical	D014635
treatment	O	O
.	O	O

Laboratory	O	O
data	O	O
revealed	O	O
hyperinsulinemia	B-Disease	D006946
with	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
.	O	O

After	O	O
the	O	O
withdrawal	O	O
of	O	O
VPA	B-Chemical	D014635
therapy	O	O
,	O	O
our	O	O
patient	O	O
showed	O	O
a	O	O
significant	O	O
weight	B-Disease	D015431
loss	I-Disease	D015431
,	O	O
a	O	O
decrease	O	O
of	O	O
body	O	O
mass	O	O
index	O	O
,	O	O
and	O	O
normalization	O	O
of	O	O
metabolic	O	O
and	O	O
endocrine	O	O
parameters	O	O
;	O	O
moreover	O	O
,	O	O
ultrasound	O	O
measurements	O	O
showed	O	O
a	O	O
complete	O	O
normalization	O	O
.	O	O

The	O	O
present	O	O
case	O	O
suggests	O	O
that	O	O
obesity	B-Disease	D009765
,	O	O
hyperinsulinemia	B-Disease	D006946
,	O	O
insulin	B-Disease	D007333
resistance	I-Disease	D007333
,	O	O
and	O	O
long	O	O
-	O	O
term	O	O
treatment	O	O
with	O	O
VPA	B-Chemical	D014635
may	O	O
be	O	O
all	O	O
associated	O	O
with	O	O
the	O	O
development	O	O
of	O	O
NAFLD	B-Disease	D065626
;	O	O
this	O	O
side	O	O
effect	O	O
is	O	O
reversible	O	O
after	O	O
VPA	B-Chemical	D014635
withdrawal	O	O
.	O	O

Carbimazole	B-Chemical	D002231
induced	O	O
ANCA	B-Disease	D056648
positive	I-Disease	D056648
vasculitis	I-Disease	D056648
.	O	O

Anti	B-Chemical	D013956
-	I-Chemical	D013956
thyroid	I-Chemical	D013956
drugs	I-Chemical	D013956
,	O	O
like	O	O
carbimazole	B-Chemical	D002231
and	O	O
propylthiouracil	B-Chemical	D011441
(	O	O
PTU	B-Chemical	D011441
)	O	O
are	O	O
commonly	O	O
prescribed	O	O
for	O	O
the	O	O
treatment	O	O
of	O	O
hyperthyroidism	B-Disease	D006980
.	O	O

One	O	O
should	O	O
be	O	O
aware	O	O
of	O	O
the	O	O
side	O	O
effects	O	O
of	O	O
antithyroid	B-Chemical	D013956
medications	I-Chemical	D013956
.	O	O

Antineutrophil	B-Disease	D056648
cytoplasmic	I-Disease	D056648
antibody	I-Disease	D056648
(	I-Disease	D056648
ANCA	I-Disease	D056648
)	I-Disease	D056648
-	I-Disease	D056648
-	I-Disease	D056648
associated	I-Disease	D056648
vasculitis	I-Disease	D056648
is	O	O
a	O	O
potentially	O	O
life	O	O
-	O	O
threatening	O	O
adverse	O	O
effect	O	O
of	O	O
antithyroidmedications	B-Chemical	D013956
.	O	O

We	O	O
report	O	O
a	O	O
patient	O	O
with	O	O
Graves'	B-Disease	D006111
disease	I-Disease	D006111
who	O	O
developed	O	O
ANCA	O	O
positive	O	O
carbimazole	B-Chemical	D002231
induced	O	O
vasculitis	B-Disease	D014657
.	O	O

The	O	O
episode	O	O
was	O	O
characterized	O	O
by	O	O
a	O	O
vasculitic	B-Disease	D014657
skin	B-Disease	D005076
rash	I-Disease	D005076
associated	O	O
with	O	O
large	O	O
joint	O	O
arthritis	B-Disease	D001168
,	O	O
pyrexia	B-Disease	D005334
and	O	O
parotiditis	B-Disease	D010309
but	O	O
no	O	O
renal	O	O
or	O	O
pulmonary	O	O
involvement	O	O
.	O	O

He	O	O
was	O	O
referred	O	O
to	O	O
us	O	O
for	O	O
neurological	O	O
evaluation	O	O
because	O	O
he	O	O
had	O	O
difficulty	O	O
in	O	O
getting	O	O
up	O	O
from	O	O
squatting	O	O
position	O	O
and	O	O
was	O	O
suspected	O	O
to	O	O
have	O	O
myositis	B-Disease	D009220
.	O	O

Carbimazole	B-Chemical	D002231
and	O	O
methimazole	B-Chemical	D008713
have	O	O
a	O	O
lower	O	O
incidence	O	O
of	O	O
reported	O	O
ANCA	O	O
positive	O	O
side	O	O
effects	O	O
than	O	O
PUT	O	O
.	O	O

To	O	O
the	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
first	O	O
ANCA	O	O
positive	O	O
carbimazole	B-Chemical	D002231
induced	O	O
vasculitis	B-Disease	D014657
case	O	O
reported	O	O
from	O	O
India	O	O
.	O	O

Aspirin	B-Chemical	D001241
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cardiovascular	O	O
events	O	O
:	O	O
an	O	O
update	O	O
of	O	O
the	O	O
evidence	O	O
for	O	O
the	O	O
U	O	O
.	O	O

S	O	O
.	O	O

Preventive	O	O
Services	O	O
Task	O	O
Force	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
and	O	O
cerebrovascular	B-Disease	D002561
disease	I-Disease	D002561
are	O	O
leading	O	O
causes	O	O
of	O	O
death	O	O
in	O	O
the	O	O
United	O	O
States	O	O
.	O	O

In	O	O
2002	O	O
,	O	O
the	O	O
U	O	O
.	O	O

S	O	O
.	O	O

Preventive	O	O
Services	O	O
Task	O	O
Force	O	O
(	O	O
USPSTF	O	O
)	O	O
strongly	O	O
recommended	O	O
that	O	O
clinicians	O	O
discuss	O	O
aspirin	B-Chemical	D001241
with	O	O
adults	O	O
who	O	O
are	O	O
at	O	O
increased	O	O
risk	O	O
for	O	O
coronary	B-Disease	D003327
heart	I-Disease	D003327
disease	I-Disease	D003327
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
determine	O	O
the	O	O
benefits	O	O
and	O	O
harms	O	O
of	O	O
taking	O	O
aspirin	B-Chemical	D001241
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
myocardial	B-Disease	D009203
infarctions	I-Disease	D009203
,	O	O
strokes	B-Disease	D020521
,	O	O
and	O	O
death	O	O
.	O	O

DATA	O	O
SOURCES	O	O
:	O	O
MEDLINE	O	O
and	O	O
Cochrane	O	O
Library	O	O
(	O	O
search	O	O
dates	O	O
,	O	O
1	O	O
January	O	O
2001	O	O
to	O	O
28	O	O
August	O	O
2008	O	O
)	O	O
,	O	O
recent	O	O
systematic	O	O
reviews	O	O
,	O	O
reference	O	O
lists	O	O
of	O	O
retrieved	O	O
articles	O	O
,	O	O
and	O	O
suggestions	O	O
from	O	O
experts	O	O
.	O	O

STUDY	O	O
SELECTION	O	O
:	O	O
English	O	O
-	O	O
language	O	O
randomized	O	O
,	O	O
controlled	O	O
trials	O	O
(	O	O
RCTs	O	O
)	O	O
;	O	O
case	O	O
-	O	O
control	O	O
studies	O	O
;	O	O
meta	O	O
-	O	O
analyses	O	O
;	O	O
and	O	O
systematic	O	O
reviews	O	O
of	O	O
aspirin	B-Chemical	D001241
versus	O	O
control	O	O
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
cardiovascular	B-Disease	D002318
disease	I-Disease	D002318
(	O	O
CVD	B-Disease	D002318
)	O	O
were	O	O
selected	O	O
to	O	O
answer	O	O
the	O	O
following	O	O
questions	O	O
:	O	O
Does	O	O
aspirin	B-Chemical	D001241
decrease	O	O
coronary	O	O
heart	O	O
events	O	O
,	O	O
strokes	B-Disease	D020521
,	O	O
death	O	O
from	O	O
coronary	O	O
heart	O	O
events	O	O
or	O	O
stroke	B-Disease	D020521
,	O	O
or	O	O
all	O	O
-	O	O
cause	O	O
mortality	O	O
in	O	O
adults	O	O
without	O	O
known	O	O
CVD?	O	O
Does	O	O
aspirin	B-Chemical	D001241
increase	O	O
gastrointestinal	B-Disease	D006471
bleeding	I-Disease	D006471
or	O	O
hemorrhagic	O	O
strokes?	O	O
DATA	O	O
EXTRACTION	O	O
:	O	O
All	O	O
studies	O	O
were	O	O
reviewed	O	O
,	O	O
abstracted	O	O
,	O	O
and	O	O
rated	O	O
for	O	O
quality	O	O
by	O	O
using	O	O
predefined	O	O
USPSTF	O	O
criteria	O	O
.	O	O

DATA	O	O
SYNTHESIS	O	O
:	O	O
New	O	O
evidence	O	O
from	O	O
1	O	O
good	O	O
-	O	O
quality	O	O
RCT	O	O
,	O	O
1	O	O
good	O	O
-	O	O
quality	O	O
meta	O	O
-	O	O
analysis	O	O
,	O	O
and	O	O
2	O	O
fair	O	O
-	O	O
quality	O	O
subanalyses	O	O
of	O	O
RCTs	O	O
demonstrates	O	O
that	O	O
aspirin	B-Chemical	D001241
use	O	O
reduces	O	O
the	O	O
number	O	O
of	O	O
CVD	B-Disease	D002318
events	O	O
in	O	O
patients	O	O
without	O	O
known	O	O
CVD	B-Disease	D002318
.	O	O

Men	O	O
in	O	O
these	O	O
studies	O	O
experienced	O	O
fewer	O	O
myocardial	B-Disease	D009203
infarctions	I-Disease	D009203
and	O	O
women	O	O
experienced	O	O
fewer	O	O
ischemic	O	O
strokes	B-Disease	D020521
.	O	O

Aspirin	B-Chemical	D001241
does	O	O
not	O	O
seem	O	O
to	O	O
affect	O	O
CVD	B-Disease	D002318
mortality	O	O
or	O	O
all	O	O
-	O	O
cause	O	O
mortality	O	O
in	O	O
either	O	O
men	O	O
or	O	O
women	O	O
.	O	O

The	O	O
use	O	O
of	O	O
aspirin	B-Chemical	D001241
for	O	O
primary	O	O
prevention	O	O
increases	O	O
the	O	O
risk	O	O
for	O	O
major	O	O
bleeding	B-Disease	D006470
events	O	O
,	O	O
primarily	O	O
gastrointestinal	B-Disease	D006471
bleeding	I-Disease	D006471
events	O	O
,	O	O
in	O	O
both	O	O
men	O	O
and	O	O
women	O	O
.	O	O

Men	O	O
have	O	O
an	O	O
increased	O	O
risk	O	O
for	O	O
hemorrhagic	O	O
strokes	B-Disease	D020521
with	O	O
aspirin	B-Chemical	D001241
use	O	O
.	O	O

A	O	O
new	O	O
RCT	O	O
and	O	O
meta	O	O
-	O	O
analysis	O	O
suggest	O	O
that	O	O
the	O	O
risk	O	O
for	O	O
hemorrhagic	O	O
strokes	B-Disease	D020521
in	O	O
women	O	O
is	O	O
not	O	O
statistically	O	O
significantly	O	O
increased	O	O
.	O	O

LIMITATIONS	O	O
:	O	O
New	O	O
evidence	O	O
on	O	O
aspirin	B-Chemical	D001241
for	O	O
the	O	O
primary	O	O
prevention	O	O
of	O	O
CVD	B-Disease	D002318
is	O	O
limited	O	O
.	O	O

The	O	O
dose	O	O
of	O	O
aspirin	B-Chemical	D001241
used	O	O
in	O	O
the	O	O
RCTs	O	O
varied	O	O
,	O	O
which	O	O
prevented	O	O
the	O	O
estimation	O	O
of	O	O
the	O	O
most	O	O
appropriate	O	O
dose	O	O
for	O	O
primary	O	O
prevention	O	O
.	O	O

Several	O	O
of	O	O
the	O	O
RCTs	O	O
were	O	O
conducted	O	O
within	O	O
populations	O	O
of	O	O
health	O	O
professionals	O	O
,	O	O
which	O	O
potentially	O	O
limits	O	O
generalizability	O	O
.	O	O

CONCLUSION	O	O
:	O	O
Aspirin	B-Chemical	D001241
reduces	O	O
the	O	O
risk	O	O
for	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
in	O	O
men	O	O
and	O	O
strokes	B-Disease	D020521
in	O	O
women	O	O
.	O	O

Aspirin	B-Chemical	D001241
use	O	O
increases	O	O
the	O	O
risk	O	O
for	O	O
serious	O	O
bleeding	B-Disease	D006470
events	O	O
.	O	O

Reducing	O	O
harm	O	O
associated	O	O
with	O	O
anticoagulation	O	O
:	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B-Chemical	C031942
therapy	O	O
in	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

Argatroban	B-Chemical	C031942
is	O	O
a	O	O
hepatically	O	O
metabolized	O	O
,	O	O
direct	O	O
thrombin	O	O
inhibitor	O	O
used	O	O
for	O	O
prophylaxis	O	O
or	O	O
treatment	O	O
of	O	O
thrombosis	B-Disease	D013927
in	O	O
heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
(	O	O
HIT	B-Disease	D013921
)	O	O
and	O	O
for	O	O
patients	O	O
with	O	O
or	O	O
at	O	O
risk	O	O
of	O	O
HIT	B-Disease	D013921
undergoing	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
(	O	O
PCI	O	O
)	O	O
.	O	O

The	O	O
objective	O	O
of	O	O
this	O	O
review	O	O
is	O	O
to	O	O
summarize	O	O
practical	O	O
considerations	O	O
of	O	O
argatroban	B-Chemical	C031942
therapy	O	O
in	O	O
HIT	B-Disease	D013921
.	O	O

The	O	O
US	O	O
FDA	O	O
-	O	O
recommended	O	O
argatroban	B-Chemical	C031942
dose	O	O
in	O	O
HIT	B-Disease	D013921
is	O	O
2	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
(	O	O
reduced	O	O
in	O	O
patients	O	O
with	O	O
hepatic	B-Disease	D008107
impairment	I-Disease	D008107
and	O	O
in	O	O
paediatric	O	O
patients	O	O
)	O	O
,	O	O
adjusted	O	O
to	O	O
achieve	O	O
activated	O	O
partial	O	O
thromboplastin	O	O
times	O	O
(	O	O
aPTTs	O	O
)	O	O
1	O	O
.	O	O

5	O	O
-	O	O
3	O	O
times	O	O
baseline	O	O
(	O	O
not	O	O
>100	O	O
seconds	O	O
)	O	O
.	O	O

Contemporary	O	O
experiences	O	O
indicate	O	O
that	O	O
reduced	O	O
doses	O	O
are	O	O
also	O	O
needed	O	O
in	O	O
patients	O	O
with	O	O
conditions	O	O
associated	O	O
with	O	O
hepatic	O	O
hypoperfusion	O	O
,	O	O
e	O	O
.	O	O

g	O	O
.	O	O

heart	B-Disease	D006333
failure	I-Disease	D006333
,	O	O
yet	O	O
are	O	O
unnecessary	O	O
for	O	O
renal	B-Disease	D007674
dysfunction	I-Disease	D007674
,	O	O
adult	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
race	O	O
/	O	O
ethnicity	O	O
or	O	O
obesity	B-Disease	D009765
.	O	O

Argatroban	B-Chemical	C031942
0	O	O
.	O	O

5	O	O
-	O	O
1	O	O
.	O	O

2	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
typically	O	O
supports	O	O
therapeutic	O	O
aPTTs	O	O
.	O	O

The	O	O
FDA	O	O
-	O	O
recommended	O	O
dose	O	O
during	O	O
PCI	O	O
is	O	O
25	O	O
microg	O	O
/	O	O
kg	O	O
/	O	O
min	O	O
(	O	O
350	O	O
microg	O	O
/	O	O
kg	O	O
initial	O	O
bolus	O	O
)	O	O
,	O	O
adjusted	O	O
to	O	O
achieve	O	O
activated	O	O
clotting	O	O
times	O	O
(	O	O
ACTs	O	O
)	O	O
of	O	O
300	O	O
-	O	O
450	O	O
sec	O	O
.	O	O

For	O	O
PCI	O	O
,	O	O
argatroban	B-Chemical	C031942
has	O	O
not	O	O
been	O	O
investigated	O	O
in	O	O
hepatically	O	O
impaired	O	O
patients	O	O
;	O	O
dose	O	O
adjustment	O	O
is	O	O
unnecessary	O	O
for	O	O
adult	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
race	O	O
/	O	O
ethnicity	O	O
or	O	O
obesity	B-Disease	D009765
,	O	O
and	O	O
lesser	O	O
doses	O	O
may	O	O
be	O	O
adequate	O	O
with	O	O
concurrent	O	O
glycoprotein	O	O
IIb	O	O
/	O	O
IIIa	O	O
inhibition	O	O
.	O	O

Argatroban	B-Chemical	C031942
prolongs	O	O
the	O	O
International	O	O
Normalized	O	O
Ratio	O	O
,	O	O
and	O	O
published	O	O
approaches	O	O
for	O	O
monitoring	O	O
the	O	O
argatroban	B-Chemical	C031942
-	O	O
to	O	O
-	O	O
warfarin	B-Chemical	D014859
transition	O	O
should	O	O
be	O	O
followed	O	O
.	O	O

Major	O	O
bleeding	B-Disease	D006470
with	O	O
argatroban	B-Chemical	C031942
is	O	O
0	O	O
-	O	O
10%	O	O
in	O	O
the	O	O
non	O	O
-	O	O
interventional	O	O
setting	O	O
and	O	O
0	O	O
-	O	O
5	O	O
.	O	O

8%	O	O
periprocedurally	O	O
.	O	O

Argatroban	B-Chemical	C031942
has	O	O
no	O	O
specific	O	O
antidote	O	O
,	O	O
and	O	O
if	O	O
excessive	O	O
anticoagulation	O	O
occurs	O	O
,	O	O
argatroban	B-Chemical	C031942
infusion	O	O
should	O	O
be	O	O
stopped	O	O
or	O	O
reduced	O	O
.	O	O

Improved	O	O
familiarity	O	O
of	O	O
healthcare	O	O
professionals	O	O
with	O	O
argatroban	B-Chemical	C031942
therapy	O	O
in	O	O
HIT	B-Disease	D013921
,	O	O
including	O	O
in	O	O
special	O	O
populations	O	O
and	O	O
during	O	O
PCI	O	O
,	O	O
may	O	O
facilitate	O	O
reduction	O	O
of	O	O
harm	O	O
associated	O	O
with	O	O
HIT	B-Disease	D013921
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

fewer	O	O
thromboses	O	O
)	O	O
or	O	O
its	O	O
treatment	O	O
(	O	O
e	O	O
.	O	O

g	O	O
.	O	O

fewer	O	O
argatroban	B-Chemical	C031942
medication	O	O
errors	O	O
)	O	O
.	O	O

Rhabdomyolysis	B-Disease	D012206
and	O	O
brain	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
in	O	O
a	O	O
heroin	B-Chemical	D003932
-	O	O
dependent	O	O
male	O	O
under	O	O
methadone	B-Chemical	D008691
maintenance	O	O
therapy	O	O
.	O	O

OBJECTIVE	O	O
:	O	O
There	O	O
are	O	O
several	O	O
complications	O	O
associated	O	O
with	O	O
heroin	B-Chemical	D003932
abuse	O	O
,	O	O
some	O	O
of	O	O
which	O	O
are	O	O
life	O	O
-	O	O
threatening	O	O
.	O	O

Methadone	B-Chemical	D008691
may	O	O
aggravate	O	O
this	O	O
problem	O	O
.	O	O

METHOD	O	O
:	O	O
A	O	O
clinical	O	O
case	O	O
description	O	O
.	O	O

RESULTS	O	O
:	O	O
A	O	O
33	O	O
-	O	O
year	O	O
-	O	O
old	O	O
man	O	O
presented	O	O
with	O	O
rhabdomyolysis	B-Disease	D012206
and	O	O
cerebral	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
after	O	O
intravenous	O	O
heroin	B-Chemical	D003932
.	O	O

He	O	O
had	O	O
used	O	O
heroin	B-Chemical	D003932
since	O	O
age	O	O
20	O	O
,	O	O
and	O	O
had	O	O
used	O	O
150	O	O
mg	O	O
methadone	B-Chemical	D008691
daily	O	O
for	O	O
6	O	O
months	O	O
.	O	O

He	O	O
was	O	O
found	O	O
unconsciousness	B-Disease	D014474
at	O	O
home	O	O
and	O	O
was	O	O
sent	O	O
to	O	O
our	O	O
hospital	O	O
.	O	O

In	O	O
the	O	O
ER	O	O
,	O	O
his	O	O
opiate	O	O
level	O	O
was	O	O
4497	O	O
ng	O	O
/	O	O
ml	O	O
.	O	O

In	O	O
the	O	O
ICU	O	O
,	O	O
we	O	O
found	O	O
rhabdomyolysis	B-Disease	D012206
,	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
and	O	O
acute	O	O
respiratory	B-Disease	D012131
failure	I-Disease	D012131
.	O	O

After	O	O
transfer	O	O
to	O	O
an	O	O
internal	O	O
ward	O	O
,	O	O
we	O	O
noted	O	O
aphasia	B-Disease	D001037
and	O	O
weakness	B-Disease	D018908
of	O	O
his	O	O
left	O	O
limbs	O	O
.	O	O

After	O	O
MRI	O	O
,	O	O
we	O	O
found	O	O
cerebral	B-Disease	D002544
ischemic	I-Disease	D002544
infarction	I-Disease	D002544
.	O	O

CONCLUSION	O	O
:	O	O
Those	O	O
using	O	O
methadone	B-Chemical	D008691
and	O	O
heroin	B-Chemical	D003932
simultaneously	O	O
may	O	O
increase	O	O
risk	O	O
of	O	O
rhabdomyolysis	B-Disease	D012206
and	O	O
ischemic	B-Disease	D002544
stroke	I-Disease	D002544
.	O	O

Patients	O	O
under	O	O
methadone	B-Chemical	D008691
maintenance	O	O
therapy	O	O
should	O	O
be	O	O
warned	O	O
regarding	O	O
these	O	O
serious	O	O
adverse	O	O
events	O	O
.	O	O

Hypotheses	O	O
of	O	O
heroin	B-Chemical	D003932
-	O	O
related	O	O
rhabdomyolysis	B-Disease	D012206
and	O	O
stroke	B-Disease	D020521
in	O	O
heroin	B-Chemical	D003932
abusers	O	O
are	O	O
discussed	O	O
.	O	O

Increased	O	O
vulnerability	O	O
to	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
hydroxydopamine	I-Chemical	D016627
lesion	O	O
and	O	O
reduced	O	O
development	O	O
of	O	O
dyskinesias	B-Disease	D004409
in	O	O
mice	O	O
lacking	O	O
CB1	O	O
cannabinoid	O	O
receptors	O	O
.	O	O

Motor	O	O
impairment	O	O
,	O	O
dopamine	B-Chemical	D004298
(	O	O
DA	B-Chemical	D004298
)	O	O
neuronal	O	O
activity	O	O
and	O	O
proenkephalin	B-Chemical	C029992
(	O	O
PENK	B-Chemical	C029992
)	O	O
gene	O	O
expression	O	O
in	O	O
the	O	O
caudate	O	O
-	O	O
putamen	O	O
(	O	O
CPu	O	O
)	O	O
were	O	O
measured	O	O
in	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
-	O	O
lesioned	O	O
and	O	O
treated	O	O
(	O	O
L	B-Chemical	C005177
-	I-Chemical	C005177
DOPA+benserazide	I-Chemical	C005177
)	O	O
CB1	O	O
KO	O	O
and	O	O
WT	O	O
mice	O	O
.	O	O

A	O	O
lesion	O	O
induced	O	O
by	O	O
6	B-Chemical	D016627
-	I-Chemical	D016627
OHDA	I-Chemical	D016627
produced	O	O
more	O	O
severe	O	O
motor	O	O
deterioration	O	O
in	O	O
CB1	O	O
KO	O	O
mice	O	O
accompanied	O	O
by	O	O
more	O	O
loss	O	O
of	O	O
DA	B-Chemical	D004298
neurons	O	O
and	O	O
increased	O	O
PENK	B-Chemical	C029992
gene	O	O
expression	O	O
in	O	O
the	O	O
CPu	O	O
.	O	O

Oxidative	O	O
/	O	O
nitrosative	O	O
and	O	O
neuroinflammatory	O	O
parameters	O	O
were	O	O
estimated	O	O
in	O	O
the	O	O
CPu	O	O
and	O	O
cingulate	O	O
cortex	O	O
(	O	O
Cg	O	O
)	O	O
.	O	O

CB1	O	O
KO	O	O
mice	O	O
exhibited	O	O
higher	O	O
MDA	B-Chemical	D008315
levels	O	O
and	O	O
iNOS	O	O
protein	O	O
expression	O	O
in	O	O
the	O	O
CPu	O	O
and	O	O
Cg	O	O
compared	O	O
to	O	O
WT	O	O
mice	O	O
.	O	O

Treatment	O	O
with	O	O
L	B-Chemical	C005177
-	I-Chemical	C005177
DOPA+benserazide	I-Chemical	C005177
(	O	O
12	O	O
weeks	O	O
)	O	O
resulted	O	O
in	O	O
less	O	O
severe	O	O
dyskinesias	B-Disease	D004409
in	O	O
CB1	O	O
KO	O	O
than	O	O
in	O	O
WT	O	O
mice	O	O
.	O	O

The	O	O
results	O	O
revealed	O	O
that	O	O
the	O	O
lack	O	O
of	O	O
cannabinoid	O	O
CB1	O	O
receptors	O	O
increased	O	O
the	O	O
severity	O	O
of	O	O
motor	O	O
impairment	O	O
and	O	O
DA	B-Chemical	D004298
lesion	O	O
,	O	O
and	O	O
reduced	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
activation	O	O
of	O	O
CB1	O	O
receptors	O	O
offers	O	O
neuroprotection	O	O
against	O	O
dopaminergic	O	O
lesion	O	O
and	O	O
the	O	O
development	O	O
of	O	O
L	B-Chemical	D007980
-	I-Chemical	D007980
DOPA	I-Chemical	D007980
-	O	O
induced	O	O
dyskinesias	B-Disease	D004409
.	O	O

Animal	O	O
model	O	O
of	O	O
mania	B-Disease	D001714
induced	O	O
by	O	O
ouabain	B-Chemical	D010042
:	O	O
Evidence	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
submitochondrial	O	O
particles	O	O
of	O	O
the	O	O
rat	O	O
brain	O	O
.	O	O

The	O	O
intracerebroventricular	O	O
(	O	O
ICV	O	O
)	O	O
administration	O	O
of	O	O
ouabain	B-Chemical	D010042
(	O	O
a	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
/	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
ATPase	O	O
inhibitor	O	O
)	O	O
in	O	O
rats	O	O
has	O	O
been	O	O
suggested	O	O
to	O	O
mimic	O	O
some	O	O
symptoms	O	O
of	O	O
human	O	O
bipolar	B-Disease	D001714
mania	I-Disease	D001714
.	O	O

Clinical	O	O
studies	O	O
have	O	O
shown	O	O
that	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
may	O	O
be	O	O
related	O	O
to	O	O
mitochondrial	B-Disease	D028361
dysfunction	I-Disease	D028361
.	O	O

Herein	O	O
,	O	O
we	O	O
investigated	O	O
the	O	O
behavioral	O	O
and	O	O
biochemical	O	O
effects	O	O
induced	O	O
by	O	O
the	O	O
ICV	O	O
administration	O	O
of	O	O
ouabain	B-Chemical	D010042
in	O	O
rats	O	O
.	O	O

To	O	O
achieve	O	O
this	O	O
aim	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
ouabain	B-Chemical	D010042
injection	O	O
immediately	O	O
after	O	O
and	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
ICV	O	O
administration	O	O
(	O	O
at	O	O
concentrations	O	O
of	O	O
10	O	O
(	O	O
-	O	O
2	O	O
)	O	O
and	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
M	O	O
)	O	O
on	O	O
locomotion	O	O
was	O	O
measured	O	O
using	O	O
the	O	O
open	O	O
-	O	O
field	O	O
test	O	O
.	O	O

Additionally	O	O
,	O	O
thiobarbituric	B-Chemical	C029684
acid	I-Chemical	C029684
reactive	O	O
substances	O	O
(	O	O
TBARSs	O	O
)	O	O
and	O	O
superoxide	B-Chemical	D013481
production	O	O
were	O	O
measured	O	O
in	O	O
submitochondrial	O	O
particles	O	O
of	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
hippocampus	O	O
,	O	O
striatum	O	O
and	O	O
amygdala	O	O
.	O	O

Our	O	O
findings	O	O
demonstrated	O	O
that	O	O
ouabain	B-Chemical	D010042
at	O	O
10	O	O
(	O	O
-	O	O
2	O	O
)	O	O
and	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
M	O	O
induced	O	O
hyperlocomotion	B-Disease	D009069
in	O	O
rats	O	O
,	O	O
and	O	O
this	O	O
response	O	O
remained	O	O
up	O	O
to	O	O
7	O	O
days	O	O
following	O	O
a	O	O
single	O	O
ICV	O	O
injection	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
the	O	O
persistent	O	O
increase	O	O
in	O	O
the	O	O
rat	O	O
spontaneous	O	O
locomotion	O	O
is	O	O
associated	O	O
with	O	O
increased	O	O
TBARS	O	O
levels	O	O
and	O	O
superoxide	B-Chemical	D013481
generation	O	O
in	O	O
submitochondrial	O	O
particles	O	O
in	O	O
the	O	O
prefrontal	O	O
cortex	O	O
,	O	O
striatum	O	O
and	O	O
amygdala	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
ouabain	B-Chemical	D010042
-	O	O
induced	O	O
mania	B-Disease	D001714
-	O	O
like	O	O
behavior	O	O
may	O	O
provide	O	O
a	O	O
useful	O	O
animal	O	O
model	O	O
to	O	O
test	O	O
the	O	O
hypothesis	O	O
of	O	O
the	O	O
involvement	O	O
of	O	O
oxidative	O	O
stress	O	O
in	O	O
bipolar	B-Disease	D001714
disorder	I-Disease	D001714
.	O	O

Intraoperative	O	O
dialysis	O	O
during	O	O
liver	O	O
transplantation	O	O
with	O	O
citrate	B-Chemical	D019343
dialysate	O	O
.	O	O

Liver	O	O
transplantation	O	O
for	O	O
acutely	O	O
ill	O	O
patients	O	O
with	O	O
fulminant	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
carries	O	O
high	O	O
intraoperative	O	O
and	O	O
immediate	O	O
postoperative	O	O
risks	O	O
.	O	O

These	O	O
are	O	O
increased	O	O
with	O	O
the	O	O
presence	O	O
of	O	O
concomitant	O	O
acute	B-Disease	D058186
kidney	I-Disease	D058186
injury	I-Disease	D058186
(	O	O
AKI	B-Disease	D058186
)	O	O
and	O	O
intraoperative	O	O
dialysis	O	O
is	O	O
sometimes	O	O
required	O	O
to	O	O
allow	O	O
the	O	O
transplant	O	O
to	O	O
proceed	O	O
.	O	O

The	O	O
derangements	O	O
in	O	O
the	O	O
procoagulant	O	O
and	O	O
anticoagulant	O	O
pathways	O	O
during	O	O
fulminant	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
can	O	O
lead	O	O
to	O	O
difficulties	O	O
with	O	O
anticoagulation	O	O
during	O	O
dialysis	O	O
,	O	O
especially	O	O
when	O	O
continued	O	O
in	O	O
the	O	O
operating	O	O
room	O	O
.	O	O

Systemic	O	O
anticoagulation	O	O
is	O	O
unsafe	O	O
and	O	O
regional	O	O
citrate	B-Chemical	D019343
anticoagulation	O	O
in	O	O
the	O	O
absence	O	O
of	O	O
a	O	O
functional	O	O
liver	O	O
carries	O	O
the	O	O
risk	O	O
of	O	O
citrate	B-Chemical	D019343
toxicity	B-Disease	D064420
.	O	O

Citrate	B-Chemical	D019343
dialysate	O	O
,	O	O
a	O	O
new	O	O
dialysate	O	O
with	O	O
citric	B-Chemical	D019343
acid	I-Chemical	D019343
can	O	O
be	O	O
used	O	O
for	O	O
anticoagulation	O	O
in	O	O
patients	O	O
who	O	O
cannot	O	O
tolerate	O	O
heparin	B-Chemical	D006493
or	O	O
regional	O	O
citrate	B-Chemical	D019343
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
a	O	O
40	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
with	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
fulminant	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
with	O	O
associated	O	O
AKI	B-Disease	D058186
who	O	O
underwent	O	O
intraoperative	O	O
dialytic	O	O
support	O	O
during	O	O
liver	O	O
transplantation	O	O
anticoagulated	O	O
with	O	O
citrate	B-Chemical	D019343
dialysate	O	O
during	O	O
the	O	O
entire	O	O
procedure	O	O
.	O	O

The	O	O
patient	O	O
tolerated	O	O
the	O	O
procedure	O	O
well	O	O
without	O	O
any	O	O
signs	O	O
of	O	O
citrate	B-Chemical	D019343
toxicity	B-Disease	D064420
and	O	O
maintained	O	O
adequate	O	O
anticoagulation	O	O
for	O	O
patency	O	O
of	O	O
the	O	O
dialysis	O	O
circuit	O	O
.	O	O

Citrate	B-Chemical	D019343
dialysate	O	O
is	O	O
a	O	O
safe	O	O
alternative	O	O
for	O	O
intradialytic	O	O
support	O	O
of	O	O
liver	O	O
transplantation	O	O
in	O	O
fulminant	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

Delirium	B-Disease	D003693
in	O	O
a	O	O
patient	O	O
with	O	O
toxic	O	O
flecainide	B-Chemical	D005424
plasma	O	O
concentrations	O	O
:	O	O
the	O	O
role	O	O
of	O	O
a	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
with	O	O
paroxetine	B-Chemical	D017374
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
describe	O	O
a	O	O
case	O	O
of	O	O
flecainide	B-Chemical	D005424
-	O	O
induced	O	O
delirium	B-Disease	D003693
associated	O	O
with	O	O
a	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
with	O	O
paroxetine	B-Chemical	D017374
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
69	O	O
-	O	O
year	O	O
-	O	O
old	O	O
white	O	O
female	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
a	O	O
history	O	O
of	O	O
confusion	B-Disease	D003221
and	O	O
paranoia	B-Disease	D010259
over	O	O
the	O	O
past	O	O
several	O	O
days	O	O
.	O	O

On	O	O
admission	O	O
the	O	O
patient	O	O
was	O	O
taking	O	O
carvedilol	B-Chemical	C043211
12	O	O
mg	O	O
twice	O	O
daily	O	O
,	O	O
warfarin	B-Chemical	D014859
2	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
folic	B-Chemical	D005492
acid	I-Chemical	D005492
1	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
levothyroxine	B-Chemical	D013974
100	O	O
microg	O	O
/	O	O
day	O	O
,	O	O
pantoprazole	B-Chemical	C064276
40	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
paroxetine	B-Chemical	D017374
40	O	O
mg	O	O
/	O	O
day	O	O
,	O	O
and	O	O
flecainide	B-Chemical	D005424
100	O	O
mg	O	O
twice	O	O
daily	O	O
.	O	O

Flecainide	B-Chemical	D005424
had	O	O
been	O	O
started	O	O
2	O	O
weeks	O	O
prior	O	O
for	O	O
atrial	B-Disease	D001281
fibrillation	I-Disease	D001281
.	O	O

Laboratory	O	O
test	O	O
findings	O	O
on	O	O
admission	O	O
were	O	O
notable	O	O
only	O	O
for	O	O
a	O	O
flecainide	B-Chemical	D005424
plasma	O	O
concentration	O	O
of	O	O
1360	O	O
microg	O	O
/	O	O
L	O	O
(	O	O
reference	O	O
range	O	O
200	O	O
-	O	O
1000	O	O
)	O	O
.	O	O

A	O	O
metabolic	O	O
drug	O	O
interaction	O	O
between	O	O
flecainide	B-Chemical	D005424
and	O	O
paroxetine	B-Chemical	D017374
,	O	O
which	O	O
the	O	O
patient	O	O
had	O	O
been	O	O
taking	O	O
for	O	O
more	O	O
than	O	O
5	O	O
years	O	O
,	O	O
was	O	O
considered	O	O
.	O	O

Paroxetine	B-Chemical	D017374
was	O	O
discontinued	O	O
and	O	O
the	O	O
dose	O	O
of	O	O
flecainide	B-Chemical	D005424
was	O	O
reduced	O	O
to	O	O
50	O	O
mg	O	O
twice	O	O
daily	O	O
.	O	O

Her	O	O
delirium	B-Disease	D003693
resolved	O	O
3	O	O
days	O	O
later	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Flecainide	B-Chemical	D005424
and	O	O
pharmacologically	O	O
similar	O	O
agents	O	O
that	O	O
interact	O	O
with	O	O
sodium	B-Chemical	D012964
channels	O	O
may	O	O
cause	O	O
delirium	B-Disease	D003693
in	O	O
susceptible	O	O
patients	O	O
.	O	O

A	O	O
MEDLINE	O	O
search	O	O
(	O	O
1966	O	O
-	O	O
January	O	O
2009	O	O
)	O	O
revealed	O	O
one	O	O
in	O	O
vivo	O	O
pharmacokinetic	O	O
study	O	O
on	O	O
the	O	O
interaction	O	O
between	O	O
flecainide	B-Chemical	D005424
,	O	O
a	O	O
CYP2D6	O	O
substrate	O	O
,	O	O
and	O	O
paroxetine	B-Chemical	D017374
,	O	O
a	O	O
CYP2D6	O	O
inhibitor	O	O
,	O	O
as	O	O
well	O	O
as	O	O
3	O	O
case	O	O
reports	O	O
of	O	O
flecainide	B-Chemical	D005424
-	O	O
induced	O	O
delirium	B-Disease	D003693
.	O	O

According	O	O
to	O	O
the	O	O
Naranjo	O	O
probability	O	O
scale	O	O
,	O	O
flecainide	B-Chemical	D005424
was	O	O
the	O	O
probable	O	O
cause	O	O
of	O	O
the	O	O
patient's	O	O
delirium	B-Disease	D003693
;	O	O
the	O	O
Horn	O	O
Drug	O	O
Interaction	O	O
Probability	O	O
Scale	O	O
indicates	O	O
a	O	O
possible	O	O
pharmacokinetic	O	O
drug	O	O
interaction	O	O
between	O	O
flecainide	B-Chemical	D005424
and	O	O
paroxetine	B-Chemical	D017374
.	O	O

CONCLUSIONS	O	O
:	O	O
Supratherapeutic	O	O
flecainide	B-Chemical	D005424
plasma	O	O
concentrations	O	O
may	O	O
cause	O	O
delirium	B-Disease	D003693
.	O	O

Because	O	O
toxicity	B-Disease	D064420
may	O	O
occur	O	O
when	O	O
flecainide	B-Chemical	D005424
is	O	O
prescribed	O	O
with	O	O
paroxetine	B-Chemical	D017374
and	O	O
other	O	O
potent	O	O
CYP2D6	O	O
inhibitors	O	O
,	O	O
flecainide	B-Chemical	D005424
plasma	O	O
concentrations	O	O
should	O	O
be	O	O
monitored	O	O
closely	O	O
with	O	O
commencement	O	O
of	O	O
CYP2D6	O	O
inhibitors	O	O
.	O	O

Efficacy	O	O
of	O	O
everolimus	B-Chemical	C107135
(	O	O
RAD001	B-Chemical	C107135
)	O	O
in	O	O
patients	O	O
with	O	O
advanced	O	O
NSCLC	B-Disease	D002289
previously	O	O
treated	O	O
with	O	O
chemotherapy	O	O
alone	O	O
or	O	O
with	O	O
chemotherapy	O	O
and	O	O
EGFR	O	O
inhibitors	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Treatment	O	O
options	O	O
are	O	O
scarce	O	O
in	O	O
pretreated	O	O
advanced	O	O
non	B-Disease	D002289
-	I-Disease	D002289
small	I-Disease	D002289
-	I-Disease	D002289
cell	I-Disease	D002289
lung	I-Disease	D002289
cancer	I-Disease	D002289
(	O	O
NSCLC	B-Disease	D002289
)	O	O
patients	O	O
.	O	O

RAD001	B-Chemical	C107135
,	O	O
an	O	O
oral	O	O
inhibitor	O	O
of	O	O
the	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-Chemical	D020123
(	O	O
mTOR	O	O
)	O	O
,	O	O
has	O	O
shown	O	O
phase	O	O
I	O	O
efficacy	O	O
in	O	O
NSCLC	B-Disease	D002289
.	O	O

METHODS	O	O
:	O	O
Stage	O	O
IIIb	O	O
or	O	O
IV	O	O
NSCLC	B-Disease	D002289
patients	O	O
,	O	O
with	O	O
two	O	O
or	O	O
fewer	O	O
prior	O	O
chemotherapy	O	O
regimens	O	O
,	O	O
one	O	O
platinum	B-Chemical	D010984
based	O	O
(	O	O
stratum	O	O
1	O	O
)	O	O
or	O	O
both	O	O
chemotherapy	O	O
and	O	O
epidermal	O	O
growth	O	O
factor	O	O
receptor	O	O
tyrosine	B-Chemical	D014443
kinase	O	O
inhibitors	O	O
(	O	O
stratum	O	O
2	O	O
)	O	O
,	O	O
received	O	O
RAD001	B-Chemical	C107135
10	O	O
mg	O	O
/	O	O
day	O	O
until	O	O
progression	O	O
or	O	O
unacceptable	O	O
toxicity	B-Disease	D064420
.	O	O

Primary	O	O
objective	O	O
was	O	O
overall	O	O
response	O	O
rate	O	O
(	O	O
ORR	O	O
)	O	O
.	O	O

Analyses	O	O
of	O	O
markers	O	O
associated	O	O
with	O	O
the	O	O
mTOR	O	O
pathway	O	O
were	O	O
carried	O	O
out	O	O
on	O	O
archival	O	O
tumor	B-Disease	D009369
from	O	O
a	O	O
subgroup	O	O
using	O	O
immunohistochemistry	O	O
(	O	O
IHC	O	O
)	O	O
and	O	O
direct	O	O
mutation	O	O
sequencing	O	O
.	O	O

RESULTS	O	O
:	O	O
Eighty	O	O
-	O	O
five	O	O
patients	O	O
were	O	O
enrolled	O	O
,	O	O
42	O	O
in	O	O
stratum	O	O
1	O	O
and	O	O
43	O	O
in	O	O
stratum	O	O
.	O	O

ORR	O	O
was	O	O
4	O	O
.	O	O

7%	O	O
(	O	O
7	O	O
.	O	O

1%	O	O
stratum	O	O
1	O	O
;	O	O
2	O	O
.	O	O

3%	O	O
stratum	O	O
2	O	O
)	O	O
.	O	O

Overall	O	O
disease	O	O
control	O	O
rate	O	O
was	O	O
47	O	O
.	O	O

1%	O	O
.	O	O

Median	O	O
progression	O	O
-	O	O
free	O	O
survivals	O	O
(	O	O
PFSs	O	O
)	O	O
were	O	O
2	O	O
.	O	O

6	O	O
(	O	O
stratum	O	O
1	O	O
)	O	O
and	O	O
2	O	O
.	O	O

7	O	O
months	O	O
(	O	O
stratum	O	O
2	O	O
)	O	O
.	O	O

Common	O	O
>	O	O
or	O	O
=grade	O	O
3	O	O
events	O	O
were	O	O
fatigue	B-Disease	D005221
,	O	O
dyspnea	B-Disease	D004417
,	O	O
stomatitis	B-Disease	D013280
,	O	O
anemia	B-Disease	D000740
,	O	O
and	O	O
thrombocytopenia	B-Disease	D013921
.	O	O

Pneumonitis	B-Disease	D011014
,	O	O
probably	O	O
or	O	O
possibly	O	O
related	O	O
,	O	O
mainly	O	O
grade	O	O
1	O	O
/	O	O
2	O	O
,	O	O
occurred	O	O
in	O	O
25%	O	O
.	O	O

Cox	O	O
regression	O	O
analysis	O	O
of	O	O
IHC	O	O
scores	O	O
found	O	O
that	O	O
only	O	O
phospho	O	O
AKT	O	O
(	O	O
pAKT	O	O
)	O	O
was	O	O
a	O	O
significant	O	O
independent	O	O
predictor	O	O
of	O	O
worse	O	O
PFS	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
RAD001	B-Chemical	C107135
10	O	O
mg	O	O
/	O	O
day	O	O
was	O	O
well	O	O
tolerated	O	O
,	O	O
showing	O	O
modest	O	O
clinical	O	O
activity	O	O
in	O	O
pretreated	O	O
NSCLC	B-Disease	D002289
.	O	O

Evaluation	O	O
of	O	O
RAD001	B-Chemical	C107135
plus	O	O
standard	O	O
therapy	O	O
for	O	O
metastatic	O	O
NSCLC	B-Disease	D002289
continues	O	O
.	O	O

Posttransplant	O	O
anemia	B-Disease	D000740
:	O	O
the	O	O
role	O	O
of	O	O
sirolimus	B-Chemical	D020123
.	O	O

Posttransplant	O	O
anemia	B-Disease	D000740
is	O	O
a	O	O
common	O	O
problem	O	O
that	O	O
may	O	O
hinder	O	O
patients'	O	O
quality	O	O
of	O	O
life	O	O
.	O	O

It	O	O
occurs	O	O
in	O	O
12	O	O
to	O	O
76%	O	O
of	O	O
patients	O	O
,	O	O
and	O	O
is	O	O
most	O	O
common	O	O
in	O	O
the	O	O
immediate	O	O
posttransplant	O	O
period	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
factors	O	O
have	O	O
been	O	O
identified	O	O
that	O	O
increase	O	O
the	O	O
risk	O	O
of	O	O
posttransplant	O	O
anemia	B-Disease	D000740
,	O	O
of	O	O
which	O	O
the	O	O
level	O	O
of	O	O
renal	O	O
function	O	O
is	O	O
most	O	O
important	O	O
.	O	O

Sirolimus	B-Chemical	D020123
,	O	O
a	O	O
mammalian	O	O
target	O	O
of	O	O
rapamycin	B-Chemical	D020123
inhibitor	O	O
,	O	O
has	O	O
been	O	O
implicated	O	O
as	O	O
playing	O	O
a	O	O
special	O	O
role	O	O
in	O	O
posttransplant	O	O
anemia	B-Disease	D000740
.	O	O

This	O	O
review	O	O
considers	O	O
anemia	B-Disease	D000740
associated	O	O
with	O	O
sirolimus	B-Chemical	D020123
,	O	O
including	O	O
its	O	O
presentation	O	O
,	O	O
mechanisms	O	O
,	O	O
and	O	O
management	O	O
.	O	O

Coronary	O	O
computerized	O	O
tomography	O	O
angiography	O	O
for	O	O
rapid	O	O
discharge	O	O
of	O	O
low	O	O
-	O	O
risk	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
.	O	O

BACKGROUND	O	O
:	O	O
Most	O	O
patients	O	O
presenting	O	O
to	O	O
emergency	O	O
departments	O	O
(	O	O
EDs	O	O
)	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
are	O	O
admitted	O	O
for	O	O
at	O	O
least	O	O
12	O	O
hours	O	O
and	O	O
receive	O	O
a	O	O
"rule	O	O
out	O	O
acute	O	O
coronary	O	O
syndrome"	O	O
protocol	O	O
,	O	O
often	O	O
with	O	O
noninvasive	O	O
testing	O	O
prior	O	O
to	O	O
discharge	O	O
.	O	O

In	O	O
patients	O	O
without	O	O
cocaine	B-Chemical	D003042
use	O	O
,	O	O
coronary	O	O
computerized	O	O
tomography	O	O
angiography	O	O
(	O	O
CTA	O	O
)	O	O
has	O	O
been	O	O
shown	O	O
to	O	O
be	O	O
useful	O	O
for	O	O
identifying	O	O
a	O	O
group	O	O
of	O	O
patients	O	O
at	O	O
low	O	O
risk	O	O
for	O	O
cardiac	O	O
events	O	O
who	O	O
can	O	O
be	O	O
safely	O	O
discharged	O	O
.	O	O

It	O	O
is	O	O
unclear	O	O
whether	O	O
a	O	O
coronary	O	O
CTA	O	O
strategy	O	O
would	O	O
be	O	O
efficacious	O	O
in	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
as	O	O
coronary	B-Disease	D003329
vasospasm	I-Disease	D003329
may	O	O
account	O	O
for	O	O
some	O	O
of	O	O
the	O	O
ischemia	B-Disease	D007511
.	O	O

We	O	O
studied	O	O
whether	O	O
a	O	O
negative	O	O
coronary	O	O
CTA	O	O
in	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
could	O	O
identify	O	O
a	O	O
subset	O	O
safe	O	O
for	O	O
discharge	O	O
.	O	O

METHODS	O	O
:	O	O
We	O	O
prospectively	O	O
evaluated	O	O
the	O	O
safety	O	O
of	O	O
coronary	O	O
CTA	O	O
for	O	O
low	O	O
-	O	O
risk	O	O
patients	O	O
who	O	O
presented	O	O
to	O	O
the	O	O
ED	O	O
with	O	O
cocaineassociated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
(	O	O
self	O	O
-	O	O
reported	O	O
or	O	O
positive	O	O
urine	O	O
test	O	O
)	O	O
.	O	O

Consecutive	O	O
patients	O	O
received	O	O
either	O	O
immediate	O	O
coronary	O	O
CTA	O	O
in	O	O
the	O	O
ED	O	O
(	O	O
without	O	O
serial	O	O
markers	O	O
)	O	O
or	O	O
underwent	O	O
coronary	O	O
CTA	O	O
after	O	O
a	O	O
brief	O	O
observation	O	O
period	O	O
with	O	O
serial	O	O
cardiac	O	O
marker	O	O
measurements	O	O
.	O	O

Patients	O	O
with	O	O
negative	O	O
coronary	O	O
CTA	O	O
(	O	O
maximal	O	O
stenosis	B-Disease	D003251
less	O	O
than	O	O
50%	O	O
)	O	O
were	O	O
discharged	O	O
.	O	O

The	O	O
main	O	O
outcome	O	O
was	O	O
30	O	O
-	O	O
day	O	O
cardiovascular	O	O
death	O	O
or	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
.	O	O

RESULTS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
59	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
were	O	O
evaluated	O	O
.	O	O

Patients	O	O
had	O	O
a	O	O
mean	O	O
age	O	O
of	O	O
45	O	O
.	O	O

6	O	O
+	O	O
/	O	O
-	O	O
6	O	O
.	O	O

6	O	O
yrs	O	O
and	O	O
were	O	O
86%	O	O
black	O	O
,	O	O
66%	O	O
male	O	O
.	O	O

Seventy	O	O
-	O	O
nine	O	O
percent	O	O
had	O	O
a	O	O
normal	O	O
or	O	O
nonspecific	O	O
ECG	O	O
and	O	O
85%	O	O
had	O	O
a	O	O
TIMI	O	O
score	O	O
<2	O	O
.	O	O

Twenty	O	O
patients	O	O
received	O	O
coronary	O	O
CTA	O	O
immediately	O	O
in	O	O
the	O	O
ED	O	O
,	O	O
18	O	O
of	O	O
whom	O	O
were	O	O
discharged	O	O
following	O	O
CTA	O	O
(	O	O
90%	O	O
)	O	O
.	O	O

Thirty	O	O
-	O	O
nine	O	O
received	O	O
coronary	O	O
CTA	O	O
after	O	O
a	O	O
brief	O	O
observation	O	O
period	O	O
,	O	O
with	O	O
37	O	O
discharged	O	O
home	O	O
following	O	O
CTA	O	O
(	O	O
95%	O	O
)	O	O
.	O	O

Six	O	O
patients	O	O
had	O	O
coronary	B-Disease	D023921
stenosis	I-Disease	D023921
>or=50%	O	O
.	O	O

During	O	O
the	O	O
30	O	O
-	O	O
day	O	O
follow	O	O
-	O	O
up	O	O
period	O	O
,	O	O
no	O	O
patients	O	O
died	O	O
of	O	O
a	O	O
cardiovascular	O	O
event	O	O
(	O	O
0%	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
0	O	O
-	O	O
6	O	O
.	O	O

1%	O	O
)	O	O
and	O	O
no	O	O
patient	O	O
sustained	O	O
a	O	O
nonfatal	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
(	O	O
0%	O	O
;	O	O
95%	O	O
CI	O	O
,	O	O
0	O	O
-	O	O
6	O	O
.	O	O

1%	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Although	O	O
cocaine	B-Chemical	D003042
-	O	O
associated	O	O
myocardial	B-Disease	D017202
ischemia	I-Disease	D017202
can	O	O
result	O	O
from	O	O
coronary	O	O
vasoconstriction	O	O
,	O	O
patients	O	O
with	O	O
cocaine	B-Chemical	D003042
associated	O	O
chest	B-Disease	D002637
pain	I-Disease	D002637
,	O	O
a	O	O
non	O	O
-	O	O
ischemic	B-Disease	D007511
ECG	O	O
,	O	O
and	O	O
a	O	O
TIMI	O	O
risk	O	O
score	O	O
<2	O	O
may	O	O
be	O	O
safely	O	O
discharged	O	O
from	O	O
the	O	O
ED	O	O
after	O	O
a	O	O
negative	O	O
coronary	O	O
CTA	O	O
with	O	O
a	O	O
low	O	O
risk	O	O
of	O	O
30	O	O
-	O	O
day	O	O
adverse	O	O
events	O	O
.	O	O

Late	O	O
fulminant	O	O
posterior	B-Disease	D054038
reversible	I-Disease	D054038
encephalopathy	I-Disease	D054038
syndrome	I-Disease	D054038
after	O	O
liver	O	O
transplant	O	O
.	O	O

OBJECTIVES	O	O
:	O	O
Posterior	B-Disease	D054038
leukoencephalopathy	I-Disease	D054038
due	O	O
to	O	O
calcineurin	O	O
-	O	O
inhibitor	O	O
-	O	O
related	O	O
neurotoxicity	B-Disease	D020258
is	O	O
a	O	O
rare	O	O
but	O	O
severe	O	O
complication	O	O
that	O	O
results	O	O
from	O	O
treatment	O	O
with	O	O
immunosuppressive	O	O
agents	O	O
(	O	O
primarily	O	O
those	O	O
administered	O	O
after	O	O
a	O	O
liver	O	O
or	O	O
kidney	O	O
transplant	O	O
)	O	O
.	O	O

The	O	O
pathophysiologic	O	O
mechanisms	O	O
of	O	O
that	O	O
disorder	O	O
remain	O	O
unknown	O	O
.	O	O

CASE	O	O
:	O	O
We	O	O
report	O	O
the	O	O
case	O	O
of	O	O
a	O	O
46	O	O
-	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
who	O	O
received	O	O
a	O	O
liver	O	O
transplant	O	O
in	O	O
our	O	O
center	O	O
as	O	O
treatment	O	O
for	O	O
alcoholic	B-Disease	D008104
cirrhosis	I-Disease	D008104
and	O	O
in	O	O
whom	O	O
either	O	O
a	O	O
fulminant	O	O
course	O	O
of	O	O
posterior	B-Disease	D054038
leukoencephalopathy	I-Disease	D054038
or	O	O
posterior	B-Disease	D054038
reversible	I-Disease	D054038
encephalopathy	I-Disease	D054038
syndrome	I-Disease	D054038
developed	O	O
110	O	O
days	O	O
after	O	O
transplant	O	O
.	O	O

After	O	O
an	O	O
initially	O	O
uneventful	O	O
course	O	O
after	O	O
the	O	O
transplant	O	O
,	O	O
the	O	O
patient	O	O
rapidly	O	O
fell	O	O
into	O	O
deep	O	O
coma	O	O
.	O	O

RESULTS	O	O
:	O	O
Cerebral	O	O
MRI	O	O
scan	O	O
showed	O	O
typical	O	O
signs	O	O
of	O	O
enhancement	O	O
in	O	O
the	O	O
pontine	O	O
and	O	O
posterior	O	O
regions	O	O
.	O	O

Switching	O	O
the	O	O
immunosuppressive	O	O
regimen	O	O
from	O	O
tacrolimus	B-Chemical	D016559
to	O	O
cyclosporine	B-Chemical	D016572
did	O	O
not	O	O
improve	O	O
the	O	O
clinical	O	O
situation	O	O
.	O	O

The	O	O
termination	O	O
of	O	O
treatment	O	O
with	O	O
any	O	O
calcineurin	O	O
inhibitor	O	O
resulted	O	O
in	O	O
a	O	O
complete	O	O
resolution	O	O
of	O	O
that	O	O
complication	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Posterior	B-Disease	D054038
reversible	I-Disease	D054038
encephalopathy	I-Disease	D054038
syndrome	I-Disease	D054038
after	O	O
liver	O	O
transplant	O	O
is	O	O
rare	O	O
.	O	O

We	O	O
recommend	O	O
a	O	O
complete	O	O
cessation	O	O
of	O	O
any	O	O
calcineurin	O	O
inhibitor	O	O
rather	O	O
than	O	O
a	O	O
dose	O	O
reduction	O	O
.	O	O

Prolonged	O	O
hypothermia	B-Disease	D007035
as	O	O
a	O	O
bridge	O	O
to	O	O
recovery	O	O
for	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
and	O	O
intracranial	B-Disease	D019586
hypertension	I-Disease	D019586
associated	O	O
with	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
.	O	O

BACKGROUND	O	O
:	O	O
To	O	O
review	O	O
evidence	O	O
-	O	O
based	O	O
treatment	O	O
options	O	O
in	O	O
patients	O	O
with	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
complicating	O	O
fulminant	B-Disease	D017114
hepatic	I-Disease	D017114
failure	I-Disease	D017114
(	O	O
FHF	B-Disease	D017114
)	O	O
and	O	O
discuss	O	O
the	O	O
potential	O	O
applications	O	O
of	O	O
hypothermia	B-Disease	D007035
.	O	O

METHOD	O	O
:	O	O
Case	O	O
-	O	O
based	O	O
observations	O	O
from	O	O
a	O	O
medical	O	O
intensive	O	O
care	O	O
unit	O	O
(	O	O
MICU	O	O
)	O	O
in	O	O
a	O	O
tertiary	O	O
care	O	O
facility	O	O
in	O	O
a	O	O
27	O	O
-	O	O
year	O	O
-	O	O
old	O	O
female	O	O
with	O	O
FHF	B-Disease	D017114
from	O	O
acetaminophen	B-Chemical	D000082
and	O	O
resultant	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
.	O	O

RESULTS	O	O
:	O	O
Our	O	O
patient	O	O
was	O	O
admitted	O	O
to	O	O
the	O	O
MICU	O	O
after	O	O
being	O	O
found	O	O
unresponsive	O	O
with	O	O
presumed	O	O
toxicity	B-Disease	D064420
from	O	O
acetaminophen	B-Chemical	D000082
which	O	O
was	O	O
ingested	O	O
over	O	O
a	O	O
2	O	O
-	O	O
day	O	O
period	O	O
.	O	O

The	O	O
patient	O	O
had	O	O
depressed	O	O
of	O	O
mental	O	O
status	O	O
lasting	O	O
at	O	O
least	O	O
24	O	O
h	O	O
prior	O	O
to	O	O
admission	O	O
.	O	O

Initial	O	O
evaluation	O	O
confirmed	O	O
FHF	B-Disease	D017114
from	O	O
acetaminophen	B-Chemical	D000082
and	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
.	O	O

The	O	O
patient	O	O
was	O	O
treated	O	O
with	O	O
hyperosmolar	O	O
therapy	O	O
,	O	O
hyperventilation	B-Disease	D006985
,	O	O
sedation	O	O
,	O	O
and	O	O
chemical	O	O
paralysis	B-Disease	D010243
.	O	O

Her	O	O
intracranial	O	O
pressure	O	O
remained	O	O
elevated	O	O
despite	O	O
maximal	O	O
medical	O	O
therapy	O	O
.	O	O

We	O	O
then	O	O
initiated	O	O
therapeutic	O	O
hypothermia	B-Disease	D007035
which	O	O
was	O	O
continued	O	O
for	O	O
5	O	O
days	O	O
.	O	O

At	O	O
re	O	O
-	O	O
warming	O	O
,	O	O
patient	O	O
had	O	O
resolution	O	O
of	O	O
her	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
and	O	O
intracranial	B-Disease	D019586
hypertension	I-Disease	D019586
.	O	O

At	O	O
discharge	O	O
,	O	O
she	O	O
had	O	O
complete	O	O
recovery	O	O
of	O	O
neurological	O	O
and	O	O
hepatic	O	O
functions	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
patients	O	O
with	O	O
FHF	B-Disease	D017114
and	O	O
cerebral	B-Disease	D001929
edema	I-Disease	D001929
from	O	O
acetaminophen	B-Chemical	D000082
overdose	B-Disease	D062787
,	O	O
prolonged	O	O
therapeutic	O	O
hypothermia	B-Disease	D007035
could	O	O
potentially	O	O
be	O	O
used	O	O
as	O	O
a	O	O
life	O	O
saving	O	O
therapy	O	O
and	O	O
a	O	O
bridge	O	O
to	O	O
hepatic	O	O
and	O	O
neurological	O	O
recovery	O	O
.	O	O

A	O	O
clinical	O	O
trial	O	O
of	O	O
hypothermia	B-Disease	D007035
in	O	O
patients	O	O
with	O	O
this	O	O
condition	O	O
is	O	O
warranted	O	O
.	O	O

Binasal	B-Disease	D014786
visual	I-Disease	D014786
field	I-Disease	D014786
defects	I-Disease	D014786
are	O	O
not	O	O
specific	O	O
to	O	O
vigabatrin	B-Chemical	D020888
.	O	O

This	O	O
study	O	O
investigated	O	O
the	O	O
visual	B-Disease	D014786
defects	I-Disease	D014786
associated	O	O
with	O	O
the	O	O
antiepileptic	O	O
drug	O	O
vigabatrin	B-Chemical	D020888
(	O	O
VGB	B-Chemical	D020888
)	O	O
.	O	O

Two	O	O
hundred	O	O
four	O	O
people	O	O
with	O	O
epilepsy	B-Disease	D004827
were	O	O
grouped	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
antiepileptic	O	O
drug	O	O
therapy	O	O
(	O	O
current	O	O
,	O	O
previous	O	O
,	O	O
or	O	O
no	O	O
exposure	O	O
to	O	O
VGB	B-Chemical	D020888
)	O	O
.	O	O

Groups	O	O
were	O	O
matched	O	O
with	O	O
respect	O	O
to	O	O
age	O	O
,	O	O
gender	O	O
,	O	O
and	O	O
seizure	B-Disease	D012640
frequency	O	O
.	O	O

All	O	O
patients	O	O
underwent	O	O
objective	O	O
assessment	O	O
of	O	O
electrophysiological	O	O
function	O	O
(	O	O
wide	O	O
-	O	O
field	O	O
multifocal	O	O
electroretinography	O	O
)	O	O
and	O	O
conventional	O	O
visual	O	O
field	O	O
testing	O	O
(	O	O
static	O	O
perimetry	O	O
)	O	O
.	O	O

Bilateral	O	O
visual	O	O
field	O	O
constriction	O	O
was	O	O
observed	O	O
in	O	O
59%	O	O
of	O	O
patients	O	O
currently	O	O
taking	O	O
VGB	B-Chemical	D020888
,	O	O
43%	O	O
of	O	O
patients	O	O
who	O	O
previously	O	O
took	O	O
VGB	B-Chemical	D020888
,	O	O
and	O	O
24%	O	O
of	O	O
patients	O	O
with	O	O
no	O	O
exposure	O	O
to	O	O
VGB	B-Chemical	D020888
.	O	O

Assessment	O	O
of	O	O
retinal	O	O
function	O	O
revealed	O	O
abnormal	O	O
responses	O	O
in	O	O
48%	O	O
of	O	O
current	O	O
VGB	B-Chemical	D020888
users	O	O
and	O	O
22%	O	O
of	O	O
prior	O	O
VGB	B-Chemical	D020888
users	O	O
,	O	O
but	O	O
in	O	O
none	O	O
of	O	O
the	O	O
patients	O	O
without	O	O
previous	O	O
exposure	O	O
to	O	O
VGB	B-Chemical	D020888
.	O	O

Bilateral	B-Disease	D014786
visual	I-Disease	D014786
field	I-Disease	D014786
abnormalities	I-Disease	D014786
are	O	O
common	O	O
in	O	O
the	O	O
treated	O	O
epilepsy	B-Disease	D004827
population	O	O
,	O	O
irrespective	O	O
of	O	O
drug	O	O
history	O	O
.	O	O

Assessment	O	O
by	O	O
conventional	O	O
static	O	O
perimetry	O	O
may	O	O
neither	O	O
be	O	O
sufficiently	O	O
sensitive	O	O
nor	O	O
specific	O	O
to	O	O
reliably	O	O
identify	O	O
retinal	B-Disease	D012164
toxicity	I-Disease	D012164
associated	O	O
with	O	O
VGB	B-Chemical	D020888
.	O	O

Smoking	O	O
of	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
as	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
HIV	B-Disease	D015658
infection	I-Disease	D015658
among	O	O
people	O	O
who	O	O
use	O	O
injection	O	O
drugs	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Little	O	O
is	O	O
known	O	O
about	O	O
the	O	O
possible	O	O
role	O	O
that	O	O
smoking	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
has	O	O
on	O	O
the	O	O
incidence	O	O
of	O	O
HIV	B-Disease	D015658
infection	I-Disease	D015658
.	O	O

Given	O	O
the	O	O
increasing	O	O
use	O	O
of	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
,	O	O
we	O	O
sought	O	O
to	O	O
examine	O	O
whether	O	O
use	O	O
of	O	O
this	O	O
illicit	O	O
drug	O	O
has	O	O
become	O	O
a	O	O
risk	O	O
factor	O	O
for	O	O
HIV	B-Disease	D015658
infection	I-Disease	D015658
.	O	O

METHODS	O	O
:	O	O
We	O	O
included	O	O
data	O	O
from	O	O
people	O	O
participating	O	O
in	O	O
the	O	O
Vancouver	O	O
Injection	O	O
Drug	O	O
Users	O	O
Study	O	O
who	O	O
reported	O	O
injecting	O	O
illicit	O	O
drugs	O	O
at	O	O
least	O	O
once	O	O
in	O	O
the	O	O
month	O	O
before	O	O
enrolment	O	O
,	O	O
lived	O	O
in	O	O
the	O	O
greater	O	O
Vancouver	O	O
area	O	O
,	O	O
were	O	O
HIV	O	O
-	O	O
negative	O	O
at	O	O
enrolment	O	O
and	O	O
completed	O	O
at	O	O
least	O	O
1	O	O
follow	O	O
-	O	O
up	O	O
study	O	O
visit	O	O
.	O	O

To	O	O
determine	O	O
whether	O	O
the	O	O
risk	O	O
of	O	O
HIV	B-Disease	D006679
seroconversion	I-Disease	D006679
among	O	O
daily	O	O
smokers	O	O
of	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
changed	O	O
over	O	O
time	O	O
,	O	O
we	O	O
used	O	O
Cox	O	O
proportional	O	O
hazards	O	O
regression	O	O
and	O	O
divided	O	O
the	O	O
study	O	O
into	O	O
3	O	O
periods	O	O
:	O	O
May	O	O
1	O	O
,	O	O
1996	O	O
-	O	O
Nov	O	O
.	O	O

30	O	O
,	O	O
1999	O	O
(	O	O
period	O	O
1	O	O
)	O	O
,	O	O
Dec	O	O
.	O	O

1	O	O
,	O	O
1999	O	O
-	O	O
Nov	O	O
.	O	O

30	O	O
,	O	O
2002	O	O
(	O	O
period	O	O
2	O	O
)	O	O
,	O	O
and	O	O
Dec	O	O
.	O	O

1	O	O
,	O	O
2002	O	O
-	O	O
Dec	O	O
.	O	O

30	O	O
,	O	O
2005	O	O
(	O	O
period	O	O
3	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Overall	O	O
,	O	O
1048	O	O
eligible	O	O
injection	O	O
drug	O	O
users	O	O
were	O	O
included	O	O
in	O	O
our	O	O
study	O	O
.	O	O

Of	O	O
these	O	O
,	O	O
137	O	O
acquired	O	O
HIV	B-Disease	D015658
infection	I-Disease	D015658
during	O	O
follow	O	O
-	O	O
up	O	O
.	O	O

The	O	O
mean	O	O
proportion	O	O
of	O	O
participants	O	O
who	O	O
reported	O	O
daily	O	O
smoking	O	O
of	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
increased	O	O
from	O	O
11	O	O
.	O	O

6%	O	O
in	O	O
period	O	O
1	O	O
to	O	O
39	O	O
.	O	O

7%	O	O
in	O	O
period	O	O
3	O	O
.	O	O

After	O	O
adjusting	O	O
for	O	O
potential	O	O
confounders	O	O
,	O	O
we	O	O
found	O	O
that	O	O
the	O	O
risk	O	O
of	O	O
HIV	B-Disease	D006679
seroconversion	I-Disease	D006679
among	O	O
participants	O	O
who	O	O
were	O	O
daily	O	O
smokers	O	O
of	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
increased	O	O
over	O	O
time	O	O
(	O	O
period	O	O
1	O	O
:	O	O
hazard	O	O
ratio	O	O
[	O	O
HR	O	O
]	O	O
1	O	O
.	O	O

03	O	O
,	O	O
95%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
0	O	O
.	O	O

57	O	O
-	O	O
1	O	O
.	O	O

85	O	O
;	O	O
period	O	O
2	O	O
:	O	O
HR	O	O
1	O	O
.	O	O

68	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

01	O	O
-	O	O
2	O	O
.	O	O

80	O	O
;	O	O
and	O	O
period	O	O
3	O	O
:	O	O
HR	O	O
2	O	O
.	O	O

74	O	O
,	O	O
95%	O	O
CI	O	O
1	O	O
.	O	O

06	O	O
-	O	O
7	O	O
.	O	O

11	O	O
)	O	O
.	O	O

INTERPRETATION	O	O
:	O	O
Smoking	O	O
of	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
was	O	O
found	O	O
to	O	O
be	O	O
an	O	O
independent	O	O
risk	O	O
factor	O	O
for	O	O
HIV	B-Disease	D006679
seroconversion	I-Disease	D006679
among	O	O
people	O	O
who	O	O
were	O	O
injection	O	O
drug	O	O
users	O	O
.	O	O

This	O	O
finding	O	O
points	O	O
to	O	O
the	O	O
urgent	O	O
need	O	O
for	O	O
evidence	O	O
-	O	O
based	O	O
public	O	O
health	O	O
initiatives	O	O
targeted	O	O
at	O	O
people	O	O
who	O	O
smoke	O	O
crack	B-Chemical	D016578
cocaine	I-Chemical	D016578
.	O	O

Fluoxetine	B-Chemical	D005473
improves	O	O
the	O	O
memory	B-Disease	D008569
deficits	I-Disease	D008569
caused	O	O
by	O	O
the	O	O
chemotherapy	O	O
agent	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
.	O	O

Cancer	B-Disease	D009369
patients	O	O
who	O	O
have	O	O
been	O	O
treated	O	O
with	O	O
systemic	O	O
adjuvant	O	O
chemotherapy	O	O
have	O	O
described	O	O
experiencing	O	O
deteriorations	O	O
in	O	O
cognition	O	O
.	O	O

A	O	O
widely	O	O
used	O	O
chemotherapeutic	O	O
agent	O	O
,	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
fluorouracil	I-Chemical	D005472
(	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
)	O	O
,	O	O
readily	O	O
crosses	O	O
the	O	O
blood	O	O
-	O	O
brain	O	O
barrier	O	O
and	O	O
so	O	O
could	O	O
have	O	O
a	O	O
direct	O	O
effect	O	O
on	O	O
brain	O	O
function	O	O
.	O	O

In	O	O
particular	O	O
this	O	O
anti	O	O
mitotic	O	O
drug	O	O
could	O	O
reduce	O	O
cell	O	O
proliferation	O	O
in	O	O
the	O	O
neurogenic	O	O
regions	O	O
of	O	O
the	O	O
adult	O	O
brain	O	O
.	O	O

In	O	O
contrast	O	O
reports	O	O
indicate	O	O
that	O	O
hippocampal	O	O
dependent	O	O
neurogenesis	O	O
and	O	O
cognition	O	O
are	O	O
enhanced	O	O
by	O	O
the	O	O
SSRI	B-Chemical	D017367
antidepressant	O	O
Fluoxetine	B-Chemical	D005473
.	O	O

In	O	O
this	O	O
investigation	O	O
the	O	O
behavioural	O	O
effects	O	O
of	O	O
chronic	O	O
(	O	O
two	O	O
week	O	O
)	O	O
treatment	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
and	O	O
(	O	O
three	O	O
weeks	O	O
)	O	O
with	O	O
Fluoxetine	B-Chemical	D005473
either	O	O
separately	O	O
or	O	O
in	O	O
combination	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
were	O	O
tested	O	O
on	O	O
adult	O	O
Lister	O	O
hooded	O	O
rats	O	O
.	O	O

Behavioural	O	O
effects	O	O
were	O	O
tested	O	O
using	O	O
a	O	O
context	O	O
dependent	O	O
conditioned	O	O
emotional	O	O
response	O	O
test	O	O
(	O	O
CER	O	O
)	O	O
which	O	O
showed	O	O
that	O	O
animals	O	O
treated	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
had	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
freezing	O	O
time	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

A	O	O
separate	O	O
group	O	O
of	O	O
animals	O	O
was	O	O
tested	O	O
using	O	O
a	O	O
hippocampal	O	O
dependent	O	O
spatial	O	O
working	O	O
memory	O	O
test	O	O
,	O	O
the	O	O
object	O	O
location	O	O
recognition	O	O
test	O	O
(	O	O
OLR	O	O
)	O	O
.	O	O

Animals	O	O
treated	O	O
only	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
showed	O	O
significant	O	O
deficits	O	O
in	O	O
their	O	O
ability	O	O
to	O	O
carry	O	O
out	O	O
the	O	O
OLR	O	O
task	O	O
but	O	O
co	O	O
administration	O	O
of	O	O
Fluoxetine	B-Chemical	D005473
improved	O	O
their	O	O
performance	O	O
.	O	O

5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
chemotherapy	O	O
caused	O	O
a	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
number	O	O
of	O	O
proliferating	O	O
cells	O	O
in	O	O
the	O	O
sub	O	O
granular	O	O
zone	O	O
of	O	O
the	O	O
dentate	O	O
gyrus	O	O
compared	O	O
to	O	O
controls	O	O
.	O	O

This	O	O
reduction	O	O
was	O	O
eliminated	O	O
when	O	O
Fluoxetine	B-Chemical	D005473
was	O	O
co	O	O
administered	O	O
with	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
.	O	O

Fluoxetine	B-Chemical	D005473
on	O	O
its	O	O
own	O	O
had	O	O
no	O	O
effect	O	O
on	O	O
proliferating	O	O
cell	O	O
number	O	O
or	O	O
behaviour	O	O
.	O	O

These	O	O
findings	O	O
suggest	O	O
that	O	O
5	B-Chemical	D005472
-	I-Chemical	D005472
FU	I-Chemical	D005472
can	O	O
negatively	O	O
affect	O	O
both	O	O
cell	O	O
proliferation	O	O
and	O	O
hippocampal	O	O
dependent	O	O
working	O	O
memory	O	O
and	O	O
that	O	O
these	O	O
deficits	O	O
can	O	O
be	O	O
reversed	O	O
by	O	O
the	O	O
simultaneous	O	O
administration	O	O
of	O	O
the	O	O
antidepressant	O	O
Fluoxetine	B-Chemical	D005473
.	O	O

Liver	O	O
-	O	O
specific	O	O
ablation	O	O
of	O	O
integrin	O	O
-	O	O
linked	O	O
kinase	O	O
in	O	O
mice	O	O
results	O	O
in	O	O
enhanced	O	O
and	O	O
prolonged	O	O
cell	O	O
proliferation	O	O
and	O	O
hepatomegaly	B-Disease	D006529
after	O	O
phenobarbital	B-Chemical	D010634
administration	O	O
.	O	O

We	O	O
have	O	O
recently	O	O
demonstrated	O	O
that	O	O
disruption	O	O
of	O	O
extracellular	O	O
matrix	O	O
(	O	O
ECM	O	O
)	O	O
/	O	O
integrin	O	O
signaling	O	O
via	O	O
elimination	O	O
of	O	O
integrin	O	O
-	O	O
linked	O	O
kinase	O	O
(	O	O
ILK	O	O
)	O	O
in	O	O
hepatocytes	O	O
interferes	O	O
with	O	O
signals	O	O
leading	O	O
to	O	O
termination	O	O
of	O	O
liver	O	O
regeneration	O	O
.	O	O

This	O	O
study	O	O
investigates	O	O
the	O	O
role	O	O
of	O	O
ILK	O	O
in	O	O
liver	O	O
enlargement	O	O
induced	O	O
by	O	O
phenobarbital	B-Chemical	D010634
(	O	O
PB	B-Chemical	D010634
)	O	O
.	O	O

Wild	O	O
-	O	O
type	O	O
(	O	O
WT	O	O
)	O	O
and	O	O
ILK	O	O
:	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
were	O	O
given	O	O
PB	B-Chemical	D010634
(	O	O
0	O	O
.	O	O

1%	O	O
in	O	O
drinking	O	O
water	O	O
)	O	O
for	O	O
10	O	O
days	O	O
.	O	O

Livers	O	O
were	O	O
harvested	O	O
on	O	O
2	O	O
,	O	O
5	O	O
,	O	O
and	O	O
10	O	O
days	O	O
during	O	O
PB	B-Chemical	D010634
administration	O	O
.	O	O

In	O	O
the	O	O
hepatocyte	O	O
-	O	O
specific	O	O
ILK	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
,	O	O
the	O	O
liver	O	O
:	O	O
body	O	O
weight	O	O
ratio	O	O
was	O	O
more	O	O
than	O	O
double	O	O
as	O	O
compared	O	O
to	O	O
0	O	O
h	O	O
at	O	O
day	O	O
2	O	O
(	O	O
2	O	O
.	O	O

5	O	O
times	O	O
)	O	O
,	O	O
while	O	O
at	O	O
days	O	O
5	O	O
and	O	O
10	O	O
,	O	O
it	O	O
was	O	O
enlarged	O	O
three	O	O
times	O	O
.	O	O

In	O	O
the	O	O
WT	O	O
mice	O	O
,	O	O
the	O	O
increase	O	O
was	O	O
as	O	O
expected	O	O
from	O	O
previous	O	O
literature	O	O
(	O	O
1	O	O
.	O	O

8	O	O
times	O	O
)	O	O
and	O	O
seems	O	O
to	O	O
have	O	O
leveled	O	O
off	O	O
after	O	O
day	O	O
2	O	O
.	O	O

There	O	O
were	O	O
slightly	O	O
increased	O	O
proliferating	O	O
cell	O	O
nuclear	O	O
antigen	O	O
-	O	O
positive	O	O
cells	O	O
in	O	O
the	O	O
ILK	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
animals	O	O
at	O	O
day	O	O
2	O	O
as	O	O
compared	O	O
to	O	O
WT	O	O
after	O	O
PB	B-Chemical	D010634
administration	O	O
.	O	O

In	O	O
the	O	O
WT	O	O
animals	O	O
,	O	O
the	O	O
proliferative	O	O
response	O	O
had	O	O
come	O	O
back	O	O
to	O	O
normal	O	O
by	O	O
days	O	O
5	O	O
and	O	O
10	O	O
.	O	O

Hepatocytes	O	O
of	O	O
the	O	O
ILK	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
continued	O	O
to	O	O
proliferate	O	O
up	O	O
until	O	O
day	O	O
10	O	O
.	O	O

ILK	O	O
/	O	O
liver	O	O
-	O	O
/	O	O
-	O	O
mice	O	O
also	O	O
showed	O	O
increased	O	O
expression	O	O
of	O	O
key	O	O
genes	O	O
involved	O	O
in	O	O
hepatocyte	O	O
proliferation	O	O
at	O	O
different	O	O
time	O	O
points	O	O
during	O	O
PB	B-Chemical	D010634
administration	O	O
.	O	O

In	O	O
summary	O	O
,	O	O
ECM	O	O
proteins	O	O
communicate	O	O
with	O	O
the	O	O
signaling	O	O
machinery	O	O
of	O	O
dividing	O	O
cells	O	O
via	O	O
ILK	O	O
to	O	O
regulate	O	O
hepatocyte	O	O
proliferation	O	O
and	O	O
termination	O	O
of	O	O
the	O	O
proliferative	O	O
response	O	O
.	O	O

Lack	O	O
of	O	O
ILK	O	O
in	O	O
the	O	O
hepatocytes	O	O
imparts	O	O
prolonged	O	O
proliferative	O	O
response	O	O
not	O	O
only	O	O
to	O	O
stimuli	O	O
related	O	O
to	O	O
liver	O	O
regeneration	O	O
but	O	O
also	O	O
to	O	O
xenobiotic	O	O
chemical	O	O
mitogens	O	O
,	O	O
such	O	O
as	O	O
PB	B-Chemical	D010634
.	O	O

Decreased	O	O
Expression	O	O
of	O	O
Na	B-Chemical	D012964
/	O	O
K	B-Chemical	D011188
-	O	O
ATPase	O	O
,	O	O
NHE3	O	O
,	O	O
NBC1	O	O
,	O	O
AQP1	O	O
and	O	O
OAT	O	O
in	O	O
Gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
Nephropathy	B-Disease	D007674
.	O	O

The	O	O
present	O	O
study	O	O
was	O	O
aimed	O	O
to	O	O
determine	O	O
whether	O	O
there	O	O
is	O	O
an	O	O
altered	O	O
regulation	O	O
of	O	O
tubular	O	O
transporters	O	O
in	O	O
gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
.	O	O

Sprague	O	O
-	O	O
Dawley	O	O
male	O	O
rats	O	O
(	O	O
200~250	O	O
g	O	O
)	O	O
were	O	O
subcutaneously	O	O
injected	O	O
with	O	O
gentamicin	B-Chemical	D005839
(	O	O
100	O	O
mg	O	O
/	O	O
kg	O	O
per	O	O
day	O	O
)	O	O
for	O	O
7	O	O
days	O	O
,	O	O
and	O	O
the	O	O
expression	O	O
of	O	O
tubular	O	O
transporters	O	O
was	O	O
determined	O	O
by	O	O
immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
.	O	O

The	O	O
mRNA	O	O
and	O	O
protein	O	O
expression	O	O
of	O	O
OAT	O	O
was	O	O
also	O	O
determined	O	O
.	O	O

Gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
rats	O	O
exhibited	O	O
significantly	O	O
decreased	O	O
creatinine	B-Chemical	D003404
clearance	O	O
along	O	O
with	O	O
increased	O	O
plasma	O	O
creatinine	B-Chemical	D003404
levels	O	O
.	O	O

Accordingly	O	O
,	O	O
the	O	O
fractional	O	O
excretion	O	O
of	O	O
sodium	B-Chemical	D012964
increased	O	O
.	O	O

Urine	O	O
volume	O	O
was	O	O
increased	O	O
,	O	O
while	O	O
urine	O	O
osmolality	O	O
and	O	O
free	O	O
water	O	O
reabsorption	O	O
were	O	O
decreased	O	O
.	O	O

Immunoblotting	O	O
and	O	O
immunohistochemistry	O	O
revealed	O	O
decreased	O	O
expression	O	O
of	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
/	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
ATPase	O	O
,	O	O
NHE3	O	O
,	O	O
NBC1	O	O
,	O	O
and	O	O
AQP1	O	O
in	O	O
the	O	O
kidney	O	O
of	O	O
gentamicin	B-Chemical	D005839
-	O	O
treated	O	O
rats	O	O
.	O	O

The	O	O
expression	O	O
of	O	O
OAT1	O	O
and	O	O
OAT3	O	O
was	O	O
also	O	O
decreased	O	O
.	O	O

Gentamicin	B-Chemical	D005839
-	O	O
induced	O	O
nephropathy	B-Disease	D007674
may	O	O
at	O	O
least	O	O
in	O	O
part	O	O
be	O	O
causally	O	O
related	O	O
with	O	O
a	O	O
decreased	O	O
expression	O	O
of	O	O
Na	B-Chemical	D012964
(	O	O
+	O	O
)	O	O
/	O	O
K	B-Chemical	D011188
(	O	O
+	O	O
)	O	O
-	O	O
ATPase	O	O
,	O	O
NHE3	O	O
,	O	O
NBC1	O	O
,	O	O
AQP1	O	O
and	O	O
OAT	O	O
.	O	O

Longitudinal	O	O
association	O	O
of	O	O
alcohol	B-Chemical	D000431
use	O	O
with	O	O
HIV	B-Disease	D015658
disease	I-Disease	D015658
progression	O	O
and	O	O
psychological	O	O
health	O	O
of	O	O
women	O	O
with	O	O
HIV	O	O
.	O	O

We	O	O
evaluated	O	O
the	O	O
association	O	O
of	O	O
alcohol	B-Chemical	D000431
consumption	O	O
and	O	O
depression	B-Disease	D003866
,	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
HIV	B-Disease	D015658
disease	I-Disease	D015658
progression	O	O
among	O	O
women	O	O
with	O	O
HIV	O	O
.	O	O

The	O	O
study	O	O
included	O	O
871	O	O
women	O	O
with	O	O
HIV	O	O
who	O	O
were	O	O
recruited	O	O
from	O	O
1993	O	O
-	O	O
1995	O	O
in	O	O
four	O	O
US	O	O
cities	O	O
.	O	O

The	O	O
participants	O	O
had	O	O
physical	O	O
examination	O	O
,	O	O
medical	O	O
record	O	O
extraction	O	O
,	O	O
and	O	O
venipuncture	O	O
,	O	O
CD4+T	O	O
-	O	O
cell	O	O
counts	O	O
determination	O	O
,	O	O
measurement	O	O
of	O	O
depression	B-Disease	D003866
symptoms	O	O
(	O	O
using	O	O
the	O	O
self	O	O
-	O	O
report	O	O
Center	O	O
for	O	O
Epidemiological	O	O
Studies	O	O
-	O	O
Depression	B-Disease	D003866
Scale	O	O
)	O	O
,	O	O
and	O	O
alcohol	B-Chemical	D000431
use	O	O
assessment	O	O
at	O	O
enrollment	O	O
,	O	O
and	O	O
semiannually	O	O
until	O	O
March	O	O
2000	O	O
.	O	O

Multilevel	O	O
random	O	O
coefficient	O	O
ordinal	O	O
models	O	O
as	O	O
well	O	O
as	O	O
multilevel	O	O
models	O	O
with	O	O
joint	O	O
responses	O	O
were	O	O
used	O	O
in	O	O
the	O	O
analysis	O	O
.	O	O

There	O	O
was	O	O
no	O	O
significant	O	O
association	O	O
between	O	O
level	O	O
of	O	O
alcohol	B-Chemical	D000431
use	O	O
and	O	O
CD4+	O	O
T	O	O
-	O	O
cell	O	O
counts	O	O
.	O	O

When	O	O
participants	O	O
were	O	O
stratified	O	O
by	O	O
antiretroviral	O	O
therapy	O	O
(	O	O
ART	O	O
)	O	O
use	O	O
,	O	O
the	O	O
association	O	O
between	O	O
alcohol	B-Chemical	D000431
and	O	O
CD4+	O	O
T	O	O
-	O	O
cell	O	O
did	O	O
not	O	O
reach	O	O
statistical	O	O
significance	O	O
.	O	O

The	O	O
association	O	O
between	O	O
alcohol	B-Chemical	D000431
consumption	O	O
and	O	O
depression	B-Disease	D003866
was	O	O
significant	O	O
(	O	O
p<0	O	O
.	O	O

001	O	O
)	O	O
.	O	O

Depression	B-Disease	D003866
had	O	O
a	O	O
significant	O	O
negative	O	O
effect	O	O
on	O	O
CD4+	O	O
T	O	O
-	O	O
cell	O	O
counts	O	O
over	O	O
time	O	O
regardless	O	O
of	O	O
ART	O	O
use	O	O
.	O	O

Our	O	O
findings	O	O
suggest	O	O
that	O	O
alcohol	B-Chemical	D000431
consumption	O	O
has	O	O
a	O	O
direct	O	O
association	O	O
with	O	O
depression	B-Disease	D003866
.	O	O

Moreover	O	O
,	O	O
depression	B-Disease	D003866
is	O	O
associated	O	O
with	O	O
HIV	B-Disease	D015658
disease	I-Disease	D015658
progression	O	O
.	O	O

Our	O	O
findings	O	O
have	O	O
implications	O	O
for	O	O
the	O	O
provision	O	O
of	O	O
alcohol	B-Chemical	D000431
use	O	O
interventions	O	O
and	O	O
psychological	O	O
resources	O	O
to	O	O
improve	O	O
the	O	O
health	O	O
of	O	O
women	O	O
with	O	O
HIV	O	O
.	O	O

Chemokine	O	O
CCL2	O	O
and	O	O
its	O	O
receptor	O	O
CCR2	O	O
are	O	O
increased	O	O
in	O	O
the	O	O
hippocampus	O	O
following	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
.	O	O

BACKGROUND	O	O
:	O	O
Neuroinflammation	B-Disease	D007249
occurs	O	O
after	O	O
seizures	B-Disease	D012640
and	O	O
is	O	O
implicated	O	O
in	O	O
epileptogenesis	O	O
.	O	O

CCR2	O	O
is	O	O
a	O	O
chemokine	O	O
receptor	O	O
for	O	O
CCL2	O	O
and	O	O
their	O	O
interaction	O	O
mediates	O	O
monocyte	O	O
infiltration	O	O
in	O	O
the	O	O
neuroinflammatory	B-Disease	D007249
cascade	O	O
triggered	O	O
in	O	O
different	O	O
brain	O	O
pathologies	O	O
.	O	O

In	O	O
this	O	O
work	O	O
CCR2	O	O
and	O	O
CCL2	O	O
expression	O	O
were	O	O
examined	O	O
following	O	O
status	B-Disease	D013226
epilepticus	I-Disease	D013226
(	O	O
SE	B-Disease	D013226
)	O	O
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
injection	O	O
.	O	O

METHODS	O	O
:	O	O
SE	B-Disease	D013226
was	O	O
induced	O	O
by	O	O
pilocarpine	B-Chemical	D010862
injection	O	O
.	O	O

Control	O	O
rats	O	O
were	O	O
injected	O	O
with	O	O
saline	O	O
instead	O	O
of	O	O
pilocarpine	B-Chemical	D010862
.	O	O

Five	O	O
days	O	O
after	O	O
SE	B-Disease	D013226
,	O	O
CCR2	O	O
staining	O	O
in	O	O
neurons	O	O
and	O	O
glial	O	O
cells	O	O
was	O	O
examined	O	O
using	O	O
imunohistochemical	O	O
analyses	O	O
.	O	O

The	O	O
number	O	O
of	O	O
CCR2	O	O
positive	O	O
cells	O	O
was	O	O
determined	O	O
using	O	O
stereology	O	O
probes	O	O
in	O	O
the	O	O
hippocampus	O	O
.	O	O

CCL2	O	O
expression	O	O
in	O	O
the	O	O
hippocampus	O	O
was	O	O
examined	O	O
by	O	O
molecular	O	O
assay	O	O
.	O	O

RESULTS	O	O
:	O	O
Increased	O	O
CCR2	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
hippocampus	O	O
after	O	O
SE	B-Disease	D013226
.	O	O

Seizures	B-Disease	D012640
also	O	O
resulted	O	O
in	O	O
alterations	O	O
to	O	O
the	O	O
cell	O	O
types	O	O
expressing	O	O
CCR2	O	O
.	O	O

Increased	O	O
numbers	O	O
of	O	O
neurons	O	O
that	O	O
expressed	O	O
CCR2	O	O
was	O	O
observed	O	O
following	O	O
SE	B-Disease	D013226
.	O	O

Microglial	O	O
cells	O	O
were	O	O
more	O	O
closely	O	O
apposed	O	O
to	O	O
the	O	O
CCR2	O	O
-	O	O
labeled	O	O
cells	O	O
in	O	O
SE	B-Disease	D013226
rats	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
rats	O	O
that	O	O
experienced	O	O
SE	B-Disease	D013226
exhibited	O	O
CCR2	O	O
-	O	O
labeling	O	O
in	O	O
populations	O	O
of	O	O
hypertrophied	B-Disease	D006984
astrocytes	O	O
,	O	O
especially	O	O
in	O	O
CA1	O	O
and	O	O
dentate	O	O
gyrus	O	O
.	O	O

These	O	O
CCR2+	O	O
astroctytes	O	O
were	O	O
not	O	O
observed	O	O
in	O	O
control	O	O
rats	O	O
.	O	O

Examination	O	O
of	O	O
CCL2	O	O
expression	O	O
showed	O	O
that	O	O
it	O	O
was	O	O
elevated	O	O
in	O	O
the	O	O
hippocampus	O	O
following	O	O
SE	B-Disease	D013226
.	O	O

CONCLUSION	O	O
:	O	O
The	O	O
data	O	O
show	O	O
that	O	O
CCR2	O	O
and	O	O
CCL2	O	O
are	O	O
up	O	O
-	O	O
regulated	O	O
in	O	O
the	O	O
hippocampus	O	O
after	O	O
pilocarpine	B-Chemical	D010862
-	O	O
induced	O	O
SE	B-Disease	D013226
.	O	O

Seizures	B-Disease	D012640
also	O	O
result	O	O
in	O	O
changes	O	O
to	O	O
CCR2	O	O
receptor	O	O
expression	O	O
in	O	O
neurons	O	O
and	O	O
astrocytes	O	O
.	O	O

These	O	O
changes	O	O
might	O	O
be	O	O
involved	O	O
in	O	O
detrimental	O	O
neuroplasticity	O	O
and	O	O
neuroinflammatory	B-Disease	D007249
changes	O	O
that	O	O
occur	O	O
following	O	O
seizures	B-Disease	D012640
.	O	O

Metallothionein	B-Chemical	D008668
induction	O	O
reduces	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
and	O	O
TNFalpha	O	O
levels	O	O
with	O	O
preservation	O	O
of	O	O
cognitive	O	O
function	O	O
and	O	O
intact	O	O
hippocampal	O	O
neurons	O	O
in	O	O
carmustine	B-Chemical	D002330
-	O	O
treated	O	O
rats	O	O
.	O	O

Hippocampal	O	O
integrity	O	O
is	O	O
essential	O	O
for	O	O
cognitive	O	O
functions	O	O
.	O	O

On	O	O
the	O	O
other	O	O
hand	O	O
,	O	O
induction	O	O
of	O	O
metallothionein	B-Chemical	D008668
(	O	O
MT	B-Chemical	D008668
)	O	O
by	O	O
ZnSO	B-Chemical	D019287
(	I-Chemical	D019287
4	I-Chemical	D019287
)	I-Chemical	D019287
and	O	O
its	O	O
role	O	O
in	O	O
neuroprotection	O	O
has	O	O
been	O	O
documented	O	O
.	O	O

The	O	O
present	O	O
study	O	O
aimed	O	O
to	O	O
explore	O	O
the	O	O
effect	O	O
of	O	O
MT	B-Chemical	D008668
induction	O	O
on	O	O
carmustine	B-Chemical	D002330
(	O	O
BCNU	B-Chemical	D002330
)	O	O
-	O	O
induced	O	O
hippocampal	O	O
cognitive	B-Disease	D003072
dysfunction	I-Disease	D003072
in	O	O
rats	O	O
.	O	O

A	O	O
total	O	O
of	O	O
60	O	O
male	O	O
Wistar	O	O
albino	O	O
rats	O	O
were	O	O
randomly	O	O
divided	O	O
into	O	O
four	O	O
groups	O	O
(	O	O
15	O	O
/	O	O
group	O	O
)	O	O
:	O	O
The	O	O
control	O	O
group	O	O
injected	O	O
with	O	O
single	O	O
doses	O	O
of	O	O
normal	O	O
saline	O	O
(	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
)	O	O
followed	O	O
24	O	O
h	O	O
later	O	O
by	O	O
BCNU	B-Chemical	D002330
solvent	O	O
(	O	O
i	O	O
.	O	O

v	O	O
)	O	O
.	O	O

The	O	O
second	O	O
group	O	O
administered	O	O
ZnSO	B-Chemical	D019287
(	I-Chemical	D019287
4	I-Chemical	D019287
)	I-Chemical	D019287
(	O	O
0	O	O
.	O	O

1	O	O
micromol	O	O
/	O	O
10	O	O
microl	O	O
normal	O	O
saline	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
,	O	O
once	O	O
)	O	O
then	O	O
BCNU	B-Chemical	D002330
solvent	O	O
(	O	O
i	O	O
.	O	O

v	O	O
)	O	O
after	O	O
24	O	O
h	O	O
.	O	O

Third	O	O
group	O	O
received	O	O
BCNU	B-Chemical	D002330
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

v	O	O
,	O	O
once	O	O
)	O	O
24	O	O
h	O	O
after	O	O
injection	O	O
with	O	O
normal	O	O
saline	O	O
(	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
)	O	O
.	O	O

Fourth	O	O
group	O	O
received	O	O
a	O	O
single	O	O
dose	O	O
of	O	O
ZnSO	B-Chemical	D019287
(	I-Chemical	D019287
4	I-Chemical	D019287
)	I-Chemical	D019287
(	O	O
0	O	O
.	O	O

1	O	O
micromol	O	O
/	O	O
10	O	O
microl	O	O
normal	O	O
saline	O	O
,	O	O
i	O	O
.	O	O

c	O	O
.	O	O

v	O	O
)	O	O
then	O	O
BCNU	B-Chemical	D002330
(	O	O
20	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

v	O	O
,	O	O
once	O	O
)	O	O
after	O	O
24	O	O
h	O	O
.	O	O

The	O	O
obtained	O	O
data	O	O
revealed	O	O
that	O	O
BCNU	B-Chemical	D002330
administration	O	O
resulted	O	O
in	O	O
deterioration	O	O
of	O	O
learning	O	O
and	O	O
short	O	O
-	O	O
term	O	O
memory	O	O
(	O	O
STM	O	O
)	O	O
,	O	O
as	O	O
measured	O	O
by	O	O
using	O	O
radial	O	O
arm	O	O
water	O	O
maze	O	O
,	O	O
accompanied	O	O
with	O	O
decreased	O	O
hippocampal	O	O
glutathione	B-Chemical	D005978
reductase	O	O
(	O	O
GR	O	O
)	O	O
activity	O	O
and	O	O
reduced	O	O
glutathione	B-Chemical	D005978
(	O	O
GSH	B-Chemical	D005978
)	O	O
content	O	O
.	O	O

Also	O	O
,	O	O
BCNU	B-Chemical	D002330
administration	O	O
increased	O	O
serum	O	O
tumor	B-Disease	D009369
necrosis	B-Disease	D009336
factor	O	O
-	O	O
alpha	O	O
(	O	O
TNFalpha	O	O
)	O	O
,	O	O
hippocampal	O	O
MT	B-Chemical	D008668
and	O	O
malondialdehyde	B-Chemical	D008315
(	O	O
MDA	B-Chemical	D008315
)	O	O
contents	O	O
as	O	O
well	O	O
as	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
in	O	O
addition	O	O
to	O	O
histological	O	O
alterations	O	O
.	O	O

ZnSO	B-Chemical	D019287
(	I-Chemical	D019287
4	I-Chemical	D019287
)	I-Chemical	D019287
pretreatment	O	O
counteracted	O	O
BCNU	B-Chemical	D002330
-	O	O
induced	O	O
inhibition	O	O
of	O	O
GR	O	O
and	O	O
depletion	O	O
of	O	O
GSH	B-Chemical	D005978
and	O	O
resulted	O	O
in	O	O
significant	O	O
reduction	O	O
in	O	O
the	O	O
levels	O	O
of	O	O
MDA	B-Chemical	D008315
and	O	O
TNFalpha	O	O
as	O	O
well	O	O
as	O	O
the	O	O
activity	O	O
of	O	O
caspase	O	O
-	O	O
3	O	O
.	O	O

The	O	O
histological	O	O
features	O	O
were	O	O
improved	O	O
in	O	O
hippocampus	O	O
of	O	O
rats	O	O
treated	O	O
with	O	O
ZnSO	B-Chemical	D019287
(	I-Chemical	D019287
4	I-Chemical	D019287
)	I-Chemical	D019287
+	O	O
BCNU	B-Chemical	D002330
compared	O	O
to	O	O
only	O	O
BCNU	B-Chemical	D002330
-	O	O
treated	O	O
animals	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
MT	B-Chemical	D008668
induction	O	O
halts	O	O
BCNU	B-Chemical	D002330
-	O	O
induced	O	O
hippocampal	O	O
toxicity	B-Disease	D064420
as	O	O
it	O	O
prevented	O	O
GR	O	O
inhibition	O	O
and	O	O
GSH	B-Chemical	D005978
depletion	O	O
and	O	O
counteracted	O	O
the	O	O
increased	O	O
levels	O	O
of	O	O
TNFalpha	O	O
,	O	O
MDA	B-Chemical	D008315
and	O	O
caspase	O	O
-	O	O
3	O	O
activity	O	O
with	O	O
subsequent	O	O
preservation	O	O
of	O	O
cognition	O	O
.	O	O

Fatal	O	O
carbamazepine	B-Chemical	D002220
induced	O	O
fulminant	B-Disease	D004802
eosinophilic	I-Disease	D004802
(	O	O
hypersensitivity	B-Disease	D004342
)	O	O
myocarditis	B-Disease	D009205
:	O	O
emphasis	O	O
on	O	O
anatomical	O	O
and	O	O
histological	O	O
characteristics	O	O
,	O	O
mechanisms	O	O
and	O	O
genetics	O	O
of	O	O
drug	B-Disease	D004342
hypersensitivity	I-Disease	D004342
and	O	O
differential	O	O
diagnosis	O	O
.	O	O

The	O	O
most	O	O
severe	O	O
adverse	O	O
reactions	O	O
to	O	O
carbamazepine	B-Chemical	D002220
have	O	O
been	O	O
observed	O	O
in	O	O
the	O	O
haemopoietic	O	O
system	O	O
,	O	O
the	O	O
liver	O	O
and	O	O
the	O	O
cardiovascular	O	O
system	O	O
.	O	O

A	O	O
frequently	O	O
fatal	O	O
,	O	O
although	O	O
exceptionally	O	O
rare	O	O
side	O	O
effect	O	O
of	O	O
carbamazepine	B-Chemical	D002220
is	O	O
necrotizing	O	O
eosinophilic	O	O
(	O	O
hypersensitivity	B-Disease	D004342
)	O	O
myocarditis	B-Disease	D009205
.	O	O

We	O	O
report	O	O
a	O	O
case	O	O
of	O	O
hypersensitivity	B-Disease	D004342
myocarditis	B-Disease	D009205
secondary	O	O
to	O	O
administration	O	O
of	O	O
carbamazepine	B-Chemical	D002220
.	O	O

Acute	O	O
hypersensitivity	B-Disease	D004342
myocarditis	B-Disease	D009205
was	O	O
not	O	O
suspected	O	O
clinically	O	O
,	O	O
and	O	O
the	O	O
diagnosis	O	O
was	O	O
made	O	O
post	O	O
-	O	O
mortem	O	O
.	O	O

Histology	O	O
revealed	O	O
diffuse	O	O
infiltration	O	O
of	O	O
the	O	O
myocardium	O	O
by	O	O
eosinophils	O	O
and	O	O
lymphocytes	O	O
with	O	O
myocyte	O	O
damage	O	O
.	O	O

Clinically	O	O
,	O	O
death	O	O
was	O	O
due	O	O
to	O	O
cardiogenic	B-Disease	D012770
shock	I-Disease	D012770
.	O	O

To	O	O
best	O	O
of	O	O
our	O	O
knowledge	O	O
this	O	O
is	O	O
the	O	O
second	O	O
case	O	O
of	O	O
fatal	O	O
carbamazepine	B-Chemical	D002220
induced	O	O
myocarditis	B-Disease	D009205
reported	O	O
in	O	O
English	O	O
literature	O	O
.	O	O

Neuropsychiatric	O	O
behaviors	O	O
in	O	O
the	O	O
MPTP	B-Chemical	D015632
marmoset	O	O
model	O	O
of	O	O
Parkinson's	B-Disease	D010302
disease	I-Disease	D010302
.	O	O

OBJECTIVES	O	O
:	O	O
Neuropsychiatric	O	O
symptoms	O	O
are	O	O
increasingly	O	O
recognised	O	O
as	O	O
a	O	O
significant	O	O
problem	O	O
in	O	O
patients	O	O
with	O	O
Parkinson's	B-Disease	D010302
disease	I-Disease	D010302
(	O	O
PD	B-Disease	D010302
)	O	O
.	O	O

These	O	O
symptoms	O	O
may	O	O
be	O	O
due	O	O
to	O	O
'sensitisation'	O	O
following	O	O
repeated	O	O
levodopa	B-Chemical	D007980
treatment	O	O
or	O	O
a	O	O
direct	O	O
effect	O	O
of	O	O
dopamine	B-Chemical	D004298
on	O	O
the	O	O
disease	O	O
state	O	O
.	O	O

The	O	O
levodopa	B-Chemical	D007980
-	O	O
treated	O	O
MPTP	B-Chemical	D015632
-	O	O
lesioned	O	O
marmoset	O	O
was	O	O
used	O	O
as	O	O
a	O	O
model	O	O
of	O	O
neuropsychiatric	B-Disease	D001523
symptoms	I-Disease	D001523
in	O	O
PD	B-Disease	D010302
patients	O	O
.	O	O

Here	O	O
we	O	O
compare	O	O
the	O	O
time	O	O
course	O	O
of	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
motor	O	O
fluctuations	O	O
and	O	O
neuropsychiatric	B-Disease	D001523
-	I-Disease	D001523
like	I-Disease	D001523
behaviors	I-Disease	D001523
to	O	O
determine	O	O
the	O	O
relationship	O	O
between	O	O
duration	O	O
of	O	O
treatment	O	O
and	O	O
onset	O	O
of	O	O
symptoms	O	O
.	O	O

METHODS	O	O
:	O	O
Marmosets	O	O
were	O	O
administered	O	O
1	B-Chemical	D015632
-	I-Chemical	D015632
methyl	I-Chemical	D015632
-	I-Chemical	D015632
4	I-Chemical	D015632
-	I-Chemical	D015632
phenyl	I-Chemical	D015632
-	I-Chemical	D015632
1	I-Chemical	D015632
,	I-Chemical	D015632
2	I-Chemical	D015632
,	I-Chemical	D015632
3	I-Chemical	D015632
,	I-Chemical	D015632
6	I-Chemical	D015632
-	I-Chemical	D015632
tetrahydropyridine	I-Chemical	D015632
(	O	O
2	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
s	O	O
.	O	O

c	O	O
.	O	O

)	O	O
for	O	O
five	O	O
days	O	O
,	O	O
resulting	O	O
in	O	O
stable	O	O
parkinsonism	B-Disease	D010302
.	O	O

Levodopa	B-Chemical	D007980
(	O	O
15	O	O
mg	O	O
/	O	O
kg	O	O
and	O	O
benserazide	B-Chemical	D001545
,	O	O
3	O	O
.	O	O

75	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
p	O	O
.	O	O

o	O	O
.	O	O

b	O	O
.	O	O

i	O	O
.	O	O

d	O	O
,	O	O
was	O	O
administered	O	O
for	O	O
30	O	O
days	O	O
.	O	O

Animals	O	O
were	O	O
evaluated	O	O
for	O	O
parkinsonian	B-Disease	D020734
disability	I-Disease	D020734
,	O	O
dyskinesia	B-Disease	D004409
and	O	O
on	O	O
-	O	O
time	O	O
(	O	O
motor	O	O
fluctuations	O	O
)	O	O
and	O	O
neuropsychiatric	B-Disease	D001523
-	I-Disease	D001523
like	I-Disease	D001523
behaviors	I-Disease	D001523
on	O	O
Day	O	O
0	O	O
(	O	O
prior	O	O
to	O	O
levodopa	B-Chemical	D007980
)	O	O
and	O	O
on	O	O
Days	O	O
1	O	O
,	O	O
7	O	O
,	O	O
13	O	O
,	O	O
27	O	O
and	O	O
30	O	O
of	O	O
treatment	O	O
using	O	O
post	O	O
hoc	O	O
DVD	O	O
analysis	O	O
by	O	O
a	O	O
trained	O	O
rater	O	O
,	O	O
blind	O	O
to	O	O
the	O	O
treatment	O	O
day	O	O
.	O	O

RESULTS	O	O
:	O	O
The	O	O
neuropsychiatric	B-Disease	D001523
-	I-Disease	D001523
like	I-Disease	D001523
behavior	I-Disease	D001523
rating	O	O
scale	O	O
demonstrated	O	O
high	O	O
interrater	O	O
reliability	O	O
between	O	O
three	O	O
trained	O	O
raters	O	O
of	O	O
differing	O	O
professional	O	O
backgrounds	O	O
.	O	O

As	O	O
anticipated	O	O
,	O	O
animals	O	O
exhibited	O	O
a	O	O
progressive	O	O
increase	O	O
in	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
motor	O	O
fluctuations	O	O
,	O	O
dyskinesia	B-Disease	D004409
and	O	O
wearing	O	O
-	O	O
off	O	O
,	O	O
that	O	O
correlated	O	O
with	O	O
the	O	O
duration	O	O
of	O	O
levodopa	B-Chemical	D007980
therapy	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
levodopa	B-Chemical	D007980
-	O	O
induced	O	O
neuropsychiatric	B-Disease	D001523
-	I-Disease	D001523
like	I-Disease	D001523
behaviors	I-Disease	D001523
were	O	O
present	O	O
on	O	O
Day	O	O
1	O	O
of	O	O
levodopa	B-Chemical	D007980
treatment	O	O
and	O	O
their	O	O
severity	O	O
did	O	O
not	O	O
correlate	O	O
with	O	O
duration	O	O
of	O	O
treatment	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
data	O	O
suggest	O	O
that	O	O
neuropsychiatric	B-Disease	D001523
disorders	I-Disease	D001523
in	O	O
PD	B-Disease	D010302
are	O	O
more	O	O
likely	O	O
an	O	O
interaction	O	O
between	O	O
levodopa	B-Chemical	D007980
and	O	O
the	O	O
disease	O	O
state	O	O
than	O	O
a	O	O
consequence	O	O
of	O	O
sensitisation	O	O
to	O	O
repeated	O	O
dopaminergic	O	O
therapy	O	O
.	O	O

Contrast	B-Chemical	D003287
medium	I-Chemical	D003287
nephrotoxicity	B-Disease	D007674
after	O	O
renal	O	O
artery	O	O
and	O	O
coronary	O	O
angioplasty	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Renal	B-Disease	D007674
dysfunction	I-Disease	D007674
induced	O	O
by	O	O
iodinated	O	O
contrast	B-Chemical	D003287
medium	I-Chemical	D003287
(	O	O
CM	B-Chemical	D003287
)	O	O
administration	O	O
can	O	O
minimize	O	O
the	O	O
benefit	O	O
of	O	O
the	O	O
interventional	O	O
procedure	O	O
in	O	O
patients	O	O
undergoing	O	O
renal	O	O
angioplasty	O	O
(	O	O
PTRA	O	O
)	O	O
.	O	O

PURPOSE	O	O
:	O	O
To	O	O
compare	O	O
the	O	O
susceptibility	O	O
to	O	O
nephrotoxic	B-Disease	D007674
effect	O	O
of	O	O
CM	B-Chemical	D003287
in	O	O
patients	O	O
undergoing	O	O
PTRA	O	O
with	O	O
that	O	O
of	O	O
patients	O	O
submitted	O	O
to	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
(	O	O
PCI	O	O
)	O	O
.	O	O

MATERIAL	O	O
AND	O	O
METHODS	O	O
:	O	O
A	O	O
total	O	O
of	O	O
33	O	O
patients	O	O
successfully	O	O
treated	O	O
with	O	O
PTRA	O	O
(	O	O
PTRA	O	O
group	O	O
,	O	O
mean	O	O
age	O	O
70+	O	O
/	O	O
-	O	O
12	O	O
years	O	O
,	O	O
23	O	O
female	O	O
,	O	O
basal	O	O
creatinine	B-Chemical	D003404
1	O	O
.	O	O

46+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

79	O	O
,	O	O
range	O	O
0	O	O
.	O	O

7	O	O
-	O	O
4	O	O
.	O	O

9	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
were	O	O
compared	O	O
with	O	O
33	O	O
patients	O	O
undergoing	O	O
successful	O	O
PCI	O	O
(	O	O
PCI	O	O
group	O	O
)	O	O
,	O	O
matched	O	O
for	O	O
basal	O	O
creatinine	B-Chemical	D003404
(	O	O
1	O	O
.	O	O

44+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
,	O	O
range	O	O
0	O	O
.	O	O

7	O	O
-	O	O
3	O	O
.	O	O

4	O	O
mg	O	O
/	O	O
dl	O	O
)	O	O
,	O	O
gender	O	O
,	O	O
and	O	O
age	O	O
.	O	O

In	O	O
both	O	O
groups	O	O
postprocedural	O	O
(	O	O
48	O	O
h	O	O
)	O	O
serum	O	O
creatinine	B-Chemical	D003404
was	O	O
measured	O	O
.	O	O

RESULTS	O	O
:	O	O
Postprocedural	O	O
creatinine	B-Chemical	D003404
level	O	O
decreased	O	O
nonsignificantly	O	O
in	O	O
the	O	O
PTRA	O	O
group	O	O
(	O	O
1	O	O
.	O	O

46+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

8	O	O
vs	O	O
.	O	O

1	O	O
.	O	O

34+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
P=NS	O	O
)	O	O
and	O	O
increased	O	O
significantly	O	O
in	O	O
the	O	O
PCI	O	O
group	O	O
(	O	O
1	O	O
.	O	O

44+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

6	O	O
vs	O	O
.	O	O

1	O	O
.	O	O

57+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

7	O	O
mg	O	O
/	O	O
dl	O	O
,	O	O
P<0	O	O
.	O	O

02	O	O
)	O	O
.	O	O

Changes	O	O
in	O	O
serum	O	O
creatinine	B-Chemical	D003404
after	O	O
intervention	O	O
(	O	O
after	O	O
-	O	O
before	O	O
)	O	O
were	O	O
significantly	O	O
different	O	O
between	O	O
the	O	O
PTRA	O	O
and	O	O
PCI	O	O
groups	O	O
(	O	O
-	O	O
0	O	O
.	O	O

12+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

5	O	O
vs	O	O
.	O	O

0	O	O
.	O	O

13+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

3	O	O
,	O	O
P=0	O	O
.	O	O

014	O	O
)	O	O
.	O	O

This	O	O
difference	O	O
was	O	O
not	O	O
related	O	O
to	O	O
either	O	O
a	O	O
different	O	O
clinical	O	O
risk	O	O
profile	O	O
or	O	O
to	O	O
the	O	O
volume	O	O
of	O	O
CM	B-Chemical	D003287
administered	O	O
.	O	O

CONCLUSION	O	O
:	O	O
In	O	O
this	O	O
preliminary	O	O
study	O	O
patients	O	O
submitted	O	O
to	O	O
PTRA	O	O
showed	O	O
a	O	O
lower	O	O
susceptibility	O	O
to	O	O
renal	B-Disease	D007674
damage	I-Disease	D007674
induced	O	O
by	O	O
CM	B-Chemical	D003287
administration	O	O
than	O	O
PCI	O	O
patients	O	O
.	O	O

The	O	O
effectiveness	O	O
of	O	O
PTRA	O	O
on	O	O
renal	O	O
function	O	O
seems	O	O
to	O	O
be	O	O
barely	O	O
influenced	O	O
by	O	O
CM	B-Chemical	D003287
toxicity	B-Disease	D064420
.	O	O

Medical	O	O
and	O	O
psychiatric	O	O
outcomes	O	O
for	O	O
patients	O	O
transplanted	O	O
for	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
:	O	O
a	O	O
case	O	O
-	O	O
control	O	O
study	O	O
.	O	O

BACKGROUND	O	O
:	O	O
Acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
hepatotoxicity	B-Disease	D056486
is	O	O
the	O	O
most	O	O
common	O	O
cause	O	O
of	O	O
acute	B-Disease	D017114
liver	I-Disease	D017114
failure	I-Disease	D017114
(	O	O
ALF	B-Disease	D017114
)	O	O
in	O	O
the	O	O
UK	O	O
.	O	O

Patients	O	O
often	O	O
consume	O	O
the	O	O
drug	O	O
with	O	O
suicidal	O	O
intent	O	O
or	O	O
with	O	O
a	O	O
background	O	O
of	O	O
substance	O	O
dependence	O	O
.	O	O

AIMS	O	O
AND	O	O
METHODS	O	O
:	O	O
We	O	O
compared	O	O
the	O	O
severity	O	O
of	O	O
pretransplant	O	O
illness	O	O
,	O	O
psychiatric	O	O
co	O	O
-	O	O
morbidity	O	O
,	O	O
medical	O	O
and	O	O
psychosocial	O	O
outcomes	O	O
of	O	O
all	O	O
patients	O	O
who	O	O
had	O	O
undergone	O	O
liver	O	O
transplantation	O	O
(	O	O
LT	O	O
)	O	O
emergently	O	O
between	O	O
1999	O	O
-	O	O
2004	O	O
for	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
(	O	O
n=36	O	O
)	O	O
with	O	O
age	O	O
-	O	O
and	O	O
sex	O	O
-	O	O
matched	O	O
patients	O	O
undergoing	O	O
emergent	O	O
LT	O	O
for	O	O
non	O	O
-	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
(	O	O
n=35	O	O
)	O	O
and	O	O
elective	O	O
LT	O	O
for	O	O
chronic	B-Disease	D008107
liver	I-Disease	D008107
disease	I-Disease	D008107
(	O	O
CLD	B-Disease	D008107
,	O	O
n=34	O	O
)	O	O
.	O	O

RESULTS	O	O
:	O	O
Acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
patients	O	O
undergoing	O	O
LT	O	O
had	O	O
a	O	O
greater	O	O
severity	O	O
of	O	O
pre	O	O
-	O	O
LT	O	O
illness	O	O
reflected	O	O
by	O	O
higher	O	O
Acute	O	O
Physiology	O	O
and	O	O
Chronic	O	O
Health	O	O
Evaluation	O	O
II	O	O
scores	O	O
and	O	O
requirement	O	O
for	O	O
organ	O	O
support	O	O
compared	O	O
with	O	O
the	O	O
other	O	O
two	O	O
groups	O	O
.	O	O

Twenty	O	O
(	O	O
56%	O	O
)	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
patients	O	O
had	O	O
a	O	O
formal	O	O
psychiatric	O	O
diagnosis	O	O
before	O	O
LT	O	O
(	O	O
non	O	O
-	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF=0	O	O
/	O	O
35	O	O
,	O	O
CLD=2	O	O
/	O	O
34	O	O
;	O	O
P<0	O	O
.	O	O

01	O	O
for	O	O
all	O	O
)	O	O
and	O	O
nine	O	O
(	O	O
25%	O	O
)	O	O
had	O	O
a	O	O
previous	O	O
suicide	O	O
attempt	O	O
.	O	O

During	O	O
follow	O	O
-	O	O
up	O	O
(	O	O
median	O	O
5	O	O
years	O	O
)	O	O
,	O	O
there	O	O
were	O	O
no	O	O
significant	O	O
differences	O	O
in	O	O
rejection	O	O
(	O	O
acute	O	O
and	O	O
chronic	O	O
)	O	O
,	O	O
graft	O	O
failure	O	O
or	O	O
survival	O	O
between	O	O
the	O	O
groups	O	O
(	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
1	O	O
year	O	O
87%	O	O
,	O	O
5	O	O
years	O	O
75%	O	O
;	O	O
non	O	O
-	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
88%	O	O
,	O	O
78%	O	O
;	O	O
CLD	B-Disease	D008107
93%	O	O
,	O	O
82%	O	O
:	O	O
P>0	O	O
.	O	O

6	O	O
log	O	O
rank	O	O
)	O	O
.	O	O

Two	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
patients	O	O
reattempted	O	O
suicide	O	O
post	O	O
-	O	O
LT	O	O
(	O	O
one	O	O
died	O	O
8	O	O
years	O	O
post	O	O
-	O	O
LT	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Despite	O	O
a	O	O
high	O	O
prevalence	O	O
of	O	O
psychiatric	O	O
disturbance	O	O
,	O	O
outcomes	O	O
for	O	O
patients	O	O
transplanted	O	O
emergently	O	O
for	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
were	O	O
comparable	O	O
to	O	O
those	O	O
transplanted	O	O
for	O	O
non	O	O
-	O	O
acetaminophen	B-Chemical	D000082
-	O	O
induced	O	O
ALF	B-Disease	D017114
and	O	O
electively	O	O
for	O	O
CLD	B-Disease	D008107
.	O	O

Multidisciplinary	O	O
approaches	O	O
with	O	O
long	O	O
-	O	O
term	O	O
psychiatric	O	O
follow	O	O
-	O	O
up	O	O
may	O	O
contribute	O	O
to	O	O
low	O	O
post	O	O
-	O	O
transplant	O	O
suicide	O	O
rates	O	O
seen	O	O
and	O	O
low	O	O
rates	O	O
of	O	O
graft	O	O
loss	O	O
because	O	O
of	O	O
non	O	O
-	O	O
compliance	O	O
.	O	O

Studies	O	O
of	O	O
synergy	O	O
between	O	O
morphine	B-Chemical	D009020
and	O	O
a	O	O
novel	O	O
sodium	B-Chemical	D012964
channel	O	O
blocker	O	O
,	O	O
CNSB002	B-Chemical	C401121
,	O	O
in	O	O
rat	O	O
models	O	O
of	O	O
inflammatory	O	O
and	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
.	O	O

OBJECTIVE	O	O
:	O	O
This	O	O
study	O	O
determined	O	O
the	O	O
antihyperalgesic	O	O
effect	O	O
of	O	O
CNSB002	B-Chemical	C401121
,	O	O
a	O	O
sodium	B-Chemical	D012964
channel	O	O
blocker	O	O
with	O	O
antioxidant	O	O
properties	O	O
given	O	O
alone	O	O
and	O	O
in	O	O
combinations	O	O
with	O	O
morphine	B-Chemical	D009020
in	O	O
rat	O	O
models	O	O
of	O	O
inflammatory	O	O
and	O	O
neuropathic	B-Disease	D009437
pain	I-Disease	D009437
.	O	O

DESIGN	O	O
:	O	O
Dose	O	O
response	O	O
curves	O	O
for	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B-Chemical	D009020
and	O	O
CNSB002	B-Chemical	C401121
given	O	O
intraperitoneally	O	O
alone	O	O
and	O	O
together	O	O
in	O	O
combinations	O	O
were	O	O
constructed	O	O
for	O	O
antihyperalgesic	O	O
effect	O	O
using	O	O
paw	O	O
withdrawal	O	O
from	O	O
noxious	O	O
heat	O	O
in	O	O
two	O	O
rat	O	O
pain	B-Disease	D010146
models	O	O
:	O	O
carrageenan	B-Chemical	D002351
-	O	O
induced	O	O
paw	O	O
inflammation	B-Disease	D007249
and	O	O
streptozotocin	B-Chemical	D013311
(	O	O
STZ	B-Chemical	D013311
)	O	O
-	O	O
induced	O	O
diabetic	B-Disease	D003929
neuropathy	I-Disease	D003929
.	O	O

RESULTS	O	O
:	O	O
The	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
were	O	O
:	O	O
morphine	B-Chemical	D009020
,	O	O
3	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
CNSB002	B-Chemical	C401121
10	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
5	O	O
.	O	O

0	O	O
mg	O	O
/	O	O
kg	O	O
CNSB002	B-Chemical	C401121
with	O	O
morphine	B-Chemical	D009020
3	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
in	O	O
combination	O	O
.	O	O

The	O	O
doses	O	O
calculated	O	O
to	O	O
cause	O	O
50%	O	O
reversal	O	O
of	O	O
hyperalgesia	B-Disease	D006930
(	O	O
ED50	O	O
)	O	O
were	O	O
7	O	O
.	O	O

54	O	O
(	O	O
1	O	O
.	O	O

81	O	O
)	O	O
and	O	O
4	O	O
.	O	O

83	O	O
(	O	O
1	O	O
.	O	O

54	O	O
)	O	O
in	O	O
the	O	O
carrageenan	B-Chemical	D002351
model	O	O
and	O	O
44	O	O
.	O	O

18	O	O
(	O	O
1	O	O
.	O	O

37	O	O
)	O	O
and	O	O
9	O	O
.	O	O

14	O	O
(	O	O
1	O	O
.	O	O

24	O	O
)	O	O
in	O	O
the	O	O
STZ	B-Chemical	D013311
-	O	O
induced	O	O
neuropathy	B-Disease	D009422
model	O	O
for	O	O
CNSB002	B-Chemical	C401121
and	O	O
morphine	B-Chemical	D009020
,	O	O
respectively	O	O
(	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
mean	O	O
,	O	O
SEM	O	O
)	O	O
.	O	O

These	O	O
values	O	O
were	O	O
greater	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
doses	O	O
.	O	O

The	O	O
ED50	O	O
values	O	O
for	O	O
morphine	B-Chemical	D009020
when	O	O
given	O	O
in	O	O
combination	O	O
with	O	O
CNSB002	B-Chemical	C401121
(	O	O
5	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
were	O	O
less	O	O
than	O	O
the	O	O
maximum	O	O
nonsedating	O	O
dose	O	O
:	O	O
0	O	O
.	O	O

56	O	O
(	O	O
1	O	O
.	O	O

55	O	O
)	O	O
in	O	O
the	O	O
carrageenan	B-Chemical	D002351
model	O	O
and	O	O
1	O	O
.	O	O

37	O	O
(	O	O
1	O	O
.	O	O

23	O	O
)	O	O
in	O	O
the	O	O
neuropathy	B-Disease	D009422
model	O	O
(	O	O
mg	O	O
/	O	O
kg	O	O
;	O	O
mean	O	O
,	O	O
SEM	O	O
)	O	O
.	O	O

The	O	O
antinociception	O	O
after	O	O
morphine	B-Chemical	D009020
(	O	O
3	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
kg	O	O
)	O	O
was	O	O
increased	O	O
by	O	O
co	O	O
-	O	O
administration	O	O
with	O	O
CNSB002	B-Chemical	C401121
from	O	O
28	O	O
.	O	O

0	O	O
and	O	O
31	O	O
.	O	O

7%	O	O
to	O	O
114	O	O
.	O	O

6	O	O
and	O	O
56	O	O
.	O	O

9%	O	O
reversal	O	O
of	O	O
hyperalgesia	B-Disease	D006930
in	O	O
the	O	O
inflammatory	O	O
and	O	O
neuropathic	B-Disease	D009422
models	O	O
,	O	O
respectively	O	O
(	O	O
P	O	O
<	O	O
0	O	O
.	O	O

01	O	O
;	O	O
one	O	O
-	O	O
way	O	O
analysis	O	O
of	O	O
variance	O	O
-	O	O
significantly	O	O
greater	O	O
than	O	O
either	O	O
drug	O	O
given	O	O
alone	O	O
)	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
The	O	O
maximum	O	O
antihyperalgesic	O	O
effect	O	O
achievable	O	O
with	O	O
nonsedating	O	O
doses	O	O
of	O	O
morphine	B-Chemical	D009020
may	O	O
be	O	O
increased	O	O
significantly	O	O
when	O	O
the	O	O
drug	O	O
is	O	O
used	O	O
in	O	O
combination	O	O
with	O	O
CNSB002	B-Chemical	C401121
.	O	O

Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
:	O	O
a	O	O
practical	O	O
review	O	O
.	O	O

Heparin	B-Chemical	D006493
-	O	O
induced	O	O
thrombocytopenia	B-Disease	D013921
(	O	O
HIT	B-Disease	D013921
)	O	O
remains	O	O
under	O	O
-	O	O
recognized	O	O
despite	O	O
its	O	O
potentially	O	O
devastating	O	O
outcomes	O	O
.	O	O

It	O	O
begins	O	O
when	O	O
heparin	B-Chemical	D006493
exposure	O	O
stimulates	O	O
the	O	O
formation	O	O
of	O	O
heparin	B-Chemical	D006493
-	O	O
platelet	O	O
factor	O	O
4	O	O
antibodies	O	O
,	O	O
which	O	O
in	O	O
turn	O	O
triggers	O	O
the	O	O
release	O	O
of	O	O
procoagulant	O	O
platelet	O	O
particles	O	O
.	O	O

Thrombosis	B-Disease	D013927
and	O	O
thrombocytopenia	B-Disease	D013921
that	O	O
follow	O	O
comprise	O	O
the	O	O
2	O	O
hallmark	O	O
traits	O	O
of	O	O
HIT	B-Disease	D013921
,	O	O
with	O	O
the	O	O
former	O	O
largely	O	O
responsible	O	O
for	O	O
significant	O	O
vascular	O	O
complications	O	O
.	O	O

The	O	O
prevalence	O	O
of	O	O
HIT	B-Disease	D013921
varies	O	O
among	O	O
several	O	O
subgroups	O	O
,	O	O
with	O	O
greater	O	O
incidence	O	O
in	O	O
surgical	O	O
as	O	O
compared	O	O
with	O	O
medical	O	O
populations	O	O
.	O	O

HIT	B-Disease	D013921
must	O	O
be	O	O
acknowledged	O	O
for	O	O
its	O	O
intense	O	O
predilection	O	O
for	O	O
thrombosis	B-Disease	D013927
and	O	O
suspected	O	O
whenever	O	O
thrombosis	B-Disease	D013927
occurs	O	O
after	O	O
heparin	B-Chemical	D006493
exposure	O	O
.	O	O

Early	O	O
recognition	O	O
that	O	O
incorporates	O	O
the	O	O
clinical	O	O
and	O	O
serologic	O	O
clues	O	O
is	O	O
paramount	O	O
to	O	O
timely	O	O
institution	O	O
of	O	O
treatment	O	O
,	O	O
as	O	O
its	O	O
delay	O	O
may	O	O
result	O	O
in	O	O
catastrophic	O	O
outcomes	O	O
.	O	O

The	O	O
treatment	O	O
of	O	O
HIT	B-Disease	D013921
mandates	O	O
an	O	O
immediate	O	O
cessation	O	O
of	O	O
all	O	O
heparin	B-Chemical	D006493
exposure	O	O
and	O	O
the	O	O
institution	O	O
of	O	O
an	O	O
antithrombotic	O	O
therapy	O	O
,	O	O
most	O	O
commonly	O	O
using	O	O
a	O	O
direct	B-Chemical	D000991
thrombin	I-Chemical	D000991
inhibitor	I-Chemical	D000991
.	O	O

Current	O	O
"diagnostic"	O	O
tests	O	O
,	O	O
which	O	O
primarily	O	O
include	O	O
functional	O	O
and	O	O
antigenic	O	O
assays	O	O
,	O	O
have	O	O
more	O	O
of	O	O
a	O	O
confirmatory	O	O
than	O	O
diagnostic	O	O
role	O	O
in	O	O
the	O	O
management	O	O
of	O	O
HIT	B-Disease	D013921
.	O	O

Special	O	O
attention	O	O
must	O	O
be	O	O
paid	O	O
to	O	O
cardiac	O	O
patients	O	O
who	O	O
are	O	O
often	O	O
exposed	O	O
to	O	O
heparin	B-Chemical	D006493
multiple	O	O
times	O	O
during	O	O
their	O	O
course	O	O
of	O	O
treatment	O	O
.	O	O

Direct	B-Chemical	D000991
thrombin	I-Chemical	D000991
inhibitors	I-Chemical	D000991
are	O	O
appropriate	O	O
,	O	O
evidence	O	O
-	O	O
based	O	O
alternatives	O	O
to	O	O
heparin	B-Chemical	D006493
in	O	O
patients	O	O
with	O	O
a	O	O
history	O	O
of	O	O
HIT	B-Disease	D013921
,	O	O
who	O	O
need	O	O
to	O	O
undergo	O	O
percutaneous	O	O
coronary	O	O
intervention	O	O
.	O	O

As	O	O
heparin	B-Chemical	D006493
remains	O	O
one	O	O
of	O	O
the	O	O
most	O	O
frequently	O	O
used	O	O
medications	O	O
today	O	O
with	O	O
potential	O	O
for	O	O
HIT	B-Disease	D013921
with	O	O
every	O	O
heparin	B-Chemical	D006493
exposure	O	O
,	O	O
a	O	O
close	O	O
vigilance	O	O
of	O	O
platelet	O	O
counts	O	O
must	O	O
be	O	O
practiced	O	O
whenever	O	O
heparin	B-Chemical	D006493
is	O	O
initiated	O	O
.	O	O

Abductor	O	O
paralysis	B-Disease	D010243
after	O	O
botox	B-Chemical	C542870
injection	O	O
for	O	O
adductor	B-Disease	D014826
spasmodic	I-Disease	D014826
dysphonia	I-Disease	D014826
.	O	O

OBJECTIVES	O	O
/	O	O
HYPOTHESIS	O	O
:	O	O
Botulinum	O	O
toxin	O	O
(	O	O
Botox	B-Chemical	C542870
)	O	O
injections	O	O
into	O	O
the	O	O
thyroarytenoid	O	O
muscles	O	O
are	O	O
the	O	O
current	O	O
standard	O	O
of	O	O
care	O	O
for	O	O
adductor	B-Disease	D014826
spasmodic	I-Disease	D014826
dysphonia	I-Disease	D014826
(	O	O
ADSD	B-Disease	D014826
)	O	O
.	O	O

Reported	O	O
adverse	O	O
effects	O	O
include	O	O
a	O	O
period	O	O
of	O	O
breathiness	O	O
,	O	O
throat	B-Disease	D010612
pain	I-Disease	D010612
,	O	O
and	O	O
difficulty	O	O
with	O	O
swallowing	O	O
liquids	O	O
.	O	O

Here	O	O
we	O	O
report	O	O
multiple	O	O
cases	O	O
of	O	O
bilateral	O	O
abductor	O	O
paralysis	B-Disease	D010243
following	O	O
Botox	B-Chemical	C542870
injections	O	O
for	O	O
ADSD	B-Disease	D014826
,	O	O
a	O	O
complication	O	O
previously	O	O
unreported	O	O
.	O	O

STUDY	O	O
DESIGN	O	O
:	O	O
Retrospective	O	O
case	O	O
series	O	O
.	O	O

METHODS	O	O
:	O	O
Patients	O	O
that	O	O
received	O	O
Botox	B-Chemical	C542870
injections	O	O
for	O	O
spasmodic	B-Disease	D055154
dysphonia	I-Disease	D055154
between	O	O
January	O	O
2000	O	O
and	O	O
October	O	O
2009	O	O
were	O	O
evaluated	O	O
.	O	O

Patients	O	O
with	O	O
ADSD	B-Disease	D014826
were	O	O
identified	O	O
.	O	O

The	O	O
number	O	O
of	O	O
treatments	O	O
received	O	O
and	O	O
adverse	O	O
effects	O	O
were	O	O
noted	O	O
.	O	O

For	O	O
patients	O	O
with	O	O
bilateral	O	O
abductor	O	O
paralysis	B-Disease	D010243
,	O	O
age	O	O
,	O	O
sex	O	O
,	O	O
paralytic	O	O
Botox	B-Chemical	C542870
dose	O	O
,	O	O
prior	O	O
Botox	B-Chemical	C542870
dose	O	O
,	O	O
and	O	O
course	O	O
following	O	O
paralysis	B-Disease	D010243
were	O	O
noted	O	O
.	O	O

RESULTS	O	O
:	O	O
From	O	O
a	O	O
database	O	O
of	O	O
452	O	O
patients	O	O
receiving	O	O
Botox	B-Chemical	C542870
,	O	O
352	O	O
patients	O	O
had	O	O
been	O	O
diagnosed	O	O
with	O	O
ADSD	B-Disease	D014826
.	O	O

Of	O	O
these	O	O
352	O	O
patients	O	O
,	O	O
eight	O	O
patients	O	O
suffered	O	O
bilateral	O	O
abductor	O	O
paralysis	B-Disease	D010243
,	O	O
and	O	O
two	O	O
suffered	O	O
this	O	O
complication	O	O
twice	O	O
.	O	O

All	O	O
affected	O	O
patients	O	O
were	O	O
females	O	O
over	O	O
the	O	O
age	O	O
of	O	O
50	O	O
years	O	O
.	O	O

Most	O	O
patients	O	O
had	O	O
received	O	O
treatments	O	O
prior	O	O
to	O	O
abductor	O	O
paralysis	B-Disease	D010243
and	O	O
continued	O	O
receiving	O	O
after	O	O
paralysis	B-Disease	D010243
.	O	O

Seven	O	O
patients	O	O
recovered	O	O
after	O	O
a	O	O
brief	O	O
period	O	O
of	O	O
activity	O	O
restrictions	O	O
,	O	O
and	O	O
one	O	O
underwent	O	O
a	O	O
tracheotomy	O	O
.	O	O

The	O	O
incidence	O	O
of	O	O
abductor	O	O
paralysis	B-Disease	D010243
after	O	O
Botox	B-Chemical	C542870
injection	O	O
for	O	O
ADSD	B-Disease	D014826
was	O	O
0	O	O
.	O	O

34%	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
Bilateral	O	O
abductor	O	O
paralysis	B-Disease	D010243
is	O	O
a	O	O
rare	O	O
complication	O	O
of	O	O
Botox	B-Chemical	C542870
injections	O	O
for	O	O
ADSD	B-Disease	D014826
,	O	O
causing	O	O
difficulty	O	O
with	O	O
breathing	O	O
upon	O	O
exertion	O	O
.	O	O

The	O	O
likely	O	O
mechanism	O	O
of	O	O
paralysis	B-Disease	D010243
is	O	O
diffusion	O	O
of	O	O
Botox	B-Chemical	C542870
around	O	O
the	O	O
muscular	O	O
process	O	O
of	O	O
the	O	O
arytenoid	O	O
to	O	O
the	O	O
posterior	O	O
cricoarytenoid	O	O
muscles	O	O
.	O	O

The	O	O
paralysis	B-Disease	D010243
is	O	O
temporary	O	O
,	O	O
and	O	O
watchful	O	O
waiting	O	O
with	O	O
restriction	O	O
of	O	O
activity	O	O
is	O	O
the	O	O
recommended	O	O
management	O	O
.	O	O

Mitochondrial	B-Disease	D028361
impairment	I-Disease	D028361
contributes	O	O
to	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
:	O	O
Prevention	O	O
by	O	O
the	O	O
targeted	O	O
antioxidant	O	O
MitoQ	B-Chemical	C476756
.	O	O

The	O	O
goal	O	O
of	O	O
this	O	O
study	O	O
was	O	O
to	O	O
assess	O	O
mitochondrial	O	O
function	O	O
and	O	O
ROS	O	O
production	O	O
in	O	O
an	O	O
experimental	O	O
model	O	O
of	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
.	O	O

We	O	O
hypothesized	O	O
that	O	O
cocaine	B-Chemical	D003042
abuse	O	O
may	O	O
lead	O	O
to	O	O
altered	O	O
mitochondrial	O	O
function	O	O
that	O	O
in	O	O
turn	O	O
may	O	O
cause	O	O
left	B-Disease	D018487
ventricular	I-Disease	D018487
dysfunction	I-Disease	D018487
.	O	O

Seven	O	O
days	O	O
of	O	O
cocaine	B-Chemical	D003042
administration	O	O
to	O	O
rats	O	O
led	O	O
to	O	O
an	O	O
increased	O	O
oxygen	B-Chemical	D010100
consumption	O	O
detected	O	O
in	O	O
cardiac	O	O
fibers	O	O
,	O	O
specifically	O	O
through	O	O
complex	O	O
I	O	O
and	O	O
complex	O	O
III	O	O
.	O	O

ROS	O	O
levels	O	O
were	O	O
increased	O	O
,	O	O
specifically	O	O
in	O	O
interfibrillar	O	O
mitochondria	O	O
.	O	O

In	O	O
parallel	O	O
there	O	O
was	O	O
a	O	O
decrease	O	O
in	O	O
ATP	B-Chemical	D000255
synthesis	O	O
,	O	O
whereas	O	O
no	O	O
difference	O	O
was	O	O
observed	O	O
in	O	O
subsarcolemmal	O	O
mitochondria	O	O
.	O	O

This	O	O
uncoupling	O	O
effect	O	O
on	O	O
oxidative	O	O
phosphorylation	O	O
was	O	O
not	O	O
detectable	O	O
after	O	O
short	O	O
-	O	O
term	O	O
exposure	O	O
to	O	O
cocaine	B-Chemical	D003042
,	O	O
suggesting	O	O
that	O	O
these	O	O
mitochondrial	B-Disease	D028361
abnormalities	I-Disease	D028361
were	O	O
a	O	O
late	O	O
rather	O	O
than	O	O
a	O	O
primary	O	O
event	O	O
in	O	O
the	O	O
pathological	O	O
response	O	O
to	O	O
cocaine	B-Chemical	D003042
.	O	O

MitoQ	B-Chemical	C476756
,	O	O
a	O	O
mitochondrial	O	O
-	O	O
targeted	O	O
antioxidant	O	O
,	O	O
was	O	O
shown	O	O
to	O	O
completely	O	O
prevent	O	O
these	O	O
mitochondrial	B-Disease	D028361
abnormalities	I-Disease	D028361
as	O	O
well	O	O
as	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
characterized	O	O
here	O	O
by	O	O
a	O	O
diastolic	B-Disease	-1
dysfunction	I-Disease	-1
studied	O	O
with	O	O
a	O	O
conductance	O	O
catheter	O	O
to	O	O
obtain	O	O
pressure	O	O
-	O	O
volume	O	O
data	O	O
.	O	O

Taken	O	O
together	O	O
,	O	O
these	O	O
results	O	O
extend	O	O
previous	O	O
studies	O	O
and	O	O
demonstrate	O	O
that	O	O
cocaine	B-Chemical	D003042
-	O	O
induced	O	O
cardiac	B-Disease	D006331
dysfunction	I-Disease	D006331
may	O	O
be	O	O
due	O	O
to	O	O
a	O	O
mitochondrial	B-Disease	D028361
defect	I-Disease	D028361
.	O	O

Trimethoprim	B-Chemical	D014295
-	O	O
induced	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
in	O	O
a	O	O
pediatric	O	O
oncology	O	O
patient	O	O
presenting	O	O
as	O	O
an	O	O
acute	O	O
hemolytic	O	O
transfusion	O	O
reaction	O	O
.	O	O

A	O	O
10	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
with	O	O
acute	B-Disease	D015470
leukemia	I-Disease	D015470
presented	O	O
with	O	O
post	O	O
-	O	O
chemotherapy	O	O
anemia	B-Disease	D000740
.	O	O

During	O	O
red	O	O
cell	O	O
transfusion	O	O
,	O	O
he	O	O
developed	O	O
hemoglobinuria	B-Disease	D006456
.	O	O

Transfusion	O	O
reaction	O	O
workup	O	O
was	O	O
negative	O	O
.	O	O

Drug	O	O
-	O	O
induced	O	O
immune	O	O
hemolytic	B-Disease	D000743
anemia	I-Disease	D000743
was	O	O
suspected	O	O
because	O	O
of	O	O
positive	O	O
direct	O	O
antiglobulin	O	O
test	O	O
,	O	O
negative	O	O
eluate	O	O
,	O	O
and	O	O
microspherocytes	O	O
on	O	O
smear	O	O
pre	O	O
-	O	O
and	O	O
post	O	O
-	O	O
transfusion	O	O
.	O	O

Drug	O	O
studies	O	O
using	O	O
the	O	O
indirect	O	O
antiglobulin	O	O
test	O	O
were	O	O
strongly	O	O
positive	O	O
with	O	O
trimethoprim	B-Chemical	D014295
and	O	O
trimethoprim	B-Chemical	D014295
-	O	O
sulfamethoxazole	B-Chemical	D013420
but	O	O
negative	O	O
with	O	O
sulfamethoxazole	B-Chemical	D013420
.	O	O

The	O	O
patient	O	O
recovered	O	O
after	O	O
discontinuing	O	O
the	O	O
drug	O	O
,	O	O
with	O	O
no	O	O
recurrence	O	O
in	O	O
2	O	O
years	O	O
.	O	O

Other	O	O
causes	O	O
of	O	O
anemia	B-Disease	D000740
should	O	O
be	O	O
considered	O	O
in	O	O
patients	O	O
with	O	O
worse	O	O
-	O	O
than	O	O
-	O	O
expected	O	O
anemia	B-Disease	D000740
after	O	O
chemotherapy	O	O
.	O	O

Furthermore	O	O
,	O	O
hemolysis	B-Disease	D006461
during	O	O
transfusion	O	O
is	O	O
not	O	O
always	O	O
a	O	O
transfusion	O	O
reaction	O	O
.	O	O

Blockade	O	O
of	O	O
endothelial	O	O
-	O	O
mesenchymal	O	O
transition	O	O
by	O	O
a	O	O
Smad3	O	O
inhibitor	O	O
delays	O	O
the	O	O
early	O	O
development	O	O
of	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

OBJECTIVE	O	O
:	O	O
A	O	O
multicenter	O	O
,	O	O
controlled	O	O
trial	O	O
showed	O	O
that	O	O
early	O	O
blockade	O	O
of	O	O
the	O	O
renin	O	O
-	O	O
angiotensin	B-Chemical	D000804
system	O	O
in	O	O
patients	O	O
with	O	O
type	B-Disease	D003922
1	I-Disease	D003922
diabetes	I-Disease	D003922
and	O	O
normoalbuminuria	O	O
did	O	O
not	O	O
retard	O	O
the	O	O
progression	O	O
of	O	O
nephropathy	B-Disease	D007674
,	O	O
suggesting	O	O
that	O	O
other	O	O
mechanism	O	O
(	O	O
s	O	O
)	O	O
are	O	O
involved	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
early	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
(	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
)	O	O
.	O	O

We	O	O
have	O	O
previously	O	O
demonstrated	O	O
that	O	O
endothelial	O	O
-	O	O
mesenchymal	O	O
-	O	O
transition	O	O
(	O	O
EndoMT	O	O
)	O	O
contributes	O	O
to	O	O
the	O	O
early	O	O
development	O	O
of	O	O
renal	O	O
interstitial	O	O
fibrosis	B-Disease	D005355
independently	O	O
of	O	O
microalbuminuria	O	O
in	O	O
mice	O	O
with	O	O
streptozotocin	B-Chemical	D013311
(	O	O
STZ	B-Chemical	D013311
)	O	O
-	O	O
induced	O	O
diabetes	B-Disease	D003920
.	O	O

In	O	O
the	O	O
present	O	O
study	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
blocking	O	O
EndoMT	O	O
reduces	O	O
the	O	O
early	O	O
development	O	O
of	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

RESEARCH	O	O
DESIGN	O	O
AND	O	O
METHODS	O	O
:	O	O
EndoMT	O	O
was	O	O
induced	O	O
in	O	O
a	O	O
mouse	O	O
pancreatic	O	O
microvascular	O	O
endothelial	O	O
cell	O	O
line	O	O
(	O	O
MMEC	O	O
)	O	O
in	O	O
the	O	O
presence	O	O
of	O	O
advanced	O	O
glycation	O	O
end	O	O
products	O	O
(	O	O
AGEs	O	O
)	O	O
and	O	O
in	O	O
the	O	O
endothelial	O	O
lineage	O	O
-	O	O
traceble	O	O
mouse	O	O
line	O	O
Tie2	O	O
-	O	O
Cre	O	O
;	O	O
Loxp	O	O
-	O	O
EGFP	O	O
by	O	O
administration	O	O
of	O	O
AGEs	O	O
,	O	O
with	O	O
nonglycated	O	O
mouse	O	O
albumin	O	O
serving	O	O
as	O	O
a	O	O
control	O	O
.	O	O

Phosphorylated	O	O
Smad3	O	O
was	O	O
detected	O	O
by	O	O
immunoprecipitation	O	O
/	O	O
Western	O	O
blotting	O	O
and	O	O
confocal	O	O
microscopy	O	O
.	O	O

Blocking	O	O
studies	O	O
using	O	O
receptor	O	O
for	O	O
AGE	O	O
siRNA	O	O
and	O	O
a	O	O
specific	O	O
inhibitor	O	O
of	O	O
Smad3	O	O
(	O	O
SIS3	O	O
)	O	O
were	O	O
performed	O	O
in	O	O
MMECs	O	O
and	O	O
in	O	O
STZ	B-Chemical	D013311
-	O	O
induced	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
in	O	O
Tie2	O	O
-	O	O
Cre	O	O
;	O	O
Loxp	O	O
-	O	O
EGFP	O	O
mice	O	O
.	O	O

RESULTS	O	O
:	O	O
Confocal	O	O
microscopy	O	O
and	O	O
real	O	O
-	O	O
time	O	O
PCR	O	O
demonstrated	O	O
that	O	O
AGEs	O	O
induced	O	O
EndoMT	O	O
in	O	O
MMECs	O	O
and	O	O
in	O	O
Tie2	O	O
-	O	O
Cre	O	O
;	O	O
Loxp	O	O
-	O	O
EGFP	O	O
mice	O	O
.	O	O

Immunoprecipitation	O	O
/	O	O
Western	O	O
blotting	O	O
showed	O	O
that	O	O
Smad3	O	O
was	O	O
activated	O	O
by	O	O
AGEs	O	O
but	O	O
was	O	O
inhibited	O	O
by	O	O
SIS3	O	O
in	O	O
MMECs	O	O
and	O	O
in	O	O
STZ	B-Chemical	D013311
-	O	O
induced	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

Confocal	O	O
microscopy	O	O
and	O	O
real	O	O
-	O	O
time	O	O
PCR	O	O
further	O	O
demonstrated	O	O
that	O	O
SIS3	O	O
abrogated	O	O
EndoMT	O	O
,	O	O
reduced	O	O
renal	O	O
fibrosis	B-Disease	D005355
,	O	O
and	O	O
retarded	O	O
progression	O	O
of	O	O
nephropathy	B-Disease	D007674
.	O	O

CONCLUSIONS	O	O
:	O	O
EndoMT	O	O
is	O	O
a	O	O
novel	O	O
pathway	O	O
leading	O	O
to	O	O
early	O	O
development	O	O
of	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
.	O	O

Blockade	O	O
of	O	O
EndoMT	O	O
by	O	O
SIS3	O	O
may	O	O
provide	O	O
a	O	O
new	O	O
strategy	O	O
to	O	O
retard	O	O
the	O	O
progression	O	O
of	O	O
diabetic	B-Disease	D003928
nephropathy	I-Disease	D003928
and	O	O
other	O	O
diabetes	B-Disease	D003920
complications	O	O
.	O	O

Cytostatic	O	O
and	O	O
anti	O	O
-	O	O
angiogenic	O	O
effects	O	O
of	O	O
temsirolimus	B-Chemical	C401859
in	O	O
refractory	O	O
mantle	B-Disease	D020522
cell	I-Disease	D020522
lymphoma	I-Disease	D020522
.	O	O

Mantle	B-Disease	D020522
cell	I-Disease	D020522
lymphoma	I-Disease	D020522
(	O	O
MCL	B-Disease	D020522
)	O	O
is	O	O
a	O	O
rare	O	O
and	O	O
aggressive	O	O
type	O	O
of	O	O
B	B-Disease	D008228
-	I-Disease	D008228
cell	I-Disease	D008228
non	I-Disease	D008228
-	I-Disease	D008228
Hodgkin's	I-Disease	D008228
lymphoma	I-Disease	D008228
.	O	O

Patients	O	O
become	O	O
progressively	O	O
refractory	O	O
to	O	O
conventional	O	O
chemotherapy	O	O
,	O	O
and	O	O
their	O	O
prognosis	O	O
is	O	O
poor	O	O
.	O	O

However	O	O
,	O	O
a	O	O
38%	O	O
remission	O	O
rate	O	O
has	O	O
been	O	O
recently	O	O
reported	O	O
in	O	O
refractory	O	O
MCL	B-Disease	D020522
treated	O	O
with	O	O
temsirolimus	B-Chemical	C401859
,	O	O
a	O	O
mTOR	O	O
inhibitor	O	O
.	O	O

Here	O	O
we	O	O
had	O	O
the	O	O
opportunity	O	O
to	O	O
study	O	O
a	O	O
case	O	O
of	O	O
refractory	O	O
MCL	B-Disease	D020522
who	O	O
had	O	O
tumor	B-Disease	D009369
regression	O	O
two	O	O
months	O	O
after	O	O
temsirolimus	B-Chemical	C401859
treatment	O	O
,	O	O
and	O	O
a	O	O
progression	O	O
-	O	O
free	O	O
survival	O	O
of	O	O
10	O	O
months	O	O
.	O	O

In	O	O
this	O	O
case	O	O
,	O	O
lymph	O	O
node	O	O
biopsies	O	O
were	O	O
performed	O	O
before	O	O
and	O	O
six	O	O
months	O	O
after	O	O
temsirolimus	B-Chemical	C401859
therapy	O	O
.	O	O

Comparison	O	O
of	O	O
the	O	O
two	O	O
biopsies	O	O
showed	O	O
that	O	O
temsirolimus	B-Chemical	C401859
inhibited	O	O
tumor	B-Disease	D009369
cell	O	O
proliferation	O	O
through	O	O
cell	O	O
cycle	O	O
arrest	O	O
,	O	O
but	O	O
did	O	O
not	O	O
induce	O	O
any	O	O
change	O	O
in	O	O
the	O	O
number	O	O
of	O	O
apoptotic	O	O
tumor	B-Disease	D009369
cells	O	O
.	O	O

Apart	O	O
from	O	O
this	O	O
cytostatic	O	O
effect	O	O
,	O	O
temsirolimus	B-Chemical	C401859
had	O	O
an	O	O
antiangiogenic	O	O
effect	O	O
with	O	O
decrease	O	O
of	O	O
tumor	B-Disease	D009369
microvessel	O	O
density	O	O
and	O	O
of	O	O
VEGF	O	O
expression	O	O
.	O	O

Moreover	O	O
,	O	O
numerous	O	O
patchy	O	O
,	O	O
well	O	O
-	O	O
limited	O	O
fibrotic	O	O
areas	O	O
,	O	O
compatible	O	O
with	O	O
post	O	O
-	O	O
necrotic	B-Disease	D009336
tissue	O	O
repair	O	O
,	O	O
were	O	O
found	O	O
after	O	O
6	O	O
-	O	O
month	O	O
temsirolimus	B-Chemical	C401859
therapy	O	O
.	O	O

Thus	O	O
,	O	O
temsirolimus	B-Chemical	C401859
reduced	O	O
tumor	B-Disease	D009369
burden	O	O
through	O	O
associated	O	O
cytostatic	O	O
and	O	O
anti	O	O
-	O	O
angiogenic	O	O
effects	O	O
.	O	O

This	O	O
dual	O	O
effect	O	O
of	O	O
temsirolimus	B-Chemical	C401859
on	O	O
tumor	B-Disease	D009369
tissue	O	O
could	O	O
contribute	O	O
to	O	O
its	O	O
recently	O	O
reported	O	O
efficiency	O	O
in	O	O
refractory	O	O
MCL	B-Disease	D020522
resistant	O	O
to	O	O
conventional	O	O
chemotherapy	O	O
.	O	O

Syncope	B-Disease	D013575
caused	O	O
by	O	O
hyperkalemia	B-Disease	D006947
during	O	O
use	O	O
of	O	O
a	O	O
combined	O	O
therapy	O	O
with	O	O
the	O	O
angiotensin	B-Chemical	D000809
-	O	O
converting	O	O
enzyme	O	O
inhibitor	O	O
and	O	O
spironolactone	B-Chemical	D013148
.	O	O

A	O	O
76	O	O
year	O	O
-	O	O
old	O	O
woman	O	O
with	O	O
a	O	O
history	O	O
of	O	O
coronary	O	O
artery	O	O
bypass	O	O
grafting	O	O
and	O	O
prior	O	O
myocardial	B-Disease	D009203
infarction	I-Disease	D009203
was	O	O
transferred	O	O
to	O	O
the	O	O
emergency	O	O
room	O	O
with	O	O
loss	B-Disease	D014474
of	I-Disease	D014474
consciousness	I-Disease	D014474
due	O	O
to	O	O
marked	O	O
bradycardia	B-Disease	D001919
caused	O	O
by	O	O
hyperkalemia	B-Disease	D006947
.	O	O

The	O	O
concentration	O	O
of	O	O
serum	O	O
potassium	B-Chemical	D011188
was	O	O
high	O	O
,	O	O
and	O	O
normal	O	O
sinus	O	O
rhythm	O	O
was	O	O
restored	O	O
after	O	O
correction	O	O
of	O	O
the	O	O
serum	O	O
potassium	B-Chemical	D011188
level	O	O
.	O	O

The	O	O
cause	O	O
of	O	O
hyperkalemia	B-Disease	D006947
was	O	O
considered	O	O
to	O	O
be	O	O
several	O	O
doses	O	O
of	O	O
spiranolactone	B-Chemical	D013148
,	O	O
an	O	O
aldosterone	B-Chemical	D000450
antagonist	O	O
,	O	O
in	O	O
addition	O	O
to	O	O
the	O	O
long	O	O
-	O	O
term	O	O
intake	O	O
of	O	O
ramipril	B-Chemical	D017257
,	O	O
an	O	O
ACE	O	O
inhibitor	O	O
.	O	O

This	O	O
case	O	O
is	O	O
a	O	O
good	O	O
example	O	O
of	O	O
electrolyte	O	O
imbalance	O	O
causing	O	O
acute	O	O
life	O	O
-	O	O
threatening	O	O
cardiac	O	O
events	O	O
.	O	O

Clinicians	O	O
should	O	O
be	O	O
alert	O	O
to	O	O
the	O	O
possibility	O	O
of	O	O
hyperkalemia	B-Disease	D006947
,	O	O
especially	O	O
in	O	O
elderly	O	O
patients	O	O
using	O	O
ACE	O	O
/	O	O
ARB	O	O
in	O	O
combination	O	O
with	O	O
potassium	B-Chemical	D011188
sparing	O	O
agents	O	O
and	O	O
who	O	O
have	O	O
mild	O	O
renal	B-Disease	D007674
disturbance	I-Disease	D007674
.	O	O

Diffuse	O	O
skeletal	O	O
pain	B-Disease	D010146
after	O	O
administration	O	O
of	O	O
alendronate	B-Chemical	D019386
.	O	O

BACKGROUND	O	O
:	O	O
Osteoporosis	B-Disease	D010024
is	O	O
caused	O	O
by	O	O
bone	O	O
resorption	O	O
in	O	O
excess	O	O
of	O	O
bone	O	O
formation	O	O
,	O	O
and	O	O
bisphosphonates	B-Chemical	D004164
,	O	O
are	O	O
used	O	O
to	O	O
inhibit	O	O
bone	O	O
resorption	O	O
.	O	O

Alendronate	B-Chemical	D019386
,	O	O
a	O	O
biphosphonate	B-Chemical	-1
,	O	O
is	O	O
effective	O	O
for	O	O
both	O	O
the	O	O
treatment	O	O
and	O	O
prevention	O	O
of	O	O
osteoporosis	B-Disease	D010024
in	O	O
postmenopausal	O	O
women	O	O
.	O	O

Side	O	O
effects	O	O
are	O	O
relatively	O	O
few	O	O
and	O	O
prominently	O	O
gastrointestinal	O	O
.	O	O

Musculoskeletal	B-Disease	D059352
pain	I-Disease	D059352
may	O	O
be	O	O
an	O	O
important	O	O
side	O	O
effect	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

We	O	O
presented	O	O
a	O	O
patient	O	O
admitted	O	O
to	O	O
our	O	O
out	O	O
-	O	O
patient	O	O
clinic	O	O
with	O	O
diffuse	O	O
skeletal	O	O
pain	B-Disease	D010146
after	O	O
three	O	O
consecutive	O	O
administration	O	O
of	O	O
alendronate	B-Chemical	D019386
.	O	O

CONCLUSION	O	O
:	O	O
We	O	O
conclude	O	O
that	O	O
patients	O	O
with	O	O
osteoporosis	B-Disease	D010024
can	O	O
report	O	O
pain	B-Disease	D010146
,	O	O
and	O	O
bisphosphonate	B-Chemical	D004164
-	O	O
related	O	O
pain	B-Disease	D010146
should	O	O
also	O	O
be	O	O
considered	O	O
before	O	O
ascribing	O	O
this	O	O
complaint	O	O
to	O	O
osteoporosis	B-Disease	D010024
.	O	O

Cerebrospinal	O	O
fluid	O	O
penetration	O	O
of	O	O
high	O	O
-	O	O
dose	O	O
daptomycin	B-Chemical	D017576
in	O	O
suspected	O	O
Staphylococcus	O	O
aureus	O	O
meningitis	B-Disease	D008581
.	O	O

OBJECTIVE	O	O
:	O	O
To	O	O
report	O	O
a	O	O
case	O	O
of	O	O
methicillin	B-Chemical	D008712
-	O	O
sensitive	O	O
Staphylococcus	O	O
aureus	O	O
(	O	O
MSSA	O	O
)	O	O
bacteremia	B-Disease	D016470
with	O	O
suspected	O	O
MSSA	O	O
meningitis	B-Disease	D008581
treated	O	O
with	O	O
high	O	O
-	O	O
dose	O	O
daptomycin	B-Chemical	D017576
assessed	O	O
with	O	O
concurrent	O	O
serum	O	O
and	O	O
cerebrospinal	O	O
fluid	O	O
(	O	O
CSF	O	O
)	O	O
concentrations	O	O
.	O	O

CASE	O	O
SUMMARY	O	O
:	O	O
A	O	O
54	O	O
-	O	O
year	O	O
-	O	O
old	O	O
male	O	O
presented	O	O
to	O	O
the	O	O
emergency	O	O
department	O	O
with	O	O
generalized	O	O
weakness	B-Disease	D018908
and	O	O
presumed	O	O
health	O	O
-	O	O
care	O	O
-	O	O
associated	O	O
pneumonia	B-Disease	D011014
shown	O	O
on	O	O
chest	O	O
radiograph	O	O
.	O	O

Treatment	O	O
was	O	O
empirically	O	O
initiated	O	O
with	O	O
vancomycin	B-Chemical	D014640
,	O	O
levofloxacin	B-Chemical	D064704
,	O	O
and	O	O
piperacillin	B-Chemical	D010878
/	O	O
tazobactam	B-Chemical	C043265
.	O	O

Blood	O	O
cultures	O	O
revealed	O	O
S	O	O
.	O	O

aureus	O	O
susceptible	O	O
to	O	O
oxacillin	B-Chemical	D010068
.	O	O

Empiric	O	O
antibiotic	O	O
treatment	O	O
was	O	O
narrowed	O	O
to	O	O
nafcillin	B-Chemical	D009254
on	O	O
day	O	O
4	O	O
.	O	O

On	O	O
day	O	O
8	O	O
,	O	O
the	O	O
patient	O	O
developed	O	O
acute	B-Disease	D058186
renal	I-Disease	D058186
failure	I-Disease	D058186
(	O	O
serum	O	O
creatinine	B-Chemical	D003404
1	O	O
.	O	O

9	O	O
mg	O	O
/	O	O
dL	O	O
,	O	O
increased	O	O
from	O	O
1	O	O
.	O	O

2	O	O
mg	O	O
/	O	O
dL	O	O
the	O	O
previous	O	O
day	O	O
and	O	O
0	O	O
.	O	O

8	O	O
mg	O	O
/	O	O
dL	O	O
on	O	O
admission	O	O
)	O	O
.	O	O

The	O	O
patient's	O	O
Glasgow	O	O
Coma	O	O
Score	O	O
was	O	O
3	O	O
,	O	O
with	O	O
normal	O	O
findings	O	O
shown	O	O
on	O	O
computed	O	O
tomography	O	O
scan	O	O
of	O	O
the	O	O
head	O	O
72	O	O
hours	O	O
following	O	O
an	O	O
episode	O	O
of	O	O
cardiac	B-Disease	D006323
arrest	I-Disease	D006323
on	O	O
day	O	O
10	O	O
.	O	O

The	O	O
patient	O	O
experienced	O	O
relapsing	O	O
MSSA	O	O
bacteremia	B-Disease	D016470
on	O	O
day	O	O
9	O	O
,	O	O
increasing	O	O
the	O	O
suspicion	O	O
for	O	O
a	O	O
central	O	O
nervous	O	O
system	O	O
(	O	O
CNS	O	O
)	O	O
infection	B-Disease	D007239
.	O	O

Nafcillin	B-Chemical	D009254
was	O	O
discontinued	O	O
and	O	O
daptomycin	B-Chemical	D017576
9	O	O
mg	O	O
/	O	O
kg	O	O
daily	O	O
was	O	O
initiated	O	O
for	O	O
suspected	O	O
meningitis	B-Disease	D008581
and	O	O
was	O	O
continued	O	O
until	O	O
the	O	O
patient's	O	O
death	O	O
on	O	O
day	O	O
16	O	O
.	O	O

Daptomycin	B-Chemical	D017576
serum	O	O
and	O	O
CSF	O	O
trough	O	O
concentrations	O	O
were	O	O
11	O	O
.	O	O

21	O	O
ug	O	O
/	O	O
mL	O	O
and	O	O
0	O	O
.	O	O

52	O	O
ug	O	O
/	O	O
mL	O	O
,	O	O
respectively	O	O
,	O	O
prior	O	O
to	O	O
the	O	O
third	O	O
dose	O	O
.	O	O

Lumbar	O	O
puncture	O	O
results	O	O
were	O	O
inconclusive	O	O
and	O	O
no	O	O
further	O	O
blood	O	O
cultures	O	O
were	O	O
positive	O	O
for	O	O
MSSA	O	O
.	O	O

Creatine	B-Chemical	D003401
kinase	O	O
levels	O	O
were	O	O
normal	O	O
prior	O	O
to	O	O
daptomycin	B-Chemical	D017576
therapy	O	O
and	O	O
were	O	O
not	O	O
reassessed	O	O
.	O	O

DISCUSSION	O	O
:	O	O
Daptomycin	B-Chemical	D017576
was	O	O
initiated	O	O
in	O	O
our	O	O
patient	O	O
secondary	O	O
to	O	O
possible	O	O
nafcillin	B-Chemical	D009254
-	O	O
induced	O	O
acute	O	O
interstitial	B-Disease	D009395
nephritis	I-Disease	D009395
and	O	O
relapsing	O	O
bacteremia	B-Disease	D016470
.	O	O

At	O	O
a	O	O
dose	O	O
of	O	O
9	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
resultant	O	O
penetration	O	O
of	O	O
5%	O	O
was	O	O
higher	O	O
than	O	O
in	O	O
previous	O	O
reports	O	O
,	O	O
more	O	O
consistent	O	O
with	O	O
inflamed	O	O
meninges	O	O
.	O	O

CONCLUSIONS	O	O
:	O	O
High	O	O
-	O	O
dose	O	O
daptomycin	B-Chemical	D017576
may	O	O
be	O	O
an	O	O
alternative	O	O
option	O	O
for	O	O
MSSA	O	O
bacteremia	B-Disease	D016470
with	O	O
or	O	O
without	O	O
a	O	O
CNS	O	O
source	O	O
in	O	O
patients	O	O
who	O	O
have	O	O
failed	O	O
or	O	O
cannot	O	O
tolerate	O	O
standard	O	O
therapy	O	O
.	O	O

Further	O	O
clinical	O	O
evaluation	O	O
in	O	O
patients	O	O
with	O	O
confirmed	O	O
meningitis	B-Disease	D008581
is	O	O
warranted	O	O
.	O	O

The	O	O
role	O	O
of	O	O
nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
in	O	O
convulsions	B-Disease	D012640
induced	O	O
by	O	O
lindane	B-Chemical	D001556
in	O	O
rats	O	O
.	O	O

Lindane	B-Chemical	D001556
is	O	O
an	O	O
organochloride	O	O
pesticide	O	O
and	O	O
scabicide	O	O
.	O	O

It	O	O
evokes	O	O
convulsions	B-Disease	D012640
mainly	O	O
trough	O	O
the	O	O
blockage	O	O
of	O	O
GABA	B-Chemical	D005680
(	O	O
A	O	O
)	O	O
receptors	O	O
.	O	O

Nitric	B-Chemical	D009569
oxide	I-Chemical	D009569
(	O	O
NO	B-Chemical	D009569
)	O	O
,	O	O
gaseous	O	O
neurotransmitter	O	O
,	O	O
has	O	O
contradictor	O	O
role	O	O
in	O	O
epileptogenesis	O	O
due	O	O
to	O	O
opposite	O	O
effects	O	O
of	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
,	O	O
precursor	O	O
of	O	O
NO	B-Chemical	D009569
syntheses	O	O
(	O	O
NOS	O	O
)	O	O
,	O	O
and	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
(	O	O
NOS	O	O
inhibitor	O	O
)	O	O
observed	O	O
in	O	O
different	O	O
epilepsy	B-Disease	D004827
models	O	O
.	O	O

The	O	O
aim	O	O
of	O	O
the	O	O
current	O	O
study	O	O
was	O	O
to	O	O
determine	O	O
the	O	O
effects	O	O
of	O	O
NO	B-Chemical	D009569
on	O	O
the	O	O
behavioral	O	O
and	O	O
EEG	O	O
characteristics	O	O
of	O	O
lindane	B-Chemical	D001556
-	O	O
induced	O	O
epilepsy	B-Disease	D004827
in	O	O
male	O	O
Wistar	O	O
albino	O	O
rats	O	O
.	O	O

The	O	O
administration	O	O
of	O	O
L	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
(	O	O
600	O	O
,	O	O
800	O	O
and	O	O
1000	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
in	O	O
dose	O	O
-	O	O
dependent	O	O
manner	O	O
significantly	O	O
increased	O	O
convulsion	B-Disease	D012640
incidence	O	O
and	O	O
severity	O	O
and	O	O
shortened	O	O
latency	O	O
time	O	O
to	O	O
first	O	O
convulsion	B-Disease	D012640
elicited	O	O
by	O	O
lower	O	O
lindane	B-Chemical	D001556
dose	O	O
(	O	O
4	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

On	O	O
the	O	O
contrary	O	O
,	O	O
pretreatment	O	O
with	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
(	O	O
500	O	O
,	O	O
700	O	O
and	O	O
900	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
decreased	O	O
convulsion	B-Disease	D012640
incidence	O	O
and	O	O
severity	O	O
and	O	O
prolonged	O	O
latency	O	O
time	O	O
to	O	O
convulsion	B-Disease	D012640
following	O	O
injection	O	O
with	O	O
a	O	O
convulsive	B-Disease	D012640
dose	O	O
of	O	O
lindane	B-Chemical	D001556
(	O	O
8	O	O
mg	O	O
/	O	O
kg	O	O
,	O	O
i	O	O
.	O	O

p	O	O
.	O	O

)	O	O
.	O	O

EEG	O	O
analyses	O	O
showed	O	O
increase	O	O
of	O	O
number	O	O
and	O	O
duration	O	O
of	O	O
ictal	O	O
periods	O	O
in	O	O
EEG	O	O
of	O	O
rats	O	O
receiving	O	O
l	B-Chemical	D001120
-	I-Chemical	D001120
arginine	I-Chemical	D001120
prior	O	O
to	O	O
lindane	B-Chemical	D001556
and	O	O
decrease	O	O
of	O	O
this	O	O
number	O	O
in	O	O
rats	O	O
pretreated	O	O
with	O	O
L	B-Chemical	D019331
-	I-Chemical	D019331
NAME	I-Chemical	D019331
.	O	O

These	O	O
results	O	O
support	O	O
the	O	O
conclusion	O	O
that	O	O
NO	B-Chemical	D009569
plays	O	O
a	O	O
role	O	O
of	O	O
endogenous	O	O
convulsant	O	O
in	O	O
rat	O	O
model	O	O
of	O	O
lindane	B-Chemical	D001556
seizures	B-Disease	D012640
.	O	O

Long	O	O
-	O	O
term	O	O
oral	O	O
galactose	B-Chemical	D005690
treatment	O	O
prevents	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
in	O	O
male	O	O
Wistar	O	O
rats	O	O
treated	O	O
intracerebroventricularly	O	O
with	O	O
streptozotocin	B-Chemical	D013311
.	O	O

Basic	O	O
and	O	O
clinical	O	O
research	O	O
has	O	O
demonstrated	O	O
that	O	O
dementia	B-Disease	D003704
of	O	O
sporadic	O	O
Alzheimer's	B-Disease	D000544
disease	I-Disease	D000544
(	O	O
sAD	O	O
)	O	O
type	O	O
is	O	O
associated	O	O
with	O	O
dysfunction	O	O
of	O	O
the	O	O
insulin	O	O
-	O	O
receptor	O	O
(	O	O
IR	O	O
)	O	O
system	O	O
followed	O	O
by	O	O
decreased	O	O
glucose	B-Chemical	D005947
transport	O	O
via	O	O
glucose	B-Chemical	D005947
transporter	O	O
GLUT4	O	O
and	O	O
decreased	O	O
glucose	B-Chemical	D005947
metabolism	O	O
in	O	O
brain	O	O
cells	O	O
.	O	O

An	O	O
alternative	O	O
source	O	O
of	O	O
energy	O	O
is	O	O
d	B-Chemical	D005690
-	I-Chemical	D005690
galactose	I-Chemical	D005690
(	O	O
the	O	O
C	O	O
-	O	O
4	O	O
-	O	O
epimer	O	O
of	O	O
d	B-Chemical	D005947
-	I-Chemical	D005947
glucose	I-Chemical	D005947
)	O	O
which	O	O
is	O	O
transported	O	O
into	O	O
the	O	O
brain	O	O
by	O	O
insulin	O	O
-	O	O
independent	O	O
GLUT3	O	O
transporter	O	O
where	O	O
it	O	O
might	O	O
be	O	O
metabolized	O	O
to	O	O
glucose	B-Chemical	D005947
via	O	O
the	O	O
Leloir	O	O
pathway	O	O
.	O	O

Exclusively	O	O
parenteral	O	O
daily	O	O
injections	O	O
of	O	O
galactose	B-Chemical	D005690
induce	O	O
memory	B-Disease	D008569
deterioration	I-Disease	D008569
in	O	O
rodents	O	O
and	O	O
are	O	O
used	O	O
to	O	O
generate	O	O
animal	O	O
aging	O	O
model	O	O
,	O	O
but	O	O
the	O	O
effects	O	O
of	O	O
oral	O	O
galactose	B-Chemical	D005690
treatment	O	O
on	O	O
cognitive	O	O
functions	O	O
have	O	O
never	O	O
been	O	O
tested	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
effects	O	O
of	O	O
continuous	O	O
daily	O	O
oral	O	O
galactose	B-Chemical	D005690
(	O	O
200	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
)	O	O
treatment	O	O
on	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
in	O	O
streptozotocin	B-Chemical	D013311
-	O	O
induced	O	O
(	O	O
STZ	B-Chemical	D013311
-	O	O
icv	O	O
)	O	O
rat	O	O
model	O	O
of	O	O
sAD	O	O
,	O	O
tested	O	O
by	O	O
Morris	O	O
Water	O	O
Maze	O	O
and	O	O
Passive	O	O
Avoidance	O	O
test	O	O
,	O	O
respectively	O	O
.	O	O

One	O	O
month	O	O
of	O	O
oral	O	O
galactose	B-Chemical	D005690
treatment	O	O
initiated	O	O
immediately	O	O
after	O	O
the	O	O
STZ	B-Chemical	D013311
-	O	O
icv	O	O
administration	O	O
,	O	O
successfully	O	O
prevented	O	O
development	O	O
of	O	O
the	O	O
STZ	B-Chemical	D013311
-	O	O
icv	O	O
-	O	O
induced	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
.	O	O

Beneficial	O	O
effect	O	O
of	O	O
oral	O	O
galactose	B-Chemical	D005690
was	O	O
independent	O	O
of	O	O
the	O	O
rat	O	O
age	O	O
and	O	O
of	O	O
the	O	O
galactose	B-Chemical	D005690
dose	O	O
ranging	O	O
from	O	O
100	O	O
to	O	O
300	O	O
mg	O	O
/	O	O
kg	O	O
/	O	O
day	O	O
.	O	O

Additionally	O	O
,	O	O
oral	O	O
galactose	B-Chemical	D005690
administration	O	O
led	O	O
to	O	O
the	O	O
appearance	O	O
of	O	O
galactose	B-Chemical	D005690
in	O	O
the	O	O
blood	O	O
.	O	O

The	O	O
increase	O	O
of	O	O
galactose	B-Chemical	D005690
concentration	O	O
in	O	O
the	O	O
cerebrospinal	O	O
fluid	O	O
was	O	O
several	O	O
times	O	O
lower	O	O
after	O	O
oral	O	O
than	O	O
after	O	O
parenteral	O	O
administration	O	O
of	O	O
the	O	O
same	O	O
galactose	B-Chemical	D005690
dose	O	O
.	O	O

Oral	O	O
galactose	B-Chemical	D005690
exposure	O	O
might	O	O
have	O	O
beneficial	O	O
effects	O	O
on	O	O
learning	O	O
and	O	O
memory	O	O
ability	O	O
and	O	O
could	O	O
be	O	O
worth	O	O
investigating	O	O
for	O	O
improvement	O	O
of	O	O
cognitive	B-Disease	D003072
deficits	I-Disease	D003072
associated	O	O
with	O	O
glucose	B-Chemical	D005947
hypometabolism	O	O
in	O	O
AD	B-Disease	D000544
.	O	O

